PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Schuppel, R; Buchele, G; Batz, L; Koenig, W				Schuppel, R; Buchele, G; Batz, L; Koenig, W			Sex differences in selection of pacemakers: retrospective observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-ARTERY DISEASE; GENDER DIFFERENCES; SINGLE-CHAMBER; WOMEN; BIAS; PRESCRIPTION; MANAGEMENT; SURVIVAL; MEN; AGE	Objective: To evaluate the effect of patients' sex on selection of pacemakers. Design: Retrospective univariate and multivariate analysis of a large database. Setting: German central pacemaker register. Subjects: Records collected at the register for 1992 and 1993 (n=31 913), covering 64% of all implantations in Germany. Main outcome measure: Probability of receiving a single chamber, dual chamber, or rate responsive pacemaker in relation to sex. Results: Univariate analysis showed that women were more likely to receive single chamber pacemakers and less likely to receive dual chamber or rate responsive systems than men. After demographic and clinical variables were controlled for, women were still more likely to receive a single chamber system (atrial pacing: odds ratio 0.89, 95% confidence interval 0.74 to 1.07; ventricular pacing: 0.85, 0.80 to 0.92) and less likely to receive a dual chamber (1.20, 1.12 to 1.30) or a rate responsive system (1.26, 1.17 to 1.37) than men. Conclusions: The data suggest sex differences in the selection of a pacemaker system which cannot be explained by the underlying cardiac disorder. Further research is needed to evaluate why guidelines for implanting pacemakers are not better adhered to.	Univ Ulm, Dept Psychotherapy & Psychosomat, Med Ctr, D-89081 Ulm, Germany; Univ Ulm, Dept Biometry & Med Documentat, D-89075 Ulm, Germany; Univ Giessen, Inst Med Technol, D-36392 Giessen, Germany; Univ Ulm, Med Ctr, Dept Internal Med 2, Ulm, Germany	Ulm University; Ulm University; Justus Liebig University Giessen; Ulm University	Schuppel, R (corresponding author), Univ Ulm, Dept Psychotherapy & Psychosomat, Med Ctr, D-89081 Ulm, Germany.							Aggarwal RK, 1996, HEART, V75, P518, DOI 10.1136/hrt.75.5.518; ALPERT MA, 1987, AM HEART J, V113, P958, DOI 10.1016/0002-8703(87)90057-3; ARMITAGE KJ, 1979, JAMA-J AM MED ASSOC, V241, P2186, DOI 10.1001/jama.241.20.2186; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; CLARKE M, 1991, BRIT HEART J, V66, P185; *EUR WORK GROUP CA, 1987, EUR HEART J SUPPL, V8, P21; FORCINITO M, 1991, J AM COLL CARDIOL, V18, P1, DOI 10.1016/S0735-1097(10)80209-8; GREENSPAN AM, 1988, NEW ENGL J MED, V318, P158, DOI 10.1056/NEJM198801213180306; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; HORTON HL, 1995, ARCH INTERN MED, V155, P2342, DOI 10.1001/archinte.155.21.2342; IRNICH W, 1994, HERZSCHRITTMACHER, V14, P239; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; LAMAS GA, 1995, CIRCULATION, V91, P1063, DOI 10.1161/01.CIR.91.4.1063; LAMAS GA, 1992, CIRCULATION, V86, P449; LAU CP, 1994, PACE, V17, P1838, DOI 10.1111/j.1540-8159.1994.tb03759.x; MARK DB, 1994, NEW ENGL J MED, V330, P1101, DOI 10.1056/NEJM199404213301601; PROCTOR EE, 1991, AM HEART J, V122, P728, DOI 10.1016/0002-8703(91)90518-M; RAY SG, 1992, BRIT HEART J, V68, P531; SHAW LJ, 1994, ANN INTERN MED, V120, P559, DOI 10.7326/0003-4819-120-7-199404010-00005; STANGL K, 1990, HERZSCHRITIMACHER EL, V1, P42; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406	24	17	17	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 16	1998	316	7143					1492	1494		10.1136/bmj.316.7143.1492	http://dx.doi.org/10.1136/bmj.316.7143.1492			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP020	9582133	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000073707700021
J	Irving, BA; Alt, FW; Killeen, N				Irving, BA; Alt, FW; Killeen, N			Thymocyte development in the absence of pre-T cell receptor extracellular immunoglobulin domains	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; ANTIGEN RECEPTOR; MUTANT MICE; ALPHA-BETA; DEFICIENT MICE; CHAIN; EXPRESSION; GENE; LCK; DIFFERENTIATION	Immature thymocytes express a pre-T cell receptor (pre-TCR) composed of the TCR beta chain paired with pre-T alpha. Signals from this receptor are essential for passage of thymocytes through a key developmental checkpoint in the thymus. These signals were efficiently delivered in vivo by a truncated form of the murine pre-TCR that lacked all of its extracellular immunoglobulin domains. De novo expression of the truncated pre-TCR or an intact alpha beta TCR was sufficient to activate characteristic TCR signaling pathways in a T cell line. These findings support the view that recognition of an extracellular ligand is not required for pre-TCR function.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Genet & Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA	University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Killeen, N (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.							Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Cheng AM, 1997, P NATL ACAD SCI USA, V94, P9797, DOI 10.1073/pnas.94.18.9797; CORCOS D, 1995, CURR BIOL, V5, P1140, DOI 10.1016/S0960-9822(95)00230-2; CROMPTON T, 1994, EUR J IMMUNOL, V24, P1903, DOI 10.1002/eji.1830240828; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; Hedrick Stephen M., 1993, P383; Hogan B., 2014, MANIPULATING MOUSE E; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, UNPUB; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; KERSH GJ, 1995, J IMMUNOL, V154, P5706; Krotkova A, 1997, J EXP MED, V186, P767, DOI 10.1084/jem.186.5.767; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; MANOLIOS N, 1994, EUR J IMMUNOL, V24, P84, DOI 10.1002/eji.1830240114; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1995, P NATL ACAD SCI USA, V92, P7420, DOI 10.1073/pnas.92.16.7420; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; OShea CC, 1997, IMMUNITY, V7, P591, DOI 10.1016/S1074-7613(00)80380-5; Papavasiliou F, 1997, CURR OPIN IMMUNOL, V9, P233, DOI 10.1016/S0952-7915(97)80141-0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; Shaffer AL, 1997, J IMMUNOL, V159, P1265; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; Swat W, 1996, P NATL ACAD SCI USA, V93, P4683, DOI 10.1073/pnas.93.10.4683; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9	43	151	152	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 8	1998	280	5365					905	908		10.1126/science.280.5365.905	http://dx.doi.org/10.1126/science.280.5365.905			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572735				2022-12-01	WOS:000073532900042
J	Kristensen, P; Judge, ME; Thim, L; Ribel, U; Christjansen, KN; Wulff, BS; Clausen, JT; Jensen, PB; Madsen, OD; Vrang, N; Larsen, PJ; Hastrup, S				Kristensen, P; Judge, ME; Thim, L; Ribel, U; Christjansen, KN; Wulff, BS; Clausen, JT; Jensen, PB; Madsen, OD; Vrang, N; Larsen, PJ; Hastrup, S			Hypothalamic CART is a new anorectic peptide regulated by leptin	NATURE			English	Article							MESSENGER-RIBONUCLEIC-ACID; NEUROPEPTIDE-Y; RNA; POLYPEPTIDE; AMPHETAMINE; COCAINE; MOUSE; RATS; FOOD; MICE	The mammalian hypothalamus strongly influences ingestive behaviour through several different signalling molecules and receptor systems(1-4). Here we show that CART (cocaine-and amphetamine-regulated transcript), a brain-located peptide(5-8), is a satiety factor and is closely associated with the actions of two important regulators of food intake, leptin and neuropeptide Y. Food-deprived animals show a pronounced decrease in expression of CART messenger RNA in the arcuate nucleus. In animal models of obesity with disrupted leptin signalling, CART mRNA is almost absent from the arcuate nucleus. Peripheral administration of leptin to obese mice stimulates CART mRNA expression. When injected intracerebroventricularly into rats, recombinant CART peptide inhibits both normal and starvation-induced feeding, and completely blocks the feeding response induced by neuropeptide Y. An antiserum against CART increases feeding in normal rats, indicating that CART may be an endogenous inhibitor of food intake in normal animals.	Novo Nordisk AS, Hlth Care Discovery, DK-2880 Bagsvaerd, Denmark; Hagedorn Res Inst, DK-2820 Gentofte, Denmark; Univ Copenhagen, Dept Anat, DK-2200 Copenhagen, Denmark	Novo Nordisk; Novo Nordisk; Hagedorn Research Institute; University of Copenhagen	Kristensen, P (corresponding author), Novo Nordisk AS, Hlth Care Discovery, Novo Alle 6A1-47, DK-2880 Bagsvaerd, Denmark.	pekr@novo.dk	Madsen, Ole D./A-7415-2011	Madsen, Ole D./0000-0002-2753-5203; Jensen, Per Bo/0000-0002-2277-1135				BERGHORN KA, 1994, J HISTOCHEM CYTOCHEM, V42, P1635, DOI 10.1177/42.12.7983364; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; Couceyro PR, 1997, J CHEM NEUROANAT, V12, P229, DOI 10.1016/S0891-0618(97)00212-3; Douglass J, 1996, GENE, V169, P241, DOI 10.1016/0378-1119(96)88651-3; DOUGLASS J, 1995, J NEUROSCI, V15, P2471; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; FENGER M, 1990, SCAND J CLIN LAB INV, V50, P229; Gautvik KM, 1996, P NATL ACAD SCI USA, V93, P8733, DOI 10.1073/pnas.93.16.8733; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; Kjeldsen T, 1996, GENE, V170, P107, DOI 10.1016/0378-1119(95)00822-5; KRISTENSEN P, 1991, J HISTOCHEM CYTOCHEM, V39, P341, DOI 10.1177/39.3.1899685; SANACORA G, 1990, ENDOCRINOLOGY, V127, P730, DOI 10.1210/endo-127-2-730; SPIESS J, 1981, BIOCHEMISTRY-US, V20, P1982, DOI 10.1021/bi00510a038; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Wang Q, 1997, DIABETES, V46, P335, DOI 10.2337/diabetes.46.3.335; Whitelegge T., 1890, REC AUST MUS, V1, P41, DOI DOI 10.3853/J.0067-1975.1.1890.1224; WILDING JPH, 1993, ENDOCRINOLOGY, V132, P1939, DOI 10.1210/en.132.5.1939	20	1016	1052	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 7	1998	393	6680					72	76		10.1038/29993	http://dx.doi.org/10.1038/29993			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590691				2022-12-01	WOS:000073497500049
J	O'Neill, RJW; O'Neill, MJ; Graves, JAM				O'Neill, RJW; O'Neill, MJ; Graves, JAM			Undermethylation associated with retroelement activation and chromosome remodelling in an interspecific mammalian hybrid	NATURE			English	Article							TRANSPOSABLE ELEMENTS; METHYLATION; SPECIATION; DROSOPHILA; EVOLUTION; GENOMES; RNA	Genetic models(1,2) predict that genomic rearrangement in hybrids can facilitate reproductive isolation and the formation of new species by preventing gene flow between the parent species and hybrid (sunflowers are an example(3)). The mechanism underlying hybridization-induced chromosome remodelling is as yet unknown, although mobile element activity has been shown to be involved in DNA rearrangement in some dysgenic Drosophila hybrids(4,5), It has been proposed that DNA methylation evolved as a means of repressing the movement of mobile elements (the host defence model(6,7)). If such a protective mechanism were to fail, mobile elements could be activated, and could cause major and rapid genome alterations(8,9), Here we demonstrate the occurrence of genome-wide undermethylation, retroviral element amplification and chromosome remodelling in an interspecific mammalian hybrid (Macropus eugenii X Wallabia bicolor). Atypically extended centromeres of Macropus eugenii derived autosomes in the hybrid were composed primarily of an unmethylated, amplified retroviral element not detectable in either parent species. These results, taken with the observation of deficient methylation and de novo chromosome change in other mammalian hybrids, indicate that the failure of DNA methylation and subsequent mobile-element activity in hybrids could facilitate rapid karyotypic evolution.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; La Trobe Univ, Dept Genet & Human Variat, Bundoora, Vic 3083, Australia	Princeton University; La Trobe University	O'Neill, RJW (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.		Graves, Jennifer A.M./A-1387-2008	Graves, Jennifer/0000-0001-6480-7856				ARNAULT C, 1994, GENETICA, V93, P149, DOI 10.1007/BF01435247; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; Curcio MJ, 1996, TRENDS GENET, V12, P436; ENGELS WR, 1984, GENETICS, V107, P657; GRANT V, 1958, COLD SPRING HARB SYM, V23, P337, DOI 10.1101/SQB.1958.023.01.034; GRAUR D, 1985, J MOL EVOL, V21, P221, DOI 10.1007/BF02102356; HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; JAENISCH R, 1985, P NATL ACAD SCI USA, V82, P1451, DOI 10.1073/pnas.82.5.1451; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LOEBEL DA, 1993, CHROMOSOMA, V102, P81, DOI 10.1007/BF00356024; PETROV DA, 1995, P NATL ACAD SCI USA, V92, P8050, DOI 10.1073/pnas.92.17.8050; RIESEBERG LH, 1995, NATURE, V375, P313, DOI 10.1038/375313a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEMPP W, 1983, HUM GENET, V63, P171, DOI 10.1007/BF00291539; SMITH MJ, 1979, AUST J ZOOL, V27, P959, DOI 10.1071/ZO9790959; SUNKEL CE, 1995, CURR OPIN GENET DEV, V5, P756, DOI 10.1016/0959-437X(95)80008-S; TEMPLETON AR, 1981, ANNU REV ECOL SYST, V12, P23, DOI 10.1146/annurev.es.12.110181.000323; Toder R, 1996, CHROMOSOME RES, V4, P295, DOI 10.1007/BF02263680; Toder R, 1997, MAMM GENOME, V8, P418, DOI 10.1007/s003359900459; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; WICHMAN HA, 1992, GENETICA, V86, P287, DOI 10.1007/BF00133727; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	24	354	359	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1998	393	6680					68	72		10.1038/29985	http://dx.doi.org/10.1038/29985			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590690				2022-12-01	WOS:000073497500048
J	Gaist, D; Tsiropoulos, I; Sindrup, SH; Hallas, J; Ramussen, BK; Kragstrup, J; Gram, LF				Gaist, D; Tsiropoulos, I; Sindrup, SH; Hallas, J; Ramussen, BK; Kragstrup, J; Gram, LF			Inappropriate use of sumatriptan: population based register and interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Odense Univ, Inst Med Biol, Dept Clin Pharmacol, DK-5000 Odense C, Denmark; Odense Univ Hosp, Dept Neurol, DK-5000 Odense, Denmark; Hillerod Hosp, Dept Neurol, Hillerod, Denmark; Odense Univ, Gen Practice Res Unit, Odense, Denmark	University of Southern Denmark; University of Southern Denmark; Odense University Hospital; University of Copenhagen; University of Southern Denmark	Gaist, D (corresponding author), Odense Univ, Inst Med Biol, Dept Clin Pharmacol, DK-5000 Odense C, Denmark.	d.gaist@winsloew.ou.dk	Gaist, David/I-4397-2014	Gaist, David/0000-0001-5205-7007; Sindrup, Soren/0000-0003-0357-8628				Gaist D, 1997, DAN MED BULL, V44, P445; Gaist D, 1997, BRIT J CLIN PHARMACO, V43, P429, DOI 10.1046/j.1365-2125.1997.00582.x; Gaist D, 1996, EUR J CLIN PHARMACOL, V50, P161, DOI 10.1007/s002280050086; RUSSELL MB, 1992, CEPHALALGIA, V12, P369, DOI 10.1111/j.1468-2982.1992.00369.x; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x	5	44	44	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 2	1998	316	7141					1352	1353		10.1136/bmj.316.7141.1352	http://dx.doi.org/10.1136/bmj.316.7141.1352			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL882	9563984	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000073483000017
J	Parganas, E; Wang, D; Stravopodis, D; Topham, DJ; Marine, JC; Teglund, S; Vanin, EF; Bodner, S; Colamonici, OR; van Deursen, JM; Grosveld, G; Ihle, JN				Parganas, E; Wang, D; Stravopodis, D; Topham, DJ; Marine, JC; Teglund, S; Vanin, EF; Bodner, S; Colamonici, OR; van Deursen, JM; Grosveld, G; Ihle, JN			Jak2 is essential for signaling through a variety of cytokine receptors	CELL			English	Article							PROTEIN-TYROSINE KINASE; STIMULATING FACTOR-RECEPTOR; TRANSCRIPTION FACTOR GATA-1; MICE LACKING JAK3; ERYTHROPOIETIN RECEPTOR; LYMPHOID DEVELOPMENT; INTERFERON-ALPHA/BETA; TRANSDUCTION PATHWAY; G-CSF; ACTIVATION	A variety of cytokines activate receptor-associated members of the Janus family of protein tyrosine kinases (Jaks). To assess the role of Jak2, we have derived Jak2-deficient mice. The mutation causes an embryonic lethality due to the absence of definitive erythropoiesis. Fetal liver myeloid progenitors, although present based on the expression of lineage specific markers, fail to respond to erythropoietin, thrombopoietin, interleukin-3 (IL-3), or granulocyte/macrophage colony-stimulating factor. In contrast, the response to granulocyte specific colony-stimulating factor is unaffected. Jak2-deficient fibroblasts failed to respond to interferon gamma (IFN gamma), although the responses to IFN alpha/beta and IL-6 were unaffected. Lastly, reconstitution experiments demonstrate that Jak2 is not required for the generation of lymphoid progenitors, their amplification, or functional differentiation. Therefore, Jak2 plays a critical, nonredundant role in the function of a specific group of cytokines receptors.	St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Expt Hematol, Memphis, TN 38105 USA; Univ Tennessee, Sch Med, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Sch Med, Dept Pathol, Memphis, TN 38105 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Ihle, JN (corresponding author), St Jude Childrens Res Hosp, Howard Hughes Med Inst, 332 N Lauderdale St, Memphis, TN 38105 USA.		Marine, Jean Christophe/J-2237-2015; Marine, Jean-Christophe/K-3292-2016; Wang, Demin/AAX-4449-2020	Marine, Jean-Christophe/0000-0003-2433-9837; Wang, Demin/0000-0001-5549-3795; Stravopodis, Dimitrios/0000-0002-9535-2134	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDUS T, 1988, EUR J IMMUNOL, V18, P739, DOI 10.1002/eji.1830180513; ARTGETSINGER LS, 1993, CELL, V74, P237; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; Barge RMY, 1996, BLOOD, V87, P2148, DOI 10.1182/blood.V87.6.2148.bloodjournal8762148; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HANAZONO Y, 1993, BLOOD, V81, P3193; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; Hogan B., 2014, MANIPULATING MOUSE E; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kieran MW, 1996, P NATL ACAD SCI USA, V93, P9126, DOI 10.1073/pnas.93.17.9126; Leonard WJ, 1995, IMMUNOL REV, V148, P97, DOI 10.1111/j.1600-065X.1995.tb00095.x; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MACHIDE M, 1995, ONCOGENE, V11, P619; MANO H, 1995, BLOOD, V85, P343; MIYAKAWA Y, 1995, BLOOD, V86, P23, DOI 10.1182/blood.V86.1.23.bloodjournal86123; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PERKINS AC, 1995, NATURE, V375, P318; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAUPRICH P, 1995, BLOOD, V86, P4500, DOI 10.1182/blood.V86.12.4500.bloodjournal86124500; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; SHIMODA K, 1994, BIOCHEM BIOPH RES CO, V203, P922, DOI 10.1006/bbrc.1994.2270; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TORIGOE T, 1992, LEUKEMIA, V6, pS94; TORIGOE T, 1992, BLOOD, V80, P617; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsubokawa M, 1997, EUR J BIOCHEM, V249, P792, DOI 10.1111/j.1432-1033.1997.t01-2-00792.x; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wollert KC, 1997, J MOL MED-JMM, V75, P492, DOI 10.1007/s001090050134; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	55	846	953	1	27	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1998	93	3					385	395		10.1016/S0092-8674(00)81167-8	http://dx.doi.org/10.1016/S0092-8674(00)81167-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590173	Bronze			2022-12-01	WOS:000073471500014
J	Pancioli, AM; Broderick, J; Kothari, R; Brott, T; Tuchfarber, A; Miller, R; Khoury, J; Jauch, E				Pancioli, AM; Broderick, J; Kothari, R; Brott, T; Tuchfarber, A; Miller, R; Khoury, J; Jauch, E			Public perception of stroke warning signs and knowledge of potential risk factors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; URGENT THERAPY; PREVENTION; MINUTES; TRIAL	Context.-Decreasing the time from stroke onset to hospital arrival and improving control of stroke risk factors depend on public knowledge of stroke warning signs and risk factors. Objective.-To assess current public knowledge of stroke warning signs and risk factors. Design.-A population-based telephone interview survey using random digit dialing conducted in 1995. Setting.-The Greater Cincinnati, Ohio, metropolitan area, the population of which is similar to that of the United States overall in age, sex, percentage of blacks, and economic status. Participants.-Respondents with age, race, and sex that matched the population of patients with acute stroke. Main Outcome Measures.-Knowledge of risk factors for stroke and warning signs of stroke as defined by the National Institute of Neurological Disorders and Stroke. Results.-Telephone calls were made to 17 634 households, which yielded 2642 demographically eligible individuals. Interviews were completed by 1880 respondents (response rate, 71.2%). A total of 1066 respondents (57%) correctly listed at least 1 of the 5 established stroke warning signs, and of all respondents, 1274 (68%) correctly listed at least 1 of the established stroke risk factors. Of the respondents, 469 (57%) of 818 respondents with a history of hypertension listed hypertension, 142 (35%) of 402 respondents who were current smokers listed smoking, and 32 (13%) of 255 respondents with diabetes listed diabetes as a risk factor for stroke. Compared with those younger than 75 years, respondents 75 years or older were less likely to correctly list at least 1 stroke warning sign (60% vs 47%, respectively; P<.001) and were less likely to list at least 1 stroke risk factor (72% vs 56%, respectively; P<.001). Conclusion.-Considerable education is needed to increase the public's awareness of the warning signs and risk factors for stroke. Respondents with self-reported risk factors for stroke are largely unaware of their increased risk The population at greatest risk for stroke, the very elderly, are the least knowledgeable about stroke warning signs and risk factors.	Univ Cincinnati, Coll Med, Dept Emergency Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Inst Policy Res, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Pancioli, AM (corresponding author), Univ Cincinnati, Coll Med, Dept Emergency Med, 231 Bethesda Ave,POB 670769, Cincinnati, OH 45267 USA.	Arthur.Pancioli@uc.edu	Khoury, Jane/O-2068-2015	Jauch, Edward/0000-0002-3533-4364	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030678] Funding Source: NIH RePORTER; NINDS NIH HHS [R0-1 NS30678-04] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARSAN WG, 1994, STROKE, V25, P2132, DOI 10.1161/01.STR.25.11.2132; BONNER LL, 1995, NEW ENGL J MED, V333, P1392; BRODERICK J, 1993, ANN EMERG MED, V22, P1438, DOI 10.1016/S0196-0644(05)81993-6; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; BRODERICK JP, 1992, NEW ENGL J MED, V326, P733, DOI 10.1056/NEJM199203123261103; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; Brott T, 1996, ARCH NEUROL-CHICAGO, V53, P1305, DOI 10.1001/archneur.1996.00550120117025; BROTT TG, 1992, STROKE, V23, P632, DOI 10.1161/01.STR.23.5.632; Brown RD, 1996, STROKE, V27, P373; Ezzati TM, 1992, VITAL HLTH STAT 2, V2, P1; Feinberg WM, 1996, CURR OPIN NEUROL, V9, P46, DOI 10.1097/00019052-199602000-00010; FREY JH, 1989, SURVEY RES TELEPHONE, P90; GORELICK PB, 1995, ARCH NEUROL-CHICAGO, V52, P347, DOI 10.1001/archneur.1995.00540280029015; HALEY EC, 1992, STROKE, V23, P641, DOI 10.1161/01.STR.23.5.641; HALEY EC, 1993, STROKE, V24, P1000, DOI 10.1161/01.STR.24.7.1000; Kothari R, 1997, STROKE, V28, P1871, DOI 10.1161/01.STR.28.10.1871; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MATCHAR DB, 1994, ANN INTERN MED, V121, P54; *NAT I NEUR DIS ST, 1997, BRAIN ATT STROK WARN; *NAT STROK ASS, 1994, BRAIN RISK UND PREV; National Stroke Association, 1996, AW KNOWL STROK PREV; *US BUR CENS, 1993, POP HOUS CHAR CENS T; Whisnant JP, 1997, STROKE, V28, P1840, DOI 10.1161/01.STR.28.9.1840; Williams LS, 1997, STROKE, V28, P912, DOI 10.1161/01.STR.28.5.912	24	368	382	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 29	1998	279	16					1288	1292		10.1001/jama.279.16.1288	http://dx.doi.org/10.1001/jama.279.16.1288			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH270	9565010	Bronze			2022-12-01	WOS:000073090300035
J	Nagy, L; Tontonoz, P; Alvarez, JGA; Chen, HW; Evans, RM				Nagy, L; Tontonoz, P; Alvarez, JGA; Chen, HW; Evans, RM			Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR gamma	CELL			English	Article							LOW-DENSITY-LIPOPROTEIN; MONOCYTE-DERIVED MACROPHAGES; NECROSIS-FACTOR-ALPHA; ADIPOCYTE DIFFERENTIATION; ATHEROSCLEROTIC LESIONS; CHOLESTEROL DEPOSITION; POTENTIAL ROLE; MESSENGER-RNA; RECEPTOR; INTERLEUKIN-1-BETA	Macrophage uptake of oxidized low-density lipoprotein (oxLDL) is thought to play a central role in foam cell formation and the pathogenesis of atherosclerosis. We demonstrate here that oxLDL activates PPAR gamma-dependent transcription through a novel signaling pathway involving scavenger receptor-mediated particle uptake. Moreover, we identify two of the major oxidized lipid components of oxLDL, 9-HODE and 13-HODE, as endogenous activators and ligands of PPAR gamma. Our data suggest that the biologic effects of oxLDL are coordinated by two sets of receptors, one on the cell surface, which binds and internalizes the particle, and one in the nucleus, which is transcriptionally activated by its component lipids. These results suggest that PPAR gamma may be a key regulator of foam cell gene expression.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	Salk Institute; Howard Hughes Medical Institute; University of California System; University of California San Diego	Evans, RM (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Nagy, Laszlo/A-3814-2008; Evans, Ronald/AAF-4001-2019	Nagy, Laszlo/0000-0001-6653-2155; Evans, Ronald/0000-0002-9986-5965				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUJA LM, 1983, ARTERIOSCLEROSIS, V3, P87, DOI 10.1161/01.ATV.3.1.87; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; FONG LG, 1991, J LIPID RES, V32, P1899; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GLAVIND J, 1952, ACTA PATHOL MIC SC, V30, P1; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAMILTON TA, 1990, J IMMUNOL, V144, P2343; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; HARLAND WA, 1971, ATHEROSCLEROSIS, V13, P239, DOI 10.1016/0021-9150(71)90026-8; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Huh HY, 1996, BLOOD, V87, P2020; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KU G, 1992, J BIOL CHEM, V267, P14183; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEHR HA, 1993, LAB INVEST, V68, P388; LENZ ML, 1990, J LIPID RES, V31, P1043; LIPTON BA, 1995, J LIPID RES, V36, P2232; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; Ohlsson BG, 1996, J CLIN INVEST, V98, P78, DOI 10.1172/JCI118780; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SIMON TC, 1989, ATHEROSCLEROSIS, V75, P31, DOI 10.1016/0021-9150(89)90204-9; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; THOMAS CE, 1991, J PHARMACOL EXP THER, V256, P1182; THOMAS CE, 1994, J LIPID RES, V35, P417; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	48	1505	1561	0	72	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1998	93	2					229	240		10.1016/S0092-8674(00)81574-3	http://dx.doi.org/10.1016/S0092-8674(00)81574-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568715	Bronze			2022-12-01	WOS:000073174000009
J	Uitterlinden, AG; Burger, H; Huang, WJ; Yue, F; McGuigan, FEA; Grant, SFA; Hofman, A; van Leeuwen, JPTM; Pols, HAP; Ralston, SH				Uitterlinden, AG; Burger, H; Huang, WJ; Yue, F; McGuigan, FEA; Grant, SFA; Hofman, A; van Leeuwen, JPTM; Pols, HAP; Ralston, SH			Relation of alleles of the collagen type I alpha 1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESTROGEN-RECEPTOR GENE; MINERAL DENSITY; OSTEOGENESIS IMPERFECTA; MASS; MUTATION; DETERMINANTS; ASSOCIATION; PREDICTION; ROTTERDAM; RICKETS	Background Osteoporosis is a common disorder with a strong genetic component. One way in which the genetic component could be expressed is through polymorphism of COLIA1, the gene for collagen type l alpha 1, a bone-matrix protein, Methods We determined the COLIA1 genotypes SS, Ss,and ss in a population-based sample of 1778 postmenopausal women using a polymerase-chain-reaction-based assay. We then related the genotypes to bone mineral density and the occurrence of osteoporotic fractures in these women. Results As compared with the 1194 women with the SS genotype, the 526 women with the Ss genotype had 2 percent lower bone mineral density at the femoral neck (P = 0.003) and the lumbar spine (P = 0.02); the 58 women with the ss genotype had reductions of 4 percent at the femoral neck (P = 0.05) and 6 percent at the lumbar spine (P = 0.005). These differences increased with age (P = 0.01 for modification by age of the effect of COLIA1 on femoral-neck bone density, and P = 0.004 for modification of the effect on lumbar-spine bone density). Women with the Ss and ss genotypes were overrepresented among the 111 women who had incident nonvertebral fractures (relative risk per copy of the s allele, 1.5; 95 percent confidence interval, 1.1 to 2.1). Conclusions The COLIA1 polymorphism is associated with reduced bone density and predisposes women to osteoporotic fractures. (C) 1998, Massachusetts Medical Society.	Erasmus Univ, Sch Med, Dept Internal Med 3, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Univ Aberdeen, Dept Med & Therapeut, Aberdeen, Scotland	Erasmus University Rotterdam; Erasmus University Rotterdam; University of Aberdeen	Uitterlinden, AG (corresponding author), Erasmus Univ, Sch Med, Dept Internal Med 3, FGG-EUR,POB 1738, NL-3000 DR Rotterdam, Netherlands.		van Leeuwen, Johannes/D-5015-2014	van Leeuwen, Johannes/0000-0002-2282-4006; Grant, Struan/0000-0003-2025-5302	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BURGER H, 1994, BONE MINER, V25, P1, DOI 10.1016/S0169-6009(08)80203-6; Burger H, 1997, J BONE MINER RES, V12, P152, DOI 10.1359/jbmr.1997.12.1.152; BYERS PH, 1992, ANNU REV MED, V43, P269, DOI 10.1146/annurev.me.43.020192.001413; Cooper GS, 1996, J BONE MINER RES, V11, P1841; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; EVANS RA, 1988, ANN INTERN MED, V109, P870, DOI 10.7326/0003-4819-109-11-870; Gong YQ, 1996, AM J HUM GENET, V59, P146; Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096-203; GRANT SFA, 1996, THESIS U ABERDEEN AB; GUEGUEN R, 1995, J BONE MINER RES, V10, P2017; Han KO, 1997, J CLIN ENDOCR METAB, V82, P991, DOI 10.1210/jc.82.4.991; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; Johnson ML, 1997, AM J HUM GENET, V60, P1326, DOI 10.1086/515470; JOUANNY P, 1995, ARTHRITIS RHEUM, V38, P61, DOI 10.1002/art.1780380110; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KELLY PJ, 1993, J BONE MINER RES, V8, P11; Kobayashi S, 1996, J BONE MINER RES, V11, P306; KRALL EA, 1993, J BONE MINER RES, V8, P1; Langdahl BL, 1997, BONE, V20, P289, DOI 10.1016/S8756-3282(96)00363-8; MALLOY PJ, 1994, J CLIN ENDOCR METAB, V78, P313, DOI 10.1210/jc.78.2.313; MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; Murray RE, 1997, BONE, V21, P89, DOI 10.1016/S8756-3282(97)00081-1; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; Seeman E, 1996, AM J PHYSIOL-ENDOC M, V270, pE320, DOI 10.1152/ajpendo.1996.270.2.E320; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; SOROKO SB, 1994, J BONE MINER RES, V9, P761; SPOTILA LD, 1994, J BONE MINER RES, V9, P923; WILLING MC, 1994, AM J HUM GENET, V55, P638	33	352	387	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1016	1021		10.1056/NEJM199804093381502	http://dx.doi.org/10.1056/NEJM199804093381502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG134	9535665	Green Published			2022-12-01	WOS:000072969500002
J	Wang, F; Nemes, A; Mendelsohn, M; Axel, R				Wang, F; Nemes, A; Mendelsohn, M; Axel, R			Odorant receptors govern the formation of a precise topographic map	CELL			English	Article							OCULAR DOMINANCE COLUMNS; RABBIT OLFACTORY-BULB; MITRAL TUFTED CELLS; IMPULSE ACTIVITY; GENE-EXPRESSION; MESSENGER-RNA; IN-VITRO; ORGANIZATION; EPITHELIUM; RAT	Olfactory neurons expressing a given odorant receptor project with precision to 2 of the 1800 glomeruli within the olfactory bulb to create a topographic map of odor quality. We demonstrate that deletions or nonsense mutations in the P2 odorant receptor gene cause the axons of these cells to wander rather than converge on a specific glomerulus. Receptor substitution experiments that replace the P2 gene with the coding region of the P3 gene result in the projection of P3-->P2 axons to a glomerulus touching the wildtype P3 glomerulus. These data, along with additional receptor substitutions, indicate that the odorant receptor plays an instructive role in the establishment of the topographic map.	Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute	Axel, R (corresponding author), Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA.			Axel, Richard/0000-0002-3141-4076	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER; NIMH NIH HHS [5 P50 MH50733] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Drescher U, 1997, CURR OPIN NEUROBIOL, V7, P75, DOI 10.1016/S0959-4388(97)80123-7; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Friedrich RW, 1997, NEURON, V18, P737, DOI 10.1016/S0896-6273(00)80314-1; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HARRIS WA, 1986, NATURE, V320, P266, DOI 10.1038/320266a0; HARRIS WA, 1989, NATURE, V339, P218, DOI 10.1038/339218a0; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; IMAMURA K, 1992, J NEUROPHYSIOL, V68, P1986, DOI 10.1152/jn.1992.68.6.1986; Joerges J, 1997, NATURE, V387, P285, DOI 10.1038/387285a0; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P658, DOI 10.1073/pnas.87.2.658; KATOH K, 1993, J NEUROPHYSIOL, V70, P2161, DOI 10.1152/jn.1993.70.5.2161; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KAUER JS, 1987, BRAIN RES, V418, P255, DOI 10.1016/0006-8993(87)90093-X; KING AJ, 1991, TRENDS NEUROSCI, V14, P31, DOI 10.1016/0166-2236(91)90181-S; LANCET D, 1982, P NATL ACAD SCI-BIOL, V79, P670, DOI 10.1073/pnas.79.2.670; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; NGAI J, 1993, CELL, V72, P667, DOI 10.1016/0092-8674(93)90396-8; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SAUER B, 1990, New Biologist, V2, P441; SCHOENFELD TA, 1994, BRAIN RES BULL, V34, P183, DOI 10.1016/0361-9230(94)90059-0; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STEWART CL, 1993, METHOD ENZYMOL, V225, P823; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STROTMANN J, 1994, CELL TISSUE RES, V278, P11, DOI 10.1007/s004410050189; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; STRYKER MP, 1986, J NEUROSCI, V6, P2117; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; vanHoof A, 1996, PLANT J, V10, P415, DOI 10.1046/j.1365-313x.1996.10030415.x; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Woolsey T.A., 1990, P461; Yoshihara Y, 1997, J NEUROSCI, V17, P5830	51	484	494	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					47	60		10.1016/S0092-8674(00)81145-9	http://dx.doi.org/10.1016/S0092-8674(00)81145-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546391	hybrid			2022-12-01	WOS:000072910800009
J	Weiner, JH; Bilous, PT; Shaw, GM; Lubitz, SP; Frost, L; Thomas, GH; Cole, JA; Turner, RJ				Weiner, JH; Bilous, PT; Shaw, GM; Lubitz, SP; Frost, L; Thomas, GH; Cole, JA; Turner, RJ			A novel and ubiquitous system for membrane targeting and secretion of cofactor-containing proteins	CELL			English	Article							DIMETHYL-SULFOXIDE REDUCTASE; ENGINEERED 3FE-4S CLUSTER; COLI FUMARATE REDUCTASE; GROWN ESCHERICHIA-COLI; DIMETHYLSULFOXIDE REDUCTASE; NITRITE REDUCTION; DMSO REDUCTASE; IDENTIFICATION; MOLYBDOENZYME; PURIFICATION	We report the identification of the proteins encoded by the mttABC operon (formerly yigTUW), which mediate a novel Sec-independent membrane targeting and translocation system in Escherichia coli that interacts with cofactor-containing redox proteins having a S/TRRXFLK "twin arginine" leader motif. A pleiotropic-negative mutant in mttA prevents the periplasmic localization of twin arginine redox enzymes, including nitrate reductase (NapA) and trimethylamine N-oxide reductase (TorA). The mutation also prevents the correct localization of the integral membrane molybdoenzyme dimethylsulfoxide reductase (DmsABC). The DmsA subunit has a twin arginine leader. Proteins with a Sec-dependent leader or which assemble spontaneously in the membrane are not affected by this mutation. MttA, B, and C are members of a large family of related sequences extending from archaebacteria to higher eukaryotes.	Univ Alberta, Dept Biochem, MRC, Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Sci Biol, Edmonton, AB T6G 2E1, Canada; Univ Birmingham, Sch Biochem, Birmingham B15 2TT, W Midlands, England	University of Alberta; University of Alberta; University of Birmingham	Weiner, JH (corresponding author), Univ Alberta, Dept Biochem, MRC, Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada.		Thomas, Gavin H/E-5753-2011; Turner, Raymond J./M-3961-2015; Frost, Laura/A-2639-2014	Thomas, Gavin H/0000-0002-9763-1313; Turner, Raymond J./0000-0002-9263-0776; Frost, Laura/0000-0002-8433-8230				Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; BERLYN MKB, 1996, ESCHERICHIA COLI SAL, P1715; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; BILOUS PT, 1985, J BACTERIOL, V162, P1151, DOI 10.1128/JB.162.3.1151-1155.1985; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; Cole J, 1996, FEMS MICROBIOL LETT, V136, P1; DARWIN A, 1993, MOL MICROBIOL, V9, P1255, DOI 10.1111/j.1365-2958.1993.tb01255.x; DARWIN A, 1993, J GEN MICROBIOL, V139, P1829, DOI 10.1099/00221287-139-8-1829; DICKIE P, 1979, CAN J BIOCHEM CELL B, V57, P813, DOI 10.1139/o79-101; DOUNG F, 1997, CELL, V91, P567; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FROST L, 1989, MOL GEN GENET, V218, P152, DOI 10.1007/BF00330578; Grove J, 1996, MOL MICROBIOL, V19, P467, DOI 10.1046/j.1365-2958.1996.383914.x; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; LATOUR DJ, 1987, J GEN MICROBIOL, V133, P597; LEMIRE BD, 1986, METHOD ENZYMOL, V126, P377; LEMIRE BD, 1983, J BACTERIOL, V155, P391, DOI 10.1128/JB.155.1.391-397.1983; LEMIRE BD, 1982, J BACTERIOL, V152, P1126; MCEWAN AG, 1994, ANTON LEEUW INT J G, V66, P151, DOI 10.1007/BF00871637; MCEWAN AG, 1984, ARCH MICROBIOL, V137, P344, DOI 10.1007/BF00410732; MCEWAN AG, 1991, BIOCHEM J, V274, P305, DOI 10.1042/bj2740305; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NEWMAN BM, 1978, J GEN MICROBIOL, V106, P1; ROTHERY RA, 1995, J BACTERIOL, V177, P2057, DOI 10.1128/jb.177.8.2057-2063.1995; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; ROTHERY RA, 1993, BIOCHEMISTRY-US, V32, P5855, DOI 10.1021/bi00073a019; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; SAMBASIVARAO D, 1990, J BACTERIOL, V172, P5938, DOI 10.1128/jb.172.10.5938-5948.1990; Sambrook J., 1989, MOL CLONING LAB MANU; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; SimalaGrant JL, 1996, MICROBIOL-SGM, V142, P3231, DOI 10.1099/13500872-142-11-3231; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; Turner RJ, 1997, PROTEIN ENG, V10, P285, DOI 10.1093/protein/10.3.285; WEINER JH, 1992, BIOCHIM BIOPHYS ACTA, V1102, P1, DOI 10.1016/0167-4838(92)90493-W; WEINER JH, 1971, J BIOL CHEM, V246, P6933; WEINER JH, 1993, J BIOL CHEM, V268, P3238	41	399	422	0	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					93	101		10.1016/S0092-8674(00)81149-6	http://dx.doi.org/10.1016/S0092-8674(00)81149-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546395	Bronze			2022-12-01	WOS:000072910800013
J	Craig, AWB; Haghighat, A; Yu, ATK; Sonenberg, N				Craig, AWB; Haghighat, A; Yu, ATK; Sonenberg, N			Interaction of polyadenylate-binding protein with the eIF4G homologue PAIP enhances translation	NATURE			English	Article							POLY(A)-BINDING PROTEIN; INITIATION; RNA; MOTIF	In the initiation of translation in eukaryotes, binding of the small ribosomal subunit to the messenger RNA results from recognition of the 5' cap structure (m(7)GpppX) of the mRNA by the cap-binding complex eIF4F(1). eIF4F is itself a three-subunit complex comprising the cap-binding protein eIF4E(2), eIF4A, an ATP-dependent RNA helicase(3), and eIF4G, which interacts with both eIF4A and eIF4E and enhances cap binding by eIF4E(4). The mRNA 3' polyadenylate tail and the associated poly(A)-binding protein (PABP) also regulate translational initiation(5), probably by interacting with the 5' end of the mRNA(6,7). In yeast(8,9) and plants(10), PABP interacts with eIF4G(8,9) but no such interaction has been reported in mammalian cells. Here, we describe a new human PABP-interacting protein, PAIP-1, whose sequence is similar to the central portion of eIF4G and which interacts with eIE4A. Overexpression of PAIP-1 in COS-7 cells stimulates translation, perhaps by providing a physical link between the mRNA termini.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Sonenberg, N (corresponding author), McGill Univ, Dept Biochem, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.		Craig, Andrew/AAC-6923-2019; Craig, Andrew/G-2312-2017	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393				ASSELBERGS FAM, 1978, EUR J BIOCHEM, V88, P483, DOI 10.1111/j.1432-1033.1978.tb12473.x; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; DONZE O, 1995, NUCLEIC ACIDS RES, V23, P861, DOI 10.1093/nar/23.5.861; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; MADER S, 1995, MOL CELL BIOL, V15, P4990; Merrick WC., 1996, TRANSLATION CONTROL, P31; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Sachs AB, 1997, TRENDS BIOCHEM SCI, V22, P189, DOI 10.1016/S0968-0004(97)01051-7; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SONENBERG N, 1979, P NATL ACAD SCI USA, V76, P4345, DOI 10.1073/pnas.76.9.4345; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; YAN RQ, 1992, J BIOL CHEM, V267, P23226; YANG HD, 1995, MOL CELL BIOL, V15, P6770	29	309	323	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					520	523		10.1038/33198	http://dx.doi.org/10.1038/33198			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548260				2022-12-01	WOS:000072875200065
J	Steinberg-Yfrach, G; Rigaud, JL; Durantini, EN; Moore, AL; Gust, D; Moore, TA				Steinberg-Yfrach, G; Rigaud, JL; Durantini, EN; Moore, AL; Gust, D; Moore, TA			Light-driven production of ATP catalysed by F0F1-ATP synthase in an artificial photosynthetic membrane	NATURE			English	Article							RECONSTITUTION PROCEDURE; LIPOSOMES; BACTERIORHODOPSIN; CHLOROPLASTS; CF0F1; SITE; ENERGY	Energy-transducing membranes of living organisms couple spontaneous to non-spontaneous processes through the intermediacy of protonmotive force (p.m.f.)-an imbalance in electrochemical potential of protons across the membrane, In most organisms, p.m.f. is generated by redox reactions that are either photochemically driven, such as those in photosynthetic reaction centres, or intrinsically spontaneous, such as those of oxidative phosphorylation in mitochondria. Transmembrane proteins (such as the cytochromes and complexes I, III and IV in the electron-transport chain in the inner mitochondrial membrane) couple the redox reactions to proton translocation, thereby conserving a fraction of the redox chemical potential as p.m.f. Many transducer proteins couple p.m.f. to the performance of biochemical work, such as biochemical synthesis and mechanical and transport processes, Recently, an artificial photosynthetic membrane was reported in which a photocyclic process was used to transport protons across a liposomal membrane, resulting in acidification of the Liposome's internal volume(1), If significant p.m.f. is generated in this system, then incorporating an appropriate transducer into the liposomal bilayer should make it possible to drive a non-spontaneous chemical process, Here we report the incorporation of F0F1-ATP synthase into liposomes containing the components of the proton-pumping photocycle, Irradiation of this artificial membrane,vith visible Light results in the uncoupler-and inhibitor-sensitive synthesis of adenosine triphosphate (ATP) against an ATP chemical potential of similar to 12 kcal mol(-1), with a quantum yield of more than 7%, This system mimics the process by which photosynthetic bacteria convert light energy into ATP chemical potential.	Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Study Early Events Photosynthesis, Tempe, AZ 85287 USA; Inst Curie, CNRS, UMR 168, Sect Rech, F-75231 Paris, France; CEA, LCR, F-75231 Paris 05, France	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Universite Paris Cite; CEA	Moore, TA (corresponding author), Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA.			Durantini, Edgardo N./0000-0001-8901-7543				Cladera J, 1996, J BIOENERG BIOMEMBR, V28, P503, DOI 10.1007/BF02110440; FROMME P, 1990, BIOCHIM BIOPHYS ACTA, V1016, P29, DOI 10.1016/0005-2728(90)90003-M; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GUST D, 1993, ACCOUNTS CHEM RES, V26, P198, DOI 10.1021/ar00028a010; HANGARTER RP, 1982, BIOCHIM BIOPHYS ACTA, V681, P397, DOI 10.1016/0005-2728(82)90181-5; PETITOU M, 1978, ANAL BIOCHEM, V91, P350, DOI 10.1016/0003-2697(78)90849-7; Pitard B, 1996, EUR J BIOCHEM, V235, P779, DOI 10.1111/j.1432-1033.1996.t01-1-00779.x; RICHARD P, 1990, EUR J BIOCHEM, V193, P921, DOI 10.1111/j.1432-1033.1990.tb19418.x; RICHARD P, 1992, EUR J BIOCHEM, V210, P287, DOI 10.1111/j.1432-1033.1992.tb17419.x; RICHARD P, 1995, J BIOL CHEM, V270, P21571, DOI 10.1074/jbc.270.37.21571; SCHMIDT G, 1985, BIOCHIM BIOPHYS ACTA, V808, P46, DOI 10.1016/0005-2728(85)90026-X; SIGALAT C, 1995, FEBS LETT, V368, P253, DOI 10.1016/0014-5793(95)00664-U; SteinbergYfrach G, 1997, NATURE, V385, P239, DOI 10.1038/385239a0	13	391	394	5	168	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					479	482		10.1038/33116	http://dx.doi.org/10.1038/33116			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548252				2022-12-01	WOS:000072875200053
J	Jochimsen, EM; Carmichael, WW; An, JS; Cardo, DM; Cookson, ST; Holmes, CEM; Antunes, MBD; de Melo, DA; Lyra, TM; Barreto, VST; Azevedo, SMFO; Jarvis, WR				Jochimsen, EM; Carmichael, WW; An, JS; Cardo, DM; Cookson, ST; Holmes, CEM; Antunes, MBD; de Melo, DA; Lyra, TM; Barreto, VST; Azevedo, SMFO; Jarvis, WR			Liver failure and death after exposure to microcystins at a hemodialysis center in Brazil	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIALYSIS CENTER; HEMOLYSIS; ANEMIA	Background Hemodialysis is a common but potentially hazardous procedure. From February 17 to 20, 1996, 116 of 130 patients (89 percent) at a dialysis center (dialysis center A) in Caruaru, Brazil, had visual disturbances, nausea, and vomiting associated with hemodialysis. By March 24, 26 of the patients had died of acute liver failure. Methods A case patient was defined as any patient undergoing dialysis at dialysis center A or Caruaru's other dialysis center (dialysis center B) during February 1996 who had acute liver failure. To determine the risk factors for and the source of the outbreak, we conducted a cohort study of the 130 patients at dialysis center A and the 47 patients at dialysis center B, reviewed the centers' water supplies, and collected water, patients' serum, and postmortem liver tissue for microcystin assays. Results One hundred one patients (all at dialysis center A) met the case definition, and 50 died. Affected patients who died were older than those who survived (median age, 47 vs. 35 years; P<0.001). Furthermore, all 17 patients undergoing dialysis on the Tuesday-, Thursday-, and Saturday-night schedule became ill, and 13 of them (76 percent) died. Both centers received water from a nearby reservoir. However, the water supplied to dialysis center B was treated, filtered, and chlorinated, whereas the water supplied to dialysis center A was not. Microcystins produced by cyanobacteria were detected in water from the reservoir and from dialysis center A and in serum and liver tissue of case patients. Conclusions Water used for hemodialysis can contain toxic materials, and its quality should therefore be carefully monitored. (C) 1998, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Hosp Infect Program, Atlanta, GA 30333 USA; Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA; Secretaria Saude Pernambuco, Recife, PE, Brazil; Hosp Barao Lucena, Recife, PE, Brazil; Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil	Centers for Disease Control & Prevention - USA; University System of Ohio; Wright State University Dayton; Universidade Federal do Rio de Janeiro	Jochimsen, EM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Hosp Infect Program, Mailstop E-69,1600 Clifton Rd, Atlanta, GA 30333 USA.		de oliveira e azevedo, sandra maria feliciano/G-8362-2015	de oliveira e azevedo, sandra maria feliciano/0000-0002-3046-0652				ALFREY AC, 1972, T AM SOC ART INT ORG, V18, P257; AN JS, 1994, TOXICON, V32, P1495, DOI 10.1016/0041-0101(94)90308-5; ARNOW PM, 1994, ANN INTERN MED, V121, P339, DOI 10.7326/0003-4819-121-5-199409010-00005; *ASS ADV MED INSTR, 1996, AAMI STAND REC PRACT, V3; AZEVEDO SMFO, 1994, J APPL PHYCOL, V6, P261, DOI 10.1007/BF02181936; BURWEN DR, 1995, KIDNEY INT, V48, P469, DOI 10.1038/ki.1995.315; CARMICHAEL WW, 1992, J APPL BACTERIOL, V72, P445, DOI 10.1111/j.1365-2672.1992.tb01858.x; Carmichael WW, 1997, ADV BOT RES, V27, P211; Dean A.G., 1994, EPI INFO VERSION 6 W; EATON JW, 1973, SCIENCE, V181, P463, DOI 10.1126/science.181.4098.463; *FOOD DRUG ADM, 1989, FDA SAF AL SOD AZ CO; FREEMAN RM, 1967, NEW ENGL J MED, V276, P1113, DOI 10.1056/NEJM196705182762003; GORDON SM, 1990, AM J NEPHROL, V10, P123, DOI 10.1159/000168066; GORDON SM, 1990, KIDNEY INT, V37, P110, DOI 10.1038/ki.1990.15; HOY RH, 1981, AM J HOSP PHARM, V38, P1512, DOI 10.1093/ajhp/38.10.1512; LEVIN NW, 1990, CLIN DIALYSIS, P172; MANZLER AD, 1970, ANN INTERN MED, V73, P409, DOI 10.7326/0003-4819-73-3-409; NICKEY WA, 1970, J AMER MED ASSOC, V214, P915, DOI 10.1001/jama.1970.03180050069020; ORRINGER EP, 1976, NEW ENGL J MED, V294, P1416, DOI 10.1056/NEJM197606242942602; PETRIE JJB, 1977, LANCET, V1, P1178; Rao PVL, 1996, TOXICOLOGY, V114, P29, DOI 10.1016/S0300-483X(96)03413-0; SCHREEDER MT, 1983, J CHRON DIS, V36, P581, DOI 10.1016/0021-9681(83)90146-7; Stotts RR, 1997, TOXICON, V35, P455, DOI 10.1016/S0041-0101(96)00120-1; Teixeira M da G, 1993, Bull Pan Am Health Organ, V27, P244; Tipple M A, 1991, ASAIO Trans, V37, P588; VELANDIA M, 1995, LANCET, V345, P1417, DOI 10.1016/S0140-6736(95)92603-8	26	832	889	1	177	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1998	338	13					873	878		10.1056/NEJM199803263381304	http://dx.doi.org/10.1056/NEJM199803263381304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD284	9516222				2022-12-01	WOS:000072669800004
J	Hartman, G; Wise, R				Hartman, G; Wise, R			Quorum sensing: potential means of treating gram-negative infections?	LANCET			English	Editorial Material							PSEUDOMONAS-AERUGINOSA; VIBRIO-FISCHERI; BACTERIA		City Hosp NHS Trust, Dept Med Microbiol, Birmingham B18 7QH, W Midlands, England		Hartman, G (corresponding author), City Hosp NHS Trust, Dept Med Microbiol, Birmingham B18 7QH, W Midlands, England.							FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; Givskov M, 1996, J BACTERIOL, V178, P6618, DOI 10.1128/jb.178.22.6618-6622.1996; KAPLAN HB, 1985, J BACTERIOL, V163, P1210, DOI 10.1128/JB.163.3.1210-1214.1985; MCKENNEY D, 1995, J BACTERIOL, V177, P6989, DOI 10.1128/jb.177.23.6989-6992.1995; SITNIKOV DM, 1995, MOL MICROBIOL, V17, P801, DOI 10.1111/j.1365-2958.1995.mmi_17050801.x; SWIFT S, 1993, MOL MICROBIOL, V10, P511, DOI 10.1111/j.1365-2958.1993.tb00923.x; Tang HB, 1996, INFECT IMMUN, V64, P37, DOI 10.1128/IAI.64.1.37-43.1996; WINSON MK, 1995, P NATL ACAD SCI USA, V92, P9427, DOI 10.1073/pnas.92.20.9427	8	33	39	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					848	849		10.1016/S0140-6736(05)70282-8	http://dx.doi.org/10.1016/S0140-6736(05)70282-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525356				2022-12-01	WOS:000072645500004
J	Tudor-Smith, C; Nutbeam, D; Moore, L; Catford, J				Tudor-Smith, C; Nutbeam, D; Moore, L; Catford, J			Effects of the Heartbeat Wales programme over five years on behavioural risks for cardiovascular disease: quasi-experimental comparison of result from Wales and a matched reference area	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-PROGRAM; INTERVENTION; EDUCATION; SMOKING	Objective: To assess the net 5 year effects of intervention of a community based demonstration project, the Heartbeat Wales programme, on modifiable behavioural risks for prevention of cardiovascular disease. Design and setting: Quasi-experimental design comparing results from two independent cross sectional population surveys conducted in 1985 and 1990 in Wales and a matched reference area in north east England. Subjects: Random, stratified samples of people aged 18-64 years (18 538 in 1985 and 13 045 in 1990) in Wales and in north east England (1483 and 4534, respectively). Intervention: A coordinated range of activities for heart health promotion in Wales entailing public education campaigns along with supportive policy and infrastructure change. In the reference area no additional community heart health promotion was planned, though considerable activity did take place, "contaminating" the reference area. Main outcome measures: Fifteen self reported behavioural indicators relating to dietary choice, smoking, frequency of exercise, and weight. Results: Positive changes (for health) in behavioural outcomes were observed among the population in Wales, including a reduction in reported smoking prevalence and improvements in dietary choice. There was no net intervention effect for the programme over and above observed change in the reference area. Conclusions: No definite conclusions can be drawn concerning the efficacy of the programme in terms of behavioural outcomes. With hindsight, the difficulties of evaluating such a complex multifaceted intervention were underestimated. Further debate on the most appropriate methods for assessing the effectiveness of community based health promotion programmes is called for.	Hlth Promot Wales, Cardiff CF4 5DZ, S Glam, Wales; Univ Sydney, Dept Publ Hlth & Community Med, Sydney, NSW 2006, Australia; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Deakin Univ, Burwood, Vic 3125, Australia	University of Sydney; University of Bristol; Deakin University	Tudor-Smith, C (corresponding author), Hlth Promot Wales, Cardiff CF4 5DZ, S Glam, Wales.		Nutbeam, Don/AAU-1571-2021	Moore, Laurence/0000-0003-2182-823X; Nutbeam, Don/0000-0001-6497-2827				BENNETT N, 1996, LIVING BRITAIN RESUL; Black N, 1996, BRIT MED J, V312, P1215; BOAZ A, 1995, CORONARY HEART DIS S; CARLETON RA, 1995, AM J PUBLIC HEALTH, V85, P777, DOI 10.2105/AJPH.85.6.777; CATFORD J, 1992, COMMUNITY PREVENTION, P164; CHAPMAN S, 1993, BRIT MED J, V307, P429, DOI 10.1136/bmj.307.6901.429; CLARKSON J, 1991, J NUTR HLTH, V7, P101; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; GREEN LW, 1993, PROMOTION ED, P11; LUEPKER RV, 1994, AM J PUBLIC HEALTH, V84, P1383, DOI 10.2105/AJPH.84.9.1383; *MIN AGR FISH FOOD, 1970, HOUS FOOD CONS EXP; MURPHY S, 1994, J NUTR HLTH, V9, P317; NUTBEAM D, 1990, PUBLIC HEALTH, V104, P353, DOI 10.1016/S0033-3506(05)80528-1; NUTBEAM D, 1993, J EPIDEMIOL COMMUN H, V47, P127, DOI 10.1136/jech.47.2.127; Nutbeam D., 1996, HEALTH PROMOT J AUST, V6, P58; PHILLIPS CJ, 1993, J EPIDEMIOL COMMUN H, V47, P215, DOI 10.1136/jech.47.3.215; PULLEN E, 1992, J EPIDEMIOL COMMUN H, V46, P455, DOI 10.1136/jech.46.4.455; PUSKA P, 1995, N KARELIA PROJECT 20; ROBERTS RJ, 1995, PUBLIC HEALTH, V109, P275, DOI 10.1016/S0033-3506(95)80205-3; ROSE G, 1984, CORONARY HEART DIS P; Shah BV, 1997, SOFTWARE STAT ANAL C; SMITH C, 1990, Health Education Research, V5, P381, DOI 10.1093/her/5.3.381; Smith C, 1994, Health Trends, V26, P18; Speller V, 1997, BRIT MED J, V315, P361; SUSSER M, 1995, AM J PUBLIC HEALTH, V85, P156, DOI 10.2105/AJPH.85.2.156; *WHO EXP COMM, 1982, WHO TECH REP SER, V678; WINKLEBY MA, 1994, AM J PUBLIC HEALTH, V84, P1369, DOI 10.2105/AJPH.84.9.1369; [No title captured]; [No title captured]	29	78	79	2	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					818	822		10.1136/bmj.316.7134.818	http://dx.doi.org/10.1136/bmj.316.7134.818			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZC488	9549451	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000072584300026
J	Perl, AK; Wilgenbus, P; Dahl, U; Semb, H; Christofori, G				Perl, AK; Wilgenbus, P; Dahl, U; Semb, H; Christofori, G			A causal role for E-cadherin in the transition from adenoma to carcinoma	NATURE			English	Article							TRANSCRIPTION FACTOR LEF-1; BETA-CATENIN; PANCREATIC-ISLETS; GROWTH-FACTOR; EXPRESSION; TUMORIGENESIS; CELLS; PROGRESSION; GENE	Development of malignant tumours is in part characterized by the ability of a tumour cell to overcome cell-cell adhesion and to invade surrounding tissue. E-cadherin is the main adhesion molecule of epithelia(1-3), and it has been implicated in carcinogenesis because it is frequently lost in human epithelial cancers(4-6). Re-establishing the functional cadherin complex in tumour cell lines results in a reversion from an invasive to a benign epithelial phenotype(7), However, it remained unresolved whether the loss of E-cadherin-mediated cell adhesion was a cause or a consequence of tumour progression in vivo, Here we report that the loss of E-cadherin expression coincides with the transition from well differentiated adenoma to invasive carcinoma in a transgenic mouse model of pancreatic beta-cell carcinogenesis (Rip1Tag2)(8). Intercrossing Rip1Tag2 mice with transgenic mice that maintain E-cadherin expression in beta-tumour cells results in arrest of tumour development at the adenoma stage, whereas expression of a dominant-negative form of E-cadherin induces early invasion and metastasis. The results demonstrate that loss of E-cadherin-mediated cell adhesion is one rate-limiting step in the progression from adenoma to carcinoma.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Umea Univ, Dept Microbiol, S-90187 Umea, Sweden	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Umea University	Christofori, G (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Perl, Anne-Karina T/M-7174-2013	Perl, Anne-Karina T/0000-0002-8445-4565; Semb, Henrik/0000-0002-6747-787X				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BIRCHMEIER W, 1993, SEMIN CANCER BIOL, V4, P231; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; Dahl U, 1996, DEVELOPMENT, V122, P2895; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GRAFF JR, 1995, CANCER RES, V55, P5195; GUMBINER BM, 1997, CURR BIOL, V7, P443; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; Hogan B., 1986, MANIPULATING MOUSE E; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; HUTTON JC, 1993, MOL ENDOCRINOL, V7, P1151, DOI 10.1210/me.7.9.1151; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; RBINFELD B, 1997, SCIENCE, V275, P1790; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	28	1156	1208	1	67	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					190	193		10.1038/32433	http://dx.doi.org/10.1038/32433			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515965				2022-12-01	WOS:000072462700065
J	Lantz, CS; Boesiger, J; Song, CH; Mach, N; Kobayashi, T; Mulligan, RC; Nawa, Y; Dranoff, G; Galli, SJ				Lantz, CS; Boesiger, J; Song, CH; Mach, N; Kobayashi, T; Mulligan, RC; Nawa, Y; Dranoff, G; Galli, SJ			Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites	NATURE			English	Article							C-KIT LIGAND; STRONGYLOIDES-VENEZUELENSIS; MICE; IL-3; INFECTION; INVIVO; DIFFERENTIATION; HEMATOPOIESIS; PROLIFERATION; ANTIBODIES	The cytokine interleukin-3 (IL-3), which can be derived from T cells and other sources, is a potentially important link between the immune and haematopoietic systems(1). IL-3 may be particularly critical for the development, survival and function of tissue mast cells(1-6) and blood basophils(7,8), which are thought to be important effector cells in immunity to parasites and other immunological responses, such as allergic reactions(9). Here we show using IL-3-deficient mice(10), that IL-3 is not essential for the generation of mast cells or basophils under physiological conditions, but that it does contribute to increased numbers of tissue mast cells, enhanced basophil production, and immunity in mice infected with the nematode Stronglyoides venezuelensis, Parasite expulsion and mast-cell development are impaired even more severely in IL-3-deficient mice that also show a marked reduction in signalling by c-kit, These findings establish a role for IL-3 in immunity to parasites and indicate that one of the functions of IL-3 in host defence against infection is to expand populations of haematopoietic effector cells.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02215 USA; Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Miyazaki Med Coll, Dept Parasitol, Miyazaki 88916, Japan; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of Miyazaki; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Galli, SJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.	sgalli@bidmc.harvard.edu	Nawa, Yukifumi/I-1147-2019					Donaldson LE, 1996, INT IMMUNOL, V8, P559, DOI 10.1093/intimm/8.4.559; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; GALLI SJ, 1987, AM J PATHOL, V127, P191; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; ICHIHARA M, 1995, EMBO J, V14, P939, DOI 10.1002/j.1460-2075.1995.tb07075.x; IHLE JN, 1983, J IMMUNOL, V131, P282; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; JACOBY W, 1984, J INVEST DERMATOL, V83, P302, DOI 10.1111/1523-1747.ep12340431; Khalil RMA, 1996, INFECT IMMUN, V64, P4960, DOI 10.1128/IAI.64.12.4960-4966.1996; KHAN AI, 1993, INT J PARASITOL, V23, P551, DOI 10.1016/0020-7519(93)90159-V; KITAMURA Y, 1978, BLOOD, V52, P447; Lantz CS, 1997, J IMMUNOL, V158, P2517; MACH N, IN PRESS BLOOD; MADDEN KB, 1991, J IMMUNOL, V147, P1387; MAEDA H, 1992, DEVELOPMENT, V116, P369; MAYER P, 1989, BLOOD, V74, P613; NAWA Y, 1994, PARASITE IMMUNOL, V16, P333, DOI 10.1111/j.1365-3024.1994.tb00358.x; Nishinakamura R, 1996, BLOOD, V88, P2458, DOI 10.1182/blood.V88.7.2458.bloodjournal8872458; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; ODY C, 1990, J EXP MED, V172, P403, DOI 10.1084/jem.172.1.403; PAUL WE, 1993, ADV IMMUNOL, V53, P1, DOI 10.1016/S0065-2776(08)60496-4; PUDDINGTON L, 1994, IMMUNITY, V1, P733, DOI 10.1016/S1074-7613(94)80015-4; Rodewald HR, 1996, SCIENCE, V271, P818, DOI 10.1126/science.271.5250.818; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SATO Y, 1990, INT J PARASITOL, V20, P63, DOI 10.1016/0020-7519(90)90174-L; SVETIC A, 1993, J IMMUNOL, V150, P3434; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; TSAI M, 1991, J EXP MED, V174, P125, DOI 10.1084/jem.174.1.125; TSUJI K, 1991, J CELL PHYSIOL, V148, P362, DOI 10.1002/jcp.1041480306	30	425	438	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					90	93		10.1038/32190	http://dx.doi.org/10.1038/32190			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510253				2022-12-01	WOS:000072373000056
J	Otto, M; Wiltfang, J; Schutz, E; Zerr, I; Otto, A; Pfahlberg, A; Gefeller, O; Uhr, M; Giese, A; Weber, T; Kretzschmar, HA; Poser, S				Otto, M; Wiltfang, J; Schutz, E; Zerr, I; Otto, A; Pfahlberg, A; Gefeller, O; Uhr, M; Giese, A; Weber, T; Kretzschmar, HA; Poser, S			Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEURON-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; NERVOUS-SYSTEM; S-100 PROTEIN; HUMAN-BRAIN; MARKER	Objective: To analyse serum concentrations of brain specific S100 protein in patients with Creutzfeldt-Jakob disease and in controls. Design: Prospective case-control study. Setting: National Creutzfeldt-Jakob disease surveillance unit. Subjects: 224 patients referred to the surveillance unit with suspected Creutzfeldt-Jakob disease and 35 control patients without dementia. Main outcome measure: Serum concentration of S100 protein in patients with Creutzfeldt-Jakob disease, in patients with other diseases causing dementia, and in the control group. Results: Of the 224 patients with suspected Creutzfeldt-Jakob disease, 65 were classed as definitely having the disease after neuropathological verification, an additional 6 were classed as definitely having the disease as a result of a genetic mutation, 43 as probably having the disease, 36 as possibly having the disease, and 74 patients were classed as having other disease. In the 108 patients classed as definitely or probably having Creutzfeldt-Jakob disease the median serum concentration of S100 was 395 pg/ml (SD 387 pg/ml). This was significantly higher than concentrations found in the 74 patients classed as having other diseases (median 109 pg/ml; SD 177 pg/ml; P = 0.0001). At a cut off point of 213 pg/ml sensitivity for the diagnosis of the disease was 77.8% (95% confidence interval 68.8% to 85.2%) and specificity was 81.1% (70.3% to 89.3%). There was a significant difference in survival at different concentrations of S100 in Kaplan-Meier curves (P = 0.023). Conclusion: Measurement of serum concentrations of S100 is a valuable tool which can be used more easily than tests on cerebrospinal fluid in the differential diagnosis of Creutzfeldt-Jakob disease. More studies are needed to determine whether serial testing of serum S100 improves diagnostic accuracy.	Univ Gottingen, Neurol Klin & Poliklin, D-37075 Gottingen, Germany; Univ Gottingen, Psychiat Klin & Poliklin, D-37075 Gottingen, Germany; Univ Gottingen, Klin Chem Abt, D-37075 Gottingen, Germany; Univ Gottingen, Abt Med Stat, D-37075 Gottingen, Germany; Max Planck Inst Psychiat, D-80804 Munich, Germany; Univ Gottingen, Inst Neuropathol, D-37075 Gottingen, Germany; Marien Hosp, Neurol Abt, Dept Neurol, D-22087 Hamburg, Germany	University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Gottingen; University of Gottingen; University of Gottingen; Max Planck Society; University of Gottingen; St. Marien Hospital	Otto, M (corresponding author), Univ Gottingen, Neurol Klin & Poliklin, Robert Koch Str 40, D-37075 Gottingen, Germany.	100634.133@compuserve.com	Cruz e Silva, Odete/AAH-5595-2020; Gefeller, Olaf/W-9604-2019; Schuetz, Ekkehard/H-3929-2013; Giese, Armin/F-3271-2010; Otto, Markus/F-4304-2015	Gefeller, Olaf/0000-0002-8985-7582; Giese, Armin/0000-0002-8238-4102; Otto, Markus/0000-0003-4273-4267; Wiltfang, Jens/0000-0003-1492-5330; Pfahlberg, Annette/0000-0002-2234-1215				ALPEROVITCH A, 1994, LANCET, V343, P918, DOI 10.1016/S0140-6736(94)90037-X; Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; JENSEN R, 1985, J NEUROCHEM, V45, P700, DOI 10.1111/j.1471-4159.1985.tb04048.x; JIMI T, 1992, CLIN CHIM ACTA, V211, P37, DOI 10.1016/0009-8981(92)90103-W; KINDBLOM LG, 1984, ACTA PATH MICRO IM A, V92, P219; Kretzschmar HA, 1996, ARCH NEUROL-CHICAGO, V53, P913, DOI 10.1001/archneur.1996.00550090125018; Lee KH, 1996, LANCET, V348, P887, DOI 10.1016/S0140-6736(96)24039-5; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Moussavian M, 1997, NEW ENGL J MED, V336, P873, DOI 10.1056/NEJM199703203361212; Otto M, 1997, J NEUROL, V244, P566, DOI 10.1007/s004150050145; Otto M, 1997, NEUROSCI LETT, V225, P210, DOI 10.1016/S0304-3940(97)00215-2; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Steinhoff BJ, 1996, ARCH NEUROL-CHICAGO, V53, P162, DOI 10.1001/archneur.1996.00550020074017; USUI A, 1989, CLIN CHEM, V35, P1942; VOLLSET SE, 1993, STAT MED, V12, P809, DOI 10.1002/sim.4780120902; WEBER T, 1995, J NEUROL, V242, P257; Will RG, 1996, LANCET, V348, P955, DOI 10.1016/S0140-6736(96)24040-1; WILL RG, 1993, BRIT MED BULL, V49, P960, DOI 10.1093/oxfordjournals.bmb.a072655; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zerr I, 1996, LANCET, V348, P846, DOI 10.1016/S0140-6736(96)08077-4; ZERR I, 1995, LANCET, V345, P1609, DOI 10.1016/S0140-6736(95)90118-3	28	101	106	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	1998	316	7131					577	582		10.1136/bmj.316.7131.577	http://dx.doi.org/10.1136/bmj.316.7131.577			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518907	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000072213200023
J	Pounder, D; Carson, D; Davison, M; Orihara, Y				Pounder, D; Carson, D; Davison, M; Orihara, Y			Evaluation of indices of obesity in men: descriptive study	BRITISH MEDICAL JOURNAL			English	Article							WAIST CIRCUMFERENCE		Dundee Royal Infirm, Dept Forens Med, Dundee DD1 9ND, Scotland		Pounder, D (corresponding author), Dundee Royal Infirm, Dept Forens Med, Dundee DD1 9ND, Scotland.							BJORNTORP P, 1992, ANN MED, V24, P15, DOI 10.3109/07853899209164140; LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/bmj.311.6998.158; POULIOT MC, 1994, AM J CARDIOL, V73, P460, DOI 10.1016/0002-9149(94)90676-9; Shaper AG, 1997, BRIT MED J, V314, P1311, DOI 10.1136/bmj.314.7090.1311; TunstallPedoe H, 1997, BMJ-BRIT MED J, V314, P1291, DOI 10.1136/bmj.314.7090.1291	5	14	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1998	316	7142					1428	1429		10.1136/bmj.316.7142.1428	http://dx.doi.org/10.1136/bmj.316.7142.1428			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN495	9572754	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000073651600030
J	Nightingale, SL				Nightingale, SL			New rule proposed for home drug abuse test kits	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1998	279	17					1339	1339		10.1001/jama.279.17.1339	http://dx.doi.org/10.1001/jama.279.17.1339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK758	9582030				2022-12-01	WOS:000073359800005
J	Lewin, RJP; Ingleton, R; Newens, AJ; Thompson, DR				Lewin, RJP; Ingleton, R; Newens, AJ; Thompson, DR			Adherence to cardiac rehabilitation guidelines: a survey of rehabilitation programmes in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article									Univ Hull, Fac Hlth, Inst Rehabil, Hull HU3 2PG, N Humberside, England	University of Hull	Lewin, RJP (corresponding author), Univ York, Dept Hlth Studies, British Heart Fdn Rehabil Res Unit, York YO10 5DQ, N Yorkshire, England.		Thompson, David R/E-2431-2018; Thompson, David R/C-6320-2009	Thompson, David R/0000-0001-8518-6307; 				*AUD COMM, 1995, DEAR OUR HEARTS COMM; LEWIN R, 1997, CARDIAC REHABILITATI, P21; Thompson DR, 1996, HEART, V75, P89, DOI 10.1136/hrt.75.1.89; Thompson DR, 1997, INT J CARDIOL, V59, P299, DOI 10.1016/S0167-5273(97)02951-3; World Health Organization [WHO], 1993, NEEDS ACT PRIOR CARD	5	47	47	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1998	316	7141					1354	1355		10.1136/bmj.316.7141.1354	http://dx.doi.org/10.1136/bmj.316.7141.1354			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL882	9563986	Green Submitted, Bronze, Green Accepted, Green Published			2022-12-01	WOS:000073483000019
J	Kelso, JAS; Fuchs, A; Lancaster, R; Holroyd, T; Cheyne, D; Weinberg, H				Kelso, JAS; Fuchs, A; Lancaster, R; Holroyd, T; Cheyne, D; Weinberg, H			Dynamic cortical activity in the human brain reveals motor equivalence	NATURE			English	Article							CELL DISCHARGE; ARM MOVEMENTS; CORTEX; DIRECTION; FIELDS	That animals and humans can accomplish the same goal using different effecters and different goals using the same effecters attests to the remarkable flexibility of the central nervous system. This phenomenon has been termed 'motor equivalence'(1,2), an example being the writing of a name with a pencil held between the toes or teeth. The idea of motor equivalence has reappeared because single-cell studies in monkeys have shown that parameters of voluntary movement (such as direction) may be specified in the brain, relegating muscle activation to spinal interneuronal systems(3,4). Using a novel experimental paradigm(5) and a full-head SQUID (for superconducting quantum interference device) array to record magnetic fields corresponding to ongoing brain activity, we demonstrate: (1), a robust relationship between time-dependent activity in sensorimotor cortex and movement velocity, independent of explicit task requirements; and (2) neural activations that are specific to task demands alone. It appears, therefore, that signatures of motor equivalence in humans may be found in dynamic patterns of cortical activity.	Florida Atlantic Univ, Ctr Complex Syst, Program Complex Syst & Brain Sci, Boca Raton, FL 33431 USA; Simon Fraser Univ, Brain Behav Lab, Burnaby, BC V5A 1S6, Canada	State University System of Florida; Florida Atlantic University; Simon Fraser University	Kelso, JAS (corresponding author), Florida Atlantic Univ, Ctr Complex Syst, Program Complex Syst & Brain Sci, Boca Raton, FL 33431 USA.			Cheyne, Douglas/0000-0002-2663-498X				BARTLETT NR, 1959, PSYCHOL REV, V66, P203, DOI 10.1037/h0046490; BIZZI E, 1991, SCIENCE, V253, P287, DOI 10.1126/science.1857964; CHEYNE D, 1989, EXP BRAIN RES, V78, P604; Dunlap K, 1910, PSYCHOL REV, V17, P399, DOI 10.1037/h0074736; Fuchs A, 1992, INT J BIFURCAT CHAOS, V2, P917, DOI 10.1142/S0218127492000537; Georgopoulos AP, 1997, NEUROSCIENTIST, V3, P52, DOI 10.1177/107385849700300115; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; Hebb DO, 1949, ORG BEHAV NEUROPSYCH; KELSO JAS, 1992, PHYS LETT A, V169, P134, DOI 10.1016/0375-9601(92)90583-8; KRISTEVA R, 1991, ELECTROEN CLIN NEURO, V81, P284, DOI 10.1016/0168-5597(91)90015-P; Lashley KS, 1930, PSYCHOL REV, V37, P1, DOI 10.1037/h0074134; MORAN DW, IN PRESS J NEUROPHYS; Romani G L, 1989, ADV BIOMAGNETISM, P33; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; UHL C, 1995, PHYS REV E, V51, P3890, DOI 10.1103/PhysRevE.51.3890; WIESENDANGER M, 1982, PHYSIOL REV, V62, P1234, DOI 10.1152/physrev.1982.62.4.1234; WING AM, 1973, PERCEPT PSYCHOPHYS, V13, P455, DOI 10.3758/BF03205802; [No title captured]	18	135	137	2	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1998	392	6678					814	818		10.1038/33922	http://dx.doi.org/10.1038/33922			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572140				2022-12-01	WOS:000073241200053
J	Hotopf, M; Carr, S; Mayou, R; Wadsworth, M; Wessely, S				Hotopf, M; Carr, S; Mayou, R; Wadsworth, M; Wessely, S			Why do children have chronic abdominal pain, and what happens to them when they grow up? Population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC-DISORDERS; BIRTH COHORT; LIFE EVENTS; FOLLOW-UP; FAMILIES; SOMATIZATION; ADOLESCENTS; SYMPTOMS	Objective: To test the hypotheses that children with abdominal pain have anxious parents and come from families with high rates of physical illness and that they grow up to suffer from high rates of medically unexplained symptoms and psychiatric disorders. Design: Population based birth cohort study. Setting: General population. Subjects: Participants in the Medical Research Council (MRC) national survey of health and development, a population based bir th cohort study established in 1946. Main outcome measures: Abdominal pain present throughout childhood in the absence of defined organic disease, and measures of physical symptoms and psychiatric disorder at age 36 years. Results: There were high rates of complaints about physical health among the parents of children with persistent abdominal pain, and the mothers had higher neuroticism scores. Children with persistent abdominal pain were more likely to suffer from psychiatric disorders in adulthood (odds ratio 2.72 (95% confidence interval 1.65 to 4.49)) but were not especially prone to physical symptoms once psychiatric disorder was controlled for (odds ratio 1.39 (0.83 to 2.36)). Conclusions: Persistent abdominal pain is associated with poor health and emotional disorder in the parents. Children with abdominal pain do not necessarily continue to experience physical symptoms into adulthood but are at increased risk of adult psychiatric disorders.	Kings Coll London, Sch Med & Dent, Dept Psychol Med, London SE5 8AZ, England; Inst Psychiat, London SE5 8AZ, England; Royal Free Hosp, Dept Paediat, London NW3 2QG, England; Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; UCL, Univ Coll & Middlesex Sch Med, Dept Epidemiol & Publ Hlth, MRC,Natl Survey Hlth & Dev, London WC1E 6BT, England	University of London; King's College London; University of London; King's College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Oxford; University of London; University College London	Hotopf, M (corresponding author), Kings Coll London, Sch Med & Dent, Dept Psychol Med, London SE5 8AZ, England.	m.hotopf@iop.bpmf.ac.uk	Hotopf, Matthew/E-4971-2010; Wessely, Simon C/A-8713-2008	Hotopf, Matthew/0000-0002-3980-4466; Wessely, Simon Charles/0000-0002-6743-9929				APLEY J, 1973, BRIT MED J, V3, P7, DOI 10.1136/bmj.3.5870.7; APLEY J, 1957, ARCH DIS CHILD, P165; CAMPO JV, 1994, J AM ACAD CHILD PSY, V33, P1223, DOI 10.1097/00004583-199411000-00003; Caspi A, 1996, ARCH GEN PSYCHIAT, V53, P1033; CHRISTENSEN MF, 1975, ARCH DIS CHILD, V50, P110, DOI 10.1136/adc.50.2.110; EYSENCK HJ, 1958, J APPL PSYCHOL, V42, P14, DOI 10.1037/h0041738; GARBER J, 1990, J AM ACAD CHILD PSY, V29, P648, DOI 10.1097/00004583-199007000-00021; GOODMAN JE, 1991, PAIN, V46, P247, DOI 10.1016/0304-3959(91)90108-A; HODGES K, 1984, J PSYCHOSOM RES, V28, P185, DOI 10.1016/0022-3999(84)90018-7; HODGES K, 1985, J PEDIATR-US, V107, P622, DOI 10.1016/S0022-3476(85)80037-8; MAGNI G, 1987, EUR J PEDIATR, V146, P72, DOI 10.1007/BF00647291; Pintner R, 1938, J EDUC PSYCHOL, V29, P93, DOI 10.1037/h0059933; ROBINSON JO, 1990, J PSYCHOSOM RES, V34, P171, DOI 10.1016/0022-3999(90)90051-5; SANDERS MR, 1994, J CONSULT CLIN PSYCH, V62, P306, DOI 10.1037/0022-006X.62.2.306; Scharff L, 1997, CLIN PSYCHOL REV, V17, P145, DOI 10.1016/S0272-7358(96)00001-3; Scott SC, 1997, J CLIN EPIDEMIOL, V50, P45, DOI 10.1016/S0895-4356(96)00312-5; WADSWORTH MEJ, 1992, J EPIDEMIOL COMMUN H, V46, P300, DOI 10.1136/jech.46.3.300; WALKER LS, 1993, J ABNORM PSYCHOL, V102, P248, DOI 10.1037/0021-843X.102.2.248; WALKER LS, 1989, J PEDIATR PSYCHOL, V14, P231, DOI 10.1093/jpepsy/14.2.231; WALKER LS, 1991, J ABNORM CHILD PSYCH, V19, P379, DOI 10.1007/BF00919084; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WOODBURY MM, 1993, PSYCHOSOMATICS, V34, P485, DOI 10.1016/S0033-3182(93)71822-8	22	224	224	0	14	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1196	1200		10.1136/bmj.316.7139.1196	http://dx.doi.org/10.1136/bmj.316.7139.1196			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZJ518	9552994	Green Published, Green Submitted			2022-12-01	WOS:000073224100019
J	Wilmoth, JR				Wilmoth, JR			The future of human longevity: A demographer's perspective	SCIENCE			English	Article							MORTALITY; LIMITS		Univ Calif Berkeley, Dept Demog, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Wilmoth, JR (corresponding author), Univ Calif Berkeley, Dept Demog, Berkeley, CA 94720 USA.	jrw@demog.berkeley.edu						AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bourgeois-pichat J, 1978, Popul Bull UN, P12; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; KANNISTO V, 1994, POPUL DEV REV, V20, P793, DOI 10.2307/2137662; LEE RD, 1992, J AM STAT ASSOC, V87, P659, DOI 10.2307/2290201; MANTON KG, 1991, POPUL DEV REV, V17, P603, DOI 10.2307/1973599; OLSHANSKY SJ, 1990, SCIENCE, V250, P634, DOI 10.1126/science.2237414; PARTRIDGE L, 1997, ZEUS SALMON BIODEMOG, P78; Preston SH, 1995, STATE HUMANITY, P30; *SOC SEC ADM, 1997, 112 SOC SEC ADM OFF; *UN, 1977, WORLD POP PROSP ASS; United Nations. Dept. for Economic and Social Information and Policy Analysis. Population Division, 1995, WORLD POP PROSP 1994; Wilmoth J., 1997, ZEUS SALMON BIODEMOG, P38; Wilmoth J. R., 1996, HLTH MORTALITY ELDER, P266	15	86	88	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1998	280	5362					395	397		10.1126/science.280.5362.395	http://dx.doi.org/10.1126/science.280.5362.395			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9575086				2022-12-01	WOS:000073159600033
J	Taylor, A				Taylor, A			Violations of the international code of marketing of breast milk substitutes: prevalence in four countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DURATION; SAMPLES	Objective: To estimate the prevalence of violations of the international code of marketing of substitutes for breast milk in one city in each of Bangladesh, Poland, South Africa, and Thailand. Design: Multistage random sampling was used to select pregnant women and mothers of infants less than or equal to 6 months old to interview at health facilities. Women were asked whether they had received free samples of substitutes for breast milk (including infant formula designed to meet the nutritional needs of infants from birth to 4 to 6 months of age, follow on formula designed to replace infant formula at the age of 4 to 6 months, and complementary foods for infants aged less than or equal to 6 months), bottles, or teats. The source of the free -sample and when it had been given to the women was also determined. 3 health workers were interviewed at each facility to assess whether the facility had received free samples, to determine how they had been used, and to determine whether gifts had been given to health workers by companies that manufactured or distributed breast milk substitutes. Compliance with the marketing code for information given to health workers was evaluated using a checklist. Setting: Health facilities in Dhaka, Bangladesh; Warsaw, Poland; Durban, South Africa; and Bangkok, Thailand. Subjects: 1468 pregnant women, 1582 mothers of infants aged less than or equal to 6 months, and 466 health workers at 165 health facilities. Main outcome measures: Number of fi-ee samples received by pregnant women, mothers, and health workers; number of gifts given to health workers; and availability of information that violated the code in health facilities. Results: 97 out of 370 (26%) mothers in Bangkok reported receiving free samples of breast milk substitutes, infant formula, bottles, or teats compared with only 1 out of 385 mothers in Dhaka. Across the four cities from 3 out of 40 (8%) to 20 out of 40 (50%) health facilities had received free samples which were not being used for research or professional evaluation; from 2 out of 123 (2%) to 21 out of 119 (18%) health workers had received gifts from companies involved in the manufacturing or distribution of breast mill; substitutes. From 6 out of 40 (15%) to 22 out of 39 (56%) health facilities information that violated the code had been provided by companies and was available to staff. Conclusion: Violations of the code were detected with a simple survey instrument in all Of the four countries studied. Governmental and non-governmental agencies should monitor the prevalence of code violations using the simple methodology developed for this study.	Unicef United Kingdom Comm, Interagcy Grp Breastfeeding Monitoring, London WC2A 3NB, England		Taylor, A (corresponding author), Unicef United Kingdom Comm, Interagcy Grp Breastfeeding Monitoring, London WC2A 3NB, England.							*BAB MILK ACT, 1994, BREAK RUL; BERGEVIN Y, 1983, LANCET, V1, P1148; Collett D., 2002, MODELLING BINARY DAT; DUNGY CI, 1992, PEDIATRICS, V90, P233; Evans C J, 1986, J Obstet Gynecol Neonatal Nurs, V15, P401, DOI 10.1111/j.1552-6909.1986.tb01414.x; FEINSTEIN JM, 1986, PEDIATRICS, V78, P210; FRANK DA, 1987, PEDIATRICS, V80, P845; INCH S, 1988, EFFECTIVE CARE PREGN; International Code Documentation Centre,, 2016, INT COD MARK BREASTM; PEREZESCAMILLA R, 1994, AM J PUBLIC HEALTH, V84, P89, DOI 10.2105/AJPH.84.1.89; SOKOL E, 1997, CODE HANDBOOK; World Health Organization, 1993, INF YOUNG CHILD NUTR; 1995, INFANT FORMULA FOLOW	13	56	56	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 11	1998	316	7138					1117	1122		10.1136/bmj.316.7138.1117	http://dx.doi.org/10.1136/bmj.316.7138.1117			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552947	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000073067500019
J	Murthy, VN; Stevens, CF				Murthy, VN; Stevens, CF			Synaptic vesicles retain their identity through the endocytic cycle	NATURE			English	Article							FROG NEUROMUSCULAR-JUNCTION; HIPPOCAMPAL SYNAPSES; NERVE-TERMINALS; DYNAMIN; POOL; TRANSMITTER; MEMBRANE; RINGS	After fusion of synaptic vesicles with presynaptic membrane and secretion of the contents of the vesicles into the synaptic cleft (a process known as exocytosis), the vesicular membrane is retrieved by endocytosis (internalization) for re-use(1,2). Several issues regarding endocytosis at central synapses are unresolved, including the location of membrane retrieval (relative to the active zone, where exocytosis occurs), the time course of various endocytic steps, and the recycling path taken by newly endocytosed membranes. The classical model of synaptic-vesicle recycling, proposed by analogy to other cellular endocytic pathways, involves retrieval of the membrane, fusion of the membrane with endosome-like compartments and, finally, budding of new synaptic vesicles from endosomes(1), although the endosomal station may not be obligatory(3). Here we test the classical model by using the fluorescent membrane dye FM1-43 (refs 4-6) with quantitative fluorescence microscopy. We find that the amount of dye per vesicle taken up by endocytosis equals the amount of dye a vesicle releases on exocytosis; therefore, we conclude that the internalized vesicles do not, as the classical picture suggests, communicate with intermediate endosome-like compartments during the recycling process.	Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Salk Institute; Salk Institute	Stevens, CF (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cfs@salk.edu		Murthy, Venkatesh/0000-0003-2443-4252				BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Ryan TA, 1997, NATURE, V388, P478, DOI 10.1038/41335; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; Schikorski T, 1997, J NEUROSCI, V17, P5858; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237	17	207	212	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					497	501		10.1038/33152	http://dx.doi.org/10.1038/33152			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548254				2022-12-01	WOS:000072875200059
J	Penn, AA; Riquelme, PA; Feller, MB; Shatz, CJ				Penn, AA; Riquelme, PA; Feller, MB; Shatz, CJ			Competition in retinogeniculate patterning driven by spontaneous activity	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; NICOTINIC ACETYLCHOLINE-RECEPTORS; PRENATAL DEVELOPMENT; MAMMALIAN RETINA; NEUROMUSCULAR-JUNCTION; GANGLION-CELLS; CONNECTIONS; NEURONS; SEGREGATION; TETRODOTOXIN	When contacts are first forming in the developing nervous system, many neurons generate spontaneous activity that has been hypothesized to shape appropriately patterned connections. In Mustela putorius furo, monocular intraocular blockade of spontaneous retinal waves of action potentials by cholinergic agents altered the subsequent eye-specific lamination pattern of the lateral geniculate nucleus (LGN). The projection from the active retina was greatly expanded into territory normally belonging to the other eye, and the projection from the inactive retina was substantially reduced. Thus, interocular competition driven by endogenous retinal activity determines the pattern of eye-specific connections from retina to LGN, demonstrating that spontaneous activity can produce highly stereotyped patterns of connections before the onset of visual experience.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Penn, AA (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, 221 Life Sci Addit, Berkeley, CA 94720 USA.				NIMH NIH HHS [MH 98108] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BADIO B, 1994, MOL PHARMACOL, V45, P563; Baldridge WH, 1996, J NEUROSCI, V16, P5060; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Cramer KS, 1997, DEV BRAIN RES, V98, P287, DOI 10.1016/S0165-3806(96)00188-5; Dan Y, 1995, PROG BRAIN RES, V105, P211; Drescher U, 1997, CURR OPIN NEUROBIOL, V7, P75, DOI 10.1016/S0959-4388(97)80123-7; DUBIN MW, 1986, J NEUROSCI, V6, P1021; Feller MB, 1996, SCIENCE, V272, P1182, DOI 10.1126/science.272.5265.1182; Fiordalisi JJ, 1996, TOXICON, V34, P213, DOI 10.1016/0041-0101(95)00135-2; GARRAGHTY PE, 1988, VISUAL NEUROSCI, V1, P93, DOI 10.1017/S0952523800001048; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; JEFFERY G, 1990, EXP BRAIN RES, V82, P408; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kittila CA, 1997, J NEUROPHYSIOL, V77, P675, DOI 10.1152/jn.1997.77.2.675; Kulak JM, 1997, J NEUROSCI, V17, P5263; LINDEN DC, 1981, J COMP NEUROL, V203, P189, DOI 10.1002/cne.902030204; Marks MJ, 1996, J PHARMACOL EXP THER, V277, P1383; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Mooney R, 1996, NEURON, V17, P863, DOI 10.1016/S0896-6273(00)80218-4; Nguyen QT, 1996, CURR OPIN NEUROBIOL, V6, P104, DOI 10.1016/S0959-4388(96)80015-8; OLIVERA T, COMMUNICATION; PRUSKY GT, 1988, VISUAL NEUROSCI, V1, P245, DOI 10.1017/S0952523800001504; RAKIC P, 1976, NATURE, V261, P467, DOI 10.1038/261467a0; RAMOA AS, 1989, P NATL ACAD SCI USA, V86, P2061, DOI 10.1073/pnas.86.6.2061; RIDDLE DR, 1995, NATURE, V378, P189, DOI 10.1038/378189a0; Sernagor E, 1996, CURR BIOL, V6, P1503, DOI 10.1016/S0960-9822(96)00755-5; SHATZ CJ, 1983, J NEUROSCI, V3, P482; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SRETAVAN DW, 1986, J NEUROSCI, V6, P234; SRETAVAN DW, 1986, J NEUROSCI, V6, P990; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; STEIN BE, 1985, J COMP NEUROL, V239, P402, DOI 10.1002/cne.902390406; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8; XIE Y, 1993, J PHARMACOL EXP THER, V264, P689; Xie Y, 1996, J PHARMACOL EXP THER, V276, P169; Yuste R, 1997, SEMIN CELL DEV BIOL, V8, P1, DOI 10.1006/scdb.1996.0114; ZOLL M, 1995, J NEUROSCI, V15, P1912	44	399	405	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2108	2112		10.1126/science.279.5359.2108	http://dx.doi.org/10.1126/science.279.5359.2108			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516112				2022-12-01	WOS:000072775600048
J	Parkins, KJ; Poets, CF; O'Brien, LM; Stebbens, VA; Southall, DP				Parkins, KJ; Poets, CF; O'Brien, LM; Stebbens, VA; Southall, DP			Effect of exposure to 15% oxygen on breathing patterns and oxygen saturation in infants: interventional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LIFE-THREATENING EVENTS; FULL-TERM INFANTS; 1ST 6 MONTHS; SLEEP; SIDS; HYPOXEMIA; ALTITUDE; SIBLINGS; TIBET; BORN	Objective: To assess the response of healthy infants to airway hypoxia (15% oxygen in nitrogen). Design: Interventional study. Settings: Infants' homes and paediatric ward. Subjects: 34 healthy infants (20 boys) born at term; mean age at study 3.1 months. 13 of the infants had siblings whose deaths had been ascribed to the sudden infant death syndrome. Intervention: Respiratory variables were measured in room air (pre-challenge), while infants were exposed to 15% oxygen (challenge), and after infants were returned to room air (post-challenge). Main outcome measures: Baseline oxygen saturation as measured by pulse oximetry, frequency of isolated and periodic apnoea, and frequency of desaturation (oxygen saturation less than or equal to 80% for greater than or equal to 4 s), Exposure to 15% oxygen was terminated if oxygen saturation fell to less than or equal to 80% for greater than or equal to 1 min. Results: Mean duration of exposure to 15% oxygen was 6.3 (SD 2.9) hours. Baseline oxygen saturation fell from a median of 97.6% (range 94.0% to 100%) in room air to 92.8% (84.7% to 100%) in 15% oxygen. There was no correlation between baseline oxygen saturation in room air and the extent of the fall in baseline oxygen saturation on exposure to 15% oxygen. During exposure to 15% oxygen there was a reduction in the proportion of time spent in regular breathing pattern and a 3.5-fold increasein the proportion of time spent in periodic apnoea (P < 0.001). There was an increase in the frequency of desaturation from 0 episodes per hour (range 0 to 0.2) to 0.4 episodes per hour (0 to 35) (P < 0.001). In 4 infants exposure to hypoxic conditions was ended early because of prolonged and severe falls in oxygen saturation. Conclusions: A proportion of infants had episodes of prolonged (less than or equal to 80% for greater than or equal to 1 min) or recurrent shorter (less than or equal to 80% for greater than or equal to 4 s) desaturation, or both, when exposed to airway hypoxia. The quality and quantity of this response was unpredictable. These findings may explain why some infants with airway hypoxia caused by respiratory infection develop more severe hypoxaemia than others. Exposure to airway hypoxia similar to that experienced during air travel or on holiday at high altitude may be harmful to some infants.	N Staffordshire Hosp, Acad Dept Paediat, Stoke On Trent ST4 6QG, Staffs, England; Sch Med, Dept Paediat, D-30623 Hannover, Germany	Keele University; University Hospital of North Staffordshire NHS Trust	Southall, DP (corresponding author), N Staffordshire Hosp, Acad Dept Paediat, Stoke On Trent ST4 6QG, Staffs, England.	cai.uk@compuserve.com						ANAS N, 1982, J PEDIATR-US, V101, P65, DOI 10.1016/S0022-3476(82)80184-4; COTTRELL JJ, 1988, CHEST, V93, P81, DOI 10.1378/chest.93.1.81; GETTS AG, 1982, DEV MED CHILD NEUROL, V24, P61; HEATH D, 1989, THORAX, V44, P981, DOI 10.1136/thx.44.12.981; HEWERTSON J, 1994, PEDIATRICS, V94, P148; HOFFMAN HJ, 1988, ANN NY ACAD SCI, V533, P13, DOI 10.1111/j.1749-6632.1988.tb37230.x; HOPPENBROUWERS T, 1989, SLEEP, V12, P265; HULTGREN HN, 1968, ANNU REV MED, V19, P119, DOI 10.1146/annurev.me.19.020168.001003; LOZANO JM, 1992, ARCH DIS CHILD, V67, P299, DOI 10.1136/adc.67.3.299; NIERMEYER S, 1995, NEW ENGL J MED, V333, P1248, DOI 10.1056/NEJM199511093331903; POETS CF, 1991, J DEV PHYSIOL, V15, P341; POETS CF, 1992, ACTA PAEDIATR, V81, P536, DOI 10.1111/j.1651-2227.1992.tb12290.x; RICHARDS JM, 1984, PEDIATRICS, V74, P763; RIGATTO H, 1972, PEDIATRICS, V50, P219; SAMUELS MP, 1994, J PEDIATR-US, V125, P441, DOI 10.1016/S0022-3476(05)83292-5; SAMUELS MP, 1992, ARCH DIS CHILD, V67, P162, DOI 10.1136/adc.67.2.162; SCHAFER T, 1993, J APPL PHYSIOL, V74, P88, DOI 10.1152/jappl.1993.74.1.88; STEBBENS VA, 1991, ARCH DIS CHILD, V66, P569, DOI 10.1136/adc.66.5.569; Tappin DM, 1996, ARCH DIS CHILD, V74, P427, DOI 10.1136/adc.74.5.427; Weil JV, 1978, SLEEP APNEA SYNDROME, P119; Zinman R, 1985, Pediatr Pulmonol, V1, P325, DOI 10.1002/ppul.1950010610	21	60	61	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 21	1998	316	7135					887	891		10.1136/bmj.316.7135.887	http://dx.doi.org/10.1136/bmj.316.7135.887			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552835	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000072713300022
J	Thomas, MK; Lloyd-Jones, DM; Thadhani, RI; Shaw, AC; Deraska, DJ; Kitch, BT; VAmvakas, EC; Dick, IM; Prince, RL; Finkelstein, JS				Thomas, MK; Lloyd-Jones, DM; Thadhani, RI; Shaw, AC; Deraska, DJ; Kitch, BT; VAmvakas, EC; Dick, IM; Prince, RL; Finkelstein, JS			Hypovitaminosis D in medical inpatients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VITAMIN-D DEFICIENCY; POSTMENOPAUSAL WOMEN; D SUPPLEMENTATION; HIP-FRACTURES; ELDERLY PERSONS; BONE LOSS; POPULATION; EXPOSURE; SUNLIGHT; CALCIUM	Background: Vitamin D deficiency is a major risk factor for bone loss and fracture. Although hypovitaminosis D has been detected frequently in elderly and housebound people, the prevalence of vitamin D deficiency among patients hospitalized on a general medical service is unknown. Methods We assessed vitamin D intake, ultraviolet-light exposure, and risk factors for hypovitaminosis D and measured serum 25-hydroxyvitamin D, parathyroid hormone, and ionized calcium in 290 consecutive patients on a general medical ward. Results A total of 164 patients (57 percent)were considered vitamin D-deficient (serum concentration of 25-hydroxyvitamin D, less than or equal to 15 ng per milliliter), of whom 65 (22 percent) were considered severely vitamin D-deficient (serum concentration of 25-hydroxyvitamin D, <8 ng.per milliliter). Serum 25-hydroxyvitamin D concentrations were related inversely to parathyroid hormone concentrations. Lower vitamin D intake, less exposure to ultraviolet light, anticonvulsant-drug therapy, renal dialysis, nephrotic syndrome, hypertension, diabetes mellitus, winter season, higher serum concentrations of parathyroid hormone and alkaline phosphatase, and lower serum concentrations of ionized calcium and albumin were significant univariate predictors of hypovitaminosis D. Sixty-six percent of the patients who consumed less than the recommended daily amount of vitamin D and 37 percent of the patients with intakes above the recommended daily amount were vitamin D-deficient. inadequate vitamin D intake, winter season, and housebound status were independent predictors of hypovitaminosis D in a multivariate model. In a subgroup of 77 patients less than 65 years of age without known risk factors for hypovitaminosis D, the prevalence of vitamin D deficiency was 42 percent. Conclusions Hypovitaminosis D is common in general medical inpatients, including those with vitamin D intakes exceeding the recommended daily amount and those without apparent risk factors for vitamin D deficiency. (C) 1998, Massachusetts Medical Society.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Western Australia, Dept Med, Perth, WA 6009, Australia; Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA 6009, Australia	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Western Australia; University of Western Australia	Finkelstein, JS (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, 55 Fruit St,Bulfinch 327, Boston, MA 02114 USA.		Finkelstein, Joel/M-6463-2019; Lloyd-Jones, Donald M/C-5899-2009; Shaw, Albert/AAD-2567-2021	Shaw, Albert/0000-0003-4970-7640; Lloyd-Jones, Donald/0000-0003-0847-6110	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007028, R29DK043341] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-1066] Funding Source: Medline; NIDDK NIH HHS [DK07028, R29-DK43341] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afifi A.A., 1984, COMPUTER AIDED MULTI; BAKER MR, 1979, BRIT MED J, V1, P589, DOI 10.1136/bmj.1.6163.589; Boonen S, 1996, J ENDOCRINOL, V149, P13, DOI 10.1677/joe.0.1490013; BOUILLON RA, 1987, AM J CLIN NUTR, V45, P755, DOI 10.1093/ajcn/45.4.755; CHAPUY MC, 1994, BRIT MED J, V308, P1081, DOI 10.1136/bmj.308.6936.1081; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; COOKE NE, 1989, ENDOCR REV, V10, P294, DOI 10.1210/edrv-10-3-294; DAWSONHUGHES B, 1991, ANN INTERN MED, V115, P505, DOI 10.7326/0003-4819-115-7-505; DAWSONHUGHES B, 1995, AM J CLIN NUTR, V61, P1140, DOI 10.1093/ajcn/61.5.1140; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; GAVISON R, 1989, J IMMUNOL, V143, P3686; GLOTH FM, 1995, J AM GERIATR SOC, V43, P822, DOI 10.1111/j.1532-5415.1995.tb07059.x; GLOTH FM, 1995, JAMA-J AM MED ASSOC, V274, P1683, DOI 10.1001/jama.274.21.1683; GOLDRAY D, 1989, J AM GERIATR SOC, V37, P589, DOI 10.1111/j.1532-5415.1989.tb01247.x; HOLICK MF, 1992, NEW ENGL J MED, V326, P1178, DOI 10.1056/NEJM199204303261802; HOLICK MF, 1990, J NUTR, V120, P1464, DOI 10.1093/jn/120.suppl_11.1464; KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602; LACHENBR.PA, 1968, TECHNOMETRICS, V10, P1, DOI 10.2307/1266219; LIPS P, 1988, J CLIN ENDOCR METAB, V67, P644, DOI 10.1210/jcem-67-4-644; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; McAlindon TE, 1996, ANN INTERN MED, V125, P353, DOI 10.7326/0003-4819-125-5-199609010-00001; MCKENNA MJ, 1992, AM J MED, V93, P69, DOI 10.1016/0002-9343(92)90682-2; MEUNIER PJ, 1993, AM J MED, V95, pS75, DOI 10.1016/0002-9343(93)90387-5; NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364; OMDAHL JL, 1982, AM J CLIN NUTR, V36, P1225, DOI 10.1093/ajcn/36.6.1225; Parfitt A. M., 1998, METABOLIC BONE DIS C, P327, DOI [10.1016/B978-012068700-8/50012-8, DOI 10.1016/B978-012068700-8/50012-8]; PEACOCK M, 1985, VITAMIN D CHEM BIOCH, P569; PENNINGTON JAT, 1994, BOWES CHURCHS FOOD V, P411; SALAMONE LM, 1993, AM J CLIN NUTR, V58, P80; SHERMAN SS, 1990, J CLIN ENDOCR METAB, V71, P405, DOI 10.1210/jcem-71-2-405; Standing Committee on the Scientific Evaluation of Dietary Reference Intakes Food and Nutrition Board Institute of Medicine, 1997, DIET REF INT CALC PH; VILLAREAL DT, 1991, J CLIN ENDOCR METAB, V72, P628, DOI 10.1210/jcem-72-3-628; WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem-67-2-373; WEBB AR, 1990, AM J CLIN NUTR, V51, P1075, DOI 10.1093/ajcn/51.6.1075; WILSON SG, 1990, CLIN ENDOCRINOL, V32, P613, DOI 10.1111/j.1365-2265.1990.tb00905.x	35	1085	1131	0	29	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1998	338	12					777	783		10.1056/NEJM199803193381201	http://dx.doi.org/10.1056/NEJM199803193381201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC163	9504937				2022-12-01	WOS:000072546800001
J	Zhou, P; Sun, LJ; Dotsch, V; Wagner, G; Verdine, GL				Zhou, P; Sun, LJ; Dotsch, V; Wagner, G; Verdine, GL			Solution structure of the core NFATC1/DNA complex	CELL			English	Article							ACTIVATED T-CELLS; TRANSCRIPTION FACTOR NFAT1; CRYSTAL-STRUCTURE; NUCLEAR FACTOR; DNA-BINDING; TATA-ELEMENT; NF-ATP; PROTEINS; DOMAIN; RECOGNITION	The nuclear factor of the activated T cell (NFAT) family of transcription factors regulates cytokine gene expression by binding to the promoter/enhancer regions of antigen-responsive genes, usually in cooperation with heterologous DNA-binding partners. Here we report the solution structure of the binary complex formed between the core DNA-binding domain of human NFATC1 and the ARRE2 DNA site from the interleukin-2 promoter. The structure reveals that DNA binding induces the folding of key structural elements that are required for both sequence-specific recognition and the establishment of cooperative protein-protein contacts. The orientation of the NFAT DNA-binding domain observed in the binary NFATC1-DBD*/DNA complex is distinct from that seen in the ternary NFATC2/AP-1/DNA complex, suggesting that the domain reorients upon formation of a cooperative transcriptional complex.	Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School	Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.		Doetsch, Volker/D-5697-2011; Zhou, Pei/O-6704-2019	Zhou, Pei/0000-0002-7823-3416; Dotsch, Volker/0000-0001-5720-212X	NIGMS NIH HHS [P01GM47467, P01 GM047467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altmann S, 1995, NUCLEIC ACIDS RES, V23, P4827, DOI 10.1093/nar/23.23.4827; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRUNGER AT, 1992, XPLOR 3 1 MANUAL; CHEN L, 1995, CURR BIOL, V5, P882, DOI 10.1016/S0960-9822(95)00178-3; CHEN L, 1998, IN PRESS NATURE; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JAIN JN, 1993, J IMMUNOL, V151, P837; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIU J, 1991, CELL, V66, P1; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MULLER CW, 1995, NATURE, V373, P301; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Saenger W, 2013, PRINCIPLES NUCL ACID; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SHORTLE D, 1994, J MAGN RESON SER B, V105, P88, DOI 10.1006/jmrb.1994.1106; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Sun LJ, 1997, P NATL ACAD SCI USA, V94, P4919, DOI 10.1073/pnas.94.10.4919; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; WOLFE SA, 1996, THESIS HARVARD U CAM; WOODROW MA, 1993, J IMMUNOL, V150, P3853; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892	43	93	100	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					687	696		10.1016/S0092-8674(00)81136-8	http://dx.doi.org/10.1016/S0092-8674(00)81136-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506523	Bronze			2022-12-01	WOS:000072406000014
J	Duthie, RA; Bruce, MF; Hutchison, JD				Duthie, RA; Bruce, MF; Hutchison, JD			Changing proximal femoral geometry in northeast Scotland: an osteometric study	BRITISH MEDICAL JOURNAL			English	Article							HIP FRACTURE; INCREASE; FEMUR; WOMEN; 1950S; 1990S		Univ Aberdeen, Sch Med, Dept Orthopaed, Aberdeen AB9 2ZD, Scotland; Marischal Coll, Dept Biomed Sci, Aberdeen AB10 1YS, Scotland	University of Aberdeen; University of Aberdeen	Duthie, RA (corresponding author), Univ Aberdeen, Sch Med, Dept Orthopaed, Aberdeen AB9 2ZD, Scotland.							FAULKNER KG, 1993, J BONE MINER RES, V8, P1211, DOI 10.1002/jbmr.5650081008; ONeill TW, 1996, OSTEOPOROSIS INT, V6, P136, DOI 10.1007/BF01623937; REID IR, 1994, BRIT MED J, V309, P508, DOI 10.1136/bmj.309.6953.508; Vega E, 1991, Osteoporos Int, V1, P81, DOI 10.1007/BF01880448; WALLACE WA, 1983, LANCET, V1, P1413	5	13	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1998	316	7143					1498	1498		10.1136/bmj.316.7143.1498	http://dx.doi.org/10.1136/bmj.316.7143.1498			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP020	9582136	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000073707700026
J	Neubauer, H; Cumano, A; Muller, M; Wu, H; Huffstadt, U; Pfeffer, K				Neubauer, H; Cumano, A; Muller, M; Wu, H; Huffstadt, U; Pfeffer, K			Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis	CELL			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION PATHWAY; COLONY-STIMULATING FACTOR; MICE LACKING JAK3; STEM-CELL FACTOR; C-KIT; ERYTHROPOIETIN RECEPTOR; LYMPHOCYTE MATURATION; DEVELOPING MOUSE; YOLK-SAC	Janus kinases (Jaks) play an important role in signal transduction via cytokine and growth factor receptors. A targeted inactivation of Jak2 was performed. Jak2(-/-) embryos are anemic and die around day 12.5 postcoitum. Primitive erythrocytes are found, but definitive erythropoiesis is absent. Compared to erythropoietin receptor-deficient mice, the phenotype of Jak2 deficiency is more severe. Fetal liver BFU-E and CFU-E colonies are completely absent. However, multilineage hematopoietic stem cells (CD34(low), c-kit(pos)) can be found, and B lymphopoiesis appears intact. In contrast to IFN alpha stimulation, Jak2(-/-) cells do not respond to IFN gamma. Jak2(-/-) embryonic stem cells are competent for LIF signaling. The data provided demonstrate that Jak2 has pivotal functions for signal transduction of a set of cytokine receptors required in definitive erythropoiesis.	Tech Univ Munich, Inst Med Microbiol & Hyg, D-81675 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Dept Mammalian Genet, D-85758 Neuherberg, Germany; Inst Pasteur, Unite Biol Mol Gene, F-75024 Paris, France; Univ Vet Med, Dept Vet Biotechnol & Mol Genet, Inst Genet & Anim Breeding, A-1210 Vienna, Austria; Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Veterinary Medicine Vienna; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Pfeffer, K (corresponding author), Tech Univ Munich, Inst Med Microbiol & Hyg, Trogerstr 9, D-81675 Munich, Germany.		Neubauer, Hans/C-4467-2016	Neubauer, Hans/0000-0002-3467-4105; Muller, Mathias/0000-0002-7879-3552; Pfeffer, Klaus/0000-0002-5652-6330; Cumano, Ana/0000-0002-4578-959X				Aguila HL, 1997, IMMUNOL REV, V157, P13, DOI 10.1111/j.1600-065X.1997.tb00971.x; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Bach EA, 1996, MOL CELL BIOL, V16, P3214; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; Chen JZ, 1996, ADV IMMUNOL, V62, P31, DOI 10.1016/S0065-2776(08)60427-7; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CUMANO A, 1993, P NATL ACAD SCI USA, V90, P6429, DOI 10.1073/pnas.90.14.6429; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; EMERSON SG, 1985, J CLIN INVEST, V76, P1286, DOI 10.1172/JCI112087; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; GREGORY CJ, 1978, BLOOD, V51, P527; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Kobayashi M, 1996, BLOOD, V88, P429, DOI 10.1182/blood.V88.2.429.bloodjournal882429; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; KRAUSE DS, 1994, BLOOD, V84, P691; Ku H, 1996, BLOOD, V87, P4544, DOI 10.1182/blood.V87.11.4544.bloodjournal87114544; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cellbio.11.1.35; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NISHINAKAMURA R, 1995, IMMUNITY, V2, P211, DOI 10.1016/1074-7613(95)90046-2; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PAZDRAK K, 1995, J IMMUNOL, V155, P397; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Sanchez MJ, 1996, IMMUNITY, V5, P513, DOI 10.1016/S1074-7613(00)80267-8; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIMODA K, 1994, BIOCHEM BIOPH RES CO, V203, P922, DOI 10.1006/bbrc.1994.2270; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; WURST W, 1993, GENE TARGETING PRACT; Yoder MC, 1997, IMMUNITY, V7, P335, DOI 10.1016/S1074-7613(00)80355-6; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Yoshida M, 1997, BRIT J HAEMATOL, V98, P254, DOI 10.1046/j.1365-2141.1997.2283045.x	69	626	712	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 1	1998	93	3					397	409		10.1016/S0092-8674(00)81168-X	http://dx.doi.org/10.1016/S0092-8674(00)81168-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590174	Bronze			2022-12-01	WOS:000073471500015
J	Dolmetsch, RE; Xu, KL; Lewis, RS				Dolmetsch, RE; Xu, KL; Lewis, RS			Calcium oscillations increase the efficiency and specificity of gene expression	NATURE			English	Article							INTRACELLULAR CA2+ STORES; NF-KAPPA-B; T-LYMPHOCYTES; ANTIGEN RECEPTOR; CYCLOSPORINE-A; CALCINEURIN; ACTIVATION; CHANNELS; CELLS; DEPLETION	Cytosolic calcium ([Ca2+](i)) oscillations are a nearly universal mode of signalling in excitable and non-excitable cells(1-4). Although Ca2+ is known to mediate a diverse array of cell functions, it is not known whether oscillations contribute to the efficiency or specificity of signalling or are merely an inevitable consequence of the feedback control of [Ca2+](i). We have developed a Ca2+ clamp technique to investigate the roles of oscillation amplitude and frequency in regulating gene expression driven by the proinflammatory transcription factors NF-AT, Oct/GAP and NF-kappa B. Here we report that oscillations reduce the effective Ca2+ threshold for activating transcription factors, thereby increasing signal detection at low levels of stimulation. In addition, specificity is encoded by the oscillation frequency: rapid oscillations stimulate all three transcription factors, whereas infrequent oscillations activate only NF-kappa B. The genes encoding the cytokines interleukin (IL)-2 and IL-8 are also frequency-sensitive in a way that reflects their degree of dependence on NF-AT versus NF-kappa B. Our results provide direct evidence that [Ca2+]i oscillations increase both the efficacy and the information content of Ca2+ signals that lead to gene expression and cell differentiation.	Stanford Univ, Sch Med, Beckman Ctr Mol & Genet Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Stanford University	Lewis, RS (corresponding author), Stanford Univ, Sch Med, Beckman Ctr Mol & Genet Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA.			Lewis, Richard/0000-0002-6010-7403	NIGMS NIH HHS [R01 GM045374] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045374] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DOLMETSCH RE, IN PRESS IMAGING LIV; DONNADIEU E, 1992, J IMMUNOL, V148, P2643; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; DURAND DB, 1987, J EXP MED, V165, P3955; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; Fields RD, 1997, J NEUROSCI, V17, P7252; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WECHSLER AS, 1994, J IMMUNOL, V153, P2515; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	30	1593	1635	1	102	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					933	936		10.1038/31960	http://dx.doi.org/10.1038/31960			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582075				2022-12-01	WOS:000073359900052
J	DeLong, E				DeLong, E			Microbiology - Archaeal means and extremes	SCIENCE			English	Editorial Material							RIBOSOMAL-RNA SEQUENCES; PHYLOGENETIC ANALYSIS; ARCHAEBACTERIA; EUKARYOTES; EVOLUTION; DIVERSITY		Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA	Monterey Bay Aquarium Research Institute	DeLong, E (corresponding author), Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA.							Barns SM, 1996, P NATL ACAD SCI USA, V93, P9188, DOI 10.1073/pnas.93.17.9188; Bintrim SB, 1997, P NATL ACAD SCI USA, V94, P277, DOI 10.1073/pnas.94.1.277; Blochl E, 1997, EXTREMOPHILES, V1, P14; Borneman J, 1997, APPL ENVIRON MICROB, V63, P2647, DOI 10.1128/AEM.63.7.2647-2653.1997; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5685, DOI 10.1073/pnas.89.12.5685; DeLong EF, 1998, APPL ENVIRON MICROB, V64, P1133; DELONG EF, 1994, NATURE, V371, P695, DOI 10.1038/371695a0; Fuhrman JA, 1997, MAR ECOL PROG SER, V150, P275, DOI 10.3354/meps150275; FUHRMAN JA, 1992, NATURE, V356, P148, DOI 10.1038/356148a0; Godon JJ, 1997, APPL ENVIRON MICROB, V63, P2802, DOI 10.1128/AEM.63.7.2802-2813.1997; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; Hershberger KL, 1996, NATURE, V384, P420, DOI 10.1038/384420a0; Holden JF, 1998, FEMS MICROBIOL ECOL, V25, P33, DOI 10.1111/j.1574-6941.1998.tb00458.x; HUBER R, 1990, NATURE, V345, P179, DOI 10.1038/345179a0; Hugenholtz P, 1998, J BACTERIOL, V180, P366, DOI 10.1128/JB.180.2.366-376.1998; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; Jurgens G, 1997, APPL ENVIRON MICROB, V63, P803, DOI 10.1128/AEM.63.2.803-805.1997; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kudo Y, 1997, BIOSCI BIOTECH BIOCH, V61, P917, DOI 10.1271/bbb.61.917; MASSANA R, 1997, NATURE, V63, P50; MCGREGOR BJ, 1997, APPL ENVIRON MICROB, V63, P1178; MCINERNEY JO, 1995, APPL ENVIRON MICROB, V61, P1646, DOI 10.1128/AEM.61.4.1646-1648.1995; Munson MA, 1997, APPL ENVIRON MICROB, V63, P4729, DOI 10.1128/AEM.63.12.4729-4733.1997; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Preston CM, 1996, P NATL ACAD SCI USA, V93, P6241, DOI 10.1073/pnas.93.13.6241; Schleper C, 1997, J BACTERIOL, V179, P7803, DOI 10.1128/jb.179.24.7803-7811.1997; Schleper C, 1997, APPL ENVIRON MICROB, V63, P321, DOI 10.1128/AEM.63.1.321-323.1997; Stein JL, 1996, J BACTERIOL, V178, P591, DOI 10.1128/jb.178.3.591-599.1996; UEDA T, 1995, EUR J SOIL SCI, V46, P415, DOI 10.1111/j.1365-2389.1995.tb01337.x; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1978, J MOL EVOL, V11, P245, DOI 10.1007/BF01734485; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	33	70	72	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					542	543		10.1126/science.280.5363.542	http://dx.doi.org/10.1126/science.280.5363.542			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9575100				2022-12-01	WOS:000073242100032
J	Chan, WP; Prete, F; Dickinson, MH				Chan, WP; Prete, F; Dickinson, MH			Visual input to the efferent control system of a fly's "gyroscope"	SCIENCE			English	Article							BLOWFLY CALLIPHORA; LOBULA PLATE; FLIGHT; HALTERE; DIPTERA; NEURONS; VICINA; LOCUST; CELLS	Dipterous insects (the true flies) have a sophisticated pair of equilibrium organs called halteres that evolved from hind wings, The halteres are sensitive to Coriolis forces that result from angular rotations of the body and mediate corrective reflexes during flight, Like the aerodynamically functional fore wings, the halteres beat during flight and are equipped with their own set of control muscles. It is shown that motoneurons innervating muscles of the haltere receive strong excitatory input from directionally sensitive visual interneurons. Visually guided flight maneuvers of flies may be mediated in part by efferent modulation of hard-wired equilibrium reflexes.	Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; De Paul Univ, Dept Psychol, Chicago, IL 60614 USA	University of California System; University of California Berkeley; DePaul University	Dickinson, MH (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.			Prete, Frederick R./0000-0001-9642-9298				AUTRUM H., 1958, EXPTL CELL RES SUPPL, V5, P426; BONHAG PF, 1948, MEM CORNELL U AGR EX, V285, P3; Chan WP, 1996, J COMP NEUROL, V369, P405, DOI 10.1002/(SICI)1096-9861(19960603)369:3&lt;405::AID-CNE6&gt;3.0.CO;2-9; COLLETT TS, 1975, J COMP PHYSIOL, V99, P1, DOI 10.1007/BF01464710; DERHAM W, 1714, PHYSICOTHEOLOGY, pCH4; Dickinson M. H., 1997, Society for Neuroscience Abstracts, V23, P769; Dickinson MH, 1997, COMP BIOCHEM PHYS A, V116, P223, DOI 10.1016/S0300-9629(96)00162-4; ECCLES J. C., 1930, PROC ROY SOC [LONDON] B, V106, P326, DOI 10.1098/rspb.1930.0032; FAUST R., 1952, ZOOL JAHRB ABT ALLG ZOOL U PHYSIOL TIERE, V63, P325; Fayyazuddin A, 1996, J NEUROSCI, V16, P5225; Fraenkel G, 1938, NATURE, V141, P919, DOI 10.1038/141919a0; GALAMBOS R, 1956, J NEUROPHYSIOL, V19, P424, DOI 10.1152/jn.1956.19.5.424; GNATZY W, 1987, ZOOMORPHOLOGY, V106, P312, DOI 10.1007/BF00312005; HAUSEN K, 1982, BIOL CYBERN, V46, P67, DOI 10.1007/BF00335352; HAUSEN K, 1976, Z NATURFORSCH C, V31, P629; Heide G, 1971, ZOOL JB PHYSL, V76, P87; HELDE G, 1968, Z VERGL PHYSIOL, V59, P456; HELDE G, 1983, BIONA REPORT, V2, P35; HENGSTENBERG R, 1982, J COMP PHYSIOL, V149, P179, DOI 10.1007/BF00619212; HENGSTENBERG R, 1986, PROC R SOC SER B-BIO, V227, P455, DOI 10.1098/rspb.1986.0034; HENGSTENBERG R, 1988, J COMP PHYSIOL A, V163, P151, DOI 10.1007/BF00612425; KUFFLER SW, 1955, J GEN PHYSIOL, V39, P155, DOI 10.1085/jgp.39.1.155; Lehmann FO, 1998, J EXP BIOL, V201, P385; MCCREA RA, 1996, BEHAV CONTINGENT PRO, P292; Mickoleit G., 1962, Zoologische Jahrbuecher Jena Anatomie, V80, P213; MIYAN JA, 1985, PHILOS T ROY SOC B, V311, P271, DOI 10.1098/rstb.1985.0154; NALBACH G, 1994, NEUROSCIENCE, V61, P149, DOI 10.1016/0306-4522(94)90068-X; NALBACH G, 1994, J COMP PHYSIOL A, V175, P695; NALBACH G, 1993, J COMP PHYSIOL A, V173, P293, DOI 10.1007/BF00212693; Pflugstaedt H, 1912, Z WISS ZOOL ABT A, V100, P1; PRINGLE JWS, 1949, J PHYSIOL-LONDON, V108, P226, DOI 10.1113/jphysiol.1949.sp004326; REICHERT H, 1985, NATURE, V315, P142, DOI 10.1038/315142a0; REICHERT H, 1985, J NEUROPHYSIOL, V53, P1201, DOI 10.1152/jn.1985.53.5.1201; SANDEMAN DC, 1980, J EXP BIOL, V85, P43; SANDEMAN DC, 1980, J COMP PHYSIOL, V136, P361, DOI 10.1007/BF00657358; SCHNEIDER G, 1953, Z VERGL PHYSIOL, V35, P416, DOI 10.1007/BF00297884; Trimarchi JR, 1997, J NEUROSCI, V17, P4700; WAGNER H, 1986, PHILOS T ROY SOC B, V312, P553, DOI 10.1098/rstb.1986.0018; WOLF H, 1993, J EXP BIOL, V182, P229	39	97	98	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					289	292		10.1126/science.280.5361.289	http://dx.doi.org/10.1126/science.280.5361.289			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535659				2022-12-01	WOS:000073082400052
J	Sakowicz, R; Berdelis, MS; Ray, K; Blackburn, CL; Hopmann, C; Faulkner, DJ; Goldstein, LSB				Sakowicz, R; Berdelis, MS; Ray, K; Blackburn, CL; Hopmann, C; Faulkner, DJ; Goldstein, LSB			A marine natural product inhibitor of kinesin motors	SCIENCE			English	Article							CRYSTAL-STRUCTURE; DOMAIN; PROTEIN; MYOSIN; NCD	Members of the kinesin superfamily of motor proteins are essential for mitotic and meiotic spindle organization, chromosome segregation, organelle and vesicle transport, and many other processes that require microtubule-based transport. A compound, adociasulfate-2, was isolated from a marine sponge, Haliclona (also known as Adocia) species, that inhibited kinesin activity by targeting its motor domain and mimicking the activity of the microtubule. Thus, the kinesin-microtubule interaction site could be a useful target for small molecule modulators, and adociasulfate-2 should serve as an archetype for specific inhibitors of kinesin functions.	Univ Calif San Diego, Howard Hughes Med Inst, Dept Pharmacol, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Institution of Oceanography	Goldstein, LSB (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Dept Pharmacol, Div Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Ray, Krishanu/0000-0001-6406-3199				Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; Faulkner DJ, 1997, NAT PROD REP, V14, P259, DOI 10.1039/np9971400259; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; Hackney DD, 1996, ANNU REV PHYSIOL, V58, P731; Hirokawa N, 1996, CELL STRUCT FUNCT, V21, P357, DOI 10.1247/csf.21.357; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Minden JS, 1996, BIOTECHNIQUES, V20, P122; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sheetz MP, 1996, CELL STRUCT FUNCT, V21, P369, DOI 10.1247/csf.21.369; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	19	87	95	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					292	295		10.1126/science.280.5361.292	http://dx.doi.org/10.1126/science.280.5361.292			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535660				2022-12-01	WOS:000073082400053
J	Mulle, C; Sailer, A; Perez-Otano, I; Dickinson-Anson, H; Castillo, PE; Bureau, I; Maron, C; Gage, FH; Mann, JR; Bettler, B; Heinemann, SF				Mulle, C; Sailer, A; Perez-Otano, I; Dickinson-Anson, H; Castillo, PE; Bureau, I; Maron, C; Gage, FH; Mann, JR; Bettler, B; Heinemann, SF			Altered synaptic physiology and reduced susceptibility to kainate-induced seizures in GluR6-deficient mice	NATURE			English	Article							KAINIC ACID; PYRAMIDAL CELLS; RECEPTORS; EXPRESSION; DEATH; HIPPOCAMPUS; PLASTICITY; SYNAPSES; CLONING; AMPA	L-glutamate, the neurotransmitter of the majority of excitatory synapses in the brain, acts on three classes of ionotropic receptors: NMDA (N-methyl-D-aspartate), AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) and kainate receptors. Little is known about the physiological role of kainate receptors because in many experimental situations it is not possible to distinguish them from AMPA receptors(1,2). Mice with disrupted kainate receptor genes enable the study of the specific role of kainate receptors in synaptic transmission as well as in the neurotoxic effects of kainate. We have now generated mutant mice lacking the kainate-receptor subunit GluR6. The hippocampal neurons in the CA3 region of these mutant mice are much less sensitive to kainate. In addition, a postsynaptic kainate current evoked in CA3 neurons by a train of stimulation of the mossy fibre system is absent in the mutant(3,4). We find that GluR6-deficient mice are less susceptible to systemic administration of kainate, as judged by onset of seizures and by the activation of immediate early genes in the hippocampus. Our results indicate that kainate receptors containing the GluR6 subunit are important in synaptic transmission as well as in the epileptogenic effects of kainate.	Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Fac Med, Dept Fisiol, Montevideo, Uruguay; City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA; Univ Bordeaux 2, CNRS, UMR 5541, F-33076 Bordeaux, France	Salk Institute; Salk Institute; Universidad de la Republica, Uruguay; City of Hope; Beckman Research Institute of City of Hope; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Heinemann, SF (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA.		bettler, bernhard/AAO-8018-2020; Perez-Otano, Isabel/S-9613-2017; Bureau, Ingrid/O-3941-2016; Sailer, Andreas/M-9913-2016	Perez-Otano, Isabel/0000-0002-7222-8202; Castillo, Pablo/0000-0002-9834-1801; Bureau, Ingrid/0000-0001-9166-2250; Mulle, Christophe/0000-0003-2709-6615; Bettler, Bernhard/0000-0003-0842-8207; Sailer, Andreas/0000-0002-9015-7946				BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; Bischoff S, 1997, J COMP NEUROL, V379, P541, DOI 10.1002/(SICI)1096-9861(19970324)379:4<541::AID-CNE6>3.0.CO;2-2; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; Clarke VRJ, 1997, NATURE, V389, P599, DOI 10.1038/39315; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; Kamiya H, 1996, J PHYSIOL-LONDON, V493, P447, DOI 10.1113/jphysiol.1996.sp021395; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; LASALLE GL, 1988, NEUROSCI LETT, V88, P127, DOI 10.1016/0304-3940(88)90112-7; Lerma J, 1997, TRENDS NEUROSCI, V20, P9, DOI 10.1016/S0166-2236(96)20055-4; MONAGHAN DT, 1982, BRAIN RES, V252, P91, DOI 10.1016/0006-8993(82)90981-7; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROBINSON JH, 1981, BRAIN RES, V221, P117, DOI 10.1016/0006-8993(81)91067-2; RodriguezMoreno A, 1997, NEURON, V19, P893, DOI 10.1016/S0896-6273(00)80970-8; Salin PA, 1996, P NATL ACAD SCI USA, V93, P13304, DOI 10.1073/pnas.93.23.13304; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; SMEYNE RJ, 1993, NATURE, V365, P279, DOI 10.1038/365279b0; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; YOUNG ST, 1991, P NATL ACAD SCI USA, V88, P1291, DOI 10.1073/pnas.88.4.1291; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	26	390	401	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					601	605		10.1038/33408	http://dx.doi.org/10.1038/33408			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9580260				2022-12-01	WOS:000072987200059
J	York, RD; Yao, H; Dillon, T; Ellig, CL; Eckert, SP; McCleskey, EW; Stork, PJS				York, RD; Yao, H; Dillon, T; Ellig, CL; Eckert, SP; McCleskey, EW; Stork, PJS			Rap1 mediates sustained MAP kinase activation induced by nerve growth factor	NATURE			English	Article							PC12 CELLS; NEURONAL DIFFERENTIATION; SIGNALING PATHWAYS; CRK PROTEIN; SH3 DOMAIN; FACTOR C3G; RECEPTOR; RAS; SPECIFICITY; SUFFICIENT	Activation of mitogen-activated protein (MAP) kinase (also known as extracellular-signal-regulated kinase, or ERK)(1) by growth factors can trigger either cell growth or differentiation. The intracellular signals that couple growth factors to MAP kinase may determine the different effects of growth factors: for example, transient activation of MAP kinase by epidermal growth factor stimulates proliferation of PC12 cells(1), whereas they differentiate in response to nerve growth factor, which acts partly by inducing a sustained activation of MAP kinase(1). Here we show that activation of MAP kinase by nerve growth factor involves two distinct pathways: the initial activation of MAP kinase requires the small G protein Ras, but its activation is sustained by the small G protein Rap1. Rap1 is activated by CRK adaptor proteins and the guanine-nucleotide-exchange factor C3G, and forms a stable complex with B-Raf, an activator of MAP kinase. Rap1 is required for at least two indices of neuronal differentiation by nerve growth factor: electrical excitability and the induction of neuron-specific genes. We propose that the activation of Rap1 by C3G represents a common mechanism to induce sustained activation of the MAP kinase cascade in cells that express B-Raf.	Oregon Hlth Sci Univ, Vollum Inst Adv Biomed Res, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Stork, PJS (corresponding author), Oregon Hlth Sci Univ, Vollum Inst Adv Biomed Res, Portland, OR 97201 USA.	stork@ohsu.edu						Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DESOUZA S, 1995, J BIOL CHEM, V270, P9106, DOI 10.1074/jbc.270.16.9106; DICHTER MA, 1977, NATURE, V268, P501, DOI 10.1038/268501a0; FANGER GR, 1993, J NEUROCHEM, V61, P1977, DOI 10.1111/j.1471-4159.1993.tb09844.x; FELLER SM, 1995, ONCOGENE, V10, P1465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; PAN MG, 1995, ONCOGENE, V11, P2005; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; TANAKA M, 1995, MOL CELL BIOL, V15, P689; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAO H, 1995, J BIOL CHEM, V270, P20748, DOI 10.1074/jbc.270.35.20748	30	757	771	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					622	626		10.1038/33451	http://dx.doi.org/10.1038/33451			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560161				2022-12-01	WOS:000072987200065
J	Parry, SM; Salmon, RL; Willshaw, GA; Cheasty, T				Parry, SM; Salmon, RL; Willshaw, GA; Cheasty, T			Risk factors for and prevention of sporadic infections with vero cytotoxin (shiga toxin) producing Escherichia coli O157	LANCET			English	Article							HEMORRHAGIC COLITIS	Background Recent outbreaks of vero cytotoxin (shiga toxin) producing Escherichia coli O157 (VTEC O157) infection have stimulated debate on food safety. However, 90% of cases in England and Wales are sporadic. We report a case-control study of sporadic VTEC O157 infection. Methods We compared 85 sporadic cases of VTEC O157 infection, identified through population surveillance, with 142 controls, randomly selected from general practitioners' lists. We matched cases and controls for age, sex, and family doctor's practice. Exposures to foods, water, animals, farms, and environmental factors were recorded. We visited the premises concerned when cases had eaten beefburgers or cooked sliced meats from caterers or had had contact with a farm. Findings Consumption of a beefburger from a catering premises other than from a fast-food chain A (a national chain) and consumption of cold cooked sliced meat leg, in a salad or sandwich) from caterers, but not butchers, was associated with VTEC O157 infection (odds ratios 4.63 [95% CI 1.33-30.14] and 3.36 [1.04-12.74), respectively). Policies for ensuring thorough cooking of burgers by one national fast-food chain differed from the other catering premises we visited. There was evidence of person-to-person spread and transmission of VTEC O157 infection from animals. Interpretation Local inspection of catering establishments that serve cooked meats together with public education to prevent spread on farms and in houses would reduce the burden of VTEC O157 infection by about 10% for each risk factor.	Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Cardiff CF4 3QX, S Glam, Wales; Welsh Combined Ctr Publ Hlth, Cardiff, S Glam, Wales; Cent Publ Hlth Lab, Lab Enter Pathogens, London NW9 5HT, England	Public Health England	Salmon, RL (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Abton House, Cardiff CF4 3QX, S Glam, Wales.							*ADV COMM MICR SAF, 1995, REP VER PROD ESCH CO; Allaby M A, 1995, Commun Dis Rep CDR Rev, V5, pR4; Breslow NE, 1980, STAT METHODS CANC RE; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; BRYANT HE, 1989, J INFECT DIS, V160, P858, DOI 10.1093/infdis/160.5.858; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P85; CHAPMAN PA, 1993, VET REC, V133, P171, DOI 10.1136/vr.133.7.171; COIA JE, 1994, RECENT ADV VEROCYTOT; Cowden J M, 1995, Commun Dis Rep CDR Rev, V5, pR109; DEV VJ, 1991, LANCET, V337, P1412, DOI 10.1016/0140-6736(91)93092-N; GREENLAND S, 1988, AM J EPIDEMIOL, V128, P1185, DOI 10.1093/oxfordjournals.aje.a115073; *INF AG SURV CTR, 1996, INFECT AGENTS SURVEI, V17, P180; LESAUX N, 1993, J INFECT DIS, V167, P500, DOI 10.1093/infdis/167.2.500; MARCH SB, 1986, J CLIN MICROBIOL, V23, P869, DOI 10.1128/JCM.23.5.869-872.1986; Mead PS, 1997, ARCH INTERN MED, V157, P204, DOI 10.1001/archinte.157.2.204; PARRY SM, 1995, LANCET, V346, P572, DOI 10.1016/S0140-6736(95)91407-2; Pennington Group, 1997, REP CIRC LEAD 1996 O; SALMON RL, 1994, RECENT ADV VEROCYTOX; *SCOTT CTR INF ENV, 1997, SCIEH WKLY REP, V31, P41; Shukla R, 1995, Commun Dis Rep CDR Rev, V5, pR86; Stevenson J, 1996, Commun Dis Rep CDR Rev, V6, pR116; Thomas A, 1996, EPIDEMIOL INFECT, V117, P1, DOI 10.1017/S0950268800001060; *WHO DIV FOOD NUTR, 1993, TRAIN CONS APPL HAZ	23	68	70	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1019	1022		10.1016/S0140-6736(97)08376-1	http://dx.doi.org/10.1016/S0140-6736(97)08376-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546508				2022-12-01	WOS:000072927200012
J	Kitazawa, S; Kimura, T; Yin, PB				Kitazawa, S; Kimura, T; Yin, PB			Cerebellar complex spikes encode both destinations and errors in arm movements	NATURE			English	Article							PURKINJE-CELL COMPLEX; MONKEY; DISCHARGE; NEURONS	Purkinje cells of the cerebellum discharge complex spikes, named after the complexity of their waveforms(1), with a frequency of similar to 1 Hz during arm movements(1-13). Despite the low frequency of firing, complex spikes have been proposed to contribute to the initiation of arm movements(2,7-10) or to the gradual improvement of motor skills(2,4-6,14-6). Here we recorded the activity of Purkinje cells from the hemisphere of cerebellar lobules IV-VI while trained monkeys made short-lasting reaching movements (of similar to 200 milliseconds in duration) to touch a visual target that appeared at a random location on a tangent screen, We examined the relationship between complex-spike discharges and the absolute touch position, and between complex-spike discharges and relative errors in touching the screen. We used information theory to show that the complex spikes occurring at the beginning of the reach movement encode the absolute destination of the reach, and the complex spikes occurring at the end of the short-lasting movements encode the relative errors, Thus, complex spikes convey multiple types of information, consistent with the idea that they contribute both to the generation of movements and to the gradual, long-term improvement of these movements.	Electrotech Lab, Informat Sci Div, Tsukuba, Ibaraki 3058568, Japan; Japan Sci & Technol Corp, PRESTO, Tsukuba, Ibaraki 3058568, Japan; Japan Sci & Technol Corp, CREST, Tsukuba, Ibaraki 3058568, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Kitazawa, S (corresponding author), Electrotech Lab, Informat Sci Div, 1-1-4 Umezono, Tsukuba, Ibaraki 3058568, Japan.							ABELES M, 1977, P IEEE, V65, P762, DOI 10.1109/PROC.1977.10559; ARBIB A, 1996, BEHAV BRAIN SCI, V19, P434; BAUSWEIN E, 1983, J PHYSIOL-LONDON, V339, P379, DOI 10.1113/jphysiol.1983.sp014722; FU QG, 1997, NEUROREPORT, V8, P253; GILBERT PFC, 1977, BRAIN RES, V128, P309, DOI 10.1016/0006-8993(77)90997-0; Houk JC, 1996, BEHAV BRAIN SCI, V19, P368, DOI 10.1017/S0140525X00081474; Ito M., 1984, CEREBELLUM NEURAL CO; KAWATO M, 1992, BIOL CYBERN, V68, P95, DOI 10.1007/BF00201431; KEATING JG, 1995, J NEUROPHYSIOL, V73, P1329, DOI 10.1152/jn.1995.73.4.1329; KITAZAWA S, 1995, J NEUROSCI, V15, P7644; MANO N, 1989, EXP BRAIN RES, V17, P265; MANO NI, 1986, J NEUROPHYSIOL, V56, P137, DOI 10.1152/jn.1986.56.1.137; OJAKANGAS CL, 1992, J NEUROPHYSIOL, V68, P2222, DOI 10.1152/jn.1992.68.6.2222; OJAKANGAS CL, 1994, J NEUROPHYSIOL, V72, P2617, DOI 10.1152/jn.1994.72.6.2617; Simpson JI, 1996, BEHAV BRAIN SCI, V19, P384, DOI 10.1017/S0140525X00081486; Thach W. T., 1996, Behavioral and Brain Sciences, V19, P411; THACH WT, 1968, J NEUROPHYSIOL, V31, P785, DOI 10.1152/jn.1968.31.5.785; THACH WT, 1970, J NEUROPHYSIOL, V33, P537, DOI 10.1152/jn.1970.33.4.537; WANG JJ, 1987, BRAIN RES, V410, P323, DOI 10.1016/0006-8993(87)90331-3	19	274	276	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					494	497		10.1038/33141	http://dx.doi.org/10.1038/33141			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548253				2022-12-01	WOS:000072875200058
J	Shiraki, H; Yoshikawa, T; Anzai, T; Negishi, K; Takahashi, T; Asakura, Y; Akaishi, M; Mitamura, H; Ogawa, S				Shiraki, H; Yoshikawa, T; Anzai, T; Negishi, K; Takahashi, T; Asakura, Y; Akaishi, M; Mitamura, H; Ogawa, S			Association between preinfarction angina and a lower risk of right ventricular infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Heart-Association	NOV 09-18, 1996	NEW ORLEANS, LA	Amer Heart Assoc, Natl Inst Alcohol Abuse & Alcoholism			ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY OCCLUSION; SHORT-TERM PROGNOSIS; COLLATERAL CIRCULATION; HEART-DISEASE; ISCHEMIA; ANGIOPLASTY; PECTORIS; SIZE; PROTECTION	Background Right ventricular infarction occurs in conjunction with inferior myocardial infarction caused by proximal occlusion of the right coronary artery. However, right ventricular infarction occurs infrequently, and the reasons for this are uncertain. Methods We retrospectively assessed the association between preinfarction angina and right ventricular infarction, as well as the short-term outcome, in 113 patients with a first acute inferior myocardial infarction caused by right-coronary-artery occlusion. The association between the timing of angina during the week before infarction and the clinical outcome was also assessed. Results The absence of preinfarction angina predicted the development of right ventricular infarction (odds ratio, 6.3; 95 percent confidence interval, 2.7 to 15.1; P<0.001), complete atrioventricular block (odds ratio, 3.6; 95 percent confidence interval, 1.4 to 10.3; P=0.01), and combined hypotension and shock (odds ratio, 12.4; 95 percent confidence interval, 4.5 to 40.6; P<0.001). Angina 24 to 72 hours before infarction was most strongly associated with reductions in the rates of right ventricular infarction (adjusted odds ratio, 0.2; 95 percent confidence interval, 0 to 0.8; P=0.02) and combined hypotension and shock (adjusted odds ratio, 0.1; 95 percent confidence interval, 0 to 0.5; P=0.02). Conclusions Preinfarction angina was an independent predictor of the absence of right ventricular infarction in patients with acute inferior myocardial infarction. The patients with preinfarction angina also had better short-term outcomes than those without preinfarction angina. (C) 1998, Massachusetts Medical Society.	Yokohama Municipal Hosp, Dept Cardiol, Hodogaya Ku, Yokohama, Kanagawa 2400062, Japan; Keio Univ, Sch Med, Dept Internal Med, Tokyo, Japan	Keio University	Shiraki, H (corresponding author), Yokohama Municipal Hosp, Dept Cardiol, Hodogaya Ku, 56 Okazawa Cho, Yokohama, Kanagawa 2400062, Japan.		Anzai, Toshihisa/J-2179-2015	Anzai, Toshihisa/0000-0003-3319-4967				ANDERSEN HR, 1987, J AM COLL CARDIOL, V10, P1223, DOI 10.1016/S0735-1097(87)80122-5; ANDERSEN HR, 1989, INT J CARDIOL, V23, P349, DOI 10.1016/0167-5273(89)90195-2; Andreotti F, 1996, NEW ENGL J MED, V334, P7, DOI 10.1056/NEJM199601043340102; ANZAI T, 1995, J AM COLL CARDIOL, V26, P319, DOI 10.1016/0735-1097(95)80002-X; ANZAI T, 1994, AM J CARDIOL, V74, P755, DOI 10.1016/0002-9149(94)90428-6; BRAAT SH, 1983, BRIT HEART J, V49, P368; CABIN HS, 1987, AM HEART J, V113, P16, DOI 10.1016/0002-8703(87)90004-4; CORTINA A, 1985, J AM COLL CARDIOL, V5, P619, DOI 10.1016/S0735-1097(85)80386-7; CRIBIER A, 1992, J AM COLL CARDIOL, V20, P578, DOI 10.1016/0735-1097(92)90011-B; CROFT CH, 1982, AM J CARDIOL, V50, P421, DOI 10.1016/0002-9149(82)90305-8; DEUTSCH E, 1990, CIRCULATION, V82, P2044, DOI 10.1161/01.CIR.82.6.2044; FUJITA M, 1987, BRIT HEART J, V57, P139; GEFT IL, 1984, AM J CARDIOL, V53, P991, DOI 10.1016/0002-9149(84)90623-4; GENSINI GG, 1969, AM J CARDIOL, V24, P393, DOI 10.1016/0002-9149(69)90434-2; GOLDSTEIN JA, 1992, J AM COLL CARDIOL, V19, P704, DOI 10.1016/S0735-1097(10)80296-7; HAUPT HM, 1983, CIRCULATION, V67, P1268, DOI 10.1161/01.CIR.67.6.1268; HIRAI T, 1992, AM HEART J, V124, P19, DOI 10.1016/0002-8703(92)90915-I; ISNER JM, 1978, AM J CARDIOL, V42, P885, DOI 10.1016/0002-9149(78)90672-0; KINCH JW, 1994, NEW ENGL J MED, V330, P1211, DOI 10.1056/NEJM199404283301707; KLONER RA, 1995, CIRCULATION, V91, P37, DOI 10.1161/01.CIR.91.1.37; KUZUYA T, 1993, CIRC RES, V72, P1293, DOI 10.1161/01.RES.72.6.1293; LEW AS, 1985, AM J CARDIOL, V55, P883, DOI 10.1016/0002-9149(85)90711-8; LOVE JC, 1984, AM HEART J, V108, P5, DOI 10.1016/0002-8703(84)90537-4; MARBER MS, 1993, CIRCULATION, V88, P1264, DOI 10.1161/01.CIR.88.3.1264; MATSUDA Y, 1984, AM HEART J, V108, P955, DOI 10.1016/0002-8703(84)90460-5; MULLER DWM, 1990, AM HEART J, V119, P224, DOI 10.1016/S0002-8703(05)80008-0; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NAKAGAWA Y, 1995, J AM COLL CARDIOL, V25, P1076, DOI 10.1016/0735-1097(94)00542-X; NICOD P, 1988, J AM COLL CARDIOL, V12, P589, DOI 10.1016/S0735-1097(88)80042-1; OPOLSKI G, 1986, INT J CARDIOL, V10, P141, DOI 10.1016/0167-5273(86)90222-6; OTTANI F, 1995, CIRCULATION, V91, P291, DOI 10.1161/01.CIR.91.2.291; RACKLEY CE, 1981, AM HEART J, V101, P215, DOI 10.1016/0002-8703(81)90668-2; RATLIFF NB, 1980, AM J CARDIOL, V45, P217, DOI 10.1016/0002-9149(80)90638-4; RENTROP KP, 1985, J AM COLL CARDIOL, V5, P587; RENTROP KP, 1988, AM J CARDIOL, V61, P677, DOI 10.1016/0002-9149(88)91048-X; SETARO J F, 1992, Cardiology Clinics, V10, P69; Yang XM, 1996, CARDIOVASC RES, V31, P777, DOI 10.1016/0008-6363(96)00026-0; Yoshida N, 1993, J AM COLL CARDIOL, V22, P426, DOI 10.1016/0735-1097(93)90046-4; YOSHIKAWA T, 1993, CARDIOLOGY, V82, P42, DOI 10.1159/000175852; ZEHENDER M, 1993, NEW ENGL J MED, V328, P981, DOI 10.1056/NEJM199304083281401	40	70	72	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					941	947		10.1056/NEJM199804023381402	http://dx.doi.org/10.1056/NEJM199804023381402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZE776	9521981	Bronze			2022-12-01	WOS:000072829800002
J	Wu, YC; Horvitz, HR				Wu, YC; Horvitz, HR			C-elegans phagocytosis and cell-migration protein CED-5 is similar to human DOCK180	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; DEATH; RECOGNITION; APOPTOSIS; MUTATIONS; ENCODES; MUSCLE	During programmed cell death, cell corpses are rapidly engulfed(1). This engulfment process involves the recognition and subsequent phagocytosis of cell corpses by engulfing cells(1-4). How cell corpses are engulfed is largely unknown, Here we report that ced-5, a gene that is required for cell-corpse engulfment in the nematode Caenorhabditis elegan(5), encodes a protein that is similar to the human protein DOCK180 and the Drosophila melanogaster protein Myoblast City (MBC), both of which have been implicated in the extension of cell surfaces(6). ced-5 mutants are defective not only in the engulfment of cell corpses but also in the migrations of two specific gonadal cells, the distal tip cells. The expression of human DOCK180 in C. elegans rescued the cell-migration defect of a ced-5 mutant. We present evidence that ced-5 functions in engulfing cells during the engulfment of cell corpses. We suggest that ced-5 acts in the extension of the surface of an engulfing cell around a dying cell during programmed cell death, We name this new family of proteins that function in the extension of cell surfaces the CDM (for CED-5, DOCK180 and MBC) family.	MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), MIT, Dept Biol, Howard Hughes Med Inst, 68-425,77 Massachusetts Ave, Cambridge, MA 02139 USA.	horvitz@mit.edu	Wu, Yi-Chun/F-7934-2012	Wu, Yi-Chun/0000-0002-8621-4098				BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; ELLIS RE, 1991, GENETICS, V129, P79; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Hart SP, 1996, EXPERIENTIA, V52, P950, DOI 10.1007/BF01920103; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HESEGAWA H, 1996, MOL CELL BIOL, V16, P1770; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; ROBERTSON AMG, 1982, J EMBRYOL EXP MORPH, V67, P89; RUSHTON E, 1995, DEVELOPMENT, V121, P1979; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	29	315	325	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					501	504		10.1038/33163	http://dx.doi.org/10.1038/33163			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548255				2022-12-01	WOS:000072875200060
J	Newman, B; Mu, H; Butler, LM; Millikan, RC; Moorman, PG; King, MC				Newman, B; Mu, H; Butler, LM; Millikan, RC; Moorman, PG; King, MC			Frequency of breast cancer attributable to BRCA1 in a population-based series of American women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OVARIAN-CANCER; FAMILIAL BREAST; GENETIC-HETEROGENEITY; SCREENING MAMMOGRAPHY; MUTATIONS; LINKAGE; JEWISH	Context.-Previous studies of BRCA1 mutation prevalence have been based on high-risk groups, yielding estimates that do not reflect the experience of the general population of US patients with breast cancer. Objective.-To determine prevalence of known disease-related mutations and other variants in BRCA1 and how it differs by race, age at diagnosis, and family history status in a population-based sample of white and black patients with breast cancer unselected for family history, Design.-Case-control study. Setting.-A 24-county area of central and eastern North Carolina. Participants.-Cases were women aged 20 to 74 years diagnosed as having a first invasive breast cancer between May 1993 and June 1996. Controls were frequency matched to cases by 5-year age range and race. The first 211 cases and 188 controls regardless of race and the subsequent 99 cases and 108 controls of African American ancestry are included in this report. Main Outcome Measure.-Germline variants at any site in the coding sequence, splice junctions, 5' untranslated region, or 3' untranslated region of the BRCA1 gene were analyzed in cases, and selected variants were analyzed in controls. Screening was performed using multiplex single-strand conformation analysis, with all potential variants confirmed using genomic sequencing. Results.-Three of 211 patients with breast cancer had disease-related variants at BRCA1, all of which were protein-truncating mutations. After adjustment for sampling probabilities, the proportion of patients with breast cancer with disease-related variants was 3.3% (95% confidence interval, 0%-7.2%) in white women and 0% in black women. Young age at diagnosis alone did not predict BRCA1 carrier status in this population, In white women, prevalence of inherited mutation was 23% for cases with family history of ovarian cancer, 13% for cases from families with at least 4 cases of breast cancer with or without ovarian cancer, and 33% for cases from families with both breast and ovarian cancer and at least 4 affected relatives. Because these results are based on few families at the highest levels of risk, confidence intervals around these estimates are wide. An additional 5 patients had rare missense mutations or a single amino acid deletion, the biological significance of which is unknown, In black women, a variant in the 3' untranslated region was statistically significantly more common in cases than in controls. Conclusions.-These data suggest that in the general US population, widespread screening of BRCA1 is not warranted. In contrast, BRCA1 mutations are sufficiently frequent in families with both breast and ovarian cancer, or at least 4 cases of breast cancer (at any age), that genotyping might be considered. The emerging picture of BRCA1 population genetics involves complex interactions of family history, age, and genetic ancestry, all of which should be taken into account when considering testing or interpreting results.	Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Div Med Genet, Dept Med, Seattle, WA 98195 USA; Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Yale University	Newman, B (corresponding author), Univ N Carolina, Dept Epidemiol, CB 7400 McGavran-Greenberg Hall, Chapel Hill, NC 27599 USA.	beth_newman@unc.edu		King, Mary-Claire/0000-0001-9426-1743	NATIONAL CANCER INSTITUTE [P50CA058223, R01CA027632] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA58223, R01-CA27632] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDRICH TE, 1995, BREAST CANCER RES TR, V35, P61, DOI 10.1007/BF00694746; *AM SOC HUM GEN AD, 1994, AM J HUM GENET, V55, P2; ARENA J, 1996, AM J HUM GENET, V59, P34; Bradley Martin B., 1992, CHURCHES CHURCH MEMB; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; COLLINS FS, 1994, JAMA-J AM MED ASSOC, V271, P785, DOI 10.1001/jama.1994.03510340075038; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; Fletcher SW, 1997, NEW ENGL J MED, V336, P1180, DOI 10.1056/NEJM199704173361612; FORD D, 1995, AM J HUM GENET, V57, P1457; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Ford LG, 1997, PROG CLIN BIOL RES, V396, P271; FRIEDMAN LS, 1995, AM J HUM GENET, V57, P1284; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Gao Q, 1997, AM J HUM GENET, V60, P1233; HALL J, 1900, SCIENCE, V250, P1684; Hartmann L., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P168; Healy B, 1997, NEW ENGL J MED, V336, P1448, DOI 10.1056/NEJM199705153362009; Hubbard R, 1996, NEW ENGL J MED, V334, P1192, DOI 10.1056/NEJM199605023341812; Hubbard R., 1993, EXPLODING GENE MYTH; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P33, DOI 10.1001/jama.276.1.33; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Langston AA, 1996, AM J HUM GENET, V58, P881; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; MARGARITTE P, 1992, AM J HUM GENET, V50, P1231; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD S, 1995, AM J HUM GENET, V57, P957; NAROD SA, 1991, LANCET, V338, P82; Neuhausen SL, 1996, AM J HUM GENET, V58, P271; NEWMAN B, 1995, BREAST CANCER RES TR, V35, P51, DOI 10.1007/BF00694745; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Peelen T, 1997, AM J HUM GENET, V60, P1041; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Puget N, 1997, CANCER RES, V57, P828; Rebbeck TR, 1996, AM J HUM GENET, V59, P547; *RES TRIANGL I, 1996, SUDAAN SOFTW STAT AN; Rothenberg K, 1997, SCIENCE, V275, P1755, DOI 10.1126/science.275.5307.1755; Rothenberg KH, 1995, J LAW MED ETHICS, V23, P312, DOI 10.1111/j.1748-720X.1995.tb01373.x; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAS, 1996, SAS STAT SOFTW CHANG; *SAS I INC, 1993, SAS STAT SOFTW GENMO; Schubert EK, 1997, AM J HUM GENET, V60, P1031; Serova OM, 1997, AM J HUM GENET, V60, P486; ShattuckEidens D, 1997, JAMA-J AM MED ASSOC, V278, P1242, DOI 10.1001/jama.278.15.1242; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; WEINBERG CR, 1991, AM J EPIDEMIOL, V134, P421, DOI 10.1093/oxfordjournals.aje.a116104; WEINBERG CR, 1990, BIOMETRICS, V46, P963, DOI 10.2307/2532441; Whittemore AS, 1997, AM J HUM GENET, V60, P496	53	288	293	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					915	921		10.1001/jama.279.12.915	http://dx.doi.org/10.1001/jama.279.12.915			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC304	9544765	Bronze			2022-12-01	WOS:000072563600031
J	Weber, T; Zemelman, BV; McNew, JA; Westermann, B; Gmachl, M; Parlati, F; Sollner, TH; Rothman, JE				Weber, T; Zemelman, BV; McNew, JA; Westermann, B; Gmachl, M; Parlati, F; Sollner, TH; Rothman, JE			SNAREpins: Minimal machinery for membrane fusion	CELL			English	Article							SYNAPTIC VESICLE DOCKING; VESICULAR TRANSPORT; RAT-BRAIN; IN-VITRO; PROTEIN; SYNTAXIN; COMPLEX; SYNAPTOBREVIN; EXOCYTOSIS; SNAP-25	Recombinant v- and t-SNARE proteins reconstituted into separate lipid bilayer vesicles assemble into SNARE-pins-SNARE complexes linking two membranes. This leads to spontaneous fusion of the docked membranes at physiological temperature. Docked unfused intermediates can accumulate at lower temperatures and can fuse when brought to physiological temperature. A supply of unassembled v-and t-SNAREs is needed for these intermediates to form, but not for the fusion that follows. These data imply that SNARE-pins are the minimal machinery for cellular membrane fusion.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Rothman, JE (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.		Zdilla, Michael J/B-4145-2011; McNew, James/ABD-8081-2020; Weber, Thomas/A-2363-2008; Wunder, Stephanie L/B-5066-2012; McNew, James/AAV-4911-2020; Weber, Thomas/GLS-9125-2022; Westermann, Benedikt/H-7766-2013	Weber, Thomas/0000-0002-0494-0484; McNew, James/0000-0001-8459-3664; Weber, Thomas/0000-0002-0494-0484; Westermann, Benedikt/0000-0002-2991-1604; Zemelman, Boris/0000-0003-2463-4887				AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; Bagai S, 1996, J CELL BIOL, V135, P73, DOI 10.1083/jcb.135.1.73; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; Binley J, 1997, NATURE, V387, P346, DOI 10.1038/387346a0; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHAPMAN CF, 1995, PHOTOCHEM PHOTOBIOL, V62, P416, DOI 10.1111/j.1751-1097.1995.tb02362.x; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; Dimitrov DS, 1997, CELL, V91, P721, DOI 10.1016/S0092-8674(00)80460-2; DUNN B, 1993, NATURE, V362, P53; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Giovane C, 1997, BIOTECHNIQUES, V22, P796, DOI 10.2144/97225bm01; Glenn DE, 1996, FEBS LETT, V386, P137, DOI 10.1016/0014-5793(96)00432-2; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LANGNER M, 1993, CHEM PHYS LIPIDS, V65, P23, DOI 10.1016/0009-3084(93)90078-H; Lentz BR, 1997, BIOCHEMISTRY-US, V36, P2076, DOI 10.1021/bi9623340; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; Linial M, 1997, J NEUROCHEM, V69, P1781; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; Monck JR, 1996, CURR OPIN CELL BIOL, V8, P524, DOI 10.1016/S0955-0674(96)80031-7; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; Orci L, 1998, P NATL ACAD SCI USA, V95, P2279, DOI 10.1073/pnas.95.5.2279; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; Pelham HRB, 1995, COLD SPRING HARB SYM, V60, P105, DOI 10.1101/SQB.1995.060.01.013; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; Rabenstein MD, 1996, BIOCHEMISTRY-US, V35, P13922, DOI 10.1021/bi961743t; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0	81	1961	1996	4	189	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					759	772		10.1016/S0092-8674(00)81404-X	http://dx.doi.org/10.1016/S0092-8674(00)81404-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529252	Bronze			2022-12-01	WOS:000072661200009
J	Leitzmann, MF; Giovannucci, EL; Rimm, EB; Stampfer, MJ; Spiegelman, D; Wing, AL; Willett, WC				Leitzmann, MF; Giovannucci, EL; Rimm, EB; Stampfer, MJ; Spiegelman, D; Wing, AL; Willett, WC			The relation of physical activity to risk for symptomatic gallstone disease in men	ANNALS OF INTERNAL MEDICINE			English	Article						cholelithiasis; exercise; obesity; weight loss	DENSITY-LIPOPROTEIN CHOLESTEROL; MALE HEALTH-PROFESSIONALS; GASTROINTESTINAL TRANSIT; HISPANIC POPULATIONS; GALLBLADDER-DISEASE; LOGISTIC-REGRESSION; GLUCOSE-UTILIZATION; INTESTINAL TRANSIT; DANISH POPULATION; DEOXYCHOLIC-ACID	Background: Gallstone disease is a major source of morbidity in the United States. Gallstones are twice as common in women as in men, but severe biliary events leading to surgery occur with equal frequency in the two sexes. Objective: To determine whether physical activity decreases risk for symptomatic gallstone disease in men. Design: Prospective cohort study. Setting: U.S. male health professionals. Patients: 45813 men 40 to 75 years of age were followed from 1986 to 1994. Measurements: Questionnaires mailed in 1986, 1988, 1990, 1992, and 1994 asked about physical activity, incidence of gallstone disease, age, body weight, dietary and alcohol intake, smoking habits, use of medications, and occurrence of diagnosed medical conditions other than gallstone disease. Results: 828 men reported having newly symptomatic gallstones (diagnosed by ultrasonography or radiography) or undergoing cholecystectomy for recent symptoms. After adjustment for multiple confounders, increased physical activity was inversely related to risk for symptomatic gallstone disease. When extreme quintiles were compared, men younger than 65 years of age had a stronger inverse association (multivariate relative risk, 0.58 [95% CI, 0.44 to 0.78]) with risk than did men 65 years of age or older (relative risk, 0.75 [CI, 0.52 to 1.09]). In contrast, sedentary behavior was positively related to risk for symptomatic gallstone disease. Men who watched television more than 40 hours per week had a higher risk for symptomatic gallstones than men who watched less than 6 hours per week (relative risk for older men, 3.32 [CI, 1.51 to 7.27]; relative risk for younger men, 1.58 [CI, 0.38 to 6.48]). Conclusions: Physical activity may play an important role in the prevention of symptomatic gallstone disease in men even beyond its benefit for control of body weight. The results of this study indicate that 34% of cases of symptomatic gallstone disease in men could be prevented by increasing exercise to 30 minutes of endurance-type training five times per week.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Leitzmann, MF (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.							AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; ALDOORI WH, 1995, GUT, V36, P276, DOI 10.1136/gut.36.2.276; ANGELICO M, 1988, HEPATOLOGY, V8, P907; ATTILI AF, 1987, DIGEST DIS SCI, V32, P349, DOI 10.1007/BF01296286; BAKER TT, 1986, METABOLISM, V35, P1037, DOI 10.1016/0026-0495(86)90040-5; BASSO L, 1992, EUR J EPIDEMIOL, V8, P629, DOI 10.1007/BF00145375; BOUCHARD G, 1994, P SOC EXP BIOL MED, V206, P409; CHAIT A, 1979, J CLIN INVEST, V64, P1309, DOI 10.1172/JCI109587; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; EVERHART JE, 1993, ANN INTERN MED, V119, P1029, DOI 10.7326/0003-4819-119-10-199311150-00010; FRIEDMAN GD, 1989, J CLIN EPIDEMIOL, V42, P127, DOI 10.1016/0895-4356(89)90086-3; FRIEDMAN GD, 1966, J CHRON DIS, V19, P273, DOI 10.1016/0021-9681(66)90132-9; HALLORAN LG, 1978, SURGERY, V84, P1; HEATON KW, 1993, LANCET, V341, P8, DOI 10.1016/0140-6736(93)92479-D; Hussaini SH, 1995, HEPATOLOGY, V22, P1735, DOI 10.1016/0270-9139(95)90199-X; JANOWITZ P, 1992, CLIN INVESTIGATOR, V70, P430, DOI 10.1007/BF00235527; JENNINGS G, 1986, CIRCULATION, V73, P30, DOI 10.1161/01.CIR.73.1.30; JORGENSEN T, 1990, SCAND J GASTROENTERO, V25, P335, DOI 10.3109/00365529009095495; JORGENSEN T, 1989, GUT, V30, P528, DOI 10.1136/gut.30.4.528; Kang J, 1996, DIABETES CARE, V19, P341, DOI 10.2337/diacare.19.4.341; KATO I, 1992, DIGEST DIS SCI, V37, P784, DOI 10.1007/BF01296440; KEELING WF, 1987, J APPL PHYSIOL, V63, P978, DOI 10.1152/jappl.1987.63.3.978; KOFFLER KH, 1992, MED SCI SPORT EXER, V24, P415; KONO S, 1995, SCAND J GASTROENTERO, V30, P372, DOI 10.3109/00365529509093293; LEE SP, 1981, J CLIN INVEST, V67, P1712, DOI 10.1172/JCI110209; Linos A D, 1989, HPB Surg, V1, P221, DOI 10.1155/1989/56539; MARCUS SN, 1986, GUT, V27, P550, DOI 10.1136/gut.27.5.550; MAURER KR, 1990, AM J EPIDEMIOL, V131, P836, DOI 10.1093/oxfordjournals.aje.a115574; MAURER KR, 1989, GASTROENTEROLOGY, V96, P487, DOI 10.1016/0016-5085(89)91575-8; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MINGRONE G, 1988, BIOCHIM BIOPHYS ACTA, V958, P52, DOI 10.1016/0005-2760(88)90245-7; *NAT CTR HLTH STAT, 1994, ADV DAT VIT HLTH STA, V278; NEPOKROEFF CM, 1974, ARCH BIOCHEM BIOPHYS, V160, P387, DOI 10.1016/0003-9861(74)90412-3; Ortega RM, 1997, J AM COLL NUTR, V16, P88, DOI 10.1080/07315724.1997.10718655; Ostrowska Lucyna, 1996, Medycyna Pracy, V47, P461; OZEKI K, 1992, GASTROENTEROLOGY, V103, P759, DOI 10.1016/0016-5085(92)90003-H; PERSSON GE, 1991, ACTA CHIR-EUR J SURG, V157, P473; PETITTI DB, 1981, NEW ENGL J MED, V304, P1396, DOI 10.1056/NEJM198106043042305; PHILLIPP E, 1992, PEPTIDES, V13, P125, DOI 10.1016/0196-9781(92)90150-2; RIMM E, 1995, AM J EPIDEMIOL, V141, pS17; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; ROSENTHAL M, 1983, DIABETES, V32, P408, DOI 10.2337/diabetes.32.5.408; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; ROTHMAN KJ, 1986, EPIDEMIOLOGY, P87; SARIN SK, 1986, DIGEST DIS SCI, V31, P1041, DOI 10.1007/BF01300256; SARLES H, 1969, AM J DIG DIS, V14, P531, DOI 10.1007/BF02232927; SCHWARTZ RS, 1992, METABOLISM, V41, P649, DOI 10.1016/0026-0495(92)90058-I; SCRAGG RKR, 1984, BMJ-BRIT MED J, V289, P521, DOI 10.1136/bmj.289.6444.521; SUBBIAH MTR, 1984, BIOCHEM BIOPH RES CO, V124, P896, DOI 10.1016/0006-291X(84)91042-8; THORNTON JR, 1981, BRIT MED J, V283, P1352, DOI 10.1136/bmj.283.6303.1352; TRAN ZV, 1983, MED SCI SPORT EXER, V15, P393; *US DEP HHS CDCP N, 1996, PHYS ACT HLTH REP SU; *US DEP HHS NAT I, 1995, NIH PUBL; *USDA AGR RES SERV, 1995, USDA NUTR DAT STAND; Utter A. C., 1995, Medicine and Science in Sports and Exercise, V27, pS57; WATKINS JB, 1994, DRUG METAB DISPOS, V22, P537; WHEELER M, 1970, GUT, V11, P430, DOI 10.1136/gut.11.5.430; WILLETT WC, 1990, NUTR EPIDEMIOLOGY, P262; WILLIAMS CN, 1980, CAN MED ASSOC J, V122, P664	62	129	132	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					417	+		10.7326/0003-4819-128-6-199803150-00001	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499324				2022-12-01	WOS:000072414700001
J	Morton, CC				Morton, CC			US dialysis survival strategy	ANNALS OF INTERNAL MEDICINE			English	Article																			0	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					514	516		10.7326/0003-4819-128-6-199803150-00039	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00039			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499351				2022-12-01	WOS:000072414700036
J	Nielsen, H; Pappot, H; Christensen, IJ; Brunner, N; Thorlacius-Ussing, O; Moesgaard, F; Dano, K; Grondahl-Hansen, J				Nielsen, H; Pappot, H; Christensen, IJ; Brunner, N; Thorlacius-Ussing, O; Moesgaard, F; Dano, K; Grondahl-Hansen, J			Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer	BRITISH MEDICAL JOURNAL			English	Article							PAI-1		Hvidovre Hosp, Dept Surg Gastroenterol, DK-2650 Hvidovre, Denmark; Rigshosp, Finsen Lab, DK-2100 Copenhagen, Denmark; Aalborg Hosp, Dept Surg Gastroenterol, DK-9000 Aalborg, Denmark	University of Copenhagen; Rigshospitalet; University of Copenhagen; Aalborg University; Aalborg University Hospital	Nielsen, H (corresponding author), Hvidovre Hosp, Dept Surg Gastroenterol, DK-2650 Hvidovre, Denmark.		Pappot, Helle/ADY-3530-2022	Nielsen, Hans Jorgen/0000-0003-2619-4379; Thorlacius-Ussing, Ole/0000-0003-4963-1551				ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; CASSLEN B, 1994, EUR J CANCER, V30A, P1302, DOI 10.1016/0959-8049(94)90178-3; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; MEIJER P, 1994, CLIN CHEM, V40, P110	5	75	77	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					829	830		10.1136/bmj.316.7134.829	http://dx.doi.org/10.1136/bmj.316.7134.829			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549453	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000072584300029
J	Saks, ME; Sampson, JR; Abelson, J				Saks, ME; Sampson, JR; Abelson, J			Evolution of a transfer RNA gene through a point mutation in the anticodon	SCIENCE			English	Article							ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; AMINO-ACIDS; DISCRIMINATOR BASE; ACCEPTOR STEM; HAIRPIN RNA; IDENTITY; CODE; SYNTHETASE; RECOGNITION	The transfer RNA (tRNA) multigene family comprises 20 amino acid-accepting groups, many of which contain isoacceptors, The addition of isoacceptors to the tRNA repertoire was critical to establishing the genetic code, yet the origin of isoacceptors remains largely unexplored, A model of tRNA evolution, termed "tRNA gene recruitment," was formulated. It proposes that a tRNA gene can be recruited from one isoaccepting group to another by a point mutation that concurrently changes tRNA amino acid identity and messenger RNA coupling capacity, A test of the model showed that an Escherichia coli strain, in which the essential tRNA(UGU)(Thr), gene was inactivated, was rendered viable when a tRNA(Arg) with a point mutation that changed its anticodon from UCU to UGU (threonine) was expressed, Insertion of threonine at threonine codons by the "recruited" tRNA(Arg) was corroborated by in vitro aminoacylation assays showing that its specificity had been changed from arginine to threonine, Therefore, the recruitment model may account for the evolution of some tRNA genes.	CALTECH, Div Biol 147 75, Pasadena, CA 91125 USA	California Institute of Technology	Saks, ME (corresponding author), Univ Oregon, Dept Biol, Eugene, OR 97403 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048560] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48560] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNER SA, 1993, RNA WORLD, P27; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BLOCH DP, 1985, BIOSYSTEMS, V17, P209, DOI 10.1016/0303-2647(85)90075-9; CEDERGREN RJ, 1980, P NATL ACAD SCI-BIOL, V77, P2791, DOI 10.1073/pnas.77.5.2791; CHANDA VB, 1990, CURRENT PROTOCOLS MO; CHATTAPADHYAY R, 1990, BIOCHEMISTRY-US, V29, P4263, DOI 10.1021/bi00470a001; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; DICK TP, 1995, J MOL EVOL, V41, P1; DIGIULIO M, 1994, J THEOR BIOL, V171, P303, DOI 10.1006/jtbi.1994.1233; DIGIULIO M, 1995, J THEOR BIOL, V177, P95, DOI 10.1016/S0022-5193(05)80007-4; EIGEN M, 1989, SCIENCE, V244, P673, DOI 10.1126/science.2497522; Felsenstein J., PHYLOGENY INFERENCE; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FITCH WM, 1987, COLD SPRING HARB SYM, V52, P759, DOI 10.1101/SQB.1987.052.01.085; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Gabriel K, 1996, SCIENCE, V271, P195, DOI 10.1126/science.271.5246.195; GAUSS DH, 1979, TRANSFER RNA STRUCTU, P518; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HASEGAWA T, 1992, BIOCHEM BIOPH RES CO, V184, P478, DOI 10.1016/0006-291X(92)91219-G; IKEMURA T, 1981, J MOL BIOL, V146, P1, DOI 10.1016/0022-2836(81)90363-6; JUKES TH, 1987, NATURE, V325, P668, DOI 10.1038/325668b0; JUKES TH, 1987, COLD SPRING HARB SYM, V52, P769, DOI 10.1101/SQB.1987.052.01.086; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LACEY JC, 1990, ORIGINS LIFE EVOL B, V20, P303, DOI 10.1007/BF01808112; LI SH, 1993, J BIOL CHEM, V268, P18335; LOFTFIELD RB, 1963, BIOCHEM J, V89, P82, DOI 10.1042/bj0890082; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; Martinis Susan A., 1995, P349; MCCLAIN WH, 1987, J MOL BIOL, V194, P635, DOI 10.1016/0022-2836(87)90240-3; MCCLAIN WH, 1990, P NATL ACAD SCI USA, V87, P9260, DOI 10.1073/pnas.87.23.9260; MCCLAIN WH, 1993, J MOL BIOL, V234, P257, DOI 10.1006/jmbi.1993.1582; MOLLER W, 1992, J MOL EVOL, V34, P471, DOI 10.1007/BF00160461; MOLLER W, 1990, BIOCHIMIE, V72, P361, DOI 10.1016/0300-9084(90)90033-D; MUENCH KH, 1966, PROCEDURES NUCLEIC A, P375; Nakamura Y, 1997, NUCLEIC ACIDS RES, V25, P244, DOI 10.1093/nar/25.1.244; Noller H.F., 1993, RNA WORLD, P137; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; OSAWA S, 1992, MICROBIOL REV, V56, P229, DOI 10.1128/MMBR.56.1.229-264.1992; PAK M, 1992, BIOCHEMISTRY-US, V31, P3303, DOI 10.1021/bi00128a001; PALLANCK L, 1992, J BIOL CHEM, V267, P7221; PALLANCK L, 1991, P NATL ACAD SCI USA, V88, P3872, DOI 10.1073/pnas.88.9.3872; Pallanck Leo, 1995, P371; Rodin S, 1996, P NATL ACAD SCI USA, V93, P4537, DOI 10.1073/pnas.93.10.4537; RODIN S, 1993, P NATL ACAD SCI USA, V90, P4723, DOI 10.1073/pnas.90.10.4723; Rodin SN, 1997, P NATL ACAD SCI USA, V94, P5183, DOI 10.1073/pnas.94.10.5183; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; SAKS ME, 1995, J MOL EVOL, V40, P509; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SCHIMMEL P, 1994, P NATL ACAD SCI USA, V91, P11283, DOI 10.1073/pnas.91.24.11283; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; Sprinzl M, 1996, NUCLEIC ACIDS RES, V24, P68, DOI 10.1093/nar/24.1.68; SQUIRES C, 1971, NATURE-NEW BIOL, V233, P274, DOI 10.1038/newbio233274a0; STAVES MP, 1988, ORIGINS LIFE EVOL B, V18, P97, DOI 10.1007/BF01808784; STAVES MP, 1987, Z NATURFORSCH C, V42, P129; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P2335, DOI 10.1093/nar/20.9.2335; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; YOUNG RA, 1979, J BIOL CHEM, V254, P2725	70	68	69	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1665	1670		10.1126/science.279.5357.1665	http://dx.doi.org/10.1126/science.279.5357.1665			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497276				2022-12-01	WOS:000072490000041
J	Renault, L; Nassar, N; Vetter, I; Becker, J; Klebe, C; Roth, M; Wittinghofer, A				Renault, L; Nassar, N; Vetter, I; Becker, J; Klebe, C; Roth, M; Wittinghofer, A			The 1.7 angstrom crystal structure of the regulator of chromosome condensation (RCC1) reveals a seven-bladed propeller	NATURE			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; GENE RCC1; G-PROTEIN; RAN; HOMOLOGY; PATHWAY; MITOSIS; PROGRAM	The gene encoding the regulator of chromosome condensation (RCC1) was cloned by virtue of its ability to complement the temperature-sensitive phenotype of the hamster cell line tsBN2, which undergoes premature chromosome condensation or arrest in the G1 phase of the cell cycle at non-permissive temperatures(1-2). RCC1 homologues have been identified in many eukaryotes, including budding and fission yeast. Mutations in the gene affect pre-messenger RNA processing and transport(3,4), mating(5), initiation of mitosis(6) and chromatin decondensation(7), suggesting that RCC1 is important in the control of nucleo-cytoplasmic transport and the cell cycle. Biochemically, RCC1 is a guanine-nucleotide-exchange factor for the nuclear Ras homologue Ran(8); it increases the dissociation of Ran-bound GDP by 10(5)-fold (ref. 9). It may also bind to DNA via a protein-protein complex(2). Here we show that the structure of human RCC1, solved to 1.7-Angstrom resolution by X-ray crystallography, consists of a seven-bladed propeller formed from internal repeats of 51-68 residues per blade. The sequence and structure of the repeats differ from those of WD40-domain proteins, which also form seven-bladed propellers and include the beta-subunits of G proteins. The nature of the structure explains the consequences of a wide range of known mutations. The region of the protein that is involved in guanine-nucleotide exchange is located opposite the region that is thought to be involved in chromosome binding.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44139 Dortmund, Germany; Inst Biol Struct Jean Pierre Ebel, Lab Cristallog & Cristallogenese Prot, F-38027 Grenoble 1, France	Max Planck Society; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Rheinlanddamm 201, D-44139 Dortmund, Germany.	alfred.wittinghofer@mpi-dortmund.mpg.de						AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; Azuma Y, 1996, J BIOCHEM-TOKYO, V120, P82; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BRUNGER AT, 1996, XPLOR VERSION 3 8; CLARK KL, 1989, MOL CELL BIOL, V9, P2682, DOI 10.1128/MCB.9.6.2682; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MATYNIA A, IN PRESS GENETICS; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; Seki T, 1996, J BIOCHEM, V120, P207; VELLIEUX FMDAP, 1995, J APPL CRYSTALLOGR, V28, P347, DOI 10.1107/S0021889894012355; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650	29	240	247	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					97	101		10.1038/32204	http://dx.doi.org/10.1038/32204			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510255				2022-12-01	WOS:000072373000058
J	Nightingale, SL				Nightingale, SL			Generic substitution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.							U.S. Food and Drug Administration, APPROVED DRUG PRODUC	1	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2022-12-01	WOS:000072192800006
J	Siersted, HC; Boldsen, J; Hansen, HS; Mostgaard, G; Hyldebrandt, N				Siersted, HC; Boldsen, J; Hansen, HS; Mostgaard, G; Hyldebrandt, N			Population based study of risk factors for underdiagnosis of asthma in adolescence: Odense schoolchild study	BRITISH MEDICAL JOURNAL			English	Article							PEAK EXPIRATORY FLOW; BRONCHIAL RESPONSIVENESS; LUNG-FUNCTION; YOUNG-ADULTS; CHILDREN; CHILDHOOD; SYMPTOMS; DIAGNOSIS; ATOPY; UNDERTREATMENT	Objective: To describe factors related to underdiagnosis of asthma in adolescence. Design: Subgroup analysis in a population based cohort study. Setting: Odense municipality, Denmark. Subjects: 495 schoolchildren aged 12 to 15 years were selected from a cohort of 1369 children investigated 3 years earlier. Selection was done by randomisation (n = 292) and by a history indicating allergy or asthma-like symptoms in subject or family (n = 203). Main outcome measures: Undiagnosed asthma defined as coexistence of asthma-like symptoms and one or more obstructive airway abnormalities (low ratio of forced expiratory volume in 1 second to forced vital capacity, hyperresponsiveness to methacholine or exercise, or peak now hypervariability) in the absence of physician diagnosed asthma. Risk factors (odds ratios) for underdiagnosis. Results: Undiagnosed asthma comprised about one third of all asthma identified. Underdiagnosis was independently associated with low physical activity, high body mass, serious family problems, passive smoking, and the absence of rhinitis. Girls were overrepresented among undiagnosed patients with asthma (69%) and underrepresented among diagnosed patients (33%). Among the risk factors identified, low physical activity and problems in the family were independently associated with female sex. The major symptom among those undiagnosed was cough (58%), whereas wheezing (35%) or breathing trouble (50%) was reported less frequently than among those diagnosed. Less than one third of those undiagnosed had reported their symptoms to a doctor. Conclusions: Asthma, as defined by combined symptoms and test criteria, was seriously underdiagnosed among adolescents. Underdiagnosis was most prevalent among girls and was associated with a low tendency to report symptoms and with several independent risk factors that may help identification of previously undiagnosed asthmatic patients.	Odense Univ Hosp, Dept Med C, Sect Resp Dis, DK-5000 Odense C, Denmark; Odense Univ Hosp, Dept Cardiol, DK-5000 Odense, Denmark; Odense Univ, Ctr Hlth & Social Policy, DK-5230 Odense M, Denmark; Private Specialist Clin, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Southern Denmark	Siersted, HC (corresponding author), Odense Univ Hosp, Dept Med C, Sect Resp Dis, DK-5000 Odense C, Denmark.							BAUMAN A, 1992, AUST NZ J MED, V22, P36, DOI 10.1111/j.1445-5994.1992.tb01706.x; CLOUGH JB, 1991, AM REV RESPIR DIS, V143, P755, DOI 10.1164/ajrccm/143.4_Pt_1.755; CUIJPERS CEJ, 1994, J ASTHMA, V31, P301, DOI 10.3109/02770909409089477; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218, DOI 10.1164/ajrccm.153.1.8542119; DuranTauleria E, 1996, BRIT MED J, V313, P148, DOI 10.1136/bmj.313.7050.148; HANNAWAY PJ, 1982, JAMA-J AM MED ASSOC, V247, P206, DOI 10.1001/jama.247.2.206; HANSEN HS, 1990, J HYPERTENS, V8, P641, DOI 10.1097/00004872-199007000-00007; Husman T, 1996, SCAND J WORK ENV HEA, V22, P5, DOI 10.5271/sjweh.103; Joyce DP, 1996, CHEST, V109, P697, DOI 10.1378/chest.109.3.697; KOLNAAR BGM, 1994, FAM PRACT, V11, P133, DOI 10.1093/fampra/11.2.133; KUHN CE, 1995, PEDIATR PULM, V19, P156, DOI 10.1002/ppul.1950190303; Mostgaard G, 1997, RESP MED, V91, P443, DOI 10.1016/S0954-6111(97)90108-6; NISH WA, 1992, ANN ALLERGY, V69, P239; NORUSIS MJ, 1990, SPSS PC PLUS ADV STA; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PEAT JK, 1987, CLIN ALLERGY, V17, P283, DOI 10.1111/j.1365-2222.1987.tb02016.x; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P957, DOI 10.1111/j.1365-2222.1993.tb00281.x; SEARS MR, 1991, ASTHMA ITS PATHOLOGY; SIERSTED HC, 1994, AM J RESP CRIT CARE, V149, P598, DOI 10.1164/ajrccm.149.3.8118624; Siersted HC, 1996, THORAX, V51, P503, DOI 10.1136/thx.51.5.503; SPEIGHT AN, 1978, BRIT MED J, V29, P331; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	27	142	143	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					651	655		10.1136/bmj.316.7132.651	http://dx.doi.org/10.1136/bmj.316.7132.651			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522784	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000072347900021
J	Granzin, J; Wilden, U; Choe, HW; Labahn, J; Krafft, B; Buldt, G				Granzin, J; Wilden, U; Choe, HW; Labahn, J; Krafft, B; Buldt, G			X-ray crystal structure of arrestin from bovine rod outer segments	NATURE			English	Article							CYCLIC-NUCLEOTIDE CASCADE; PHOSPHORYLATED RHODOPSIN; PHOSPHODIESTERASE ACTIVATION; 48-KDA PROTEIN; BINDING; TRANSDUCIN; VISION; GTP	Retinal arrestin is the essential protein for the termination of the light response in vertebrate rod outer segments. It plays an important role in quenching the light-induced enzyme cascade by its ability to bind to phosphorylated light-activated rhodopsin (P-Rh*). Arrestins are found in various G-protein-coupled amplification cascades. Here we report on the three-dimensional structure of bovine arrestin (relative molecular mass, 45,300) at 3.3 Angstrom resolution. The crystal structure comprises two domains of antiparallel beta-sheets connected through a hinge region and one short alpha-helix on the back of the amino-terminal fold. The binding region for phosphorylated light-activated rhodopsin is located at the N-terminal domain, as indicated by the docking of the photoreceptor to the three-dimensional structure of arrestin. This ag rees with the interpretation of binding studies on partially digested and mutated arrestin.	Forschungszentrum Julich, Inst Biol Informationsverarbeitung, D-52425 Julich, Germany; Chonbuk Natl Univ, Coll Nat Sci, Dept Chem, Chongju 560756, South Korea	Helmholtz Association; Research Center Julich; Jeonbuk National University	Granzin, J (corresponding author), Forschungszentrum Julich, Inst Biol Informationsverarbeitung, Postfach 1913, D-52425 Julich, Germany.	J.Granzin@fz-juelich.de	Buldt, Georg/K-5345-2013; Büldt, Georg/H-9509-2014; Labahn, Jörg/G-9593-2013; Granzin, Joachim/G-8937-2013	Labahn, Jörg/0000-0002-0648-8145; Granzin, Joachim/0000-0001-6604-950X				Attwood TK, 1997, NUCLEIC ACIDS RES, V25, P212, DOI 10.1093/nar/25.1.212; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, X PLOR VERSION 3 1 3; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLEYWEGT GJ, 1996, CCP4 ESF EACBM NEWSL, V32, P32; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; Pogozheva ID, 1997, BIOPHYS J, V72, P1963, DOI 10.1016/S0006-3495(97)78842-8; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; UCHIDA S, 1981, J CYCLIC NUCL PROT, V7, P95; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; WILDEN U, 1995, BIOCHEMISTRY-US, V34, P1446, DOI 10.1021/bi00004a040; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1986, FEBS LETT, V207, P292, DOI 10.1016/0014-5793(86)81507-1; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; Wilden U, 1997, FEBS LETT, V415, P268, DOI 10.1016/S0014-5793(97)01137-X; XINYU Z, 1995, BIOPHYS CHEM, V56, P183	28	187	193	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	1998	391	6670					918	921		10.1038/36147	http://dx.doi.org/10.1038/36147			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495348				2022-12-01	WOS:000072230900059
J	Kalgutkar, AS; Crews, BC; Rowlinson, SW; Garner, C; Seibert, K; Marnett, LJ				Kalgutkar, AS; Crews, BC; Rowlinson, SW; Garner, C; Seibert, K; Marnett, LJ			Aspirin-like molecules that covalently inactivate cyclooxygenase-2	SCIENCE			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; SELECTIVE-INHIBITION; EPITHELIAL-CELLS; ACID; ACETYLATION; BINDING; MECHANISM; AGENTS; DRUGS; OVINE	Many of aspirin's therapeutic effects arise from its acetylation of cyclooxygenase-2 (COX-2), whereas its antithrombotic and ulcerogenic effects result from its acetylation of COX-1. Here, aspirin-like molecules were designed that preferentially acetylate and irreversibly inactivate COX-2. The most potent of these compounds was o-(acetoxyphenyl)hept-2-ynyl sulfide (APHS). Relative to aspirin, APHS was 60 times as reactive against COX-2 and 100 times as selective for its inhibition; it also inhibited COX-2 in cultured macrophages and colon cancer cells and in the rat air pouch in vivo. Such compounds may lead to the development of aspirin-like drugs for the treatment or prevention of immunological and proliferative diseases without gastrointestinal or hematologic side effects.	Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res,Canc Ctr, Ctr Mol Toxicol,Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res,Canc Ctr, Ctr Mol Toxicol,Dept Chem, Nashville, TN 37232 USA; Searle Monsanto, St Louis, MO 63167 USA	Vanderbilt University; Vanderbilt University; Monsanto	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, AB Hancock Jr Mem Lab Canc Res,Canc Ctr, Ctr Mol Toxicol,Dept Biochem, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [R35CA047479, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA47479, CA68485] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; Dreser M. H., 1970, PFLUGERS ARCH, V76, P306, DOI [10.1007/bf01662127, DOI 10.1007/BF01662127]; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; Kawamori T, 1998, CANCER RES, V58, P409; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; ROTH GJ, 1975, P NATL ACAD SCI USA, V72, P3073, DOI 10.1073/pnas.72.8.3073; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V109, P1; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANE JR, 1990, STROKE, V21, P12; VANE JR, 1996, SCAND J RHEUMAT S102, V25, P9, DOI DOI 10.3109/03009749609097226; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u	24	239	256	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1268	1270		10.1126/science.280.5367.1268	http://dx.doi.org/10.1126/science.280.5367.1268			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596581				2022-12-01	WOS:000073852500050
J	Nevitt, MC; Ettinger, B; Black, DM; Stone, K; Jamal, SA; Ensrud, K; Segal, M; Genant, HK; Cummings, SR				Nevitt, MC; Ettinger, B; Black, DM; Stone, K; Jamal, SA; Ensrud, K; Segal, M; Genant, HK; Cummings, SR			The association of radiographically detected vertebral fractures with back pain and function: A prospective study	ANNALS OF INTERNAL MEDICINE			English	Article						spinal fractures; back pain; osteoporosis, postmenopausal; activities of daily living	RESTRICTED ACTIVITY DAYS; BONE-MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; OLDER ADULTS; WOMEN; DISABILITY; DEFORMITIES; ALENDRONATE; PREDICTORS; MANAGEMENT	Background: Vertebral fractures are a hallmark of postmenopausal osteoporosis and an important end point in trials of osteoporosis treatment, but the clinical significance of these fractures remains uncertain. Objective: To determine the association of new vertebral fractures with back pain and back-related functional limitation in older women. Design: Prospective observational study. Setting: Multicenter Study of Osteoporotic Fractures. Participants: 7223 white women aged 65 years and older. Measurements: Lateral spine radiographs were obtained at baseline and at a follow-up examination an average of 3.7 years later. Prevalent and incident radiographic vertebral fractures were assessed by quantitative morphometry. Frequency and severity of back pain, disability in doing six activities involving the back, and days of bed rest and days of limited activity due to back pain were assessed annually by questionnaire during follow-up. Results: Among women without a vertebral fracture at baseline, those with at least one incident vertebral fracture were more likely to have increased back pain (odds ratio [OR], 2.4 [95% CI, 1.7 to 3.3]) and back disability (OR, 2.6 [CI, 1.9 to 3.7]) and at least 1 day of bed rest due to back pain (OR, 6.7 [CI, 4.4 to 10.2]) and 7 days of limited activity due to back pain per year (OR, 3.8 [CI, 2.7 to 5.0]). Among women with a fracture at baseline, those with an incident vertebral fracture also had a greater risk for increased back pain (OR, 2.0 [CI, 1.4 to 2.8]) and back disability (OR, 2.2 [CI, 1.5 to 3.1]) and at least 1 day of bed rest (OR, 7.9 [CI, 4.9 to 12.9]) and 7 days of limited activity per year (OR, 3.5 [CI, 2.4 to 5.0]). Women with incident fracture had about 10 additional limited-activity days and 1 to 2 days of bed rest per year. New vertebral fractures that did not come to medical attention were associated with increased back pain and functional limitation. Conclusion: New vertebral fractures, even those not recognized clinically, are associated with substantial increases in back pain and functional limitation due to back pain in older white women. Prevention of new vertebral fractures should reduce the burden of back pain and functional limitation in women with vertebral osteoporosis.	Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94105 USA; Kaiser Permanente Med Care Program, Oakland, CA USA; Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA; Vet Affairs Med Ctr, Minneapolis, MN USA	University of California System; University of California San Francisco; Kaiser Permanente; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Nevitt, MC (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 74 New Montgomery St,Suite 600, San Francisco, CA 94105 USA.			Ensrud, Kristine/0000-0002-9069-3036	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005407, R01AG005394] Funding Source: NIH RePORTER; NIAMS NIH HHS [1-RO1-AR35582] Funding Source: Medline; NIA NIH HHS [5-RO1-AG05394, 1-RO1-AG05407] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLACK DM, 1995, J BONE MINER RES, V10, P890; BLACK DM, 1991, J BONE MINER RES, V6, P883; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; BURGER H, 1994, BRIT MED J, V309, P991, DOI 10.1136/bmj.309.6960.991; COOK DJ, 1993, ARTHRITIS RHEUM, V36, P750, DOI 10.1002/art.1780360603; COOPER C, 1991, OSTEOPOROSIS INT, V2, P48, DOI 10.1007/BF01627079; COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; CUMMINGS SR, 1995, J BONE MINER RES, V10, P518; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; ETTINGER B, 1992, J BONE MINER RES, V7, P449; ETTINGER B, 1988, MATURITAS, V10, P283, DOI 10.1016/0378-5122(88)90064-3; ETTINGER B, 1994, OSTEOPOROSIS INT, V4, P55, DOI 10.1007/BF02352262; FROST HM, 1981, ORTHOP CLIN N AM, V12, P671; Genant HK, 1996, J BONE MINER RES, V11, P984; GENANT HK, 1995, VERTEBRAL FRACTURE O; Gold DT, 1996, BONE, V18, pS185, DOI 10.1016/8756-3282(95)00500-5; Hallal J C, 1991, Geriatr Nurs, V12, P285, DOI 10.1016/S0197-4572(05)80266-6; Huang C, 1996, J BONE MINER RES, V11, P1026; KOSOROK MR, 1992, AM J PUBLIC HEALTH, V82, P1263, DOI 10.2105/AJPH.82.9.1263; LANE NE, 1993, J RHEUMATOL, V20, P1911; LEIDIG G, 1990, BONE MINER, V8, P217, DOI 10.1016/0169-6009(90)90107-Q; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; LYLES KW, 1993, AM J MED, V94, P595, DOI 10.1016/0002-9343(93)90210-G; McCullagh P, 2019, GEN LINEAR MODELS; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; NEVITT MC, 1992, AM J EPIDEMIOL, V135, P490, DOI 10.1093/oxfordjournals.aje.a116315; NICHOLSON PHF, 1993, OSTEOPOROSIS INT, V3, P300, DOI 10.1007/BF01637315; PAK CYC, 1994, ANN INTERN MED, V120, P625, DOI 10.7326/0003-4819-120-8-199404150-00001; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Ross P D, 1991, Osteoporos Int, V1, P134, DOI 10.1007/BF01625442; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; RYAN PJ, 1994, BONE, V15, P27, DOI 10.1016/8756-3282(94)90887-7; SCHOLES D, 1991, AM J PUBLIC HEALTH, V81, P485, DOI 10.2105/AJPH.81.4.485; SPECTOR TD, 1993, J BONE MINER RES, V8, P817; WAGNER EH, 1993, J AM GERIATR SOC, V41, P241, DOI 10.1111/j.1532-5415.1993.tb06700.x; WIPF JE, 1995, MED CLIN N AM, V79, P231, DOI 10.1016/S0025-7125(16)30065-7; ZETTERBERG C, 1990, SPINE, V15, P783, DOI 10.1097/00007632-199008010-00009	38	602	613	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1998	128	10					793	+		10.7326/0003-4819-128-10-199805150-00001	http://dx.doi.org/10.7326/0003-4819-128-10-199805150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM889	9599190				2022-12-01	WOS:000073586500001
J	Glynn, MK; Bopp, C; Dewitt, W; Dabney, P; Mokhtar, M; Angulo, FJ				Glynn, MK; Bopp, C; Dewitt, W; Dabney, P; Mokhtar, M; Angulo, FJ			Emergence of multidrug-resistant Salmonella enterica serotype typhimurium DT104 infections in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENTERITIDIS; ANIMALS; HUMANS	Background Strains of salmonella that are resistant to antimicrobial agents have become a worldwide health problem. A distinct strain of Salmonella enterica serotype typhimurium, known as definitive type 104 (DT104), is resistant to ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracycline and has become a major cause of illness in humans and animals in Europe, especially the United Kingdom. Methods To characterize typhimurium DT104 infections in the United States, we analyzed data collected by local and state health departments and public health laboratories between 1979 and 1996 in national surveys of the antimicrobial-drug resistance of salmonella. Selected typhimurium isolates with the five-drug pattern of resistance were phage typed. Results The prevalence of typhimurium isolates with the five-drug pattern of resistance increased from 0.6 percent in 1979-1980 to 34 percent in 1996. In 1994-1995, such isolates were identified in samples from 36 of the 46 surveillance sites (78 percent). Thirty-nine of 43 typhimurium isolates with the five-drug pattern of resistance identified in 1994-1995 and 1996 were phage type DT104 or a closely related phage type. Conclusions Multidrug-resistant typhimurium DT104 has become a widespread pathogen in the United States. More prudent use of antimicrobial agents in farm animals and more effective disease prevention on farms are necessary to reduce the dissemination of multidrug-resistant typhimurium DT104 and to slow the emergence of resistance to additional agents in this and other strains of salmonella. (C)1998, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; US FDA, Rockville, MD 20857 USA	Centers for Disease Control & Prevention - USA; US Food & Drug Administration (FDA)	Glynn, MK (corresponding author), Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, 1600 Clifton Rd,MS A-38, Atlanta, GA 30333 USA.							ANDERSON ES, 1977, J HYG-CAMBRIDGE, V78, P297, DOI 10.1017/S0022172400056187; ANGULO FJ, 1995, CLIN INFECT DIS, V21, pS84, DOI 10.1093/clinids/21.Supplement_1.S84; Barry AL., 1991, MANUAL CLIN MICROBIO, P117; BEAN NH, 1992, AM J PUBLIC HEALTH, V82, P1273, DOI 10.2105/AJPH.82.9.1273; Besser TE, 1997, VET REC, V140, P75; BLACK PH, 1960, NEW ENGL J MED, V262, P921, DOI 10.1056/NEJM196005052621806; BLACK PH, 1960, NEW ENGL J MED, V262, P864, DOI 10.1056/NEJM196004282621706; BLASER MJ, 1981, J INFECT DIS, V143, P743, DOI 10.1093/infdis/143.5.743; *CDCP, 1996, SALMONELLA SURVILLAN; CELUM CL, 1987, J INFECT DIS, V156, P998, DOI 10.1093/infdis/156.6.998; CHALKER RB, 1988, REV INFECT DIS, V10, P111; CODY S, 1997, 35 ANN M INF DIS SOC, P77; COHEN ML, 1986, SCIENCE, V234, P964, DOI 10.1126/science.3535069; *DIV EM OTH COMM D, 1997, WHO M BERL GERM 13 1; Fone D L, 1994, Commun Dis Rep CDR Rev, V4, pR136; FRIEDMAN CR, 1998, KINT C EM INF DIS AT, P68; Hargrett-Bean N T, 1988, MMWR CDC Surveill Summ, V37, P25; HELMICK CG, 1994, NIH PUBLICATION, P85; LEE LA, 1994, J INFECT DIS, V170, P128, DOI 10.1093/infdis/170.1.128; LEVY SB, 1976, NEW ENGL J MED, V295, P583, DOI 10.1056/NEJM197609092951103; MACDONALD KL, 1987, JAMA-J AM MED ASSOC, V258, P1496, DOI 10.1001/jama.258.11.1496; MISHU B, 1994, J INFECT DIS, V169, P547, DOI 10.1093/infdis/169.3.547; OBRIEN TF, 1982, NEW ENGL J MED, V307, P1, DOI 10.1056/NEJM198207013070101; Ramos JM, 1996, EUR J CLIN MICROBIOL, V15, P85, DOI 10.1007/BF01586193; RILEY LW, 1984, J INFECT DIS, V149, P878, DOI 10.1093/infdis/149.6.878; TAUXE RV, 1991, J FOOD PROTECT, V54, P563, DOI 10.4315/0362-028X-54.7.563; TAUXE RV, 1997, TXB INTERNAL MED, P1639; Threlfall E.J., 1997, Euro Surveill, V2, P81; THRELFALL EJ, 1993, EPIDEMIOL INFECT, V111, P189, DOI 10.1017/S0950268800056892; Wall P G, 1994, Commun Dis Rep CDR Rev, V4, pR130; 1997, MMWR MORB MORTAL WKL, V46, P308; 1996, MMWR MORB MORTAL WKL, V45, P110	32	460	473	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1998	338	19					1333	1338		10.1056/NEJM199805073381901	http://dx.doi.org/10.1056/NEJM199805073381901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL720	9571252				2022-12-01	WOS:000073463700001
J	Carter, CS; Braver, TS; Barch, DM; Botvinick, MM; Noll, D; Cohen, JD				Carter, CS; Braver, TS; Barch, DM; Botvinick, MM; Noll, D; Cohen, JD			Anterior cingulate cortex, error detection, and the online monitoring of performance	SCIENCE			English	Article							PET; ACTIVATION; ATTENTION; SYSTEM	An unresolved question in neuroscience and psychology is how the brain monitors performance to regulate behavior. It has been proposed that the anterior cingulate cortex (ACC), on the medial surface of the frontal lobe, contributes to performance monitoring by detecting errors. In this study, event-related functional magnetic resonance imaging was used to examine ACC function. Results confirm that this region shows activity during erroneous responses. However, activity was also observed in the same region during correct responses under conditions of increased response competition. This suggests that the ACC detects conditions under which errors are likely to occur rather than errors themselves.	Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA; Presbyterian Univ Hosp, Univ Pittsburgh Hlth Syst, Magnet Resonance Res Ctr, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Carnegie Mellon University	Carter, CS (corresponding author), Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA.	cscarter+@pitt.edu	Barch, Deanna M/G-8638-2013; Kennedy, Kristen M/B-4699-2008; Noll, Douglas C/D-8124-2014	Kennedy, Kristen M/0000-0001-5373-9026; Noll, Douglas C/0000-0002-0983-3805; Braver, Todd/0000-0002-2631-3393	NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH001306, R01MH052864] Funding Source: NIH RePORTER; NIMH NIH HHS [K08MH01306, R01MH52864] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; BENCH CJ, 1992, PSYCHOL MED, V22, P607, DOI 10.1017/S003329170003806X; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Cabeza R, 1997, J COGNITIVE NEUROSCI, V9, P1, DOI 10.1162/jocn.1997.9.1.1; Carter CS, 1997, AM J PSYCHIAT, V154, P1670, DOI 10.1176/ajp.154.12.1670; Carter CS, 1995, NEUROIMAGE, V2, P264, DOI 10.1006/nimg.1995.1034; Cohen JD, 1996, PHILOS T R SOC B, V351, P1515, DOI 10.1098/rstb.1996.0138; COLES MGH, 1995, ACTA PSYCHOL, V90, P129, DOI 10.1016/0001-6918(95)00020-U; DEHAENE S, 1994, PSYCHOL SCI, V5, P303, DOI 10.1111/j.1467-9280.1994.tb00630.x; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; FALKENSTEIN M, 1995, PERSPECTIVES EVENT S, V44, P287; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; FRITH CD, 1991, NEUROPSYCHOLOGIA, V29, P1137, DOI 10.1016/0028-3932(91)90029-8; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; GHERING WJ, 1990, PSYCHOPHYSIOLOGY S, V27, pS34; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; NOLL DC, 1995, JMRI-J MAGN RESON IM, V5, P49, DOI 10.1002/jmri.1880050112; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; POSNER MI, 1994, TRENDS NEUROSCI, V17, P75, DOI 10.1016/0166-2236(94)90078-7; VOGT BA, 1992, CEREB CORTEX, V2, P435, DOI 10.1093/cercor/2.6.435-a; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	23	2464	2518	2	173	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1998	280	5364					747	749		10.1126/science.280.5364.747	http://dx.doi.org/10.1126/science.280.5364.747			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZL268	9563953				2022-12-01	WOS:000073415600051
J	Nabel, GJ				Nabel, GJ			From rhyme to reason	NATURE			English	Editorial Material							GENE-EXPRESSION INVIVO; ARTERIAL-WALL; DELIVERY; THERAPY		Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Biol Chem, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Nabel, GJ (corresponding author), Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Internal Med, 1150 W Med Ctr Dr,4520 MSRBI, Ann Arbor, MI 48109 USA.							ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; Bach FH, 1996, IMMUNOL TODAY, V17, P379, DOI 10.1016/0167-5699(96)10024-4; Bach FH, 1997, NAT MED, V3, P944, DOI 10.1038/nm0997-944; BLAU HM, 1995, NEW ENGL J MED, V333, P1554, DOI 10.1056/NEJM199512073332308; BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6; CHANG PL, 1995, SOMAT GENET HER; CHEN KS, 1995, J NEUROSCI, V15, P2819; Ellem KAO, 1997, CANCER IMMUNOL IMMUN, V44, P10, DOI 10.1007/s002620050349; EMERICH DP, 1997, NATURE, V27, P395; Grill R, 1997, J NEUROSCI, V17, P5560; Kim S, 1997, J CLIN INVEST, V100, P1006, DOI 10.1172/JCI119611; KREMERS E, 1940, HIST PHARM, V3, P286; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; Magovern CJ, 1997, HUM GENE THER, V8, P215, DOI 10.1089/hum.1997.8.2-215; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; Nabel GJ, 1996, P NATL ACAD SCI USA, V93, P15388, DOI 10.1073/pnas.93.26.15388; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; Parker W, 1996, IMMUNOL TODAY, V17, P373, DOI 10.1016/0167-5699(96)10028-1; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; Petsko GA, 1996, NATURE, V384, P7; Simons JW, 1997, CANCER RES, V57, P1537; Stopeck AT, 1997, J CLIN ONCOL, V15, P341, DOI 10.1200/JCO.1997.15.1.341; Tsurumi Y, 1997, CIRCULATION, V96, P382; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0	26	8	9	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679		S			3	4						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK760	9579854				2022-12-01	WOS:000073360100002
J	Karkoschka, E				Karkoschka, E			Clouds of high contrast on Uranus	SCIENCE			English	Article							VOYAGER-2	Near-infrared images of Uranus taken with the Hubble Space Telescope in July and October 1997 revealed discrete clouds with contrasts exceeding 10 times the highest contrast observed before with other techniques. At visible wavelengths, these 10 clouds had lower contrasts than clouds seen by Voyager 2 in 1986. Uranus' rotational rates for southern latitudes were identical in 1986 and 1997. Clouds in northern latitudes rotate slightly more slowly than clouds in opposite southern latitudes.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	University of Arizona	Karkoschka, E (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.							BAINES KH, 1995, ICARUS, V114, P328, DOI 10.1006/icar.1995.1065; Hammel H. B., 1997, B AM ASTRON SOC, V29, P994; KARKOSCHKA E, 1993, ICARUS, V106, P428, DOI 10.1006/icar.1993.1183; LINDAL GF, 1987, J GEOPHYS RES, V92, P14987, DOI 10.1029/JA092iA13p14987; Lorenz RD, 1997, ICARUS, V127, P173, DOI 10.1006/icar.1997.5687; RAGES K, 1991, ICARUS, V89, P359, DOI 10.1016/0019-1035(91)90183-T; SMITH BA, 1986, SCIENCE, V233, P43, DOI 10.1126/science.233.4759.43	7	42	43	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					570	572		10.1126/science.280.5363.570	http://dx.doi.org/10.1126/science.280.5363.570			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554844				2022-12-01	WOS:000073242100041
J	Nakagawa, T; Roth, W; Wong, P; Nelson, A; Farr, A; Deussing, J; Villadangos, JA; Ploegh, H; Peters, C; Rudensky, AY				Nakagawa, T; Roth, W; Wong, P; Nelson, A; Farr, A; Deussing, J; Villadangos, JA; Ploegh, H; Peters, C; Rudensky, AY			Cathepsin L: Critical role in Ii degradation and CD4 T cell selection in the thymus	SCIENCE			English	Article							MHC CLASS-II; INVARIANT-CHAIN; ANTIGEN PRESENTATION; MONOCLONAL-ANTIBODY; EPITHELIAL-CELLS; MOLECULES; COMPLEXES; PEPTIDE; MICE; EXPRESSION	Degradation of invariant chain (li) is a critical step in major histocompatibility complex class II-restricted antigen presentation. Cathepsin L was found to be necessary for li degradation in cortical thymic epithelial cells (cTECs), but not in bone marrow (BM)derived antigen-presenting cells (APCs). Consequently, positive selection of CD4(+) T cells, was reduced. Because different cysteine proteinases are responsible for specific li degradation steps in cTECs and BM-derived APCs, the proteolytic environment in cells mediating positive and negative selection may be distinct. The identification of a protease involved in class II presentation in a tissue-specific manner suggests a potential means of manipulating CD4(+) T cell responsiveness in vivo.	Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; Univ Freiburg Klinikum, Abt Heamatol Onkol, D-79106 Freiburg, Germany; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Freiburg; University of Washington; University of Washington Seattle; Harvard University; Harvard Medical School	Rudensky, AY (corresponding author), Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA.	sasha@nucleus.immunol.washington.edu	Deussing, Jan M/ABB-5993-2021; Villadangos, Jose A/AAU-1404-2020	Villadangos, Jose A/0000-0001-6771-8891; Deussing, Jan/0000-0002-9329-5252				ADKINS B, 1988, IMMUNOGENETICS, V27, P180, DOI 10.1007/BF00346584; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; Bevec T, 1996, J EXP MED, V183, P1331, DOI 10.1084/jem.183.4.1331; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; Denzin LK, 1997, SCIENCE, V278, P106, DOI 10.1126/science.278.5335.106; Eastman S, 1996, EUR J IMMUNOL, V26, P385, DOI 10.1002/eji.1830260218; ENGELHARD VH, 1994, ANNU REV IMMUNOL, V12, P181, DOI 10.1146/annurev.iy.12.040194.001145; Farr A, 1996, EUR J IMMUNOL, V26, P3185, DOI 10.1002/eji.1830261252; FARR AG, 1986, ANAT REC, V216, P85, DOI 10.1002/ar.1092160115; Fineschi B, 1996, J IMMUNOL, V157, P3211; FINK PJ, 1995, ADV IMMUNOL, V59, P99, DOI 10.1016/S0065-2776(08)60630-6; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; Liljedahl M, 1996, EMBO J, V15, P4817, DOI 10.1002/j.1460-2075.1996.tb00862.x; MARIC MA, 1994, P NATL ACAD SCI USA, V91, P2171, DOI 10.1073/pnas.91.6.2171; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; Martin WD, 1996, CELL, V84, P543, DOI 10.1016/S0092-8674(00)81030-2; MASON RW, 1989, BIOCHEM J, V257, P125, DOI 10.1042/bj2570125; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; MORKOWSKI S, 1995, J EXP MED, V182, P1403, DOI 10.1084/jem.182.5.1403; NAKAGAWA T, UNPUB; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; RODRIGUEZ GM, 1995, EUR J IMMUNOL, V25, P1823, DOI 10.1002/eji.1830250705; ROTH WR, UNPUB; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; SURH GD, 1997, IMMUNITY, V7, P209; Tourne S, 1997, IMMUNITY, V7, P187, DOI 10.1016/S1074-7613(00)80522-1; VANNOORT JM, 1994, EUR J IMMUNOL, V24, P2175, DOI 10.1002/eji.1830240936; Villadangos JA, 1997, J EXP MED, V186, P549, DOI 10.1084/jem.186.4.549; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411; Wong P, 1996, J IMMUNOL, V156, P2133	32	559	570	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1998	280	5362					450	453		10.1126/science.280.5362.450	http://dx.doi.org/10.1126/science.280.5362.450			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545226				2022-12-01	WOS:000073159600052
J	Bradley, DC; Chang, GC; Andersen, RA				Bradley, DC; Chang, GC; Andersen, RA			Encoding of three-dimensional structure-from-motion by primate area MT neurons	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; PERCEPTION; INTEGRATION; STEREOPSIS; MONKEY; DEPTH	We see the world as three-dimensional, but because the retinal image is flat, we must derive the third dimension, depth, from two-dimensional cues. Image movement provides one of the most potent cues for depth(1-6). For example, the shadow of a contorted wire appears flat when the wire is stationary, but rotating the wire causes motion in the shadow, which suddenly appears three-dimensional. The neural mechanism of this effect, known as 'structure-from-motion', has not been discovered. Here we study cortical area MT, a primate region that is involved in visual motion perception. Two rhesus monkeys were trained to fixate their gaze while viewing two-dimensional projections of transparent, revolving cylinders. These stimuli appear to be three-dimensional, but the surface order perceived (front as opposed to back) tends to reverse spontaneously. These reversals occur because the stimulus does not specify which surface is in front or at the back, Monkeys reported which surface order they perceived after viewing the stimulus. In many of the neurons tested, there was a reproducible change in activity that coincided with reversals of the perceived surface order, even though the stimulus remained identical. This suggests that area MT has a basic role in structure-from-motion perception.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Andersen, RA (corresponding author), CALTECH, Div Biol, 391 S Holliston Ave, Pasadena, CA 91125 USA.	andersen@vis.caltech.edu						ANDERSEN RA, 1990, NEUROSCI IN, P163; BRADDICK O, 1993, TRENDS NEUROSCI, V16, P263, DOI 10.1016/0166-2236(93)90179-P; BRADLEY DC, 1995, NATURE, V373, P609, DOI 10.1038/373609a0; HILDRETH EC, 1995, VISION RES, V35, P117, DOI 10.1016/0042-6989(94)E0068-V; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1148, DOI 10.1152/jn.1983.49.5.1148; Miles WR, 1931, AM J PSYCHOL, V43, P392, DOI 10.2307/1414610; NAWROT M, 1991, VISUAL NEUROSCI, V6, P219, DOI 10.1017/S0952523800006234; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; Ringach DL, 1996, VISION RES, V36, P1479, DOI 10.1016/0042-6989(95)00285-5; ROGERS B, 1982, VISION RES, V22, P261, DOI 10.1016/0042-6989(82)90126-2; SIEGEL RM, 1988, NATURE, V331, P259, DOI 10.1038/331259a0; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; WALLACH H, 1953, J EXP PSYCHOL, V45, P205, DOI 10.1037/h0056880	15	235	237	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 16	1998	392	6677					714	717		10.1038/33688	http://dx.doi.org/10.1038/33688			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565031				2022-12-01	WOS:000073129000058
J	Glas, R; Bogyo, M; McMaster, JS; Gaczynska, M; Ploegh, HL				Glas, R; Bogyo, M; McMaster, JS; Gaczynska, M; Ploegh, HL			A proteolytic system that compensates for loss of proteasome function	NATURE			English	Article							CLASS-I MOLECULES; SACCHAROMYCES-CEREVISIAE; DEGRADATION; LACTACYSTIN; INACTIVATION; ACIDOPHILUM; INHIBITORS; PROTEINS; PEPTIDES; PATHWAY	Proteolysis is essential for the execution of many cellular functions. These include removal of incorrectly folded or damaged proteins(1), the activation of transcription factors(2), the ordered degradation of proteins involved in cell cycle control(3), and the generation of peptides destined for presentation by class I molecules of the major histocompatibility complex(4). A multisubunit protease complex, the proteasome(5), accomplishes these tasks. Here we show that in mammalian cells inactivation of the proteasome by covalent inhibitors allows the outgrowth of inhibitor-resistant cells. The growth of such adapted cells is apparently maintained by the induction of other proteolytic systems that compensate for the loss of proteasomal activity.	MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Ploegh, HL (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Bogyo, Matthew/0000-0003-3753-4412				BAI A, J IMMUNOL, V159, P2139; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HAMMERLING GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4737, DOI 10.1073/pnas.79.15.4737; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILT W, 1995, MOL BIOL REP, V21, P3, DOI 10.1007/BF00990964; KETTNER C, 1981, METHOD ENZYMOL, V80, P826; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Sheaff RJ, 1996, CHEM BIOL, V3, P869, DOI 10.1016/S1074-5521(96)90174-X; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; Vinitsky A, 1997, J IMMUNOL, V159, P554	29	224	225	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					618	622		10.1038/33443	http://dx.doi.org/10.1038/33443			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560160				2022-12-01	WOS:000072987200064
J	Niskar, AS; Kieszak, SM; Holmes, A; Esteban, E; Rubin, C; Brody, DJ				Niskar, AS; Kieszak, SM; Holmes, A; Esteban, E; Rubin, C; Brody, DJ			Prevalence of hearing loss among children 6 to 19 years of age - The Third National Health and Nutrition Examination Survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOISE	Context.-Hearing loss in children influences the development of communication and behavioral skills, but few studies in the United States have used pure-tone audiometry to derive hearing loss prevalence estimates for children. Objective.-To describe the prevalence of hearing loss among US children by sociodemographic characteristics, reported hearing loss, and audiometric screening factors. Design.-National population-based cross-sectional survey with an in-person interview and audiometric testing at 0.5 to 8 kHz. Setting/Participants.-A total of 6166 children aged 6 to 19 years completed audiometry in the mobile examination center of the Third National Health and Nutrition Examination Survey conducted between 1988 and 1994. Main Outcome Measure.-Hearing loss, defined as audiometric threshold values of at least 16-dB hearing level based on a low or high pure-tone average. Results.-A total of 14.9% of children had low-frequency or high-frequency hearing loss of at least 16-dB hearing level, 7.1% had low-frequency hearing loss of at least 16-dB hearing level, and 12.7% had high-frequency hearing loss of at least 16-dB hearing level, Most hearing loss was unilateral and slight in severity (16- to 25-dB hearing level), Of those with measured hearing loss, 10.8% were reported to have current hearing loss during the interview. Conclusions.-This analysis indicates that 14.9% of US children have low-frequency or high-frequency hearing loss of at least 16-dB hearing level in 1 or both ears, Among children in elementary, middle, and high school, audiometric screening should include low-frequency and high-frequency testing to detect hearing loss.	Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30341 USA; Univ Florida, Gainesville, FL USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; State University System of Florida; University of Florida; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Niskar, AS (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Hwy NE,MS F46, Atlanta, GA 30341 USA.	abn0@cdc.gov						ANDERSON K L, 1991, Seminars in Hearing, V12, P340, DOI 10.1055/s-0028-1085507; ANDERSON KL, 1992, P ASHA AUD SUP, V21, P38; [Anonymous], 1979, JAMA-J AM MED ASSOC, V241, P2055; BARONE JA, 1987, J OCCUP ENVIRON MED, V29, P741; Barrett K.A., 1994, HDB CLIN AUDIOLOGY, P476; BEHRMAN RE, 1992, NELSON TXB PEDIAT, P1602; BROOKHOUSER PE, 1992, LARYNGOSCOPE, V102, P645, DOI 10.1288/00005537-199206000-00010; BROOKHOUSER PE, 1994, PREV MED, V23, P665, DOI 10.1006/pmed.1994.1111; Clark J G, 1981, ASHA, V23, P493; COZAD RL, 1974, J SCHOOL HEALTH, V44, P92, DOI 10.1111/j.1746-1561.1974.tb05207.x; EZZATI T, 1992, VITAL HLTH STAT, V2; Goodman A., 1965, ASHA, V7, P262; GULYA AJ, 1995, PRIMARY CARE MED OFF, P985; HANNER P, 1988, SCAND AUDIOL, V17, P57, DOI 10.3109/01050398809042181; Holmes A E, 1996, J Am Acad Audiol, V7, P332; Holmes AE, 1997, LANG SPEECH HEAR SER, V28, P70, DOI 10.1044/0161-1461.2801.70; JOHNSON C, 1994, NHANES 3 ANAL REPORT; KLEIN JO, 1992, SCREENING CHILDREN A, P31; Lee DJ, 1996, AM J EPIDEMIOL, V144, P442; Leske M C, 1981, ASHA, V23, P229; Naeem Z, 1996, BRIT J AUDIOL, V30, P332, DOI 10.3109/03005369609076781; *NAT CTR HLTH STAT, 1967, VIT HLTH STAT, V1; *NAT CTR HLTH STAT, 1975, VIT HLTH STAT, V11; *NAT CTR HLTH STAT, 1994, VIT HLTH STAT, V1; National Center for Health Statistics, 1988, NAT HLTH NUTR EX SUR, VIII; National Center for Health Statistics, 1996, NHANES 3 REF MAN REP; *NIH, 1990, NCI MON, P3; RIES PW, 1994, VITAL HLTH STAT, V10, P9; RYTZNER B, 1981, SCAND AUDIOL, V10, P213, DOI 10.3109/01050398109076183; *SAS I INC, 1990, SAS LANG VERS 6; SHAL BV, 1991, SUDAAN USERS MANUAL; 1987, FED REG, V52, P44117	32	262	280	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1071	1075		10.1001/jama.279.14.1071	http://dx.doi.org/10.1001/jama.279.14.1071			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF216	9546565	Bronze			2022-12-01	WOS:000072875300030
J	Horton, B				Horton, B			Seeking the bigger picture in the puzzle	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					417	419		10.1038/32948	http://dx.doi.org/10.1038/32948			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537330				2022-12-01	WOS:000072713600060
J	Harrison, CN; Linch, DC; Machin, SJ				Harrison, CN; Linch, DC; Machin, SJ			Desirability and problems of early diagnosis of essential thrombocythaemia	LANCET			English	Editorial Material							RISK		UCL, Sch Med, Dept Haematol, London WC1E 6HX, England	University of London; University College London; UCL Medical School	Harrison, CN (corresponding author), UCL, Sch Med, Dept Haematol, London WC1E 6HX, England.							CORTELAZZO S, 1995, NEW ENGL J MED, V332, P1132, DOI 10.1056/NEJM199504273321704; CORTELAZZO S, 1990, J CLIN ONCOL, V8, P556, DOI 10.1200/JCO.1990.8.3.556; ElKassar N, 1997, BLOOD, V89, P128, DOI 10.1182/blood.V89.1.128.128_128_134; Gale RE, 1997, BRIT J HAEMATOL, V98, P512, DOI 10.1046/j.1365-2141.1997.2573078.x; GILES FJ, 1988, LANCET, V2, P70; Harrison Claire N., 1997, Blood, V90, p347A; Harrison CN, 1997, AM J MED, V102, P317; Horikawa Y, 1997, BLOOD, V90, P4031, DOI 10.1182/blood.V90.10.4031; Lengfelder E, 1998, BRIT J HAEMATOL, V100, P15, DOI 10.1046/j.1365-2141.1998.00529.x; MURPHY S, 1986, SEMIN HEMATOL, V23, P177; Petitt RM, 1997, SEMIN HEMATOL, V34, P51; Sterkers Y, 1998, BLOOD, V91, P616, DOI 10.1182/blood.V91.2.616.616_616_622; Tahara T, 1996, BRIT J HAEMATOL, V93, P783, DOI 10.1046/j.1365-2141.1996.d01-1741.x	13	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					846	847		10.1016/S0140-6736(98)22012-5	http://dx.doi.org/10.1016/S0140-6736(98)22012-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525354				2022-12-01	WOS:000072645500002
J	Lo, JC; Mulligan, K; Tai, VW; Algren, H; Schambelan, M				Lo, JC; Mulligan, K; Tai, VW; Algren, H; Schambelan, M			"Buffalo hump" in men with HIV-1 infection	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; CUSHINGS-SYNDROME; OBESITY; METABOLISM	Background: Enlargement of the dorsocervical fat pad ("buffalo hump") has been reported in numerous HIV-1-infected patients. Some investigators have speculated that this finding is associated with protease-inhibitor treatment. Methods: Between June, 1995, and October, 1997, we studied eight HIV-1-infected men who had developed a buffalo hump while otherwise stable on antiretroviral therapy. Measurement of 24 h urinary free cortisol excretion and an overnight low-dose dexamethasone suppression test were done to screen for Cushing's syndrome. In one patient, plasma cortisol concentrations were measured every 4 h for 24 h to assess the circadian rhythm of cortisol. Results of total and regional body-composition analysis by dual-energy X-ray absorptiometry, and glucose, cholesterol, triglyceride, and cortisol concentrations were compared with those obtained in a control population of 15 HIV-1-positive men whose age, body-mass index (BMI), and CD4-lymphocyte count were within the range of values in the eight study patients. Findings: The eight patients with a buffalo hump were clinically stable on various antiretroviral regimens, four of which included a protease inhibitor. No other signs of Cushing's syndrome were observed, and plasma cortisol values did not differ significantly from those of controls, 24 h urinary free cortisol excretion was normal in seven patients and slightly raised in one (248 nmoles). In this patient, a repeat 24 h urinary free cortisol was 175 nmoles and plasma cortisol concentrations over 24 h showed a normal circadian pattern (nadir 83 nmol/L at 2400 h). All eight patients had normal suppression of cortisol values after dexamethasone 1 mg (plasma cortisol less than 83 nmol/L). When compared with HIV-1-positive controls, men with a buffalo hump had a significantly greater proportion of fat in the trunk region, suggesting central fat accumulation. Triglyceride but not cholesterol values were higher in the patients than in controls but this difference was not significant. Fasting glucose values did not differ significantly. Interpretation: The development of a buffalo hump cannot be attributed to hypercortisolism in these eight men. Furthermore, its occurrence is not unique to patients on protease inhibitors. Although the mechanism for dorsocervical fat accumulation is unclear, we speculate that regional abnormalities in lipogenesis and lipolysis occur, possibly influenced by the hormonal and metabolic changes seen with HIV-1 infection and its treatment.	San Francisco Gen Hosp, Div Endocrinol, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Lo, JC (corresponding author), San Francisco Gen Hosp, Div Endocrinol, Bldg 100,Room 321, San Francisco, CA 94110 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045833] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45833] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bjorntorp P, 1996, INT J OBESITY, V20, P291; Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8; CRAPO L, 1979, METABOLISM, V28, P955, DOI 10.1016/0026-0495(79)90097-0; FINDLING JW, 1994, ENDOCRIN METAB CLIN, V23, P511, DOI 10.1016/S0889-8529(18)30081-1; FOK ACK, 1991, STEROIDS, V56, P549, DOI 10.1016/0039-128X(91)90011-J; FUJIOKA S, 1987, METABOLISM, V36, P54, DOI 10.1016/0026-0495(87)90063-1; GRUNFELD C, 1992, J CLIN ENDOCR METAB, V74, P1045, DOI 10.1210/jc.74.5.1045; HELLERSTEIN MK, 1993, J CLIN ENDOCR METAB, V76, P559, DOI 10.1210/jc.76.3.559; Hengel RL, 1997, LANCET, V350, P1596, DOI 10.1016/S0140-6736(05)64011-1; MATSUZAWA Y, 1995, ANN NY ACAD SCI, V748, P399; MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106; MENGDEN T, 1992, CLIN INVESTIGATOR, V70, P545; Mulligan K, 1997, J ACQ IMMUN DEF SYND, V15, P43, DOI 10.1097/00042560-199705010-00007; MURPHY BEP, 1967, J CLIN ENDOCR METAB, V27, P973, DOI 10.1210/jcem-27-7-973; NUGENT CA, 1965, ARCH INTERN MED, V116, P172, DOI 10.1001/archinte.1965.03870020012006; PAVLATOS FC, 1965, JAMA-J AM MED ASSOC, V193, P96; Peeke PM, 1995, ANN NY ACAD SCI, V771, P665, DOI 10.1111/j.1749-6632.1995.tb44719.x; Ramsay TG, 1996, ENDOCRIN METAB CLIN, V25, P847, DOI 10.1016/S0889-8529(05)70358-3; REBUFFESCRIVE M, 1988, J CLIN ENDOCR METAB, V67, P1122, DOI 10.1210/jcem-67-6-1122; REBUFFESCRIVE M, 1990, J CLIN ENDOCR METAB, V71, P1215, DOI 10.1210/jcem-71-5-1215; RUANE PJ, 1997, 37 INT C ANT AG CHEM, pI185; SCHAMBELAN M, 1995, MED MANAGEMENT AIDS, P345; YANOVSKI JA, 1994, ENDOCRIN METAB CLIN, V23, P487, DOI 10.1016/S0889-8529(18)30080-X	23	439	444	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					867	870		10.1016/S0140-6736(97)11443-X	http://dx.doi.org/10.1016/S0140-6736(97)11443-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525364				2022-12-01	WOS:000072645500013
J	Genick, UK; Soltis, SM; Kuhn, P; Canestrelli, IL; Getzoff, ED				Genick, UK; Soltis, SM; Kuhn, P; Canestrelli, IL; Getzoff, ED			Structure at 0.85 angstrom resolution of an early protein photocycle intermediate	NATURE			English	Article							PHOTOACTIVE YELLOW PROTEIN; LINKED 4-HYDROXYCINNAMYL CHROMOPHORE; ECTOTHIORHODOSPIRA-HALOPHILA; PHOTOTROPHIC BACTERIUM; CRYSTALLOGRAPHY; SPECTROSCOPY; TEMPERATURE; CRYSTALS	Protein photosensors from all kingdoms of life(1,2) use bound organic molecules, known as chromophores, to detect light, A specific double bond within each chromophore is isomerized by light, triggering slower changes in the protein as a whole, The initial movements of the chromophore, which can occur in femtoseconds, are tightly constrained by the surrounding protein, making it difficult to see how isomerization can occur, be recognized, and be appropriately converted into a protein-wide structural change and biological signal, Here we report how this dilemma is resolved in the photoactive yellow protein (PYP). We trapped a key early intermediate in the light cycle of PYP at temperatures below -100 degrees C, and determined its structure at better than 1 Angstrom resolution, The 4-hydroxycinnamoyl chromophore(3,4) isomerizes by flipping its thioester linkage with the protein, thus avoiding collisions resulting from large-scale movement of its aromatic ring during the initial light reaction, A protein-to-chromophore hydrogen bond that is present in both the preceding dark state(5) and the subsequent signalling state(6) of the photosensor breaks, forcing one of the hydrogen-bonding partners into a hydrophobic pocket. The isomerized bond is distorted into a conformation resembling that in the transition state. The resultant stored energy is used to drive the PYP light cycle. These results suggest a model for phototransduction, with implications for bacteriorhodopsin(7,8), photoactive proteins(1,2), PAS domains(9), and signalling proteins.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA	Scripps Research Institute; Scripps Research Institute; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Getzoff, ED (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Genick, Ulrich/0000-0002-6526-3552				BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Bourgeois D, 1996, J SYNCHROTRON RADIAT, V3, P65, DOI 10.1107/S090904959501661X; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; HAJDU J, 1993, ANNU REV BIOPH BIOM, V22, P467, DOI 10.1146/annurev.bb.22.060193.002343; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Imamoto Y, 1996, BIOCHEMISTRY-US, V35, P14047, DOI 10.1021/bi961342d; Kay SA, 1997, SCIENCE, V276, P753, DOI 10.1126/science.276.5313.753; KIM M, 1995, BIOCHEMISTRY-US, V34, P12669, DOI 10.1021/bi00039a024; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; MEYER TE, 1989, BIOPHYS J, V56, P559, DOI 10.1016/S0006-3495(89)82703-1; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; SCHERTLER GFX, 1991, EMBO J, V10, P2353, DOI 10.1002/j.1460-2075.1991.tb07774.x; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SHELDRICK GM, IN PRESS CRYSTALLOGR, V7; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VANBREDERODE ME, 1995, BIOPHYS J, V68, P1101, DOI 10.1016/S0006-3495(95)80284-5; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035	27	311	317	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					206	209		10.1038/32462	http://dx.doi.org/10.1038/32462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515969				2022-12-01	WOS:000072462700069
J	Ranger, AM; Grusby, MJ; Hodge, MR; Gravallese, EM; de la Brousse, FC; Hoey, T; Mickanin, C; Baldwin, HS; Glimcher, LH				Ranger, AM; Grusby, MJ; Hodge, MR; Gravallese, EM; de la Brousse, FC; Hoey, T; Mickanin, C; Baldwin, HS; Glimcher, LH			The transcription factor NF-ATc is essential for cardiac valve formation	NATURE			English	Article							T-CELL ACTIVATION; NEUREGULIN RECEPTOR; MICE LACKING; HEART; PROTEINS; DEFECTS; FAMILY; RAT	Nuclear factor of activated T cells (NF-AT) is the name of a family of four related transcription factors that may be needed for cytokine gene expression in activated lymphocytes(1-4). Here we report that mice with a targeted disruption of the NF-ATc gene show an unexpected and dramatic defect in cardiac morphogenesis, with selective absence of the aortic and pulmonary valves, leading to death in utero from congestive heart failure at days 13.5-17.5 of gestation, In contrast, tricuspid and mitral valve morphogenesis is normal, NF-ATc is the first transcription factor known to be expressed only in the endothelial cells of the heart, As in T cells, nuclear translocation of NF-ATc in cardiac endothelial cells is controlled by the calcium-regulated phosphatase calcineurin(5,6): NF-ATc remains cytoplasmic in normal embryos cultured with cyclosporin A, an inhibitor of calcineurin. Abnormal development of the cardiac valves and septae is the most frequent form of birth defect, yet few molecular regulators of valve formation are known, Our results indicate that NF-ATc may play a critical role in signal-transduction processes required for normal cardiac valve formation.	Harvard Univ, Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Tularik Inc, S San Francisco, CA 94080 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Glimcher, LH (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Biol, 665 Huntington Ave, Boston, MA 02115 USA.	lglimche@hsph.harvard.edu						BALDWIN HS, 1991, DIFFERENTIATION, V47, P163, DOI 10.1111/j.1432-0436.1991.tb00234.x; BROWN PAJ, 1985, BIOL NEONATE, V48, P172; CLARK EB, 1987, GENETICS CARDIOVASCU, P3; COOP AJ, 1995, TRENDS GENET, V11, P87; EISENBURG LM, 1995, CIRC RES, V77, P106; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FERENCZ C, 1985, AM J EPIDEMIOL, V121, P31, DOI 10.1093/oxfordjournals.aje.a113979; Fishman MC, 1997, DEVELOPMENT, V124, P2099; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HURLE JM, 1980, ANAT EMBRYOL, V160, P83, DOI 10.1007/BF00315651; KWEE L, 1995, DEVELOPMENT, V121, P489; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MARKWALD RR, 1994, ROLE EXTRACELLULAR M, P323; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MIYABARA S, 1994, HEART VESSELS, V9, P49, DOI 10.1007/BF01744495; MOENS CB, 1993, DEVELOPMENT, V119, P485; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; RUNYAN RB, 1990, CELL REGUL, V1, P301, DOI 10.1091/mbc.1.3.301; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; STURM K, 1993, METHOD ENZYMOL, V225, P164; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Yamamura H, 1997, DEV BIOL, V186, P58, DOI 10.1006/dbio.1997.8559; YANG JT, 1995, DEVELOPMENT, V121, P549	30	478	487	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 12	1998	392	6672					186	190		10.1038/32426	http://dx.doi.org/10.1038/32426			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515964				2022-12-01	WOS:000072462700064
J	Palumbo, PE; Raskino, C; Fiscus, S; Pahwa, S; Fowler, MG; Spector, SA; Englund, JA; Baker, CJ				Palumbo, PE; Raskino, C; Fiscus, S; Pahwa, S; Fowler, MG; Spector, SA; Englund, JA; Baker, CJ			Predictive value of quantitative plasma HIV RNA and CD4(+) lymphocyte count in HIV-infected infants and children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MARKERS; VIRUS; THERAPY	Context.-Pediatric human immunodeficiency virus (HIV) infection has unique viral pathogenetic features that preclude routine extrapolation from adult studies and require specific analysis. Objectives.-To evaluate the prognostic value of 2 key laboratory markers-plasma RNA and CD4(+) lymphocyte count-for HIV disease progression in infants and children and to establish targeted values for optimal outcome. Design.-Data from a cohort of 566 infants and children who participated in a randomized, placebo-controlled trial of nucleoside reverse transcriptase inhibitors (ACTG 152) were analyzed. The trial was conducted between 1991 and 1995 and enrolled a heterogenous cohort of antiretroviral therapy-naive children (age, 3 months to 18 years); patients had a median follow-up of 32 months. Main Outcome Measures.-The trial clinical end points consisted of time to first HIV disease progression (growth failure, decline in neurologic or neurodevelopmental function, opportunistic infections) or death. Results.-Baseline plasma RNA levels were high (age group medians, 5x10(4) to >10(6) copies/mL), and both baseline RNA and CD4(+) lymphocyte count were independently predictive of subsequent clinical course. Risk reduction for disease progression between 49% and 64% was observed for each log(10) reduction in baseline RNA and was linear without suggestion of a threshold or age effect. Disease progression predictive power was enhanced by the combined use of plasma RNA and CD4(+) cell count, Marker values of less than 10 000 copies/mL for plasma RNA and greater than 500 x 10(6)/L (<6.5 years of age) or greater than 200 x 10(6)/L (>6.5 years) for CD4(+) cell count were associated with a 2-year disease progression rate of less than 5%. Conclusions.-Two key laboratory markers-plasma RNA and CD4(+) lymphocyte count-are independent predictors of clinical course among HIV-infected infants and children. The linear, age-independent relationship between log(10) plasma RNA and relative risk of disease progression strongly supports therapeutic efforts to achieve plasma virus levels as low as possible.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pediat, Newark, NJ 07103 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA; NYU, Sch Med, N Shore Univ Hosp, Dept Pediat, Manhasset, NY USA; NIAID, Bethesda, MD 20892 USA; Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; University of North Carolina; University of North Carolina Chapel Hill; New York University; Northwell Health; North Shore University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Diego; Baylor College of Medicine; Baylor College of Medicine	Palumbo, PE (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pediat, 185 S Orange Ave, Newark, NJ 07103 USA.		Pahwa, Savita/AAA-4900-2019	Pahwa, Savita/0000-0002-4470-4216				Altman DG, 1991, PRACTICAL STAT MED R; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Englund JA, 1997, NEW ENGL J MED, V336, P1704, DOI 10.1056/NEJM199706123362403; Englund JA, 1996, PEDIATR INFECT DIS J, V15, P1025, DOI 10.1097/00006454-199611000-00018; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; Kalbfleisch M, 1980, STAT ANAL FAILURE TI; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; KIEVITS T, 1991, J VIROL METHODS, V35, P273, DOI 10.1016/0166-0934(91)90069-C; KROGSTAD P, 1997, 4 C RETR OPP INF JAN; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; MCKINNEY R, 1997, 35 ANN M INF DIS SOC; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Melvin AJ, 1997, PEDIATR INFECT DIS J, V16, P968, DOI 10.1097/00006454-199710000-00013; Mofenson LM, 1997, J INFECT DIS, V175, P1029, DOI 10.1086/516441; MUELLER BU, 1997, 4 C RETR OPP INF JAN; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; PALUMBO PE, 1995, J PEDIATR-US, V126, P592, DOI 10.1016/S0022-3476(95)70357-8; PALUMBO PE, 1997, 4 C RETR OPP INF JAN; Rich KC, 1997, CLIN DIAGN LAB IMMUN, V4, P358, DOI 10.1128/CDLI.4.3.358-361.1997; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; SCHLESINGER M, 1995, PEDIATR RES, V38, P390, DOI 10.1203/00006450-199509000-00020; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901	24	170	175	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1998	279	10					756	761		10.1001/jama.279.10.756	http://dx.doi.org/10.1001/jama.279.10.756			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA474	9508151	Bronze			2022-12-01	WOS:000072366900032
J	Evans, SJW				Evans, SJW			Commentary: Identifying the correct risks in diagnosis	BRITISH MEDICAL JOURNAL			English	Editorial Material									London Sch Hyg & Trop Med, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	Evans, SJW (corresponding author), London Sch Hyg & Trop Med, London WC1, England.			Evans, Stephen/0000-0002-1474-2596					0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					656	656						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522785				2022-12-01	WOS:000072347900023
J	Hopes, E; McDougall, C; Christie, G; Dewar, J; Wheatley, A; Hall, IP; Helms, PJ				Hopes, E; McDougall, C; Christie, G; Dewar, J; Wheatley, A; Hall, IP; Helms, PJ			Association of glutamine 27 polymorphism of beta(2) adrenoceptor with reported childhood asthma: population based study	BRITISH MEDICAL JOURNAL			English	Article							ABERDEEN SCHOOLCHILDREN; RESPIRATORY SYMPTOMS; ATOPY		Univ Aberdeen, Sch Med, Dept Child Hlth, Aberdeen AB25 2ZD, Scotland; Univ Nottingham Hosp, Queens Med Ctr, Dept Med, Nottingham NG7 2UH, England	University of Aberdeen; University of Nottingham	Helms, PJ (corresponding author), Univ Aberdeen, Sch Med, Dept Child Hlth, Aberdeen AB25 2ZD, Scotland.			Henry, Amanda/0000-0001-6299-7676				Dewar JC, 1997, J ALLERGY CLIN IMMUN, V100, P261, DOI 10.1016/S0091-6749(97)70234-3; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; Omran M, 1996, BRIT MED J, V312, P34, DOI 10.1136/bmj.312.7022.34	5	71	76	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					664	664		10.1136/bmj.316.7132.664	http://dx.doi.org/10.1136/bmj.316.7132.664			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522789	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000072347900028
J	Lancaster, T; Swart, AM; Jick, H				Lancaster, T; Swart, AM; Jick, H			Risk of serious haematological toxicity with use of chloramphenicol eye drops in a British general practice database	BRITISH MEDICAL JOURNAL			English	Article									Univ Oxford, Imperial Canc Res Fund, Gen Practice Res Grp, Div Publ Hlth & Primary Care,Inst Hlth Sci, Oxford OX3 7LF, England; Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, Lexington, MA 02173 USA	University of Oxford; Boston University	Lancaster, T (corresponding author), Univ Oxford, Imperial Canc Res Fund, Gen Practice Res Grp, Div Publ Hlth & Primary Care,Inst Hlth Sci, Oxford OX3 7LF, England.			Jick, Hershel/0000-0003-4270-5992	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		DOONA M, 1995, BRIT MED J, V310, P1217, DOI 10.1136/bmj.310.6989.1217; JICK H, 1995, PHARMACOTHERAPY, V15, P176; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Rayner SA, 1996, DRUG SAFETY, V14, P273, DOI 10.2165/00002018-199614050-00001	4	31	31	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					667	667		10.1136/bmj.316.7132.667	http://dx.doi.org/10.1136/bmj.316.7132.667			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522792	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000072347900031
J	Stewart, JH; Andrews, J; Cartlidge, PHT				Stewart, JH; Andrews, J; Cartlidge, PHT			Numbers of deaths related to intrapartum asphyxia and timing of birth in all Wales perinatal survey, 1993-5	BRITISH MEDICAL JOURNAL			English	Article							OBSTETRIC CARE; ACCIDENTS	Objectives: To investigate the relation between the timing of birth and the occurrence of death related to an intrapartum event Design: Analysis of 107 206 births to Welsh residents in 1993-5, including 608 cases of stillbirth and 407 of neonatal death identified in the all Wales perinatal survey, the cause of death classified with the clinicopathological system. Subjects: 79 normally formed babies stillborn or who died in the neonatal period, birth weight > 1499 g, for whom cause of death was related to an intrapartum event. Main outcome measures: Relative risk of death due to an intrapartum event according to the hour, day, and month of birth. Results: Mortality was higher in babies born between 9 00 pm and 8 59 am than in those born between 9 00 am and 8 59 pm; relative risk (95% confidence interval) 2.18 (1.37 to 3.47). July and August births also had a higher death rate than births in other months; relative risk 1.99 (1.23 to 3.23). Weekend births had a higher death rate but it was not significant. Conclusions: The excess of deaths at night and during months when annual leave is popular may indicate an overreliance on inexperienced staff at these times. Errors of judgment may also be related to physical and mental fatigue, demanding a more disciplined systematic approach at night. Mistakes may be ameliorated by increasing shiftwork, but shifts should be carefully designed to avoid undue disruption of circadian rhythms. In addition, greater supervision by senior staff may be required at night and during summer months.	Univ Wales Coll Med, Dept Child Hlth, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Cartlidge, PHT (corresponding author), Univ Wales Coll Med, Dept Child Hlth, Cardiff CF4 4XN, S Glam, Wales.							ANDREWS J, 1996, REP MAT DAT INF ASP; *BRIT POSTGR MED F, 1991, PATT HOSP MED STAFF; *CEPOD, 1997, NAT CONF ENQ PER DEA; *DEP HLTH, 1993, CONF ENQ STILLB DEAT; DRISCOLL P, 1995, RISK MANAGEMENT ACCI; Field D J, 1988, Paediatr Perinat Epidemiol, V2, P213, DOI 10.1111/j.1365-3016.1988.tb00209.x; GAFFNEY G, 1994, BRIT MED J, V308, P743, DOI 10.1136/bmj.308.6931.743; GOLD DR, 1992, AM J PUBLIC HEALTH, V82, P1011, DOI 10.2105/AJPH.82.7.1011; Kapur N, 1997, J ROY COLL PHYS LOND, V31, P162; KEELING JW, 1989, ARCH DIS CHILD, V64, P1345, DOI 10.1136/adc.64.10_Spec_No.1345; KIELY JL, 1985, AM J OBSTET GYNECOL, V153, P721, DOI 10.1016/0002-9378(85)90331-X; MACFARLANE A, 1984, BIRTH COUNTS STAT PR; *MAT CHILD HLTH RE, 1997, 4 MAT CHILD HLTH RES; MEER L, 1990, BRIT MED J, V301, P118; NISWANDER K, 1984, LANCET, V2, P827; *PER SURV OFF, 1997, WAL PER SURV CONF EN; WIGGLESWORTH JS, 1980, LANCET, V2, P684	17	85	87	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					657	660		10.1136/bmj.316.7132.657	http://dx.doi.org/10.1136/bmj.316.7132.657			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522787	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000072347900026
J	Shajahan, PM; Cavanagh, JTO				Shajahan, PM; Cavanagh, JTO			Admission for depression among men in Scotland, 1980-95: retrospective study	BRITISH MEDICAL JOURNAL			English	Article									Royal Edinburgh Hosp, MRC, Brain Metab Unit, Edinburgh EH10 5HF, Midlothian, Scotland; Univ Edinburgh, Royal Edinburgh Hosp, Dept Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Shajahan, PM (corresponding author), Royal Edinburgh Hosp, MRC, Brain Metab Unit, Edinburgh EH10 5HF, Midlothian, Scotland.							BECK P, 1994, BRIT MED J, V308, P789, DOI 10.1136/bmj.308.6931.789; GEDDES JR, 1993, BRIT J PSYCHIAT, V163, P620, DOI 10.1192/bjp.163.5.620; POUNDER DJ, 1991, FORENSIC SCI INT, V51, P79, DOI 10.1016/0379-0738(91)90207-Y; WEISSMAN MM, 1993, J AFFECT DISORDERS, V29, P77, DOI 10.1016/0165-0327(93)90025-F	4	9	9	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1998	316	7143					1496	1497		10.1136/bmj.316.7143.1496	http://dx.doi.org/10.1136/bmj.316.7143.1496			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZP020	9582135	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000073707700024
J	Klein, JL; Millman, GC				Klein, JL; Millman, GC			Prospective, hospital based study of fever in children in the United Kingdom who had recently spent time in the tropics	BRITISH MEDICAL JOURNAL			English	Article									Northwick Pk & St Marks NHS Trust, Childrens Serv Directorate, Harrow HA1 3UJ, Middx, England	Imperial College London	Klein, JL (corresponding author), 177 Purves Rd,Kensal Rise, London NW10 5TH, England.							Brabin BJ, 1997, ARCH DIS CHILD, V77, P76, DOI 10.1136/adc.77.1.76; DOHERTY JF, 1995, QJM-INT J MED, V88, P277; SHINGADIA D, 1996, CURR PAEDIAT, V6, P108	3	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1998	316	7142					1425	1426		10.1136/bmj.316.7142.1425	http://dx.doi.org/10.1136/bmj.316.7142.1425			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN495	9572752	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000073651600028
J	Bray, D; Levin, MD; Morton-Firth, CJ				Bray, D; Levin, MD; Morton-Firth, CJ			Receptor clustering as a cellular mechanism to control sensitivity	NATURE			English	Article							BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; COVALENT MODIFICATION; FLAGELLAR MOTOR; PHOSPHORYLATION; CHEMORECEPTOR; COMPLEX; PROTEIN; CHEY	Chemotactic bacteria such as Escherichia coli can detect and respond to extremely low concentrations of attractants, concentrations of less than 5 nM in the case of aspartate(1), They also sense gradients of attractants extending over five orders of magnitude in concentration (up to 1 mM aspartate)(2,3). Here we consider the possibility that this combination of sensitivity and range of response depends on the clustering of chemotactic receptors on the surface of the bacterium(4). We examine what will happen if ligand binding changes the activity of a receptor, propagating this change in activity to neighbouring receptors in a cluster(5,6). Calculations based on these assumptions show that sensitivity to extracellular ligands increases with the extent of spread of activity through an array of receptors, but that the range of concentrations over which the array works is severely diminished. However, a combination of low threshold of response and wide dynamic range can be attained if the cell has both clusters and single receptors on its surface, particularly if the extent of activity spread can adapt to external conditions. A mechanism of this kind can account quantitatively for the sensitivity and response range of E. coli to aspartate.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University of Cambridge	Bray, D (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	d.bray@zoo.cam.ac.uk						AKSAMIT RR, 1975, J BACTERIOL, V123, P1000, DOI 10.1128/JB.123.3.1000-1005.1975; BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BERG HC, 1975, P NATL ACAD SCI USA, V72, P3235, DOI 10.1073/pnas.72.8.3235; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; EISENBACH M, 1990, MOL MICROBIOL, V4, P161, DOI 10.1111/j.1365-2958.1990.tb00584.x; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; HAZELBAUER GL, 1981, J BACTERIOL, V145, P43, DOI 10.1128/JB.145.1.43-49.1981; KHAN S, 1993, BIOPHYS J, V65, P2368, DOI 10.1016/S0006-3495(93)81317-1; KUO SC, 1989, J BACTERIOL, V171, P6279, DOI 10.1128/jb.171.11.6279-6287.1989; Levin MD, 1998, BIOPHYS J, V74, P175, DOI 10.1016/S0006-3495(98)77777-X; Li JY, 1997, BIOCHEMISTRY-US, V36, P11851, DOI 10.1021/bi971510h; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MADDOCK JR, 1993, SCIENCE, V259, P1717; MESIBOV R, 1973, J GEN PHYSIOL, V62, P203, DOI 10.1085/jgp.62.2.203; NINFA EG, 1991, J BIOL CHEM, V266, P9764; PARKINSON JS, 1993, SCIENCE, V259, P1701, DOI 10.1126/science.8456297; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SEGALL JE, 1986, P NATL ACAD SCI USA, V83, P8987, DOI 10.1073/pnas.83.23.8987; STEWART RC, 1993, J BIOL CHEM, V268, P1921; STOCK A, 1985, P NATL ACAD SCI USA, V82, P7989, DOI 10.1073/pnas.82.23.7989; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; Wu JG, 1996, BIOCHEMISTRY-US, V35, P4984, DOI 10.1021/bi9530189; YONEKAWA H, 1986, FEBS LETT, V198, P21, DOI 10.1016/0014-5793(86)81176-0	27	506	512	0	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1998	393	6680					85	88		10.1038/30018	http://dx.doi.org/10.1038/30018			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590695				2022-12-01	WOS:000073497500053
J	Croft, PR; Macfarlane, GJ; Papageorgiou, AC; Thomas, E; Silman, AJ				Croft, PR; Macfarlane, GJ; Papageorgiou, AC; Thomas, E; Silman, AJ			Outcome of low back pain in general practice: a prospective study	BRITISH MEDICAL JOURNAL			English	Article								Objectives: To investigate the claim that 90% of episodes of low back pain that present to general practice have resolved within one month. Design: Prospective study of all adults consulting in general practice because of low back pain over 12 months with follow up at 1 week, 3 months, and 12 months after consultation. Setting: Two general practices in south Manchester. Subjects: 490 subjects (203 men, 287 women) aged 18-75 years. Main outcome measures: Proportion of patients who have ceased to consult with low back pain after 3 months; proportion of patients who are free of pain and back related disability at 3 and 12 months. Results: Annual cumulative consultation late among adults in the practices was 6.4%. Of the 463 patients who consulted with a new episode of low back pain, 275 (59%) had only a single consultation, and 150 (32%) had repeat consultations confined to the 3 months after initial consultation. However, of those interviewed at 3 and 12 months follow up, only 39/188 (21%) and 42/170 (25%) respectively had completely recovered in terms of pain and disability. Conclusions: The results are consistent with the interpretation that 90% of patients with low back pain in primary care will have stopped consulting with symptoms within three months. However most will still be experiencing low back pain and related disability one year after consultation.	Univ Manchester, Sch Epidemiol & Hlth Sci, ARC Epidemiol Res Unit, Manchester M13 9PT, Lancs, England; Keele Univ, Postgrad Med Sch, Ind & Community Hlth Res Ctr, Stoke On Trent ST4 7QB, Staffs, England	University of Manchester; Keele University	Macfarlane, GJ (corresponding author), Univ Manchester, Sch Epidemiol & Hlth Sci, ARC Epidemiol Res Unit, Stopford Bldg, Manchester M13 9PT, Lancs, England.		Macfarlane, Gary J/I-9521-2014	Macfarlane, Gary J/0000-0003-2322-3314				Clinical Standards Advisory Group, 1994, EP REV EP COST BACK; COSTE J, 1994, BRIT MED J, V308, P577, DOI 10.1136/bmj.308.6928.577; DEYO RA, 1993, SPINE, V18, P2153, DOI 10.1097/00007632-199311000-00002; DIXON ASJ, 1973, RHEUM REHABILITATION, V12, P165; Kohlmann T, 1996, Rehabilitation (Stuttg), V35, pI; MASON V, 1994, PREVALENCE BACK PAIN; MCCORMICK A, 1995, MORBIDITY STAT G MB5; *OFF POP CENS SURV, 1994, OPCS MON MB5 94 1 MO; PAPAGEORGIOU AC, 1995, SPINE, V20, P1889, DOI 10.1097/00007632-199509000-00009; Papageorgiou AC, 1996, PAIN, V66, P181, DOI 10.1016/0304-3959(96)03022-9; ROLAND MO, 1983, BRIT MED J, V286, P523, DOI 10.1136/bmj.286.6364.523; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; WALSH K, 1992, J EPIDEMIOL COMMUN H, V46, P227, DOI 10.1136/jech.46.3.227	13	457	460	3	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1998	316	7141					1356	1359		10.1136/bmj.316.7141.1356	http://dx.doi.org/10.1136/bmj.316.7141.1356			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL882	9563990	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000073483000021
J	Friedmann, PD; Saitz, R; Samet, JH				Friedmann, PD; Saitz, R; Samet, JH			Management of adults recovering from alcohol or other drug problems - Relapse prevention in primary care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED TRIAL; SUBSTANCE-ABUSE; PREVALENCE; DEPENDENCE; DEPRESSION; ADDICTION; PHYSICIAN; DRINKING	Patients recovering from substance use disorders are commonly seen in the primary care setting, and relapse is a serious long-term problem for these patients. Extrapolating from therapeutic strategies effective in specialty addiction treatment settings, this article outlines a practical approach to relapse prevention in the primary care setting. Working within a supportive patient-physician relationship, the primary care physician can help recovering patients decrease their susceptibility to relapse, recognize and manage high-risk situations, and use available self-help, pharmacological, and specialty resources, Drawing on the therapeutic relationship and skills they already possess, primary care physicians can have an important, productive, and satisfying role in the long-term management of patients in recovery from alcohol or other drug problems.	Univ Chicago, Pritzker Sch Med, Dept Med, Gen Internal Med Sect, Chicago, IL 60637 USA; Boston Univ, Sch Med, Boston Med Ctr, Dept Med,Sect Gen Internal Med,Clin Addict Res & E, Boston, MA 02118 USA	University of Chicago; Boston Medical Center; Boston University	Friedmann, PD (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Med, Gen Internal Med Sect, 5841 S Maryland Ave,MC2007, Chicago, IL 60637 USA.	pfriedman@medicine.bsd.uchicago.edu		/0000-0002-2535-1427; Samet, Jeffrey/0000-0002-0897-3400	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010019, K08DA000320] Funding Source: NIH RePORTER; NIAAA NIH HHS [5R01-AA10870] Funding Source: Medline; NIDA NIH HHS [1K08-DA00320, 5R01-DA10019] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		*ALC AN WORLD SERV, 1952, 12 STEPS 12 TRAD; *ALC AN WORLD SERV, 1975, ALC AN; *ALC AN WORLD SERV, 1975, LIV SOB; Allen J, 1997, ADDICTION, V92, P1671; Allen JP, 1997, J STUD ALCOHOL, V58, P7; *AM SOC ADD MED, 1997, ASAM NEWS, V17, P17; Babor TF, 1996, AM J PUBLIC HEALTH, V86, P948; Barnes HN, 1997, MED CLIN N AM, V81, P867, DOI 10.1016/S0025-7125(05)70553-8; BARNES HN, 1995, SUBST ABUSE, V16, P31; BIGBY JA, 1987, ALCOHOLISM GUIDE PRI, P66; BUCHSBAUM DG, 1995, ARCH INTERN MED, V155, P104, DOI 10.1001/archinte.155.1.104; Carroll KM, 1996, EXP CLIN PSYCHOPHARM, V4, P46, DOI 10.1037/1064-1297.4.1.46; COLLETTI G, 1980, J CONSULT CLIN PSYCH, V48, P665, DOI 10.1037/0022-006X.48.5.665; Connors GJ, 1996, ADDICTION, V91, pS173, DOI 10.1111/j.1360-0443.1996.tb02337.x; Connors GJ, 1996, ADDICTION, V91, pS5, DOI 10.1111/j.1360-0443.1996.tb02323.x; Connors GJ, 1996, ADDICTION, V91, pS191, DOI 10.1111/j.1360-0443.1996.tb02338.x; DALEY DC, 1989, RELAPSE CONCEPTUAL R, P3; DEJONG W, 1994, DHHS PUBLICATION; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; FLITCRAFT AH, 1994, AM MED ASS DIAGNOSTI; GORSKI T.T, 1988, STAYING SOBER WORKBO; GORSKI TT, 1989, RELAPSE CONCEPTUAL R, P153; GORSKI TT, 1991, ADDICT RECOVERY, V3, P17; HASIN DS, 1990, ARCH INTERN MED, V150, P397, DOI 10.1001/archinte.150.2.397; HAWKINS JD, 1985, INT J ADDICT, V20, P917, DOI 10.3109/10826088509047759; Hirschfeld RMA, 1997, NEW ENGL J MED, V337, P910, DOI 10.1056/NEJM199709253371307; HOFFMANN NG, 1996, COMMITTEE BENEFITS P; HUNT WA, 1971, J CLIN PSYCHOL, V27, P455, DOI 10.1002/1097-4679(197110)27:4<455::AID-JCLP2270270412>3.0.CO;2-R; Institute of Medicine, 1997, DISP MYTHS ADD; KIMBALL HR, 1994, JAMA-J AM MED ASSOC, V271, P315, DOI 10.1001/jama.271.4.315; KRISTENSON H, 1983, ALCOHOL CLIN EXP RES, V7, P203, DOI 10.1111/j.1530-0277.1983.tb05441.x; KURTZ E, 1982, J STUD ALCOHOL, V43, P38, DOI 10.15288/jsa.1982.43.38; Larson MJ, 1997, MED CLIN N AM, V81, P1053, DOI 10.1016/S0025-7125(05)70563-0; Liebschutz JM, 1997, ARCH INTERN MED, V157, P1093, DOI 10.1001/archinte.157.10.1093; Marlatt G. A., 1985, RELAPSE PREVENTION M; Mason BJ, 1996, JAMA-J AM MED ASSOC, V275, P761, DOI 10.1001/jama.275.10.761; MCAULIFFE WE, 1990, J PSYCHOACTIVE DRUGS, V22, P197, DOI 10.1080/02791072.1990.10472544; MCCRADY BS, 1996, TREATING SUBSTANCE A, P117; MCLELLAN AT, 1983, ARCH GEN PSYCHIAT, V40, P620; Miller WR, 1996, ADDICTION, V91, pS15, DOI 10.1111/j.1360-0443.1996.tb02324.x; Miller WR., 2012, MOTIVATIONAL INTERVI; *NARC AN WORLD SER, 1983, NARC AN; *NAT I ALC AB ALC, 1995, NIH PUBL; NOWINSKI J, 1995, DHHS PUBLICATION, V1; O'Connor P. G., 1996, JGIM, V11, P53; O'Connor PG, 1997, AM J MED, V103, P477, DOI 10.1016/S0002-9343(97)00271-4; OBrien CP, 1997, SCIENCE, V278, P66, DOI 10.1126/science.278.5335.66; OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2; OFARELL TJ, 1993, TREATING ALCOHOL PRO; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; ROBINS LN, 1984, ARCH GEN PSYCHIAT, V41, P949; ROUNSAVILLE BJ, 1987, ARCH GEN PSYCHIAT, V44, P505; Saitz R, 1997, AM J DRUG ALCOHOL AB, V23, P343, DOI 10.3109/00952999709016881; Saitz R, 1997, MED CLIN N AM, V81, P881, DOI 10.1016/S0025-7125(05)70554-X; Samet J. H., 1995, JGIM, V10, P48; Samet JH, 1996, ARCH INTERN MED, V156, P2287, DOI 10.1001/archinte.156.20.2287; Sobell LC, 1996, AM J PUBLIC HEALTH, V86, P966, DOI 10.2105/AJPH.86.7.966; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, V2nd; WALLACE BC, 1989, J SUBST ABUSE TREAT, V6, P95, DOI 10.1016/0740-5472(89)90036-6; Warner EA, 1997, MED CLIN N AM, V81, P909, DOI 10.1016/S0025-7125(05)70555-1; Wilk AI, 1997, J GEN INTERN MED, V12, P274; Ziedonis D, 1997, MED CLIN N AM, V81, P1017, DOI 10.1016/S0025-7125(05)70561-7; ZIEDONIS DM, 1991, PSYCHOPHARMACOL BULL, V27, P337	63	89	90	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1998	279	15					1227	1231		10.1001/jama.279.15.1227	http://dx.doi.org/10.1001/jama.279.15.1227			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZG133	9555766				2022-12-01	WOS:000072969400039
J	Banatvala, JE				Banatvala, JE			Rubella - could do better	LANCET			English	Editorial Material							CONGENITAL-RUBELLA; DIAGNOSIS		United Med & Dent Sch Guys & St Thomas Hosp, Dept Virol, London SE1 7EH, England	University of London; King's College London	Banatvala, JE (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, Dept Virol, London SE1 7EH, England.							BANATVALA JE, 1997, TOPLEY WILSONS MICRO, P551; BOSMA TJ, 1995, J CLIN MICROBIOL, V33, P2881, DOI 10.1128/JCM.33.11.2881-2887.1995; Cutts FT, 1997, B WORLD HEALTH ORGAN, V75, P55; Cutts FT, 1998, BMJ-BRIT MED J, V316, P765, DOI 10.1136/bmj.316.7133.765; DOWDLE WR, 1970, B WORLD HEALTH ORGAN, V42, P314; Eckstein MB, 1996, BRIT MED J, V312, P161; MENSER MA, 1967, LANCET, V2, P387; PECKHAM C, 1985, REV INFECT DIS, V7, pS11; PHIROMSAWAT S, 1988, Journal of the Medical Association of Thailand, V71, P26; PRUKSANANONDA P, 1983, Southeast Asian Journal of Tropical Medicine and Public Health, V14, P380; Robertson SE, 1997, B WORLD HEALTH ORGAN, V75, P69; SALISBURY DM, 1991, EPI GLOB ADV GROUP M	12	9	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					849	850		10.1016/S0140-6736(05)70283-X	http://dx.doi.org/10.1016/S0140-6736(05)70283-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525357				2022-12-01	WOS:000072645500005
J	Perman, B; Srajer, V; Ren, Z; Teng, TY; Pradervand, C; Ursby, T; Bourgeois, D; Schotte, F; Wulff, M; Kort, R; Hellingwerf, K; Moffat, K				Perman, B; Srajer, V; Ren, Z; Teng, TY; Pradervand, C; Ursby, T; Bourgeois, D; Schotte, F; Wulff, M; Kort, R; Hellingwerf, K; Moffat, K			Energy transduction on the nanosecond time scale: Early structural events in a xanthopsin photocycle	SCIENCE			English	Article							PHOTOACTIVE YELLOW PROTEIN; GREEN FLUORESCENT PROTEIN; P-COUMARIC ACID; LINKED 4-HYDROXYCINNAMYL CHROMOPHORE; ECTOTHIORHODOSPIRA-HALOPHILA; LAUE DIFFRACTION; PHOTOTROPHIC BACTERIUM; PHOTORECEPTOR; REFINEMENT; CRYSTALLOGRAPHY	Photoactive yellow protein (PYP) is a member of the xanthopsin family of eubacterial blue-light photoreceptors. On absorption of light, PYP enters a photocycle that ultimately transduces the energy contained in a light signal into an altered biological response, Nanosecond time-resolved x-ray crystallography was used to determine the structure of the short-lived, red-shifted, intermediate state denoted [pR], which develops within 1 nanosecond after photoelectronic excitation of the chromophore of PYP by absorption of light. The resulting structural model demonstrates that the [pR] state possesses the cis conformation of the 4-hydroxyl cinnamic thioester chromophore, and that the process of trans to cis isomerization is accompanied by the specific formation of new hydrogen bonds that replace those broken upon excitation of the chromophore. Regions of flexibility that compose the chromophore-binding pocket serve to lower the activation energy barrier between the dark state, denoted pG, and [pR], and help initiate entrance into the photocycle. Direct structural evidence is provided for the initial processes of transduction of light energy, which ultimately translate into a physiological signal.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Consortium Adv Radiat Sources, Chicago, IL 60637 USA; Univ Lund, Ctr Chem, S-22100 Lund, Sweden; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Univ Amsterdam, EC Slater Inst Biochem Res, Microbiol Lab, NL-1018 WS Amsterdam, Netherlands	University of Chicago; University of Chicago; Lund University; European Synchrotron Radiation Facility (ESRF); University of Amsterdam	Moffat, K (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58th St, Chicago, IL 60637 USA.		Pradervand, Claude/GPF-4155-2022; , Bourgeois/AAI-2337-2020; Pradervand, Claude P/I-8114-2013; Kort, Remco/ABH-1915-2021	Pradervand, Claude/0000-0001-5251-3930; Kort, Remco/0000-0003-3674-598X				BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; Baltuska A, 1997, CHEM PHYS LETT, V270, P263, DOI 10.1016/S0009-2614(97)00376-X; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Bourgeois D, 1996, J SYNCHROTRON RADIAT, V3, P65, DOI 10.1107/S090904959501661X; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chosrowjan H, 1997, CHEM PHYS LETT, V270, P267, DOI 10.1016/S0009-2614(97)00365-5; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HOFF WD, 1992, PHOTOCHEM PHOTOBIOL, V56, P529, DOI 10.1111/j.1751-1097.1992.tb02197.x; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; IMAMOTO Y, 1995, FEBS LETT, V374, P157, DOI 10.1016/0014-5793(95)01096-W; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KIM M, 1995, BIOCHEMISTRY-US, V34, P12669, DOI 10.1021/bi00039a024; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; KORT R, 1996, EMBO J, V15, P101; Kroon AR, 1996, J BIOL CHEM, V271, P31949, DOI 10.1074/jbc.271.50.31949; MEYER TE, 1991, BIOPHYS J, V59, P988, DOI 10.1016/S0006-3495(91)82313-X; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; NG K, 1995, BIOCHEMISTRY-US, V34, P879, DOI 10.1021/bi00003a022; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; REN Z, 1995, J APPL CRYSTALLOGR, V28, P461, DOI 10.1107/S0021889895003207; REN Z, 1995, J APPL CRYSTALLOGR, V28, P482, DOI 10.1107/S0021889895003219; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; TERWILLIGER TC, 1995, ACTA CRYSTALLOGR D, V51, P609, DOI 10.1107/S0907444994013247; VANBREDERODE ME, 1995, BIOPHYS J, V68, P1101, DOI 10.1016/S0006-3495(95)80284-5; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; ZHOU F, COMMUNICATION	38	273	280	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1946	1950		10.1126/science.279.5358.1946	http://dx.doi.org/10.1126/science.279.5358.1946			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506946				2022-12-01	WOS:000072613300049
J	Kubo, Y; Miyashita, T; Murata, Y				Kubo, Y; Miyashita, T; Murata, Y			Structural basis for a Ca2+-sensing function of the metabotropic glutamate receptors	SCIENCE			English	Article							LONG-TERM DEPRESSION; MGLUR1 MUTANT MICE; MOLECULAR CHARACTERIZATION; SIGNAL-TRANSDUCTION; EXTRACELLULAR CALCIUM; SENSING RECEPTOR; EXPRESSION; CLONING; RAT; CHANNEL	The metabotropic glutamate receptors (mGluRs) are widely distributed in the brain and play important roles in synaptic plasticity. Here it is shown that some types of mGluRs are activated not only by glutamate but also by extracellular Ca2+(Ca-o(2+)). A single amino acid residue was found to determine the sensitivity of mGluRs to Ca-o(2+). One of the receptors, mGluR1 alpha, but not its point mutant with reduced sensitivity to Ca-o(2+), caused morphological changes when transfected into mammalian cells, Thus, the sensing of Ca-o(2+) by mGluRs may be important in cells under physiological condition.	Tokyo Metropolitan Inst Neurosci, Dept Neurophysiol, Tokyo 1838526, Japan; Meiji Coll Pharm, Dept Med Physiol, Tokyo 154003, Japan	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Meiji Pharmaceutical University	Kubo, Y (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Neurophysiol, Musashidai 2-6, Tokyo 1838526, Japan.		Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Kubo, Yoshihiro/0000-0001-6707-0837; Murata, Yoshimichi/0000-0002-2070-7949				ABE T, 1992, J BIOL CHEM, V267, P13361; AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Kano M, 1997, NEURON, V18, P71, DOI 10.1016/S0896-6273(01)80047-7; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUBO Y, UNPUB; Kubokawa K, 1996, FEBS LETT, V392, P71, DOI 10.1016/0014-5793(96)00786-7; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Vassilev PM, 1997, BIOPHYS J, V72, P2103, DOI 10.1016/S0006-3495(97)78853-2	26	188	209	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1722	1725		10.1126/science.279.5357.1722	http://dx.doi.org/10.1126/science.279.5357.1722			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497291				2022-12-01	WOS:000072490000056
J	de la Pompa, JL; Timmerman, LA; Takimoto, H; Yoshida, H; Elia, AJ; Samper, E; Potter, J; Wakeham, A; Marengere, L; Langille, BL; Crabtree, GR; Mak, TW				de la Pompa, JL; Timmerman, LA; Takimoto, H; Yoshida, H; Elia, AJ; Samper, E; Potter, J; Wakeham, A; Marengere, L; Langille, BL; Crabtree, GR; Mak, TW			Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum	NATURE			English	Article							T-CELL ACTIVATION; CYCLOSPORINE-A; GENE; CALCINEURIN; FAMILY; IDENTIFICATION; CONTAINS; PROTEINS; MEMBER	In lymphocytes, the expression of early immune response genes is regulated by NF-AT transcription factors(1,2) which translocate to the nucleus after dephosphorylation by the Ca2+-dependent phosphatase, calcineurin(3). We report here that mice bearing a disruption in the NF-ATc gene fail to develop normal cardiac valves and septa and die of circulatory failure before day 14.5 of development. NF-ATc is first expressed in the heart at day 7.5, and is restricted to the endocardium, a specialized endothelium that gives rise to the valves and septum. Within the endocardium, specific inductive events appear to activate NF-ATc: it is localized to the nucleus only in endocardial cells that are adjacent to the interface with the cardiac jelly and myocardium, which are thought to give the inductive stimulus to the valve primordia(4). Treatment of wild-type embryos with FK506, a specific calcineurin inhibitor(5), prevents nuclear localization of NF-ATc. These data indicate that the Ca2+/calcineurin/NF-ATc signalling pathway is essential for normal cardiac valve and septum morphogenesis; hence, NF-ATc and its regulatory pathways are candidates for genetic defects underlying congenital human heart disease.	Univ Toronto, Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA; Univ Toronto, Dept Pathol, Toronto, ON M5S 1A8, Canada; Toronto Gen Div, Max Bell Res Ctr, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Howard Hughes Medical Institute; Stanford University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Mak, TW (corresponding author), Univ Toronto, Ontario Canc Inst, Amgen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.	t.mak@oci.utoronto.ca	De La Pompa, José Luis/F-9719-2014	De La Pompa, José Luis/0000-0001-6761-7265				Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Bennett PC, 1996, BRAIN RES, V730, P107; Buck Clayton A., 1993, Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie, V316, P838; CHANG HY, 1995, NATURE, V376, P686, DOI 10.1038/376686a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P155; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926; Koop KE, 1996, MECH DEVELOP, V59, P73, DOI 10.1016/0925-4773(96)00582-5; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RUNYAN RB, 1990, CELL REGUL, V1, P301, DOI 10.1091/mbc.1.3.301; SASSOON DA, 1988, DEVELOPMENT, V104, P155; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; TRUMPP A, 1992, GENE DEV, V6, P14, DOI 10.1101/gad.6.1.14	24	507	511	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					182	186		10.1038/32419	http://dx.doi.org/10.1038/32419			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515963				2022-12-01	WOS:000072462700063
J	Gray, RA; Pertsov, AM; Jalife, J				Gray, RA; Pertsov, AM; Jalife, J			Spatial and temporal organization during cardiac fibrillation	NATURE			English	Article							VENTRICULAR-FIBRILLATION; REENTRANT ACTIVITY; SPIRAL WAVES; TERMINATION; MECHANISM; HEART; MUSCLE	Cardiac fibrillation (spontaneous, asynchronous contractions of cardiac muscle fibres) is the leading cause of death in the industrialized world(1), yet it is not dear how it occurs. It has been debated whether or not fibrillation is a random phenomenon. There is some determinism during fibrillation(2,3), perhaps resulting from rotating waves of electrical activity(4-6). Here we present a new algorithm that markedly reduces the amount of data required to depict the complex spatiotemporal patterns of fibrillation. We use a potentiometric dye(7) and video imaging(8,9) to record the dynamics of transmembrane potentials at many sites during fibrillation. Transmembrane signals at each site exhibit a strong periodic component centred near 8 Hz. This periodicity is seen as an attractor in two-dimensional-phase space and each site can be represented by its phase around the attractor, Spatial phase maps at each instant reveal the 'sources' of fibrillation in the form of topological defects, or phase singularities(10), at a few sites. Using our method of identifying phase singularities, we can elucidate the mechanisms for the formation and termination of these singularities, and represent an episode of fibrillation by locating singularities. Our results indicate an unprecedented amount of temporal and spatial organization during cardiac fibrillation.	SUNY Hlth Sci Ctr, Dept Pharmacol, Syracuse, NY 13210 USA; Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Pertsov, AM (corresponding author), SUNY Hlth Sci Ctr, Dept Pharmacol, 766 Irving Ave, Syracuse, NY 13210 USA.	rag@crml.uab.edu	Jalife, Jose/AAJ-9156-2021; Jalife, Jose/L-4833-2015; Gray, Richard/F-3916-2015	Jalife, Jose/0000-0003-0080-3500; Jalife, Jose/0000-0003-0080-3500; Gray, Richard/0000-0003-2798-6378				AGLADZE KI, 1982, NATURE, V296, P424, DOI 10.1038/296424a0; Allessie M.A., 1985, CARDIAC ELECTROPHYSI, P265, DOI DOI 10.1016/J.HRTHM.2012.03.008; BAYLY PV, 1993, J CARDIOVASC ELECTR, V4, P533, DOI 10.1111/j.1540-8167.1993.tb01242.x; BOVE RT, 1996, CIRCULATION, V94, P1; CHA YM, 1994, CIRC RES, V74, P495, DOI 10.1161/01.RES.74.3.495; DAVIDENKO JM, 1992, NATURE, V355, P349, DOI 10.1038/355349a0; FAST V G, 1990, Biophysics (English Translation of Biofizika), V35, P489; FITZHUGH R, 1961, BIOPHYS J, V1, P445, DOI 10.1016/S0006-3495(61)86902-6; Garfinkel A, 1997, J CLIN INVEST, V99, P305, DOI 10.1172/JCI119159; Glass L., 1988, CLOCKS CHAOS RHYTHMS; GOLDBETER A, 1975, NATURE, V253, P540, DOI 10.1038/253540a0; Gotoh M, 1997, CIRCULATION, V95, P2141, DOI 10.1161/01.CIR.95.8.2141; Gray RA, 1996, INT J BIFURCAT CHAOS, V6, P415, DOI 10.1142/S0218127496000163; GRAY RA, 1995, CIRCULATION, V91, P2454, DOI 10.1161/01.CIR.91.9.2454; GRAY RA, 1995, SCIENCE, V270, P1222, DOI 10.1126/science.270.5239.1222; Gray RA, 1997, CIRCULATION, V95, P1038; Ikeda T, 1996, CIRCULATION, V94, P1962, DOI 10.1161/01.CIR.94.8.1962; KRINSKY VI, 1978, PHARMACOL THER PT B, V3, P539, DOI 10.1016/S0306-039X(78)90020-X; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; Lee JJ, 1996, CIRC RES, V78, P660, DOI 10.1161/01.RES.78.4.660; MOE GK, 1959, AM HEART J, V58, P59, DOI 10.1016/0002-8703(59)90274-1; MYERBURG RJ, 1990, CARDIAC ELECTROPHYSI; PERTSOV AM, 1993, CIRC RES, V72, P631, DOI 10.1161/01.RES.72.3.631; SALZBERG BM, 1973, NATURE, V246, P508, DOI 10.1038/246508a0; Takens F., 1981, LECT NOTES MATH, P366, DOI [10.1007/BFb0091924, DOI 10.1007/BFB0091924]; WINFREE AT, 1973, SCIENCE, V181, P937, DOI 10.1126/science.181.4103.937; WINFREE AT, 1994, SCIENCE, V266, P1003, DOI 10.1126/science.7973648; WINFREE AT, 1987, TIME BREAKS DOWN; WITKOWSKI FX, 1995, PHYS REV LETT, V75, P1230, DOI 10.1103/PhysRevLett.75.1230; Zykov V S, 1987, SIMULATION WAVE PROC	30	718	736	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					75	78		10.1038/32164	http://dx.doi.org/10.1038/32164			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510249				2022-12-01	WOS:000072373000052
J	Corcoran, AE; Riddell, A; Krooshoop, D; Venkitaraman, AR				Corcoran, AE; Riddell, A; Krooshoop, D; Venkitaraman, AR			Impaired immunoglobulin gene rearrangement in mice lacking the IL-7 receptor	NATURE			English	Article							B-CELL DEVELOPMENT; LYMPHOCYTES-B; FETAL LIVER; BONE-MARROW; EXPRESSION; HEAVY; DIFFERENTIATION; TRANSCRIPTION; SEGMENTS; REGION	To generate the full diversity of antibody heavy-chain genes, hundreds of dispersed germline V segments must undergo recombination following D-J segment joining. Here we report that this process is regulated by the alpha-chain of the receptor for interleukin-7, a cytokine that stimulates B-cell lymphopoiesis(1). D-J joining occurs normally in immature B lymphocytes from mice lacking the alpha-chain of the interleukin-7 receptor (IL-7R alpha). But recombination of V segments is progressively impaired as their distance increases upstream of D/J, causing infrequent rearrangement of most V segments, which markedly reduces diversity. This is not simply due to defective cell proliferation or impaired recombinase expression. Rather, germline transcripts from distal, unrearranged V segments, a marker of chromatin changes that precede recombination, are specifically silenced. So too is expression of Pax-5, which binds to heavy-chain locus control elements and normally stimulates recombination, suggesting a mechanism for these effects. Thus ligands of the interleukin-7 receptor deliver an extrinsic signal that targets. V segment recombination in the heavy-chain locus by altering the accessibility of DNA substrates to the recombinase. This mechanism augments the recombinational diversity of the primary antibody repertoire.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Venkitaraman, AR (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	arv@mrc-lmb.cam.ac.uk						ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; CHANG Y, 1992, EMBO J, V11, P1891, DOI 10.1002/j.1460-2075.1992.tb05241.x; Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EHLICH A, 1994, CURR BIOL, V4, P127; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HONJO T, 1995, IMMUNOGLOBULIN GENES, P145; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Marshall AJ, 1996, J IMMUNOL, V156, P2077; Michaelson JS, 1996, J IMMUNOL, V156, P2349; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; RATHBUN GA, 1987, EMBO J, V6, P2931, DOI 10.1002/j.1460-2075.1987.tb02597.x; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; tenBoekel E, 1997, IMMUNITY, V7, P357; TENBOEKEL E, 1995, INT IMMUNOL, V7, P1013; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WU GE, 1986, EMBO J, V5, P3475, DOI 10.1002/j.1460-2075.1986.tb04672.x; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1984, NATURE, V311, P727, DOI 10.1038/311727a0	30	271	275	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					904	907		10.1038/36122	http://dx.doi.org/10.1038/36122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495344				2022-12-01	WOS:000072230900055
J	Nagar, B; Jones, RG; Diefenbach, RJ; Isenman, DE; Rini, JM				Nagar, B; Jones, RG; Diefenbach, RJ; Isenman, DE; Rini, JM			X-ray crystal structure of C3d: A C3 fragment and ligand for complement receptor 2	SCIENCE			English	Article							B-CELL RESPONSE; SEQUENCE ALIGNMENTS; ACQUIRED-IMMUNITY; PROTEIN-STRUCTURE; 3RD COMPONENT; BINDING-SITE; PROGRAM; LYMPHOCYTES; THIOESTER; MODULES	Activation and covalent attachment of complement component C3 to pathogens is the key step in complement-mediated host defense. Additionally, the antigen-bound C3d fragment interacts with complement receptor 2 (CR2; also known as CD21) on B cells and thereby contributes to the initiation of an acquired humoral response. The x-ray crystal structure of human C3d solved at 2.0 angstroms resolution reveals an a-a barrel with the residues responsible for thioester formation and covalent attach ment at one end and an acidic pocket at the other. The structure supports a model whereby the transition of native C3 to its functionally active stale involves the disruption of a complementary domain interface and provides insight into the basis for the interaction between C3d and CR2.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Rini, JM (corresponding author), Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada.		Jones, Russell/AAC-2861-2022; Nagar, Bhushan/C-1297-2010; Diefenbach, Russell J./E-9602-2015; Jones, Russell Graham/ABD-5261-2021	Diefenbach, Russell J./0000-0002-8433-4336; Jones, Russell Graham/0000-0003-2250-4675				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; ALESHIN A, 1992, J BIOL CHEM, V267, P19291; Alzari PM, 1996, STRUCTURE, V4, P265, DOI 10.1016/S0969-2126(96)00031-7; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger A. T, 1992, XPLOR 3 1 SYSTEM XRA; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; DIEFENBACH RJ, 1995, J IMMUNOL, V154, P2303; Dodds AW, 1996, NATURE, V379, P177, DOI 10.1038/379177a0; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.iy.13.040195.001015; Fischer MB, 1996, J IMMUNOL, V157, P549; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GADJEVA M, IN PRESS J IMMNOL; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hubbard S.J., 1993, NACCESS COMPUTER PRO, VVolume 2; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; ISAAC L, 1992, J BIOL CHEM, V267, P10062; Isaac L, 1998, BIOCHEM J, V329, P705, DOI 10.1042/bj3290705; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIS JD, 1985, P NATL ACAD SCI USA, V82, P4235, DOI 10.1073/pnas.82.12.4235; LAW SK, 1977, P NATL ACAD SCI USA, V74, P2701, DOI 10.1073/pnas.74.7.2701; LAW SKA, 1983, BIOCHEM J, V211, P381, DOI 10.1042/bj2110381; Law SKA, 1997, PROTEIN SCI, V6, P263; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MOLINA H, 1995, J IMMUNOL, V154, P5426; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; RICHARDS FM, 1993, Q REV BIOPHYS, V26, P423, DOI 10.1017/S0033583500002845; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1	40	158	181	3	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1277	1281		10.1126/science.280.5367.1277	http://dx.doi.org/10.1126/science.280.5367.1277			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596584				2022-12-01	WOS:000073852500053
J	Lieberman, DE				Lieberman, DE			Sphenoid shortening and the evolution of modern human cranial shape	NATURE			English	Article							HOMINID FACE; MORPHOLOGY; ONTOGENY; SKULLS; HOMO	Crania of 'anatomically modern' Homo sapiens from the Holocene and Upper Pleistocene epochs differ from those of other Homo taxa, including Neanderthals, by only a few features. These include a globular braincase, a vertical forehead, a dimunitive browridge, a canine fossa and a pronounced chin(1-4). Humans are also unique among mammals in lacking facial projection: the face of the adult H. sapiens Lies almost entirely beneath the anterior cranial fossa, whereas the face in all other adult mammals, including Neanderthals, projects to some extent in front of the braincase. Here I use radiographs and computed tomography to show that many of these unique human features stem partly from a single, ontogenetically early reduction in the length of the sphenoid, the central bone of the cranial base from which the re face grows forward. Sphenoid reduction, through its effects on facial projection and cranial shape, may account for the apparently rapid evolution of modern human cranial form, and suggests that Neanderthals and other archaic Homo should be excluded from H. sapiens.	Rutgers State Univ, Dept Anthropol, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick	Lieberman, DE (corresponding author), Rutgers State Univ, Dept Anthropol, New Brunswick, NJ 08903 USA.							Aiello L., 1990, INTRO HUMAN EVOLUTIO; ARENSBURG B, 1990, AM J PHYS ANTHROPOL, V83, P137, DOI 10.1002/ajpa.1330830202; BILSBOROUGH A, 1988, AM J PHYS ANTHROPOL, V76, P61, DOI 10.1002/ajpa.1330760107; BROMAGE TG, 1992, J HUM EVOL, V23, P235, DOI 10.1016/S0047-2484(05)80002-8; BROMAGE TG, 1989, J HUM EVOL, V18, P751, DOI 10.1016/0047-2484(89)90088-2; CORRUCCINI RS, 1992, AM J PHYS ANTHROPOL, V87, P433, DOI 10.1002/ajpa.1330870405; DUTERLOO HS, 1970, AM J ANAT, V127, P357, DOI 10.1002/aja.1001270403; Enlow D. H., 1990, FACIAL GROWTH; ENLOW DH, 1975, MORPHOGENESIS MALFOR, P217; Fant G., 1960, ACOUSTIC THEORY SPEE; Howells W. W., 1989, PEABODY MUSEUM PAPER, V79; KRNGS M, 1997, CELL, V90, P19; Lahr M. M, 1996, EVOLUTION MODERN HUM; Lieberman DE, 1996, AM J PHYS ANTHROPOL, V101, P217, DOI 10.1002/(SICI)1096-8644(199610)101:2<217::AID-AJPA7>3.0.CO;2-Z; LIEBERMAN DE, 1995, CURR ANTHROPOL, V36, P159, DOI 10.1086/204348; Lieberman P., 1984, BIOL EVOLUTION LANGU; Lumley M. A, 1982, HOMO ERECTUS PLACE H, P814; MACCAMMON R, 1970, HUMAN GROWTH DEV; RAVOSA MJ, 1991, AM J PHYS ANTHROPOL, V85, P95, DOI 10.1002/ajpa.1330850111; Ruff CB, 1997, NATURE, V387, P173, DOI 10.1038/387173a0; Schwartz JH, 1996, P NATL ACAD SCI USA, V93, P10852, DOI 10.1073/pnas.93.20.10852; SHEA BT, 1985, AM J PHYS ANTHROPOL, V68, P329, DOI 10.1002/ajpa.1330680304; Smith F. H., 1992, CONTINUITY REPLACEME, P157; SPENCER MA, 1995, AM J PHYS ANTHROPOL, V91, P1; Stevens K.N., 1972, HUMAN COMMUNICATION, P51; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; TRINKAUS E, 1987, J HUM EVOL, V16, P429, DOI 10.1016/0047-2484(87)90071-6; WEIDENREICH FRANZ, 1941, TRANS AMER PHIL SOC, V31, P321; White T.D., 1991, HUMAN OSTEOLOGY	29	112	115	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1998	393	6681					158	162		10.1038/30227	http://dx.doi.org/10.1038/30227			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZN200	9603517				2022-12-01	WOS:000073619900045
J	Billuart, P; Bienvenu, T; Ronce, N; Des Portes, V; Vinet, MC; Zemni, R; Roest Crollius, H; Carrie, A; Fauchereau, F; Cherry, M; Briault, S; Hamel, B; Fryns, JP; Beldjord, C; Kahn, A; Moraine, C; Chelly, J				Billuart, P; Bienvenu, T; Ronce, N; Des Portes, V; Vinet, MC; Zemni, R; Roest Crollius, H; Carrie, A; Fauchereau, F; Cherry, M; Briault, S; Hamel, B; Fryns, JP; Beldjord, C; Kahn, A; Moraine, C; Chelly, J			Oligophrenin-1 encodes a rhoGAP protein involved in X-linked mental retardation	NATURE			English	Article							GRADIENT GEL-ELECTROPHORESIS; MUTATIONS; GTPASES; GENES; RAS	Primary or nonspecific X-linked mental retardation (MRX) is a heterogeneous condition in which affected patients do not have any distinctive clinical or biochemical features in common apart from cognitive impairment(1). Although it is present in approximately 0.15-0.3% of males(2), most of the genetic defects associated with MRX, which may involve more than ten different genes, remain unknown(3). Here we report the characterization of a new gene on the long arm of the X-chromosome (position Xq12) and the identification in unrelated individuals of different mutations that are predicted to cause a loss of function. This gene is highly expressed in fetal brain and encodes a protein of relative molecular mass 91K, named oligophrenin-1, which contains a domain typical of a Rho-GTPase-activating protein (rhoGAP)(4,5). By enhancing their GTPase activity, GAP proteins inactivate small Rho and Pas proteins, so inactivation of rhoGAP proteins might cause constitutive activation of their GTPase targets. Such activation is known to affect cell migration and outgrowth of axons and dendrites in vivo(6-8). Our results demonstrate an association between cognitive impairment and a defect in a signalling pathway that depends on a Ras-like GTPase.	Fac Med Cochin, ICGM, INSERM, U129, F-75014 Paris, France; CHU Tours, Hop Bretonneau, Serv Genet, F-37044 Tours, France; Max Planck Inst Mol Genet, Berlin, Germany; CHU Nancy, Genet Lab, F-54511 Vandoeuvre Les Nancy, France; Univ Nijmegen Hosp, Dept Human Genet 417, NL-6500 HB Nijmegen, Netherlands; Univ Hosp Gasthuisberg, Ctr Human Genet, Clin Genet Unit, B-3000 Louvain, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU Tours; Max Planck Society; CHU de Nancy; Radboud University Nijmegen; KU Leuven; University Hospital Leuven	Chelly, J (corresponding author), Fac Med Cochin, ICGM, INSERM, U129, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	chelly@cochin.inserm.fr	Billuart, Pierre/K-3832-2017; Chelly, Jamel/J-7528-2015	Billuart, Pierre/0000-0003-1913-1687; Chelly, Jamel/0000-0002-0939-8719; ROEST CROLLIUS, Hugues/0000-0002-8209-173X				[Anonymous], 1982, MOL CLONING LAB MANU; Bienvenu T, 1997, EUR J HUM GENET, V5, P105, DOI 10.1159/000484743; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Davies HR, 1997, J MED GENET, V34, P158, DOI 10.1136/jmg.34.2.158; FERNANDEZ E, 1993, PCR METH APPL, V3, P122; Gedeon AK, 1996, AM J MED GENET, V64, P158, DOI 10.1002/(SICI)1096-8628(19960712)64:1<158::AID-AJMG26>3.3.CO;2-V; HERBST DS, 1980, AM J MED GENET, V7, P461, DOI 10.1002/ajmg.1320070407; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; KEL AE, 1993, COMPUT APPL BIOSCI, V9, P617; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; Lubs HA, 1996, AM J MED GENET, V64, P147, DOI 10.1002/(SICI)1096-8628(19960712)64:1<147::AID-AJMG25>3.0.CO;2-M; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	20	355	363	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 30	1998	392	6679					923	926		10.1038/31940	http://dx.doi.org/10.1038/31940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582072				2022-12-01	WOS:000073359900049
J	Puri, KD; Chen, SQ; Springer, TA				Puri, KD; Chen, SQ; Springer, TA			Modifying the mechanical property and shear threshold of L-selectin adhesion independently of equilibrium properties	NATURE			English	Article							HYDRODYNAMIC SHEAR; ROLLING ADHESIONS; SIALOMUCIN CD34; P-SELECTIN; LIGAND; FLOW; BOND	Interactions between adhesion molecules on two different cells differ from interactions between receptors and soluble ligands in that the adhesion molecule interaction (bond) is often subjected to force. It is widely assumed by cell biologists that the 'strength' of a bond is a simple function of the affinity of one adhesion molecule for the other, whereas biophysicists suggest that bonds have 'mechanical properties' that affect their strength. Mechanical properties are a function of the shape of the energy landscape related to bond formation and dissociation, whereas affinity is related only to the net energy change(1-5). Mechanical properties determine the amount by which the kinetics and affinity of bonds are altered by applied force. To date there has been no experimental manipulation of an adhesion molecule that has been shown to affect mechanical properties. L-selectin is an adhesion molecule that mediates lymphocyte binding to, and rolling on, high endothelial venules; these are prerequisites for the emigration of lymphocytes from the bloodstream into lymph nodes. Here we report a selective and reversible chemical modification of a mucin-like ligand that alters the mechanical properties of its bond with L-selectin. The effect of force on the rate of bond dissociation, that is, on a mechanical property, is altered, whereas there is little or no effect of the modification on the rate of bond dissociation in the absence of force. Moreover, the puzzling requirement for hydrodynamic shear flow above a threshold level for L-selectin interactions(6-9) is dramatically altered.	Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School	Springer, TA (corresponding author), Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.							Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; Bruinsma R, 1997, P NATL ACAD SCI USA, V94, P375, DOI 10.1073/pnas.94.2.375; Chen SQ, 1997, P NATL ACAD SCI USA, V94, P3172, DOI 10.1073/pnas.94.7.3172; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; DEMBO M, 1994, LECT MATH LIFE SCI, V25, P1; Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kyte J., 1995, STRUCTURE PROTEIN CH; LASKY LA, 1992, INFLAMMATION BASIC P, V2, P407; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; LECKBAND D, 1995, BIOPHYS J, V69, P1162, DOI 10.1016/S0006-3495(95)79990-8; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; Pierres A, 1996, J PHYS III, V6, P807, DOI 10.1051/jp3:1996156; Puri KD, 1996, J BIOL CHEM, V271, P5404, DOI 10.1074/jbc.271.10.5404; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; Puri KD, 1997, J IMMUNOL, V158, P405; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Taylor AD, 1996, BIOPHYS J, V71, P3488, DOI 10.1016/S0006-3495(96)79544-9	24	63	68	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					930	933		10.1038/31954	http://dx.doi.org/10.1038/31954			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582074				2022-12-01	WOS:000073359900051
J	Zou, L; Stillman, B				Zou, L; Stillman, B			Formation of a preinitiation complex by S-phase cyclin CDK-dependent loading of Cdc45p onto chromatin	SCIENCE			English	Article							DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; CDC6 PROTEIN; YEAST; ORIGINS; TRANSITION; KINASES	Cdc45p, a protein essential for initiation of DNA replication, associates with chromatin after "start" in late G(1) and during the S phase of the cell cycle. Binding of Cdc45p to chromatin depends on Clb-Cdc28 kinase activity as well as functional Cdc6p and Mcm2p, which suggests that Cdc45p associates with the prereplication complex after activation of S-phase cyclin-dependent kinases (CDKs). As indicated by the timing and the CDK dependence, binding of Cdc45p to chromatin is crucial for commitment to initiation of DNA replication, During S phase, Cdc45p physically interacts with minichromosome maintenance (MCM) proteins on chromatin; however, dissociation of Cdc45p from chromatin is slower than that of MCMs, which indicates that the proteins are released by different mechanisms.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Grad Program Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Stillman, B (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	stillman@cshl.org		Stillman, Bruce/0000-0002-9453-4091	NIGMS NIH HHS [GM45436] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045436] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Dalton S, 1997, MOL CELL BIOL, V17, P5867, DOI 10.1128/MCB.17.10.5867; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Elsasser S, 1996, MOL BIOL CELL, V7, P1723, DOI 10.1091/mbc.7.11.1723; Hardy CFJ, 1997, GENE, V187, P239, DOI 10.1016/S0378-1119(96)00761-5; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; Hopwood B, 1996, P NATL ACAD SCI USA, V93, P12309, DOI 10.1073/pnas.93.22.12309; Hoyt MA, 1997, CELL, V91, P149, DOI 10.1016/S0092-8674(00)80396-7; Jallepalli PV, 1996, GENE DEV, V10, P541, DOI 10.1101/gad.10.5.541; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LIANG C, GENES DEV, V11, P3375; Lopez-Girona A, 1998, MOL BIOL CELL, V9, P63, DOI 10.1091/mbc.9.1.63; LUCCHINI G, 1990, GENE, V90, P99, DOI 10.1016/0378-1119(90)90444-V; NASMYTH K, 1996, DNA REPLICATION EUKA, P311; Owens JC, 1997, P NATL ACAD SCI USA, V94, P12521, DOI 10.1073/pnas.94.23.12521; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; WEINREICH M, UNPUB; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553; ZOU L, UNPUB	32	272	272	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1998	280	5363					593	596		10.1126/science.280.5363.593	http://dx.doi.org/10.1126/science.280.5363.593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554851				2022-12-01	WOS:000073242100048
J	Pantev, C; Oostenveld, R; Engelien, A; Ross, B; Roberts, LE; Hoke, M				Pantev, C; Oostenveld, R; Engelien, A; Ross, B; Roberts, LE; Hoke, M			Increased auditory cortical representation in musicians	NATURE			English	Article							ABSOLUTE PITCH; TONOTOPIC ORGANIZATION; CORTEX; FIELDS; ADULT	Acoustic stimuli are processed throughout the auditory projection pathway including the neocortex, by neurons that are aggregated into 'tonotopic' maps according to their specific frequency tunings(1-3). Research on animals has shown that tonotopic representations are not statically fixed in the adult organism but can reorganize after damage to the cochlea(4) or after training the intact subject to discriminate between auditory stimuli(5). Here we used functional magnetic source imaging (single dipole model) to measure cortical representations int highly skilled musicians. Dipole moments for piano tones, but not for pure tones of similar fundamental frequency (matched in loudness), were found to be enlarged by about 25% in musicians compared with control subjects who had never played an instrument. Enlargement was correlated with the age at which musicians began to practise and did not differ between musicians with absolute or relative pitch. These results, when interpreted with evidence for modified somatosensory representations of the fingering digits in skilled violinists(6), suggest that use-dependent functional reorganization extends across the sensory cortices to reflect the pattern of sensory input processed by the subject during development of musical skill.	Univ Munster, Inst Expt Audiol, Biomagnetism Ctr, D-48129 Munster, Germany; Univ Munster, Dept Neurol, D-48129 Munster, Germany; McMaster Univ, Dept Psychol, Hamilton, ON L8S 4K1, Canada	University of Munster; University of Munster; McMaster University	Pantev, C (corresponding author), Univ Munster, Inst Expt Audiol, Biomagnetism Ctr, D-48129 Munster, Germany.	pantev@uni-muenster.de	Oostenveld, Robert/D-3259-2009	Oostenveld, Robert/0000-0002-1974-1293; Ross, Bernhard/0000-0001-7290-631X				BARNEA A, 1994, INT J PSYCHOPHYSIOL, V16, P29, DOI 10.1016/0167-8760(94)90039-6; BENGUEREL AP, 1991, MUSIC PERCEPT, V9, P105; ELBERT T, 1995, SCIENCE, V270, P305, DOI 10.1126/science.270.5234.305; Irvine D. R. F., 1995, ADV HEARING RES, P3; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; MERZENICH MM, 1976, J COMP NEUROL, V166, P387, DOI 10.1002/cne.901660402; MERZENICH MM, 1973, BRAIN RES, V63, P343, DOI 10.1016/0006-8993(73)90101-7; PANTEV C, 1988, ELECTROEN CLIN NEURO, V69, P160, DOI 10.1016/0013-4694(88)90211-8; RAUSCHECKER JP, 1995, SCIENCE, V268, P111, DOI 10.1126/science.7701330; RECANZONE GH, 1993, J NEUROSCI, V13, P87; SCHLAUG G, 1995, SCIENCE, V267, P699, DOI 10.1126/science.7839149; TAKEUCHI AH, 1993, PSYCHOL BULL, V113, P345, DOI 10.1037/0033-2909.113.2.345; WILLIAMSON SJ, 1990, AUDITORY EVOKED MAGN, P1; Yakovlev P., 1967, REGIONAL DEV BRAIN E, P3	14	575	588	2	81	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1998	392	6678					811	814		10.1038/33918	http://dx.doi.org/10.1038/33918			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZJ679	9572139				2022-12-01	WOS:000073241200052
J	Zhang, PJ; Toyoshima, C; Yonekura, K; Green, NM; Stokes, DL				Zhang, PJ; Toyoshima, C; Yonekura, K; Green, NM; Stokes, DL			Structure of the calcium pump from sarcoplasmic reticulum at 8-angstrom resolution	NATURE			English	Article							AMINO-ACIDS; NA,K PUMP; CA-2+-ATPASE; MEMBRANE; ATPASE; CA2+-ATPASE; THAPSIGARGIN; MUTAGENESIS; LOCATION; MUTATION	The calcium pump from sarcoplasmic reticulum (Ca2+-ATPase) is typical of the large family of P-type cation pumps. These couple ATP hydrolysis with cation transport, generating cation gradients across membranes. Ca2+-ATPase specifically maintains the low cytoplasmic calcium concentration of resting muscle by pumping calcium into the sarcoplasmic reticulum; subsequent release is used to initiate contraction. No high-resolution structure of a P-type pump has yet been determined, although a 14-Angstrom structure of Ca2+-ATPase, obtained by electron microscopy of frozen-hydrated, tubular crystals(1), showed a large cytoplasmic head connected to the transmembrane domain by a narrow stalk. We have now improved the resolution to 8 Angstrom and can discern ten transmembrane ol-helices, four of which continue into the stalk. On the basis of constraints from transmembrane topology, site-directed mutagenesis and disulphide crosslinking, we have made tentative assignments for these alpha-helices within the amino-acid sequence. A distinct cavity leads to the putative calcium-binding site, providing a plausible path for calcium release to the lumen of the sarcoplasmic reticulum.	NYU, Med Ctr, Skirball Inst Biomol Med, New York, NY 10016 USA; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 113, Japan; Natl Inst Med Res, London NW7 1AA, England	New York University; University of Tokyo; MRC National Institute for Medical Research	Stokes, DL (corresponding author), NYU, Med Ctr, Skirball Inst Biomol Med, 540 1st Ave, New York, NY 10016 USA.		Toyoshima, Chikashi/R-4153-2019; YONEKURA, Koji/N-5060-2015	Yonekura, Koji/0000-0001-5520-4391; Toyoshima, Chikashi/0000-0001-9640-0778				Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BEORUKHIM R, 1997, ULTRAMICROSCOPY, V70, P57; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DUX L, 1983, J BIOL CHEM, V258, P2599; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GREEN NM, 1994, SODIUM PUMP, P110; GREEN NM, 1989, BIOCHEM SOC T, V17, P970; Guerini D, 1996, BIOCHEMISTRY-US, V35, P3290, DOI 10.1021/bi952572f; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; HUA SM, 1995, BIOCHEMISTRY-US, V34, P5137, DOI 10.1021/bi00015a026; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; STOKES DL, 1994, J BIOL CHEM, V269, P11606; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TANI K, 1997, ULTRAMICROSCOPY, V65, P31; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; TOYOSHIMA C, 1993, ULTRAMICROSCOPY, V48, P165, DOI 10.1016/0304-3991(93)90179-2	26	271	275	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 23	1998	392	6678					835	839		10.1038/33959	http://dx.doi.org/10.1038/33959			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572145				2022-12-01	WOS:000073241200059
J	Dell'Angelica, EC; Klumperman, J; Stoorvogel, W; Bonifacino, JS				Dell'Angelica, EC; Klumperman, J; Stoorvogel, W; Bonifacino, JS			Association of the AP-3 adaptor complex with clathrin	SCIENCE			English	Article							PROTEIN; VESICLES; MEMBRANE; SUBUNITS; BINDING; GOLGI	A heterotetrameric complex termed AP-3 is involved in signal-mediated protein sorting to endosomal-lysosomal organelles. AP-3 has been proposed to be a component of a nonclathrin coat. In vitro binding assays showed that mammalian AP-3 did associate with clathrin by interaction of the appendage domain of its beta 3 subunit with the amino-terminal domain of the clathrin heavy chain. The beta 3 appendage domain contained a conserved consensus motif for clathrin binding. AP-3 colocalized with clathrin in cells as observed by immunofluorescence and immunoelectron microscopy. Thus, AP-3 function in protein sorting may depend on clathrin.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Univ Utrecht, Sch Med, Dept Cell Biol, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Utrecht University	Bonifacino, JS (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	juan@helix.nih.gov		Bonifacino, Juan S./0000-0002-5673-6370				BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; Brodsky FM, 1997, TRENDS CELL BIOL, V7, P175, DOI 10.1016/S0962-8924(97)01038-6; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; DELLANGELICA EC, UNPUB; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; Ooi CE, 1997, EMBO J, V16, P4508; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; Ramjaun A. R., 1997, Molecular Biology of the Cell, V8, p93A; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; Seymour A. B., 1997, Molecular Biology of the Cell, V8, p227A; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x	27	298	303	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1998	280	5362					431	434		10.1126/science.280.5362.431	http://dx.doi.org/10.1126/science.280.5362.431			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545220				2022-12-01	WOS:000073159600046
J	O'Brien, KL; Selanikio, JD; Hecdivert, C; Placide, MF; Louis, M; Barr, DB; Barr, JR; Hospedales, CJ; Lewis, MJ; Schwartz, B; Philen, RM; St Victor, S; Espindola, J; Needham, LL; Denerville, K				O'Brien, KL; Selanikio, JD; Hecdivert, C; Placide, MF; Louis, M; Barr, DB; Barr, JR; Hospedales, CJ; Lewis, MJ; Schwartz, B; Philen, RM; St Victor, S; Espindola, J; Needham, LL; Denerville, K		Acute Renal Failure Invest Team	Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG	Context.-Contaminated pharmaceutical products can result in substantial morbidity and mortality and should be included in the differential diagnosis of deaths of unknown origin. Objective.-To investigate an outbreak of deaths among children from acute renal failure in Haiti to determine the etiology and institute control measures. Design.-Case-control study, cohort study, and laboratory toxicologic evaluation. Setting.-Pediatric population of Haiti. Participants.-Cases were defined as Haitian residents younger than 18 years with idiopathic anuria or severe oliguria for 24 hours or longer, Febrile hospitalized children without renal failure were enrolled as control subjects. Main Outcome Measure.-The odds of exposure to suspected etiologic agents among cases and controls. Results.-We identified 109 cases of acute renal failure among children. The clinical syndrome included renal failure, hepatitis, pancreatitis, central nervous system impairment, coma, and death, Of 87 patients with follow-up information who remained in Haiti for treatment, 85 (98%) died; 3 (27%) of 11 patients transported to the United States for intensive care unit management died before hospital discharge. A locally manufactured acetaminophen syrup was highly associated with disease (odds ratio, 52.7; 95% confidence interval, 15.2-197.2), Diethylene glycol (DEG) was found in patients' bottles in a median concentration of 14.4%, The median estimated toxic dose of DEG was 1.34 mL/kg (range, 0.22-4.42 mL/kg). Glycerin, a raw material imported to Haiti and used in the acetaminophen formulation, was contaminated with 24% DEG. Conclusions.-An epidemic of severe systemic toxicity and deaths from DEG-contaminated acetaminophen syrup occurred in Haiti. Good manufacturing practice regulations should be used by all pharmaceutical manufacturers to prevent such tragedies.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Resp Dis Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Epidem Intelligence Serv, Atlanta, GA 30333 USA; Minist Publ & Populat, Port au Prince, Haiti; Univ Etat Haiti, Inst Haiten Enfance, Port au Prince, Haiti; Pan Amer Hlth Org, Port au Prince, Haiti; Pan Amer Hlth Org, Caribbean Epidemiol Ctr, Port of Spain, Trinidad Tobago	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Pan American Health Organization; Pan American Health Organization	O'Brien, KL (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Resp Dis Branch, 1600 Clifton Rd,Mailstop C-23, Atlanta, GA 30333 USA.		Needham, Larry/E-4930-2011; Barr, Dana B/E-2276-2013; Barr, Dana B/E-6369-2011	O'Brien, Katherine/0000-0002-0164-4030				CALVERY H. 0., 1939, SOUTHERN MED JOUR, V32, P1105; CANTARELL MC, 1987, ANN INTERN MED, V106, P478, DOI 10.7326/0003-4819-106-3-478_2; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P649; CLAESON M, 1990, PEDIATR INFECT DIS J, V9, P345, DOI 10.1097/00006454-199005000-00008; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; Douglas R M, 1991, Semin Respir Infect, V6, P217; DRUT R, 1994, MEDICINA-BUENOS AIRE, V54, P1; Geiling EMK., 1938, J AM MED ASS, V111, P919, DOI [10.1001/jama.1938.72790360005007, DOI 10.1001/JAMA.1938.72790360005007]; GRANT JP, 1988, STATE WORLDS CHILDRE; HANIF M, 1995, BRIT MED J, V311, P88, DOI 10.1136/bmj.311.6997.88; KENYON TA, 1994, B WORLD HEALTH ORGAN, V72, P615; OKUONGHAE HO, 1992, ANN TROP PAEDIATR, V12, P235, DOI 10.1080/02724936.1992.11747577; PANDYA SK, 1988, BRIT MED J, V297, P117, DOI 10.1136/bmj.297.6641.117; *POISINDEX ED STAF, 1998, POISINDEX SYST, V95; WAX PM, 1995, ANN INTERN MED, V122, P456, DOI 10.7326/0003-4819-122-6-199503150-00009	15	123	129	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1998	279	15					1175	1180		10.1001/jama.279.15.1175	http://dx.doi.org/10.1001/jama.279.15.1175			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG133	9555756	Bronze			2022-12-01	WOS:000072969400030
J	Treiber, DK; Rook, MS; Zarrinkar, PP; Williamson, JR				Treiber, DK; Rook, MS; Zarrinkar, PP; Williamson, JR			Kinetic intermediates trapped by native interactions in RNA folding	SCIENCE			English	Article							GROUP-I RIBOZYME; TETRAHYMENA RIBOZYME; TERTIARY STRUCTURE; DOMAIN; BARRIERS; LYSOZYME; PATHWAY	In the magnesium ion-dependent folding of the Tetrahymena ribozyme, a kinetic intermediate accumulates in which the P4-P6 domain is formed, but the P3-P7 domain is not. The kinetic barriers to P3-P7 formation were investigated with the use of in vitro selection to identify mutant RNA molecules in which the folding rate of the P3-P7 domain was increased. The critical mutations disrupt native tertiary interactions within the P4-P6 domain and increase the rate of P3-P7 formation by destabilizing a kinetically trapped intermediate. Hence, kinetic traps stabilized by native interactions, and not simply by mispaired nonnative structures, can present a substantial barrier to RNA folding.	Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA; MIT, Dept Chem, Cambridge, MA 02139 USA	Scripps Research Institute; Massachusetts Institute of Technology (MIT)	Williamson, JR (corresponding author), Scripps Res Inst, Dept Biol Mol, MB33,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Williamson, James/AAL-2104-2021; Williamson, James R/B-2891-2009	Williamson, James/0000-0002-8772-468X; Williamson, James R/0000-0002-8772-468X				BANERJEE AR, 1995, BIOCHEMISTRY-US, V34, P6504, DOI 10.1021/bi00019a031; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Cate JH, 1997, NAT STRUCT BIOL, V4, P553, DOI 10.1038/nsb0797-553; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4358, DOI 10.1021/bi00773a024; DILL KA, 1994, NAT STRUCT BIOL, V4, P10; Downs WD, 1996, RNA, V2, P718; Draper DE, 1996, TRENDS BIOCHEM SCI, V21, P145; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; LAGGERBAUER B, 1994, EMBO J, V13, P2669, DOI 10.1002/j.1460-2075.1994.tb06557.x; Lehnert V, 1996, CHEM BIOL, V3, P993, DOI 10.1016/S1074-5521(96)90166-0; MIRANKER A, 1993, SCIENCE, V262, P896, DOI 10.1126/science.8235611; Munson M, 1997, FOLD DES, V2, P77, DOI 10.1016/S1359-0278(97)00008-4; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; Pan J, 1997, J MOL BIOL, V273, P7, DOI 10.1006/jmbi.1997.1311; Pan T, 1997, NAT STRUCT BIOL, V4, P931, DOI 10.1038/nsb1197-931; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; ROOK MS, UNPUB; Rothwarf DM, 1996, BIOCHEMISTRY-US, V35, P13797, DOI 10.1021/bi9608119; SCIAVI B, 1998, SCIENCE, V279, P1940; SCIAVI B, 1997, J MOL BIOL, V266, P144; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; Thirumalai D, 1996, ACCOUNTS CHEM RES, V29, P433, DOI 10.1021/ar9500933; TREIBER DK, UNPUB; Waldburger CD, 1996, P NATL ACAD SCI USA, V93, P2629, DOI 10.1073/pnas.93.7.2629; Weeks KM, 1996, SCIENCE, V271, P345, DOI 10.1126/science.271.5247.345; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Wildegger G, 1997, J MOL BIOL, V270, P294, DOI 10.1006/jmbi.1997.1030; WOODSON SA, 1991, BIOCHEMISTRY-US, V30, P2042, DOI 10.1021/bi00222a006; Zarrinkar PP, 1996, RNA, V2, P564; Zarrinkar PP, 1996, NAT STRUCT BIOL, V3, P432, DOI 10.1038/nsb0596-432; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848	34	191	195	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1998	279	5358					1943	1946		10.1126/science.279.5358.1943	http://dx.doi.org/10.1126/science.279.5358.1943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506945				2022-12-01	WOS:000072613300048
J	Blendon, RJ; Young, JT				Blendon, RJ; Young, JT			The public and the war on illicit drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								This article presents what Americans think about the policies subsumed under the label of the "War on Drugs." It is based on an analysis of 47 national surveys conducted between 1978 and 1997. The major results are that most Americans rely on the mass media for information about the scope of the drug abuse problem; Americans do not think that the Wars on Drugs have succeeded, but they do not want to quit on these efforts; weak support exists for increasing funding for drug treatment; support for preventive education has increased during the 1990s; criminal justice responses remain very popular; for many, illicit drug use is a moral rather than a public health issue; the public supports allowing physicians to prescribe marijuana for severe illness, but opposes the general legalization of marijuana and other illicit drugs; and needle exchange programs are supported by a bare majority, but only when they are told that the American Medical Association supports these programs.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA; Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Blendon, RJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02215 USA.							[Anonymous], 1996, NY TIMES; [Anonymous], 1996, WASHINGTON POST; [Anonymous], 1995, US TODAY; [Anonymous], 1988, WASHINGTON POST; [Anonymous], 1996, CBS NEWS POLL; [Anonymous], 1990, WASHINGTON POST; BUCKLEY W, 1996, NATL REV        0212; Canadian Institute of Public Opinion (CIPO), 1990, GALLUP POLL; Danielian LH, 1989, COMMUNICATION CAMPAI, P29; Davis James A., GEN SOCIAL SURVEYS 1; *FED AM SCI, 1997, PRINC PRACT DRUG POL; FRIEDMAN M, 1998, NY TIMES        0111, V149, P19; HART PD, 1994, DRUG STRATEGIES; *LINDSM FDN, 1997, LAK RES POLL; Lundberg GD, 1997, JAMA-J AM MED ASSOC, V278, P946, DOI 10.1001/jama.278.11.946; MacCoun R, 1996, J POLICY ANAL MANAG, V15, P330, DOI 10.1002/(SICI)1520-6688(199622)15:3<330::AID-PAM1>3.0.CO;2-J; MAGINNIS RL, 1997, AM ASSESS MED MARIJU; MERRIAM JE, 1989, COMMUNICATION CAMPAI, P21; Newsweek, 1995, NEWSWEEK; *OFF APP STUD, 1997, 17 DAWN OFF APPL STU; *PRINC SURV RES AS, 1995, HJ KAIS FAM FDN POLL; Reese S.D., 1989, COMMUNICATION CAMPAI, P29, DOI DOI 10.1080/08838158909364073; *ROP CTR PUBL OP R, 1990, PARTN DRUG FREE AM G; *ROP CTR PUBL OP R, 1996, ABC NEWS POLL; SOROS G, 1997, WASHINGTON POST 0202; *SUBST AB MENT HLT, 1997, NAT ADM SUBST AB TRE; *SUBST AB MENT HLT, 1997, PREL FIL 1996 NAT HO; *SUBST AB MENT HLT, 1996, 18 SUBST AB MENT HLT; U. S. Bureau of the Census, 1996, STAT ABSTR US; *U VIRG, 1997, POST MOD PROJ; YANKELOVICH, 1997, TIME             JUN; YANKELOVICH, 1993, TIME; 1996, CBS NEWS POLL    OCT; 1997, CBS NEWS POLL; 1996, NEWSWEEK POLL; 1996, WASHINGTON POST 0703; 1997, ABC WASHINGTON POST; 1986, CBS NEWS NY TIMES; 1995, CNN US TODAY     AUG	39	71	71	0	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					827	832		10.1001/jama.279.11.827	http://dx.doi.org/10.1001/jama.279.11.827			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA943	9515986				2022-12-01	WOS:000072417600012
J	Epstein, RM; Morse, DS; Frankel, RM; Frarey, L; Anderson, K; Beckman, HB				Epstein, RM; Morse, DS; Frankel, RM; Frarey, L; Anderson, K; Beckman, HB			Awkward moments in patient-physician communication about HIV risk	ANNALS OF INTERNAL MEDICINE			English	Article						communication; physician-patient relations; human immunodeficiency virus infections; physician's role; risk	PRIMARY-CARE PHYSICIANS; AIDS; PREVENTION; SKILLS; ATTITUDES; KNOWLEDGE; INFECTION	Background: Physicians frequently encounter patients who are at risk for HIV infection, but they often evaluate risk behaviors ineffectively. Objective: To describe the barriers to and facilitators of comprehensive HIV risk evaluation in primary care office visits. Design: Qualitative thematic and sequential analysis of videotaped patient-physician discussions about HIV risk. Tapes were reviewed independently by physician and patient and were coded by the research team. Setting: Physicians' offices. Participants: Convenience sample of 17 family physicians and general internists. Twenty-six consenting patients 18 to 45 years of age who indicated concern about or risks for HIV infection on a 10-item questionnaire administered before the physician visit were included. Measurements: A thematic coding scheme and a five-level description of the depth of HIV-related discussion. Results: In 73% of the encounters, physicians did not elicit enough information to characterize patients' HIV risk status. The outcome of HIV-related discussions was substantially influenced by the manner in which the physician introduced the topic, handled awkward moments, and dealt with problematic language and the extent to which the physician sought the patient's perspective. Feelings of ineffectiveness and strong emotions interfered with some physicians' ability to assess HIV risk. Physicians easily recognized problematic communication during reviews of their own videotapes. Conclusions: Comprehensive HIV risk discussions included providing a rationale for discussion, effectively negotiating awkward moments, repairing problematic language, persevering with the topic, eliciting the patient's perspective, responding to fears and expectations, and being empathic. Educational programs should use videotape review and should concentrate on physicians' personal reactions to discussing emotionally charged topics.	Univ Rochester, Highland Hosp, Sch Med & Dent, Primary Care Inst,Dept Family Med, Rochester, NY 14620 USA; Rochester Gen Hosp, Gen Med Unit, Rochester, NY 14621 USA; Univ Rochester, Highland Hosp, Sch Med & Dent, Primary Care Inst,Dept Internal Med, Rochester, NY 14620 USA	University of Rochester; Rochester General Hospital; University of Rochester	Epstein, RM (corresponding author), Univ Rochester, Highland Hosp, Sch Med & Dent, Primary Care Inst,Dept Family Med, 885 South Ave, Rochester, NY 14620 USA.			Morse, Diane/0000-0001-9603-0324				Altheide D., 1987, QUALITATIVE SOCIOLOG, V10, P65, DOI [10.1007/BF00988269, DOI 10.1007/BF00988269]; BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; BOWMAN MA, 1992, ARCH INTERN MED, V152, P1823, DOI 10.1001/archinte.152.9.1823; BROWN JB, 1989, CAN FAM PHYSICIAN, V35, P153; CAMASSO MJ, 1994, SOC SCI MED, V38, P733, DOI 10.1016/0277-9536(94)90464-2; Deci EL., 1985, INTRINSIC MOTIVATION, DOI [10.1007/978-1-4899-2271-7, DOI 10.1007/978-1-4899-2271-7]; DRUMMOND K, 1991, MISCOMMUNICATION PRO, P301; ENDE J, 1984, ARCH INTERN MED, V144, P558, DOI 10.1001/archinte.144.3.558; EPSTEIN R, 1991, J FAM PRACTICE, V32, P373; Epstein R M, 1993, Fam Med, V25, P264; Epstein R M, 1993, Arch Fam Med, V2, P159, DOI 10.1001/archfami.2.2.159; EPSTEIN RM, 1997, PSYCHOSOM MED, P623; Frankel R.M., 1982, STRAIGHT TALK EXPLOR, P71; FREDMAN L, 1989, AM J PREV MED, V5, P188, DOI 10.1016/S0749-3797(18)31079-1; GEMSON DH, 1991, ARCH INTERN MED, V151, P1102, DOI 10.1001/archinte.151.6.1102; GERBERT B, 1988, JAMA-J AM MED ASSOC, V260, P3481, DOI 10.1001/jama.260.23.3481; GERBERT B, 1992, J GEN INTERN MED, V7, P657, DOI 10.1007/BF02599211; Gerbert B, 1993, Arch Fam Med, V2, P45, DOI 10.1001/archfami.2.1.45; GERBERT B, 1990, AM J PUBLIC HEALTH, V80, P467, DOI 10.2105/AJPH.80.4.467; GREEN L W, 1988, American Journal of Preventive Medicine, V4, P101; Heath C., 1986, BODY MOVEMENT SPEECH, DOI DOI 10.1017/CBO9780511628221; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; KELLY JA, 1987, AM J PUBLIC HEALTH, V77, P789, DOI 10.2105/AJPH.77.7.789; KORSCH BM, 1968, PEDIATRICS, V42, P855; KUZEL AJ, 1992, RES METH PR, V3, P31; LEVINSON W, 1993, J GEN INTERN MED, V8, P318, DOI 10.1007/BF02600146; LEWIS CE, 1987, AM J PUBLIC HEALTH, V77, P795, DOI 10.2105/AJPH.77.7.795; LEWIS CE, 1986, J GEN INTERN MED, V1, P287, DOI 10.1007/BF02596205; LEWIS CE, 1994, W J MED, V169, P651; MAGUIRE P, 1986, BRIT MED J, V292, P1573, DOI 10.1136/bmj.292.6535.1573; MATHEWS WC, 1989, J GEN INTERN MED, V4, P34, DOI 10.1007/BF02596487; MCPHEE SJ, 1984, ARCH INTERN MED, V144, P1265, DOI 10.1001/archinte.144.6.1265; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Patton M., 1980, QUALITATIVE EVALUATI; PLATT FW, 1995, CONVERSATION REPAIR; PRITCHARD JG, 1988, J FAM PRACTICE, V27, P639; PRITCHARD JG, 1988, J FAM PRACTICE, V27, P637; PROCHASKA JO, 1982, PSYCHOTHER-THEOR RES, V19, P276, DOI 10.1037/h0088437; RABIN DL, 1994, ANN INTERN MED, V121, P513, DOI 10.7326/0003-4819-121-7-199410010-00007; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; Samet JH, 1997, PEDIATRICS, V100, P371, DOI 10.1542/peds.100.3.371; SCHLEGOFF EA, 1977, LANGUAGE, V53, P361; SIMPSON M, 1991, BRIT MED J, V303, P1385, DOI 10.1136/bmj.303.6814.1385; STANGE KC, 1994, J GEN INTERN MED, V9, P278, DOI 10.1007/BF02599656; STARFIELD B, 1981, AM J PUBLIC HEALTH, V71, P127, DOI 10.2105/AJPH.71.2.127; STEWART M, 1989, CAN FAM PHYSICIAN, V35, P159; STREET RL, 1992, MED CARE, V30, P976, DOI 10.1097/00005650-199211000-00002; WAITZKIN H, 1990, MED CARE, V28, P473, DOI 10.1097/00005650-199006000-00001; Wenrich MD, 1997, J GEN INTERN MED, V12, P107, DOI 10.1046/j.1525-1497.1997.00015.x; WEST C, 1991, MISCOMMUNICATION PRO, P166; [No title captured]	51	106	107	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					435	+		10.7326/0003-4819-128-6-199803150-00003	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499326				2022-12-01	WOS:000072414700003
J	Albee, AL; Palluconi, FD; Arvidson, RE				Albee, AL; Palluconi, FD; Arvidson, RE			Mars global surveyor mission: Overview and status	SCIENCE			English	Article								The Mars Global Surveyor (MGS) spacecraft achieved a 45-hour elliptical orbit at Mars on 11 September 1997 after an 11-month cruise from Earth, The mission is acquiring high-quality global observations of the martian surface and atmosphere and of its magnetic and gravitational fields. These observations will continue for one martian year.	CALTECH, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Washington Univ, St Louis, MO 63130 USA	California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Washington University (WUSTL)	Albee, AL (corresponding author), CALTECH, Pasadena, CA 91125 USA.							Smith DE, 1998, SCIENCE, V279, P1686, DOI 10.1126/science.279.5357.1686; 1992, J GEOPHYS RES, V97, P7663	2	114	117	3	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1671	1672		10.1126/science.279.5357.1671	http://dx.doi.org/10.1126/science.279.5357.1671			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497277				2022-12-01	WOS:000072490000042
J	Bottomley, PA; Weiss, RG				Bottomley, PA; Weiss, RG			Non-invasive magnetic-resonance detection of creatine depletion in non-viable infarcted myocardium	LANCET			English	Article							CORONARY-ARTERY DISEASE; HUMAN SKELETAL-MUSCLE; SPECTROSCOPY; TOMOGRAPHY; METABOLISM; EXERCISE; INVIVO	Background Presented energy metabolism is essential for myocardial viability and the creatine kinase reaction is central to energy production and reserve. Although the appearance of myocardial creatine kinase enzyme in the blood is widely used to diagnose cardiac necrosis, there are no non-invasive ways to measure local creatine concentrations in the healthy and diseased human heart. Methods We measured total myocardial creatine by spatially-localised, water-suppressed hydrogen magnetic-resonance spectroscopy (H-1-MRS) on a clinical (1.5 T) magnetic-resonance-imaging systemin ten healthy volunteers (controls) and ten patients with a history of myocardial infarction. We validated this technique by comparison of H-1-MRS Values of creatine with biopsy assays in an animal model of infarction. Findings Total creatine was measured in the posterior and anterior left ventricle and septum, and was significantly lower in regions of infarction (10 [9] SD mu mol/g wet weight) than in non-infarcted regions (26 [11] mu mol/g, p=0.001) of myocardium in patients or in the myocardium of healthy controls (28 [6] mu mol/g, p<0.0001). Interpretation Spatially localised H-1-MRS can be used to measure total creatine non-invasively throughout the human heart. The detection of regional creatine depletion may provide a metabolic means to distinguish healthy from infarcted non-viable myocardium.	Johns Hopkins Univ, Sch Med, Dept Radiol, Div Magnet Resonance Res, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Weiss, RG (corresponding author), Johns Hopkins Hosp, Carnegie 584,600 N Wolfe St, Baltimore, MD 21205 USA.	rgweiss@rad.jhu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052315, R01HL056882] Funding Source: NIH RePORTER; NHLBI NIH HHS [1RO1-HL56882, SCOR-HL-52315-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAER FM, 1995, CIRCULATION, V91, P1006, DOI 10.1161/01.CIR.91.4.1006; BONGERS H, 1992, MAGN RESON IMAGING, V10, P957, DOI 10.1016/0730-725X(92)90450-E; Bottomley PA, 1997, RADIOLOGY, V204, P403, DOI 10.1148/radiology.204.2.9240527; BOTTOMLEY PA, 1994, RADIOLOGY, V191, P593, DOI 10.1148/radiology.191.3.8184033; Bottomley PA, 1996, MAGNET RESON MED, V35, P664, DOI 10.1002/mrm.1910350507; BOTTOMLEY PA, 1995, P SMR, V1, P90; BRUHN H, 1991, MAGN RESON MED, V17, P82, DOI 10.1002/mrm.1910170113; DELANGHE J, 1988, ANN CLIN BIOCHEM, V25, P383, DOI 10.1177/000456328802500410; DENHOLLANDER JA, 1994, MAGN RESON MED, V32, P175, DOI 10.1002/mrm.1910320205; DILSIZIAN V, 1990, NEW ENGL J MED, V323, P141, DOI 10.1056/NEJM199007193230301; INGWALL JS, 1993, CIRCULATION, V87, P58; INGWALL JS, 1985, NEW ENGL J MED, V313, P1050, DOI 10.1056/NEJM198510243131704; JENNINGS RB, 1981, AM J PATHOL, V102, P241; LEE TH, 1986, ANN INTERN MED, V105, P221, DOI 10.7326/0003-4819-105-2-221; MANNING WJ, 1991, J AM COLL CARDIOL, V18, P959, DOI 10.1016/0735-1097(91)90754-W; SNYDER WS, 1984, REPORT TASK GROUP RE, P34; SWAIN JL, 1982, P NATL ACAD SCI-BIOL, V79, P655, DOI 10.1073/pnas.79.2.655; TILLISCH J, 1986, NEW ENGL J MED, V314, P884, DOI 10.1056/NEJM198604033141405; WEISS RG, 1990, NEW ENGL J MED, V323, P1593, DOI 10.1056/NEJM199012063232304; YABE T, 1994, CIRCULATION, V89, P1709, DOI 10.1161/01.CIR.89.4.1709; YABE T, 1995, CIRCULATION, V92, P15, DOI 10.1161/01.CIR.92.1.15	21	113	115	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					714	718		10.1016/S0140-6736(97)06402-7	http://dx.doi.org/10.1016/S0140-6736(97)06402-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504516	hybrid			2022-12-01	WOS:000072463800009
J	Lindberg, G; Bingefors, K; Ranstam, J; Rastam, L; Melander, A				Lindberg, G; Bingefors, K; Ranstam, J; Rastam, L; Melander, A			Use of calcium channel blockers and risk of suicide: ecological findings confirmed in population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEPRESSION; BLOCKADE	Objective: To investigate possible associations between use of cardiovascular drugs and suicide. Design: Cross sectional ecological study based on rates of use of eight cardiovascular drug groups by outpatients. A population based cohort study including users of drugs to control hypertension. Subjects: The ecological study included 152 of Sweden's 284 municipalities, The cohort study included all inhabitants of one Swedish municipality who during 1988 or 1989 had purchased cardiovascular agents from pharmacies within the municipality. Six hundred and seventeen subjects (18.2%) were classified as users of calcium channel blockers and 2780 (81.8%) as non-users. Main outcome measures: Partial correlations (least squares method) between rates of use of cardiovascular drugs and age standardised mortality from suicide in Swedish municipalities. Hazard ratios for risk of suicide with adjustments for difference in age and sex in users of calcium channel blockers compared with users of other hypertensive drugs. Results: Among the Swedish municipalities the use of each cardiovascular drug group except angiotensin converting enzyme inhibitors correlated significantly and positively with suicide rates, After adjustment for the use of other cardiovascular drug groups, as a substitute for the prevalence of cardiovascular morbidity, only the correlation with calcium channel blockers remained significant (r = 0.29, P < 0.001). In the cohort study, five users and four non-users of calcium channel blockers committed suicide during the follow up until the end of 1994. The absolute risk associated with use of calcium channel blockers was 1.1 suicides per 1000 person years. The relative risk, adjusted for differences in age and sex, among users versus non-users was 5.4 (95% confidence interval 1.4 to 20.5). Conclusions: Use of calcium channel blockers may increase the risk of suicide.	Malmo Univ Hosp Fdn, Swedish Network Pharmacoepidemiol, SE-20502 Malmo, Sweden; Uppsala Univ, Dept Pharmaceut Serv Res, SE-75123 Uppsala, Sweden; Lund Univ, Malmo Univ Hosp, Dept Community Med, SE-20502 Malmo, Sweden	Uppsala University; Lund University; Skane University Hospital	Lindberg, G (corresponding author), Malmo Univ Hosp Fdn, Swedish Network Pharmacoepidemiol, SE-20502 Malmo, Sweden.	gunnar.lindberg@nepi.a.se	Ranstam, Jonas/A-4386-2009	Ranstam, Jonas/0000-0002-8287-7273				AVORN J, 1986, JAMA-J AM MED ASSOC, V255, P357, DOI 10.1001/jama.255.3.357; BIRIELI C, 1989, BRIT MED J, V299, P796, DOI 10.1136/bmj.299.6702.796; BOLANDER AM, 1981, MED ASPECTS MORTALIT, P236; Capella D, 1993, WHO Reg Publ Eur Ser, V45, P55; DASSYLVA B, 1993, CAN J PSYCHIAT, V38, P299, DOI 10.1177/070674379303800420; Hallas J, 1996, EPIDEMIOLOGY, V7, P478, DOI 10.1097/00001648-199609000-00005; HULLETT FJ, 1988, AM J PSYCHIAT, V145, P1277; KAHN JK, 1986, AM J MED, V81, P705, DOI 10.1016/0002-9343(86)90561-9; MCALLISTERWILLIAMS RH, 1990, BRIT J PSYCHIAT, V157, P618, DOI 10.1192/bjp.157.4.618; NIELSEN AC, 1980, ARCH GEN PSYCHIAT, V37, P999	10	48	49	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	1998	316	7133					741	745		10.1136/bmj.316.7133.741	http://dx.doi.org/10.1136/bmj.316.7133.741			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZB358	9529409	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000072463700031
J	Bannon, MJ; Ross, EM				Bannon, MJ; Ross, EM			Administration of medicines in school: who is responsible?	BRITISH MEDICAL JOURNAL			English	Article							TEACHERS; ASTHMA; CHILDREN; EPILEPSY; ILLNESS; SERVICE; AGE		Northwick Pk Hosp, Northwick Pk & St Marks NHS Trust, Harrow HA1 3UJ, Middx, England; Univ London Kings Coll, Mary Sheridan Ctr, London SE11 4QW, England	Imperial College London; University of London; King's College London	Bannon, MJ (corresponding author), Northwick Pk Hosp, Northwick Pk & St Marks NHS Trust, Harrow HA1 3UJ, Middx, England.							ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; BAGNALL P, 1996, DIFFERENT LIGHT SCH; BANNON M. J., 1995, PROG COM CH HLTH, V1, P125; BANNON MJ, 1992, ARCH DIS CHILD, V67, P1467, DOI 10.1136/adc.67.12.1467; BEVIS M, 1990, ARCH DIS CHILD, V65, P622, DOI 10.1136/adc.65.6.622; Billingham K, 1998, BRIT MED J, V316, P406, DOI 10.1136/bmj.316.7129.406; *BMA COMM HLTH DOC, 1994, MED SCH; BRADBURY AJ, 1983, ARCH DIS CHILD, V58, P692, DOI 10.1136/adc.58.9.692; CASEY FA, 1994, ARCH DIS CHILD, V70, P382, DOI 10.1136/adc.70.5.382; CELANO MP, 1993, J LEARN DISABIL-US, V26, P23, DOI 10.1177/002221949302600103; CHETCUTI P, 1993, ARCH DIS CHILD, V68, P167, DOI 10.1136/adc.68.2.167; *DEP ED EMPL DEP H, 1996, SUPP PUP MED NEEDS S; Dyer J, 1996, Prof Nurse, V11, P518; Eboh W O, 1996, Br J Nurs, V5, P30; EISER C, 1995, ARCH DIS CHILD, V72, P302, DOI 10.1136/adc.72.4.302; FILIMORE EJ, 1997, ARCH DIS CHILD, V77, P420; FOX TK, 1991, PUBLIC HEALTH, V105, P399, DOI 10.1016/S0033-3506(05)80600-6; Leffert Nancy, 1993, Current Opinion in Pediatrics, V5, P429; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; *NHS MAN EX, 1992, PAT CHART PRIM HLTH; *NHS MAN EX, 1995, CHILDR CHART; PAPOLA P, 1994, PEDIATRICS, V94, P914; Polnay L, 1995, HLTH NEEDS SCH AGE C; STURNIOLO MG, 1994, ARCH DIS CHILD, V70, P424, DOI 10.1136/adc.70.5.424; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; VERITY CM, 1985, PAEDIAT PERSPECTIVES; WHITMORE K, 1984, PROGR CHILD HLTH, V1; 1991, CONTACT FAMILY DIREC	28	11	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1998	316	7144					1591	1593		10.1136/bmj.316.7144.1591	http://dx.doi.org/10.1136/bmj.316.7144.1591			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ495	9596602	Green Published			2022-12-01	WOS:000073867800031
J	Farley, KA; Montanari, A; Shoemaker, EM; Shoemaker, CS				Farley, KA; Montanari, A; Shoemaker, EM; Shoemaker, CS			Geochemical evidence for a comet shower in the Late Eocene	SCIENCE			English	Article							INTERPLANETARY DUST; OORT CLOUD; MASS EXTINCTIONS; ORIGIN; MASSIGNANO; SEDIMENTS; IMPACTS; FLUX	Analyses of pelagic limestones indicate that the flux of extraterrestrial helium-3 to Earth was increased for a 2.5-million year (My) period in the late Eocene. The enhancement began similar to 1 My before and ended similar to 1.5 My after the major impact events that produced the large Popigai and Chesapeake Bay craters similar to 36 million years ago. The correlation between increased concentrations of helium-3, a tracer of fine-grained interplanetary dust, and large impacts indicates that the abundance of Earth-crossing objects and dustiness in the inner solar system were simultaneously but only briefly enhanced. These observations provide evidence for a comet shower triggered by an impulsive perturbation of the Oort cloud.	CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Ecole Mines, Paris, France; Osservatorio Geol Coldigioco, I-62020 Frontale Apiro, Apiro, Italy; US Geol Survey, Flagstaff, AZ 86001 USA	California Institute of Technology; UDICE-French Research Universities; PSL Research University Paris; MINES ParisTech; United States Department of the Interior; United States Geological Survey	Farley, KA (corresponding author), CALTECH, Div Geol & Planetary Sci, MS 170-25, Pasadena, CA 91125 USA.	farley@gps.caltech.edu	Farley, Kenneth/AAE-7735-2020	Farley, Kenneth/0000-0002-7846-7546				AMARI S, 1985, NATURE, V317, P520, DOI 10.1038/317520a0; Bottomley R, 1997, NATURE, V388, P365, DOI 10.1038/41073; Clymer AK, 1996, GEOLOGY, V24, P483, DOI 10.1130/0091-7613(1996)024<0483:SQFTLE>2.3.CO;2; DERMOTT SF, 1984, NATURE, V312, P505, DOI 10.1038/312505a0; Dermott SF, 1996, ASTR SOC P, V104, P143; FARLEY KA, 1995, NATURE, V376, P153, DOI 10.1038/376153a0; Farley KA, 1997, GEOCHIM COSMOCHIM AC, V61, P2309, DOI 10.1016/S0016-7037(97)00068-9; Gladman BJ, 1997, SCIENCE, V277, P197, DOI 10.1126/science.277.5323.197; Grieve RAF, 1996, EARTH MOON PLANETS, V72, P357, DOI 10.1007/BF00117541; HAZEL J, 1988, PALAIOS, V4, P318; HILLS JG, 1981, ASTRON J, V86, P1730, DOI 10.1086/113058; HUT P, 1987, NATURE, V329, P118, DOI 10.1038/329118a0; KELLER G, 1983, SCIENCE, V221, P150, DOI 10.1126/science.221.4606.150; Koeberl C, 1996, SCIENCE, V271, P1263, DOI 10.1126/science.271.5253.1263; Lanci L, 1996, EARTH PLANET SC LETT, V143, P37, DOI 10.1016/0012-821X(96)00136-7; LIOU JC, 1995, PLANET SPACE SCI, V43, P717, DOI 10.1016/0032-0633(95)00065-D; Liou JC, 1996, ICARUS, V123, P491, DOI 10.1006/icar.1996.0174; LOVE SG, 1993, SCIENCE, V262, P550, DOI 10.1126/science.262.5133.550; MARZARI F, 1995, ICARUS, V113, P168, DOI 10.1006/icar.1995.1014; MATESE JJ, 1995, ICARUS, V116, P255, DOI 10.1006/icar.1995.1124; MERRIHUE C, 1964, ANN NY ACAD SCI, V119, P351; MOLINA E, 1993, GEOL MAG, V130, P483, DOI 10.1017/S0016756800020550; MONTANARI A, 1993, PALAIOS, V8, P420, DOI 10.2307/3515017; OZIMA M, 1984, NATURE, V311, P448, DOI 10.1038/311448a0; PATTERSON DB, UNPUB; Pierrard O, 1998, GEOLOGY, V26, P307, DOI 10.1130/0091-7613(1998)026<0307:ENRSIU>2.3.CO;2; PREMOLISILVA I, 1988, EOCENE OLIGOCENE BOU; RAMPINO MR, 1984, NATURE, V308, P709, DOI 10.1038/308709a0; SHOEMAKER EM, 1990, GEOL S AM S, V247, P155; VISHNEVSKY SA, UNPUB; WEISSMAN P, COMMUNICATION; WEISSMAN PR, 1990, NATURE, V344, P825, DOI 10.1038/344825a0	32	135	141	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 22	1998	280	5367					1250	1253		10.1126/science.280.5367.1250	http://dx.doi.org/10.1126/science.280.5367.1250			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596575				2022-12-01	WOS:000073852500044
J	Ford, CE; Skiba, NP; Bae, HS; Daaka, YH; Reuveny, E; Shekter, LR; Rosal, R; Weng, GZ; Yang, CS; Iyengar, R; Miller, RJ; Jan, LY; Lefkowitz, RJ; Hamm, HE				Ford, CE; Skiba, NP; Bae, HS; Daaka, YH; Reuveny, E; Shekter, LR; Rosal, R; Weng, GZ; Yang, CS; Iyengar, R; Miller, RJ; Jan, LY; Lefkowitz, RJ; Hamm, HE			Molecular basis for interactions of G protein beta gamma subunits with effectors	SCIENCE			English	Article							HETEROTRIMERIC G-PROTEIN; PHOSPHOLIPASE-C; POTASSIUM CHANNEL; CRYSTAL-STRUCTURE; ACTIVATION; ADENYLYL-CYCLASE-2; MODULATION; BINDING	Both the alpha and beta gamma subunits of heterotrimeric guanine nucleotide-binding proteins (G proteins) communicate signals from receptors to effecters. G beta gamma subunits, can regulate a diverse array of effecters, including ion channels and enzymes. G alpha subunits bound to guanine diphosphate (G alpha-GDP) inhibit signal transduction through G beta gamma subunits, suggesting a common interface on G beta gamma subunits for G alpha binding and effector interaction. The molecular basis for interaction of G beta gamma with effecters was characterized by mutational analysis of G beta residues that make contact with G alpha-GDP. Analysis of the ability of these mutants to regulate the activity of calcium and potassium channels, adenylyl cyclase 2, phospholipase C-beta 2, and beta-adrenergic receptor kinase revealed the G beta residues required for activation of each effector and provides evidence for partially overlapping domains on G beta for regulation of these effecters. This organization of interaction regions on G beta for different effecters and G alpha explains why subunit dissociation is crucial for signal transmission through G beta gamma subunits.	Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA; Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Weizmann Inst Sci, Dept Membrane Res & Biophys, IL-76100 Rehovot, Israel; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA; Mt Sinai Sch Med, Dept Pharmacol, New York, NY 10029 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol & Biochem, San Francisco, CA 94143 USA	Northwestern University; Northwestern University; Duke University; Duke University; Howard Hughes Medical Institute; Weizmann Institute of Science; University of Chicago; Icahn School of Medicine at Mount Sinai; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hamm, HE (corresponding author), Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA.		Lefkowitz, Robert/AAW-2649-2021; Hamm, Heidi E/G-2374-2014; Bae, Hyunsu/ABH-6248-2020	Bae, Hyunsu/0000-0002-0299-3582; YANG, CHII-SHEN/0000-0002-2792-6247; Jan, Lily/0000-0003-3938-8498	NIDA NIH HHS [DA02575, DA02121] Funding Source: Medline; NIMH NIH HHS [MH40165] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH040165, R01MH040165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002121, R01DA002575] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Bluml K, 1997, EMBO J, V16, P4908, DOI 10.1093/emboj/16.16.4908; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHEN J, 1995, SCIENCE, V268, P1168; Chen YB, 1997, P NATL ACAD SCI USA, V94, P2711, DOI 10.1073/pnas.94.6.2711; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; DEVIVO M, 1994, METHOD ENZYMOL, V238, P131; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; GRISHIN AV, 1994, MOL CELL BIOL, V14, P4571, DOI 10.1128/MCB.14.7.4571; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; KATADA T, 1994, METHOD ENZYMOL, V237, P131; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Pellegrino S, 1997, J BIOL CHEM, V272, P25360, DOI 10.1074/jbc.272.40.25360; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; Schneider T, 1997, TRENDS PHARMACOL SCI, V18, P8, DOI 10.1016/S0165-6147(96)01001-2; Shekter LR, 1997, MOL PHARMACOL, V52, P282, DOI 10.1124/mol.52.2.282; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Stoffel RH, 1997, J MEMBRANE BIOL, V157, P1, DOI 10.1007/s002329900210; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Weng GZ, 1996, J BIOL CHEM, V271, P26445, DOI 10.1074/jbc.271.43.26445; Yamauchi J, 1997, J BIOL CHEM, V272, P7602, DOI 10.1074/jbc.272.12.7602; Yan K, 1997, J BIOL CHEM, V272, P2056; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597; Zhang SY, 1996, J BIOL CHEM, V271, P20208, DOI 10.1074/jbc.271.33.20208	40	353	363	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1271	1274		10.1126/science.280.5367.1271	http://dx.doi.org/10.1126/science.280.5367.1271			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596582				2022-12-01	WOS:000073852500051
J	Posfai, M; Buseck, PR; Bazylinski, DA; Frankel, RB				Posfai, M; Buseck, PR; Bazylinski, DA; Frankel, RB			Reaction sequence of iron sulfide minerals in bacteria and their use as biomarkers	SCIENCE			English	Article							MAGNETOTACTIC MICROORGANISM; GREIGITE FE3S4; BIOMINERALIZATION; PYRITE; LIFE; FES	Some bacteria form intracellular nanometer-scale crystals of greigite (Fe3S4) that cause the bacteria to be oriented in magnetic fields. Transmission electron microscope observations showed that ferrimagnetic greigite in these bacteria forms from nonmagnetic mackinawite (tetragonal FeS) and possibly from cubic FeS. These precursors apparently transform into greigite by rearrangement of iron atoms over a period of days to weeks. Neither pyrrhotite nor pyrite was found. These results have implications for the interpretation of the presence of pyrrhotite and greigite in the martian meteorite ALH84001.	Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; Arizona State Univ, Dept Chem Biochem, Tempe, AZ 85287 USA; Iowa State Univ, Dept Microbiol Immunol & Prevent Med, Ames, IA 50011 USA; Calif Polytech State Univ San Luis Obispo, Dept Phys, San Luis Obispo, CA 93407 USA; Univ Veszprem, Dept Earth & Environm Sci, H-8200 Veszprem, Hungary	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Iowa State University; California State University System; California Polytechnic State University San Luis Obispo; University of Pannonia	Posfai, M (corresponding author), Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA.		Pósfai, Mihály/C-1792-2012	Pósfai, Mihály/0000-0001-9355-3533				Bazylinski D. A., 1990, IRON BIOMINERALS, P239; Bazylinski DA, 1997, REV MINERAL, V35, P181; BAZYLINSKI DA, 1995, APPL ENVIRON MICROB, V61, P3232, DOI 10.1128/AEM.61.9.3232-3239.1995; BERNER RA, 1967, AM J SCI, V265, P773, DOI 10.2475/ajs.265.9.773; Bertaut EF, 1965, SOLID STATE COMMUN, V3, P335, DOI 10.1016/0038-1098(65)90090-6; DELONG EF, 1993, SCIENCE, V259, P803, DOI 10.1126/science.259.5096.803; FARINA M, 1983, BIOL CELL, V48, P85; FARINA M, 1990, NATURE, V343, P256, DOI 10.1038/343256a0; Frankel RB, 1997, BIOPHYS J, V73, P994, DOI 10.1016/S0006-3495(97)78132-3; HEYWOOD BR, 1991, MATER RES SOC SYMP P, V218, P93; KRUPP RE, 1994, EUR J MINERAL, V6, P265; Lennie AR, 1997, AM MINERAL, V82, P302; MANN S, 1990, NATURE, V343, P258, DOI 10.1038/343258a0; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MEDICIS RD, 1970, SCIENCE, V170, P1191, DOI 10.1126/science.170.3963.1191; MORSE JW, 1987, EARTH-SCI REV, V24, P1, DOI 10.1016/0012-8252(87)90046-8; MUROWCHICK JB, 1986, AM MINERAL, V71, P1243; MUROWOHICK JB, 1989, GEOL SOC AM PROGR AB, V21, pA120; Rickard D., 1969, STOCK CONTRIB GEOL, V20, P67; RICKARD DT, 1969, STOCKHOLM CONTRIB GE, V20, P55; SCHOONEN MAA, 1991, GEOCHIM COSMOCHIM AC, V55, P1505, DOI 10.1016/0016-7037(91)90123-M; SKINNER BJ, 1964, AM MINERAL, V49, P543; WACHTERSHAUSER G, 1988, SYST APPL MICROBIOL, V10, P207; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; WILLIAMS RJP, 1990, NATURE, V343, P213, DOI 10.1038/343213a0; WINTENBERGER M, 1978, J PHYS-PARIS, V39, P965, DOI 10.1051/jphys:01978003909096500	26	160	164	2	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1998	280	5365					880	883		10.1126/science.280.5365.880	http://dx.doi.org/10.1126/science.280.5365.880			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572727	Green Submitted			2022-12-01	WOS:000073532900034
J	Nightingale, SL				Nightingale, SL			Ultrasound device for evaluating bone strength approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1998	279	17					1339	1339		10.1001/jama.279.17.1339	http://dx.doi.org/10.1001/jama.279.17.1339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK758	9582030				2022-12-01	WOS:000073359800006
J	Grodstein, F; Martinez, ME; Platz, EA; Giovannucci, E; Colditz, GA; Kautzky, M; Fuchs, C; Stampfer, MJ				Grodstein, F; Martinez, ME; Platz, EA; Giovannucci, E; Colditz, GA; Kautzky, M; Fuchs, C; Stampfer, MJ			Postmenopausal hormone use and risk for colorectal cancer and adenoma	ANNALS OF INTERNAL MEDICINE			English	Article						colorectal neoplasms; estrogen replacement therapy; adenoma; colonoscopy; sigmoidoscopy	LARGE-BOWEL-CANCER; EXOGENOUS FEMALE HORMONES; COLON-CANCER; REPRODUCTIVE FACTORS; ESTROGEN-RECEPTOR; PROGESTERONE RECEPTORS; REPLACEMENT THERAPY; PROSPECTIVE COHORT; UNITED-STATES; CELL-LINES	Background: Accumulating evidence suggests that postmenopausal hormone use may decrease the risk for colorectal cancer. Objective: To examine the relation of postmenopausal hormone therapy to colorectal adenoma and cancer. Design: Prospective cohort and nested case-control studies. Setting: Nurses' Health Study, a study of registered nurses recruited from 11 U.S. states. Participants: 59 002 postmenopausal participants in the Nurses' Health Study. Measurements: Self-reported data on hormone use and cases of distal colorectal adenoma and colorectal cancer obtained from biennial questionnaires completed from 1980 to 1994. Cases of colorectal adenoma and cancer were confirmed by medical record review. Results: 470 women developed colorectal cancer, and 838 developed distal colorectal adenomas. Current use of postmenopausal hormones was associated with a decreased risk for colorectal cancer (relative risk [RR], 0.65 [95% CI, 0.50 to 0.83]). This association was attenuated in past users (RR, 0.84 [CI, 0.67 to 1.05]) and disappeared 5 years after hormone use was discontinued (RR, 0.92 [Cl, 0.70 to 1.21]). Longer duration of current use did not afford greater protection (RR with greater than or equal to 5 years of use. 0.72 [CI, 0.53 to 0.96]). Even after exclusion of women who reported having screening sigmoidoscopy, the relative risk for colorectal cancer seen with current hormone use was 0.64 (CI, 0.49 to 0.82). This suggests that the apparent protection is unlikely to be due to more intensive screening among hormone users. Current users also had a lower risk for large (greater than or equal to 1 cm) adenomas than did women who had never used hormones (RR, 0.74 [CI, 0.55 to 0.99]), although no overall material association was seen between colorectal adenoma and current hormone use (RR, 0.91 [CI, 0.77 to 1.08]). Conclusions: The risk for colorectal cancer was decreased among women currently receiving postmenopausal hormone therapy, but the apparent reduction substantially diminished upon cessation of therapy. Hormone use was inversely associated with large colorectal adenomas but not small ones.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Grodstein, F (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA40356] Funding Source: Medline; NIA NIH HHS [AG13482] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG013482] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BOSTICK RM, 1994, CANCER CAUSE CONTROL, V5, P38, DOI 10.1007/BF01830725; BURCH JC, 1975, ESTROGENS POST MENOP, P208; CALLE EE, 1995, J NATL CANCER I, V87, P517, DOI 10.1093/jnci/87.7.517; CHUTE CG, 1991, EPIDEMIOLOGY, V2, P395, DOI 10.1097/00001648-199109000-00019; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; CONCOLINO G, 1986, CANCER DETECT PREV, V9, P477; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS FG, 1989, INT J CANCER, V43, P587, DOI 10.1002/ijc.2910430409; DEVERDIER MG, 1992, CANCER CAUSE CONTROL, V3, P355, DOI 10.1007/BF00146889; FURNER SE, 1989, CANCER RES, V49, P4936; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; HENDRICKSE CW, 1993, BRIT J SURG, V80, P636, DOI 10.1002/bjs.1800800531; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JACOBS EJ, 1994, CANCER CAUSE CONTROL, V5, P359, DOI 10.1007/BF01804987; JACOBSON JS, 1995, CANCER CAUSE CONTROL, V6, P513, DOI 10.1007/BF00054159; Kampman E, 1997, CANCER CAUSE CONTROL, V8, P146, DOI 10.1023/A:1018459911147; LOINTIER P, 1992, ANTICANCER RES, V12, P1327; MAMINTA MLD, 1991, MOL CELL ENDOCRINOL, V78, P61, DOI 10.1016/0303-7207(91)90186-V; MCMICHAEL AJ, 1980, J NATL CANCER I, V65, P1201; MOROTOMI M, 1990, CANCER RES, V50, P3595; NEWCOMB PA, 1995, JNCI-J NATL CANCER I, V87, P1067, DOI 10.1093/jnci/87.14.1067; Peipins LA, 1997, CANCER EPIDEM BIOMAR, V6, P671; PETERS RK, 1990, BRIT J CANCER, V61, P741, DOI 10.1038/bjc.1990.166; Potter JD, 1996, CANCER EPIDEM BIOMAR, V5, P779; POTTER JD, 1995, JNCI-J NATL CANCER I, V87, P1039, DOI 10.1093/jnci/87.14.1039; POTTER JD, 1983, J NATL CANCER I, V71, P703; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RISCH HA, 1995, CANCER EPIDEM BIOMAR, V4, P21; Rothman KJ, 1979, NIH PUBLICATION, V79-1649, P31; SICA V, 1984, CANCER RES, V44, P4670; SINGH S, 1994, ANTICANCER RES, V14, P1037; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006; THOMAS ML, 1993, ENDOCRINOLOGY, V132, P426, DOI 10.1210/en.132.1.426; Troisi R, 1997, CANCER CAUSE CONTROL, V8, P130, DOI 10.1023/A:1018455810238; WEISS NS, 1981, J NATL CANCER I, V67, P57; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WU AH, 1987, BRIT J CANCER, V55, P687, DOI 10.1038/bjc.1987.140; WUWILLIAMS AH, 1991, CANCER RES, V51, P2307; XU XM, 1994, MOL CELL ENDOCRINOL, V105, P197	43	230	236	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					705	+		10.7326/0003-4819-128-9-199805010-00001	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556463				2022-12-01	WOS:000073363800001
J	Thiadens, HA; de Bock, GH; Deker, FW; Huysman, JAN; van Houwelingen, JC; Springer, MP; Postma, DS				Thiadens, HA; de Bock, GH; Deker, FW; Huysman, JAN; van Houwelingen, JC; Springer, MP; Postma, DS			Identifying asthma and chronic obstructive pulmonary disease in patients with persistent cough presenting to general practitioners: descriptive study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WORKING PARTY STANDARDIZATION; EUROPEAN RESPIRATORY SOCIETY; BRONCHIAL HYPERRESPONSIVENESS; OFFICIAL STATEMENT; RESPONSIVENESS; BRONCHODILATOR; ASSOCIATION; COMMUNITY; SYMPTOMS; ADULTS	Objective: To determine the prevalence of asthma and chronic obstructive pulmonary disease in patients not known to have these disorders, who present in general practice with persistent cough, and to ascertain criteria to help general practitioners in diagnosis. Design: Descriptive study. Setting: Primary healthcare centre in the Netherlands. Subjects: 192 patients aged 18-75 years, not known to have asthma or chronic obstructive pulmonary disease, attending their general practitioner with cough persisting for at least 2 weeks. Methods: A diagnosis of asthma or chronic obstructive pulmonary was based on the recurrence of airway symptoms in the past year accompanied by spirometric measurements (including bronchodilator testing) and methacholine provocation tests. A scoring formula to estimate the probability of asthma or chronic obstructive pulmonary disease, based on history and physical examination, was generated by means of logistic regression. Results: 74 patients (39%) were classified as having asthma, 14 (7%) as hating chronic obstructive pulmonary disease. The best formula for predicting asthma or chronic obstructive pulmonary disease used scores for three symptoms: (reported) wheeze, (reported) dyspnoea, and allergen induced symptoms, together with prolonged expiration, pack years of smoking, and female sex variables were scored 1 when present and 0 when absent except for allergen induced symptoms (1.5) and number of pack years of smoking (n/25). With a cut off value of 3 on the scoring formula 76% of the patients could be classified correctly. Conclusions: About half of patients with persistent cough who present to a general practitioner have asthma or chronic obstructive pulmonary disease. With a simple formula based on three symptoms and prolonged expiration, pack years of smoking, and female sex most patients may be identified correctly in general practice.	Leiden Univ, Med Ctr, Dept Gen Practice, NL-2301 CB Leiden, Netherlands; Leiden Univ, Med Ctr, Med Decis Making Unit, NL-2301 CB Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Med Stat, NL-2301 CB Leiden, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; Univ Groningen Hosp, Dept Lung Dis, NL-9700 RB Groningen, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen	Thiadens, HA (corresponding author), Leiden Univ, Med Ctr, Dept Gen Practice, POB 2088, NL-2301 CB Leiden, Netherlands.		de Bock, Geertruida Hendrika/F-6529-2014; van houwelingen, hans c/C-1872-2008; Dekker, Friedo/B-6452-2011	de Bock, Geertruida Hendrika/0000-0003-3104-4471; van houwelingen, hans c/0000-0002-0494-4637; Dekker, Friedo/0000-0002-2433-2494	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOEZEN HM, 1995, THORAX, V50, P121, DOI 10.1136/thx.50.2.121; BOTTEMA BJA, 1993, THESIS U AMSTERDAM A, P64; BRAND PLP, 1992, THORAX, V47, P429, DOI 10.1136/thx.47.6.429; CERVERI I, 1993, EUR RESPIR REV, V14, P424; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; DALES RE, 1988, AM REV RESPIR DIS, V138, P317, DOI 10.1164/ajrccm/138.2.317; HALLETT JS, 1985, ANN ALLERGY, V55, P568; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640, DOI 10.1164/ajrccm/141.3.640; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; RIJCKEN B, 1995, AM J RESP CRIT CARE, V151, P1377, DOI 10.1164/ajrccm.151.5.7735588; RUTTEN GEHM, 1988, HUISARTS WETENSCHAP, V31, P293; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; TRIGG CJ, 1990, THORAX, V45, P866, DOI 10.1136/thx.45.11.866; VANDELENDE R, 1991, SCAND J RESPIR DIS, V4, P612; WILLIAMSON HA, 1987, J FAM PRACTICE, V24, P35; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	19	45	47	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	1998	316	7140					1286	1290		10.1136/bmj.316.7140.1286	http://dx.doi.org/10.1136/bmj.316.7140.1286			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554899	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000073335900023
J	Cheng, YK; Rossky, PJ				Cheng, YK; Rossky, PJ			Surface topography dependence of biomolecular hydrophobic hydration	NATURE			English	Article							MOLECULAR-DYNAMICS; PROTEIN; WATER; MELITTIN; SOLVENT; SOLVATION	Many biomolecules are characterized by surfaces containing extended nonpolar regions(1), and the aggregation and subsequent removal of such surfaces from water is believed to play a critical role in the biomolecular assembly in cells(2). A better understanding of the hydrophobic hydration of biomolecules may therefore yield new insights into intracellular assembly, Conventional views hold that the hydration shell of small hydrophobic solutes is clathrate-like, characterized by local cage-like hydrogen-bonding structures and a distinct loss in entropy(2). The hydration of extended nonpolar planar surfaces, however, appears to involve structures that are orientationally inverted relative to clathrate-like hydration shells(3,4), with unsatisfied hydrogen bonds that are directed towards the hydrophobic surface. Here we present computer simulations of the interaction between the polypeptide melittin and water that demonstrate that the two different hydration structures also exist near a biomolecular surface. We find that the two structures are distinguished by a substantial difference in the water-water interaction enthalpy, and that their relative contributions depend strongly on the surface topography of the melittin molecule: clathrate-like structures dominate near con-vex surface patches, whereas the hydration shell near flat surfaces fluctuates between clathrate-like and less-ordered or inverted structures. The strong influence of surface topography on the structure and free energy of hydrophobic hydration is likely to hold in general, and will be particularly important for the many biomolecules whose surfaces contain convex patches, deep or shallow concave grooves and roughly planar areas(5).	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Rossky, PJ (corresponding author), Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA.			Cheng, Yuen-Kit/0000-0002-5643-5949				Berendsen H.J.C., 1981, INTERMOLECULAR FORCE, P331; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLOKZIJL W, 1993, ANGEW CHEM INT EDIT, V32, P1545, DOI 10.1002/anie.199315451; Clarke Anthony R., 1996, P167, DOI 10.1016/B978-012237455-5/50008-7; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DU Q, 1994, SCIENCE, V264, P826, DOI 10.1126/science.264.5160.826; FREIRE E, 1992, BIOCHEMISTRY-US, V31, P250, DOI 10.1021/bi00116a034; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KITAO A, 1991, CHEM PHYS, V158, P447, DOI 10.1016/0301-0104(91)87082-7; KUHN LA, 1992, J MOL BIOL, V228, P13, DOI 10.1016/0022-2836(92)90487-5; LEE CY, 1984, J CHEM PHYS, V80, P4448, DOI 10.1063/1.447226; MEHROTRA PK, 1980, J AM CHEM SOC, V102, P4287, DOI 10.1021/ja00533a001; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PASCUALAHUIR JL, 1994, J COMPUT CHEM, V15, P1127, DOI 10.1002/jcc.540151009; ROSSKY PJ, 1979, J AM CHEM SOC, V101, P1913, DOI 10.1021/ja00502a001; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SanchezRuiz JM, 1996, EUR BIOPHYS J BIOPHY, V24, P261; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; TEETER MM, 1991, ANNU REV BIOPHYS BIO, V20, P577, DOI 10.1146/annurev.biophys.20.1.577; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6010; VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98; ZICHI DA, 1985, J CHEM PHYS, V83, P797, DOI 10.1063/1.449495	22	360	360	1	105	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1998	392	6677					696	699		10.1038/33653	http://dx.doi.org/10.1038/33653			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565030				2022-12-01	WOS:000073129000052
J	Simon, JB				Simon, JB			Should all people over the age of 50 have regular fecal occult-blood tests? Postpone population screening until problems are solved	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COLORECTAL-CANCER; COST-EFFECTIVENESS; MORTALITY; PROGRAM; CHANCE		Queens Univ, Kingston, ON K7L 5G2, Canada	Queens University - Canada	Simon, JB (corresponding author), Hotwl Dieu Hosp, Div Gastroenterol, 166 Brock St, Kingston, ON K7L 5G2, Canada.							AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; Hardcastle JD, 1996, LANCET, V348, P1472, DOI 10.1016/S0140-6736(96)03386-7; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; LIEBERMAN DA, 1995, GASTROENTEROLOGY, V109, P1781, DOI 10.1016/0016-5085(95)90744-0; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; MORRIS JB, 1991, AM J SURG, V161, P101, DOI 10.1016/0002-9610(91)90368-N; Simon J B, 1998, Gastroenterologist, V6, P66; SIMON JB, 1990, JAMA-J AM MED ASSOC, V264, P84, DOI 10.1001/jama.264.1.84; WAGNER JL, 1991, ANN INTERN MED, V115, P807, DOI 10.7326/0003-4819-115-10-807; Wagner JL, 1996, PREVENTION EARLY DET, P321; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; WINCHESTER DP, 1980, CANCER, V45, P2955, DOI 10.1002/1097-0142(19800615)45:12<2955::AID-CNCR2820451211>3.0.CO;2-T; WINDELER J, 1987, INT J COLORECTAL DIS, V2, P223, DOI 10.1007/BF01649510; Wolf AMD, 1996, ARCH INTERN MED, V156, P1069, DOI 10.1001/archinte.156.10.1069	16	28	28	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1151	1152						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9545367				2022-12-01	WOS:000073070100012
J	Vita, AJ; Terry, RB; Hubert, HB; Fries, JF				Vita, AJ; Terry, RB; Hubert, HB; Fries, JF			Aging, health risks, and cumulative disability	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; ELDERLY POPULATION; COLLEGE ALUMNI; OLDER PERSONS; LONGER LIFE; FOLLOW-UP; MEN; COMPRESSION; MORBIDITY	Background Persons with lower health risks tend to live longer than those with higher health risks, but there has been concern that greater longevity may bring with it greater disability. We performed a longitudinal study to determine whether persons with lower potentially modifiable health risks have more or less cumulative disability. Methods We studied 1741 university alumni who were surveyed first in 1962 (average age, 43 years) and then annually starting in 1986, Strata of high, moderate, and low risk were defined on the basis of smoking, body-mass index, and exercise patterns. Cumulative disability was determined with a health-assessment questionnaire and scored on a scale of 0 to 3. Cumulative disability from 1986 to 1994 (average age in 1994, 75 years) or death was the measure of lifetime disability. Results Persons with high health risks in 1962 or 1986 had twice the cumulative disability of those with low health risks (disability index, 1.02 vs. 0.49; P < 0.001). The results were consistent among survivors, subjects who died, men, and women and for both the last year and the last two years of observation. The onset of disability was postponed by more than five years in the low-risk group as compared with the high-risk group. The disability index for the low-risk subjects who died was half that for the high-risk subjects in the last one or two years of observation. Conclusions Smoking, body-mass index, and exercise patterns in midlife and late adulthood are predictors of subsequent disability. Not only do persons with better health habits survive longer, but in such persons, disability is postponed and compressed into fewer years at the end of life. (C) 1998, Massachusetts Medical Society.	Stanford Univ, Sch Med, Dept Med, Stanford, CA USA	Stanford University	Fries, JF (corresponding author), 1000 Welch Rd,Suite 203, Palo Alto, CA 94304 USA.		Fries, James F/F-6271-2011		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR043584] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43584] Funding Source: Medline; NICHD NIH HHS [R01 HD35641-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; BROWN JH, 1984, AM J PUBLIC HEALTH, V74, P159, DOI 10.2105/AJPH.74.2.159; CRIMMINS EM, 1990, J INSURANCE MED, V22, P89; *DEP HLTH HUM SERV, 1990, DHHS PUBL PHS; *DEP HLTH HUM SERV, 1996, DHHS PUBL PHS; DUFFY ME, 1990, GERONTOLOGIST, V30, P503, DOI 10.1093/geront/30.4.503; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; FRIES JF, 1994, ANN INTERN MED, V121, P502, DOI 10.7326/0003-4819-121-7-199410010-00005; FRIES JF, 1989, MILBANK Q, V67, P208, DOI 10.2307/3350138; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; FRIES JF, 1982, J RHEUMATOL, V9, P789; Fries JF, 1981, VITALITY AGING; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; HJERMANN I, 1981, LANCET, V2, P1303; HOUSE JS, 1990, MILBANK Q, V68, P383, DOI 10.2307/3350111; HUBERT HB, 1993, J RHEUMATOL, V20, P480; Hubert Helen B., 1994, Annals of Epidemiology, V4, P285; LEE IM, 1995, JAMA-J AM MED ASSOC, V273, P1179, DOI 10.1001/jama.273.15.1179; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; LEIGH JP, 1994, INT J AGING HUM DEV, V39, P233, DOI 10.2190/XQXR-UTGP-WA8X-9FQJ; Lewis CE, 1997, AM J PUBLIC HEALTH, V87, P635, DOI 10.2105/AJPH.87.4.635; MANTON KG, 1993, J GERONTOL, V48, pS153, DOI 10.1093/geronj/48.4.S153; MANTON KG, 1982, MILBANK FUND Q, V60, P183, DOI 10.2307/3349767; MYERS GC, 1984, GERONTOLOGIST, V24, P346, DOI 10.1093/geront/24.4.346; Nusselder WJ, 1996, GERONTOLOGIST, V36, P773, DOI 10.1093/geront/36.6.773; OCONNOR GT, 1995, AM J EPIDEMIOL, V142, P1147, DOI 10.1093/oxfordjournals.aje.a117573; OLSHANSKY SJ, 1986, MILBANK Q, V64, P355, DOI 10.2307/3350025; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1994, MED SCI SPORT EXER, V26, P857; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Ramey D., 1996, QUALITY LIFE PHARMAC, V2nd ed, P227; Ramey D R, 1992, Arthritis Care Res, V5, P119, DOI 10.1002/art.1790050303; ROGERS A, 1990, GERONTOLOGIST, V30, P640, DOI 10.1093/geront/30.5.640; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; *SAS I, 1989, SAS STAT US GUID VER; SIMONSICK EM, 1993, AM J PUBLIC HEALTH, V83, P1443, DOI 10.2105/AJPH.83.10.1443; STEWART AL, 1993, GERONTOLOGIST, V33, P782, DOI 10.1093/geront/33.6.782; VERBRUGGE LM, 1984, MILBANK FUND Q, V62, P475, DOI 10.2307/3349861; WAIDMANN T, 1995, MILBANK Q, V73, P253, DOI 10.2307/3350259; WARNER KE, 1992, AM J PUBLIC HEALTH, V82, P126, DOI 10.2105/AJPH.82.1.126; WARNER KE, 1988, J OCCUP ENVIRON MED, V30, P106	43	435	440	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1035	1041		10.1056/NEJM199804093381506	http://dx.doi.org/10.1056/NEJM199804093381506			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZG134	9535669				2022-12-01	WOS:000072969500006
J	Nathanson, V				Nathanson, V			Cambodia - after the killing fields	BRITISH MEDICAL JOURNAL			English	Article									BMA, Profess Resources & Res Grp, London WC1H 9JP, England		Nathanson, V (corresponding author), BMA, Profess Resources & Res Grp, London WC1H 9JP, England.								0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1082	1086						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552916				2022-12-01	WOS:000072987400037
J	Lebron, JA; Bennett, MJ; Vaughn, DE; Chirino, AJ; Snow, PM; Mintier, GA; Feder, JN; Bjorkman, PJ				Lebron, JA; Bennett, MJ; Vaughn, DE; Chirino, AJ; Snow, PM; Mintier, GA; Feder, JN; Bjorkman, PJ			Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor	CELL			English	Article							NEONATAL FC RECEPTOR; CLASS-I MOLECULES; HEREDITARY HEMOCHROMATOSIS; VIRAL PEPTIDES; BINDING; ASSOCIATION; RESOLUTION; PROGRAM; HLA-A2	HFE is an MHC-related protein that is mutated in the iron-overload disease hereditary hemochromatosis. HFE binds to transferrin receptor (TfR) and reduces its affinity for iron-loaded transferrin, implicating HFE in iron metabolism. The 2.6 Angstrom crystal structure of HFE reveals the locations of hemochromatosis mutations and a patch of histidines that could be involved in pH-dependent interactions. We also demonstrate that soluble TfR and HFE bind tightly at the basic pH of the cell surface, but not at the acidic pH of intracellular vesicles. TfR:HFE stoichiometry (2:1) differs from TfR: transferrin stoichiometry (2:2), implying a different mode of binding for HFE and transferrin to TfR, consistent with our demonstration that HFE, transferrin, and TfR form a ternary complex.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Caltech Prot Express Ctr, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Progenitor Inc, Menlo Park, CA 94025 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; California Institute of Technology	Lebron, JA (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.							BACON BR, 1996, HEPATOLOGY TXB LIVER; Bebbington CRH, 1987, DNA CLONING; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Beutler E, 1997, AM J HUM GENET, V61, P762; BORHANI DW, 1991, J MOL BIOL, V218, P685, DOI 10.1016/0022-2836(91)90255-5; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; Chapman TL, 1998, J VIROL, V72, P460, DOI 10.1128/JVI.72.1.460-466.1998; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; Cuthbert JA, 1997, J INVEST MED, V45, P518; ENNS CA, 1981, J BIOL CHEM, V256, P9820; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025; Fersht A., 1985, ENZYME STRUCTURE MEC; Hashimoto K, 1997, BIOCHEM BIOPH RES CO, V230, P35, DOI 10.1006/bbrc.1996.5889; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Junghans RP, 1997, IMMUNOL RES, V16, P29, DOI 10.1007/BF02786322; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuziemko GM, 1996, BIOCHEMISTRY-US, V35, P6375, DOI 10.1021/bi952314i; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Malmqvist Magnus, 1994, Methods (Orlando), V6, P95, DOI 10.1006/meth.1994.1012; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MCLAREN GD, 1991, J LAB CLIN MED, V117, P390; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P8318; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P16309; Vaughn DE, 1997, BIOCHEMISTRY-US, V36, P9374, DOI 10.1021/bi970841r; Vaughn DE, 1998, STRUCTURE, V6, P63, DOI 10.1016/S0969-2126(98)00008-2; Waheed A, 1997, P NATL ACAD SCI USA, V94, P12384, DOI 10.1073/pnas.94.23.12384; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	50	506	520	1	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					111	123		10.1016/S0092-8674(00)81151-4	http://dx.doi.org/10.1016/S0092-8674(00)81151-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546397	Bronze			2022-12-01	WOS:000072910800015
J	Marais, R; Light, Y; Mason, C; Paterson, H; Olson, MF; Marshall, CJ				Marais, R; Light, Y; Mason, C; Paterson, H; Olson, MF; Marshall, CJ			Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C	SCIENCE			English	Article							PLASMA-MEMBRANE; TYROSINE PHOSPHORYLATION; MAMMALIAN-CELLS; MAP KINASE; PATHWAY; GROWTH; HYDROLYSIS; MUTANT	Receptor tyrosine kinase-mediated activation of the Raf-1 protein kinase is coupled to the small guanosine triphosphate (GTP)-binding protein Ras, By contrast, protein kinase C (PKC)-mediated activation of Raf-1 is thought to be Ras independent, Nevertheless, stimulation of PKC in COS cells led to activation of Ras and formation of Ras-Raf-1 complexes containing active Raf-1, Raf-1 mutations that prevent its association with Ras blocked activation of Raf-1 by PKC, However, the activation of Raf-1 by PKC was not blocked by dominant negative Ras, indicating that PKC activates Ras by a mechanism distinct from that initiated by activation of receptor tyrosine kinases.	Inst Canc Res, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Marshall, CJ (corresponding author), Inst Canc Res, CRC, Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.		Olson, Michael/ABA-4240-2021; Olson, Michael F/A-3240-2011	Olson, Michael/0000-0003-3428-3507; Marais, Richard/0000-0001-7484-4183; Mason, Clive/0000-0003-3179-6622				Blobe GC, 1996, CANCER SURV, V27, P213; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Cox ME, 1997, J NEUROCHEM, V69, P1119; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINNEY R, 1995, METHOD ENZYMOL, V255, P310; GUPTA S, 1994, J BIOL CHEM, V269, P17349; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LOU Z, 1997, MOL CELL BIOL, V17, P46; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARAIS R, UNPUB; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SMITS AMM, 1992, NATURE, V357, P602; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Whelchel A, 1997, AM J RESP CELL MOL, V16, P589, DOI 10.1165/ajrcmb.16.5.9160841; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	45	384	386	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					109	112		10.1126/science.280.5360.109	http://dx.doi.org/10.1126/science.280.5360.109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525855				2022-12-01	WOS:000072885100047
J	DiGuiseppi, C; Li, L; Roberts, I				DiGuiseppi, C; Li, L; Roberts, I			Influence of travel patterns on mortality from injury among teenagers in England and Wales, 1985-95: trend analysis	BRITISH MEDICAL JOURNAL			English	Article									UCL, Sch Med, Inst Child Hlth, Dept Epidemiol,Child Hlth Monitoring Unit, London WC1N 1EH, England	University of London; University College London; UCL Medical School	DiGuiseppi, C (corresponding author), UCL, Sch Med, Inst Child Hlth, Dept Epidemiol,Child Hlth Monitoring Unit, London WC1N 1EH, England.		DiGuiseppi, Carolyn/AAU-1341-2020	DiGuiseppi, Carolyn/0000-0002-6440-7817				*DEP TRANSP, 1992, TRANSP STAT REP NAT; Department of Health, 1992, HLTH NAT STRAT HLTH; DiGuiseppi C, 1997, BRIT MED J, V314, P710, DOI 10.1136/bmj.314.7082.710; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; WOODROFFE C, 1993, CHILDREN TEENAGERS H	5	8	9	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					904	905		10.1136/bmj.316.7135.904	http://dx.doi.org/10.1136/bmj.316.7135.904			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552840	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000072713300030
J	Lean, MEJ; Han, TS; Seidell, JC				Lean, MEJ; Han, TS; Seidell, JC			Impairment of health and quality of life in people with large waist circumference	LANCET			English	Article							WEIGHT-GAIN; UNITED-STATES; RISK; OBESITY; PERSPECTIVE; OVERWEIGHT; COST	Background Symptoms and secondary disorders associated with excess central fat distribution are being increasingly recognised. We aimed to define the symptoms and assess risks of chronic disorders in people with large waist circumferences, Methods We did a cross-sectional study of 5887 men and 7018 women aged 20-59 years from the general population of Maastricht, Amsterdam, and Doetinchem, Netherlands. We assessed in health centres respiratory insufficiency, low back pain, degree of physicical function, presence of noninsulin-dependent diabetes, and cardiovascular risk factors. We measured bodyweight, body-mass index, and waist circumference by action levels (men: less than action level 1<94.0 cm, action levels 1-2 94.0-101.9 cm, more than action level 2 greater than or equal to 102.0 cm; women: less than action level 1 <80.0 cm, action levels 1-2 80.0-87.9 cm) more than action level 2 greater than or equal to 88.0 cm). The reference group were people with waist circumferences lower than action level 1. Findings All symptoms and risks increased among participants higher than action level 2, after adjustment for age and lifestyle, by 3.1(95% CI 2.5-3.7) in men and 2.7 (2.3-3.1) in women for shortness of breath when walking upstairs; 4.5 (2.5-7.8) and 3.8 (1.9-7.3) for non-insulin-dependent diabetes; and 4.2 (3.6-5.0) and 2.8 (2.4-3.2) for at least one major cardiovascular risk factor. Above action level 2, compared with the reference group, men and women were at twice the risk of difficulties in everyday activities, women were 1.5 times more likely to have low back pain or symptoms of intervertebral disc herniation, with secondary problems including hindrance to daily activities. Interpretation People with large waist circumferences have excess burden of ill health. Waist action levels could be useful for health promotion to raise awareness of the need for weight management.	Univ Glasgow, Glasgow Royal Infirm, Dept Human Nutr, Glasgow G31 2ER, Lanark, Scotland; Natl Inst Publ Hlth & Environm, Dept Chron Dis & Environm Epidemiol, NL-3720 BA Bilthoven, Netherlands	University of Glasgow; Netherlands National Institute for Public Health & the Environment	Lean, MEJ (corresponding author), Univ Glasgow, Glasgow Royal Infirm, Dept Human Nutr, Glasgow G31 2ER, Lanark, Scotland.		seidell, jacob c/N-7427-2013; seidell, jacob/AAF-5362-2019	seidell, jacob/0000-0002-9262-9062; Han, Thang/0000-0003-2570-0938				[Anonymous], 1995, WHO TECH REP SER; Bennett N, 1995, HLTH SURVEY ENGLAND; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; GARFINKEL L, 1992, ANN INTERN MED, V103, P1032; Gregory J., 1990, DIETARY NUTR SURVEY; Han TS, 1997, INT J OBESITY, V21, P600, DOI 10.1038/sj.ijo.0800448; Han TS, 1997, INT J OBESITY, V21, P127, DOI 10.1038/sj.ijo.0800377; Han TS, 1997, INT J OBESITY, V21, P83, DOI 10.1038/sj.ijo.0800371; HAN TS, 1995, BRIT MED J, V311, P1041; KUCZMARSKI R J, 1992, American Journal of Clinical Nutrition, V55, p495S, DOI 10.1093/ajcn/55.2.495s; LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/bmj.311.6998.158; LEE J, 1994, INT J EPIDEMIOL, V23, P201, DOI 10.1093/ije/23.1.201; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; Medical Outcome Trust, 1994, SCOR SF36 HLTH SURV SCOR SF36 HLTH SURV; RISSANEN A, 1990, BRIT MED J, V301, P835, DOI 10.1136/bmj.301.6756.835; SEGAL L, 1994, PHARMACOECONOMICS, V5, P45, DOI 10.2165/00019053-199400051-00009; SEIDELL JC, 1995, INT J OBESITY, V19, pS13; Seidell JC, 1997, J INTERN MED, V242, P401, DOI 10.1046/j.1365-2796.1997.00235.x; SEIDELL JC, 1995, INT J OBES S3, V19, P1; WOLF AM, 1994, PHARMACOECONOMICS, V5, P34, DOI 10.2165/00019053-199400051-00007	21	352	366	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					853	856		10.1016/S0140-6736(97)10004-6	http://dx.doi.org/10.1016/S0140-6736(97)10004-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525361				2022-12-01	WOS:000072645500010
J	Miller, KD; Jones, E; Yanovski, JA; Shankar, R; Feuerstein, I; Falloon, J				Miller, KD; Jones, E; Yanovski, JA; Shankar, R; Feuerstein, I; Falloon, J			Visceral abdominal-fat accumulation associated with use of indinavir	LANCET			English	Article							COMPUTED-TOMOGRAPHY; BODY-FAT; INFECTION; OBESITY	Background After the addition of the protease inhibitor indinavir to combination drug regimens for HIV-1 infection, some patients have experienced an increase in abdominal girth with symptoms of abdominal fullness, distension, or bloating. We aimed to find out whether this collection of symptoms was associated with changes in abdominal fat and whether such changes were associated with indinavir use. Methods Abdominal computed tomography was used in ten HIV-1-positive patients who had such abdominal symptoms to measure total adipose tissue (TAT) and visceral adipose tissue (VAT) at the umbilicus (L4 vertebral level). The VAT:TAT ratio in the ten cases was compared with that in ten HIV-1-infected patients who had been using indinavir without abdominal symptoms for at least 6 months and ten HIV-1-infected patients who were not using indinavir. Findings The mean VAT:TAT ratios for the three groups-non-users, symptom-free indinavir users, and symptomatic indinavir users-were 0.40 (SD 0.15), 0.59 (0.18), and 0.70 (0.20), respectively (p=0.004). The VAT:TAT ratio correlated with duration of indinavir use (r=0.47, p=0.01). The mean areas of VAT for the three groups were 106 cm(2) (SD 72), 141 cm(2) (65) and 202 cm(2) (93), respectively (p=0.03). The mean body-mass index of the groups was similar, and patients in the two indinavir groups did not gain a significant amount of weight after starting the drug. Serum triglyceride values increased after starting indinavir and correlated with VAT:TAT ratios. Interpretation Our data suggest that some HIV-1-infected patients on indinavir treatment accumulate intraabdominal fat that may cause abdominal symptoms. Recent evidence suggests that other HIV-1 protease inhibitors may be associated with changes in body-fat distribution. Larger studies of protease-inhibitor treatment are needed to investigate this association further and to investigate metabolic or endocrine mechanisms that may underlie this phenomenon.	NICHHD, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA; NICHHD, Dept Radiol, Warren Grant Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA; NICHHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Miller, KD (corresponding author), NICHHD, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, NIH, Bldg 10,Room 8C410, Bethesda, MD 20892 USA.	kmiller@atlas.niaid.nih.gov		Yanovski, Jack/0000-0001-8542-1637				Bartlett JG, 1996, ANN INTERN MED, V124, P1086, DOI 10.7326/0003-4819-124-12-199606150-00011; BAUMGARTNER RN, 1988, AM J CLIN NUTR, V48, P936, DOI 10.1093/ajcn/48.4.936; BORKAN GA, 1982, AM J CLIN NUTR, V36, P172, DOI 10.1093/ajcn/36.1.172; CARR A, 1998, 5 C RETR OPP INF, P410; Corey L, 1996, NEW ENGL J MED, V335, P1142, DOI 10.1056/NEJM199610103351509; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DIXON AK, 1983, CLIN RADIOL, V34, P189, DOI 10.1016/S0009-9260(83)80303-1; ENZI G, 1986, AM J CLIN NUTR, V44, P739, DOI 10.1093/ajcn/44.6.739; FUJIOKA S, 1987, METABOLISM, V36, P54, DOI 10.1016/0026-0495(87)90063-1; GRAUER WO, 1984, AM J CLIN NUTR, V39, P631, DOI 10.1093/ajcn/39.4.631; Hengel RL, 1997, LANCET, V350, P1596, DOI 10.1016/S0140-6736(05)64011-1; Herry I, 1997, CLIN INFECT DIS, V25, P937, DOI 10.1086/597649; JAMES JS, 1997, AIDS TREATMENT NEWS; LO JC, 1998, 5 C RETR OPP INF, P409; Macor C, 1997, METABOLISM, V46, P123, DOI 10.1016/S0026-0495(97)90288-2; MATSUZAWA Y, 1995, OBES RES, V3, P645; Matsuzawa Y., 1995, OBES RES S2, V3, p187S; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; RUANE PJ, 1997, 37 INT C ANT AG CHEM, pI185; VANDERKOOY K, 1993, INT J OBESITY, V17, P187; VanLoan MD, 1996, AM J CLIN NUTR, V64, P787, DOI 10.1093/ajcn/64.5.787; Vehmas T, 1996, INT J OBESITY, V20, P570; WAJCHENBERG BL, 1995, J CLIN ENDOCR METAB, V80, P2791, DOI 10.1210/jc.80.9.2791; WEITS T, 1988, INT J OBESITY, V12, P217; 1997, MED LETT DRUGS THER, V39, P111	25	545	550	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					871	875		10.1016/S0140-6736(97)11518-5	http://dx.doi.org/10.1016/S0140-6736(97)11518-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525365				2022-12-01	WOS:000072645500014
J	Sobel, N; Prabhakaran, V; Desmond, JE; Glover, GH; Goode, RL; Sullivan, EV; Gabrieli, JDE				Sobel, N; Prabhakaran, V; Desmond, JE; Glover, GH; Goode, RL; Sullivan, EV; Gabrieli, JDE			Sniffing and smelling: separate subsystems in the human olfactory cortex	NATURE			English	Article							DISCRIMINATION; DEFICITS; DISEASE	The sensation and perception of smell (olfaction) are largely dependent on snifting, which is an active stage of stimulus transport and therefore an integral component of mammalian olfaction(1,2). Electrophysiological data obtained from study of the hedgehog, rat, rabbit, dog and monkey indicate that sniffing (whether or not an odorant is present) induces an oscillation of activity in the olfactory bulb, driving the piriform cortex in the temporal lobe, in other words, the piriform is driven by the olfactory bulb at the frequency of sniffing(1-4). Here we use functional magnetic resonance imaging (fMRI) that is dependent on the level of oxygen in the blood to determine whether sniffing can induce activation in the piriform of humans, and whether this activation can be differentiated from activation induced by an odorant, We find that sniffing, whether odorant is present or absent, induces activation primarily in the piriform cortex of the temporal lobe and in the medial and posterior orbito-frontal gyri of the frontal lobe. The source of the sniff-induced activation is the somatosensory stimulation that is induced by air flow through the nostrils. In contrast, a smell, regardless of snifting, induces activation mainly in the lateral and anterior orbito-frontal gyri of the frontal lobe. The dissociation between regions activated by olfactory exploration (sniffing) and regions activated by olfactory content (smell) shows a distinction in brain organization in terms of human olfaction.	Stanford Univ, Program Neurosci, Stanford, CA 94305 USA; Stanford Univ, Dept Psychol, Stanford, CA 94305 USA; Stanford Univ, Dept Radiol, Stanford, CA 94305 USA; Stanford Univ, Dept ENT Surg, Stanford, CA 94305 USA; Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; Palo Alto VA Hosp, Palo Alto, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University	Sobel, N (corresponding author), Stanford Univ, Program Neurosci, Stanford, CA 94305 USA.	nsobel@leland.stanford.edu	Gabrieli, John/AAJ-2869-2020; Sullivan, Edith V/ABD-5684-2021	Sullivan, Edith V/0000-0001-6739-3716; prabhakaran, vivek/0000-0002-1974-3125; Sobel, Noam/0000-0002-3232-9391	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB015891] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Adrian ED, 1942, J PHYSIOL-LONDON, V100, P459, DOI 10.1113/jphysiol.1942.sp003955; ALLISON AC, 1954, J ANAT, V88, P481; BRESSLER SL, 1980, ELECTROEN CLIN NEURO, V50, P19, DOI 10.1016/0013-4694(80)90319-3; BRESSLER SL, 1987, BRAIN RES, V409, P294, DOI 10.1016/0006-8993(87)90714-1; Desmond JE, 1997, HUM BRAIN MAPP, V5, P58, DOI 10.1002/(SICI)1097-0193(1997)5:1<58::AID-HBM6>3.0.CO;2-M; Doty R L, 1991, Geriatrics, V46 Suppl 1, P47; DOTY RL, 1988, NEUROLOGY, V38, P1237, DOI 10.1212/WNL.38.8.1237; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; ELIAN M, 1991, J NEUROL NEUROSUR PS, V54, P927, DOI 10.1136/jnnp.54.10.927; Eslinger P J, 1982, Brain Cogn, V1, P259, DOI 10.1016/0278-2626(82)90028-8; FRISTON KJ, 1994, HUMAN BRAIN MAPPING, V1, P153, DOI DOI 10.1002/HBM.460010207; GLOVER GH, 1998, MAGN RESON MED, V39; Henkin R I, 1977, Trans Am Neurol Assoc, V102, P146; JONES AS, 1989, CLIN OTOLARYNGOL, V14, P285, DOI 10.1111/j.1365-2273.1989.tb00375.x; JONES AS, 1986, ACTA OTO-LARYNGOL, V101, P328, DOI 10.3109/00016488609132846; JONESGOTMAN M, 1988, NEUROPSYCHOLOGIA, V26, P387, DOI 10.1016/0028-3932(88)90093-0; LAING DG, 1983, PERCEPTION, V12, P99, DOI 10.1068/p120099; Le Magnen J., 1945, ANN PSYCHOL, V45, P77; POTTER H, 1979, NEUROSCIENCE, V4, P361, DOI 10.1016/0306-4522(79)90099-X; POTTER H, 1980, NEUROPSYCHOLOGIA, V18, P621, DOI 10.1016/0028-3932(80)90101-3; PRICE JL, 1991, OLFACTION, P101; Price JL, 1990, HUMAN NERVOUS SYSTEM, P979; Sobel N, 1997, J NEUROSCI METH, V78, P115, DOI 10.1016/S0165-0270(97)00140-4; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; UEKI S, 1961, J NEUROPHYSIOL, V24, P12, DOI 10.1152/jn.1961.24.1.12; VONBONIN G, 1949, J COMP NEUROL, V92, P243; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0; ZATORRE RJ, 1990, PERCEPT PSYCHOPHYS, V47, P526, DOI 10.3758/BF03203105; ZATORRE RJ, 1991, BRAIN, V114, P71; ZATORRE RJ, 1992, NATURE, V360, P339, DOI 10.1038/360339a0	30	354	358	4	52	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					282	286		10.1038/32654	http://dx.doi.org/10.1038/32654			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZC739	9521322				2022-12-01	WOS:000072612300047
J	Dillin, A; Rine, J				Dillin, A; Rine, J			Roles for ORC in M phase and S phase	SCIENCE			English	Article							ORIGIN RECOGNITION COMPLEX; YEAST SACCHAROMYCES-CEREVISIAE; CONTROLLING DNA-REPLICATION; BUDDING YEAST; CELL-CYCLE; XENOPUS; MITOSIS; ACTIVATION; PROTEIN; GENES	The origin recognition complex (ORC), a six-subunit protein, functions as the replication initiator in the yeast Saccharomyces cerevisiae. Initiation depends on the assembly of the prereplication complex in late M phase and activation in S phase. One subunit of ORC, Orc5p, was required at G(1)/S and in early M phase. Asynchronous cells with a temperature-sensitive orc5-1 allele arrested in early M phase. In contrast, cells that were first synchronized in M phase, shifted to the restrictive temperature, and then released from the block arrested at the G(1)/S boundary, The G(1)/S arrest phenotype could not be suppressed by introducing wild-type Orc5p during G(1). Although all orc2 and orc5 mutations were recessive in the conventional sense, this dominant phenotype was shared with other orc5 alleles and an orc2 allele, The dominant inhibition to cell-cycle progression exhibited by the ore mutants was restricted to the nucleus, suggesting that chromosomes with mutant ORC complexes were capable of sending a signal that blocked initiation on chromosomes containing functional origins.	Univ Calif Berkeley, Div Genet, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Rine, J (corresponding author), Univ Calif Berkeley, Div Genet, 401 Baker Hall, Berkeley, CA 94720 USA.				NIEHS NIH HHS [P30ESO1896-12] Funding Source: Medline; NIGMS NIH HHS [GM-31105] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031105, R01GM031105] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Dillin A, 1997, GENETICS, V147, P1053; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MAINE GT, 1984, GENETICS, V106, P365; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rose MD, 1996, ANNU REV CELL DEV BI, V12, P663, DOI 10.1146/annurev.cellbio.12.1.663; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652	24	50	51	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1733	1737		10.1126/science.279.5357.1733	http://dx.doi.org/10.1126/science.279.5357.1733			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497294				2022-12-01	WOS:000072490000059
J	Cherfils, J; Menetrey, J; Mathieu, M; La Bras, G; Robineau, S; Beraud-Dufour, S; Antonny, B; Chardin, P				Cherfils, J; Menetrey, J; Mathieu, M; La Bras, G; Robineau, S; Beraud-Dufour, S; Antonny, B; Chardin, P			Structure of the Sec7 domain of the Arf exchange factor ARNO	NATURE			English	Article							NUCLEOTIDE EXCHANGE; GDP; PROTEIN; RESIDUES; BINDING	Small G proteins switch from a resting, GDP-bound state to an active, GTP-bound state. As spontaneous GDP release is slow, guanine-nucleotide-exchange factors (GEFs) are required to promote fast activation of small G proteins through replacement of GDP with GTP in vivo(1). Families of GEFs with no sequence similarity to other GEF families have now been assigned to most families of small G proteins. In the case of the small G protein Arf1, the exchange of bound GDP for GTP promotes the coating of secretory vesicles in Golgi traffic(2). An exchange factor for human Arf1, ARNO(3), and two closely related proteins, named cytohesin 1 (ref. 4) and GPS1 (ref. 5), have been identified. These three proteins are modular proteins with an amino-terminal coiled-coil, a Central Sec7-like domain and a carboxy-terminal pleckstrin homolog domain. The Sec7 domain contains the exchange-factor activity(3). It was first found in Sec7, a yeast protein and is present in several other proteins, including the yeast exchange factors for Arf, Gea1 and Gea2 (refs 7-9). Here we report the crystal structure of the Sec7 domain of human ARNO at 2 Angstrom resolution and the identification of the site of interaction of ARNO with Arf.	CNRS, UPR 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; CNRS, UPR 411, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Cherfils, J (corresponding author), CNRS, UPR 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.	cherfiles@lebs.cnrs-gif.fr	Ménétrey, Julie/AAM-6408-2021; Antonny, Bruno/ABH-7434-2020; BERAUD-DUFOUR, Sophie/M-4641-2016	Antonny, Bruno/0000-0002-9166-8668; BERAUD-DUFOUR, Sophie/0000-0002-0062-6842				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; MADEJ T, 1995, PROTEINS, V23, P356, DOI 10.1002/prot.340230309; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schimmoller F, 1997, CURR BIOL, V7, pR235, DOI 10.1016/S0960-9822(06)00109-6; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0	30	145	150	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					101	105		10.1038/32210	http://dx.doi.org/10.1038/32210			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510256				2022-12-01	WOS:000072373000059
J	Lauer, MS; Lytle, B; Pashkow, F; Snader, CE; Marwick, TH				Lauer, MS; Lytle, B; Pashkow, F; Snader, CE; Marwick, TH			Prediction of death and myocardial infarction by screening with exercise-thallium testing after coronary-artery-bypass grafting	LANCET			English	Article							EMISSION COMPUTED-TOMOGRAPHY; SURGERY; REVASCULARIZATION; DISEASE; PATENCY; PERFUSION	Background The role of myocardial-perfusion imaging in calculating risk in symptom-free patients who have had coronary-artery-bypass grafting (CABG) is unclear. Practice guidelines have argued against routine screening of these patients. We sought to find out the independent and incremental prognostic value of exercise thallium-201 single-photon-emission computed tomography (SPECT) for prediction of death and non-fatal myocardial infarction (MI) in these patients. Methods Analyses were based on 873 symptom-free patients undergoing symptom-limited exercise thallium-201 SPECT between September, 1990, and December, 1993. All had undergone CABG and none had recurrent angina or other major intercurrent coronary events. Exercise and thallium-perfusion Variables were analysed to determine their prognostic importance during 3 years of follow-up. Findings Myocardial-perfusion defects were noted in 508 (58%) patients, There were 57 deaths and 72 patients had major events (death or non-fatal MI), Patients with thallium-perfusion defects were more likely to die (9% vs 3%, p=0.0004) or suffer a major event (11% vs 4%, p=0.0002). Reversible defects were also predictive of death (12% vs 5%, p=0.002) and major events (13% vs 7%, p=0.004). The exercise variable with the strongest predictive power was an impaired (less than or equal to 6 METs [measure of oxygen consumption equal to 3.5 mL/kg/min]) exercise capacity; poor exercise capacity was predictive of death (18% vs 4%, p<0.0001) and death or non-fatal MI (19% vs 5%, p<0.0001). After adjusting for baseline clinical variables, surgical variables, time elapsed since CABG, and standard cardiovascular risk factors, thallium-perfusion defects remained predictive of death (adjusted relative risk 2.78, 95% CI 1.44-5.39) and major events (2.63, 1.49-4.66), Similarly, impaired exercise remained strongly predictive of death (4.16, 2.38-7.29) and major events (3.61, 2.22-5.87) after adjusting for confounders. Interpretation In this group of patients who were symptom-free after CABG, thallium-perfusion defects and impaired exercise capacity were strong and independent predictors of subsequent death or non-fatal MI. Recommendations against routine screening exercise myocardial-perfusion studies in this setting should be reconsidered.	Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplant Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiothorac Surg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, George M & Linda H Kaufman Ctr Heart Failure, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Lauer, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplant Med, Desk F-25,9500 Euclid Ave, Cleveland, OH 44195 USA.	lauerm@cesmtp.ccf.org	Lauer, Michael S/L-9656-2013; Marwick, Thomas H/C-7261-2013	Lauer, Michael S/0000-0002-9217-8177; Marwick, Thomas H/0000-0001-9065-0899				Alazraki N P, 1996, Q J Nucl Med, V40, P85; *AM COLL SPORTS ME, 1985, GUID GRAD EX TEST EX; BRUCE RA, 1971, ANN CLIN RES, V3, P323; CAMPEAU L, 1984, NEW ENGL J MED, V311, P1329, DOI 10.1056/NEJM198411223112101; Campeau L, 1997, NEW ENGL J MED, V336, P153; COSGROVE DM, 1985, ANN SURG, V202, P480, DOI 10.1097/00000658-198510000-00008; COX DR, 1972, J R STAT SOC B, V34, P187; FIORETTI P, 1988, EUR HEART J, V9, P1332, DOI 10.1093/oxfordjournals.eurheartj.a062451; GIBSON RS, 1983, J AM COLL CARDIOL, V1, P804, DOI 10.1016/S0735-1097(83)80194-6; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GO RT, 1985, NUCL MED ANN, P171; Khoury AF, 1997, J AM COLL CARDIOL, V29, P1290, DOI 10.1016/S0735-1097(97)00045-4; LAKKIS NM, 1995, AM J CARDIOL, V76, P107, DOI 10.1016/S0002-9149(99)80039-3; Lauer MS, 1996, AM J CARDIOL, V78, P278, DOI 10.1016/S0002-9149(96)00277-9; NWASOKWA ON, 1995, ANN INTERN MED, V123, P528, DOI 10.7326/0003-4819-123-7-199510010-00009; PALMAS W, 1995, J AM COLL CARDIOL, V25, P403, DOI 10.1016/0735-1097(94)00380-9; Pilote L, 1998, AM J CARDIOL, V81, P219, DOI 10.1016/S0002-9149(97)00871-0; RASMUSSEN SL, 1984, EUR HEART J, V5, P494, DOI 10.1093/oxfordjournals.eurheartj.a061696; RITCHIE JL, 1995, J AM COLL CARDIOL, V25, P521, DOI 10.1016/0735-1097(95)90027-6; RITCHIE JL, 1977, CIRCULATION, V56, P830, DOI 10.1161/01.CIR.56.5.830; ROSE G, 1992, STRATEGY PREVENTIVE, P15; SINGH RN, 1983, J THORAC CARDIOV SUR, V86, P359	22	97	102	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					615	622		10.1016/S0140-6736(97)07062-1	http://dx.doi.org/10.1016/S0140-6736(97)07062-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500316				2022-12-01	WOS:000072364200006
J	Low-Beer, TS				Low-Beer, TS			How the colon begets gallstones	LANCET			English	Editorial Material							INTESTINAL TRANSIT; DEOXYCHOLIC-ACID; CHOLESTEROL SATURATION; BILE		Selly Oak Hosp, Birmingham B29 6RB, W Midlands, England		Low-Beer, TS (corresponding author), Selly Oak Hosp, Birmingham B29 6RB, W Midlands, England.							Berr F, 1996, GASTROENTEROLOGY, V111, P1611, DOI 10.1016/S0016-5085(96)70024-0; Carey MC, 1997, GUT, V41, P721, DOI 10.1136/gut.41.5.721; Dowling RH, 1997, CAN J GASTROENTEROL, V11, P57, DOI 10.1155/1997/532036; HEATON KW, 1993, LANCET, V341, P8, DOI 10.1016/0140-6736(93)92479-D; HOFFMANN AF, 1977, AM J CLIN NUTR, V30, P993; Hussaini SH, 1995, HEPATOLOGY, V22, P1735, DOI 10.1016/0270-9139(95)90199-X; LOWBEER TS, 1975, BRIT MED J, V1, P438, DOI 10.1136/bmj.1.5955.438; LOWBEER TS, 1978, LANCET, V2, P1063; MARCUS SN, 1986, GUT, V27, P550, DOI 10.1136/gut.27.5.550; POMARE EW, 1976, AM J DIG DIS, V21, P521, DOI 10.1007/BF01464757; POMARE EW, 1973, CLIN SCI MOL MED, V48, P315; SHODA J, 1995, HEPATOLOGY, V21, P1291, DOI 10.1016/0270-9139(95)90050-0; THORNTON JR, 1981, BRIT MED J, V282, P1018, DOI 10.1136/bmj.282.6269.1018; 1997, GUT, V3	14	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					612	613		10.1016/S0140-6736(05)78424-5	http://dx.doi.org/10.1016/S0140-6736(05)78424-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500314				2022-12-01	WOS:000072364200004
J	McCowan, C; Neville, RG; Thomas, GE; Crombie, IK; Clark, RA; Ricketts, IW; Cairns, AY; Warner, FC; Greene, SA; White, E				McCowan, C; Neville, RG; Thomas, GE; Crombie, IK; Clark, RA; Ricketts, IW; Cairns, AY; Warner, FC; Greene, SA; White, E			Effect of asthma and its treatment on growth: four year follow up of cohort of children from general practices in Tayside, Scotland	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRIMARY SCHOOL-CHILDREN; CHILDHOOD ASTHMA; SOCIAL-FACTORS; HEIGHT; ENGLAND; RETARDATION; DIAGNOSIS; CHARTS; TRIAL	Objective: To investigate whether asthma or its treatment impairs children's growth, after allowing for socioeconomic group. Design: 4 year follow up of a cohort of children aged 1-15. Setting: 12 general practices in the Tayside region of Scotland. Subjects: 3347 children with asthma or features suggestive of asthma registered with the general practices. Main outcome measures: Height and weight standard deviation scores. Results: Children who lived in areas of social deprivation (assessed by postcode) had lower height and weight than their contemporaries (mean standard deviation score -0.26 (SD 1.02) and -0.18 (1.15) respectively, P < 0.001 for both). Children who were receiving greater than or equal to 400 mu g daily of inhaled steroids and who were attending both hospital and general practice for asthma care had lower height and weight than average, independent of the effect of deprivation (mean standard deviation score -0.62 (1.01), P = 0.002, for height and -0.58 (0.94), P = 0.005, for weight). Children receiving high doses of inhaled corticosteroids also showed lower growth rates (mean change in standard deviation score -0.19 (0.51), P = 0.003). However, no other children with asthma showed growth impairment. Conclusion: Most children with asthma were of normal height and weight and had normal growth rates. However, children receiving high doses of inhaled steroids and requiring both general practice and hospital services had a significant reduction in their stature. This effect was independent from but smaller than the effect of socioeconomic group on stature.	Univ Dundee, Tayside Ctr Gen Practice, Dundee DD2 4AD, Scotland	University of Dundee	McCowan, C (corresponding author), Univ Dundee, Tayside Ctr Gen Practice, Dundee DD2 4AD, Scotland.	c.mccowan@dundee.ac.uk		McCowan, Colin/0000-0002-9466-833X				AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; *BRIT THOR SOC, 1993, THORAX, V48, pS1; BRYCE FP, 1995, BRIT MED J, V310, P838, DOI 10.1136/bmj.310.6983.838; COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/sim.4780111005; Cole TJ, 1997, ARCH DIS CHILD, V76, P47, DOI 10.1136/adc.76.1.47; COLE TJ, 1994, BMJ-BRIT MED J, V308, P641, DOI 10.1136/bmj.308.6929.641; *DEP ENV, 1995, 1991 DEPR IND REV AP; GULLIFORD MC, 1991, ARCH DIS CHILD, V66, P235, DOI 10.1136/adc.66.2.235; HALL DMB, 1995, BRIT MED J, V311, P583, DOI 10.1136/bmj.311.7005.583; HAUSPIE RC, 1979, HUM BIOL, V51, P507; LITTLEWOOD JM, 1988, LANCET, V1, P115; Mielck A, 1996, INT J EPIDEMIOL, V25, P388, DOI 10.1093/ije/25.2.388; MURRAY AB, 1976, LANCET, V2, P197; Neville RG, 1996, ANN HUM BIOL, V23, P323, DOI 10.1080/03014469600004552; NEVILLE RG, 1992, BRIT J GEN PRACT, V42, P501; NINAN TK, 1992, ARCH DIS CHILD, V67, P703, DOI 10.1136/adc.67.6.703; POWER C, 1995, ARCH DIS CHILD, V73, P298, DOI 10.1136/adc.73.4.298; RONA RJ, 1978, J EPIDEMIOL COMMUN H, V32, P147, DOI 10.1136/jech.32.3.147; RUSSELL G, 1994, RESP MED, V88, P31, DOI 10.1016/S0954-6111(05)80038-1; SMITH AM, 1980, ANN HUM BIOL, V7, P115, DOI 10.1080/03014468000004131; TANNER JM, 1966, ARCH DIS CHILD, V41, P454, DOI 10.1136/adc.41.219.454; VOSS L, 1989, ACTA PAEDIATR SCAND, P65; WALES JKH, 1991, LANCET, V338, P1535, DOI 10.1016/0140-6736(91)92362-6; White E, 1995, J Med Screen, V2, P140; WHITE EM, 1995, ARCH DIS CHILD, V72, P38, DOI 10.1136/adc.72.1.38; WOLTHERS OD, 1991, BMJ-BRIT MED J, V303, P163, DOI 10.1136/bmj.303.6795.163	27	35	40	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	1998	316	7132					668	672		10.1136/bmj.316.7132.668	http://dx.doi.org/10.1136/bmj.316.7132.668			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522793	Green Submitted, Green Published, Bronze, Green Accepted			2022-12-01	WOS:000072347900032
J	Podar, M; Chu, VT; Pyle, AM; Perlman, PS				Podar, M; Chu, VT; Pyle, AM; Perlman, PS			Group II intron splicing in vivo by first-step hydrolysis	NATURE			English	Article							MITOCHONDRIAL GENE-EXPRESSION; RNA; DNA; COMPONENT; SELECTION; PRODUCTS; DOMAIN-5; OXIDASE; MUTANTS; LARIAT	Group I, group II and spliceosomal introns splice by two sequential transesterification reactions(1). For both spliceosomal and group II introns, the first-step reaction occurs by nucleophilic attack on the 5' splice junction by the 2' hydroxyl of an internal adenosine, forming a 2'-5' phosphodiester branch in the intron. The second reaction joins the two exons with a 3'-5' phosphodiester bond and releases intron lariat. In vitro, group II introns can self-splice by an efficient alternative pathway in which the first-step reaction occurs by hydrolysis. The resulting linear splicing intermediate participates in normal second-step reactions, forming spliced exon and linear intron RNAs2,3. Here we show that the group II intron first-step hydrolysis reaction occurs in vivo in place of transesterification in the mitochondria of yeast strains containing branch-site mutations. As expected, the mutations block branching, but surprisingly still allow accurate splicing. This hydrolysis pathway may have been a step in the evolution of splicing mechanisms.	Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Columbia University	Perlman, PS (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	perlman@utsw.swmed.edu	Podar, Mircea/B-7299-2012	Podar, Mircea/0000-0003-2776-0205				ARNBERG AC, 1980, CELL, V19, P313, DOI 10.1016/0092-8674(80)90505-X; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; BOULANGER SC, 1995, MOL CELL BIOL, V15, P4479; Boulanger SC, 1996, MOL CELL BIOL, V16, P5896; Butow R A, 1996, Methods Enzymol, V264, P265, DOI 10.1016/S0076-6879(96)64026-9; CECH TR, 1993, RNA WORLD, P239; CHANFREAU G, 1993, EMBO J, V12, P5173, DOI 10.1002/j.1460-2075.1993.tb06212.x; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; CONTRADWEBB H, 1990, NUCLEIC ACIDS RES, V18, P1369; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; Daniels DL, 1996, J MOL BIOL, V256, P31, DOI 10.1006/jmbi.1996.0066; Eskes R, 1997, CELL, V88, P865, DOI 10.1016/S0092-8674(00)81932-7; GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357; HENSGENS LAM, 1983, J MOL BIOL, V164, P35, DOI 10.1016/0022-2836(83)90086-4; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JARRELL KA, 1988, J BIOL CHEM, V263, P3432; Liu QL, 1997, J MOL BIOL, V267, P163, DOI 10.1006/jmbi.1996.0845; Margossian SP, 1996, TRENDS BIOCHEM SCI, V21, P392, DOI 10.1016/S0968-0004(96)90129-2; Margossian SP, 1996, CELL, V84, P199, DOI 10.1016/S0092-8674(00)80975-7; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; PEEBLES CL, 1993, J BIOL CHEM, V268, P11929; PERLMAN P, 1995, METHOD ENZYMOL, V264, P66; PODAR M, 1995, RNA, V1, P828; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6	27	81	82	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					915	918		10.1038/36142	http://dx.doi.org/10.1038/36142			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495347				2022-12-01	WOS:000072230900058
J	Jamal, SA; Browner, WS; Bauer, DC; Cummings, SR				Jamal, SA; Browner, WS; Bauer, DC; Cummings, SR		Study Osteoporotic Fractures Res Grp	Warfarin use and risk for osteoporosis in elderly women	ANNALS OF INTERNAL MEDICINE			English	Article							SERUM UNDERCARBOXYLATED OSTEOCALCIN; BONE-MINERAL DENSITY; HIP FRACTURE; VITAMIN-K; CIRCULATING LEVELS; ANTICOAGULANT; THERAPY; NECK; MASS	Background: Vitamin K deficiency may be associated with osteoporosis. Objective: To assess the effects of warfarin on bone. Design: Prospective observational study. Setting: Four centers in the United States. Participants: 6201 elderly, postmenopausal women. Measurements: Self-reported warfarin use, bone mineral density at the hip and the heel, hip bone loss over 2 years, and fractures during 3.5 years of follow-up. Analyses were adjusted for baseline differences, age, weight, and estrogen use. Results: Compared with warfarin nonusers (n = 6052), warfarin users (n = 149) more frequently had poor health, involuntary weight loss, nonthiazide diuretic use, and frailty but had similar bone mineral density at the hip (difference, 1.6% [95% CI, -0.7% to 4.1%]) and heel (difference, 2.1% [CI, -1.6% to 5.6%]). Users and nonusers had similar rates of bone loss (1.1% and 0.8%; P = 0.18) and fractures (relative hazard, 1.0 [CI, 0.60 to 1.7]). Conclusion: In this population, warfarin use did not decrease bone mineral density or increase fracture rates.	Prevent Sci Grp, Suite 512,74 New Montgomery St, San Francisco, CA 94105 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)		sophie_jamal@quickmail.ucsf.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35582] Funding Source: Medline; NIA NIH HHS [AG05394, AG05407] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BINKLEY NC, 1995, J NUTR, V125, P1812, DOI 10.1093/jn/125.7.1812; BITENSKY L, 1988, J BONE JOINT SURG BR, V70, P663, DOI 10.1302/0301-620X.70B4.3403621; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; FIORE CE, 1990, SOUTH MED J, V83, P538, DOI 10.1097/00007611-199005000-00013; HART JP, 1984, LANCET, V2, P283, DOI 10.1016/S0140-6736(84)90321-0; HART JP, 1985, J CLIN ENDOCR METAB, V60, P1268, DOI 10.1210/jcem-60-6-1268; HODGES SJ, 1993, J BONE MINER RES, V8, P1241; HODGES SJ, 1991, BONE, V12, P387, DOI 10.1016/8756-3282(91)90027-G; HOUVENAGEL E, 1989, REV RHUM, V56, P677; MENON RK, 1987, J CLIN ENDOCR METAB, V64, P59, DOI 10.1210/jcem-64-1-59; MONREAL M, 1991, LANCET, V338, P706, DOI 10.1016/0140-6736(91)91292-3; PHILIP WJU, 1995, QJM-INT J MED, V88, P635; PIRO LD, 1982, J CLIN ENDOCR METAB, V54, P470, DOI 10.1210/jcem-54-2-470; PRICE PA, 1985, VITAM HORM, V42, P65; RESCH H, 1991, EUR HEART J, V12, P439, DOI 10.1093/oxfordjournals.eurheartj.a059914; ROSEN HN, 1993, AM J MED, V94, P62, DOI 10.1016/0002-9343(93)90121-5; Sato Y, 1997, STROKE, V28, P2390, DOI 10.1161/01.STR.28.12.2390; STEIGER P, 1992, J BONE MINER RES, V7, P625; SZULC P, 1994, J BONE MINER RES, V9, P1591; SZULC P, 1993, J CLIN INVEST, V91, P1769, DOI 10.1172/JCI116387	20	109	115	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1998	128	10					829	832		10.7326/0003-4819-128-10-199805150-00006	http://dx.doi.org/10.7326/0003-4819-128-10-199805150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM889	9599195				2022-12-01	WOS:000073586500006
J	Tucker, AW; Haddix, AC; Bresee, JS; Holman, RC; Parashar, UD; Glass, RI				Tucker, AW; Haddix, AC; Bresee, JS; Holman, RC; Parashar, UD; Glass, RI			Cost-effectiveness analysis of a rotavirus immunization program for the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ECONOMIC-ANALYSIS; YOUNG-CHILDREN; US CHILDREN; DIARRHEA; GASTROENTERITIS; INFECTION; VACCINES; INFANTS; TRIAL; MORTALITY	Context.-Rotavirus is the most common cause of severe diarrhea in children, and a live, oral vaccine may soon be licensed for prevention. Objective.-To estimate the economic impact of a national rotavirus immunization program in the United States. Design.-Cost-effectiveness was analyzed from the perspectives of the health care system and society. A decision tree used estimates of disease burden, costs, vaccine coverage, efficacy, and price obtained from published and unpublished sources. Intervention.-The proposed vaccine would be administered to infants at ages 2, 4, and 6 months as part of the routine schedule of childhood immunizations. Main Outcome Measures.-Total costs, outcomes prevented, and incremental cost-effectiveness. Results.-A routine, universal rotavirus immunization program would prevent 1.08 million cases of diarrhea, avoiding 34 000 hospitalizations, 95 000 emergency department visits, and 227 000 physician visits in the first 5 years of life. At $20 per dose, the program would cost $289 million and realize a net loss of $107 million to the health care system-$103 per case prevented. The program would provide a net savings of $296 million to society. Threshold analysis identified a break-even price per dose of $9 for the health care system and $51 for the societal perspective. Greater disease burden and greater vaccine efficacy and lower vaccine price increased cost-effectiveness. Conclusions.-A US rotavirus immunization program would be cost-effective from the perspectives of society and the health care system, although the cost of the immunization program would not be fully offset by the reduction in health care cost of rotavirus diarrhea unless the price fell to $9 per dose.	Ctr Dis Control & Prevent, Viral Gastroenteritis Sect, Resp & Enter Viruses Branch, US DHHS, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Prevent Effectiveness Branch, Div Prevent Res & Analyt Methods, Epidemiol Program Off, Atlanta, GA 30333 USA; Ctr Dis Control, Natl Ctr Infect Dis, Off Director, Div Viral & Rickettsial Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Glass, RI (corresponding author), Ctr Dis Control & Prevent, Viral Gastroenteritis Sect, Resp & Enter Viruses Branch, US DHHS, 1600 Clifton Rd NE,Mailstom G04, Atlanta, GA 30333 USA.							*ADV COMM IMM PRAC, 1997, ROT VACC PREV ROT DI, P1; AVENDANO P, 1993, PEDIATR INFECT DIS J, V12, P897, DOI 10.1097/00006454-199311000-00001; BERNSTEIN DI, 1995, JAMA-J AM MED ASSOC, V273, P1191, DOI 10.1001/jama.273.15.1191; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P57; CHALMERS TC, 1982, CONTROL CLIN TRIALS, P285; CHUNG MA, 1997, THESIS YALE U NEW HA; Clark HF, 1996, J INFECT DIS, V174, pS73, DOI 10.1093/infdis/174.Supplement_1.S73; CLEMENS JD, 1992, AM J EPIDEMIOL, V135, P865, DOI 10.1093/oxfordjournals.aje.a116382; DRUMMOND MF, 1984, CONTROL CLIN TRIALS, V5, P115, DOI 10.1016/0197-2456(84)90118-1; Glass RI, 1996, J INFECT DIS, V174, pS5, DOI 10.1093/infdis/174.Supplement_1.S5; GLASS RI, 1990, PROSPECTS PUBLIC HLT, V2, P102; GONZALEZ ML, 1996, SOCIOECONOMIC CHARAC, P77; GRIFFITHS RI, 1995, ARCH PEDIAT ADOL MED, V149, P407, DOI 10.1001/archpedi.1995.02170160061009; GURWITH M, 1981, J INFECT DIS, V144, P218, DOI 10.1093/infdis/144.3.218; GURWITH M, 1983, J INFECT DIS, V147, P685, DOI 10.1093/infdis/147.4.685; HADDIX A, 1994, PRACTICAL GUIDE PREV; *HEALTHC CONS AM, 1996, 1996 PHYS FEE COD GU, P42; HO MS, 1988, J INFECT DIS, V158, P1112, DOI 10.1093/infdis/158.5.1112; Jin SX, 1996, PEDIATR INFECT DIS J, V15, P397, DOI 10.1097/00006454-199605000-00004; Joensuu J, 1997, LANCET, V350, P1205, DOI 10.1016/S0140-6736(97)05118-0; KAPIKIAN AZ, 1993, JAMA-J AM MED ASSOC, V269, P627, DOI 10.1001/jama.269.5.627; KILGORE PE, 1995, JAMA-J AM MED ASSOC, V274, P1143, DOI 10.1001/jama.274.14.1143; KOOPMAN JS, 1984, AM J EPIDEMIOL, V119, P114, DOI 10.1093/oxfordjournals.aje.a113712; KOTLOFF KL, 1988, PEDIATR INFECT DIS J, V7, P753, DOI 10.1097/00006454-198811000-00002; LIEU TA, 1994, JAMA-J AM MED ASSOC, V271, P375, DOI 10.1001/jama.271.5.375; MARGOLIS HS, 1995, JAMA-J AM MED ASSOC, V274, P1201, DOI 10.1001/jama.274.15.1201; MATSON DO, 1990, J INFECT DIS, V162, P598, DOI 10.1093/infdis/162.3.598; *NAT CTR HLTH STAT, 1996, US DEP HLTH HUM SERV; Parashar UD, 1998, J INFECT DIS, V177, P13, DOI 10.1086/513808; PerezSchael I, 1997, NEW ENGL J MED, V337, P1181, DOI 10.1056/NEJM199710233371701; Rennels MB, 1996, PEDIATRICS, V97, P7; RODRIGUEZ WJ, 1980, AM J DIS CHILD, V134, P777, DOI 10.1001/archpedi.1980.02130200047015; RODRIGUEZ WJ, 1987, PEDIATR INFECT DIS J, V6, P170, DOI 10.1097/00006454-198702000-00006; Santosham M, 1997, J PEDIATR-US, V131, P632, DOI 10.1016/S0022-3476(97)70076-3; SMITH JC, 1995, PEDIATRICS, V96, P609; United States Census Bureau, 1996, CURR POP REP POP PRO	36	252	263	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1998	279	17					1371	1376		10.1001/jama.279.17.1371	http://dx.doi.org/10.1001/jama.279.17.1371			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK758	9582045	Bronze			2022-12-01	WOS:000073359800029
J	Chua, PR; Roeder, GS				Chua, PR; Roeder, GS			Zip2, a meiosis-specific protein required for the initiation of chromosome synapsis	CELL			English	Article							SYNAPTONEMAL COMPLEX-FORMATION; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; ESCHERICHIA-COLI; GENE-EXPRESSION; SHUTTLE VECTORS; RECA HOMOLOGS; DNA-REPAIR; YEAST	We describe the identification and characterization of the Saccharomyces cerevisiae ZIP2 gene, which encodes a novel meiosis-specific protein essential for synaptonemal complex formation. In the zip2 mutant, chromosomes are homologously paired but not synapsed. The Zip2 protein localizes to discrete foci on meiotic chromosomes; these foci correspond to sites of convergence between paired homologs that are believed to be sites of synapsis initiation. Localization of Zip2p requires the initiation of meiotic recombination. In a mutant defective in double-strand break repair, Zip2p colocalizes with proteins involved in double-strand break formation and processing. We propose that Zip2p promotes the initiation of chromosome synapsis and that localization of Zip2p to sites of interhomolog recombination ensures synapsis between homologous chromosomes.	Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Genet, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University	Chua, PR (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA.				NIGMS NIH HHS [GM28904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALBINI SM, 1987, CHROMOSOMA, V95, P324, DOI 10.1007/BF00293179; Anderson LK, 1997, P NATL ACAD SCI USA, V94, P6868, DOI 10.1073/pnas.94.13.6868; ANDERSON LK, 1988, CHROMOSOMA, V97, P96, DOI 10.1007/BF00331799; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BUCKINGHAM LE, 1990, P NATL ACAD SCI USA, V87, P9406, DOI 10.1073/pnas.87.23.9406; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; BYERS B, 1975, P NATL ACAD SCI USA, V72, P5056, DOI 10.1073/pnas.72.12.5056; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; Chua PR, 1997, GENE DEV, V11, P1786, DOI 10.1101/gad.11.14.1786; DEMASSY B, 1994, P NATL ACAD SCI USA, V91, P11929, DOI 10.1073/pnas.91.25.11929; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; GILBERTSON LA, 1994, P NATL ACAD SCI USA, V91, P11934, DOI 10.1073/pnas.91.25.11934; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; IVANOV EL, 1992, GENETICS, V132, P651; JOHZUKA K, 1995, GENETICS, V139, P1521; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KLECKNER N, 1991, COLD SH Q B, V56, P729; LOIDL J, 1994, J CELL BIOL, V125, P1191, DOI 10.1083/jcb.125.6.1191; LOIDL J, 1986, CHROMOSOMA, V93, P420, DOI 10.1007/BF00285824; McKee AHZ, 1997, GENETICS, V146, P797; MCKNIGHT GL, 1981, CELL, V25, P409, DOI 10.1016/0092-8674(81)90059-3; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; MOENS PB, 1969, CHROMOSOMA, V28, P1, DOI 10.1007/BF00325986; NAG DK, 1995, GENETICS, V141, P75; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; NEWLON CS, 1991, GENETICS, V129, P343; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Prinz S, 1997, GENETICS, V146, P781; RASMUSSEN SW, 1978, CARLSBERG RES COMMUN, V43, P275, DOI 10.1007/BF02906106; ROCKMILL B, 1995, GENE DEV, V9, P2684, DOI 10.1101/gad.9.21.2684; ROCKMILL B, 1990, GENETICS, V126, P563; ROCKMILL B, 1991, GENE DEV, V5, P2392, DOI 10.1101/gad.5.12b.2392; ROEDER GS, 1995, P NATL ACAD SCI USA, V92, P10450, DOI 10.1073/pnas.92.23.10450; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; Schwacha A, 1997, CELL, V90, P1123, DOI 10.1016/S0092-8674(00)80378-5; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; SEIFERT HS, 1986, GENETIC ENG PRINCIPL, P123; Sharpe PT, 1995, CONNECT TISSUE RES, V32, P17, DOI 10.3109/03008209509013701; Sherman F., 1986, METHODS YEAST GENETI; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; STACK S, 1986, CHROMOSOMA, V94, P253, DOI 10.1007/BF00290853; Storlazzi A, 1996, P NATL ACAD SCI USA, V93, P9043, DOI 10.1073/pnas.93.17.9043; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1995, J CELL BIOL, V128, P455, DOI 10.1083/jcb.128.4.455; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; Tettelin H, 1997, NATURE, V387, P81, DOI 10.1038/387s081; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; TUNG KS, 1998, IN PRESS GENETICS; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; ZICKLER D, 1992, GENETICS, V132, P135	66	188	190	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1998	93	3					349	359		10.1016/S0092-8674(00)81164-2	http://dx.doi.org/10.1016/S0092-8674(00)81164-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590170	hybrid			2022-12-01	WOS:000073471500011
J	Fabbri, S; Fruscoloni, P; Bufardeci, E; Negri, EDN; Baldi, MI; Attardi, DG; Mattoccia, E; Tocchini-Valentini, GP				Fabbri, S; Fruscoloni, P; Bufardeci, E; Negri, EDN; Baldi, MI; Attardi, DG; Mattoccia, E; Tocchini-Valentini, GP			Conservation of substrate recognition mechanisms by tRNA splicing endonucleases	SCIENCE			English	Article							INTRON	Accuracy in transfer RNA (tRNA) splicing is essential for the formation of functional tRNAs, and hence for gene expression, in both Eukaryotes and Archaea. The specificity for recognition of the tRNA precursor (pre-tRNA) resides in the endonuclease, which removes the intron by making two independent endonucleolytic cleavages. Although the eukaryal and archaeal enzymes appear to use different features of pre-tRNAs to determine the sites of cleavage, analysis of hybrid pre-tRNA substrates containing eukaryal and archaeal sequences, described here, reveals that the eukaryal enzyme retains the ability to use the archaeal recognition signals. This result indicates that there may be a common ancestral mechanism for recognition of pre-tRNA by proteins.	CNR, Ist Biol Cellulare, I-00137 Rome, Italy; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Ist Guido Donegani SpA, EniChem, Lab Biotecnol, I-00015 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Chicago	Tocchini-Valentini, GP (corresponding author), CNR, Ist Biol Cellulare, Viale Marx 43, I-00137 Rome, Italy.		Di Nicola Negri, Elisa/G-2251-2014	Di Nicola, Elisa/0000-0003-3659-9708				ATTARDI DG, 1989, METHOD ENZYMOL, V181, P510; BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; Belfort M, 1997, CELL, V89, P1003, DOI 10.1016/S0092-8674(00)80287-1; Li H, 1998, SCIENCE, V280, P279, DOI 10.1126/science.280.5361.279; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; Negri ED, 1997, CELL, V89, P859, DOI 10.1016/S0092-8674(00)80271-8; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; THOMPSON LD, 1990, J BIOL CHEM, V265, P18104; THOMPSON LD, 1988, J BIOL CHEM, V263, P1751; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6	10	50	55	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					284	286		10.1126/science.280.5361.284	http://dx.doi.org/10.1126/science.280.5361.284			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535657				2022-12-01	WOS:000073082400050
J	Li, H; Trotta, CR; Abelson, J				Li, H; Trotta, CR; Abelson, J			Crystal structure and evolution of a transfer RNA splicing enzyme	SCIENCE			English	Article							PROTEIN MODELS; RECOGNITION; GENES; CONFORMATION; BACTERIA; INTRONS	The splicing of transfer RNA precursors is similar in Eucarya and Archaea. In both kingdoms an endonuclease recognizes the splice sites and releases the intron, but the mechanism of splice site recognition is different in each kingdom. The crystal structure of the endonuclease from the archaeon Methanococcus jannaschii was determined to a resolution of 2.3 angstroms. The structure indicates that the cleavage reaction is similar to that of ribonuclease A and the arrangement of the active sites is conserved between the archaeal and eucaryal enzymes. These results suggest an evolutionary pathway for splice site recognition.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Abelson, J (corresponding author), CALTECH, Div Biol, Mail Code 147-75, Pasadena, CA 91125 USA.	abelson@cco.caltech.edu		Li, Hong/0000-0003-2046-9861	NIGMS NIH HHS [F32 GM188930-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BINISZKIEWICZ D, 1994, EMBO J, V13, P4629, DOI 10.1002/j.1460-2075.1994.tb06785.x; BLAKE CCF, 1974, J MOL BIOL, V88, P1, DOI 10.1016/0022-2836(74)90291-5; BRUNGER AT, 1996, XPLOR VERSION 3 1 SY; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; CULBERTSON MR, 1989, YEAST, V5, P405, DOI 10.1002/yea.320050602; DANIELS CJ, COMMUNICATION; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FABBRI S, 1998, IN PRESS SCIENCE; HO CK, 1990, EMBO J, V9, P1245, DOI 10.1002/j.1460-2075.1990.tb08232.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KJERNS J, 1989, CAN J MICROBIOL, V35, P210; KlemanLeyer K, 1997, CELL, V89, P839, DOI 10.1016/S0092-8674(00)80269-X; KRAUT J, 1962, P NATL ACAD SCI USA, V48, P1417, DOI 10.1073/pnas.48.8.1417; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LESLIE AGW, 1996, CCP4 ESF EACMB NEWSL, V32, P2; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; LykkeAndersen J, 1997, EMBO J, V16, P6290, DOI 10.1093/emboj/16.20.6290; Minor W., 1993, XDISPLAYF PROGRAM; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PALMER JR, 1992, BIOCHIM BIOPHYS ACTA, V1132, P315, DOI 10.1016/0167-4781(92)90168-Y; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P34; THOMPSON LD, 1990, J BIOL CHEM, V265, P18104; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; TROTTA CR, UNPUB; WALSH CT, 1979, ENZYMATIC REACTION M; Westaway Shawn K., 1995, P79	38	116	124	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1998	280	5361					279	284		10.1126/science.280.5361.279	http://dx.doi.org/10.1126/science.280.5361.279			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535656				2022-12-01	WOS:000073082400049
J	Palella, FJ; Delaney, KM; Moorman, AC; Loveless, MO; Fuhrer, J; Satten, GA; Aschman, DJ; Holmberg, SD				Palella, FJ; Delaney, KM; Moorman, AC; Loveless, MO; Fuhrer, J; Satten, GA; Aschman, DJ; Holmberg, SD		HIV Outpatient Study Investigators	Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DYNAMICS IN-VIVO; HIV-1 INFECTION; CLINICAL-PRACTICE; CUBIC MILLIMETER; THERAPY; ZIDOVUDINE; PLASMA; COUNTS; MARKERS; ADULTS	Background and Methods National surveillance data show recent, marked reductions in morbidity and mortality associated with the acquired immunodeficiency syndrome (AIDS). To evaluate these declines, we analyzed data on 1255 patients, each of whom had at least one CD4+ count below 100 cells per cubic millimeter, who were seen at nine clinics specializing in the treatment of human immunodeficiency virus (HIV) infection in eight U.S. cities from January 1994 through June 1997. Results Mortality among the patients declined from 29.4 per 100 person-years in 1995 to 8.8 per 100 person-years in the second quarter of 1997. There were reductions in mortality regardless of sex, race, age, and risk factors for transmission of HIV. The incidence of any of three major opportunistic infections (Pneumocystis carinii pneumonia, Mycobacterium avium complex disease, and cytomegalovirus retinitis) declined from 21.9 per 100 person-years in 1994 to 3.7 per 100 person-years by mid-1997. In a failure-rate model, increases in the intensity of antiretroviral therapy (classified as none, monotherapy, combination therapy without a protease inhibitor, and combination therapy with a protease inhibitor) were associated with stepwise reductions in morbidity and mortality. Combination antiretroviral therapy was associated with the most benefit; the inclusion of protease inhibitors in such regimens conferred additional benefit. Patients with private insurance were more often prescribed protease inhibitors and had lower mortality rates than those insured by Medicare or Medicaid. Conclusions The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies. (C) 1998, Massachusetts Medical Society.	Northwestern Univ, Sch Med, Chicago, IL 60611 USA; Hlth Res Network Apache Med Syst, Chicago, IL USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; SUNY Stony Brook, Stony Brook, NY 11794 USA	Northwestern University; Centers for Disease Control & Prevention - USA; Oregon Health & Science University; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Palella, FJ (corresponding author), Northwestern Univ, Sch Med, 303 E Super St,Passavant Pavil,Rm 828, Chicago, IL 60611 USA.			Moorman, Anne/0000-0003-2411-2798; Satten, Glen/0000-0001-7275-5371	PHS HHS [UC64/CCU5096889-03] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; Bartlett JA, 1996, ANN INTERN MED, V125, P161, DOI 10.7326/0003-4819-125-3-199608010-00001; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; CHAISSON MA, 1997, 4 C RETR OPP INF WAS, P133; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; GULICK R, 1996, 11 INT C AIDS VANC S, P19; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Ho DD, 1996, SCIENCE, V272, P1124, DOI 10.1126/science.272.5265.1124; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; MARKSON LE, 1994, ARCH INTERN MED, V154, P1497, DOI 10.1001/archinte.154.13.1497; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MOUTON Y, 1997, 4 C RETR OPP INF WAS; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; SELIGMANN M, 1994, LANCET, V343, P871; Torres RA, 1997, NEW ENGL J MED, V336, P1531, DOI 10.1056/NEJM199705223362118; 1997, MMWR MORB MORTAL WKL, V46, P165	27	7470	7698	10	784	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1998	338	13					853	860		10.1056/NEJM199803263381301	http://dx.doi.org/10.1056/NEJM199803263381301			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD284	9516219				2022-12-01	WOS:000072669800001
J	Cheng, CH; Kussie, P; Pavletich, N; Shuman, S				Cheng, CH; Kussie, P; Pavletich, N; Shuman, S			Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases	CELL			English	Article							ACTIVE-SITE; ESCHERICHIA-COLI; FLP RECOMBINASE; STRAND CLEAVAGE; DNA CLEAVAGE; DUPLEX DNA; PROTEIN; MUTANTS; BINDING; RESOLUTION	Vaccinia DNA topoisomerase breaks and rejoins DNA strands through a DNA-(3'-phosphotyrosyl)-enzyme intermediate. A C-terminal catalytic domain, Topo(81-314), suffices for transesterification chemistry. The domain contains a constellation of five amino acids, conserved in all eukaryotic type IB topoisomerases, that catalyzes attack of the tyrosine nucleophile on the scissile phosphate. The structure of the catalytic domain, consisting of ten alpha helices and a three-strand beta sheet, resembles the catalytic domains of site-specific recombinases that act via a topoisomerase IB-like mechanism. The topoisomerase catalytic pentad is conserved in the tertiary structures of the recombinases despite scant sequence similarity overall. This implies that the catalytic domains of type IB topoisomerases and recombinases derive from a common ancestral strand transferase.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Sloan Kettering Inst, Cellular Biochem Program, New York, NY 10021 USA; Sloan Kettering Inst, Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.				NIGMS NIH HHS [GM46330] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI K, 1986, J BIOL CHEM, V261, P391; BRUNGER AT, 1991, X PLOR SYSTEM CRYSTA; Caron P R, 1994, Adv Pharmacol, V29B, P271; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; Cornet F, 1997, J BIOL CHEM, V272, P21927, DOI 10.1074/jbc.272.35.21927; ENG W, 1989, J BIOL CHEM, V262, P13373; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HAN YPW, 1993, EMBO J, V12, P4577, DOI 10.1002/j.1460-2075.1993.tb06146.x; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JAXEL C, 1991, J BIOL CHEM, V266, P20418; Jensen AD, 1996, EUR J BIOCHEM, V236, P389, DOI 10.1111/j.1432-1033.1996.00389.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LEE J, 1993, J BIOL CHEM, V268, P17564; Lue N, 1995, STRUCTURE, V3, P1315, DOI 10.1016/S0969-2126(01)00269-6; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; Petersen BO, 1996, J MOL BIOL, V263, P181, DOI 10.1006/jmbi.1996.0568; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; Petersen BO, 1997, VIROLOGY, V230, P197, DOI 10.1006/viro.1997.8495; Rothenberg ML, 1997, ANN ONCOL, V8, P837, DOI 10.1023/A:1008270717294; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P3649, DOI 10.1093/nar/25.18.3649; Sekiguchi J, 1996, J BIOL CHEM, V271, P19436, DOI 10.1074/jbc.271.32.19436; Sekiguchi JA, 1996, P NATL ACAD SCI USA, V93, P785, DOI 10.1073/pnas.93.2.785; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; Shuman S, 1997, EMBO J, V16, P6584, DOI 10.1093/emboj/16.21.6584; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; SHUMAN S, 1991, P NATL ACAD SCI USA, V88, P10104, DOI 10.1073/pnas.88.22.10104; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; SHUMAN S, 1997, P NATL ACAD SCI USA, V16, P6584; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Tirumalai RS, 1997, P NATL ACAD SCI USA, V94, P6104, DOI 10.1073/pnas.94.12.6104; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang LK, 1997, BIOCHEMISTRY-US, V36, P3909, DOI 10.1021/bi962754p; Wang LK, 1997, BIOCHEMISTRY-US, V36, P7944, DOI 10.1021/bi970498q; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; Yang W, 1997, STRUCTURE, V5, P1401, DOI 10.1016/S0969-2126(97)00290-6	55	206	227	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					841	850		10.1016/S0092-8674(00)81411-7	http://dx.doi.org/10.1016/S0092-8674(00)81411-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529259	Bronze			2022-12-01	WOS:000072661200016
J	Sclavi, B; Sullivan, M; Chance, MR; Brenowitz, M; Woodson, SA				Sclavi, B; Sullivan, M; Chance, MR; Brenowitz, M; Woodson, SA			RNA folding at millisecond intervals by synchrotron hydroxyl radical footprinting	SCIENCE			English	Article							GROUP-I RIBOZYME; TETRAHYMENA RIBOZYME; TERTIARY STRUCTURE; RIBONUCLEIC-ACID; DOMAIN; KINETICS; MOLECULE; CLEAVAGE; PATHWAY	Radiolysis of water with a synchrotron x-ray beam permits the hydroxyl radical-accessible surface of an RNA to be mapped with nucleotide resolution in 10 milliseconds. Application of this method to folding of the Tetrahymena ribozyme revealed that the most stable domain of the tertiary structure, P4-P6, formed cooperatively within 3 seconds. Exterior helices became protected from hydroxyl radicals in 10 seconds, whereas the catalytic center required minutes to be completely folded. The results show that rapid collapse to a partially disordered state is followed by a slow search for the active structure.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Ctr Synchrotron Biosci, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Ctr Synchrotron Biosci, Bronx, NY 10461 USA; Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University System of Maryland; University of Maryland College Park	Chance, MR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Ctr Synchrotron Biosci, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Sclavi, Bianca/AAT-4554-2021; sclavi, bianca/F-8536-2010	Sclavi, Bianca/0000-0002-3883-8592; Woodson, Sarah/0000-0003-0170-1987	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039929, R01GM052348, R01GM039929] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39929, GM51506, GM52348] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE AR, 1995, BIOCHEMISTRY-US, V34, P6504, DOI 10.1021/bi00019a031; BREHM SL, 1983, BIOCHEMISTRY-US, V22, P2390, DOI 10.1021/bi00279a014; Cate JH, 1997, NAT STRUCT BIOL, V4, P553, DOI 10.1038/nsb0797-553; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1996, NUCL ACIDS MOL BIOL, V10, P1; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; Chance MR, 1997, STRUCTURE, V5, P865, DOI 10.1016/S0969-2126(97)00241-4; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4358, DOI 10.1021/bi00773a024; CROTHERS DM, 1974, J MOL BIOL, V87, P63, DOI 10.1016/0022-2836(74)90560-9; Doherty EA, 1997, BIOCHEMISTRY-US, V36, P3159, DOI 10.1021/bi962428+; DOUDNA JA, 1995, RNA, V1, P31; Downs WD, 1996, RNA, V2, P718; Draper DE, 1996, NAT STRUCT BIOL, V3, P397, DOI 10.1038/nsb0596-397; EMERICK VL, 1994, P NATL ACAD SCI USA, V91, P9675, DOI 10.1073/pnas.91.21.9675; JAEGER L, 1996, NUCL ACIDS MOL BIOL, V10, P34; LAGGERBAUER B, 1994, EMBO J, V13, P2699; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; Lehnert V, 1996, CHEM BIOL, V3, P993, DOI 10.1016/S1074-5521(96)90166-0; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; Pan J, 1997, J MOL BIOL, V273, P7, DOI 10.1006/jmbi.1997.1311; PRICE MA, 1992, METHOD ENZYMOL, V212, P194; Sclavi B, 1997, J MOL BIOL, V266, P144, DOI 10.1006/jmbi.1996.0775; SCLAVI B, IN PRESS METHODS ENZ; Thirumalai D, 1996, ACCOUNTS CHEM RES, V29, P433, DOI 10.1021/ar9500933; Treiber DK, 1998, SCIENCE, V279, P1943, DOI 10.1126/science.279.5358.1943; TULIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469; Zarrinkar PP, 1996, RNA, V2, P564; Zarrinkar PP, 1996, NAT STRUCT BIOL, V3, P432, DOI 10.1038/nsb0596-432; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	33	328	335	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1940	1943		10.1126/science.279.5358.1940	http://dx.doi.org/10.1126/science.279.5358.1940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506944				2022-12-01	WOS:000072613300047
J	Yeh, WC; de la Pompa, JL; McCurrach, ME; Shu, HB; Elia, AJ; Shahinian, A; Ng, M; Wakeham, A; Khoo, W; Mitchell, K; El-Deiry, WS; Lowe, SW; Goeddel, DV; Mak, TW				Yeh, WC; de la Pompa, JL; McCurrach, ME; Shu, HB; Elia, AJ; Shahinian, A; Ng, M; Wakeham, A; Khoo, W; Mitchell, K; El-Deiry, WS; Lowe, SW; Goeddel, DV; Mak, TW			FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis	SCIENCE			English	Article							DOMAIN-CONTAINING RECEPTOR; DEATH-DOMAIN; PROTEIN; CELLS; CD95; INTERACTS; GENES; MICE; FAS	FADD (also known as Mort-1) is a signal transducer downstream of cell death receptor CD95 (also called Fas), CD95, tumor necrosis factor receptor type 1 (TNFR-1), and death receptor 3 (DR3) did not induce apoptosis in FADD-deficient embryonic fibroblasts, whereas DR4, oncogenes E1A and c-myc, and chemotherapeutic agent adriamycin did. Mice with a deletion in the FADD gene did not survive beyond day 11.5 of embryogenesis; these mice showed signs of cardiac failure and abdominal hemorrhage. Chimeric embryos showing a high contribution of FADD null mutant cells to the heart reproduce the phenotype of FADD-deficient mutants. Thus, not only death receptors, but also receptors that couple to developmental programs, may use FADD for signaling.	Univ Toronto, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Cold Spring Harbor Labs, Cold Spring Harbor, NY 11724 USA; Tularik, S San Francisco, CA 94080 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; University of Pennsylvania	Mak, TW (corresponding author), Univ Toronto, Amgen Inst, 610 Univ Ave, Toronto, ON M5G 2C1, Canada.		El-Deiry, Wafik/AAJ-6080-2020; De La Pompa, José Luis/F-9719-2014	El-Deiry, Wafik/0000-0002-9577-8266; De La Pompa, José Luis/0000-0001-6761-7265	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, CELL, V270, P803; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MCCURRACH ME, UNPUB; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; MOENS CB, 1993, DEVELOPMENT, V119, P485; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YEH WJ, UNPUB	29	778	805	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1954	1958		10.1126/science.279.5358.1954	http://dx.doi.org/10.1126/science.279.5358.1954			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506948				2022-12-01	WOS:000072613300051
J	Nyquist, AC; Gonzales, R; Steiner, JF; Sande, MA				Nyquist, AC; Gonzales, R; Steiner, JF; Sande, MA			Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; YOUNG-CHILDREN; DAY-CARE; EXPECTATIONS; CARRIAGE	Context.-The spread of antibiotic-resistant bacteria is associated with antibiotic use. Children receive a significant proportion of the antibiotics prescribed each year and represent an important target group for efforts aimed at reducing unnecessary antibiotic use. Objective.-To evaluate antibiotic-prescribing practices for children younger than 18 years who had received a diagnosis of cold, upper respiratory tract infection (URI), or bronchitis in the United States. Design.-Representative national survey of practicing physicians participating in the National Ambulatory Medical Care Survey conducted in 1992 with a response rate of 73%. Setting.-Office-based physician practices. Participants.-Physicians completing patient record forms for patients younger than 18 years. Main Outcome Measures.-Principal diagnoses and antibiotic prescriptions. Results.-A total of 531 pediatric office visits were recorded that included a principal diagnosis of cold, URI, or bronchitis, Antibiotics were prescribed to 44% of patients with common colds, 46% with URIs, and 75% with bronchitis. Extrapolating to the United States, 6.5 million prescriptions (12% of all prescriptions for children) were written for children diagnosed as having a URI or nasopharyngitis (common cold), and 4.7 million (9% of all prescriptions for children) were written for children diagnosed as having bronchitis. After controlling for confounding factors, antibiotics were prescribed more often for children aged 5 to 11 years than for younger children (odds ratio [OR], 1.94; 95% confidence interval [CI], 1.13-3.33) and rates were lower for pediatricians than for nonpediatricians (OR, 0.57; 95% CI, 0.35-0.92), Children aged 0 to 4 years received 53% of all antibiotic prescriptions, and otitis media was the most frequent diagnosis for which antibiotics were prescribed (30% of all prescriptions). Conclusions.-Antibiotic prescribing for children diagnosed as having colds, URIs, and bronchitis, conditions that typically do not benefit from antibiotics, represents a substantial proportion of total antibiotic prescriptions to children in the United States each year.	Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Div Infect Dis, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Utah System of Higher Education; University of Utah	Gonzales, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Box B-180,4200 E 9th Ave, Denver, CO 80262 USA.	Ralph.Gonzales@uchsc.edu			BHP HRSA HHS [5 T32 PE10006-04] Funding Source: Medline	BHP HRSA HHS		Arnold KE, 1996, J PEDIATR-US, V128, P757, DOI 10.1016/S0022-3476(96)70326-8; BAUCHNER H, 1997, AMBUL CHILD HLTH, V3, P171; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; GADOMSKI AM, 1993, PEDIATR INFECT DIS J, V12, P115, DOI 10.1097/00006454-199302000-00002; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; GROB PR, 1992, SCAND J INFECT DIS, P7; Hamm R M, 1996, J Okla State Med Assoc, V89, P267; Hamm RM, 1996, J FAM PRACTICE, V43, P56; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; Holmes Sandra J., 1997, Pediatric Research, V41, p122A; HOWIE JGR, 1983, SCAND J INFECT DIS, P68; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; Mainous AG, 1996, J FAM PRACTICE, V42, P357; Mainous AG, 1997, LANCET, V350, P1077, DOI 10.1016/S0140-6736(05)70457-8; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SCHAPPERT SM, 1994, ADV DATA VITAL HLTH, V5253; Schwartz RH, 1997, PEDIATR INFECT DIS J, V16, P185, DOI 10.1097/00006454-199702000-00004; SOYKA LF, 1975, PEDIATRICS, V55, P552; *US DEP HHS, 1988, INT CLASS DIS 9 REV; VINSON DC, 1993, J FAM PRACTICE, V37, P23	21	509	534	2	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					875	877		10.1001/jama.279.11.875	http://dx.doi.org/10.1001/jama.279.11.875			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA943	9516004				2022-12-01	WOS:000072417600036
J	Nightingale, SL				Nightingale, SL			Teleconference on natural rubber/latex allergy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2022-12-01	WOS:000072192800007
J	Whited, JD; Grichnik, JM				Whited, JD; Grichnik, JM			Does this patient have a mole or a melanoma?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CUTANEOUS MALIGNANT-MELANOMA; BENIGN PIGMENTED LESIONS; PRIMARY-CARE PHYSICIANS; 7-POINT CHECKLIST; SKIN-CANCER; GENERAL-PRACTITIONERS; MELANOCYTIC NEVI; DYSPLASTIC NEVI; HIGH-RISK; DIAGNOSIS	Lifetime risk for malignant melanoma has increased from 1 in 1500 in the United States in 1930 to 1 in 75 projected for the year 2000, Because the tumor's thickness at excision is the primary prognostic determinant, early detection through the history and physical examination can play an important role in the patient's clinical course, Two checklists have been developed as diagnostic aids, the ABCD (A indicates asymmetry; B, border irregularity; C, irregular color; and D, diameter >6 mm) and the revised 7-point checklists, These checklists should be interpreted with some discretion, but 2 studies have found the sensitivity for the ABCD checklist to be 92% (95% confidence interval [CI], 82%-96%) and 100% (95% CI, 54%-100%); 1 study found the specificity to be 98% (95% CI, 95%-99%), The revised 7-point checklist has been reported to have a sensitivity of 79% (95% CI, 70%-85%) to 100% (95% CI, 94%-100%) and specificity of 30% (95% CI, 21%-39%) to 37% (95% CI, 28%-46%), Physicians' global assessments for detecting the presence or absence of melanoma are estimated to have a specificity of 96% to 99%, while sensitivity ranges widely from 50% to 97%. Nondermatologists' examinations appear to be less sensitive than examinations performed by dermatologists.	Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA; Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Dermatol, Durham, NC 27710 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; Duke University	Whited, JD (corresponding author), Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, 152,508 Fulton St, Durham, NC 27705 USA.		Grichnik, James/R-3887-2019	Grichnik, James/0000-0002-9185-0056				*AM AC DERM, 1996, PROGR SCREEN GUID NA, P37; BARNHILL RL, 1992, J AM ACAD DERMATOL, V26, P185, DOI 10.1016/0190-9622(92)70023-9; BARNHILL RL, 1993, DERMATOLOGY GEN MED, P1078; CASSILETH BR, 1986, J AM ACAD DERMATOL, V14, P555, DOI 10.1016/S0190-9622(86)70068-6; CURLEY RK, 1989, BRIT MED J, V299, P16, DOI 10.1136/bmj.299.6690.16; DAY CL, 1982, CA-CANCER J CLIN, V32, P113, DOI 10.3322/canjclin.32.2.113; DECOSTE SD, 1993, ARCH DERMATOL, V129, P57, DOI 10.1001/archderm.129.1.57; DUVIVIER AWP, 1991, CLIN EXP DERMATOL, V16, P344, DOI 10.1111/j.1365-2230.1991.tb00397.x; Elwood JM, 1988, PIGMENT CELL RES, V9, P118; FITZPATRICK TB, 1988, PIGMENT CELL, V9, P110; FRIEDMAN RJ, 1985, CA-CANCER J CLIN, V35, P130, DOI 10.3322/canjclin.35.3.130; Gerbert B, 1996, ARCH DERMATOL, V132, P1030, DOI 10.1001/archderm.132.9.1030; GREENE MH, 1985, ANN INTERN MED, V102, P458, DOI 10.7326/0003-4819-102-4-458; GRIN CM, 1990, ARCH DERMATOL, V126, P763, DOI 10.1001/archderm.126.6.763; HALL WH, 1992, JAMA-J AM MED ASSOC, V268, P1314, DOI 10.1001/jama.1992.03490100112037; HEALSMITH MF, 1994, BRIT J DERMATOL, V130, P48, DOI 10.1111/j.1365-2133.1994.tb06881.x; HIGGINS EM, 1992, CLIN EXP DERMATOL, V17, P313, DOI 10.1111/j.1365-2230.1992.tb00218.x; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; KEEFE M, 1990, CLIN EXP DERMATOL, V15, P167, DOI 10.1111/j.1365-2230.1990.tb02064.x; KOH HK, 1990, CANCER, V65, P375, DOI 10.1002/1097-0142(19900115)65:2<375::AID-CNCR2820650233>3.0.CO;2-Z; KOH HK, 1992, J AM ACAD DERMATOL, V26, P914, DOI 10.1016/0190-9622(92)70132-Y; Koh HK, 1996, J AM ACAD DERMATOL, V34, P971, DOI 10.1016/S0190-9622(96)90274-1; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; KROL S, 1991, ACTA DERM-VENEREOL, V71, P317; MACKIE RM, 1990, BRIT MED J, V301, P1005, DOI 10.1136/bmj.301.6759.1005; MASRI GD, 1990, J AM ACAD DERMATOL, V22, P1042, DOI 10.1016/0190-9622(90)70149-C; MCGEE R, 1994, NEW ZEAL MED J, V107, P287; MCGOVERN TW, 1992, J DERMATOL SURG ONC, V18, P22, DOI 10.1111/j.1524-4725.1992.tb03296.x; MCMULLAN FH, 1956, ARCH DERMATOL, V74, P618, DOI 10.1001/archderm.1956.01550120038009; Meyer LJ, 1996, J AM ACAD DERMATOL, V34, P618, DOI 10.1016/S0190-9622(96)80061-2; PAINE SL, 1994, MED J AUSTRALIA, V161, P188, DOI 10.5694/j.1326-5377.1994.tb127380.x; RAMSAY DL, 1981, ARCH DERMATOL, V117, P620, DOI 10.1001/archderm.117.10.620; RIES LA, 1991, CANC STAT REV 1973 1; Rigel DS, 1996, J AM ACAD DERMATOL, V34, P839, DOI 10.1016/S0190-9622(96)90041-9; RIGEL DS, 1989, CANCER, V63, P386, DOI 10.1002/1097-0142(19890115)63:2<386::AID-CNCR2820630231>3.0.CO;2-6; RIGEL DS, 1986, J AM ACAD DERMATOL, V14, P857, DOI 10.1016/S0190-9622(86)70100-X; SHAW HM, 1992, J AM ACAD DERMATOL, V27, P679, DOI 10.1016/0190-9622(92)70236-9; SWERDLOW AJ, 1986, BRIT MED J, V292, P1555, DOI 10.1136/bmj.292.6535.1555; TIERSTEN AD, 1991, J DERMATOL SURG ONC, V17, P44, DOI 10.1111/j.1524-4725.1991.tb01592.x; TITUSERNSTOFF L, 1989, CANCER DETECT PREV, V13, P317; Tucker MA, 1997, JAMA-J AM MED ASSOC, V277, P1439, DOI 10.1001/jama.277.18.1439; WICK MM, 1980, CANCER, V45, P2684, DOI 10.1002/1097-0142(19800515)45:10<2684::AID-CNCR2820451033>3.0.CO;2-2	42	73	77	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					696	701		10.1001/jama.279.9.696	http://dx.doi.org/10.1001/jama.279.9.696			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496989				2022-12-01	WOS:000072192800035
J	de Bruijn, SFTM; Stam, J; Koopman, MMW; Vandenbroucke, JP				de Bruijn, SFTM; Stam, J; Koopman, MMW; Vandenbroucke, JP		Cerebral Venous Sinus Thrombosis Study Grp	Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions	BRITISH MEDICAL JOURNAL			English	Article							PROTEIN-C; VENOUS THROMBOSIS; FACTOR-V; COAGULATION; PREVALENCE; DEFICIENCY	Objective: To investigate whether users of oral contraceptives who are carriers of a hereditary prothrombotic condition (factor V Leiden mutation, protein C, S, or antithrombin deficiency) have an increased risk of cerebral sinus thrombosis. Design: Comparison of a prospective series of cases of cerebral sinus thrombosis with population data. Setting: Neurological teaching hospitals from different regions in the Netherlands (cases) and a representative sample of the non-institutionalised Dutch population (controls). Subjects: 40 women aged 18-54 years with cerebral sinus thrombosis (cases) and 2248 women aged 18-49 years (controls). Main outcome measure: Current use of oral contraceptives at the time of the thrombosis (cases) or at the time of the questionnaire (controls), Prevalences of a hereditary prothrombotic condition in patients and in the population with odds ratios. Results: 34 of 40 (85%) women with cerebral sinus thrombosis used oral contraceptives, versus 1007 of 2248 (45%) of the control women; the age adjusted odds ratio was 13 (95% confidence interval 5 to 37), Seven of 36 patients (19%) had a prothrombotic deficiency, versus 7% expected in the population; this corresponds to a threefold to fourfold increase in risk, Ln women who used oral contraceptives and also carried a prothrombotic defect, the odds ratio for cerebral sinus thrombosis was about 30 relative to women who had neither risk factor. Conclusion: The use of oral contraceptives and being a carrier of a hereditary prothrombotic condition increase the risk of and interact in a multiplicative way in the development of cerebral sinus thrombosis.	Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; Univ Leiden Hosp, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC)	Stam, J (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, POB 22700, NL-1100 DE Amsterdam, Netherlands.	j.stam@amc.uva.nl	Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				BOUSSER MG, 1985, STROKE, V16, P199, DOI 10.1161/01.STR.16.2.199; BOYER C, 1984, THROMB RES, V36, P579, DOI 10.1016/0049-3848(84)90197-X; *CBS, 1996, CENTR BUR STAT STAT, P502; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; Deschiens MA, 1996, STROKE, V27, P1724, DOI 10.1161/01.STR.27.10.1724; DEUTZTERLOUW PP, 1989, CLIN CHIM ACTA, V186, P321; HACHWUNDERLE V, 1993, DEUT MED WOCHENSCHR, V118, P187, DOI 10.1055/s-2008-1059317; PETERS M, 1982, THROMB RES, V28, P773, DOI 10.1016/0049-3848(82)90103-7; POULTER NR, 1995, LANCET, V346, P1575; Ridker PM, 1997, JAMA-J AM MED ASSOC, V277, P1305, DOI 10.1001/jama.277.16.1305; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; Statistics Netherlands, 1996, NETH HLTH INT SURV 1; TAIT RC, 1995, THROMB HAEMOSTASIS, V73, P87; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4	15	197	205	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					589	592		10.1136/bmj.316.7131.589	http://dx.doi.org/10.1136/bmj.316.7131.589			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518910	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000072213200027
J	Veit, B; Briggs, SP; Schmidt, RJ; Yanofsky, MF; Hake, S				Veit, B; Briggs, SP; Schmidt, RJ; Yanofsky, MF; Hake, S			Regulation of leaf initiation by the terminal ear 1 gene of maize	NATURE			English	Article							CELL-LINEAGE PATTERNS; SHOOT APICAL MERISTEM; EXPRESSION; PROTEINS; MEIOSIS	Higher plants elaborate much of their architecture post-embryonically through development initiated at the tips of shoots(1,2) During vegetative growth, leaf primordia arise at predictable sires to give characteristic leaf arrangements, or phyllotaxies(3,4). How these sites are determined is a long-standing question(5,6) that bears on the nature of pattern-formation mechanisms in plants, Fate-mapping studies in several species indicate that each leaf primordium becomes organized from a group of 100-200 cells on the flank of the shoot apes'. Although molecular studies indicate that the regulated expression of specific homeobox genes plays some part in this determination process(8-11), mechanisms that regulate the timing and position of leaf initiation are less well understood. Here we describe a gene from maize, terminal ear 1. Patterns of expression of this gene in the shoot and phenotypes of mutants indicate a role for terminal ear 1 in regulating leaf initiation. The te1 gene product contains conserved RNA-binding motifs, indicating that it may function through an RNA-binding activity.	Massey Univ, Inst Mol Biosci, Palmerston North, New Zealand; Univ Calif Berkeley, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Pioneer Hi Bred Int Inc, Johnston, IA 50131 USA	Massey University; United States Department of Agriculture (USDA); University of California System; University of California Berkeley; University of California System; University of California San Diego; DuPont; Pioneer Hi-Bred International, Inc.	Veit, B (corresponding author), Massey Univ, Inst Mol Biosci, Palmerston North, New Zealand.							BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHANDLER VL, 1992, ADV GENET, V30, P77, DOI 10.1016/S0065-2660(08)60319-3; CHURCH AH, 1904, RELATION PHYLLOTAXY; Doebley J, 1997, NATURE, V386, P485, DOI 10.1038/386485a0; ITIS H, 1983, SCIENCE, V222, P886; JACKSON D, 1994, DEVELOPMENT, V120, P405; KIESSELBACH TA, 1949, STRUCTURE REPRODUCTI; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; MATTHEWS DL, 1974, J AGR SCI-CAMBRIDGE, V82, P433, DOI 10.1017/S0021859600051327; MCDANIEL CN, 1988, PLANTA, V175, P13, DOI 10.1007/BF00402877; POETHIG RS, 1987, AM J BOT, V74, P581, DOI 10.2307/2443838; RICHARDS FJ, 1951, PHILOS T ROY SOC B, V235, P509, DOI 10.1098/rstb.1951.0007; Scanlon MJ, 1996, DEVELOPMENT, V122, P1683; SMITH LG, 1992, PLANT CELL, V4, P1017, DOI 10.1105/tpc.4.9.1017; SMITH LG, 1992, DEVELOPMENT, V116, P21; Steeves TA, 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; SUSSEX IM, 1989, CELL, V56, P225, DOI 10.1016/0092-8674(89)90895-7; WALBOT V, 1985, TRENDS GENET, V1, P165, DOI 10.1016/0168-9525(85)90071-X; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; WATANABE Y, 1988, EMBO J, V7, P761, DOI 10.1002/j.1460-2075.1988.tb02873.x; Watanabe Y, 1997, NATURE, V386, P187, DOI 10.1038/386187a0	23	105	118	2	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1998	393	6681					166	168		10.1038/30239	http://dx.doi.org/10.1038/30239			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN200	9603518				2022-12-01	WOS:000073619900047
J	Stanley, CA; Lieu, YK; Hsu, BYL; Burlina, AB; Greenberg, CR; Hopwood, NJ; Perlman, K; Rich, BH; Zammarchi, E; Poncz, M				Stanley, CA; Lieu, YK; Hsu, BYL; Burlina, AB; Greenberg, CR; Hopwood, NJ; Perlman, K; Rich, BH; Zammarchi, E; Poncz, M			Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SULFONYLUREA RECEPTOR GENE; INSULIN RELEASE; AMINO-ACID; HYPOGLYCEMIA; LEUCINE; ORGANIZATION; SITE	Background A new form of congenital hyperinsulinism characterized by hypoglycemia and hyperammonemia was described recently. We hypothesized that this syndrome of hyperinsulinism and hyperammonemia was caused by excessive activity of glutamate dehydrogenase, which oxidizes glutamate to alpha-ketoglutarate and which is a potential regulator of insulin secretion in pancreatic beta cells and of ureagenesis in the liver. Methods We measured glutamate dehydrogenase activity in lymphoblasts from eight unrelated children with the hyperinsulinism-hyperammonemia syndrome: six with sporadic cases and two with familial cases. We identified mutations in the glutamate dehydrogenase gene by sequencing glutamate dehydrogenase complementary DNA prepared from lymphoblast messenger RNA. Site-directed mutagenesis was used to express the mutations in COS-7 cells. Results The sensitivity of glutamate dehydrogenase to inhibition by guanosine 5'-triphosphate was a quarter of the normal level in the patients with sporadic hyperinsulinism-hyperammonemia syndrome and half the normal level in patients with familiar cases and their affected relatives, findings consistent with overactivity of the enzyme. These differences in enzyme insensitivity correlated with differences in the severity of hypoglycemia in the two groups. All eight children were heterozygous for the wild-type allele and had a mutation in the proposed allosteric domain of the enzyme. Four different mutations were identified in the six patients with sporadic cases; the two patients with familiar cases shared a fifth mutation. In two clones of COS-7 cells transfected with the mutant sequence from one patient, the sensitivity of the enzyme to guanosine 5'-triphosphate was reduced, findings similar to those in the child's lymphoblasts. Conclusions The hyperinsulinism-hyperammonemia syndrome is caused by mutations in the glutamate dehydrogenase gene that impair the control of enzyme activity. (C)1998, Massachusetts Medical Society.	Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Endocrinol, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Hematol, Philadelphia, PA 19104 USA; Univ Padua, Dept Pediat, Padua, Italy; Univ Manitoba, Dept Pediat & Child Hlth, Sect Genet & Metab, Winnipeg, MB R3T 2N2, Canada; Univ Michigan, CS Mott Childrens Hosp, Sch Med, Div Endocrinol, Ann Arbor, MI USA; Univ Toronto, Hosp Sick Children, Sch Med, Div Endocrinol, Toronto, ON M5G 1X8, Canada; Univ Chicago, Chicago Childrens Hosp, Pritzker Sch Med, Endocrinol Sect, Chicago, IL 60637 USA; Univ Florence, Dept Pediat, Florence, Italy	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Padua; University of Manitoba; University of Michigan System; University of Michigan; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Chicago; University of Florence	Stanley, CA (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Endocrinol, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.		burlina, alberto/AHE-6095-2022	STANLEY, CHARLES/0000-0003-4881-9392	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000240] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00240] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BRUNHUBER NMW, 1994, CRIT REV BIOCHEM MOL, V29, P415, DOI 10.3109/10409239409083486; BRUSILOW SW, 1995, METABOLIC BASIS INHE, V1, P1187; BRYLA J, 1994, METABOLISM, V43, P1187, DOI 10.1016/0026-0495(94)90064-7; Cho SW, 1996, BIOCHEMISTRY-US, V35, P13907, DOI 10.1021/bi9618575; COLMAN RF, 1991, STUDY ENZYMES, V2, P173; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; FAHIEN LA, 1981, ARCH BIOCHEM BIOPHYS, V212, P247, DOI 10.1016/0003-9861(81)90364-7; Glaser B, 1998, NEW ENGL J MED, V338, P226, DOI 10.1056/NEJM199801223380404; GYLFE E, 1976, ACTA DIABETOL LAT, V13, P20, DOI 10.1007/BF02591577; Kukuvitis A, 1997, J CLIN ENDOCR METAB, V82, P1192, DOI 10.1210/jc.82.4.1192; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSCHINSKY FM, 1996, DIABETES REV, V4, P130; MICHAELIDIS TM, 1993, GENOMICS, V16, P150, DOI 10.1006/geno.1993.1152; NAKATANI Y, 1988, NUCLEIC ACIDS RES, V16, P6237, DOI 10.1093/nar/16.13.6237; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; PERMUTT MA, 1996, DIABETES REV, V4, P347; Plaitakis A, 1993, Can J Neurol Sci, V20 Suppl 3, pS109; SENER A, 1980, NATURE, V288, P187, DOI 10.1038/288187a0; SENER A, 1981, P NATL ACAD SCI-BIOL, V78, P5460, DOI 10.1073/pnas.78.9.5460; Stanley CA, 1997, PEDIATR CLIN N AM, V44, P363, DOI 10.1016/S0031-3955(05)70481-8; STEWART PM, 1980, J BIOL CHEM, V255, P5270; TELLER JK, 1995, BBA-PROTEIN STRUCT M, V1247, P231, DOI 10.1016/0167-4838(94)00240-H; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; THORNTON PS, 1991, J PEDIATR-US, V119, P721, DOI 10.1016/S0022-3476(05)80286-0; Thornton PS, 1998, J PEDIATR-US, V132, P9, DOI 10.1016/S0022-3476(98)70477-9; Weinzimer SA, 1997, J PEDIATR-US, V130, P661, DOI 10.1016/S0022-3476(97)70256-7; WRZESZCZYNSKI KO, 1994, BIOCHEMISTRY-US, V33, P11544, DOI 10.1021/bi00204a017; Zammarchi E, 1996, METABOLISM, V45, P957, DOI 10.1016/S0026-0495(96)90262-0	30	517	543	1	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1998	338	19					1352	1357		10.1056/NEJM199805073381904	http://dx.doi.org/10.1056/NEJM199805073381904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL720	9571255				2022-12-01	WOS:000073463700004
J	Alroy, J				Alroy, J			Cope's rule and the dynamics of body mass evolution in North American fossil mammals	SCIENCE			English	Article							ISLAND RULE; SIZE; PHYLOGENY; TRENDS; RECORD	Body mass estimates for 1534 North American fossil mammal species show that new species are on average 9.1% larger than older species in the same genera. This within-lineage effect is not a sampling bias. It persists throughout the Cenozoic; accounting for the gradual overall increase in average mass (Cope's rule). The effect is stronger for larger mammals, being near zero for small mammals. This variation partially explains the unwavering lower size limit and the gradually expanding mid-sized gap, but not the sudden large increase in the upper size limit, at the Cretaceous-Tertiary boundary.	Smithsonian Inst, Dept Paleobiol, Washington, DC 20560 USA	Smithsonian Institution; Smithsonian National Museum of Natural History	Alroy, J (corresponding author), Smithsonian Inst, Dept Paleobiol, MRC 121, Washington, DC 20560 USA.		Alroy, John/B-4585-2009	Alroy, John/0000-0002-9882-2111				ALROY J, 1994, PALEOBIOLOGY, V20, P191, DOI 10.1017/S0094837300012677; Alroy J, 1996, PALAEOGEOGR PALAEOCL, V127, P285, DOI 10.1016/S0031-0182(96)00100-9; ALROY J, 1992, PALEOBIOLOGY, V18, P326, DOI 10.1017/S0094837300010873; ARNOLD AJ, 1995, J PALEONTOL, V69, P203, DOI 10.1017/S0022336000034557; Brown J.H., 1995, MACROECOLOGY; BROWN JH, 1991, AM NAT, V138, P1478, DOI 10.1086/285297; BROWN JH, 1986, NATURE, V324, P248, DOI 10.1038/324248a0; BROWN JH, 1993, AM NAT, V142, P574; Cope ED., 1887, ORIGIN FITTEST; DAMUTH J, 1993, NATURE, V365, P748, DOI 10.1038/365748a0; Damuth J., 1990, P229; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FISHER DC, 1994, INTERPRETING HIERARC, P133; Foote M, 1996, PALEOBIOLOGY, V22, P121, DOI 10.1017/S0094837300016134; Foote M, 1996, PALEOBIOLOGY, V22, P141, DOI 10.1017/S0094837300016146; GAUTHIER J, 1988, CLADISTICS, V4, P105, DOI 10.1111/j.1096-0031.1988.tb00514.x; Gingerich P.D., 1979, P41; GINGERICH PD, 1980, ANNU REV EARTH PL SC, V8, P407, DOI 10.1146/annurev.ea.08.050180.002203; GOULD SJ, 1988, J PALEONTOL, V62, P319, DOI 10.1017/S0022336000059126; Gunnell GF., 1989, U MICH PAP PALEONT, V27, P1; Gunnell Gregg F., 1996, Contributions from the Museum of Paleontology University of Michigan, V29, P413; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Hitchin R, 1997, PALEOBIOLOGY, V23, P20, DOI 10.1017/S0094837300016626; Huelsenbeck JP, 1997, PALEOBIOLOGY, V23, P174, DOI 10.1017/S0094837300016778; HUELSENBECK JP, 1994, PALEOBIOLOGY, V20, P470, DOI 10.1017/S009483730001294X; Jablonski D, 1997, NATURE, V385, P250, DOI 10.1038/385250a0; Jablonski David, 1996, P256; KURTEN BJORN, 1953, ACTA ZOOL FENNICA, V76, P1; Legendre S., 1986, Palaeovertebrata (Montpellier), V16, P191; Legendre S., 1988, Historical Biology, V1, P85; LOMOLINO MV, 1985, AM NAT, V125, P310, DOI 10.1086/284343; MacFadden B.J., 1990, P337; MACFADDEN BJ, 1986, PALEOBIOLOGY, V12, P355, DOI 10.1017/S0094837300003109; Martins E.P., 1996, PHYLOGENIES COMP MET; MAURER BA, 1992, EVOLUTION, V46, P939, DOI 10.1111/j.1558-5646.1992.tb00611.x; McKinney M.L., 1990, P75; MCKINNEY ML, 1986, PALEOBIOLOGY, V12, P282, DOI 10.1017/S0094837300013786; McNamara K.J., 1990, P205; MCSHEA DW, 1994, EVOLUTION, V48, P1747, DOI 10.1111/j.1558-5646.1994.tb02211.x; Miles DB, 1996, EVOLUTION, V50, P594, DOI 10.1111/j.1558-5646.1996.tb03871.x; NEWELL ND, 1949, EVOLUTION, V3, P103, DOI 10.2307/2405545; NORRIS RD, 1991, PALEOBIOLOGY, V17, P388, DOI 10.1017/S0094837300010721; RUMMEL JD, 1985, EVOLUTION, V39, P1009, DOI 10.1111/j.1558-5646.1985.tb00444.x; STANLEY SM, 1973, EVOLUTION, V27, P1, DOI 10.1111/j.1558-5646.1973.tb05912.x; Trammer J, 1997, ACTA PALAEONTOL POL, V42, P1; WAGNER PJ, 1995, PALEOBIOLOGY, V21, P153, DOI 10.1017/S009483730001318X; WILSON EO, 1959, EVOLUTION, V13, P122, DOI 10.2307/2405948; WING SL, 1995, PALAEOGEOGR PALAEOCL, V115, P117, DOI 10.1016/0031-0182(94)00109-L	48	339	346	0	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					731	734		10.1126/science.280.5364.731	http://dx.doi.org/10.1126/science.280.5364.731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563948	Green Submitted			2022-12-01	WOS:000073415600046
J	Doll, JJ				Doll, JJ			The patenting of DNA	SCIENCE			English	Editorial Material									US Patent & Trademark Off, Technol Ctr 1600, Washington, DC 20231 USA		Doll, JJ (corresponding author), US Patent & Trademark Off, Technol Ctr 1600, Washington, DC 20231 USA.							COLLINS FS, 1997, SCIENCE, V278, P180	1	61	65	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					689	690		10.1126/science.280.5364.689	http://dx.doi.org/10.1126/science.280.5364.689			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9599146				2022-12-01	WOS:000073415600030
J	Faundez, V; Horng, JT; Kelly, RB				Faundez, V; Horng, JT; Kelly, RB			A function for the AP3 coat complex in synaptic vesicle formation from endosomes	CELL			English	Article							GUINEA-PIG MEGAKARYOCYTE; ADP-RIBOSYLATION FACTOR; TRANSPORT VESICLES; GOLGI MEMBRANES; ENDOPLASMIC-RETICULUM; BREFELDIN-A; DEPENDENT FORMATION; GUANINE-NUCLEOTIDE; ARF PROTEIN; CLATHRIN	Synaptic vesicles can be coated in vitro in a reaction that is ARF-, ATP-, and temperature-dependent and requires synaptic vesicle membrane proteins. The coat is largely made up of the heterotetrameric complex, adaptor protein 3, recently implicated in Golgi-to-vacuole traffic in yeast. Depletion of AP3 from brain cytosol inhibits small vesicle formation from PC12 endosomes in vitro. Budding from washed membranes can be reconstituted with purified AP3 and recombinant ARF1. We conclude that AP3 coating is involved in at least one pathway of small vesicle formation from endosomes.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kelly, RB (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.		Faundez, Victor/H-5539-2012	Faundez, Victor/0000-0002-2114-5271	NIDA NIH HHS [DA10154] Funding Source: Medline; NINDS NIH HHS [NS09878, NS15927] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015927, R01NS009878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010154] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; DELLANGELICA EC, 1998, IN PRESS SCIENCE; DESNOS C, 1995, J CELL BIOL, V130, P1041, DOI 10.1083/jcb.130.5.1041; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Erickson RP, 1997, P NATL ACAD SCI USA, V94, P8924, DOI 10.1073/pnas.94.17.8924; Estes PS, 1996, J NEUROSCI, V16, P5443; FAUNDEZ V, 1992, J BIOL CHEM, V267, P20363; Faundez V, 1997, J CELL BIOL, V138, P505, DOI 10.1083/jcb.138.3.505; FRANCO M, 1993, J BIOL CHEM, V268, P24531; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; HANDAGAMA P, 1993, J CLIN INVEST, V91, P193, DOI 10.1172/JCI116170; HANDAGAMA PJ, 1989, J CLIN INVEST, V84, P73, DOI 10.1172/JCI114173; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LEPOOLE IC, 1993, EXP CELL RES, V205, P388, DOI 10.1006/excr.1993.1102; LERNER AB, 1979, COLD SPRING HARBOR C, V6, P187; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; NOEBELS JL, 1989, J NEUROGENET, V6, P53, DOI 10.3109/01677068909107100; OKA T, 1994, J CELL BIOL, V124, P25; Ooi CE, 1997, EMBO J, V16, P4508; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PEVSNER J, 1994, GENE, V146, P279, DOI 10.1016/0378-1119(94)90306-9; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHRAERMEYER U, 1994, CELL TISSUE RES, V276, P273, DOI 10.1007/BF00306113; Seymour A. B., 1997, Molecular Biology of the Cell, V8, p227A; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; VANDEGOOR J, 1995, P NATL ACAD SCI USA, V92, P5739, DOI 10.1073/pnas.92.12.5739; WAGNER JA, 1978, BIOCHEMISTRY-US, V17, P1199, DOI 10.1021/bi00600a010; WHITNEY JA, 1995, CELL, V83, P703; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	60	239	244	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 1	1998	93	3					423	432		10.1016/S0092-8674(00)81170-8	http://dx.doi.org/10.1016/S0092-8674(00)81170-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590176	Bronze			2022-12-01	WOS:000073471500017
J	Rodig, SJ; Meraz, MA; White, JM; Lampe, PA; Riley, JK; Arthur, CD; King, KL; Sheehan, KCF; Yin, L; Pennica, D; Johnson, EM; Schreiber, RD				Rodig, SJ; Meraz, MA; White, JM; Lampe, PA; Riley, JK; Arthur, CD; King, KL; Sheehan, KCF; Yin, L; Pennica, D; Johnson, EM; Schreiber, RD			Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the jaks in cytokine-lnduced biologic responses	CELL			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION PATHWAY; LEUKEMIA INHIBITORY FACTOR; MICE LACKING JAK3; TARGETED DISRUPTION; INTERFERON-GAMMA; LYMPHOID DEVELOPMENT; INTERLEUKIN-6 FAMILY; CYTOPLASMIC DOMAIN; FACTOR-RECEPTOR	Herein we report the generation of mice lacking the ubiquitously expressed Janus kinase, Jak1. Jak1(-/-) mice are runted at birth, fail to nurse, and die perinatally. Although Jak1(-/-) cells are responsive to many cytokines, they fail to manifest biologic responses to cytokines that bind to three distinct families of cytokine receptors. These include all class II cytokine receptors, cytokine receptors that utilize the gamma(c) subunit for signaling, and the family of cytokine receptors that depend on the gp130 subunit for signaling. Our results thus demonstrate that Jak1 plays an essential and nonredundant role in promoting biologic responses induced by a select subset of cytokine receptors, including those in which Jak utilization was thought to be nonspecific.	Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, S San Francisco, CA 94080 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Roche Holding; Genentech; Roche Holding; Genentech	Schreiber, RD (corresponding author), Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA.		MERAZ RIOS, MARCO ANTONIO/F-4194-2016; Lampe, Patricia/AAH-9545-2020; Rodig, Scott/Y-3889-2019; Schreiber, Robert/Q-7550-2019; Schreiber, Robert D/A-1276-2013	MERAZ RIOS, MARCO ANTONIO/0000-0001-6748-8117; Schreiber, Robert D/0000-0001-6311-0432; Schreiber, Robert/0000-0003-1590-2341; White, James Michael/0000-0001-5110-6567	NCI NIH HHS [CA43059] Funding Source: Medline; NIA NIH HHS [AG12947] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043059, R37CA043059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012947] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DIGHE AS, 1995, IMMUNITY, V3, P657, DOI 10.1016/1074-7613(95)90136-1; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRIBAUDO G, 1985, J BIOL CHEM, V260, P9936; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HO ASY, 1995, MOL CELL BIOL, V15, P5043; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; King KL, 1996, ENDOCRINE, V5, P85, DOI 10.1007/BF02738660; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; Leonard WJ, 1995, IMMUNOL REV, V148, P97, DOI 10.1111/j.1600-065X.1995.tb00095.x; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SUDA T, 1989, BLOOD, V74, P1936; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WARE CB, 1995, DEVELOPMENT, V121, P1283; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	37	629	736	1	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 1	1998	93	3					373	383		10.1016/S0092-8674(00)81166-6	http://dx.doi.org/10.1016/S0092-8674(00)81166-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590172	Bronze			2022-12-01	WOS:000073471500013
J	Eberstadt, M; Huang, BH; Chen, ZH; Meadows, RP; Ng, SC; Zheng, LX; Lenardo, MJ; Fesik, SW				Eberstadt, M; Huang, BH; Chen, ZH; Meadows, RP; Ng, SC; Zheng, LX; Lenardo, MJ; Fesik, SW			NMR structure and mutagenesis of the FADD (Mort1) death-effector domain	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CELL-DEATH; PROTEINS; PROTEASE; FAS; INTERACTS; C-13	When activated, membrane-bound receptors for Fas and tumour-necrosis factor initiate programmed cell death by recruiting the death domain of the adaptor protein FADD(1) (Mort1; ref, 2) to the membrane. FADD then activates caspase 8 (ref. 3) (also known as FLICE4 or MACH(5)) through an interaction between the death-effector domains of FADD and caspase 8. This ultimately leads to the apoptotic response. Death-effector domains and homologous protein modules known as caspase-recruitment domains(6) have been found in several proteins(1-14) and are important regulators of caspase (FLICE) activity and of apoptosis. Here we describe the solution structure of a soluble, biologically active mutant of the FADD death-effector domain. The structure consists of six antiparallel, amphipathic alpha-helices and resembles the overall fold of the death domains of Fas(15) and p75 (ref. 16). Despite this structural similarity, mutations that inhibit protein-protein interactions involving the Fas death domain have no effect when introduced into the FADD death-effector domain. Instead, a hydrophobic region of the FADD death-effector domain that is not present in the death domains is vital for binding to FLICE and for apoptotic activity.	Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA; NIH, Immunol Lab, Bethesda, MD 20892 USA	Abbott Laboratories; National Institutes of Health (NIH) - USA	Fesik, SW (corresponding author), Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRUNGER AT, 1992, XPLOR 3 2 MANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Eberstadt M, 1997, NAT STRUCT BIOL, V4, P983, DOI 10.1038/nsb1297-983; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Keane MM, 1996, CANCER RES, V56, P4791; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005	28	195	203	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					941	945		10.1038/31972	http://dx.doi.org/10.1038/31972			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582077				2022-12-01	WOS:000073359900054
J	Cebul, RD; Snow, RJ; Pine, R; Hertzer, NR; Norris, DG				Cebul, RD; Snow, RJ; Pine, R; Hertzer, NR; Norris, DG			Indications, outcomes, and provider volumes for carotid endarterectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AD-HOC-COMMITTEE; VASCULAR-SURGERY; OPERATIONS; EXPERIENCE; GUIDELINES; MORTALITY; SPECIALTY; STENOSIS; PERFECT; STROKE	Context.-While trials have demonstrated that carotid endarterectomy is superior to best medical therapy, most recently among asymptomatic patients, uses and outcomes of the procedure in more representative settings have not been established. Objectives.-To profile the use and outcomes of carotid endarterectomy in a representative sample of Ohio's Medicare beneficiaries and to examine the relationships between provider-specific procedural volumes and patient outcomes. Design.-Retrospective cohort using Medicare Provider Analysis and Review files supplemented by detailed reviews of medical records on a random sample of patients. Setting.-Ohio hospitals performing carotid endarterectomy. Patients.-A random sample of 678 charts of the 4120 non-health maintenance organization Medicare beneficiaries who underwent carotid endarterectomy between July 1, 1993, and June 30, 1994. Main Outcome Measures.-Nonfatal stroke or death within 30 days of surgery. Results.-The reviewed patients were similar to all eligible patients in sociodemographic characteristics and 30-day mortality rates. Among the 678 patients, indications for surgery were asymptomatic carotid stenosis in 167 (24.6%), transient ischemic attack in 294 (43.4%), completed stroke in 62 (9.1%), and nonspecific symptoms in 155 (22.9%), Thirty-two patients (4.7%) died or suffered nonfatal strokes by 30 days postoperatively. In univariate analyses, rates varied by hospital volume (P=.004) but not surgeons' volume (P=.47), although power to detect this difference was limited. Patients at higher- and lower-volume hospitals had similar indications and distributions of comorbidities. In analyses controlling for indications, comorbid conditions, and surgeon's volume, being operated on in a higher-volume hospital conferred a 71% reduction in risk for 30-day stroke or death (odds ratio, 0.29; 95% confidence interval, 0.12-0.69; P=.006). Conclusions.-Almost half (47.5%) of the carotid endarterectomies among Ohio's Medicare population are performed on persons who are asymptomatic or who have nonspecific symptoms. These results highlight the importance of identifying patients and providers having the most favorable outcome profiles. The higher rate of adverse outcomes observed in lower-volume hospitals deserves further investigation, as it does not appear to be due to differences in patient selection.	Case Western Reserve Univ, Metrohlth Med Ctr, Inst Publ Hlth Sci, Dept Epidemiol & Biostat, Cleveland, OH 44109 USA; Case Western Reserve Univ, Metrohlth Med Ctr, Inst Publ Hlth Sci, Dept Med, Cleveland, OH 44109 USA; Cleveland Clin Fdn, Dept Vasc Surg, Cleveland, OH 44106 USA; Peer Review Syst Inc, Westerville, OH USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University; MetroHealth System; Cleveland Clinic Foundation	Cebul, RD (corresponding author), Case Western Reserve Univ, Metrohlth Med Ctr, Inst Publ Hlth Sci, Dept Epidemiol & Biostat, 2500 MetroHlth Dr,Room 220A, Cleveland, OH 44109 USA.	rdc@po.cwru.edu		Hertzer, Norman/0000-0002-9698-1776	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG010418] Funding Source: NIH RePORTER; AHRQ HHS [HS-00059-03] Funding Source: Medline; NIA NIH HHS [AG-10418-03] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARNETT HJM, 1991, STROKE, V22, P711, DOI 10.1161/01.STR.22.6.711; BARNETT HJM, 1995, NEW ENGL J MED, V332, P238, DOI 10.1056/NEJM199501263320408; Barnett HJM, 1996, NEUROLOGY, V46, P603, DOI 10.1212/WNL.46.3.603; BROTT T, 1984, STROKE, V15, P950, DOI 10.1161/01.STR.15.6.950; CEBUL RD, 1989, ANN INTERN MED, V111, P660, DOI 10.7326/0003-4819-111-8-660; CEBUL RD, 1993, QUAL REV B, P150; EASTON JD, 1977, STROKE, V8, P565, DOI 10.1161/01.STR.8.5.565; FISHER ES, 1989, AM J PUBLIC HEALTH, V79, P1617, DOI 10.2105/AJPH.79.12.1617; FLOOD AB, 1984, MED CARE, V22, P115, DOI 10.1097/00005650-198402000-00003; FLOOD AB, 1984, MED CARE, V22, P98, DOI 10.1097/00005650-198402000-00002; FRIEDMANN P, 1988, STROKE, V19, P1323, DOI 10.1161/01.STR.19.11.1323; HERTZER NR, 1995, J VASC SURG, V21, P6, DOI 10.1016/S0741-5214(95)70239-3; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; KEMPCZINSKI RF, 1986, J VASC SURG, V3, P911, DOI 10.1067/mva.1986.avs0030911; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; MATTOS MA, 1995, J VASC SURG, V21, P719, DOI 10.1016/S0741-5214(05)80003-5; MOORE WS, 1995, CIRCULATION, V91, P566, DOI 10.1161/01.CIR.91.2.566; MOORE WS, 1992, J VASC SURG, V15, P469, DOI 10.1016/0741-5214(92)90185-B; Moore WS, 1996, J VASC SURG, V23, P323, DOI 10.1016/S0741-5214(96)70277-X; RICHARDSON JD, 1989, J VASC SURG, V9, P65, DOI 10.1067/mva.1989.vs0090065; Ruby ST, 1996, ANN VASC SURG, V10, P22, DOI 10.1007/BF02002337; Sarasin FP, 1995, NEUROLOGY, V45, P2147, DOI 10.1212/WNL.45.12.2147; *SAS I INC, 1996, SAS COMP PROGR VERS; Segal H E, 1993, QRB Qual Rev Bull, V19, P152; SLAKENBORG GJ, 1997, ARCH NEUROL-CHICAGO, V54, P826; SLAVISH LG, 1984, STROKE, V15, P956, DOI 10.1161/01.STR.15.6.956; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TOOLE JF, 1989, STROKE, V20, P844; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WHITE LJ, 1989, ANN INTERN MED, V111, P675, DOI 10.7326/0003-4819-111-8-675	32	168	169	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 29	1998	279	16					1282	1287		10.1001/jama.279.16.1282	http://dx.doi.org/10.1001/jama.279.16.1282			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH270	9565009	Bronze			2022-12-01	WOS:000073090300034
J	Shmerling, D; Hegyi, I; Fischer, M; Blattler, T; Brandner, S; Gotz, J; Rulicke, T; Flechsig, E; Cozzio, A; von Mering, C; Hangartner, C; Aguzzi, A; Weissmann, C				Shmerling, D; Hegyi, I; Fischer, M; Blattler, T; Brandner, S; Gotz, J; Rulicke, T; Flechsig, E; Cozzio, A; von Mering, C; Hangartner, C; Aguzzi, A; Weissmann, C			Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions	CELL			English	Article							HUMAN PRION PROTEIN; TRANSGENIC MICE; SYNAPTIC TRANSMISSION; PURKINJE-CELLS; KNOCKOUT MICE; NULL MICE; WILD-TYPE; SCRAPIE; GENE; NEURODEGENERATION	The physiological role of prion protein (PrP) remains unknown. Mice devoid of PrP develop normally but are resistant to scrapie; introduction of a PrP transgene restores susceptibility to the disease. To identify the regions of PrP necessary for this activity, we prepared PrP knockout mice expressing PrPs with amino-proximal deletions. Surprisingly, PrP lacking residues 32-121 or 32-134, but not with shorter deletions, caused severe ataxia and neuronal death limited to the granular layer of the cerebellum as early as 1-3 months after birth. The defect was completely abolished by introducing one copy of a wild-type PrP gene. We speculate that these truncated PrPs may be nonfunctional and compete with some other molecule with a PrP-like function for a common ligand.	Univ Zurich, Inst Mol Biol, Abt 1, CH-8093 Zurich, Switzerland; Universitatsspital Zurich, Inst Neuropathol, CH-8091 Zurich, Switzerland; Universitatsspital Zurich, Biol Zent Lab, CH-8091 Zurich, Switzerland	University of Zurich	Weissmann, C (corresponding author), Univ Zurich, Inst Mol Biol, Abt 1, CH-8093 Zurich, Switzerland.		von Mering, Christian/B-3300-2008; Aguzzi, Adriano/A-3351-2008; Brandner, Sebastian/J-4562-2014; Götz, Jürgen/C-2448-2014	von Mering, Christian/0000-0001-7734-9102; Brandner, Sebastian/0000-0002-9821-0342; Götz, Jürgen/0000-0001-8501-7896; Aguzzi, Adriano/0000-0002-0344-6708				BARRY RA, 1988, J IMMUNOL, V140, P1188; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colling SB, 1996, NEUROSCI LETT, V209, P49, DOI 10.1016/0304-3940(96)12596-9; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; FISCHER M, 1995, RESTORATION SUSCEPTI; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HALTIA M, 1993, ACTA NEUROPATHOL, V85, P241; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; Herms JW, 1995, EUR J NEUROSCI, V7, P2508, DOI 10.1111/j.1460-9568.1995.tb01049.x; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; Lledo PM, 1996, P NATL ACAD SCI USA, V93, P2403, DOI 10.1073/pnas.93.6.2403; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Martins VR, 1997, NAT MED, V3, P1376, DOI 10.1038/nm1297-1376; MCANDREW J, 1995, ENDOCRINOLOGY, V136, P4479, DOI 10.1210/en.136.10.4479; MCKUSICK VA, 1988, MENDELIAN INHERITANC; Muramoto T, 1997, NAT MED, V3, P750, DOI 10.1038/nm0797-750; Norman RM, 1940, BRAIN, V63, P365, DOI 10.1093/brain/63.4.365; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PASCUALCASTROVIEJO I, 1994, NEUROPEDIATRICS, V25, P183, DOI 10.1055/s-2008-1073020; PETTY KJ, 1996, CURRENT PROTOCOLS PR; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; SAKAGUCHI S, 1995, J VIROL, V69, P7586, DOI 10.1128/JVI.69.12.7586-7592.1995; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMSON JAV, 1994, LAB INVEST, V71, P680; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; Weissmann C, 1996, CURR BIOL, V6, P1359, DOI 10.1016/S0960-9822(96)00729-4; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; WHITTINGTON MA, 1995, NAT GENET, V9, P197, DOI 10.1038/ng0295-197; WILMUT I, 1991, J REPROD FERTIL, V92, P245, DOI 10.1530/jrf.0.0920245; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Yehiely F, 1997, NEUROBIOL DIS, V3, P339, DOI 10.1006/nbdi.1997.0130	45	424	430	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					203	214		10.1016/S0092-8674(00)81572-X	http://dx.doi.org/10.1016/S0092-8674(00)81572-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568713	Bronze, Green Accepted			2022-12-01	WOS:000073174000007
J	Xie, JY; McCobb, DP				Xie, JY; McCobb, DP			Control of alternative splicing of potassium channels by stress hormones	SCIENCE			English	Article							PITUITARY-ADRENOCORTICAL AXIS; ADRENAL CHROMAFFIN CELLS; EXPRESSION; GENE; IDENTIFICATION; DEXAMETHASONE; CLONING	Many molecular mechanisms for neural adaptation to stress remain unknown. Expression of alternative splice variants of Slo, a gene encoding calcium-and voltage-activated potassium channels, was measured in rat adrenal chromaffin tissue from normal and hypophysectomized animals. Hypophysectomy triggered an abrupt decrease in the proportion of Slo transcripts containing a "STREX" exon. The decrease was prevented by adrenocorticotropic hormone injections. In Xenopus oocytes, STREX variants produced channels with functional properties associated with enhanced repetitive firing Thus, the hormonal stress axis is likely to control the excitable properties of epinephrine-secreting cells by regulating alternative splicing of Slo messenger RNA.	Cornell Univ, Neurobiol & Behav Sect, Ithaca, NY 14853 USA	Cornell University	McCobb, DP (corresponding author), Cornell Univ, Neurobiol & Behav Sect, Seeley G Mudd Hall, Ithaca, NY 14853 USA.	dpm9@cornell.edu	Xie, Jiuyong/D-2899-2013	Xie, Jiuyong/0000-0003-2909-1033				ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; ATTARDI B, 1993, RECEPTOR CHANNEL, V1, P287; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CECCATELLI S, 1989, ACTA PHYSIOL SCAND, V137, P559, DOI 10.1111/j.1748-1716.1989.tb08800.x; Coupland RE., 1965, NATURAL HIST CHROMAF; DIVIACCO S, 1992, GENE, V122, P313, DOI 10.1016/0378-1119(92)90220-J; EBERT SN, 1994, J BIOL CHEM, V269, P20885; Ferrer J, 1996, DIABETOLOGIA, V39, P891, DOI 10.1007/BF00403907; Kraus JE, 1996, MOL BRAIN RES, V41, P97, DOI 10.1016/0169-328X(96)00072-1; LAKE RC, 1985, CATECHOLAMINES PSYCH; Levitan ES, 1996, NEUROPHARMACOLOGY, V35, P1001, DOI 10.1016/0028-3908(96)00095-0; Lingle C J, 1996, Ion Channels, V4, P261; McCobb D. P., 1997, Society for Neuroscience Abstracts, V23, P1477; MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V269, pH767, DOI 10.1152/ajpheart.1995.269.3.H767; Nussdorfer GG, 1996, PHARMACOL REV, V48, P495; ROSS ME, 1990, J NEUROSCI, V10, P520; Saito M, 1997, J BIOL CHEM, V272, P11710, DOI 10.1074/jbc.272.18.11710; SOLARO CR, 1995, J NEUROSCI, V15, P6110; STACHOWIAK MK, 1988, MOL BRAIN RES, V3, P275, DOI 10.1016/0169-328X(88)90050-2; TAKIMOTO K, 1993, NEURON, V11, P359, DOI 10.1016/0896-6273(93)90191-S; TAKIMOTO K, 1994, CIRC RES, V75, P1; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; VISKUPIC E, 1994, J NEUROCHEM, V63, P808; WONG DL, 1992, FASEB J, V6, P3310, DOI 10.1096/fasebj.6.14.1426768; WONG DL, 1985, BRAIN RES, V330, P209, DOI 10.1016/0006-8993(85)90679-1; WURTMAN RJ, 1966, J BIOL CHEM, V241, P2301; Xie J., 1997, Society for Neuroscience Abstracts, V23, P309; XIE J, 1996, SOC NEUR ABSTR, V22, P402	29	247	250	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					443	446		10.1126/science.280.5362.443	http://dx.doi.org/10.1126/science.280.5362.443			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545224				2022-12-01	WOS:000073159600050
J	Manian, FA				Manian, FA			Should we accept mediocrity?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Infect Dis Consultants, St Louis, MO 63141 USA		Manian, FA (corresponding author), Infect Dis Consultants, St Louis, MO 63141 USA.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1067	1069		10.1056/NEJM199804093381513	http://dx.doi.org/10.1056/NEJM199804093381513			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG134	9535676				2022-12-01	WOS:000072969500013
J	Zambrowicz, BP; Friedrich, GA; Buxton, EC; Lilleberg, SL; Person, C; Sands, AT				Zambrowicz, BP; Friedrich, GA; Buxton, EC; Lilleberg, SL; Person, C; Sands, AT			Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells	NATURE			English	Article							GENOME PROJECT; PROMOTER TRAPS; MICE; VECTORS	The dramatic increase in sequence information in the form of expressed sequence tags (ESTs)(1) and genomic sequence has created a 'gene function gap', with the identification of new genes far outpacing the rate at which their function can be identified. The ability to create mutations in embryonic stem (ES) cells on a large scale by tagged random mutagenesis provides a powerful approach for determining gene function in a mammalian system; this approach is well established in lower organisms(2,3). Here we describe a high-throughput mutagenesis method based on gene trapping that allows the automated identification of sequence tags from the mutated genes, This method traps and mutates genes regardless of their expression status in ES cells, To facilitate the study of gene function on a large scale, we are using these techniques to create a library of ES cells called Omnibank, from which sequence-tagged mutations in 2,000 genes are described.	Lexicon Genet, The Woodlands, TX 77381 USA	Lexicon Pharmaceuticals	Zambrowicz, BP (corresponding author), Lexicon Genet, 4000 Res Forest Dr, The Woodlands, TX 77381 USA.							ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CHANG W, 1993, VIROLOGY, V193, P737, DOI 10.1006/viro.1993.1182; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; DEWEERS M, 1993, EUR J IMMUNOL, V23, P319; FRIEDRICH G, 1993, METHOD ENZYMOL, V225, P681; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GOSSLER A, 1993, GENE TARGETING PRACT, P181; HASTY P, 1991, MOL CELL BIOL, V11, P4509, DOI 10.1128/MCB.11.9.4509; Hicks GG, 1997, NAT GENET, V16, P338, DOI 10.1038/ng0897-338; Oeltjen JC, 1997, GENOME RES, V7, P315, DOI 10.1101/gr.7.4.315; PLASTERK RHA, 1992, BIOESSAYS, V14, P629, DOI 10.1002/bies.950140911; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; SORIANO P, 1991, J VIROL, V65, P2314, DOI 10.1128/JVI.65.5.2314-2319.1991; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Townley DJ, 1997, GENOME RES, V7, P293, DOI 10.1101/gr.7.3.293; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; ZAMBROWICZ P, 1997, P NATL ACAD SCI USA, V94, P3789; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	20	394	425	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					608	611		10.1038/33423	http://dx.doi.org/10.1038/33423			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560157				2022-12-01	WOS:000072987200061
J	Hollander, GA; Zuklys, S; Morel, C; Mizoguchi, E; Mobisson, K; Simpson, S; Terhorst, C; Wishart, W; Golan, DE; Bhan, AK; Burakoff, SJ				Hollander, GA; Zuklys, S; Morel, C; Mizoguchi, E; Mobisson, K; Simpson, S; Terhorst, C; Wishart, W; Golan, DE; Bhan, AK; Burakoff, SJ			Monoallelic expression of the interleukin-2 locus	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; VERSUS-HOST DISEASE; CELL GROWTH-FACTOR; T-CELLS; CD28 RECEPTOR; RECOMBINANT INTERLEUKIN-2; SIGNAL-TRANSDUCTION; AUTOIMMUNE-DISEASE; PROTEIN-TYROSINE; ANTIGEN RECEPTOR	The lymphokine interleukin-2 (IL-2) is responsible for autocrine cell cycle progression and regulation of immune responses. Uncontrolled secretion of IL-2 results in adverse reactions ranging from anergy, to aberrant T cell activation, to autoimmunity. With the use of fluorescent in situ hybridization and single-cell polymerase chain reaction in cells with different IL-2 alleles; IL-2 expression in mature thymocytes and T cells was found to be tightly controlled by monoallelic expression. Because IL-2 is encoded at a nonimprinted autosomal locus, this result represents an unusual regulatory mode for controlling the precise expression of a single gene.	Univ Basel, Sch Med, Dept Res, CH-4031 Basel, Switzerland; Univ Basel, Sch Med, Childrens Hosp, CH-4031 Basel, Switzerland; Harvard Univ, Sch Med, Dept Pediat, Dana Farber Canc Inst,Div Pediat Oncol, Boston, MA 02115 USA; Novartis Pharmaceut, Preclin Res, CH-4002 Basel, Switzerland; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Hematol Oncol, Boston, MA 02115 USA	University of Basel; University of Basel; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Novartis; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Burakoff, SJ (corresponding author), Univ Basel, Sch Med, Dept Res, CH-4031 Basel, Switzerland.			Hollander, Georg/0000-0002-8790-0874	NATIONAL CANCER INSTITUTE [P01CA039542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047677] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA39542-09] Funding Source: Medline; NIAID NIH HHS [R01 AI17258-18] Funding Source: Medline; NIDDK NIH HHS [R01 DK47677] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREUSANCHEZ JL, 1991, J EXP MED, V173, P1323, DOI 10.1084/jem.173.6.1323; Beechey C. V., 1994, Mouse Genome, V92, P108; BOGEN SA, 1993, J IMMUNOL, V150, P4197; CERFBENSUSSAN N, 1984, J IMMUNOL, V132, P2244; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHATILA T, 1989, NEW ENGL J MED, V320, P696, DOI 10.1056/NEJM198903163201104; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; COLLINS TL, 1994, CURR OPIN IMMUNOL, V6, P385, DOI 10.1016/0952-7915(94)90117-1; DAVIS MM, 1990, ANNU REV BIOCHEM, V59, P475, DOI 10.1146/annurev.biochem.59.1.475; DESILVA DR, 1991, J IMMUNOL, V147, P3261; DISANTO JP, 1990, J EXP MED, V171, P1697, DOI 10.1084/jem.171.5.1697; ESSERY G, 1988, IMMUNOLOGY, V64, P413; FIORENTINO L, 1989, GENOMICS, V5, P651, DOI 10.1016/0888-7543(89)90039-6; FUSE A, 1984, NUCLEIC ACIDS RES, V12, P9323, DOI 10.1093/nar/12.24.9323; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GUTIERREZRAMOS JC, 1992, EUR J IMMUNOL, V22, P2867, DOI 10.1002/eji.1830221117; HOLBROOK NJ, 1984, P NATL ACAD SCI-BIOL, V81, P1634, DOI 10.1073/pnas.81.6.1634; HOLLANDER GA, UNPUB; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KNOLL JHM, 1994, NAT GENET, V6, P41, DOI 10.1038/ng0194-41; KRAMER S, 1994, EUR J IMMUNOL, V24, P2317, DOI 10.1002/eji.1830241009; Kroemer G, 1992, Semin Immunol, V4, P167; LAWRENCE JB, 1988, CELL, V52, P51; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LOPEZBOTET M, 1982, J IMMUNOL, V128, P679; MALKOVSKY M, 1985, P NATL ACAD SCI USA, V82, P536, DOI 10.1073/pnas.82.2.536; MATESANZ F, 1993, IMMUNOGENETICS, V38, P300, DOI 10.1007/BF00188809; Matesanz F, 1996, EUR J IMMUNOL, V26, P1675, DOI 10.1002/eji.1830260802; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; NIEDERKORN JY, 1987, TRANSPLANTATION, V43, P523, DOI 10.1097/00007890-198704000-00014; OHNO T, 1987, CLIN IMMUNOL IMMUNOP, V45, P471, DOI 10.1016/0090-1229(87)90098-5; PAGANELLI R, 1983, CLIN EXP IMMUNOL, V51, P338; PAHWA R, 1989, P NATL ACAD SCI USA, V86, P5069, DOI 10.1073/pnas.86.13.5069; PFEIFER K, 1987, GENE DEV, V8, P1867; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROCHA B, 1988, SCAND J IMMUNOL, V27, P47, DOI 10.1111/j.1365-3083.1988.tb02322.x; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; RUMP JA, 1992, CLIN EXP IMMUNOL, V89, P204; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SAKAMOTO H, 1991, P NATL ACAD SCI USA, V88, P10890, DOI 10.1073/pnas.88.23.10890; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SORENSEN RU, 1992, J PEDIATR-US, V121, P873, DOI 10.1016/S0022-3476(05)80331-2; SYKES M, 1994, BLOOD, V83, P2560; TANIGUCHI T, 1986, IMMUNOL REV, V92, P121, DOI 10.1111/j.1600-065X.1986.tb01497.x; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WEBB GC, 1990, CYTOGENET CELL GENET, V54, P164, DOI 10.1159/000132985; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406	55	201	204	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 27	1998	279	5359					2118	2121		10.1126/science.279.5359.2118	http://dx.doi.org/10.1126/science.279.5359.2118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516115				2022-12-01	WOS:000072775600051
J	Romesberg, FE; Spiller, B; Schultz, PG; Stevens, RC				Romesberg, FE; Spiller, B; Schultz, PG; Stevens, RC			Immunological origins of binding and catalysis in a Diels-Alderase antibody	SCIENCE			English	Article							TOXIN PEPTIDE COMPLEX; CHORISMATE MUTASE; CRYSTAL-STRUCTURE; MOLECULAR REPLACEMENT; ACTIVE-SITE; RESOLUTION; DIVERSITY; PROTEINS; FAMILY; GENES	The three-dimensional structure of an antibody (39-A11) that catalyzes a Diels-Alder reaction has been determined, The structure suggests that the antibody catalyzes this pericyclic reaction through a combination of packing and hydrogen-bonding interactions that control the relative geometries of the bound substrates and electronic distribution in the dienophile. A single somatic mutation, serine-91 of the light chain to valine, is largely responsible for the increase in affinity and catalytic activity of the affinity-matured antibody. Structural and functional studies of the germ-line precursor suggest that 39-A11 and related antibodies derive from a family of germ-line genes that have been selected throughout evolution for the ability of the encoded proteins to form a polyspecific combining site. Germ line-encoded antibodies of this type, which can rapidly evolve into high-affinity receptors for a broad range of structures, may help to expand the binding potential associated with the structural diversity of the primary antibody repertoire.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Schultz, PG (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.		Stevens, Raymond/K-7272-2015; Romesberg, Floyd/M-2821-2017	Stevens, Raymond/0000-0002-4522-8725; Romesberg, Floyd/0000-0001-6317-1315				AVEVALO JH, 1993, NATURE, V365, P859; AVEVALO JH, 1994, J MOL BIOL, V241, P663; AVEVALO JH, 1993, J MOL BIOL, V231, P103; BRAISTED AC, 1990, J AM CHEM SOC, V112, P7430, DOI 10.1021/ja00176a073; BRUICE TC, 1960, J AM CHEM SOC, V82, P5858, DOI 10.1021/ja01507a023; BRUNGER AT, 1992, XPLOR VERSION 3 851; Charbonnier JB, 1997, SCIENCE, V275, P1140, DOI 10.1126/science.275.5303.1140; CHOOK YM, 1993, P NATL ACAD SCI USA, V90, P8600, DOI 10.1073/pnas.90.18.8600; DEVERSON E, 1987, EUR J IMMUNOL, V17, P9, DOI 10.1002/eji.1830170103; FLEMING I, 1976, FRONTIER ORBITALS OR; GOUVERNEUR VE, 1993, SCIENCE, V262, P204, DOI 10.1126/science.8211138; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HAYNES M, 1996, ISRAEL J CHEM, V136, P151; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; HsiehWilson LC, 1996, P NATL ACAD SCI USA, V93, P5363, DOI 10.1073/pnas.93.11.5363; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; KIM HNG, 1989, J IMMUNOL, V143, P638; LEVY R, 1989, BIOCHEMISTRY-US, V28, P7168, DOI 10.1021/bi00444a006; Liu DR, 1996, J AM CHEM SOC, V118, P1789, DOI 10.1021/ja953151o; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SCHERF T, 1992, BIOCHEMISTRY-US, V31, P6884, DOI 10.1021/bi00145a004; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SHOHAM M, 1993, J MOL BIOL, V232, P1169, DOI 10.1006/jmbi.1993.1469; SHOHAM M, 1991, PROTEINS, V11, P218, DOI 10.1002/prot.340110306; SIMS MJ, 1992, J IMMUNOL, V149, P1642; STORM DR, 1970, P NATL ACAD SCI USA, V66, P445, DOI 10.1073/pnas.66.2.445; TAIRA K, 1988, J MED CHEM, V31, P129, DOI 10.1021/jm00396a019; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; Ulrich HD, 1997, NATURE, V389, P271, DOI 10.1038/38470; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; XUE YF, 1995, P NATL ACAD SCI USA, V92, P10595, DOI 10.1073/pnas.92.23.10595; XUE YF, 1994, P NATL ACAD SCI USA, V91, P10814, DOI 10.1073/pnas.91.23.10814; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	41	142	141	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1929	1933		10.1126/science.279.5358.1929	http://dx.doi.org/10.1126/science.279.5358.1929			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506942				2022-12-01	WOS:000072613300045
J	Nguyen, QT; Parsadanian, AS; Snider, WD; Lichtman, JW				Nguyen, QT; Parsadanian, AS; Snider, WD; Lichtman, JW			Hyperinnervation of neuromuscular junctions caused by GDNF overexpression in muscle	SCIENCE			English	Article							CILIARY NEUROTROPHIC FACTOR; FACIAL MOTOR-NEURONS; SKELETAL-MUSCLE; IN-VIVO; POLYNEURONAL INNERVATION; SYNAPSE ELIMINATION; LIMB BUD; MOTONEURONS; EXPRESSION; SURVIVAL	Overexpression of glial cell line-derived neurotrophic factor (GDNF) by muscle greatly increased the number of motor axons innervating neuromuscular junctions in neonatal mice. The extent of hyperinnervation correlated with the amount of GDNF expressed in four transgenic lines. Overexpression of GDNF by glia and overexpression of neurotrophin-3 and neurotrophin-4 in muscle did not cause hyperinnervation. Thus, increased amounts of GDNF in postsynaptic target cells can regulate the number of innervating axons.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Lichtman, JW (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.							BETZ WJ, 1979, J PHYSIOL-LONDON, V297, P463, DOI 10.1113/jphysiol.1979.sp013051; BLONDET B, 1989, DEV BIOL, V132, P153, DOI 10.1016/0012-1606(89)90213-3; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CARONI P, 1990, J CELL BIOL, V110, P1307, DOI 10.1083/jcb.110.4.1307; CARONI P, 1992, J NEUROSCI, V12, P3849; Causing CG, 1997, NEURON, V18, P257, DOI 10.1016/S0896-6273(00)80266-4; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; ENGLISH AW, 1995, DEV BIOL, V169, P57, DOI 10.1006/dbio.1995.1126; FLADBY T, 1987, ACTA PHYSIOL SCAND, V129, P229, DOI 10.1111/j.1748-1716.1987.tb08063.x; FUNAKOSHI H, 1995, SCIENCE, V268, P1495, DOI 10.1126/science.7770776; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Houenou LJ, 1996, CELL TISSUE RES, V286, P219, DOI 10.1007/s004410050690; Jordan CL, 1996, DEV NEUROSCI-BASEL, V18, P185, DOI 10.1159/000111407; Keller-Peck C. R., 1997, Society for Neuroscience Abstracts, V23, P620; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; KWON YW, 1995, J NEUROBIOL, V28, P35, DOI 10.1002/neu.480280105; MERLIE JP, 1994, J BIOL CHEM, V269, P2461; Molliver DC, 1997, NEURON, V19, P849, DOI 10.1016/S0896-6273(00)80966-6; Nguyen QT, 1996, CURR OPIN NEUROBIOL, V6, P104, DOI 10.1016/S0959-4388(96)80015-8; Oppenheim RW, 1996, NEURON, V17, P195, DOI 10.1016/S0896-6273(00)80151-8; PRANZATELLI MR, 1990, CLIN NEUROPHARMACOL, V13, P329, DOI 10.1097/00002826-199008000-00008; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; ROSMAN NP, 1984, J DEV BEHAV PEDIATR, V54, P263; ROTTOPERCELAY DM, 1992, BRAIN RES, V574, P291, DOI 10.1016/0006-8993(92)90829-X; SCHMUED LC, 1982, J HISTOCHEM CYTOCHEM, V30, P123, DOI 10.1177/30.2.6174560; Snider WD, 1996, MOL CELL NEUROSCI, V7, P433, DOI 10.1006/mcne.1996.0031; TSUZUKI T, 1995, ONCOGENE, V10, P191; Wright DE, 1997, NEURON, V19, P503, DOI 10.1016/S0896-6273(00)80367-0; Wright DE, 1996, CELL TISSUE RES, V286, P209, DOI 10.1007/s004410050689; Yamamoto M, 1996, NEUROCHEM RES, V21, P929, DOI 10.1007/BF02532343; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; YAN Q, 1993, J NEUROBIOL, V24, P1555, DOI 10.1002/neu.480241202	37	216	223	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1725	1729		10.1126/science.279.5357.1725	http://dx.doi.org/10.1126/science.279.5357.1725			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497292				2022-12-01	WOS:000072490000057
J	Zheng, M; Aslund, F; Storz, G				Zheng, M; Aslund, F; Storz, G			Activation of the OxyR transcription factor by reversible disulfide bond formation	SCIENCE			English	Article							ESCHERICHIA-COLI; NEGATIVE MUTANTS; DNA-BINDING; GLUTATHIONE; STABILIZATION; REACTIVITY; REGULATOR; CHEMISTRY; PROTEINS; STRESS	The OxyR transcription factor is sensitive to oxidation and activates the expression of antioxidant genes in response to hydrogen peroxide in Escherichia coli. Genetic and biochemical studies revealed that OxyR is activated through the formation of a disulfide bond and is deactivated by enzymatic reduction with glutaredoxin 1 (Grx1). The gene encoding Grx1 is regulated by OxyR, th us providing a mechanism for autoregulation. The redox potential of OxyR was determined to be -185 millivolts, ensuring that OxyR is reduced in the absence of stress. These results represent an example of redox signaling through disulfide bond formation and reduction.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Harvard Medical School	Storz, G (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	storz@helix.nih.gov		Storz, Gisela/0000-0001-6698-1241				Altuvia S, 1997, CELL, V90, P43, DOI 10.1016/S0092-8674(00)80312-8; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; BLOCK E, 1974, J AM CHEM SOC, V96, P3929, DOI 10.1021/ja00819a034; Branden C., 1999, INTRO PROTEIN STRUCT; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; DAVIS FA, 1986, J ORG CHEM, V51, P1033, DOI 10.1021/jo00357a017; DAVIS FA, 1981, J AM CHEM SOC, V103, P7016, DOI 10.1021/ja00413a064; DAVIS NK, 1982, J GEN MICROBIOL, V128, P1631; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Ding HG, 1996, J BIOL CHEM, V271, P33173, DOI 10.1074/jbc.271.52.33173; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GONZALEZFLECHA B, REACTIVE OXYGEN SPEC; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hidalgo E, 1997, CELL, V88, P121, DOI 10.1016/S0092-8674(00)81864-4; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jamieson D. J., 1997, OXIDATIVE STRESS MOL, P91; KICE JL, 1980, ADV PHYS ORG CHEM, V17, P65; KULLIK I, 1995, J BACTERIOL, V177, P1285, DOI 10.1128/jb.177.5.1285-1291.1995; LULLIK I, 1995, J BACTERIOL, V177, P1275; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; PRIVALLE CT, 1990, J BIOL CHEM, V265, P21966; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; RUSSEL M, 1986, THIOREDOXIN GLUTARED, P331; SCHULTZ GE, 1979, PRINCIPLES PROTEIN S; STAMLER JS, 1992, ANAL CHEM, V64, P779, DOI 10.1021/ac00031a014; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Tao K, 1997, J BACTERIOL, V179, P5967, DOI 10.1128/jb.179.18.5967-5970.1997; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1	35	942	969	1	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 13	1998	279	5357					1718	1721		10.1126/science.279.5357.1718	http://dx.doi.org/10.1126/science.279.5357.1718			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497290				2022-12-01	WOS:000072490000055
J	Donovan, JP; Schafer, DF; Shaw, BW; Sorrell, MF				Donovan, JP; Schafer, DF; Shaw, BW; Sorrell, MF			Cerebral oedema and increased intracranial pressure in chronic liver disease	LANCET			English	Article							FULMINANT HEPATIC-FAILURE	Background Cerebral oedema is a cause of morbidity and mortality in fulminant hepatic failure but has not been well documented as a complication of chronic liver diseases. We report here the development of cerebral oedema and increased intracranial pressure in 12 patients with chronic liver disease. Methods Between July 1, 1987, and Dec 31, 1993, we studied 12 patients aged 29-67 years with end-stage chronic liver disease. All the patients had cirrhosis. portal hypertension, hypoprothrombinaemia, hepatic encephalopathy, and decreased serum concentrations of albumin (<25 g/L). During the study, the patients developed signs of increased intracranial pressure and had documented intracranial hypertension, cerebral oedema, or both. Intracranial hypertension was suspected on physical examination and confirmed by epidural catheters. We detected cerebral oedema by computed axial tomography of the head and necropsy of the brain when possible. Findings All the patients had intracranial hypertension and cerebral oedema. Two patients had successful treatment of cerebral hypertension with improvement of intracranial pressure such that orthotopic liver transplantation was undertaken. Both patients became neurologically normal after transplantation. Eight patients had only a transient reponse to treatment and died of cerebral oedema before a transplant could be done. Interpretation Cerebral oedema and increased intracranial pressure can occur in chronic liver disease and presents as neurological deterioration. Treatment guided by monitoring of intracranial pressure can lead to the reversal of intracranial hypertension, but in most patients cerebral oedema contributes to death or places them at too high a risk for liver transplantation.	Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Surg, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Donovan, JP (corresponding author), Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.							CANALESE J, 1982, GUT, V23, P625, DOI 10.1136/gut.23.7.625; CONOMY JP, 1968, NEW ENGL J MED, V278, P876, DOI 10.1056/NEJM196804182781603; JABBOUR N, 1994, J OKLA STATE MED ASS, V84, P501; LIDOFSKY SD, 1992, HEPATOLOGY, V16, P1, DOI 10.1002/hep.1840160102; Plum F, 1980, DIAGNOSIS STUPOR COM, P177; Schafer DF, 1990, HEPATOLOGY, P447; SCHAFER DF, 1990, CURRENT THERAPY GAST, P451; WENDON JA, 1992, HEPATOLOGY, V15, P1067, DOI 10.1002/hep.1840150616; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6	9	123	131	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					719	721		10.1016/S0140-6736(97)07373-X	http://dx.doi.org/10.1016/S0140-6736(97)07373-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504517				2022-12-01	WOS:000072463800010
J	Naas, AAO; Davidson, NC; Thompson, C; Cummings, F; Ogston, SA; Jung, RT; Newton, RW; Struthers, AD				Naas, AAO; Davidson, NC; Thompson, C; Cummings, F; Ogston, SA; Jung, RT; Newton, RW; Struthers, AD			QT and QTc dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin dependent diabetes: cohort study	BRITISH MEDICAL JOURNAL			English	Article									Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Ctr Diabet, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Epidemiol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Struthers, AD (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland.			Cummings, Fraser/0000-0002-9659-3247; Struthers, Allan/0000-0002-2926-2528				BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; Darbar D, 1996, BRIT MED J, V312, P874; DINEEN S, 1995, DIABETES S1, V44, pA124; Fu GS, 1997, EUR HEART J, V18, P281; SAWICKI PT, 1996, DIABETES S2, V45, pA128	5	114	117	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1998	316	7133					745	746		10.1136/bmj.316.7133.745	http://dx.doi.org/10.1136/bmj.316.7133.745			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB358	9529410	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000072463700032
J	Pahor, M; Psaty, BM; Furberg, CD				Pahor, M; Psaty, BM; Furberg, CD			Treatment of hypertensive patients with diabetes	LANCET			English	Editorial Material									Univ Tennessee, Dept Prevent Med, Memphis, TN 38105 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Epidemiol, Seattle, WA USA; Univ Washington, Dept Hlth Serv, Seattle, WA USA; Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University	Pahor, M (corresponding author), Univ Tennessee, Dept Prevent Med, Memphis, TN 38105 USA.							Alderman M, 1998, LANCET, V351, P216, DOI 10.1016/S0140-6736(05)78175-7; Byington RP, 1997, LANCET, V350, P1075, DOI 10.1016/S0140-6736(05)70455-4; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; DiPasquale P, 1997, J CARDIOVASC PHARM, V29, P202; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; Pahor M, 1998, DIABETES CARE, V21, P193, DOI 10.2337/diacare.21.1.193; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; TATTI P, 1997, CIRCULATION S1, V96, P764; TATTI P, IN PRESS DIABETES CA; Vaughan DE, 1997, CIRCULATION, V96, P442	11	62	63	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					689	690		10.1016/S0140-6736(05)78489-0	http://dx.doi.org/10.1016/S0140-6736(05)78489-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504510				2022-12-01	WOS:000072463800003
J	George, SE; Simokat, K; Hardin, J; Chisholm, AD				George, SE; Simokat, K; Hardin, J; Chisholm, AD			The VAB-1 Eph receptor tyrosine kinase functions in neural and epithelial morphogenesis in C-elegans	CELL			English	Article							CAENORHABDITIS-ELEGANS; DROSOPHILA GASTRULATION; MOLECULAR-CLONING; COMMISSURAL AXONS; IN-VITRO; GENE; PROTEIN; ENCODES; FAMILY; IDENTIFICATION	Mutations in the C. elegans vab-1 gene disrupt the coordinated movements of cells during two periods of embryogenesis. vab-1 mutants are defective in the movement of neuroblasts during closure of the ventral gastrulation cleft and in the movements of epidermal cells during ventral enclosure of the embryo by the epidermis. We show that vab-1 encodes a receptor tyrosine kinase of the Eph family. Disruption of the kinase domain of VAB-1 causes weak mutant phenotypes, indicating that VAB-1 may have both kinase-dependent and kinase-independent activities. VAB-1 is expressed in neurons during epidermal enclosure and is required in these cells for normal epidermal morphogenesis, demonstrating that cell-cell interactions are required between neurons and epidermal cells for epidermal morphogenesis.	Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA; Univ Wisconsin, Dept Zool, Program Cellular & Mol Biol, Madison, WI 53706 USA	University of California System; University of California Santa Cruz; University of Wisconsin System; University of Wisconsin Madison	Chisholm, AD (corresponding author), Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA.			Chisholm, Andrew/0000-0001-5091-0537	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054657] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54657] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; BARD JB, 1992, MORPHOGENESIS; BRANDLI AW, 1995, DEV DYNAM, V203, P119; BRENNER S, 1974, GENETICS, V77, P71; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Chen J, 1996, ONCOGENE, V12, P979; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHISHOLM AD, 1995, NATURE, V377, P52, DOI 10.1038/377052a0; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; CLARK SG, 1994, GENETICS, V137, P987; Connor RJ, 1995, ONCOGENE, V11, P2429; COSTA M, 1994, CELL, V76, P1075, DOI 10.1016/0092-8674(94)90384-0; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Flanagan JG, 1997, CELL, V90, P403; FOX GM, 1995, ONCOGENE, V10, P897; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gao PP, 1996, P NATL ACAD SCI USA, V93, P11161, DOI 10.1073/pnas.93.20.11161; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; HEDGECOCK EM, 1995, GENETICS, V141, P989; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HERMAN RK, 1995, CAENORHABDITIS ELEGA, P123; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Hodgkin J, 1997, C ELEGANS, P881; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Knust E, 1997, CURR BIOL, V7, pR558, DOI 10.1016/S0960-9822(06)00281-8; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller LM, 1996, GENETICS, V143, P1181; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RUIZ JC, 1994, MECH DEVELOP, V46, P87; RUIZ JC, 1994, MECH DEVELOP, V48, P153, DOI 10.1016/0925-4773(94)90056-6; SCHEDL T, 1988, GENETICS, V119, P43; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WilliamsMasson EM, 1997, DEVELOPMENT, V124, P2889; Winning RS, 1996, DEV BIOL, V179, P309, DOI 10.1006/dbio.1996.0262; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xu QL, 1995, DEVELOPMENT, V121, P4005; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807	50	186	191	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					633	643		10.1016/S0092-8674(00)81131-9	http://dx.doi.org/10.1016/S0092-8674(00)81131-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506518	Bronze			2022-12-01	WOS:000072406000009
J	Hylek, EM; Heiman, H; Skates, SJ; Sheehan, MA; Singer, DE				Hylek, EM; Heiman, H; Skates, SJ; Sheehan, MA; Singer, DE			Acetaminophen and other risk factors for excessive warfarin anticoagulation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTI-COAGULANT THERAPY; VITAMIN-K; BLEEDING COMPLICATIONS; POTENTIATION; OUTPATIENTS; DRUGS; WINE	Context.-Warfarin is highly effective in preventing thromboembolism, but increases the risk of hemorrhage, particularly at an international normalized ratio (INR) greater than 4.0. Identifying causes of excessive anticoagulation in clinical practice could help target patients at risk for elevated INRs. Objective.-To determine causes of INRs greater than 6.0 in a clinical practice setting. Design.-Case-control study. Setting.-Outpatient anticoagulant therapy unit, Patients.-Outpatients followed up prospectively from April 1995 to March 1996 who had been taking warfarin for more than 1 month, had a target INR of 2.0 to 3.0, and were able to be interviewed within 24 hours of their reported INR. Case patients had INRs greater than 6.0; controls were randomly selected from patients having INRs between 1.7 and 3.3. Main Outcome Measures.-Factors associated with INRs greater than 6.0, including medication use, recent diet, illness, alcohol consumption, and actual warfarin use. Results.-A total of 93 cases and 196 controls were interviewed; they did not differ in age, indication for warfarin, length of therapy, warfarin dose, number of prescription medications, or previous INR or long-term INR variability. Acetaminophen ingestion was independently associated in a dose-dependent manner with having an INR greater than 6.0 (P for trend <.001). For the highest-dose category of acetaminophen intake, 9100 mg/wk or more, the odds of having an INR greater than 6.0 were increased 10-fold (95% confidence interval [CI], 2.6-37.9). Other factors independently associated with an INR greater than 6.0 were new medication known to potentiate warfarin (odds ratio [OR], 8.5; 95% CI, 2.9-24.7), advanced malignancy (OR, 16.4; 95% CI, 2.4-111.0), recent diarrheal illness (OR, 3.5; 95% CI, 1.4-8.6), decreased oral intake (OR, 3.6; 95% CI, 1.3-9.7), and taking more warfarin than prescribed (OR, 8.1; 95% CI, 2.2-30.0). Higher vitamin K intake (OR, 0.7; 95% CI, 0.5-0.9) and habitual alcohol consumption of from 1 drink every other day to 2 drinks a day (OR, 0.2; 95% CI, 0.1-0.7) were associated with decreased risk. Conclusions.-These data suggest that acetaminophen is an underrecognized cause of overanticoagulation in the outpatient setting. Several other clinically important risk factors were identified. Increased monitoring of INR values when such risk factors are present or modification of the risk factors themselves should reduce the frequency of dangerously high levels of anticoagulation.	Massachusetts Gen Hosp, Med Practices Evaluat Ctr, Div Med Genet, Clin Epidemiol Unit,Dept Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Hylek, EM (corresponding author), Massachusetts Gen Hosp, Med Practices Evaluat Ctr, Div Med Genet, Clin Epidemiol Unit,Dept Med, S50-9, Boston, MA 02114 USA.			Hylek, Elaine/0000-0001-8263-8304	NATIONAL INSTITUTE ON AGING [R01AG015478] Funding Source: NIH RePORTER; NIA NIH HHS [AG15478] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHLBOM A, 1990, INTRO MODERN EPIDEMI, P47; ANTLITZ AM, 1969, CURR THER RES CLIN E, V11, P360; ANTLITZ AM, 1968, CURR THER RES CLIN E, V10, P501; BARTLE WR, 1991, JAMA-J AM MED ASSOC, V265, P1260, DOI 10.1001/jama.265.10.1260; BENNETT DR, 1995, DRUG EVALUATIONS ANN, P773; BLACK JA, 1994, LANCET, V344, P1373, DOI 10.1016/S0140-6736(94)90737-4; BOEIJINGA JJ, 1982, LANCET, V1, P506; Booth Sarah L., 1993, Journal of Food Composition and Analysis, V6, P109, DOI 10.1006/jfca.1993.1014; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; CARON J, 1992, MEYLERS SIDE EFFECTS, P900; CHOW WH, 1990, POSTGRAD MED J, V66, P855, DOI 10.1136/pgmj.66.780.855; COLE P, 1971, BRIT J PREV SOC MED, V25, P242; DALE J, 1980, AM HEART J, V99, P746, DOI 10.1016/0002-8703(80)90625-0; DEGROOT MH, 1986, PROBABILITY STAT, P552; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P148; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; JONES RH, 1993, LONGITUDINAL DATA SE, P171; KARLSON B, 1986, ACTA MED SCAND, V220, P347; KATER RMH, 1969, AM J MED SCI, V258, P35, DOI 10.1097/00000441-196907000-00005; KEMPIN SJ, 1983, NEW ENGL J MED, V308, P1229; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P299; LALIBERTE R, 1977, J PHARMACOL EXP THER, V200, P44; LALIBERTE R, 1976, J PHARMACOL EXP THER, V196, P194; LANDEFELD CS, 1989, AM J MED, V87, P144; MAJERUS PW, 1996, GOODMAN GILMANS PHAR, P1346; *MED EC DAT PROD C, 1995, PHYS DESK REF; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; OREILLY RA, 1981, ARCH INTERN MED, V141, P458, DOI 10.1001/archinte.141.4.458; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; PEDERSEN FM, 1991, J INTERN MED, V229, P517, DOI 10.1111/j.1365-2796.1991.tb00388.x; PORTER RS, 1986, APPL PHARMACOKINETIC; ROGERS AS, 1991, PHARMACOEPIDEM DR S, P64; RUBIN RN, 1984, CLIN RES, V32, pA698; Schlesselman J., 1982, CASE CONTROL STUDIES, P144; SCHULMAN S, 1989, BR J RHEUMATOL, V38, P46; SHORR RI, 1993, ARCH INTERN MED, V153, P1665, DOI 10.1001/archinte.153.14.1665; SNEDECOR GW, 1980, STATISTICAL METHODS, P206; Stafford RS, 1996, ARCH INTERN MED, V156, P2537, DOI 10.1001/archinte.156.22.2537; STOCKLEY IH, 1991, DRUG INTERACTIONS SO, P196; *US PHARM CONV INC, 1997, US PHARM DISP INF DR, P232; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; WELLS PS, 1994, ANN INTERN MED, V121, P676, DOI 10.7326/0003-4819-121-9-199411010-00009	44	265	272	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					657	662		10.1001/jama.279.9.657	http://dx.doi.org/10.1001/jama.279.9.657			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496982	Bronze			2022-12-01	WOS:000072192800028
J	Withers, DJ; Gutierrez, JS; Towery, H; Burks, DJ; Ren, JM; Previs, S; Zhang, YT; Bernal, D; Pons, S; Shulman, GI; Bonner-Weir, S; White, MF				Withers, DJ; Gutierrez, JS; Towery, H; Burks, DJ; Ren, JM; Previs, S; Zhang, YT; Bernal, D; Pons, S; Shulman, GI; Bonner-Weir, S; White, MF			Disruption of IRS-2 causes type 2 diabetes in mice	NATURE			English	Article							INSULIN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; KINASE; PATHOGENESIS; STIMULATION; ACTIVATION; ADIPOCYTES; WORTMANNIN; PATHWAY; PROTEIN	Human type 2 diabetes is characterized by defects in both insulin action and insulin secretion, It has been difficult to identify a single molecular abnormality underlying these features, Insulin-receptor substrates (IRS proteins) may be involved in type 2 diabetes: they mediate pleiotropic signals initiated by receptors for insulin and other cytokines(1). Disruption of IRS-1 hl mice retards growth, but diabetes does not develop because insulin secretion increases to compensate for the mild resistance to insulin(2,3). Here we show that disruption of IRS-2 impairs both peripheral insulin signalling-and pancreatic beta-cell function. IRS-2-deficient mice show progressive deterioration of glucose homeostasis because of insulin resistance in the liver and skeletal muscle and a lack of beta-cell compensation for this insulin resistance, Our results indicate that dysfunction of IRS-2 may contribute to the pathophysiology of human type 2 diabetes.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr,Dept Med, Boston, MA 02215 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Med, New Haven, CT 06520 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Yale University	White, MF (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr,Dept Med, Boston, MA 02215 USA.	Whitemor@joslab.harvard.edu	Withers, Dominic J/D-7671-2014; Shulman, Gerald I./P-7176-2019; Pons, Sebastian/K-7794-2014; Bernal, Dolores/K-7769-2014	Withers, Dominic J/0000-0002-8009-7521; Shulman, Gerald I./0000-0003-1529-5668; Pons, Sebastian/0000-0003-1027-0621; Bernal, Dolores/0000-0003-4627-8393	NIDDK NIH HHS [R01 DK040936] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BonnerWeir S, 1995, INT CONGR SER, V1100, P179; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; KLOPPEL G, 1985, SURV SYN PATHOL RES, V4, P110; MONTANA E, 1994, J CLIN INVEST, V93, P1577, DOI 10.1172/JCI117137; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; OKADA T, 1994, J BIOL CHEM, V269, P3568; Papaioannou V., 1993, Gene targeting: a practical approach., P107; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PONS S, 1995, MOL CELL BIOL, V15, P4453; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; Scaglia L, 1997, ENDOCRINOLOGY, V138, P1736, DOI 10.1210/en.138.4.1736; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Warram J.H., 1994, JOSLINS DIABETES MEL, P201	22	1250	1312	0	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					900	904		10.1038/36116	http://dx.doi.org/10.1038/36116			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495343				2022-12-01	WOS:000072230900054
J	Thomson, R; McElroy, H; Sudlow, M				Thomson, R; McElroy, H; Sudlow, M			Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation in content and implications for treatment	BRITISH MEDICAL JOURNAL			English	Article								Objective: To describe the content of guidelines on the use of anticoagulant treatment in patients with atrial fibrillation and the impact of variations in guidelines on treatment. Design: Postal survey of guidelines, semistructured interview with lead developers of guidelines, and application of guidelines to patient sample. Subjects: 15 lead developers of the 20 guidelines identified in the postal survey were interviewed. 100 patients over 65 with atrial fibrillation to whom the guidelines were applied. Main outcome measures: Evaluation of guidelines and the methods of dissemination, implementation, review and evaluation; proportion of patients recommended for anticoagulant treatment by each guideline; and level of agreement between guidelines. Results: There was considerable variation in whether anticoagulant treatment was recommended for subjects (range 13% to 100%, kappa = 0.12). Guidelines varied greatly in advice on treatment by age, the use of echocardiography, and the target value or range of the international normalised ratio (8 of the 20 guidelines included values unlikely to be effective). Development was unsystematic; evidence based approaches were rarely used, 9 of the 15 lead developers had developed the guidelines themselves, and the 6 guidelines developed by groups relied on informal consensus, Methods to support effective dissemination, implementation, and evaluation were limited. Conclusion: The widespread non-systematic production of guidelines has led to considerable variation with implications for the quality of care and clinical decision making, There is a need for a central, well funded programme of guideline development to ensure that valid guidelines are produced and disseminated.	Univ Newcastle Upon Tyne, Sch Med, Dept Epidemiol & Publ Hlth, Sch Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Med, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Thomson, R (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Epidemiol & Publ Hlth, Sch Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	Richard.Thomson@newcastle.ac.uk						BATH PMW, 1993, BRIT MED J, V307, P1045, DOI 10.1136/bmj.307.6911.1045; CHANG HJ, 1990, ARCH INTERN MED, V150, P83, DOI 10.1001/archinte.150.1.83; CLUZEAU F, 1995, J INTERPROF CARE, V9, P227; Eccles M, 1996, QUAL HEALTH CARE, V5, P44, DOI 10.1136/qshc.5.1.44; Fahey TP, 1996, BMJ-BRIT MED J, V313, P93, DOI 10.1136/bmj.313.7049.93; Glaser B. G., 1978, THEORETICAL SENSITIV; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; Grimshaw J, 1995, J Eval Clin Pract, V1, P37, DOI 10.1111/j.1365-2753.1995.tb00006.x; Grimshaw J M, 1994, Qual Health Care, V3, P45, DOI 10.1136/qshc.3.1.45; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HENDRY A, 1994, SCOT MED J, V39, P110, DOI 10.1177/003693309403900404; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lawson F, 1996, J AM GERIATR SOC, V44, P708, DOI 10.1111/j.1532-5415.1996.tb01837.x; LIP GYH, 1994, BRIT HEART J, V71, P92; LOK N, 1997, INT J CARDIOL, V48, P271; NHS Executive, 1996, CLIN GUID US CLIN GU; OConnell JE, 1996, AGE AGEING, V25, P307, DOI 10.1093/ageing/25.4.307; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; Sudlow M, 1997, QUAL HEALTH CARE, V6, P60, DOI 10.1136/qshc.6.2.60; THOMSON R, 1995, BMJ-BRIT MED J, V311, P237, DOI 10.1136/bmj.311.6999.237; Varonen H, 1997, QUAL HEALTH CARE, V6, P75, DOI 10.1136/qshc.6.2.75; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; 1994, EFFECTIVE HLTH CARE, V8	24	95	100	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					509	513		10.1136/bmj.316.7130.509	http://dx.doi.org/10.1136/bmj.316.7130.509			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501712	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000072097400019
J	Duesbery, NS; Webb, CP; Leppla, SH; Gordon, VM; Klimpel, KR; Copeland, TD; Ahn, NG; Oskarsson, MK; Fukasawa, K; Paull, KD; Vande Woude, GF				Duesbery, NS; Webb, CP; Leppla, SH; Gordon, VM; Klimpel, KR; Copeland, TD; Ahn, NG; Oskarsson, MK; Fukasawa, K; Paull, KD; Vande Woude, GF			Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor	SCIENCE			English	Article							BACILLUS-ANTHRACIS; PROTECTIVE ANTIGEN; ADENYLATE-CYCLASE; MAMMALIAN-CELLS; TOXIN; PROTEIN; INHIBITORS; TRANSFORMATION; COMPONENTS; INVITRO	Anthrax lethal toxin, produced by the bacterium Bacillus anthracis, is the major cause of death in animals infected with anthrax. One component of this toxin, lethal factor (LF), is suspected to be a metalloprotease, but no physiological substrates have been identified. Here it is shown that LF is a protease that cleaves the amino terminus of mitogen-activated protein kinase kinases 1 and 2 (MAPKK1 and MAPKK2) and that this cleavage inactivates MAPKK1 and inhibits the MAPK signal transduction pathway. The identification of a cleavage site for LF may facilitate the development of LF inhibitors.	NCI, Adv Biosci Lab, Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; NIDR, NIH, Bethesda, MD 20892 USA; Univ Colorado, Dept Chem & Biochem, Howard Hughes Med Inst, Boulder, CO 80309 USA; Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; NCI, Div Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Vande Woude, GF (corresponding author), NCI, Adv Biosci Lab, Basic Res Program, Frederick Canc Res & Dev Ctr, POB B, Frederick, MD 21702 USA.		Webb, Craig/I-8123-2012	Duesbery, Nicholas/0000-0002-5708-4984; DUESBERY, NICK/0000-0002-4258-5655				DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Duesbery NS, 1997, P NATL ACAD SCI USA, V94, P9165, DOI 10.1073/pnas.94.17.9165; DUESBERY NS, UNPUB; EZZELL JW, 1984, INFECT IMMUN, V45, P761, DOI 10.1128/IAI.45.3.761-767.1984; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; HAMMOND SE, 1997, 97 GEN M AM SOC MICR; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; KOCHI SK, 1994, FEMS MICROBIOL LETT, V124, P343, DOI 10.1111/j.1574-6968.1994.tb07306.x; Koo HM, 1996, CANCER RES, V56, P5211; Leppla S. H., 1995, Bacterial toxins and virulence factors in disease., P543; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEPPLA SH, 1988, METHOD ENZYMOL, V165, P103; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Matten Wayne T., 1994, Seminars in Developmental Biology, V5, P173, DOI 10.1006/sedb.1994.1023; Menard A, 1996, BIOCHEM J, V320, P687, DOI 10.1042/bj3200687; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Moriguchi T, 1996, Adv Pharmacol, V36, P121, DOI 10.1016/S1054-3589(08)60579-7; Murakami MS, 1997, METHOD ENZYMOL, V283, P584; PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SINGH Y, 1994, J BIOL CHEM, V269, P29039; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	31	852	908	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1998	280	5364					734	737		10.1126/science.280.5364.734	http://dx.doi.org/10.1126/science.280.5364.734			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563949				2022-12-01	WOS:000073415600047
J	Juvonen, J; Juvonen, T; Laurila, A; Kuusisto, J; Alarakkola, E; Sarkioja, T; Bodian, CA; Kairaluoma, MI; Saikku, P				Juvonen, J; Juvonen, T; Laurila, A; Kuusisto, J; Alarakkola, E; Sarkioja, T; Bodian, CA; Kairaluoma, MI; Saikku, P			Can degenerative aortic valve stenosis be related to persistent Chlamydia pneumoniae infection?	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERIES; DISEASE; TWAR; HEART	Background: The cause of age-related degenerative (tricuspid) aortic valve calcification is largely unknown, but one typical characteristic is an active inflammatory process. The presence of Chlamydia pneumoniae in aortic valve stenosis was recently shown. Objective: To test the hypothesis that if persistent C. pneumoniae infection plays an active role in the development of aortic stenosis, the organism can be detected in the healthy aortic valves of young persons. Design: A cadaver study. Setting: Oulu University Hospital, Oulu, Finland. Subjects: 46 consecutive cadavers undergoing autopsy. Measurements: Macroscopic and histologic pathology of aortic valves was determined. The presence of C, pneumoniae was determined by immunohistochemistry. Results: 34 of 46 valves were macroscopically normal. Early lesions of aortic valve disease were found in 12 valves (no lesions in valves from persons 20 to 40 years of age [n = 15], 4 lesions in valves from persons 41 to 60 years of age [n = 16], and 8 lesions in valves from persons older than 60 years of age [n = 15]; P = 0.004). Fifteen of 34 normal valves (44%) and 10 of 12 valves with early lesions (83%) had positive results on staining for C. pneumoniae (P = 0.02). In persons older than 60 years of age, the chance of an early lesion was higher if the valve tested positive for C. pneumoniae (7 of 8 valves with C. pneumoniae infection compared with 1 of 7 valves without C. pneumoniae infection; P = 0.01). Conclusions: Chlamydia pneumoniae is frequently present in aortic valves and is associated with early lesions of aortic valve stenosis in elderly persons.	Oulu Univ Hosp, Dept Surg, Natl Publ Hlth Inst, FIN-90220 Oulu, Finland; Univ Oulu, Dept Forens Med, FIN-90220 Oulu, Finland; Kuopio Univ Hosp, Dept Internal Med, FIN-70211 Kuopio, Finland; Univ Kuopio, FIN-70211 Kuopio, Finland; Mt Sinai Sch Med, Dept Biomath, New York, NY 10029 USA	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; Kuopio University Hospital; University of Eastern Finland; Icahn School of Medicine at Mount Sinai	Juvonen, T (corresponding author), Oulu Univ Hosp, Dept Surg, Natl Publ Hlth Inst, FIN-90220 Oulu, Finland.							DARE AJ, 1993, HUM PATHOL, V24, P1330, DOI 10.1016/0046-8177(93)90267-K; Davies MJ, 1996, HEART, V75, P174, DOI 10.1136/hrt.75.2.174; GRAYSTON JT, 1995, CIRCULATION, V92, P3397, DOI 10.1161/01.CIR.92.12.3397; HAMMERSCHLAG MR, 1992, CLIN INFECT DIS, V14, P178, DOI 10.1093/clinids/14.1.178; HSU SM, 1981, AM J CLIN PATHOL, V75, P734, DOI 10.1093/ajcp/75.5.734; Juvonen J, 1997, J AM COLL CARDIOL, V29, P1054, DOI 10.1016/S0735-1097(97)00003-X; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; KUO CC, 1995, CLIN MICROBIOL REV, V8, P451, DOI 10.1128/CMR.8.4.451; LEINONEN M, 1990, MICROB PATHOGENESIS, V9, P67, DOI 10.1016/0882-4010(90)90042-O; LINDROOS M, 1993, J AM COLL CARDIOL, V21, P1220, DOI 10.1016/0735-1097(93)90249-Z; Mabey D. C. W., 1992, Reviews in Medical Microbiology, V3, P112; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; ODEH M, 1992, EUR J CLIN MICROBIOL, V11, P885, DOI 10.1007/BF01962368; OLSSON M, 1994, J AM COLL CARDIOL, V23, P1162, DOI 10.1016/0735-1097(94)90606-8; OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SAIKKU P, 1985, J INFECT DIS, V151, P832, DOI 10.1093/infdis/151.5.832; WALLER BF, 1994, CLIN CARDIOL, V17, P150, DOI 10.1002/clc.4960170308; WARD C, 1974, LANCET, V2, P734; Ward ME, 1995, APMIS, V103, P769, DOI 10.1111/j.1699-0463.1995.tb01436.x	20	48	50	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					741	744		10.7326/0003-4819-128-9-199805010-00007	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556468				2022-12-01	WOS:000073363800006
J	McCarthy, EP; Burns, RB; Coughlin, SS; Freund, KM; Rice, J; Marwill, SL; Ash, A; Shwartz, M; Moskowitz, MA				McCarthy, EP; Burns, RB; Coughlin, SS; Freund, KM; Rice, J; Marwill, SL; Ash, A; Shwartz, M; Moskowitz, MA			Mammography use helps to explain differences in breast cancer stage at diagnosis between older black and white women	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	19th Annual National Meeting of the Society-of-General-Internal-Medicine	MAY 02-04, 1996	WASHINGTON, D.C.	Soc Gen Internal Med		mammography; breast neoplasms; neoplasm staging; racial stocks	SOCIOECONOMIC-STATUS; HEALTH-SERVICES; RACE; AGE; SURVIVAL; INSURANCE; COVERAGE; DISEASE; EXTENT; CARE	Background: Older black women are less likely to undergo mammography and are more often given a diagnosis of advanced-stage breast cancer than older white women. Objective: To investigate the extent to which previous mammography explains observed differences in cancer stage at diagnosis between older black and white women with breast cancer. Design: Retrospective cohort study using the Linked Medicare-Tumor Registry Database. Setting: Population-based data from three geographic areas of the United States included in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program (Connecticut; metropolitan Atlanta, Georgia; and Seattle-Puget Sound, Washington). Participants: Black and white women 67 years of age and older in whom breast cancer was diagnosed between 1987 and 1989. Measurements: Medicare claims were used to classify women according to mammography use in the 2 years before diagnosis as nonusers (no previous mammography), regular users (greater than or equal to 2 mammographies done at least 10 months apart), or peri-diagnosis users (mammography done only within 3 months before diagnosis). Information on mammography use was linked with SEER data to determine cancer stage at diagnosis. Stage was classified as early (in situ or local) or late (regional or distant). Results: Black women were more likely to not undergo mammography (odds ratio [OR], 3.00 [95% Cl, 2.41 to 3.75]) and to be given a diagnosis of late-stage disease (OR, 2.49 [CI, 1.59 to 3.92]) than white women. When women were stratified by previous mammography use, the black-white difference in cancer stage occurred only among nonusers (adjusted OR, 2.54 [CI, 1.37 to 4.71]). Among regular users, cancer was diagnosed in black and white women at similar stages (adjusted OR, 1.34 [CI, 0.40 to 4.51]). In logistic modeling, previous mammography alone explained about 30% of the excess late-stage disease in black women. In a separate model, previous mammography explained 12% of the excess late-stage disease among black women after adjustment for sociodemographic and comorbidity information. Conclusion: Differences in breast cancer stage at diagnosis between older black and white women are related to previous mammography use. Increased regular use of mammography may result in a shift toward earlier-stage disease at diagnosis and narrow the observed differences in stage at diagnosis between older black and white women.	Boston Med Ctr, Evans Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA; Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat, New Orleans, LA 70112 USA; Boston Univ, Sch Management, Boston, MA 02215 USA	Boston Medical Center; Tulane University; Boston University	McCarthy, EP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, 330 Brookline Ave,Libby 326, Boston, MA 02215 USA.		Ash, Arlene/AAG-2914-2019	Ash, Arlene/0000-0002-8448-0253; Freund, Karen/0000-0002-9049-5574	PHS HHS [30-P-90665/6] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; BLUSTEIN J, 1995, NEW ENGL J MED, V332, P1138, DOI 10.1056/NEJM199504273321706; *BUR DAT MAN STRAT, 1997, US DEP HLTH HUM SERV; BURACK RC, 1989, AM J PUBLIC HEALTH, V79, P721, DOI 10.2105/AJPH.79.6.721; Burns RB, 1996, ANN INTERN MED, V125, P173, DOI 10.7326/0003-4819-125-3-199608010-00002; Burns RB, 1996, J AM GERIATR SOC, V44, P922, DOI 10.1111/j.1532-5415.1996.tb01861.x; CAPLAN LS, 1992, J GERONTOL, V47, P101; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; FARLEY TA, 1989, AM J PUBLIC HEALTH, V79, P1508, DOI 10.2105/AJPH.79.11.1508; GOODWIN JS, 1986, J AM GERIATR SOC, V34, P20, DOI 10.1111/j.1532-5415.1986.tb06335.x; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P434, DOI 10.2105/AJPH.81.4.434; HOLMES FF, 1981, J AM GERIATR SOC, V29, P55, DOI 10.1111/j.1532-5415.1981.tb01227.x; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; HUNTER CP, 1993, J NATL CANCER I, V85, P1129, DOI 10.1093/jnci/85.14.1129; JONES BA, 1995, CANCER, V75, P2103, DOI 10.1002/1097-0142(19950415)75:8<2103::AID-CNCR2820750813>3.0.CO;2-2; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; MCWHORTER WP, 1989, CANCER, V63, P982, DOI 10.1002/1097-0142(19890301)63:5<982::AID-CNCR2820630533>3.0.CO;2-I; OMalley MS, 1997, AM J PUBLIC HEALTH, V87, P782, DOI 10.2105/AJPH.87.5.782; POTOSKY AL, 1993, MED CARE, V31, P732; Preston JA, 1997, J AM GERIATR SOC, V45, P1310, DOI 10.1111/j.1532-5415.1997.tb02929.x; *SAS I, 1992, SAS STAT US GUID VER, V2; *SAS I, 1992, SAS STAT US GUID VER, V1; SATARIANO WA, 1986, AM J PUBLIC HEALTH, V76, P779, DOI 10.2105/AJPH.76.7.779; *SEER PROGR, 1994, NIH PUBL; SONDIK EJ, 1994, CANCER, V74, P995, DOI 10.1002/1097-0142(19940801)74:3+<995::AID-CNCR2820741504>3.0.CO;2-M; SWANSON GM, 1993, CANCER, V72, P788, DOI 10.1002/1097-0142(19930801)72:3<788::AID-CNCR2820720326>3.0.CO;2-C; SWANSON GM, 1990, CANCER, V66, P1267; WELLS BL, 1992, AM J PUBLIC HEALTH, V82, P1383, DOI 10.2105/AJPH.82.10.1383; YANCIK R, 1989, CANCER, V63, P976, DOI 10.1002/1097-0142(19890301)63:5<976::AID-CNCR2820630532>3.0.CO;2-A; ZAPKA JG, 1989, AM J PUBLIC HEALTH, V79, P1499, DOI 10.2105/AJPH.79.11.1499; 1995, MMWR MORB MORTAL WKL, V45, P57; 1995, MMWR MORB MORTAL WKL, V44, P777	35	148	148	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					729	+		10.7326/0003-4819-128-9-199805010-00005	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZK790	9556466				2022-12-01	WOS:000073363800004
J	Holland, NB; Qiu, YX; Ruegsegger, M; Marchant, RE				Holland, NB; Qiu, YX; Ruegsegger, M; Marchant, RE			Biomimetic engineering of non-adhesive glycocalyx-like surfaces using oligosaccharide surfactant polymers	NATURE			English	Article							FORCE MICROSCOPY; LIQUID; ADSORPTION; INTERFACES; GRAPHITE	The external region of a cell membrane, known as the glycocalyx, is dominated by glycosylated molecules(1-3), which direct specific interactions such as cell-cell recognition and contribute to the steric repulsion that prevents undesirable non-specific adhesion of other molecules and cells. Mimicking the non-adhesive properties of a glycocalyx provides a potential solution to the clinical problems, such as thrombosis(4), that are associated with implantable devices owing to non-specific adsorption of plasma proteins. Here we describe a biomimetic surface modification of graphite using oligosaccharide surfactant polymers, which, like a glycocalyx, provides a dense and confluent layer of oligosaccharides. The surfactant polymers consist of a flexible poly(vinyl amine) with dextran and alkanoyl side chains. We show that alkanoyl side chains assemble on graphite through hydrophobic interaction and epitaxial adsorption. This constrains the polymer backbone to lie parallel to the substrate, with solvated dextran side chains protruding into the aqueous phase, creating a glycocalyx-like coating. The resulting biomimetic surface is effective in suppressing protein adsorption from human plasma protein solution.	Case Western Reserve Univ, Dept Macromol Sci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Marchant, RE (corresponding author), Case Western Reserve Univ, Dept Macromol Sci, Cleveland, OH 44106 USA.	rxm4@po.cwru.edu	Holland, Nolan B./F-6933-2011	Holland, Nolan B./0000-0002-0752-6887				Badesso R. J., 1993, P AM CHEM SOC DIV PO, V69, P251; BONGRAND P, 1987, PHYSICAL BASIS CELL, P1; EVANS WH, 1991, MEMBRANE STRUCTURE F, P1; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; Golander C. G., 1992, POLYETHYLENE GLYCOL, P221, DOI DOI 10.1007/978-1-4899-0703-5_15.; GROSZEK AJ, 1970, PROC R SOC LON SER-A, V314, P473, DOI 10.1098/rspa.1970.0019; HELMUS MN, 1993, CARDIOVASC PATHOL, V2, pS53; MANNE S, 1994, LANGMUIR, V10, P4409, DOI 10.1021/la00024a003; MANNE S, 1995, SCIENCE, V270, P1480, DOI 10.1126/science.270.5241.1480; MCGONIGAL GC, 1990, APPL PHYS LETT, V57, P28, DOI 10.1063/1.104234; MILNER ST, 1991, SCIENCE, V251, P905, DOI 10.1126/science.251.4996.905; NEMANICH RJ, 1977, SOLID STATE COMMUN, V23, P117, DOI 10.1016/0038-1098(77)90663-9; OSTERBERG E, 1995, J BIOMED MATER RES, V29, P741, DOI 10.1002/jbm.820290610; PUTMAN CAJ, 1994, APPL PHYS LETT, V64, P2454, DOI 10.1063/1.111597; Qiu Y., 1997, T SOC BIOMATER, V20, P224; Qiu YX, 1998, MACROMOLECULES, V31, P165, DOI 10.1021/ma9707401; RABE JP, 1991, SCIENCE, V253, P424, DOI 10.1126/science.253.5018.424; Salzman E. W., 1994, HEMOSTASIS THROMBOSI, P1469; Sharma R, 1995, ACS SYM SER, V615, P1; WELLINGHOFF S, 1974, J MACROMOL SCI PHYS, VB 10, P1, DOI 10.1080/00222347408219394; WHITTMANN JC, 1990, PROG POLYM SCI, V15, P909; Zhang TH, 1996, J COLLOID INTERF SCI, V177, P419, DOI 10.1006/jcis.1996.0054	22	270	296	2	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					799	801		10.1038/33894	http://dx.doi.org/10.1038/33894			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572137				2022-12-01	WOS:000073241200048
J	Grossniklaus, U; Vielle-Calzada, JP; Hoeppner, MA; Gagliano, WB				Grossniklaus, U; Vielle-Calzada, JP; Hoeppner, MA; Gagliano, WB			Maternal control of embryogenesis by medea, a Polycomb group gene in Arabidopsis	SCIENCE			English	Article							DROSOPHILA; EXPRESSION; ENDOSPERM; TRITHORAX; TRANSFORMATION; REGULATOR; EVOLUTION; MUTATION; ENHANCER; THALIANA	The gametophytic maternal effect mutant medea (mea) shows aberrant growth regulation during embryogenesis in Arabidopsis thaliana. Embryos derived from mea eggs grow excessively and die during seed desiccation. Embryo lethality is independent of the paternal contribution and gene dosage. The mea phenotype is consistent with the parental conflict theory for the evolution of parent-of-origin-specific effects. MEA encodes a SET domain protein similar to Enhancer of zeste, a member of the Polycomb group. In animals, Polycomb group proteins ensure the stable inheritance of expression patterns through cell division and regulate the control of cell proliferation.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Grossniklaus, U (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd,POB 100, Cold Spring Harbor, NY 11724 USA.	grossnik@cshl.org	Grossniklaus, Ueli/E-9995-2016; Vielle-Calzada, Jean-Philippe/AAG-4036-2019; Grossniklaus, Ueli/A-2736-2012	Grossniklaus, Ueli/0000-0002-0522-8974; Vielle-Calzada, Jean-Philippe/0000-0002-3017-2490				ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; BERLETH T, 1993, DEVELOPMENT, V118, P575; BOUHARMONT J, 1972, J GENET CYTOL, V14, P257; CAPOWSKI EE, 1991, GENETICS, V129, P1061; Carrington EA, 1996, DEVELOPMENT, V122, P4073; CASTLE LA, 1993, MOL GEN GENET, V241, P504, DOI 10.1007/BF00279892; Chaudhury AM, 1997, P NATL ACAD SCI USA, V94, P4223, DOI 10.1073/pnas.94.8.4223; Colombo L, 1997, PLANT CELL, V9, P703, DOI 10.1105/tpc.9.5.703; EDWARDS K, 1991, NUCLEIC ACIDS RES, V19, P1349, DOI 10.1093/nar/19.6.1349; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GUERCHE P, 1990, PLANT CELL, V2, P469, DOI 10.1105/tpc.2.5.469; HAIG D, 1991, PHILOS T ROY SOC B, V333, P1, DOI 10.1098/rstb.1991.0057; HAIG D, 1991, CELL, V64, P1045; HAIG D, 1989, AM NAT, V134, P147, DOI 10.1086/284971; Hobert O, 1996, MOL CELL BIOL, V16, P3066; HOLDERMAN R, COMMUNICATION; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; KERMICLE J, 1990, DEVELOPMENT S, V1, P9; LIN BY, 1982, GENETICS, V100, P475; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; MALUSZYNSKA J, 1993, ANN BOT-LONDON, V71, P479, DOI 10.1006/anbo.1993.1063; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; McDowell JM, 1996, GENETICS, V142, P587; Ohad N, 1996, P NATL ACAD SCI USA, V93, P5319, DOI 10.1073/pnas.93.11.5319; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; PHILLIPS MD, 1990, GENETICS, V125, P91; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Ray S, 1996, DEV BIOL, V180, P365, DOI 10.1006/dbio.1996.0309; Reik W, 1997, TRENDS GENET, V13, P330, DOI 10.1016/S0168-9525(97)01200-6; ROBBELEN G, 1966, ARABID INF SERV, V3, P16; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; SPRINGER PS, 1995, SCIENCE, V268, P877, DOI 10.1126/science.7754372; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; TKACHUK DC, 1992, CELL, V71, P869; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; VANDERVEEN JH, 1973, ARABID INF SERV, V10, P11; VIELLECALZADA JP, UNPUB; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YU BD, 1995, NATURE, V378, P595	43	662	713	5	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					446	450		10.1126/science.280.5362.446	http://dx.doi.org/10.1126/science.280.5362.446			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545225				2022-12-01	WOS:000073159600051
J	Legault, P; Li, J; Mogridge, J; Kay, LE; Greenblatt, J				Legault, P; Li, J; Mogridge, J; Kay, LE; Greenblatt, J			NMR structure of the bacteriophage lambda N peptide/boxB RNA complex: Recognition of a GNRA fold by an arginine-rich motif	CELL			English	Article							NUSA GENE PROTEIN; ESCHERICHIA-COLI; RIBOSOMAL-RNA; TRANSCRIPTION ANTITERMINATION; HAMMERHEAD RIBOZYME; CRYSTAL-STRUCTURE; ANTI-TERMINATION; GAAA TETRALOOP; PHAGE-LAMBDA; LOOP	The structure of the complex formed by the arginine-rich motif of the transcriptional antitermination protein N of phage lambda and boxB RNA was determined by heteronuclear magnetic resonance spectroscopy. A bent alpha helix in N recognizes primarily the shape and negatively charged surface of the boxB hairpin through multiple hydrophobic and ionic interactions. The GAAGA boxB loop forms a GNRA fold, previously described for tetraloops, which is essential for N binding. The fourth nucleotide of the loop extrudes from the GNRA fold to enable the E. coli elongation factor NusA to recognize the N protein/RNA complex. This structure reveals a new mode of RNA-protein recognition and shows how a small RNA element can facilitate a protein-protein interaction and thereby nucleate formation of a large ribonucleoprotein complex.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Prot Engn Network Ctr Excellence, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Chem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Legault, P (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 100 Coll St, Toronto, ON M5S 1A8, Canada.			Legault, Pascale/0000-0003-1782-5204				Abramovitz DL, 1997, J MOL BIOL, V266, P493, DOI 10.1006/jmbi.1996.0810; Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; ALLEN P, 1995, VIROLOGY, V209, P327, DOI 10.1006/viro.1995.1264; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARAFA YD, 1990, J MOL BIOL, V216, P835, DOI 10.1016/S0022-2836(99)80005-9; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CHATTOPADHYAY S, 1995, P NATL ACAD SCI USA, V92, P4061, DOI 10.1073/pnas.92.9.4061; Chattopadhyay S, 1995, P NATL ACAD SCI USA, V92, P12131, DOI 10.1073/pnas.92.26.12131; Cilley CD, 1997, RNA, V3, P57; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; deQuinto SL, 1997, J VIROL, V71, P4171; DOELLING JH, 1989, NUCLEIC ACIDS RES, V17, P5565, DOI 10.1093/nar/17.14.5565; FRANKLIN NC, 1993, J MOL BIOL, V231, P343, DOI 10.1006/jmbi.1993.1287; FRANKLIN NC, 1985, J MOL BIOL, V181, P75, DOI 10.1016/0022-2836(85)90325-0; FRIEDMAN DI, 1995, MOL MICROBIOL, V18, P191, DOI 10.1111/j.1365-2958.1995.mmi_18020191.x; GLUCK A, 1992, J MOL BIOL, V226, P411, DOI 10.1016/0022-2836(92)90956-K; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; GUTELL RR, 1994, MICROBIOL REV, V58, P10, DOI 10.1128/MMBR.58.1.10-26.1994; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jucker FM, 1996, J MOL BIOL, V264, P968, DOI 10.1006/jmbi.1996.0690; JUCKER FM, 1995, RNA, V1, P219; Konrat R, 1997, J BIOMOL NMR, V9, P409, DOI 10.1023/A:1018354712430; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LeCuyer KA, 1996, EMBO J, V15, P6847, DOI 10.1002/j.1460-2075.1996.tb01076.x; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; Mogridge J, 1998, MOL CELL, V1, P265, DOI 10.1016/S1097-2765(00)80027-1; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; MUNOZ V, 1995, NAT STRUCT BIOL, V2, P380, DOI 10.1038/nsb0595-380; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; OLSON ER, 1984, J MOL BIOL, V180, P1053, DOI 10.1016/0022-2836(84)90270-5; ORITA M, 1993, NUCLEIC ACIDS RES, V21, P5670, DOI 10.1093/nar/21.24.5670; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; Saenger W, 2013, PRINCIPLES NUCL ACID; SALSTROM JS, 1978, J MOL BIOL, V124, P195, DOI 10.1016/0022-2836(78)90156-0; Schultze P, 1997, NATURE, V387, P668, DOI 10.1038/42632; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; Su LL, 1997, GENE DEV, V11, P2214, DOI 10.1101/gad.11.17.2214; Su LL, 1997, BIOCHEMISTRY-US, V36, P12722, DOI 10.1021/bi971408k; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; VanGilst MR, 1997, BIOCHEMISTRY-US, V36, P1514, DOI 10.1021/bi961920q; Varani G, 1997, ACCOUNTS CHEM RES, V30, P189, DOI 10.1021/ar960035x; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wijmenga S. S., 1993, NMR MACROMOLECULES P, P217; Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6; Ye XM, 1996, NAT STRUCT BIOL, V3, P1026, DOI 10.1038/nsb1296-1026; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	58	223	226	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					289	299		10.1016/S0092-8674(00)81579-2	http://dx.doi.org/10.1016/S0092-8674(00)81579-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568720	Bronze			2022-12-01	WOS:000073174000014
J	Anand, SS; Wells, PS; Hunt, D; Brill-Edwards, P; Cook, D; Ginsberg, JS				Anand, SS; Wells, PS; Hunt, D; Brill-Edwards, P; Cook, D; Ginsberg, JS			Does this patient have deep vein thrombosis?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUSPECTED VENOUS THROMBOSIS; SERIAL IMPEDANCE PLETHYSMOGRAPHY; TIME COMPRESSION ULTRASONOGRAPHY; B-MODE ULTRASONOGRAPHY; SYMPTOMATIC OUTPATIENTS; DIAGNOSTIC MANAGEMENT; CLINICAL EXAMINATION; PULMONARY-EMBOLISM; D-DIMER; VENOGRAPHY	Objective.-To review the validity of the clinical assessment and diagnostic tests in patients with suspected deep vein thrombosis (DVT). Methods.-A comprehensive review of the literature was conducted by searching MEDLINE from 1966 to April 1997. Results.-Individual symptoms and signs alone do nor reliably predict which patients have DVT, Overall, the diagnostic properties of the clinical examination are poor; the sensitivity of the clinical examination ranges from 60% to 96%, and the specificity ranges from 20% to 72%, However, using specific combinations of risk factors, symptoms, and physical signs for DVT, clinicians can reliably stratify patients with suspected DVT into low, moderate, or high pretest probability categories of actually suffering from DVT, This stratification process in combination with noninvasive testing, such as compression ultrasonography, simplifies the management strategies for patients with suspected DVT. Conclusions.-Use of a clinical prediction guide that includes specific factors from both the history and physical examination in combination with noninvasive tests simplifies management strategies for patients with suspected DVT.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol, Hamilton, ON L8S 4L8, Canada; Ottawa Civic Hosp, Dept Med, Ottawa, ON K1Y 4E9, Canada	McMaster University; McMaster University; University of Ottawa; Ottawa Hospital Research Institute	Anand, SS (corresponding author), Hamilton Gen Hosp, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	anands@ths.momaster.ca	ginsberg, jeffrey s/ABC-1065-2020					ANDERSON DR, 1993, ANN INTERN MED, V118, P25, DOI 10.7326/0003-4819-118-1-199301010-00005; BARNES RW, 1975, JAMA-J AM MED ASSOC, V234, P605, DOI 10.1001/jama.234.6.605; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; BROWSE N, 1969, BRIT MED J, V684, P676; COGO A, 1994, ARCH INTERN MED, V154, P164, DOI 10.1001/archinte.154.2.164; COGO A, 1994, ANGIOLOGY, V45, P377, DOI 10.1177/000331979404500507; COGO A, 1993, ARCH INTERN MED, V153, P2777, DOI 10.1001/archinte.153.24.2777; COGO A, 1995, THROMB HAEMOSTASIS, V73, P1098; COGO A, 1993, THROMB HAEMOSTASIS, V70, P404; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; GINSBERG JS, 1994, ARCH INTERN MED, V154, P1930, DOI 10.1001/archinte.154.17.1930; Ginsberg JS, 1996, NEW ENGL J MED, V335, P1816, DOI 10.1056/NEJM199612123352407; GUNINTINI C, 1995, CHEST, V107, pS3; HAEGER K, 1969, ANGIOLOGY, V20, P219, DOI 10.1177/000331976902000406; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HEIJBOER H, 1992, ARCH INTERN MED, V152, P1901, DOI 10.1001/archinte.152.9.1901; HIRSH J, 1995, CHEST, V108, pS258, DOI 10.1378/chest.108.4_Supplement.258S; Hirsh J, 1996, CIRCULATION, V93, P2212, DOI 10.1161/01.CIR.93.12.2212; HIRSH J, 1986, J AM COLL CARDIOL, V8, pB114, DOI 10.1016/S0735-1097(86)80013-4; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HULL R, 1977, NEW ENGL J MED, V296, P1497, DOI 10.1056/NEJM197706302962604; HULL R, 1976, CIRCULATION, V53, P696, DOI 10.1161/01.CIR.53.4.696; HULL R, 1981, ANN INTERN MED, V94, P12, DOI 10.7326/0003-4819-94-1-12; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; HULL RD, 1984, CLIN CHEST MED, V5, P439; HYERS TM, 1995, CHEST, V108, pS335, DOI 10.1378/chest.108.4_Supplement.335S; LANDEFELD CS, 1990, AM J MED, V88, P388; LENSING AWA, 1990, RADIOLOGY, V177, P503, DOI 10.1148/radiology.177.2.2217792; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1994, HEMOSTASIS THROMBOSI, P1297; MATTOS MA, 1992, J VASC SURG, V15, P366, DOI 10.1016/0741-5214(92)90258-A; MCLACHLIN J, 1962, ARCH SURG-CHICAGO, V85, P738; MOLLOY W, 1982, IRISH MED J, V75, P119; ODONNELL TF, 1980, SURG GYNECOL OBSTET, V150, P69; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P229; PRANDONI P, 1991, THROMB HAEMOSTASIS, V65, P233; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SALE S, 1994, THROMB HEMOST, V71, P270; SALZMAN EW, 1994, HEMOSTASIS THROMBOSI, P1275; SIMPSON FG, 1980, LANCET, V1, P331; VINE HS, 1981, AM J ROENTGENOL, V136, P167, DOI 10.2214/ajr.136.1.167; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WELLS P, 1997, LANCET, V356, P1795; Wells PS, 1995, THROMB HAEMOSTASIS, V74, P1423; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; WELLS PS, 1995, CIRCULATION, V91, P2184, DOI 10.1161/01.CIR.91.8.2184; WHITE RH, 1989, ANN INTERN MED, V111, P297, DOI 10.7326/0003-4819-111-4-297	51	133	136	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1094	1099		10.1001/jama.279.14.1094	http://dx.doi.org/10.1001/jama.279.14.1094			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF216	9546569				2022-12-01	WOS:000072875300034
J	Owsley, C; Ball, K; McGwin, G; Sloane, ME; Roenker, DL; White, MF; Overley, ET				Owsley, C; Ball, K; McGwin, G; Sloane, ME; Roenker, DL; White, MF; Overley, ET			Visual processing impairment and risk of motor vehicle crash among older adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY DRIVERS; ACCIDENTS; FIELD; SENSITIVITY; ATTENTION; AGE	Context.-Motor vehicle crash risk in older drivers has been associated with visual acuity loss, but only weakly so, suggesting other factors contribute. The useful field of view is a measure that reflects decline in visual sensory function, slowed visual processing speed, and impaired visual attention skills. Objective.-To identify whether measures of visual processing ability, including the useful field of view test, are associated with crash involvement by older drivers. Design.-Prospective cohort study with 3 years of follow-up, 1990-1993. Setting.-Ophthalmology clinic assessment of community-based sample. Patients.-A total of 294 drivers aged 55 to 87 years at enrollment. Main Outcome Measure.-Motor vehicle crash occurrence. Results.-Older drivers with a 40% or greater impairment in the useful field of view were 2.2 times (95% confidence interval, 1.2-4.1) more likely to incur a crash during 3 years of follow-up, after adjusting for age, sex, race, chronic medical conditions, mental status, and days driven per week, This association was primarily mediated by difficulty in dividing attention under brief target durations. Conclusion.-Reduction in the useful field of view increases crash risk in older drivers, Given the relatively high prevalence of visual processing impairment among the elderly, visual dysfunction and eye disease deserve further examination as causes of motor vehicle crashes and injury.	Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA; Univ Alabama Birmingham, Sch Med, Dept Psychol, Birmingham, AL USA; Univ Alabama Birmingham, Sch Med, Dept Epidemiol, Birmingham, AL USA; Univ Alabama Birmingham, Sch Med, Dept Physiol Opt, Birmingham, AL USA; Western Kentucky Univ, Dept Psychol, Bowling Green, KY 42101 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Western Kentucky University	Owsley, C (corresponding author), Univ Alabama Birmingham, Sch Med, Eye Fdn Hosp, Dept Ophthalmol,Clin Res Unit, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.	owsley@eyes.uab.edu		Ball, Karlene/0000-0003-1811-9870	NIA NIH HHS [AG11684, AG05739, AG04212] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG005739, R01AG005739, P50AG011684, R01AG004212] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allison P.D., 2010, SURVIVAL ANAL USING; BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; Ball K, 1993, J Am Optom Assoc, V64, P71; Ball K., 1990, DEV ATTENTION RES TH, V69, P489, DOI DOI 10.1016/S0166-4115(08)60472-0; BALL K, IN PRESS ACCID ANAL; BALL KK, 1988, J OPT SOC AM A, V5, P2210, DOI 10.1364/JOSAA.5.002210; BRENTON RS, 1986, OPHTHALMOLOGICA, V193, P56, DOI 10.1159/000309679; Collett, 2014, MODELLING SURVIVAL D; COOPER PJ, 1993, J SAFETY RES, V24, P9, DOI 10.1016/0022-4375(93)90047-Q; DECINA LE, 1993, ACCIDENT ANAL PREV, V25, P267, DOI 10.1016/0001-4575(93)90021-N; DRACHMAN DA, 1988, ANN NEUROL, V24, P787, DOI 10.1002/ana.410240614; EVANS L, 1988, J TRAUMA, V28, P368, DOI 10.1097/00005373-198803000-00013; Evans Leonard, 1991, TRAFFIC SAFETY DRIVE; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0; FLAHERTY JH, 1995, CLIN GERIATR MED, V3, P44; FOLEY DJ, 1995, J AM GERIATR SOC, V43, P776, DOI 10.1111/j.1532-5415.1995.tb07049.x; Haapanen N, 1997, AM J EPIDEMIOL, V145, P762, DOI 10.1093/aje/145.8.762; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; Janke MK, 1994, TRANSPORT RES REC, V1438, P77; Johansson K, 1996, J AM GERIATR SOC, V44, P1198, DOI 10.1111/j.1532-5415.1996.tb01369.x; JOHNSON CA, 1983, ARCH OPHTHALMOL-CHIC, V101, P371; KAHNEMAN D, 1973, J APPL PSYCHOL, V58, P113, DOI 10.1037/h0035426; KELTNER JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1697, DOI 10.1001/archopht.1992.01080240037023; Kleinbaum D, 1996, SURVIVAL ANAL SELF L; KOEPSEL TD, 1994, J AM GERIATR SOC, V42, P695, DOI 10.1111/j.1532-5415.1994.tb06526.x; LEVEILLE SG, 1994, EPIDEMIOLOGY, V5, P591, DOI 10.1097/00001648-199411000-00006; MAROTTOLI RA, 1994, ANN INTERN MED, V121, P842, DOI 10.7326/0003-4819-121-11-199412010-00003; MARTINEZ R, 1995, JAMA-J AM MED ASSOC, V274, P1060, DOI 10.1001/jama.274.13.1060; Mattis S., 1976, GERIATRIC PSYCHIAT, P77; MCKNIGHT AJ, 1982, HS806336 DOT; Murakami E, 1997, COMP COMPUTER ASSIST; *NAT HIGHW TRAFF S, 1989, C RES DEV NEED IMPR; OWSLEY C, 1995, VISION RES, V35, P579, DOI 10.1016/0042-6989(94)00166-J; OWSLEY C, 1991, PSYCHOL AGING, V6, P403, DOI 10.1037/0882-7974.6.3.403; OWSLEY C, IN PRESS OPHTHALMIC; PELLI DG, 1988, CLIN VISION SCI, V2, P187; RAY WA, 1992, AM J EPIDEMIOL, V136, P873, DOI 10.1093/aje/136.7.873; REUBEN DB, 1988, J AM GERIATR SOC, V36, P1135, DOI 10.1111/j.1532-5415.1988.tb04403.x; ROENKER DL, 1997, INVEST OPHTHALMOL  S, V38, P871; Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557; SANDERS A F, 1970, Ergonomics, V13, P101, DOI 10.1080/00140137008931124; SIMONS K, 1981, ARCH OPHTHALMOL-CHIC, V99, P446; Transportation Research Board, 1988, TRANSP AG SOC, V1; WALLER JA, 1967, J CHRON DIS, V20, P615, DOI 10.1016/0021-9681(67)90038-0	44	566	571	0	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1083	1088		10.1001/jama.279.14.1083	http://dx.doi.org/10.1001/jama.279.14.1083			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZF216	9546567	Bronze			2022-12-01	WOS:000072875300032
J	Montgomery, SM; Morris, DL; Thompson, NP; Subhani, J; Pounder, RE; Wakefield, AJ				Montgomery, SM; Morris, DL; Thompson, NP; Subhani, J; Pounder, RE; Wakefield, AJ			Prevalence of inflammatory bowel disease in British 26 year olds: national longitudinal birth cohort	BRITISH MEDICAL JOURNAL			English	Article									Univ London, Royal Free Hosp, Sch Med, Dept Med, London NW3 2PF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Montgomery, SM (corresponding author), Univ London, Royal Free Hosp, Sch Med, Dept Med, London NW3 2PF, England.		Montgomery, Scott/AAN-2546-2020	Montgomery, Scott/0000-0001-6328-5494				EKINSMYTH C, 1993, INTEGRATED APPROACH; EVANS JG, 1965, GUT, V6, P311, DOI 10.1136/gut.6.4.311; KEIGHLEY A, 1976, SCAND J GASTROENTERO, V2, P293; MAYBERRY J, 1979, GUT, V20, P602, DOI 10.1136/gut.20.7.602; Montgomery SM, 1997, LANCET, V349, P472, DOI 10.1016/S0140-6736(05)61183-X	5	38	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 4	1998	316	7137					1058	1059						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552907				2022-12-01	WOS:000072987400025
J	Greenhalgh, T; Helman, C; Chowdhury, AM				Greenhalgh, T; Helman, C; Chowdhury, AM			Health beliefs and folk models of diabetes in British Bangladeshis: A qualitative study	BRITISH MEDICAL JOURNAL			English	Article							OJIBWAY	Objective: To explore the experience of diabetes in British Bangladeshis, since successful management of diabetes requires attention not just to observable behaviour but to the underlying attitudes and belief systems which drive that behaviour. Design: Qualitative study of subjects' experience of diabetes using narratives, semi-structured interviews, focus groups, and pile sorting exercises. A new qualitative method, the structured vignette, was developed for validating researchers' understanding of primary level culture. Subjects: 40 British Bangladeshi patients with diabetes, and 10 non-Bangladeshi controls, recruited from primary care. Result: Several constructs were detected in relation to body image, cause and nature of diabetes, food classification, and knowledge of complications. In some areas, the similarities between Bangladeshi and non-Bangladeshi subjects were as striking as their differences. There was little evidence of a fatalistic or deterministic attitude to prognosis, and most informants seemed highly motivated to alter their diet and comply with treatment Structural and material barriers to behaviour change were at least as important as "cultural" ones. Conclusion: Bangladeshi culture is neither seamless nor static, but some widely held beliefs and behaviours have been identified. Some of these have a potentially beneficial effect on health and should be used as the starting point for culturally sensitive diabetes education.	UCL, Royal Free Hosp,Sch Med,Whittington Hosp, Joint Dept Primary Care & Populat, Qualitat Res Unit, London N19 5NF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Greenhalgh, T (corresponding author), UCL, Royal Free Hosp,Sch Med,Whittington Hosp, Joint Dept Primary Care & Populat, Qualitat Res Unit, London N19 5NF, England.	p.greenhalgh@ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIRHIHENBUWA CO, 1992, AIDS EDUC PREV, V4, P267; AIRHIHENBUWA CO, 1995, HLTH CULTURE W PARAD, P25; ANDERSON JM, 1995, SOC SCI MED, V41, P181, DOI 10.1016/0277-9536(94)00324-M; Becker M H, 1986, Public Health Rev, V14, P15; BRADLEY C, 1994, DIABETIC MED, V11, P510, DOI 10.1111/j.1464-5491.1994.tb00316.x; Calman KC, 1997, BRIT MED J, V314, P1187, DOI 10.1136/bmj.314.7088.1187a; CHOWDHURY AM, 1986, THESIS U EXETER EXET; Crawford Robert, 1984, ISSUES POLITICAL EC, P60; Daniel M, 1995, DIABET SPECTRUM, V8, P80; Garro L C, 1995, Soc Sci Med, V40, P37, DOI 10.1016/0277-9536(94)00125-D; Gittelsohn J, 1996, HEALTH EDUC QUART, V23, P365, DOI 10.1177/109019819602300307; Grams GD, 1996, CAN MED ASSOC J, V155, P1563; Greenhalgh PM, 1997, DIABETIC MED, V14, P10; HALL ET, 1977, BEYOND CULTURE; HAYES BE, 1994, QUALITY PROGR    FEB, P41; HELMAN C, 1994, CULTURE HLTH ILLNESS, P21; Helman C.G., 1994, CULTURE HLTH ILLNESS, V3rd ed.; HELMAN CG, 1991, PRIMARY CARE RES TRA, P105; Hiller, 1996, RES CULTURAL DIFFERE, P220; *HLTH ED AUTH, 1994, HLTH LIF SURV BLACK; KITZINGER J, 1994, SOCIOLOGY HLTH ILLNE, V16, P104; LAMBERT H, 1992, SOC SCI MED, V34, P1069, DOI 10.1016/0277-9536(92)90280-4; LAMBERT H, 1996, MISUNDERSTANDING SCI, P65, DOI DOI 10.1017/CBO9780511563737.004; Morse JM., 1994, HDB QUALITATIVE RES, P230; PIERCE M, 1997, THESIS U LONDON LOND; [No title captured]	26	195	196	0	14	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					978	983		10.1136/bmj.316.7136.978	http://dx.doi.org/10.1136/bmj.316.7136.978			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550958	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000072856100022
J	Hamman, BD; Hendershot, LM; Johnson, AE				Hamman, BD; Hendershot, LM; Johnson, AE			BiP maintains the permeability barrier of the ER membrane by sealing the lumenal end of the translocon pore before and early in translocation	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN DISULFIDE-ISOMERASE; SECRETORY PROTEINS; YEAST; COMPLEX; BINDING; TRANSPORT; CO	Secretory proteins are cotranslationally translocated across the mammalian ER membrane through an aqueous pore in the translocon while the permeability barrier is maintained by a tight ribosome-membrane junction. The lumenal end of the pore is also blocked early in translocation. Extraction of soluble lumenal proteins from microsomes and reconstitution with purified proteins demonstrate, by fluorescence collisional quenching, that BiP seals the lumenal end of this pore. BiP also seals translocons that are assembled but are not engaged in translocation. These ribosome-free translocons have smaller pores (9-15 Angstrom diameter versus 40-60 Angstrom in functioning translocons) and are generated when ribosomes dissociate from functioning translocons with large pores. BiP therefore maintains the permeability barrier by sealing both nontranslocating and newly targeted translocons.	Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; St Jude Children's Research Hospital	Johnson, AE (corresponding author), Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA.		Hendershot, Linda/N-8124-2018; Johnson, Arthur E/G-3457-2012	Hendershot, Linda/0000-0002-5473-0274; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054068, R01GM026494] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54068, GM 26494] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; Corsi AK, 1997, J CELL BIOL, V137, P1483, DOI 10.1083/jcb.137.7.1483; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Johnson AE, 1997, TRENDS CELL BIOL, V7, P90, DOI 10.1016/S0962-8924(97)01029-5; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; MAYINGER P, 1995, J CELL BIOL, V131, P1377, DOI 10.1083/jcb.131.6.1377; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PAVER JL, 1989, BIOCHEM J, V257, P657, DOI 10.1042/bj2570657; Powers T, 1996, CURR BIOL, V6, P331, DOI 10.1016/S0960-9822(02)00484-0; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROWLING PJE, 1994, PROTEIN EXPRES PURIF, V5, P331, DOI 10.1006/prep.1994.1049; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670	33	345	350	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					747	758		10.1016/S0092-8674(00)81403-8	http://dx.doi.org/10.1016/S0092-8674(00)81403-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529251	Bronze			2022-12-01	WOS:000072661200008
J	MacBeath, G; Kast, P; Hilvert, D				MacBeath, G; Kast, P; Hilvert, D			Redesigning enzyme topology by directed evolution	SCIENCE			English	Article							CHORISMATE MUTASE; PROTEIN; DOMAIN; SELECTION; MECHANISM; CREATION; SEQUENCE; MONOMER; SITE; ROP	Genetic selection was exploited in combination with structure-based design to transform an intimately entwined, dimeric chorismate mutase into a monomeric, four-helix-bundle protein with near native activity. Successful reengineering depended on choosing a thermostable starting protein, introducing point mutations that preferentially destabilize the wild-type dimer, and using directed evolution to optimize an inserted interhelical turn, Contrary to expectations based on studies of other four-helix-bundle proteins, only a small fraction of possible turn sequences (fewer than 0.05 percent) yielded well-behaved, monomeric, and highly active enzymes, Selection for catalytic function thus provides an efficient yet stringent method for rapidly assessing correctly folded polypeptides and may prove generally useful for protein design.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Hilvert, D (corresponding author), Swiss Fed Inst Technol ETH, Dept Chem, CH-8092 Zurich, Switzerland.							Albright RA, 1996, BIOCHEMISTRY-US, V35, P735, DOI 10.1021/bi951958n; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BORCHERT TV, 1994, P NATL ACAD SCI USA, V91, P1515, DOI 10.1073/pnas.91.4.1515; Braisted AC, 1996, P NATL ACAD SCI USA, V93, P5688, DOI 10.1073/pnas.93.12.5688; BRUNET AP, 1993, NATURE, V364, P355, DOI 10.1038/364355a0; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CASTAGNOLI L, 1994, J MOL BIOL, V237, P378, DOI 10.1006/jmbi.1994.1241; Dickason RR, 1996, NATURE, V379, P652, DOI 10.1038/379652a0; DIDONATO A, 1994, J BIOL CHEM, V269, P17394; FACBEATH G, UNPUB; Galopin CC, 1996, TETRAHEDRON LETT, V37, P8675, DOI 10.1016/S0040-4039(96)02007-2; Galopin CC, 1997, TETRAHEDRON LETT, V38, P1467; Gu W, 1997, Microb Comp Genomics, V2, P141, DOI 10.1089/omi.1.1997.2.141; Haslam E, 1993, SHIKIMIC ACID METABO; Kast P, 1996, P NATL ACAD SCI USA, V93, P5043, DOI 10.1073/pnas.93.10.5043; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90, DOI DOI 10.1007/S00249-009-0425-1; LEE AY, 1995, J AM CHEM SOC, V117, P3627, DOI 10.1021/ja00117a038; MacBeath G, 1998, PROTEIN SCI, V7, P325; MOSSING MC, 1990, SCIENCE, V250, P1712, DOI 10.1126/science.2148648; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; Oakley MG, 1997, BIOCHEMISTRY-US, V36, P2544, DOI 10.1021/bi962391t; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; PREDKI PF, 1995, BIOCHEMISTRY-US, V34, P9834, DOI 10.1021/bi00031a003; Schliebs W, 1997, BIOCHEMISTRY-US, V36, P9655, DOI 10.1021/bi963086a; TRINKL S, 1994, PROTEIN SCI, V3, P1392, DOI 10.1002/pro.5560030905	27	102	109	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1958	1961		10.1126/science.279.5358.1958	http://dx.doi.org/10.1126/science.279.5358.1958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506949				2022-12-01	WOS:000072613300052
J	Wallin, JJ; Gackstetter, ER; Koshland, ME				Wallin, JJ; Gackstetter, ER; Koshland, ME			Dependence of BSAP repressor and activator functions on BSAP concentration	SCIENCE			English	Article							B-CELL DIFFERENTIATION; J-CHAIN GENE; TRANSCRIPTION FACTOR BSAP; IMMUNOGLOBULIN-J-CHAIN; 3'ALPHA ENHANCER; NF-HB; EXPRESSION; PROMOTER; INTERLEUKIN-2; BINDING	During a B cell immune response, the transcription factor BSAP maintains its activator functions but is relieved of its repressor functions. This selective targeting of BSAP activities was shown to be regulated by a concentration-dependent mechanism whereby activator motifs for BSAP had a 20-fold higher binding affinity than repressor motifs. An exchange of activator and repressor motifs, however, showed that the context of the motif, rather than the affinity, determined whether BSAP operated as an activator or repressor.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Wallin, JJ (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA.			Wallin, Jeffrey/0000-0002-5952-3813	NCI NIH HHS [CA09179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BUSSLINGER M, 1995, CURR OPIN GENET DEV, V5, P595, DOI 10.1016/0959-437X(95)80028-X; COGNE M, 1994, CELL, V77, P737, DOI 10.1016/0092-8674(94)90057-4; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; Gaffen SL, 1996, CYTOKINE, V8, P513, DOI 10.1006/cyto.1996.0070; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LAMSON G, 1984, J EXP MED, V160, P877, DOI 10.1084/jem.160.3.877; LANSFORD RD, 1992, P NATL ACAD SCI USA, V89, P5966, DOI 10.1073/pnas.89.13.5966; LLAO F, 1994, J IMMUNOL, V152, P2904; MCFADDEN HJ, 1991, P NATL ACAD SCI USA, V88, P11027, DOI 10.1073/pnas.88.24.11027; Michaelson JS, 1996, J IMMUNOL, V156, P2349; NEURATH MF, 1995, IMMUNOL TODAY, V16, P564, DOI 10.1016/0167-5699(95)80078-6; NEURATH MF, 1994, J IMMUNOL, V153, P730; NILES MJ, 1995, P NATL ACAD SCI USA, V92, P2884, DOI 10.1073/pnas.92.7.2884; Rinkenberger JL, 1996, IMMUNITY, V5, P377, DOI 10.1016/S1074-7613(00)80263-0; Sambrook J., 1989, MOL CLONING LAB MANU; Sato S, 1997, J IMMUNOL, V158, P4662; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; Small S, 1991, CURR OPIN GENET DEV, V1, P255, DOI 10.1016/S0959-437X(05)80079-6; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Usui T, 1997, J IMMUNOL, V158, P3197	25	48	52	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1961	1964		10.1126/science.279.5358.1961	http://dx.doi.org/10.1126/science.279.5358.1961			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506950				2022-12-01	WOS:000072613300053
J	Zhang, YP; Xiong, Y; Yarbrough, WG				Zhang, YP; Xiong, Y; Yarbrough, WG			ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways	CELL			English	Article							CELL-CYCLE CONTROL; RETINOBLASTOMA PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; GENE-PRODUCT; CANCER; COMPLEX; UBIQUITINATION; AMPLIFICATION; EXPRESSION	The INK4a-ARF locus encodes two unrelated proteins that both function in tumor suppression. p16(INK4a) binds to and inhibits the activity of CDK4 and CDK6, and ARF arrests the cell cycle in a p53-dependent manner. We show here that ARF binds to MDM2 and promotes the rapid degradation of MDM2. This interaction is mediated by the exon 1 beta-encoded N-terminal domain of ARF and a C-terminal region of MDM2. ARF-promoted MDM2 degradation is associated with MDM2 modification and concurrent p53 stabilization and accumulation. The functional consequence of ARF-regulated p53 levels via MDM2 proteolysis is evidenced by the ability of ectopically expressed ARF to restore a; p53-imposed G1 cell cycle arrest that is otherwise abrogated by MDM2. Thus, deletion of the ARF-INK4a locus simultaneously impairs both the INK4a-cyclin D/CDK4-RB and the ARF-MDM2-p53 pathways.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Surg, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Xiong, Y (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.				NCI NIH HHS [KO8-CA72968, R01-CA65572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA072968, R01CA065572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BUTZ K, 1995, ONCOGENE, V10, P927; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DURO D, 1995, ONCOGENE, V11, P21; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KATO J, 1993, GENE DEV, V7, P331; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LEACH FS, 1993, CANCER RES, V53, P2231; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; MAO L, 1995, CANCER RES, V55, P2995; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1997, P NATL ACAD SCI USA, V94, P3436; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; STONE S, 1995, CANCER RES, V55, P2988; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XIONG Y, 1993, GENE DEV, V7, P1527; Yarbrough WG, 1996, J NATL CANCER I, V88, P1489, DOI 10.1093/jnci/88.20.1489	47	1331	1370	2	54	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					725	734		10.1016/S0092-8674(00)81401-4	http://dx.doi.org/10.1016/S0092-8674(00)81401-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529249	Bronze, Green Published			2022-12-01	WOS:000072661200006
J	Okuda-Ashitaka, E; Minami, T; Tachibana, S; Yoshihara, Y; Nishiuchi, Y; Kimura, T; Ito, S				Okuda-Ashitaka, E; Minami, T; Tachibana, S; Yoshihara, Y; Nishiuchi, Y; Kimura, T; Ito, S			Nocistatin, a peptide that blocks nociceptin action in pain transmission	NATURE			English	Article							OPIOID RECEPTOR FAMILY; ORPHANIN-FQ; TISSUE DISTRIBUTION; REGIONAL DISTRIBUTION; PROSTAGLANDIN E(2); MOLECULAR-CLONING; GENE; NEUROPEPTIDE; PRECURSOR; MEMBER	Prolonged tissue damage or injury often leads to chronic pain states such that noxious stimuli evoke hyperalgesia and innocuous tactile stimuli evoke pain (allodynia)(1,2), The neuropeptide nociceptin(3,4), also known as orphanin FQ (ref. 5), is an endogenous ligand for the orphan opioid-like receptor(6-8) which induces both hyperalgesia and allodynia when administered by injection through the theca of the spinal cord into the subarachnoid space (that is, intrathecally)(4,9). Here we show that the nociceptin precursor(3,10-13) contains another biologically active peptide which we call nocistatin, Nocistatin blocks nociceptin-induced allodynia and hyperalgesia, and attenuates pain evoked by prostaglandin E-2. It is the carboxy-terminal hexapeptide of nocistatin (Glu-Gln-Lys-Gln-Leu-Gin), which is conserved in bovine, human and murine species, that possesses allodynia-blocking activity, We have also isolated endogenous nocistatin from bovine brain, Furthermore, intrathecal pretreatment with anti-nocistatin antibody decreases the threshold for nociceptin-induced allodynia, Although nocistatin does not bind to the nociceptin receptor, it binds to the membrane of mouse brain and of spinal cord with high affinity, Our results show that nocistatin is a new biologically active peptide produced from the same precursor as nociceptin and indicate that these two peptides may play opposite roles in pain transmission.	Kansai Med Univ, Dept Med Chem, Moriguchi, Osaka 570, Japan; Osaka Med Coll, Dept Anesthesiol, Takatsuki, Osaka 569, Japan; Osaka Med Coll, Dept Biochem, Takatsuki, Osaka 569, Japan; Natl Univ Singapore, Sch Biol Sci, Singapore 119260, Singapore; Osaka Biosci Inst, Dept Neurosci, Suita, Osaka 565, Japan; Prot Res Fdn, Peptide Inst Inc, Minoh 562, Japan	Kansai Medical University; Osaka Medical College; Osaka Medical College; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore	Ito, S (corresponding author), Kansai Med Univ, Dept Med Chem, Moriguchi, Osaka 570, Japan.		Yoshihara, Yoshihiro/N-6481-2015	Yoshihara, Yoshihiro/0000-0002-0319-7166				AMANO F, 1988, J CELL PHYSIOL, V135, P502, DOI 10.1002/jcp.1041350319; BUNZOW JR, 1994, FEBS LETT, V347, P284, DOI 10.1016/0014-5793(94)00561-3; DRAY A, 1994, TRENDS PHARMACOL SCI, V15, P190, DOI 10.1016/0165-6147(94)90147-3; Florin S, 1997, NEUROREPORT, V8, P705, DOI 10.1097/00001756-199702100-00025; FUKUDA K, 1994, FEBS LETT, V343, P42, DOI 10.1016/0014-5793(94)80603-9; Hara N, 1997, BRIT J PHARMACOL, V121, P401, DOI 10.1038/sj.bjp.0701146; Houtani T, 1996, BIOCHEM BIOPH RES CO, V219, P714, DOI 10.1006/bbrc.1996.0300; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MINAMI T, 1994, BRIT J PHARMACOL, V112, P735, DOI 10.1111/j.1476-5381.1994.tb13139.x; MINAMI T, 1994, PAIN, V57, P217, DOI 10.1016/0304-3959(94)90226-7; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; Mollereau C, 1996, P NATL ACAD SCI USA, V93, P8666, DOI 10.1073/pnas.93.16.8666; Nothacker HP, 1996, P NATL ACAD SCI USA, V93, P8677, DOI 10.1073/pnas.93.16.8677; OkudaAshitaka E, 1996, J BIOL CHEM, V271, P31255, DOI 10.1074/jbc.271.49.31255; OkudaAshitaka E, 1996, MOL BRAIN RES, V43, P96, DOI 10.1016/S0169-328X(96)00165-9; Pan YX, 1996, BIOCHEM J, V315, P11, DOI 10.1042/bj3150011; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Reinscheid RK, 1996, J BIOL CHEM, V271, P14163, DOI 10.1074/jbc.271.24.14163; Saito Y, 1996, J BIOL CHEM, V271, P15615, DOI 10.1074/jbc.271.26.15615; TAIWO YO, 1988, J NEUROSCI, V8, P1346; WOOLF CJ, 1994, TXB PAIN, P101	22	203	215	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					286	289		10.1038/32660	http://dx.doi.org/10.1038/32660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521323				2022-12-01	WOS:000072612300048
J	Ifudu, O; Mayers, JD; Matthew, JJ; Fowler, AM; Homel, P; Friedman, EA				Ifudu, O; Mayers, JD; Matthew, JJ; Fowler, AM; Homel, P; Friedman, EA			Standardized hemodialysis prescriptions promote inadequate treatment in patients with large body mass	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES; MORTALITY; DIALYSIS; MORBIDITY; ADEQUACY; PAYMENT; WEIGHT	Background: Although a relation between the adequacy of hemodialysis and mortality has been established, hemodialysis prescription is rarely individualized precisely in adults with end-stage renal disease in the United States. Objective: To test whether persons who receive standardized hemodialysis prescriptions have an increased risk for inadequate hemodialysis with increasing body mass. Design: Cross-sectional study. Setting: Four ambulatory hemodialysis facilities in Brooklyn, New York. Patients: 214 patients receiving hemodialysis. Patients were sorted by body weight into quartiles (groups 1 through 4, in ascending order). Measurements: Urea reduction ratio (percentage reduction in blood urea nitrogen concentration after a hemodialysis session), prescribed length of hemodialysis, and body weight quartile at the start of the study. Urea reduction ratio was measured at the start of the study and at weeks 4, 8, and 12, and a mean value was calculated for each patient. Inadequate hemodialysis was defined by a urea reduction ratio of 65% or less. Results: Women had a higher mean urea reduction ratio (72% +/- 6%)than men (67.6% +/- 7%) (P < 0.001). The urea reduction ratio was inversely related to body weight (r = -0.47; P = 0.001). It was greater in group 1 (74% +/- 5.2%) than in group 2 (70% +/- 5.7%), group 3 (68% +/- 5.8%), or group 4 (66% +/- 8.4%) (P < 0.05). Logistic regression done with a urea reduction ratio of 65% or less as the outcome Variable showed that the odds of receiving inadequate hemodialysis were increased 3.5-fold in men(95% CI, 1.53-fold to 8-fold; P = 0.003), 10-fold in group 3 (CI, 2.1-fold to 50.3-fold; P = 0.003), and 13-fold in group 4 (CI, 2.6-fold to 61.6-fold; P = 0.001). Conclusions: Standardized hemodialysis prescriptions result in inadequate hemodialysis in many patients who weigh more than 68.2 kg.	SUNY Hlth Sci Ctr, Dept Med, Renal Dis Div, Brooklyn, NY 11203 USA; SUNY Hlth Sci Ctr, Dept Nursing, Brooklyn, NY 11203 USA; SUNY Hlth Sci Ctr, Sci Acad Comp Ctr, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Ifudu, O (corresponding author), SUNY Hlth Sci Ctr, Dept Med, Renal Dis Div, 450 Clarkson Ave, Brooklyn, NY 11203 USA.							BARTH RH, 1994, DEV NEPHROL, V35, P143; Berwick DM, 1996, NEW ENGL J MED, V335, P1227, DOI 10.1056/NEJM199610173351611; CHARRA B, 1992, KIDNEY INT, V41, P1286, DOI 10.1038/ki.1992.191; HAKIM RM, 1994, AM J KIDNEY DIS, V23, P661, DOI 10.1016/S0272-6386(12)70276-7; HAKIM RM, 1993, AM J KIDNEY DIS, V21, P125, DOI 10.1016/S0272-6386(12)81083-3; HELD PJ, 1994, AM J KIDNEY DIS, V24, P974, DOI 10.1016/S0272-6386(12)81108-5; HELD PJ, 1992, KIDNEY INT, V42, pS16; Ifudu O, 1997, AM J KIDNEY DIS, V30, P28, DOI 10.1016/S0272-6386(97)90561-8; IFUDU O, 1994, AM J KIDNEY DIS, V23, P394, DOI 10.1016/S0272-6386(12)81002-X; Ifudu O, 1996, NEW ENGL J MED, V334, P420, DOI 10.1056/NEJM199602153340702; KESHAVIAH PR, 1994, J AM SOC NEPHROL, V4, P1475; KOPPLE JD, 1994, AM J KIDNEY DIS, V24, P968, DOI 10.1016/S0272-6386(12)81071-7; *NIH NAT I DIAB DI, 1996, US REN DAT SYST ANN; Norusis M.J., 1993, SPSS WINDOWS ADV STA, P1; NYENGAARD JR, 1992, ANAT REC, V232, P194, DOI 10.1002/ar.1092320205; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; Sherman R A, 1993, ASAIO J, V39, P933, DOI 10.1097/00002480-199310000-00020; Tabbush V, 1996, ARCH INTERN MED, V156, P357, DOI 10.1001/archinte.156.4.357; TISHER CC, 1994, ANN INTERN MED, V121, P62; Walter F, 1939, J EXP MED, V69, P467, DOI 10.1084/jem.69.3.467	20	29	29	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					451	454		10.7326/0003-4819-128-6-199803150-00005	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499328				2022-12-01	WOS:000072414700005
J	Copeland, JRM				Copeland, JRM			Assessment of dementia	LANCET			English	Editorial Material							VASCULAR DEMENTIA; CRITERIA		Univ Liverpool, Royal Liverpool Hosp, Dept Psychiat, Liverpool L69 3BX, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Copeland, JRM (corresponding author), Univ Liverpool, Royal Liverpool Hosp, Dept Psychiat, Liverpool L69 3BX, Merseyside, England.							Amar K, 1996, AGE AGEING, V25, P51, DOI 10.1093/ageing/25.1.51; Chui H, 1997, NEUROLOGY, V49, P925, DOI 10.1212/WNL.49.4.925; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; Wetterling T, 1996, STROKE, V27, P30, DOI 10.1161/01.STR.27.1.30	4	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					769	770		10.1016/S0140-6736(05)78923-6	http://dx.doi.org/10.1016/S0140-6736(05)78923-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519943				2022-12-01	WOS:000072521200004
J	Martinez-Martinez, L; Pascual, A; Jacoby, GA				Martinez-Martinez, L; Pascual, A; Jacoby, GA			Quinolone resistance from a transferable plasmid	LANCET			English	Article							ESCHERICHIA-COLI; BETA-LACTAMASES; KLEBSIELLA-PNEUMONIAE; APPARENT ABSENCE	Background Bacteria can mutate to acquire quinolone resistance by target alterations or diminished drug accumulation. Plasmid-mediated resistance to quinolones in clinical isolates has been claimed but not confirmed. We investigated whether a multiresistance plasmid could transfer resistance to quinolones between bacteria. Methods We transferred resistance between strains by conjugation. The resistance plasmid was visualised in different hosts by agarose-gel electrophoresis. We determined the frequency of spontaneous mutations to ciprofloxacin or nalidixic-acid resistance in Escherichia coli strains, with or without the quinolone resistance plasmid. Findings A multiresistance plasmid (pMG252) from a clinical isolate of Klebsiella pneumoniae was found to increase quinolone resistance to minimum inhibitory concentrations (MICs) as high as 32 mu g/mL for ciprofloxacin when transferred to strains of K pneumoniae deficient in outer-membrane porins. Much lower resistance was seen when pMG252 was introduced into It pneumoniae or E coli strains with normal porins. The plasmid had a wide host range and expressed quinolone resistance in other enterobacteriaceae and in Pseudomonas aeruginosa. From a plasmid-containing E coli strain with ciprofloxacin MIC of 0.25 mu g/mL and nalidixic-acid MIC of 32 mu g/mL, quinolone-resistant mutants could be obtained at more than 100 times the frequency of a plasmid-free strain, reaching MICs for ciprofloxacin of 4 mu g/mL and for nalidixic acid of 256 mu g/mL. Interpretation Transferable resistance to fluoroquinines and nalidixic acid has been found in a clinical isolate of It pneumoniae on a broad host range plasmid. Although resistance was low in wild-type strains, higher levels of quinolone resistance arose readily by mutation. Such a plasmid can speed the development and spread of resistance to these valuable antimicrobial agents.	Lahey Hitchcock Clin, Burlington, MA 01805 USA; Univ Seville, Sch Med, Dept Clin Microbiol, Seville, Spain; Vet Adm Med Ctr, Burlington, MA USA	Lahey Hospital & Medical Center; University of Sevilla; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Jacoby, GA (corresponding author), Lahey Hitchcock Clin, 41 Mall Rd, Burlington, MA 01805 USA.		Martínez, Luis Martínez/U-1801-2017; Jacoby, George A/G-2604-2011; Pascual, Alvaro/Y-5854-2018	Martínez, Luis Martínez/0000-0002-6091-4045; Pascual, Alvaro/0000-0002-8672-5891				BURMAN LG, 1977, J ANTIMICROB CHEMOTH, V3, P509, DOI 10.1093/jac/3.5.509; COURVALIN P, 1990, ANTIMICROB AGENTS CH, V34, P681, DOI 10.1128/AAC.34.5.681; DILICA K, 1997, MICROBIOL MOL BIOL R, V61, P377; Goldman JD, 1996, ANTIMICROB AGENTS CH, V40, P1266, DOI 10.1128/AAC.40.5.1266; Goldstein F W, 1995, Drugs, V49 Suppl 2, P36; Hooper David C., 1993, P97; Jacoby GA, 1996, J CLIN MICROBIOL, V34, P908, DOI 10.1128/JCM.34.4.908-911.1996; JACOBY GA, 1974, ANTIMICROB AGENTS CH, V6, P239, DOI 10.1128/AAC.6.3.239; MACRINA FL, 1978, PLASMID, V1, P417, DOI 10.1016/0147-619X(78)90056-2; MartinezMartinez L, 1996, ANTIMICROB AGENTS CH, V40, P342, DOI 10.1128/AAC.40.2.342; MATTHEW M, 1975, J GEN MICROBIOL, V88, P169, DOI 10.1099/00221287-88-1-169; MEDEIROS AA, 1985, ANTIMICROB AGENTS CH, V27, P715, DOI 10.1128/AAC.27.5.715; MUNSHI MH, 1987, LANCET, V2, P4419; Murphy OM, 1997, LANCET, V349, P1028, DOI 10.1016/S0140-6736(05)62932-7; *NCCLS, 1997, M7A4 NCCLS, P1; PEARCE LE, 1968, J GEN MICROBIOL, V50, P173, DOI 10.1099/00221287-50-1-173; Threlfall EJ, 1997, LANCET, V349, P403, DOI 10.1016/S0140-6736(97)80024-4; TOMAS JM, 1986, INFECT IMMUN, V54, P85	18	816	920	0	86	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					797	799		10.1016/S0140-6736(97)07322-4	http://dx.doi.org/10.1016/S0140-6736(97)07322-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519952				2022-12-01	WOS:000072521200013
J	Smith, DE; Zuber, MT; Frey, HV; Garvin, JB; Head, JW; Muhleman, DO; Pettengill, GH; Phillips, RJ; Solomon, SC; Zwally, HJ; Banerdt, WB				Smith, DE; Zuber, MT; Frey, HV; Garvin, JB; Head, JW; Muhleman, DO; Pettengill, GH; Phillips, RJ; Solomon, SC; Zwally, HJ; Banerdt, WB			Topography of the northern hemisphere of Mars from the Mars orbiter laser altimeter	SCIENCE			English	Article							RADIO OCCULTATION MEASUREMENTS; MARINER-9; DICHOTOMY; VOLCANISM; IMPACT; ATMOSPHERE	The first 18 tracks of laser altimeter data across the northern hemisphere of Mars from the Mars Global Surveyor spacecraft show that the planet at latitudes north of 50 degrees is exceptionally flat; slopes and surface roughness increase toward the equator. The polar layered terrain appears to be a thick ice-rich formation with a non-equilibrium planform indicative of ablation near the periphery. Slope relations suggest that the northern Tharsis province was uplifted in the past. A profile across Ares Vallis channel suggests that the discharge through the chan nel was much greater than previously estimated. The martian atmosphere shows significant 1-micrometer atmospheric opacities, particularly in low-lying areas such as Valles Marineris.	NASA, Earth Sci Directorate, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; MIT, Cambridge, MA 02139 USA; Brown Univ, Providence, RI 02912 USA; CALTECH, Pasadena, CA 91125 USA; Washington Univ, St Louis, MO 63130 USA; Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; NASA, Terr Phys Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Massachusetts Institute of Technology (MIT); Brown University; California Institute of Technology; Washington University (WUSTL); Carnegie Institution for Science; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Smith, DE (corresponding author), NASA, Earth Sci Directorate, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA.		Banerdt, William/Q-7324-2019	Banerdt, William/0000-0003-3125-1542				Baker V.R., 1992, CHANNELS VALLEY NETW, P493; BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; BANERDT WB, 1992, MARS, P249; BATSON RM, 1995, PHOTOGRAMM ENG REM S, V61, P1499; BLASIUS RK, 1982, ICARUS, V50, P140; BUDD WF, 1986, POLARFORSCHUNG, V56, P43; Carr M., 1981, SURFACE MARS; Carr M. H., 1977, Journal of Geophysical Research, V82, P4055, DOI 10.1029/JS082i028p04055; Carr M.H, 1996, WATER MARS; CARR MH, 1973, J GEOPHYS RES, V78, P4049, DOI 10.1029/JB078i020p04049; CONRATH B, 1973, J GEOPHYS RES, V78, P4267, DOI 10.1029/JB078i020p04267; CRR MH, 1972, ICARUS, V16, P17; DOWNS GS, 1982, J GEOPHYS RES, V87, P9747, DOI 10.1029/JB087iB12p09747; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; FRANCIS PW, 1983, J GEOPHYS RES, V88, P8333, DOI 10.1029/JB088iB10p08333; FREY H, 1988, GEOPHYS RES LETT, V15, P229, DOI 10.1029/GL015i003p00229; Granger RA, 1995, FLUID MECH-SOV RES; GREELEY R, 1987, SCIENCE, V236, P1653, DOI 10.1126/science.236.4809.1653; HORD CW, 1972, ICARUS, V17, P443, DOI 10.1016/0019-1035(72)90010-3; HOWARD AD, 1982, ICARUS, V50, P245, DOI 10.1016/0019-1035(82)90125-7; JANKOWSKI DG, 1992, ICARUS, V100, P26, DOI 10.1016/0019-1035(92)90015-Y; JORDAN JF, 1975, ICARUS, V25, P146, DOI 10.1016/0019-1035(75)90194-3; KLIORE AJ, 1972, ICARUS, V17, P484, DOI 10.1016/0019-1035(72)90014-0; Komatsu G, 1997, J GEOPHYS RES-PLANET, V102, P4151, DOI 10.1029/96JE02564; LINDAL GF, 1979, J GEOPHYS RES, V84, P8443, DOI 10.1029/JB084iB14p08443; Lingenfelter R. E., 1973, Moon, V7, P172, DOI 10.1007/BF00578814; LOPES RMC, 1980, MOON PLANETS, V22, P221, DOI 10.1007/BF00898433; Malin MC, 1998, SCIENCE, V279, P1681, DOI 10.1126/science.279.5357.1681; MALIN MC, 1986, GEOPHYS RES LETT, V13, P444, DOI 10.1029/GL013i005p00444; MORGAN JP, 1995, J GEOPHYS RES-SOL EA, V100, P8045, DOI 10.1029/94JB02887; Mouginis-Mark P.J., 1992, MARS PP, P424; PAIGE DA, 1994, J GEOPHYS RES, V99, P25595; PHILLIPS RJ, 1990, J GEOPHYS RES-SOLID, V95, P5089, DOI 10.1029/JB095iB04p05089; Schubert G., 1992, MARS, P147, DOI [10.2307/j.ctt207g59v.9, DOI 10.2307/J.CTT207G59V.9]; Smith DE, 1996, SCIENCE, V271, P184, DOI 10.1126/science.271.5246.184; SMITH DE, 1993, J GEOPHYS RES-PLANET, V98, P20871, DOI 10.1029/93JE01839; Soderblom L.A., 1992, MARS, P557; SOLOMON SC, 1982, J GEOPHYS RES, V87, P9755, DOI 10.1029/JB087iB12p09755; Tanaka K. L., 1992, MARS, P345; Thomas P., 1992, MARS, P767; WILHELMS DE, 1984, NATURE, V309, P138, DOI 10.1038/309138a0; WISE DU, 1979, ICARUS, V38, P456, DOI 10.1016/0019-1035(79)90200-8; Zuber MT, 1997, J GEOPHYS RES-PLANET, V102, P28673, DOI 10.1029/97JE02527; ZUBER MT, 1992, J GEOPHYS RES-PLANET, V97, P7781, DOI 10.1029/92JE00341; [No title captured]	45	183	186	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1686	1692		10.1126/science.279.5357.1686	http://dx.doi.org/10.1126/science.279.5357.1686			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497281				2022-12-01	WOS:000072490000046
J	Jorgensen, RA; Atkinson, RG; Forster, RLS; Lucas, WJ				Jorgensen, RA; Atkinson, RG; Forster, RLS; Lucas, WJ			Research: Botany - An RNA-based information superhighway in plants	SCIENCE			English	Article							TRANSGENIC PLANTS; GENE-EXPRESSION; VIRUS-RESISTANCE; COSUPPRESSION; PLASMODESMATA; SUPPRESSION; PATTERNS; DNA		Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA; HortRes, Auckland, New Zealand; Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA	University of Arizona; New Zealand Institute for Plant & Food Research Ltd; University of California System; University of California Davis	Jorgensen, RA (corresponding author), Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA.		Atkinson, Ross G/A-4140-2008	Atkinson, Ross G/0000-0002-7062-6952; Jorgensen, Richard/0000-0002-0382-2371				ATKINSON RS, UNPUB; Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; BOLLMANN J, 1991, PLANT CELL, V3, P1327, DOI 10.1105/tpc.3.12.1327; Covey SN, 1997, NATURE, V385, P781, DOI 10.1038/385781a0; DE CARVALHO-NIEBEL F, 1995, PLANT CELL, V7, P347, DOI 10.2307/3869856; DOUGHERTY WG, 1995, CURR OPIN CELL BIOL, V7, P399, DOI 10.1016/0955-0674(95)80096-4; Gilbertson RL, 1996, TRENDS PLANT SCI, V1, P260; Goodwin J, 1996, PLANT CELL, V8, P95, DOI 10.1105/tpc.8.1.95; Guo HS, 1997, MOL PLANT MICROBE IN, V10, P160, DOI 10.1094/MPMI.1997.10.2.160; JORGENSEN R, 1990, TRENDS BIOTECHNOL, V8, P340, DOI 10.1016/0167-7799(90)90220-R; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; Jorgensen RA, 1996, PLANT MOL BIOL, V31, P957, DOI 10.1007/BF00040715; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; Kunz C, 1996, PLANT J, V10, P437, DOI 10.1046/j.1365-313X.1996.10030437.x; Lee KY, 1997, PLANT J, V12, P1127, DOI 10.1046/j.1365-313X.1997.12051127.x; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; LUCAS WJ, 1993, NEW PHYTOL, V125, P435, DOI 10.1111/j.1469-8137.1993.tb03897.x; MATTHEWS REF, 1991, PLANT VIROLOGY, P445; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; Mezitt LA, 1996, PLANT MOL BIOL, V32, P251, DOI 10.1007/BF00039385; MOORE CV, UNPUB; Palauqui JC, 1996, PLANT PHYSIOL, V112, P1447, DOI 10.1104/pp.112.4.1447; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; Que QD, 1998, PLANT J, V13, P401, DOI 10.1046/j.1365-313X.1998.00038.x; Que QD, 1997, PLANT CELL, V9, P1357, DOI 10.1105/tpc.9.8.1357; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; SMITH CJS, 1990, MOL GEN GENET, V224, P477, DOI 10.1007/BF00262443; Tanzer MM, 1997, PLANT CELL, V9, P1411, DOI 10.1105/tpc.9.8.1411; Vaucheret H, 1997, PLANT CELL, V9, P1495, DOI 10.1105/tpc.9.8.1495; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215	32	184	203	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1486	1487		10.1126/science.279.5356.1486	http://dx.doi.org/10.1126/science.279.5356.1486			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9508725				2022-12-01	WOS:000072372900051
J	Albert, ML; Sauter, B; Bhardwaj, N				Albert, ML; Sauter, B; Bhardwaj, N			Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs	NATURE			English	Article							TOXIC LYMPHOCYTES-T; INFLUENZA-VIRUS; MATRIX PROTEIN; HUMAN BLOOD; GENERATION; RESPONSES; HLA-A2; VIVO	CD8(+) cytotoxic T lymphocytes (CTLs) mediate resistance to infectious agents and tumours. Classically, CTLs recognize antigens that are localized in the cytoplasm of target cells, processed and presented as peptide complexes with class I molecules of the major histocompatibility complex (MHC)(1). However, there is evidence for an exogenous pathway whereby antigens that are not expected to gain access to the cytoplasm are presented on MHC class I molecules(2-6). The most dramatic example is the in vivo phenomenon of cross-priming(7): antigens from donor cells are acquired by bone-marrow-derived host antigen-presenting cells (APCs) and presented on MHC class I molecules. Two unanswered questions concern the identity of this bone-marrow-derived cell and how such antigens are acquired. Here we show that human dendritic cells, but not macrophages, efficiently present antigen derived from apoptotic cells, stimulating class I-restricted CD8(+) CTLs, Our findings suggest a mechanism by which potent APCs acquire antigens from tumours, transplants, infected cells, or even self-tissue, for stimulation or tolerization of CTLs.	Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA	Rockefeller University	Bhardwaj, N (corresponding author), Rockefeller Univ, Cellular Physiol & Immunol Lab, 1230 York Ave, New York, NY 10021 USA.	bhardwn@rockvax.rockefeller.edu	Albert, Matthew L/C-9782-2009					BACHMANN MF, 1996, EUR J IMMUNOL, V26, P1; Badley AD, 1997, J EXP MED, V185, P55, DOI 10.1084/jem.185.1.55; BENDER A, 1995, J EXP MED, V182, P1663, DOI 10.1084/jem.182.6.1663; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; BENDER A, IN PRESS IMMUNOBIOLO; BEVAN MJ, 1977, J IMMUNOL, V118, P1370; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BHARDWAJ N, 1994, J CLIN INVEST, V94, P797, DOI 10.1172/JCI117399; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; DEPANFILIS G, 1986, J INVEST DERMATOL, V87, P510, DOI 10.1111/1523-1747.ep12455586; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FESQ H, 1994, IMMUNOBIOLOGY, V190, P175, DOI 10.1016/S0171-2985(11)80292-5; FOSSUM S, 1986, EUR J IMMUNOL, V16, P440, DOI 10.1002/eji.1830160422; GOTCH F, 1988, J EXP MED, V168, P2045, DOI 10.1084/jem.168.6.2045; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; Hofmann P, 1997, J LEUKOCYTE BIOL, V61, P408, DOI 10.1002/jlb.61.4.408; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; NOTBURY CC, 1997, EUR J IMMUNOL, V27, P280; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; Rubartelli A, 1997, EUR J IMMUNOL, V27, P1893, DOI 10.1002/eji.1830270812; Shen ZH, 1997, J IMMUNOL, V158, P2723; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821	29	1922	2030	2	82	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1998	392	6671					86	89		10.1038/32183	http://dx.doi.org/10.1038/32183			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510252				2022-12-01	WOS:000072373000055
J	Wagner, L; Yang, OO; Garcia-Zepeda, EA; Ge, YM; Kalams, SA; Walker, BD; Pasternack, MS; Luster, AD				Wagner, L; Yang, OO; Garcia-Zepeda, EA; Ge, YM; Kalams, SA; Walker, BD; Pasternack, MS; Luster, AD			beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans	NATURE			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; HEPARAN-SULFATE; VIRUS-REPLICATION; SERINE ESTERASE; LYMPHOCYTES-T; RECEPTOR; HIV-1; IDENTIFICATION; LOCALIZATION; MIP-1-BETA	CD8(+) lymphocytes are believed to be important in host defence against the human immunodeficiency virus (HIV)-1, inhibiting HIV-1 replication through both cytolytic and non-cytolytic pathways(1-13). The cytolytic pathway involves calcium-dependent exocytosis of perforin and granzyme proteases, as well as Fas-mediated programmed cell death(4), whereas the noncytolytic pathway involves the release of chemokines that prevent viral entry(5). Using-granzyme A as a marker of cytolytic granule proteins, and macrophage inflammatory protein (MIP)-1 alpha and RANTES as markers of HIV-1 inhibitory chemokines, we show that these two very different mediators of viral inhibition are both localized in the cytolytic granules of HIV-1-specific CD8(+) cytotoxic T lymphocytes (CTL). Following antigen-specific activation, these mediators are secreted together facilitating both lysis of virion-producing cells and the inhibition of free virus. In addition, RANTES, MIP-1 alpha and MIP-1 beta are secreted by CTL as a macromolecular complex containing sulphated proteoglycans. This association appears to have a functional significance, because heparan sulphate facilitates RANTES inhibition of HIV-1 infection of monocytes.	Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Infect Dis Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Infect Dis Unit, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital	Luster, AD (corresponding author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA.	luster@helix.mgh.harvard.edu	Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; KAPLAN KL, 1979, BLOOD, V53, P604; LEVINE SP, 1990, BLOOD, V75, P902; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; MACDERMOTT RP, 1985, J EXP MED, V162, P1771, DOI 10.1084/jem.162.6.1771; Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341; Oravecz T, 1997, J IMMUNOL, V159, P4587; PASTERNACK MS, 1986, NATURE, V322, P740, DOI 10.1038/322740a0; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; STEVENS RL, 1987, J IMMUNOL, V139, P863; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TSCHOPP J, 1987, MOL IMMUNOL, V24, P907, DOI 10.1016/0161-5890(87)90002-2; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; UHLINHANSEN L, 1989, J BIOL CHEM, V264, P14916; Verani A, 1997, J EXP MED, V185, P805, DOI 10.1084/jem.185.5.805; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; Yang OO, 1997, J VIROL, V71, P3120, DOI 10.1128/JVI.71.4.3120-3128.1997; YEAMAN C, 1993, J CELL PHYSIOL, V157, P413, DOI 10.1002/jcp.1041570226	28	291	298	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					908	911		10.1038/36129	http://dx.doi.org/10.1038/36129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495345				2022-12-01	WOS:000072230900056
J	Kostrikis, LG; Tyagi, S; Mhlanga, MM; Ho, DD; Kramer, FR				Kostrikis, LG; Tyagi, S; Mhlanga, MM; Ho, DD; Kramer, FR			Molecular beacons - Spectral genotyping of human alleles	SCIENCE			English	Article							HIV-1 INFECTION; HYBRIDIZATION; INDIVIDUALS; PROGRESSION; RESISTANCE; PROBES; GENE; DNA		Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Publ Hlth Res Inst, Dept Mol Genet, New York, NY 10016 USA	Rockefeller University	Kostrikis, LG (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA.		Mhlanga, Musa/D-1283-2011; Tyagi, Sanjay/F-1109-2010; KOSTRIKIS, LEONDIOS G/A-5330-2016	Mhlanga, Musa/0000-0003-1381-3409; KOSTRIKIS, LEONDIOS G/0000-0002-5340-7109; Tyagi, Sanjay/0000-0001-7303-5827	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043521] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43521] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONNET GV, UNPUB; Cantor CR, 1996, NAT BIOTECHNOL, V14, P264, DOI 10.1038/nbt0396-264; COTTON R, 1997, MUTAT DETECTION; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Ehricht R, 1997, NUCLEIC ACIDS RES, V25, P4697, DOI 10.1093/nar/25.22.4697; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; KEEN J, 1991, TRENDS GENET, V7, P5; KOSTRIKIS L, IN PRESS NAT MED; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MATSUO T, IN PRESS BIOCH BIOPH; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Rappaport J, 1997, LANCET, V349, P922, DOI 10.1016/S0140-6736(05)62697-9; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49	18	256	324	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1228	1229		10.1126/science.279.5354.1228	http://dx.doi.org/10.1126/science.279.5354.1228			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9508692				2022-12-01	WOS:000072115200049
J	Ekbom, A; Lundegardh, G; McLaughlin, JK; Nyren, O				Ekbom, A; Lundegardh, G; McLaughlin, JK; Nyren, O			Relation of vagotomy to subsequent risk of lung cancer: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							DUODENAL-ULCER; SMOKING; TRIAL		Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Ekbom, A (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, S-17177 Stockholm, Sweden.							DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; HOFFMANN J, 1989, ANN SURG, V209, P40, DOI 10.1097/00000658-198901000-00006; KATSCHINSKI BD, 1991, EUR J GASTROEN HEPAT, V3, P443; LAURITSEN K, 1985, NEW ENGL J MED, V312, P958, DOI 10.1056/NEJM198504113121505; MACINTYRE IMC, 1994, GUT, V35, P451, DOI 10.1136/gut.35.4.451	5	22	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					518	519		10.1136/bmj.316.7130.518	http://dx.doi.org/10.1136/bmj.316.7130.518			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501714	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000072097400021
J	Kheradmand, F; Werner, E; Tremble, P; Symons, M; Werb, Z				Kheradmand, F; Werner, E; Tremble, P; Symons, M; Werb, Z			Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change	SCIENCE			English	Article							NF-KAPPA-B; GENE-EXPRESSION; RAS TRANSFORMATION; NADPH OXIDASE; FIBROBLASTS; FIBRONECTIN; ACTIVATION; TRANSLOCATION; RECEPTOR; PROTEINS	Integrin-mediated reorganization of cell shape leads to an altered cellular phenotype. Disruption of the actin cytoskeleton, initiated by binding of soluble antibody to alpha 5 beta 1 integrin, led to increased expression of the collagenase-1 gene in rabbit synovial fibroblasts. Activation of the guanosine triphosphate-binding protein Rac1, which was downstream of the integrin, was necessary for this process, and expression of activated Rac1 was sufficient to increase expression of collagenase-1. Rac1 activation generated reactive oxygen species that were essential for nuclear factor kappa B-dependent transcriptional regulation of interleukin-1 alpha, which, in an autocrine manner, induced collagenase-1 gene expression. Remodeling of the extracellular matrix and consequent alterations of integrin-mediated adhesion and cytoarchitecture are central to development, wound healing, inflammation, and malignant disease, The resulting activation of Rac1 may lead to altered gene regulation and alterations in cellular morphogenesis, migration, and invasion.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Werb, Z (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	zena@itsa.ucsf.edu			NHLBI NIH HHS [HL03732] Funding Source: Medline; NIAMS NIH HHS [AR20684] Funding Source: Medline; NIDCR NIH HHS [DE10306] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; AGGELER J, 1984, J CELL BIOL, V98, P1662, DOI 10.1083/jcb.98.5.1662; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; DASH D, 1995, J BIOL CHEM, V270, P17321, DOI 10.1074/jbc.270.29.17321; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FORSAYETH JR, 1994, BIOTECHNIQUES, V17, P354; HARRIS ED, 1975, NATURE, V257, P243, DOI 10.1038/257243a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHERADMAND F, UNPUB; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; MICHIELS F, 1995, NATURE, V375, P388; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Roskelley CD, 1995, BIOCHEM CELL BIOL, V73, P391, DOI 10.1139/o95-046; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; RUCH W, 1983, J IMMUNOL METHODS, V63, P347, DOI 10.1016/S0022-1759(83)80008-8; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cb.11.110195.003001; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; TREMBLE P, 1994, MOL BIOL CELL, V5, P439, DOI 10.1091/mbc.5.4.439; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WESTMAYS JA, 1995, P NATL ACAD SCI USA, V92, P6768, DOI 10.1073/pnas.92.15.6768; XU XM, 1994, J BIOL CHEM, V269, P23569; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X	43	313	319	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1998	280	5365					898	902		10.1126/science.280.5365.898	http://dx.doi.org/10.1126/science.280.5365.898			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572733				2022-12-01	WOS:000073532900040
J	Maguire, EA; Burgess, N; Donnett, JG; Frackowiak, RSJ; Frith, CD; O'Keefe, J				Maguire, EA; Burgess, N; Donnett, JG; Frackowiak, RSJ; Frith, CD; O'Keefe, J			Knowing where and getting there: A human navigation network	SCIENCE			English	Article							CEREBRAL-CORTEX; BASAL GANGLIA; RAT; HIPPOCAMPUS; PROJECTION; LESIONS	The neural basis of navigation by humans was investigated with functional neuroimaging of brain activity during navigation ina familiar, yet complex virtual reality town. Activation of the right hippocampus was strongly associated with knowing accurately where places were located and navigating accurately between them. Getting to those places quickly was strongly associated with activation of the right caudate nucleus. These two right-side brain structures function in the context of associated activity in right inferior parietal and bilateral medial parietal regions that support egocentric movement through the virtual town, and activity in other left-side regions (hippocampus, frontal cortex) probably involved in nonspatial aspects of navigation. These findings outline a network of brain areas that support navigation in humans and link the functions of these regions to physiological observations in other mammals.	UCL, Neurol Inst, Wellcome Dept Cognit Neurol, London WC1N 3BG, England; UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; UCL, Inst Cognit Neurosci, London WC1E 6BT, England	University of London; University College London; University of London; University College London; University of London; University College London	Maguire, EA (corresponding author), UCL, Neurol Inst, Wellcome Dept Cognit Neurol, 12 Queen Sq, London WC1N 3BG, England.	e.maguire@fil.ion.ucl.ac.uk	Frith, Chris D/A-2171-2009; Frackowiak, Richard S/I-1809-2013; Burgess, Neil/B-2420-2009; Frackowiak, Richard/H-4383-2011	Frith, Chris D/0000-0002-8665-0690; Burgess, Neil/0000-0003-0646-6584; Frackowiak, Richard/0000-0002-3151-822X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aguirre GK, 1997, J NEUROSCI, V17, P2512; Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Andersen RA, 1997, PHILOS T ROY SOC B, V352, P1421, DOI 10.1098/rstb.1997.0128; [Anonymous], 1983, CANADIAN PSYCHOL; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; Buchel C, 1996, NEUROIMAGE, V4, P60, DOI 10.1006/nimg.1996.0029; Burgess N, 1997, PHILOS T ROY SOC B, V352, P1397, DOI 10.1098/rstb.1997.0125; Burgess N, 1996, HIPPOCAMPUS, V6, P749; DEJONG BM, 1994, BRAIN, V117, P1039; Devan BD, 1996, NEUROBIOL LEARN MEM, V66, P305, DOI 10.1006/nlme.1996.0072; Elliott R, 1997, NEUROPSYCHOLOGIA, V35, P1395, DOI 10.1016/S0028-3932(97)00055-9; Evans AC, 1993, P IEEE NUCL SCI S ME; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Ghaem O, 1997, NEUROREPORT, V8, P739, DOI 10.1097/00001756-199702100-00032; HOUK JC, 1995, CEREB CORTEX, V5, P95, DOI 10.1093/cercor/5.2.95; Karnath HO, 1997, PHILOS T ROY SOC B, V352, P1411, DOI 10.1098/rstb.1997.0127; KELLEY AE, 1982, NEUROSCIENCE, V7, P615, DOI 10.1016/0306-4522(82)90067-7; Luria A.R., 1966, HIGHER CORTICAL FUNC, P3; Maguire EA, 1996, P ROY SOC B-BIOL SCI, V263, P1745, DOI 10.1098/rspb.1996.0255; Maguire EA, 1998, J COGNITIVE NEUROSCI, V10, P61, DOI 10.1162/089892998563789; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; Maguire EA, 1997, J NEUROSCI, V17, P7103; MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0; Milner B, 1972, Clin Neurosurg, V19, P421; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKeefe J, 1991, BRAIN SPACE, P273, DOI DOI 10.1016/j.neuron.2015.06.011; OKEEFE J, IN PRESS PHILOS T B; Passingham R., 1995, FRONTAL LOBES VOLUNT; PASSINGHAM RE, 1987, NEURAL BEHAV APPROAC; POTEGAL M, 1908, SPATIAL ABILITIES DE; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; SWANSON LW, 1986, J NEUROSCI, V6, P3010; TAUBE JS, 1990, J NEUROSCI, V10, P420; Tournoux P., 1988, COPLANAR STEREOTACTI; Vallar G, 1997, PHILOS T ROY SOC B, V352, P1401, DOI 10.1098/rstb.1997.0126; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; WIENER SI, 1993, J NEUROSCI, V13, P3802; Wood F., 1975, SHORT TERM MEMORY, P257	42	1015	1030	4	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1998	280	5365					921	924		10.1126/science.280.5365.921	http://dx.doi.org/10.1126/science.280.5365.921			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572740				2022-12-01	WOS:000073532900047
J	Fischer, MB; Goerg, S; Shen, LM; Prodeus, AP; Goodnow, CC; Kelsoe, G; Carroll, MC				Fischer, MB; Goerg, S; Shen, LM; Prodeus, AP; Goodnow, CC; Kelsoe, G; Carroll, MC			Dependence of germinal center B cells on expression of CD21/CD35 for survival	SCIENCE			English	Article							FOLLICULAR DENDRITIC CELL; LYMPHOCYTES-B; COMPLEMENT RECEPTOR-1; IMMUNE-RESPONSE; ANTIGEN; MICE; CR-2; MEMORY; CD19; C3D	Affinity-driven selection of B lymphocytes within germinal centers is critical for the development of high-affinity memory cells and host protection. To investigate the role of the CD21/CD35 coreceptor in B cell competition for follicular retention and survival within the germinal center, either Cr2(+) or Cr2(null) lysozyme-specific transgenic B cells were adoptively transferred into normal mice immunized with duck (DEL) or turkey (TEL) lysozyme, which bind with different affinities. In mice injected with high-affinity turkey lysozyme, Cr2(null) B cells responded by follicular retention; however, they could not survive within germinal centers. This suggests that CD21 provides a signal independent of antigen that is required for survival of B cells in the germinal center.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Australian Natl Univ, John Curtin Sch Med Res, Med Genome Ctr, Canberra, ACT 2601, Australia; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	Harvard University; Harvard Medical School; Australian National University; John Curtin School of Medical Research; University System of Maryland; University of Maryland Baltimore	Carroll, MC (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.		Fischer, Michael/AAU-5579-2020; Goodnow, Christopher C/V-8108-2018	Fischer, Michael/0000-0002-5876-0243; Goodnow, Christopher C/0000-0001-5296-6155				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; Cook MC, 1997, J EXP MED, V186, P631, DOI 10.1084/jem.186.5.631; Croix DA, 1996, J EXP MED, V183, P1857, DOI 10.1084/jem.183.4.1857; Dempsey PW, 1996, SCIENCE, V271, P348, DOI 10.1126/science.271.5247.348; Diacovo TG, 1996, SCIENCE, V273, P252, DOI 10.1126/science.273.5272.252; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FEARON DT, 1983, ANNU REV IMMUNOL, V1, P243, DOI 10.1146/annurev.iy.01.040183.001331; Fischer M., UNPUB; Fischer MB, 1996, J IMMUNOL, V157, P549; FISCHER MB, IN PRESS J IMMUNOL; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; KLAUS GGB, 1980, IMMUNOL REV, V53, P3, DOI 10.1111/j.1600-065X.1980.tb01038.x; LAVOIE TB, 1992, J IMMUNOL, V148, P503; LAW SK, 1980, P NATL ACAD SCI-BIOL, V77, P7194, DOI 10.1073/pnas.77.12.7194; MOLINA H, 1990, J IMMUNOL, V145, P2974; Molina H, 1996, P NATL ACAD SCI USA, V93, P3357, DOI 10.1073/pnas.93.8.3357; PRAGER EM, 1971, J BIOL CHEM, V246, P5978; QIN DL, UNPUB; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; Tooze RM, 1997, IMMUNITY, V7, P59, DOI 10.1016/S1074-7613(00)80510-5; VANNOESEL CJM, 1993, IMMUNOL TODAY, V9, P8; WEIS JJ, 1984, P NATL ACAD SCI-BIOL, V81, P881, DOI 10.1073/pnas.81.3.881; Wu JH, 1996, J IMMUNOL, V157, P3404; ZHENG B, 1996, J EXP MED, V184, P1	27	211	216	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					582	585		10.1126/science.280.5363.582	http://dx.doi.org/10.1126/science.280.5363.582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554848				2022-12-01	WOS:000073242100045
J	Mazel, D; Dychinco, B; Webb, VA; Davies, J				Mazel, D; Dychinco, B; Webb, VA; Davies, J			A distinctive class of integron in the Vibrio cholerae genome	SCIENCE			English	Article							SITE-SPECIFIC INTEGRATION; GENES; EVOLUTION; ELEMENTS; BACTERIA; FAMILY	The ability of bacteria to acquire and disseminate heterologous genes has been a major factor in the development of multiple drug resistance. A gene, intl4, was identified that encodes a previously unknown integrase that is associated with a "gene-VCR" organization (VCRs are Vibrio cholerae repeated sequences), similar to that of the well-characterized antibiotic resistance integrons, The similarity was confirmed by Intl1-mediated recombination of a gene-VCR cassette into a class 1 integron. VCR cassettes are found in a number of Vibrio species including a strain of V. metschnikovii isolated in 1888, suggesting that this mechanism of heterologous gene acquisition predated the antibiotic era.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Davies, J (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.		Mazel, Didier/F-9200-2013	Mazel, Didier/0000-0001-6482-6002				Barker A, 1997, MICROBIOL-SGM, V143, P1805, DOI 10.1099/00221287-143-6-1805; BARKER A, 1994, J BACTERIOL, V176, P5450, DOI 10.1128/JB.176.17.5450-5458.1994; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BUNNY KL, 1995, ANTIMICROB AGENTS CH, V39, P686, DOI 10.1128/AAC.39.3.686; *GENB, U14749 GENB; HALL RM, 1993, GENETICA, V90, P115, DOI 10.1007/BF01435034; KITATSUKAMOTO K, 1993, INT J SYST BACTERIOL, V43, P8, DOI 10.1099/00207713-43-1-8; Kovach ME, 1996, MICROBIOL-SGM, V142, P2165, DOI 10.1099/13500872-142-8-2165; Lee CA, 1996, INFECT AGENT DIS, V5, P1; MARTINEZ E, 1988, MOL GEN GENET, V211, P320, DOI 10.1007/BF00330610; MARTINEZ E, 1990, EMBO J, V9, P1275, DOI 10.1002/j.1460-2075.1990.tb08236.x; MAZEL D, UNPUB; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; OGAWA A, 1993, MICROBIOL IMMUNOL, V37, P607, DOI 10.1111/j.1348-0421.1993.tb01683.x; Recchia GD, 1997, TRENDS MICROBIOL, V5, P389, DOI 10.1016/S0966-842X(97)01123-2; Recchia GD, 1995, MICROBIOL-UK, V141, P3015, DOI 10.1099/13500872-141-12-3015; van Dongen WMAM, 1987, MOL GEN LIFE SCI ADV, V6, P85; Vicente ACP, 1997, J MED MICROBIOL, V46, P398, DOI 10.1099/00222615-46-5-398; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910	19	284	320	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					605	608		10.1126/science.280.5363.605	http://dx.doi.org/10.1126/science.280.5363.605			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554855				2022-12-01	WOS:000073242100052
J	Kolk, MH; van der Graaf, M; Wijmenga, SS; Pleij, CWA; Heus, HA; Hilbers, CW				Kolk, MH; van der Graaf, M; Wijmenga, SS; Pleij, CWA; Heus, HA; Hilbers, CW			NMR structure of a classical pseudoknot: Interplay of single- and double-stranded RNA	SCIENCE			English	Article							MOSAIC-VIRUS RNA; IMPROVED SENSITIVITY; VIRAL RNAS; TYMV-RNA; C-13; SPECTROSCOPY; PROTEINS; RIBOZYME; PROTONS; VALINE	Pseudoknot formation folds the 3' ends of many plant viral genomic RNAs into structures that resemble transfer RNA in global folding and in their reactivity to transfer RNA-specific proteins. The solution structure of the pseudoknotted T arm and acceptor arm of the transfer RNA-like structure of turnip yellow mosaic virus (TYMV) was determined by nuclear magnetic resonance (NMR) spectroscopy. The molecule is stabilized by the hairpin formed by the 5' end of the RNA, and by the intricate interactions related to the loops of the pseudoknot. Loop 1 spans the major groove of the helix with only two of its four nucleotides. Loop 2, which crosses the minor groove, interacts closely with its opposing helix, in particular through hydrogen bonds with a highly conserved adenine. The structure resulting from this interaction between the minor groove and single-stranded RNA at helical junctions displays internal mobility, which may be a general feature of RNA pseudoknots that regulates their interaction with proteins or other RNA molecules.	Univ Nijmegen, Biophys Chem Lab, Nijmegen SON Res Ctr Mol Struct Design & Synth, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	Hilbers, CW (corresponding author), Univ Nijmegen, Biophys Chem Lab, Nijmegen SON Res Ctr Mol Struct Design & Synth, Toernooiveld, NL-6525 ED Nijmegen, Netherlands.		van der Graaf, Marinette/D-4086-2009; Heus, Hans/F-9696-2015	Heus, Hans/0000-0001-7256-4241				BARSUKOV IL, 1993, NMR MACROMOLECULES P, P315; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BRIERLEY I, 1995, J GEN VIROL, V76, P1885, DOI 10.1099/0022-1317-76-8-1885; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CHASTAIN M, 1993, BIOCHEMISTRY-US, V32, P14220, DOI 10.1021/bi00214a022; DEIMAN BAL, IN PRESS J VIROL; Du ZH, 1996, BIOCHEMISTRY-US, V35, P4187, DOI 10.1021/bi9527350; DUMAS P, 1987, J BIOMOL STRUCT DYN, V4, P707, DOI 10.1080/07391102.1987.10507674; FLORENTZ C, 1982, EMBO J, V1, P269, DOI 10.1002/j.1460-2075.1982.tb01158.x; FOLMER RHA, 1995, J BIOMOL NMR, V5, P427, DOI 10.1007/BF00182287; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Hall T C, 1979, Int Rev Cytol, V60, P1, DOI 10.1016/S0074-7696(08)61257-7; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEGAULT P, 1995, FEBS LETT, V362, P156, DOI 10.1016/0014-5793(95)00232-X; LEGAULT P, 1994, J AM CHEM SOC, V116, P2203, DOI 10.1021/ja00084a094; MANS RMW, 1991, EUR J BIOCHEM, V201, P303, DOI 10.1111/j.1432-1033.1991.tb16288.x; MANS RMW, 1990, NUCLEIC ACIDS RES, V18, P3479, DOI 10.1093/nar/18.12.3479; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4507, DOI 10.1093/nar/20.17.4507; PINCK M, 1970, NATURE, V226, P954, DOI 10.1038/226954a0; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; PLEIJ CWA, 1994, CURR OPIN STRUC BIOL, V4, P337, DOI 10.1016/S0959-440X(94)90101-5; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; RIETVELD K, 1982, NUCLEIC ACIDS RES, V10, P1929, DOI 10.1093/nar/10.6.1929; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUDINGER J, 1992, NUCLEIC ACIDS RES, V20, P1865, DOI 10.1093/nar/20.8.1865; SCHIMMEL P, 1989, CELL, V58, P9, DOI 10.1016/0092-8674(89)90395-4; Schweisguth DC, 1997, J MOL BIOL, V267, P505, DOI 10.1006/jmbi.1996.0903; SHEN LX, 1995, J MOL BIOL, V247, P963, DOI 10.1006/jmbi.1995.0193; Simorre JP, 1995, J BIOMOL NMR, V6, P427; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; TENDAM E, 1992, BIOCHEMISTRY-US, V31, P11665, DOI 10.1021/bi00162a001; VANBELKUM A, 1989, EUR J BIOCHEM, V183, P591; VANBELKUM A, 1988, NUCLEIC ACIDS RES, V16, P1931, DOI 10.1093/nar/16.5.1931; VUISTER GW, 1993, J AM CHEM SOC, V115, P5334, DOI 10.1021/ja00065a071; Wijmenga SS, 1997, J BIOMOL NMR, V10, P337, DOI 10.1023/A:1018348123074; Yao LJ, 1997, J BIOMOL NMR, V9, P229, DOI 10.1023/A:1018618606857; YOT P, 1970, P NATL ACAD SCI USA, V67, P1345, DOI 10.1073/pnas.67.3.1345	43	128	130	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					434	438		10.1126/science.280.5362.434	http://dx.doi.org/10.1126/science.280.5362.434			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545221				2022-12-01	WOS:000073159600047
J	Saito, H; Kanamori, Y; Takemori, T; Nariuchi, H; Kubota, E; Takahashi-Iwanaga, H; Iwanaga, T; Ishikawa, H				Saito, H; Kanamori, Y; Takemori, T; Nariuchi, H; Kubota, E; Takahashi-Iwanaga, H; Iwanaga, T; Ishikawa, H			Generation of intestinal T cells from progenitors residing in gut cryptopatches	SCIENCE			English	Article							RECEPTOR-ALPHA-BETA; INTRAEPITHELIAL LYMPHOCYTES; GAMMA-DELTA; NEGATIVE SELECTION; DEFICIENT MICE; IMMUNE-SYSTEM; MUTANT MICE; EPITHELIUM; DIFFERENTIATION; IDENTIFICATION	Cryptopatches (CPs) are part of the murine intestinal immune compartment, Cells isolated from CPs of the small intestine that were c-kit positive (c-kit(+)) but lineage markers negative (Lin(-)) gave rise to T cell receptor (TCR) alpha beta and TCR gamma delta intestinal intraepithelial T cells after in vivo transfer or tissue engraftment into severe combined immunodeficient mice. In contrast, cells from Peyer's patches and mesenteric lymph nodes, which belong in the same intestinal immune compartment but lack c-kit(+)Lin(-) cells, failed lo do so, These findings and results of electron microscopic analysis provide evidence of a local intestinal T cell precursor that develops in the CPs.	Keio Univ, Sch Med, Dept Microbiol, Tokyo 160, Japan; Natl Inst Infect Dis, Dept Immunol, Tokyo 162, Japan; Univ Tokyo, Inst Med Sci, Dept Allergol, Tokyo 108, Japan; Kanagawa Dent Coll, Dept Oral & Maxillofacial Surg, Yokosuka, Kanagawa 238, Japan; Hokkaido Univ, Sch Med, Dept Anat, Sapporo, Hokkaido 060, Japan; Hokkaido Univ, Grad Sch Vet Med, Lab Anat, Sapporo, Hokkaido 060, Japan	Keio University; National Institute of Infectious Diseases (NIID); University of Tokyo; Kanagawa Dental College; Hokkaido University; Hokkaido University	Ishikawa, H (corresponding author), Keio Univ, Sch Med, Dept Microbiol, Tokyo 160, Japan.		Takemori, Toshitada/A-5909-2016; Takahashi-Iwanaga, Hiromi/A-4294-2012					Aranda R, 1997, J IMMUNOL, V158, P3464; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BANDEIRA A, 1991, P NATL ACAD SCI USA, V88, P43, DOI 10.1073/pnas.88.1.43; BARRETT TA, 1992, J IMMUNOL, V149, P1124; BONNEVILLE M, 1988, NATURE, V336, P479, DOI 10.1038/336479a0; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CHOWERS Y, 1994, J EXP MED, V180, P183, DOI 10.1084/jem.180.1.183; DEUSCH K, 1991, EUR J IMMUNOL, V21, P1053, DOI 10.1002/eji.1830210429; Fujihashi K, 1996, J EXP MED, V183, P1929, DOI 10.1084/jem.183.4.1929; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; Guehler SR, 1996, J EXP MED, V184, P493, DOI 10.1084/jem.184.2.493; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; Huleatt JW, 1996, IMMUNITY, V5, P263, DOI 10.1016/S1074-7613(00)80321-0; Kagnoff MF, 1996, IMMUNOL TODAY, V17, P57, DOI 10.1016/0167-5699(96)80579-2; Kanamori Y, 1996, J EXP MED, V184, P1449, DOI 10.1084/jem.184.4.1449; Kawamoto H, 1997, INT IMMUNOL, V9, P1011, DOI 10.1093/intimm/9.7.1011; Klein JR, 1996, J EXP MED, V184, P1203, DOI 10.1084/jem.184.4.1203; KLEIN JR, 1986, J EXP MED, V164, P309, DOI 10.1084/jem.164.1.309; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P6147, DOI 10.1073/pnas.92.13.6147; LEFRANCOIS L, 1995, IMMUNOL TODAY, V16, P16, DOI 10.1016/0167-5699(95)80065-4; LEFRANCOIS L, 1991, J IMMUNOL, V147, P1746; LEFRANCOIS L, 1990, CELL, V63, P333, DOI 10.1016/0092-8674(90)90166-C; LIN T, 1994, EUR J IMMUNOL, V24, P1080, DOI 10.1002/eji.1830240511; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; Mizoguchi A, 1996, J EXP MED, V184, P707, DOI 10.1084/jem.184.2.707; MOSLEY RL, 1992, J EXP MED, V176, P1365, DOI 10.1084/jem.176.5.1365; Mowat AM, 1997, IMMUNOL REV, V156, P145, DOI 10.1111/j.1600-065X.1997.tb00966.x; PARK SY, 1995, EUR J IMMUNOL, V25, P2107, DOI 10.1002/eji.1830250746; PASQUIER LD, 1993, EVOLUTION IMMUNE SYS, P199; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; POUSSIER P, 1992, J EXP MED, V176, P187, DOI 10.1084/jem.176.1.187; POUSSIER P, 1993, J EXP MED, V178, P1947, DOI 10.1084/jem.178.6.1947; Regnault A, 1996, EUR J IMMUNOL, V26, P914, DOI 10.1002/eji.1830260429; ROCHA B, 1994, J EXP MED, V180, P681, DOI 10.1084/jem.180.2.681; ROCHA B, 1991, J EXP MED, V173, P483, DOI 10.1084/jem.173.2.483; Shanahan F, 1997, SCIENCE, V275, P1897, DOI 10.1126/science.275.5308.1897; SIM GK, 1995, ADV IMMUNOL, V58, P297, DOI 10.1016/S0065-2776(08)60622-7; SPRENT J, 1991, J EXP MED, V174, P717, DOI 10.1084/jem.174.3.717; Strober W, 1997, IMMUNOL TODAY, V18, P61, DOI 10.1016/S0167-5699(97)01000-1; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; TOMONAGA S, 1973, Zoological Magazine (Tokyo), V82, P215; VANKERCKHOVE C, 1992, J EXP MED, V175, P57, DOI 10.1084/jem.175.1.57; Wang J, 1997, SCIENCE, V275, P1937, DOI 10.1126/science.275.5308.1937; Weiner HL, 1997, ANNU REV MED, V48, P341; ZAPATA A, 1983, B I PASTEUR, V81, P165	47	246	254	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					275	278		10.1126/science.280.5361.275	http://dx.doi.org/10.1126/science.280.5361.275			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535655				2022-12-01	WOS:000073082400048
J	Jin, DY; Spencer, F; Jeang, KT				Jin, DY; Spencer, F; Jeang, KT			Human T cell leukemia virus type 1 oncoprotein tax targets the human mitotic checkpoint protein MAD1	CELL			English	Article							SPINDLE ASSEMBLY CHECKPOINT; BUDDING YEAST; I TAX; ACTIVATION; EXPRESSION; HTLV; GENE; P53; MITOSIS; LINE	In searching for cellular targets of the HTLV-I oncoprotein Tax, we identified TXBP181,which we characterized as the human homolog of yeast mitotic checkpoint MAD1 protein. Evidence supporting TXBP181 as HsMAD1 includes sequence conservation with yeast MAD1, hyperphosphorylation during S/G(2)/M phases and upon treatment of cells with nocodazole, and binding to HsMAD2. HsMAD1 functions as a homodimer. It localizes to the centrosome during metaphase and to the spindle midzone and the midbody during anaphase and telophase. Expression of either Tax or a transdominant-negative TXBP181 results in multinucleated cells, a phenotype consistent with a loss of HsMAD1 function. We propose a model of viral transformation in which Tax targets TXBP181, thereby abrogating a mitotic checkpoint.	NIAID, Mol Microbiol Lab, Bethesda, MD 20892 USA; Johns Hopkins Univ, Ctr Genet Med, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University	Jeang, KT (corresponding author), NIAID, Mol Microbiol Lab, Bethesda, MD 20892 USA.		Jeang, Kuan-Teh/A-2424-2008					Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Glotzer M, 1997, CURR OPIN CELL BIOL, V9, P815, DOI 10.1016/S0955-0674(97)80082-8; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KIKUCHI M, 1986, HEMATOL ONCOL, V4, P67, DOI 10.1002/hon.2900040109; Knecht H, 1996, ONCOGENE, V13, P947; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Laird AD, 1997, CELL SIGNAL, V9, P249, DOI 10.1016/S0898-6568(96)00176-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li XR, 1997, MOL CELL BIOL, V17, P2723, DOI 10.1128/MCB.17.5.2723; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Oegema K, 1997, P NATL ACAD SCI USA, V94, P4817, DOI 10.1073/pnas.94.10.4817; Pangilinan F, 1996, MOL BIOL CELL, V7, P1195, DOI 10.1091/mbc.7.8.1195; Pockwinse SM, 1997, P NATL ACAD SCI USA, V94, P3022, DOI 10.1073/pnas.94.7.3022; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P6815, DOI 10.1073/pnas.77.11.6815; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; TAGUCHI H, 1993, CANCER, V71, P133, DOI 10.1002/1097-0142(19930101)71:1<133::AID-CNCR2820710121>3.0.CO;2-G; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	55	447	468	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					81	91		10.1016/S0092-8674(00)81148-4	http://dx.doi.org/10.1016/S0092-8674(00)81148-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546394	hybrid			2022-12-01	WOS:000072910800012
J	Nightingale, SL				Nightingale, SL			New rules require financial disclosure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Lane, Rockville, MD 20857 USA.							1998, FED REG 5233, V63, P5233	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					984	984		10.1001/jama.279.13.984	http://dx.doi.org/10.1001/jama.279.13.984			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533484				2022-12-01	WOS:000072669700004
J	Andersen, RE; Crespo, CJ; Bartlett, SJ; Cheskin, LJ; Pratt, M				Andersen, RE; Crespo, CJ; Bartlett, SJ; Cheskin, LJ; Pratt, M			Relationship of physical activity and television watching with body weight and level of fatness among children - Results from the Third National Health and Nutrition Examination Survey	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDHOOD WEIGHT; US ADULTS; ADOLESCENTS; OVERWEIGHT; OBESITY; EXERCISE; PREVALENCE; MORTALITY; STATEMENT; MORBIDITY	Context.-Physical inactivity contributes to weight gain in adults, but whether this relationship is true for children of different ethnic groups is not well established, Objective.-To assess participation in vigorous activity and television watching habits and their relationship to body weight and fatness in US children, Design.-Nationally representative cross-sectional survey with an in-person interview and medical examination, Setting and Participants.-Between 1988 and 1994, 4063 children aged 8 through 16 years were examined as part of the National Health and Nutrition Examination Survey III, Mexican Americans and non-Hispanic blacks were oversampled to produce reliable estimates for these groups, Main Outcome Measures.-Episodes of weekly vigorous activity and daily hours of television watched, and their relationship to body mass index and body fatness. Results.-Eighty percent of US children reported performing 3 or more bouts of vigorous activity each week, This rate was lower in non-Hispanic black and Mexican American girls (69% and 73%, respectively). Twenty percent of US children participated in 2 or fewer bouts of vigorous activity per week, and the rate was higher in girls (26%) than in boys (17%), Overall, 26% of US children watched 4 or more hours of television per day and 67% watched at least 2 hours per day, Non-Hispanic black children had the highest rates of watching 4 or more hours of television per day (42%), Boys and girls who watch 4 or more hours of television each day had greater body fat (P<.001) and had a greater body mass index (P<.001) than those who watched less than 2 hours per day, Conclusions.-Many US children watch a great deal of television and are inadequately vigorously active. Vigorous activity levels are lowest among girls, non-Hispanic blacks, and Mexican Americans, Intervention strategies to promote lifelong physical activity among US children are needed to stem the adverse health consequences of inactivity.	Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Div Gastroenterol, Baltimore, MD 21224 USA; NHLBI, Dept Hlth & Fitness, NIH, Bethesda, MD 20892 USA; Ctr Dis Control & Prevent, Phys Act & Hlth Branch, Atlanta, GA USA	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centers for Disease Control & Prevention - USA	Andersen, RE (corresponding author), Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, 333 Cassell Dr,Suite 1640, Baltimore, MD 21224 USA.		Cheskin, Lawrence/AAM-1094-2021; Bartlett, Susan J./J-9864-2012; Bartlett, Susan Joan/AAD-4103-2020	Cheskin, Lawrence/0000-0003-0262-1030; Bartlett, Susan Joan/0000-0001-9755-2490				ABRAHAM S, 1971, HEALTH SERV REP, V86, P273, DOI 10.2307/4594149; Andersen RE, 1997, ANN INTERN MED, V127, P395, DOI 10.7326/0003-4819-127-5-199709010-00010; ANDERSEN RE, 1992, HLTH FITNESS CLUB LE; ANDERSEN RE, 1995, MED EXERC NUTR HLTH, V4, P57; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; [Anonymous], VITAL HLTH STAT; BRICK JM, 1997, USERS GUIDE WESVAR P; BROWN JR, 1974, USES MASS COMMUNICAT, P93; BROWNELL KD, 1992, J CONSULT CLIN PSYCH, V60, P505, DOI 10.1037/0022-006X.60.4.505; *CDCP, 1994, 1994 BRFSS SUMM PREV; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; COOPER DM, 1994, MED SCI SPORT EXER, V26, P733, DOI 10.1249/00005768-199406000-00013; Crespo CJ, 1996, ARCH INTERN MED, V156, P93, DOI 10.1001/archinte.156.1.93; DIETZ WH, 1985, PEDIATRICS, V75, P807; DIETZ WH, 1991, CURR PROBL PEDIATR, V1, P8; DIPIETRO L, 1994, INT J OBESITY, V18, P585; DURANT RH, 1994, PEDIATRICS, V94, P449; Epstein LH, 1996, MED SCI SPORT EXER, V28, P428, DOI 10.1097/00005768-199604000-00006; Epstein LH, 1997, HEALTH PSYCHOL, V16, P107, DOI 10.1037/0278-6133.16.2.107; Ezzati T M, 1992, Vital Health Stat 2, P1; Fletcher GF, 1996, CIRCULATION, V94, P857, DOI 10.1161/01.CIR.94.4.857; GUO SS, 1994, AM J CLIN NUTR, V59, P810, DOI 10.1093/ajcn/59.4.810; JEFFREY DB, 1982, HLTH ED Q, V9, P78; KANN L, 1993, PUBLIC HEALTH REP, V108, P47; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; MALINA RM, 1990, EXERCISE, FITNESS, AND HEALTH, P637; NIETO FJ, 1992, AM J EPIDEMIOL, V136, P201, DOI 10.1093/oxfordjournals.aje.a116486; PATRICK K, 1994, PHYSICIAN SPORTSMED, V22, P245; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; ROCHE AF, 1981, AM J CLIN NUTR, V34, P2831, DOI 10.1093/ajcn/34.12.2831; SALLIS JF, 1991, RES Q EXERCISE SPORT, V62, P124, DOI 10.1080/02701367.1991.10608701; SALLIS JF, 1994, PEDIATR EXERC SCI, V6, P302; SALLIS JF, 1994, HLTH FITNESS PHYS ED, P31; SAS Institute Inc, 1989, SAS STAT US GUID VER; SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/pmed.1993.1014; Strasburger V C, 1992, Pediatr Rev, V13, P144, DOI 10.1542/pir.13-4-144; Tanner J., 1983, ASSESSMENT SKELETAL; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005; *US DEP HHS, 1991, HLTH PEOPL 2000 NAT; US Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301; Williams TM, 1986, IMPACT TELEVISION NA, P143; 1994, PREVENTION, V46, P65	43	872	894	1	108	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					938	942		10.1001/jama.279.12.938	http://dx.doi.org/10.1001/jama.279.12.938			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZC304	9544768				2022-12-01	WOS:000072563600034
J	Jacobson, J				Jacobson, J			After the miracle	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					906	906		10.1001/jama.279.12.906	http://dx.doi.org/10.1001/jama.279.12.906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC304	9544753				2022-12-01	WOS:000072563600011
J	Alvarez, ME; Pennell, RI; Meijer, PJ; Ishikawa, A; Dixon, RA; Lamb, C				Alvarez, ME; Pennell, RI; Meijer, PJ; Ishikawa, A; Dixon, RA; Lamb, C			Reactive oxygen intermediates mediate a systemic signal network in the establishment of plant immunity	CELL			English	Article							DISEASE RESISTANCE RESPONSE; ACQUIRED-RESISTANCE; SALICYLIC-ACID; CELL-DEATH; ARABIDOPSIS-THALIANA; GENE; APOPTOSIS; TRANSDUCTION; EXPRESSION; INFECTION	Recognition of an avirulent pathogen stimulates an oxidative burst generating O-2(-) and H2O2, and these reactive oxygen intermediates (ROIs) cue the induction of defense genes and cell death in the development of a restricted lesion. This localized hypersensitive response (HR) is accompanied by the development of systemic acquired resistance to virulent pathogens. Here we show that inoculation of Arabidopsis leaves with avirulent Pseudomonas syringae induces secondary oxidative bursts in discrete cells in distant tissues, leading to low-frequency systemic micro-HRs. The primary oxidative burst induces these systemic responses, and both the primary burst and the secondary microbursts are required for systemic immunity. Hence, ROIs mediate a reiterative signal network underlying systemic as well as local resistance responses.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73402 USA	Salk Institute; Noble Research Institute	Lamb, C (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA.			Alvarez, Maria Elena/0000-0001-7001-5898				Bauerle PA, 1996, CELL, V87, P13; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; Bent AF, 1996, PLANT CELL, V8, P1757, DOI 10.1105/tpc.8.10.1757; Bestwick CS, 1997, PLANT CELL, V9, P209, DOI 10.1105/tpc.9.2.209; Breda C, 1996, MOL PLANT MICROBE IN, V9, P713, DOI 10.1094/MPMI-9-0713; Buschges R, 1997, CELL, V88, P695, DOI 10.1016/S0092-8674(00)81912-1; CAMERON RK, 1994, PLANT J, V5, P715, DOI 10.1111/j.1365-313X.1994.00715.x; Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; Dietrich RA, 1997, CELL, V88, P685, DOI 10.1016/S0092-8674(00)81911-X; DOARES SH, 1995, P NATL ACAD SCI USA, V92, P4095, DOI 10.1073/pnas.92.10.4095; Glazener JA, 1996, PLANT PHYSIOL, V110, P759, DOI 10.1104/pp.110.3.759; Gray J, 1997, CELL, V89, P25, DOI 10.1016/S0092-8674(00)80179-8; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; HammondKosack KE, 1996, PLANT PHYSIOL, V110, P1381, DOI 10.1104/pp.110.4.1381; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jabs T, 1996, SCIENCE, V273, P1853, DOI 10.1126/science.273.5283.1853; KOCH E, 1990, PLANT CELL, V2, P437, DOI 10.1105/tpc.2.5.437; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; NEUENSCHWANDER U, 1995, PLANT J, V8, P227, DOI 10.1046/j.1365-313X.1995.08020227.x; Pallas JA, 1996, PLANT J, V10, P281, DOI 10.1046/j.1365-313X.1996.10020281.x; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; RASMUSSEN JB, 1991, PLANT PHYSIOL, V97, P1342, DOI 10.1104/pp.97.4.1342; Ryals J, 1997, PLANT CELL, V9, P425, DOI 10.1105/tpc.9.3.425; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; Shirasu K, 1997, PLANT CELL, V9, P261, DOI 10.1105/tpc.9.2.261; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; ThordalChristensen H, 1997, PLANT J, V11, P1187, DOI 10.1046/j.1365-313X.1997.11061187.x; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VERNOOIJ B, 1994, PLANT CELL, V6, P959, DOI 10.1105/tpc.6.7.959; WU G, 1995, PLANT CELL, V7, P619; Wu GS, 1997, PLANT PHYSIOL, V115, P427, DOI 10.1104/pp.115.2.427	38	874	956	2	103	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					773	784		10.1016/S0092-8674(00)81405-1	http://dx.doi.org/10.1016/S0092-8674(00)81405-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529253	Bronze			2022-12-01	WOS:000072661200010
J	Stefanadis, C; Vlachopoulos, C; Tsiamis, E; Diamantopoulos, L; Toutouzas, K; Giatrakos, N; Vaina, S; Tsekoura, D; Toutouzas, P				Stefanadis, C; Vlachopoulos, C; Tsiamis, E; Diamantopoulos, L; Toutouzas, K; Giatrakos, N; Vaina, S; Tsekoura, D; Toutouzas, P			Unfavorable effects of passive smoking on aortic function in men	ANNALS OF INTERNAL MEDICINE			English	Article						tobacco smoke pollution; aorta; elasticity; ventricular function, left; coronary circulation	CORONARY-ARTERY DISEASE; HEALTHY-YOUNG ADULTS; CIGARETTE-SMOKING; ASCENDING AORTA; DISTENSIBILITY ABNORMALITIES; HABITUAL SMOKERS; BLOOD-FLOW; VASOCONSTRICTION; TERM; CIRCULATION	Background: The aorta acts as both a conduit and an elastic buffering chamber that modulates left ventricular function and coronary blood flow. Previous studies have shown that active smoking has unfavorable effects on aortic elasticity. Objective: To study the association between passive smoking and the elastic properties of the human aorta. Design: Comparison of nonsmokers during passive smoking studies and smokers during active smoking or sham smoking studies. Setting: Academic medical center. Participants: 16 male nonsmokers were assigned to passive smoking studies, and 32 current, long-term, male smokers were randomly assigned to either active smoking (16 patients) or sham smoking (16 patients) studies. Intervention: All participants underwent diagnostic catheterization. In the passive smoking group, environmental tobacco smoke was vented into an exposure cham-ber for 5 minutes (mean carbon monoxide level, 30 parts per million). Each participant in the active smoking group smoked one filtered cigarette (1.0 mg of nicotine) under standardized conditions within 5 minutes; each participant in the sham smoking group performed a similar pattern of inhalation with one unlit cigarette. Measurements: Aortic elastic properties were studied by measuring the aortic pressure-diameter relation before and for 20 minutes after passive, active, or sham smoking. Instantaneous diameter of the thoracic aorta was measured with a high-fidelity ultrasonic dimension catheter. Instantaneous aortic pressure and diameter were measured at the same site. Results: Both passive and active smoking were associated with changes in the aortic pressure-diameter relation (change in mean distensibility in the passive smoking group, from 2.02 to 1.59 x 10(-6) cm(2) dyne(-1) [for comparisons of time course between passive and sham smoking groups. P < 0.001]; change in mean distensibility in the active smoking group, from 2.08 to 1.51 x 10(-6) cm(2) dyne(-1) [for comparisons of time course between active and sham smoking groups. P < 0.001]). These changes represent decreases of 21% and 27%, respectively. No changes in aortic elasticity were seen in the sham smoking group. Conclusions: Both passive and active smoking are associated with an acute deterioration in the elastic properties of the aorta. This association between exposure to tobacco smoke and aortic elasticity indicates that aortic function deteriorates during passive or active smoking.	Univ Athens, Hippokrat Hosp, Sch Med, Dept Cardiol, Athens 11527, Greece	Athens Medical School; Hippokration General Hospital; National & Kapodistrian University of Athens	Stefanadis, C (corresponding author), 9 Tepeleniou Str, Athens 15452, Greece.		Stefanadis, Christodoulos/ABH-2232-2020; Tsekoura, Dorothea/AAJ-9815-2020; TSEKOURA, Dorothea/AAD-7275-2019; TSEKOURA, Dorothea/AFP-6835-2022	Stefanadis, Christodoulos/0000-0001-5974-6454; TSEKOURA, DOROTHEA/0000-0002-9896-964X				ARONOW WS, 1978, NEW ENGL J MED, V299, P21, DOI 10.1056/NEJM197807062990105; BELZ GG, 1995, CARDIOVASC DRUG THER, V9, P73, DOI 10.1007/BF00877747; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; BERLIN I, 1990, EUR J CLIN PHARMACOL, V38, P57, DOI 10.1007/BF00314804; BINKLEY PF, 1991, CARDIOTONIC DRUGS CL, P37; BOGREN HG, 1989, AM HEART J, V118, P234, DOI 10.1016/0002-8703(89)90181-6; Boudoulas H., 1996, FUNCTIONAL ABNORMALI, P3; BROWN RE, 1993, CIRCULATION, V88, P260; CARO CG, 1987, LANCET, V2, P11; CELERMAJER DS, 1993, CIRCULATION, V88, P2149, DOI 10.1161/01.CIR.88.5.2149; Celermajer DS, 1996, NEW ENGL J MED, V334, P150, DOI 10.1056/NEJM199601183340303; CRYER PE, 1976, NEW ENGL J MED, V295, P573, DOI 10.1056/NEJM197609092951101; CZERNIN J, 1995, CIRCULATION, V91, P2891, DOI 10.1161/01.CIR.91.12.2891; DART AM, 1991, LANCET, V338, P270, DOI 10.1016/0140-6736(91)90415-L; DAVIS JW, 1985, J LAB CLIN MED, V105, P479; DEANFIELD JE, 1986, AM J CARDIOL, V57, P1005, DOI 10.1016/0002-9149(86)90665-X; EVERITT B, 1992, TALKING STAT, P85; GIANNATTASIO C, 1994, J HYPERTENS, V12, P691; ISNARD RN, 1989, J AM COLL CARDIOL, V13, P399, DOI 10.1016/0735-1097(89)90518-4; KELLY RP, 1992, CIRC RES, V71, P490, DOI 10.1161/01.RES.71.3.490; KIOWSKI W, 1994, CIRCULATION, V90, P27, DOI 10.1161/01.CIR.90.1.27; KOOL MJF, 1993, J AM COLL CARDIOL, V22, P1881, DOI 10.1016/0735-1097(93)90773-T; Lekakis J, 1997, AM J CARDIOL, V79, P529, DOI 10.1016/S0002-9149(96)00805-3; MAOUAD J, 1986, CATHETER CARDIO DIAG, V12, P366, DOI 10.1002/ccd.1810120603; Milnor W.R., 1989, HEMODYNAMICS, V2nd, P58; MOLITERNO DJ, 1994, NEW ENGL J MED, V330, P454, DOI 10.1056/NEJM199402173300702; MOREYRA AE, 1992, AM HEART J, V124, P392, DOI 10.1016/0002-8703(92)90603-S; MURGO JP, 1980, CIRCULATION, V62, P105, DOI 10.1161/01.CIR.62.1.105; NADLER JL, 1983, LANCET, V1, P1248; NICHOLS WW, 1990, MCDONALDS BLOOD FLOW, P77; NICHOLS WW, 1990, MCDONALDS BLOOD FLOW, P251; NICOD P, 1984, J AM COLL CARDIOL, V4, P964, DOI 10.1016/S0735-1097(84)80058-3; OHTSUKA S, 1994, J AM COLL CARDIOL, V24, P1406, DOI 10.1016/0735-1097(94)90127-9; QUILLEN JE, 1993, J AM COLL CARDIOL, V22, P642, DOI 10.1016/0735-1097(93)90170-6; STEFANADIS C, 1995, CIRCULATION, V92, P2210, DOI 10.1161/01.CIR.92.8.2210; STEFANADIS C, 1990, EUR HEART J, V11, P990, DOI 10.1093/oxfordjournals.eurheartj.a059639; STEFANADIS C, 1987, AM J CARDIOL, V59, P1300, DOI 10.1016/0002-9149(87)90908-8; Stefanadis C, 1997, CIRCULATION, V96, P1853, DOI 10.1161/01.CIR.96.6.1853; STEFANADIS C, 1994, CHEST, V105, P1017, DOI 10.1378/chest.105.4.1017; Stefanadis C, 1997, CIRCULATION, V95, P31, DOI 10.1161/01.CIR.95.1.31; STEFANADIS C, 1995, CIRCULATION, V91, P2669, DOI 10.1161/01.CIR.91.10.2669; STRATOS C, 1992, AM J MED, V93, P505, DOI 10.1016/0002-9343(92)90577-X; URSCHEL CW, 1968, AM J PHYSIOL, V214, P298, DOI 10.1152/ajplegacy.1968.214.2.298; WATANABE H, 1993, J AM COLL CARDIOL, V21, P1497, DOI 10.1016/0735-1097(93)90330-4; WINNIFORD MD, 1986, CIRCULATION, V73, P662, DOI 10.1161/01.CIR.73.4.662	45	107	111	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					426	+		10.7326/0003-4819-128-6-199803150-00002	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499325				2022-12-01	WOS:000072414700002
J	Block, JA				Block, JA			Hydroxychloroquine and retinal safety	LANCET			English	Editorial Material									Rush Presbyterian St Lukes Med Ctr, Dept Internal Med, Rheumatol Sect, Chicago, IL 60612 USA	Rush University	Block, JA (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Internal Med, Rheumatol Sect, Chicago, IL 60612 USA.			Block, Joel/0000-0002-0330-7353				BERNSTEIN HN, 1992, SOUTHERN MED J, V85, P274, DOI 10.1097/00007611-199203000-00010; Easterbrook M, 1997, J RHEUMATOL, V24, P1390; HOBBS HE, 1959, LANCET, V2, P478; Levy GD, 1997, ARTHRITIS RHEUM, V40, P1482, DOI 10.1002/art.1780400817; SCHERBEL AL, 1965, NEW ENGL J MED, V273, P360, DOI 10.1056/NEJM196508122730704; Silman A, 1997, BRIT J RHEUMATOL, V36, P599; WEISE EE, 1974, AM J OPHTHALMOL, V78, P204, DOI 10.1016/0002-9394(74)90077-4	7	38	41	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					771	771		10.1016/S0140-6736(05)78925-X	http://dx.doi.org/10.1016/S0140-6736(05)78925-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519945				2022-12-01	WOS:000072521200006
J	Marahrens, Y; Loring, J; Jaenisch, R				Marahrens, Y; Loring, J; Jaenisch, R			Role of the Xist gene in X chromosome choosing	CELL			English	Article							PARTHENOGENETIC MOUSE EMBRYOS; INACTIVATION CENTER; LINKED GENES; TRANSLOCATION; EXPRESSION; MEMBRANES	In female mammals a "random choice" mechanism decides which of the two X chromosomes will be inactivated. It has been postulated that Xist is crucial for heterochromatinization and thus functions downstream of the choice mechanism. Here we report that females heterozygous for an internal deletion in the Xist gene, which includes part of exon 1 and extends to exon 5, undergo primary nonrandom inactivation of the wild-type X chromosome. The Xist gene, therefore, not only has a role in chromatin remodeling, but also includes an element required for X chromosome choosing. In conflict with the prevailing view of how choosing occurs, the element identified by the deletion plays a positive role in the choice mechanism and forces a reassessment of how X chromosome choosing is thought to occur.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Jaenisch, R (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Loring, Jeanne F/A-1620-2011	Loring, Jeanne F/0000-0001-6226-9767	NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA44339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER ID, 1989, GENET RES, V53, P77, DOI 10.1017/S0016672300027944; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; CATTANACH BM, 1981, GENET RES, V38, P57, DOI 10.1017/S0016672300020401; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; ENDO F, 1981, HUM GENET, V56, P349, DOI 10.1007/BF00274691; GRUMBACH MM, 1963, P NATL ACAD SCI USA, V49, P581, DOI 10.1073/pnas.49.5.581; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; Hogan B., 2014, MANIPULATING MOUSE E; KAUFMAN MH, 1978, NATURE, V271, P547, DOI 10.1038/271547a0; Lee JT, 1997, CURR OPIN GENET DEV, V7, P274, DOI 10.1016/S0959-437X(97)80138-4; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LYON MF, 1964, CYTOGENETICS, V3, P306, DOI 10.1159/000129820; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MCMAHON A, 1983, GENET RES, V41, P69, DOI 10.1017/S0016672300021078; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Plenge RM, 1997, NAT GENET, V17, P353, DOI 10.1038/ng1197-353; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RASTAN S, 1980, NATURE, V288, P172, DOI 10.1038/288172a0; RUSSELL LB, 1963, SCIENCE, V140, P976, DOI 10.1126/science.140.3570.976; RUSSELL LB, 1965, GENETICS, V52, P470; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; TADA T, 1993, GENET RES, V62, P139, DOI 10.1017/S0016672300031736; TADA T, 1992, MOL REPROD DEV, V31, P20, DOI 10.1002/mrd.1080310105; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0	33	131	135	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					657	664		10.1016/S0092-8674(00)81133-2	http://dx.doi.org/10.1016/S0092-8674(00)81133-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506520	Bronze			2022-12-01	WOS:000072406000011
J	Gunn, RA; Rolfs, RT; Greenspan, JR; Seidman, RL; Wasserheit, JN				Gunn, RA; Rolfs, RT; Greenspan, JR; Seidman, RL; Wasserheit, JN			The changing paradigm of sexually transmitted disease control in the era of managed health care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARTNER NOTIFICATION; REPRODUCTIVE HEALTH; CHAIN-REACTION; HIV-INFECTION; CRACK COCAINE; SYPHILIS; INTERVENTION; PREVENTION; DIAGNOSIS	Several trends in sexually transmitted diseases (STDs) have laid the foundation for a new paradigm for STD treatment and prevention that: encompasses a community-wide, population-oriented approach, Public health STD programs, in partnership with a wide variety of community collaborators, will need to carry out the essential functions of public health-assessment, policy development, and assurance-by developing resources for community organizing and planning, enhanced information systems, and comprehensive training programs for professional staff and community partners, Community providers (particularly practicing clinicians and community and hospital clinics) will need to deliver primary prevention (community health promotion and clinical preventive services) and secondary prevention (screening and treatment) services while categorical STD clinics focus on providing care for high-risk, high-frequency STD transmitters who serve as the reservoir for much of a community's bacterial STDs, Managed care organizations and public health STD programs will need to formalize collaborative arrangements and capitalize on the strengths of each organization in order to have a population-level impact on STD transmission.	Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV STD TB Prevent, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA; Hlth & Human Serv Agcy, San Diego, CA USA; Utah Dept Hlth, Salt Lake City, UT 84116 USA; San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); California State University System; San Diego State University	Gunn, RA (corresponding author), Ctr Dis Control & Prevent, Off Commun, Natl Ctr HIV STD TB Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA.	rag5@cdc.gov						*AM MED ASS DEP AD, 1992, GUID AD PREV SERV; *AM SOC HLTH ASS, 1996, STD NEWS, V3, P5; *AM SOC HLTH ASS, 1996, STD NEWS, V3, P1; ANDRUS JK, 1990, ANN INTERN MED, V112, P539, DOI 10.7326/0003-4819-112-7-539; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; BAKER EL, 1994, JAMA-J AM MED ASSOC, V272, P1276, DOI 10.1001/jama.272.16.1276; BRUNHAM RC, 1990, MED CLIN N AM, V74, P1339, DOI 10.1016/S0025-7125(16)30484-9; Cates W, 1996, SEX TRANSM DIS, V23, P68, DOI 10.1097/00007435-199601000-00013; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P366; *CDCP, 1996, SEX TRANSM DIS PREV; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V42, P988; CHERNESKY MA, 1994, J CLIN MICROBIOL, V32, P2682, DOI 10.1128/JCM.32.11.2682-2685.1994; Childs James E., 1993, Morbidity and Mortality Weekly Report, V42, P1; COOPER ML, 1994, HEALTH PSYCHOL, V13, P251, DOI 10.1037/0278-6133.13.3.251; DONOVAN P, 1993, TESTING POSITIVE SEX; EDLIN BR, 1994, NEW ENGL J MED, V331, P1422, DOI 10.1056/NEJM199411243312106; ENGELGAU MM, 1995, SEX TRANSM DIS, V22, P203, DOI 10.1097/00007435-199507000-00001; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; GUNN RA, 1995, SEX TRANSM DIS, V22, P60, DOI 10.1097/00007435-199501000-00010; Gunn RA, 1997, SEX TRANSM DIS, V24, P90, DOI 10.1097/00007435-199702000-00006; Hessol NA, 1996, SEX TRANSM DIS, V23, P157, DOI 10.1097/00007435-199603000-00012; HIBBS JR, 1991, AM J PUBLIC HEALTH, V81, P1259, DOI 10.2105/AJPH.81.10.1259; *I MED, 1997, IMPR HLTH COMM ROL P; *I MED, 1996, HIDD EP CONFR SEX TR; Institute of Medicine, 1996, HLTH COMM NEW PARTN; Institute of Medicine (US) Committee for the study of the future of public health, 1988, FUT PUBL HLTH, DOI 10.17226/1091; JAFFE HW, 1979, AM J PUBLIC HEALTH, V69, P1181, DOI 10.2105/AJPH.69.11.1181; Jensen GA, 1997, HEALTH AFFAIR, V16, P125, DOI 10.1377/hlthaff.16.1.125; Kann Laura, 1996, Morbidity and Mortality Weekly Report, V45, P1; MAJER LS, 1992, J SCHOOL HEALTH, V62, P294, DOI 10.1111/j.1746-1561.1992.tb01246.x; Marrazzo JM, 1997, SEX TRANSM DIS, V24, P131, DOI 10.1097/00007435-199703000-00003; RAWITSCHER LA, 1995, PEDIATRICS, V96, P52; StLouis ME, 1997, AM J PUBLIC HEALTH, V87, P10, DOI 10.2105/AJPH.87.1.10; *US DEP HHS, 1993, PLANN APPR COMM HLTH; *US DEP HHS, 1991, ASS PROT EXC PUBL HL; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P269; VALDISERRI RO, 1995, J COMMUN HEALTH, V20, P87, DOI 10.1007/BF02260331; Wasserheit JN, 1996, J INFECT DIS, V174, pS201, DOI 10.1093/infdis/174.Supplement_2.S201; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; WIESENFELD HC, 1994, SEX TRANSM DIS, V21, P268, DOI 10.1097/00007435-199409000-00004	41	40	41	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					680	684		10.1001/jama.279.9.680	http://dx.doi.org/10.1001/jama.279.9.680			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YY849	9496986				2022-12-01	WOS:000072192800032
J	Crimlisk, HL; Bhatia, K; Cope, H; David, A; Marsden, CD; Ron, MA				Crimlisk, HL; Bhatia, K; Cope, H; David, A; Marsden, CD; Ron, MA			Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms	BRITISH MEDICAL JOURNAL			English	Article							CONVERSION DISORDER; FREQUENCY; HYSTERIA	Objective: To investigate psychiatric and neurological morbidity diagnostic stability and indicators of prognosis in patients previously identified as having London medically unexplained motor symptoms. Design: Follow up study. Setting: National Hospital for Neurology and Neurosurgery; London-a secondary and tertiary referral hospital for neurological disorders. Subjects: 73 patients with medically unexplained motel symptoms admitted consecutively in 1989-91. 35 (48%) patients had absence of motor function (for example, hemiplegia) and 35 (52%,) had abnormal motor activity (for example, tremour dystonia, or ataxia). Main outcome measures: Neurological clinical diagnosis at face to face reassessment by a neurologist and a psychiatric diagnosis after a standardised assessment interview-the schedule for affective disorders and schizophrenia-conducted by a psychiatrist. Results: Good follow up data were available for 64 subjects (88%). Only three subjects had new organic neurological disorders at follow up that fully or partly explained their previous symptoms. 44/59 (75%) subjects had had psychiatric disorders; in 33 (75%) patients, the psychiatric diagnosis coincided with their unexplained motor symptoms. 31/59 (45%) patients had a personality disorder: Three subjects had developed new psychiatric illnesses at follow up, but in only one did the diagnosis account for the previous motor symptoms. Resolution of physical symptoms was associated with shaft length of symptoms, comorbid psychiatric disorder, and a cl-range in marital status during follow up. Conclusions: Unlike Slater's study of 1965, a low incidence of physical or psychiatric diagnoses which explained these patients' symptoms or disability was found. However, a high level of psychiatric comorbidity existed.	Inst Neurol, London WC1N 3BG, England; Inst Psychiat, London SE5 8AF, England	University of London; University College London; University of London; King's College London	Ron, MA (corresponding author), Inst Neurol, Queen Sq, London WC1N 3BG, England.		David, Anthony/O-1750-2019; David, Anthony S/C-1315-2011	David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X; Crimlisk, Helen/0000-0003-0448-4850				BAKER JHE, 1987, J NEUROL NEUROSUR PS, V50, P375, DOI 10.1136/jnnp.50.4.375; COUPRIE W, 1995, J NEUROL NEUROSUR PS, V58, P750, DOI 10.1136/jnnp.58.6.750; DEMIRKIRAN M, 1995, ANN NEUROL, V38, P571, DOI 10.1002/ana.410380405; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; EWALD H, 1994, ACTA PSYCHIAT SCAND, V89, P174, DOI 10.1111/j.1600-0447.1994.tb08088.x; FACTOR SA, 1995, J NEUROL NEUROSUR PS, V59, P406, DOI 10.1136/jnnp.59.4.406; GATFIELD PD, 1962, DIS NERV SYST, V23, P623; LEMPERT T, 1990, ACTA NEUROL SCAND, V82, P335; Mace CJ, 1996, BRIT J PSYCHIAT, V169, P282, DOI 10.1192/bjp.169.3.282; MACE CJ, 1991, J ROY SOC MED, V84, P471, DOI 10.1177/014107689108400808; MARSDEN CD, 1986, PSYCHOL MED, V16, P277, DOI 10.1017/S0033291700009090; RASKIN M, 1966, J AMER MED ASSOC, V197, P530, DOI 10.1001/jama.197.7.530; ROY A, 1980, J PSYCHOSOM RES, V24, P53, DOI 10.1016/0022-3999(80)90053-7; SLATER E, 1965, BRIT MED J, V1, P1395, DOI 10.1136/bmj.1.5447.1395; SLATER ETO, 1965, J PSYCHOSOM RES, V9, P9, DOI 10.1016/0022-3999(65)90004-8; STEPHANSSON JG, 1976, ACTA PSYCHIAT SCAND, V53, P119; WATSON CG, 1979, J NERV MENT DIS, V167, P243, DOI 10.1097/00005053-197904000-00008; WILSONBARNETT J, 1985, BRIT J PSYCHIAT, V146, P601, DOI 10.1192/bjp.146.6.601; World Health Organization, 1992, CLIN DESCR DIAGN GUI	19	223	226	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					582	586		10.1136/bmj.316.7131.582	http://dx.doi.org/10.1136/bmj.316.7131.582			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YZ031	9518908	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000072213200024
J	Wang, DG; Fan, JB; Siao, CJ; Berno, A; Young, P; Sapolsky, R; Ghandour, G; Perkins, N; Winchester, E; Spencer, J; Kruglyak, L; Stein, L; Hsie, L; Topaloglou, T; Hubbell, E; Robinson, E; Mittmann, M; Morris, MS; Shen, NP; Kilburn, D; Rioux, J; Nusbaum, C; Rozen, S; Hudson, TJ; Lipshutz, R; Chee, M; Lander, ES				Wang, DG; Fan, JB; Siao, CJ; Berno, A; Young, P; Sapolsky, R; Ghandour, G; Perkins, N; Winchester, E; Spencer, J; Kruglyak, L; Stein, L; Hsie, L; Topaloglou, T; Hubbell, E; Robinson, E; Mittmann, M; Morris, MS; Shen, NP; Kilburn, D; Rioux, J; Nusbaum, C; Rozen, S; Hudson, TJ; Lipshutz, R; Chee, M; Lander, ES			Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome	SCIENCE			English	Article							ARRAYS; HYBRIDIZATION; MAP	Single-nucleotide polymorphisms (SNPs) are the most frequent type of variation in the human genome, and they provide powerful tools for a variety of medical genetic studies. In a large-scale survey for SNPs, 2.3 megabases of human genomic DNA was examined by a combination of gel-based sequencing and high-density variation-detection DNA chips. A total of 3241 candidate SNPs were identified. A genetic map was constructed showing the location of 2227 of these SNPs. Prototype genotyping chips were developed that allow simultaneous genotyping of 500 SNPs. The results provide a characterization of human diversity at the nucleotide level and demonstrate the feasibility of large-scale identification of human SNPs.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Affymetrix Inc, Santa Clara, CA 95051 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Affymetrix	Lipshutz, R (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Rioux, John D/A-9599-2015; Rozen, Steven G./J-5939-2013	Rioux, John D/0000-0001-7560-8326; Hubbell, Earl/0000-0001-7301-3759; Spencer, Jessica/0000-0001-8156-514X; Rozen, Steven G./0000-0002-4288-0056	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG001323] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00098, HG01323] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AYALA FJ, 1995, SCIENCE, V270, P1930, DOI 10.1126/science.270.5244.1930; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; COOPER DN, 1990, HUM GENET, V85, P55; Cronin MT, 1996, HUM MUTAT, V7, P244, DOI 10.1002/(SICI)1098-1004(1996)7:3<244::AID-HUMU9>3.3.CO;2-D; DEANGELIS MM, 1995, NUCLEIC ACIDS RES, V23, P4742, DOI 10.1093/nar/23.22.4742; deJong D. H., UNPUB; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; KOONTZ WLG, 1972, IEEE T COMPUT, VC 21, P171, DOI 10.1109/TC.1972.5008922; Kruglyak L, 1997, NAT GENET, V17, P21, DOI 10.1038/ng0997-21; Lewontin R.C., 1972, EVOLUTIONARY BIOL, P381, DOI DOI 10.1007/978-1-4684-9063-3_14; Li W.H., 1997, MOL EVOLUTION; NEI M, 1984, EVOL BIOL, V17, P73; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Takahata N, 1997, P NATL ACAD SCI USA, V94, P4811, DOI 10.1073/pnas.94.9.4811; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22	19	1573	1968	2	169	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1077	1082		10.1126/science.280.5366.1077	http://dx.doi.org/10.1126/science.280.5366.1077			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9582121				2022-12-01	WOS:000073663600047
J	Leakey, MG; Feibel, CS; McDougall, I; Ward, C; Walker, A				Leakey, MG; Feibel, CS; McDougall, I; Ward, C; Walker, A			New specimens and confirmation of an early ape for Australopithecus anamensis	NATURE			English	Article							1974-1977 COLLECTIONS; HADAR FORMATION; ETHIOPIA; HOMINID	The discovery of Australopithecus anamensis fossils(1) from strata lying between tephra dated at 4.17 and 4.12 million years ago, and from slightly higher strata not well constrained in age by overlying dated units, provoked the claim that more than one species might be represented: it was suggested that the stratigraphically higher fossils, which include the important tibia, humerus and a large, presumed male, mandible (KNM-KP 29287), might belong to a later, more derived hominid(2). We have recovered new fossils from Kanapoi and Allia Bay Kenya, during field work in 1995-1997 that confirm the primitive status of Austalopithecus anamensis, the earliest species of Australopithecus. Isotope dating confirms A. anamensis' intermediate age as being between those of Ardipithecus ramidus(3,4) and Australopithecus afarensis(5,6). New specimens of maxilla, mandible and capitate show that this species is demonstrably more primitive than A. afarensis. A lower first deciduous molar (dm1) is intermediate in morphology between that reported for Ardipithecus ramidus(4) and A. afarensis(7). Single-crystal 40Ar-39Ar age determinations on the Kanapoi Tuff show that, except for a large mandible, all of the hominid fossils from Kanapoi are from sediments deposited between 4.17 +/- 0.03 and 4.07 +/- 0.02 million years ago.	Natl Museums Kenya, Nairobi, Kenya; Rutgers State Univ, Dept Anthropol, New Brunswick, NJ 08901 USA; Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Univ Missouri, Dept Antropol & Pathol, Columbia, MO 65211 USA; Univ Missouri, Dept Anat Sci, Columbia, MO 65211 USA; Penn State Univ, Dept Anthropol, University Pk, PA 16802 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA	Rutgers State University New Brunswick; Australian National University; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Leakey, MG (corresponding author), Natl Museums Kenya, POB 40658, Nairobi, Kenya.	mfgupa@iconnect.co.ke		Ward, Carol/0000-0001-6255-9668				ANDREWS P, 1995, NATURE, V376, P555, DOI 10.1038/376555a0; BUSH ME, 1982, AM J PHYS ANTHROPOL, V57, P651, DOI 10.1002/ajpa.1330570410; Cebula G. T., 1986, TERRA COGNITA, V6, P139; Gould SJ, 1997, NAT HIST, V106, P20; GOULD SJ, 1997, NAT HIST, V106, P69; HAFLEAB B, 1995, GEOCHEMISTRY GEOCHRO; JOHANSON DC, 1982, AM J PHYS ANTHROPOL, V57, P545, DOI 10.1002/ajpa.1330570406; JOHANSON DC, 1979, SCIENCE, V203, P321, DOI 10.1126/science.104384; KIMBEL WH, 1994, NATURE, V368, P449, DOI 10.1038/368449a0; LEAKEY MG, 1995, NATURE, V376, P565, DOI 10.1038/376565a0; MCDOUGALL I, 1988, GEOCHRONOLOGY THERMO; POWERS DW, 1980, GEOLOGY MIOCENE SEDI; Robinson J.T., 1972, EARLY HOMINID POSTUR; WHITE TD, 1995, NATURE, V375, P88, DOI 10.1038/375088a0; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0	15	197	203	0	28	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 7	1998	393	6680					62	66		10.1038/29972	http://dx.doi.org/10.1038/29972			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590689				2022-12-01	WOS:000073497500046
J	Olson, TM; Michels, VV; Thibodeau, SN; Tai, YS; Keating, MT				Olson, TM; Michels, VV; Thibodeau, SN; Tai, YS; Keating, MT			Actin mutations in dilated cardiomyopathy, a heritable form of heart failure	SCIENCE			English	Article							HYPERTROPHIC CARDIOMYOPATHY; ALPHA-ACTININ; MUSCLE; GENE; EXPRESSION	To test the hypothesis that actin dysfunction leads to heart failure, patients with hereditary idiopathic dilated cardiomyopathy (IDC) were examined for mutations in the cardiac actin gene (ACTC). Missense mutations in ACTC that cosegregate with IDC were identified in two unrelated families. Both mutations affect universally conserved amino acids in domains of actin that attach to Z bands and intercalated discs. Coupled with previous data showing that dystrophin mutations also cause dilated cardiomyopathy, these results raise the possibility that defective transmission of force in cardiac myocytes is a mechanism underlying heart failure.	Univ Utah, Hlth Sci Ctr, Dept Pediat, Div Cardiol, Salt Lake City, UT 84112 USA; Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Univ Utah, Hlth Sci Ctr, Dept Human Genet, Eccles Inst Human Genet,Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Mayo Clinic; Mayo Clinic; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Olson, TM (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Pediat, Div Cardiol, Salt Lake City, UT 84112 USA.				NCRR NIH HHS [M01-RR00064] Funding Source: Medline; NHLBI NIH HHS [5-P50-HL-53773] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL053773] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham WT, 1997, CIRCULATION, V96, P2755, DOI 10.1161/01.CIR.96.9.2755; Bowles KR, 1996, J CLIN INVEST, V98, P1355, DOI 10.1172/JCI118922; DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; GIMONA M, 1994, CELL MOTIL CYTOSKEL, V27, P108, DOI 10.1002/cm.970270203; Gregorio CC, 1997, CELL STRUCT FUNCT, V22, P191, DOI 10.1247/csf.22.191; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P5901, DOI 10.1073/pnas.79.19.5901; HENNESSEY ES, 1993, BIOCHEM J, V282, P657; HENRY WL, 1980, CIRCULATION, V62, P1054, DOI 10.1161/01.CIR.62.5.1054; Herman IM, 1993, CURR OPIN CELL BIOL, V5, P48, DOI 10.1016/S0955-0674(05)80007-9; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KASPER EK, 1994, J AM COLL CARDIOL, V23, P586, DOI 10.1016/0735-1097(94)90740-4; KUHLMAN PA, 1992, FEBS LETT, V304, P201, DOI 10.1016/0014-5793(92)80619-R; Kumar A, 1997, P NATL ACAD SCI USA, V94, P4406, DOI 10.1073/pnas.94.9.4406; LANKFORD EB, 1995, J CLIN INVEST, V95, P1409, DOI 10.1172/JCI117795; LEVINE BA, 1992, FEBS LETT, V298, P44, DOI 10.1016/0014-5793(92)80019-D; LU MH, 1992, J CELL BIOL, V117, P1007, DOI 10.1083/jcb.117.5.1007; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; MESTRONI L, 1994, BRIT HEART J, V72, pS35; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; MICHELS VV, 1985, AM J CARDIOL, V55, P1232, DOI 10.1016/0002-9149(85)90675-7; Olson TM, 1997, TRENDS CARDIOVAS MED, V7, P60, DOI 10.1016/S1050-1738(96)00139-9; Olson TM, 1996, J CLIN INVEST, V97, P528, DOI 10.1172/JCI118445; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITZLOPEZ R, 1997, CIRCULATION, V95, P2434; Reisler E, 1993, CURR OPIN CELL BIOL, V5, P41, DOI 10.1016/S0955-0674(05)80006-7; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; VANDEKERCKHOVE J, 1986, J BIOL CHEM, V261, P1838; Watkins H, 1996, J CLIN INVEST, V98, P2456, DOI 10.1172/JCI119063	30	530	553	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					750	752		10.1126/science.280.5364.750	http://dx.doi.org/10.1126/science.280.5364.750			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563954				2022-12-01	WOS:000073415600052
J	Quensen, JF; Mueller, SA; Jain, MK; Tiedje, JM				Quensen, JF; Mueller, SA; Jain, MK; Tiedje, JM			Reductive dechlorination of DDE to DDMU in marine sediment microcosms	SCIENCE			English	Article								DDT is reductively dechlorinated to DDD and dehydrochlorinated to DDE; it has been thought that DDE is not degraded further in the environment. Laboratory experiments with DDE-containing marine sediments showed that DDE is dechlorinated to DDMU in both methanogenic and sulfidogenic microcosms and that DDD is dehydrochlorinated to DDMU three orders of magnitude more slowly. Thus, DDD does not appear to be an important precursor of the DDMU found in these sediments. These results imply that remediation decisions and risk assessments based on the recalcitrance of DDE in marine and estuarine sediments should be reevaluated.	MBI Int, Lansing, MI 48909 USA; Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA	Michigan State University	Quensen, JF (corresponding author), MBI Int, 3900 Collins Rd,POB 27609, Lansing, MI 48909 USA.							LEE HJ, 1994, DISTRIBUTION CHARACT; LIST EJ, 1997, UNPUB EROSION PALOS; LIST EJ, 1997, BIODEGRADATION DDT D; Niedoroda AW, 1996, SCI TOTAL ENVIRON, V179, P109, DOI 10.1016/0048-9697(95)04875-8; QUENSEN JF, 1988, SCIENCE, V242, P752, DOI 10.1126/science.242.4879.752; QUENSEN JF, 1990, APPL ENV MIROBIOL, V56, P2368; ROCHKIND ML, 1986, MICROBIAL DECOMPOSIT, P138; Sayles GD, 1997, ENVIRON SCI TECHNOL, V31, P3448, DOI 10.1021/es9701669; VOGEL TM, 1987, ENVIRON SCI TECHNOL, V21, P722, DOI 10.1021/es00162a001; WEDEMEYER G, 1967, APPL MICROBIOL, V15, P569, DOI 10.1128/AEM.15.3.569-574.1967; World Health Organization (WHO), 1979, ENV HLTH CRIT, V9; [No title captured]	12	134	144	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					722	724		10.1126/science.280.5364.722	http://dx.doi.org/10.1126/science.280.5364.722			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563945				2022-12-01	WOS:000073415600043
J	Kubori, T; Matsushima, Y; Nakamura, D; Uralil, J; Lara-Tejero, M; Sukhan, A; Galan, JE; Aizawa, S				Kubori, T; Matsushima, Y; Nakamura, D; Uralil, J; Lara-Tejero, M; Sukhan, A; Galan, JE; Aizawa, S			Supramolecular structure of the Salmonella typhimurium type III protein secretion system	SCIENCE			English	Article							FUNCTIONAL CONSERVATION; INVASION GENES; HOST-CELLS; BASAL BODY; IDENTIFICATION; COMPLEX; FAMILY	The type III secretion system of Salmonella typhimurium directs the translocation of proteins into host cells. Evolutionarily related to the flagellar assembly machinery, this system is also present in other pathogenic bacteria, but its organization is unknown. Electron microscopy revealed supramolecular structures spanning the inner and outer membranes of flagellated and nonflagellated strains; such structures were not detected in strains carrying null mutations in components of the type III apparatus. Isolated structures were found to contain at least three proteins of this secretion system. Thus, the type III apparatus of S. typhimurium, and presumably other bacteria, exists as a supramolecular structure in the bacterial envelope.	Teikyo Univ, Dept Biosci, Utsunomiya, Tochigi 320, Japan; SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Teikyo University; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Galan, JE (corresponding author), Teikyo Univ, Dept Biosci, 1-1 Toyosatodai, Utsunomiya, Tochigi 320, Japan.		Kubori, Tomoko/AAH-3609-2019	Kubori, Tomoko/0000-0003-1098-6021; Aizawa, Shin-Ichi/0000-0002-9068-0825				AIZAWA S, 1985, J BACTERIOL, V161, P836, DOI 10.1128/JB.161.3.836-849.1985; Aizawa SI, 1996, MOL MICROBIOL, V19, P1, DOI 10.1046/j.1365-2958.1996.344874.x; Collazo CM, 1996, INFECT IMMUN, V64, P3524, DOI 10.1128/IAI.64.9.3524-3531.1996; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Galan JE, 1996, MOL MICROBIOL, V20, P263, DOI 10.1111/j.1365-2958.1996.tb02615.x; GALAN JE, 1996, ANNU REV CELL DEV BI, V12, P219; GINOCCHIO CC, 1995, INFECT IMMUN, V63, P729, DOI 10.1128/IAI.63.2.729-732.1995; GINOCCHIO CC, 1994, CELL, V76, P717, DOI 10.1016/0092-8674(94)90510-X; Hardt WD, 1997, P NATL ACAD SCI USA, V94, P9887, DOI 10.1073/pnas.94.18.9887; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; KANIGA K, 1994, MOL MICROBIOL, V13, P555, DOI 10.1111/j.1365-2958.1994.tb00450.x; Koster M, 1997, MOL MICROBIOL, V26, P789, DOI 10.1046/j.1365-2958.1997.6141981.x; KUBORI T, 1992, J MOL BIOL, V226, P433, DOI 10.1016/0022-2836(92)90958-M; KUBORI T, UNPUB; Linderoth NA, 1997, SCIENCE, V278, P1635, DOI 10.1126/science.278.5343.1635; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; PEGUES DA, 1995, MOL MICROBIOL, V17, P169, DOI 10.1111/j.1365-2958.1995.mmi_17010169.x; Roine E, 1997, P NATL ACAD SCI USA, V94, P3459, DOI 10.1073/pnas.94.7.3459; ROSQVIST R, 1995, EMBO J, V14, P4187, DOI 10.1002/j.1460-2075.1995.tb00092.x; Shea JE, 1996, P NATL ACAD SCI USA, V93, P2593, DOI 10.1073/pnas.93.6.2593; UENO T, 1994, J MOL BIOL, V236, P546, DOI 10.1006/jmbi.1994.1164; YAMAGUCHI S, 1986, J BACTERIOL, V166, P187, DOI 10.1128/jb.166.1.187-193.1986	24	684	714	1	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					602	605		10.1126/science.280.5363.602	http://dx.doi.org/10.1126/science.280.5363.602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554854				2022-12-01	WOS:000073242100051
J	Molkentin, JD; Lu, JR; Antos, CL; Markham, B; Richardson, J; Robbins, J; Grant, SR; Olson, EN				Molkentin, JD; Lu, JR; Antos, CL; Markham, B; Richardson, J; Robbins, J; Grant, SR; Olson, EN			A calcineurin-dependent transcriptional pathway for cardiac hypertrophy	CELL			English	Article							NATRIURETIC-PEPTIDE GENE; T-CELL ACTIVATION; MYOCYTES IN-VITRO; HEAVY-CHAIN GENE; PROTEIN-KINASE-C; CYCLOSPORINE-A; FACTOR NFAT1; MECHANICAL-STRESS; NUCLEAR FACTOR; FAMILY MEMBER	In response to numerous pathologic stimuli, the myocardium undergoes a hypertrophic response characterized by increased myocardial cell size and activation of fetal cardiac genes. We show that cardiac hypertrophy is induced by the calcium-dependent phosphatase calcineurin, which dephosphorylates the transcription factor NF-AT3, enabling it to translocate to the nucleus. NF-AT3 interacts with the cardiac zinc finger transcription factor GATA4, resulting in synergistic activation of cardiac transcription. Transgenic mice that express activated forms of calcineurin or NF-AT3 in the heart develop cardiac hypertrophy and heart failure that mimic human heart disease. Pharmacologic inhibition of calcineurin activity blocks hypertrophy in vivo and in vitro. These results define a novel hypertrophic signaling pathway and suggest pharmacologic approaches to prevent cardiac hypertrophy and heart failure.	Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75225 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75225 USA; Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Univ N Texas, Hlth Sci Ctr, Lab Cardiac & Vasc Mol Genet, Inst Cardiovasc Res, Ft Worth, TX 76107 USA; Warner Lambert Parke Davis, Ann Arbor, MI 48105 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cincinnati Children's Hospital Medical Center; University of North Texas System; University of North Texas Health Science Center; Pfizer	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, 6000 Harry Hines Blvd, Dallas, TX 75225 USA.		Antos, Christopher L/E-8171-2010; Lu, Jianrong/F-5240-2013	Lu, Jianrong/0000-0002-4969-6040; Molkentin, Jeffery/0000-0002-3558-6529	NHLBI NIH HHS [R01 HL053351] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053351] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOTINELLI R, 1997, CIRC RES, V82, P106; BUSTAMANTE JO, 1991, J CARDIOVASC PHARM, V17, pS110, DOI 10.1097/00005344-199117002-00024; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; Evans T, 1997, TRENDS CARDIOVAS MED, V7, P75, DOI 10.1016/S1050-1738(97)00010-8; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; Hasegawa K, 1997, CIRCULATION, V96, P3943; HAVERICH A, 1994, TRANSPLANT P, V26, P2713; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HONGO K, 1995, AM J PHYSIOL-CELL PH, V269, pC690, DOI 10.1152/ajpcell.1995.269.3.C690; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; JONES WK, 1994, DEV DYNAM, V200, P117, DOI 10.1002/aja.1002000204; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KARLINER JS, 1990, EXPERIENTIA, V46, P81, DOI 10.1007/BF01955423; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KovacicMilivojevic B, 1996, ENDOCRINOLOGY, V137, P1108, DOI 10.1210/en.137.3.1108; Kudoh S, 1997, CIRC RES, V80, P139, DOI 10.1161/01.RES.80.1.139; LEGUENNEC JY, 1991, EXP PHYSIOL, V76, P975, DOI 10.1113/expphysiol.1991.sp003560; LEITE MF, 1994, AM J PHYSIOL-HEART C, V267, pH2193, DOI 10.1152/ajpheart.1994.267.6.H2193; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Loh C, 1996, MOL CELL BIOL, V16, P3945; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; MARBAN E, 1987, P NATL ACAD SCI USA, V84, P6005, DOI 10.1073/pnas.84.16.6005; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Molkentin JD, 1997, CIRCULATION, V96, P3833; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OGAWA Y, 1995, J MOL MED-JMM, V73, P457; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Palmiter KA, 1997, BASIC RES CARDIOL, V92, P63, DOI 10.1007/BF00794070; Park JC, 1996, J BIOL CHEM, V271, P20914, DOI 10.1074/jbc.271.34.20914; PERREAULT CL, 1994, AM J PHYSIOL, V266, pH2436, DOI 10.1152/ajpheart.1994.266.6.H2436; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; REID CJ, 1988, BRIT HEART J, V59, P397; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SAEKI Y, 1993, ADV EXP MED BIOL, V332, P639; SCHWINGER RHG, 1995, CIRCULATION, V92, P3220, DOI 10.1161/01.CIR.92.11.3220; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; SU QX, 1995, EUR J BIOCHEM, V230, P469, DOI 10.1111/j.1432-1033.1995.0469h.x; THORBURN A, 1993, J BIOL CHEM, V268, P2244; Vikstrom KL, 1996, CURR OPIN CELL BIOL, V8, P97, DOI 10.1016/S0955-0674(96)80053-6; WATKINS H, 1995, HUM MOL GENET, V4, P1721, DOI 10.1093/hmg/4.suppl_1.1721; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; Woods A., 1994, LAB HISTOPATHOLOGY C; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; Yamazaki T, 1997, CIRCULATION, V95, P1260; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	61	2087	2237	3	110	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					215	228		10.1016/S0092-8674(00)81573-1	http://dx.doi.org/10.1016/S0092-8674(00)81573-1			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568714	Green Accepted, Bronze			2022-12-01	WOS:000073174000008
J	Casares, F; Mann, RS				Casares, F; Mann, RS			Control of antennal versus leg development in Drosophila	NATURE			English	Article							ECTOPIC EXPRESSION; GENE-EXPRESSION; IMAGINAL DISKS; MELANOGASTER; PROTEIN; SPECIFICATION; EXTRADENTICLE; SEGMENTATION; ORGANIZATION; LOCALIZATION	During the evolution of insects from a millipede-like ancestor, the Hox genes are thought to have promoted the diversification of originally identical body structures(1,2). In Drosophila melanogaster ter, antennae and legs are homologous structures that differ from each other as a result of the Hox gene Antennapedia (Antp), which promotes leg identities by repressing unknown antennal-determining genes(3-7). Here we present four lines of evidence that identify extradenticle (exd) and homothorax (hth) as antennal-determining genes. First, removing the function of exd(8,9) or hth, which is required for the nuclear localization of Exd protein(10), transforms the antenna into leg; such transformations occur without activation of Antp. Second, hth is expressed and Exd is nuclear in most antennal cells, whereas both are restricted to proximal cells of the leg. Third, Antp is a repressor of hth. Fourth, ectopic expression of Meisl, a murine hth homologue(10), can trigger antennal development elsewhere in the fly. Taken together, these data indicate that hth is an antennal selector gene, and that Antp promotes leg development by repressing hth and consequently nuclear Exd.	Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University	Mann, RS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, Ctr Neurobiol & Behav, 701 W 168th St,HHSC 1108, New York, NY 10032 USA.		Casares, Fernando/M-5451-2019	Casares, Fernando/0000-0002-2181-3858	NIGMS NIH HHS [R01 GM058575, R01 GM054510] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054510, R01GM058575] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT MK, 1986, GENETICS, V114, P919; AKAM M, 1988, DEVELOPMENT S, P123; Azpiazu N, 1998, GENE DEV, V12, P261, DOI 10.1101/gad.12.2.261; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brower, 1991, DROSOPHILA INFORMATI, V70, P52; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; CARROLL SB, 1986, CELL, V47, P113, DOI 10.1016/0092-8674(86)90372-7; Casares F, 1997, DEV GENES EVOL, V207, P216, DOI 10.1007/s004270050110; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; Freeland DE, 1996, MECH DEVELOP, V56, P61, DOI 10.1016/0925-4773(96)00511-4; Gehring W., 1966, ARCH JULIUS KALAUSST, V41, P44; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZCRESPO S, 1995, DEVELOPMENT, V121, P2117; GonzalezCrespo S, 1996, DEVELOPMENT, V122, P3921; KAUFMAN TC, 1980, GENETICS, V94, P115; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; PANGANIBAN G, 1995, SCIENCE, V270, P1363, DOI 10.1126/science.270.5240.1363; Pignoni F, 1997, DEVELOPMENT, V124, P271; RAUSKOLB C, 1995, DEVELOPMENT, V121, P3663; RAUSKOLB C, 1993, CELL, V74, P1; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; SCHNEUWLY S, 1987, EMBO J, V6, P201, DOI 10.1002/j.1460-2075.1987.tb04739.x; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; STRUHL G, 1981, NATURE, V292, P635, DOI 10.1038/292635a0; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; WIRZ J, 1986, EMBO J, V5, P3327, DOI 10.1002/j.1460-2075.1986.tb04647.x	31	244	247	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1998	392	6677					723	726		10.1038/33706	http://dx.doi.org/10.1038/33706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565034				2022-12-01	WOS:000073129000061
J	Hall, RA; Premont, RT; Chow, CW; Blitzer, JT; Pitcher, JA; Claing, A; Stoffel, RH; Barak, LS; Shenolikar, S; Weinman, EJ; Grinstein, S; Lefkowitz, RJ				Hall, RA; Premont, RT; Chow, CW; Blitzer, JT; Pitcher, JA; Claing, A; Stoffel, RH; Barak, LS; Shenolikar, S; Weinman, EJ; Grinstein, S; Lefkowitz, RJ			The beta(2)-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange	NATURE			English	Article							NA-H EXCHANGE; BETA-ADRENERGIC-RECEPTOR; PARATHYROID-HORMONE; PROXIMAL TUBULE; CAMP; SEQUESTRATION; REABSORPTION; ACTIVATION; INHIBITION; COFACTOR	Stimulation of beta(2)-adrenergic receptors on the cell surface by adrenaline or noradrenaline leads to alterations in the metabolism, excitability, differentiation and growth of many cell types. These effects have traditionally been thought to be mediated exclusively by receptor activation of intracellular G proteins(1). However, certain physiological effects of beta(2)-adrenergic receptor stimulation, notably the regulation of cellular pH by modulation of Na+/H+ exchanger (NHE) function, do not seem to be entirely dependent on G-protein activation(2-7). We report here a direct agonist-promoted association of the beta(2)-adrenergic receptor with the Na+/H+ exchanger regulatory factor (NHERF), a protein that regulates the activity of the Na+/H+ exchanger type 3 (NHE3)(8). NHERF binds to the beta(2)-adrenergic receptor by means of a PDZ-domain-mediated interaction with the last few residues of the carboxy-terminal cytoplasmic domain of the receptor. Mutation of the final residue of the beta(2)-adrenergic receptor from leucine to alanine abolishes the receptor's interaction with NHERF and also markedly alters beta(2)-adrenergic receptor regulation of NHE3 in cells without altering receptor-mediated activation of adenylyl cyclase. Our findings indicate that agonist-defendent beta(2)-adrenergic receptor binding of NHERF plays a role in beta(2)-adrenergic receptor-mediated regulation of Na+/H+ exchange.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Hosp Sick Children, Res Inst, Div Cell Biol, Toronto, ON M5G 1X8, Canada; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; W Virginia Univ, Dept Med, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA; Dept Vet Affairs Med Ctr, Med Serv, Clarksburg, WV 26301 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Duke University; West Virginia University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA.		Pitcher, Julie/ABH-2078-2020; Chow, Chung-Wai/AAP-5533-2020; Lefkowitz, Robert/AAW-2649-2021	Chow, Chung-Wai/0000-0001-9344-8522; Premont, Richard/0000-0002-8053-5026; Hall, Randy/0000-0002-8318-8728				AGUS ZS, 1971, J CLIN INVEST, V50, P617, DOI 10.1172/JCI106532; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BARBER DL, 1992, MOL PHARMACOL, V41, P1056; BELLOREUSS E, 1980, AM J PHYSIOL, V238, pF347, DOI 10.1152/ajprenal.1980.238.5.F347; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; Cabado AG, 1996, J BIOL CHEM, V271, P3590; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOLSON GM, 1985, AM J PHYSIOL, V249, pF409, DOI 10.1152/ajprenal.1985.249.3.F409; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/cjpp-74-10-1095; GANZ MB, 1990, J BIOL CHEM, V265, P8989; KAHN AM, 1985, AM J PHYSIOL, V248, pF212, DOI 10.1152/ajprenal.1985.248.2.F212; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; WEINMAN EJ, 1987, AM J PHYSIOL, V252, pF19, DOI 10.1152/ajprenal.1987.252.1.F19; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; WEINMAN EJ, 1982, J MEMBRANE BIOL, V69, P107, DOI 10.1007/BF01872270; WEINMAN EJ, 1993, ANNU REV PHYSIOL, V55, P289, DOI 10.1146/annurev.ph.55.030193.001445; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	30	482	490	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					626	630		10.1038/33458	http://dx.doi.org/10.1038/33458			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560162				2022-12-01	WOS:000072987200066
J	van der Horst, CMAM; Koster, PHL; de Borgie, CAJM; Bossuyt, PMM; van Gemert, MJC				van der Horst, CMAM; Koster, PHL; de Borgie, CAJM; Bossuyt, PMM; van Gemert, MJC			Effect of the timing of treatment of port-wine stains with the flash-lamp-pumped pulsed dye-laser	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-EXPERIENCE; CHILDREN; THERAPY	Background Port-wine stains can be treated with a flash-lamp-pumped pulsed-dye laser, but it is uncertain whether this treatment is more effective if administered early in life, when the skin is thinner and the lesion is smaller, Methods We prospectively studied 100 patients with a previously untreated part-wine stain of the head or neck. They were treated with the flash-lamp-pumped pulsed-dye laser and divided into four age groups (0 to 5, 6 to 12, 12 to 17, and 18 to 31 years), The outcome measure was lightening of the port-wine stain (reduction in the difference in color between the skin with the stain and contralateral healthy skin) as measured with a colorimeter after an average of five treatments (range, three to seven) of the entire lesion. Results Of the 100 patients, 11 could not be included in the analysis because they had received fewer than three or more than seven treatments, had an erroneous base-line color measurement, or were lost to follow-up, The sizes, locations, and colors of the port-wine stains were similar among the groups. When all 89 patients were analyzed together, the average reduction in the difference in color between the skin with the port-wine stain and contralateral healthy skin was 40 percent, The differences between age groups in the average reduction in color differences were not significant (P = 0.26). By the end of the study, only 7 of 89 patients had completed laser therapy, and in no case was clearance complete. Treatment was discontinued in all seven because the last three treatments did not lead to further lightening. Conclusions We found no evidence that treatment of port-wine stains with the flash-lamp-pumped pulsed-dye laser in early childhood is more effective than treatment at a later age. (C) 1998, Massachusetts Medical Society.	Univ Amsterdam, Acad Med Ctr, Dept Plast Reconstruct & Hand Surg, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Ctr Laser, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	van der Horst, CMAM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Plast Reconstruct & Hand Surg, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Bossuyt, Patrick M./B-4557-2016; Bossuyt, Patrick M/AAR-1183-2021	Bossuyt, Patrick M./0000-0003-4427-0128; Bossuyt, Patrick M/0000-0003-4427-0128; van der Horst, chantal/0000-0002-4937-3786				ACHAUER BM, 1990, ANN PLAS SURG, V25, P344, DOI 10.1097/00000637-199011000-00002; ALSTER TS, 1994, ANN PLAS SURG, V32, P478, DOI 10.1097/00000637-199405000-00007; Altman DG, 1991, PRACTICAL STAT MED R; ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; ASHINOFF R, 1991, J AM ACAD DERMATOL, V24, P467, DOI 10.1016/0190-9622(91)70075-D; DIXON JA, 1984, PLAST RECONSTR SURG, V73, P771, DOI 10.1097/00006534-198405000-00009; Fiskerstrand EJ, 1996, BRIT J DERMATOL, V134, P1039, DOI 10.1046/j.1365-2133.1996.d01-898.x; GARDEN JM, 1989, NEW ENGL J MED, V321, P901; GARDEN JM, 1988, ARCH DERMATOL, V124, P889, DOI 10.1001/archderm.124.6.889; GOLDMAN MP, 1993, J PEDIATR-US, V122, P71, DOI 10.1016/S0022-3476(05)83489-4; GOLDMAN MP, 1994, CUTANEOUS LASER SURG, P19; HELLER A, 1985, AM J DIS CHILD, V139, P257, DOI 10.1001/archpedi.1985.02140050051021; JACOBS AH, 1976, PEDIATRICS, V58, P218; KAUVAR ANB, 1995, DERMATOL SURG, V21, P515, DOI 10.1111/j.1524-4725.1995.tb00256.x; LANIGAN SW, 1989, BRIT J DERMATOL, V121, P209, DOI 10.1111/j.1365-2133.1989.tb01800.x; MORELLI JG, 1995, ARCH PEDIAT ADOL MED, V149, P1142, DOI 10.1001/archpedi.1995.02170230096014; MORELLI JG, 1992, MANAGEMENT TREATMENT; NOE JM, 1980, PLAST RECONSTR SURG, V65, P130, DOI 10.1097/00006534-198002000-00002; ONIZUKA K, 1995, BRIT J PLAST SURG, V48, P271, DOI 10.1016/0007-1226(95)90064-0; REYES BA, 1990, J AM ACAD DERMATOL, V23, P1142, DOI 10.1016/0190-9622(90)70348-L; SCHEEPERS JH, 1994, BRIT J PLAST SURG, V47, P112, DOI 10.1016/0007-1226(94)90169-4; TAN OT, 1989, NEW ENGL J MED, V320, P416, DOI 10.1056/NEJM198902163200702; vanderHorst CMAM, 1997, BRIT J PLAST SURG, V50, P463, DOI 10.1016/S0007-1226(97)90335-0; vanGemert MJC, 1997, PHYS MED BIOL, V42, P41, DOI 10.1088/0031-9155/42/1/002; WESTERHOF W, 1986, PHOTODERMATOLOGY, V3, P310; Wyszecki G., 1982, COLOR SCI CONCEPTS M, V2nd, P130	26	121	121	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1028	1033		10.1056/NEJM199804093381504	http://dx.doi.org/10.1056/NEJM199804093381504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG134	9535667				2022-12-01	WOS:000072969500004
J	Jaglo-Ottosen, KR; Gilmour, SJ; Zarka, DG; Schabenberger, O; Thomashow, MF				Jaglo-Ottosen, KR; Gilmour, SJ; Zarka, DG; Schabenberger, O; Thomashow, MF			Arabidopsis CBF1 overexpression induces COR genes and enhances freezing tolerance	SCIENCE			English	Article							CIS-ACTING ELEMENT; LOW-TEMPERATURE; MOLECULAR-CLONING; COLD-ACCLIMATION; THALIANA COR15A; EXPRESSION; DROUGHT; STRESS; ABA	Many plants, including Arabidopsis, show increased resistance to freezing after they have been exposed to low nonfreezing temperatures. This response, termed cold acclimation, is associated with the induction of COR (cold-regulated) genes mediated by the C-repeat/drought-responsive element (CRT/DRE) DNA regulatory element, Increased expression of Arabidopsis CBF1, a transcriptional activator that binds to the CRT/DRE sequence, induced COR gene expression and increased the freezing tolerance of nonacclimated Arabidopsis plants, We conclude that CBF1 is a likely regulator of the cold acclimation response, controlling the level of COR gene expression, which in turn promotes tolerance to freezing.	Michigan State Univ, Dept Crop & Soil Sci, E Lansing, MI 48824 USA	Michigan State University	Thomashow, MF (corresponding author), Michigan State Univ, Dept Crop & Soil Sci, Plant & Soil Sci Bldg, E Lansing, MI 48824 USA.							Artus NN, 1996, P NATL ACAD SCI USA, V93, P13404, DOI 10.1073/pnas.93.23.13404; BAKER SS, 1994, PLANT MOL BIOL, V24, P701, DOI 10.1007/BF00029852; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Crosatti C, 1996, THEOR APPL GENET, V93, P975, DOI 10.1007/BF00224101; GILMOUR SJ, 1988, PLANT PHYSIOL, V87, P735; GILMOUR SJ, UNPUB; GUY CL, 1990, ANNU REV PLANT PHYS, V41, P187, DOI 10.1146/annurev.pp.41.060190.001155; HAJELA RK, 1990, PLANT PHYSIOL, V93, P1246, DOI 10.1104/pp.93.3.1246; HOUDE M, 1992, MOL GEN GENET, V234, P43, DOI 10.1007/BF00272343; Hughes MA, 1996, J EXP BOT, V47, P291, DOI 10.1093/jxb/47.3.291; Jiang C, 1996, PLANT MOL BIOL, V30, P679, DOI 10.1007/BF00049344; Larcher W., 1981, Physiological processes limiting plant productivity [Johnson, C.B. (Editor)]., P253; Larcher W., 1981, PHYSIOLOGICAL PLANT, P403; METZ AM, 1992, GENE, V120, P313, DOI 10.1016/0378-1119(92)90112-3; MOHAPATRA SS, 1989, PLANT PHYSIOL, V89, P375, DOI 10.1104/pp.89.1.375; NORDIN K, 1993, PLANT MOL BIOL, V21, P641, DOI 10.1007/BF00014547; ROTHSTEIN SJ, 1987, GENE, V53, P153, DOI 10.1016/0378-1119(87)90003-5; Sambrook J., 1989, MOL CLONING LAB MANU; *SAS I, 1989, SAS STAT US GUID VER; Stockinger EJ, 1997, P NATL ACAD SCI USA, V94, P1035, DOI 10.1073/pnas.94.3.1035; SUKUMARAN N P, 1972, Hortscience, V7, P467; Thomashow M. F., 1990, Advances in Genetics, V28, P99; THOMASHOW MF, 1994, ARABIDOPSIS, P807, DOI DOI 10.1101/0.807-834; vanHoof A, 1996, PLANT J, V10, P415, DOI 10.1046/j.1365-313x.1996.10030415.x; WANG H, 1995, PLANT MOL BIOL, V28, P605, DOI 10.1007/BF00021187; YAMAGUCHISHINOZAKI K, 1994, PLANT CELL, V6, P251, DOI 10.1105/tpc.6.2.251	26	1245	1487	4	297	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					104	106		10.1126/science.280.5360.104	http://dx.doi.org/10.1126/science.280.5360.104			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525853				2022-12-01	WOS:000072885100045
J	Pagan-Westphal, SM; Tabin, CJ				Pagan-Westphal, SM; Tabin, CJ			The transfer of left-right positional information during chick embryogenesis	CELL			English	Article							LEFT-RIGHT ASYMMETRY; SONIC HEDGEHOG; NODAL EXPRESSION; INDUCTION; GENE; RECEPTOR; MICE; CONSERVATION; PATHWAY; EMBRYO	The earliest known left-right asymmetric genes are expressed at Hensen's node during chick gastrulation. Gene expression following reorientation of the node shows asymmetry is instructed by adjacent tissue, hence left-right information originates outside the node. Subsequently, the node signals back to the lateral tissue, initiating a cascade leading to left-sided expression of nodal in the lateral plate mesoderm. Loss of nodal expression in the presence of blocking antibodies confirms that Sonic hedgehog is the key signal conveying left-right information from the node; however, manipulation of explant cultures suggests that the induction of nodal requires secondary signals produced in the paraxial mesoderm. These experiments establish the time of action of these signals to and from Hensen's node in establishing left-right asymmetry.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.							ABERCROMBIE M, 1950, PHILOS T R SOC B, V234, P317, DOI 10.1098/rstb.1950.0004; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; EKKER SC, 1995, DEVELOPMENT, V121, P2337; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Heymer J, 1997, MECH DEVELOP, V66, P5, DOI 10.1016/S0925-4773(97)00084-1; HYATT BA, 1998, CELL, V93; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; KING T, 1997, CURR BIOL, V7, pF212; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; LEVIN M, 1996, THESIS HARVARD U CAM; LOHR JL, 1997, DEVELOPMENT, V124, P1467; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; Marigo V, 1996, DEVELOPMENT, V122, P1225; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; Nascone N, 1997, DEV BIOL, V189, P68, DOI 10.1006/dbio.1997.8635; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; Pannett C.A., 1924, LANCET, V206, P381; Psychoyos D, 1996, DEVELOPMENT, V122, P3263; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Sampath K, 1997, DEVELOPMENT, V124, P3293; Schultheiss TM, 1995, DEVELOPMENT, V121, P4203; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1	31	152	156	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					25	35		10.1016/S0092-8674(00)81143-5	http://dx.doi.org/10.1016/S0092-8674(00)81143-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546389	Bronze			2022-12-01	WOS:000072910800007
J	Schacter, DL				Schacter, DL			Memory and awareness	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; IMPLICIT MEMORY; HIPPOCAMPUS; ACTIVATION; HUMANS		Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA	Harvard University	Schacter, DL (corresponding author), Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.			Schacter, Daniel/0000-0002-2460-6061	NATIONAL INSTITUTE ON AGING [R37AG008441, R01AG008441] Funding Source: NIH RePORTER; NIA NIH HHS [AG08441] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berns GS, 1997, SCIENCE, V276, P1272, DOI 10.1126/science.276.5316.1272; Blaxton TA, 1996, J NEUROSCI, V16, P4032; BOWERS JS, 1990, J EXP PSYCHOL LEARN, V16, P404, DOI 10.1037/0278-7393.16.3.404; Clark RE, 1998, SCIENCE, V280, P77, DOI 10.1126/science.280.5360.77; CURRAN T, 1997, HDB IMPLICIT LEARNIN, P365; GRAF P, 1984, J EXP PSYCHOL LEARN, V10, P164, DOI 10.1037/0278-7393.10.1.164; McKone E, 1997, MEM COGNITION, V25, P352, DOI 10.3758/BF03211291; MERIKLE PM, 1991, J EXP PSYCHOL LEARN, V17, P224, DOI 10.1037/0278-7393.17.2.224; Rugg MD, 1997, NEUROREPORT, V8, P1283, DOI 10.1097/00001756-199703240-00045; Schacter DL, 1998, NEURON, V20, P185, DOI 10.1016/S0896-6273(00)80448-1; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SHANKS DR, 1994, BEHAV BRAIN SCI, V17, P367, DOI 10.1017/S0140525X00035032; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; UNGERLEIDER LG, 1995, SCIENCE, V270, P769, DOI 10.1126/science.270.5237.769	16	45	46	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					59	60		10.1126/science.280.5360.59	http://dx.doi.org/10.1126/science.280.5360.59			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZF314	9556454				2022-12-01	WOS:000072885100033
J	Heine, A; Stura, EA; Yli-Kauhaluoma, JT; Gao, CS; Deng, QL; Beno, BR; Houk, KN; Janda, KD; Wilson, IA				Heine, A; Stura, EA; Yli-Kauhaluoma, JT; Gao, CS; Deng, QL; Beno, BR; Houk, KN; Janda, KD; Wilson, IA			An antibody exo Diels-Alderase inhibitor complex at 1.95 angstrom resolution	SCIENCE			English	Article							CATALYTIC ANTIBODIES; 3-DIMENSIONAL STRUCTURE; REACTIVE IMMUNIZATION; COMPUTER-SIMULATIONS; ANTIGEN INTERACTIONS; STEPWISE MECHANISMS; AUTOMATED DOCKING; CRYSTAL-STRUCTURE; TRANSITION-STATE; ACCELERATION	A highly specific Diels-Alder protein catalyst was made by manipulating the antibody repertoire of the immune system, The catalytic antibody 13G5 catalyzes a disfavored exo Diels-Alder transformation in a reaction for which there is no natural enzyme counterpart and that yields a single regioisomer in high enantiomeric excess. The crystal structure of the antibody Fab in complex with a ferrocenyl inhibitor containing the essential haptenic core that elicited 13G5 was determined at 1.95 angstrom resolution, Three key antibody residues appear to be responsible for the observed catalysis and product control, Tyrosine-L36 acts as a Lewis acid activating the dienophile for nucleophilic attack, and asparagine-L91 and aspartic acid-H50 form hydrogen bonds to the carboxylate side chain that substitutes for the carbamate diene substrate, This hydrogen-bonding scheme leads to rate acceleration and also pronounced stereoselectivity, Docking experiments with the four possible ortho transition states of the reaction explain the specific exo effect and suggest that the (3R, 4R)-exo stereoisomer is the preferred product.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; University of California System; University of California Los Angeles; Scripps Research Institute; Scripps Research Institute	Heine, A (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118; Yli-Kauhaluoma, Jari/0000-0003-0370-7653	NCI NIH HHS [CA27489, P01 CA27489] Funding Source: Medline; NIGMS NIH HHS [GM-43858] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043858, R01GM043858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; Barone V, 1997, J CHEM PHYS, V106, P8727, DOI 10.1063/1.473933; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; Beno BR, 1996, J AM CHEM SOC, V118, P9984, DOI 10.1021/ja9615278; Bjornestedt R, 1996, J AM CHEM SOC, V118, P11720, DOI 10.1021/ja9620797; BLAKE JF, 1991, J AM CHEM SOC, V113, P7430, DOI 10.1021/ja00019a055; BLAKE JF, 1994, J ORG CHEM, V59, P803, DOI 10.1021/jo00083a021; BRAISTED AC, 1990, J AM CHEM SOC, V112, P7430, DOI 10.1021/ja00176a073; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CANNIZZARO C, COMMUNICATION; Charbonnier JB, 1997, SCIENCE, V275, P1140, DOI 10.1126/science.275.5303.1140; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P439; CRAVATT BF, 1994, J AM CHEM SOC, V116, P6013, DOI 10.1021/ja00092a080; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREMONT DH, COMMUNICATION; Frisch M.J., 2009, GAUSSIAN16; Goldstein E, 1996, J AM CHEM SOC, V118, P6036, DOI 10.1021/ja9601494; GOLINELLIPIMPANEAU B, 1994, STRUCTURE, V2, P175, DOI 10.1016/S0969-2126(00)00019-8; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; GOUVERNEUR VE, 1993, SCIENCE, V262, P204, DOI 10.1126/science.8211138; GRIECO PA, 1983, TETRAHEDRON LETT, V24, P1897, DOI 10.1016/S0040-4039(00)81800-6; GUO JC, 1995, P NATL ACAD SCI USA, V92, P1694, DOI 10.1073/pnas.92.5.1694; Haynes MR, 1996, ISR J CHEM, V36, P133; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; Hehre W. J., 1986, AB INITIO MOL ORBITA, P76; HEINE A, UNPUB; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; JANDA KD, 1989, SCIENCE, V244, P437, DOI 10.1126/science.2717936; JANDA KD, 1993, SCIENCE, V259, P490, DOI 10.1126/science.8424171; JANDA KD, 1996, COMPREHENSIVE SUPRAM, P43; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN WL, 1994, J CHEM SOC FARADAY T, V90, P1727, DOI 10.1039/ft9949001727; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; KEINAN E, 1996, ISR J CHEM, V36, P133; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lavey BJ, 1995, ACS SYM SER, V604, P123, DOI 10.1021/bk-1995-0604.ch010; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; LI Y, 1993, J AM CHEM SOC, V115, P7478, DOI 10.1021/ja00069a055; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OIKAWA H, 1995, J CHEM SOC CHEM COMM, P1321, DOI 10.1039/c39950001321; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PALENIK GJ, 1969, INORG CHEM, V8, P2744, DOI 10.1021/ic50082a041; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; PURVIS GD, 1986, J MOL GRAPH, V4; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RIDEOUT DC, 1980, J AM CHEM SOC, V102, P7816, DOI 10.1021/ja00546a048; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; SAUER J, 1980, ANGEW CHEM INT EDIT, V19, P779, DOI 10.1002/anie.198007791; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SHELDRICK GM, 1996, SHELXL 96 PROGRAM CR; SHERIFF S, 1993, IMMUNOMETHODS, V3, P191; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; Streitwieser A. J., 1981, INTRO ORGANIC CHEM, V2nd; STURA EA, 1993, IMMUNOMETHODS, V3, P164; TAKUSAGAWA F, 1979, ACTA CRYSTALLOGR B, V35, P2888, DOI 10.1107/S0567740879010906; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775; YLIKAUHALUOMA JT, 1995, J AM CHEM SOC, V117, P7041, DOI 10.1021/ja00132a001; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	68	117	119	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1934	1940		10.1126/science.279.5358.1934	http://dx.doi.org/10.1126/science.279.5358.1934			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506943	Green Submitted			2022-12-01	WOS:000072613300046
J	Soker, S; Takashima, S; Miao, HQ; Neufeld, G; Klagsbrun, M				Soker, S; Takashima, S; Miao, HQ; Neufeld, G; Klagsbrun, M			Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor	CELL			English	Article							HEPARIN-LIKE MOLECULES; TYROSINE KINASE; FACTOR VEGF; PERMEABILITY FACTOR; ANGIOGENESIS FACTOR; MEMBRANE-PROTEIN; NERVOUS-SYSTEM; BINDING; DIFFERENTIATION; GENE	Vascular endothelial growth factor (VEGF), a major regulator of angiogenesis, binds to two receptor tyrosine kinases, KDR/Flk-1 and Flt-1. We now describe the purification and the expression cloning from tumor cells of a third VEGF receptor, one that binds VEGF(165) but not VEGF(121). This isoform-specific VEGF receptor (VEGF(165)R) is identical to human neuropilin-1, a receptor for the collapsin/semaphorin family that mediates neuronal cell guidance. When coexpressed in cells with KDR, neuropilin-1 enhances the binding of VEGF(165) to KDR and VEGF(165)-mediated chemotaxis. Conversely, inhibition of VEGF(165) binding to neuropilin-1 inhibits its binding to KDR and its mitogenic activity for endothelial cells. We propose that neuropilin-1 is a novel VEGF receptor that modulates VEGF binding to KDR and subsequent bioactivity and therefore may regulate VEGF-induced angiogenesis.	Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Technion Israel Institute of Technology	Klagsbrun, M (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA.		Neufeld, Gera/F-1524-2019		NATIONAL CANCER INSTITUTE [R01CA037392, P01CA045548, R37CA037392] Funding Source: NIH RePORTER; NCI NIH HHS [CA37392, CA45548] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BREIER G, 1992, DEVELOPMENT, V114, P521; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1995, AM J PATHOL, V146, P1029; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; ENOMOTO T, 1994, BIOCHEM BIOPH RES CO, V202, P1716, DOI 10.1006/bbrc.1994.2133; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FLAMME I, 1995, DEV BIOL, V169, P699, DOI 10.1006/dbio.1995.1180; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fujisawa H, 1995, DEV NEUROSCI-BASEL, V17, P343, DOI 10.1159/000111304; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Joukov V, 1996, EMBO J, V15, P1751; KAWAKAMI A, 1995, J NEUROBIOL, V29, P1; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Omura T, 1997, J BIOL CHEM, V272, P23317, DOI 10.1074/jbc.272.37.23317; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILCHEK M, 1982, BIOCHEM INT, V4, P629; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566	60	1933	2080	2	99	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					735	745		10.1016/S0092-8674(00)81402-6	http://dx.doi.org/10.1016/S0092-8674(00)81402-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529250	Bronze			2022-12-01	WOS:000072661200007
J	Chen, QY; Kirsch, GE; Zhang, DM; Brugada, R; Brugada, J; Brugada, P; Potenza, D; Moya, A; Borggrefe, M; Breithardt, G; Ortiz-Lopez, R; Wang, Z; Antzelevitch, C; O'Brien, RE; Schulze-Bahr, E; Keating, MT; Towbin, JA; Wang, Q				Chen, QY; Kirsch, GE; Zhang, DM; Brugada, R; Brugada, J; Brugada, P; Potenza, D; Moya, A; Borggrefe, M; Breithardt, G; Ortiz-Lopez, R; Wang, Z; Antzelevitch, C; O'Brien, RE; Schulze-Bahr, E; Keating, MT; Towbin, JA; Wang, Q			Genetic basis and molecular mechanism for idiopathic: ventricular fibrillation	NATURE			English	Article							INHERITED CARDIAC-ARRHYTHMIA; ST SEGMENT ELEVATION; LONG-QT SYNDROME; BUNDLE-BRANCH BLOCK; SODIUM-CHANNEL; HEART-DISEASE; J-WAVE; DEATH; MUTATIONS	Ventricular fibrillation causes more than 300,000 sudden deaths each year in the USA alone(1,2). In approximately 5-12% of these cases, there are no demonstrable cardiac or non-cardiac causes to account for the episode, which is therefore classified as idiopathic ventricular fibrillation (IVF)(3-6). A distinct group of IVF patients has been found to present with a characteristic electrocardiographic pattern(7-15). Because of the small size of most pedigrees and the high incidence of sudden death, however, molecular genetic studies of NF have not yet been done. Because IVF causes cardiac rhythm disturbance, we investigated whether malfunction of ion channels could cause the disorder by studying mutations in the cardiac sodium channel gene SCN5A. We have now identified a missense mutation, a splice-donor mutation, and a frameshift mutation in the coding region of SCN5A in three IVF families. We show that sodium channels with the missense mutation recover from inactivation more rapidly than normal and that the frameshift mutation causes the sodium channel to be non-functional. Our results indicate that mutations in cardiac ion-channel genes contribute to the risk of developing IVF.	Baylor Coll Med, Dept Pediat Cardiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med Cardiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cardiovasc Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Case Western Reserve Univ, Rammelkamp Ctr Res, Cleveland, OH 44109 USA; Univ Barcelona, Hosp Clin, Cardiovasc Inst, Arrhythmia Unit, E-08036 Barcelona, Spain; OLV Hosp, Ctr Cardiovasc, B-9300 Aalst, Belgium; IRCCS, Dept Cardiol, S Giovanni Rotondo, Italy; Hosp Gen Valle Hebron, Dept Cardiol, Barcelona 08020, Spain; Hosp Univ Munster, Inst Arteriosclerosis Res, Dept Cardiol & Angiol, D-48129 Munster, Germany; Masonic Med Res Lab, Utica, NY 13504 USA; Univ Utah, Howard Hughes Med Inst, Dept Human Genet & Med, Salt Lake City, UT 84112 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Case Western Reserve University; MetroHealth System; University of Barcelona; Hospital Clinic de Barcelona; Cardiovascular Center Aalst; Hospital Universitari Vall d'Hebron; University of Munster; Masonic Medical Research Laboratory; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Wang, Q (corresponding author), Baylor Coll Med, Dept Pediat Cardiol, Houston, TX 77030 USA.	qwang@bcm.tmc.edu	Ortiz-Lopez, Rocio/F-7020-2014; Towbin, Jeffrey A./J-5595-2019	Ortiz-Lopez, Rocio/0000-0002-7783-026X; Towbin, Jeffrey A./0000-0002-6585-714X; Antzelevitch, Charles/0000-0001-7349-1582; BRUGADA, JOSEP/0000-0002-5662-8302; Antzelevitch, Charles/0000-0001-5215-4667				AIZAWA Y, 1993, AM HEART J, V126, P1473, DOI 10.1016/0002-8703(93)90550-S; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; BJERREGAARD P, 1994, AM HEART J, V127, P1426, DOI 10.1016/0002-8703(94)90070-1; Brugada J, 1997, J CARDIOVASC ELECTR, V8, P325, DOI 10.1111/j.1540-8167.1997.tb00796.x; BRUGADA J, 1996, PACE, V19, P599; BRUGADA J, 1997, CIRCULATION, V96, P1151; BRUGADA P, 1992, J AM COLL CARDIOL, V20, P1391, DOI 10.1016/0735-1097(92)90253-J; COBB LA, 1994, HURSTS HEART, P947; Dumaine R, 1996, CIRC RES, V78, P916, DOI 10.1161/01.RES.78.5.916; HOFFMAN EP, 1995, CELL, V80, P681, DOI 10.1016/0092-8674(95)90345-3; KANNEL WB, 1987, AM HEART J, V113, P799, DOI 10.1016/0002-8703(87)90722-8; KRISHNAN SC, 1993, CIRCULATION, V87, P562, DOI 10.1161/01.CIR.87.2.562; KRISHNAN SC, 1991, CIRC RES, V69, P277, DOI 10.1161/01.RES.69.2.277; MARTINI B, 1989, AM HEART J, V118, P1203, DOI 10.1016/0002-8703(89)90011-2; Miyanuma H, 1993, Kokyu To Junkan, V41, P287; Miyazaki T, 1996, J AM COLL CARDIOL, V27, P1061, DOI 10.1016/0735-1097(95)00613-3; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; SUMIYOSHI M, 1993, JPN HEART J, V34, P661; TRAPPE HJ, 1988, J AM COLL CARDIOL, V12, P166, DOI 10.1016/0735-1097(88)90370-1; TUNG RT, 1994, PACE, V17, P1405, DOI 10.1111/j.1540-8159.1994.tb02460.x; VISKIN S, 1990, AM HEART J, V120, P661, DOI 10.1016/0002-8703(90)90025-S; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WANG Q, 1995, HUM MOL GENET, V4, P1603, DOI 10.1093/hmg/4.9.1603; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236; WICHTER T, 1995, CARDIAC ARRHYTHMIA M, P1219; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; Yan GX, 1996, CIRCULATION, V93, P372, DOI 10.1161/01.CIR.93.2.372; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0	30	1269	1336	3	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					293	296		10.1038/32675	http://dx.doi.org/10.1038/32675			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521325				2022-12-01	WOS:000072612300050
J	Juliano, SL				Juliano, SL			Neurobiology - Mapping the sensory mosaic	SCIENCE			English	Article							PRIMARY SOMATOSENSORY CORTEX; LONG-TERM ENHANCEMENT; ADULT FLYING-FOX; RECEPTIVE-FIELDS; CEREBRAL-CORTEX; STRIATE CORTEX; CAT; REORGANIZATION; ACETYLCHOLINE; THALAMUS		Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Juliano, SL (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, Bethesda, MD 20814 USA.	sjuliano@mx3.usuhs.mil	Juliano, Sharon/AAO-1030-2020					Bakin JS, 1996, P NATL ACAD SCI USA, V93, P11219, DOI 10.1073/pnas.93.20.11219; CALFORD MB, 1988, NATURE, V332, P446, DOI 10.1038/332446a0; CALFORD MB, 1991, J NEUROPHYSIOL, V65, P178, DOI 10.1152/jn.1991.65.2.178; DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; Dykes RW, 1997, CAN J PHYSIOL PHARM, V75, P535, DOI 10.1139/cjpp-75-5-535; Faggin BM, 1997, P NATL ACAD SCI USA, V94, P9428, DOI 10.1073/pnas.94.17.9428; Gil Z, 1997, NEURON, V19, P679, DOI 10.1016/S0896-6273(00)80380-3; HOHMANN CF, IN PRESS PERSPECTIVE; Huntley GW, 1997, CEREB CORTEX, V7, P143, DOI 10.1093/cercor/7.2.143; JULIANO SL, 1990, J COMP NEUROL, V297, P106, DOI 10.1002/cne.902970108; JULIANO SL, 1991, P NATL ACAD SCI USA, V88, P780, DOI 10.1073/pnas.88.3.780; Kawaguchi Y, 1997, J NEUROPHYSIOL, V78, P1743, DOI 10.1152/jn.1997.78.3.1743; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; KOSSUT M, UNPUB; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; MCCORMICK DA, 1985, P NATL ACAD SCI USA, V82, P6344, DOI 10.1073/pnas.82.18.6344; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; MCCORMICK DA, 1993, PROG BRAIN RES, V98, P303; METHERATE R, 1987, NEUROSCIENCE, V22, P75, DOI 10.1016/0306-4522(87)90198-9; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RASMUSSON DD, 1988, EXP BRAIN RES, V70, P276; Richardson R.T, 1991, ACTIVATION ACQUISITI; Tang AC, 1997, CEREB CORTEX, V7, P502, DOI 10.1093/cercor/7.6.502; WALL PD, 1977, PHILOS T R SOC B, V278, P361, DOI 10.1098/rstb.1977.0048; Weinberger N M, 1993, Curr Opin Neurobiol, V3, P570, DOI 10.1016/0959-4388(93)90058-7; WEINBERGER NM, 1995, ANNU REV NEUROSCI, V18, P129	27	19	21	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1653	1654		10.1126/science.279.5357.1653	http://dx.doi.org/10.1126/science.279.5357.1653			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9518376				2022-12-01	WOS:000072490000037
J	Cibelli, JB; Stice, SL; Golueke, PJ; Kane, JJ; Jerry, J; Blackwell, C; de Leon, FAP; Robl, JM				Cibelli, JB; Stice, SL; Golueke, PJ; Kane, JJ; Jerry, J; Blackwell, C; de Leon, FAP; Robl, JM			Cloned transgenic calves produced from nonquiescent fetal fibroblasts	SCIENCE			English	Article							TRANSPLANT RABBIT EMBRYOS; CELL-CYCLE STAGE; NUCLEAR TRANSFER; LIVESTOCK	An efficient system for genetic modification and large-scale cloning of cattle is of importance for agriculture, biotechnology, and human medicine. Here, actively dividing fetal fibroblasts were genetically modified with a marker gene, a clonal line was selected, and the cells were fused to enucleated mature oocytes. Out of 28 embryos transferred to 11 recipient cows, three healthy, identical, transgenic calves were generated. Furthermore, the life-span of near senescent fibroblasts could be extended by nuclear transfer, as indicated by population doublings in fibroblast lines derived from a 40-day-old fetal clone. With the ability to extend the life-span of these primary cultured cells, this system would be useful for inducing complex genetic modifications in cattle.	Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; Adv Cell Technol Inc, Worcester, MA 01605 USA; Coll Agr Food & Environm Sci, St Paul, MN 55108 USA	University of Massachusetts System; University of Massachusetts Amherst	Robl, JM (corresponding author), Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA.			Cibelli, Jose/0000-0002-2176-3854; Ponce de Leon, Federico/0000-0001-8645-553X				BONDIOLI KR, 1993, MOL REPROD DEV, V36, P274, DOI 10.1002/mrd.1080360229; CLEMENTSENGEWALD A, 1992, BERL MUNCH TIERARZTL, V105, P15; COLLAS P, 1992, BIOL REPROD, V46, P501, DOI 10.1095/biolreprod46.3.501; COLLAS P, 1992, BIOL REPROD, V46, P492, DOI 10.1095/biolreprod46.3.492; FIEDRICH G, 1991, GENE DEV, V5, P1513; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; PURSEL VG, 1993, J ANIM SCI, V71, P10, DOI 10.2527/1993.71suppl_310x; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; SAITO S, 1992, ROUX ARCH DEV BIOL, V201, P134, DOI 10.1007/BF00188711; Stice SL, 1996, BIOL REPROD, V54, P100, DOI 10.1095/biolreprod54.1.100; SUSKOPARRISH JL, 1994, DEV BIOL, V166, P729, DOI 10.1006/dbio.1994.1351; Walker SK, 1996, THERIOGENOLOGY, V45, P111, DOI 10.1016/0093-691X(95)00360-K; WALL RJ, 1992, J CELL BIOCHEM, V49, P113, DOI 10.1002/jcb.240490203; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	15	994	1258	0	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1256	1258		10.1126/science.280.5367.1256	http://dx.doi.org/10.1126/science.280.5367.1256			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596577				2022-12-01	WOS:000073852500046
J	Ebinu, JO; Bottorff, DA; Chan, EYW; Stang, SL; Dunn, RJ; Stone, JC				Ebinu, JO; Bottorff, DA; Chan, EYW; Stang, SL; Dunn, RJ; Stone, JC			RasGRP, a Ras guanyl nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs	SCIENCE			English	Article							EXCHANGE FACTOR; KINASE-C; ACTIVATION; RECEPTORS; NEURONS; CLONING; PATHWAY; GRF	RasGRP, a guanyl nucleotide-releasing protein for the small guanosine triphosphatase Ras, was characterized. Besides the catalytic domain, RasGRP has an atypical pair of "EF hands" that bind calcium and a diacylglycerol (DAG)-binding domain. RasGRP activated Ras and caused transformation in fibroblasts. A DAG analog caused sustained activation of Ras-Erk signaling and changes in cell morphology. Signaling was associated with partitioning of RasGRP protein into the membrane fraction. Sustained ligand-induced signaling and membrane partitioning were absent when the DAG-binding domain was deleted. RasGRP is expressed in the nervous system, where it may couple changes in DAG and possibly calcium concentrations to Ras activation.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Montreal Gen Hosp, Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada	University of Alberta; McGill University	Stone, JC (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.		Chan, Edmond Y.W./A-1940-2013	Chan, Edmond Y.W./0000-0001-9777-0252				AITKEN A, 1984, EUR J BIOCHEM, V139, P663, DOI 10.1111/j.1432-1033.1984.tb08055.x; AMBAR I, 1993, EUR J PHARM-MOLEC PH, V245, P31, DOI 10.1016/0922-4106(93)90166-7; ARIS JP, 1993, BIOCHIM BIOPHYS ACTA, V1174, P171, DOI 10.1016/0167-4781(93)90111-P; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BORASIO GD, 1989, NEURON, V2, P1087; BOTTORFF D, 1995, MOL CELL BIOL, V15, P5113; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; Chan E., UNPUB; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; EBINU JO, UNPUB; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Leonardsen L, 1996, ONCOGENE, V13, P2177; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; Stang S, 1997, MOL CELL BIOL, V17, P3047, DOI 10.1128/MCB.17.6.3047; STONE JC, 1993, MOL CELL BIOL, V13, P7311, DOI 10.1128/MCB.13.12.7311; STONE JC, 1991, MOL CELL BIOL, V11, P6158, DOI 10.1128/MCB.11.12.6158; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TANAKA Y, 1986, J BIOCHEM-TOKYO, V99, P257, DOI 10.1093/oxfordjournals.jbchem.a135467; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704	31	531	546	3	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1082	1086		10.1126/science.280.5366.1082	http://dx.doi.org/10.1126/science.280.5366.1082			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9582122				2022-12-01	WOS:000073663600048
J	Howe, JR; Roth, S; Ringold, JC; Summers, RW; Jarvinen, HJ; Sistonen, P; Tomlinson, IPM; Houlston, RS; Bevan, S; Mitros, FA; Stone, EM; Aaltonen, LA				Howe, JR; Roth, S; Ringold, JC; Summers, RW; Jarvinen, HJ; Sistonen, P; Tomlinson, IPM; Houlston, RS; Bevan, S; Mitros, FA; Stone, EM; Aaltonen, LA			Mutations in the SMAD4/DPC4 gene in juvenile polyposis	SCIENCE			English	Article							TUMOR-SUPPRESSOR GENE; COLORECTAL CANCERS; DPC4 GENE; CARCINOMA	Familial juvenile polyposis is an autosomal dominant disease characterized by a predisposition to hamartomatous polyps and gastrointestinal cancer. Here it is shown that a subset of juvenile polyposis families carry germ line mutations in the gene SMAD4 (also known as DPC4), located on chromosome 18q21.1, that encodes a critical cytoplasmic mediator in the transforming growth factor-beta signaling pathway. The mutant SMAD4 proteins are predicted to be truncated at the carboxyl-terminus and lack sequences required for normal function. These results confirm an important role for SMAD4 in the development of gastrointestinal tumors.	Univ Iowa, Coll Med, Dept Surg, Iowa City, IA 52242 USA; Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Iowa, Coll Med, Dept Med, Iowa City, IA 52242 USA; Univ Helsinki, Cent Hosp, Dept Surg 2, FIN-00290 Helsinki, Finland; Finnish Red Cross & Blood Transfus Serv, Helsinki 00130, Finland; Imperial Canc Res Fund, Mol Populat Genet Lab, London WC2A 3PX, England; Inst Canc Res, Sect Can Genet, Surrey SM2 5NG, England; Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA	University of Iowa; University of Helsinki; University of Iowa; University of Helsinki; Helsinki University Central Hospital; Cancer Research UK; University of London; Institute of Cancer Research - UK; University of Iowa; University of Iowa	Howe, JR (corresponding author), Univ Iowa, Coll Med, Dept Surg, Iowa City, IA 52242 USA.		Aaltonen, Lauri/A-5375-2010	Aaltonen, Lauri/0000-0001-6839-4286; Houlston, Richard/0000-0002-5268-0242; Stone, Edwin M./0000-0003-3343-4414; Bevan, Steve/0000-0003-0490-6830; Howe, James/0000-0001-5312-5972				AALTONEN LA, UNPUB; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Eng C, 1998, AM J HUM GENET, V62, P1020, DOI 10.1086/301847; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Grau AM, 1997, CANCER RES, V57, P3929; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; HOWE JM, UNPUB; Howe JR, 1998, AM J HUM GENET, V62, P1129, DOI 10.1086/301840; Howe JR, 1997, HISTOL HISTOPATHOL, V12, P595; JARVINEN H, 1984, GUT, V25, P792, DOI 10.1136/gut.25.7.792; Jass J.R., 1994, FAMILIAL ADENOMATOUS, P203; Kim SK, 1996, CANCER RES, V56, P2519; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Li DM, 1997, CANCER RES, V57, P2124; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Marsh DJ, 1997, CANCER RES, V57, P5017; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Moskaluk CA, 1997, DIAGN MOL PATHOL, V6, P85, DOI 10.1097/00019606-199704000-00003; Olschwang S, 1998, NAT GENET, V18, P12, DOI 10.1038/ng0198-12; REGGINS GJ, 1997, J NEG OBS GEN ONCOL, V1, P1; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; STEMPER TJ, 1975, ANN INTERN MED, V83, P639, DOI 10.7326/0003-4819-83-5-639; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Wrana J, 1997, NATURE, V388, P28, DOI 10.1038/40290; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1	30	671	696	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1086	1088		10.1126/science.280.5366.1086	http://dx.doi.org/10.1126/science.280.5366.1086			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9582123				2022-12-01	WOS:000073663600049
J	Lie, RT; Rasmussen, S; Brunborg, H; Gjessing, HK; Lie-Nielsen, E; Irgens, LM				Lie, RT; Rasmussen, S; Brunborg, H; Gjessing, HK; Lie-Nielsen, E; Irgens, LM			Fetal and maternal contributions to risk of pre-eclampsia: population based study	BRITISH MEDICAL JOURNAL			English	Article							PREECLAMPSIA; PREGNANCY; HYPERTENSION; GENE; ANGIOTENSINOGEN; ASSOCIATION; RECURRENCE; MOTHER; FETUS	Objective: To use familial patterns of recurrence of pre-eclampsia to investigate whether paternal genes expressed in the fetus contribute to the mother's risk of pre-eclampsia and whether mother's susceptibility to pre-eclampsia is related to maternal inheritance by mitochondrial DNA. Design: Linked data on pregnancies of different women who had children with the same father, and subsequently linked data on pregnancies of half sisters who either had same mother and different fathers or had same father and different mothers. Setting: Population based data from the Medical Birth Registry of Norway covering all births since 1967 (about 1.7 million) and the Norwegian Central Population Register. Main outcome measures: Relative risk of pre-eclampsia after a previous pre-eclamptic pregnancy in the family. Relative risks approximated by odds ratios. Results: If a woman becomes pregnant by a man who has already fathered a pre-eclamptic pregnancy in a different woman her risk of developing pre-eclampsia is 1.8 (95% confidence interval 1.2 to 2.6). If the woman has a half sister who had pre-eclampsia and with whom she shares the same mother but different fathers the risk of pre-eclampsia is 1.6 (0.9 to 2.6). If the two sisters have the same father but different mothers the risk is 1.8 (1.01 to 2.9). Conclusions: Both the mother and the fetus contribute to the risk of pre-eclampsia, the contribution of the fetus being affected by paternal genes. Mitochondrial genes, which are transmitted by mothers, do not seem to contribute to the risk.	Univ Bergen, Haukeland Hosp, Div Med Stat, N-5021 Bergen, Norway; Haukeland Hosp, Med Birth Registry Norway, N-5021 Bergen, Norway; Stat Norway, N-0033 Oslo, Norway	University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; Statistics Norway	Lie, RT (corresponding author), Univ Bergen, Haukeland Hosp, Div Med Stat, Hansens Bldg, N-5021 Bergen, Norway.	rolv.lie@smis.uib.no	Gjessing, Hakon K/A-5871-2012					ADAMS EM, 1961, LANCET, V2, P1375; ARNGRIMSSON R, 1993, NAT GENET, V4, P114, DOI 10.1038/ng0693-114; ARNGRIMSSON R, 1990, BRIT J OBSTET GYNAEC, V97, P762, DOI 10.1111/j.1471-0528.1990.tb02569.x; CHESLEY LC, 1986, BRIT J OBSTET GYNAEC, V93, P898, DOI 10.1111/j.1471-0528.1986.tb08006.x; ENGELMAN L, 1990, BMDP STAT SOFTWARE; Folgero T, 1996, AM J OBSTET GYNECOL, V174, P1626, DOI 10.1016/S0002-9378(96)70619-1; HAIG D, 1993, Q REV BIOL, V68, P495, DOI 10.1086/418300; KILPATRICK DC, 1990, TISSUE ANTIGENS, V35, P178, DOI 10.1111/j.1399-0039.1990.tb01776.x; LIE RT, 1994, NEW ENGL J MED, V331, P1, DOI 10.1056/NEJM199407073310101; LISTON WA, 1991, BRIT J OBSTET GYNAEC, V98, P1079, DOI 10.1111/j.1471-0528.1991.tb15358.x; LOUDON I, 1991, BRIT J OBSTET GYNAEC, V98, P853, DOI 10.1111/j.1471-0528.1991.tb13505.x; MACGILLIVRAY I, 1958, J OBSTET GYNAECOL, V65, P536; Olsen J, 1997, EPIDEMIOLOGY, V8, P6, DOI 10.1097/00001648-199701000-00001; Olson JM, 1996, GENET EPIDEMIOL, V13, P489, DOI 10.1002/(SICI)1098-2272(1996)13:5<489::AID-GEPI5>3.0.CO;2-Y; ROBILLARD PY, 1994, LANCET, V344, P973, DOI 10.1016/S0140-6736(94)91638-1; SAFTLAS AF, 1990, AM J OBSTET GYNECOL, V163, P460, DOI 10.1016/0002-9378(90)91176-D; SHANKLIN DR, 1990, AM J OBSTET GYNECOL, V163, P943, DOI 10.1016/0002-9378(90)91102-I; SIBAI BM, 1991, AM J OBSTET GYNECOL, V165, P1408; Takimoto E, 1996, SCIENCE, V274, P995, DOI 10.1126/science.274.5289.995; Trupin LS, 1996, EPIDEMIOLOGY, V7, P240, DOI 10.1097/00001648-199605000-00004; VINATIER D, 1995, EUR J OBSTET GYN R B, V61, P85, DOI 10.1016/0301-2115(95)02106-H	21	330	341	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 2	1998	316	7141					1343	1347		10.1136/bmj.316.7141.1343	http://dx.doi.org/10.1136/bmj.316.7141.1343			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL882	9563982	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000073483000014
J	Hourihane, JO; Roberts, SA; Warner, JO				Hourihane, JO; Roberts, SA; Warner, JO			Resolution of peanut allergy: case-control study	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL COURSE; HYPERSENSITIVITY; CHILDREN; MILK	Objectives: To determine whether there are any differences between children who remain mildly or moderately allergic to peanut and children with similar histories but a negative reaction on challenge with peanut Design: Case-controls matched for age and sex. Setting: Children's day wards in two teaching hospitals. Intervention: Open food challenge with peanut. Subjects: 15 children with resolved peanut allergy (resolvers) and 15 with persistent allergy (persisters). Main outcome measure: Reaction on challenge with peanut, serum total and peanut specific IgE concentrations. Results: The groups had a similar median age at first reaction to peanut (11 months, range 5-38) and similar symptoms. Allergy to other foods was less common in resolvers (2/15) than persisters (9/15) (P = 0.02). On skin prick testing with peanut all 13 resolvers tested but only 3/14 persisters had a weal of < 6 mm CP < 0.0001). Total and peanut specific IgE concentrations did not differ much between the groups. Conclusion: Appropriately trained clinicians must be prepared to challenge preschool children with peanut as some will be tolerant despite a history of reactions to peanut and a positive skin prick test with peanut Preschool children whose apparent peanut allergy is refuted by food challenge show allergy to other foods less often than those in whom peanut allergy persists. The size of weal on skin prick testing to peanut predicts reactivity but not severity on peanut challenge.	Univ Southampton, Southampton SO16 6YD, Hants, England; Univ S Manchester Hosp, Withington Hosp, Manchester M20 2LR, Lancs, England	University of Southampton; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Hourihane, JO (corresponding author), Inst Child Hlth, 30 Guilford St, London WC1N 1EH, England.		Warner, John/AAF-9587-2020					BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; Cooke SK, 1997, J IMMUNOL, V159, P2026; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; Ewan PW, 1996, BRIT MED J, V312, P1074; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P1101; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; HOST A, 1997, J ALLERGY CLIN IMM 2, V99, pS491; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sporik R, 1996, BRIT MED J, V313, P1477, DOI 10.1136/bmj.313.7070.1477c; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514	15	203	206	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1998	316	7140					1271	1275		10.1136/bmj.316.7140.1271	http://dx.doi.org/10.1136/bmj.316.7140.1271			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK548	9554896	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000073335900020
J	Meier, DE; Emmons, CA; Wallenstein, S; Quill, T; Morrison, RS; Cassel, CK				Meier, DE; Emmons, CA; Wallenstein, S; Quill, T; Morrison, RS; Cassel, CK			A national survey of physician-assisted suicide and euthanasia in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ONCOLOGISTS; ATTITUDES; DEATH; ILL	Background Although there have been many studies of physician-assisted suicide and euthanasia in the United States, national data are lacking. Methods In 1996, we mailed questionnaires to a stratified probability sample of 3102 physicians in the 10 specialties in which doctors are most likely to receive requests from patients for assistance with suicide or euthanasia. We weighted the results to obtain nationally representative data. Results We received 1902 completed questionnaires (response rate, 61 percent). Eleven percent of the physicians said that under current legal constraints; there were circumstances in which they would be willing to hasten a patient's death by prescribing medication, and 7 percent said that they would provide a lethal injection; 36 percent and 24 percent, respectively, said that they would do so if it were legal. Since entering practice, 18.3 percent of the physicians (unweighted number, 320) reported having received a request from a patient for assistance with suicide and 11.1 percent (unweighted number, 196) had received a request for a lethal injection. Sixteen percent of the physicians receiving such requests (unweighted number, 42), or 3.3 percent of the entire sample, reported that they had written at least one prescription to be used to hasten death, and 4.7 percent (unweighted number, 59), said that they had administered at least one lethal injection. Conclusions A substantial proportion of physicians in the United States in the specialties surveyed report that they receive requests for physician-assisted suicide and euthanasia, and about 6 percent have complied with such requests at least once. (C)1998, Massachusetts Medical Society.	Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Biomath Sci, New York, NY 10029 USA; Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Chicago	Meier, DE (corresponding author), Mt Sinai Sch Med, Dept Geriatr & Adult Dev, Box 1070, New York, NY 10029 USA.				NINR NIH HHS [1RO3NR03109] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCH [R03NR003109] Funding Source: NIH RePORTER	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; CARSON R, 1992, HASTINGS CENT REP, V22, P7, DOI 10.2307/3562559; CHRISTAKIS NA, 1995, AM J PUBLIC HEALTH, V85, P367, DOI 10.2105/AJPH.85.3.367; CRANE D, 1977, SANCTITY SOCIAL LIFE; DOUKAS DJ, 1995, J CLIN ONCOL, V13, P1055, DOI 10.1200/JCO.1995.13.5.1055; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Ganzini L, 1997, NEW ENGL J MED, V336, P1824, DOI 10.1056/NEJM199706193362511; Hendin H, 1997, JAMA-J AM MED ASSOC, V277, P1720, DOI 10.1001/jama.277.21.1720; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; JOBE JB, 1989, AM J PUBLIC HEALTH, V79, P1053, DOI 10.2105/AJPH.79.8.1053; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; McKeogh M, 1997, NEW ENGL J MED, V337, P56, DOI 10.1056/NEJM199707033370118; Meier DE, 1997, ANN INTERN MED, V127, P225, DOI 10.7326/0003-4819-127-3-199708010-00008; MEIER DE, 1993, PHYSICIAN ASSISTED D; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; Ryan CJ, 1996, NEW ENGL J MED, V334, P326, DOI 10.1056/NEJM199602013340512; Slome LR, 1997, NEW ENGL J MED, V336, P417, DOI 10.1056/NEJM199702063360606; TAYLOR H, 1995, DOCTOR ASSISTED SUCI	22	366	367	2	69	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1193	1201		10.1056/NEJM199804233381706	http://dx.doi.org/10.1056/NEJM199804233381706			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554861				2022-12-01	WOS:000073208400006
J	Matsuoka, K; Orci, L; Amherdt, M; Bednarek, SY; Hamamoto, S; Schekman, R; Yeung, T				Matsuoka, K; Orci, L; Amherdt, M; Bednarek, SY; Hamamoto, S; Schekman, R; Yeung, T			COPII-coated vesicle formation reconstituted with purified coat proteins and chemically defined liposomes	CELL			English	Article							GTP-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; PHOSPHATIDYLINOSITOL 4-KINASE; SACCHAROMYCES-CEREVISIAE; MEMBRANE GLYCOPROTEIN; GOLGI-APPARATUS; YEAST; TRANSPORT; COMPLEX; SEC23P	COPII vesicle formation requires only three coat assembly subunits: Sar1p, Sec13/31p, and Sec23/24p. PI 4-phosphate or PI 4,5-bisphosphate is required for the binding of these proteins to liposomes. The GTP-bound form of Sar1p recruits Sec23/24p to the liposomes as well as to the ER membranes, and this Sar1p-Sec23/24p complex is required for the binding of Sec13/31p. Ultrastructural analysis shows that the binding of COPII coat proteins to liposomes results in coated patches, coated buds, and coated vesicles of 50-90 nm in diameter. Budding proceeds without rupture of the donor liposome or vesicle product. These observations suggest that the assembly of the COPII coat on the ER occurs by a sequential binding of coat proteins to specific lipids and that this assembly promotes the budding of COPII-coated vesicles.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Geneva, Sch Med, Dept Morphol, CH-1211 Geneva 4, Switzerland	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Geneva	Schekman, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.		Taylor, Graham/A-4027-2012; Matsuoka, Ken/E-3215-2010					Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bednarek SY, 1996, TRENDS CELL BIOL, V6, P468, DOI 10.1016/0962-8924(96)84943-9; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; Gimeno RE, 1996, MOL BIOL CELL, V7, P1815, DOI 10.1091/mbc.7.11.1815; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MATSUOKA K, 1995, J CELL BIOL, V130, P1307, DOI 10.1083/jcb.130.6.1307; Nakagawa T, 1996, BIOCHEM J, V320, P643, DOI 10.1042/bj3200643; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; ORCI L, 1991, P NATL ACAD SCI USA, V88, P8611, DOI 10.1073/pnas.88.19.8611; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Salama NR, 1997, MOL BIOL CELL, V8, P205, DOI 10.1091/mbc.8.2.205; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shaywitz DA, 1997, J BIOL CHEM, V272, P25413, DOI 10.1074/jbc.272.41.25413; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; WAGNER S, 1994, YEAST, V10, P1429, DOI 10.1002/yea.320101106; Waksman M, 1997, J BIOL CHEM, V272, P36; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124; Yeung T, 1995, J BIOL CHEM, V270, P30567, DOI 10.1074/jbc.270.51.30567; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	48	495	506	1	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					263	275		10.1016/S0092-8674(00)81577-9	http://dx.doi.org/10.1016/S0092-8674(00)81577-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568718	Bronze			2022-12-01	WOS:000073174000012
J	McKeegan, KD; Leshin, LA; Russell, SS; MacPherson, GJ				McKeegan, KD; Leshin, LA; Russell, SS; MacPherson, GJ			Oxygen isotopic abundances in calcium-aluminum-rich inclusions from ordinary chondrites: Implications for nebular heterogeneity	SCIENCE			English	Article							SOLAR NEBULA; CARBONACEOUS CHONDRITES; ALLENDE INCLUSIONS; METEORITES; ORIGIN; COMPONENT; ANOMALIES; AL-26	The oxygen isotopic compositions of two calcium-aluminum-rich inclusions (CAIs) from the unequilibrated ordinary chondrite meteorites Quinyambie and Semarkona are enriched in O-16 by an amount similar to that in CAIs from carbonaceous chondrites. This may indicate that most CAIs formed in a restricted region of the solar nebula and were then unevenly distributed throughout the various chondrite accretion regions. The Semarkona CAI is isotopically homogeneous and contains highly O-16-enriched melilite, supporting the hypothesis that all CAI minerals were originally O-16-rich, but that in most carbonaceous chondrite inclusions some minerals exchanged oxygen isotopes with an external reservoir following crystallization.	Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Smithsonian Inst, Museum Natl Hist Nat, Dept Mineral Sci, Washington, DC 20560 USA	University of California System; University of California Los Angeles; Smithsonian Institution; Smithsonian National Museum of Natural History	McKeegan, KD (corresponding author), Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA.	kdm@ess.ucla.edu	McKeegan, Kevin D/A-4107-2008	McKeegan, Kevin D/0000-0002-1827-729X; Russell, Sara/0000-0001-5531-7847				BISCHOFF A, 1984, GEOCHIM COSMOCHIM AC, V48, P693, DOI 10.1016/0016-7037(84)90096-6; BLANDER M, 1975, GEOCHIM COSMOCHIM AC, V39, P1605, DOI 10.1016/0016-7037(75)90083-6; BOYNTON WV, 1975, GEOCHIM COSMOCHIM AC, V39, P569, DOI 10.1016/0016-7037(75)90003-4; CHEN JH, 1981, EARTH PLANET SC LETT, V52, P1, DOI 10.1016/0012-821X(81)90202-8; Choi BG, 1997, METEORIT PLANET SCI, V32, pA28; Clayton R. N., 1983, CHONDRULES THEIR ORI, P37; CLAYTON RN, 1977, GEOPHYS RES LETT, V4, P295, DOI 10.1029/GL004i007p00295; CLAYTON RN, 1977, EARTH PLANET SC LETT, V34, P209, DOI 10.1016/0012-821X(77)90005-X; CLAYTON RN, 1991, GEOCHIM COSMOCHIM AC, V55, P2317, DOI 10.1016/0016-7037(91)90107-G; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.ea.21.050193.000555; CLAYTON RN, 1978, EARTH PLANET SC LETT, V40, P168, DOI 10.1016/0012-821X(78)90087-0; CLAYTON RN, 1973, SCIENCE, V182, P485, DOI 10.1126/science.182.4111.485; CLAYTON RN, 1976, EARTH PLANET SC LETT, V30, P10, DOI 10.1016/0012-821X(76)90003-0; CLAYTON RN, 1983, EARTH PLANET SC LETT, V62, P1, DOI 10.1016/0012-821X(83)90066-3; CLAYTON RN, 1986, TERRA COGNITA, V6, P130; Engrand C, 1997, METEORIT PLANET SCI, V32, pA39; FAHEY AJ, 1988, THESIS WASHINGTON U; GOSWAMI JN, 1997, LUNAR PLANET SCI, V28, P349; GRAHAM A. L., 1985, CATALOGUE METEORITES; KIMURA M, 1993, GEOCHIM COSMOCHIM AC, V57, P2329, DOI 10.1016/0016-7037(93)90573-F; Leshin LA, 1997, GEOCHIM COSMOCHIM AC, V61, P835, DOI 10.1016/S0016-7037(96)00374-2; MacPherson G.J., 1988, METEORITES EARLY SOL, P746; MACPHERSON GJ, 1995, METEORITICS, V30, P365, DOI 10.1111/j.1945-5100.1995.tb01141.x; MAYEDA TK, 1986, LUNAR PLANET SCI, V17, P526; McKeegan K.D., 1996, METEORIT PLANET SCI, V31, pA86; MCKEEGAN KD, 1987, SCIENCE, V237, P1468, DOI 10.1126/science.237.4821.1468; PODOSEK FA, 1994, METEORITICS, V29, P6, DOI 10.1111/j.1945-5100.1994.tb00649.x; PODOSEK FA, 1991, GEOCHIM COSMOCHIM AC, V55, P1083, DOI 10.1016/0016-7037(91)90165-2; ROWE MW, 1994, GEOCHIM COSMOCHIM AC, V58, P5341, DOI 10.1016/0016-7037(94)90317-4; Russell SS, 1997, METEORIT PLANET SCI, V32, pA111; Russell SS, 1996, SCIENCE, V273, P757, DOI 10.1126/science.273.5276.757; RYERSON FJ, 1994, GEOCHIM COSMOCHIM AC, V58, P3713, DOI 10.1016/0016-7037(94)90161-9; SAXTON JM, 1995, METEORITICS, V30, P571; Sears D.W.G., 1988, METEORITES EARLY SOL, P3; SHENG YJ, 1991, GEOCHIM COSMOCHIM AC, V55, P581, DOI 10.1016/0016-7037(91)90014-V; Shu FH, 1996, SCIENCE, V271, P1545, DOI 10.1126/science.271.5255.1545; SLODZIAN G, 1987, CAMECA NEWS      MAY, P1; Tilton G. G., 1988, METEORITES EARLY SOL, P259; VALLEY JW, IN PRESS SOC EC GEOL, V7	39	111	112	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 17	1998	280	5362					414	418		10.1126/science.280.5362.414	http://dx.doi.org/10.1126/science.280.5362.414			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545215				2022-12-01	WOS:000073159600041
J	Zhang, ZL; Huang, LS; Shulmeister, VM; Chi, YI; Kim, KK; Hung, LW; Crofts, AR; Berry, EA; Kim, SH				Zhang, ZL; Huang, LS; Shulmeister, VM; Chi, YI; Kim, KK; Hung, LW; Crofts, AR; Berry, EA; Kim, SH			Electron transfer by domain movement in cytochrome bc(1)	NATURE			English	Article							CYTOCHROME-C OXIDOREDUCTASE; IRON-SULFUR PROTEIN; HEART UBIQUINOL; COMPLEX; SITE; CRYSTALLIZATION; MITOCHONDRIA; RESOLUTION; REDUCTASE; SUBUNIT	The cytochrome bc(1) is one of the three major respiratory enzyme complexes residing in the inner mitochondrial membrane. Cytochrome bc(1) transfers electrons from ubiquinol to cytochrome c and uses the energy thus released to form an electrochemical gradient across the inner membrane. Our X-ray crystal structures of the complex from chicken, cow and rabbit In both the presence and absence of inhibitors of quinone oxidation, reveal two different locations for the extrinsic domain of one component of the enzyme, an Iron-sulphur protein. One location Is close enough to the supposed quinol oxidation site to allow reduction of the Fe-S protein by ubiquinol. The other site is close enough to cytochrome cl to allow oxidation of the Fe-S protein by the cytochrome. As neither location will allow both reactions to proceed at a suitable rate, the reaction mechanism must involve movement of the extrinsic domain of the Fe-S component In order to shuttle electrons from ubiquinol to cytochrome c(1). Such a mechanism has not previously been observed in redox protein complexes.	Univ Calif Berkeley, EO Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Grad Grp Biophys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Illinois, Ctr Biophys & Comptat Biol, Urbana, IL 61801 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Illinois System; University of Illinois Urbana-Champaign	Berry, EA (corresponding author), Univ Calif Berkeley, EO Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA.		Zhang, Zhaolei/G-2369-2017	Huang, Li-Shar/0000-0003-1427-2544				AMBLER RP, 1991, BIOCHIM BIOPHYS ACTA, V1058, P42, DOI 10.1016/S0005-2728(05)80266-X; BEAUTEMENT K, 1991, PESTIC SCI, V31, P499, DOI 10.1002/ps.2780310406; BERRY EA, 1992, J MOL BIOL, V224, P1161, DOI 10.1016/0022-2836(92)90476-Z; BERRY EA, 1995, ACTA CRYSTALLOGR D, V51, P235, DOI 10.1107/S0907444994010486; BERRY EA, 1991, J BIOL CHEM, V266, P9064; BRANDT U, 1993, J BIOL CHEM, V268, P8387; BROGER C, 1983, EUR J BIOCHEM, V131, P349, DOI 10.1111/j.1432-1033.1983.tb07269.x; CLOUGH JM, 1995, CHEM BRIT, V31, P466; Crofts A.R., 1985, ENZYMES BIOL MEMBR, P347; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; CROFTS AR, 1997, IN PRESS PHOTOTROPHI; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; HINKLE PC, 1991, BIOCHEMISTRY-US, V30, P3576, DOI 10.1021/bi00228a031; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, P CCP4 STUD WEEK MOL, P91; KIM CH, 1983, J BIOL CHEM, V258, P3543; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBOTA T, 1991, J MOL BIOL, V221, P379, DOI 10.1016/0022-2836(91)80059-4; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; LINK TA, FRONTIERS CELLULAR B; LINK TA, 1987, CYTOCHROME SYSTEMS M, P289; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MOSER CC, 1995, J BIOENERG BIOMEMBR, V27, P263, DOI 10.1007/BF02110096; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RAYMENT I, 1983, ACTA CRYSTALLOGR A, V39, P102, DOI 10.1107/S0108767383000197; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; SAUTER H, 1996, CROP PROTECTION AGEN, P50; Schagger H, 1995, METHOD ENZYMOL, V260, P82, DOI 10.1016/0076-6879(95)60132-5; SCHLAGGER H, 1986, METHOD ENZYMOL, V126, P224; *SERC UK COLL COMP, 1995, ACTA CRYSTALLOGR D, V50, P760; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; Smith A.L., 1967, METHOD ENZYMOL, V10, P81, DOI [DOI 10.1016/0076-6879(67)10016-5, 10.1016/0076-6879(67)10016-5]; STONEHUERNER J, 1985, J BIOL CHEM, V260, P5392; VANDOREN SR, 1993, BIOCHEMISTRY-US, V32, P628, DOI 10.1021/bi00053a031; WEISS H, 1987, CHEM SCRIPTA, V27B, P73; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YUE WH, 1991, BIOCHEMISTRY-US, V30, P2303, DOI 10.1021/bi00223a002	42	923	944	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 16	1998	392	6677					677	684		10.1038/33612	http://dx.doi.org/10.1038/33612			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565029				2022-12-01	WOS:000073129000047
J	Ditzel, L; Lowe, J; Stock, D; Stetter, KO; Huber, H; Huber, R; Steinbacher, S				Ditzel, L; Lowe, J; Stock, D; Stetter, KO; Huber, H; Huber, R; Steinbacher, S			Crystal structure of the thermosome, the archaeal chaperonin and homolog of CCT	CELL			English	Article							T-COMPLEX POLYPEPTIDE-1; GROEL-GROES COMPLEXES; MOLECULAR CHAPERONE; CYTOPLASMIC CHAPERONIN; HEAT-SHOCK; THERMOPHILIC ARCHAEBACTERIUM; SULFOLOBUS-SOLFATARICUS; PROTEIN SUBSTRATE; BINDING DOMAINS; ATP HYDROLYSIS	We have determined to 2.6 Angstrom resolution the crystal structure of the thermosome, the archaeal group II chaperonin from T. acidophilum. The hexadecameric homolog of the eukaryotic chaperonin CCT/TRiC shows an (alpha beta)(4)(alpha beta)(4) subunit assembly. Domain folds are homologous to GroEL but form a novel type of inter-ring contact. The domain arrangement resembles the GroEL-GroES cis-ring. Parts of the apical domains form a lid creating a closed conformation. The lid substitutes for a GroES-like cochaperonin that is absent in the CCT/TRiC system. The central cavity has a polar surface implicated in protein folding. Binding of the transition state analog MS-ADP-AIF(3) suggests that the closed conformation corresponds to the ATP form.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Regensburg, Inst Mikrobiol, D-93053 Regensburg, Germany	Max Planck Society; University of Regensburg	Steinbacher, S (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Löwe, Jan/X-6998-2019; Löwe, Jan/B-3882-2011	Lowe, Jan/0000-0002-5218-6615				Andra S, 1996, FEBS LETT, V379, P127, DOI 10.1016/0014-5793(95)01493-4; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; Coyle JE, 1997, FOLD DES, V2, pR93, DOI 10.1016/S1359-0278(97)00046-1; DARLAND G, 1971, J GEN MICROBIOL, V67, P9, DOI 10.1099/00221287-67-1-9; Dobrzynski JK, 1996, BIOCHEMISTRY-US, V35, P15870, DOI 10.1021/bi961114j; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; GUAGLIARDI A, 1994, PROTEIN SCI, V3, P1436, DOI 10.1002/pro.5560030910; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KNAPP S, 1994, J MOL BIOL, V242, P397; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1991, RECENT CHANGES MOSFL; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; MARCO S, 1994, FEBS LETT, V341, P152, DOI 10.1016/0014-5793(94)80447-8; MARCO S, 1994, BIOPHYS J, V67, P364, DOI 10.1016/S0006-3495(94)80489-8; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Nitsch M, 1997, J MOL BIOL, V267, P142, DOI 10.1006/jmbi.1996.0849; PHIPPS BM, 1993, NATURE, V361, P475, DOI 10.1038/361475a0; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; TURK D, 1992, THESIS TU MUNCHEN; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; WALDMANN T, 1995, EUR J BIOCHEM, V227, P848, DOI 10.1111/j.1432-1033.1995.tb20210.x; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Willison KR, 1994, BIOL HEAT SHOCK PROT, P299; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; YIFRACH O, 1994, J MOL BIOL, V243, P397, DOI 10.1006/jmbi.1994.1667	80	361	370	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1998	93	1					125	138		10.1016/S0092-8674(00)81152-6	http://dx.doi.org/10.1016/S0092-8674(00)81152-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546398	Bronze			2022-12-01	WOS:000072910800016
J	Hertz, R; Magenheim, J; Berman, I; Bar-Tana, J				Hertz, R; Magenheim, J; Berman, I; Bar-Tana, J			Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4 alpha	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; ESCHERICHIA-COLI; ACID; PROLIFERATORS; PROTEINS; PROMOTER; BINDING; LIPIDS; GENE	Dietary fatty acids specifically modulate the onset and progression of various diseases, including cancer(1,2), atherogenesis(3), hyperlipidaemia(4), insulin resistance(5) and hypertension(6), as well as blood coagulability and fibrinolytic defects(7); their effects depend on their chain length and degree of saturation. Hepatocyte nuclear factor-4 alpha (ref. 8) (HNF-4 alpha) is an orphan transcription factor of the superfamily of nuclear receptors and controls the expression of genes (reviewed in ref. 9) that govern the pathogenesis and course of some of these diseases. Here we show that long-chain fatty acids directly modulate the transcriptional activity of HNF-4 alpha by binding as their acyl-CoA thioesters to the ligand-binding domain of HNF-4 alpha, This binding may shift the oligomeric-dimeric equilibrium of HNF-4 alpha or may modulate the affinity of HNF-4 alpha for its cognate promoter element, resulting in either activation or inhibition of HNF-4 alpha transcriptional activity as a function of chain length and the degree of saturation of the fatty acyl-CoA ligands, In addition to their roles as substrates to yield energy, as an energy store, or as constituents of membrane phospholipids, dietary fatty acids may affect the course of a disease by modulating the expression of HNF-4 alpha-controlled genes.	Hebrew Univ Jerusalem, Fac Med, Dept Human Nutr & Metab, IL-91010 Jerusalem, Israel	Hebrew University of Jerusalem	Bar-Tana, J (corresponding author), Hebrew Univ Jerusalem, Fac Med, Dept Human Nutr & Metab, POB 12272, IL-91010 Jerusalem, Israel.							CAVE WT, 1991, FASEB J, V5, P2160, DOI 10.1096/fasebj.5.8.1673664; CHIN JPF, 1994, PROSTAG LEUKOTR ESS, V50, P211, DOI 10.1016/0952-3278(94)90156-2; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; DAHLBERG E, 1980, ANAL BIOCHEM, V106, P380, DOI 10.1016/0003-2697(80)90537-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Gossett RE, 1996, LIPIDS, V31, P895, DOI 10.1007/BF02522684; GRUNDY SM, 1990, J LIPID RES, V31, P1149; HERTZ R, 1994, EUR J BIOCHEM, V221, P611, DOI 10.1111/j.1432-1033.1994.tb18773.x; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Hultin M B, 1991, Prog Hemost Thromb, V10, P215; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; KERSTEN S, 1995, P NATL ACAD SCI USA, V92, P8645, DOI 10.1073/pnas.92.19.8645; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; LEFF T, 1989, J BIOL CHEM, V264, P16132; Malik S, 1996, MOL CELL BIOL, V16, P1824; MORRIS MC, 1993, CIRCULATION, V88, P523, DOI 10.1161/01.CIR.88.2.523; NAGGERT J, 1991, BIOCHEM J, V273, P787, DOI 10.1042/bj2730787; ORI A, 1994, VIROLOGY, V204, P600, DOI 10.1006/viro.1994.1574; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; THOLSTRUP T, 1994, AM J CLIN NUTR, V59, P371, DOI 10.1093/ajcn/59.2.371; WELSCH CW, 1992, CANCER RES, V52, pS2040; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	29	430	446	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					512	516		10.1038/33185	http://dx.doi.org/10.1038/33185			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548258				2022-12-01	WOS:000072875200063
J	Nightingale, SL				Nightingale, SL			New warning for isotretinoin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					984	984		10.1001/jama.279.13.984	http://dx.doi.org/10.1001/jama.279.13.984			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533484				2022-12-01	WOS:000072669700006
J	Clement, K; Vaisse, C; Lahlou, N; Cabrol, S; Pelloux, V; Cassuto, D; Gourmelen, M; Dina, C; Chambaz, J; Lacorte, JM; Basdevant, A; Bougneres, P; Lebouc, Y; Froguel, P; Guy-Grand, B				Clement, K; Vaisse, C; Lahlou, N; Cabrol, S; Pelloux, V; Cassuto, D; Gourmelen, M; Dina, C; Chambaz, J; Lacorte, JM; Basdevant, A; Bougneres, P; Lebouc, Y; Froguel, P; Guy-Grand, B			A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction	NATURE			English	Article							GROWTH-HORMONE; OB/OB MICE; MOUSE; EXPRESSION; PROTEINS; CLONING; SERUM	The adipocyte-specific hormone leptin, the product of the obese (ob) gene, regulates adipose-tissue mass through hypothalamic effects on satiety and energy expenditure(1-4), Leptin acts through the leptin receptor, a single-transmembrane-domain receptor of the cytokine-receptor family(5-7). In rodents, homozygous mutations in genes encoding leptin(1) or the leptin receptor(6) cause early-onset morbid obesity, hyperphagia and reduced energy expenditure, These rodents also show hypercortisolaemia, alterations in glucose homeostasis, dyslipidaemia, and infertility due to hypogonadotropic hypogonadism(8). In humans. leptin deficiency due to a mutation in the leptin gene is associated with early-onset obesity(9), Here we describe a homozygous mutation in the human leptin receptor gene that results in a truncated leptin receptor lacking both the transmembrane and the intracellular domains, In addition to their early-onset morbid obesity, patients homozygous for this mutation have no pubertal development and their secretion of growth hormone and thyrotropin is reduced. These results indicate that leptin is an important physiological regulator of several endocrine functions in humans.	Hotel Dieu, Lab Nutr, F-75004 Paris, France; Hotel Dieu, Serv Med & Nutr, F-75004 Paris, France; Inst Pasteur, Inst Biol, CNRS, EP10, F-59000 Lille, France; Hop St Vincent de Paul, INSERM, U342, F-75674 Paris, France; Serv Endocrinol Diabete Enfant, F-75014 Paris, France; Hop Enfant Armand Trousseu, F-75012 Paris, France; INSERM, CJF 9508, F-75005 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Froguel, P (corresponding author), Hotel Dieu, Lab Nutr, Pl Parvis Notre Dame, F-75004 Paris, France.		Dina, Christian R/D-3535-2015; Vaisse, Christian/F-1067-2011; FROGUEL, Philippe/O-6799-2017; Clément, karine/R-1120-2017	Dina, Christian R/0000-0002-7722-7348; FROGUEL, Philippe/0000-0003-2972-0784; 				Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; BERNINI GP, 1990, CLIN ENDOCRINOL, V32, P453, DOI 10.1111/j.1365-2265.1990.tb00885.x; Bjorntorp P, 1997, NUTRITION, V13, P795, DOI 10.1016/S0899-9007(97)00191-3; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Carro E, 1997, ENDOCRINOLOGY, V138, P2203, DOI 10.1210/en.138.5.2203; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Clayton PE, 1997, CLIN ENDOCRINOL, V46, P727, DOI 10.1046/j.1365-2265.1997.2081026.x; Clement K, 1997, INT J OBESITY, V21, P556, DOI 10.1038/sj.ijo.0800440; COLEMAN DL, 1973, DIABETOLOGIA, V9, P287, DOI 10.1007/BF01221856; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Diamond FB, 1997, BIOCHEM BIOPH RES CO, V233, P818, DOI 10.1006/bbrc.1997.6538; Echwald SM, 1997, BIOCHEM BIOPH RES CO, V233, P248, DOI 10.1006/bbrc.1997.6430; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HARDOUIN S, 1989, J CLIN ENDOCR METAB, V69, P1291, DOI 10.1210/jcem-69-6-1291; Houseknecht KL, 1996, DIABETES, V45, P1638, DOI 10.2337/diabetes.45.11.1638; HUMMEL KP, 1972, BIOCHEM GENET, V7, P1, DOI 10.1007/BF00487005; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Liu CL, 1997, ENDOCRINOLOGY, V138, P3548, DOI 10.1210/en.138.8.3548; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P1066, DOI 10.1210/jc.82.4.1066; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; TANNENBAUM GS, 1990, ENDOCRINOLOGY, V127, P3080; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; THISSEN JP, 1994, ENDOCR REV, V15, P80, DOI 10.1210/er.15.1.80; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; VIGNOLO M, 1988, EUR J PEDIATR, V147, P242, DOI 10.1007/BF00442687; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	30	1649	1710	1	110	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					398	401		10.1038/32911	http://dx.doi.org/10.1038/32911			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537324				2022-12-01	WOS:000072713600054
J	Mitchell, A				Mitchell, A			Visionaries seek UK national strategy	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					419	420		10.1038/32952	http://dx.doi.org/10.1038/32952			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537331				2022-12-01	WOS:000072713600061
J	Pomerantz, J; Schreiber-Agus, N; Liegeois, NJ; Silverman, A; Alland, L; Chin, L; Potes, J; Chen, K; Orlow, I; Lee, HW; Cordon-Cardo, C; DePinho, RA				Pomerantz, J; Schreiber-Agus, N; Liegeois, NJ; Silverman, A; Alland, L; Chin, L; Potes, J; Chen, K; Orlow, I; Lee, HW; Cordon-Cardo, C; DePinho, RA			The Ink4a tumor suppressor gene product, p19(Arf), interacts with MDM2 and neutralizes MDM2's inhibition of p53	CELL			English	Article							CELL-CYCLE CONTROL; WILD-TYPE P53; RETINOBLASTOMA-PROTEIN; TRANSCRIPTIONAL ACTIVATION; GROWTH SUPPRESSION; GERMLINE MUTATIONS; ONCOPROTEIN MDM2; TRANSGENIC MICE; T-ANTIGEN; TRANSFORMATION	The INK4a gene encodes two distinct growth inhibitors-the cyclin-dependent kinase inhibitor p16(Ink4a), which is a component of the Rb pathway, and the tumor suppressor p19(Arf), which has been functionally linked to p53. Here we show that p19(Arf) potently suppresses oncogenic transformation in primary cells and that this function is abrogated when p53 is neutralized by viral oncoproteins and dominant-negative mutants but not by the p53 antagonist MDM2. This finding, coupled with the observations that p19(Arf) and MDM2 physically interact and that p19(Arf) blocks MDM2-induced p53 degradation and transactivational silencing, suggests that p19(Arf) functions mechanistically to prevent MDM2's neutralization of p53. Together, our findings ascribe INK4a's potent tumor suppressor activity to the cooperative actions of its two protein products and their relation to the two central growth control pathways, Rb and p53.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Div Pediat Hematol Oncol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Dermatol, Bronx, NY 10461 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center	DePinho, RA (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [CADK97650, CA47538, CA47179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA047538, P01CA047179, R01CA047538] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bartkova J, 1996, CANCER RES, V56, P5475; Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1995, MOL MED, V1, P141; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRUIS NA, 1995, AM J PATHOL, V146, P1199; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Heinzel PA, 1996, INT J CANCER, V68, P420, DOI 10.1002/(SICI)1097-0215(19961115)68:4<420::AID-IJC3>3.0.CO;2-2; Henning W, 1997, J VIROL, V71, P7609, DOI 10.1128/JVI.71.10.7609-7618.1997; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kinoshita I, 1996, CANCER RES, V56, P5557; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUNGER K, 1989, J VIROL, V63, P4417; NEWCOMB EW, 1995, MOL CARCINOGEN, V14, P141, DOI 10.1002/mc.2940140302; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; QUELLE DE, 1995, ONCOGENE, V11, P635; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHREIBERAGUS N, 1994, ONCOGENE, V9, P3167; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; VANDYKE TA, 1994, SEMIN CANCER BIOL, V5, P47; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	66	1285	1321	1	47	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					713	723		10.1016/S0092-8674(00)81400-2	http://dx.doi.org/10.1016/S0092-8674(00)81400-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529248	Bronze			2022-12-01	WOS:000072661200005
J	Chen, L; Glover, JNM; Hogan, PG; Rao, A; Harrison, SC				Chen, L; Glover, JNM; Hogan, PG; Rao, A; Harrison, SC			Structure of the DNA binding domains from NFAT, Fos and Jun bound specifically to DNA	NATURE			English	Article							ACTIVATED T-CELLS; TRANSCRIPTION FACTOR NFAT1; NUCLEAR FACTOR; CRYSTAL-STRUCTURE; CYCLOSPORINE-A; CALCINEURIN; FAMILY; COMPLEX; GENE; AP-1	The nuclear factor of activated T cells (NFAT) and the AP-1 heterodimer, Fos-Jun, cooperatively bind a composite DNA site and synergistically activate the expression of many immune-response genes. A 2.7-Angstrom-resolution crystal structure of the DNA-binding domains of NFAT, Fos and Jun, in a quaternary complex with a DNA fragment containing the distal antigen-receptor response element from the interleukin-2 gene promoter, shows an extended interface between NFAT and AP-1, facilitated by the bending of Fos and DNA, The tight association of the three proteins on DNA creates a continuous groove for the recognition of 15 base pairs.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Harvard University; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Harrison, SC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	schadmin@crystal.harvard.edu	chen, Lin/A-3392-2008	chen, Lin/0000-0003-4798-6199				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRUNGER A, 1992, XPLOR VERSION 3 0 SY; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHEN L, 1995, CURR BIOL, V5, P882, DOI 10.1016/S0960-9822(95)00178-3; CHEN L, 1994, THESIS HARVARD U; Chytil M, 1996, CURR OPIN STRUC BIOL, V6, P91, DOI 10.1016/S0959-440X(96)80100-X; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JAIN JN, 1993, J IMMUNOL, V151, P837; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; JONES TA, 1989, CRYSTALLOGRAPHIC COM; KLEYWEGT GJ, 1994, 1 MAP FINAL MODEL; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sun LJ, 1997, P NATL ACAD SCI USA, V94, P4919, DOI 10.1073/pnas.94.10.4919; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; YAMAMOTO KR, 1992, TRANSCRIPTIONAL REGU, P1169	50	408	427	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					42	48		10.1038/32100	http://dx.doi.org/10.1038/32100			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510247				2022-12-01	WOS:000072373000042
J	Davis, GW; Goodman, CS				Davis, GW; Goodman, CS			Synapse-specific control of synaptic efficacy at the terminals of a single neuron	NATURE			English	Article							GROWTH CONE GUIDANCE; FUNCTIONAL COMPONENTS; GENETIC DISSECTION; PLASTICITY; DROSOPHILA; EXPRESSION; MEMORY	The regulation of synaptic efficacy is essential for the proper functioning of neural circuits, If synaptic gain is set too high or too low cells are either activated inappropriately or remain silent. There is extra complexity because synapses are not static, but form, retract, expand, strengthen, and weaken throughout life, Homeostatic regulatory mechanisms that control synaptic efficacy presumably exist to ensure that neurons remain functional within a meaningful physiological range(1-5). One of the best defined systems for analysis of the mechanisms that regulate synaptic efficacy is the neuromuscular junction. It has been shown, in organisms ranging from insects to humans, that changes in synaptic efficacy are tightly coupled to changes in muscle size during development(1,6-8). It has been proposed that a signal from muscle to motor neuron maintains this coupling(9). Here we show, by genetically manipulating muscle innervation, that there are two independent mechanisms by which muscle regulates synaptic efficacy at the terminals of single motor neurons. Increased muscle innervation results in a compensatory, target-specific decrease in presynaptic transmitter release, implying a retrograde regulation of presynaptic release, Decreased muscle innervation results in a compensatory increase in quantal size.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Davis, GW (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Div Neurobiol, LSA Room 519, Berkeley, CA 94720 USA.	gdavis@coreys.berkeley.edu						Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; [Anonymous], [No title captured]; Bear MF, 1996, P NATL ACAD SCI USA, V93, P13453, DOI 10.1073/pnas.93.24.13453; BRAND AH, 1993, DEVELOPMENT, V118, P401; Davis GW, 1997, NEURON, V19, P561, DOI 10.1016/S0896-6273(00)80372-4; FRANK E, 1973, J PHYSIOL-LONDON, V233, P635, DOI 10.1113/jphysiol.1973.sp010327; GOVIND CK, 1981, SCIENCE, V212, P1522, DOI 10.1126/science.7233240; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; KESHISHIAN H, 1995, J NEUROBIOL, V24, P575; LICHTMAN JW, 1987, J NEUROSCI, V7, P1215; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Marder E, 1996, P NATL ACAD SCI USA, V93, P13481, DOI 10.1073/pnas.93.24.13481; Miller KD, 1996, NEURON, V17, P371, DOI 10.1016/S0896-6273(00)80169-5; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; Schuster CM, 1996, NEURON, V17, P641, DOI 10.1016/S0896-6273(00)80197-X; Stewart BA, 1996, J NEUROSCI, V16, P3877; STEWART BA, 1994, J COMP PHYSL, V175, P175	19	187	188	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1998	392	6671					82	86		10.1038/32176	http://dx.doi.org/10.1038/32176			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510251				2022-12-01	WOS:000072373000054
J	Brenner, H; Rothenbacher, D; Bode, G; Adler, G				Brenner, H; Rothenbacher, D; Bode, G; Adler, G			Parental history of gastric or duodenal ulcer and prevalence of Helicobacter pylori infection in preschool children: population based study	BRITISH MEDICAL JOURNAL			English	Article									Univ Ulm, Dept Epidemiol, D-89069 Ulm, Germany; Univ Ulm, Dept Internal Med 1, D-7900 Ulm, Germany	Ulm University; Ulm University	Brenner, H (corresponding author), Univ Ulm, Dept Epidemiol, D-89069 Ulm, Germany.		Brenner, Hermann/ABE-6383-2020; Brenner, Hermann/B-4627-2017	Brenner, Hermann/0000-0002-6129-1572; Brenner, Hermann/0000-0002-6129-1572; Rothenbacher, Dietrich/0000-0002-3563-2791				GOODMAN KJ, 1995, INT J EPIDEMIOL, V24, P875, DOI 10.1093/ije/24.5.875; MALATY HM, 1994, ANN INTERN MED, V120, P982, DOI 10.7326/0003-4819-120-12-199406150-00002; ROTHENBACHER D, IN PRESS INT J EPIDE; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	5	36	36	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					665	665		10.1136/bmj.316.7132.665	http://dx.doi.org/10.1136/bmj.316.7132.665			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522790	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000072347900029
J	Delacretaz, E; Michalopoulos, PG; Ruiz, J; Saner, H; Meier, B				Delacretaz, E; Michalopoulos, PG; Ruiz, J; Saner, H; Meier, B			Management of hyperlipidaemia after coronary revascularisation: follow up study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; CHOLESTEROL; PREVENTION		Univ Hosp Bern, CH-3010 Bern, Switzerland; Univ Lausanne Hosp, Div Endocrinol, CH-1011 Lausanne, Switzerland	University of Bern; University Hospital of Bern; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Delacretaz, E (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	edelacreta@bics.bwh.harvard.edu						BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Luepker Russell V., 1997, American Journal of Medicine, V102, P37, DOI 10.1016/S0002-9343(97)00466-X; PEDERSEN TR, 1994, LANCET, V344, P1383; PYORALA K, 1994, EUR HEART J, V15, P1300	5	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 16	1998	316	7143					1499	1499		10.1136/bmj.316.7143.1499	http://dx.doi.org/10.1136/bmj.316.7143.1499			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP020	9582137	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000073707700027
J	Francis, ST; Duncan, KR; Moore, RJ; Baker, PN; Johnson, IR; Gowland, PA				Francis, ST; Duncan, KR; Moore, RJ; Baker, PN; Johnson, IR; Gowland, PA			Non-invasive mapping of placental perfusion	LANCET			English	Article							PLANAR MAGNETIC-RESONANCE; FETAL GROWTH-RETARDATION; PREGNANCY; WEIGHT	Background. We aim to develop a clinical technique for the non-invasive measurement of placental perfusion, to enable early detection of intrauterine growth restriction (IUGR). Pregnancies with this complication are characterised by low placental perfusion. Methods. We measured placental perfusion by means of perfusion-sensitive echoplanar imaging (EPI); a rapid method of making magnetic resonance images. Perfusion measurements were done on six healthy volunteers with normal pregnancies and nine with pregnancies complicated by IUGR. Perfusion maps were created to assess the relation between placental perfusion and fetal size at birth. Findings. Pregnancies complicated by IUGR differed significantly from normal pregnancies in patterns of perfusion within the placenta (p < 0.0001, ANOVA). Subsequent analysis showed that the proportion of placentas with low perfusion rates was higher in the IUGR group than in the normal group. A significant correlation between areas of reduced placental perfusion and fetal size was demonstrated (p = 0.041, Spearman's rank correlation). Interpretation. Non-invasive imaging of placental perfusion by means of EPI has potential as a clinical tool in assessing the dynamics of placental perfusion.	Univ Nottingham, Dept Phys, Magnet Resonance Ctr, Nottingham NG7 2RD, England; City Hosp, Dept Obstet & Gynaecol, Nottingham NG5 1PB, England	University of Nottingham; University of Nottingham	Gowland, PA (corresponding author), Univ Nottingham, Dept Phys, Magnet Resonance Ctr, Nottingham NG7 2RD, England.		Gowland, Penny A./I-9016-2012	Gowland, Penny A./0000-0002-4900-4817; Baker, Philip/0000-0002-4592-6427				BAKER PN, 1994, LANCET, V343, P644, DOI 10.1016/S0140-6736(94)92638-7; BAKER PN, 1994, AM J OBSTET GYNECOL, V170, P32; BODIS J, 1985, EUR J NUCL MED, V10, P286, DOI 10.1007/BF00254477; DOBSON PC, 1981, AUST NZ J OBSTET GYN, V21, P69, DOI 10.1111/j.1479-828X.1981.tb00781.x; Duncan K, 1996, BRIT MED J, V312, P1421; GOWLAND PA, IN PRESS MAGN RESON; HOWSEMAN AM, 1988, BRIT J RADIOL, V61, P822, DOI 10.1259/0007-1285-61-729-822; KWONG KK, 1995, MAGNET RESON MED, V34, P878, DOI 10.1002/mrm.1910340613; MANSFIELD P, 1990, BRIT J RADIOL, V63, P833, DOI 10.1259/0007-1285-63-755-833; NICOLAIDES KH, 1988, BRIT MED J, V297, P1026, DOI 10.1136/bmj.297.6655.1026; SHEPPARD BL, 1981, BRIT J OBSTET GYNAEC, V88, P695, DOI 10.1111/j.1471-0528.1981.tb01268.x; WILCOX MA, 1993, BRIT J OBSTET GYNAEC, V100, P342, DOI 10.1111/j.1471-0528.1993.tb12977.x	12	74	78	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 9	1998	351	9113					1397	1399		10.1016/S0140-6736(97)07089-X	http://dx.doi.org/10.1016/S0140-6736(97)07089-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM665	9593410				2022-12-01	WOS:000073563400010
J	Petukhova, G; Stratton, S; Sung, P				Petukhova, G; Stratton, S; Sung, P			Catalysis of homologous DNA pairing by yeast Rad51 and Rad54 proteins	NATURE			English	Article							STRAND EXCHANGE; RECOMBINATION; GENE	The Saccharomyces cerevisiae RAD51 and RAD54 genes are both required for the occurrence of homologous recombination and for the repair of double-stranded DNA breaks(1). Previous studies have indicated that Rad51 protein, together with the single-stranded DNA-binding factor replication protein A (RPA), can promote the formation of heteroduplex DNA(2-4), which is a key intermediate in homologous recombination(1), Here we report the purification of the Rad54 protein to near homogeneity and the biochemical testing of its molecular function. We find that Rad54 protein possesses a double-stranded DNA-dependent ATPase activity, and GRAPHICS that it interacts with the Rad51 protein. Addition of Rad54 protein to reactions containing Rad51 strongly stimulates the rate of pairing between homologous single-stranded and double-stranded DNA molecules. We conclude that Rad54 acts to overcome kinetic impediments that would limit homologous DNA pairing between recombining chromosomes in vivo.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Sung, P (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA.	sung@uthscsa.edu						Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RANDERATH K, 1964, J CHROMATOGR, V16, P111, DOI 10.1016/S0021-9673(01)82445-6; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4	17	341	352	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1998	393	6680					91	94		10.1038/30037	http://dx.doi.org/10.1038/30037			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590697				2022-12-01	WOS:000073497500055
J	Vu, TH; Shipley, JM; Bergers, G; Berger, JE; Helms, JA; Hanahan, D; Shapiro, SD; Senior, RM; Werb, Z				Vu, TH; Shipley, JM; Bergers, G; Berger, JE; Helms, JA; Hanahan, D; Shapiro, SD; Senior, RM; Werb, Z			MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes	CELL			English	Article							MATRIX METALLOPROTEINASES; IN-VITRO; INTERSTITIAL COLLAGENASE; MOUSE DEVELOPMENT; INDIAN HEDGEHOG; BONE-GROWTH; EXPRESSION; GENE; DEGRADATION; CARTILAGE	Homozygous mice with a null mutation in the MMP-9/gelatinase B gene exhibit an abnormal pattern of skeletal growth plate vascularization and ossification. Although hypertrophic chondrocytes develop normally, apoptosis, vascularization, and ossification are delayed, resulting in progressive lengthening of the growth plate to about eight times normal. After 3 weeks postnatal, aberrant apoptosis, vascularization, and ossification compensate to remodel the enlarged growth plate and ultimately produce an axial skeleton of normal appearance. Transplantation of wild-type bone marrow cells rescues vascularization and ossification in gelatinase B-null growth plates, indicating that these processes are mediated by gelatinase B-expressing cells of bone marrow origin, designated chondroclasts. Growth plates from gelatinase B-null mice in culture show a delayed release of an angiogenic activator, establishing a role for this proteinase in controlling angiogenesis.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Dept Orthoped Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Hormone Res Inst, San Francisco, CA 94143 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Internal Med,Div Pulm & Crit Care Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)	Vu, TH (corresponding author), Univ Calif San Francisco, Dept Anat, Box 0452, San Francisco, CA 94143 USA.		Bergers, Gabriele/AAJ-5535-2020	Bergers, Gabriele/0000-0003-3545-5171; Helms, Jill/0000-0002-0463-396X	NCI NIH HHS [R01 CA037395, R37 CA037395, R01 CA037395-19] Funding Source: Medline; NHLBI NIH HHS [R01 HL047328-08, HL47328, T32 HL007185, R01 HL047328, T32 HL007185-26] Funding Source: Medline; NICHD NIH HHS [P01 HD026732-070003, HD26732] Funding Source: Medline; NIDCR NIH HHS [DE10306, P50 DE010306-05S10005] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD026732] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R37CA037395, R01CA037395] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047328, T32HL007185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AHARINEJAD S, 1995, ANAT REC, V242, P111, DOI 10.1002/ar.1092420115; Albrecht U, 1997, MOL CELLULAR METHODS, P23; Alexander CM, 1996, DEVELOPMENT, V122, P1723; Alini M, 1996, DEV BIOL, V176, P124, DOI 10.1006/dbio.1996.9989; Amizuka N, 1996, ENDOCRINOLOGY, V137, P5055, DOI 10.1210/en.137.11.5055; ANDERSON CE, 1966, J BONE JOINT SURG AM, VA 48, P899, DOI 10.2106/00004623-196648050-00008; BEHRENDTSEN O, 1992, DEVELOPMENT, V114, P447; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BROWN CC, 1989, J BONE JOINT SURG AM, V71A, P580, DOI 10.2106/00004623-198971040-00014; CANCEDDA FD, 1995, EUR J CELL BIOL, V66, P60; CAPLAN AI, 1988, CIBA F SYMP, V136, P3; Carlevaro MF, 1997, J CELL BIOL, V136, P1375, DOI 10.1083/jcb.136.6.1375; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; ELIMA K, 1993, BIOCHEM J, V289, P247, DOI 10.1042/bj2890247; FARNUM CE, 1989, J ORTHOPAED RES, V7, P654, DOI 10.1002/jor.1100070505; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; Fisher S. J., 1995, EXTRACELLULAR MATRIX, P261; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HATORI M, 1995, J BONE MINER RES, V10, P1960, DOI 10.1002/jbmr.5650101216; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Iwasaki M, 1997, MECH DEVELOP, V69, P197, DOI 10.1016/S0925-4773(97)00145-7; JINGUSHI S, 1995, J ORTHOPAED RES, V13, P761, DOI 10.1002/jor.1100130516; KARELINA TV, 1995, J INVEST DERMATOL, V105, P411, DOI 10.1111/1523-1747.ep12321097; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kuettner K.E., 1983, SEFER RABIAH, V1, P281; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEWINSON D, 1992, ANAT REC, V233, P504, DOI 10.1002/ar.1092330403; MOSES MA, 1991, J CELL BIOCHEM, V47, P230, DOI 10.1002/jcb.240470308; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; OHSAWA Y, 1993, J HISTOCHEM CYTOCHEM, V41, P1075, DOI 10.1177/41.7.8515049; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; POOLE AR, 1991, CARTILAGE MOL ASPECT, P179; Rantakokko J, 1996, FEBS LETT, V393, P307, DOI 10.1016/0014-5793(96)00907-6; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; SCHENK RK, 1968, ACTA ANAT, V69, P1; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; SIRES UI, 1995, J CLIN INVEST, V95, P2089, DOI 10.1172/JCI117896; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	46	1438	1490	0	71	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1998	93	3					411	422		10.1016/S0092-8674(00)81169-1	http://dx.doi.org/10.1016/S0092-8674(00)81169-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590175	Green Accepted, Bronze			2022-12-01	WOS:000073471500016
J	Kemp, M				Kemp, M			Hesse-Honegger's hand-work	NATURE			English	Editorial Material								Cornelia Hesse-Honegger is fascinated by the beauty of bugs. After the Chernobyl disaster she set out with her paintbox on the trail of mutated insects, convinced that they were the result of radiation poisoning.	Univ Oxford, Dept Hist Art, Oxford OX1 2PG, England	University of Oxford	Kemp, M (corresponding author), Univ Oxford, Dept Hist Art, 35 Beaumont St, Oxford OX1 2PG, England.								0	1	1	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					555	555		10.1038/33298	http://dx.doi.org/10.1038/33298			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560149	Bronze			2022-12-01	WOS:000072987200035
J	Colwell, JE; Horanyi, M; Grun, E				Colwell, JE; Horanyi, M; Grun, E			Capture of interplanetary and interstellar dust by the Jovian magnetosphere	SCIENCE			English	Article							EJECTA; DYNAMICS; GALILEO	Interplanetary and interstellar dust grains entering Jupiter's magnetosphere form a detectable diffuse faint ring of exogenic material, This ring is composed of particles in the size range of 0.5 to 1.5 micrometers on retrograde and prograde orbits in a 4:1 ratio, with semimajor axes 3 < a < 20 jovian radii, eccentricities 0.1 < e < 0.3, and inclinations i less than or similar to 20 degrees or i greater than or similar to 160 degrees, The size range and the orbital characteristics are consistent with in situ detections of micrometer-sized grains by the Galileo dust detector, and the measured rates match the number densities predicted from numerical trajectory integrations.	Univ Colorado, Atmospher & Space Phys Lab, Boulder, CO 80309 USA; Max Planck Inst Kernphys, D-69117 Heidelberg, Germany	University of Colorado System; University of Colorado Boulder; Max Planck Society	Colwell, JE (corresponding author), Univ Colorado, Atmospher & Space Phys Lab, Campus Box 392, Boulder, CO 80309 USA.	colwell@casper.colorado.edu	Colwell, Joshua/AAP-2692-2020	Colwell, Joshua/0000-0001-8269-6408; Horanyi, Mihaly/0000-0002-5920-9226				ASADA N, 1985, J GEOPHYS RES-SOLID, V90, P2445, DOI 10.1029/JB090iB14p12445; BAGENAL F, 1989, NASA SPEC PUBL SP, V494; BAGUHL M, 1995, SPACE SCI REV, V72, P471, DOI 10.1007/BF00768822; Burns J.A., 1984, IAU COLLO Q 75 PLANE, P200; COLWELL JE, 1993, ICARUS, V106, P536, DOI 10.1006/icar.1993.1191; Colwell JE, 1996, J GEOPHYS RES-PLANET, V101, P2169, DOI 10.1029/95JE03103; CONNERNEY JEP, 1993, J GEOPHYS RES-PLANET, V98, P18659, DOI 10.1029/93JE00980; DIVINE N, 1993, J GEOPHYS RES-PLANET, V98, P17029, DOI 10.1029/93JE01203; DIVINE N, 1983, J GEOPHYS RES-SPACE, V88, P6889, DOI 10.1029/JA088iA09p06889; Gault D. E., 1973, Moon, V6, P32, DOI 10.1007/BF02630651; GRUN E, 1985, ICARUS, V62, P244, DOI 10.1016/0019-1035(85)90121-6; GRUN E, 1992, SPACE SCI REV, V60, P317, DOI 10.1007/BF00216860; GRUN E, IN PRESS GEOPHYS RES; Horanyi M, 1996, ANNU REV ASTRON ASTR, V34, P383, DOI 10.1146/annurev.astro.34.1.383; HORANYI M, 1991, J GEOPHYS RES-SPACE, V96, P19283, DOI 10.1029/91JA01982; HORANYI M, 1994, GEOPHYS RES LETT, V21, P1039, DOI 10.1029/94GL01326; HOUSEN KR, 1983, J GEOPHYS RES, V88, P2485, DOI 10.1029/JB088iB03p02485; Opik E.J., 1951, P R IRISH ACAD A, V54, P165; SITTLER EC, 1987, J GEOPHYS RES, V92, P5741, DOI 10.1029/JA092iA06p05741; STOFFLER D, 1975, J GEOPHYS RES, V80, P4062, DOI 10.1029/JB080i029p04062; Zook H. A., 1982, LUNAR PLANETARY SCI, V13, P893; ZOOK HA, 1985, LUNAR PLANET SCI, V16, P946	22	37	38	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					88	91		10.1126/science.280.5360.88	http://dx.doi.org/10.1126/science.280.5360.88			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525863				2022-12-01	WOS:000072885100040
J	Ogino, H; Yasuda, K				Ogino, H; Yasuda, K			Induction of lens differentiation by activation of a bZIP transcription factor, L-maf	SCIENCE			English	Article							A-CRYSTALLIN GENE; DEVELOPMENTAL REGULATION; ENHANCER ELEMENT; EYELESS GENE; V-MAF; EXPRESSION; BINDING; ONCOGENE; PROTEIN; ENCODES	After the vertebrate lens is induced from head ectoderm, lens-specific genes are expressed. Transcriptional regulation of the lens-specific alpha A-crystallin gene is controlled by an enhancer element, alpha CE2. A gene encoding an alpha CE2-binding protein, L-maf (lens-specific maf), was isolated. L-maf expression is initiated in the lens placode and is restricted to lens cells. The gene product L-Maf regulates the expression of multiple genes expressed in the lens, and ectopic expression of this transcription factor converts chick embryonic ectodermal cells and cultured cells into lens fibers. Thus, vertebrate lens induction and differentiation can be triggered by the activation of L-Maf.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma 6300101, Japan	Nara Institute of Science & Technology	Yasuda, K (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Ikoma 6300101, Japan.	kyasuda@bs.aist-nara.ac.jp	Ogino, Hajime/G-5279-2019	Ogino, Hajime/0000-0003-2707-2330				ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; AYA T, UNPUB; CEPKO CL, 1992, CURRENT PROTOCOLS MO; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; Duncan MK, 1996, MECH DEVELOP, V57, P79, DOI 10.1016/0925-4773(96)00533-3; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GORING DR, 1993, DEV DYNAM, V196, P143, DOI 10.1002/aja.1001960208; GRAINGER RM, 1992, TRENDS GENET, V8, P349, DOI 10.1016/0168-9525(92)90280-H; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HAYASHI S, 1987, GENE DEV, V1, P818, DOI 10.1101/gad.1.8.818; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; ISHIBASHI S, UNPUB; JACOBSON AG, 1966, SCIENCE, V152, P25, DOI 10.1126/science.152.3718.25; KAMACHI Y, 1995, EMBO J, V14, P3510, DOI 10.1002/j.1460-2075.1995.tb07357.x; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; LEE YM, 1995, DEVELOPMENT, V121, P825; Manzanares M, 1997, NATURE, V387, P191, DOI 10.1038/387191a0; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; MATSUO I, 1992, NUCLEIC ACIDS RES, V20, P3701, DOI 10.1093/nar/20.14.3701; MATSUO I, 1991, DEVELOPMENT, V113, P539; Muramatsu Tatsuo, 1996, Animal Science and Technology, V67, P906; NAKAMURA T, 1990, MOL CELL BIOL, V10, P3700, DOI 10.1128/MCB.10.7.3700; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Oliver G, 1995, DEVELOPMENT, V121, P4045; Oliver G, 1996, MECH DEVELOP, V60, P233, DOI 10.1016/S0925-4773(96)00632-6; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; Porter FD, 1997, DEVELOPMENT, V124, P2935; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SAKAL M, 1997, ONCOGENE, V14; SAWADA K, 1993, JPN J OPHTHALMOL, V37, P355; SHINOHARA T, 1976, P NATL ACAD SCI USA, V73, P2808, DOI 10.1073/pnas.73.8.2808; Spemann H, 1901, VERH ANAT GESELLSCH, V15, P61; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; Tokui M, 1997, BIOCHEM BIOPH RES CO, V233, P527, DOI 10.1006/bbrc.1997.6485; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Wilkinson D.G., 1993, ESSENTIAL DEV BIOL P, P257; Yasuda K, 1986, Oxf Surv Eukaryot Genes, V3, P183; Yoshida K, 1997, INVEST OPHTH VIS SCI, V38, P2679	41	236	242	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					115	118		10.1126/science.280.5360.115	http://dx.doi.org/10.1126/science.280.5360.115			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525857				2022-12-01	WOS:000072885100049
J	Grazzini, E; Guillon, G; Mouillac, B; Zingg, HH				Grazzini, E; Guillon, G; Mouillac, B; Zingg, HH			Inhibition of oxytocin receptor function by direct binding of progesterone	NATURE			English	Article							RAT GLOMERULOSA CELLS; RECIPROCAL MODULATION; VASOPRESSIN RECEPTOR; ANTAGONIST BINDING; PREGNANCY; AGONIST; SPECIFICITY; EXPRESSION; UTERUS; LIGAND	The steroid hormone progesterone (P-4) is essential for establishing and maintaining pregnancy in mammals(1-3). One of its functions includes maintenance of uterine quiescence by decreasing uterine sensitivity to the uterotonic peptide hormone oxytocin(3-5). Although it is generally held that steroid hormones such as P-4 act at a genomic level by binding to nuclear receptors and modulating the expression of specific target genes(6), we show here that the effect of P-4 on uterine sensitivity to oxytocin involves direct, nongenomic action of P-4 on the uterine oxytocin receptor (OTR), a member of the G-protein-coupled receptor family. P-4 inhibits oxytocin binding to OTR-containing membranes in virro, binds with high affinity to recombinant rat OTR expressed in CHO cells, and suppresses oxytocin-induced inositol phosphate production and calcium mobilization. These effects are highly steroid-and receptor-specific, because binding and signalling functions of the closely related human OTR are not affected by P-4 itself but by the P-4 metabolite 5 beta-dihydroprogesterone. Our findings provide the first evidence for a direct Interaction between a steroid hormone and a G-protein-coupled receptor and define a new level of crosstalk between the peptide-and steroid-hormone signalling pathways.	McGill Univ, Royal Victoria Hosp, Mol Endocrinol Lab, Res Inst, Montreal, PQ H3A 1A1, Canada; CNRS, INSERM, Ctr Pharmacol Endocrinol, U469, F-34094 Montpellier, France	McGill University; Royal Victoria Hospital; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Zingg, HH (corresponding author), McGill Univ, Royal Victoria Hosp, Mol Endocrinol Lab, Res Inst, Montreal, PQ H3A 1A1, Canada.	zingg@rvhri.lan.mcgill.ca	Zingg, Hans/GPS-9984-2022; MOUILLAC, Bernard/M-3896-2014	MOUILLAC, Bernard/0000-0002-3906-8673				Blackmore PF, 1996, MOL PHARMACOL, V49, P727; BURGISSER E, 1982, P NATL ACAD SCI-BIOL, V79, P1732, DOI 10.1073/pnas.79.6.1732; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; CSAPO AI, 1981, PROSTAGLANDINS, V22, P131, DOI 10.1016/0090-6980(81)90060-5; ELANDS J, 1988, EUR J PHARMACOL, V147, P197, DOI 10.1016/0014-2999(88)90778-9; FUCHS AR, 1983, ENDOCRINOLOGY, V113, P742, DOI 10.1210/endo-113-2-742; GARFIELD RE, 1982, AM J OBSTET GYNECOL, V142, P21; Grazzini E, 1996, MOL PHARMACOL, V50, P1273; Grazzini E, 1996, CELL CALCIUM, V19, P29, DOI 10.1016/S0143-4160(96)90011-1; GREEN RD, 1984, J NEUROSCI, V4, P2472; GUILLON G, 1995, ENDOCRINOLOGY, V136, P1285, DOI 10.1210/en.136.3.1285; Jeng YJ, 1996, NEUROPEPTIDES, V30, P557, DOI 10.1016/S0143-4179(96)90039-6; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; LARCHER A, 1995, ENDOCRINOLOGY, V136, P5350, DOI 10.1210/en.136.12.5350; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; PEPE GJ, 1995, ENDOCR REV, V16, P608, DOI 10.1210/er.16.5.608; PEPE GJ, 1974, ENDOCRINOLOGY, V95, P275, DOI 10.1210/endo-95-1-275; SCHMIDT A, 1991, FEBS LETT, V282, P77, DOI 10.1016/0014-5793(91)80448-C; SCHUMACHER M, 1989, P NATL ACAD SCI USA, V86, P6798, DOI 10.1073/pnas.86.17.6798; SOLOFF MS, 1983, CAN J BIOCHEM CELL B, V61, P625, DOI 10.1139/o83-078; SUNDARAM H, 1993, BIOCHEM PHARMACOL, V45, P1003, DOI 10.1016/0006-2952(93)90243-P; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VALERA S, 1992, P NATL ACAD SCI USA, V89, P9949, DOI 10.1073/pnas.89.20.9949; WASSERMAN WJ, 1980, P NATL ACAD SCI-BIOL, V77, P1534, DOI 10.1073/pnas.77.3.1534; WESTPHAL RS, 1994, MOL PHARMACOL, V46, P937; WONG M, 1994, J NEUROENDOCRINOL, V6, P347, DOI 10.1111/j.1365-2826.1994.tb00592.x; Zingg HH, 1996, BAILLIERE CLIN ENDOC, V10, P75, DOI 10.1016/S0950-351X(96)80314-4	27	371	384	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					509	512		10.1038/33176	http://dx.doi.org/10.1038/33176			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548257				2022-12-01	WOS:000072875200062
J	Deckert, G; Warren, PV; Gaasterland, T; Young, WG; Lenox, AL; Graham, DE; Overbeek, R; Snead, MA; Keller, M; Aujay, M; Huber, R; Feldman, RA; Short, JM; Olsen, GJ; Swanson, RV				Deckert, G; Warren, PV; Gaasterland, T; Young, WG; Lenox, AL; Graham, DE; Overbeek, R; Snead, MA; Keller, M; Aujay, M; Huber, R; Feldman, RA; Short, JM; Olsen, GJ; Swanson, RV			The complete genome of the hyperthermophilic bacterium Aquifex aeolicus	NATURE			English	Article							HYDROGEN-OXIDIZING BACTERIA; FACTOR-BASED VECTOR; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; HUMAN DNA; SP-NOV; GENE; PYROPHILUS; EXPRESSION; PROTEINS	Aquifex aeolicus was one of the earliest diverging, and is one of the most thermophilic, bacteria known. It can grow on hydrogen, oxygen, carbon dioxide, and mineral salts. The complex metabolic machinery needed for A. aeolicus to function as a chemolithoautotroph (an organism which uses an inorganic carbon source for biosynthesis and an inorganic chemical energy source) is encoded within a genome that is only one-third the size of the E, coli genome, Metabolic flexibility seems Po be reduced as a result of the limited genome size, The use of oxygen (albeit at very low concentrations) as an electron acceptor is allowed by the presence of a complex respiratory apparatus. Although this organism grows at 95 degrees C, the extreme thermal limit of the Bacteria, only a few specific indications of thermophily are apparent from the genome. Here we describe the complete genome sequence of 1,551,335 base pairs of this evolutionarily and physiologically interesting organism.	Diversa Corp, San Diego, CA 92121 USA; Argonne Natl Lab, Div Math & Comp Sci, Argonne, IL 60439 USA; Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Univ Regensburg, Lehrstuhl Mikrobiol, D-8400 Regensburg, Germany	United States Department of Energy (DOE); Argonne National Laboratory; University of Illinois System; University of Illinois Urbana-Champaign; University of Regensburg	Swanson, RV (corresponding author), Diversa Corp, 10665 Sorrento Valley Rd, San Diego, CA 92121 USA.	Robert.huber@biologie.uni-regensburg.de; rswanson@diversa.com	Keller, Martin/C-4416-2012; Graham, David E/F-8578-2010	Graham, David E/0000-0001-8968-7344; Swanson, Ronald/0000-0002-6486-2676				ALTINGMEES MA, 1989, NUCLEIC ACIDS RES, V17, P9494, DOI 10.1093/nar/17.22.9494; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baldauf SL, 1996, P NATL ACAD SCI USA, V93, P7749, DOI 10.1073/pnas.93.15.7749; BEH M, 1993, ARCH MICROBIOL, V160, P306, DOI 10.1007/BF00292082; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bocchetta M, 1995, J MOL EVOL, V41, P803; BOHM G, 1994, INT J PEPT PROT RES, V43, P97; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BROCK TD, 1995, ANNU REV MICROBIOL, V49, P1; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGGRAF S, 1992, SYST APPL MICROBIOL, V15, P352, DOI 10.1016/S0723-2020(11)80207-9; Choi IG, 1997, EXTREMOPHILES, V1, P125, DOI 10.1007/s007920050025; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FUCHS G, 1987, AUTOTROPHIC BACTERIA, P365; Gaasterland T, 1996, BIOCHIMIE, V78, P302, DOI 10.1016/0300-9084(96)84761-4; Gaasterland T, 1996, TRENDS GENET, V12, P76, DOI 10.1016/0168-9525(96)81406-5; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HUBER R, 1992, SYST APPL MICROBIOL, V15, P340, DOI 10.1016/S0723-2020(11)80206-7; Jarrell KF, 1996, J BACTERIOL, V178, P5057, DOI 10.1128/jb.178.17.5057-5064.1996; Kaneko T, 1996, DNA Res, V3, P109; KAWASUMI T, 1984, INT J SYST BACTERIOL, V34, P5, DOI 10.1099/00207713-34-1-5; KIM UJ, 1992, NUCLEIC ACIDS RES, V20, P1083, DOI 10.1093/nar/20.5.1083; KLENK HP, 1994, MOL BIOL ARCHAEA, P139; KRISTJANSSON JK, 1985, ARCH MICROBIOL, V140, P321, DOI 10.1007/BF00446971; KRYUKOV VR, 1983, MICROBIOLOGY+, V52, P611; LANDER E S, 1988, Genomics, V2, P231; Lim JH, 1997, FEBS LETT, V406, P142, DOI 10.1016/S0014-5793(97)00262-7; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Mai XH, 1996, J BACTERIOL, V178, P5890, DOI 10.1128/jb.178.20.5890-5896.1996; MOTOSHIMA H, 1990, AGR BIOL CHEM TOKYO, V54, P2385, DOI 10.1080/00021369.1990.10870335; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PITULLE C, 1994, INT J SYST BACTERIOL, V44, P620, DOI 10.1099/00207713-44-4-620; REYSENBACH AL, 1994, APPL ENVIRON MICROB, V60, P2113, DOI 10.1128/AEM.60.6.2113-2119.1994; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; RUDOLPH J, 1995, EMBO J, V14, P4249, DOI 10.1002/j.1460-2075.1995.tb00099.x; Setchell W A, 1903, Science, V17, P934, DOI 10.1126/science.17.441.934; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; WEISBURG WG, 1989, SYST APPL MICROBIOL, V11, P128, DOI 10.1016/S0723-2020(89)80051-7; WELCH M, 1994, BIOCHEMISTRY-US, V33, P10470, DOI 10.1021/bi00200a031; WETMUR JG, 1994, J BIOL CHEM, V269, P25928	49	940	1792	1	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 26	1998	392	6674					353	358		10.1038/32831	http://dx.doi.org/10.1038/32831			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537320	Bronze			2022-12-01	WOS:000072713600041
J	Mitchell, R; McCulloch, D; Lutz, E; Johnson, M; MacKenzie, C; Fennell, M; Fink, G; Zhou, W; Sealfon, SC				Mitchell, R; McCulloch, D; Lutz, E; Johnson, M; MacKenzie, C; Fennell, M; Fink, G; Zhou, W; Sealfon, SC			Rhodopsin-family receptors associate with small G proteins to activate phospholipase D	NATURE			English	Article							ADP-RIBOSYLATION-FACTOR; GUANINE-NUCLEOTIDE; HL-60 CELLS; GTP; ARF; RHO; EXCHANGE; FRACTIONS; FLUORIDE; CONTAINS	G-protein-coupled receptors of the rhodopsin family transduce many important neural and endocrine signals, These receptors activate heterotrimeric G proteins and in many cases also cause activation of phospholipase D, an enzyme that can be controlled by the small G proteins ARF and RhoA(1-3). Here we show that the activation of phospholipase D that is induced by many, but not all, Ca2+-mobilizing G-protein-coupled receptors is sensitive to inhibitors of ARF and of RhoA. Receptors of this type were coimmunoprecipitated with ARF or RhoA on exposure to agonists, and the effects of GTP analogues on ligand binding to the receptor changed to a profile that is characteristic of small G proteins, These receptors contain the amino-acid sequence Asn-ProXXTyr in their seventh transmembrane domain, whereas receptors capable of activating phospholipase D without involving ARF contain the sequence AspProXXTyr. Mutation of this latter sequence to AsnProXXTyr in the gonadotropin-releasing hormone receptor conferred sensitivity to an inhibitor of ARF, and the reciprocal mutation in the 5-HT2A receptor for 5-hydroxy-tryptamine reduced its sensitivity to the inhibitor, Receptors carrying the AsnProXXTyr motif thus seem to form functional complexes with ARF and RhoA.	MRC, Brain Metab Unit, Edinburgh EH8 9JZ, Midlothian, Scotland; Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; Mt Sinai Sch Med, Fishberg Ctr Neurobiol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Mitchell, R (corresponding author), MRC, Brain Metab Unit, 1 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland.			Fink, George/0000-0002-0713-527X; SEALFON, Stuart/0000-0001-5791-1217	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAVANAGH MM, 1996, J BIOL CHEM, V271, P21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FENG DM, 1995, J MED CHEM, V38, P4125, DOI 10.1021/jm00020a029; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GILL DM, 1987, BIOCHEMISTRY-US, V26, P6364, DOI 10.1021/bi00394a009; Hoffenberg S, 1996, MOL PHARMACOL, V49, P156; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; Martin A, 1996, J BIOL CHEM, V271, P17397, DOI 10.1074/jbc.271.29.17397; MITCHELL R, 1995, BIOCHEM SOC T, V23, pS208, DOI 10.1042/bst023208s; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; NIETO M, 1994, MOL PHARMACOL, V46, P406; OGIER SA, 1987, J ENDOCRINOL, V115, P151, DOI 10.1677/joe.0.1150151; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; WALL SJ, 1991, MOL PHARMACOL, V40, P783; Whatmore J, 1996, BIOCHEM J, V320, P785, DOI 10.1042/bj3200785; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG LX, 1994, ENDOCRINOLOGY, V134, P1446, DOI 10.1210/en.134.3.1446; ZHOU W, 1994, MOL PHARMACOL, V45, P165	30	183	185	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					411	414		10.1038/32937	http://dx.doi.org/10.1038/32937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537328				2022-12-01	WOS:000072713600058
J	Zhang, JK; Cado, D; Chen, A; Kabra, NH; Winoto, A				Zhang, JK; Cado, D; Chen, A; Kabra, NH; Winoto, A			Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; DOMAIN-CONTAINING RECEPTOR; DEATH-DOMAIN; SIGNALING COMPLEX; CD95 FAS/APO-1; LYMPHOCYTES-T; PROTEIN; INTERACTS; THYMOCYTES; FADD	Programmed cell death, or apoptosis, is important in homeostasis of the immune system: for example, non-functional or autoreactive lymphocytes are eliminated through apoptosis, One member of the tumour necrosis factor receptor (TNFR) family; Fas (also known as CD95 or Apo-1), can trigger cell death and is essential for lymphocyte homeostasis(1,2). FADD/Mort1 (refs 3-6) is a Pas-associated protein that is thought to mediate apoptosis by recruiting the protease caspase-8 (refs 7, 8), A dominant-negative mutant of FADD inhibits apoptosis initiated by Fas and other TNFR family members(6,9-14). Other proteins, notably Daax, also bind Fas and presumably mediate a FADD-independent apoptotic pathway(15). Here we investigate the role of FADD in vivo by generating FADD-deficient mice. As homozygous mice die in utero, we generated FADD(-/-) embryonic stem cells and FADD(-/-) chimaeras in a background devoid of the recombination activating gene RAG-1, which activates rearrangement of the immunoglobulin and T-cell receptor genes, We found that thymocyte subpopulations were apparently normal in newborn chimaeras. Fas-induced apoptosis was completely blocked, indicating that there are no redundant Fas apoptotic pathways, As these mice age, their thymocytes decrease to an undetectable level, although peripheral T cells are present in all older FADD(-/-) chimaeras, Unexpectedly, activation-induced proliferation is impaired in these FADD(-/-) T cells, despite production of the cytokine interleukin (IL)-2, These results and the similarities between FADD(-/-) mice and mice lacking the P-subunit of the IL-2 receptor suggest that there is an unexpected connection between cell proliferation and apoptosis.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Winoto, A (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, 469 LSA, Berkeley, CA 94720 USA.			Shi, Yufang/0000-0001-8964-319X; Zhang, Jianke/0000-0002-5822-2226				Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; Fournel S, 1996, J IMMUNOL, V157, P4309; HERNANDEZCASELLES T, 1993, J IMMUNOL, V151, P3999; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Lenardo M J, 1997, Semin Immunol, V9, P1, DOI 10.1006/smim.1996.0050; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Matiba B, 1997, Semin Immunol, V9, P59, DOI 10.1006/smim.1996.0054; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; Parijs LV, 1997, J IMMUNOL, V158, P3738; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhang J, 1996, MOL CELL BIOL, V16, P2756	30	622	637	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					296	300		10.1038/32681	http://dx.doi.org/10.1038/32681			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521326				2022-12-01	WOS:000072612300051
J	Walker, BR; McConnachie, A; Noon, JP; Webb, DJ; Watt, GCM				Walker, BR; McConnachie, A; Noon, JP; Webb, DJ; Watt, GCM			Contribution of parental blood pressures to association between low birth weight and adult high blood pressure: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR RISK; FETAL GROWTH; HYPERTENSION; CHILDREN; PREGNANCY; WOMEN	Objective: To examine the possibility that low birth weight is a feature of the inherited predisposition to high blood pressure. Design: Cross sectional study. Setting: Primary care medical centre in Edinburgh. Subjects: One offspring of 12 families (231 men and 221 women aged 16-26 years) in whom blood pressure, weight, and height were measured in 1986 and whose parents had blood pressure measured in 1979. Birth weights were obtained from case records (270 offspring) or by questionnaires sent to the mothers (182 offspring). Main outcome measures: Birth weight and adult systolic blood pressure in offspring in relation to parental blood pressure. Results: If parental blood pressures were not considered, a 1 kg decrease in birth weight was associated with a 2.24 mm Hg increase in systolic blood pressure of offspring (P = 0.06) after correction for current weight and sex. However, parental blood pressures correlated positively with blood pressure of offspring, and higher maternal blood pressure was associated with lower birth weight (-3.03 g/mm Hg, P < 0.01). After correction for parental blood pressures, a 1 kg decrease in birth weight was associated with only a 1.71 mm Hg increase in the systolic blood pressure of the offspring (P = 0.15). Conclusions: Low birth weight is a feature of the inherited predisposition to hypertension, perhaps because it is associated with higher maternal blood pressure during pregnancy. Parental blood pressure may be an important confounding factor in the relation between low birth weight and subsequent hypertension.	Univ Edinburgh, Western Gen Hosp, Dept Med, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Glasgow, Woodside Hlth Ctr, Dept Gen Practice, Glasgow G20 7LR, Lanark, Scotland	University of Edinburgh; University of Glasgow	Walker, BR (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Med, Edinburgh EH4 2XU, Midlothian, Scotland.							BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CHESLEY LC, 1980, CLIN EXP HYPERTENS, V2, P777, DOI 10.3109/10641968009037142; Churchill D, 1997, LANCET, V349, P7, DOI 10.1016/S0140-6736(96)06297-6; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; DGANI J, 1992, J PERINAT MED, V20, P365, DOI 10.1515/jpme.1992.20.5.365; Godfrey K, 1996, BRIT MED J, V312, P410, DOI 10.1136/bmj.312.7028.410; Harrap SB, 1997, CIRCULATION, V96, P556; HIMMELMANN A, 1994, J INTERN MED, V235, P347, DOI 10.1111/j.1365-2796.1994.tb01085.x; Lalande M, 1996, ANNU REV GENET, V30, P173, DOI 10.1146/annurev.genet.30.1.173; LangleyEvans SC, 1996, CLIN SCI, V91, P607, DOI 10.1042/cs0910607; Law CM, 1996, J HYPERTENS, V14, P935; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LUMEY LH, 1995, EUR J OBSTET GYN R B, V61, P23, DOI 10.1016/0028-2243(95)02149-M; LUMEY LH, 1994, INT J EPIDEMIOL, V23, P1006, DOI 10.1093/ije/23.5.1006; McCowan LME, 1996, BRIT J OBSTET GYNAEC, V103, P123, DOI 10.1111/j.1471-0528.1996.tb09662.x; MORTON NE, 1955, ANN HUM GENET, V20, P125; Noon JP, 1997, J CLIN INVEST, V99, P1873, DOI 10.1172/JCI119354; SEIDMAN DS, 1991, BRIT J OBSTET GYNAEC, V98, P1009, DOI 10.1111/j.1471-0528.1991.tb15339.x; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; Taittonen L, 1996, PEDIATR RES, V40, P627, DOI 10.1203/00006450-199610000-00019; Troy LM, 1996, INT J EPIDEMIOL, V25, P122, DOI 10.1093/ije/25.1.122; WATT GCM, 1991, J HYPERTENS, V9, P55; WHINCUP P, 1994, J HUM HYPERTENS, V8, P337	26	77	79	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					834	837		10.1136/bmj.316.7134.834	http://dx.doi.org/10.1136/bmj.316.7134.834			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549456	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000072584300034
J	Cnattingius, S; Haglund, B; Kramer, MS				Cnattingius, S; Haglund, B; Kramer, MS			Differences in late fetal death rates in association with determinants of small for gestational age fetuses: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							INTRAUTERINE GROWTH-RETARDATION; RISK-FACTORS; MATERNAL AGE; STILLBIRTH; BIRTH; MALFORMATIONS; COMPLICATIONS; ANTEPARTUM; DURATION; SMOKING	Objective: To examine differences in late fetal death rates in association with determinants of small for gestational age fetuses. Design: Population based cohort study. Subjects: 1 026 249 pregnancies without congenital malformations. Setting: Sweden 1983-92. Main outcome measure: Late fetal death rate. Results: Depending on underlying determinants late fetal death rates were greatly increased in extremely small for gestational age fetuses (range 16 to 45 per 1000) compared with non-small for gestational age fetuses (1.4 to 4.6). In extremely small for gestational age fetuses late fetal death rates were increased from 31 per 1000 in mothers aged less than 35 years to 45 per 1000 in older mothers, and from 22 per 1000 in women < 155 cm in height to 33 per 1000 in women greater than or equal to 175 cm tall. Late fetal death rates were also higher in extremely small for gestational age fetuses in singleton compared with twin pregnancies and in non-hypertensive pregnancies compared with pregnancies complicated by severe pre-eclampsia or other hypertensive disorders. Slightly higher late fetal death rates were observed in nulliparous compared with parous women and in non-smokers compared with smokers. Conclusions: Although the risk of late fetal death is greatly increased in fetuses that are extremely small for gestational age the risk is strongly modified by underlying determinants-for example, there is a lower risk of late fetal death in a small for gestational age fetus if the mother is of short stature, has a twin pregnancy, or has hypertension.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Natl Board Hlth & Welf, Ctr Epidemiol, Stockholm, Sweden; McGill Univ, Fac Med, Dept Pediat, Montreal, PQ, Canada	Karolinska Institutet; National Board of Health & Welfare; McGill University	Cnattingius, S (corresponding author), Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden.							ABDELLA TN, 1984, OBSTET GYNECOL, V63, P365; Aberg A, 1992, Int J Technol Assess Health Care, V8 Suppl 1, P20; ALESSANDRI LM, 1992, BRIT J OBSTET GYNAEC, V99, P711, DOI 10.1111/j.1471-0528.1992.tb13868.x; BARROS FC, 1992, PEDIATRICS, V90, P238; Cnattingius S, 1998, NEW ENGL J MED, V338, P147, DOI 10.1056/NEJM199801153380302; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; CNATTINGIUS S, 1990, International Journal of Feto-Maternal Medicine, V3, P15; Cnattingius S, 1997, AM J EPIDEMIOL, V145, P319; GARDOSI J, 1992, LANCET, V339, P283, DOI 10.1016/0140-6736(92)91342-6; GENEST DR, 1992, OBSTET GYNECOL, V80, P575; Haglund B, 1993, Paediatr Perinat Epidemiol, V7, P33, DOI 10.1111/j.1365-3016.1993.tb00599.x; HEINRICH UE, 1992, BAILLIERE CLIN ENDOC, V6, P589, DOI 10.1016/S0950-351X(05)80114-4; Hogberg U, 1997, ACTA OBSTET GYN SCAN, V76, P907, DOI 10.3109/00016349709034900; KHOURY MJ, 1988, PEDIATRICS, V82, P83; KRAMER MS, 1990, PEDIATRICS, V86, P18; KRAMER MS, 1987, PEDIATRICS, V80, P502; Lang JM, 1996, EPIDEMIOLOGY, V7, P369, DOI 10.1097/00001648-199607000-00006; LITTLE RE, 1993, AM J EPIDEMIOL, V137, P1177, DOI 10.1093/oxfordjournals.aje.a116620; NAEYE RL, 1983, OBSTET GYNECOL, V61, P210; NAEYE RL, 1979, EARLY HUM DEV, V3, P229, DOI 10.1016/0378-3782(79)90031-8; OUNSTED M, 1981, EARLY HUM DEV, V5, P367, DOI 10.1016/0378-3782(81)90017-7; Radestad I, 1996, BRIT MED J, V312, P1505, DOI 10.1136/bmj.312.7045.1505; RAYMOND EG, 1994, BRIT J OBSTET GYNAEC, V101, P301, DOI 10.1111/j.1471-0528.1994.tb13614.x; RAYMOND EG, 1993, ACTA OBSTET GYN SCAN, V72, P633, DOI 10.3109/00016349309021156; RYDHSTROM H, 1994, ACTA OBSTET GYN SCAN, V73, P779, DOI 10.3109/00016349409072504; SANDERSON DA, 1994, BRIT J OBSTET GYNAEC, V101, P310, DOI 10.1111/j.1471-0528.1994.tb13616.x; Sciscione AC, 1996, AM J OBSTET GYNECOL, V175, P544; SNIJDERS RJM, 1993, AM J OBSTET GYNECOL, V168, P547, DOI 10.1016/0002-9378(93)90491-Z; Wennergren M, 1992, Int J Technol Assess Health Care, V8 Suppl 1, P147; YUDKIN PL, 1987, LANCET, V1, P1192; 1990, AM J OBSTET GYNECOL, V163, P1689	31	124	125	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1998	316	7143					1483	1487		10.1136/bmj.316.7143.1483	http://dx.doi.org/10.1136/bmj.316.7143.1483			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP020	9582131	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000073707700019
J	Smith, SS; Gong, QH; Hsu, FC; Markowitz, RS; ffrench-Mullen, JMH; Li, HS				Smith, SS; Gong, QH; Hsu, FC; Markowitz, RS; ffrench-Mullen, JMH; Li, HS			GABA(A) receptor alpha 4 subunit suppression prevents withdrawal properties of an endogenous steroid	NATURE			English	Article							A RECEPTOR; RAT-BRAIN; PROGESTERONE; METABOLITES; DEPENDENCE; ETHANOL; WOMEN; MODEL	The hormone progesterone is readily converted to 3 alpha-OH-5 alpha-pregnan-20-one (3 alpha,5 alpha-THP) in the brains of males and females(1,2), In the brain, 3 alpha,5 alpha-THP acts like a sedative(3-5), decreasing anxiety and reducing seizure activity, by enhancing the function of GABA (gamma-aminobutyric acid)(6-8), the brain's major inhibitory neurotransmitter, Symptoms of premenstrual syndrome (PMS), such as anxiety(9) and seizure(10,11) susceptibility, are associated with sharp declines in circulating levels of progesterone and, consequently, of levels of 3 alpha,5 alpha-THP in the brain. Abrupt discontinuation of use of sedatives such as benzodiazepines(12) and ethanol(13) can also produce PMS-like withdrawal symptoms. Here we report a progesterone-withdrawal paradigm, designed to mimic PMS and post-partum syndrome in a rat model. In this model, withdrawal of progesterone leads to increased seizure susceptibility and insensitivity to benzodiazepine sedatives through an effect on gene transcription. Specifically, this effect was due to reduced levels of 3 alpha,5 alpha-THP which enhance transcription of the gene encoding the alpha 4 subunit of the GABA(A) receptor. We also find that increased susceptibility to seizure after progesterone withdrawal is due to a sixfold decrease in the decay time for GABA currents and consequent decreased inhibitory function. Blockade of the alpha 4 gene transcript prevents these withdrawal properties. PMS symptoms may therefore be attributable, in part, to alterations in expression of GABA(A) receptor subunits as a result of progesterone withdrawal.	Allegheny Univ Hlth Sci, Dept Neurobiol & Anat, EPPI, Philadelphia, PA 19129 USA; Zeneca Inc, Zeneca Pharmaceut, RIN Biosci, Wilmington, DE 19850 USA	AstraZeneca	Smith, SS (corresponding author), Allegheny Univ Hlth Sci, Dept Neurobiol & Anat, EPPI, 3200 Henry Ave, Philadelphia, PA 19129 USA.			Smith, Sheryl/0000-0003-4308-3267				ATOR NA, 1993, EUR J PHARMACOL, V241, P237, DOI 10.1016/0014-2999(93)90208-Y; BACKSTROM T, 1984, ACTA NEUROL SCAND, V69, P240; BELELLI D, 1989, EUR J PHARMACOL, V166, P325, DOI 10.1016/0014-2999(89)90077-0; BITRAN D, 1991, BRAIN RES, V561, P157, DOI 10.1016/0006-8993(91)90761-J; Brot MD, 1997, EUR J PHARMACOL, V325, P1, DOI 10.1016/S0014-2999(97)00096-4; BUCK KJ, 1990, J PHARMACOL EXP THER, V253, P713; COSTA AMN, 1995, J NEUROPHYSIOL, V74, P464, DOI 10.1152/jn.1995.74.1.464; DENNERSTEIN L, 1985, BRIT MED J, V290, P1617, DOI 10.1136/bmj.290.6482.1617; Devaud LL, 1997, J NEUROCHEM, V69, P126; FILE SE, 1990, NEUROSCI BIOBEHAV R, V14, P135, DOI 10.1016/S0149-7634(05)80214-3; FRIEDMAN L, 1993, MOL PHARMACOL, V44, P191; GALLO MA, 1993, PHARMACOL BIOCHEM BE, V46, P897, DOI 10.1016/0091-3057(93)90219-J; HERZOG AG, 1995, NEUROLOGY, V45, P1660, DOI 10.1212/WNL.45.9.1660; Holt RA, 1996, NEUROPHARMACOLOGY, V35, P1457, DOI 10.1016/S0028-3908(96)00064-0; KERN W, 1994, J NEUROCHEM, V62, P764; KOKKA N, 1993, ALCOHOL CLIN EXP RES, V17, P525, DOI 10.1111/j.1530-0277.1993.tb00793.x; LAU EC, 1993, J STEROID BIOCHEM, V46, P751, DOI 10.1016/0960-0760(93)90315-N; LAVOIE AM, 1997, BIOPHYS J, V73, P1; Mahmoudi M, 1997, J NEUROCHEM, V68, P2485; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MOSSIER B, 1994, J BIOL CHEM, V269, P25777; PURDY RH, 1991, P NATL ACAD SCI USA, V88, P4553, DOI 10.1073/pnas.88.10.4553; SMITH SS, 1994, PROG NEUROBIOL, V44, P55, DOI 10.1016/0301-0082(94)90057-4; SMITH SS, 1987, BRAIN RES, V400, P353, DOI 10.1016/0006-8993(87)90634-2; Sundstrom I, 1997, PSYCHONEUROENDOCRINO, V22, P25, DOI 10.1016/S0306-4530(96)00035-2; TWYMAN RE, 1992, J PHYSIOL-LONDON, V456, P215, DOI 10.1113/jphysiol.1992.sp019334; TYNDALE RF, 1994, J NEUROSCI, V14, P5417; Wafford KA, 1996, MOL PHARMACOL, V50, P670; WISDEN W, 1991, FEBS LETT, V289, P227, DOI 10.1016/0014-5793(91)81076-K; YU XJ, 1994, MOL PHARMACOL, V47, P603	30	462	474	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					926	930		10.1038/31948	http://dx.doi.org/10.1038/31948			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582073				2022-12-01	WOS:000073359900050
J	Rogal, AP				Rogal, AP			Brignole	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Rogal, AP (corresponding author), 200 South St, Brookline, MA 02167 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					691	692		10.7326/0003-4819-128-8-199804150-00016	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537945				2022-12-01	WOS:000073052500012
J	Schacker, TW; Hughes, JP; Shea, T; Coombs, RW; Corey, L				Schacker, TW; Hughes, JP; Shea, T; Coombs, RW; Corey, L			Biological and virologic characteristics of primary HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article						human immunodeficiency virus infections; disease progression; RNA, viral; CD4 lymphocyte count; viral load	HUMAN-IMMUNODEFICIENCY-VIRUS; MULTICENTER AIDS COHORT; CLINICAL MANIFESTATIONS; IMMUNE-DEFICIENCY; TYPE-1 INFECTION; PLASMA; ZIDOVUDINE; RNA; QUANTITATION; PROGRESSION	Background: The clinical events surrounding acute HIV-1 infection have been well described, but little is known about whether the virologic course of acute HIV-1 infection influences the subsequent progression of disease. Objective: To define the virologic natural history of acute and very early HIV infection. Design: Prospective, longitudinal cohort study. Setting: University of Washington Research Clinic. Participants: 74 adults enrolled soon after acquisition of HIV (mean, 69 days). Measurements: Plasma HIV-1 RNA levels; quantitative cell cultures; CD4 cell counts; and detailed clinical assessments done at study entry, biweekly for 1 month, monthly for 2 months, and quarterly thereafter. Results: In the first 30 days after acquisition of HIV, HIV-1 RNA levels varied greatly among participants (range, 27 200 to 1.6 x 10(6) copies per mt of plasma). Levels of HIV-1 RNA decreased by a mean of 6.5% per week for the first 120 days and then increased by a mean of 0.15% per week. CD4 cell counts decreased by a mean of 5.2 cells/mm(3) per week for the first 160 days and by a mean of 1.9 cells/mm(3) per week thereafter (P < 0.01). Disease progressed faster in participants who sought medical care for their acute seroconversion syndrome (P = 0.01) and those who had high plasma HIV-1 RNA levels 120 to 365 days after acquisition (P < 0.01). Peak levels in the first 120 days were not predictive of disease progression. Conclusions: The variability in viral RNA levels associated with acute HIV-1 infection is greater than previously appreciated. Within 120 days of acquisition, plasma HIV RNA levels rapidly decrease to an inflection point, after which they gradually increase. Virus-host interactions soon after acquisition seem to have a major influence on the long-term outcome of HIV-1 disease.	Univ Washington, Dept Lab Med 357110, Seattle, WA 98195 USA; Univ Washington, Seattle, WA 98122 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Minnesota System; University of Minnesota Twin Cities; Fred Hutchinson Cancer Center	Corey, L (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St,M-115, Seattle, WA 98104 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001228] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-45206, AI-01228, AI-26657] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTELSMAN JFWM, 1990, ENDOSCOPY, V22, P184, DOI 10.1055/s-2007-1012836; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Cleveland W. S., 1992, STAT MODELS S PACIFI; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DIGGLE PJ, 1994, ANAL LONGITUDINAL DA, P253; FISCUS SA, 1995, J INFECT DIS, V171, P305, DOI 10.1093/infdis/171.2.305; FOX R, 1987, AIDS, V1, P35; GRAHAM BS, 1995, NEW ENGL J MED, V333, P1331, DOI 10.1056/NEJM199511163332007; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HENRARD DR, 1995, J ACQ IMMUN DEF SYND, V9, P305; HO DD, 1985, ANN INTERN MED, V103, P880, DOI 10.7326/0003-4819-103-6-880; KASLOW RA, 1987, ANN INTERN MED, V107, P474, DOI 10.7326/0003-4819-107-4-474; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LEAVITT R, 1996, 36 INT C ANT AG CHEM; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; LETVIN NL, 1993, NEW ENGL J MED, V329, P1400, DOI 10.1056/NEJM199311043291908; LOES SKD, 1993, CLIN INFECT DIS, V17, P59, DOI 10.1093/clinids/17.1.59; McElrath MJ, 1996, P NATL ACAD SCI USA, V93, P3972, DOI 10.1073/pnas.93.9.3972; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MILLER RG, 1981, SURVIVAL ANAL, P7; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; Perrin L, 1996, AIDS, V10, P1233, DOI 10.1097/00002030-199609000-00009; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; PIATAK M, 1993, LANCET, V341, P1099, DOI 10.1016/0140-6736(93)92463-4; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RABENECK L, 1990, JAMA-J AM MED ASSOC, V263, P2318, DOI 10.1001/jama.263.17.2318; Revets H, 1996, J CLIN MICROBIOL, V34, P1058, DOI 10.1128/JCM.34.5.1058-1064.1996; SAIMOT AG, 1996, INT C AIDS, V11, P112; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SCHECHTER MT, 1990, AIDS, V4, P185, DOI 10.1097/00002030-199003000-00002; SINICCO A, 1993, J ACQ IMMUN DEF SYND, V6, P575; TAMELET C, 1996, INT C AIDS, V11, P113; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; TURNBULL BW, 1976, J R STAT SOC B, V38, P290	40	225	230	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					613	+		10.7326/0003-4819-128-8-199804150-00001	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537934				2022-12-01	WOS:000073052500001
J	Birse, CE; Minvielle-Sebastia, L; Lee, BA; Keller, W; Proudfoot, NJ				Birse, CE; Minvielle-Sebastia, L; Lee, BA; Keller, W; Proudfoot, NJ			Coupling termination of transcription to messenger RNA maturation in yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; POLYMERASE-II; POLYADENYLATION SIGNAL; POLY(A) POLYMERASE; GLOBIN GENE; END; SITE; PURIFICATION; SEPARATION; COMPONENTS	The direct association between messenger RNA (mRNA) 3'-end processing and the termination of transcription was established for the CYC1 gene of Saccharomyces cerevisiae. The mutation of factors involved in the initial cleavage of the primary transcript at the poly(A) site (RNA 14, RNA 15, and PCF11) disrupted transcription termination at the 3' end of the CYC1 gene. In contrast, the mutation of factors involved in the subsequent polyadenylation step (PAP1, FIP1, and YTH1) had little effect. Thus, cleavage factors link transcription termination of RNA polymerase II with pre-mRNA 3'-end processing.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Basel, Biozentrum, Dept Cell Biol, CH-4056 Basel, Switzerland	University of Oxford; University of Basel	Proudfoot, NJ (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.		Minvielle-Sebastia, Lionel/M-7154-2014	Proudfoot, Nicholas/0000-0001-8646-3222	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Amrani N, 1997, MOL CELL BIOL, V17, P1102, DOI 10.1128/MCB.17.3.1102; AMRANI N, 1997, MOL CELL BIOL, V17, P3674; BARABINO ML, 1997, GENE DEV, V11, P1703; BARRY K, 1987, MOL CELL BIOL, V7, P632, DOI 10.1128/MCB.7.2.632; Birse CE, 1997, EMBO J, V16, P3633, DOI 10.1093/emboj/16.12.3633; BIRSE CE, UNPUB; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; EDWALDSGILBERT G, 1993, MOL CELL BIOL, V13, P3472, DOI 10.1128/MCB.13.6.3472; Fink G., 1991, METHOD ENZYMOL, V194, P14; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GODING CR, UNPUB; Guo ZJ, 1996, TRENDS BIOCHEM SCI, V21, P477, DOI 10.1016/S0968-0004(96)10057-8; HEIDMANN S, 1992, MOL CELL BIOL, V12, P4215, DOI 10.1128/MCB.12.9.4215; Keller W, 1997, CURR OPIN CELL BIOL, V9, P329, DOI 10.1016/S0955-0674(97)80004-X; Kessler MM, 1996, J BIOL CHEM, V271, P27167, DOI 10.1074/jbc.271.43.27167; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; LANOIX J, 1988, EMBO J, V7, P2515, DOI 10.1002/j.1460-2075.1988.tb03099.x; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; Manley JL, 1996, SCIENCE, V274, P1481, DOI 10.1126/science.274.5292.1481; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MinvielleSebastia L, 1997, P NATL ACAD SCI USA, V94, P7897, DOI 10.1073/pnas.94.15.7897; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; Preker PJ, 1997, EMBO J, V16, P4727, DOI 10.1093/emboj/16.15.4727; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; RUSSO P, 1995, YEAST, V11, P447, DOI 10.1002/yea.320110507; RUSSO P, 1989, P NATL ACAD SCI USA, V86, P8348, DOI 10.1073/pnas.86.21.8348; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; Zhao J, 1997, J BIOL CHEM, V272, P10831	36	207	208	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					298	301		10.1126/science.280.5361.298	http://dx.doi.org/10.1126/science.280.5361.298			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535662				2022-12-01	WOS:000073082400055
J	MacKinnon, R; Cohen, SL; Kuo, AL; Lee, A; Chait, BT				MacKinnon, R; Cohen, SL; Kuo, AL; Lee, A; Chait, BT			Structural conservation in prokaryotic and eukaryotic potassium channels	SCIENCE			English	Article							SHAKER K+ CHANNEL; PEPTIDE INHIBITOR; CHARYBDOTOXIN; PORE; CONDUCTANCE; MECHANISM; RECEPTOR; GEOMETRY; RESIDUES; BLOCK	Toxins from scorpion venom interact with potassium channels. Resin-attached, mutant K+ channels from Streptomyces lividans were used to screen venom from Leiurus quinquestriatus hebraeus, and the toxins that interacted with the channel were rapidly identified by mass spectrometry. One of the toxins, agitoxin2, was further studied by mutagenesis and radioligand binding. The results show that a prokaryotic K+ channel has the same pore structure as eukaryotic K+ channels. This structural conservation, through application of techniques presented here, offers a new approach for K+ channel pharmacology.	Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10021 USA.				NIGMS NIH HHS [GM43949] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043949] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Cohen SL, 1996, ANAL CHEM, V68, P31, DOI 10.1021/ac9507956; DEBIN JA, 1993, AM J PHYSL SOC, V264, pC369; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GARCIA ML, 1991, J BIOENERG BIOMEMBR, V23, P615, DOI 10.1007/BF00785814; GIANGIACOMO KM, 1992, BIOCHEMISTRY-US, V31, P6719, DOI 10.1021/bi00144a011; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KREZEL AM, 1995, PROTEIN SCI, V4, P1478, DOI 10.1002/pro.5560040805; LIPPENS G, 1995, BIOCHEMISTRY-US, V34, P13, DOI 10.1021/bi00001a003; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509	23	357	366	3	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					106	109		10.1126/science.280.5360.106	http://dx.doi.org/10.1126/science.280.5360.106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525854				2022-12-01	WOS:000072885100046
J	Davis, DL; Gottlieb, MB; Stampnitzky, JR				Davis, DL; Gottlieb, MB; Stampnitzky, JR			Reduced ratio of male to female births in several industrial countries - A sentinel health indicator?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN SEX-RATIO; AIR-POLLUTION; ABNORMALITIES; CHILDREN; EXPOSURE	Context.-The sex ratio of 1.06:1, the ratio of male to female births, has declined over the past decades. Recent reports from a number of industrialized countries indicate that the proportion of males born has significantly decreased, while some male reproductive tract disorders have increased. Objectives.-To examine the evidence for declines in the male proportion at birth and suspected causes for this decline, and to determine whether altered sex ratio can be considered a sentinel health event. Data Sources.-Birth records were analyzed from national statistical agencies. Study Selection.-Published analyses of trends in ratio of males to females at birth and studies of sex determinants evaluating epidemiological and endocrinological factors. Data Extraction.-Proportion of males born, 1950-1994 in Denmark; 1950-1994 in the Netherlands; 1970-1990 in Canada; and 1970-1990 in the United States, Data Synthesis.-Since 1950, significant declines in the proportion of males born have been reported in Denmark and the Netherlands. Similar declines have been reported for Canada and the United States since 1970 and parallel declines also have occurred in Sweden, Germany, Norway, and Finland. In Denmark, the proportion of males declined from 0.515 in 1950 to 0.513 in 1994. In the Netherlands, the proportion of males declined from 0.516 in 1950 to 0.513 in 1994, Similar declines in the proportion of males born in Canada and the United States are equivalent to a shift from male to female births of 8600 and 38 000 births, respectively. Known and hypothesized risk factors for reduced sex ratio at birth cannot fully account for recent trends. Conclusion.-Patterns of reduced sex ratio need to be carefully assessed to determine whether they are occurring more generally, whether temporal or spatial variations are evident, and whether they constitute a sentinel health event.	World Resources Inst, Washington, DC 20006 USA; Yeshiva Univ, Stern Coll Women, New York, NY 10016 USA	Yeshiva University	Davis, DL (corresponding author), World Resources Inst, 1709 New York Ave NW, Washington, DC 20006 USA.	davra@wri.org						Allan BB, 1997, CAN MED ASSOC J, V156, P37; BERKOVITZ GD, 1992, SEMIN PERINATOL, V16, P289; BRUIN KMV, 1997, LANCET, V349, P62; DAVIS DL, 1992, REPROD TOXICOL, V6, P289, DOI 10.1016/0890-6238(92)90190-5; DECOCK J, 1995, OCCUP ENVIRON MED, V52, P429; Dodds L, 1997, CAN MED ASSOC J, V156, P46; FEITOSA MF, 1992, HUM BIOL, V64, P523; Foster P. M. D., 1997, CIIT ACTIVITIES, V17, P1; GarciaRodriguez J, 1996, ENVIRON HEALTH PERSP, V104, P1090, DOI 10.2307/3433122; Garry VF, 1996, ENVIRON HEALTH PERSP, V104, P394, DOI 10.2307/3432683; GIWERCMAN A, 1993, ENVIRON HEALTH PERSP, V101, P65, DOI 10.2307/3431378; GOLDSMITH JR, 1984, ARCH ENVIRON HEALTH, V39, P85, DOI 10.1080/00039896.1984.10545840; Gustafson ML, 1995, REPROD MED SURG, P39; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; Hardell L, 1997, INT J CANCER, V73, P828; Jacobson JL, 1996, NEW ENGL J MED, V335, P783, DOI 10.1056/NEJM199609123351104; JAMES WH, 1986, J THEOR BIOL, V118, P427, DOI 10.1016/S0022-5193(86)80163-1; JAMES WH, 1995, ANN HUM GENET, V59, P243, DOI 10.1111/j.1469-1809.1995.tb00744.x; JAMES WH, 1987, HUM BIOL, V59, P721; Manning JT, 1997, NATURE, V389, P344, DOI 10.1038/38647; MILHAM S, 1993, AM J IND MED, V23, P829, DOI 10.1002/ajim.4700230516; Mocarelli P, 1996, LANCET, V348, P409, DOI 10.1016/S0140-6736(05)65030-1; Moller H, 1998, APMIS, V106, P232, DOI 10.1111/j.1699-0463.1998.tb01341.x; Moller H, 1996, LANCET, V348, P828, DOI 10.1016/S0140-6736(05)65253-1; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.1289/ehp.9710570; *NAT AC SCI, 1989, BIOL MARK REPR TOX; *NAT CTR HLTH STAT, 1996, VIT STAT US 1992 M 2, V2; *NAT CTR HLTH STAT, 1997, US 1996 1997 INJ CHA; PARKIN DM, 1997, IARC SCI PUBLICATION, V143; Paulozzi LJ, 1997, PEDIATRICS, V100, P831, DOI 10.1542/peds.100.5.831; PELLINIEMI LJ, 1994, MATERNAL FETAL ENDOC; POTASHNIK G, 1984, ANDROLOGIA, V16, P213; Pyeritz RE, 1998, JAMA-J AM MED ASSOC, V279, P269, DOI 10.1001/jama.279.4.269; RUDER A, 1985, AM J HUM GENET, V37, P362; Sas M, 1980, Orv Hetil, V121, P2807; Sharpe RM, 1995, ENVIRON HEALTH PERSP, V103, P1136, DOI 10.2307/3432610; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SHY C, 1994, ENVIRON HEALTH PERSP, V102, P316, DOI 10.1289/ehp.94102316; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.1289/ehp.96104s4741; TOPPARI J, 1995, INT WORKSH ENV PROT; WHORTON MD, 1994, OCCUP ENVIRON MED, V51, P761, DOI 10.1136/oem.51.11.761; WILLIAMS FLR, 1992, INT J EPIDEMIOL, V21, P311, DOI 10.1093/ije/21.2.311; WILLIAMS FLR, 1995, OCCUP ENVIRON MED, V52, P164, DOI 10.1136/oem.52.3.164; WYATT R, 1973, BRIT MED J, V1, P675, DOI 10.1136/bmj.1.5854.675-a; Zonta LA, 1996, HUM BIOL, V68, P415	45	233	246	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1018	1023		10.1001/jama.279.13.1018	http://dx.doi.org/10.1001/jama.279.13.1018			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533502				2022-12-01	WOS:000072669700031
J	De Felipe, C; Herrero, JF; O'Brien, JA; Palmer, JA; Doyle, CA; Smith, AJH; Laird, JMA; Belmonte, C; Cervero, F; Hunt, SP				De Felipe, C; Herrero, JF; O'Brien, JA; Palmer, JA; Doyle, CA; Smith, AJH; Laird, JMA; Belmonte, C; Cervero, F; Hunt, SP			Altered nociception, analgesia and aggression in mice lacking the receptor for substance P	NATURE			English	Article							STRESS-INDUCED ANALGESIA; PRIMARY SENSORY NEURONS; DORSAL HORN; SPINAL-CORD; RAT; ANTAGONIST; ACTIVATION; INHIBITION; INDUCTION; LOCALIZATION	The peptide neurotransmitter substance P modulates sensitivity to pain by activating the neurokinin-1 (NK-1) receptor, which is expressed by discrete populations of neurons throughout the central nervous system(1-4). Substance P is synthesized by small-diameter sensory 'pain' fibres(5), and release of the peptide into the dorsal horn of the spinal cord following intense peripheral stimulation(6) promotes central hyperexcitability and increased sensitivity to pain(7-10). However, despite the availability of specific NK-1 antagonists(4), the function of substance P in the perception of pain remains unclear Here we investigate the effect of disrupting the gene encoding the NK-1 receptor in mice, We found that the mutant mice were healthy and fertile, but the characteristic amplification ('wind up') and intensity coding of nociceptive reflexes was absent, Although substance P did not mediate the signalling of acute pain or hyperalgesia, it was essential for the full development of stress-induced analgesia and for an aggressive response to territorial challenge, demonstrating that the peptide plays an unexpected role in the adaptive response to stress.	MRC, Mol Neurobiol Lab, Div Neurobiol, Cambridge CB2 2QH, England; Univ Miguel Hernandez, Inst Neurociencias, Alicante 03080, Spain; Univ Alcala de Henares, Fac Med, Dept Fisiol, Madrid 28871, Spain; Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN); Universidad de Alcala; University of Edinburgh	Hunt, SP (corresponding author), MRC, Mol Neurobiol Lab, Div Neurobiol, Hills Rd, Cambridge CB2 2QH, England.	hunt@mrc-lmb.cam.ac.uk	de Felipe, Carmen/D-3813-2012; HUNT, STEPHEN P/C-1646-2008	Laird, Jennifer/0000-0001-6570-3995; Herrero, Juan F./0000-0003-1986-3482				Abbadie C, 1997, PAIN, V69, P101, DOI 10.1016/S0304-3959(96)03285-X; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; CERVERO F, 1985, J PHYSIOL-LONDON, V365, P223, DOI 10.1113/jphysiol.1985.sp015768; Chapman V, 1996, J NEUROPHYSIOL, V76, P1817, DOI 10.1152/jn.1996.76.3.1817; DEFELIPE C, 1995, SCIENCE, V267, P899, DOI 10.1126/science.7531367; DUGGAN AW, 1988, BRAIN RES, V451, P261, DOI 10.1016/0006-8993(88)90771-8; HERRERO JF, 1993, BRIT J PHARMACOL, V110, P303, DOI 10.1111/j.1476-5381.1993.tb13809.x; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; Konig M, 1996, NATURE, V383, P535, DOI 10.1038/383535a0; LAIRD JMA, 1993, BRIT J PHARMACOL, V109, P713, DOI 10.1111/j.1476-5381.1993.tb13632.x; MA QP, 1995, J PHYSIOL-LONDON, V486, P769, DOI 10.1113/jphysiol.1995.sp020852; MAENO H, 1993, MOL BRAIN RES, V18, P43, DOI 10.1016/0169-328X(93)90172-L; MAGGI CA, 1993, J AUTON PHARMACOL, V13, P23, DOI 10.1111/j.1474-8673.1993.tb00396.x; MANTYH PW, 1989, J NEUROSCI, V9, P258; MAREK P, 1992, BRAIN RES, V578, P197, DOI 10.1016/0006-8993(92)90248-8; MCCARTHY PW, 1989, NEUROSCIENCE, V28, P745, DOI 10.1016/0306-4522(89)90019-5; NAKAYA Y, 1994, J COMP NEUROL, V347, P249, DOI 10.1002/cne.903470208; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; Neumann S, 1996, NATURE, V384, P360, DOI 10.1038/384360a0; NOGUCHI K, 1992, J NEUROSCI, V12, P2563; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; Rupniak NMJ, 1996, PAIN, V67, P189, DOI 10.1016/0304-3959(96)03109-0; SIEGEL A, 1995, AGGRESSIVE BEHAV, V21, P49, DOI 10.1002/1098-2337(1995)21:1<49::AID-AB2480210108>3.0.CO;2-2; VANDERAH TW, 1992, J PHARMACOL EXP THER, V262, P190; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; XU XJ, 1992, EUR J PHARMACOL, V216, P337, DOI 10.1016/0014-2999(92)90428-7; YAKSH TL, 1994, TXB PAIN, P165; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	29	612	619	1	38	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 26	1998	392	6674					394	397		10.1038/32904	http://dx.doi.org/10.1038/32904			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537323				2022-12-01	WOS:000072713600053
J	Wickware, P				Wickware, P			Action at the edges in cancer research	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					417	417		10.1038/32945	http://dx.doi.org/10.1038/32945			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537329				2022-12-01	WOS:000072713600059
J	Kahn, J; Walcheck, B; Migaki, GI; Jutila, MA; Kishimoto, TK				Kahn, J; Walcheck, B; Migaki, GI; Jutila, MA; Kishimoto, TK			Calmodulin regulates L-selectin adhesion molecule expression and function through a protease-dependent mechanism	CELL			English	Article							MEMBRANE-PROXIMAL CLEAVAGE; CROSS-LINKING; GLYCOPROTEIN LIGAND-1; HUMAN NEUTROPHILS; KINASE-C; HYDRODYNAMIC SHEAR; CYTOPLASMIC DOMAIN; LEUKOCYTE ADHESION; HOMING RECEPTOR; CELL-SURFACE	Expression of the L-selectin adhesion molecule is rapidly down-regulated upon cell activation through proteolysis at a membrane-proximal site. Here we demonstrate that calmodulin, an intracellular calcium regulatory protein, specifically coprecipitates with L-selectin through a direct association with the cytoplasmic domain of L-selectin. Furthermore, calmodulin inhibitors disrupt L-selectin-dependent adhesion by inducing proteolytic release of L-selectin from the cell surface. The effects of the calmodulin inhibitors on L-selectin expression and function can be prevented by cotreatment with a hydroxamic acid-based metalloprotease inhibitor. Our results suggest a novel role for calmodulin in regulating the expression and function of an integral membrane protein through a protease-dependent mechanism. These findings may have broader implications for other cell surface proteins that also undergo regulated proteolysis.	Boehringer Ingelheim Pharmaceut Inc, Dept Immunol Dis, Ridgefield, CT 06877 USA; Montana State Univ, Vet Mol Biol Lab, Bozeman, MT 59717 USA	Boehringer Ingelheim; Montana State University System; Montana State University Bozeman	Kishimoto, TK (corresponding author), Boehringer Ingelheim Pharmaceut Inc, Dept Immunol Dis, 90 E Ridge POB 368, Ridgefield, CT 06877 USA.							ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; Allport JR, 1997, J IMMUNOL, V158, P4365; ALOBAIDI T, 1981, BIOCHIM BIOPHYS ACTA, V675, P316, DOI 10.1016/0304-4165(81)90020-9; Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; Bennett TA, 1996, J IMMUNOL, V156, P3093; BERGER M, 1985, J IMMUNOL, V135, P1342; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BRENNER B, 1996, P NATL ACAD SCI USA, V93, P15736; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CROCKETTTORABI E, 1995, J IMMUNOL, V154, P2291; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ELFERINK JGR, 1982, RES COMMUN CHEM PATH, V38, P77; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; Gnegy M E, 1995, Prog Drug Res, V45, P33; Guyer DA, 1996, FASEB J, V10, P3536; Haribabu B, 1997, J BIOL CHEM, V272, P13961, DOI 10.1074/jbc.272.21.13961; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; Hwang ST, 1996, J EXP MED, V184, P1343, DOI 10.1084/jem.184.4.1343; JONES HP, 1984, METHOD ENZYMOL, V105, P389; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAUDANNA C, 1994, J BIOL CHEM, V269, P4021; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; MCDONALD JR, 1989, J BIOL CHEM, V264, P9611; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mullberg J, 1997, FEBS LETT, V401, P235, DOI 10.1016/S0014-5793(96)01480-9; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; SIMON SI, 1995, J IMMUNOL, V155, P1502; SMITH RJ, 1981, IMMUNOLOGY, V44, P677; SOBUE K, 1983, P NATL ACAD SCI-BIOL, V80, P6868, DOI 10.1073/pnas.80.22.6868; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steeber DA, 1997, J IMMUNOL, V159, P952; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; Tu LL, 1996, J IMMUNOL, V157, P3995; VANELDIK LJ, 1984, BIOCHEM BIOPH RES CO, V124, P752, DOI 10.1016/0006-291X(84)91022-2; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; WELSH MJ, 1982, SCIENCE, V216, P642, DOI 10.1126/science.6280283; WRIGHT CD, 1987, BIOCHEM BIOPH RES CO, V142, P53, DOI 10.1016/0006-291X(87)90450-5; Zouki C, 1997, J CLIN INVEST, V100, P522, DOI 10.1172/JCI119561	65	172	178	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					809	818		10.1016/S0092-8674(00)81408-7	http://dx.doi.org/10.1016/S0092-8674(00)81408-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529256	Bronze			2022-12-01	WOS:000072661200013
J	Vahava, O; Morell, R; Lynch, ED; Weiss, S; Kagan, ME; Ahituv, N; Morrow, JE; Lee, MK; Skvorak, AB; Morton, CC; Blumenfeld, A; Frydman, M; Friedman, TB; King, MC; Avraham, KB				Vahava, O; Morell, R; Lynch, ED; Weiss, S; Kagan, ME; Ahituv, N; Morrow, JE; Lee, MK; Skvorak, AB; Morton, CC; Blumenfeld, A; Frydman, M; Friedman, TB; King, MC; Avraham, KB			Mutation in transcription factor POU4F3 associated with inherited progressive hearing loss in humans	SCIENCE			English	Article							DNA-BINDING; DOMAIN FACTORS; BRN-3 FAMILY; DEAFNESS; MOUSE; CELLS; SPECIFICITY; RECOGNITION; SUBSETS; NEURONS	The molecular basis for autosomal dominant progressive nonsyndromic hearing loss in an Israeli Jewish family, Family H, has been determined. Linkage analysis placed this deafness locus, DFNA15, on chromosome 5q31, The human homolog of mouse Pou4f3, a member of the POU-domain family of transcription factors whose targeted inactivation causes profound deafness in mice, was physically mapped to the 25-centimorgan DFNA15-linked region. An 8-base pair deletion in the POU homeodomain of human POU4F3 was identified in Family H. A truncated protein presumably impairs high-affinity binding of this transcription factor in a dominant negative fashion, leading to progressive hearing loss.	Tel Aviv Univ, Sackler Sch Med, Dept Human Genet, IL-69978 Tel Aviv, Israel; NIDCD, NIH, Bethesda, MD 20850 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; Hadassah Univ Hosp, Unit Dev Mol Biol & Genet Engn, IL-91240 Jerusalem, Israel; Chaim Sheba Med Ctr, Genet Inst, IL-52621 Tel Hashomer, Israel; Harvard Univ, Sch Med, Boston, MA 02115 USA	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Hebrew University of Jerusalem; Chaim Sheba Medical Center; Harvard University; Harvard Medical School	Avraham, KB (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Genet, IL-69978 Tel Aviv, Israel.	karena@post.tau.ac.il	Morell, Robert James/Q-2042-2019	King, Mary-Claire/0000-0001-9426-1743; Morell, Robert/0000-0003-1537-7356; Ahituv, Nadav/0000-0002-7434-8144; Avraham, Karen B/0000-0002-4913-251X	NIDCD NIH HHS [R01 DC01076, Z01 DC 00039] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001076] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; BOTFIELD MC, 1992, BIOCHEMISTRY-US, V31, P5841, DOI 10.1021/bi00140a020; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Gruber CA, 1997, MOL CELL BIOL, V17, P2391, DOI 10.1128/MCB.17.5.2391; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Maquat LE, 1996, AM J HUM GENET, V59, P279; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Morris PJ, 1997, NEUROREPORT, V8, P2041, DOI 10.1097/00001756-199705260-00047; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; NEITZEL H, 1986, HUM GENET, V73, P320, DOI 10.1007/BF00279094; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; RYAN A, COMMUNICATION; Schuknecht HF., 1993, PATHOLOGY EAR; Scott DA, 1998, NATURE, V391, P32, DOI 10.1038/34079; STEEL KP, 1994, TRENDS GENET, V10, P428, DOI 10.1016/0168-9525(94)90113-9; Theil T, 1995, J BIOL CHEM, V270, P30958, DOI 10.1074/jbc.270.52.30958; THEIL T, 1994, CYTOGENET CELL GENET, V66, P267, DOI 10.1159/000133709; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; XIA YR, 1993, GENOMICS, V18, P126, DOI 10.1006/geno.1993.1435; Xiang MQ, 1997, P NATL ACAD SCI USA, V94, P9445, DOI 10.1073/pnas.94.17.9445; XIANG MQ, 1995, J NEUROSCI, V15, P4762	36	238	260	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1998	279	5358					1950	1954		10.1126/science.279.5358.1950	http://dx.doi.org/10.1126/science.279.5358.1950			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506947				2022-12-01	WOS:000072613300050
J	Malin, MC; Carr, MH; Danielson, GE; Davies, ME; Hartmann, WK; Ingersoll, AP; James, PB; Masursky, H; McEwen, AS; Soderblom, LA; Thomas, P; Veverka, J; Caplinger, MA; Ravine, MA; Soulanille, TA				Malin, MC; Carr, MH; Danielson, GE; Davies, ME; Hartmann, WK; Ingersoll, AP; James, PB; Masursky, H; McEwen, AS; Soderblom, LA; Thomas, P; Veverka, J; Caplinger, MA; Ravine, MA; Soulanille, TA			Early views of the Martian surface from the Mars orbiter camera of Mars global surveyor	SCIENCE			English	Article							SOUTH POLAR-CAP; VALLES-MARINERIS; LAYERED DEPOSITS; RESOLUTION; VOLCANISM; REGIONS; ORIGIN; VIKING; WATER; DUNES	High-resolution images of the martian surface at scales of a few meters show ubiquitous erosional and depositional eolian landforms. Dunes, sandsheets, and drifts are prevalent and exhibit a range of morphology, composition (inferred from albedo), and age (as seen in occurrences of different dune orientations at the same location). Steep walls of topographic depressions such as canyons, valleys, and impact craters show the martian crust to be stratified at scales of a few tens of meters. The south polar layered terrain and superposed permanent ice cap display diverse surface textures that may reflect the complex interplay of volatile and non-volatile components, Low resolution regional views of the planet provide synoptic observations of polar cap retreat, condensate clouds, and the lifecycle of local and regional dust storms.	Malin Space Sci Syst, San Diego, CA 92191 USA; US Geol Survey, Menlo Park, CA 94025 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Rand Corp, Santa Monica, CA 90406 USA; Planetary Sci Inst, Tucson, AZ 85719 USA; Univ Toledo, Dept Phys & Astron, Toledo, OH 43606 USA; US Geol Survey, Flagstaff, AZ 86001 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY 14853 USA; Prama Corp, Pasadena, CA 91116 USA	United States Department of the Interior; United States Geological Survey; California Institute of Technology; RAND Corporation; University System of Ohio; University of Toledo; United States Department of the Interior; United States Geological Survey; University of Arizona; Cornell University	Malin, MC (corresponding author), Malin Space Sci Syst, POB 910148, San Diego, CA 92191 USA.							BELL JF, 1997, LUNAR PLANET SCI, V28, P87; BLASIUS RK, 1982, ICARUS, V50, P140; BRIGGS GA, 1979, J GEOPHYS RES, V84, P2795, DOI 10.1029/JB084iB06p02795; Carr M., 1981, SURFACE MARS; Carr M.H, 1996, WATER MARS; CUTTS JA, 1973, J GEOPHYS RES, V78, P4231, DOI 10.1029/JB078i020p04231; EDGETT KS, 1994, ICARUS, V112, P448, DOI 10.1006/icar.1994.1197; EDGETT KS, IN PRESS ICARUS; ERARD S, 1991, P LUNAR PLANET SCI, V21, P437; GEISSLER PE, 1990, J GEOPHYS RES-SOLID, V95, P14399, DOI 10.1029/JB095iB09p14399; GREELEY R, 1987, SCIENCE, V236, P1653, DOI 10.1126/science.236.4809.1653; GREELEY R, 1993, J GEOPHYS RES-PLANET, V98, P3183, DOI 10.1029/92JE02580; Greeley R., 1992, MARS, P730; HERKENHOFF KE, 1990, J GEOPHYS RES-SOLID, V95, P14511, DOI 10.1029/JB095iB09p14511; HUNT GE, 1981, NATURE, V293, P1; JAMES PB, 1979, J GEOPHYS RES, V84, P2889, DOI 10.1029/JB084iB06p02889; JAMES PB, 1982, ICARUS, V50, P368, DOI 10.1016/0019-1035(82)90130-0; Kahn R. A., 1992, MARS, P1017; Keating GM, 1998, SCIENCE, V279, P1672, DOI 10.1126/science.279.5357.1672; Kieffer H. H., 1992, MARS, P1180; KIEFFER HH, 1976, SCIENCE, V194, P1341, DOI 10.1126/science.194.4271.1341; LEE P, 1995, J GEOPHYS RES-PLANET, V100, P5381, DOI 10.1029/95JE00225; Lucchitta B.K., 1992, CANYON SYSTEM MARS, P453; MAHONEY JJ, 1997, GEOPHYS MONOGR SER, V100; Malin M. C., 1991, International Journal of Imaging Systems and Technology, V3, P76, DOI 10.1002/ima.1850030205; MALIN MC, 1992, J GEOPHYS RES-PLANET, V97, P7699, DOI 10.1029/92JE00340; MALIN MC, 1979, NASA C PUBL, V2072, P54; MCCAULEY JF, 1972, ICARUS, V17, P289, DOI 10.1016/0019-1035(72)90003-6; MUHLEMAN DO, 1991, SCIENCE, V253, P1508, DOI 10.1126/science.253.5027.1508; MURRAY BC, 1972, ICARUS, V17, P328, DOI 10.1016/0019-1035(72)90004-8; NEDELL SS, 1987, ICARUS, V70, P409, DOI 10.1016/0019-1035(87)90086-8; Nummedal D., 1978, CHANNELED SCABLAND; PAIGE DA, 1992, ICARUS, V99, P15, DOI 10.1016/0019-1035(92)90167-6; PLAUT JJ, 1988, ICARUS, V75, P357; Schubert G., 1992, MARS, P147, DOI [10.2307/j.ctt207g59v.9, DOI 10.2307/J.CTT207G59V.9]; SCHULTZ PH, 1988, ICARUS, V73, P91, DOI 10.1016/0019-1035(88)90087-5; SCOTT DH, 1982, J GEOPHYS RES, V87, P1179, DOI 10.1029/JB087iB02p01179; SHARP RP, 1973, J GEOPHYS RES, V78, P4063, DOI 10.1029/JB078i020p04063; SODERBLOM LA, 1973, J GEOPHYS RES, V78, P4197, DOI 10.1029/JB078i020p04197; Squyres S. W., 1992, MARS, P523; Tanaka K. L., 1992, MARS, P345; TANAKA KL, 1986, J GEOPHYS RES-SOLID, V91, pE139, DOI 10.1029/JB091iB13p0E139; Tanaka KL, 1989, P LUN PLAN SCI C, V19, P383, DOI DOI 10.1017/CB09781107415324.004; Thomas P., 1992, MARS, P767; WARD AW, 1985, J GEOPHYS RES-SOLID, V90, P2038, DOI 10.1029/JB090iB02p02038; ZIMBELMAN JR, 1987, ICARUS, V71, P257, DOI 10.1016/0019-1035(87)90151-5; Zurek R.W., 1992, MARS, P835	47	193	193	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1681	1685		10.1126/science.279.5357.1681	http://dx.doi.org/10.1126/science.279.5357.1681			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497280				2022-12-01	WOS:000072490000045
J	Deisseroth, K; Heist, EK; Tsien, RW				Deisseroth, K; Heist, EK; Tsien, RW			Translocation of calmodulin to the nucleus supports CREB phosphorylation in hippocampal neurons	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CAMP-RESPONSIVE ELEMENT; CENTRAL-NERVOUS-SYSTEM; LONG-TERM-MEMORY; C-FOS EXPRESSION; BINDING PROTEIN; PYRAMIDAL NEURONS; TRANSCRIPTION; CHANNELS; CALCIUM	Activation of the transcription factor CREB is thought to be important in the formation of long-term memory in several animal species(1-3). The phosphorylation of a serine residue at position 133 of CREB is critical for activation of CREB4. This phosphorylation is rapid when driven by brief synaptic activity in hippocampal neurons(5), It is initiated by a highly local, rise in calcium ion concentration(5) near the cell membrane, but culminates in the activation of a specific calmodulin-dependent kinase known as CaMK IV (ref. 7), which is constitutively present in the neuronal nucleus(7,8). It is unclear how the signal is conveyed from the synapse to the nucleus, We show here that brief bursts of activity cause a swift (similar to 1 min) translocation of calmodulin from the cytoplasm to the nucleus, and that this translocation is important for the rapid phosphorylation of CREB, Certain Ca2+ entry systems (L-type Ca2+ channels and NMDA receptors) are able to cause mobilization of calmodulin, whereas others (N- and P/Q-type Ca2+ channels) are not. This translocation of calmodulin provides a form of cellular communication that combines the specificity of local Ca2+ signalling with the ability to produce action at a distance.	Stanford Univ, Sch Med, Beckman Ctr Mol & Genet Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University; Stanford University	Tsien, RW (corresponding author), Stanford Univ, Sch Med, Beckman Ctr Mol & Genet Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA.							Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAHN KM, 1990, J BIOL CHEM, V265, P20335; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; Kavalali ET, 1997, NEURON, V18, P651, DOI 10.1016/S0896-6273(00)80305-0; LUBYPHELPS K, 1995, J BIOL CHEM, V270, P21532, DOI 10.1074/jbc.270.37.21532; MAGEE JC, 1995, J PHYSIOL-LONDON, V487, P67, DOI 10.1113/jphysiol.1995.sp020862; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MITSUI K, 1993, J BIOL CHEM, V268, P13422; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; PRUSCHY M, 1994, J CELL BIOL, V127, P1527, DOI 10.1083/jcb.127.6.1527; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; VENDRELL M, 1992, MOL BRAIN RES, V14, P285, DOI 10.1016/0169-328X(92)90095-S; Wang JH, 1995, J BIOL CHEM, V270, P30245, DOI 10.1074/jbc.270.51.30245; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; Xia ZG, 1996, J NEUROSCI, V16, P5425; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	30	516	562	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					198	202		10.1038/32448	http://dx.doi.org/10.1038/32448			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515967				2022-12-01	WOS:000072462700067
J	Robinson, H; Gao, YG; McCrary, BS; Edmondson, SP; Shriver, JW; Wang, AHJ				Robinson, H; Gao, YG; McCrary, BS; Edmondson, SP; Shriver, JW; Wang, AHJ			The hyperthermophile chromosomal protein Sac7d sharply kinks DNA	NATURE			English	Article							COLD-SHOCK PROTEIN; CRYSTAL-STRUCTURE; SULFOLOBUS-ACIDOCALDARIUS; BINDING PROPERTIES; MINOR-GROOVE; ARCHAEA; SOLFATARICUS; COMPLEX; HISTONE; SYSTEM	The proteins Sac7d and Sso7d belong to a class of small chromosomal proteins from the hyperthermophilic archaeon Sulfolobus acidocaldarius and S. solfactaricus, respectively(1,2). These proteins are extremely stable to heat, acid and chemical agents', Sac7d binds to DNA without any particular sequence preference and thereby increases its melting temperature by similar to 40 degrees C (ref. 4). We have now solved and refined the crystal structure of Sac7d in complex with two DNA sequences to high resolution, The structures are examples of a nonspecific DNA-binding protein bound to DNA, and reveal that Sac7d binds in the minor groove, causing a sharp kinking of the DNA helix that is more marked than that induced by an): sequence-specific DNA-binding proteins, The kink results from the intercalation of specific hydrophobic side chains of Sac7d into the DNA structure, but without causing any significant distortion of the protein structure relative to the uncomplexed protein in solution.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; So Illinois Univ, Sch Med, Dept Med Biochem, Carbondale, IL 62901 USA	University of Illinois System; University of Illinois Urbana-Champaign; Southern Illinois University System; Southern Illinois University	Wang, AHJ (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA.							BAUMANN H, 1994, NAT STRUCT BIOL, V1, P808, DOI 10.1038/nsb1194-808; BAUMANN H, 1995, J MOL BIOL, V247, P840, DOI 10.1006/jmbi.1995.0184; Brunger A. T, 1992, XPLOR 3 1 SYSTEM XRA; CHOLI T, 1988, J BIOL CHEM, V263, P7087; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P4783, DOI 10.1021/bi00641a004; Dijk J., 1986, BACTERIAL CHROMATIN, P185; EDMONDSON SP, 1995, BIOCHEMISTRY-US, V34, P13289, DOI 10.1021/bi00041a004; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Grayling RA, 1996, FEMS MICROBIOL REV, V18, P203; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCAFEE JG, 1995, BIOCHEMISTRY-US, V34, P10063, DOI 10.1021/bi00031a031; McAfee JG, 1996, BIOCHEMISTRY-US, V35, P4034, DOI 10.1021/bi952555q; McCrary BS, 1996, J MOL BIOL, V264, P784, DOI 10.1006/jmbi.1996.0677; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; RONIMUS RS, 1995, FEMS MICROBIOL LETT, V134, P79; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Starich MR, 1996, J MOL BIOL, V255, P187, DOI 10.1006/jmbi.1996.0016; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	27	156	168	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					202	205		10.1038/32455	http://dx.doi.org/10.1038/32455			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515968				2022-12-01	WOS:000072462700068
J	Lee, JO; Russo, AA; Pavletich, NP				Lee, JO; Russo, AA; Pavletich, NP			Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7	NATURE			English	Article							ONCOGENIC POINT MUTATIONS; LARGE T-ANTIGEN; GENE-PRODUCT; CELL-CYCLE; INCOMPLETE PENETRANCE; SUSCEPTIBILITY GENE; COMPLEX-FORMATION; ADENOVIRUS E1A; RB GENE; PROTEIN	The pocket domain of the retinoblastoma (Rb) tumour suppressor is central to Rb function, and is frequently inactivated by the binding of the human papilloma virus E7 oncoprotein in cervical cancer. The crystal structure of the Rb pocket bound to a nine-residue E7 peptide containing the LxCxE motif, shared by other Rb-binding viral and cellular proteins, shows that the LxCxE peptide binds a highly conserved groove on the B-box portion of the pocket; the A-box portion appears to be required for the stable folding of the B box. Also highly consented is the extensive A-B interface, suggesting that it may be an additional protein-binding site. The A and B boxes each contain the cyclin-fold structural motif, with the LxCxE-binding site on the B-box cyclin fold being similar to a Cdk2-binding site of cyclin A and to a TBP-binding site of TFIIB.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	Nikola@xray2.mskcc.org	Lee, Jie-Oh/C-1581-2011; Lee, Jie-Oh/AAG-4302-2020	Lee, Jie-Oh/0000-0001-6519-6049				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P946, DOI 10.1093/nar/22.6.946; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Grafi G, 1996, P NATL ACAD SCI USA, V93, P8962, DOI 10.1073/pnas.93.17.8962; Gulliver GA, 1997, J VIROL, V71, P5905, DOI 10.1128/JVI.71.8.5905-5914.1997; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES RE, 1990, J BIOL CHEM, V265, P12782; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; Kim HY, 1997, NAT STRUCT BIOL, V4, P390, DOI 10.1038/nsb0597-390; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KRATZKE RA, 1994, ONCOGENE, V9, P1321; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; OCONNOR RJ, 1994, J VIROL, V68, P6848, DOI 10.1128/JVI.68.11.6848-6862.1994; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	48	350	363	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	1998	391	6670					859	865		10.1038/36038	http://dx.doi.org/10.1038/36038			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495340				2022-12-01	WOS:000072230900042
J	White, RH; Zhou, H; Romano, PS				White, RH; Zhou, H; Romano, PS			Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California	ANNALS OF INTERNAL MEDICINE			English	Article							EPIDEMIOLOGY; COAGULATION	Background: Few studies have compared the incidence of deep venous thrombosis among ethnic groups. Objective: To determine the incidence of deep venous thrombosis among ethnic groups. Design: Analysis of the linked California Patient Discharge Data Set from 1991 to 1994. Setting: California. Patients: 17 991 patients with idiopathic deep venous thrombosis (thrombosis without cancer or hospitalization within preceding 6 months) and 5573 patients with secondary thromboembolism (thromboembolism occurring within 3 months of seven different events). Measurements: Ethnicity was determined by using race as documented in the data set. For idiopathic deep venous thrombosis, standardized age- and sex-adjusted incidences were calculated. For secondary thromboembolism, proportional hazards modeling was done. Results: The annual incidence of idiopathic deep venous thrombosis per 1 000 000 persons older than 18 years of age was 230 for white persons, 293 for African Americans (rate ratio, 1.27 [95% CI, 1.07 to 1.51]), 139 for Hispanic persons (rate ratio, 0.60 [CI, 0.54 to 0.67]), and 60 for Asians and Pacific Islanders (rate ratio, 0.26 [CI, 0.22 to 0.30]). Compared with white persons, Asians and Pacific Islanders who developed secondary thromboembolism had a significantly lower relative risk (range, 0.22 to 0.61) for all seven conditions analyzed. Conclusions: Compared with white persons, Asians and Pacific Islanders have a very low incidence of idiopathic deep venous thrombosis and a very low relative risk for secondary venous thromboembolism.	Univ Calif Davis, Sacramento, CA 95817 USA	University of California System; University of California Davis	White, RH (corresponding author), Primary Care Ctr, Room 3107,2221 Stockton Blvd, Sacramento, CA 95817 USA.		Romano, Patrick S/N-4225-2014	Romano, Patrick S/0000-0001-6749-3979				ATICHARTAKARN V, 1988, ARCH INTERN MED, V148, P1349, DOI 10.1001/archinte.148.6.1349; *CENS BUR, 1992, 1990 CENS POP HOUS; CUNNINGHAM IG, 1974, BRIT J SURG, V61, P482, DOI 10.1002/bjs.1800610616; DUTHIE SJ, 1989, BRIT J OBSTET GYNAEC, V96, P4, DOI 10.1111/j.1471-0528.1989.tb01568.x; INADA K, 1983, AM J SURG, V145, P775, DOI 10.1016/0002-9610(83)90138-1; KATZ MH, 1993, J GEN INTERN MED, V8, P702, DOI 10.1007/BF02598295; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861, DOI 10.1001/archinte.154.8.861; Lauderdale DS, 1996, AM J PUBLIC HEALTH, V86, P712, DOI 10.2105/AJPH.86.5.712; MEUX EF, 1990, EVALUATION RELIABILI; NANDI P, 1980, BRIT J SURG, V67, P251, DOI 10.1002/bjs.1800670407; NATHWANI AC, 1992, BAILLIERE CLIN HAEM, V5, P383, DOI 10.1016/S0950-3536(11)80025-9; Price DT, 1997, ANN INTERN MED, V127, P895, DOI 10.7326/0003-4819-127-10-199711150-00007; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; Ridker PM, 1997, JAMA-J AM MED ASSOC, V277, P1305, DOI 10.1001/jama.277.16.1305; ROTHMAN K, 1986, MODERN EPIDEMIOLOGY, P211; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P41; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; TSO SC, 1980, BRIT J HAEMATOL, V46, P603, DOI 10.1111/j.1365-2141.1980.tb06018.x	18	271	278	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1998	128	9					737	740		10.7326/0003-4819-128-9-199805010-00006	http://dx.doi.org/10.7326/0003-4819-128-9-199805010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK790	9556467				2022-12-01	WOS:000073363800005
J	Kumar, S; Hedges, SB				Kumar, S; Hedges, SB			A molecular timescale for vertebrate evolution	NATURE			English	Article							CLOCK; DIVERGENCE; PHYLOGENY; ORIGINS; MAMMALS	A timescale is necessary for estimating rates of molecular and morphological change in organisms and for interpreting patterns of macroevolution and biogeography(1-9). Traditionally, these times have been obtained from the fossil record, where the earliest representatives of two lineages establish a minimum time of divergence of these lineages(10). The clock-like accumulation of sequence differences in some genes provides an alternative method(11) by which the mean divergence time can be estimated. Estimates from single genes may have large statistical errors, but multiple genes can be studied to obtain a more reliable estimate of divergence time(1,12-13). However, until recently, the number of genes available for estimation of divergence time has been limited. Here we present divergence-time estimates for mammalian orders and major lineages of vertebrates, from an analysis of 658 nuclear genes. The molecular times agree with most early (Palaeozoic) and late (Cenozoic) fossil-based times, but indicate major gaps in the Mesozoic fossil record. At least five lineages of placental mammals arose more than 100 million years ago, and most of the modern orders seem to have diversified before the Cretaceous/Tertiary extinction of the dinosaurs.	Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA; Penn State Univ, Inst Mol Evolutionary Genet, Mueller Lab 208, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Hedges, SB (corresponding author), Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA.		Kumar, Sudhir/F-1411-2011	Kumar, Sudhir/0000-0002-9918-8212				[Anonymous], 1993, MEGA MOL EVOLUTIONAR; Archibald JD, 1996, SCIENCE, V272, P1150, DOI 10.1126/science.272.5265.1150; Avise John C., 1994, pi; Benefit BR, 1997, NATURE, V388, P368, DOI 10.1038/41078; BENTON MJ, 1990, J MOL EVOL, V30, P409, DOI 10.1007/BF02101113; Benton MJ, 1997, VERTEBRATE PALEONTOL; BENTON MJ, 1993, FOSSIL RECORD, V2; Carroll RL., 1988, VERTEBRATE PALEONTOL; Cooper A, 1997, SCIENCE, V275, P1109, DOI 10.1126/science.275.5303.1109; DURET L, 1994, NUCLEIC ACIDS RES, V22, P2360, DOI 10.1093/nar/22.12.2360; Easteal S., 1995, MAMMALIAN MOL CLOCK; Gee C. H. R., COMMUNICATION; Gerhart J, 1997, CELLS EMBRYOS EVOLUT; Gheerbrant E, 1996, NATURE, V383, P68, DOI 10.1038/383068a0; Hallam A, 1995, OUTLINE PHANEROZOIC; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; JAEGER JJ, 1986, CR ACAD SCI II, V302, P917; Kay RF, 1997, SCIENCE, V275, P797, DOI 10.1126/science.275.5301.797; Kielan-Jaworowska Z., 1992, Historical Biology, V6, P185; MARTIN RD, 1993, NATURE, V363, P223, DOI 10.1038/363223a0; Nei M., 1987, MOL EVOLUTIONARY GEN; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; PARKER PH, 1996, THESIS PENNSYLVANIA; Pilbeam D, 1996, MOL PHYLOGENET EVOL, V5, P155, DOI 10.1006/mpev.1996.0010; Springer MS, 1997, NATURE, V388, P61, DOI 10.1038/40386; TAJIMA F, 1993, GENETICS, V135, P599; TAKEZAKI N, 1995, MOL BIOL EVOL, V12, P823; Ward Steve, 1997, P269; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; ZUCKERKANDL E, 1987, J MOL EVOL, V26, P34, DOI 10.1007/BF02111280	30	1552	1594	3	375	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					917	920		10.1038/31927	http://dx.doi.org/10.1038/31927			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582070				2022-12-01	WOS:000073359900047
J	Akhter, SA; Luttrell, LM; Rockman, HA; Iaccarino, G; Lefkowitz, RJ; Koch, WJ				Akhter, SA; Luttrell, LM; Rockman, HA; Iaccarino, G; Lefkowitz, RJ; Koch, WJ			Targeting the receptor-G(q) interface to inhibit in vivo pressure overload myocardial hypertrophy	SCIENCE			English	Article							CARDIAC GENE-EXPRESSION; VENTRICULAR MYOCYTES; PATHWAYS MEDIATE; MICE; CARDIOMYOCYTES; INDUCTION; MECHANISM; KINASE	Hormones and neurotransmitters may mediate common responses through receptors that couple to the same class of heterotrimeric guanine nucleotide-binding (G) protein. For example, several receptors that couple to G(q) class proteins can induce cardiomyocyte hypertrophy. Class-specific inhibition of G(q)-mediated signaling was produced in the hearts of transgenic mice by targeted expression of a carboxyl-terminal peptide of the alpha subunit G alpha(q). When pressure overload was surgically induced, the transgenic mice developed significantly less ventricular hypertrophy than control animals. The data demonstrate the role of myocardial G(q) in the initiation of myocardial hypertrophy and indicate a possible strategy for preventing pathophysiological signaling by simultaneously blocking multiple receptors coupled to G(q).	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Univ N Carolina, Dept Med Cardiol, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Koch, WJ (corresponding author), Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.	koch0002@mc.duke.edu	IACCARINO, Guido/A-7702-2010; Iaccarino, Guido/D-4540-2009; Lefkowitz, Robert/AAW-2649-2021	IACCARINO, Guido/0000-0002-8997-835X; Iaccarino, Guido/0000-0002-8997-835X; Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, K08HL003041, F32HL009436, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-03041, HL-16037, HL-09436] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKHTER SA, UNPUB; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITO H, 1994, CIRCULATION, V89, P2198, DOI 10.1161/01.CIR.89.5.2198; KNOWLTON KU, 1995, J CLIN INVEST, V96, P1311, DOI 10.1172/JCI118166; Koch WJ, 1996, CIRC RES, V78, P511, DOI 10.1161/01.RES.78.4.511; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; ROCKMAN HA, 1994, AM J PHYSIOL, V266, pH2468, DOI 10.1152/ajpheart.1994.266.6.H2468; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023	22	380	393	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1998	280	5363					574	577		10.1126/science.280.5363.574	http://dx.doi.org/10.1126/science.280.5363.574			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554846				2022-12-01	WOS:000073242100043
J	Lacey, DL; Timms, E; Tan, HL; Kelley, MJ; Dunstan, CR; Burgess, T; Elliott, R; Colombero, A; Elliott, G; Scully, S; Hsu, H; Sullivan, J; Hawkins, N; Davy, E; Capparelli, C; Eli, A; Qian, YX; Kaufman, S; Sarosi, I; Shalhoub, V; Senaldi, G; Guo, J; Delaney, J; Boyle, WJ				Lacey, DL; Timms, E; Tan, HL; Kelley, MJ; Dunstan, CR; Burgess, T; Elliott, R; Colombero, A; Elliott, G; Scully, S; Hsu, H; Sullivan, J; Hawkins, N; Davy, E; Capparelli, C; Eli, A; Qian, YX; Kaufman, S; Sarosi, I; Shalhoub, V; Senaldi, G; Guo, J; Delaney, J; Boyle, WJ			Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation	CELL			English	Article							BONE-RESORPTION; IDENTIFICATION; CULTURES; MATRIX	The ligand for osteoprotegerin has been identified, and it is a TNF-related cytokine that replaces the requirement for stromal cells, vitamin D3, and glucocorticoids in the coculture model of in vitro osteoclastogenesis. OPG ligand (OPGL) binds to a unique hematopoeitic progenitor cell that is committed to the osteoclast lineage and stimulates the rapid induction of genes that typify osteoclast development. OPGL directly activates isolated mature osteoclasts in vitro, and shortterm administration into normal adult mice results in osteoclast activation associated with systemic hypercalcemia. These data suggest that OPGL is an osteoclast differentiation and activation factor. The effects of OPGL are blocked in vitro and in vivo by OPG, suggesting that OPGL and OPG are key extracellular regulators of osteoclast development.	Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Prot Chem, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Mammalian Cell Mol Biol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Bacterial Express, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Proc Sci, Thousand Oaks, CA 91320 USA	Amgen; Amgen; Amgen; Amgen; Amgen; Amgen	Boyle, WJ (corresponding author), Amgen Inc, Dept Cell Biol, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.		Dunstan, Colin/G-6214-2013	Dunstan, Colin/0000-0001-7586-4071; Sullivan, John/0000-0001-9840-852X				ABE E, 1986, P NATL ACAD SCI USA, V83, P5958, DOI 10.1073/pnas.83.16.5958; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ARNETT TR, 1986, ENDOCRINOLOGY, V119, P119, DOI 10.1210/endo-119-1-119; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; CHEN PCH, 1995, J BIOL CHEM, V270, P2874, DOI 10.1074/jbc.270.6.2874; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; EVANS RA, 1979, MINER ELECTROL METAB, V2, P179; FULLER K, 1991, BIOCHEM BIOPH RES CO, V181, P67, DOI 10.1016/S0006-291X(05)81382-8; HENTUNEN TA, 1994, BONE MINER, V25, P183, DOI 10.1016/S0169-6009(08)80238-3; HORTON JE, 1972, SCIENCE, V177, P793, DOI 10.1126/science.177.4051.793; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; LACEY DL, 1995, ENDOCRINOLOGY, V136, P2367, DOI 10.1210/en.136.6.2367; LEE MY, 1991, P NATL ACAD SCI USA, V88, P8500, DOI 10.1073/pnas.88.19.8500; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; Udagawa N, 1996, BONE, V18, P511, DOI 10.1016/8756-3282(96)00076-2; WILCOX JN, 1993, J HISTOCHEM CYTOCHEM, V41, P1725, DOI 10.1177/41.12.8245419; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; YONEDA T, 1993, J PERIODONTAL RES, V28, P521, DOI 10.1111/j.1600-0765.1993.tb02117.x	24	4251	4553	12	204	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					165	176		10.1016/S0092-8674(00)81569-X	http://dx.doi.org/10.1016/S0092-8674(00)81569-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568710	Bronze			2022-12-01	WOS:000073174000004
J	Herrada, J; Cabanillas, F; Rice, L; Manning, J; Pugh, W				Herrada, J; Cabanillas, F; Rice, L; Manning, J; Pugh, W			The clinical behavior of localized and multicentric Castleman disease	ANNALS OF INTERNAL MEDICINE			English	Review							LYMPH-NODE HYPERPLASIA; SYSTEMIC MANIFESTATIONS; KAPOSIS SARCOMA; POEMS SYNDROME; INTERLEUKIN-6; EXPRESSION; RADIOTHERAPY	Background: Castleman disease, an unusual condition of unknown cause consisting of a massive proliferation of lymphoid tissue, remains a clinicopathologic diagnosis. Three histologic variants (hyaline vascular, plasma-cell, and mixed) and two clinical types (localized and multicentric) of Castleman disease have been described. Objective: To analyze the clinical features, management, and outcome of patients with Castleman disease. Design: Case series. Setting: University referral hospitals. Patients: All patients with Castleman disease who were seen at Texas Medical Center, Houston, Texas, between 1977 and 1995. Interventions: Surgical excision for localized disease; surgery, combination chemotherapy, or prednisone for multicentric disease. Measurements: Patients were identified according to initial presentation as having localized or multicentric Castleman disease. Patients within each group were further subdivided according to whether they had hyaline vascular, plasma-cell, or mixed disease. Results: Data from 15 patients were analyzed. All 7 patients with localized disease underwent surgical excision and remain free of disease. The 8 patients with multicentric disease were further subdivided according to initial treatment: Three patients who received combination chemotherapy are currently alive and free of disease; 2 patients treated with prednisone are alive but have needed intermittent maintenance therapy for disease reactivations; and 2 patients treated with surgery only have died, 1 of infectious complications and 1 of non-Hodgkin lymphoma. Conclusions: Localized and multicentric Castleman disease are different clinical disorders with overlapping histologic features. Localized disease can be cured with surgery, but complete remissions in patients with multicentric disease have been achieved only with chemotherapy or prednisone given at the time of diagnosis.	Univ Texas, Md Anderson Canc Ctr, Dept Hematol, Lymphoma Sect,Baylor Coll Med, Houston, TX 77030 USA; Baylor Coll Med, Methodist Hosp, Hematol Oncol Sect, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston	Cabanillas, F (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Hematol, Lymphoma Sect,Baylor Coll Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Cabanillas, Fernando/0000-0001-9234-7893				AISENBERG AC, 1991, MALIGNANT LYMPHOMA B, P11; BARDWICK PA, 1980, MEDICINE, V59, P311, DOI 10.1097/00005792-198007000-00006; BARTOLI E, 1980, AM J CLIN PATHOL, V73, P423; BECK JT, 1994, NEW ENGL J MED, V330, P602, DOI 10.1056/NEJM199403033300904; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; CASTLEMAN B, 1956, CANCER, V9, P822, DOI 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4; CHAN TM, 1993, NEPHRON, V65, P628, DOI 10.1159/000187576; CROS D, 1990, NEW ENGL J MED, V323, P895; FEIGERT JM, 1990, ANN INTERN MED, V113, P362, DOI 10.7326/0003-4819-113-5-362; Flendrig J., 1969, FOLIA MED NEERD, V12, P119; FRIZZERA G, 1985, J CLIN ONCOL, V3, P1202, DOI 10.1200/JCO.1985.3.9.1202; FRIZZERA G, 1988, SEMIN DIAGN PATHOL, V5, P346; FRIZZERA G, 1992, NEOPLASTIC HEMATOPAT, P454; GABA AR, 1978, AM J CLIN PATHOL, V69, P86; GILI A, 1991, J AM ACAD DERMATOL, V25, P955, DOI 10.1016/0190-9622(91)70293-B; HANCHARD B, 1987, W INDIAN MED J, V36, P104; HSU SM, 1993, HUM PATHOL, V24, P833, DOI 10.1016/0046-8177(93)90132-Z; KELLER AR, 1972, CANCER-AM CANCER SOC, V29, P670, DOI 10.1002/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#; KESSLER E, 1985, CANCER-AM CANCER SOC, V56, P2446, DOI 10.1002/1097-0142(19851115)56:10<2446::AID-CNCR2820561020>3.0.CO;2-4; LACHANT NA, 1985, AM J CLIN PATHOL, V83, P27, DOI 10.1093/ajcp/83.1.27; LEGERRAVET MB, 1991, BLOOD, V78, P2923; LOTZ M, 1993, CANCER INVEST, V11, P732, DOI 10.3109/07357909309046948; MARTI S, 1983, CANCER, V51, P808, DOI 10.1002/1097-0142(19830301)51:5<808::AID-CNCR2820510510>3.0.CO;2-5; MARTIN JME, 1985, AM J CLIN PATHOL, V84, P439, DOI 10.1093/ajcp/84.4.439; MUNOZ G, 1990, HISTOPATHOLOGY, V17, P172, DOI 10.1111/j.1365-2559.1990.tb00692.x; NAKANISHI T, 1984, NEUROLOGY, V34, P712, DOI 10.1212/WNL.34.6.712; NORDSTROM DG, 1978, INT J RADIAT ONCOL, V4, P1045, DOI 10.1016/0360-3016(78)90019-6; ORDI J, 1993, AM J CLIN PATHOL, V100, P394, DOI 10.1093/ajcp/100.4.394; PAVLIDIS NA, 1990, MED PEDIATR ONCOL, V18, P333, DOI 10.1002/mpo.2950180416; PAVLIDIS NA, 1992, ANN ONCOL, V3, P85, DOI 10.1093/oxfordjournals.annonc.a058082; PETERSON BA, 1993, SEMIN ONCOL, V20, P636; REPETTO L, 1986, HEMATOL ONCOL, V4, P213, DOI 10.1002/hon.2900040305; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; STEINBERG D, 1992, NEW ENGL J MED, V327, P1014; SUMMERFIELD GP, 1983, J CLIN PATHOL, V36, P1005, DOI 10.1136/jcp.36.9.1005; Ushio T, 1994, Nihon Kyobu Shikkan Gakkai Zasshi, V32, P1175; WEISENBURGER DD, 1985, HUM PATHOL, V16, P162, DOI 10.1016/S0046-8177(85)80065-4; WEISENBURGER DD, 1979, CANCER, V44, P457, DOI 10.1002/1097-0142(197908)44:2<457::AID-CNCR2820440212>3.0.CO;2-4; YOSHIZAKI K, 1989, BLOOD, V74, P1360	39	298	324	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					657	662		10.7326/0003-4819-128-8-199804150-00010	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537940				2022-12-01	WOS:000073052500007
J	Garvican, L; Grimsey, E; Littlejohns, P; Lowndes, S; Sacks, N				Garvican, L; Grimsey, E; Littlejohns, P; Lowndes, S; Sacks, N			Satisfaction with clinical nurse specialists in a breast care clinic: Questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Univ London St Georges Hosp, Breast Unit, London SW17 0QT, England; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, Hlth Care Evaluat Unit, London SW17 0RE, England	St Georges University London; St Georges University London	Garvican, L (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, Hlth Care Evaluat Unit, London SW17 0RE, England.							*BRIT ASS SURG ONC, 1995, EUR J SURG ONCOL S, V21, pA13; BROWN LA, 1991, CYTOPATHOLOGY, V2, P1, DOI 10.1111/j.1365-2303.1991.tb00377.x; English T, 1997, BRIT MED J, V314, P661, DOI 10.1136/bmj.314.7081.661; HAMMOND C, 1994, THESIS U SURREY; WATSON M, 1988, COUNSEL PSYCHOL Q, V1, P25	5	28	28	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					976	+		10.1136/bmj.316.7136.976	http://dx.doi.org/10.1136/bmj.316.7136.976			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550957	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000072856100021
J	McConnell, J; Horton, R				McConnell, J; Horton, R			The Lancet and the Internet, mark II	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		McConnell, J (corresponding author), Lancet, London WC1B 3SL, England.			McConnell, John/0000-0002-9928-6568					0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					852	852						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525360				2022-12-01	WOS:000072645500009
J	Lin, L; DeMartino, GN; Greene, WC				Lin, L; DeMartino, GN; Greene, WC			Cotranslational biogenesis of NF-kappa B p50 by the 26S proteasome	CELL			English	Article							NASCENT POLYPEPTIDE-CHAINS; DNA-BINDING SUBUNIT; MOLECULAR CHAPERONES; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; PRECURSOR P105; BETA-LACTONE; IN-VIVO; PROTEIN	The NFKB1 gene encodes two functionally distinct proteins termed p50 and p105. p50 corresponds to the N terminus of p105 and with p65 (RelA) forms the prototypical NF-kappa B transcription factor complex. In contrast, p105 functions as a Rel-specific inhibitor (I kappa B) and has been proposed to be the precursor of p50. Our studies now demonstrate that p50 is generated by a unique cotranslational processing event involving the 26S proteasome, whereas cotranslational folding of sequences near the C terminus of p50 abrogates proteasome processing acid leads to p105 production. These results indicate that p105 is not the precursor of p50 and reveal a novel mechanism of gene regulation that ensures the balanced production and independent function of the p50 and p105 proteins.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Immunol & Microbiol, San Francisco, CA 94141 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lin, L (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA.				NIAID NIH HHS [P30AI27763] Funding Source: Medline; NIDDK NIH HHS [R01 DK46181] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046181] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dick LR, 1997, J BIOL CHEM, V272, P182; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; HANSEN WJ, 1994, J BIOL CHEM, V269, P26610; Harhaj EW, 1996, ONCOGENE, V12, P2385; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE JI, 1992, CELL, V66, P1109; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Komar AA, 1997, J BIOL CHEM, V272, P10646; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Lin L, 1996, MOL CELL BIOL, V16, P2248; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; NEUMANN M, 1993, EMBO J, V12, P213; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cellbio.10.1.405; STEWART ML, 1971, P NATL ACAD SCI USA, V68, P97, DOI 10.1073/pnas.68.1.97; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; WEISSMAN JS, 1995, SCIENCE, V268, P523, DOI 10.1126/science.7725096	63	241	248	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					819	828		10.1016/S0092-8674(00)81409-9	http://dx.doi.org/10.1016/S0092-8674(00)81409-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529257	Bronze			2022-12-01	WOS:000072661200014
J	Waldrip, WR; Bikoff, EK; Hoodless, PA; Wrana, JL; Robertson, EJ				Waldrip, WR; Bikoff, EK; Hoodless, PA; Wrana, JL; Robertson, EJ			Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo	CELL			English	Article							BONE-MORPHOGENETIC PROTEIN-4; GERM LAYER FORMATION; STEM-CELLS; MAD PROTEINS; TRANSCRIPTION FACTOR; MESODERM FORMATION; NEURAL PLATE; VG1 PROTEIN; GENE; ENDODERM	Smad proteins transmit TGF beta signals from the cell surface to the nucleus. Here we analyze Smad2 mutant embryos created using ES cell technology. Smad2 function is not required for mesoderm production per se, but, rather unexpectedly, in the absence of Smad2 the entire epiblast adopts a mesodermal fate giving rise to a normal yolk sac and fetal blood cells. In contrast, Smad2 mutants entirely lack tissues of the embryonic germ layers. Smad2 signals serve to restrict the site of primitive streak formation and establish anterior-posterior identity within the epiblast. Chimera experiments demonstrate these essential activities are contributed by the extraembryonic tissues. Thus, the extraembryonic tissues play critical roles in establishing the body plan during early mouse development.	Harvard Univ, Dept Mol & Cell Biol, Cambridge, MA 02138 USA; Hosp Sick Children, Div Gastroenterol, Program Dev Biol, Toronto, ON M5G 1X8, Canada	Harvard University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Robertson, EJ (corresponding author), Harvard Univ, Dept Mol & Cell Biol, Cambridge, MA 02138 USA.		Wrana, Jeffrey/F-8857-2013	Hoodless, Pamela/0000-0003-1371-0725	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025208] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25208] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, DEVELOPMENT, V120, P2979; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BARON MH, 1994, MOL CELL BIOL, V14, P3108, DOI 10.1128/MCB.14.5.3108; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P131; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; CONLON FL, 1991, DEVELOPMENT, V111, P969; CONLON FL, 1994, DEVELOPMENT, V120, P1919; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DZIADEK M, 1978, J EMBRYOL EXP MORPH, V46, P135; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heasman J, 1997, DEVELOPMENT, V124, P4179; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hermesz E, 1996, DEVELOPMENT, V122, P41; Hogan B., 2014, MANIPULATING MOUSE E; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; JONES CM, 1991, DEVELOPMENT, V111, P531; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAWSON KA, 1987, DEVELOPMENT, V101, P627; LAWSON KA, 1991, DEVELOPMENT, V113, P891; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MARCIASSILVA M, 1996, CELL, V87, P1215; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Popperl H, 1997, DEVELOPMENT, V124, P2997; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; ROSENQUIST TA, 1995, MECH DEVELOP, V49, P117, DOI 10.1016/0925-4773(94)00308-A; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Rossant Janet, 1995, Seminars in Developmental Biology, V6, P237, DOI 10.1016/S1044-5781(06)80049-6; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; THOMAS P, 1997, IN PRESS COLD SPRING, V62; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VARIET I, 1997, DEVELOPMENT, V122, P1033; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILKINSON DG, 1992, HYBRIDIZATION PRACTI, P75; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Zhang HB, 1996, DEVELOPMENT, V122, P2977; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	69	385	400	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					797	808		10.1016/S0092-8674(00)81407-5	http://dx.doi.org/10.1016/S0092-8674(00)81407-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529255	Bronze			2022-12-01	WOS:000072661200012
J	Camps, M; Nichols, A; Gillieron, C; Antonsson, B; Muda, M; Chabert, C; Boschert, U; Arkinstall, S				Camps, M; Nichols, A; Gillieron, C; Antonsson, B; Muda, M; Chabert, C; Boschert, U; Arkinstall, S			Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase	SCIENCE			English	Article							DUAL-SPECIFICITY PHOSPHATASE; SIGNAL-REGULATED KINASE; OF-FUNCTION MUTATION; MAP KINASE; TYROSINE-PHOSPHATASE; GENE-PRODUCT; TRANSFORMATION; EXPRESSION; CELLS	MAP kinase phosphatase-3 (MKP-3) dephosphorylates phosphotyrosine and phosphothreonine and inactivates selectively ERK family mitogen-activated protein (MAP) kinases. MKP-3 was activated by direct binding to purified ERK2. Activation was independent of protein kinase activity and required binding of ERK2 to the noncatalytic amino-terminus of MKP-3. Neither the gain-of-function Sevenmaker ERK2 mutant D319N nor c-Jun amino-terminal kinase-stress-activated protein kinase (JNK/SAPK) or p38 MAP kinases bound MKP-3 or caused its catalytic activation. These kinases were also resistant to enzymatic inactivation by MKP-3. Another homologous but nonselective phosphatase, MKP-4, bound and was activated by ERK2, JNK/SAPK, and p38 MAP kinases. Catalytic activation of MAP kinase phosphatases through substrate binding may regulate MAP kinase activation by a large number of receptor systems.	Glaxo Wellcome Res & Dev SA, Geneva Biomed Res Inst, CH-1228 Geneva, Switzerland	GlaxoSmithKline	Arkinstall, S (corresponding author), Glaxo Wellcome Res & Dev SA, Geneva Biomed Res Inst, CH-1228 Geneva, Switzerland.			Camps, Montserrat/0000-0002-9849-8657				BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CAMPS M, UNPUB; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Kornhauser JM, 1997, NEURON, V18, P839, DOI 10.1016/S0896-6273(00)80322-0; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; MUDA M, 1998, EMBO J, V273, P9323; Reszka AA, 1997, MOL BIOL CELL, V8, P1219, DOI 10.1091/mbc.8.7.1219; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	28	421	430	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1262	1265		10.1126/science.280.5367.1262	http://dx.doi.org/10.1126/science.280.5367.1262			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596579				2022-12-01	WOS:000073852500048
J	Baker, EH; Dong, YB; Sagnella, GA; Rothwell, M; Onipinla, AK; Markandu, ND; Cappuccio, FP; Cook, DG; Persu, A; Corvol, P; Jeunemaitre, X; Carter, ND; MacGregor, GA				Baker, EH; Dong, YB; Sagnella, GA; Rothwell, M; Onipinla, AK; Markandu, ND; Cappuccio, FP; Cook, DG; Persu, A; Corvol, P; Jeunemaitre, X; Carter, ND; MacGregor, GA			Association of hypertension with T594M mutation in beta subunit of epithelial sodium channels in black people resident in London	LANCET			English	Article							LIDDLES SYNDROME; GAMMA-SUBUNIT	Background. Liddle's syndrome is a rare inherited form of hypertension in which mutations of the epithelial sodium channel result in increased renal sodium reabsorption. Essential hypertension in black patients also shows clinical features of sodium retention so we screened black people for the T594M mutation, the most commonly identified sodium-channel mutation. Methods. In a case-control study, 206 hypertensive (mean age 48.0 [SD 11.8] years, men:women 80:126) and 142 normotensive (48.7 [7.4] years; 61:81) black people who lived in London, UK, were screened for T594M. Part of the last exon of the epithelial sodium-channel beta subunit from genomic DNA was amplified by PCR. The T594M variant was detected by single-strand conformational polymorphism analysis of PCR products and confirmed by DNA sequencing. Findings. 17 (8.3%) of 206 hypertensive participants compared with three (2.1%) of 142 normotensive partcipants possessed the T594M variant (odds ratio [OR]=4.17 [95% CI 1.12-18.25], p = 0.029). A high proportion of participants with the T594M variant were women (15 of 17 hypertensive participants and all three normotensive participants), whereas women comprised a lower proportion of the individuals screened (61.2% hypertensive, 57.7% normotensive). However, the association between the T594M variant and hypertension persisted after adjustment for sex and body-mass index (Mantel-Haenszel OR=5.52 [1.40-30.61], p = 0.012). Plasma renin activity was significantly lower in 13 hypertensive participants with the T594M variant (median=0.19 ng mL(-1) h(-1)) than in 39 untreated hypertensive individuals without the variant (median=0.45 ng mL(-1) h(-1), p=0.009). Interpretation. Among black London people the T594M sodium-channel beta subunit mutation occurs more frequently in people with hypertension than those without. The T594M variant may increase sodium-channel activity and could raise blood pressure in affected people by increasing renal tubular sodium reabsorption. These findings suggest that the T594M mutation could be the most common secondary cause of essential hypertension in black people identified to date.	St George Hosp, Sch Med, Dept Pharmacol, London SW17 0RE, England; St George Hosp, Sch Med, Blood Pressure Unit, London SW17 0RE, England; St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; St George Hosp, Sch Med, Med Genet Unit, London SW17 0RE, England; Coll France, INSERM, U36, F-75231 Paris, France	St Georges University London; St Georges University London; St Georges University London; St Georges University London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Baker, EH (corresponding author), St George Hosp, Sch Med, Dept Pharmacol, London SW17 0RE, England.	ebaker@sghms.ac.uk	JEUNEMAITRE, Xavier/AAQ-4853-2021; Cappuccio, Francesco/D-3028-2009; Cappuccio, Francesco Paolo/ABF-1094-2020	JEUNEMAITRE, Xavier/0000-0001-5925-381X; Cappuccio, Francesco Paolo/0000-0002-7842-5493; Baker, Emma/0000-0002-0871-3721; Persu, Alexandre/0000-0002-4007-9695; Cook, Derek/0000-0002-9723-5759				[Anonymous], 1985, J HYPERTENS, V3, P293; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; Cappuccio FP, 1997, HEART, V78, P555, DOI 10.1136/hrt.78.6.555; Chang HG, 1996, J HYPERTENS, V14, P1417, DOI 10.1097/00004872-199612000-00005; CURTIS JJ, 1983, NEW ENGL J MED, V309, P1009, DOI 10.1056/NEJM198310273091702; DEWARDENER HE, 1982, LANCET, V1, P1450; GEORGE CF, 1975, BRIT HEART J, V37, P804; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; JAMES VHT, 1976, METHODOLOGICAL DEV B, V5, P149; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; MUNROE PB, 1997, AM J HYPERTENS, V10, pA5; PERSU A, 1998, IN PRESS HYPERTENSIO; ROULSTON JE, 1978, CLIN CHIM ACTA, V88, P45, DOI 10.1016/0009-8981(78)90147-X; SAMMONS DW, 1981, ELECTROPHORESIS, V2, P135, DOI 10.1002/elps.1150020303; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Su YR, 1996, J AM SOC NEPHROL, V7, P2543; VOILLEY N, 1995, GENOMICS, V28, P560, DOI 10.1006/geno.1995.1188	19	198	204	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 9	1998	351	9113					1388	1392		10.1016/S0140-6736(97)07306-6	http://dx.doi.org/10.1016/S0140-6736(97)07306-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM665	9593408				2022-12-01	WOS:000073563400008
J	Cullen, MR				Cullen, MR			Chrysotile asbestos: enough is enough	LANCET			English	Editorial Material							MORTALITY; MESOTHELIOMA; TREMOLITE; EXPOSURE; CANCER		Yale Univ, Sch Med, Yale Occupat & Environm Med Program, New Haven, CT 06510 USA	Yale University	Cullen, MR (corresponding author), Yale Univ, Sch Med, Yale Occupat & Environm Med Program, 333 Cedar St, New Haven, CT 06510 USA.							AMANDUS HE, 1987, AM J IND MED, V11, P15, DOI 10.1002/ajim.4700110103; CULLEN MR, 1987, OCCUP MED, V2, P259; DEMENT JM, 1983, AM J IND MED, V4, P421, DOI 10.1002/ajim.4700040304; Liddell FDK, 1997, ANN OCCUP HYG, V41, P13, DOI 10.1016/S0003-4878(96)00044-0; Liddell FDK, 1998, ANN OCCUP HYG, V42, P7, DOI 10.1016/S0003-4878(97)00053-7; MCDONALD AD, 1983, BRIT J IND MED, V40, P361; McDonald AD, 1997, ANN OCCUP HYG, V41, P707, DOI 10.1016/S0003-4878(97)00020-3; MCDONALD JC, 1989, CANCER, V63, P1544, DOI 10.1002/1097-0142(19890415)63:8<1544::AID-CNCR2820630815>3.0.CO;2-G; McDonald JC, 1997, ANN OCCUP HYG, V41, P699, DOI 10.1093/annhyg/41.6.699; MCDONALD JC, 1998, ANN OCCUP HYG, V42, P1; Smith AH, 1996, AM J IND MED, V30, P252, DOI 10.1002/(SICI)1097-0274(199609)30:3<252::AID-AJIM2>3.0.CO;2-0; Stayner LT, 1996, AM J PUBLIC HEALTH, V86, P179, DOI 10.2105/AJPH.86.2.179; WAGNER JC, 1982, BRIT J CANCER, V45, P352, DOI 10.1038/bjc.1982.61	13	27	27	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	1998	351	9113					1377	1378		10.1016/S0140-6736(05)79440-X	http://dx.doi.org/10.1016/S0140-6736(05)79440-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM665	9593405				2022-12-01	WOS:000073563400005
J	Fryer, CJ; Archer, TK				Fryer, CJ; Archer, TK			Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex	NATURE			English	Article							MMTV PROMOTER; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; STEROID-RECEPTORS; NUCLEAR RECEPTORS; BINDING; COACTIVATOR; NUCLEOSOME; PROTEIN; CBP	The assembly of transcriptional regulatory DNA sequences into chromatin plays a fundamental role in modulating gene expression(1,2). The promoter of the mouse mammary-tumour virus (MMTV) is packaged into a regular array of nucleosomes when it becomes stably integrated into mammalian chromosomes, and has been used to investigate the relationship between chromatin architecture and transcriptional activation by the hormone-bound glucocorticoid and progesterone receptors(3,4). In mammalian cells that express both of these receptors, the progesterone receptor activates transcription from transiently transfected MMTV DNA(5,6) but not from organized chromatin templates(7). Moreover, the activated progesterone receptor inhibits the chromatin remodelling and consequent transcriptional stimulation that is mediated by the glucocorticoid receptor. Here we investigate the mechanism of this inhibition by characterizing the interaction of the glucocorticoid receptor with transcriptional co-activator and chromatin remodelling protein complexes(2,8). We show that when this receptor is prevented from interacting with the hBRG1/BAF chromatin remodelling complex, it can activate transcription from transiently transfected DNA but not from organized chromatin templates. Our results indicate that it may be possible to separate the transcriptional activation and chromatin remodelling activities of proteins that interact with hormone receptors.	Univ Western Ontario, London Reg Canc Ctr, Dept Obstet & Gynaecol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Biochem, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Oncol, London, ON N6A 4L6, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Archer, TK (corresponding author), Univ Western Ontario, London Reg Canc Ctr, Dept Obstet & Gynaecol, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.		Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644				ARCHER TK, 1995, J STEROID BIOCHEM, V53, P421, DOI 10.1016/0960-0760(95)00088-H; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; MCKNIGHT GS, 1980, CELL, V22, P469; MCKNIGHT GS, 1997, NATURE, V387, P677; MIZUTANI T, 1992, J STEROID BIOCHEM, V42, P695, DOI 10.1016/0960-0760(92)90110-5; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	30	403	412	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1998	393	6680					88	91		10.1038/30032	http://dx.doi.org/10.1038/30032			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590696				2022-12-01	WOS:000073497500054
J	Varon, R; Vissinga, C; Platzer, M; Cerosaletti, KM; Chrzanowska, KH; Saar, K; Beckmann, G; Seemanova, E; Cooper, PR; Nowak, NJ; Stumm, M; Weemaes, CMR; Gatti, RA; Wilson, RK; Digweed, M; Rosenthal, A; Sperling, K; Concannon, P; Reis, A				Varon, R; Vissinga, C; Platzer, M; Cerosaletti, KM; Chrzanowska, KH; Saar, K; Beckmann, G; Seemanova, E; Cooper, PR; Nowak, NJ; Stumm, M; Weemaes, CMR; Gatti, RA; Wilson, RK; Digweed, M; Rosenthal, A; Sperling, K; Concannon, P; Reis, A			Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome	CELL			English	Article							CHROMOSOMAL INSTABILITY DISORDER; ATAXIA-TELANGIECTASIA; HUMAN GENOME; HUMAN MRE11; GENE; IMMUNODEFICIENCY; COMPLEMENTATION; MAP	Nijmegen breakage syndrome (NBS) Is an autosomal recessive chromosomal instability syndrome characterized by microcephaly, growth retardation, immunodeficiency, and cancer predisposition. Cells from NBS patients are hypersensitive to ionizing radiation with cytogenetic features indistinguishable from ataxia telangiectasia. We describe the positional cloning of a gene encoding a novel protein, nibrin. It contains two modules found in cell cycle checkpoint proteins, a forkhead-associated domain adjacent to a breast cancer carboxy-terminal domain. A truncating 5 bp deletion was identified in the majority of NBS patients, carrying a conserved marker haplotype. Five further truncating mutations were identified in patients with other distinct haplotypes. The domains found in nibrin and the NBS phenotype suggest that this disorder is caused by defective responses to DNA double-strand breaks.	Humboldt Univ, Charite, Inst Human Genet, D-13353 Berlin, Germany; Univ Washington, Sch Med, Virginia Mason Res Ctr, Seattle, WA 98101 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98101 USA; Inst Mol Biol, Dept Genome Anal, D-07745 Jena, Germany; Childrens Mem Hlth Inst, Dept Med Genet, PL-04736 Warsaw, Poland; Max Delbruck Ctr Mol Med, Mikrosatellitenzentrum, D-14059 Berlin, Germany; Max Delbruck Ctr Mol Med, Dept Bioinformat, D-13125 Berlin, Germany; Charles Univ Prague, Dept Med Genet, CR-15018 Prague, Czech Republic; Roswell Pk Canc Inst, Dept Human Genet, Buffalo, NY 14263 USA; Univ Magdeburg, Inst Human Genet, D-39112 Magdeburg, Germany; Univ Nijmegen Hosp, NL-6500 HB Nijmegen, Netherlands; Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Washington; University of Washington Seattle; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; Children's Memorial Health Institute; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Charles University Prague; Roswell Park Cancer Institute; Otto von Guericke University; Radboud University Nijmegen; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Washington University (WUSTL)	Reis, A (corresponding author), Humboldt Univ, Charite, Inst Human Genet, Augustenburger Pl 1, D-13353 Berlin, Germany.		Reis, André/D-2309-2009; Wilson, Richard K./AAF-4139-2019; Weemaes, C.M.R./L-4747-2015	Reis, André/0000-0002-6301-6363; Wilson, Richard K./0000-0002-1992-1358; Chrzanowska, Krystyna/0000-0003-3888-0624; Concannon, Patrick/0000-0002-5801-1859; Cooper, Paul/0000-0003-1305-7287; Saar, Kathrin/0000-0002-4483-1557	NATIONAL CANCER INSTITUTE [R01CA063333, R01CA057569] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000333] Funding Source: NIH RePORTER; NCI NIH HHS [CA57569, CA63333, R01 CA057569] Funding Source: Medline; NHGRI NIH HHS [HG00333] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Beckmann G, 1998, J MOL BIOL, V275, P725, DOI 10.1006/jmbi.1997.1510; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; CHRZANOWSKA KH, 1995, AM J MED GENET, V57, P462, DOI 10.1002/ajmg.1320570321; Concannon P, 1997, HUM MUTAT, V10, P100, DOI 10.1002/(SICI)1098-1004(1997)10:2<100::AID-HUMU2>3.0.CO;2-O; DIGWEED M, 1993, TOXICOL LETT, V67, P259, DOI 10.1016/0378-4274(93)90061-2; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; HANAWALT P, 1985, ATAXIA TELANGIECTASI, P67; Hendrickson EA, 1997, AM J HUM GENET, V61, P795, DOI 10.1086/514895; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; JASPERS NGJ, 1988, AM J HUM GENET, V42, P66; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; Komatsu K, 1996, AM J HUM GENET, V58, P885; LICHTER P, 1992, HUMAN CYTOGENETICS P, P157; Matsuura K, 1998, BIOCHEM BIOPH RES CO, V242, P602, DOI 10.1006/bbrc.1997.7924; MEYN MS, 1995, CANCER RES, V55, P5991; MORRAL N, 1994, NAT GENET, V7, P169, DOI 10.1038/ng0694-169; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; Platzer M, 1997, GENOME RES, V7, P592, DOI 10.1101/gr.7.6.592; Saar K, 1997, AM J HUM GENET, V60, P605; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVOV A, 1992, NUCLEIC ACIDS RES, V20, P6741, DOI 10.1093/nar/20.24.6741; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SEYSCHAB H, 1992, EUR J PEDIATR, V151, P756, DOI 10.1007/BF01959085; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stumm M, 1997, AM J HUM GENET, V60, P1246; TAALMAN RDFM, 1983, MUTAT RES, V112, P23, DOI 10.1016/0167-8817(83)90021-4; TROELSTRA C, 1994, CURR BIOL, V4, P1149, DOI 10.1016/S0960-9822(00)00260-8; vanderBurgt I, 1996, J MED GENET, V33, P153, DOI 10.1136/jmg.33.2.153; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; WEEMAES CMR, 1981, ACTA PAEDIATR SCAND, V70, P557, DOI 10.1111/j.1651-2227.1981.tb05740.x; WEGNER RD, 1988, CLIN GENET, V33, P20; WEGNER RD, 1998, IN PRESS PRIMARY IMM; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016	40	798	822	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1998	93	3					467	476		10.1016/S0092-8674(00)81174-5	http://dx.doi.org/10.1016/S0092-8674(00)81174-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590180	Green Submitted, Bronze			2022-12-01	WOS:000073471500021
J	Tontonoz, P; Nagy, L; Alvarez, JGA; Thomazy, VA; Evans, RM				Tontonoz, P; Nagy, L; Alvarez, JGA; Thomazy, VA; Evans, RM			PPAR gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL	CELL			English	Article							LOW-DENSITY-LIPOPROTEIN; ACTIVATED RECEPTOR-GAMMA; RETINOIC ACID; ADIPOCYTE DIFFERENTIATION; CHOLESTEROL DEPOSITION; GENE-EXPRESSION; THYROID-HORMONE; HUMAN CD36; MACROPHAGE; BINDING	The formation of foam cells from macrophages in the arterial wall is characterized by dramatic changes in lipid metabolism, including increased expression of scavenger receptors and the uptake of oxidized low-density lipoprotein (oxLDL). We demonstrate here that the nuclear receptor PPAR gamma is induced in human monocytes following exposure to oxLDL and is expressed at high levels in the foam cells of atherosclerotic lesions. Ligand activation of the PPBR gamma:RXR alpha heterodimer in myelomonocytic cell lines induces changes characteristic of monocytic differentiation and promotes uptake of oxLDL through transcriptional induction of the scavenger receptor CD36. These results reveal a novel signaling pathway controlling differentiation and lipid metabolism in monocytic cells, and suggest that endogenous PPAR gamma ligands may be important regulators of gene expression during atherogenesis.	Howard Hughes Med Inst, La Jolla, CA 92037 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Texas, Sch Med, Dept Pathol, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Integrat Biol, Houston, TX 77225 USA	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego; University of Texas System; University of Texas System	Evans, RM (corresponding author), Howard Hughes Med Inst, La Jolla, CA 92037 USA.		Nagy, Laszlo/A-3814-2008; Evans, Ronald/AAF-4001-2019	Nagy, Laszlo/0000-0001-6653-2155; Evans, Ronald/0000-0002-9986-5965				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUJA LM, 1983, ARTERIOSCLEROSIS, V3, P87, DOI 10.1161/01.ATV.3.1.87; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GRAVES RA, 1992, MOL CELL BIOL, V12, P1202, DOI 10.1128/MCB.12.3.1202; Greene M. E., 1995, Gene Expression, V4, P281; GREENWALT DE, 1995, J CLIN INVEST, V96, P1382, DOI 10.1172/JCI118173; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUBBERT M, 1991, BLOOD, V77, P909; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; MOULTON KS, 1992, P NATL ACAD SCI USA, V89, P8102, DOI 10.1073/pnas.89.17.8102; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; NAGELKERKE JF, 1984, ARTERIOSCLEROSIS, V4, P256, DOI 10.1161/01.ATV.4.3.256; NAGY L, 1995, MOL CELL BIOL, V15, P3540; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSS TK, 1994, VITAM HORM, V49, P281; SANAN DA, 1998, IN PRESS P ACAD NATL; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SFEIR Z, 1997, ESSENT FATTY ACIDS, V57, P17; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STARY HC, 1994, ARTERIOSCLER THROMB, V14, P840, DOI 10.1161/01.ATV.14.5.840; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837; Yesner LM, 1996, ARTERIOSCL THROM VAS, V16, P1019, DOI 10.1161/01.ATV.16.8.1019; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	55	1515	1571	1	93	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					241	252		10.1016/S0092-8674(00)81575-5	http://dx.doi.org/10.1016/S0092-8674(00)81575-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568716	Bronze			2022-12-01	WOS:000073174000010
J	Stollberger, C; Chnupa, P; Kronik, G; Brainin, M; Finsterer, J; Schneider, B; Slany, J				Stollberger, C; Chnupa, P; Kronik, G; Brainin, M; Finsterer, J; Schneider, B; Slany, J		ELAT Study Grp	Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation	ANNALS OF INTERNAL MEDICINE			English	Article						echocardiography, transesophageal; atrial fibrillation; embolism and thrombosis; cerebrovascular disorders; atrial function, left	SPONTANEOUS ECHO CONTRAST; MITRAL-VALVE DISEASE; APPENDAGE THROMBUS; ANATOMIC CORRELATIONS; CLINICAL-APPLICATIONS; THROMBOEMBOLIC RISK; STROKE	Background: Transesophageal echocardiography visualizes the left atrium and its appendage, thrombi, and spontaneous echocardiographic contrast. Objective: To assess the association of transesophageal echocardiographic characteristics with stroke or embolism in atrial fibrillation. Design: Multicenter observational follow-up study. Setting: Hospitals in Austria and Slovakia. Patients: 409 outpatients with nonrheumatic atrial fibrillation and without recent stroke. Intervention: Patients with thrombi received anticoagulation, and patients without thrombi received aspirin. Measurements: Primary events were stroke or embolism. Secondary events were death not caused by stroke or embolism and need for anticoagulation. Results: In the left atrium or left atrial appendage, 10 patients (2.5%) had thrombi and 47 (12%) had spontaneous echocardiographic contrast. The appendage had a mean (+/- SD) length of 44 +/- 10 mm, a mean width of 23 +/- 6 mm, and a mean area of 5.8 +/- 2.5 cm(2). Follow-up ranged from 1 to 74 months (mean, 58 months). Fifty patients had stroke or embolism, 53 died of a cause other than stroke or embolism, and 38 required anticoagulation. On univariate analysis, thrombi (risk ratio, 3.9 [95% CI, 1.4 to 10.1]; P = 0.009), length of the left atrial appendage (risk ratio, 1.6 [CI, 1.05 to 2.5]; P = 0.03), and width of the left atrial appendage (risk ratio, 2.4 [CI, 1.2 to 4.8]; P = 0.01) were associated with stroke or embolism. Multivariate analysis identified hypertension (risk ratio, 3.6 [CI, 1.8 to 8.4]; P = 0.001), previous stroke (risk ratio, 3.7 [CI, 1.5 to 7.5]; P = 0.002), and age (risk ratio, 1.1 [CI, 1.0 to 1.1]; P < 0.001) as risk factors for stroke or embolism and provided evidence of an association between thrombi and stroke or embolism (risk ratio, 2.4 [CI, 0.9 to 6.9]; P = 0.09). Conclusions: In outpatients with atrial fibrillation and without recent stroke, thrombi of the left atrium or left atrial appendage and length and width of the left atrial appendage were associated with stroke or embolism in univariate analysis. In a multivariate analysis, age, hypertension, and previous stroke were risk factors for stroke or embolism, and thrombi of the left atrium or left atrial appendage were possible risk factors. In these patients, history may be more useful than transesophageal echocardiography for the assessment of embolic risk.	Ustav Kardiovaskularnych Chorob, SK-81105 Bratislava, Slovakia; Krankenhaus Krems, A-3500 Krems, Austria; Neurol Krankenhaus, A-3400 Maria Gugging, Austria; Neurol Krankenhaus Rosenhugel, Inst Med Stat, A-1130 Vienna, Austria; Krankenanstalt Rudolfstiftung Wien, Vienna, Austria	Rudolfstiftung Hospital	Stollberger, C (corresponding author), Steingasse 31-18, A-1030 Vienna, Austria.		Finsterer, J/AAE-5733-2020					ABERG H, 1969, ACTA MED SCAND, V185, P373; ARCHER SL, 1995, AM HEART J, V130, P287, DOI 10.1016/0002-8703(95)90442-5; ASCHENBERG W, 1986, J AM COLL CARDIOL, V7, P163, DOI 10.1016/S0735-1097(86)80275-3; BEPPU S, 1985, J AM COLL CARDIOL, V6, P744, DOI 10.1016/S0735-1097(85)80476-9; BLACK IW, 1993, J AM COLL CARDIOL, V21, P451, DOI 10.1016/0735-1097(93)90688-W; BRAININ M, 1992, NEUROEPIDEMIOLOGY, V11, P190, DOI 10.1159/000110931; CHAN SK, 1995, AM J CARDIOL, V76, P528, DOI 10.1016/S0002-9149(99)80147-7; DANIEL WG, 1988, J AM COLL CARDIOL, V11, P1204, DOI 10.1016/0735-1097(88)90283-5; DUNN M, 1989, CHEST, V95, pS118, DOI 10.1378/chest.95.2_Supplement.118S; ERNST G, 1995, ANAT REC, V242, P553, DOI 10.1002/ar.1092420411; FATKIN D, 1994, J AM COLL CARDIOL, V23, P961, DOI 10.1016/0735-1097(94)90644-0; KRONIK G, 1995, BRIT HEART J, V74, P80; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LEUNG DYC, 1994, J AM COLL CARDIOL, V24, P755, DOI 10.1016/0735-1097(94)90025-6; MANNING WJ, 1995, J AM COLL CARDIOL, V25, P1354, DOI 10.1016/0735-1097(94)00560-D; MANNING WJ, 1995, ANN INTERN MED, V123, P817, DOI 10.7326/0003-4819-123-11-199512010-00001; MCBRIDE R, 1990, NEW ENGL J MED, V322, P863; MUGGE A, 1990, American Journal of Cardiac Imaging, V4, P173; MUGGE A, 1994, J AM COLL CARDIOL, V23, P599; Orsinelli DA, 1996, AM HEART J, V131, P622, DOI 10.1016/S0002-8703(96)90553-0; POLLICK C, 1991, CIRCULATION, V84, P223, DOI 10.1161/01.CIR.84.1.223; Pozzoli M, 1991, J Am Soc Echocardiogr, V4, P435; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SEWARD JB, 1990, MAYO CLIN PROC, V65, P1193, DOI 10.1016/S0025-6196(12)62744-X; SEWARD JB, 1988, MAYO CLIN PROC, V63, P649, DOI 10.1016/S0025-6196(12)65529-3; SHERMAN DG, 1986, ARCH NEUROL-CHICAGO, V43, P68, DOI 10.1001/archneur.1986.00520010062024; STODDARD MF, 1995, J AM COLL CARDIOL, V25, P452, DOI 10.1016/0735-1097(94)00396-8; STOLLBERGER C, 1995, CARDIOLOGY, V86, P457, DOI 10.1159/000176923	28	145	151	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					630	+		10.7326/0003-4819-128-8-199804150-00004	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537936				2022-12-01	WOS:000073052500003
J	Maison, P; Balkau, B; Simon, D; Chanson, P; Rosselin, G; Eschwege, E				Maison, P; Balkau, B; Simon, D; Chanson, P; Rosselin, G; Eschwege, E			Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study	BRITISH MEDICAL JOURNAL			English	Article									Fac Med Paris Sud, INSERM, U21, F-94807 Villejuif, France; Hop St Antoine, INSERM, U55, F-75571 Paris, France; Hop Bicetre, Serv Endocrinol, Le Kremlin Bicetre, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Maison, P (corresponding author), Fac Med Paris Sud, INSERM, U21, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.		Chanson, Philippe/F-8511-2013	Chanson, Philippe/0000-0001-5096-5722				BALKAU B, 1993, BRIT MED J, V307, P295, DOI 10.1136/bmj.307.6899.295; BENGTSSON BA, 1988, ACTA MED SCAND, V223, P327; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; ROSSELIN G, 1966, NATURE, V212, P355, DOI 10.1038/212355a0; SACCA L, 1994, ENDOCR REV, V15, P555, DOI 10.1210/er.15.5.555	5	61	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1998	316	7138					1132	1133		10.1136/bmj.316.7138.1132	http://dx.doi.org/10.1136/bmj.316.7138.1132			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH054	9552951	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000073067500024
J	Rosenberg, L; Rao, S; Palmer, JR; Strom, BL; Stolley, PD; Zauber, AG; Warshauer, ME; Shapiro, S				Rosenberg, L; Rao, S; Palmer, JR; Strom, BL; Stolley, PD; Zauber, AG; Warshauer, ME; Shapiro, S			Calcium channel blockers and the risk of cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL-CELL CARCINOMA; DEPENDENT TISSUES; KIDNEY CANCER; APOPTOSIS; DEATH; DIURETICS; DISEASE; HYPERTENSION; INCREASE; OBESITY	Context.-Recent epidemiologic studies have raised the concern that calcium channel blocker use may increase the risk of cancer overall and of several specific cancers. Objective.-To assess whether calcium channel blocker use increases the risk of cancer overall and of specific cancers, Design,-Case-control drug surveillance study based on data collected from 1983 to 1996. Setting.-Hospitals in Baltimore, Md, New York, NY, and Philadelphia, Pa. Patients.-A total of 9513 patients aged 40 to 69 years with incident cancer of various sites and 6492 controls aged 40 to 69 years admitted for nonmalignant conditions. Main Outcome Measures.-Incident cancer overall and 23 specific cancers, Results.-Calcium channel blocker use was unrelated to the risk of cancer overall (relative risk [RR], 1.1; 95% confidence interval [CI], 0.9-1.3). Use was not significantly associated with increased risks of individual cancers, including those previously implicated, except cancer of the kidney (RR, 1.8; 95% CI, 1.1-2.7). Recent use, use for 5 or more years, and use of individual calcium channel blocker drugs were also not associated with cancer incidence, Use of beta-blockers and angiotensin-converting enzyme inhibitors was generally unrelated to cancer overall or individual cancers, but both were associated with kidney cancer (RR, 1.8; 95% CI, 1.3-2.5; and RR, 1.9, 95% CI, 1.2-3.0, respectively). Conclusions.-The present study suggests that the use of calcium channel blockers is unrelated to an increase in the overall risk of cancer or of individual cancers, except kidney cancer, which has been associated with hypertension or drugs to treat hypertension in previous studies.	Boston Univ, Sch Med, Sch Publ Hlth, Sloan Epidemiol Unit, Brookline, MA 02146 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Cornell Univ, Med Ctr, New York Hosp, Dept Publ Hlth, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA	Boston University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University System of Maryland; University of Maryland Baltimore; Cornell University; NewYork-Presbyterian Hospital; Memorial Sloan Kettering Cancer Center	Rosenberg, L (corresponding author), Boston Univ, Sch Med, Sch Publ Hlth, Sloan Epidemiol Unit, 1371 Beacon St, Brookline, MA 02146 USA.			Palmer, Julie/0000-0002-6534-335X; Rosenberg, Lynn/0000-0003-2760-2987	NATIONAL CANCER INSTITUTE [R01CA045762] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA45762] Funding Source: Medline; FDA HHS [FD-U-000082] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS		ASAL NR, 1988, CANCER DETECT PREV, V13, P263; Balakumaran A, 1996, TOXICOL APPL PHARM, V139, P122, DOI 10.1006/taap.1996.0150; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CONNOR J, 1988, PROSTATE, V13, P119, DOI 10.1002/pros.2990130204; Daling JR, 1996, AM J HYPERTENS, V9, P713; FINKLE WD, 1993, CANC CAUSES CONTROL, V4, P55; Fitzpatrick AL, 1997, CANCER, V80, P1438, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6; Heath CW, 1997, AM J EPIDEMIOL, V145, P607, DOI 10.1093/oxfordjournals.aje.a009157; HIATT RA, 1994, CANCER CAUSE CONTROL, V5, P319, DOI 10.1007/BF01804982; Jick H, 1997, LANCET, V349, P525, DOI 10.1016/S0140-6736(97)80084-0; JUNTTIBERGGREN L, 1993, SCIENCE, V261, P86, DOI 10.1126/science.7686306; KREIGER N, 1993, CANCER CAUSE CONTROL, V4, P101, DOI 10.1007/BF00053150; LINDBLAD P, 1993, INT J CANCER, V55, P5, DOI 10.1002/ijc.2910550103; MCCREDIE M, 1992, CANCER CAUSE CONTROL, V3, P323, DOI 10.1007/BF00146885; MCLAUGHLIN JK, 1984, JNCI-J NATL CANCER I, V72, P275; MCLAUGHLIN JK, 1995, INT J CANCER, V63, P216, DOI 10.1002/ijc.2910630212; MELLEMGAARD A, 1992, CANCER CAUSE CONTROL, V3, P309, DOI 10.1007/BF00146883; Olsen JH, 1997, HYPERTENSION, V29, P1091, DOI 10.1161/01.HYP.29.5.1091; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; Prineas RJ, 1997, EPIDEMIOLOGY, V8, P31, DOI 10.1097/00001648-199701000-00005; RAY SD, 1993, FASEB J, V7, P453, DOI 10.1096/fasebj.7.5.8462787; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SEN S, 1992, BIOL REV, V67, P287, DOI 10.1111/j.1469-185X.1992.tb00727.x; Shapiro S., 1994, PHARMACOEPIDEM DR S, P301; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; YU MC, 1986, JNCI-J NATL CANCER I, V77, P351	31	126	126	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1000	1004		10.1001/jama.279.13.1000	http://dx.doi.org/10.1001/jama.279.13.1000			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533498	Bronze			2022-12-01	WOS:000072669700027
J	Crane, BR; Arvai, AS; Ghosh, DK; Wu, CQ; Getzoff, ED; Stuehr, DJ; Tainer, JA				Crane, BR; Arvai, AS; Ghosh, DK; Wu, CQ; Getzoff, ED; Stuehr, DJ; Tainer, JA			Structure of nitric oxide synthase oxygenase dimer with pterin and substrate	SCIENCE			English	Article							L-ARGININE; TETRAHYDROBIOPTERIN; NO; MECHANISM; BINDING; ENZYME; SITE	Crystal structures of the murine cytokine-inducible nitric oxide synthase oxygenase dimer with active-center water molecules, the substrate L-arginine (L-Arg), or product analog thiocitrulline reveal how dimerization, cofactor tetrahydrobiopterin, and L-Arg binding complete the catalytic center for synthesis of the essential biological signal and cytotoxin nitric oxide. Pterin binding refolds the central interface region, recruits new structural elements, creates a 30 angstrom deep active-center channel, and causes a 35 degrees helical tilt to expose a heme edge and the adjacent residue tryptophan-366 for likely reductase domain interactions and caveolin inhibition. Heme propionate interactions with pterin and L-Arg suggest that pterin has electronic influences on heme-bound oxygen. L-Arginine binds to glutamic acid-371 and stacks with heme in an otherwise hydrophobic pocket to aid activation of heme-bound oxygen by direct proton donation and thereby differentiate the two chemical steps of nitric oxide synthesis.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Cleveland Clinic Foundation; Scripps Research Institute; Scripps Research Institute	Tainer, JA (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058883] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58883] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; ABUSOUD HM, IN PRESS BIOCHEMISTR; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chabin RM, 1996, BIOCHEMISTRY-US, V35, P9567, DOI 10.1021/bi960476o; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Cubberley RR, 1997, BIOCHEM J, V323, P141, DOI 10.1042/bj3230141; DIX TA, 1988, ACCOUNTS CHEM RES, V21, P101, DOI 10.1021/ar00147a002; Erlandsen H, 1997, NAT STRUCT BIOL, V4, P995, DOI 10.1038/nsb1297-995; GACHHUI R, 1997, IN PRESS BIOCHEMISTR, V36, P5097; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; KAUFMAN S, 1993, ADV ENZYMOL RAMB, V67, P77; KLATT P, 1994, J BIOL CHEM, V269, P13861; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MASTERS BSS, 1998, OXIDANTS ANTIOXIDANT; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; NAVAZA L, 1993, ACTA CRYSTALLOGR D, V49, P127; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; PRESTA A, IN PRESS J AM CHEM S; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sennequier N, 1996, BIOCHEMISTRY-US, V35, P5883, DOI 10.1021/bi952844e; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; STUEHR D, 1997, ANN REV PHARM TOXICO, V18, P707; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WHITEVEEN KE, 1996, J BIOL CHEM, V271, P4143	48	600	610	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2121	2126		10.1126/science.279.5359.2121	http://dx.doi.org/10.1126/science.279.5359.2121			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516116				2022-12-01	WOS:000072775600052
J	Goldring, O				Goldring, O			Therapeutics: a glimpse of the future	NATURE			English	Editorial Material																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					420	420		10.1038/32957	http://dx.doi.org/10.1038/32957			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537332				2022-12-01	WOS:000072713600063
J	Gerlach, M; Koutsilieri, E; Riederer, P				Gerlach, M; Koutsilieri, E; Riederer, P			N-methyl-(R)-salsolinol and its relevance to Parkinson's disease	LANCET			English	Editorial Material							DOPAMINERGIC NEUROTOXIN		Univ Wurzburg, Dept Psychiat, Div Clin Neurochem, D-97060 Wurzburg, Germany	University of Wurzburg	Gerlach, M (corresponding author), Univ Wurzburg, Dept Psychiat, Div Clin Neurochem, Fuchsleinstr 15, D-97060 Wurzburg, Germany.							Gerlach M, 1996, J NEURAL TRANSM, V103, P987, DOI 10.1007/BF01291788; Jellinger KA, 1988, HDB EXPT PHARM, V88, P47, DOI DOI 10.1007/978-3-642-73899-9_2; Maruyama W, 1996, ANN NEUROL, V40, P119, DOI 10.1002/ana.410400120; Naoi M, 1997, NEUROSCI LETT, V235, P81, DOI 10.1016/S0304-3940(97)00723-4; NAOI M, 1995, LIFE SCI, V57, P1061, DOI 10.1016/0024-3205(95)02051-J; Naoi M, 1998, ANN NEUROL, V43, P212, DOI 10.1002/ana.410430211; Naoi M, 1997, J NEURAL TRANSM-SUPP, P89; ROMMELSPACHER H, 1995, ALCOHOL, V12, P309, DOI 10.1016/0741-8329(95)00004-B; TAKAHASHI T, 1994, J NEURAL TRANSM-GEN, V98, P107, DOI 10.1007/BF01277014	9	19	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					850	851		10.1016/S0140-6736(05)70284-1	http://dx.doi.org/10.1016/S0140-6736(05)70284-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525358				2022-12-01	WOS:000072645500006
J	Meier, R; Owen, TC; Jewitt, DC; Matthews, HE; Senay, M; Biver, N; Bockelee-Morvan, D; Crovisier, J; Gautier, D				Meier, R; Owen, TC; Jewitt, DC; Matthews, HE; Senay, M; Biver, N; Bockelee-Morvan, D; Crovisier, J; Gautier, D			Deuterium in comet C 1995 O1 (Hale-Bopp): Detection of DCN	SCIENCE			English	Article							DENSE INTERSTELLAR CLOUDS; SOLAR NEBULA; WATER; CHEMISTRY; TAURUS; HCN	Deuterated hydrogen cyanide (DCN) was detected in a comet, C/1995 O1 (Hale-Bopp), with the use of the James Clerk Maxwell Telescope on Mauna Kea, Hawaii. The inferred deuterium/hydrogen (D/H) ratio in hydrogen cyanide (HCN) is (D/H)(HCN) = (2.3 +/- 0.4) x 10(-3). This ratio is higher than the D/H ratio found in cometary water and supports the interstellar origin of cometary ices. The observed values of D/H in water and HCN imply a kinetic temperature greater than or equal to 30 +/- 10 K in the fragment of interstellar cloud that formed the solar system.	Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; Natl Res Council Canada, Herzberg Inst Astrophys, Victoria, BC V8X 4M6, Canada; Joint Astron Ctr, Hilo, HI 96720 USA; Univ Massachusetts, Five Coll Radio Astron Observ, Amherst, MA 01003 USA; Observ Paris, F-92195 Meudon, France	University of Hawaii System; National Research Council Canada; University of Massachusetts System; University of Massachusetts Amherst; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris	Meier, R (corresponding author), Univ Hawaii, Inst Astron, 2680 Woodlawn Dr, Honolulu, HI 96822 USA.	meier@uhifa.ifa.hawall.edu						ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BALSIGER H, 1995, J GEOPHYS RES, V100, P5287; Bates D. R., 1988, RATE COEFFICIENTS AS, P41; BIVER N, 1997, B AM ASTRON SOC, V29, P1047; BOCKELEEMORVAN D, 1994, PLANET SPACE SCI, V42, P655, DOI 10.1016/0032-0633(94)90043-4; BOCKELEEMORVAN D, 1997, B AM ASTRON SOC, V29, P1047; BOSS AP, 1989, ORIGIN EVOLUTION PLA, P35; BROWN PD, 1989, MON NOT R ASTRON SOC, V237, P661, DOI 10.1093/mnras/237.3.661; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; DUBRULLE B, 1993, ICARUS, V106, P59, DOI 10.1006/icar.1993.1158; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; Fegley B.J., 1989, FORMATION EVOLUTION, P171; Gautier D, 1995, SPACE SCI S, P547; Gautier D, 1997, ASTRON ASTROPHYS, V323, pL9; Geiss J., 1993, ORIGIN EVOLUTION ELE, V89; Greenfield J.C., 1981, COMETS ORIGIN LIFE, P111; Irvine WM, 1989, ORIGIN EVOLUTION PLA, P3; JACQ T, 1990, ASTRON ASTROPHYS, V228, P447; Jewitt DC, 1997, SCIENCE, V278, P90, DOI 10.1126/science.278.5335.90; JONES AP, 1984, MON NOT R ASTRON SOC, V209, P955, DOI 10.1093/mnras/209.4.955; KIM K, 1979, J CHEM PHYS, V71, P1967, DOI 10.1063/1.438510; Krasnopolsky VA, 1997, SCIENCE, V277, P1488, DOI 10.1126/science.277.5331.1488; KRASNOPOLSKY VA, 1997, 6625 IAU; LECLUSE C, 1994, GEOCHIM COSMOCHIM AC, V58, P2927, DOI 10.1016/0016-7037(94)90126-0; LUNINE JI, 1991, ICARUS, V94, P333, DOI 10.1016/0019-1035(91)90232-I; Meier R, 1998, SCIENCE, V279, P842, DOI 10.1126/science.279.5352.842; MEIER RR, UNPUB; MILLAR TJ, 1989, ASTROPHYS J, V340, P906, DOI 10.1086/167444; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; OWEN T, 1995, AIP C P, V341, P123; POINTER RL, 1985, APPL OPTICS, V24, P2235; THANH NV, 1993, J MOL SPECTROSC, V157, P68, DOI 10.1006/jmsp.1993.1006; UNGERECHTS H, 1987, ASTROPHYS J SUPPL S, V63, P645, DOI 10.1086/191176; van Dishoeck E. F., 1993, PROTOSTARS PLANETS, P163; WATSON WD, 1976, REV MOD PHYS, V48, P513, DOI 10.1103/RevModPhys.48.513; Williams TL, 1996, MON NOT R ASTRON SOC, V282, P413, DOI 10.1093/mnras/282.2.413; Wootten A, 1987, IAU S, P311	38	141	143	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1707	1710		10.1126/science.279.5357.1707	http://dx.doi.org/10.1126/science.279.5357.1707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497286				2022-12-01	WOS:000072490000051
J	Hegde, RS; Voigt, S; Rapoport, TA; Lingappa, VR				Hegde, RS; Voigt, S; Rapoport, TA; Lingappa, VR			TRAM regulates the exposure of nascent secretory proteins to the cytosol during translocation into the endoplasmic reticulum	CELL			English	Article							APOLIPOPROTEIN-B; SIGNAL SEQUENCE; ER MEMBRANE; PROTEOLIPOSOMES; LIPOPROTEINS; MICROSOMES; TRANSPORT; BINDING	Translocational pausing is a mechanism used by certain specialized secretory proteins whereby discrete domains of a nascent chain destined for the endoplasmic reticulum lumen are transiently exposed to the cytosol. Proteoliposomes reconstituted from total endoplasmic reticulum proteins properly assemble translocationally paused intermediates. The capacity of the translocon to correctly pause the nascent chain is dependent on a glycoprotein fraction whose active component is TRAM. In the absence of TRAM, the normally sealed ribosome-membrane junction still opens in response to a pause transfer sequence. However, nascent chain domains that are not exposed to the cytosol in the presence of TRAM are so exposed in its absence. Thus, TRAM regulates which domains of the nascent chain are visible to the cytosol during a translocational pause.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	Lingappa, VR (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.			Hegde, Ramanujan/0000-0001-8338-852X; Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002132] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45480] Funding Source: Medline; NIA NIH HHS [AG 02132] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; BULLEID NJ, 1993, ADV PROTEIN CHEM, V44, P125, DOI 10.1016/S0065-3233(08)60566-5; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DIXON JL, 1993, J LIPID RES, V34, P167; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Du EZ, 1996, J LIPID RES, V37, P1309; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; HIGH S, 1993, J BIOL CHEM, V268, P26745; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; Kivlen MH, 1997, J LIPID RES, V38, P1149; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	34	75	75	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					621	631		10.1016/S0092-8674(00)81130-7	http://dx.doi.org/10.1016/S0092-8674(00)81130-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506517	Bronze			2022-12-01	WOS:000072406000008
J	Wiholm, BE; Kelly, JP; Kaufman, D; Issaragrisil, S; Levy, M; Anderson, T; Shapiro, S				Wiholm, BE; Kelly, JP; Kaufman, D; Issaragrisil, S; Levy, M; Anderson, T; Shapiro, S			Relation of aplastic anaemia to use of chloramphenicol eye drops in two international case-control studies	BRITISH MEDICAL JOURNAL			English	Article									Huddinge Univ Hosp, Karolinska Inst, Dept Clin Pharmacol, Med Pharmacoepidemiol Unit, S-14186 Huddinge, Sweden; Boston Univ, Sch Med, Slone Epidemiol Unit, Brookline, MA 02146 USA; Mahidol Univ, Bangkok 10700, Thailand; Hadassah Univ Hosp, IL-91120 Jerusalem, Israel	Karolinska Institutet; Boston University; Mahidol University; Hebrew University of Jerusalem	Wiholm, BE (corresponding author), Med Prod Agcy, POB 26, S-75103 Uppsala, Sweden.			Issaragrisil, Surapol/0000-0002-8924-0646; Kaufman, David/0000-0002-2150-5070	NHLBI NIH HHS [R01-HL35068] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035068] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DOONA M, 1995, BRIT MED J, V310, P1217, DOI 10.1136/bmj.310.6989.1217; Issaragrisil S, 1997, BLOOD, V89, P4034; Kaufman DW, 1991, DRUG ETIOLOGY AGRANU; THOMAS DG, 1971, APPLIED STATISTICS, V20, P105, DOI DOI 10.2307/2346643	4	28	29	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					666	666		10.1136/bmj.316.7132.666	http://dx.doi.org/10.1136/bmj.316.7132.666			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522791	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000072347900030
J	Behrens, J; Jerchow, BA; Wurtele, M; Grimm, J; Asbrand, C; Wirtz, R; Kuhl, M; Wedlich, D; Birchmeier, W				Behrens, J; Jerchow, BA; Wurtele, M; Grimm, J; Asbrand, C; Wirtz, R; Kuhl, M; Wedlich, D; Birchmeier, W			Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3 beta	SCIENCE			English	Article							TUMOR-SUPPRESSOR PROTEIN; E-CADHERIN; XENOPUS; ASSOCIATION; EXPRESSION; MIGRATION; MESODERM; COMPLEX	Control of stability of beta-catenin is central in the wnt signaling pathway. Here, the protein conductin was found to form a complex with both beta-catenin and the tumor suppressor gene product adenomatous polyposis coli (APC), Conductin induced beta-catenin degradation, whereas mutants of conductin that were deficient in complex formation stabilized beta-catenin. Fragments of APC that contained a conductin-binding domain also blocked beta-catenin degradation. Thus, conductin is a component of the multiprotein complex that directs beta-catenin to degradation and is located downstream of APC. In Xenopus embryos, conductin interfered with wnt-induced axis formation.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Univ Ulm, D-89081 Ulm, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ulm University	Birchmeier, W (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.	wbirch@mdc-berlin.de	Würtele, Martin/D-2686-2012	Jerchow, Boris-Alexander/0000-0002-7031-8730				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ABERLE H, 1994, J CELL SCI, V107, P3655; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BLADT D, 1996, NATURE, V376, P768; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; GUGER KA, 1995, DEV BIOL, V172, P115, DOI 10.1006/dbio.1995.0009; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhl M, 1996, MECH DEVELOP, V54, P71, DOI 10.1016/0925-4773(95)00462-9; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Morrison EE, 1997, NEUROSCIENCE, V81, P553, DOI 10.1016/S0306-4522(97)00099-7; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	35	1070	1101	2	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1998	280	5363					596	599		10.1126/science.280.5363.596	http://dx.doi.org/10.1126/science.280.5363.596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554852				2022-12-01	WOS:000073242100049
J	Nelms, BE; Maser, RS; MacKay, JF; Lagally, MG; Petrini, JHJ				Nelms, BE; Maser, RS; MacKay, JF; Lagally, MG; Petrini, JHJ			In situ visualization of DNA double-strand break repair in human fibroblasts	SCIENCE			English	Article							CULTURED MAMMALIAN-CELLS; ULTRASOFT X-RAYS; ESCHERICHIA-COLI; RAD51 GENE; RECOMBINATION; DAMAGE; PROTEIN; INACTIVATION; RADIATIONS; EXPRESSION	A method was developed to examine DNA repair within the intact cell. Ultrasoft x-rays were used to induce DNA double-strand breaks (DSBs) in defined subnuclear volumes of human fibroblasts and DNA repair was visualized at those sites. The DSBs remained in a fixed position during the initial stages of DNA repair, and the DSB repair protein hMre11 migrated to the sites of damage within 30 minutes. In contrast, hRad51, a human RecA homolog, did not localize at sites of DNA damage, a finding consistent with the distinct roles of these proteins in DNA repair.	Univ Wisconsin, Sch Med, Genet Lab, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Med Phys, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Mat Sci & Engn, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Petrini, JHJ (corresponding author), Univ Wisconsin, Sch Med, Genet Lab, Madison, WI 53706 USA.		Maser, Richard/B-2970-2012		NIGMS NIH HHS [5T32GM07133, 5T32GM08349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008349, T32GM007133] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADIE C, 1995, CANCER RES, V55, P1232; BADIE C, 1995, RADIAT RES, V144, P26, DOI 10.2307/3579232; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Botchway SW, 1997, RADIAT RES, V148, P317, DOI 10.2307/3579516; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; CORNFORTH MN, 1983, SCIENCE, V222, P1141, DOI 10.1126/science.6648528; COX R, 1977, INT J RADIAT BIOL, V31, P561, DOI 10.1080/09553007714550661; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Flygare J, 1996, BBA-MOL CELL RES, V1312, P231, DOI 10.1016/0167-4889(96)00040-7; GOODHEAD DT, 1993, INT J RADIAT BIOL, V63, P543, DOI 10.1080/09553009314450721; GOODHEAD DT, 1979, INT J RADIAT BIOL, V36, P101, DOI 10.1080/09553007914550861; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; Jackson SP, 1996, CANCER SURV, V28, P261; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Kanaar Roland, 1997, Genes and Function, V1, P165; KODYM R, 1995, INT J RADIAT BIOL, V68, P133, DOI 10.1080/09553009514551031; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; Li X, 1995, CELL PROLIFERAT, V28, P571, DOI 10.1111/j.1365-2184.1995.tb00045.x; Lobrich M, 1995, P NATL ACAD SCI USA, V92, P12050, DOI 10.1073/pnas.92.26.12050; MACKAY JF, IN PRESS MED PHYS; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; NELMS BE, IN PRESS RAD RES; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NEVALDINE B, 1993, RADIAT RES, V133, P370, DOI 10.2307/3578224; Park MS, 1996, P NATL ACAD SCI USA, V93, P8368, DOI 10.1073/pnas.93.16.8368; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Singer RH, 1997, CELL, V91, P291, DOI 10.1016/S0092-8674(00)80411-0; Strouboulis J, 1996, J CELL SCI, V109, P1991; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; VIRSIKPEUCKERT RP, 1983, RAD INDUCED CHROMOSO, V4, P51; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; Yamamoto A, 1996, MOL GEN GENET, V251, P1	42	411	419	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					590	592		10.1126/science.280.5363.590	http://dx.doi.org/10.1126/science.280.5363.590			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554850				2022-12-01	WOS:000073242100047
J	Nureki, O; Vassylyev, DG; Tateno, M; Shimada, A; Nakama, T; Fukai, S; Konno, M; Hendrickson, TL; Schimmel, P; Yokoyama, S				Nureki, O; Vassylyev, DG; Tateno, M; Shimada, A; Nakama, T; Fukai, S; Konno, M; Hendrickson, TL; Schimmel, P; Yokoyama, S			Enzyme structure with two catalytic sites for double-sieve selection of substrate	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASES; PROTEIN-SYNTHESIS; VALINE; ISOLEUCINE; DISCRIMINATION; RECOGNITION; MECHANISMS; RESIDUES; ERRORS	High-fidelity transfers of genetic information in the central dogma can be achieved by a reaction called editing. The crystal structure of an enzyme with editing activity in translation is presented here at 2.5 angstroms resolution. The enzyme, isoleucyl-transfer RNA synthetase, activates not only the cognate substrate L-isoleucine but also the minimally distinct L-valine in the first, aminoacylation step. Then, in a second, "editing" step, the synthetase itself rapidly hydrolyzes only the valylated products. For this two-step substrate selection, a "double-sieve" mechanism has already been proposed. The present crystal structures of the synthetase in complexes with L-isoleucine and L-valine demonstrate that the first sieve is on the aminoacylation domain containing the Rossmann fold, whereas the second, editing sieve exists on a globular beta-barrel domain that protrudes from the aminoacylation domain.	Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 113, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 35101, Japan; Matsushita Elect Ind Co Ltd, Int Inst Adv Res, Cent Res Labs, Kyoto 61902, Japan; Ochanomizu Univ, Fac Sci, Dept Chem, Bunkyo Ku, Tokyo 112, Japan; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	University of Tokyo; RIKEN; Panasonic; Ochanomizu University; Scripps Research Institute	Yokoyama, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.	yokoyama@y-sun.biochem.s.u-tokyo.ac.jp	Vassylyev, Dmitry/A-9005-2008; Fukai, Shuya/X-4838-2018; Yokoyama, Shigeyuki/N-6911-2015	Fukai, Shuya/0000-0002-1241-1443; Yokoyama, Shigeyuki/0000-0003-3133-7338; Shimada, Atsushi/0000-0002-4108-770X	NIGMS NIH HHS [GM15539] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015539, R01GM015539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; BURGESS SM, 1993, TRENDS BIOCHEM SCI, V18, P381, DOI 10.1016/0968-0004(93)90094-4; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FARRASH MA, 1994, J VIROL, V68, P233; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FREIST W, 1985, BIOCHEMISTRY-US, V24, P7014, DOI 10.1021/bi00345a040; FREIST W, 1989, BIOCHEMISTRY-US, V28, P6787, DOI 10.1021/bi00443a001; FUKAI S, UNPUB; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; MILLER M, 1993, FEBS LETT, V328, P275, DOI 10.1016/0014-5793(93)80943-O; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; NUREKI O, UNPUB; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pauling L., 1957, FESTSCHRIFT ARTHUR S, P597; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SCHMIDT EG, UNPUB; SNEDDON SF, 1992, BIOCHEMISTRY-US, V31, P2842, DOI 10.1021/bi00125a028; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; TAKANO K, 1995, J MOL BIOL, V254, P62, DOI 10.1006/jmbi.1995.0599; Zhang ZY, 1996, CANCER RES, V56, P3926	34	310	323	3	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 24	1998	280	5363					578	582		10.1126/science.280.5363.578	http://dx.doi.org/10.1126/science.280.5363.578			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554847				2022-12-01	WOS:000073242100044
J	Fletcher, RH				Fletcher, RH			Should all people over the age of 50 have regular fecal occult-blood tests? If it works, why not do it?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COLORECTAL-CANCER; PREVENTION		Harvard Univ, Sch Med, Dep Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Fletcher, RH (corresponding author), Harvard Univ, Sch Med, Dep Ambulatory Care & Prevent, 126 Brookline Ave, Boston, MA 02215 USA.							Allison JE, 1996, NEW ENGL J MED, V334, P155, DOI 10.1056/NEJM199601183340304; Byers T, 1997, CA-CANCER J CLIN, V47, P154, DOI 10.3322/canjclin.47.3.154; Church TR, 1997, JNCI-J NATL CANCER I, V89, P1440, DOI 10.1093/jnci/89.19.1440; Ederer F, 1997, J NATL CANCER I, V89, P1423, DOI 10.1093/jnci/89.19.1423; FLEISHER M, 1991, ANN INTERN MED, V114, P875, DOI 10.7326/0003-4819-114-10-875; Hardcastle JD, 1996, LANCET, V348, P1472, DOI 10.1016/S0140-6736(96)03386-7; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; MANDEL JS, 1993, NEW ENGL J MED, V329, P672; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; Wagner JL, 1996, PREVENTION EARLY DET, P321; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WINAWER SJ, 1995, B WORLD HEALTH ORGAN, V73, P7; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P1060; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; 1995, MMWR MORB MORTAL WKL, V45, P57	16	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1153	1154						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9547141				2022-12-01	WOS:000073070100013
J	Reynolds, T				Reynolds, T			Epilepsy treatment enters a new era	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1998	128	8					702	704		10.7326/0003-4819-128-8-199804150-00039	http://dx.doi.org/10.7326/0003-4819-128-8-199804150-00039			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG912	9537959				2022-12-01	WOS:000073052500032
J	Zatonski, WA; McMichael, AJ; Powles, JW				Zatonski, WA; McMichael, AJ; Powles, JW			Ecological study of reasons for sharp decline in mortality from ischaemic heart disease in Poland since 1991	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIET; ACID	Objective: To investigate the reasons for the decline in deaths attributed to ischaemic heart disease in Poland since 1991 after two decades of rising rates. Design: Recent changes in mortality were measured as percentage deviations in 1994 from rates predicted by extrapolation of sex and age specific death rates for 1980-91 for diseases of the circulatory system and selected other categories, Available data on national and household food availability, alcohol consumption, cigarette smoking, socioeconomic indices, and medical services over time were reviewed. Main outcome measures: Age specific and age standardised rates of death attributed to ischaemic heart disease and related causes. Results: The change in trend in mortality attributed to diseases of the circulatory system was similar in men and women and most marked (> 20%) in early middle age, For ages 45 to 64 the decrease was greatest for deaths attributed to ischaemic heart disease and atherosclerosis (around 25%) and less for stroke (< 10%), For most of the potentially explanatory variables considered, there were no corresponding changes in trend. However, between 1986-90 and 1994 there was a marked switch from animal fats (estimated availability down 23%) to vegetable fats (up 48%) and increased imports of fruit. Conclusion: Reporting biases are unlikely to have exaggerated the true fall in ischaemic heart disease; neither is it likely to be mainly due to changes in smoking, drinking, stress, or medical care, Changes in type of dietary fat and increased supplies of fresh fruit and vegetables seem to be the best candidates.	Maria Sklodowska Curie Mem Canc Ctr, Dept Epidemiol & Canc Prevent, PL-02781 Warsaw, Poland; Inst Oncol, PL-02781 Warsaw, Poland; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1E 7HT, England; Inst Publ Hlth, Cambridge CB2 2SR, England	Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology; University of London; London School of Hygiene & Tropical Medicine; University of Cambridge	Zatonski, WA (corresponding author), Maria Sklodowska Curie Mem Canc Ctr, Dept Epidemiol & Canc Prevent, PL-02781 Warsaw, Poland.	zatonskiw@coi.waw.pl		Powles, John/0000-0002-0766-7989				Bobak M, 1996, BRIT MED J, V312, P421; BRUTHANS J, 1997, CAN J CARDIOL SB, V13; BURR ML, 1989, LANCET, V2, P757; *CENTR STAT OFF, 1995, ROCZN STAT DEM; *CENTR STAT OFF, 1995, ROCZN STAT; *CENTR STAT OFF, 1970, ROCZN STAT; CHALLARAJ G, 1996, TRENDS HLTH STATUS S, V2, P44; CHARNOCK JS, 1994, PROG LIPID RES, V33, P355, DOI 10.1016/0163-7827(94)90023-X; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; *DEP STAT INF AN, 1995, HLTH CAR NUMB; DESPAIGNET ET, 1991, AUSTR I HLTH MORTALI, V1, P94; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; HEINEMANN L, 1994, ACTA CARDIOL, V44, P338; KHAW KT, 1995, BRIT MED J, V310, P1559, DOI 10.1136/bmj.310.6994.1559; KOZAK LJ, 1988, COMP INT VITAL HLTH, V5; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6; McLennan P, 1996, EUR J PHARMACOL, V300, P83, DOI 10.1016/0014-2999(95)00861-6; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; OKOLSKI M, 1994, STUD DEMOGR, V17, P3; OLES P, 1983, WORLD SMOKING HLTH, V8, P38; Pajak A, 1996, Przegl Lek, V53, P707; Powles JW, 1996, LANCET, V348, P898, DOI 10.1016/S0140-6736(05)64777-0; SCHWARTZ S, 1994, AM J PUBLIC HEALTH, V84, P819, DOI 10.2105/AJPH.84.5.819; Sekula W, 1996, FOOD CONSUMPTION POL; SEKULA W, 1970, BUDZETY GOSPONDARSTW; SIEROSLAWSKI J, 1995, ALKOHOLIZM NARKOMANI, V3, P57; STEWART AW, 1994, INT J EPIDEMIOL, V23, P505; STROM A, 1948, ACTA MED SCAND, V214, P22; STROM A, LANCET, V1, P126; Thiel Christine, 1996, Reviews on Environmental Health, V11, P35; THOM TJ, 1992, NIH PUBL; Waterhouse J., 1976, CANCER INCIDENCE 5 C, V3, P456; WATSON P, 1996, E W LIFE EXP GAP EUR, P152; *WHO, 1997, HLTH DATA BAS COMP P; *WHO, 1960, WORLD HLTH STAT ANN; *WHO, 1988, WORLD HLTH STAT ANN, pR17; *WORLD BANK, 1996, PLAN MARK WORLD DEV, P173; Zatonski W, 1995, Public Health Rev, V23, P139; ZATONSKI W, 1996, EVOLUTION HLTH POLAN, P27	40	145	148	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 4	1998	316	7137					1047	1051						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552904				2022-12-01	WOS:000072987400022
J	Curhan, GC; Willett, WC; Speizer, FE; Stampfer, MJ				Curhan, GC; Willett, WC; Speizer, FE; Stampfer, MJ			Beverage use and risk for kidney stones in women	ANNALS OF INTERNAL MEDICINE			English	Article						kidney calculi; beverages; fluid intake; coffee; alcoholic beverages	FOOD FREQUENCY QUESTIONNAIRE; DIETARY CALCIUM; CONSUMPTION; REPRODUCIBILITY; VALIDITY; NEPHROLITHIASIS; UROLITHIASIS; PREVENTION; DISEASE; JUICE	Background: An increase in fluid intake is routinely recommended for patients who have had kidney stones to decrease the likelihood of recurrence. However, data on the effect of particular beverages on stone formation in women are limited. Objective: To examine the association between the intake of 17 beverages and risk for kidney stones in women. Design: Prospective cohort study with 8 years of follow-up. Setting: United States. Participants: 81093 women in the Nurses' Health Study who were 40 to 65 years of age in 1986 and had no history of kidney stones. Measurements: Beverage use and diet were assessed in 1986 and 1990 with a validated, self-administered food-frequency questionnaire. The main outcome measure was incident symptomatic kidney stones. Results: During 553081 person-years of follow-up over an 8-year period, 719 cases of kidney stones were documented. After risk factors other than fluid intake were controlled for, the relative risk for stone formation for women in the highest quintile of total fluid intake compared with women in the lowest quintile was 0.62 (95% CI, 0.48 to 0.80). Inclusion of consumption of specific beverages in the multivariate model significantly added to prediction of risk for kidney stones (P < 0.001). In a multivariate model that adjusted simultaneously for the 17 beverages and other possible risk factors, risk for stone formation decreased by the following amount for each 240-mL (8-oz) serving consumed daily: 10% (CI, 5% to 15%) for caffeinated coffee, 9% (CI, 2% to 15%) for decaffeinated coffee, 8% (CI, 1% to 15%) for tea, and 59% (CI, 32% to 75%) for wine. In contrast, a 44% (CI, 9% to 92%) increase in risk was seen for each 240-mL serving of grapefruit juice consumed daily. Conclusions: An increase in total fluid intake can reduce risk for kidney stones, and the choice of beverage may be meaningful.	Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Curhan, GC (corresponding author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.				NCI NIH HHS [CA40356] Funding Source: Medline; NIDDK NIH HHS [DK45362] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045362] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY DG, 1994, CLIN PHARMACOKINET, V26, P91, DOI 10.2165/00003088-199426020-00002; BRINKLEY LJ, 1990, J UROLOGY, V144, P94, DOI 10.1016/S0022-5347(17)39377-1; BROADUS AE, 1979, NEW ENGL J MED, V300, P839, DOI 10.1056/NEJM197904123001507; Colditz G A, 1995, J Am Med Womens Assoc (1972), V50, P40; Curhan GC, 1996, AM J EPIDEMIOL, V143, P240, DOI 10.1093/oxfordjournals.aje.a008734; Curhan GC, 1997, ANN INTERN MED, V126, P497, DOI 10.7326/0003-4819-126-7-199704010-00001; CURHAN GC, 1993, NEW ENGL J MED, V328, P833, DOI 10.1056/NEJM199303253281203; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; HASLING C, 1992, J NUTR, V122, P1119, DOI 10.1093/jn/122.5.1119; KASIDAS GP, 1980, J HUM NUTR, V34, P255; Krieger JN, 1996, AM J KIDNEY DIS, V28, P195, DOI 10.1016/S0272-6386(96)90301-7; LJUNGHALL S, 1988, EUR UROL, V14, P381; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MCKAY DW, 1995, J AM DIET ASSOC, V95, P360, DOI 10.1016/S0002-8223(95)00093-3; PAK CYC, 1980, ANN INTERN MED, V93, P36, DOI 10.7326/0003-4819-93-1-36; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; ROBERTSON GL, 1992, KIDNEY PHYSL PATHOPH; ROTHMAN KJ, 1986, MOERN EPIDEMIOLOGY; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SHUSTER J, 1992, J CLIN EPIDEMIOL, V45, P911, DOI 10.1016/0895-4356(92)90074-W; SHUSTER J, 1985, J CHRON DIS, V38, P907, DOI 10.1016/0021-9681(85)90126-2; SMITH LH, 1978, NEW ENGL J MED, V298, P87, DOI 10.1056/NEJM197801122980207; Soucie JM, 1996, AM J EPIDEMIOL, V143, P487; STRAUSS AL, 1982, AM J MED, V72, P17, DOI 10.1016/0002-9343(82)90566-6; VANDERHORST G, 1984, S AFR MED J, V66, P755; WABNER CL, 1993, J UROLOGY, V149, P1405, DOI 10.1016/S0022-5347(17)36401-7; WEISS GH, 1992, UROLOGY, V39, P331, DOI 10.1016/0090-4295(92)90208-E; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	32	186	189	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					534	+		10.7326/0003-4819-128-7-199804010-00003	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518397				2022-12-01	WOS:000072803500003
J	An, WG; Kanekal, M; Simon, MC; Maltepe, E; Blagosklonny, MV; Neckers, LM				An, WG; Kanekal, M; Simon, MC; Maltepe, E; Blagosklonny, MV; Neckers, LM			Stabilization of wild-type p53 by hypoxia-inducible factor 1 alpha	NATURE			English	Article							DNA-BINDING ACTIVITY; GROWTH-FACTOR GENE; FACTOR-I; TRANSCRIPTION FACTOR; ERYTHROPOIETIN GENE; SIGNAL-TRANSDUCTION; ACTIVATION; EXPRESSION; RECEPTOR; PROTEIN	Although hypoxia (lack of oxygen in body tissues) is perhaps the most physiological inducer of the wild-type p53 gene(1), the mechanism of this induction is unknown. Cells may detect low oxygen levels through a haem-containing sensor protein(2), The hypoxic state can be mimicked by using cobalt chloride and the iron chelator desferrioxamine(2-5): like hypoxia, cobalt chloride and desferrioxamine activate hypoxia-inducible factor 1 alpha (HIF-1 alpha) (ref. 6), which stimulates the transcription of several genes that are associated with hypoxia(6-9). Here we show that these treatments induce accumulation of wild-type p53 through HIF-1 alpha-dependent stabilization of p53 protein. Induction of p53 does not occur in either a mutant hepatoma cell line that is unable to induce HIF-1 alpha (ref. 10) or embryonic stem cells derived from mice lacking HIF-1 beta (ref. 11). HIF-1 alpha is found in p53 immunoprecipitates from II MCF7 cells that express wild-type p53 and are either hypoxic or have been exposed to desferrioxamine. Similarly, anti-haemagglutinin immunoprecipitates from lysates of normoxic PC3M cells that had been co-transfected with haemagglutinin-tagged HIF-1 alpha and wild-type p53 also contain p53. Transfection of normoxic MCF7 cells with HIF-1 alpha. stimulates a co-transfected p53-dependent reporter plasmid and increases the amount of endogenous p53. Our results suggest that hypoxic induction of transcriptionally active wild-type p53 is achieved as a result of the stabilization of p53 by its association with HIF-1 alpha.	NCI, Med Branch, NIH, Rockville, MD 20850 USA; NCI, Dept Cell & Canc Biol, Med Branch, NIH, Bethesda, MD 20892 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Dept Pathol, Chicago, IL 60637 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	Neckers, LM (corresponding author), NCI, Med Branch, NIH, Key W Facil,9610 Med Ctr Dr,Room 300, Rockville, MD 20850 USA.	len@helix.nih.gov	Simon, Celeste/AAG-3941-2021					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gradin K, 1996, MOL CELL BIOL, V16, P5221; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Maki CG, 1996, CANCER RES, V56, P2649; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117	23	726	761	3	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 26	1998	392	6674					405	408		10.1038/32925	http://dx.doi.org/10.1038/32925			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537326				2022-12-01	WOS:000072713600056
J	Kengaku, M; Capdevila, J; Rodriguez-Esteban, C; De La Pena, J; Johnson, RL; Belmonte, JCI; Tabin, CJ				Kengaku, M; Capdevila, J; Rodriguez-Esteban, C; De La Pena, J; Johnson, RL; Belmonte, JCI; Tabin, CJ			Distinct WNT pathways regulating AER formation and dorsoventral polarity in the chick limb bud	SCIENCE			English	Article							TRANSCRIPTION FACTOR LEF-1; BETA-CATENIN; VERTEBRATE LIMB; XENOPUS EMBRYOS; GENE-EXPRESSION; SONIC-HEDGEHOG; CELL FATE; AXIS; INDUCTION; DOMAINS	The apical ectodermal ridge (AER) is an essential structure for vertebrate limb development. Wnt3a is expressed during the induction of the chick AER, and misexpression of Wnt3a induces ectopic expression of AER-specific genes in the limb ectoderm. The genes beta-catenin and Lef1 can mimic the effect of Wnt3a, and blocking the intrinsic Lef1 activity disrupts AER formation. Hence, Wnt3a functions in AER formation through the beta-catenin/LEF1 pathway. In contrast, neither beta-catenin nor Lef1 affects the Wnt7a-regulated dorsoventral polarity of the limb. Thus, two related Wnt genes elicit distinct responses in the same tissues by using different intracellular pathways.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Salk Institute; Harvard University; Harvard Medical School; University of Texas System; UTMD Anderson Cancer Center	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DU SJ, 1995, MOL CELL BIOL, V15, P2625; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GASTROP J, 1992, EUR J IMMUNOL, V22, P1327, DOI 10.1002/eji.1830220531; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Greco TL, 1996, GENE DEV, V10, P313, DOI 10.1101/gad.10.3.313; HOLLYDAY M, 1995, MECH DEVELOP, V52, P9, DOI 10.1016/0925-4773(95)00385-E; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KENGAKU M, UNPUB; KENGAKU M, 1998, COLD SPRING HARBOR L, V12, P421; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MCGREW LL, 1995, DEV BIOL, V172, P337, DOI 10.1006/dbio.1995.0027; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; Noramly S, 1996, DEV BIOL, V179, P339, DOI 10.1006/dbio.1996.0265; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; RodriguezEsteban C, 1997, NATURE, V386, P360, DOI 10.1038/386360a0; ROS MA, 1992, DEVELOPMENT, V116, P811; Ros MA, 1997, DEVELOPMENT, V124, P1821; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SAWAI S, 1990, MOL CELL BIOL, V10, P2017, DOI 10.1128/MCB.10.5.2017; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vogel A, 1996, DEVELOPMENT, V122, P1737; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; YOKOUCHI Y, 1991, DEVELOPMENT, V113, P431; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	46	355	363	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1274	1277		10.1126/science.280.5367.1274	http://dx.doi.org/10.1126/science.280.5367.1274			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596583				2022-12-01	WOS:000073852500052
J	Dwyer, ND; Troemel, ER; Sengupta, P; Bargmann, CI				Dwyer, ND; Troemel, ER; Sengupta, P; Bargmann, CI			Odorant receptor localization to olfactory cilia is mediated by ODR-4, a novel membrane-associated protein	CELL			English	Article							ACHIEVE BASOLATERAL LOCALIZATION; DOMINANT RETINITIS-PIGMENTOSA; CYCLOPHILIN HOMOLOG NINAA; CANINE KIDNEY-CELLS; CAENORHABDITIS-ELEGANS; C-ELEGANS; MICROSCOPY; CHAPERONE; RHODOPSIN; TRANSPORT	Seven transmembrane domain receptors can be localized to different parts of the plasma membrane or to different intracellular compartments in a receptor-specific and cell type-specific fashion. We show here that the C. elegans genes odr-4 and odr-8 are required for localization of a subset of seven transmembrane domain odorant receptors to the cilia of olfactory neurons. Other cilia-signaling proteins, including ion channels, a G alpha protein, and even other receptor types, are localized via an odr-4/odr-8-independent pathway. odr-4 encodes a novel membrane protein that is expressed exclusively on intracellular membranes of chemosensory neurons, where it acts cell-autonomously to facilitate odorant receptor folding or localization.	Univ Calif San Francisco, Howard Hughes Med Inst, Program Dev Biol, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Genet Program, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bargmann, CI (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Program Dev Biol, Dept Anat, San Francisco, CA 94143 USA.			Bargmann, Cornelia/0000-0002-8484-0618; Dwyer, Noelle/0000-0002-1995-7203				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Bohm SK, 1997, J BIOL CHEM, V272, P2363; BRENNER S, 1974, GENETICS, V77, P71; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; Chou JH, 1996, COLD SPRING HARB SYM, V61, P157; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Colbert HA, 1997, J NEUROSCI, V17, P8259; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Mombaerts P, 1996, COLD SPRING HARB SYM, V61, P135; Ng GYK, 1997, ENDOCRINOLOGY, V138, P4199, DOI 10.1210/en.138.10.4199; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Saunders C, 1996, J BIOL CHEM, V271, P995, DOI 10.1074/jbc.271.2.995; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1994, J NEUROSCI, V14, P5818; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; WILLIAMS BD, 1992, GENETICS, V131, P609; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wozniak M, 1997, J RECEPT SIGNAL TR R, V17, P373, DOI 10.3109/10799899709036615; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Yu R, 1997, MOL PHARMACOL, V51, P785, DOI 10.1124/mol.51.5.785; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P12162, DOI 10.1073/pnas.94.22.12162	46	197	211	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1998	93	3					455	466		10.1016/S0092-8674(00)81173-3	http://dx.doi.org/10.1016/S0092-8674(00)81173-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590179	Bronze			2022-12-01	WOS:000073471500020
J	Epstein, R; Kanwisher, N				Epstein, R; Kanwisher, N			A cortical representation of the local visual environment	NATURE			English	Article							SPATIAL REORIENTATION; LANDMARK STABILITY	Medial temporal brain regions such as the hippocampal formation and parahippocampal cortex have been generally implicated in navigation(1-6) and visual memory(7-9). However, the specific function of each of these regions is not yet clear, Here we present evidence that a particular area within human parahippocampal cortex is involved in a critical component of navigation: perceiving the local visual environment, This region, which we name the 'parahippocampal place area' (PPA), responds selectively and automatically in functional magnetic resonance imaging (fMRI) to passively viewed scenes, but only weakly to single objects and not at all to faces, The critical factor for this activation appears to be the presence in the stimulus of information about the layout of local space. The response in the PPA to scenes with spatial layout but no discrete objects (empty rooms) is as strong as the response to complex meaningful scenes containing multiple objects (the same rooms furnished) and over twice as strong as the response to arrays of multiple objects without three-dimensional spatial context (the furniture from these rooms on a blank background). This response is reduced if the surfaces in the scene are rearranged so that they no longer define a coherent space, We propose that the PPA represents places by encoding the geometry of the local environment.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Epstein, R (corresponding author), MIT, Dept Brain & Cognit Sci, E10-238,79 Amherst St, Cambridge, MA 02139 USA.	epstein@psyche.mit.edu	Kennedy, Kristen M/B-4699-2008; Epstein, Russell/G-4517-2013	Kennedy, Kristen M/0000-0001-5373-9026; 				Aguirre GK, 1998, P NATL ACAD SCI USA, V95, P839, DOI 10.1073/pnas.95.3.839; Aguirre GK, 1997, J NEUROSCI, V17, P2512; Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; BIEGLER R, 1993, NATURE, V361, P631, DOI 10.1038/361631a0; BOHBOT V, IN PRESS NEUROPSYCHO; CHENG K, 1986, COGNITION, V23, P149, DOI 10.1016/0010-0277(86)90041-7; Fodor JA., 1983, MODULARITY MIND; Gabrieli JDE, 1997, SCIENCE, V276, P264, DOI 10.1126/science.276.5310.264; GAFFAN D, 1994, J COGNITIVE NEUROSCI, V6, P305, DOI 10.1162/jocn.1994.6.4.305; Gallistel C.R., 1990, ORG LEARNING; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; Hermer L, 1996, COGNITION, V61, P195, DOI 10.1016/S0010-0277(96)00714-7; HERMER L, 1994, NATURE, V370, P57, DOI 10.1038/370057a0; ISHAI A, 1997, NEUROIMAGE, V5, pS149; Kanwisher N, 1997, J NEUROSCI, V17, P4302; KNIERIM JJ, 1995, J NEUROSCI, V15, P1648, DOI 10.1523/JNEUROSCI.15-03-01648.1995; LANDIS T, 1986, ARCH NEUROL-CHICAGO, V43, P132, DOI 10.1001/archneur.1986.00520020026011; Maguire EA, 1996, P ROY SOC B-BIOL SCI, V263, P1745, DOI 10.1098/rspb.1996.0255; Maguire EA, 1997, J NEUROSCI, V17, P7103; MAGUIRE EA, 1996, NEUROPSYCHOLOGIA, V34, P994; MARGULES J, 1988, ANIM LEARN BEHAV, V16, P404, DOI 10.3758/BF03209379; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Rolls ET, 1997, EUR J NEUROSCI, V9, P1789, DOI 10.1111/j.1460-9568.1997.tb01538.x; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660	24	1987	2013	6	176	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					598	601		10.1038/33402	http://dx.doi.org/10.1038/33402			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZG300	9560155				2022-12-01	WOS:000072987200058
J	Jollis, JG; Romano, PS				Jollis, JG; Romano, PS			Sounding board - Pennsylvania's Focus on Heart Attack - Grading the scorecard	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADMISSION SEVERITY; DISCHARGE DATA; MORTALITY; OUTCOMES; COMORBIDITIES; MEDISGROUPS; INFARCTION; VOLUME; CARE		Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA; Duke Clin Res Inst, Durham, NC 27710 USA	University of California System; University of California Davis; Duke University	Jollis, JG (corresponding author), Duke Univ, Med Ctr, Box 3254, Durham, NC 27710 USA.		Romano, Patrick S/N-4225-2014	Romano, Patrick S/0000-0001-6749-3979	AHRQ HHS [HS08574] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Berwick DM, 1996, JAMA-J AM MED ASSOC, V275, P877, DOI 10.1001/jama.275.11.877; BLUMBERG MS, 1991, JAMA-J AM MED ASSOC, V265, P2965; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; Ellis SG, 1996, CIRCULATION, V93, P431, DOI 10.1161/01.CIR.93.3.431; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; Ghali WA, 1997, JAMA-J AM MED ASSOC, V277, P379, DOI 10.1001/jama.277.5.379; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; IEZZONI LI, 1995, ANN INTERN MED, V123, P763, DOI 10.7326/0003-4819-123-10-199511150-00004; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; Jencks SF, 1997, JAMA-J AM MED ASSOC, V277, P419; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; JOLLIS JG, 1994, NEW ENGL J MED, V331, P1625, DOI 10.1056/NEJM199412153312406; Jollis JG, 1996, MAYO CLIN PROC, V71, P1016, DOI 10.1016/S0025-6196(11)63780-4; KRAKAUER H, 1992, HEALTH SERV RES, V27, P317; LEGNINI MW, 1996, 2 OFF STAT HLTH PLAN, V2; MCMAHON LF, 1986, ANN INTERN MED, V104, P562, DOI 10.7326/0003-4819-104-4-562; *PA HLTH CAR COST, 1996, RES PLAN 1993 HEART; Pennsylvania Health Care Cost Containment Council, 1996, FOC HEART ATT PENNS; *PRACT MAN INF, 1991, INT CLASS DIS; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P2438; STEEN PM, 1993, INQUIRY-J HEALTH CAR, V30, P128; TOPOL EJ, 1994, ANN INTERN MED, V120, P65, DOI 10.7326/0003-4819-120-1-199401010-00011	27	48	48	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					983	987		10.1056/NEJM199804023381410	http://dx.doi.org/10.1056/NEJM199804023381410			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE776	9521989				2022-12-01	WOS:000072829800010
J	Fisher, K; Hanspal, RS				Fisher, K; Hanspal, RS			Phantom pain, anxiety depression, and their relation in consecutive patients with amputated limbs: case reports	BRITISH MEDICAL JOURNAL			English	Article									Royal Natl Orthopaed Hosp Trust, Disablement Serv Ctr, Stanmore HA7 4LP, Middx, England	University of London; University College London; Royal National Orthopaedic Hospital NHS Trust	Fisher, K (corresponding author), Royal Natl Orthopaed Hosp Trust, Disablement Serv Ctr, Brockley Hill, Stanmore HA7 4LP, Middx, England.							KATZ J, 1990, PAIN, V43, P319, DOI 10.1016/0304-3959(90)90029-D; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; PARKES CM, 1973, J PSYCHOSOM RES, V17, P97, DOI 10.1016/0022-3999(73)90010-X; Sherman R, 1995, J MILIT PSYCHOL, V7, P28; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	5	34	37	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					903	904		10.1136/bmj.316.7135.903	http://dx.doi.org/10.1136/bmj.316.7135.903			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD691	9552839	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000072713300029
J	Dolk, H				Dolk, H			Rise in prevalence of hypospadias	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Environm Epidemiol Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Dolk, H (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Environm Epidemiol Unit, London WC1E 7HT, England.							CALZOLARI E, 1986, J MED GENET, V23, P333, DOI 10.1136/jmg.23.4.333; *EUROCAT WORK GROU, 1997, 7 EUROCAT SCI I PUBL; *INT CTR BIRTH DEF, 1982, INT CLEAR BIRTH DEF; KALLEN B, 1986, ACTA PAEDIATR SCAND, P1; KALLEN B, 1986, J MED GENET, V23, P333; MATLAI P, 1985, LANCET, V1, P108; Paulozzi LJ, 1997, PEDIATRICS, V100, P831, DOI 10.1542/peds.100.5.831; RAMANWILMS L, 1995, OBSTET GYNECOL, V85, P141, DOI 10.1016/0029-7844(94)00341-A; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.1289/ehp.96104s4741	10	65	69	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 14	1998	351	9105					770	770		10.1016/S0140-6736(05)78924-8	http://dx.doi.org/10.1016/S0140-6736(05)78924-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519944				2022-12-01	WOS:000072521200005
J	Tang, MX; Stern, Y; Marder, K; Bell, K; Gurland, B; Lantigua, R; Andrews, H; Feng, L; Tycko, B; Mayeux, R				Tang, MX; Stern, Y; Marder, K; Bell, K; Gurland, B; Lantigua, R; Andrews, H; Feng, L; Tycko, B; Mayeux, R			The APOE-epsilon 4 allele and the risk of Alzheimer disease among African Americans, Whites, and Hispanics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARADIGM-BASED DIAGNOSIS; APOLIPOPROTEIN-E; HETEROGENEOUS POPULATION; DEMENTIA; EPSILON-4; ASSOCIATION; EDUCATION; COMMUNITY; SURVIVAL	Context.-Although the association between Alzheimer disease (AD) and the apolipoprotein E epsilon 4 (APOE-epsilon 4) allele has been confirmed worldwide, it appears to be inconsistent among African Americans, Hispanics, and Nigerians. Objective.-To investigate the association between the APOE-epsilon 4 allele and AD in elderly African Americans, Hispanics, and whites. Design.-Prospective, population-based, longitudinal study over a 5-year period (1991-1996). Setting.-The Washington Heights-Inwood community of New York City. Participants.-A total of 1079 Medicare recipients without AD or a related disorder at baseline. Main Outcome Measures.-Risk of clinically diagnosed AD in the 3 ethnic groups and among individuals with and without an APOE-epsilon 4 allele. Results.-Compared with individuals with the APOE-epsilon 3/epsilon 3 genotype, the relative risk (RR) of AD associated with 1 or more copies of the APOE-epsilon 4 allele was significantly increased among whites (RR, 2.5; 95% confidence interval [CI], 1.1-6.4), but not among African Americans (RR, 1.0; 95% CI, 0.6-1.6) or Hispanics (RR, 1.1; 95% CI, 0.7-1.6). In the absence of the APOE-epsilon 4 allele, the cumulative risks of AD to age 90 years, adjusted for education and sex, were 4 times higher for African Americans (RR, 4.4; 95% CI, 2.3-8.6) and 2 times higher for Hispanics (RR, 2.3; 95% CI, 1.2-4.3) than for whites. In the presence of an APOE-epsilon 4 allele, the cumulative risk of AD to age 90 years was similar for individuals in all 3 ethnic groups. Conclusion.-The presence of an APOE-epsilon 4 allele is a determinant of AD risk in whites, but African Americans and Hispanics have an increased frequency of AD regardless of their APOE genotype. These results suggest that other genes or risk factors may contribute to the increased risk of AD in African Americans and Hispanics.	Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Taub Ctr Alzheimers Dis Res, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Sch Publ Hlth, Div Biostat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Morris W Stroud III Ctr Study Qual Life, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, Dept Stat, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; NewYork-Presbyterian Hospital; New York State Psychiatry Institute	Mayeux, R (corresponding author), Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, 630 W 168th St, New York, NY 10032 USA.	rpm2@columbia.edu		Stern, Yaakov/0000-0001-7542-3241	NATIONAL INSTITUTE ON AGING [P50AG008702, R35AG010963, P01AG007232] Funding Source: NIH RePORTER; NIA NIH HHS [AG10963, AG08702, AG07232] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd; BOHNSTEDT M, 1994, J CLIN EPIDEMIOL, V47, P1381, DOI 10.1016/0895-4356(94)90082-5; Bureau of the Census, 1991, 1990 CENS POP HOUS S; Collett D, 1994, MODELLING SURVIVAL D, P149; CORDER EH, 1995, NEUROLOGY, V45, P1323, DOI 10.1212/WNL.45.7.1323; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cox DR., 1984, ANAL SURVIVAL DATA; DELAMONTE SM, 1989, J NATL MED ASSOC, V81, P644; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; FLEISS JL, 1981, STATISTICAL METHODS, P160; GURLAND B, 1995, AM J GERIAT PSYCHIAT, V3, P6, DOI 10.1097/00019442-199524310-00002; Gurland B, 1997, RACIAL AND ETHNIC DIFFERENCES IN THE HEALTH OF OLDER AMERICANS, P233; HENDERSON AS, 1995, LANCET, V346, P1387, DOI 10.1016/S0140-6736(95)92405-1; HENDRIE HC, 1995, ANN NEUROL, V37, P118, DOI 10.1002/ana.410370123; HIXSON JE, 1990, J LIPID RES, V31, P545; HOBBS FB, 1996, PUBLICATION BUR CENS; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Korn EL, 1997, AM J EPIDEMIOL, V145, P72; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; OSUNTOKUN BO, 1995, ANN NEUROL, V38, P463, DOI 10.1002/ana.410380319; PITTMAN J, 1992, ARCH NEUROL-CHICAGO, V49, P461, DOI 10.1001/archneur.1992.00530290043010; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; Sahota A, 1997, ANN NEUROL, V42, P659, DOI 10.1002/ana.410420418; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; Scott WK, 1997, ANN NEUROL, V42, P376, DOI 10.1002/ana.410420317; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; Stern Y, 1997, ANN NEUROL, V41, P615, DOI 10.1002/ana.410410510; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; Tang MX, 1996, AM J HUM GENET, V58, P574; VANDUIJN CM, 1995, ANN NEUROL, V37, P605, DOI 10.1002/ana.410370510; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74	36	548	556	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1998	279	10					751	755		10.1001/jama.279.10.751	http://dx.doi.org/10.1001/jama.279.10.751			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA474	9508150	Bronze			2022-12-01	WOS:000072366900031
J	Siersted, HC				Siersted, HC			Commentary: Improving the diagnostic rate in asthma: a community issue	BRITISH MEDICAL JOURNAL			English	Editorial Material									Odense Univ Hosp, Dept Med C, Sect Resp Dis, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital	Siersted, HC (corresponding author), Odense Univ Hosp, Dept Med C, Sect Resp Dis, DK-5000 Odense C, Denmark.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					657	657						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522786				2022-12-01	WOS:000072347900025
J	Goyder, EC; McNally, PG; Drucquer, M; Spiers, N; Botha, JL				Goyder, EC; McNally, PG; Drucquer, M; Spiers, N; Botha, JL			Shifting of care for diabetes from secondary to primary care, 1990-5: review of general practices	BRITISH MEDICAL JOURNAL			English	Review									Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England; Leicester Royal Infirm NHS Trust, Dept Endocrinol & Diabet, Leicester LE1 5WW, Leics, England; S Wigston Hlth Ctr, Leicester LE8 2SE, Leics, England	University of Leicester	Goyder, EC (corresponding author), Univ Sydney, Dept Publ Hlth & Community Med, Edward Ford Bldg A27, Sydney, NSW 2006, Australia.		Goyder, Elizabeth E/A-2146-2010	Goyder, Elizabeth E/0000-0003-3691-1888				Alexander WD, 1997, LANCET, V349, P578, DOI 10.1016/S0140-6736(97)80134-1; Krans H., 1992, DIABETES CARE RES EU; LEESE B, 1995, BRIT MED J, V311, P546, DOI 10.1136/bmj.311.7004.546; LOWY A, 1993, BRIT MED J, V307, P413, DOI 10.1136/bmj.307.6901.413; MARKS L, 1996, COUNTING COST REAL I	5	50	51	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1998	316	7143					1505	1506		10.1136/bmj.316.7143.1505	http://dx.doi.org/10.1136/bmj.316.7143.1505			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP020	9582142	Green Published			2022-12-01	WOS:000073707700032
J	Tynell, E; Andersson, S; Lithander, E; Arneborn, M; Blomberg, J; Hansson, HB; Krook, A; Nomberg, M; Ramstedt, K; Shanwell, A; Bjorkman, A				Tynell, E; Andersson, S; Lithander, E; Arneborn, M; Blomberg, J; Hansson, HB; Krook, A; Nomberg, M; Ramstedt, K; Shanwell, A; Bjorkman, A			Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA-LYMPHOMA VIRUS; HTLV-I; TRANSMISSION; TRANSFUSION; ANTIBODIES; RECIPIENTS; PREVALENCE; JAPAN	Objective: To analyse the cost effectiveness of a national programme to screen blood donors for infection with the human T cell leukaemia/lymphoma virus. Design: Three models for calculating the costs and benefits of screening were developed. The first model analysed the cost of continuously testing all donations; the second analysed the cost of initially testing nerv blood dollars and then retesting them after five years; the third analysed the cost of testing donors only at the time of their first donation, Patients who had received blood components from donors confirmed to be infected with the virus were offered testing. Setting: Sweden. Main outcome measures: Prevalence of infection with the virus among blood donors, the risk of transmission of the virus, screening costs, and the outcome of infection. Results: 648 497 donations were tested for the virus; 1625 samples tested positive by enzyme linked immunosorbent assay, 6 were confirmed positive by western blotting. The prevalence of infection with the virus was 2/100 000 donors. 35 patients who had received blood infected with the virus were tested; 3 were positive. The cost of testing every donation was calculated to be $3.02m (pound 1.88m); this is 18 times higher than the cost of testing new donors only, and only 1 additional positive donor would be discovered in 7 years. Regardless of the model used, screening was estimated to prevent only 1 death every 200 years at a minimum cost of $36m (pound 22.5m). Conclusion: Based on these estimates the Swedish National Board of Health and Welfare decided that only new blood donors would be screened for infection with the virus.	Danderyd Univ Hosp, Karolinska Inst, Div Infect Dis, Danderyd, Sweden; Swedish Inst Infect Dis, Stockholm, Sweden; Karolinska Inst, Stockholm, Sweden; Natl Board Hlth & Welf, Stockholm, Sweden; Univ Lund, Dept Med Microbiol, Sect Virol, Lund, Sweden; Univ Hosp MAS, Reg Ctr Communicable Dis Control, Malmo, Sweden; Huddinge Univ Hosp, Karolinska Inst, Div Infect Dis, S-14186 Huddinge, Sweden; South Hosp, Div Transfus Med, Stockholm, Sweden	Danderyds Hospital; Karolinska Institutet; Swedish Institute for Infectious Disease Control; Karolinska Institutet; National Board of Health & Welfare; Lund University; Lund University; Skane University Hospital; Karolinska Institutet	Tynell, E (corresponding author), Danderyd Univ Hosp, Karolinska Inst, Div Infect Dis, Danderyd, Sweden.	elsa.tynell@inf.ds.sll.se	Krook, Anna/K-1192-2015	Krook, Anna/0000-0002-0891-0258; Blomberg, Jonas/0000-0001-6492-2491				ANDERSSON S, 1994, 10 INT C AIDS STD YO; BOHNCHRISTANSEN C, 1995, J ACQ IMMUN DEF SYND, V10, P251; BRENNAN M, 1993, BRIT MED J, V307, P1235, DOI 10.1136/bmj.307.6914.1235; COUROUCE AM, 1993, AIDS, V7, P841, DOI 10.1097/00002030-199306000-00013; DALGLEISH AG, 1993, BRIT MED J, V307, P1224, DOI 10.1136/bmj.307.6914.1224; DEFER C, 1995, TRANSFUSION, V35, P506; DONEGAN E, 1994, TRANSFUSION, V34, P478, DOI 10.1046/j.1537-2995.1994.34694295061.x; Goubau P, 1996, J ACQ IMMUN DEF SYND, V13, P68; IWATA K, 1994, JPN J CANCER RES, V85, P231, DOI 10.1111/j.1349-7006.1994.tb02087.x; KAGESON P, 1993, GETTING PRICES RIGHT, P114; KAJIYAMA W, 1986, J INFECT DIS, V154, P851, DOI 10.1093/infdis/154.5.851; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KAMIHIRA S, 1987, VOX SANG, V52, P43, DOI 10.1111/j.1423-0410.1987.tb02987.x; Krook A, 1997, J ACQ IMMUN DEF SYND, V15, P381, DOI 10.1097/00042560-199708150-00009; KWOK S, 1990, TRANSFUSION, V30, P491, DOI 10.1046/j.1537-2995.1990.30690333477.x; LEE HH, 1991, LANCET, V337, P1435, DOI 10.1016/0140-6736(91)93126-T; MURPHY E, 1990, HUMAN RETROVIROLOGY, P290; Nyambi Phillipe N., 1995, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, V10, P258; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; OSAME M, 1987, ANN NEUROL, V21, P117, DOI 10.1002/ana.410210203; PILLONEL J, 1995, J ACQ IMMUN DEF SYND, V10, P251; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SULLIVAN MT, 1991, ARCH INTERN MED, V151, P2043, DOI 10.1001/archinte.151.10.2043; Tajima K., 1995, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, V10, P285; YAMAGUCHI K, 1994, LANCET, V343, P213, DOI 10.1016/S0140-6736(94)90994-6; ZAAIJER HL, 1994, TRANSFUSION, V34, P1; 1988, MMWR MORB MORTAL WKL, V37, P736; 1966, ECONOMIST       0316, P29; 1992, WHO WKLY EPIDEMIOLOG, V29, P213	29	31	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1998	316	7142					1417	1422		10.1136/bmj.316.7142.1417	http://dx.doi.org/10.1136/bmj.316.7142.1417			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZN495	9572750	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000073651600025
J	Pier, GB; Grout, M; Zaidi, T; Meluleni, G; Mueschenborn, SS; Banting, G; Ratcliff, R; Evans, MJ; Colledge, WH				Pier, GB; Grout, M; Zaidi, T; Meluleni, G; Mueschenborn, SS; Banting, G; Ratcliff, R; Evans, MJ; Colledge, WH			Salmonella typhi uses CFTR to enter intestinal epithelial cells	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; FIBROSIS MOUSE MODEL; GENE; INVASION; MURINE	Homozygous mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) cause cystic fibrosis (CF). In the heterozygous state, increased resistance to infectious diseases may maintain mutant CFTR alleles at high levels in selected populations'. Here we investigate whether typhoid fever could be one such disease. The disease is initiated when Salmonella typhi enters gastrointestinal epithelial cells for submucosal translocation(2). We found that S, typhi but not the related murine pathogen S. typhimurium, uses CFTR for entry into epithelial cells. Cells expressing wild-type CFTR internalized more S. typhi than isogenic cells expressing the most common CFTR mutation, a phenylalanine deleted at residue 508 (Delta 508). Monoclonal antibodies and synthetic peptides containing a sequence corresponding to the first predicted extracellular domain of CFTR inhibited uptake of S. typhi. Heterozygous Delta F508 Cftr mice translocated 86% fewer S. typhi into the gastrointestinal submucosa than wild-type Cftr mice; no translocation occurred in Delta F508 Cftr homozygous mice. The Cftr genotype had no effect on the translocation of S. typhimurium. Immunoelectron microscopy revealed that more CFTR bound to S. typhi in the submucosa of Cftr wild-type mice than in Delta F508 heterozygous mice. We conclude that diminished levels of CFTR in heterozygotes may decrease susceptibility to typhoid fever.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Univ Bristol, Mol Recognit Ctr, Dept Biochem & Biotechnol & Biol Sci Res Council, Bristol BS8 1TD, Avon, England; Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England; Univ Cambridge, Wellcome CRC Inst Canc & Dev Biol, Cambridge CB2 1QR, England; Univ Cambridge, Dept Genet, Cambridge CB2 1QR, England	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Bristol; University of Cambridge; University of Cambridge; University of Cambridge	Pier, GB (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA.	gpier@channing.harvard.edu	Colledge, William/X-4976-2019; Pier, Gerald/AAO-2692-2021	Colledge, William/0000-0002-9603-4429; Pier, Gerald/0000-0002-9112-2331; Banting, George/0000-0001-8249-1621	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALPUCHEARANDA CM, 1995, INFECT IMMUN, V63, P4456, DOI 10.1128/IAI.63.11.4456-4462.1995; Beatty WL, 1997, INFECT IMMUN, V65, P4395, DOI 10.1128/IAI.65.11.4395-4404.1997; BERTRANPETIT J, 1996, VARIATION HUMAN GENO, P97; CHENG SH, 1995, AM J PHYSIOL-LUNG C, V268, pL615, DOI 10.1152/ajplung.1995.268.4.L615; COLLEDGE WH, 1995, NAT GENET, V10, P445, DOI 10.1038/ng0895-445; CUTHBERT AW, 1995, J PHYSIOL-LONDON, V482, P449, DOI 10.1113/jphysiol.1995.sp020531; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FLEISZIG SMJ, 1995, INFECT IMMUN, V63, P4072, DOI 10.1128/IAI.63.10.4072-4077.1995; FLOTTE TR, 1993, P NATL ACAD SCI USA, V90, P10613, DOI 10.1073/pnas.90.22.10613; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; Ishibashi Y, 1996, MICROB PATHOGENESIS, V21, P435, DOI 10.1006/mpat.1996.0074; JONES BD, 1994, J EXP MED, V180, P15, DOI 10.1084/jem.180.1.15; Jones BD, 1996, ANNU REV IMMUNOL, V14, P533, DOI 10.1146/annurev.immunol.14.1.533; MILLS SD, 1994, MICROB PATHOGENESIS, V17, P409, DOI 10.1006/mpat.1994.1086; OLSEN JC, 1992, HUM GENE THER, V3, P253, DOI 10.1089/hum.1992.3.3-253; ORIORDAN CR, 1995, J BIOL CHEM, V270, P17033, DOI 10.1074/jbc.270.28.17033; PASCOPELLA L, 1995, INFECT IMMUN, V63, P4329, DOI 10.1128/IAI.63.11.4329-4335.1995; Pier GB, 1997, P NATL ACAD SCI USA, V94, P12088, DOI 10.1073/pnas.94.22.12088; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; POLLITZNER R, 1959, CHOLERA; ROMEO G, 1989, HUM GENET, V84, P1, DOI 10.1007/BF00210660; ROSNER B, 1990, FUNDAMENTALS BIOSTAT, P498; TSUI LC, 1995, AM J RESP CRIT CARE, V151, pS47, DOI 10.1164/ajrccm/151.3_Pt_2.S47; VANHEYNINGEN WE, 1983, CHOLERA AM SCI ENCOU, P1; WALKER J, 1995, J CELL SCI, V108, P2433	25	244	256	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1998	393	6680					79	82		10.1038/30006	http://dx.doi.org/10.1038/30006			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590693				2022-12-01	WOS:000073497500051
J	Marciniak, TA; Ellerbeck, EF; Radford, MJ; Kresowik, TF; Gold, JA; Krumholz, HM; Kiefe, CI; Allman, RM; Vogel, RA; Jencks, SF				Marciniak, TA; Ellerbeck, EF; Radford, MJ; Kresowik, TF; Gold, JA; Krumholz, HM; Kiefe, CI; Allman, RM; Vogel, RA; Jencks, SF			Improving the quality of care for Medicare patients with acute myocardial infarction - Results from the Cooperative Cardiovascular Project	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUIDELINES; MANAGEMENT; ASSURANCE	Context.-Medicare has a legislative mandate for quality assurance, but the effectiveness of its population-based quality improvement programs has been difficult to establish. Objective.-To improve the quality of care for Medicare patients with acute myocardial infarction. Design.-Quality improvement project with baseline measurement, feedback, remeasurement, and comparison samples. Setting.-All acute care hospitals in the United States. Patients.-Preintervention and postintervention samples included all Medicare patients in Alabama, Connecticut, Iowa, and Wisconsin discharged with principal diagnoses of acute myocardial infarctions during 2 periods, June 1992 through December 1992 and August 1995 through November 1995, Indicator comparisons were made with a random sample of Medicare patients in the rest of the nation discharged with acute myocardial infarctions from August 1995 through November 1995, Mortality comparisons involved all Medicare patients nationwide with inpatient claims for acute myocardial infarctions during 2 periods, June 1992 through May 1993 and August 1995 through July 1996. Intervention.-Data feedback by peer review organizations. Main Outcome Measures.-Quality indicators derived from clinical practice guidelines, length of stay, and mortality. Results.-Performance on all quality indicators improved significantly in the 4 pilot states. Administration of aspirin during hospitalization in patients without contraindications improved from 84% to 90% (P<.001), and prescription of beta-blockers at discharge improved from 47% to 68% (P<.001), Mortality at 30 days decreased from 18.9% to 17.1% (P=.005) and at 1 year from 32.3% to 29.6% (P<.001). These improvements in quality occurred during a period when median length of stay decreased from 8 days to 6 days. Performance on all quality indicators except reperfusion was better in the pilot states than in the rest of the nation in 1995, and the differences were statistically significant for aspirin use at discharge (P<.001), beta-blocker use (P<.001), and smoking cessation counseling (P=.02), Postinfarction mortality was not significantly different between the pilot states and the rest of the nation during the baseline period, although it was slightly but significantly better in the pilot states during the follow-up period (absolute mortality difference at 1 year, 0.9%, P=.004). Conclusions.-The quality of care for Medicare patients with acute myocardial infarction has improved in the Cooperative Cardiovascular Project pilot states. Performance on the defined quality indicators appeared to be better in the pilot states than in the rest of the nation in 1995 and was associated with reduced mortality.	US Hlth Care Financing Adm, Baltimore, MD 21244 USA; Iowa Fdn Med Care, Des Moines, IA USA; Univ Kansas, Med Ctr, Kansas City, KS 66103 USA; Connecticut Peer Review Org, Middletown, CT USA; Univ Connecticut, Div Cardiol, Farmington, CT USA; Univ Iowa, Dept Surg, Iowa City, IA 52242 USA; MetaStar Inc, Madison, WI USA; Med Coll Wisconsin, Dept Prevent Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Hlth Policy Inst, Milwaukee, WI 53226 USA; Yale Univ, Sch Med, Cardiovasc Sect, New Haven, CT USA; Alabama Qual Assurance Fdn, Birmingham, AL USA; Dept Vet Affairs, Birmingham, AL USA; Univ Alabama, Div Prevent Med, Birmingham, AL USA; Univ Alabama, Ctr Aging, Birmingham, AL USA; Univ Maryland, Dept Cardiol, Baltimore, MD 21201 USA	University of Kansas; University of Kansas Medical Center; University of Connecticut; University of Iowa; Medical College of Wisconsin; Medical College of Wisconsin; Yale University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University System of Maryland; University of Maryland Baltimore	Marciniak, TA (corresponding author), US Hlth Care Financing Adm, 7500 Secur Blvd,Bldg S2-11-07, Baltimore, MD 21244 USA.	tmarciniak@hcfa.gov	Ellerbeck, Edward/I-8438-2014; Allman, Richard M/D-5964-2011; Allman, Richard M./O-1693-2019; , Harlan/AAI-2875-2020	Ellerbeck, Edward/0000-0002-7774-2729; Allman, Richard M./0000-0002-1850-6515; Radford, Martha/0000-0001-7503-9557; Kresowik, Timothy/0000-0003-4163-1573				Angell M, 1996, NEW ENGL J MED, V335, P883, DOI 10.1056/NEJM199609193351209; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; Ghali WA, 1997, JAMA-J AM MED ASSOC, V277, P379, DOI 10.1001/jama.277.5.379; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; Kerr EA, 1996, JAMA-J AM MED ASSOC, V276, P1236, DOI 10.1001/jama.276.15.1236; LAMBERTHUBER DA, 1994, CLIN PERFORMANCE QUA, V2, P219; Meehan TP, 1996, JOINT COMM J QUAL IM, V22, P751, DOI 10.1016/S1070-3241(16)30280-2; National Heart Attack Alert Program Coordinating Committee, 1993, EM DEP RAP ID TREATM; Normand SLT, 1996, JAMA-J AM MED ASSOC, V275, P1322, DOI 10.1001/jama.275.17.1322; Paik, 2003, STAT METHODS RATES P, P598; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; *SAS I INC, 1996, SAS COMP SOFTW REL 6; *TEX STAT CORP, 1995, STAT STAT SOFTW REL	16	412	412	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1998	279	17					1351	1357		10.1001/jama.279.17.1351	http://dx.doi.org/10.1001/jama.279.17.1351			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK758	9582042				2022-12-01	WOS:000073359800026
J	Nightingale, SL				Nightingale, SL			Advisory on medical telemetry system interference problem	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1998	279	17					1339	1339		10.1001/jama.279.17.1339	http://dx.doi.org/10.1001/jama.279.17.1339			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZK758	9582030				2022-12-01	WOS:000073359800007
J	Stams, T; Niranjanakumari, S; Fierke, CA; Christianson, DW				Stams, T; Niranjanakumari, S; Fierke, CA; Christianson, DW			Ribonuclease P protein structure: Evolutionary origins in the translational apparatus	SCIENCE			English	Article							GEL RETARDATION ANALYSIS; ELONGATION-FACTOR-G; COLI RNASE-P; 4.5 S-RNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; M1 RNA; MAGNESIUM-IONS; CATALYTIC RNA; NUCLEOTIDE-SEQUENCE	The crystal structure of Bacillus subtilis ribonuclease P protein is reported at 2.6 angstroms resolution. This protein binds to ribonuclease P RNA to form a ribonucleoprotein holoenzyme with optimal catalytic activity. Mutagenesis and biochemical data indicate that an unusual left-handed beta alpha beta crossover connection and a large central cleft in the protein form conserved RNA binding sites; a metal binding loop may comprise a third RNA binding site. The unusual topology is partly shared with ribosomal protein S5 and the ribosomal translocase elongation factor G, which suggests evolution from a common RNA binding ancestor in the primordial translational apparatus.	Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	University of Pennsylvania; Duke University	Christianson, DW (corresponding author), Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA.	chris@xtal.chem.upenn.edu	Stams, Travis/R-5730-2019		NIGMS NIH HHS [GM55387] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAER MF, 1989, J BACTERIOL, V171, P6862, DOI 10.1128/jb.171.12.6862-6866.1989; Beebe JA, 1996, BIOCHEMISTRY-US, V35, P10493, DOI 10.1021/bi960870m; BOTHWELL ALM, 1976, J BIOL CHEM, V251, P7709; Brown JW, 1998, NUCLEIC ACIDS RES, V26, P351, DOI 10.1093/nar/26.1.351; BROWN S, 1989, J MOL BIOL, V209, P79, DOI 10.1016/0022-2836(89)90171-X; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Czworkowski J, 1997, BIOCHEMISTRY-US, V36, P10327, DOI 10.1021/bi970610k; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; GARDINER KJ, 1985, J BIOL CHEM, V260, P5415; Gopalan V, 1997, J MOL BIOL, V267, P818, DOI 10.1006/jmbi.1997.0906; GUERRIERTAKADA C, 1984, SCIENCE, V223, P285, DOI 10.1126/science.6199841; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HANSEN FG, 1985, GENE, V38, P85, DOI 10.1016/0378-1119(85)90206-9; HARDT WD, 1993, NUCLEIC ACIDS RES, V21, P3521, DOI 10.1093/nar/21.15.3521; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIRSEBOM LA, 1995, MOL MICROBIOL, V17, P411, DOI 10.1111/j.1365-2958.1995.mmi_17030411.x; KIRSEBOM LA, 1989, J MOL BIOL, V207, P837, DOI 10.1016/0022-2836(89)90250-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurz JC, 1998, BIOCHEMISTRY-US, V37, P2393, DOI 10.1021/bi972530m; Loria A, 1997, BIOCHEMISTRY-US, V36, P6317, DOI 10.1021/bi970115o; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURZIN AG, 1995, NAT STRUCT BIOL, V2, P25, DOI 10.1038/nsb0195-25; NIRANJANAKUMARI S, UNPUB; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; OTWINOWSKI Z, 1994, ACTA CRYSTALLOGR D, V50, P760; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PACE NR, 1995, J BACTERIOL, V177, P1919, DOI 10.1128/jb.177.8.1919-1928.1995; PAN T, 1995, BIOCHEMISTRY-US, V34, P902, DOI 10.1021/bi00003a024; PECKMILLER KA, 1991, J MOL BIOL, V221, P1; PERREAULT JP, 1992, J MOL BIOL, V226, P399, DOI 10.1016/0022-2836(92)90955-J; PERREAULT JP, 1993, J MOL BIOL, V230, P750, DOI 10.1006/jmbi.1993.1197; RAMAKRISHNAN V, 1992, NATURE, V358, P768, DOI 10.1038/358768a0; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P341; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SURRATT CK, 1990, J BIOL CHEM, V265, P22513; SVARD SG, 1993, NUCLEIC ACIDS RES, V21, P427, DOI 10.1093/nar/21.3.427; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1399, DOI 10.1021/bi00172a016; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1406, DOI 10.1021/bi00172a017; TALLSJO A, 1993, NUCLEIC ACIDS RES, V21, P51, DOI 10.1093/nar/21.1.51; Westhof E, 1996, J MOL BIOL, V258, P600, DOI 10.1006/jmbi.1996.0272; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0	52	137	142	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1998	280	5364					752	755		10.1126/science.280.5364.752	http://dx.doi.org/10.1126/science.280.5364.752			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563955				2022-12-01	WOS:000073415600053
J	Garcia-Cardena, G; Fan, R; Shah, V; Sorrentino, R; Cirino, G; Papapetropoulos, A; Sessa, WC				Garcia-Cardena, G; Fan, R; Shah, V; Sorrentino, R; Cirino, G; Papapetropoulos, A; Sessa, WC			Dynamic activation of endothelial nitric oxide synthase by Hsp90	NATURE			English	Article							RECEPTOR TYROSINE KINASE; PALMITOYLATION; DROSOPHILA; SEVENLESS; PATHWAYS; CELLS	Heat-shock protein 90 (Hsp90) coordinates the trafficking and regulation of diverse signalling proteins, but its precise role in regulating specific cellular targets is not known(1,2). Here we show that Hsp90 associates with endothelial nitric oxide synthase (eNOS) and is rapidly recruited to the eNOS complex by agonists that stimulate production of nitric oxide, namely vascular endothelial growth factor, histamine and fluid shear stress. Moreover, the binding of Hsp90 to eNOS enhances the activation of eNOS. Inhibition of signalling through Hsp90 attenuates both agonist-stimulated production of nitric oxide and endothelium-dependent relaxation of isolated blood vessels. Our results indicate that Hsp90 facilitates signalling mediated by growth-factor, G-protein and mechanotransduction pathways that lead to the activation of eNOS. These observations indicate that in addition to its role as a molecular chaperone involved in protein folding and maturation, Hsp90 may also be recruited to cellular targets depending on the activation state of the cell.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Mol Cardiobiol Program, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Med, New Haven, CT 06536 USA; Univ Naples Federico II, Dipartimento Farmacol Sperimentale, I-80131 Naples, Italy	Yale University; Yale University; Yale University; University of Naples Federico II	Sessa, WC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.	william.sessa@yale.edu	Garcia-Cardena, Guillermo/Q-6649-2019; Sessa, William C/B-6844-2011; Andreas, Papapetropoulos/AAJ-3089-2020	Sessa, William C/0000-0001-5759-1938; Papapetropoulos, Andreas/0000-0002-4253-5930; Cirino, Giuseppe/0000-0003-3954-4083; SORRENTINO, RAFFAELLA/0000-0002-0284-5424				BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GIMBRONE MA, 1976, PROGR HEMOSTASIS THR, P1; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; MONCADA S, 1991, PHARMACOL REV, V43, P109; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; NAGAO T, 1992, AM J PHYSIOL, V263, pH1090, DOI 10.1152/ajpheart.1992.263.4.H1090; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SESSA WC, 1994, J VASC RES, V31, P131, DOI 10.1159/000159039; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; vanderStraten A, 1997, EMBO J, V16, P1961, DOI 10.1093/emboj/16.8.1961; VENEMA VJ, 1996, BIOCHEM BIOPH RES CO, V155, P801; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	30	834	859	2	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					821	824		10.1038/33934	http://dx.doi.org/10.1038/33934			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9580552				2022-12-01	WOS:000073241200055
J	Stenager, EN; Madsen, C; Stenager, E; Boldsen, J				Stenager, EN; Madsen, C; Stenager, E; Boldsen, J			Suicide in patients with stroke: epidemiological study	BRITISH MEDICAL JOURNAL			English	Article									Odense Municipal Dept Social Med, DK-5000 Odense C, Denmark; Odense Univ Hosp, Dept Neurol, DK-5000 Odense, Denmark; Esbjerg Cent Sygehus, Dept Neurol, Esbjerg, Denmark; Odense Univ, Inst Community Hlth, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark	Stenager, EN (corresponding author), Odense Municipal Dept Social Med, Vindegade 18, DK-5000 Odense C, Denmark.		Stenager, Egon/AAU-4463-2020; Stenager, Egon/O-2275-2017					ANDERSEN G, 1995, ACTA PSYCHIAT SCAND, V92, P193, DOI 10.1111/j.1600-0447.1995.tb09567.x; HOUSE A, 1991, BRIT J PSYCHIAT, V158, P83, DOI 10.1192/bjp.158.1.83; ROBINS M, 1981, STROKE S1, V12, P45; STENAGER EN, 1992, ARCH NEUROL-CHICAGO, V49, P1296, DOI 10.1001/archneur.1992.00530360098025; Stenager EN, 1997, DIS PAIN SUICIDAL BE	5	84	85	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1206	1206		10.1136/bmj.316.7139.1206	http://dx.doi.org/10.1136/bmj.316.7139.1206			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9583928	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000073224100022
J	Wu, GQ; D'Agati, V; Cai, YQ; Markowitz, G; Park, JH; Reynolds, DM; Maeda, Y; Le, TC; Hou, H; Kucherlapati, R; Edelmann, W; Somlo, S				Wu, GQ; D'Agati, V; Cai, YQ; Markowitz, G; Park, JH; Reynolds, DM; Maeda, Y; Le, TC; Hou, H; Kucherlapati, R; Edelmann, W; Somlo, S			Somatic inactivation of Pkd2 results in polycystic kidney disease	CELL			English	Article							PROTEIN; GENE; CELLS; PATTERN; ENCODES; PRODUCT; ADULT; FETAL	Germline mutations in PKD2 cause autosomal dominant polycystic kidney disease. We have introduced a mutant exon 1 in tandem with the wild-type exon 1 at the mouse Pkd2 locus. This is an unstable allele that undergoes somatic inactivation by intragenic homologous recombination to produce a true null allele. Mice heterozygous and homozygous for this mutation, as well as Pkd(+/-) mice, develop polycystic kidney and liver lesions that are indistinguishable from the human phenotype. In all cases, renal cysts arise from renal tubular cells that lose the capacity to produce Pkd2 protein. Somatic loss of Pkd2 expression is both necessary and sufficient for renal cyst formation in ADPKD, suggesting that PKD2 occurs by a cellular recessive mechanism.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Columbia University	Somlo, S (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Kucherlapati, Raju/ABC-8807-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048383] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48383] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brasier JL, 1997, J CLIN INVEST, V99, P194, DOI 10.1172/JCI119147; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; CALVET JP, 1993, KIDNEY INT, V43, P101, DOI 10.1038/ki.1993.17; Chen KS, 1997, NAT GENET, V17, P154, DOI 10.1038/ng1097-154; DAGATI V, 1992, J AM SOC NEPHROL, V3, P975; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; EVAN AP, 1992, CYSTIC KIDNEY, P22; EVERSON GT, 1993, AM J KIDNEY DIS, V22, P520, DOI 10.1016/S0272-6386(12)80923-1; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GABOW PA, 1997, DIS KIDNEY, P521; Geng L, 1996, J CLIN INVEST, V98, P2674, DOI 10.1172/JCI119090; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Griffin MD, 1996, P ASSOC AM PHYSICIAN, V108, P185; Harris PC, 1997, NEPHROL DIAL TRANSPL, V12, P1089, DOI 10.1093/ndt/12.6.1089; HASTY P, 1991, MOL CELL BIOL, V11, P4509, DOI 10.1128/MCB.11.9.4509; Hayashi T, 1997, GENOMICS, V44, P131, DOI 10.1006/geno.1997.4851; HOYER JR, 1979, KIDNEY INT, V16, P279, DOI 10.1038/ki.1979.130; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; IbraghimovBeskrovnaya O, 1997, P NATL ACAD SCI USA, V94, P6397, DOI 10.1073/pnas.94.12.6397; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; Laitinen L, 1987, J HISTOCHEM CYTOCHEM, V35, P55, DOI 10.1177/35.1.3794309; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Ong ACM, 1997, LANCET, V349, P1039, DOI 10.1016/S0140-6736(05)62286-6; Palsson R, 1996, MOL MED, V2, P702, DOI 10.1007/BF03401654; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; Peral B, 1996, AM J HUM GENET, V58, P86; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; Peters DJM, 1996, LAB INVEST, V75, P221; Qian F, 1997, AM J HUM GENET, V61, P1000, DOI 10.1086/301618; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; RAVINE D, 1992, LANCET, V340, P1330, DOI 10.1016/0140-6736(92)92503-8; Roelfsema JH, 1997, AM J HUM GENET, V61, P1044, DOI 10.1086/301600; SIROTKIN AM, 1995, P NATL ACAD SCI USA, V92, P6434, DOI 10.1073/pnas.92.14.6434; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; vanAdelsberg J, 1997, AM J PHYSIOL-RENAL, V272, pF602, DOI 10.1152/ajprenal.1997.272.5.F602; Veldhuisen B, 1997, AM J HUM GENET, V61, P547, DOI 10.1086/515497; Ward CJ, 1996, P NATL ACAD SCI USA, V93, P1524, DOI 10.1073/pnas.93.4.1524; WARD CJ, 1994, CELL, V77, P881; Wu GQ, 1997, GENOMICS, V45, P220, DOI 10.1006/geno.1997.4920	44	415	423	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					177	188		10.1016/S0092-8674(00)81570-6	http://dx.doi.org/10.1016/S0092-8674(00)81570-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568711	hybrid			2022-12-01	WOS:000073174000005
J	Ahmad, M; Jarillo, JA; Smirnova, O; Cashmore, AR				Ahmad, M; Jarillo, JA; Smirnova, O; Cashmore, AR			Cryptochrome blue-light photoreceptors of Arabidopsis implicated in phototropism	NATURE			English	Article							INHIBITED HYPOCOTYL ELONGATION; THALIANA; MUTATIONS; PROTEIN; MUTANTS; GENE; DEPENDENCE; ENCODES	Phototropism-bending towards the light-is one of the best known plant tropic responses(1,2) Despite being reported by Darwin and others(3,4) over a century ago to be specifically under the control of blue light, the photoreceptors mediating phototropism have remained unknown. We have characterized a blue-light photoreceptor from Arabidopsis named CRY1 for cryptochrome 1 (ref, 5); this photoreceptor is a flavoprotein that mediates numerous blue-light-dependent responses(6). In Arabidopsis, HY4 (the gene encoding CRY1) is a member of a small gene family that also encodes a related photoreceptor, CRY2 (refs 7, 8), which shares considerable functional overlap with CRY1 (ref, 9). Here we report that mutant plants lacking both the CRY1 and the CRY2 blue-light photoreceptors are deficient in the phototropic response. Transgenic Arabidopsis plants overexpressing CRY1 or CRY2 show enhanced phototropic curvature. We conclude that cryptochrome is one of the photoreceptors mediating phototropism in plants.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA	University of Pennsylvania	Ahmad, M (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA.	mahmad@mail.sas.upenn.edu		Ahmad, Margaret/0000-0003-4524-5813; Jarillo, Jose Antonio/0000-0002-2963-7641				AHMAD M, 1995, PLANT J, V8, P653, DOI 10.1046/j.1365-313X.1995.08050653.x; Ahmad M, 1998, PLANT CELL, V10, P197, DOI 10.1105/tpc.10.2.197; Ahmad M, 1997, PLANT J, V11, P421, DOI 10.1046/j.1365-313X.1997.11030421.x; Ahmad M, 1996, PLANT MOL BIOL, V30, P851, DOI 10.1007/BF00020798; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Bagnall DJ, 1996, PLANTA, V200, P278, DOI 10.1007/BF00208319; DARWIN C, 1981, POWER MOVEMENT PLANT; Hoffman PD, 1996, MOL GEN GENET, V253, P259, DOI 10.1007/s004380050321; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; IINO M, 1990, PLANT CELL ENVIRON, V13, P633, DOI 10.1111/j.1365-3040.1990.tb01080.x; Janoudi AK, 1997, PHYSIOL PLANTARUM, V101, P278, DOI 10.1034/j.1399-3054.1997.1010204.x; Janoudi AK, 1997, PLANT PHYSIOL, V113, P975, DOI 10.1104/pp.113.3.975; KHURANA J P, 1989, Planta (Heidelberg), V178, P400, DOI 10.1007/BF00391868; Koncz C., 1992, METHODS ARABIDOPSIS; KONJEVIC R, 1989, P NATL ACAD SCI USA, V86, P9876, DOI 10.1073/pnas.86.24.9876; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; Lin C., 1996, PLANT PHYSIOL, V110, P1047; Lin CT, 1996, PLANT J, V10, P893, DOI 10.1046/j.1365-313X.1996.10050893.x; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; LISCUM E, 1995, PLANT CELL, V7, P473, DOI 10.1105/tpc.7.4.473; Liscum E, 1996, PLANT PHYSIOL, V112, P291, DOI 10.1104/pp.112.1.291; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; POFF LK, 1994, ARABIDOPSIS, P639; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; SACHS J, 1864, BOT Z, P353; SHROPSHIRE W, 1958, PLANT PHYSIOL, V33, P360, DOI 10.1104/pp.33.5.360; SMALL GD, 1995, PLANT MOL BIOL, V28, P443, DOI 10.1007/BF00020393; YOUNG JC, 1992, PLANTA, V188, P106, DOI 10.1007/BF00198946	28	126	141	1	38	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 16	1998	392	6677					720	723		10.1038/33701	http://dx.doi.org/10.1038/33701			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565033				2022-12-01	WOS:000073129000060
J	Nibu, Y; Zhang, HL; Levine, M				Nibu, Y; Zhang, HL; Levine, M			Interaction of short-range repressors with Drosophila CtBP in the embryo	SCIENCE			English	Article							LOOP-HELIX REPRESSOR; TRANSCRIPTIONAL REPRESSION; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; PROTEIN-INTERACTION; E1A PROTEIN; HAIRY; DOMAIN; TRANSFORMATION; SEGMENTATION	Human CtBP attenuates transcriptional activation and tumorigenesis mediated by the adenovirus E1A protein. The E1A sequence motif that interacts with CtBP, Pro-X-Asp-Leu-Ser-X-Lys (P-DLS-K), is present in the repression domains of two unrelated short-range repressors in Drosophila, Knirps and Snail, and is essential for the interaction of these proteins with Drosophila CtBP (dCtBP). A P-element-induced mutation in dCtBP exhibits gene-dosage interactions with a null mutation in knirps, which is consistent with the occurrence of Knirps-dCtBP interactions in vivo, These observations suggest that CtBP and dCtBP are engaged in an evolutionarily conserved mechanism of transcriptional repression, which is used in both Drosophila and mammals.	Univ Calif Berkeley, Dept Mol & Cellular Biol, Div Genet, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Levine, M (corresponding author), Univ Calif Berkeley, Dept Mol & Cellular Biol, Div Genet, 401 Barker Hall, Berkeley, CA 94720 USA.		Nibu, Yutaka/J-4136-2019	Nibu, Yutaka/0000-0002-4696-7503; Levine, Michael/0000-0001-7629-0081	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046638, R37GM046638] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46638] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnosti DN, 1996, EMBO J, V15, P3659, DOI 10.1002/j.1460-2075.1996.tb00735.x; Barolo S, 1997, EMBO J, V16, P2883, DOI 10.1093/emboj/16.10.2883; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; CAL HN, 1996, P NATL ACAD SCI USA, V93, P9309; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; Gray S, 1996, GENE DEV, V10, P700, DOI 10.1101/gad.10.6.700; HannaRose W, 1997, MOL CELL BIOL, V17, P4820, DOI 10.1128/MCB.17.8.4820; HERSCHBACH BM, 1994, NATURE, V370, P309, DOI 10.1038/370309a0; HOCH M, 1992, SCIENCE, V256, P94, DOI 10.1126/science.1348871; Ip YT, 1997, CURR BIOL, V7, pR216, DOI 10.1016/S0960-9822(06)00104-7; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KOSMAN D, 1991, SCIENCE, V254, P188; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NIBU Y, UNPUB; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; PANKRATZ MJ, 1990, CELL, V61, P30; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Perrimon N, 1996, GENETICS, V144, P1681; POORTINGA G, IN PRESS EMBO J; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; Small S, 1996, DEV BIOL, V175, P314, DOI 10.1006/dbio.1996.0117; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Sourdive DJD, 1997, NUCLEIC ACIDS RES, V25, P1476, DOI 10.1093/nar/25.8.1476; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764	38	212	214	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					101	104		10.1126/science.280.5360.101	http://dx.doi.org/10.1126/science.280.5360.101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525852				2022-12-01	WOS:000072885100044
J	Hansen, JA; Gooley, TA; Martin, PJ; Appelbaum, F; Chauncey, TR; Clift, RA; Petersdorf, EW; Radich, J; Sanders, JE; Storb, RF; Sullivan, KM; Anasetti, C				Hansen, JA; Gooley, TA; Martin, PJ; Appelbaum, F; Chauncey, TR; Clift, RA; Petersdorf, EW; Radich, J; Sanders, JE; Storb, RF; Sullivan, KM; Anasetti, C			Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; VERSUS-HOST DISEASE; CYTOMEGALOVIRUS DISEASE; INTERFERON-ALPHA; ACUTE GRAFT; PROPHYLAXIS; COMPLICATIONS; METHOTREXATE; CYCLOSPORINE; EXPERIENCE	Background Chronic myeloid leukemia can be cured by marrow transplantation from an HLA-identical sibling donor. The use of transplants from unrelated donors is an option for the 70 percent of patients without an HLA-identical sibling, but the morbidity and mortality associated with such transplants have been cause for concern. We analyzed the safety and efficacy of transplants from unrelated donors for the treatment of chronic myeloid leukemia and identified variables that predict a favorable outcome. Methods Between May 1985 and December 1994, 196 patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase received marrow transplants from unrelated donors. Results The median follow-up was 5 years (range, 1.2 to 10.1). Graft failure occurred in 5 percent of patients wile could be evaluated. Acute graft-versus-host disease of grade III or IV severity was observed in 35 percent of patients who received HLA-matched transplants, and the estimated cumulative incidence of relapse at five years was 10 percent. The Kaplan-Meier estimate of survival at five years was 57 percent. Survival was adversely affected by an interval from diagnosis to transplantation of one year or more, an HLA-DRB1 mismatch, a high body-weight index, and an age of more than 50 years. Survival was improved by the prophylactic use of fluconazole and ganciclovir. The Kaplan-Meier estimate of survival at five years was 74 percent (95 percent confidence interval, 62 to 86 percent) for patients who were 50 years of age or younger who received a transplant from an HLA-matched donor within one year after diagnosis. Conclusions Transplantation of marrow from an HLA-matched, unrelated donor is safe and effective therapy for selected patients with chronic myeloid leukemia. (C)1998, Massachusetts Medical Society.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Vet Affairs Med Ctr, Seattle, WA 98108 USA; Univ Washington, Sch Med, Seattle, WA USA	Fred Hutchinson Cancer Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle	Hansen, JA (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Chauncey, Thomas/AAK-1331-2021	Chauncey, Thomas/0000-0003-2815-7301	NCI NIH HHS [CA18029, CA15704] Funding Source: Medline; NIAID NIH HHS [AI33484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA018029, P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN NC, 1995, LANCET, V345, P1392, DOI 10.1016/S0140-6736(95)92596-1; Anasetti C, 1995, Cancer Treat Res, V76, P137; ANASETTI C, 1994, TRANSFUS SCI, V15, P221, DOI 10.1016/0955-3886(94)90134-1; BEATTY PG, 1985, NEW ENGL J MED, V313, P765, DOI 10.1056/NEJM198509263131301; BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; BEATTY PG, 1989, BONE MARROW TRANSPL, V4, P287; BLAZAR BR, 1985, BLOOD, V66, P1436; Buckner C. Dean, 1995, Bone Marrow Transplantation, V15, pS203; CLIFT RA, 1994, BLOOD, V84, P2036, DOI 10.1182/blood.V84.6.2036.2036; DURNAM DM, 1989, BLOOD, V74, P2220; GOLDMAN JM, 1993, BLOOD, V82, P2235; GOLDMAN JM, 1986, NEW ENGL J MED, V314, P202, DOI 10.1056/NEJM198601233140403; GOODRICH JM, 1993, ANN INTERN MED, V118, P173, DOI 10.7326/0003-4819-118-3-199302010-00003; GOODRICH JM, 1994, CLIN INFECT DIS, V19, P287, DOI 10.1093/clinids/19.2.287; HANSEN JA, 1992, MANUAL CLIN LAB IMMU, P850; HATHAWAY ML, 1960, 10 USDA, P111; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lee SJ, 1997, ANN INTERN MED, V127, P1080, DOI 10.7326/0003-4819-127-12-199712150-00005; MACKINNON S, 1990, EXP HEMATOL, V18, P421; MARKS DI, 1993, ANN INTERN MED, V119, P207, DOI 10.7326/0003-4819-119-3-199308010-00005; McCullough J, 1989, Oncology (Williston Park), V3, P63; MCGLAVE, 1990, BLOOD, V76, P654; MCGLAVE P, 1993, BLOOD, V81, P543; MCGLAVE PB, 1990, BLOOD, V75, P1728; Mickelson EM, 1996, TISSUE ANTIGENS, V47, P27, DOI 10.1111/j.1399-0039.1996.tb02511.x; MICKELSON EM, 1994, TISSUE ANTIGENS, V44, P83, DOI 10.1111/j.1399-0039.1994.tb02363.x; NASH RA, 1992, BLOOD, V80, P1838; PEPE MS, 1993, BRIT J HAEMATOL, V83, P602, DOI 10.1111/j.1365-2141.1993.tb04697.x; Petersdorf EW, 1997, BLOOD, V89, P1818, DOI 10.1182/blood.V89.5.1818.1818_1818_1823; PETERSDORF EW, 1995, BLOOD, V86, P1606, DOI 10.1182/blood.V86.4.1606.bloodjournal8641606; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; SLAVIN MA, 1995, J INFECT DIS, V171, P1545, DOI 10.1093/infdis/171.6.1545; SPENCER A, 1995, BLOOD, V86, P3590, DOI 10.1182/blood.V86.9.3590.bloodjournal8693590; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; SULLIVAN KM, 1991, SEMIN HEMATOL, V28, P250; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; TURA S, 1994, NEW ENGL J MED, V330, P820	39	470	487	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					962	968		10.1056/NEJM199804023381405	http://dx.doi.org/10.1056/NEJM199804023381405			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE776	9521984				2022-12-01	WOS:000072829800005
J	Preiss, T; Hentze, MW				Preiss, T; Hentze, MW			Dual function of the messenger RNA cap structure in poly(A)-tail-promoted translation in yeast	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; INTERNAL INITIATION; POLY(A) TAIL	The messenger RNA 3' poly(A) tail critically affects the initiation and control of translation in eukaryotes(1-3). By analogy to elements involved in transcription initiation, the poly(A) tail has been described as a 'translational enhancer' that enhances the 'translational promoter' activity of the mRNA 5'-cap structure(3,4). Elongation or shortening of the poly(A) tail regulates translation during development(2). Here we show, using cell-free and in vivo translation analyses in SRccharomyces cerevisiae, that the poly(A) tail can act as an independent 'translational promoter: delivering ribosomes to uncapped mRNAs even if their 5' end is blocked. When mRNAs compete for ribosome binding, neither the cap structure nor the poly(A) tail alone is enough to drive efficient translation, but together they synergize and direct ribosome entry to the 5' end. The cap structure both promotes ribosome recruitment, together with the poly(A) tail, and tethers recruited ribosomes to the 5' end, Correct choice of translation initiation codons and the function of translational regulators acting on the 5' untranslated region are thus ensured by the functional interaction of the poly(A) tail with the cap structure.	European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Hentze, MW (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Preiss, Thomas/F-7355-2010; Hentze, Matthias W/V-3980-2017	Preiss, Thomas/0000-0001-6273-784X; Hentze, Matthias W/0000-0002-4023-7876				EVERETT JG, 1992, YEAST, V8, P1007, DOI 10.1002/yea.320081203; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; JOHANSSON HE, 1994, NUCLEIC ACIDS RES, V22, P4591, DOI 10.1093/nar/22.22.4591; MASSON DC, 1995, MOL CELL BIOL, V15, P2763; Muckenthaler M, 1997, RNA, V3, P983; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Proweller A, 1997, J BIOL CHEM, V272, P6004, DOI 10.1074/jbc.272.9.6004; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Wickens M., 1996, TRANSLATIONAL CONTRO, P411	19	215	248	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					516	520		10.1038/33192	http://dx.doi.org/10.1038/33192			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548259				2022-12-01	WOS:000072875200064
J	Bernstein, M				Bernstein, M			The genie in the bottle	ANNALS OF INTERNAL MEDICINE			English	Article											Bernstein, M (corresponding author), 19 Warren Pl, Murray Hill, NJ 07974 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					595	596		10.7326/0003-4819-128-7-199804010-00013	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518407				2022-12-01	WOS:000072803500013
J	Cowl, CT; Jones, MP; Lynch, CF; Sprince, NL; Zwerling, C; Fuortes, LJ				Cowl, CT; Jones, MP; Lynch, CF; Sprince, NL; Zwerling, C; Fuortes, LJ			Factors associated with fatalities and injuries from hot-air balloon crashes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Despite the increased popularity of hot-air balloon flight, data on injuries and fatalities associated with hot-air balloon crashes are limited. Objective.-To determine factors associated with injury and death in hot-air balloon crashes, Design.-Retrospective review of data collected from reports and investigations by the Civil Aeronautics Board and the National Transportation Safety Board. Study Subjects.-Individuals involved in US hot-air balloon crashes from 1964 to 1995. Main Outcome Measures.-Total number of crashes and factors associated with fatality or serious injury. Results.-Form 1964 to 1995, a total of 495 hot-air balloon crashes involving 1533 persons were reported and included 92 fatalities and 384 serious injuries. Pilot error or incapacitation was determined subjectively by crash investigators to contribute to 85.1% of the crashes. In univariate analysis, collision with the ground was the most significant predictor of a fatality or serious injury (P<.001), and power-line contact was the most significant predictor of fatality (P<.001). In multiple logistic regression, only the type of object struck by a balloon predicted a fatal crash or a fatality or serious injury. Conclusions.-Although a number of factors likely contribute to increased seventy of hot-air balloon crashes, the object struck during a crash is most predictive of fatality or serious injury. Preventive efforts are needed to decrease future injuries.	Mayo Clin & Mayo Fdn, Mayo Med Sch, Div Prevent & Occupat Med, Rochester, MN 55905 USA; Univ Iowa, Injury Prevent Res Ctr, Iowa City, IA USA	Mayo Clinic; University of Iowa	Cowl, CT (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med Sch, Div Prevent & Occupat Med, Rochester, MN 55905 USA.				CIT NIH HHS [T01/CCT710440] Funding Source: Medline	CIT NIH HHS		*FED AV ADM, 1994, FED AV REG REG 145; *FED AV ADM, 1994, FED AV REG REG 61; *FED AV ADM, 1994, FED AV REG REG 31; *FED AV ADM, 1994, FED AV REG REG 91; *FED AV ADM, 1994, FED AV REG REG 43; *FED AV ADM, 1995, US CIV AIRM STAT ANN; *FED AV ADM, 1994, FED AV REG REG 1; *FED AV ADM, 1994, FED AV REG REG 141; FRANKENFIELD DL, 1994, AVIAT SPACE ENVIR MD, V65, P3; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.2307/2332323; MARCUS NA, 1981, AM J SPORT MED, V9, P318, DOI 10.1177/036354658100900506; MCCONNELL TS, 1985, J FORENSIC SCI, V30, P350	12	14	14	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1011	1014		10.1001/jama.279.13.1011	http://dx.doi.org/10.1001/jama.279.13.1011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533500	Bronze			2022-12-01	WOS:000072669700029
J	Romo, R; Hernandez, A; Zainos, A; Salinas, E				Romo, R; Hernandez, A; Zainos, A; Salinas, E			Somatosensory discrimination based on cortical microstimulation	NATURE			English	Article							PSYCHOPHYSICAL MEASUREMENTS; AREA MT; MONKEYS; PERFORMANCE; FREQUENCY; DIRECTION; NEURONS; EVENTS	The sensation of flutter is produced when mechanical vibrations in the range of 5-50 Hz are applied to the skin(1-3). A flutter stimulus activates neurons in the primary somatosensory cortex (S1) that somatotopically map to the site of stimulation(4,5). A subset of these neurons-those with quickly adapting properties, associated with Meissner's corpuscles-are strongly entrained by periodic flutter vibrations, firing with a probability that oscillates at the input frequency(1,6) Hence, quickly adapting neurons provide a dynamic representation of such flutter stimuli. However, are these neurons directly involved in the perception of flutter? Here we investigate this in monkeys trained to discriminate the difference in frequency between two flutter stimuli delivered sequentially on the fingertips(1,7). Microelectrodes were inserted into area 3b of S1 and the second stimulus was substituted with a train of injected current pulses. Animals reliably indicated whether the frequency of the second (electrical) signal was higher or lower than that of the first (mechanical) signal, even though both frequencies changed from trial to trial. Almost identical results were obtained with periodic and aperiodic stimuli of equal average frequencies. Thus, the quickly adapting neurons in area 3b activate the circuit leading to the perception of flutter. Furthermore, as far as can be psychophysically quantified during discrimination, the neural code underlying the sensation of flutter can be finely manipulated, to the extent that the behavioural responses produced by natural and artificial stimuli are indistinguishable.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Romo, R (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico.			zainos, antonio/0000-0001-6137-1794; Salinas, Emilio/0000-0001-7411-5693; romo, ranulfo/0000-0003-3529-3635				BAIR W, 1994, J NEUROSCI, V14, P2870; Hernandez A, 1997, J NEUROSCI, V17, P6391; LAMOTTE RH, 1979, J NEUROPHYSIOL, V42, P400, DOI 10.1152/jn.1979.42.2.400; LAMOTTE RH, 1975, J NEUROPHYSIOL, V38, P539, DOI 10.1152/jn.1975.38.3.539; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; MOUNTCASTLE VB, 1990, J NEUROSCI, V10, P3032; MOUNTCASTLE VB, 1991, J NEUROSCI METH, V36, P77, DOI 10.1016/0165-0270(91)90140-U; POWELL TPS, 1959, B JOHNS HOPKINS HOSP, V105, P133; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; SALZMAN CD, 1990, NATURE, V346, P174, DOI 10.1038/346174a0; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; SUR M, 1984, J NEUROPHYSIOL, V51, P724, DOI 10.1152/jn.1984.51.4.724; TALBOT WH, 1968, J NEUROPHYSIOL, V31, P301, DOI 10.1152/jn.1968.31.2.301; Vallbo Ake B., 1995, P237; Zainos A, 1997, EXP BRAIN RES, V115, P357, DOI 10.1007/PL00005704; [No title captured]; [No title captured]	17	336	348	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					387	390		10.1038/32891	http://dx.doi.org/10.1038/32891			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537321				2022-12-01	WOS:000072713600051
J	Farrell, L				Farrell, L			No cure for the 'flu	LANCET			English	Editorial Material																			0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					920	920		10.1016/S0140-6736(05)70350-0	http://dx.doi.org/10.1016/S0140-6736(05)70350-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525412				2022-12-01	WOS:000072645500078
J	McConnell, J				McConnell, J			WHO's tuberculosis research initiative	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		McConnell, J (corresponding author), Lancet, London WC1B 3SL, England.			McConnell, John/0000-0002-9928-6568					0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					852	852						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525360				2022-12-01	WOS:000072645500008
J	Nightingale, SL				Nightingale, SL			Promotional practices of pharmacy benefits management companies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg, Rockville, MD 20857 USA.								0	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2022-12-01	WOS:000072192800004
J	Yoon, SS; Macdonald, SC; Parrish, RG				Yoon, SS; Macdonald, SC; Parrish, RG			Deaths from unintentional carbon monoxide poisoning and potential for prevention with carbon monoxide detectors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Unintentional carbon monoxide (CO) poisoning causes approximately 2100 deaths in the United States per year, but the use of CO detectors could potentially prevent many of these deaths. Objective.-To describe the epidemiology of potentially preventable unintentional CO poisoning deaths in New Mexico. Design.-Descriptive analysis. Population Studied.-A total of 136 deaths from CO poisoning investigated by the New Mexico Office of the Medical Investigator, 1980 through 1995. Main Outcome Measures.-Characteristics of deaths from CO poisoning; estimates of the number of deaths potentially preventable with CO detectors. Results.-Of 136 people whose deaths were classified as "unintentional carbon monoxide poisoning, not fire related," 49 (36%) most likely were asleep when poisoned. Thirty-nine (49%) of 80 people whose deaths were identified as "residential fatalities" most likely were asleep vs 10 (18%) of 56 of those whose deaths were identified as occurring in or around motor vehicles. A blood-alcohol level greater than 0.01% was present in 56 (42%) of the decedents. Among decedents who had a negative blood-alcohol level (52 in residences and 26 in vehicles), an electronic audible CO detector may have prevented CO poisoning; whereas, among those who had a negative blood-alcohol level and most likely were awake at the time of CO exposure (28 in residences and 23 in vehicles), an electronic detector or a nonaudible, chemical reagent type detector may have prevented CO poisoning. Conclusion.-Differences exist between deaths due to unintentional CO poisoning that occur in residences and those that occur in or around motor vehicles. Carbon monoxide detectors, whether the electronic or chemical reagent types, may have prevented approximately half of these deaths, The high proportion of decedents with alcohol in their blood indicates that effective public health campaigns must address the role of alcohol in CO poisoning deaths.	Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Surveillance & Programs Branch, Div Environm Hazzards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Yoon, SS (corresponding author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Mail Stop F47,4770 Buford Hwy NE, Atlanta, GA 30341 USA.							BALL LB, 1997, EP INT SERV C CTR DI; BARON RC, 1979, AM J PUBLIC HEALTH, V9, P1656; BARRET L, 1985, CLIN TOXICOL, V23, P309; CAPLAN YH, 1986, J FORENSIC SCI, V31, P117; COOK M, 1995, AM J PUBLIC HEALTH, V85, P988, DOI 10.2105/AJPH.85.7.988; FAWCETT TA, 1992, J OCCUP ENVIRON MED, V34, P12; GAJODS P, 1992, ARCH ENVIRON HEALTH, V46, P373; KLEINMAN MT, 1989, ARCH ENVIRON HEALTH, V44, P361, DOI 10.1080/00039896.1989.9935908; Krenzelok EP, 1996, AM J EMERG MED, V14, P484, DOI 10.1016/S0735-6757(96)90159-X; Leikin JB, 1996, AM J EMERG MED, V14, P90, DOI 10.1016/S0735-6757(96)90025-X; Rao R, 1997, ANN EMERG MED, V29, P290, DOI 10.1016/S0196-0644(97)70284-1; SILVERS SM, 1995, JAMA-J AM MED ASSOC, V274, P1614; WOOLF A, 1994, VET HUM TOXICOL, V6, P344; 1984, DRUG THER B, V22, P81	14	65	65	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					685	687		10.1001/jama.279.9.685	http://dx.doi.org/10.1001/jama.279.9.685			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496987	Bronze			2022-12-01	WOS:000072192800033
J	Oliveira, DBG				Oliveira, DBG			Membranous nephropathy: an IgG4-mediated disease	LANCET			English	Article							IMMUNE-COMPLEXES; ANTIBODY-RESPONSE; IGG4 SUBCLASS; CELLS; RAT; INTERLEUKIN-4; AUTOIMMUNITY; PATHOGENESIS; COMPLEMENT; KIDNEY	Membranous nephropathy is characterised by the deposition of immunoglobulin, predominantly of the IgG4 subclass, along the epithelial surface of the glomerular-basement membrane. Current models of pathogenesis usually assume in-situ immune-complex formation involving an as yet uncharacterised fixed glomerular antigen. I argue that the properties of IgG4 (inability to fix complement and therefore impaired clearance of IgG4-containing complexes; low affinity and therefore ability for IgG4-containing complexes to dissociate and traverse the glomerular-basement membrane) are compatible with a pathogenic mechanism that involves the deposition of circulating IgG4 immune complexes containing diverse antigens.	Univ London St Georges Hosp, Sch Med, Div Renal Med, London SW17 0RE, England	St Georges University London	Oliveira, DBG (corresponding author), Univ London St Georges Hosp, Sch Med, Div Renal Med, London SW17 0RE, England.			Oliveira, David/0000-0002-7507-5651				ADLER SG, 1983, J CLIN INVEST, V71, P487, DOI 10.1172/JCI110793; BAKER PJ, 1989, AM J PATHOL, V135, P185; COGGINS CH, 1993, DISEASES KIDNEY, P1785; COUSER WG, 1978, J CLIN INVEST, V62, P1275, DOI 10.1172/JCI109248; DAVIS P, 1973, BRIT MED J, V3, P676, DOI 10.1136/bmj.3.5882.676; DEVEY ME, 1985, IMMUNOLOGY, V55, P565; DIXON FJ, 1968, AM J MED, V44, P493, DOI 10.1016/0002-9343(68)90050-8; DOI T, 1991, NEPHRON, V57, P131, DOI 10.1159/000186239; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; FLEUREN G, 1980, KIDNEY INT, V17, P631, DOI 10.1038/ki.1980.74; FRENCH MAH, 1984, CLIN EXP IMMUNOL, V56, P473; GOLDMAN M, 1991, IMMUNOL TODAY, V12, P223, DOI 10.1016/0167-5699(91)90034-Q; GOODYER PR, 1986, BIOCHEM CELL BIOL, V64, P441, DOI 10.1139/o86-062; Imai H, 1997, KIDNEY INT, V51, P270, DOI 10.1038/ki.1997.32; KERJASCHKI D, 1989, KIDNEY INT, V35, P1418; Kermarrec N, 1995, NEPHROL DIAL TRANSPL, V10, P2187, DOI 10.1093/ndt/10.12.2187; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; NGU JL, 1985, CLIN NEPHROL, V24, P128; OLIVEIRA DBG, 1995, EUR J IMMUNOL, V25, P2259, DOI 10.1002/eji.1830250822; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; PRIGENT P, 1995, J CLIN INVEST, V96, P1484, DOI 10.1172/JCI118185; SCHIFFERLI JA, 1986, NEW ENGL J MED, V315, P488; VANDERZEE JS, 1986, CLIN EXP IMMUNOL, V64, P415	23	65	70	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					670	671		10.1016/S0140-6736(97)04122-6	http://dx.doi.org/10.1016/S0140-6736(97)04122-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500350				2022-12-01	WOS:000072364200043
J	Avorn, J; Monette, J; Lacour, A; Bohn, RL; Monane, M; Mogun, H; LeLorier, J				Avorn, J; Monette, J; Lacour, A; Bohn, RL; Monane, M; Mogun, H; LeLorier, J			Persistence of use of lipid-lowering medications - A cross-national study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHOLESTEROL-REDUCTION; CLINICAL-TRIALS; MEDICAID DATA; DRUG-THERAPY; PATIENT; PRAVASTATIN; COSTS	Context.-Although clinical trials have demonstrated the benefits of lipid-lowering therapy, little is known about how these drugs are prescribed or used in the general population. Objective.-To estimate predictors of persistence with therapy for lipid-lowering drug regimens in typical populations of patients in the United States and Canada. Design.-A cohort study defining all prescriptions filled for lipid-lowering drugs during 1 year, as well as patients' demographic and clinical characteristics. Setting.-New Jersey's Medicaid and Pharmacy Assistance for the Aged and Disabled programs and Quebec's provincial medical care program. Patients.-All continuously enrolled patients older than 65 years who filled 1 or more prescriptions for lipid-lowering drugs (N = 5611 in the US programs, and N = 1676 drawn from a 10% sample in Quebec). Main Outcome Measures.-Proportion of days during the study year for which patients had filled prescriptions for lipid-lowering drugs; predictors of good vs poor persistence with therapy. Results.-In both populations, patients failed to fill prescriptions for lipid-lowering drugs for about 40% of the study year. Persistence rates with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors were significantly higher than those seen with cholestyramine (64.3% vs 36.6% of days with drug available, respectively). Patients with hypertension, diabetes, or coronary artery disease had significantly higher rates of persistence with lipid-lowering regimens. In New Jersey, multivariable analysis indicated that the poorest patients (those enrolled in Medicaid) had lower rates of drug use than less indigent patients (those enrolled in Pharmacy Assistance for the Aged and Disabled) after adjusting for possible confounders, despite virtually complete drug coverage in both programs. When rates of use were measured in the US population for the 5 years following the study year, only 52% of surviving patients who were initially prescribed lipid-lowering drugs were still filling prescriptions for this drug class. Conclusion.-In all populations studied, patients who were prescribed lipid-lowering drug regimens remained without filled prescriptions for over a third of the study year on average. Rates of persistence varied substantially with choice of agent prescribed, comorbidity, and socioeconomic status, despite universal coverage of prescription drug costs. After 5 years, about half of the surviving original cohort in the United States had stopped using lipid-lowering therapy altogether.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA; Univ Montreal, Hotel Dieu, Ctr Rech, Montreal, PQ, Canada	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Laval University; Universite de Montreal	Avorn, J (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 221 Londwood Ave, Boston, MA 02115 USA.							ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V42, P937, DOI 10.1016/0895-4356(89)90158-3; CARON HS, 1968, J AMER MED ASSOC, V203, P922, DOI 10.1001/jama.203.11.922; COX DR, 1990, ANAL BINARY DATA; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; DONOVAN JL, 1995, INT J TECHNOL ASSESS, V11, P443, DOI 10.1017/S0266462300008667; EFRON B, 1991, J AM STAT ASSOC, V86, P9, DOI 10.2307/2289707; EVANS L, 1983, DRUGS, V25, P63, DOI 10.2165/00003495-198325010-00004; Garber AM, 1996, ANN INTERN MED, V124, P515, DOI 10.7326/0003-4819-124-5-199603010-00013; GLICKMAN L, 1994, J AM GERIATR SOC, V42, P992, DOI 10.1111/j.1532-5415.1994.tb06594.x; HERSHEY JC, 1980, AM J PUBLIC HEALTH, V70, P1081, DOI 10.2105/AJPH.70.10.1081; HULLEY SB, 1994, JAMA-J AM MED ASSOC, V272, P1372, DOI 10.1001/jama.272.17.1372; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; LAROSA JC, 1994, ARCH INTERN MED, V154, P529, DOI 10.1001/archinte.154.5.529; MELLIES MJ, 1993, ATHEROSCLEROSIS, V101, P97, DOI 10.1016/0021-9150(93)90105-4; Monane M, 1996, AM J PUBLIC HEALTH, V86, P1805, DOI 10.2105/AJPH.86.12.1805; MONANE M, 1994, ARCH INTERN MED, V154, P433, DOI 10.1001/archinte.154.4.433; National Council on Patient Information and Education, 1990, TALK INF ED; Oster G, 1996, ARCH INTERN MED, V156, P731, DOI 10.1001/archinte.156.7.731; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; ROSENSTOCK IM, 1988, AM J PREV MED, V4, P349, DOI 10.1016/S0749-3797(18)31145-0; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P302; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SALZMAN C, 1995, J CLIN PSYCHIAT, V56, P18; *SAS I INC, 1988, SAS STAT US GUID REL, P405; SPAETH GL, 1970, INVEST OPHTH VISUAL, V9, P73; STEPHENSON BJ, 1993, JAMA-J AM MED ASSOC, V269, P2779, DOI 10.1001/jama.269.21.2779; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H	30	510	515	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1998	279	18					1458	1462		10.1001/jama.279.18.1458	http://dx.doi.org/10.1001/jama.279.18.1458			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL718	9600480	Bronze			2022-12-01	WOS:000073463500035
J	Williams, DH; Maguire, AJ; Tsuzuki, W; Westwell, MS				Williams, DH; Maguire, AJ; Tsuzuki, W; Westwell, MS			An analysis of the origins of a cooperative binding energy of dimerization	SCIENCE			English	Article								The cooperativity between binding of cell wall precursor analogs (ligands)to and antibiotic dimerization of the clinically important vancomycin group antibiotics was investigated by nuclear magnetic resonance. When dimerization was weak in the absence of a ligand, the increase in the dimerization constant in the presence of a ligand derived largely from changes associated with tightening of the dimer interface. When dimerization was strong in the absence of a ligand,, the increase in the dimerization constant in the presence of a ligand derived largely from changes associated with tightening of the ligand-antibiotic interface. These results illustrate how, when a protein has a loose structure, the binding energy of another molecule to the protein can derive in part from changes occurring within the protein.	Univ Cambridge, Dept Chem, Cambridge Ctr Mol Recognit, Cambridge CB2 1EW, England; Addenbrookes Hosp, Clin Microbiol & Publ Hlth Lab, Cambridge CB2 2QW, England; Minist Agr Forestry & Fisheries, Natl Food Res Inst, Tsukuba, Ibaraki 305, Japan; Univ Oxford, Dyson Perrins Lab, Oxford OX1 3QY, England	University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Ministry of Agriculture Forestry & Fisheries - Japan; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan; University of Oxford	Williams, DH (corresponding author), Univ Cambridge, Dept Chem, Cambridge Ctr Mol Recognit, Lensfield Rd, Cambridge CB2 1EW, England.							BEAUREGARD DA, 1995, ANTIMICROB AGENTS CH, V39, P781, DOI 10.1128/AAC.39.3.781; BOHM HJ, 1994, J COMPUT AID MOL DES, V8, P243, DOI 10.1007/BF00126743; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4501; Loll PJ, 1997, J AM CHEM SOC, V119, P1516, DOI 10.1021/ja963566p; MACKAY JP, 1994, J AM CHEM SOC, V116, P4581, DOI 10.1021/ja00090a006; Schafer M, 1996, STRUCTURE, V4, P1509, DOI 10.1016/S0969-2126(96)00156-6; SEARLE MS, 1996, J CHEM SOC P1, V10, P2781; SHELDRICK GM, 1995, ACTA CRYSTALLOGR B, V51, P89, DOI 10.1107/S0108768194010190; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; STRYER L, 1988, BIOCHEMISTRY-US, P82; Williams DH, 1997, CHEM BIOL, V4, P507, DOI 10.1016/S1074-5521(97)90322-7; WILLIAMS DH, 1991, J AM CHEM SOC, V113, P7020, DOI 10.1021/ja00018a047; WILLIAMS DH, 1996, CHEM BIOL, V3, P6953	13	152	154	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					711	714		10.1126/science.280.5364.711	http://dx.doi.org/10.1126/science.280.5364.711			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563941				2022-12-01	WOS:000073415600039
J	Takenaka, K; Moriguchi, T; Nishida, E				Takenaka, K; Moriguchi, T; Nishida, E			Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest	SCIENCE			English	Article							XENOPUS-OOCYTE MATURATION; MAP KINASE; CELL-CYCLE; TYROSINE PHOSPHORYLATION; MEIOTIC MATURATION; MAMMALIAN-CELLS; CASCADE; INDUCTION; METAPHASE; HOMOLOG	The mitogen-activated protein kinase (MAPK) superfamily comprises classical MAPK (also called ERK), c-Jun amino-terminal or stress-activated protein kinase (JNK or SAPK), and p38. Although MAPK is essential for meiotic processes in Xenopus oocytes and the spindle assembly checkpoint in Xenopus egg extracts, the role of members of the MAPK superfamily in M phase or the spindle assembly checkpoint during somatic cell cycles has not been elucidated. The kinase p38, but not MAPK or JNK, was activated in mammalian cultured cells when the cells were arrested in M phase by disruption of the spindle with nocodazole, Addition of activated recombinant p38 to Xenopus cell-free extracts caused arrest of the extracts in M phase, and injection of activated p38 into cleaving embryos induced mitotic arrest. Treatment of NIH 3T3 cells with a specific inhibitor of p38 suppressed activation of the checkpoint by nocodazole, Thus, p38 functions as a component of the spindle assembly checkpoint in somatic cell cycles.	Kyoto Univ, Grad Sch Sci, Sakyo Ku, Kyoto 60601, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Sci, Sakyo Ku, Kyoto 60601, Japan.		Moriguchi, Tetsuo/D-7061-2012	Moriguchi, Tetsuo/0000-0002-9598-4991				Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MASUYAMA N, UNPUB; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P573; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; TAKENAKA K, UNPUB; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738	40	231	240	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					599	602		10.1126/science.280.5363.599	http://dx.doi.org/10.1126/science.280.5363.599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554853				2022-12-01	WOS:000073242100050
J	Neumayr, G; Schratzberger, P; Friedrich, G; Ganzer, H; Wiedermann, CJ				Neumayr, G; Schratzberger, P; Friedrich, G; Ganzer, H; Wiedermann, CJ			Effect of electrical cardioversion on myocardial cells in patients in intensive care	BRITISH MEDICAL JOURNAL			English	Article									Univ Innsbruck, Dept Internal Med, Med & Intens Care Unit, A-6020 Innsbruck, Austria	University of Innsbruck	Neumayr, G (corresponding author), Univ Innsbruck, Dept Internal Med, Med & Intens Care Unit, Anichstr 35, A-6020 Innsbruck, Austria.		Wiedermann, Christian J./ABG-9521-2020					DOHERTY PW, 1979, AM J CARDIOL, V43, P225, DOI 10.1016/S0002-9149(79)80008-9; EHSANI A, 1976, AM J CARDIOL, V37, P12, DOI 10.1016/0002-9149(76)90492-6; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; LOWN B, 1962, JAMA-J AM MED ASSOC, V182, P548; METCALFE MJ, 1988, BRIT MED J, V296, P1364, DOI 10.1136/bmj.296.6633.1364	5	8	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1207	1207		10.1136/bmj.316.7139.1207	http://dx.doi.org/10.1136/bmj.316.7139.1207			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9552995	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000073224100023
J	Hartman, JJ; Mahr, J; McNally, K; Okawa, K; Iwamatsu, A; Thomas, S; Cheesman, S; Heuser, J; Vale, RD; McNally, FJ				Hartman, JJ; Mahr, J; McNally, K; Okawa, K; Iwamatsu, A; Thomas, S; Cheesman, S; Heuser, J; Vale, RD; McNally, FJ			Katanin, a microtubule-severing protein, is a novel AAA ATPase that targets to the centrosome using a WD40-containing subunit	CELL			English	Article							SENSITIVE FUSION PROTEIN; DYNAMIC INSTABILITY; GAMMA-TUBULIN; CAENORHABDITIS-ELEGANS; STABLE MICROTUBULES; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MITOTIC SPINDLE; BETA-GAMMA; COMPLEX	Microtubule disassembly at centrosomes is involved in mitotic spindle function. The microtubule-severing protein katanin, a heterodimer of 60 and 80 kDa subunits, was previously purified and shown to localize to centrosomes in vivo. Here we report the sequences and activities of the katanin subunits, p60 is a new member of the AAA family of ATPases, and we show that expressed p60 has microtubule-stimulated ATPase and microtubule-severing activities in the absence of p80. p80 is a novel protein containing WD40 repeats, which are frequently involved in protein-protein interactions. The p80 WD40 domain does not participate in p60 dimerization, but localizes to centrosomes in transfected mammalian cells. These results indicate katanin's activities are segregated into a subunit (p60) that possesses enzymatic activity and a subunit (p80) that targets the enzyme to the centrosome.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Kanagawa, Japan; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California Davis; Kirin Brewery Company Limited; Washington University (WUSTL)	McNally, FJ (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.				NIGMS NIH HHS [GM53060, GM49752] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049752, R01GM053060] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APTE AN, 1993, BIOTECHNIQUES, V15, P890; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Caplow M, 1996, MOL BIOL CELL, V7, P663, DOI 10.1091/mbc.7.4.663; CLARKMAGUIRE S, 1994, GENETICS, V136, P533; CLARKMAGUIRE S, 1994, J CELL BIOL, V126, P199, DOI 10.1083/jcb.126.1.199; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DESAI A, 1995, J CELL BIOL, V28, P1; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HEUSELE C, 1987, EUR J BIOCHEM, V165, P613, DOI 10.1111/j.1432-1033.1987.tb11484.x; HEUSER J, 1989, J ELECTRON MICR TECH, V13, P244, DOI 10.1002/jemt.1060130310; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; KITANISHIYUMURA T, 1987, CELL MOTIL CYTOSKEL, V8, P106, DOI 10.1002/cm.970080203; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Komachi K, 1997, MOL CELL BIOL, V17, P6023, DOI 10.1128/MCB.17.10.6023; KOWALSKI RJ, 1993, J BIOL CHEM, V268, P9847; LIN CC, 1995, INT J CANCER, V63, P140, DOI 10.1002/ijc.2910630125; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; LYNCH TJ, 1986, J BIOL CHEM, V261, P7156; MCNALLY FJ, 1993, CELL, V75, P419, DOI 10.1016/0092-8674(93)90377-3; McNally FJ, 1996, J CELL SCI, V109, P561; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MORGAN A, 1994, J BIOL CHEM, V269, P29347; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; OEGEMA K, 1995, J CELL BIOL, V131, P1261, DOI 10.1083/jcb.131.5.1261; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; SHIINA N, 1992, EMBO J, V11, P4723, DOI 10.1002/j.1460-2075.1992.tb05577.x; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TUMA PL, 1994, J BIOL CHEM, V269, P30842; VALE RD, 1991, CELL, V64, P827, DOI 10.1016/0092-8674(91)90511-V; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Waters JC, 1996, MOL BIOL CELL, V7, P1547, DOI 10.1091/mbc.7.10.1547; WEISS SA, 1995, BACULOVIRUS EXPRESSI, P79; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	58	261	271	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					277	287		10.1016/S0092-8674(00)81578-0	http://dx.doi.org/10.1016/S0092-8674(00)81578-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568719	Bronze			2022-12-01	WOS:000073174000013
J	Gostin, LO; Webber, DW				Gostin, LO; Webber, DW			HIV infection and AIDS in the public health and health care systems - The role of law and litigation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RIGHTS COMMISSION DECISIONS; TRANSMISSION; PROJECT; COURT	The AIDS Litigation Project has reviewed nearly 600 reported cases involving individuals with human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) in the federal and state courts in the United States between 1991 and 1997. Cases were identified through a federal and 50-state computer and library search. An important subset of litigation relates to HIV/AIDS in the public health and health care systems, since the law affects health care institutions and professionals, patients, and public health policy in America. This subset of HIV/AIDS litigation includes testing and reporting; privacy, the duty to warn, and the right to know; physician standards of care in prevention and treatment; and discrimination and access to health care. In broad terms, the review demonstrates a reliance on voluntary testing and protection of patient privacy through HIV-specific statutes and the common law. Negligence with potential civil and criminal liability has been alleged in cases of erroneous or missed diagnosis of HIV infection. In the first AIDS case to be considered by the Supreme Court, the Court will decide whether patients with asymptomatic HIV infection are protected under the Americans with Disabilities Act. Considerable progress has been made, both socially and legally, during the first 2 decades of the epidemic, but much still needs to be accomplished to protect privacy, prevent discrimination, and promote tolerance.	Georgetown Johns Hopkins Program Law & Publ Hlth, Washington, DC USA; Georgetown Johns Hopkins Program Law & Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.							[Anonymous], 1991, MMWR Recomm Rep, V40, P1; BAYER R, 1991, NEW ENGL J MED, V324, P1500, DOI 10.1056/NEJM199105233242111; Burris S, 1996, AM J PUBLIC HEALTH, V86, P1161, DOI 10.2105/AJPH.86.8_Pt_1.1161; Burris Scott, 1992, Univ Miami Law Rev, V47, P291; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CDC, 1985, MMWR-MORBID MORTAL W, V34, P1; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P861; Centers for Disease Control and Prevention, 1997, HIV PREV B MED ADV P; *EEOC, 1993, EEOC INT GUID APPL A; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; GOSTIN L, 1998, AM DISABILITIES ACT; Gostin L O, 1997, Emory Law J, V46, P587; Gostin LO, 1997, NEW ENGL J MED, V337, P1162, DOI 10.1056/NEJM199710163371611; GOSTIN LO, 1994, JAMA-J AM MED ASSOC, V271, P1436, DOI 10.1001/jama.271.18.1436; Gostin LO, 1997, JAMA-J AM MED ASSOC, V277, P53, DOI 10.1001/jama.277.1.53; GOSTIN LO, 1990, NEW ENGL J MED, V322, P1743, DOI 10.1056/NEJM199006143222411; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P1961, DOI 10.1001/jama.263.14.1961; Gostin LO, 1996, JAMA-J AM MED ASSOC, V275, P1921, DOI 10.1001/jama.275.24.1921; GOSTIN LO, 1990, JAMA-J AM MED ASSOC, V263, P2086, DOI 10.1001/jama.263.15.2086; GOSTIN LO, IN PRESS DUKE J GEND; GOSTIN LO, 1990, AIDS HLTH CARE SYSTE; MILLER P, 1997, AM J PUBLIC HEALTH, V87, P1558; NORMAND J, 1995, PREVENTING HIV TRANS; *NY DEP HLTH, 1997, 972 NEW YORK DEP HLT; Parmet WE, 1997, AM J LAW MED, V23, P7; *PC, 1988, REP PRES COMM HUM IM; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; WEBBER DW, 1997, AIDS LAW	28	23	24	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1998	279	14					1108	1113		10.1001/jama.279.14.1108	http://dx.doi.org/10.1001/jama.279.14.1108			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZF216	9546571				2022-12-01	WOS:000072875300036
J	Feig, DS; Naylor, CD				Feig, DS; Naylor, CD			Eating for two: are guidelines for weight gain during pregnancy too liberal?	LANCET			English	Editorial Material							3RD-TRIMESTER; DELIVERY; GROWTH; BIRTH; RISK		Univ Toronto, Dept Med, Toronto, ON, Canada; Mt Sinai Hosp, Div Endocrinol & Metab, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Naylor, CD (corresponding author), Sunnybrook Hlth Sci Ctr, Inst Clin Evaluat Sci, G-106,2075 Bayview Ave, N York, ON M4N 3M5, Canada.		Feig, Denice/C-4606-2015					*AM COLL OBST GYN, 1993, ACOG TECHN B, V179, P1; Barker DJP, 1996, NUTR REV, V54, pS1; Churchill D, 1997, LANCET, V349, P7, DOI 10.1016/S0140-6736(96)06297-6; *I MED, 1990, NUTR PREGN WEIGHT GA; JOHNSON JWC, 1992, AM J OBSTET GYNECOL, V167, P353, DOI 10.1016/S0002-9378(11)91414-8; Johnson JWC, 1996, AM J OBSTET GYNECOL, V174, P254, DOI 10.1016/S0002-9378(96)70403-9; KEPPEL KG, 1993, AM J PUBLIC HEALTH, V83, P1100, DOI 10.2105/AJPH.83.8.1100; KRAMER M, 1995, COCHRANE PREGNANCY C, P1; KRAMER MS, 1992, AM J EPIDEMIOL, V136, P574, DOI 10.1093/oxfordjournals.aje.a116535; KRAMER MS, 1995, COCHRANE PREGNANCY C; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; *REP PAN DIET REF, 1991, DIET REF VAL FOOD EN, P30; Sanderson M, 1996, EPIDEMIOLOGY, V7, P34, DOI 10.1097/00001648-199601000-00007; SCHOLL TO, 1995, OBSTET GYNECOL, V86, P423, DOI 10.1016/0029-7844(95)00190-3; SHEPARD MJ, 1986, AM J OBSTET GYNECOL, V155, P947, DOI 10.1016/0002-9378(86)90323-6; SiegaRiz AM, 1996, J NUTR, V126, P146, DOI 10.1093/jn/126.1.146; SMITH DE, 1994, JAMA-J AM MED ASSOC, V271, P1747, DOI 10.1001/jama.271.22.1747; STEIN AD, 1995, HUM BIOL, V67, P135; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665	19	52	55	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 4	1998	351	9108					1054	1055		10.1016/S0140-6736(97)06261-2	http://dx.doi.org/10.1016/S0140-6736(97)06261-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546528				2022-12-01	WOS:000072927200045
J	Doyle, DA; Cabral, JM; Pfuetzner, RA; Kuo, AL; Gulbis, JM; Cohen, SL; Chait, BT; MacKinnon, R				Doyle, DA; Cabral, JM; Pfuetzner, RA; Kuo, AL; Gulbis, JM; Cohen, SL; Chait, BT; MacKinnon, R			The structure of the potassium channel: Molecular basis of K+ conduction and selectivity	SCIENCE			English	Article							PEPTIDE INHIBITOR; CALCIUM CHANNELS; ION PERMEATION; TEA BLOCKADE; ALPHA-HELIX; PORE; CHARYBDOTOXIN; MUTATIONS; RECEPTOR; RESOLUTION	The potassium channel from Streptomyces lividans is an integral membrane protein with sequence similarity to all known K+ channels, particularly in the pore region. X-ray analysis with data to 3.2 angstroms reveals that four identical subunits create an inverted teepee, or cone, cradling the selectivity filter of the pore in its outer end, The narrow selectivity filter is only 12 angstroms long, whereas the remainder of the pore is wider and lined with hydrophobic amino acids, A large water-filled cavity and helix dipoles are positioned so as to overcome electrostatic destabilization of an ion in the pore at the center of the bilayer. Main chain carbonyl oxygen atoms from the K+ channel signature sequence line the selectivity filter, which is held open by structural constraints to coordinate K+ ions but not smaller Na+ ions. The selectivity filter contains two K+ ions about 7.5 angstroms apart. This configuration promotes ion conduction by exploiting electrostatic repulsive forces to overcome attractive forces between K+ ions and the selectivity filler. The architecture of the pore establishes the physical principles underlying selective K+ conduction.	Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10021 USA.	mackinn@rockvax.rockefeller.edu	Oka, Yoshitaka/C-9670-2010; Morais-Cabral, Joao H/J-4914-2013	Oka, Yoshitaka/0000-0002-3482-3051; Morais-Cabral, Joao H/0000-0002-4461-9716				AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; ARMSTRONG CM, 1972, J GEN PHYSIOL, V59, P388, DOI 10.1085/jgp.59.4.388; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P588, DOI 10.1085/jgp.60.5.588; BRUNGER AT, XPLOR VERSION 3 851; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; GAMBLIN SJ, 1996, P CCP4 STUD WEEK DAR, P163; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; HAGIWARA S, 1977, J GEN PHYSIOL, V70, P269, DOI 10.1085/jgp.70.3.269; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; Hille B., 1992, IONIC CHANNELS EXCIT; HODGKIN AL, 1955, J PHYSIOL-LONDON, V128, P61, DOI 10.1113/jphysiol.1955.sp005291; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREUSCH A, 1994, J MOL BIOL, V243, P891, DOI 10.1006/jmbi.1994.1690; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LOCKHART DJ, 1992, SCIENCE, V257, P947, DOI 10.1126/science.1502559; LOCKHART DJ, 1993, SCIENCE, V260, P198, DOI 10.1126/science.8469972; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; NEYTON J, 1988, J GEN PHYSIOL, V92, P569, DOI 10.1085/jgp.92.5.569; NEYTON J, 1988, J GEN PHYSIOL, V92, P549, DOI 10.1085/jgp.92.5.549; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PARSEGIAN VA, 1975, ANN NY ACAD SCI, V264, P161, DOI 10.1111/j.1749-6632.1975.tb31481.x; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SCHEMPF H, 1995, EMBO J, V14, P5170; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Smart OS, 1996, J MOL GRAPH MODEL, V14, P354, DOI 10.1016/S0263-7855(97)00009-X; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509; TATE MW, 1995, J APPL CRYSTALLOGR, V28, P196, DOI 10.1107/S0021889894007867; THIEL DJ, 1996, REV SCI INSTRUM, V67, P1; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	55	5417	5570	98	1217	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 3	1998	280	5360					69	77		10.1126/science.280.5360.69	http://dx.doi.org/10.1126/science.280.5360.69			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525859	Green Submitted			2022-12-01	WOS:000072885100036
J	Schiff, GD; Rucker, TD				Schiff, GD; Rucker, TD			Computerized prescribing - Building the electronic infrastructure for better medication usage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PHYSICIAN ORDER ENTRY; PRACTICE GUIDELINES; DECISION-SUPPORT; HEALTH-CARE; PATIENT; INFORMATION; SYSTEM; ERRORS; DRUGS; PREVENTION	Computerized prescribing in the practice of medicine is a change that is overdue. Virtually all prescriptions in the United States are still handwritten. instead, medications should be ordered on a computer interacting with 3 databases: patient drug history, scientific drug information and guideline reference, and patient-specific (weight, laboratory) data. Current problems with prescribing on which computerized prescribing could have a positive impact include (1) drug selection; (2) patient role in pharmacotherapy risk-benefit decision making; (3) screening for interactions (drug-drug, drug-laboratory, drug-disease); (4) linkages between laboratory and pharmacy; (5) dosing calculations and scheduling; (6) coordination between team members, particularly concerning patient education; (7) monitoring and documenting adverse effects; and (8) postmarketing surveillance of therapy outcomes, Computerized prescribing is an important component of clinician order entry. Development of this tool has been impeded by a number of conceptual, implementation, and policy barriers. Overcoming these constraints will require clinically and professionally guided vision and leadership.	Cook Cty Hosp, Dept Med, Collaborat Res Unit, Chicago, IL 60612 USA; Univ Illinois, Coll Pharm, Chicago, IL USA	John H Stroger Junior Hospital Cook County; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Schiff, GD (corresponding author), Cook Cty Hosp, Dept Med, Collaborat Res Unit, 1825 W Harrison St,Room 220,Adm Bldg, Chicago, IL 60612 USA.	gdschiff@aol.com						*AG HLTH CAR POL R, 1995, AHCPR PUBL; Amatayakul M, 1997, Health Data Manag, V5, P56; Andrade Susan E., 1996, Pharmacoepidemiology and Drug Safety, V5, P113; [Anonymous], 1997, LANCET, V349, P369; Balas EA, 1996, ARCH FAM MED, V5, P271, DOI 10.1001/archfami.5.5.271; Balas EA, 1996, J GEN INTERN MED, V11, P584, DOI 10.1007/BF02599025; BARKER KN, 1995, AM J HEALTH-SYST PH, V52, P400, DOI 10.1093/ajhp/52.4.400; Bates D W, 1994, Qual Manag Health Care, V2, P18; Bates DW, 1996, DRUG SAFETY, V15, P303, DOI 10.2165/00002018-199615050-00001; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1996, AM J HEALTH-SYST PH, V53, P747; BERWICK DM, 1991, MED CARE, V29, P1212, DOI 10.1097/00005650-199112000-00004; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BLOBEL B, 1997, ELECT PATIENT REC, V5, P3; Bradley CP, 1997, BRIT MED J, V314, P744, DOI 10.1136/bmj.314.7082.744; Cannon B, 1996, J Am Pharm Assoc (Wash), VNS36, P668; Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; Chewning B, 1996, SOC SCI MED, V42, P389, DOI 10.1016/0277-9536(95)00156-5; Chin T L, 1997, Health Data Manag, V5, P78; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Cohen MR, 1996, AM J HEALTH-SYST PH, V53, P737, DOI 10.1093/ajhp/53.7.737; *COUNC COMP, 1998, HIGHW HLTH TRANSF US; CROSS MA, 1996, HLTH DATA MANAGE, V4, P70; DAVIS P, 1996, CONTESTED GROUND PUB; DOYLE E, 1995, AM COLL PHYS OBSERVE, V15, P7; ELLINOY BJ, 1989, AM J HOSP PHARM, V46, P1549, DOI 10.1093/ajhp/46.8.1549a; Elson RB, 1997, J AM MED INFORM ASSN, V4, P266, DOI 10.1136/jamia.1997.0040266; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; Faich Gerald A., 1996, Pharmacoepidemiology and Drug Safety, V5, P393, DOI 10.1002/(SICI)1099-1557(199611)5:6<393::AID-PDS235>3.3.CO;2-8; Felkey BG, 1997, AM J HEALTH-SYST PH, V54, P274, DOI 10.1093/ajhp/54.3.274; Gabrieli E R, 1991, Top Health Rec Manage, V11, P27; Garibaldi RA, 1998, NEW ENGL J MED, V338, P259, DOI 10.1056/NEJM199801223380411; GIBBS S, 1990, J ROY SOC MED, V83, P292, DOI 10.1177/014107689008300505; GLABMAN M, 1996, AM COLL PHYS OBS OCT, V16, P8; GRAY BH, 1997, HLTH AFF MILLWOOD, V16, P106; Grimshaw J, 1995, J Eval Clin Pract, V1, P37, DOI 10.1111/j.1365-2753.1995.tb00006.x; Hampton C. E., 1997, Journal of Investigative Medicine, V45, p311A; HART JT, 1992, LANCET, V340, P772, DOI 10.1016/0140-6736(92)92304-X; Hayward RSA, 1996, J GEN INTERN MED, V11, P176, DOI 10.1007/BF02600272; Hayward RSA, 1997, CAN MED ASSOC J, V156, P1715; HEADDEN S, 1996, US NEWS WORLD R 0826, P47; *I MED COMM IMPR M, 1991, COMP BAS PAT REC ESS; *INT SOC PHARM, 1997, DAT PRIV MED REC CON; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; LAMB GC, 1994, ARCH INTERN MED, V154, P2753, DOI 10.1001/archinte.1994.00420230150018; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEGLER JD, 1990, M D COMPUT, V7, P155; Lesar TS, 1997, JAMA-J AM MED ASSOC, V277, P312, DOI 10.1001/jama.277.4.312; LIPTON HL, 1995, INT J TECHNOL ASSESS, V11, P485, DOI 10.1017/S0266462300008692; LIPTON HL, 1993, MED CARE, V31, P1069, DOI 10.1097/00005650-199312000-00001; LORTIE FM, 1986, CAN MED ASSOC J, V135, P27; Lyons RF, 1996, J CLIN PHARM THER, V21, P221, DOI 10.1111/j.1365-2710.1996.tb01142.x; Marsa L., 1997, PRESCRIPTION PROFIT; MARTIN J, 1995, GRET TRANSITION USIN; Martin R, 1996, BRIT MED J, V312, P1418; MARUYAMA H, 1989, ANN INTERN MED, V110, P333; McCarthy R, 1997, Bus Health, V15, P39; MCCARTHY R, 1997, DRUG BENEFIT TRENDS, V9, P36; McDonald CJ, 1997, J AM MED INFORM ASSN, V4, P213, DOI 10.1136/jamia.1997.0040213; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; McDonald CJ, 1997, ANN INTERN MED, V127, P675, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00049; MILES P, 1995, JOINT COMM J QUAL IM, V21, P32; Miller RA, 1997, J AM MED INFORM ASSN, V4, P442, DOI 10.1136/jamia.1997.0040442; Morris LA, 1997, MED CARE, V35, P996, DOI 10.1097/00005650-199710000-00002; MUIRHEAD G, 1996, DRUG TOPICS, V140, P61; Mullen PD, 1997, BRIT MED J, V314, P691, DOI 10.1136/bmj.314.7082.691; *NAT COUNC PAT INF, 1995, PRESCR MED COMPL REV; NIGHTINGALE SL, 1995, INT J TECHNOL ASSESS, V11, P399, DOI 10.1017/S026646230000862X; Overhage JM, 1997, J AM MED INFORM ASSN, V4, P364, DOI 10.1136/jamia.1997.0040364; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; Poikonen J, 1997, AM J HEALTH-SYST PH, V54, P281, DOI 10.1093/ajhp/54.3.281; POWSNER SM, 1994, LANCET, V344, P386, DOI 10.1016/S0140-6736(94)91406-0; RASON JT, 1990, HUMAN ERROR; RAY WA, 1993, NEW ENGL J MED, V329, P2029, DOI 10.1056/NEJM199312303292710; RELMAN AS, 1982, NEW ENGL J MED, V306, P669, DOI 10.1056/NEJM198203183061109; Rovelli F, 1996, LANCET, V348, P169; RUCKER TD, 1990, MED CARE, V28, P928, DOI 10.1097/00005650-199010000-00007; RUCKER TD, 1974, JAMA-J AM MED ASSOC, V230, P889; SCHIFF GD, 1991, ANN INTERN MED, V114, P748, DOI 10.7326/0003-4819-114-9-748; SCHIFF GD, 1995, JOINT COMM J QUAL IM, V21, P549, DOI 10.1016/S1070-3241(16)30181-X; SCHIFF GD, 1996, EX ERR HLTH CAR DEV; SCHIFF GD, 1993, U S P OP C PAT ED RO, P13; SCHNEIDER R, 1995, AM J HEALTH-SYST PH, V52, P2184, DOI 10.1093/ajhp/52.20.2184; SCHOENENBERGER RA, 1995, JAMA-J AM MED ASSOC, V274, P1622, DOI 10.1001/jama.274.20.1622; Schriger DL, 1997, JAMA-J AM MED ASSOC, V278, P1585, DOI 10.1001/jama.278.19.1585; Schulman KA, 1996, ANN INTERN MED, V124, P906, DOI 10.7326/0003-4819-124-10-199605150-00008; Shea S, 1996, J AM MED INFORM ASSN, V3, P399, DOI 10.1136/jamia.1996.97084513; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P108, DOI 10.1136/jamia.1994.95236142; Siwicki B, 1997, Health Data Manag, V5, P54; SOUMERAI SB, 1995, NEW ENGL J MED, V332, P1641, DOI 10.1056/NEJM199506153322411; *SOW UN PRIM CAR I, 1996, PROD PUBL, V24; SZOLOVITS P, 1996, ELECT PATIENT RECORD, V4, P8; Thompson CA, 1996, AM J HEALTH-SYST PH, V53, P712, DOI 10.1093/ajhp/53.7.712; TOGNONI G, 1986, LANCET, V2, P1028; Tuttle MS, 1997, J AM MED INFORM ASSN, V4, P322, DOI 10.1136/jamia.1997.0040322; United States Department of Health and Human Services, 1996, HLTH PEOPL 2000 REV HLTH PEOPL 2000 REV; VANDERLEI J, 1993, ANN INTERN MED, V119, P1036, DOI 10.7326/0003-4819-119-10-199311150-00011; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; Walton RT, 1997, BRIT MED J, V315, P791; Weed LL, 1997, BRIT MED J, V315, P231, DOI 10.1136/bmj.315.7102.231; Weingarten S, 1997, JAMA-J AM MED ASSOC, V277, P1977, DOI 10.1001/jama.277.24.1977; WIJNANDS MJH, 1992, BRIT J RHEUMATOL, V31, P253, DOI 10.1093/rheumatology/31.4.253; Wolinsky H, 1997, ANN INTERN MED, V127, P953, DOI 10.7326/0003-4819-127-10-199711150-00026; WYATT J, 1995, BRIT MED J, V311, P1181, DOI 10.1136/bmj.311.7014.1181; 1996, LANCET, V347, P1127; 1995, FED REG, V60, P44182; 1994, DRUG THER B, V32, P32	108	174	180	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1024	1029		10.1001/jama.279.13.1024	http://dx.doi.org/10.1001/jama.279.13.1024			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD283	9533503				2022-12-01	WOS:000072669700032
J	Guilford, P; Hopkins, J; Harraway, J; McLeod, M; McLeod, N; Harawira, P; Taite, H; Scoular, R; Miller, A; Reeve, AE				Guilford, P; Hopkins, J; Harraway, J; McLeod, M; McLeod, N; Harawira, P; Taite, H; Scoular, R; Miller, A; Reeve, AE			E-cadherin germline mutations in familial gastric cancer	NATURE			English	Article							INVASION-SUPPRESSOR GENE; LOBULAR BREAST CANCERS; CARCINOMA CELL-LINES; EXPRESSION; EXTRACTION; STOMACH	The identification of genes predisposing to familial cancer is an essential step towards understanding the molecular events underlying tumorigenesis and is critical for the clinical management of affected families. Despite a declining incidence, gastric cancer remains a major cause of cancer death worldwide(1), and about 10% of cases show familial clustering(2,3), The relative contributions of inherited susceptibility and environmental effects to familial gastric cancer are poorly understood because little is known of the genetic events that predispose to gastric cancer. Here we describe the identification of the gene responsible for early-onset, histologically poorly differentiated, high grade, diffuse gastric cancer(4) in a large kindred from New Zealand (Aotearoa), Genetic linkage analysis demonstrated significant Linkage to markers flanking the gene for the calcium-dependent cell-adhesion protein E-cadherin. Sequencing of the E-cadherin gene revealed a G-->T nucleotide substitution in the donor splice consensus sequence of exon 7, leading to a truncated gene product, Diminished E-cadherin expression is associated with aggressive, poorly differentiated carcinomas(5). Underexpression of E-cadherin is a prognostic marker of poor clinical outcome in many tumour types(6), and restored expression of E-cadherin in tumour models can suppress the invasiveness of epithelial tumour cells(7,8). The role of E-cadherin in gastric cancer susceptibility was confirmed by identifying inactivating mutations in other gastric cancer families, In one family a frameshift mutation,vas identified in exon 15, and in a second family a premature stop codon interrupted exon 13, These results describe, to our knowledge for the first time, a molecular basis for familial gastric cancer, and confirm the important role of E-cadherin mutations in cancer.	Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, Aotearoa, New Zealand; Kimi Hauora Hlth Clin, Mt Maunganui S, Aotearoa, New Zealand; Tauranga Publ Hosp, Tauranga, Aotearoa, New Zealand; Univ Otago, Dept Pathol, Dunedin, Aotearoa, New Zealand	University of Otago; University of Otago	Guilford, P (corresponding author), Univ Otago, Dept Biochem, Canc Genet Lab, POB 56, Dunedin, Aotearoa, New Zealand.	parry.guilford@stonebow.otago.ac.nz		Guilford, Parry/0000-0002-7256-9576				BANERJEE SK, 1995, BIOTECHNIQUES, V18, P768; BECKER KF, 1994, CANCER RES, V54, P3845; BERX G, 1995, GENOMICS, V26, P281, DOI 10.1016/0888-7543(95)80212-5; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GRAFF JR, 1995, CANCER RES, V55, P5195; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; JONES E. G., 1964, NEW ZEAL MED J, V63, P287; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LAVECCHIA C, 1992, CANCER, V70, P50, DOI 10.1002/1097-0142(19920701)70:1<50::AID-CNCR2820700109>3.0.CO;2-I; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muta H, 1996, JPN J CANCER RES, V87, P843, DOI 10.1111/j.1349-7006.1996.tb02109.x; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Tamura G, 1996, JPN J CANCER RES, V87, P1153, DOI 10.1111/j.1349-7006.1996.tb03125.x; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; ZANGHIERI G, 1990, CANCER, V66, P2047, DOI 10.1002/1097-0142(19901101)66:9<2047::AID-CNCR2820660934>3.0.CO;2-G	29	1205	1267	3	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					402	405		10.1038/32918	http://dx.doi.org/10.1038/32918			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537325				2022-12-01	WOS:000072713600055
J	Steven, R; Kubiseski, TJ; Zheng, H; Kulkarni, S; Mancillas, J; Morales, AR; Hogue, CWV; Pawson, T; Culotti, J				Steven, R; Kubiseski, TJ; Zheng, H; Kulkarni, S; Mancillas, J; Morales, AR; Hogue, CWV; Pawson, T; Culotti, J			UNC-73 activates the Rac GTPase and is required for cell and growth cone migrations in C-elegans	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; TRANSMEMBRANE TYROSINE PHOSPHATASE; CAENORHABDITIS-ELEGANS; BINDING PROTEIN; AXON MIGRATIONS; SH3 DOMAINS; GENE; DROSOPHILA; NEURONS; KINASE	unc-73 is required for cell migrations and axon guidance in C. elegans and encodes overlapping isoforms of 283 and 189 kDa that are closely related to the vertebrate Trio and Kalirin proteins, respectively. UNC-73A contains, in order, eight spectrin-like repeats, a Dbl/Pleckstrin homology (DH/PH) element, an SH3-like domain, a second DH/PH element, an immunoglobulin domain, and a fibronectin type ill domain. UNC-73B terminates just downstream of the SH3-like domain. The first DR/PH element specifically activates the Rac GTPase in vitro and stimulates actin polymerization when expressed in Rat2 cells. Both functions are eliminated by introducing the S1216F mutation of unc-73(rh40) into this DH domain. Our results suggest that UNC-73 acts cell autonomously in a protein complex to regulate actin dynamics during cell and growth cone migrations.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Calif Los Angeles, Dept Anat & Cell Biol, Los Angeles, CA 90024 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of California System; University of California Los Angeles	Culotti, J (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Hogue, Christopher/B-6726-2008; Culotti, Joseph/G-6467-2013; Pawson, Tony J/E-4578-2013; Hogue, Christopher W V/AAZ-3934-2020	Hogue, Christopher W V/0000-0002-3107-5246; Culotti, Joseph/0000-0001-6325-4612; Kubiseski, Terrance/0000-0001-9388-8608				Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARSAGI D, 1995, METHOD ENZYMOL, V255, P436; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Bryant SH, 1996, PROTEINS, V26, P172; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Chen EB, 1997, DEV BIOL, V182, P88, DOI 10.1006/dbio.1996.8473; Chen WN, 1996, J BIOL CHEM, V271, P26362, DOI 10.1074/jbc.271.42.26362; Chen WN, 1996, GENE, V180, P217, DOI 10.1016/S0378-1119(96)00414-3; CHEN WN, 1994, J BIOL CHEM, V269, P32394; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Forrester WC, 1997, DEVELOPMENT, V124, P1831; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARRIGA G, 1993, DEVELOPMENT, V117, P1071; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HART MJ, 1994, J BIOL CHEM, V269, P62; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Lin Chi-Hung, 1994, Current Opinion in Neurobiology, V4, P640, DOI 10.1016/0959-4388(94)90004-3; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORI I, 1988, GENETICS, V120, P397; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rost B, 1996, METHOD ENZYMOL, V266, P525; Run JQ, 1996, GENETICS, V143, P225; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SIDDIQUI SS, 1990, NEUROSCI RES, pS171, DOI 10.1016/0921-8696(90)90047-7; SIDDIQUI SS, 1991, J NEUROGENET, V7, P193, DOI 10.3109/01677069109167433; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; WAY JC, 1992, DEV DYNAM, V194, P289, DOI 10.1002/aja.1001940405; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wightman B, 1997, DEVELOPMENT, V124, P2571; Xie GF, 1995, GENET ANAL-BIOMOL E, V12, P95, DOI 10.1016/1050-3862(95)00112-3; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	56	261	266	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1998	92	6					785	795		10.1016/S0092-8674(00)81406-3	http://dx.doi.org/10.1016/S0092-8674(00)81406-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529254	Bronze			2022-12-01	WOS:000072661200011
J	Passaro, DJ; Werner, SB; McGee, J; Mac Kenzie, WR; Vugia, DJ				Passaro, DJ; Werner, SB; McGee, J; Mac Kenzie, WR; Vugia, DJ			Wound botulism associated with black tar heroin among injecting drug users	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							22-YEAR FOLLOW-UP; INFECTIONS; ADDICTS; ABUSERS; CARE	Context.-Wound botulism (WB) is a potentially lethal, descending, flaccid, paralysis that results when spores of Clostridium botulinum germinate in a wound and elaborate neurotoxin. Since 1988, California has experienced a dramatic increase in WB associated with injecting "black tar" heroin (BTH), a dark, tarry form of the drug. Objective.-To identify risk factors for WB among injecting drug users (IDUs). Design.-Case-control study based on data from in-person and telephone interviews. Participants.-Case patients (n=26) were IDUs who developed WB from January 1994 through February 1996. Controls (n=110) were IDUs newly enrolled in methadone detoxification programs in 4 counties. Main Outcome Measures.-Factors associated with the development of WB. Results.-Among the 26 patients, the median age was 41.5 years, 15 (58%) were women, 14 (54%) were non-Hispanic white, 11 (42%) were Hispanic, and none were positive for the human immunodeficiency virus. Nearly all participants (96% of patients and 97% of controls) injected BTH, and the mean cumulative dose of BTH used per month was similar for patients and controls (27 g and 31 g, respectively; P=.6). Patients were more likely than controls to inject drugs subcutaneously or intramuscularly (92% vs 44%, P<.001) and used this route of drug administration more times per month (mean, 67 vs 24, P<.001), with a greater cumulative monthly dose of BTH (22.3 g vs 6.3 g, P<.001). A dose-response relationship was observed between the monthly cumulative dose of BTH injected subcutaneously or intramuscularly and the development of WB (chi(2) for linear trend, 26.5; P<.001). In the final regression model, subcutaneous or intramuscular injection of BTH was the only behavior associated with WB among IDUs (odds ratio, 13.7; 95% confidence interval, 3.0-63.0). The risk for development of WB was not affected by cleaning the skin, cleaning injection paraphernalia, or sharing needles. Conclusions.-Injection of BTH intramuscularly or subcutaneously is the primary risk factor for the development of WB. Physicians in the western United States, where BTH is widely used, should be aware of the potential for WB to occur among IDUs.	Calif Dept Hlth Serv, Div Communicable Dis, Berkeley, CA 94704 USA; Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Div Field Epidemiol, Atlanta, GA USA	California Department of Health Care Services; Stanford University; Centers for Disease Control & Prevention - USA	Passaro, DJ (corresponding author), Calif Dept Hlth Serv, Div Communicable Dis, Berkeley, CA 94704 USA.	dpass@ix.netcom.com	Kenzie, William R Mac/F-1528-2013	Kenzie, William R Mac/0000-0001-7723-0339				BALDWIN WA, 1993, CHEST, V103, P21, DOI 10.1378/chest.103.1.21; *CAL DEP HLTHS ERV, 1986, CALIFORNIA MORB, V26, P1; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P889; GILL DM, 1982, MICROBIOL REV, V46, P86, DOI 10.1128/MMBR.46.1.86-94.1982; Goldstein A, 1995, DRUG ALCOHOL DEPEN, V40, P139, DOI 10.1016/0376-8716(95)01205-2; GRONBLADH L, 1990, ACTA PSYCHIAT SCAND, V82, P223, DOI 10.1111/j.1600-0447.1990.tb03057.x; HAVERKOS HW, 1990, J INFECT DIS, V161, P894, DOI 10.1093/infdis/161.5.894; MACDONALD KL, 1985, ANN INTERN MED, V102, P616, DOI 10.7326/0003-4819-102-5-616; MARX A, 1994, INT J ADDICT, V29, P837, DOI 10.3109/10826089409047914; OPPENHEIMER E, 1994, ADDICTION, V89, P1299, DOI 10.1111/j.1360-0443.1994.tb03309.x; STEIN MD, 1990, J GEN INTERN MED, V5, P249, DOI 10.1007/BF02600544; *US DEP HHS, 1995, FIN REP 1994 HOUS SU; *US DRUG ENF ADM, 1994, DOM MON PROGR 1993 A; VLAHOV D, 1992, PUBLIC HEALTH REP, V107, P595; WEBER JT, 1993, CLIN INFECT DIS, V16, P635, DOI 10.1093/clind/16.5.635; WERNER SB, 1996, 36 ANN INT C ANT AG; WYSKOWSKI DK, 1993, PUBLIC HLTH REP, V108, P565; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804	18	148	152	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					859	863		10.1001/jama.279.11.859	http://dx.doi.org/10.1001/jama.279.11.859			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZA943	9516001	Bronze			2022-12-01	WOS:000072417600033
J	Craven, DE; Duncan, RA; Stram, JR; O'Hara, CJ; Steger, KA; Jhamb, K; Hirschhorn, LR				Craven, DE; Duncan, RA; Stram, JR; O'Hara, CJ; Steger, KA; Jhamb, K; Hirschhorn, LR			Response of lymphoepithelial parotid cysts to antiretroviral treatment in HIV-infected adults	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	35th Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 07-16, 1997	SAN FRANCISCO, CA	Infect Dis Soc Amer			ACQUIRED-IMMUNODEFICIENCY-SYNDROME; SALIVARY-GLANDS; VIRUS-INFECTION; LESIONS; AIDS	Background: Surgical resection has been the usual therapy for HIV-infected patients with lymphoepithelial parotid cysts. Objective: To study antiretroviral therapy for lymphoepithelial parotid cysts. Design: Case series. Setting: HIV outpatient clinics. Patients: HIV-infected patients with lymphoepithelial parotid cysts. Intervention: Antiretroviral therapy. Measurements: Change in size of the parotid cyst, CD4 lymphocyte count, and HIV viral load. Results: Nine HIV-infected adults presented with chronic, large parotid cysts, eight of which were bilateral. in at least seven patients, the cysts were the initial sign of HIV infection. In six patients, the cysts resolved completely with combination antiretroviral therapy. Four of these patients also received prednisone. Three patients who did not comply with antiretroviral therapy had partial responses followed by relapses. Conclusions: Parotid cysts are an unrecognized sign of early HIV infection. These cysts respond to combination antiretroviral therapy, with or without corticosteroids. Surgical resection should be reserved for patients in whom medical therapy has failed or those who refuse or are poorly compliant with medical therapy.	Boston Univ, Med Ctr, Sch Med, Dept Otolaryngol, Boston, MA 02118 USA; Lahey Hitchcock Clin, Infect Dis Sect, Burlington, MA 01805 USA; Boston Med Ctr, Dept Pathol, Boston, MA 02118 USA; Boston Med Ctr, Dept Gen Internal Med, Boston, MA 02118 USA; Dimock Community Hlth Ctr, Roxbury, MA 02119 USA	Boston University; Lahey Hospital & Medical Center; Boston Medical Center; Boston Medical Center	Craven, DE (corresponding author), Boston Univ, Med Ctr, Sch Med, Dept Otolaryngol, Dowling 3 N,1 Boston Med Ctr, Boston, MA 02118 USA.			Stram, John/0000-0003-3526-157X; O'Hara, Carl/0000-0001-7404-3597				BEITLER JJ, 1995, HEAD NECK-J SCI SPEC, V17, P31, DOI 10.1002/hed.2880170107; BERNIER JL, 1958, CANCER, V11, P1156, DOI 10.1002/1097-0142(195811/12)11:6<1156::AID-CNCR2820110611>3.0.CO;2-2; ELLIOTT JN, 1990, AM J CLIN PATHOL, V93, P39, DOI 10.1093/ajcp/93.1.39; FINFER MD, 1988, ARCH OTOLARYNGOL, V114, P1290; IOACHIM HL, 1988, ARCH PATHOL LAB MED, V112, P1224; ITESCU S, 1990, ANN INTERN MED, V112, P3, DOI 10.7326/0003-4819-112-1-3; LEE KC, 1992, OTOLARYNG CLIN N AM, V25, P1287; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; SCHIODT M, 1992, ORAL SURG ORAL MED O, V74, P326, DOI 10.1016/0030-4220(92)90069-3; SHAHA AR, 1993, AM J SURG, V166, P403, DOI 10.1016/S0002-9610(05)80342-3; SHUGAR JMA, 1988, LARYNGOSCOPE, V98, P772; Smith F B, 1990, Prog AIDS Pathol, V2, P61; SPERLING NM, 1990, HEAD NECK-J SCI SPEC, V12, P337, DOI 10.1002/hed.2880120411; TERRY JH, 1991, AM J SURG, V162, P324, DOI 10.1016/0002-9610(91)90141-Y; TUNKEL DE, 1989, LARYNGOSCOPE, V99, P590; Wagner RP, 1996, CLIN INFECT DIS, V22, P369, DOI 10.1093/clinids/22.2.369; WEIDNER N, 1986, AM J CLIN PATHOL, V85, P395, DOI 10.1093/ajcp/85.4.395; IN PRESS MMWR MORB M	19	29	30	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					455	459		10.7326/0003-4819-128-6-199803150-00006	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZA914	9499329				2022-12-01	WOS:000072414700006
J	Collins, S; Woodman, CBJ; Threlfall, A; Prior, P				Collins, S; Woodman, CBJ; Threlfall, A; Prior, P			Survival rates from interval cancer in NHS breast screening programme	BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Christie Hosp NHS Trust, Ctr Canc Epidemiol, Manchester M20 4QL, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Collins, S (corresponding author), Univ Manchester, Christie Hosp NHS Trust, Ctr Canc Epidemiol, Manchester M20 4QL, Lancs, England.							ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; Day N, 1995, J Med Screen, V2, P180; HAKULINEN T, 1985, COMPUT PROG BIOMED, V19, P197, DOI 10.1016/0010-468X(85)90011-X; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; WOODMAN CBJ, 1995, BRIT MED J, V310, P224, DOI 10.1136/bmj.310.6974.224	5	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 14	1998	316	7134					832	833		10.1136/bmj.316.7134.832	http://dx.doi.org/10.1136/bmj.316.7134.832			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549455	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000072584300032
J	Kobayashi, T; Stang, E; Fang, KS; de Moerloose, P; Parton, RG; Gruenberg, J				Kobayashi, T; Stang, E; Fang, KS; de Moerloose, P; Parton, RG; Gruenberg, J			A lipid associated with the antiphospholipid syndrome regulates endosome structure and function	NATURE			English	Article							MONOCLONAL-ANTIBODIES; 6-PHOSPHATE RECEPTOR; FUSION INVITRO; BHK-CELLS; BINDING; STEREOCONFIGURATION; RECOGNITION; TRANSPORT; LYSOSOMES; GROWTH	Little is known about the structure and function of membrane domains in the vacuolar apparatus of animal cells. A unique feature of late endosomes, which are part of the pathway that leads to lysosomes, is that they contain a complex system of poorly characterized internal membranes in their lumen. These endosomes are therefore known as multivesicular or multilamellar organelles(1,2). Some proteins distribute preferentially within these internal membranes, whereas others are exclusively localized to the organelle's limiting membrane(3). The composition and function of this membrane system are poorly understood. Here we show that these internal membranes contain large amounts of a unique lipid, and thus form specialized domains within endosomes, These specialized domains are involved in sorting the multifunctional receptor(4) for insulin-like growth factor 2 and ligands bearing mannose-6-phosphate, in particular lysosomal enzymes, We also show that this unique lipid is a specific antigen for human antibodies associated with the antiphospholipid syndrome(5,6). These antibodies may act intracellularly by altering the protein-sorting functions of endosomes.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; Univ Queensland, Ctr Microscopy & Microanal, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Univ Queensland, Ctr Mol & Cellular Biol, St Lucia, Qld 4072, Australia; Univ Hosp Geneva, Div Angiol & Haemostasis, CH-1211 Geneva 14, Switzerland	University of Geneva; University of Queensland; University of Queensland; University of Geneva	Gruenberg, J (corresponding author), Univ Geneva, Dept Biochem, 30 Quai E Ansermet, CH-1211 Geneva 4, Switzerland.	jean.gruenberg@biochemunige.ch	Kobayashi, Toshihide/B-6298-2015; KOBAYASHI, TOSHIHIDE/S-8313-2019; Parton, Robert G/C-5673-2009	Kobayashi, Toshihide/0000-0002-4811-7270; KOBAYASHI, TOSHIHIDE/0000-0002-4811-7270; Parton, Robert G/0000-0002-7494-5248				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; AlarconSegovia D, 1996, J RHEUMATOL, V23, P1319; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; ASHERSON RA, 1996, ANTIPHOSPHOLIPID SYN, P1; BROTHERUS J, 1974, CHEM PHYS LIPIDS, V13, P178, DOI 10.1016/0009-3084(74)90034-6; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Groskopf JC, 1997, ENDOCRINOLOGY, V138, P2835, DOI 10.1210/en.138.7.2835; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; Horkko S, 1996, J CLIN INVEST, V98, P815, DOI 10.1172/JCI118854; JOUTTI A, 1979, BIOCHIM BIOPHYS ACTA, V575, P10, DOI 10.1016/0005-2760(79)90125-5; KARASAWA K, 1991, LIPIDS, V26, P1122, DOI 10.1007/BF02536514; Khamashta Munther A., 1996, Lupus, V5, P343; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; MCNEIL HP, 1991, ADV IMMUNOL, V49, P193; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; REBER G, 1990, THROMB RES, V57, P215, DOI 10.1016/0049-3848(90)90321-3; SOMERHARJU P, 1979, BIOCHIM BIOPHYS ACTA, V573, P83, DOI 10.1016/0005-2760(79)90175-9; UMEDA M, 1989, J IMMUNOL, V143, P2273; Volpert O, 1996, ENDOCRINOLOGY, V137, P3871, DOI 10.1210/en.137.9.3871; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WHERRETT JR, 1972, J BIOL CHEM, V247, P4114	30	632	641	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 12	1998	392	6672					193	197		10.1038/32440	http://dx.doi.org/10.1038/32440			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515966				2022-12-01	WOS:000072462700066
J	Mattingley, JB; Husain, M; Rorden, C; Kennard, C; Driver, J				Mattingley, JB; Husain, M; Rorden, C; Kennard, C; Driver, J			Motor role of human inferior parietal lobe revealed in unilateral neglect patients	NATURE			English	Article							DIRECTIONAL HYPOKINESIA; ATTENTION; REPRESENTATION; CORTEX	The exact role of the parietal lobe in spatial cognition is controversial. One influential hypothesis proposes that it subserves spatial perception(1), whereas other accounts suggest that its primary role is to direct spatial movement(2,3). For humans, it has been suggested that these functions may be divided between inferior and superior parietal lobes, respectively(2,4). In apparent support of a purely perceptual function for the inferior parietal lobe (IPL), patients with lesions to this structure, particularly in the right hemisphere, exhibit unilateral spatial neglect (deficient awareness for the side of space opposite to that of their lesion)(5). Here we show that patients with right IPL lesions also have a specific difficulty in initiating leftward movements towards visual targets on the left side of space, This motor impairment was not found in neglect patients,vith frontal lesions, contrary to precious proposals that motor aspects of neglect are particularly associated with anterior damage(6-9). Our results suggest that the human IPL operates as a sensorimotor interface, rather than subserving only perceptual functions.	Charing Cross Hosp, Imperial Coll Sch Med, Div Neurosci & Psychol Med, London W6 8RF, England; UCL, Inst Cognit Neurosci, Dept Psychol, London WC1E 6BT, England; Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England	Imperial College London; University of London; University College London; University of Cambridge	Husain, M (corresponding author), Charing Cross Hosp, Imperial Coll Sch Med, Div Neurosci & Psychol Med, London W6 8RF, England.	m.husain@cxwms.ac.uk	Husain, Masud/C-2074-2008; Mattingley, Jason/J-1537-2014; Driver, Jon/A-4779-2010	Husain, Masud/0000-0002-6850-9255; Mattingley, Jason/0000-0003-0929-9216; Rorden, Chris/0000-0002-7554-6142	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andersen RA, 1997, ANNU REV NEUROSCI, V20, P303, DOI 10.1146/annurev.neuro.20.1.303; BISIACH E, 1993, Q J EXP PSYCHOL-A, V46, P435, DOI 10.1080/14640749308401056; BISIACH E, 1990, NEUROLOGY, V40, P1278, DOI 10.1212/WNL.40.8.1278; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; Damasio H., 1989, LESION ANAL NEUROPSY; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; Duncan John, 1995, P721; Graziano Michael S. A., 1996, Society for Neuroscience Abstracts, V22, P398; Heilman K.M., 1985, INT J CLIN NEUROPSYC, V2nd, P243; Husain M, 1996, J NEUROL, V243, P652, DOI 10.1007/BF00878662; HUSAIN M, 1997, NATURE, V385, P184; HUSAIN M, 1991, VISION VISUAL DYSFUN, V13, P12; Kinsbourne M, 1970, Trans Am Neurol Assoc, V95, P143; MATTINGLEY JB, 1992, BRAIN, V115, P1849, DOI 10.1093/brain/115.6.1849; MATTINGLEY JB, 1997, PARIETAL LOBE CONTRI, P309, DOI DOI 10.1007/978-3-642-60661-8_18; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; Mesulam MM., 1985, PRINCIPLES BEHAV NEU; Milner AD., 1997, PARIETAL LOBE CONTRI, P3; Milner D., 1995, VISUAL BRAIN ACTION; PERENIN MT, 1988, BRAIN, V111, P643, DOI 10.1093/brain/111.3.643; POSNER MI, 1984, J NEUROSCI, V4, P1863; RIDDOCH MJ, 1983, NEUROPSYCHOLOGIA, V21, P589, DOI 10.1016/0028-3932(83)90056-8; ROBERTSON IH, 1993, UNILATERAL NEGLECT C; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; TEGNER R, 1991, BRAIN, V114, P1943, DOI 10.1093/brain/114.4.1943; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549	26	223	224	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					179	182		10.1038/32413	http://dx.doi.org/10.1038/32413			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515962				2022-12-01	WOS:000072462700062
J	Martin, W; Muller, M				Martin, W; Muller, M			The hydrogen hypothesis for the first eukaryote	NATURE			English	Article							TRICHOMONAS-VAGINALIS; AMITOCHONDRIATE EUKARYOTE; MITOCHONDRIA; PROTIST; ORIGIN; GENE; ENDOSYMBIONT; METABOLISM; EVOLUTION; ARCHAEA	A new hypothesis for the origin of eukaryotic cells is proposed, based on the comparative biochemistry of energy metabolism. Eukaryotes are suggested to have arisen through symbiotic association of an anaerobic, strictly hydrogen-dependent, strictly autotrophic archaebacterium (the host) with a eubacterium (the symbiont) that was able to respire, but generated molecular hydrogen as a waste product of anaerobic heterotrophic metabolism. The host's dependence upon molecular hydrogen produced by the symbiont is put forward as the selective principle that forged the common ancestor of eukaryotic cells.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Genet, D-38023 Braunschweig, Germany; Rockefeller Univ, New York, NY 10021 USA	Braunschweig University of Technology; Rockefeller University	Muller, M (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Genet, Spielmannstr 7, D-38023 Braunschweig, Germany.	w.martin@tu-bs.de; mmuller@rockvax.rockefeller.edu	Martin, William F./O-5446-2015; Martin, William/C-5680-2008	Martin, William F./0000-0003-1478-6449; 				Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Brinkmann H, 1996, PLANT MOL BIOL, V30, P65, DOI 10.1007/BF00017803; BROERS CAM, 1990, EUR J PROTISTOL, V25, P369, DOI 10.1016/S0932-4739(11)80130-6; BRYANT MP, 1967, ARCH MIKROBIOL, V59, P20, DOI 10.1007/BF00406313; Bui ETN, 1996, P NATL ACAD SCI USA, V93, P9651, DOI 10.1073/pnas.93.18.9651; CAVALIER-SMITH T, 1987, ANN NY ACAD SCI, V503, P7; CavalierSmith T, 1996, J MOL EVOL, V43, P551, DOI 10.1007/BF02202103; CAVALIERSMITH T, 1987, NATURE, V326, P332, DOI 10.1038/326332a0; CLARK CG, 1995, P NATL ACAD SCI USA, V92, P6518, DOI 10.1073/pnas.92.14.6518; Conrad R, 1996, MICROBIOL REV, V60, P609, DOI 10.1128/MMBR.60.4.609-640.1996; Coombs Graham H., 1995, P33, DOI 10.1016/B978-012473345-9/50004-0; de Duve C, 1991, BLUEPRINT CELL NATUR; DOOLITTLE WF, 1996, S SOC GEN MICROBIOL, V54, P1; EMBLEY TM, 1995, P ROY SOC B-BIOL SCI, V262, P87, DOI 10.1098/rspb.1995.0180; Fenchel T., 1995, ECOLOGY EVOLUTION AN; FINLAY BJ, 1993, J GEN MICROBIOL, V139, P371, DOI 10.1099/00221287-139-2-371; Germot A, 1996, P NATL ACAD SCI USA, V93, P14614, DOI 10.1073/pnas.93.25.14614; Gibson JL, 1996, ARCH MICROBIOL, V166, P141, DOI 10.1007/s002030050369; GRAY MW, 1982, MICROBIOL REV, V46, P1; Gupta RS, 1996, TRENDS BIOCHEM SCI, V21, P166, DOI 10.1016/S0968-0004(96)20013-1; HENZE K, 1995, P NATL ACAD SCI USA, V92, P9122, DOI 10.1073/pnas.92.20.9122; Horner DS, 1996, P ROY SOC B-BIOL SCI, V263, P1053, DOI 10.1098/rspb.1996.0155; HRDY I, 1995, J MOL EVOL, V41, P388, DOI 10.1007/BF01215186; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; Kaneko T, 1996, DNA Res, V3, P109; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; Keeling PJ, 1997, P NATL ACAD SCI USA, V94, P1270, DOI 10.1073/pnas.94.4.1270; LAKE JA, 1994, P NATL ACAD SCI USA, V91, P2880, DOI 10.1073/pnas.91.8.2880; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; MARKOS A, 1993, J MOL EVOL, V37, P631, DOI 10.1007/BF00182749; Martin W, 1997, CURR GENET, V32, P1, DOI 10.1007/s002940050241; MULLER M, 1988, ANNU REV MICROBIOL, V42, P465, DOI 10.1146/annurev.mi.42.100188.002341; Muller M, 1998, SYST ASSOC SPEC VOL, V56, P109; MULLER M, 1993, J GEN MICROBIOL, V139, P2879, DOI 10.1099/00221287-139-12-2879; MULLER M, 1996, CG EHRENBERGFESTSCHR, P63; MURRELL JC, 1992, FEMS MICROBIOL LETT, V88, P233, DOI 10.1016/0378-1097(92)90805-X; Poole AM, 1998, J MOL EVOL, V46, P1, DOI 10.1007/PL00006275; Roger AJ, 1996, P NATL ACAD SCI USA, V93, P14618, DOI 10.1073/pnas.93.25.14618; Rosenthal B, 1997, J BACTERIOL, V179, P3736, DOI 10.1128/jb.179.11.3736-3745.1997; ROSPERT S, 1991, ARCH MICROBIOL, V156, P49, DOI 10.1007/BF00418187; Sanchez LB, 1996, FEBS LETT, V378, P240, DOI 10.1016/0014-5793(95)01463-2; SCHONHEIT P, 1995, WORLD J MICROB BIOT, V11, P26, DOI 10.1007/BF00339135; Searcy Dennis G., 1992, P47; SOGIN ML, 1996, S SOC GEN MICROBIOL, V54, P167; STEVENS TO, 1995, SCIENCE, V270, P450, DOI 10.1126/science.270.5235.450; Thauer Rudolf K., 1993, P209; WHATLEY JM, 1979, PROC R SOC SER B-BIO, V204, P165, DOI 10.1098/rspb.1979.0020; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Yamamoto A, 1997, J MOL EVOL, V44, P98, DOI 10.1007/PL00006127; ZILLIG W, 1989, ENDOCYT CELL RES, V6, P1	50	858	888	10	175	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					37	41		10.1038/32096	http://dx.doi.org/10.1038/32096			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510246				2022-12-01	WOS:000072373000041
J	Finkelstein, BS; Silvers, JB; Marrero, U; Neuhauser, D; Cuttler, L				Finkelstein, BS; Silvers, JB; Marrero, U; Neuhauser, D; Cuttler, L			Insurance coverage, physician recommendations, and access to emerging treatments - Growth hormone therapy for childhood short stature	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Association-of-Health-Services-Research	JUN 15-17, 1997	CHICAGO, ILLINOIS	Assoc Hlth Serv Res			HEALTH-INSURANCE; CHILDREN; CARE; DEFICIENCY; COMPANIES; DIAGNOSIS; DRUG	Context.-There is concern in both the medical community and the general public about mechanisms of medical decision making and the interplay of physician and insurer decisions in determining access to care. Objective.-To examine the medical process influencing access to growth hormone (GH) therapy for childhood short stature by comparing coverage policies of US insurers with the treatment recommendations of US physicians. Design and Participants.-Independent national representative surveys were mailed to insurers (private, Blue Cross/Blue Shield, health maintenance organizations, programs for Children with Special Health Care Needs, and Medicaid programs, n=113), primary care physicians (n=1504), and pediatric endocrinologists (n=534) with response rates of 75%, 60%, and 81%, respectively, Each survey included identical case scenarios. Primary care physicians were asked decisions about referrals to pediatric endocrinologists, Endocrinologists were asked GH treatment recommendations. Insurers were asked coverage decisions for GH therapy. Main Outcome Measures.-Insurer coverage decisions for GH in specific case scenarios were compared with the recommendations of primary care physicians and pediatric endocrinologists. Results.-Physician recommendations and insurance coverage decisions differed strikingly, For example, while 96% of pediatric endocrinologists recommended GH therapy for children with Turner syndrome, insurer policies covered GH therapy for only 52% of these children, Overall, referral and treatment decisions by physicians resulted in recommendations for GH therapy in 78% of children with GH deficiency, Turner syndrome, or renal failure; of those recommended for treatment, 28% were denied coverage by insurers. Similarly, GH therapy would be recommended by physicians for only 9% of children with idiopathic short stature, but insurers would not cover GH for the vast majority of these children. Furthermore, the data indicated considerable variation among insurers regarding coverage policies for GH (P<.01). Conclusions.-Access to GH therapy differs depending on the type of insurance coverage. The deep discord between physician recommendations and insurance coverage decisions, exemplified by these findings, represents a major challenge to mechanisms of health care decision making, access, and costs.	Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Weatherhead Sch Management, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Cuttler, L (corresponding author), Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, 11000 Euclid Ave, Cleveland, OH 44106 USA.				AHRQ HHS [T32 HS00059-03] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABRAMOWICZ M, 1994, MED LETT DRUGS THER, V36, P77; ADAY LA, 1993, MED CARE, V31, P1013, DOI 10.1097/00005650-199311000-00004; *AM MED ASS DEP DA, 1995, PHYS CHAR DISTR US 1; Berlin CM, 1997, PEDIATRICS, V99, P122; BUCHANAN RJ, 1994, ANN PHARMACOTHER, V28, P528, DOI 10.1177/106002809402800418; *C RES SERV, 1993, MED SOURC BOOK BACKG; Cuttler L, 1996, JAMA-J AM MED ASSOC, V276, P531, DOI 10.1001/jama.276.7.531; FURLANETTO RW, 1995, J PEDIATR-US, V127, P857; *GROUP HLTH ASS AM, 1993, 1993 HMO NAT DIR; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HALL MA, 1992, U PENN LAW REV, V140, P1637, DOI 10.2307/3312428; LANTOS J, 1989, JAMA-J AM MED ASSOC, V261, P1020, DOI 10.1001/jama.261.7.1020; Lewit EM, 1995, FUTURE CHILD, V5, P192, DOI 10.2307/1602375; LIGHT DW, 1994, NEW ENGL J MED, V330, P498, DOI 10.1056/NEJM199402173300711; LIPPE BM, 1993, RECENT PROG HORM RES, V48, P179; MILHOLLAND AV, 1973, NEW ENGL J MED, V288, P1272, DOI 10.1056/NEJM197306142882405; Moore K G, 1992, Womens Health Issues, V2, P40, DOI 10.1016/S1049-3867(05)80136-7; MOORE KC, 1993, J PEDIATR-US, V122, P687, DOI 10.1016/S0022-3476(06)80005-3; NEWACHECK PW, 1988, PEDIATRICS, V81, P385; NEWACHECK PW, 1995, HEALTH AFFAIR, V14, P244, DOI 10.1377/hlthaff.14.1.244; *NIH CAR MAN AG HL, 1995, MED NEC S POL ISS IM; OCONNER M, 1995, CHICAGO TRIBUNE 0722, P5; PETERS WP, 1994, NEW ENGL J MED, V330, P473, DOI 10.1056/NEJM199402173300707; ROSENFELD RG, 1994, ENDOCRINOLOGIST, V4, P351, DOI 10.1097/00019616-199409000-00006; ROSENFELD RG, 1995, J CLIN ENDOCR METAB, V80, P1532, DOI 10.1210/jc.80.5.1532; ROSENFIELD RL, 1995, ENDOCRINOLOGY, P2549; ROSENTHAL E, 1996, NY TIMES        0524, pA1; ROSENTHAL E, 1996, NY TIMES        0715, pA7; SALMON JW, 1995, INT J HEALTH SERV, V25, P11, DOI 10.2190/YLBF-L031-6MN8-JE01; SINGH J, IN PRESS MED CARE; Steiner CA, 1996, J GEN INTERN MED, V11, P294, DOI 10.1007/BF02598272; TANNER JM, 1985, J PEDIATR-US, V107, P317, DOI 10.1016/S0022-3476(85)80501-1; UNDERWOOD LE, 1992, HOSP PRACT, V27, P192; *US BUR CENS, 1995, STAT ABSTR US 1993, P118; *US REN DAT SYST, 1995, USRDS 1995 ANN DATA, pB11; VIMPANI GV, 1977, BMJ-BRIT MED J, V2, P427, DOI 10.1136/bmj.2.6084.427; WIT JM, 1997, ENDOCR NEWS, V22, P1; WYATT DT, 1995, J CLIN ENDOCR METAB, V80, P3292, DOI 10.1210/jc.80.11.3292	38	41	41	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					663	668		10.1001/jama.279.9.663	http://dx.doi.org/10.1001/jama.279.9.663			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YY849	9496983				2022-12-01	WOS:000072192800029
J	Perez-Reyes, E; Cribbs, LL; Daud, A; Lacerda, AE; Barclay, J; Williamson, MP; Fox, M; Rees, M; Lee, JH				Perez-Reyes, E; Cribbs, LL; Daud, A; Lacerda, AE; Barclay, J; Williamson, MP; Fox, M; Rees, M; Lee, JH			Molecular characterization of a neuronal low-voltage-activated T-type calcium channel	NATURE			English	Article							ABSENCE EPILEPSY; CA2+ CHANNELS; CELLS; INACTIVATION; CONDUCTANCE; PERMEATION; MOTIF; MOUSE	The molecular diversity of voltage-activated calcium channels was established by studies showing that channels could be distinguished by their voltage-dependence, deactivation and single-channel conductance(1-3). Low-voltage-activated channels are called 'T' type because their currents are both transient (owing. to fast inactivation) and tiny (owing to small conductance)(2). T-type channels are thought to be involved in pacemaker activity, low-threshold calcium spikes, neuronal oscillations and resonance, and rebound burst firing(4). Here we report the identification of a neuronal T-type channel. Our cloning strategy began with an analysis of Genbank sequences defined as sharing homology with calcium channels. We sequenced an expressed sequence tag (EST), then used it to done a full-length complementary DNA from rat brain. Northern blot analysis indicated that this gene is expressed predominantly in brain, in particular the amygdala, cerebellum and thalamus. We mapped the human gene to chromosome 17q22, and the mouse gene to chromosome 11. Functional expression of the channel was measured in Xenopus oocytes. Based on the channel's distinctive voltage dependence, slow deactivation kinetics, and 7.5-pS single-channel conductance, we conclude that this channel is a low-voltage-activated T-type calcium channel.	Loyola Univ, Med Ctr, Dept Physiol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Cardiovasc Inst, Maywood, IL 60153 USA; Metrohlth Med Ctr, Rammelkamp Ctr Res & Educ, Cleveland, OH 44109 USA; Univ London Univ Coll, Sch Med, Rayne Inst, Dept Paediat, London WC1E 6JJ, England; Galton Lab, MRC, Human Biochem Genet Unit, London NW1 2HE, England	Loyola University Chicago; Loyola University Chicago; MetroHealth System; University of London; King's College London; University College London; UCL Medical School; University of London; University College London	Perez-Reyes, E (corresponding author), Loyola Univ, Med Ctr, Dept Physiol, Maywood, IL 60153 USA.	eperez@luc.edu		Williamson, Magali/0000-0002-7183-7495				Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; Bernal J, 1997, J PHARMACOL EXP THER, V282, P172; Bourinet E, 1996, J NEUROSCI, V16, P4983; BREEN M, 1994, HUM MOL GENET, V3, P621, DOI 10.1093/hmg/3.4.621; CARBONE E, 1984, NATURE, V310, P501, DOI 10.1038/310501a0; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DROOGMANS G, 1989, J PHYSIOL-LONDON, V419, P627, DOI 10.1113/jphysiol.1989.sp017890; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.physiol.58.1.329; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; LACERDA AE, 1994, BIOPHYS J, V66, P1833, DOI 10.1016/S0006-3495(94)80977-4; Lambert RC, 1997, J NEUROSCI, V17, P6621; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MEIER H, 1967, ARCH NEUROL-CHICAGO, V16, P59, DOI 10.1001/archneur.1967.00470190063008; Montgomery JC, 1997, MAMM GENOME, V7, pS190, DOI 10.1007/s003359900323; NILIUS B, 1985, NATURE, V316, P443, DOI 10.1038/316443a0; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Randall AD, 1997, NEUROPHARMACOLOGY, V36, P879, DOI 10.1016/S0028-3908(97)00086-5; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; SHUBA YM, 1991, J PHYSIOL-LONDON, V443, P25, DOI 10.1113/jphysiol.1991.sp018820; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; VanDongen AMJ, 1996, BIOPHYS J, V70, P1303, DOI 10.1016/S0006-3495(96)79687-X; WAKAMORI M, 1994, RECEPTOR CHANNEL, V2, P303; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0	30	612	641	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	1998	391	6670					896	900		10.1038/36110	http://dx.doi.org/10.1038/36110			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495342				2022-12-01	WOS:000072230900053
J	Di Cunto, F; Topley, G; Calautti, E; Hsiao, J; Ong, L; Seth, PK; Dotto, GP				Di Cunto, F; Topley, G; Calautti, E; Hsiao, J; Ong, L; Seth, PK; Dotto, GP			Inhibitory function of p21(Cip1/WAF1) in differentiation of primary mouse keratinocytes independent of cell cycle control	SCIENCE			English	Article							P21(WAF1/CIP1) EXPRESSION; TERMINAL DIFFERENTIATION; GROWTH; P21; PROTEIN; PROGRESSION; WAF1/CIP1; CALCIUM; PCNA	The cyclin-dependent kinase inhibitor p21(Cip1/WAF1) has been implicated as an inducer of differentiation. However, although expression of p21 is increased in postmitotic cells immediately adjacent to the proliferative compartment, its expression is decreased in cells further along the differentiation program. Expression of the p21 protein was decreased in terminally differentiated primary keratinocytes of mice, and this occurred by a proteasome-dependent pathway. Forced expression of p21 in these cells inhibited the expression of markers of terminal differentiation at both the protein and messenger RNA levels. These inhibitory effects on differentiation were not observed with a carboxyl-terminal truncation mutant or with the unrelated cyclin-dependent kinase inhibitor p16(INK4a), although all these molecules exerted similar inhibition of cell growth. These findings reveal an inhibitory role of p21 in the late stages of differentiation that does not result from the effects of p21 on the cell cycle.	Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Turin, Dept Genet Biol & Med Chem, Torino, Italy; NCI, Med Branch, Breast Canc Sect, Bethesda, MD 20892 USA	Harvard University; Massachusetts General Hospital; Harvard University; University of Turin; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dotto, GP (corresponding author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, 13th St, Charlestown, MA 02129 USA.	Paolo_Dotto@cbrc.mgh.harvard.edu	Calautti, Enzo/M-8283-2018; Di Cunto, Ferdinando/K-5575-2016	Calautti, Enzo/0000-0002-4439-9709; di cunto, ferdinando/0000-0001-9367-6357	NATIONAL CANCER INSTITUTE [P01CA016038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039190] Funding Source: NIH RePORTER; NCI NIH HHS [CA16038] Funding Source: Medline; NIAMS NIH HHS [AR39190] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Brissette JL, 1996, GENE DEV, V10, P2212, DOI 10.1101/gad.10.17.2212; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DELALLE I, 1996, SOC NEUR ABSTR, V22, P254; DICUNTO F, UNPUB; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Harper JW, 1997, CANCER SURV, V29, P91; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li LW, 1996, J INVEST DERMATOL, V106, P254, DOI 10.1111/1523-1747.ep12340654; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576	24	240	244	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1069	1072		10.1126/science.280.5366.1069	http://dx.doi.org/10.1126/science.280.5366.1069			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9582119				2022-12-01	WOS:000073663600045
J	Feray, C; Gigou, M; Samuel, D; Ducot, B; Maisonneuve, P; Reynes, M; Bismuth, A; Bismuth, H				Feray, C; Gigou, M; Samuel, D; Ducot, B; Maisonneuve, P; Reynes, M; Bismuth, A; Bismuth, H			Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation	ANNALS OF INTERNAL MEDICINE			English	Article						hepatitis C; liver transplantation; immunoglobulins; hepatitis C antibodies	VIRUS-INFECTION; IMMUNE GLOBULIN; NON-A; PREVENTION; IMMUNOPROPHYLAXIS; NEUTRALIZATION; REINFECTION; CHIMPANZEES	Background: Recurrence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection after liver transplantation is a clinical problem. Polyclonal immunoglobulins against hepatitis B surface antigen (HBIGs) prevent the recurrence of HBV infection, but no effective prophylaxis is available for HCV infection. Before screening of blood donors was introduced in France, HBIGs may have contained antibody to HCV (anti-HCV). Objective: io determine the influence of HBIG on the occurrence of hepatitis C after liver transplantation before and after 1990. Design: Retrospective cohort study. Setting: Liver transplantation unit of a university hospital. Patients: 428 consecutive patients who had liver transplantation because of cirrhosis between 1984 and 1994. Measurements: Detection of serum HCV RNA before and 1 year after transplantation and findings on liver graft biopsy. Results: Among the 218 patients who had HCV infection before transplantation, the incidence of HCV viremia after transplantation was lower in those receiving HBIG than in those not receiving HBIG (25 of 46 patients [54%] compared with 162 of 172 patients [94%]; P < 0.001). In patients receiving HBIG, the incidence of HCV viremia after transplantation was lower among those who had transplantation before March 1990 than among those who had transplantation after this date (15 of 33 patients [45%] compared with 10 of 13 patients [77%]; P = 0.05). Among the 210 patients without HCV infection before transplantation, acquired infection was significantly less frequent in those receiving HBIG than in those not receiving HBIG (18 of 68 patients [26%] compared with 40 of 86 patients [47%]; P < 0.001). Passively transmitted anti-HCV was transiently detected in patients receiving HBIG before March 1990. Multivariate analysis in patients with HCV infection before transplantation showed that the absence of HBIG and transplantation after March 1990 were independent significant risk factors for chronic hepatitis C after transplantation. Conclusions: Polyclonal immunoglobulins that are treated for viral decontamination and contain anti-HCV could prevent HCV infection.	Hop Paul Brousse, Ctr Hepatobiliare, Lab Anat Bathol & Transfus Sanguine, F-94800 Villejuif, France; Univ Paris Sud, Villejuif, France; Ctr Transfus Sanguine, Le Chesnay, France; CHU Bicetre, INSERM, U292, Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Feray, C (corresponding author), Hop Paul Brousse, Ctr Hepatobiliare, Lab Anat Bathol & Transfus Sanguine, 14 Ave Paul Vaillant Couturier, F-94800 Villejuif, France.		Feray, Cyrille/S-2559-2018	cyrille, feray/0000-0002-8627-9676				ALBERTI A, 1995, J HEPATOL, V22, P38; BJORO K, 1994, NEW ENGL J MED, V331, P1607, DOI 10.1056/NEJM199412153312402; CHOO QL, 1994, P NATL ACAD SCI USA, V91, P1294, DOI 10.1073/pnas.91.4.1294; FARCI P, 1994, P NATL ACAD SCI USA, V91, P7792, DOI 10.1073/pnas.91.16.7792; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; FARGES O, 1994, TRANSPLANTATION, V58, P891, DOI 10.1097/00007890-199410270-00006; FARGES O, 1996, HEPATOLOGY, V5, P569; FERAY C, 1992, J CLIN INVEST, V89, P1361, DOI 10.1172/JCI115723; FERAY C, 1990, TRANSPLANTATION, V49, P1155, DOI 10.1097/00007890-199006000-00025; FERAY C, 1994, HEPATOLOGY, V20, P1137, DOI 10.1016/0270-9139(94)90748-X; KNODELL RG, 1976, LANCET, V1, P557; Krawczynski K, 1996, J INFECT DIS, V173, P822, DOI 10.1093/infdis/173.4.822; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LEFRERE JJ, 1993, LANCET, V341, P834, DOI 10.1016/0140-6736(93)90615-N; NEUHAUS P, 1994, LANCET, V344, P423; NOWAK T, 1992, J MED VIROL, V36, P209, DOI 10.1002/jmv.1890360311; SAMUEL D, 1991, LANCET, V337, P813, DOI 10.1016/0140-6736(91)92515-4; SAMUEL D, 1993, NEW ENGL J MED, V329, P1842, DOI 10.1056/NEJM199312163292503; SANCHEZQUIJANO A, 1988, LANCET, V1, P1245; SCOTTO J, 1983, HEPATOLOGY, V3, P279; SHIMIZU YK, 1994, J VIROL, V68, P1494, DOI 10.1128/JVI.68.3.1494-1500.1994; WRIGHT TL, 1992, GASTROENTEROLOGY, V103, P317, DOI 10.1016/0016-5085(92)91129-R; YAP PL, 1994, J HEPATOL, V21, P455, DOI 10.1016/S0168-8278(05)80328-9	23	106	107	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1998	128	10					810	+		10.7326/0003-4819-128-10-199805150-00003	http://dx.doi.org/10.7326/0003-4819-128-10-199805150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM889	9599192				2022-12-01	WOS:000073586500003
J	Hirsch, RE; Lewis, BD; Spalding, EP; Sussman, MR				Hirsch, RE; Lewis, BD; Spalding, EP; Sussman, MR			A role for the AKT1 potassium channel in plant nutrition	SCIENCE			English	Article							RECTIFYING K+ CHANNELS; ARABIDOPSIS-THALIANA; ION-TRANSPORT; LINEAR COMPONENT; CORN ROOTS; INWARD; MECHANISM; EXPRESSION; AMMONIUM; CELLS	In plants, potassium serves an essential role as an osmoticum and charge carrier. Its uptake by roots occurs by poorly defined mechanisms. To determine the role of potassium channels in planta, we performed a reverse genetic screen and identified an Arabidopsis thaliana mutant in which the AKT1 channel gene was disrupted. Roots of this mutant lacked inward-rectifying potassium channels and displayed reduced potassium (rubidium-86) uptake. Compared with wild type, mutant plants grew poorly on media with a potassium concentration of 100 micromolar or less. These results and membrane potential measurements suggest that the AKT1 channel mediates potassium uptake from solutions that contain as little as 10 micromolar potassium.	Univ Wisconsin, Dept Hort, Ctr Biotechnol, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Biol Program, Madison, WI 53706 USA; Univ Wisconsin, Dept Bot, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Sussman, MR (corresponding author), Univ Wisconsin, Dept Hort, Ctr Biotechnol, 1575 Linden Dr, Madison, WI 53706 USA.		Spalding, Edgar P/ABF-3253-2021; Spalding, Edgar P/GWC-1811-2022; Spalding, Edgar P/A-9034-2008	Spalding, Edgar P/0000-0002-6890-4765; Spalding, Edgar P/0000-0002-6890-4765	NIGMS NIH HHS [GM07215] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; CAO YW, 1993, PLANT PHYSIOL, V102, P983, DOI 10.1104/pp.102.3.983; Cho MH, 1996, P NATL ACAD SCI USA, V93, P8134, DOI 10.1073/pnas.93.15.8134; EPSTEIN E, 1963, P NATL ACAD SCI USA, V49, P684, DOI 10.1073/pnas.49.5.684; GASSMANN W, 1994, PLANT PHYSIOL, V105, P1399, DOI 10.1104/pp.105.4.1399; GASSMANN W, 1993, PLANT CELL, V5, P1491, DOI 10.2307/3869732; Gaymard F, 1996, J BIOL CHEM, V271, P22863, DOI 10.1074/jbc.271.37.22863; KOCHIAN LV, 1982, PLANT PHYSIOL, V70, P1723, DOI 10.1104/pp.70.6.1723; KOCHIAN LV, 1985, PLANT PHYSIOL, V79, P771, DOI 10.1104/pp.79.3.771; Krysan PJ, 1996, P NATL ACAD SCI USA, V93, P8145, DOI 10.1073/pnas.93.15.8145; Lagarde D, 1996, PLANT J, V9, P195, DOI 10.1046/j.1365-313X.1996.09020195.x; Lewis BD, 1997, PLANT PHYSIOL, V114, P1327, DOI 10.1104/pp.114.4.1327; MAATHUIS FJM, 1993, PLANTA, V191, P302, DOI 10.1007/BF00195686; MAATHUIS FJM, 1994, P NATL ACAD SCI USA, V91, P9272, DOI 10.1073/pnas.91.20.9272; MAATHUIS FJM, 1995, PLANTA, V197, P456, DOI 10.1007/BF00196667; Roberts SK, 1995, PLANT J, V8, P811, DOI 10.1046/j.1365-313X.1995.8060811.x; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; SCHROEDER JI, 1991, P NATL ACAD SCI USA, V88, P11583, DOI 10.1073/pnas.88.24.11583; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; VALE FR, 1987, PLANT PHYSIOL, V84, P1416, DOI 10.1104/pp.84.4.1416; VALE FR, 1988, PLANTA, V173, P424, DOI 10.1007/BF00401031; Walker DJ, 1996, P NATL ACAD SCI USA, V93, P10510, DOI 10.1073/pnas.93.19.10510	23	503	564	2	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 8	1998	280	5365					918	921		10.1126/science.280.5365.918	http://dx.doi.org/10.1126/science.280.5365.918			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572739				2022-12-01	WOS:000073532900046
J	Packer, C; Tatar, M; Collins, A				Packer, C; Tatar, M; Collins, A			Reproductive cessation in female mammals	NATURE			English	Article							MENOPAUSE; LIONS; COSTS	In female mammals, fertility declines abruptly at an advanced age. The human menopause is one example, but reproductive cessation has also been documented in non-human primates, rodents, whales, dogs, rabbits, elephants and domestic livestock(1-3). The human menopause has been considered an evolutionary adaptation(4-7), assuming that elderly women avoid the increasing complications of continued childbirth to better nurture their current children and grandchildren. But an abrupt reproductive decline might be only a non-adaptive by-product of life-history patterns. Because so many individuals die from starvation, disease and predation, detrimental genetic traits can persist (or even be favoured) as long as their deleterious effects are delayed until an advanced age is reached, and, for a given pattern of mortality, there should be an age by which selection would be too weak to prevent the onset of reproductive senescence(4,5,8). We provide a systematic test of these alternatives using field data from two species in which grandmothers frequently engage in kin-directed behaviour. Both species show abrupt age-specific changes in reproductive performance that are characteristic of menopause. But elderly females do not suffer increased mortality costs of reproduction, nor do post-reproductive females enhance the fitness of grandchildren or older children. Instead, reproductive cessation appears to result from senescence.	Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA; Brown Univ, Dept Ecol & Evolut Biol, Providence, RI 02912 USA; Gombe Stream Res Ctr, Kigoma, Tanzania	University of Minnesota System; University of Minnesota Twin Cities; Brown University	Packer, C (corresponding author), Univ Minnesota, Dept Ecol Evolut & Behav, 1987 Upper Buford Circle, St Paul, MN 55108 USA.	packer@biosci.umn.edu		Tatar, Marc/0000-0003-3232-6884				Altmann J., 1970, LAB ANIM DIG, V6, P7; Caswell H., 1989, MATRIX POPULATION MO; Charlesworth B., 1994, EVOLUTION AGE STRUCT; Finch CE., 1990, LONGEVITY SENESCENCE; Gouzoules S., 1987, P299; HAMILTON WD, 1966, J THEOR BIOL, V12, P12, DOI 10.1016/0022-5193(66)90184-6; Hawkes K, 1997, CURR ANTHROPOL, V38, P551, DOI 10.1086/204646; HEINSOHN R, 1995, SCIENCE, V269, P1260, DOI 10.1126/science.7652573; Hill K, 1991, Hum Nat, V2, P313, DOI 10.1007/BF02692196; Johnstone, 1975, ELEPHANTS THEIR HABI; Lee E, 2013, STAT METHODS SURVIVA; MCCOMB K, 1994, ANIM BEHAV, V47, P379, DOI 10.1006/anbe.1994.1052; Medawar P.B, 1952, UNIQUENESS INDIVIDUA; PACKER C, 1990, AM NAT, V136, P1, DOI 10.1086/285079; PACKER C, 1995, AM NAT, V145, P833, DOI 10.1086/285771; PACKER C, 1995, NATURE, V373, P60, DOI 10.1038/373060a0; PUSEY AE, 1994, BEHAV ECOL, V5, P362, DOI 10.1093/beheco/5.4.362; REZNICK D, 1985, OIKOS, V44, P257, DOI 10.2307/3544698; ROGERS AR, 1993, EVOL ECOL, V7, P406, DOI 10.1007/BF01237872; Stolwijk AM, 1997, FERTIL STERIL, V67, P702, DOI 10.1016/S0015-0282(97)81370-2; vanNoord PAH, 1997, FERTIL STERIL, V68, P95, DOI 10.1016/S0015-0282(97)81482-3; VAUPEL JW, 1985, AM STAT, V39, P176, DOI 10.2307/2683925; Vom Saal Frederick S., 1994, P1213; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67	25	229	234	1	110	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					807	811		10.1038/33910	http://dx.doi.org/10.1038/33910			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572138				2022-12-01	WOS:000073241200051
J	Barrat, JA; Gillet, P; Lecuyer, C; Sheppard, SMF; Lesourd, M				Barrat, JA; Gillet, P; Lecuyer, C; Sheppard, SMF; Lesourd, M			Formation of carbonates in the Tatahouine meteorite	SCIENCE			English	Article							ALH84001	The Tatahouine meteorite, in southern Tunisia, shows terrestrial contamination that developed during 63 years of exposure on Earth's surface. Samples collected on the day of the fall in 1931 contained fractures, with no secondary minerals, whereas samples collected in 1994 contain calcite aggregates (70 to 150 micrometers) and rod-shaped forms (100 to 600 nanometers in length and 70 to 80 nanometers in diameter) on the fractures. Carbon isotope analysis of the carbonates within the Tatahouine meteorite [delta(13)C = -2.0 per mil Pee Dee belemnite standard (PDB)] and the underlying ground (delta(13)C = -3.2 per mil PDB) confirm their terrestrial origin.	Univ Angers, Geol Lab, F-49045 Angers, France; Ecole Normale Super Lyon, Lab Ctr Terre, CNRS, UMR 5570, F-69364 Lyon 07, France; Ecole Normale Super Lyon, Inst Univ France, F-69364 Lyon 07, France; Fac Med, CNRS, F-49045 Angers, France; Fac Med, Serv Commun Microscopie Elect, F-49045 Angers, France	Universite d'Angers; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Ecole Normale Superieure de Lyon (ENS de LYON); Institut Universitaire de France; Centre National de la Recherche Scientifique (CNRS); Universite d'Angers; Universite de Franche-Comte; Universite d'Angers; Universite de Franche-Comte	Barrat, JA (corresponding author), Univ Angers, Geol Lab, 2 Blvd Lavoisier, F-49045 Angers, France.		Lecuyer, Christophe/C-8297-2012; Jean-Alix, BARRAT/F-8035-2012; Barrat, Jean-Alix/C-8416-2017; Lecuyer, Christophe/AAO-8154-2021	Barrat, Jean-Alix/0000-0003-3158-3109; Lecuyer, Christophe/0000-0001-9513-2492				BISCHOFF WD, 1985, AM MINERAL, V70, P581; Bradley JP, 1997, NATURE, V390, P454, DOI 10.1038/37257; Clayton RN, 1996, GEOCHIM COSMOCHIM AC, V60, P1999, DOI 10.1016/0016-7037(96)00074-9; Folk RL, 1997, J SEDIMENT RES, V67, P583; GILLET P, 1993, PHYS CHEM MINER, V20, P1; GOODING JL, 1988, GEOCHIM COSMOCHIM AC, V52, P909, DOI 10.1016/0016-7037(88)90361-4; Jull AJT, 1997, J GEOPHYS RES-PLANET, V102, P1663, DOI 10.1029/96JE03111; Kerr RA, 1997, SCIENCE, V278, P1706, DOI 10.1126/science.278.5344.1706; Lacroix A, 1931, CR HEBD ACAD SCI, V193, P305; Mason B., 1992, SMITHSON CONTRIB EAR, V30, P17; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; McKay DS, 1997, NATURE, V390, P455, DOI 10.1038/37257-c1; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; Nealson KH, 1997, ANNU REV EARTH PL SC, V25, P403, DOI 10.1146/annurev.earth.25.1.403; URMOS J, 1991, AM MINERAL, V76, P641; Zolensky M., 1988, METEORITES EARLY SOL, P114	16	45	47	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					412	414		10.1126/science.280.5362.412	http://dx.doi.org/10.1126/science.280.5362.412			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545214				2022-12-01	WOS:000073159600040
J	Melek, M; Gellert, M; van Gent, DC				Melek, M; Gellert, M; van Gent, DC			Rejoining of DNA by the RAG1 and RAG2 proteins	SCIENCE			English	Article							V(D)J RECOMBINATION; INTEGRATION; GENE	Assembly of immunoglobulin and T cell receptor genes from separate gene segments [V(D)J recombination] begins with DNA double-strand breakage by the RAG1 and RAG2 proteins, acting at a pair of recombination signal sequences (RSSs). Here, the RAG proteins are shown to reverse the cleavage reaction by joining an RSS to a broken coding sequence end. These "hybrid joints" have also been found in lymphoid cells, even when the normal pathway of DNA double-strand break repair is inactive, and can now be explained by this activity of the RAG proteins.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Erasmus University Rotterdam	Gellert, M (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.			van Gent, Dik C./0000-0003-1473-8148				Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Bogue MA, 1997, IMMUNITY, V7, P37, DOI 10.1016/S1074-7613(00)80508-7; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Han JO, 1997, MOL CELL BIOL, V17, P2226, DOI 10.1128/MCB.17.4.2226; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MORZYCKAWROBLEWSKA E, 1988, SCIENCE, V242, P261, DOI 10.1126/science.3140378; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Steen SB, 1997, EMBO J, V16, P2656, DOI 10.1093/emboj/16.10.2656; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; VANGENT DC, 1997, EMBO J, V16, P2265; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7	19	88	88	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					301	303		10.1126/science.280.5361.301	http://dx.doi.org/10.1126/science.280.5361.301			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535663				2022-12-01	WOS:000073082400056
J	Martin, JN; Ganem, DE; Osmond, DH; Page-Shafer, KA; Macrae, D; Kedes, DH				Martin, JN; Ganem, DE; Osmond, DH; Page-Shafer, KA; Macrae, D; Kedes, DH			Sexual transmission and the natural history of human herpesvirus 8 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; FRANCISCO MENS HEALTH; KAPOSIS-SARCOMA; DNA-SEQUENCES; REGRESSION MODELS; ANTIBODIES; AIDS; RISK; SEROCONVERSION	Background Although human herpesvirus 8 (HHV-8) has been suspected to be the etiologic agent of Kaposi's sarcoma, little is known about its seroprevalence in the population, its modes of transmission, and its natural history. Methods The San Francisco Men's Wealth Study, begun in 1984, is a study of a population-based sample of men in an area with a high incidence of human immunodeficiency virus (HIV) infection. We studied all 400 men infected at base line with HIV and a sample of 400 uninfected men, Base-line serum samples were assayed for antibodies to HHV-8 latency-associated nuclear antigen (anti-LANA). In addition to the seroprevalence and risk factors for anti-LANA seropositivity, we analyzed the time to the development of Kaposi's sarcoma. Results Anti-LANA antibodies were: found in 223 of 593 men (37.6 percent) who reported any homosexual activity in the previous five years and in none of 195 exclusively heterosexual men, Anti-LANA seropositivity correlated with a history of sexually transmitted diseases and had a linear association with the number of male sexual-intercourse partners. Among the men who were infected with both HIV and HHV-8 at base line, the 10-year probability of Kaposi's sarcoma was 49.6 percent, Base-line anti-LANA seropositivity preceded and was independently associated with subsequent Kaposi's sarcoma, even after adjustment; for CD4 cell counts and the number of homosexual partners. Conclusions The prevalence of HHV-8 infection is high among homosexual men, correlates with the number of homosexual partners, and is temporally and independently associated with Kaposi's sarcoma, These observations are further evidence that HHV-8 has an etiologic Pole in Kaposi's sarcoma and is sexually transmitted among men. (C) 1998 Massachusetts Medical Society.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; San Francisco Gen Hosp, Ctr Aids Prevent Studies, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Dept Epidemiol & Biostat, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Dept Med, AIDS Program, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Dept Med, Div Infect Dis, San Francisco, CA 94110 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kedes, DH (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, Box 0414, San Francisco, CA 94143 USA.			Page, Kimberly/0000-0002-7120-1673	NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019105] Funding Source: NIH RePORTER; NIMH NIH HHS [T32 MH-19105] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; Chuck S, 1996, J INFECT DIS, V173, P248, DOI 10.1093/infdis/173.1.248; COX DR, 1972, J R STAT SOC B, V34, P187; Davis DA, 1997, J INFECT DIS, V175, P1071, DOI 10.1086/516444; DREW WL, 1982, LANCET, V2, P125; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; HUANG YQ, 1992, LANCET, V339, P515, DOI 10.1016/0140-6736(92)90338-4; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kedes DH, 1997, JAMA-J AM MED ASSOC, V277, P478, DOI 10.1001/jama.277.6.478; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kleinbaum DG, 1996, SURVIVAL ANAL; LANG W, 1987, JAMA-J AM MED ASSOC, V257, P326, DOI 10.1001/jama.257.3.326; Lefrere JJ, 1996, J INFECT DIS, V174, P283, DOI 10.1093/infdis/174.2.283; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Lin SF, 1997, J VIROL, V71, P3069, DOI 10.1128/JVI.71.4.3069-3076.1997; Martin JN, 1996, NEW ENGL J MED, V335, P819, DOI 10.1056/NEJM199609123351112; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; PIAZZA T, 1986, TECHNICAL REPORT NAT; *SAS I, 1996, SAS VERS 6 11; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; Smith MS, 1997, J INFECT DIS, V176, P84, DOI 10.1086/514043; *STAT CORP, 1997, STAT VERS 5 0; *STAT CORP, 1997, SURV EST REF MAN VER, P400; WANG RYH, 1993, CLIN INFECT DIS, V17, P724, DOI 10.1093/clinids/17.4.724; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; Wolter K., 1985, INTRO VARIANCE ESTIM	33	519	543	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					948	954		10.1056/NEJM199804023381403	http://dx.doi.org/10.1056/NEJM199804023381403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE776	9521982				2022-12-01	WOS:000072829800003
J	Meigs, JB; Nathan, DM; Wilson, PWF; Cupples, LA; Singer, DE				Meigs, JB; Nathan, DM; Wilson, PWF; Cupples, LA; Singer, DE			Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance - The Framingham Offspring Study	ANNALS OF INTERNAL MEDICINE			English	Article						glucose intolerance; diabetes mellitus, non-insulin-dependent; cardiovascular diseases; risk factors; insulin resistance	CORONARY HEART-DISEASE; UNITED-STATES POPULATION; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; PIMA-INDIANS; ASYMPTOMATIC HYPERGLYCEMIA; PRECIPITATION PROCEDURE; DIAGNOSTIC-CRITERIA; ORIGINAL COHORT	Background: Categorical definitions for glucose intolerance imply that risk thresholds exist, but metabolic risk for type 2 diabetes mellitus or cardiovascular disease may increase continuously as glucose intolerance increases. Objective: To examine the distributions of the following meta belie risk factors across the spectrum of glucose tolerance: overall and central obesity, hypertension, low levels of high-density lipoprotein cholesterol, and increased triglyceride and insulin levels. Design: Cross-sectional analysis. Setting: The community-based Framingham Offspring Study. Participants: 2583 adults without previously diagnosed diabetes. Measurements: Clinical data; fasting glucose, insulin, and lipid levels; and glucose and insulin levels taken 2 hours after oral challenge were collected from 1991 to 1993. Glucose tolerance was determined by 1980 World Health Organization criteria. Patients with normal glucose tolerance were categorized into quintiles of fasting glucose. The distributions of each metabolic risk factor and the metabolic sum of the six risk factors were assessed across seven categories from the lowest quintile of normal fasting glucose level through impaired glucose tolerance and previously undiagnosed diabetes. Results: The mean age of patients was 54 years (range, 26 to 82 years); 52.7% of patients were women. Glucose tolerance testing found that 12.7% of patients had impaired glucose tolerance and 4.8% had previously undiagnosed diabetes. Multivariable-adjusted mean measures of risk factors and odds ratios for obesity, elevated waist-to-hip ratio, hypertension, low levels of high-density lipoprotein cholesterol, elevated triglyceride levels, and hyperinsulinemia showed continuous increases across the spectrum of nondiabetic glucose tolerance. Although a threshold effect near the upper range of nondiabetic glucose tolerance could not be ruled out for triglyceride levels in men and for insulin levels Z hours after oral challenge in men and women, no other metabolic risk factors showed clear evidence of thresholds for increased risk. Conclusions: Metabolic risk factors for type 2 diabetes mellitus and for cardiovascular disease worsen continuously across the spectrum of glucose tolerance categories, beginning in the lowest quintiles of normal fasting glucose level.	Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Boston Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Boston, MA 02118 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; NHLBI, Framingham, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Boston University; Harvard University; Massachusetts General Hospital; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Meigs, JB (corresponding author), Massachusetts Gen Hosp, Div Gen Med, Staniford 50-9, Boston, MA 02114 USA.	jmeigs@sol.mgh.harvard.edu	Meigs, James/P-3927-2019	Meigs, James/0000-0002-2439-2657; Cupples, L. Adrienne/0000-0003-0273-7965	NHLBI NIH HHS [N01-HC-38083] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RL, 1995, AM J EPIDEMIOL, V142, P724, DOI 10.1093/aje/142.7.724; BARRETTCONNOR E, 1984, J CHRON DIS, V37, P773, DOI 10.1016/0021-9681(84)90046-8; BURCHFIEL CM, 1990, AM J EPIDEMIOL, V131, P57, DOI 10.1093/oxfordjournals.aje.a115485; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DONAHUE RP, 1987, DIABETES, V36, P689, DOI 10.2337/diabetes.36.6.689; Eastman RC, 1997, DIABETES CARE, V20, P127, DOI 10.2337/diacare.20.2.127; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; Edelstein SL, 1997, DIABETES, V46, P701, DOI 10.2337/diabetes.46.4.701; EVERHART JE, 1985, NIH PUBLICATION; FESKENS EJM, 1992, J CLIN EPIDEMIOL, V45, P1327, DOI 10.1016/0895-4356(92)90173-K; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FUJIMOTO WY, 1987, DIABETES, V36, P730, DOI 10.2337/diabetes.36.6.730; FULLER JH, 1980, LANCET, V1, P1373; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gerstein HC, 1996, LANCET, V347, P949, DOI 10.1016/S0140-6736(96)91420-8; GIDEZ LI, 1982, J LIPID RES, V23, P1206; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; HARRIS M, 1979, DIABETES, V28, P1039; HARRIS MI, 1989, DIABETES CARE, V12, P464, DOI 10.2337/diacare.12.7.464; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; Jarrett R J, 1984, Diabet Med, V1, P279; JARRETT RJ, 1982, DIABETOLOGIA, V22, P79, DOI 10.1007/BF00254833; JARRETT RJ, 1987, DIABETIC MED, V4, P544, DOI 10.1111/j.1464-5491.1987.tb00927.x; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KEEN H, 1982, DIABETOLOGIA, V22, P73, DOI 10.1007/BF00254832; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; LAAKSO M, 1989, ARTERIOSCLEROSIS, V9, P665, DOI 10.1161/01.ATV.9.5.665; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; Meigs JB, 1996, J CLIN EPIDEMIOL, V49, P411, DOI 10.1016/0895-4356(95)00513-7; MITCHELL BD, 1990, AM J EPIDEMIOL, V131, P423, DOI 10.1093/oxfordjournals.aje.a115517; MITRAKOU A, 1992, NEW ENGL J MED, V326, P22, DOI 10.1056/NEJM199201023260104; Mooy JM, 1996, DIABETOLOGIA, V39, P298, DOI 10.1007/BF00418345; MYKKANEN L, 1992, DIABETES CARE, V15, P1020, DOI 10.2337/diacare.15.8.1020; NATHAN DM, 1981, CLIN CHEM, V27, P1261; NATHAN DM, 1984, NEW ENGL J MED, V310, P341, DOI 10.1056/NEJM198402093100602; Nathan DM, 1997, LANCET S1, V350, pSI4, DOI DOI 10.1016/S0140-6736(97)90021-0; OLEFSKY JM, 1974, DIABETES, V23, P449, DOI 10.2337/diab.23.5.449; OSULLIVAN JB, 1964, DIABETES, V13, P278; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REWERS M, 1992, AM J EPIDEMIOL, V135, P1321, DOI 10.1093/oxfordjournals.aje.a116243; RICCARDI G, 1985, AM J EPIDEMIOL, V121, P422, DOI 10.1093/oxfordjournals.aje.a114014; Rodriguez BL, 1996, DIABETES CARE, V19, P587, DOI 10.2337/diacare.19.6.587; SAAD MF, 1988, BRIT MED J, V297, P1438, DOI 10.1136/bmj.297.6661.1438; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; *SAS I, 1989, SAS STAT US GUID VER; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STERN MP, 1993, DIABETES CARE, V16, P978, DOI 10.2337/diacare.16.7.978; STERN MP, 1985, ARTERIOSCLEROSIS, V5, P311, DOI 10.1161/01.ATV.5.4.311; Stokes 3rd J, 1989, HYPERTENSION S1, V13, pI13; United Kingdom Prospective Diabetes Study (UKPDS), 1995, BMJ-BRIT MED J, V310, P83, DOI DOI 10.1136/BMJ.310.6972.83; *US PREV SERV TASK, 1996, GUID LIN PREV SERV; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WILSON PW, 1981, AM J EPIDEMIOL, V114, P697, DOI 10.1093/oxfordjournals.aje.a113240; WINGARD DL, 1987, AM J EPIDEMIOL, V125, P948, DOI 10.1093/oxfordjournals.aje.a114633; World Health Organisation, 1980, WHO EXP COMM DIAB ME; YUDKIN JS, 1990, BRIT MED J, V301, P397, DOI 10.1136/bmj.301.6749.397; 1985, ANN INTERN MED 2, V103, P1073	68	149	154	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					524	+		10.7326/0003-4819-128-7-199804010-00002	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518396				2022-12-01	WOS:000072803500002
J	Agid, Y; Chase, T; Marsden, D				Agid, Y; Chase, T; Marsden, D			Adverse reactions to levodopa: drug toxicity or progression of disease?	LANCET			English	Editorial Material							DOPA		Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France; Hop La Pitie Salpetriere, Federat Neurol, F-75013 Paris, France; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; NINDS, Bethesda, MD 20892 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Agid, Y (corresponding author), Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France.							BONNET AM, 1987, NEUROLOGY, V37, P1539, DOI 10.1212/WNL.37.9.1539; DIAMOND SG, 1987, ANN NEUROL, V22, P8, DOI 10.1002/ana.410220105; Dziewczapolski G, 1997, NEUROREPORT, V8, P975, DOI 10.1097/00001756-199703030-00031; Fahn S, 1996, NEUROLOGY, V47, pS184, DOI 10.1212/WNL.47.6_Suppl_3.184S; Han SK, 1996, J NEUROCHEM, V66, P501; MARSDEN CD, 1980, CURRENT PROGR PROBLE, P241; Mena MA, 1996, NEUROREPORT, V7, P441, DOI 10.1097/00001756-199601310-00016; MOURADIAN MM, 1994, MOVEMENT DISORD, V3, P181; YAHR MD, 1972, NEUROLOGY, V22, P56, DOI 10.1212/WNL.22.5_Part_2.56	9	32	33	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					851	852		10.1016/S0140-6736(05)70285-3	http://dx.doi.org/10.1016/S0140-6736(05)70285-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525359				2022-12-01	WOS:000072645500007
J	Nicolaou, KC; Yang, Z; Shi, GQ; Gunzner, JL; Agrios, KA; Gartner, P				Nicolaou, KC; Yang, Z; Shi, GQ; Gunzner, JL; Agrios, KA; Gartner, P			Total synthesis of brevetoxin A	NATURE			English	Article							ORGANIC-SYNTHESIS; STEREOCONTROLLED SYNTHESIS; GENERATION STRATEGIES; CONSTRUCTION; SYSTEMS; ETHERS; BINDING; OXIDANT; TOXINS; CHAIN	Brevetoxin A is the most potent neurotoxin secreted by Gymnodinium breve Davis, a marine organism often associated with harmful algal blooms known as 'red tides'(1-3). The compound, whose mechanism of action involves binding to and opening of sodium channels(4-7), is sufficiently toxic to kill fish at concentrations of nanogams per mi (refs 3, 4) and, after accumulation in filter-feeding shellfish, to poison human consumers. The precise pathway by which nature constructs brevetoxin A is at present unknown(8,9), but strategies for its total synthesis have been contemplated for some time. The synthetic challenge posed by brevetoxin A reflects the high complexity of its molecular structure: 10 oxygen atoms and a chain of 44 carbon atoms are woven into a polycyclic macromolecule that includes 10 rings (containing between 5 and 9 atoms) and 22 stereogenic centres. Particularly challenging are the 7-, 8- and 9-membered rings which allow the molecule to undergo slow conformational changes and force a 90 degrees twist at one of its rings(1-6). Here we describe the successful incorporation of methods that were specifically developed for the construction of these rings(10,11) into an overall strategy for the total synthesis of brevetoxin A in its naturally occurring form. The convergent synthesis reported here renders this scarce neurotoxin synthetically available and, more importantly, allows the design and synthesis of analogues for further biochemical studies.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego	Nicolaou, KC (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Yang, Zhen/J-6306-2015; Yang, Zhen/GWQ-4960-2022; Zanardi, Franca/L-6551-2017	Yang, Zhen/0000-0001-8036-934X; Zanardi, Franca/0000-0001-7451-781X; Gaertner, Peter/0000-0003-1569-5020				Anderson DM, 1997, NATURE, V388, P513, DOI 10.1038/41415; ANDERSON DM, 1992, OCEANUS, V35, P55; ANDERSON DM, 1994, SCI AM, V271, P62, DOI 10.1038/scientificamerican0894-62; ARHART RJ, 1972, J AM CHEM SOC, V94, P4997, DOI 10.1021/ja00769a035; Barker R, 1997, WATERS TURNED BLOOD; CHOU HN, 1987, J AM CHEM SOC, V109, P2184, DOI 10.1021/ja00241a048; Clayden J, 1996, ANGEW CHEM INT EDIT, V35, P241, DOI 10.1002/anie.199602411; COREY EJ, 1972, J AM CHEM SOC, V94, P7210, DOI 10.1021/ja00775a089; DESS DB, 1983, J ORG CHEM, V48, P4155, DOI 10.1021/jo00170a070; FEIXAS J, 1994, TETRAHEDRON, V50, P8539, DOI 10.1016/S0040-4020(01)85572-1; FREEMAN JP, 1990, ORG SYNTH COLLECT, V7, P139; GAWLEY RE, 1995, CHEM BIOL, V2, P533, DOI 10.1016/1074-5521(95)90187-6; HOMAKA Y, 1993, FOOD ADDIT CONTAM, V10, P71; HOVEYDA AH, 1993, CHEM REV, V93, P1307, DOI 10.1021/cr00020a002; INANAGA J, 1979, B CHEM SOC JPN, V52, P1989, DOI 10.1246/bcsj.52.1989; KLINDGREN BO, 1973, ACTA CHEM SCAND, V27, P888; LEE MS, 1987, NEW J CHEM, V11, P753; LEE MS, 1989, J AM CHEM SOC, V111, P6234, DOI 10.1021/ja00198a039; LEY SV, 1994, SYNTHESIS-STUTTGART, P639; MAHONEY WS, 1997, J AM CHEM SOC, V119, P8105; MUKAIYAMA T, 1974, J AM CHEM SOC, V96, P7503, DOI 10.1021/ja00831a019; Nicolaou KC, 1997, J AM CHEM SOC, V119, P8105, DOI 10.1021/ja971219p; NICOLAOU KC, 1991, ANGEW CHEM INT EDIT, V30, P299, DOI 10.1002/anie.199102991; NICOLAOU KC, 1995, J AM CHEM SOC, V117, P10239, DOI 10.1021/ja00146a009; NICOLAOU KC, 1990, J AM CHEM SOC, V112, P3696, DOI 10.1021/ja00165a085; Nicolaou KC, 1997, J AM CHEM SOC, V119, P5467, DOI 10.1021/ja970619+; Nicolaou KC, 1996, ANGEW CHEM INT EDIT, V35, P589; NICOLAOU KC, 1989, J AM CHEM SOC, V111, P5330, DOI 10.1021/ja00196a043; NICOLAOU KC, 1995, J AM CHEM SOC, V117, P10252, DOI 10.1021/ja00146a010; NICOLAOU KC, 1989, J AM CHEM SOC, V111, P5321, DOI 10.1021/ja00196a042; NICOLAOU KC, 1995, J AM CHEM SOC, V117, P10227, DOI 10.1021/ja00146a008; Okaichi T., 1989, RED TIDES BIOL ENV S; PARIKH JR, 1967, J AM CHEM SOC, V89, P5505, DOI 10.1021/ja00997a067; PAWLAK J, 1987, J AM CHEM SOC, V109, P1144, DOI 10.1021/ja00238a025; REIN KS, 1994, J ORG CHEM, V59, P2101, DOI 10.1021/jo00087a027; REIN KS, 1994, J ORG CHEM, V59, P2107, DOI 10.1021/jo00087a028; Rodenheaver G.T., 1971, CHEM COMMUN, P818; SCHREIBER J, 1971, ANGEW CHEM INT EDIT, V10, P330, DOI 10.1002/anie.197103301; SHIMIZU Y, 1986, J CHEM SOC CHEM COMM, P1656, DOI 10.1039/c39860001656; SHIMIZU Y, 1986, J AM CHEM SOC, V108, P314; TAMURA Y, 1986, TETRAHEDRON LETT, V27, P955; Xie MQ, 1996, J ORG CHEM, V61, P5178, DOI 10.1021/jo960355u; YASUMOTO T, 1993, CHEM REV, V93, P1897, DOI 10.1021/cr00021a011; ZAGORSKI MG, 1988, J ORG CHEM, V53, P4156, DOI 10.1021/jo00252a068	44	144	147	1	52	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					264	269		10.1038/32623	http://dx.doi.org/10.1038/32623			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	ZC739	9521320				2022-12-01	WOS:000072612300042
J	Turner, RC; Millns, H; Neil, HAW; Stratton, IM; Manley, SE; Matthews, DR; Holman, RR				Turner, RC; Millns, H; Neil, HAW; Stratton, IM; Manley, SE; Matthews, DR; Holman, RR		United Kingdom Prospective Diabet Study Grp	Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United kingdom prospective diabetes study (UKPDS : 23)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; SERUM-CHOLESTEROL CONCENTRATION; LOW-DENSITY-LIPOPROTEIN; 11-YEAR FOLLOW-UP; CARDIOVASCULAR MORTALITY; GLUCOSE-INTOLERANCE; BODY-WEIGHT; WOMEN; HYPERTRIGLYCERIDEMIA; HYPERGLYCEMIA	Objective: To evaluate baseline risk factors for coronary artery disease in patients with type 2 diabetes mellitus. Design: A stepwise selection procedure, adjusting for age and sex, was used in 2693 subjects with complete data to determine which risk factors for coronary artery disease should be included in a Cox proportional hazards model. Subjects: 3055 white patients (mean age 52) with recently diagnosed type 2 diabetes mellitus and without evidence of disease related to atheroma. Median duration of follow up was 7.9 years. 335 patients developed coronary artery disease within 10 years. Outcome measures: Angina with confirmatory abnormal electrocardiogram; non-fatal and fatal myocardial infarction. Results: Coronary artery disease was significantly associated with increased concentrations of low density lipoprotein cholesterol, decreased concentrations of high density lipoprotein cholesterol, and increased triglyceride concentration, haemoglobin A(1c), systolic blood pressure, fasting plasma glucose concentration, and a history of smoking. The estimated hazard ratios for the upper third relative to the lower third were 2.26 (95% confidence interval 1.70 to 3.00) for low density lipoprotein cholesterol, 0.55 (0.41 to 0.73) for high density lipoprotein cholesterol, 1.52 (1.15 to 2.01) for haemoglobin A(1c), and 1.82 (1.34 to 2.47) for systolic blood pressure. The estimated hazard ratio for smokers was 1.41(1.06 to 1.88). Conclusion: A quintet of potentially modifiable risk factors for coronary artery disease exists in patients with type 2 diabetes mellitus. These risk factors are increased concentrations of low density lipoprotein cholesterol, decreased concentrations of high density lipoprotein cholesterol, raised brood pressure, hyperglycaemia, and smoking.	Univ Oxford, Radcliffe Infirm, Diabet Res Labs, Dept Med, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Turner, RC (corresponding author), Univ Oxford, Radcliffe Infirm, Diabet Res Labs, Dept Med, Oxford OX2 6HE, England.	robert.turner@drl.ox.ac.uk	Adiels, Martin/C-9278-2011; stratton, irene/AAZ-3627-2020	stratton, irene/0000-0003-1172-7865; Manley, Susan/0000-0002-8298-4511				AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; BROWNLEE M, 1992, DIABETES CARE, V15, P1835, DOI 10.2337/diacare.15.12.1835; BUTLER WJ, 1985, AM J EPIDEMIOL, V121, P541; BYERS T, 1995, NEW ENGL J MED, V333, P723, DOI 10.1056/NEJM199509143331109; COLEMAN MP, 1989, PERSON YEARS PYRS FO; COX DR, 1972, J R STAT SOC B, V34, P187; CULL C, 1993, DIABETOLOGIA, V36, P1021; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; Folsom AR, 1997, DIABETES CARE, V20, P935, DOI 10.2337/diacare.20.6.935; FONTBONNE A, 1989, DIABETOLOGIA, V32, P300, DOI 10.1007/BF00265546; GALL MA, 1995, DIABETES, V44, P1303, DOI 10.2337/diabetes.44.11.1303; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HEYDEN S, 1980, J CHRON DIS, V33, P265, DOI 10.1016/0021-9681(80)90021-1; JARRETT RJ, 1976, LANCET, V2, P1009; KANNEL WB, 1995, MED CLIN N AM, V79, P951, DOI 10.1016/S0025-7125(16)30016-5; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; KAWAMURA M, 1994, J CLIN INVEST, V94, P771, DOI 10.1172/JCI117396; KLEIN R, 1995, DIABETES CARE, V18, P258, DOI 10.2337/diacare.18.2.258; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LAAKSO M, 1993, CIRCULATION, V88, P1421, DOI 10.1161/01.CIR.88.4.1421; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; Lehto S, 1997, DIABETES, V46, P1354, DOI 10.2337/diabetes.46.8.1354; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANLEY SE, 1994, DIABETIC MED, V11, P534; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MODAN M, 1986, DIABETOLOGIA, V29, P82, DOI 10.1007/BF00456115; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; PEDERSEN TR, 1994, LANCET, V344, P1383; *POP CENS SURV OFF, 1994, MORT STTAT REV REG G; PYORALA K, 1995, DIABETES, V44, pA35; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SCHECTMAN G, 1993, CLIN CHEM, V39, P1495; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STENSVOLD I, 1993, BMJ-BRIT MED J, V307, P1318, DOI 10.1136/bmj.307.6915.1318; Stratton I, 1996, DIABETOLOGIA, V39, P1554, DOI 10.1007/s001250050614; STRATTON IM, 1995, DIABETES, V43, pS434; TURNER RC, 1991, DIABETOLOGIA, V34, P877; UK Prospective Diabetes Study Group, 1996, ANN INTERN MED, V124, P136; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063; WALTERS DP, 1994, DIABETIC MED, V11, P968, DOI 10.1111/j.1464-5491.1994.tb00255.x; World Health Organization, 1978, INT CLASS PROC MED	47	1407	1481	0	37	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 14	1998	316	7134					823	828		10.1136/bmj.316.7134.823	http://dx.doi.org/10.1136/bmj.316.7134.823			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC488	9549452	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000072584300028
J	Ytterstad, B; Norton, R				Ytterstad, B; Norton, R			Does CPAP prevent injuries?	LANCET			English	Editorial Material									Injury Prevent Res Ctr, Auckland 1, New Zealand		Ytterstad, B (corresponding author), Injury Prevent Res Ctr, Private Bag 92019, Auckland 1, New Zealand.							Krieger J, 1997, CHEST, V112, P1561, DOI 10.1378/chest.112.6.1561; LANGLEY JD, 1988, ACCIDENT ANAL PREV, V20, P1, DOI 10.1016/0001-4575(88)90009-7; Lindqvist KS, 1996, ACCIDENT ANAL PREV, V28, P209, DOI 10.1016/0001-4575(95)00065-8; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Norton R, 1997, ACCIDENT ANAL PREV, V29, P699, DOI 10.1016/S0001-4575(97)00018-3; Wright J, 1997, BRIT MED J, V314, P851; YTTERSTAD B, 1995, ACCIDENT ANAL PREV, V27, P111, DOI 10.1016/0001-4575(94)00036-L	7	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					692	692		10.1016/S0140-6736(05)78491-9	http://dx.doi.org/10.1016/S0140-6736(05)78491-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZB359	9504512				2022-12-01	WOS:000072463800005
J	Lin, DCH; Grossman, AD				Lin, DCH; Grossman, AD			Identification and characterization of a bacterial chromosome partitioning site	CELL			English	Article							BACILLUS-SUBTILIS; SMC FAMILY; SPORULATION; PLASMIDS; CONDENSATION; SEGREGATION; INITIATION; GENES	We have identified a DNA site involved in chromosome partitioning in B. subtilis. This site was identified in vivo as the binding site for the chromosome partitioning protein Spo0J, a member of the ParB family of partitioning proteins. Spo0J is a site-specific DNA-binding protein that recognizes a 16 bp sequence found in spo0J. Allowing two mismatches, this sequence occurs ten times in the entire B. subtilis chromosome, all in the origin-proximal similar to 20%. Eight of the ten sequences are bound to Spo0J in vivo. The presence of a site on an otherwise unstable plasmid stabilized the plasmid in a Spo0J-dependent manner, demonstrating that this site, called parS, can function as a partitioning site. This site and Spo0J are conserved in a wide range of bacterial species.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Grossman, AD (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041934] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41934] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN S, 1990, CELL, V60, P351, DOI 10.1016/0092-8674(90)90584-2; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; Bickel SE, 1996, BIOESSAYS, V18, P293, DOI 10.1002/bies.950180407; Glaser P, 1997, GENE DEV, V11, P1160, DOI 10.1101/gad.11.9.1160; Gordon GS, 1997, CELL, V90, P1113, DOI 10.1016/S0092-8674(00)80377-3; Grossman AD, 1995, ANNU REV GENET, V29, P477, DOI 10.1146/annurev.ge.29.120195.002401; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Harwood C.R., 1990, MOL BIOL METHODS BAC; Hassan AKM, 1997, J BACTERIOL, V179, P2494, DOI 10.1128/jb.179.8.2494-2502.1997; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Heck MMS, 1997, CELL, V91, P5, DOI 10.1016/S0092-8674(01)80002-7; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; JAACKS KJ, 1989, J BACTERIOL, V171, P4121, DOI 10.1128/JB.171.8.4121-4129.1989; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lewis PJ, 1997, MOL MICROBIOL, V25, P945, DOI 10.1111/j.1365-2958.1997.mmi530.x; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; Niki H, 1997, CELL, V90, P951, DOI 10.1016/S0092-8674(00)80359-1; NORDSTROM K, 1989, ANNU REV GENET, V23, P37, DOI 10.1146/annurev.genet.23.1.37; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; Oguro A, 1996, GENE, V172, P17, DOI 10.1016/0378-1119(96)00181-3; PETERSON CL, 1994, CELL, V79, P389, DOI 10.1016/0092-8674(94)90247-X; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; VASANTHA N, 1980, J BACTERIOL, V144, P1119, DOI 10.1128/JB.144.3.1119-1125.1980; Wake RG, 1995, ANNU REV GENET, V29, P41; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1	33	337	343	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					675	685		10.1016/S0092-8674(00)81135-6	http://dx.doi.org/10.1016/S0092-8674(00)81135-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506522	Green Published, Bronze			2022-12-01	WOS:000072406000013
J	Donaldson, GC; Tchernjavskii, VE; Ermakov, SP; Bucher, K; Keatinge, WR				Donaldson, GC; Tchernjavskii, VE; Ermakov, SP; Bucher, K; Keatinge, WR			Winter mortality and cold stress in Yekaterinburg, Russia: interview survey	BRITISH MEDICAL JOURNAL			English	Article							PLASMA-FIBRINOGEN; DISEASE; TEMPERATURE; INCREASES; DEATH	Objectives: To evaluate how mortality and protective measures against exposure to cold change as temperatures fall between October and March in a region of Russia with a mean winter temperature below -6 degrees C. Design: Interview to assess factors associated with cold stress both indoors and outdoors, to measure temperatures in living room, and to survey unheated rooms. Setting: Sverdlovsk Oblast (district), Yekaterinburg, Russia. Subjects: Residents aged 50-59 and 65-74 living within approximately 140 km of Yekaterinburg in Sverdlovsk Oblast. Survey of sample of 1000 residents equally distributed by sex and age groups. Main outcome measures: Regression analysis was used to relate data on indoor heating and temperatures, the amount of clothing worn, the amount of physical activity, and shivering while outside, to outdoor temperature; results were compared with mortality patterns for ischaemic heart disease, cerebrovascular disease, respiratory disease, and mortality from all causes. Results: As mean daily temperatures fell to 0 degrees C the amount of clothing worn outdoors increased, physical activity while outdoors became more continuous, and only 11 (6.6%) of the 167 people surveyed who went outdoors at temperatures above 0 degrees C reported shivering. The mean temperature in living rooms in the evening remained above 21.9 degrees C. Mortality from ischaemic heart disease, cerebrovascular disease, respiratory disease, and all causes did not change. As the temperature fell below 0 degrees C the number of items of clothing worn plateaued at 16.0 and the number of layers at 3.7. With regression analysis, shivering outdoors was found to increase progressively to 34.6% (P < 0.001) of excursions at -25 degrees C, and mortality (after declining slightly) rose progressively (all cause mortality rose by 1.15% for each 1 degrees C drop in temperature from 0 degrees C to -29.6 degrees C, 95% confidence interval 0.97% to 1.32%). 94.2% of bedrooms were directly heated, and evening temperatures in the living room averaged 19.8 degrees C even when outside temperatures reached -25 degrees C. Conclusions: Outdoor cold stress and mortality in Yekaterinburg increased only when the mean daily temperature dropped below 0 degrees C. At temperatures down to 0 degrees C cold stress and excess mortality were prevented by increasing the number of items of clothing worn and the amount of physical activity outdoors in combination with maintaining warmth in houses.	Univ London Queen Mary & Westfield Coll, Dept Physiol, London E1 4NS, England; Russian Minist Hlth, Moscow 127254, Russia; Forschungsstelle Deutschen Wetterdienstes, Dezemat Biosynopt Zentralen Med Meteorol, D-7800 Freiburg, Germany	University of London; Queen Mary University London; Ministry of Health of the Russian Federation	Keatinge, WR (corresponding author), Univ London Queen Mary & Westfield Coll, Dept Physiol, London E1 4NS, England.	wr.keatinge@qmw.ac.uk	Donaldson, Gavin/M-7992-2017; Ermakov, Sergey/G-1709-2016	Ermakov, Sergey/0000-0003-1072-1162; Donaldson, Gavin/0000-0002-5538-4190				BAINTON D, 1978, INT J EPIDEMIOL, V7, P231, DOI 10.1093/ije/7.3.231; BULL G M, 1978, Age and Ageing, V7, P210, DOI 10.1093/ageing/7.4.210; Donaldson GC, 1997, J EPIDEMIOL COMMUN H, V51, P643, DOI 10.1136/jech.51.6.643; FROST DB, 1992, INT J BIOMETEOROL, V36, P14, DOI 10.1007/BF01208729; GRAY PG, 1950, J ROY STAT SOC A STA, V113, P150, DOI 10.2307/2981039; HAYWARD MG, 1981, J PHYSIOL-LONDON, V320, P229, DOI 10.1113/jphysiol.1981.sp013946; HEUNIS JC, 1995, S AFR MED J, V85, P1016; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2; KEATINGE WR, 1984, BMJ-BRIT MED J, V289, P1405, DOI 10.1136/bmj.289.6456.1405; LOVETT AA, 1986, SOC SCI MED, V23, P935, DOI 10.1016/0277-9536(86)90251-0; NEILD PJ, 1994, CLIN SCI, V86, P43, DOI 10.1042/cs0860043; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	12	58	61	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					514	518		10.1136/bmj.316.7130.514	http://dx.doi.org/10.1136/bmj.316.7130.514			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501713	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000072097400020
J	Hankinson, SE; Willett, WC; Colditz, GA; Hunter, DJ; Michaud, DS; Deroo, B; Rosner, B; Speizer, FE; Pollak, M				Hankinson, SE; Willett, WC; Colditz, GA; Hunter, DJ; Michaud, DS; Deroo, B; Rosner, B; Speizer, FE; Pollak, M			Circulating concentrations of insulin-like growth factor-I and risk of breast cancer	LANCET			English	Article							FACTOR-BINDING PROTEIN-3; BODY-MASS INDEX; CELL-PROLIFERATION; SERUM LEVELS; IGF-II; MICE; HORMONE; STAGE; SEX; ADOLESCENTS	Background. Insulin-like growth factor (IGF)-I, a mitogenic and antiapoptotic peptide, can affect the proliferation of breast epithelial cells, and is thought to have a role in breast cancer. We hypothesised that high circulating IGF-I concentrations would be associated with an increased risk of breast cancer. Methods. We carried out a nested case-control study within the prospective Nurses' Health Study cohort. Plasma concentrations of IGF-I and IGF binding protein 3 (IGFBP-3) were measured in blood samples collected in 1989-90. We identified 397 women who had a diagnosis of breast cancer after this date and 620 age-matched controls, IGF-I concentrations were compared by logistic regression with adjustment for other breast-cancer risk factors. Findings. There was no association between IGF-I concentrations and breast-cancer risk among the whole study group. In postmenopausal women there was no association between IGF-I concentrations and breast-cancer risk (top vs bottom quintile of IGF-I, relative risk 0.85 [95% CI 0.53-1.39]). The relative risk of breast cancer among premenopausal women by IGF-I concentration (top vs bottom tertile) was 2.33 (1.06-5.16; p for trend 0.08). Among premenopausal women less than 50 years old at the time of blood collection, the relative risk was 4.58 (1.75-12.0; p for trend 0.02). After further adjustment for plasma IGFBP-3 concentrations these relative risks were 2.88 and 7.28, respectively. Interpretation. A positive relation between circulating IGF-I concentration and risk of breast cancer was found among premenopausal but not postmenopausal women. Plasma IGF-I concentrations may be useful in the identification of women at high risk of breast cancer and in the development of risk reduction strategies. Additional larger studies of this association among premenopausal women are needed to provide more precise estimates of effect.	Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Oncol,Canc Prevent Res Unit, Montreal, PQ H3T 1E2, Canada	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Hankinson, SE (corresponding author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.		Pollak, Michael/G-9094-2011; Colditz, Graham/A-3963-2009; Michaud, Dominique S/I-5231-2014	Pollak, Michael/0000-0003-3047-0604; Colditz, Graham/0000-0002-7307-0291; 	NATIONAL CANCER INSTITUTE [R01CA049449, R01CA040356, U01CA049449, R37CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA-49449, CA-40356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; BRUNING PF, 1995, INT J CANCER, V62, P266, DOI 10.1002/ijc.2910620306; CAMPAGNOLI C, 1993, GYNECOL ENDOCRINOL, V7, P251, DOI 10.3109/09513599309152509; Cats A, 1996, CANCER RES, V56, P523; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chen NY, 1997, ENDOCRINOLOGY, V138, P851, DOI 10.1210/en.138.2.851; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; GoodmanGruen D, 1997, AM J EPIDEMIOL, V145, P970, DOI 10.1093/oxfordjournals.aje.a009065; Gucev ZS, 1996, CANCER RES, V56, P1545; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; HANKINSON SE, 1995, J NATL CANCER I, V87, P1297, DOI 10.1093/jnci/87.17.1297; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; HUNTER DJ, 1993, EPIDEMIOL REV, V15, P110, DOI 10.1093/oxfordjournals.epirev.a036096; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JUUL A, 1995, J CLIN ENDOCR METAB, V80, P2534, DOI 10.1210/jc.80.8.2534; JUUL A, 1994, J CLIN ENDOCR METAB, V78, P744, DOI 10.1210/jc.78.3.744; Michels KB, 1996, LANCET, V348, P1542, DOI 10.1016/S0140-6736(96)03102-9; Ng ST, 1997, NAT MED, V3, P1141, DOI 10.1038/nm1097-1141; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; Osorio M, 1996, EARLY HUM DEV, V46, P15, DOI 10.1016/0378-3782(96)01737-9; PEYRAT JP, 1993, EUR J CANCER, V29A, P492, DOI 10.1016/S0959-8049(05)80137-6; Pollak M, 1997, ADJ THER CANC, V8, P145; POLLAK M, 1990, J NATL CANCER I, V82, P1693, DOI 10.1093/jnci/82.21.1693; Pollak MN, 1998, P SOC EXP BIOL MED, V217, P143; Pollak MN, 1998, BREAST CANCER RES TR, V47, P209, DOI 10.1023/A:1005950916707; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; Rozen F, 1997, J NATL CANCER I, V89, P652, DOI 10.1093/jnci/89.9.652; RUAN W, 1997, P END SOC 79 ANN M, V79, P165; RUAN W, 1995, ENDOCRINOLOGY, V36, P1296; RUGGERI B, 1998, CANCER RES, V49, P4135; SINHA YN, 1979, INT J CANCER, V24, P40; TORNELL J, 1992, J STEROID BIOCHEM, V43, P237, DOI 10.1016/0960-0760(92)90213-3; Yang XF, 1996, CANCER RES, V56, P1509; ZARANDI M, 1994, P NATL ACAD SCI USA, V91, P12298, DOI 10.1073/pnas.91.25.12298	36	1456	1504	3	50	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 9	1998	351	9113					1393	1396		10.1016/S0140-6736(97)10384-1	http://dx.doi.org/10.1016/S0140-6736(97)10384-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM665	9593409				2022-12-01	WOS:000073563400009
J	Boddy, MN; Furnari, B; Mondesert, O; Russell, P				Boddy, MN; Furnari, B; Mondesert, O; Russell, P			Replication checkpoint enforced by kinases Cds1 and Chk1	SCIENCE			English	Article							FISSION YEAST; CDC2; PHOSPHORYLATION; MITOSIS; PATHWAY; CELLS	Cdc2, the kinase that induces mitosis, is regulated by checkpoints that couple mitosis to the completion of DNA replication and repair. The repair checkpoint kinase Chk1 regulates Cdc25, a phosphatase that activates Cdc2, Effecters of the replication checkpoint evoked by hydroxyurea (HU) are unknown. Treatment of fission yeast with HU stimulated the kinase Cds1, which appears to phosphorylate the kinase Wee1, an inhibitor of Cdc2, The protein kinase Cds1 was also required for a large HU-induced increase in the amount of Mik1, a second inhibitor of Cdc2. HU-induced arrest of cell division was abolished in cds? chk1 cells. Thus, Cds1 and Chk1 appear to jointly enforce the replication checkpoint.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Russell, P (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.	prussell@scripps.edu	Boddy, Michael/A-7214-2009					Aligue R, 1997, J BIOL CHEM, V272, P13320, DOI 10.1074/jbc.272.20.13320; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; BODDY MN, UNPUB; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; RHIND N, UNPUB; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; Shiozaki K, 1997, METHOD ENZYMOL, V283, P506; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0	23	287	296	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1998	280	5365					909	912		10.1126/science.280.5365.909	http://dx.doi.org/10.1126/science.280.5365.909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572736				2022-12-01	WOS:000073532900043
J	Nachtigal, MW; Hirokawa, Y; Enyeart-VanHouten, DL; Flanagan, JN; Hammer, GD; Ingraham, HA				Nachtigal, MW; Hirokawa, Y; Enyeart-VanHouten, DL; Flanagan, JN; Hammer, GD; Ingraham, HA			Wilms' tumor 1 and DAX-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression	CELL			English	Article							VENTROMEDIAL HYPOTHALAMIC NUCLEUS; ADRENAL HYPOPLASIA CONGENITA; AFFINITY DNA-BINDING; TRANSCRIPTION FACTOR; SUBNUCLEAR LOCALIZATION; STEROIDOGENIC FACTOR-1; WT1; MUTATIONS; PROTEIN; MICE	Products of steroidogenic factor 1 (SF-1) and Wilms' tumor 1 (WT1) genes are essential for mammalian gonadogenesis prior to sexual differentiation. In males, SF-1 participates in sexual development by regulating expression of the polypeptide hormone Mullerian inhibiting substance (MIS). Here, we show that WT1 -KTS isoforms associate and synergize with SF-1 to promote MIS expression. In contrast, WT1 missense mutations, associated with male pseudohermaphroditism in Denys-Drash syndrome, fail to synergize with SF-1. Additionally, the X-linked, candidate dosage-sensitive sex-reversal gene, Dax-1, antagonizes synergy between SF-1 and WT1, most likely through a direct interaction with SF-1. We propose that WT1 and Dax-1 functionally oppose each other in testis development by modulating SF-1-mediated transactivation.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ingraham, HA (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.		Flanagan, John/AAG-4857-2019	Flanagan, John/0000-0001-6957-756X; Nachtigal, Mark/0000-0003-3291-8628				Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Giuili G, 1997, DEVELOPMENT, V124, P1799; Guo WW, 1996, GENE, V178, P31, DOI 10.1016/0378-1119(96)00320-4; HATANO O, 1994, DEVELOPMENT, V120, P2787; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Kent J, 1996, DEVELOPMENT, V122, P2813; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Lalli E, 1997, MOL ENDOCRINOL, V11, P1950, DOI 10.1210/me.11.13.1950; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MOFFETT P, 1995, P NATL ACAD SCI USA, V92, P11105, DOI 10.1073/pnas.92.24.11105; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; Swain A, 1998, NATURE, V391, P761, DOI 10.1038/35799; Tamai KT, 1996, MOL ENDOCRINOL, V10, P1561, DOI 10.1210/me.10.12.1561; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899; ZHANG P, 1996, MOL ENDOCRINOL, V6, P1249	43	460	475	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 1	1998	93	3					445	454		10.1016/S0092-8674(00)81172-1	http://dx.doi.org/10.1016/S0092-8674(00)81172-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590178	Bronze			2022-12-01	WOS:000073471500019
J	Philips, AV; Timchenko, LT; Cooper, TA				Philips, AV; Timchenko, LT; Cooper, TA			Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy	SCIENCE			English	Article							CARDIAC TROPONIN-T; SKELETAL-MUSCLE; HYPERTROPHIC CARDIOMYOPATHY; ALPHA-TROPOMYOSIN; REPEAT EXPANSION; EXPRESSION; MUTATIONS; ISOFORMS; LENGTH; CELLS	Myotonic dystrophy (DM) is caused by a CTG expansion in the 3' untranslated region of the DM gene. One model of DM pathogenesis suggests that RNAs from the expanded allele create a gain-of-function mutation by the inappropriate binding of proteins to the CUG repeats. Data presented here indicate that the conserved heterogeneous nuclear ribonucleoprotein, CUG-binding protein (CUG-BP), may mediate the trans-dominant effect of the RNA. CUG-BP was found to bind to the human cardiac troponin T (cTNT) pre-messenger RNA and regulate its alternative splicing. Splicing of cTNT was disrupted in DM striated muscle and in normal cells expressing transcripts that contain CUG repeats. Altered expression of genes regulated posttranscriptionally by CUG-BP therefore may contribute to DM pathogenesis.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Cooper, TA (corresponding author), Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.	tcooper@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045565, R01HL045565] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45565] Funding Source: Medline; NIAMS NIH HHS [AR 44387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON PAW, 1991, CIRC RES, V69, P1226, DOI 10.1161/01.RES.69.5.1226; Bertrand E, 1997, RNA, V3, P75; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Caskey CT, 1996, COLD SPRING HARB SYM, V61, P607; COOPER TA, 1992, J BIOL CHEM, V267, P5330; COOPER TA, 1985, J BIOL CHEM, V260, P1140; COOPER TA, 1984, SCIENCE, V226, P979, DOI 10.1126/science.6095446; COOPER TM, UNPUB; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDOM F, 1994, DEV BIOL, V164, P219, DOI 10.1006/dbio.1994.1193; Hamshere MG, 1997, P NATL ACAD SCI USA, V94, P7394, DOI 10.1073/pnas.94.14.7394; Harper P.S., 1989, MYOTONIC DYSTROPHY; HUNTER A, 1992, J MED GENET, V29, P774, DOI 10.1136/jmg.29.11.774; Korade-Mirnics Z, 1998, NUCLEIC ACIDS RES, V26, P1363, DOI 10.1093/nar/26.6.1363; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; Phillips MF, 1997, CARDIOVASC RES, V33, P13, DOI 10.1016/S0008-6363(96)00163-0; REDMAN JB, 1993, JAMA-J AM MED ASSOC, V269, P1960, DOI 10.1001/jama.269.15.1960; Roberts R, 1997, P NATL ACAD SCI USA, V94, P13221, DOI 10.1073/pnas.94.24.13221; Roeder E., 1994, American Journal of Human Genetics, V55, pA7; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Timchenko LT, 1996, HUM MOL GENET, V5, P115, DOI 10.1093/hmg/5.1.115; TOKGOZOGLU LS, 1995, JAMA-J AM MED ASSOC, V274, P813, DOI 10.1001/jama.274.10.813; TOWNSEND PJ, 1995, J MOL CELL CARDIOL, V27, P2223, DOI 10.1016/S0022-2828(95)91587-7; TOYOTA N, 1983, MUSCULAR DYSTROPHY B, P89; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; WANG JZ, 1995, HUM MOL GENET, V4, P599, DOI 10.1093/hmg/4.4.599; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334	33	639	657	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					737	741		10.1126/science.280.5364.737	http://dx.doi.org/10.1126/science.280.5364.737			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563950				2022-12-01	WOS:000073415600048
J	Rao, JH; Lahiri, J; Isaacs, L; Weis, RM; Whitesides, GM				Rao, JH; Lahiri, J; Isaacs, L; Weis, RM; Whitesides, GM			A trivalent system from vancomycin center dot D-Ala-D-Ala with higher affinity than avidin center dot biotin	SCIENCE			English	Article							STRONGLY INHIBIT AGGLUTINATION; INFLUENZA-VIRUS; BINDING; ANTIBIOTICS; ERYTHROCYTES; RECOGNITION; COMPLEXES; PEPTIDES; DIMERS	Tris(vancomycin carboxamide) binds a trivalent ligand derived from D-Ala-D-Ala with very high affinity: dissociation constant (K-d) approximate to 4 x 10(-17) +/- 1 x 10(-17) M. High-affinity trivalent binding and monovalent binding are fundamentally different. In trivalent (and more generally, polyvalent) binding, dissociation occurs in stages, and its rate can be accelerated by monovalent ligand at sufficiently high concentrations. In monovalent binding, dissociation is determined solely by the rate constant for dissociation and cannot be accelerated by added monomer. Calorimetric measurements for the trivalent system indicate an approximately additive gain in enthalpy relative to the corresponding monomers. This system is one of the most stable organic receptor-ligand pairs involving small molecules that is known. It illustrates the practicality of designing very high-affinity systems based on polyvalency.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	Harvard University; University of Massachusetts System; University of Massachusetts Amherst	Whitesides, GM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.	gwhitesides@gmwgroup.harvard.edu	Isaacs, Lyle D/B-4472-2009	Isaacs, Lyle D/0000-0002-4079-332X	NIGMS NIH HHS [GM 30367, GM 51559, GM 53210] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030367, R01GM051559, R37GM030367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Breslow R, 1996, J AM CHEM SOC, V118, P8495, DOI 10.1021/ja961567b; COOPER A, 1993, PHILOS T R SOC A, V345, P23, DOI 10.1098/rsta.1993.0114; DEFREES SA, 1995, J AM CHEM SOC, V117, P66, DOI 10.1021/ja00106a008; GERHARD U, 1993, J AM CHEM SOC, V115, P232, DOI 10.1021/ja00054a033; GREEN NM, 1963, BIOCHEM J, V89, P585, DOI 10.1042/bj0890585; GROVES P, 1995, J AM CHEM SOC, V117, P7958, DOI 10.1021/ja00135a014; HARRIS CM, 1982, J AM CHEM SOC, V104, P4293, DOI 10.1021/ja00379a062; HORNICK CL, 1972, IMMUNOCHEMISTRY, V9, P325, DOI 10.1016/0019-2791(72)90096-1; LEE YC, 1995, ACCOUNTS CHEM RES, V28, P321, DOI 10.1021/ar00056a001; Loll PJ, 1997, J AM CHEM SOC, V119, P1516, DOI 10.1021/ja963566p; MATROSOVICH MN, 1989, FEBS LETT, V252, P1, DOI 10.1016/0014-5793(89)80879-8; NIETO M, 1971, BIOCHEM J, V123, P773, DOI 10.1042/bj1230773; POPIENIEK PH, 1991, J AM CHEM SOC, V113, P2264, DOI 10.1021/ja00006a053; Rao JH, 1997, J AM CHEM SOC, V119, P10286, DOI 10.1021/ja971225l; ROY R, 1988, J CHEM SOC CHEM COMM, P1058, DOI 10.1039/c39880001058; Schafer M, 1996, STRUCTURE, V4, P1509, DOI 10.1016/S0969-2126(96)00156-6; Sigal GB, 1996, J AM CHEM SOC, V118, P3789, DOI 10.1021/ja953729u; SPALTENSTEIN A, 1991, J AM CHEM SOC, V113, P686, DOI 10.1021/ja00002a053; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SUNDRAM UN, 1995, J ORG CHEM, V60, P1102, DOI 10.1021/jo00110a004; Sundram UN, 1996, J AM CHEM SOC, V118, P13107, DOI 10.1021/ja9621298; WILLIAMS DH, 1984, ACCOUNTS CHEM RES, V17, P364, DOI 10.1021/ar00106a004; WILLIAMSON MP, 1984, TETRAHEDRON, V40, P569, DOI 10.1016/0040-4020(84)85062-0; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	24	264	280	0	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					708	711		10.1126/science.280.5364.708	http://dx.doi.org/10.1126/science.280.5364.708			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563940				2022-12-01	WOS:000073415600038
J	Yao, TP; Oh, SP; Fuchs, M; Zhou, ND; Ch'ng, LE; Newsome, D; Bronson, RT; Li, E; Livingston, DM; Eckner, R				Yao, TP; Oh, SP; Fuchs, M; Zhou, ND; Ch'ng, LE; Newsome, D; Bronson, RT; Li, E; Livingston, DM; Eckner, R			Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300	CELL			English	Article							CREB-BINDING-PROTEIN; COACTIVATOR CBP; BHLH PROTEINS; NEURAL-TUBE; COMPLEX; ACETYLTRANSFERASE; SUPPRESSOR; ACTIVATION; EXPRESSION; LETHALITY	The transcriptional coactivator and integrator p300 and its closely related family member CBP mediate multiple, signal-dependent transcriptional events. We have generated mice lacking a functional p300 gene. Animals nullizygous for p300 died between days 9 and 11.5 of gestation, exhibiting defects in neurulation, cell proliferation, and heart development. Cells derived from p300-deficient embryos displayed specific transcriptional defects and proliferated poorly. Surprisingly, p300 heterozygotes also manifested considerable embryonic lethality. Moreover, double heterozygosity for p300 and cbp was invariably associated with embryonic death. Thus, mouse development is exquisitely sensitive to the overall gene dosage of p300 and cbp. Our results provide genetic evidence that a coactivator endowed with histone acetyltransferase activity is essential for mammalian cell proliferation and development.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02115 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Vet Med, Boston, MA 02111 USA; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Tufts University; Tufts University; University of Zurich	Livingston, DM (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.							Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NEVINS JR, 1992, SCIENCE, V258, P424; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parker D, 1996, MOL CELL BIOL, V16, P694; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VANTAGGIATI ML, 1997, CELL, V89, P1175; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WHITE P, 1989, CELL, V56, P67; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	55	787	814	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 1	1998	93	3					361	372		10.1016/S0092-8674(00)81165-4	http://dx.doi.org/10.1016/S0092-8674(00)81165-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590171	Bronze			2022-12-01	WOS:000073471500012
J	Femino, A; Fay, FS; Fogarty, K; Singer, RH				Femino, A; Fay, FS; Fogarty, K; Singer, RH			Visualization of single RNA transcripts in situ	SCIENCE			English	Article							ACTIN GENE-TRANSCRIPTION; HUMAN-COMPLEMENT GENES; INSITU HYBRIDIZATION; MESSENGER-RNA; GROWTH-FACTOR; C-MYC; CELLS; MICROFILAMENTS; LOCALIZATION; FLUORESCENCE	Fluorescence in situ hybridization (FISH) and digital imaging microscopy were modified to allow detection of single RNA molecules. Oligodeoxynucleotide probes were synthesized with five fluorochromes per molecule, and the light emitted by a single probe was calibrated. Points of light in exhaustively deconvolved images of hybridized cells gave fluorescent intensities and distances between probes consistent with single messenger RNA molecules. Analysis of beta-actin transcription sites after serum induction revealed synchronous and cyclical transcription from single genes. The rates of transcription initiation and termination and messenger RNA processing could be determined by positioning probes along the transcription unit. This approach extends the power of FISH to yield quantitative molecular information on a single cell.	Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Univ Massachusetts, Sch Med, Biomed Engn Facil, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	Yeshiva University; Albert Einstein College of Medicine; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Singer, RH (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA.				NIGMS NIH HHS [GM 54887] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; ASHFIELD R, 1991, EMBO J, V10, P4197, DOI 10.1002/j.1460-2075.1991.tb04998.x; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; DIRKS RW, 1995, J CELL SCI, V108, P2565; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; Fay F S, 1986, Soc Gen Physiol Ser, V40, P51; FAY FS, 1989, J MICROSC-OXFORD, V153, P133, DOI 10.1111/j.1365-2818.1989.tb00554.x; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; LAWRENCE JB, 1985, NUCLEIC ACIDS RES, V13, P1777; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; OSHEIM YN, 1985, CELL, V43, P143, DOI 10.1016/0092-8674(85)90019-4; SCHWARTZ RJ, 1981, BIOCHEMISTRY-US, V20, P412; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TANEJA KL, 1990, J CELL BIOCHEM, V44, P241, DOI 10.1002/jcb.240440406; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; THUMMEL CS, 1992, SCIENCE, V255, P39, DOI 10.1126/science.1553530; Xing YG, 1995, J CELL BIOL, V131, P1635, DOI 10.1083/jcb.131.6.1635; ZHANG GH, 1994, NATURE, V372, P809	24	893	946	9	145	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					585	590		10.1126/science.280.5363.585	http://dx.doi.org/10.1126/science.280.5363.585			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ684	9554849				2022-12-01	WOS:000073242100046
J	Nimmo, ER; Pidoux, AL; Perry, PE; Allshire, RC				Nimmo, ER; Pidoux, AL; Perry, PE; Allshire, RC			Defective meiosis in telomere-silencing mutants of Schizosaccharomyces pombe	NATURE			English	Article							POSITION-EFFECT VARIEGATION; FISSION YEAST CENTROMERES; CHROMOSOME MOVEMENT; MEIOTIC PROPHASE; EXPRESSION; MUTATIONS; DISRUPT; GENOME; GENE	During meiotic prophase, chromosomes frequently adopt a bouquet-like arrangement, with their telomeres clustered close to the nuclear periphery(1-3). A dramatic example of this occurs in the fission yeast, Schizosaccharomyces pombe, where all telomeres aggregate adjacent to the spindle pole body (SPB)(4-7). Nuclei then undergo rapid traverses of the cell, known as 'horsetail' movement, which is led by the SPB dragging telomeres and chromosomes behind(4,6,7). This process may initiate or facilitate chromosome pairing before recombination and meiosis. With the aim of identifying components involved in telomere structure and function, we report here the isolation of S. pombe mutants defective in the ability to impose transcriptional silencing on genes placed near telomeres(8). Two of these mutants, lot2-s17 and lot3-uv3, also display a dramatic lengthening of telomeric repeats. lot3-uv3 carries a mutation in Tazl (ref. 9), a telomere-binding protein containing a Myb-like moth similar to two human telomere-binding proteins(10,11). Meiosis is aberrant in these mutant yeast strains, and our analysis demonstrates a decreased association of telomeres with the SPB in meiotic prophase, This results in defective 'horsetail' movement, a significant reduction in recombination, low spore viability and chromosome missegregation through meiosis.	Univ Edinburgh, Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Western Gen Hosp, Canc Res Campaign Project, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Allshire, RC (corresponding author), Univ Edinburgh, Western Gen Hosp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	robin.allshire@hgu.mrc.ac.uk		Allshire, Robin/0000-0002-8005-3625				ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bass HW, 1997, J CELL BIOL, V137, P5, DOI 10.1083/jcb.137.1.5; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Chikashige Y, 1997, EMBO J, V16, P193, DOI 10.1093/emboj/16.1.193; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; DERNBURG AF, 1995, TELOMERES, P295; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; Ekwall K, 1996, J CELL SCI, V109, P2637; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; HELM R, 1995, NATURE, V373, P663; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KOHLI J, 1994, CURR BIOL, V4, P724, DOI 10.1016/S0960-9822(00)00160-3; Lamb NE, 1997, HUM MOL GENET, V6, P1391, DOI 10.1093/hmg/6.9.1391; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MOLNAR M, 1995, GENETICS, V141, P61; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MUNZ P, 1994, GENETICS, V137, P701; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; NIWA O, 1985, CURR GENET, V9, P463, DOI 10.1007/BF00434051; PARVINEN M, 1976, NATURE, V260, P534, DOI 10.1038/260534a0; SCHERTHAN H, 1994, J CELL BIOL, V127, P273, DOI 10.1083/jcb.127.2.273; Scherthan H, 1996, J CELL BIOL, V134, P1109, DOI 10.1083/jcb.134.5.1109; Shimanuki M, 1997, MOL GEN GENET, V254, P238, DOI 10.1007/s004380050412; SVOBODA A, 1995, CHROMOSOMA, V104, P203, DOI 10.1007/s004120050109; THON G, 1992, GENETICS, V131, P287	30	218	221	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					825	828		10.1038/33941	http://dx.doi.org/10.1038/33941			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572142				2022-12-01	WOS:000073241200056
J	Sorensen, HT; Mellemkjaer, L; Steffensen, FH; Olsen, JH; Nielsen, GL				Sorensen, HT; Mellemkjaer, L; Steffensen, FH; Olsen, JH; Nielsen, GL			The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Several small studies have indicated an association between deep venous thrombosis or pulmonary embolism and a subsequent diagnosis of cancer, but the subject is controversial. Methods We conducted a nationwide study of a cohort of patients with deep venous thrombosis or pulmonary embolism that was drawn from the Danish National Registry of Patients for the years 1977 th rough 1992. The occurrence of cancer in the cohort was determined by linkage to the Danish Cancer Registry. The expected number of cancer cases was estimated on the basis of national age-, sex-, and site-specific incidence rates. Results A total of 15,348 patients with deep venous thrombosis and 11,305 patients with pulmonary embolism were identified. We observed 1737 cases of cancer in the cohort with deep venous thrombosis, as compared with 1372 expected cases (standardized incidence ratio, 1.3; 95 percent confidence interval, 1.21 to 1.33). Among the patients with pulmonary embolism, the standardized incidence ratio was 1.3, with a 95 percent confidence interval of 1.22 to 1.41. The risk was substantially elevated only during the first six months of follow-up and declined rapidly thereafter to a constant level slightly above 1.0 one year after the thrombotic event. Forty percent of the patients given a diagnosis of cancer within one year after hospitalization for thromboembolism had distant metastases at the time of the diagnosis of cancer. There were strong associations with several cancers, most pronounced for those of the pancreas, ovary, liver (primary hepatic cancer), and brain. Conclusions An aggressive search for a hidden cancer in a patient with a primary deep venous thrombosis or pulmonary embolism is not warranted. (C)1998, Massachusetts Medical Society.	Aarhus Univ, Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, DK-8000 Aarhus, Denmark; Aarhus Univ, Dept Internal Med, DK-8000 Aarhus, Denmark; Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark; Aalborg Hosp, Dept Internal Med M, Aalborg, Denmark	Aarhus University; Aarhus University; Danish Cancer Society; Aalborg University; Aalborg University Hospital	Sorensen, HT (corresponding author), Aarhus Univ, Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, Hoegh Guldbergs Gade 10, DK-8000 Aarhus, Denmark.		Sorensen, Henrik Toft/Z-6181-2019; Steffensen, Flemming Hald/AAH-8742-2020	Sorensen, Henrik Toft/0000-0003-4299-7040; Steffensen, Flemming Hald/0000-0003-0252-6631; Olsen, Jorgen Helge/0000-0001-9633-5662				Cornuz J, 1996, ANN INTERN MED, V125, P785, DOI 10.7326/0003-4819-125-10-199611150-00001; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; GRIFFIN MR, 1987, ARCH INTERN MED, V147, P1907, DOI 10.1001/archinte.147.11.1907; LEVINE M, 1990, SEMIN ONCOL, V17, P160; MONREAL M, 1991, CANCER, V67, P541, DOI 10.1002/1097-0142(19910115)67:2<541::AID-CNCR2820670237>3.0.CO;2-J; Naschitz JE, 1996, CANCER-AM CANCER SOC, V77, P1759; NORDSTROM M, 1994, BRIT MED J, V308, P891, DOI 10.1136/bmj.308.6933.891; OCONNOR NTJ, 1984, POSTGRAD MED J, V60, P275, DOI 10.1136/pgmj.60.702.275; Piccioli A, 1996, AM HEART J, V132, P850, DOI 10.1016/S0002-8703(96)90321-X; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; PRINS MH, 1994, ARCH INTERN MED, V154, P1310, DOI 10.1001/archinte.154.12.1310; ROTHMAN KJ, 1979, DHHS PUBLICATION; Sorensen H T, 1997, Int J Risk Saf Med, V10, P1, DOI 10.3233/JRS-1997-10101; Storm HH, 1997, DAN MED BULL, V44, P535; STORM HH, 1996, CANC INCIDENCE DENMA; *SUNDH, 1981, AKT SYG 1979; *SUNDH, 1976, KLASS SYGD; Trousseau A., 1872, LECT CLIN MED DELIVE, P281	18	471	491	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1169	1173		10.1056/NEJM199804233381701	http://dx.doi.org/10.1056/NEJM199804233381701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554856				2022-12-01	WOS:000073208400001
J	Wolters-Arts, M; Lush, WM; Mariani, C				Wolters-Arts, M; Lush, WM; Mariani, C			Lipids are required for directional pollen-tube growth	NATURE			English	Article							DRY STIGMAS; ARABIDOPSIS; POLLINATION; PLANTS; COMPONENTS; NICOTIANA; RESPONSES; GRADIENTS; BRASSICA; FIELDS	Successful pollination and fertilization are absolute requirements for sexual reproduction in higher plants. Pollen hydration, germination and penetration of the stigma by pollen tubes are influenced by the exudate on wet stigmas(1) and by the pollen coat in species with dry stigmas(2-5). The exudate allows pollen tubes to grow directly into the stigma, whereas the pollen coat establishes the contact with the stigma. Pollen tubes then grow into the papillae, which are covered by a cuticle. The components of the exudate or pollen coat that are responsible for pollen tube penetration are not known. To discover the role of the exudate, we tested selected compounds for their ability to act as functional substitutes for exudate in the initial stages of pollen-tube growth on transgenic stigmaless tobacco plants' that did not produce exudate. Here we show that lipids are the essential factor needed for pollen tubes to penetrate the stigma, and that, in the presence of these lipids, pollen tubes will also penetrate leaves. We propose that lipids direct pollen-tube growth by controlling the flow of water to pollen in species with dry and wet stigmas.	Catholic Univ Nijmegen, Dept Expt Bot, Grad Sch Expt Plant Sci, NL-6525 ED Nijmegen, Netherlands; Univ Melbourne, Sch Bot, Plant Cell Biol Res Ctr, Parkville, Vic 3052, Australia	Radboud University Nijmegen; University of Melbourne	Wolters-Arts, M (corresponding author), Catholic Univ Nijmegen, Dept Expt Bot, Grad Sch Expt Plant Sci, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	mwolters@sci.kun.nl	Mariani, Celestina/C-6920-2013					BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; Boden N., 1994, MICELLES MEMBRANES M, P153; Cheung AY, 1996, P NATL ACAD SCI USA, V93, P3853, DOI 10.1073/pnas.93.9.3853; CRESTI M, 1986, AM J BOT, V73, P1713, DOI 10.2307/2444237; DICKINSON H, 1995, SEX PLANT REPROD, V8, P1, DOI 10.1007/BF00228756; DICKINSON H, 1993, NATURE, V364, P573, DOI 10.1038/364573a0; DICKINSON H, 1994, NATURE, V367, P517, DOI 10.1038/367517a0; DUMAS C, 1977, PLANTA, V137, P177, DOI 10.1007/BF00387556; Elleman CJ, 1996, NEW PHYTOL, V133, P197, DOI 10.1111/j.1469-8137.1996.tb01886.x; ELLEMAN CJ, 1992, NEW PHYTOL, V121, P413, DOI 10.1111/j.1469-8137.1992.tb02941.x; EVANS DE, 1990, PLANT PHYSIOL, V92, P418; GOLDMAN MHS, 1994, EMBO J, V13, P2976, DOI 10.1002/j.1460-2075.1994.tb06596.x; HULSKAMP M, 1995, PLANT J, V8, P703, DOI 10.1046/j.1365-313X.1995.08050703.x; HYDE GJ, 1995, EUR J CELL BIOL, V67, P356; Ikeda S, 1997, SCIENCE, V276, P1564, DOI 10.1126/science.276.5318.1564; KANDASAMY MK, 1994, DEVELOPMENT, V120, P3405; KONAR RN, 1966, PLANTA, V71, P378; LABARCA C, 1970, PLANT PHYSIOL, V46, P150, DOI 10.1104/pp.46.1.150; LOLLE SJ, 1993, DEV BIOL, V155, P250, DOI 10.1006/dbio.1993.1022; Lolle SJ, 1997, DEV BIOL, V189, P311, DOI 10.1006/dbio.1997.8671; MALHO R, 1992, SEX PLANT REPROD, V5, P57, DOI 10.1007/BF00714558; MARET G, 1985, TOP APPL PHYS, V57, P143; MARIANI C, 1990, NATURE, V347, P737, DOI 10.1038/347737a0; Piffanelli P, 1997, PLANT J, V11, P549, DOI 10.1046/j.1365-313X.1997.11030549.x; PREUSS D, 1993, GENE DEV, V7, P974, DOI 10.1101/gad.7.6.974; Pruitt RE, 1997, TRENDS PLANT SCI, V2, P328, DOI 10.1016/S1360-1385(97)84615-8; REGER BJ, 1992, SEX PLANT REPROD, V5, P47, DOI 10.1007/BF00714557; ROBBERTSE PJ, 1990, S AFR J BOT, V56, P487, DOI 10.1016/S0254-6299(16)31046-8; Taylor LP, 1997, ANNU REV PLANT PHYS, V48, P461, DOI 10.1146/annurev.arplant.48.1.461; WoltersArts M, 1996, SEX PLANT REPROD, V9, P243, DOI 10.1007/BF02152698	30	278	289	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					818	821		10.1038/33929	http://dx.doi.org/10.1038/33929			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572141				2022-12-01	WOS:000073241200054
J	Eccles, M; Freemantle, N; Mason, J				Eccles, M; Freemantle, N; Mason, J			North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; METAANALYSIS		Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Univ York, Ctr Hlth Econ, York YP1 5DD, N Yorkshire, England	Newcastle University - UK; University of York - UK	Eccles, M (corresponding author), Univ Newcastle Upon Tyne, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.	Martin.Eccles@nd.ac.uk	Mason, James M/D-9904-2011; Eccles, Martin P/AAD-4029-2020	Mason, James M/0000-0001-9210-4082; Freemantle, Nick/0000-0001-5807-5740				Adams P, 1996, BMJ-BRIT MED J, V312, P827; Anderson J, 1996, BMJ-BRIT MED J, V312, P762; [Anonymous], 1994, EFF HLTH CAR B; Cook T.D., 1979, QUASIEXPERIMENTATION; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Eccles M, 1996, QUAL HEALTH CARE, V5, P44, DOI 10.1136/qshc.5.1.44; Eccles M, 1996, BMJ-BRIT MED J, V312, P760; ECCLES M, IN PRESS BMJ; Field MJ, 1992, GUIDELINES CLIN PRAC; Freemantle N, 1997, ANN INTERN MED, V126, P81, DOI 10.7326/0003-4819-126-1-199701010-00011; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GRIMSHAW JM, 1994, QUAL HEALTH CARE, V3, P552; HEDGES LV, 1992, J EDUC STAT, V17, P279, DOI 10.2307/1165125; IOANNIDIS JPA, 1995, ANN INTERN MED, V122, P856, DOI 10.7326/0003-4819-122-11-199506010-00009; *N ENGL ASTHM GUID, 1997, EV BAS CLIN PRACT GU; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; Olkin I, 2014, STAT METHODS METAANA; US Department of Health and Human Services Public Health Services Agency for Health Care Policy and Research, 1992, AC PAIN MAN OP MED P; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	21	88	93	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1998	316	7139					1232	1235		10.1136/bmj.316.7139.1232	http://dx.doi.org/10.1136/bmj.316.7139.1232			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ518	9553004	Green Published			2022-12-01	WOS:000073224100032
J	Feneley, MR				Feneley, MR			Electrovaporisation of the prostate	LANCET			English	Editorial Material							HYPERPLASIA		Royal Hosp NHS Trust, Dept Urol, London, England	University of London; Queen Mary University London	Feneley, MR (corresponding author), Royal Hosp NHS Trust, Dept Urol, London, England.							Cetinkaya M, 1996, BRIT J UROL, V78, P901, DOI 10.1046/j.1464-410X.1996.23616.x; Chen SS, 1997, UROLOGY, V50, P235, DOI 10.1016/S0090-4295(97)00214-8; Kaplan SA, 1996, UROLOGY, V48, P876, DOI 10.1016/S0090-4295(96)00487-6; Lim LM, 1997, UROLOGY, V49, P851, DOI 10.1016/S0090-4295(97)00092-7; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; NARAYAN P, 1995, J UROLOGY, V154, P2083, DOI 10.1016/S0022-5347(01)66701-6; Schatzl G, 1997, J UROLOGY, V158, P105, DOI 10.1097/00005392-199707000-00029; Shokeir AA, 1997, BRIT J UROL, V80, P570, DOI 10.1046/j.1464-410X.1997.00428.x; TE AE, 1997, CURR OPIN UROL, V7, P25; Tewari A, 1996, BRIT J UROL, V78, P667, DOI 10.1046/j.1464-410X.1996.01771.x; Thomas KJ, 1997, BRIT J UROL, V79, P186, DOI 10.1046/j.1464-410X.1997.03098.x; WASSON JH, 1995, NEW ENGL J MED, V332, P75, DOI 10.1056/NEJM199501123320202	12	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					999	1001		10.1016/S0140-6736(05)78989-3	http://dx.doi.org/10.1016/S0140-6736(05)78989-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546499				2022-12-01	WOS:000072927200003
J	Rosendorff, C				Rosendorff, C			Statins for prevention of stroke	LANCET			English	Editorial Material							DISEASE		CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Rosendorff, C (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.							Bucher HC, 1998, ANN INTERN MED, V128, P89, DOI 10.7326/0003-4819-128-2-199801150-00002; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001	7	11	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 4	1998	351	9108					1002	1003		10.1016/S0140-6736(05)78991-1	http://dx.doi.org/10.1016/S0140-6736(05)78991-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546501				2022-12-01	WOS:000072927200005
J	Zheng, WJ; Johnston, SA; Joshua-Tor, L				Zheng, WJ; Johnston, SA; Joshua-Tor, L			The unusual active site of Gal6/bleomycin hydrolase can act as a carboxypeptidase, aminopeptidase, and peptide ligase	CELL			English	Article							BINDING CYSTEINE PROTEASE; HUMAN BLEOMYCIN HYDROLASE; 20S PROTEASOME; CRYSTAL-STRUCTURE; CLONING; PROTEINASE; DNA; EXPRESSION; RESOLUTION; PROGRAM	The Gal6 protease is in a class of cysteine peptidases identified by their ability to inactivate the anti-cancer drug bleomycin. The protein forms a barrel structure with the active sites embedded in a channel as in the proteasome. In Gal6 the C termini lie in the active site clefts. We show that Gal6 acts as a carboxypeptidase on its C terminus to convert itself to an aminopeptidase and peptide ligase. The substrate specificity of the peptidase activity is determined by the position of the C terminus of Gal6 rather than the sequence of the substrate. We propose a model to explain these diverse activities and Gal6's singular ability to inactivate bleomycin.	Cold Spring Harbor Lab, WM Keck Struct Biol Lab, Cold Spring Harbor, NY 11724 USA; Univ Texas, SW Med Ctr, Dept Med, Ctr Biomed Invent, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Cold Spring Harbor Laboratory; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Joshua-Tor, L (corresponding author), Cold Spring Harbor Lab, WM Keck Struct Biol Lab, POB 100, Cold Spring Harbor, NY 11724 USA.			Joshua-Tor, Leemor/0000-0001-8185-8049	NCI NIH HHS [CA67982, R01-CA71746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071746, R01CA067982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi H, 1997, EUR J BIOCHEM, V245, P283, DOI 10.1111/j.1432-1033.1997.t01-1-00283.x; AKIYAMA S, 1981, BIOCHEM BIOPH RES CO, V101, P55, DOI 10.1016/S0006-291X(81)80009-5; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bromme D, 1996, BIOCHEMISTRY-US, V35, P6706, DOI 10.1021/bi960092y; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHAPOTCHARTIER MP, 1993, APPL ENVIRON MICROB, V59, P330, DOI 10.1128/AEM.59.1.330-333.1993; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; ENENKEL C, 1993, J BIOL CHEM, V268, P7036; Ferrando AA, 1996, CANCER RES, V56, P1746; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KAMBOURIS NG, 1992, J BIOL CHEM, V267, P21570; Klein JR, 1997, MICROBIOL-SGM, V143, P527, DOI 10.1099/00221287-143-2-527; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAZO JS, 1983, P NATL ACAD SCI-BIOL, V80, P3064, DOI 10.1073/pnas.80.10.3064; Lazo JS, 1996, CANC CHEMOTHERAPY BI; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; MAGDOLEN U, 1993, BIOCHIM BIOPHYS ACTA, V1171, P299, DOI 10.1016/0167-4781(93)90069-P; Mata L, 1997, BIOCHEM J, V328, P343, DOI 10.1042/bj3280343; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; OTWINSOWSKI Z, 1993, DATA COLLECTION PROC; SCHECTER I, 1968, BIOCHEM BIOPH RES CO, V32, P888; SCHRODER E, 1993, FEBS LETT, V315, P38, DOI 10.1016/0014-5793(93)81128-M; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; Takeda A, 1996, J BIOCHEM-TOKYO, V120, P353; TONG L, 1993, J MOL BIOL, V230, P228, DOI 10.1006/jmbi.1993.1139; XU HE, 1994, J BIOL CHEM, V269, P21177; ZHENG W, 1997, IN PRESS MOL CELL BI; Zheng WJ, 1997, J BIOL CHEM, V272, P30350, DOI 10.1074/jbc.272.48.30350	32	45	46	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					103	109		10.1016/S0092-8674(00)81150-2	http://dx.doi.org/10.1016/S0092-8674(00)81150-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546396	Bronze			2022-12-01	WOS:000072910800014
J	Phanuphak, P				Phanuphak, P			Ethical issues in studies in Thailand of the vertical transmission of HIV	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Thai Red Cross Soc, Program AIDS, Bangkok 10330, Thailand	Thai Red Cross Society	Phanuphak, P (corresponding author), Thai Red Cross Soc, Program AIDS, 1871 Rama IV Rd, Bangkok 10330, Thailand.							CHAISILWATTANA P, 1997, C GLOB STRAT PREV HI; CONOR EM, 1994, NEW ENGL J MED, V331, P1173; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; SRIPLIENCHAN S, 1997, C GLOB STRAT PREV HI; *WHO, 1994, REC M MOTH INF TRANS	5	25	26	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1998	338	12					834	835		10.1056/NEJM199803193381212	http://dx.doi.org/10.1056/NEJM199803193381212			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC163	9504948				2022-12-01	WOS:000072546800012
J	Christensen, PR; Anderson, DL; Chase, SC; Clancy, RT; Clark, RN; Conrath, BJ; Kieffer, HH; Kuzmin, RO; Malin, MC; Pearl, JC; Roush, TL				Christensen, PR; Anderson, DL; Chase, SC; Clancy, RT; Clark, RN; Conrath, BJ; Kieffer, HH; Kuzmin, RO; Malin, MC; Pearl, JC; Roush, TL			Results from the Mars global surveyor thermal emission spectrometer	SCIENCE			English	Article							GREAT DUST STORMS; SOUTH POLAR-CAP; SNC METEORITES; ATMOSPHERE; VIKING; CLOUDS	The Thermal Emission Spectrometer spectra of low albedo surface materials suggests that a four to one mixture of pyroxene to plagioclase, together with about a 35 percent dust component provides the best fit to the spectrum. Qualitative upper limits can be placed on the concentration of carbonates (<10 percent), olivine (<10 percent), clay minerals (<20 percent), and quartz (<5 percent) in the limited regions observed. Limb observations in the northern hemisphere reveal low-lying dust hazes and detached water-ice clouds at altitudes up to 55 kilometers. At an aerocentric longitude of 224 degrees a major dust storm developed in the Noachis Terra region, The south polar cap retreat was similar to that observed by Viking.	Arizona State Univ, Tempe, AZ 85287 USA; Univ Colorado, Goleta, CA 93017 USA; US Geol Survey, Denver, CO 80225 USA; Cornell Univ, Ithaca, NY 14850 USA; US Geol Survey, Flagstaff, AZ 86001 USA; VI Vernadskii Inst Geochem & Analyt Chem, Moscow 117975, Russia; Malin Space Sci Syst, San Diego, CA USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Santa Barbara Remote Sensing, Goleta, CA 93017 USA	Arizona State University; Arizona State University-Tempe; University of Colorado System; United States Department of the Interior; United States Geological Survey; Cornell University; United States Department of the Interior; United States Geological Survey; Russian Academy of Sciences; Vernadsky Institute of Geochemistry & Analytical Chemistry; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Christensen, PR (corresponding author), Arizona State Univ, Tempe, AZ 85287 USA.	phil.christensen@asu.edu						ADAMS JB, 1969, J GEOPHYS RES, V74, P4851, DOI 10.1029/JB074i020p04851; Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; CHASE SC, 1978, APPL OPTICS, V17, P1243, DOI 10.1364/AO.17.001243; CHRISTENSEN PR, 1992, J GEOPHYS RES-PLANET, V97, P7719, DOI 10.1029/92JE00453; Christensen PR, 1998, J GEOPHYS RES-PLANET, V103, P1733, DOI 10.1029/97JE02114; CLANCY RT, 1991, ICARUS, V93, P135, DOI 10.1016/0019-1035(91)90169-T; CONRATH B, 1973, J GEOPHYS RES, V78, P4267, DOI 10.1029/JB078i020p04267; CURRAN RJ, 1973, SCIENCE, V182, P381, DOI 10.1126/science.182.4110.381; FISCHBACHER GE, 1969, 951547 JET PROP LAB; Hamilton VE, 1997, J GEOPHYS RES-PLANET, V102, P25593, DOI 10.1029/97JE01874; HANEL RA, 1972, SCIENCE, V175, P305, DOI 10.1126/science.175.4019.305; Hanel RA, 1992, EXPLORATION SOLAR SY; JAMES PB, 1979, J GEOPHYS RES, V84, P2889, DOI 10.1029/JB084iB06p02889; JAMES PB, 1982, ICARUS, V50, P368, DOI 10.1016/0019-1035(82)90130-0; JAMES PB, 1994, MARS; Kieffer H. H., 1977, Journal of Geophysical Research, V82, P4249, DOI 10.1029/JS082i028p04249; KIEFFER HH, 1976, SCIENCE, V193, P780, DOI 10.1126/science.193.4255.780; MARTIN TZ, 1986, ICARUS, V66, P2, DOI 10.1016/0019-1035(86)90003-5; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MUSTARD JF, 1993, J GEOPHYS RES-PLANET, V98, P3387, DOI 10.1029/92JE02682; MUSTARD JF, 1995, SCIENCE, V267, P1623, DOI 10.1126/science.7886449; POLLACK JB, 1990, J GEOPHYS RES-SOLID, V95, P1447, DOI 10.1029/JB095iB02p01447; Ramsey MS, 1998, J GEOPHYS RES-SOL EA, V103, P577, DOI 10.1029/97JB02784; Ruff SW, 1997, J GEOPHYS RES-SOL EA, V102, P14899, DOI 10.1029/97JB00593; SINGER RB, 1990, RESOURCES NEAR EARTH; SINGER RB, 1985, B AM ASTRON SOC, V17, P737; SINGER RB, 1980, LUNAR PLANET SCI C, V11, P1045; Smith PH, 1997, SCIENCE, V278, P1758, DOI 10.1126/science.278.5344.1758; TILLMAN JE, 1993, J GEOPHYS RES-PLANET, V98, P10963, DOI 10.1029/93JE01084; ZUREK RW, 1982, ICARUS, V50, P288, DOI 10.1016/0019-1035(82)90127-0	30	165	167	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1692	1698		10.1126/science.279.5357.1692	http://dx.doi.org/10.1126/science.279.5357.1692			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497282				2022-12-01	WOS:000072490000047
J	Groh, V; Steinle, A; Bauer, S; Spies, T				Groh, V; Steinle, A; Bauer, S; Spies, T			Recognition of stress-induced MHC molecules by intestinal epithelial gamma delta T cells	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; HUMAN INTRAEPITHELIAL LYMPHOCYTES; MONOCLONAL-ANTIBODY; NONPEPTIDE ANTIGENS; PERIPHERAL-BLOOD; RECEPTOR; GENE; EXPRESSION; DIVERSITY	T cells with variable region V(delta)1 gamma delta T cell receptors (TCRs) are distributed throughout the human intestinal epithelium and may function as sentinels that respond to self antigens. The expression of a major histocompatibility complex (MHC) class I-related molecule, MICA, matches this localization. MICA and the closely related MICE were recognized by intestinal epithelial T cells expressing diverse V(delta)1 gamma delta TCRs, These interactions involved the alpha 1 beta 2 domains of MICA and MICE but were independent of antigen processing. With intestinal epithelial cell lines, the expression and recognition of MICA and MICE could be stress-induced. Thus, these molecules may broadly regulate protective responses by the V(delta)1 gamma delta T cells in the epithelium of the intestinal tract.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Groh, V (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Steinle, Alexander/E-6131-2012	Steinle, Alexander/0000-0001-5081-8503; Bauer, Stefan/0000-0002-8462-1845	NCI NIH HHS [P01 CA18221] Funding Source: Medline; NIAID NIH HHS [R01 AI30581] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA018221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030581] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; Arden Bernhard, 1995, Immunogenetics, V42, P455; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; Bahram S, 1996, IMMUNOGENETICS, V43, P230, DOI 10.1007/BF00587305; BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; BOISMENU R, 1994, SCIENCE, V266, P1253, DOI 10.1126/science.7973709; BORST J, 1988, J EXP MED, V167, P1625, DOI 10.1084/jem.167.5.1625; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CHOWERS Y, 1994, J EXP MED, V180, P183, DOI 10.1084/jem.180.1.183; DELIBERO G, 1991, J EXP MED, V173, P1311, DOI 10.1084/jem.173.6.1311; DEUSCH K, 1991, EUR J IMMUNOL, V21, P1053, DOI 10.1002/eji.1830210429; EBERT EC, 1989, GASTROENTEROLOGY, V97, P1372, DOI 10.1016/0016-5085(89)90379-X; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fodil N, 1996, IMMUNOGENETICS, V44, P351, DOI 10.1007/s002510050136; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; HATA S, 1988, SCIENCE, V240, P1541, DOI 10.1126/science.3259726; HAVRAN WL, 1991, SCIENCE, V252, P1430, DOI 10.1126/science.1828619; HOLOSHITZ J, 1993, INT IMMUNOL, V5, P1437, DOI 10.1093/intimm/5.11.1437; Holtmeier W, 1997, J IMMUNOL, V158, P5632; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; KABELITZ D, 1990, J EXP MED, V171, P667, DOI 10.1084/jem.171.3.667; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KONING F, 1989, EUR J IMMUNOL, V19, P2099, DOI 10.1002/eji.1830191120; Koopmann JO, 1997, CURR OPIN IMMUNOL, V9, P80, DOI 10.1016/S0952-7915(97)80163-X; LOH EY, 1988, P NATL ACAD SCI USA, V85, P9714, DOI 10.1073/pnas.85.24.9714; LUNDQVIST C, 1995, INT IMMUNOL, V7, P1473, DOI 10.1093/intimm/7.9.1473; Maeurer MJ, 1996, J EXP MED, V183, P1681, DOI 10.1084/jem.183.4.1681; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MODLIN RL, 1989, NATURE, V339, P544, DOI 10.1038/339544a0; MORITA CT, 1995, IMMUNITY, V3, P495, DOI 10.1016/1074-7613(95)90178-7; PARHAM P, 1979, J IMMUNOL, V123, P342; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SPENCER J, 1989, EUR J IMMUNOL, V19, P1335, DOI 10.1002/eji.1830190728; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; TAX WJM, 1983, NATURE, V304, P445, DOI 10.1038/304445a0; WATANABE M, 1995, J CLIN INVEST, V95, P2945, DOI 10.1172/JCI118002; WEINTRAUB BC, 1994, J IMMUNOL, V153, P3051; WHITESIDE TL, 1986, INT J CANCER, V37, P803, DOI 10.1002/ijc.2910370602; WU YJ, 1988, J IMMUNOL, V141, P1476; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	48	973	1012	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1737	1740		10.1126/science.279.5357.1737	http://dx.doi.org/10.1126/science.279.5357.1737			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497295				2022-12-01	WOS:000072490000060
J	Murray, JB; Terwey, DP; Maloney, L; Karpeisky, A; Usman, N; Beigelman, L; Scott, WG				Murray, JB; Terwey, DP; Maloney, L; Karpeisky, A; Usman, N; Beigelman, L; Scott, WG			The structural basis of hammerhead ribozyme self-cleavage	CELL			English	Article							CATALYTIC RNA; MECHANISM; ENZYME; PHOSPHOROTHIOATE; CONFORMATION	We have captured an 8.7 Angstrom conformational change that takes place in the cleavage site of the hammerhead ribozyme during self-cleavage, using X-ray crystallography combined with physical and chemical trapping techniques. This rearrangement brings the hammerhead ribozyme from the ground state into a conformation that is poised to form the transition state geometry required for hammerhead RNA self-cleavage. Use of a 5'-C-methylated ribose adjacent to the cleavage site permits this ordinarily transient conformational change to be kinetically trapped and observed crystallographically after initiating the hammerhead ribozyme reaction in the crystal. Cleavage of the corresponding unmodified hammerhead ribozyme in the crystal under otherwise identical conditions is faster than in solution, indicating that we have indeed trapped a catalytically relevant intermediate form of this RNA enzyme.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA; Ribosyme Pharmaceut Inc, Boulder, CO 80301 USA	Indiana University System; Indiana University Bloomington	Scott, WG (corresponding author), Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.			Karpeisky, Alexander/0000-0002-9226-8789; Scott, William/0000-0002-9273-3564	NIGMS NIH HHS [R01 GM087721] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amiri KMA, 1996, J MOL BIOL, V261, P125, DOI 10.1006/jmbi.1996.0446; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bassi GS, 1996, RNA, V2, P756; Bassi GS, 1997, EMBO J, V16, P7481, DOI 10.1093/emboj/16.24.7481; BEIGELMAN L, 1995, NUCLEOS NUCLEOT, V14, P901, DOI 10.1080/15257779508012498; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; BRUNGER AT, 1993, XPLOR 3 1 SYSTEM CRY; ClouetDOrval B, 1996, RNA, V2, P483; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; Feig AL, 1998, SCIENCE, V279, P81, DOI 10.1126/science.279.5347.81; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HERMAN T, 1998, IN PRESS EUR J BIOPH; Hermann T, 1997, NUCLEIC ACIDS RES, V25, P3421, DOI 10.1093/nar/25.17.3421; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; JONES TA, 1997, O VERSION 6 1 0 DEP; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; McKay DB, 1996, RNA, V2, P395; MOFFAT K, 1995, CURR OPIN STRUC BIOL, V5, P656, DOI 10.1016/0959-440X(95)80059-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PEARSON RG, 1963, J AM CHEM SOC, V85, P3533, DOI 10.1021/ja00905a001; Peracchi A, 1997, J BIOL CHEM, V272, P26822, DOI 10.1074/jbc.272.43.26822; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065; Scott WG, 1996, TRENDS BIOCHEM SCI, V21, P220; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SIGURDSSON ST, 1995, RNA, V1, P575; Simorre JP, 1997, BIOCHEMISTRY-US, V36, P518, DOI 10.1021/bi9620520; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; THOMSON JB, 1996, NUCL ACIDS MOL BIOL, V10, P173; UCHIMARU T, 1993, NUCL ACIDS S SER, V29, P179; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VANTOL H, 1990, NUCLEIC ACIDS RES, V18, P1971, DOI 10.1093/nar/18.8.1971; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	41	201	205	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1998	92	5					665	673		10.1016/S0092-8674(00)81134-4	http://dx.doi.org/10.1016/S0092-8674(00)81134-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506521	Green Published, Bronze			2022-12-01	WOS:000072406000012
J	Rabouille, C; Kondo, H; Newman, R; Hui, N; Freemont, P; Warren, G				Rabouille, C; Kondo, H; Newman, R; Hui, N; Freemont, P; Warren, G			Syntaxin 5 is a common component of the NSF- and p97-mediated reassembly pathways of Golgi cisternae from mitotic Golgi fragments in vitro	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; SENSITIVE FUSION PROTEIN; CELL-FREE SYSTEM; VESICULAR TRANSPORT; ENDOPLASMIC-RETICULUM; VESICLE FUSION; ALPHA-SNAP; PEROXISOME BIOGENESIS; SYNAPTIC VESICLES; YEAST	A cell-free system that mimics the reassembly of Golgi stacks at the end of mitosis requires two ATPases, NSF and p97, to rebuild Golgi cisternae. Morphological studies now show that alpha-SNAP, a component of the NSF pathway, can inhibit the p97 pathway, whereas p47, a component of the p97 pathway, can inhibit the NSF pathway. Anti-syntaxin 5 antibodies and a soluble, recombinant syntaxin 5 inhibited both pathways, suggesting that this t-SNARE is a common component. Biochemical studies confirmed this, showing that p47 binds directly to syntaxin 5 and competes for binding with alpha-SNAP. p47 also mediates the binding of p97 to syntaxin 5 and so plays an analogous role to alpha-SNAP, which mediates the binding of NSF.	Imperial Canc Res Fund, Cell Biol Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Mol Struct & Funct Lab, London WC2A 3PX, England	Cancer Research UK; Cancer Research UK	Warren, G (corresponding author), Imperial Canc Res Fund, Cell Biol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.			Freemont, Paul/0000-0002-5658-8486				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Bock JB, 1997, NATURE, V387, P133, DOI 10.1038/387133a0; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DASCHER C, 1994, J BIOL CHEM, V269, P29363; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; HUI N, 1997, CELL BIOL LAB HDB, P46; INOUE A, 1992, J BIOL CHEM, V267, P10613; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Levine TP, 1996, J BIOL CHEM, V271, P17304, DOI 10.1074/jbc.271.29.17304; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; MELLMAN I, 1995, CELL, V82, P869, DOI 10.1016/0092-8674(95)90018-7; MISTELI T, 1995, J CELL BIOL, V130, P1027, DOI 10.1083/jcb.130.5.1027; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; Saxton WO, 1996, J STRUCT BIOL, V116, P230, DOI 10.1006/jsbi.1996.0035; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLIMENA CW, 1995, J CELL BIOL, V128, P637; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPONG AP, 1993, J CELL BIOL, V123, P535, DOI 10.1083/jcb.123.3.535; Subramaniam VN, 1997, J BIOL CHEM, V272, P25441, DOI 10.1074/jbc.272.41.25441; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	62	219	226	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					603	610		10.1016/S0092-8674(00)81128-9	http://dx.doi.org/10.1016/S0092-8674(00)81128-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506515	Bronze			2022-12-01	WOS:000072406000006
J	Shim, JK; Johnson, S; Samore, MH; Bliss, DZ; Gerding, DN				Shim, JK; Johnson, S; Samore, MH; Bliss, DZ; Gerding, DN			Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea	LANCET			English	Article							NOSOCOMIAL ACQUISITION; CROSS-INFECTION; COLITIS; COLONIZATION; ENVIRONMENT	Background Little is known about whether patients who develop Clostridium-difficile-associated diarrhoea (CDAD) are culture-positive or culture-negative before illness. The most important risk factor is antibiotic exposure. We aimed to find out whether patients identified as primary symptom-free C difficile carriers are at higher risk of developing CDAD than patients who are culture-negative. Method We reviewed four longitudinal studies in which 810 patients admitted to hospital were followed up by prospective rectal-swab culture. At least two consecutive weekly cultures were obtained. We calculated the difference in risk of CDAD between colonised and non-colonised patients in each study and combined the results of the four studies in a random-effects model. Findings Of 618 non-colonised patients (mean follow-up 1.7 weeks [SD 1.3]), 22 (3.6%) developed CDAD, whereas only two (1.0%) of 192 primary symptom-free carriers (1.5 [1.5]) developed CDAD (pooled risk difference -2.3% [95% CI 0.3-4.3], p=0.021). Of patients who received antibiotics, the risk difference was increased: 22 (4.5%) of 491 non-colonised patients compared with two (1.1%) of 176 colonised patients developed CDAD (-3.2% [0.4-6.0], p=0.024). Of the primary symptom-free C difficile carriers, 95 were colonised with toxigenic strains, 76 with nontoxigenic strains, 12 with both toxigenic and non-toxigenic strains (non-concurrently), and nine with strains of undetermined toxigenicity. Nine of the 12 toxogenic strains of C difficile isolates that cause CDAD were also recovered from stools of symptom-free patients. Interpretation Primary symptomless C difficile colonisation is associated with a decreased risk of CDAD. Although the mechanism is unknown, risk reduction is found in colonisation with non-toxigenic and toxigenic strains.	Vet Affairs Healthcare Syst, Lakeside Div, Dept Med, Infect Dis Sect, Chicago, IL USA; Northwestern Univ, Sch Med, Chicago, IL USA; Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA; Beth Israel Deaconess Med Ctr, Dept Med, Infect Dis Sect, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Northwestern University; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Gerding, DN (corresponding author), VACHS Lakeside, Med Serv, 333 E Huron, Chicago, IL 60611 USA.			Johnson, Stuart/0000-0001-9548-229X	NATIONAL INSTITUTE OF NURSING RESEARCH [F32NR006746] Funding Source: NIH RePORTER; NINR NIH HHS [IF 32-NR06746] Funding Source: Medline	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		BLISS D, 1994, 34 INT C ANT AG CHEM; BORRIELLO SP, 1985, J MED MICROBIOL, V19, P339, DOI 10.1099/00222615-19-3-339; CLABOTS CR, 1993, J CLIN MICROBIOL, V31, P1870, DOI 10.1128/JCM.31.7.1870-1875.1993; CLABOTS CR, 1992, J INFECT DIS, V166, P561, DOI 10.1093/infdis/166.3.561; CUMMING AD, 1986, BRIT MED J, V292, P238, DOI 10.1136/bmj.292.6515.238; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; GERDING DN, 1986, ARCH INTERN MED, V146, P95, DOI 10.1001/archinte.146.1.95; HASSELBLAD V, 1995, MED CARE, V33, P202; HEARD SR, 1986, J INFECT DIS, V153, P159, DOI 10.1093/infdis/153.1.159; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KIM KH, 1981, J INFECT DIS, V143, P42, DOI 10.1093/infdis/143.1.42; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; MULLIGAN ME, 1979, CURR MICROBIOL, V3, P173, DOI 10.1007/BF02601862; Petitti D.B., 1994, METAANALYSIS DECISIO; SAMORE MH, 1994, CLIN INFECT DIS, V18, P181, DOI 10.1093/clinids/18.2.181; SEAL D, 1987, EUR J CLIN MICROBIOL, V6, P51, DOI 10.1007/BF02097191; SHANHOLTZER CJ, 1983, J CLIN MICROBIOL, V17, P906, DOI 10.1128/JCM.17.5.906-908.1983; WILSON KH, 1983, J INFECT DIS, V147, P733, DOI 10.1093/infdis/147.4.733; WILSON KH, 1993, CLIN INFECT DIS S4, V16, P214	20	268	288	0	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					633	636		10.1016/S0140-6736(97)08062-8	http://dx.doi.org/10.1016/S0140-6736(97)08062-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500319				2022-12-01	WOS:000072364200009
J	Williams, RJ; Heymann, DL				Williams, RJ; Heymann, DL			Containment of antibiotic resistance	SCIENCE			English	Article							ANTIMICROBIAL DRUGS		WHO, Div Emerging & Other Communicable Dis Surveillanc, CH-1211 Geneva, Switzerland	World Health Organization	Williams, RJ (corresponding author), WHO, Div Emerging & Other Communicable Dis Surveillanc, CH-1211 Geneva, Switzerland.							Acar JF, 1997, CLIN INFECT DIS, V24, pS17, DOI 10.1093/clinids/24.Supplement_1.S17; BAGER F, 1997, CONSUMPTION ANTIMICR; DUA V, 1994, SOC SCI MED, V38, P717, DOI 10.1016/0277-9536(94)90462-6; FORDER AA, 1993, J HOSP INFECT, V24, P87, DOI 10.1016/0195-6701(93)90070-G; Goldmann DA, 1997, CLIN INFECT DIS, V24, pS139, DOI 10.1093/clinids/24.Supplement_1.S139; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; *GROUP DEP ET PREV, 1994, ACTA CLIN BELG, P108; KLUGMAN KP, 1994, J ANTIMICROB CHEMOTH, V34, P191, DOI 10.1093/jac/34.2.191; Kondro W, 1997, LANCET, V349, P1156, DOI 10.1016/S0140-6736(05)63043-7; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; Management Science for Health & World Health Organization, 1997, MAN DRUG SUPPL SEL P; OBrien TF, 1997, CLIN INFECT DIS, V24, pS2, DOI 10.1093/clinids/24.Supplement_1.S2; Qazi SA, 1996, B WORLD HEALTH ORGAN, V74, P501; Schwartz B, 1997, JAMA-J AM MED ASSOC, V278, P944, DOI 10.1001/jama.278.11.944; Seto WH, 1996, BRIT J CLIN PHARMACO, V41, P229, DOI 10.1111/j.1365-2125.1996.tb00187.x; TOUWOTTEN FWMM, 1992, FAM PRACT, V9, P255, DOI 10.1093/fampra/9.3.255; *WHO, 1992, TECHN REP SER WHO, V823; *WHO, 1997, US ESS DRUGS; Witte W, 1998, SCIENCE, V279, P996, DOI 10.1126/science.279.5353.996; World Health Organization, 1988, ETH CRIT MED DRUG PR; 1992, MORB MORTAL WKLY REP, V41, P783	21	141	147	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1153	1154		10.1126/science.279.5354.1153	http://dx.doi.org/10.1126/science.279.5354.1153			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9508688				2022-12-01	WOS:000072115200025
J	McCord, TB; Hansen, GB; Fanale, FP; Carlson, RW; Matson, DL; Johnson, TV; Smythe, WD; Crowley, JK; Martin, PD; Ocampo, A; Hibbitts, CA; Granahan, JC				McCord, TB; Hansen, GB; Fanale, FP; Carlson, RW; Matson, DL; Johnson, TV; Smythe, WD; Crowley, JK; Martin, PD; Ocampo, A; Hibbitts, CA; Granahan, JC		NIMS Team	Salts an Europa's surface detected by Galileo's Near Infrared Mapping Spectrometer	SCIENCE			English	Article							MAGNETOSPHERIC ION-BOMBARDMENT; PLAYA EVAPORITE MINERALS; AMORPHOUS SOLID WATER; MU-M; DEATH-VALLEY; SATELLITES; REFLECTANCE; SPECTRA; ICE; SPECTROSCOPY	Reflectance spectra in the 1- to 2.5-micrometer wavelength region of the surface of Europa obtained by Galileo's Near Infrared Mapping Spectrometer exhibit distorted water absorption bands that indicate the presence of hydrated minerals, The laboratory spectra of hydrated salt minerals such as magnesium sulfates and sodium carbonates and mixtures of these minerals provide a close match to the Europa spectra. The distorted bands are only observed in the optically darker areas of Europa, including the lineaments, and may represent evaporite deposits formed by water, rich in dissolved salts, reaching the surface from a water-rich layer underlying an ice crust.	Univ Hawaii, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; US Geol Survey, Reston, VA 22091 USA; STI Inc, Honolulu, HI 96813 USA	University of Hawaii System; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); United States Department of the Interior; United States Geological Survey	McCord, TB (corresponding author), Univ Hawaii, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA.		Hibbitts, Charles/B-7787-2016	Hibbitts, Charles/0000-0001-9089-4391				Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; CALVIN WM, 1995, J GEOPHYS RES-PLANET, V100, P19041, DOI 10.1029/94JE03349; Carlson R, 1996, SCIENCE, V274, P385, DOI 10.1126/science.274.5286.385; CARLSON RW, 1992, SPACE SCI REV, V60, P457, DOI 10.1007/BF00216865; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CARR MH, 1997, LUNAR PLANET SCI, V28, P207; CASSEN P, 1980, GEOPHYS RES LETT, V7, P987, DOI 10.1029/GL007i011p00987; CASSEN P, 1979, GEOPHYS RES LETT, V6, P731, DOI 10.1029/GL006i009p00731; CLARK RN, 1980, ICARUS, V44, P388, DOI 10.1016/0019-1035(80)90033-0; CLARK RN, 1981, J GEOPHYS RES, V86, P3087, DOI 10.1029/JB086iB04p03087; CLARK RN, 1982, ICARUS, V49, P244, DOI 10.1016/0019-1035(82)90075-6; Crowley JK, 1996, ECON GEOL BULL SOC, V91, P622, DOI 10.2113/gsecongeo.91.3.622; CROWLEY JK, 1991, J GEOPHYS RES-SOL EA, V96, P16231, DOI 10.1029/91JB01714; CROWLEY JK, 1993, REMOTE SENS ENVIRON, V44, P337, DOI 10.1016/0034-4257(93)90025-S; FANALE FP, 1998, LUNAR PLANET SCI, V29, P1248; FANALE FP, UNPUB; FANALE FP, 1977, PLANETARY SATELLITES, P379; FINK UWE, 1975, ICARUS, V24, P411, DOI 10.1016/0019-1035(75)90058-5; Gaines R.V., 1998, DANAS NEW MINERALOGY, V120, P2693; GRANAHAN JC, 1997, B AM ASTRON SOC, V29, P982; GRANAHAN JC, 1997, EOS S, V78, pF417; GRUNDY WM, IN PRESS J GEOPHYS R; HAGEN W, 1981, CHEM PHYS, V56, P367, DOI 10.1016/0301-0104(81)80158-9; HAGEN W, 1982, SPECTROCHIM ACTA A, V38, P1089, DOI 10.1016/0584-8539(82)80040-8; HANSEN GB, 1997, LUNAR PLANET SCI, V28, P505; HARDIE LA, 1968, GEOCHIM COSMOCHIM AC, V32, P1279, DOI 10.1016/0016-7037(68)90029-X; HOBBS PV, 1974, ICE PHYSICS; Hunt G. R., 1973, Modern Geology, V4, P85; Hunten D. M., 1971, Comments on Astrophysics and Space Physics, V3, P1; IRVINE WM, 1968, ICARUS, V8, P324, DOI 10.1016/0019-1035(68)90083-3; JOHNSON RE, 1988, ICARUS, V75, P423, DOI 10.1016/0019-1035(88)90155-8; JOHNSON TV, 1983, J GEOPHYS RES, V88, P5789, DOI 10.1029/JB088iB07p05789; JOHNSON TV, 1971, ASTROPHYS J, V169, P589, DOI 10.1086/151177; KARGEL JS, 1991, ICARUS, V94, P368, DOI 10.1016/0019-1035(91)90235-L; Kempe S, 1989, ORIGIN EVOLUTION MOD, P29; KIEFFER HH, 1974, ICARUS, V21, P506, DOI 10.1016/0019-1035(74)90153-5; KUIPER GP, 1961, SOLAR SYSTEM, V3, P305; LANE AL, 1981, NATURE, V292, P38, DOI 10.1038/292038a0; Luchitta B. K., 1982, SATELLITES JUPITER, P521; MALIN MC, 1986, SATELLITES, P689; McCord TB, 1998, J GEOPHYS RES-PLANET, V103, P8603, DOI 10.1029/98JE00788; McCord TB, 1997, SCIENCE, V278, P271, DOI 10.1126/science.278.5336.271; MCCORD TB, 1997, EOS T AGU S, V78, pF407; MCCORD TB, 1998, LUNAR PLANET SCI, V29, P1560; MCCORD TB, 1997, EOS S, V78, pS202; MOROZ VI, 1965, T SOVIET ASTRON A J, V9, P999; NELSON RM, 1987, ICARUS, V72, P358, DOI 10.1016/0019-1035(87)90180-1; NOLL KS, 1995, J GEOPHYS RES-PLANET, V100, P19057, DOI 10.1029/94JE03294; OCKMAN N, 1958, ADV PHYS, V7, P199, DOI 10.1080/00018735800101227; PITCHER CB, 1972, SCIENCE, V178, P1087; POLLACK JB, 1978, ICARUS, V36, P271, DOI 10.1016/0019-1035(78)90110-0; POSPIESZALSKA MK, 1989, ICARUS, V78, P1, DOI 10.1016/0019-1035(89)90065-1; REYNOLDS RT, 1983, ICARUS, V56, P246, DOI 10.1016/0019-1035(83)90037-4; SACK NJ, 1992, ICARUS, V100, P534, DOI 10.1016/0019-1035(92)90116-O; SMITH BA, 1979, SCIENCE, V206, P927, DOI 10.1126/science.206.4421.927; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; STANIER RY, 1986, MICROBIAL WORLD, P22; Swayze G., 1993, B AM ASTRON SOC, V25, P1033; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206; WISCOMBE WJ, 1980, J ATMOS SCI, V37, P2712, DOI 10.1175/1520-0469(1980)037<2712:AMFTSA>2.0.CO;2	60	298	305	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 22	1998	280	5367					1242	1245		10.1126/science.280.5367.1242	http://dx.doi.org/10.1126/science.280.5367.1242			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596573				2022-12-01	WOS:000073852500042
J	Herzog, KH; Chong, MJ; Kapsetaki, M; Morgan, JI; McKinnon, PJ				Herzog, KH; Chong, MJ; Kapsetaki, M; Morgan, JI; McKinnon, PJ			Requirement for Atm in ionizing radiation-induced cell death in the developing central nervous system	SCIENCE			English	Article							ATAXIA-TELANGIECTASIA; DEFICIENT MICE; P53; APOPTOSIS; CYCLE	Ataxia telangiectasia (AT) is characterized by progressive neurodegeneration that results from mutation of the ATM gene. However, neither the normal function of ATM in the nervous system nor the biological basis of the degeneration in AT is known. Resistance to apoptosis in the developing central nervous system (CNS) of Atm(-/-) mice was observed after ionizing radiation, This lack of death occurred in diverse regions of the CNS, including the cerebellum, which is markedly affected in AT. In wild-type, but not Atm(-/-) mice, up-regulation of p53 coincided with cell death, suggesting that Atm-dependent apoptosis in the CNS is mediated by p53, Further, p53 null mice showed a similar lack of radiation-induced cell death in the developing nervous system, Atm may function at a developmental survival checkpoint that serves to eliminate neurons with excessive DNA damage.	St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38101 USA; St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38101 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	McKinnon, PJ (corresponding author), St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale, Memphis, TN 38101 USA.	peter.mckinnon@stjude.org	Morgan, James/GRO-2905-2022; Morgan, James/N-8104-2018	Morgan, James/0000-0002-8920-1065; 	NCI NIH HHS [CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Cowan W M, 1980, Curr Top Dev Biol, V15 Pt 1, P103; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; Heintz N, 1996, CURR OPIN NEUROL, V9, P137, DOI 10.1097/00019052-199604000-00014; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kuljis RO, 1997, P NATL ACAD SCI USA, V94, P12688, DOI 10.1073/pnas.94.23.12688; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MIDGLEY CA, 1992, J CELL SCI, V101, P183; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Sedgwick RP, 1991, HDB CLIN NEUROLOGY, P347; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SOARES HA, IN PRESS NEUROSCIENC; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; WOOD KA, 1995, J NEUROSCI, V15, P5851; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437	29	359	372	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1089	1091		10.1126/science.280.5366.1089	http://dx.doi.org/10.1126/science.280.5366.1089			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9582124				2022-12-01	WOS:000073663600050
J	Weil, MD; Lamborn, K; Edwards, MSB; Wara, WM				Weil, MD; Lamborn, K; Edwards, MSB; Wara, WM			Influence of a child's sex on medulloblastoma outcome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADIATION-THERAPY; ADJUVANT CHEMOTHERAPY; PEDIATRIC-PATIENTS; SURVIVAL; TUMORS; VINCRISTINE; IRRADIATION; PATTERNS; GROWTH; TRIAL	Context.-Aggressive treatment of medulloblastoma, the most common pediatric brain tumor, has not improved survival. Identifying better prognostic indicators may warrant less morbid therapy. Objective.-To investigate the role of sex on outcome of medulloblastoma. Design.-Retrospective study of significant factors for survival with a median follow-up of 82 months. Setting.-University medical center. Patients.-A total of 109 consecutive, pediatric patients treated for primary medulloblastoma from 1970 to 1995 with surgery and postoperative radiotherapy and, after 1979, chemotherapy. Main Outcome Measures.-Factors independently associated with survival. Results.-The final multivariate model predicting improved survival included sex (hazard ratio, 0.52; 95% confidence interval [CI], 0.29-0.92; P=.03; favoring female), metastases at presentation (hazard ratio, 2.01,95% CI, 1.14-3.52; P=.02), and extent of surgical resection (hazard ratio, 0.60; 95% CI, 0.34-1.04; P=.07; favoring greater resection). The overall, 5-year freedom from progression was 40% and survival was 49%. Radiotherapy dose (P=.72), and chemotherapy (P=.90) did not significantly affect a disease outcome. Conclusions.-The sex of the child was an important predictor for survival of medulloblastoma; girls had a much better outcome. The difference in survival between sexes should be evaluated in prospective, clinical trials.	Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weil, MD (corresponding author), Univ Colorado, Ctr Canc, Dept Radiat Oncol, Box A031, Denver, CO 80262 USA.							AGARD ET, 1985, HEALTH PHYS, V48, P447, DOI 10.1097/00004032-198504000-00007; BLOOM HJG, 1969, AMER J ROENTGENOL RA, V105, P43, DOI 10.2214/ajr.105.1.43; BOURNE JP, 1992, J NEURO-ONCOL, V14, P263; BROWN IH, 1983, ARCH DIS CHILD, V58, P722, DOI 10.1136/adc.58.9.722; COX DR, 1972, J R STAT SOC B, V34, P187; Danjoux CE, 1996, MED PEDIATR ONCOL, V26, P1, DOI 10.1002/(SICI)1096-911X(199601)26:1<1::AID-MPO1>3.0.CO;2-Q; DIDCOCK E, 1995, J CLIN ONCOL, V13, P2503, DOI 10.1200/JCO.1995.13.10.2503; DUFFNER PK, 1985, CANCER-AM CANCER SOC, V56, P1841, DOI 10.1002/1097-0142(19851001)56:7+<1841::AID-CNCR2820561325>3.0.CO;2-C; EVANS AE, 1990, J NEUROSURG, V72, P572, DOI 10.3171/jns.1990.72.4.0572; FARWELL JR, 1984, J NEUROSURG, V61, P657, DOI 10.3171/jns.1984.61.4.0657; GARTON GR, 1990, MAYO CLIN PROC, V65, P1077, DOI 10.1016/S0025-6196(12)62720-7; HUGHES EN, 1988, CANCER, V61, P1992, DOI 10.1002/1097-0142(19880515)61:10<1992::AID-CNCR2820611011>3.0.CO;2-J; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KHALID H, 1995, CANCER, V75, P2571, DOI 10.1002/1097-0142(19950515)75:10<2571::AID-CNCR2820751026>3.0.CO;2-U; MOSS SD, 1988, NEUROSURGERY, V22, P758; NOVAKOVIC B, 1994, MED PEDIATR ONCOL, V23, P480, DOI 10.1002/mpo.2950230606; PACKER RJ, 1994, J NEUROSURG, V81, P690, DOI 10.3171/jns.1994.81.5.0690; PACKER RJ, 1991, J NEUROSURG, V74, P433, DOI 10.3171/jns.1991.74.3.0433; PRADOS MD, 1994, INT J RADIAT ONCOL, V28, P431, DOI 10.1016/0360-3016(94)90067-1; PRESTONMARTIN S, 1993, NEUROEPIDEMIOLOGY, V12, P270, DOI 10.1159/000110328; SILBER JH, 1992, J CLIN ONCOL, V10, P1390, DOI 10.1200/JCO.1992.10.9.1390; TAIT DM, 1990, EUR J CANCER, V26, P464; WARA WM, 1994, INT J RADIAT ONCOL, V30, P551, DOI 10.1016/0360-3016(92)90940-J	23	60	60	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1998	279	18					1474	1476		10.1001/jama.279.18.1474	http://dx.doi.org/10.1001/jama.279.18.1474			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL718	9600483	Bronze			2022-12-01	WOS:000073463500038
J	Epping-Jordan, MP; Watkins, SS; Koob, GF; Markou, A				Epping-Jordan, MP; Watkins, SS; Koob, GF; Markou, A			Dramatic decreases in brain reward function during nicotine withdrawal	NATURE			English	Article							ABSTINENCE SYNDROME; NUCLEUS-ACCUMBENS; SMOKING CESSATION; RAT; STIMULATION; DEPENDENCE; ANTAGONIST; TOLERANCE; THRESHOLD; INFUSION	Tobacco smoking is a worldwide public health problem. In the United States alone, over 400,000 deaths and $50 billion in medical costs annually are directly attributed to smoking(1). Accumulated evidence indicates that nicotine is the component of tobacco smoke that leads to addiction(2), but the means by which nicotine produces addiction remain unclear. Nicotine is less effective as a positive reinforcer than other drugs of abuse in non-dependent animals(3). Nevertheless, nicotine-withdrawal symptoms, including depressed mood, anxiety, irritability and craving(4,5) in dependent subjects may contribute to the addictive liability of nicotine(6,7). We show here that spontaneous nicotine withdrawal in rats resulted in a significant decrease in brain reward function, as measured by elevations in brain reward thresholds, which persisted for four days. Further, systemic injections of a competitive nicotinic-receptor antagonists led to a dose-dependent increase in brain reward thresholds in chronic nicotine-treated rats. The decreased function in brain reward systems during nicotine withdrawal is comparable in magnitude and duration to that of other major drugs of abuse(9-13), and may constitute an important motivational factor that contributes to craving, relapse and continued tobacco consumption in humans(7).	Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA	Scripps Research Institute	Markou, A (corresponding author), Scripps Res Inst, Dept Neuropharmacol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552				BAUCO P, 1994, J PHARMACOL EXP THER, V271, P294; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; DAMAJ MI, 1995, PSYCHOPHARMACOLOGY, V117, P67, DOI 10.1007/BF02245100; DOHERTY K, 1995, PSYCHOPHARMACOLOGY, V119, P171, DOI 10.1007/BF02246158; GELLERT VF, 1978, J PHARMACOL EXP THER, V205, P536; Hildebrand BE, 1997, PSYCHOPHARMACOLOGY, V129, P348, DOI 10.1007/s002130050200; HUGHES JR, 1992, HEALTH PSYCHOL, V11, P331, DOI 10.1037/0278-6133.11.5.331; HUGHES JR, 1991, ARCH GEN PSYCHIAT, V48, P52; HUSTONLYONS D, 1992, PHARMACOL BIOCHEM BE, V41, P755, DOI 10.1016/0091-3057(92)90223-3; KILLEN JD, 1991, PSYCHOPHARMACOLOGY, V105, P191, DOI 10.1007/BF02244308; KORNETSKY C, 1979, FED PROC, V38, P2473; LEITH NJ, 1976, PSYCHOPHARMACOLOGIA, V46, P19, DOI 10.1007/BF00421544; MALARCHER AM, 1997, MMWR-MORBID MORTAL W, V46, P444; MALIN DH, 1993, PSYCHOPHARMACOLOGY, V112, P339, DOI 10.1007/BF02244930; MALIN DH, 1994, PSYCHOPHARMACOLOGY, V115, P180, DOI 10.1007/BF02244770; MALIN DH, 1992, PHARMACOL BIOCHEM BE, V43, P779, DOI 10.1016/0091-3057(92)90408-8; MARKOU A, 1992, PHYSIOL BEHAV, V51, P111, DOI 10.1016/0031-9384(92)90211-J; MARKOU A, 1991, NEUROPSYCHOPHARMACOL, V4, P17; Markou A, 1998, NEUROPSYCHOPHARMACOL, V18, P135, DOI 10.1016/S0893-133X(97)00113-9; MENDELSON JH, 1979, NEW ENGL J MED, V301, P912, DOI 10.1056/NEJM197910253011704; MURRIN LC, 1987, LIFE SCI, V40, P1699, DOI 10.1016/0024-3205(87)90020-8; NISELL M, 1994, PHARMACOL TOXICOL, V75, P348, DOI 10.1111/j.1600-0773.1994.tb00373.x; OKAMOTO M, 1976, EUR J PHARMACOL, V40, P107, DOI 10.1016/0014-2999(76)90360-5; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; RISNER ME, 1983, J PHARMACOL EXP THER, V224, P319; SCHULTEIS G, 1995, P NATL ACAD SCI USA, V92, P5880, DOI 10.1073/pnas.92.13.5880; SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391; Shiffman S, 1996, J CONSULT CLIN PSYCH, V64, P993, DOI 10.1037/0022-006X.64.5.993; STOLERMAN IP, 1995, PSYCHOPHARMACOLOGY, V117, P2, DOI 10.1007/BF02245088; *US DEP HHS, 1988, HLTH CONS SMOK NIC A	30	524	536	2	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1998	393	6680					76	79		10.1038/30001	http://dx.doi.org/10.1038/30001			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590692				2022-12-01	WOS:000073497500050
J	Taylor, S; Lever, JH; Harvey, RP				Taylor, S; Lever, JH; Harvey, RP			Accretion rate of cosmic spherules measured at the South Pole	NATURE			English	Article							DEEP-SEA SEDIMENTS; NATURAL-CONVECTION; MASS-DISTRIBUTION; BLUE ICE; DUST; ANTARCTICA; GREENLAND; INFLUX; WATER	Micrometeorites are terrestrially collected, extraterrestrial particles smaller than about 1 mm, which account for most of the mass being accreted to the Earth(1,2). Compared with meteorites, micrometeorites more completely represent the Earth-crossing meteoroid complex(3,4) and should include fragments of asteroids, comets, Mars and our Moon, as well as pre-solar and interstellar grains(3,6). Previous measurements of the flux of micrometeoroids that survive to the Earth's surface have large uncertainties owing to the destruction of particles by weathering(7-9), inefficiencies in magnetic collection or separation techniques(7-9), low particle counts(10,11), poor age constraint(7-9,12,13) or highly variable concentrating processes(12,13), Here we describe an attempt to circumvent these problems through the collection of thousands of well preserved and dated micrometeorites from the bottom of the South Pole water well, which supplies drinking water for the Scott-Amundsen station. Using this collection, we have determined precise estimates of the flu and mass distribution for 50-700-mu m cosmic spherules (melted micrometeorites). Allowing for the expected abundance of unmelted micrometeorites(1)4 in the samples, our results indicate that about 90% of the incoming mass of submillimetre particles evaporates during atmospheric entry. Our data indicate the loss of glass-rich and small stony spherules from deep-sea deposits(7,8), and they provide constraints for models describing the survival probability of micrometeoroids(15,16).	USA, Cold Reg Res & Engn Lab, Hanover, NH 03755 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	United States Department of Defense; United States Army; U.S. Army Corps of Engineers; U.S. Army Engineer Research & Development Center (ERDC); Cold Regions Research & Engineering Laboratory (CRREL); Case Western Reserve University	Lever, JH (corresponding author), USA, Cold Reg Res & Engn Lab, 72 Lyme Rd, Hanover, NH 03755 USA.	jlever@crrel.usace.army.mil						BLANCHARD MB, 1980, EARTH PLANET SC LETT, V46, P178, DOI 10.1016/0012-821X(80)90004-7; Bradley J. P., 1988, METEORITES EARLY SOL, P861; Brownlee D. E., 1993, 24 LUN PLAN SCI C, P205; Brownlee DE, 1997, METEORIT PLANET SCI, V32, P157, DOI 10.1111/j.1945-5100.1997.tb01257.x; BROWNLEE DE, 1981, SEA, pCH19; FIREMAN EL, 1965, GEOCHIM COSMOCHIM AC, V29, P21, DOI 10.1016/0016-7037(65)90074-8; *FLUENT INC, 1995, FLUENT VERS 4 3; FLYNN GJ, 1989, ICARUS, V77, P287, DOI 10.1016/0019-1035(89)90091-2; GRUN E, 1985, ICARUS, V62, P244, DOI 10.1016/0019-1035(85)90121-6; HARVEY RP, 1991, P LUNAR PLANET SCI, V21, P569; KOEBERL C, 1989, GEOCHIM COSMOCHIM AC, V53, P937, DOI 10.1016/0016-7037(89)90039-2; Kuivinen K.C., 1982, ANTARCT J US, V17, P89; KYTE FT, 1983, THESIS U CALIFORNIA; LANKFORD KE, 1986, J HEAT TRANS-T ASME, V108, P755, DOI 10.1115/1.3247009; LEVER JH, 1996, LUNAR PLANET SCI, V27, P747; LIN DS, 1987, J HEAT TRANS-T ASME, V109, P899, DOI 10.1115/1.3248201; LOVE SG, 1991, ICARUS, V89, P26, DOI 10.1016/0019-1035(91)90085-8; LOVE SG, 1993, SCIENCE, V262, P550, DOI 10.1126/science.262.5133.550; MAURETTE M, 1991, NATURE, V351, P44, DOI 10.1038/351044a0; MAURETTE M, 1986, SCIENCE, V233, P869, DOI 10.1126/science.233.4766.869; MAURETTE M, 1987, NATURE, V328, P699, DOI 10.1038/328699a0; MAURETTE M, 1990, MANTLE METEORITES, P87; MCCORKELL RH, 1970, INT ASS SCI HYDROL, V86, P25; MURRELL MT, 1980, GEOCHIM COSMOCHIM AC, V44, P2067, DOI 10.1016/0016-7037(80)90204-5; PENG HC, 1989, METEORITICS, V24, P315; PeuckerEhrenbrink B, 1996, GEOCHIM COSMOCHIM AC, V60, P3187, DOI 10.1016/0016-7037(96)00161-5; TAYLOR S, 1997, 971 COLD REG RES ENG; VANONI VA, 1975, ASCE MANUALS REPORTS, V54, P91; YIOU F, 1987, METEORITICS, V22, P539; YIOU F, 1989, METEORITICS, V24, P344	30	156	158	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					899	903		10.1038/31894	http://dx.doi.org/10.1038/31894			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582069				2022-12-01	WOS:000073359900041
J	Balaban, N; Goldkorn, T; Nhan, RT; Dang, LB; Scott, S; Ridgley, RM; Rasooly, A; Wright, SC; Larrick, JW; Rasooly, R; Carlson, JR				Balaban, N; Goldkorn, T; Nhan, RT; Dang, LB; Scott, S; Ridgley, RM; Rasooly, A; Wright, SC; Larrick, JW; Rasooly, R; Carlson, JR			Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus	SCIENCE			English	Article							REGULATORY RNA MOLECULE; PSEUDOMONAS-AERUGINOSA; RESISTANCE	Staphylococcus aureus causes pathologies ranging from minor skin infections to life-threatening diseases. Pathogenic effects are largely due to production of bacterial toxin, which is regulated by an RNA molecule, RNAIII. The S. aureus protein called RAP (RNAIII activating protein) activates RNAIII, and a peptide called RIP (RNAIII inhibiting peptide), produced by a nonpathogenic bacteria, inhibits RNAIII. Mice vaccinated with RAP or treated with purified or synthetic RIP were protected from S. aureus pathology. Thus, these two molecules may provide useful approaches for the prevention and treatment of diseases caused by S. aureus.	Univ Calif Davis, Dept Med Pathol, Davis, CA 95616 USA; Univ Calif Davis, Davis Med Ctr, Dept Internal Med, Davis, CA 95616 USA; Univ Maryland, Dept Microbiol, College Pk, MD 20742 USA; Palo Alto Inst Mol Med, Mt View, CA 94043 USA	University of California System; University of California Davis; University of California System; University of California Davis; University System of Maryland; University of Maryland College Park	Balaban, N (corresponding author), Univ Calif Davis, Dept Med Pathol, Davis, CA 95616 USA.	nbalaban@ucdavis.edu	Rasooly, Avraham/AAH-4518-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI040830] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40830] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTHUR M, 1993, ANTIMICROB AGENTS CH, V37, P1563, DOI 10.1128/AAC.37.8.1563; BALABAN N, 1995, FEMS MICROBIOL LETT, V133, P155, DOI 10.1016/0378-1097(95)00356-A; BALABAN N, 1995, P NATL ACAD SCI USA, V92, P1619, DOI 10.1073/pnas.92.5.1619; BUNCE C, 1992, INFECT IMMUN, V60, P2636, DOI 10.1128/IAI.60.7.2636-2640.1992; GUANGYONG J, 1995, P NATL ACAD SCI USA, V92, P12055; Lee JC, 1996, TRENDS MICROBIOL, V4, P162, DOI 10.1016/0966-842X(96)10021-4; MAGNUSON R, 1994, CELL, V77, P207, DOI 10.1016/0092-8674(94)90313-1; MOERFELDT E, 1995, EMBO J, V14, P4569; NASO R, 1996, NOVEL STRATEGIES DES, P133; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582; PEARSON JP, 1995, P NATL ACAD SCI USA, V92, P1490, DOI 10.1073/pnas.92.5.1490; RAPPUOLI R, 1995, SIGNAL TRANSDUCTION, P1; ROYCHOUDHURY S, 1993, P NATL ACAD SCI USA, V90, P965, DOI 10.1073/pnas.90.3.965; SILVERSTEIN SC, 1990, MICROBIOLOGY, P485; Swift Simon, 1994, Trends in Microbiology, V2, P193, DOI 10.1016/0966-842X(94)90110-Q; WEST TE, 1985, J CLIN MICROBIOL, V21, P490, DOI 10.1128/JCM.21.4.490-492.1985	18	177	210	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					438	440		10.1126/science.280.5362.438	http://dx.doi.org/10.1126/science.280.5362.438			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545222				2022-12-01	WOS:000073159600048
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Beauty in simplicity	SCIENCE			English	Article									Harvard Univ, Sch Med, Boston, MA 02115 USA; NCI, Bethesda, MD 20892 USA	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Peters, R (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Arras M, 1998, NAT BIOTECHNOL, V16, P159, DOI 10.1038/nbt0298-159; BATTLER A, 1993, J AM COLL CARDIOL, V22, P2001, DOI 10.1016/0735-1097(93)90790-8; ITO W, COMMUNICATION	3	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					456	457						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9575088				2022-12-01	WOS:000073159600055
J	Veazey, RS; DeMaria, M; Chalifoux, LV; Shvetz, DE; Pauley, DR; Knight, HL; Rosenzweig, M; Johnson, RP; Desrosiers, RC; Lackner, AA				Veazey, RS; DeMaria, M; Chalifoux, LV; Shvetz, DE; Pauley, DR; Knight, HL; Rosenzweig, M; Johnson, RP; Desrosiers, RC; Lackner, AA			Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; INTESTINAL LAMINA PROPRIA; RHESUS-MONKEYS; HIV-INFECTION; NEF GENE; LYMPHOCYTES; MACAQUES; ANTIGEN; AIDS; EXPRESSION	Human and simian immunodeficiency virus (HIV and SIV) replicate optimally in activated memory CD4(+) T cells, a cell type that is abundant in the intestine. SIV infection of rhesus monkeys resulted in profound and selective depletion of CD4(+) T cells in the intestine within days of infection, before any such changes in peripheral lymphoid tissues. The loss of CD4(+) T cells in the intestine occurred coincident with productive infection of large numbers of mononuclear cells at this site. The intestine appears to be a major target for SIV replication and the major site of CD4(+) T cell loss in early SIV infection.	Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Southborough, MA 01772 USA	Harvard University	Lackner, AA (corresponding author), Harvard Univ, New England Reg Primate Res Ctr, Sch Med, 1 Pine Hill Dr,POB 9102, Southborough, MA 01772 USA.	alackner@warren.med.harvard.edu	Abrams, William R/A-5782-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI025328, R01AI025328, R01AI038559] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050550] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38559, AI25328] Funding Source: Medline; NIDDK NIH HHS [DK50550] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amadori A, 1996, IMMUNOL TODAY, V17, P414, DOI 10.1016/0167-5699(96)10049-9; CERFBENSUSSAN N, 1991, GASTROENTEROL CLIN N, V20, P549; Clayton F, 1997, CLIN EXP IMMUNOL, V107, P288, DOI 10.1111/j.1365-2249.1997.236-ce1111.x; CLAYTON F, 1992, GASTROENTEROLOGY, V103, P919, DOI 10.1016/0016-5085(92)90026-U; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DESROSIERS RC, 1989, INTERVIROLOGY, V30, P301, DOI 10.1159/000150108; HEISE C, 1993, AM J PATHOL, V142, P1759; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HORVATH CJ, 1993, J LEUKOCYTE BIOL, V53, P532, DOI 10.1002/jlb.53.5.532; ILYINSKII PO, 1994, J VIROL, V68, P5933, DOI 10.1128/JVI.68.9.5933-5944.1994; KAWAI T, 1994, TRANSPLANT P, V26, P1845; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KRAEHENBUHL JP, 1992, PHYSIOL REV, V72, P853, DOI 10.1152/physrev.1992.72.4.853; Lackner A A, 1994, Curr Top Microbiol Immunol, V188, P35; Lane JH, 1996, AM J PATHOL, V149, P1097; LIM SG, 1993, CLIN EXP IMMUNOL, V92, P448, DOI 10.1111/j.1365-2249.1993.tb03419.x; MacDonald TT, 1994, GASTROINTESTINAL HEP, P1; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MORI K, 1992, J VIROL, V66, P2067, DOI 10.1128/JVI.66.4.2067-2075.1992; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; REIMANN KA, 1994, J VIROL, V68, P2362, DOI 10.1128/JVI.68.4.2362-2370.1994; RODGERS VD, 1986, GASTROENTEROLOGY, V90, P552, DOI 10.1016/0016-5085(86)91108-X; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; Sasseville VG, 1996, AM J PATHOL, V149, P163; SCHIEFERDECKER HL, 1992, J IMMUNOL, V149, P2816; SCHNEIDER T, 1994, CLIN EXP IMMUNOL, V95, P430, DOI 10.1111/j.1365-2249.1994.tb07014.x; SCHNEIDER T, 1995, GUT, V37, P524, DOI 10.1136/gut.37.4.524; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SCHRAPPEBACHER M, 1990, J ACQ IMMUN DEF SYND, V3, P238; VANNOESEL CJ, 1990, J CLIN INVEST, V86; Veazey RS, 1997, CLIN IMMUNOL IMMUNOP, V82, P230, DOI 10.1006/clin.1996.4318; VEAZEY RS, UNPUB; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZEITZ M, 1988, GASTROENTEROLOGY, V94, P647, DOI 10.1016/0016-5085(88)90235-1	35	1139	1169	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					427	431		10.1126/science.280.5362.427	http://dx.doi.org/10.1126/science.280.5362.427			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9545219				2022-12-01	WOS:000073159600045
J	Nelson, K; Brown, ME; Lurie, N				Nelson, K; Brown, ME; Lurie, N			Hunger in an adult patient population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITALIZED-PATIENTS; FOOD INSECURITY; MALNUTRITION	Context.-Although clinical observations suggest that some patients experience hunger and food insecurity, there are limited data on the prevalence of hunger in adult patients. Objective.-To determine the prevalence of hunger and food insecurity in adult patients at an urban county hospital. Design.-Cross-sectional survey conducted in 1997. Patients.-The primary survey included all patients aged 18 years or older who were admitted to the medicine, surgery, and neurology services during a 2-week period, and all patients who attended the hospital's general medicine clinic during 1 week. A second survey included primary care patients who received insulin from the hospital pharmacy during a 1-month period. Main Outcome Measures.-Rates of hunger and food insecurity. Results.-Of 709 eligible patients, 567 (participation rate, 80%) were interviewed in either the clinic (n=281) or hospital (n=286). An additional 170 patients who received insulin were interviewed by telephone (response rate, 75%). Of the primary sample, 68 (12%) respondents reported not having enough food, 75 (13%) reported not eating for an entire day, acid 77 (14%) reported going hungry but not eating because they could not afford food. A total of 222 (40%) had received food stamps in the previous year and of those, 113 (50%) had their food stamps reduced or eliminated. Recipients whose food stamps had been eliminated or reduced were more likely to report not having enough food (18% vs 13%, P=.006), not eating for a whole day (20% vs 16%, P=.01), going hungry but not eating (20% vs 16%, P=.08), and cutting down on the size of meals or skipping meals (33% vs 27%, P=.01). In multivariate analysis, independent predictors of hunger included an annual income of less than $10 000 (odds ratio [OR], 7.55; 95% CI, 3.01-18.92), drug use (OR, 3.56; 95% CI, 1.46-8.66), and a reduction in food stamp benefits (OR, 1.73; 95% CI, 1.01-2.96). Predictors of food insecurity included an annual income of less than $10 000 (OR, 4.12; 95% confidence interval [CI], 1.98-8.58), drug use (OR, 2.11; 95% CI, 1.66-5.08), and a reduction in food stamps (OR, 2.02; 95% CI, 1.23-3.32). In addition, 103 (61%) patients in the sample of diabetics reported hypoglycemic reactions; 32 (31%) of these were attributed to inability to afford food. Conclusion.-Hunger and food insecurity are common among patients seeking care at an urban county hospital.	Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA; Univ Minnesota, Sch Publ Hlth, Inst Hlth Serv Res, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Lurie, N (corresponding author), Univ Minnesota, Sch Med, Dept Med, 420 Delaware St SE,Box 741, Minneapolis, MN 55455 USA.							BROWN JL, 1988, ANNU REV PUBL HEALTH, V9, P503; CAMPBELL CC, 1991, J NUTR, V121, P408, DOI 10.1093/jn/121.3.408; Cohen B. E., 1990, NUTR TODAY, V25, P23, DOI DOI 10.1097/00017285-199007000-00004; EDMUND EJ, 1994, ADV DATA VITAL HLTH, V278; EPSTEIN AM, 1988, NEW ENGL J MED, V318, P1579, DOI 10.1056/NEJM198806163182405; GURALNIK JM, 1993, NEW ENGL J MED, V329, P110, DOI 10.1056/NEJM199307083290208; HAMILTON WL, 1997, MEASURING FOOD SECUR; KENDALL A, 1995, J NUTR, V125, P2793; KINSEY JD, 1994, J NUTR, V124, pS1878, DOI 10.1093/jn/124.suppl_9.1878S; Maslow, 1954, MOTIVATION PERSONALI; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; *PHYS TASK FOR HUN, 1985, HUNG AM GROW EP; PINCUS T, 1994, J CLIN EPIDEMIOL, V47, P355, DOI 10.1016/0895-4356(94)90156-2; ROSENBERG E, 1992, SOC WORK HEALTH CARE, V16, P83, DOI 10.1300/J010v16n03_08; ROUBENOFF R, 1987, ARCH INTERN MED, V147, P1462, DOI 10.1001/archinte.147.8.1462; SMITH AD, 1997, BRIT MED J, V314, P547; STEFFEE WP, 1980, JAMA-J AM MED ASSOC, V244, P2630, DOI 10.1001/jama.244.23.2630; UVIN P, 1994, NUTR REV, V52, P151, DOI 10.1111/j.1753-4887.1994.tb01411.x; WILLIAMS MV, 1995, JAMA-J AM MED ASSOC, V274, P1677	19	82	85	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1998	279	15					1211	1214		10.1001/jama.279.15.1211	http://dx.doi.org/10.1001/jama.279.15.1211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG133	9555762	Bronze			2022-12-01	WOS:000072969400036
J	Golbe, LI				Golbe, LI			Pallidotomy for Parkinson's disease: hitting the target?	LANCET			English	Editorial Material									Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Golbe, LI (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08901 USA.							Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Fazzini E, 1997, NEUROLOGY, V48, P1273, DOI 10.1212/WNL.48.5.1273; Kishore A, 1997, BRAIN, V120, P729, DOI 10.1093/brain/120.5.729; Lang AE, 1997, NEW ENGL J MED, V337, P1036, DOI 10.1056/NEJM199710093371503; Ondo WG, 1998, NEUROLOGY, V50, P266, DOI 10.1212/WNL.50.1.266; Samuel M, 1998, BRAIN, V121, P59, DOI 10.1093/brain/121.1.59; Shannon KM, 1998, NEUROLOGY, V50, P434, DOI 10.1212/WNL.50.2.434	7	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					998	999		10.1016/S0140-6736(98)22014-9	http://dx.doi.org/10.1016/S0140-6736(98)22014-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546498				2022-12-01	WOS:000072927200002
J	Bennett, CL; Weinberg, PD; Rozenberg-Ben-Dror, K; Yarnold, PR; Kwaan, HC; Green, D				Bennett, CL; Weinberg, PD; Rozenberg-Ben-Dror, K; Yarnold, PR; Kwaan, HC; Green, D			Thrombotic thrombocytopenic purpura associated with ticlopidine - A review of 60 cases	ANNALS OF INTERNAL MEDICINE			English	Review							BINDING; ADP; RAT	Background: Thrombotic thrombocytopenic purpura, a life-threatening multisystem disease, has been infrequently associated with use of ticlopidine, a platelet antiaggregating agent. Purpose: To review 60 cases of ticlopidine-associated thrombotic thrombocytopenic purpura. Data Sources: Medical records, published case reports, and case reports submitted to the U.S. Food and Drug Administration. Study Selection: Instances of ticlopidine-associated thrombotic thrombocytopenic purpura were identified. Data Synthesis: Ticlopidine had been prescribed for less than 1 month in 80% of the patients, and normal platelet counts had been found within 2 weeks of the onset of thrombotic thrombocytopenic purpura in most patients. Mortality rates were higher among patients who were not treated with plasmapheresis than amog those who underwent plasmapheresis (50% compared with 24%; P<0.05). Conclusions: Ticlopidine use may be associated with the development of thrombotic thrombocytopenic purpura, usually within 1 month of initiation of therapy. The onset of ticlopidine-associated thrombotic thrombocytopenic purpura is difficult to predict, despite close monitoring of platelet counts.	Chicago Vet Affairs Healthcare Syst, Lakeside Div, Chicago, IL 60611 USA; Northwestern Univ, Chicago, IL 60611 USA	Northwestern University	Bennett, CL (corresponding author), Vet Affairs Med Sci Bldg,205,400 E Ontario, Chicago, IL 60611 USA.		Bennett, Charles L/C-2050-2008	Yarnold, Paul/0000-0002-1648-739X				Ariyoshi K, 1997, AM J HEMATOL, V54, P175; BELL WR, 1991, NEW ENGL J MED, V325, P398, DOI 10.1056/NEJM199108083250605; CAPRA R, 1992, ACTA NEUROL BELG, V92, P83; DEFREYN G, 1989, SEMIN THROMB HEMOST, V15, P159, DOI 10.1055/s-2007-1002699; deMaat MPM, 1996, THROMB HAEMOSTASIS, V76, P166; ELLIE E, 1992, STROKE, V23, P922, DOI 10.1161/01.STR.23.6.922; GACHET C, 1990, BIOCHEM PHARMACOL, V40, P229, DOI 10.1016/0006-2952(90)90683-C; Gordon LI, 1997, SEMIN HEMATOL, V34, P140; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; Kodama K, 1996, Rinsho Ketsueki, V37, P1334; KOVACS MJ, 1993, ANN PHARMACOTHER, V27, P1060, DOI 10.1177/106002809302700910; Kupfer Y, 1997, NEW ENGL J MED, V337, P1245, DOI 10.1056/NEJM199710233371717; PAGE Y, 1991, LANCET, V337, P774, DOI 10.1016/0140-6736(91)91383-6; PIOVELLA F, 1985, BLOOD, V66, P311; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; ROSE M, 1993, BLOOD REV, V7, P94, DOI 10.1016/S0268-960X(05)80019-0; ROSE M, 1987, AM J MED, V83, P437, DOI 10.1016/0002-9343(87)90753-4; SAVI P, 1994, J PHARMACOL EXP THER, V269, P772; TOROK TJ, 1995, AM J HEMATOL, V50, P84, DOI 10.1002/ajh.2830500203; Wysowksi DK, 1996, JAMA-J AM MED ASSOC, V276, P952, DOI 10.1001/jama.1996.03540120030022	20	297	301	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					541	544		10.7326/0003-4819-128-7-199804010-00004	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518398				2022-12-01	WOS:000072803500004
J	Cao, YQ; Mantyh, PW; Carlson, EJ; Gillespie, AM; Epstein, CJH; Basbaum, AI				Cao, YQ; Mantyh, PW; Carlson, EJ; Gillespie, AM; Epstein, CJH; Basbaum, AI			Primary afferent tachykinins are required to experience moderate to intense pain	NATURE			English	Article							DORSAL HORN NEURONS; SUBSTANCE-P; RECEPTOR; RAT; HYPERALGESIA; INFLAMMATION; INHIBITION; ACTIVATION; GLUTAMATE; FORMALIN	The excitatory neurotransmitter glutamate coexists,vith the peptide known as substance P in primary afferents that respond to painful stimulation(1). Because blockers of glutamate receptors reliably reduce pain behaviour(2-4), it is assumed that 'pain' messages are mediated by glutamate action on dorsal horn neurons, The contribution of substance P, however, is still unclear, We have now disrupted the mouse preprotachykinin A gene (PPT-A), which encodes substance P and a related tachykinin, neurokinin A (ref. 5). We find that although the behavioural response to mildly painful stimuli is intact in these mice, the response to moderate to intense pain is significantly reduced. Neurogenic inflammation, which results from peripheral release of substance P and neurokinin A (ref. 6), is almost absent in the mutant mice. We conclude that the release of tachykinins from primary afferent pain-sensing receptors (nociceptors) is required to produce moderate to intense pain.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Fdn, Ctr Integrat Neurosci, Dept Pediat, San Francisco, CA 94143 USA; Vet Adm Med Ctr, Mol Neurobiol Lab, Minneapolis, MN 55417 USA; Univ Minnesota, Dept Psychiat, Minneapolis, MN 55417 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities	Basbaum, AI (corresponding author), Univ Calif San Francisco, Dept Anat, UCSF Box 0452, San Francisco, CA 94143 USA.	aib@phy.ucsf.edu						Abbadie C, 1997, J NEUROSCI, V17, P8049; AMANN R, 1995, N-S ARCH PHARMACOL, V352, P201; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; DEBIASI S, 1988, P NATL ACAD SCI USA, V85, P7820; DEFELIPE C, 1997, NEUR ABSTR, V23, P2354; DUGGAN AW, 1995, NEUROSCIENCE, V65, P849, DOI 10.1016/0306-4522(94)00541-C; GYIRES K, 1984, ARCH INT PHARMACOD T, V267, P131; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HERRERO JF, 1997, NEUR ABSTR, V23, P2354; HUNTER JC, 1994, NEUROSCI LETT, V174, P217, DOI 10.1016/0304-3940(94)90025-6; HYLDEN JLK, 1992, J NEUROSCI, V12, P1716; KAKO K, 1993, BIOMED RES-TOKYO, V14, P253, DOI 10.2220/biomedres.14.253; LANEUVILLE O, 1988, LIFE SCI, V42, P1295, DOI 10.1016/0024-3205(88)90223-8; Lawson SN, 1997, J PHYSIOL-LONDON, V505, P177, DOI 10.1111/j.1469-7793.1997.00177.x; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MAGGI CA, 1995, GEN PHARMACOL-VASC S, V26, P911, DOI 10.1016/0306-3623(94)00292-U; Malmberg AB, 1997, SCIENCE, V278, P279, DOI 10.1126/science.278.5336.279; MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937; MANTYH PW, 1989, J NEUROSCI, V9, P258; Marvizon JCG, 1997, J NEUROSCI, V17, P8129; MELLER ST, 1993, NEUROREPORT, V4, P879, DOI 10.1097/00001756-199307000-00010; MUNRO FE, 1993, NEUROPEPTIDES, V25, P299, DOI 10.1016/0143-4179(93)90047-E; NAWA H, 1984, NATURE, V312, P729, DOI 10.1038/312729a0; Rupniak NMJ, 1996, PAIN, V67, P189, DOI 10.1016/0304-3959(96)03109-0; RUSIN KI, 1992, J NEUROPHYSIOL, V68, P265, DOI 10.1152/jn.1992.68.1.265; SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265, DOI 10.1111/j.1476-5381.1995.tb15035.x; VIGNA SR, 1994, J NEUROSCI, V14, P834; WILCOX GL, 1991, PAIN RES CL, V4, P97; Zimmer A, 1998, P NATL ACAD SCI USA, V95, P2630, DOI 10.1073/pnas.95.5.2630	29	472	497	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					390	394		10.1038/32897	http://dx.doi.org/10.1038/32897			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537322				2022-12-01	WOS:000072713600052
J	McKinstry, RC; Feinberg, DA				McKinstry, RC; Feinberg, DA			A new window on brain research	SCIENCE			English	Article							SENSORY STIMULATION; MR; STROKE; MOTION		Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Neuroradiol Sect, St Louis, MO 63110 USA	Washington University (WUSTL)	McKinstry, RC (corresponding author), Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Neuroradiol Sect, St Louis, MO 63110 USA.	mckinstry@mirlink.wustl.edu						Binder J, 1997, NEUROSURG CLIN N AM, V8, P383; BLEIER AR, 1991, MAGNET RESON MED, V21, P132, DOI 10.1002/mrm.1910210116; Chen YCI, 1997, MAGNET RESON MED, V38, P389, DOI 10.1002/mrm.1910380306; Davis TL, 1998, P NATL ACAD SCI USA, V95, P1834, DOI 10.1073/pnas.95.4.1834; EHMAN RL, 1997, RADIOLOGY P, V205, P487; ENZMANN DR, 1992, RADIOLOGY, V185, P653, DOI 10.1148/radiology.185.3.1438741; ERNST T, 1994, MAGN RESON MED, V32, P146, DOI 10.1002/mrm.1910320122; FEINBERG D, 1986, RADIOLOGY, V161, P571; FEINBERG DA, 1987, RADIOLOGY, V163, P793, DOI 10.1148/radiology.163.3.3575734; FEINBERG DA, 1995, MAGNET RESON MED, V33, P529, DOI 10.1002/mrm.1910330411; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Hennig J., 1993, MAGMA, V1, P39, DOI 10.1007/BF02660372; Hu XP, 1997, MAGNET RESON MED, V37, P877, DOI 10.1002/mrm.1910370612; Kim SG, 1997, MAGN RESON MED, V38, P59, DOI 10.1002/mrm.1910380110; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Malonek D, 1996, SCIENCE, V272, P551, DOI 10.1126/science.272.5261.551; MANSFIELD P, 1977, J PHYS C SOLID STATE, V10, pL55, DOI 10.1088/0022-3719/10/3/004; MARGOS P, 1986, HLTH CARE INSTR, V1, P295; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; Mueller WM, 1997, NEUROSURG CLIN N AM, V8, P373; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; Ojemann JG, 1997, NEUROIMAGE, V6, P156, DOI 10.1006/nimg.1997.0289; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; PONCELET BP, 1992, RADIOLOGY, V185, P645, DOI 10.1148/radiology.185.3.1438740; ROBERTS DA, 1994, P NATL ACAD SCI USA, V91, P33, DOI 10.1073/pnas.91.1.33; ROSEN BR, 1991, MAGNET RESON MED, V19, P285, DOI 10.1002/mrm.1910190216; SILVERMAN SG, 1995, RADIOLOGY, V197, P175, DOI 10.1148/radiology.197.1.7568819; Sorensen AG, 1996, RADIOLOGY, V199, P391, DOI 10.1148/radiology.199.2.8668784; TURNER R, 1990, J MAGN RESON, V86, P445, DOI 10.1016/0022-2364(90)90023-3; VanEssen DC, 1997, J NEUROSCI, V17, P7079; WARACH S, 1992, NEUROLOGY, V42, P1717, DOI 10.1212/WNL.42.9.1717; Yang YH, 1998, MAGNET RESON MED, V39, P61, DOI 10.1002/mrm.1910390111	33	8	8	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1965	1966		10.1126/science.279.5358.1965	http://dx.doi.org/10.1126/science.279.5358.1965			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9537906				2022-12-01	WOS:000072613300054
J	Lee, A				Lee, A			The Helicobacter pylori genome - New insights into pathogenesis and therapeutics	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ New S Wales, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Lee, A (corresponding author), Univ New S Wales, Sydney, NSW 2052, Australia.							Cohen J, 1997, SCIENCE, V275, P767, DOI 10.1126/science.275.5301.767; Deitsch KW, 1997, MICROBIOL MOL BIOL R, V61, P281, DOI 10.1128/.61.3.281-293.1997; Lee A, 1996, ALIMENT PHARM THER, V10, P129, DOI 10.1046/j.1365-2036.1996.22164013.x; Smith DR, 1996, TRENDS BIOTECHNOL, V14, P290, DOI 10.1016/0167-7799(96)10038-X; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483	5	15	15	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1998	338	12					832	833		10.1056/NEJM199803193381211	http://dx.doi.org/10.1056/NEJM199803193381211			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC163	9504947				2022-12-01	WOS:000072546800011
J	Frankel, S; Gunnell, DJ; Peters, TJ; Maynard, M; Smith, GD				Frankel, S; Gunnell, DJ; Peters, TJ; Maynard, M; Smith, GD			Childhood energy intake and adult mortality from cancer: the Boyd Orr cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; CALORIC RESTRICTION; COLORECTAL-CANCER; RISK-FACTORS; BODY HEIGHT; EARLY-LIFE; DISEASE; WOMEN; DIET; LONGEVITY	Objective: To examine the relation between energy intake in childhood and adult mortality from cancer. Study design: Cohort study. Setting: 16 rural and urban centres in England and Scotland. Subjects: 3834 people who took part in Lord Boyd Orr's Carnegie survey of family diet and health in prewar Britain between 1937 and 1939 who were followed up with the NHS central register. Standardised methods were used to measure household dietary intake during a one week period. Main outcome measures: Cancer mortality. Results: Significant associations between childhood energy intake and cancer mortality were seen when the confounding effects of social variables were taken into account in proportional hazards models (relative hazard for all cancer mortality 1.15 (95% confidence interval 1.06 to 1.24), P = 0.001, for every MJ increase in adult equivalent daily intake in fully adjusted models). This effect was essentially limited to cancers not related to smoking (relative hazard 1.20; 1.07 to 1.34; P = 0.001), with similar effects seen in men and women. Conclusion: This positive association between childhood energy intake and later cancer is consistent with animal evidence linking energy restriction with reduced incidence of cancer and the association between height and human cancer, implying that higher levels of energy intake in childhood increase the risk of later development of cancer. This evidence for long term effects of early diet confirm the importance of optimal nutrition in childhood and suggest that the unfavourable trends seen in die incidence of some cancers may have their origins in early life.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Frankel, S (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	stephen.frankel.@bristol.ac.uk	Davey Smith, George/A-7407-2013; Gunnell, David/ABE-6653-2020	Davey Smith, George/0000-0002-1407-8314; Gunnell, David/0000-0002-0829-6470; Peters, Tim/0000-0003-2881-4180				ALBANES D, 1988, CANCER RES, V48, P1658; ALBANES D, 1990, NUTR CANCER, V14, P69, DOI 10.1080/01635589009514078; ANDERSSON SO, 1995, CANCER EPIDEM BIOMAR, V4, P187; [Anonymous], 1992, DIET REF VAL FOOD EN; BARKER DJP, 1990, ANN HUM BIOL, V17, P1, DOI 10.1080/03014469000000732; BERG BN, 1960, J NUTR, V71, P255; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; *BRIT MED ASS, 1933, REP COMM NUTR; CHUTE CG, 1991, CANCER CAUSE CONTROL, V2, P117, DOI 10.1007/BF00053131; GUNNELL D, 1996, J EPIDEMIOL COMMUNIT, V50, P580; Gunnell DJ, 1996, PUBLIC HEALTH, V110, P85, DOI 10.1016/S0033-3506(96)80052-7; GUNNELL DJ, 1937, IN PRESS PAEDIAT PER; HISLOP TG, 1986, CANCER DETECT PREV, V9, P47; KAGAWA Y, 1978, PREV MED, V7, P205, DOI 10.1016/0091-7435(78)90246-3; KRISTAL BS, 1994, MODULATION AGING PRO, P1; KRITCHEVSKY D, 1995, EUR J CANCER PREV, V4, P445, DOI 10.1097/00008469-199512000-00002; KUNE GA, 1990, NUTR CANCER, V13, P9, DOI 10.1080/01635589009514041; LEON DA, 1995, J EPIDEMIOL COMMUN H, V49, P5, DOI 10.1136/jech.49.1.5; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; PALMER JR, 1995, AM J EPIDEMIOL, V141, P845, DOI 10.1093/oxfordjournals.aje.a117520; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; PRYOR M, 1989, CANCER RES, V49, P2161; ROSS MH, 1971, J NATL CANCER I, V47, P1095; Rous P, 1914, J EXP MED, V20, P433, DOI 10.1084/jem.20.5.433; SHIMOKAWA I, 1991, J GERONTOL, V46, pB228, DOI 10.1093/geronj/46.6.B228; SHIMOKAWA I, 1994, MODULATION AGING PRO, P247; STAT, 1996, STAT SOFTW REL 5 0; Tannenbaum A, 1940, ARCH PATHOL, V30, P509; TANNER JM, 1982, ANN HUM BIOL, V9, P411, DOI 10.1080/03014468200005951; Thorling EB, 1996, NUTR RES, V16, P315, DOI 10.1016/0271-5317(96)00015-2; Tretli S, 1996, CANCER CAUSE CONTROL, V7, P507, DOI 10.1007/BF00051882; VALLEJO EA, 1956, REV CLIN ESP, V63, P25; VATTEN LJ, 1990, BRIT J CANCER, V61, P881, DOI 10.1038/bjc.1990.197; Vatten LJ, 1996, BREAST, V5, P5, DOI 10.1016/S0960-9776(96)90042-9; WEINDRUCH R, 1992, EXP GERONTOL, V27, P575, DOI 10.1016/0531-5565(92)90012-O; YU BP, 1982, J GERONTOL, V37, P130, DOI 10.1093/geronj/37.2.130	38	134	136	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	1998	316	7130					499	504		10.1136/bmj.316.7130.499	http://dx.doi.org/10.1136/bmj.316.7130.499			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501710	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000072097400017
J	Westphal, RS; Anderson, KA; Means, AR; Wadzinski, BE				Westphal, RS; Anderson, KA; Means, AR; Wadzinski, BE			A signaling complex of Ca2+-calmodulin-dependent protein kinase IV and protein phosphatase 2A	SCIENCE			English	Article							TRANSCRIPTION FACTOR NFAT1; T-LYMPHOCYTES; CREB; PHOSPHORYLATION; ACTIVATION; AUTOPHOSPHORYLATION; DEPHOSPHORYLATION; PROLIFERATION; EXPRESSION; ANTIGENS	Stimulation of T lymphocytes results in a rapid increase in intracellular calcium concentration ([Ca2+](i)) that parallels the activation of Ca2+-calmodulin-dependent protein kinase IV (CaMKIV), a nuclear enzyme that can phosphorylate and activate the cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB). However, inactivation of CaMKIV occurs despite the sustained increase in [Ca2+](i) that is required for T cell activation. A stable and stoichiometric complex of CaM KIV with protein serine-threonine phosphatase 2A (PP2A) was identified in wh ich PP2A dephosphorylates CaMKIV and functions as a negative regulator of CaMKIV signaling. In Jurkat T cells, inhibition of PP2A activity by small t antigen enhanced activation of CREB-mediated transcription by CaMKIV. These findings reveal an intracellular signaling mechanism whereby a protein serine-threonine kinase (CaMKIV) is regulated by a tightly associated protein serine-threonine phosphatase (PP2A).	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Vanderbilt University; Duke University	Wadzinski, BE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA.				NICHD NIH HHS [HD07503] Funding Source: Medline; NIGMS NIH HHS [GM51366, GM33976] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976, R01GM051366, R56GM051366] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON K, UNPUB; Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; KAMESHITA I, 1993, J BIOCHEM-TOKYO, V113, P583, DOI 10.1093/oxfordjournals.jbchem.a124087; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WESTPHAL R, UNPUB	32	219	226	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 22	1998	280	5367					1258	1261		10.1126/science.280.5367.1258	http://dx.doi.org/10.1126/science.280.5367.1258			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596578				2022-12-01	WOS:000073852500047
J	Zuany-Amorim, C; Ruffie, C; Haile, S; Vargaftig, BB; Pereira, P; Pretolani, M				Zuany-Amorim, C; Ruffie, C; Haile, S; Vargaftig, BB; Pereira, P; Pretolani, M			Requirement for gamma delta T cells in allergic airway inflammation	SCIENCE			English	Article							EOSINOPHILIC INFLAMMATION; IMMUNE-RESPONSES; TRANSGENIC MICE; IN-VIVO; ASTHMA; INTERLEUKIN-4; IGE; RECRUITMENT; LYMPHOCYTE; THYMOCYTES	The factors that contribute to allergic asthma are unclear but the resulting condition is considered a consequence of a type-2 T helper (T(H)2) cell response. In a model of pulmonary allergic inflammation, mice that lacked gamma delta T cells had decreases in specific immunoglobulin E (IgE) and IgG1 and pulmonary interleukin-5 (IL-5) release as well as in eosinophil and T cell infiltration compared with wild-type mice. These responses were restored by administration of IL-4 to gamma delta T cell-deficient mice during the primary immunization. Thus, gamma delta T cells are essential for inducing IL-4-dependent IgE and IgG1 responses and for T(H)2-mediated airway inflammation to peptidic antigens.	Inst Pasteur, Unite Pharmacol Cellulaire, U485, Paris, France; Inst Pasteur, Immunol Unit, CNRS, URA 1961, Paris, France; Inst Pasteur, Hepatol Unit, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Pretolani, M (corresponding author), Inst Pasteur, Unite Pharmacol Cellulaire, U485, Paris, France.		Pereira, Pablo/M-7224-2014; Pretolani, Marina/G-6643-2017; Vargaftig, Bernardo Boris B.B.J./C-3323-2013	Pereira, Pablo/0000-0003-1784-2776				ARASE H, 1993, EUR J IMMUNOL, V23, P307, DOI 10.1002/eji.1830230151; Azuara V, 1997, EUR J IMMUNOL, V27, P544, DOI 10.1002/eji.1830270228; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425, DOI 10.1165/ajrcmb.14.5.8624247; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Brown DR, 1996, J EXP MED, V184, P1295, DOI 10.1084/jem.184.4.1295; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; CORRY DB, 1996, J EXP MED, V183, P1; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54, DOI 10.1165/ajrcmb.13.1.7598937; ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588; Eum SY, 1995, P NATL ACAD SCI USA, V92, P12290, DOI 10.1073/pnas.92.26.12290; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404, DOI 10.1165/ajrcmb.12.4.7695919; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; VAJDY M, 1995, J EXP MED, V181, P41, DOI 10.1084/jem.181.1.41; Vicari AP, 1996, EUR J IMMUNOL, V26, P1424, DOI 10.1002/eji.1830260704; Wen L, 1996, J EXP MED, V183, P2271, DOI 10.1084/jem.183.5.2271; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; Zhang Y, 1996, J EXP MED, V184, P1507, DOI 10.1084/jem.184.4.1507; ZuanyAmorim C, 1996, J IMMUNOL, V157, P377; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	28	227	236	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 22	1998	280	5367					1265	1267		10.1126/science.280.5367.1265	http://dx.doi.org/10.1126/science.280.5367.1265			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZQ351	9596580				2022-12-01	WOS:000073852500049
J	Hemingway, H; Shipley, M; Christie, D; Marmot, M				Hemingway, H; Shipley, M; Christie, D; Marmot, M			Is cardiothoracic ratio in healthy middle aged men an independent predictor of coronary heart disease mortality? Whitehall study 25 year follow up	BRITISH MEDICAL JOURNAL			English	Article									Univ Newcastle, Dept Environm & Occupat Hlth, Newcastle, NSW 2308, Australia; Kensington Chelsea & Westminster Hlth Author, Dept Res & Dev, London W2 6LX, England; UCL, Sch Med, Dept Epidemiol & Publ Hlth, Int Ctr Hlth & Soc, London WC1E 6BT, England	University of Newcastle; University of London; University College London; UCL Medical School	Hemingway, H (corresponding author), UCL, Sch Med, Dept Epidemiol & Publ Hlth, Int Ctr Hlth & Soc, Mortimer St, London WC1E 6BT, England.	h.hemingway@public-health.ucl.ac.uk	Hemingway, Harry/C-1219-2009; Marmot, M G/Y-3920-2019	Hemingway, Harry/0000-0003-2279-0624; Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		CHAMBERS J, 1995, BRIT MED J, V311, P273, DOI 10.1136/bmj.311.7000.273; CHRISTIE D, 1978, ACTA RADIOL DIAGN, V19, P732, DOI 10.1177/028418517801900503; DAVIS JL, 1986, AM J CARDIOL, V58, P658, DOI 10.1016/0002-9149(86)90300-0; RAUTAHARJU PM, 1988, AM J CARDIOL, V62, P59, DOI 10.1016/0002-9149(88)91365-3; REID DD, 1974, LANCET, V1, P469	5	13	13	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 2	1998	316	7141					1353	1354		10.1136/bmj.316.7141.1353	http://dx.doi.org/10.1136/bmj.316.7141.1353			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL882	9563985	Green Published, Green Submitted			2022-12-01	WOS:000073483000018
J	Brooke, NM; Garcia-Fernandez, J; Holland, PWH				Brooke, NM; Garcia-Fernandez, J; Holland, PWH			The ParaHox gene cluster is an evolutionary sister of the Hox gene cluster	NATURE			English	Article							HOMEOBOX GENES; MOUSE CHROMOSOME-5; DROSOPHILA; EXPRESSION; INSIGHTS; ZOOTYPE; EMBRYOS; IPF1	Genes of the Hox cluster are restricted to the animal kingdom and play a central role in axial patterning in divergent animal phyla(1). Despite its evolutionary and developmental significance, the origin of the Hox gene cluster is obscure. The consensus is that a primordial Hox cluster arose by tandem gene duplication close to animal origins(2-5). Several homeobox genes with high sequence identity to Hox genes are found outside the Hox cluster and are known as 'dispersed' Hox-like genes; these genes may have been transposed away from an expanding clusters. Here we show that three of these dispersed homeobox genes form a novel gene cluster in the cephalochordate amphioxus, We argue that this 'ParaHox' gene cluster is an ancient paralogue (evolutionary sister) of the Hox gene cluster; the two gene clusters arose by duplication of a ProtoHox gene cluster. Furthermore, we show that amphioxus ParaHox genes have co-linear developmental expression patterns in anterior, middle and posterior tissues. We propose that the origin of distinct Hox and ParaHox genes by gene-duster duplication facilitated an increase in body complexity during the Cambrian explosion.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; Univ Barcelona, Fac Biol, Dept Genet, E-08028 Barcelona, Spain	University of Reading; University of Barcelona	Holland, PWH (corresponding author), Univ Reading, Sch Anim & Microbial Sci, POB 228, Reading RG6 6AJ, Berks, England.		Garcia-Fernandez, Jordi/B-3839-2013	Garcia-Fernandez, Jordi/0000-0001-5677-5970; Holland, Peter/0000-0003-1533-9376				Averof M, 1996, SEMIN CELL DEV BIOL, V7, P539, DOI 10.1006/scdb.1996.0068; Burglin Thomas R., 1994, P25; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; FELSENSTEIN J, 1993, PHYLIP VERSION 3 5C; FIEDOREK FT, 1995, GENOMICS, V28, P581, DOI 10.1006/geno.1995.1193; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.bi.63.070194.002415; GORBMAN A, 1983, AM ZOOL, V23, P639; HOLLAND PWH, 1992, DEVELOPMENT, V116, P653; Irvine SQ, 1997, MOL PHYLOGENET EVOL, V7, P331, DOI 10.1006/mpev.1997.0407; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KAPPEN C, 1989, P NATL ACAD SCI USA, V86, P5458; KOZAK CA, 1994, MAMM GENOME, V5, pS65; LEHRACH H, 1990, GENOME ANAL, V1, P38; Li H, 1996, EMBO J, V15, P714, DOI 10.1002/j.1460-2075.1996.tb00407.x; MILLER DJ, 1993, NATURE, V365, P215, DOI 10.1038/365215b0; MORRIS SC, 1994, DEVELOPMENT, P1; Offield MF, 1996, DEVELOPMENT, V122, P983; Popodi E, 1996, MOL BIOL EVOL, V13, P1078, DOI 10.1093/oxfordjournals.molbev.a025670; SCHUBERT FR, 1993, P NATL ACAD SCI USA, V90, P143, DOI 10.1073/pnas.90.1.143; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; STOFFEL M, 1995, GENOMICS, V28, P125, DOI 10.1006/geno.1995.1120; Szucsik JC, 1997, DEV BIOL, V191, P230, DOI 10.1006/dbio.1997.8733; Williams NA, 1996, NATURE, V383, P490, DOI 10.1038/383490a0; WRIGHT CVE, 1988, DEVELOPMENT, V104, P787; WYSOCKADILLER J, 1995, DEV BIOL, V171, P439, DOI 10.1006/dbio.1995.1294; Zhang JZ, 1996, GENETICS, V142, P295	30	341	354	6	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					920	922		10.1038/31933	http://dx.doi.org/10.1038/31933			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582071				2022-12-01	WOS:000073359900048
J	Schriger, DL; Kalafut, M; Starkman, S; Krueger, M; Saver, JL				Schriger, DL; Kalafut, M; Starkman, S; Krueger, M; Saver, JL			Cranial computed tomography interpretation in acute stroke - Physician accuracy in determining eligibility for thrombolytic therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Intracranial hemorrhage must be excluded prior to administration of thrombolytic agents in acute stroke. Objective.-To evaluate physician accuracy in cranial computed tomography scan interpretation for determining eligibility for thrombolytic therapy in acute stroke. Design.-Administration of randomly selected, randomly ordered series of 15 computed tomography scans from a pool of 54 scans that demonstrated intracerebral hemorrhage, acute infarction, intracerebral calcifications (impostor for hemorrhage), old cerebral infarction (impostor for acute infarction), and normal findings. Participants.-A convenience sample of 38 emergency physicians, 29 neurologists, and 36 general radiologists. Main Outcome Measures.-Physician determination of eligibility for thrombolytic therapy based on computed tomography scan interpretation. Results.-Average correct score by all physicians on all computed tomography scans was 77% (95% confidence interval, 74%-80%), Of 569 computed tomography readings by emergency physicians, 67% were correct; of 435 readings by neurologists, 83% were correct; and of 540 readings by radiologists, 83% were correct. Overall sensitivity for detecting hemorrhage was 82% (95% confidence interval, 78%-85%); 17% of emergency physicians, 40% of neurologists, and 52% of radiologists achieved 100% sensitivity for identification of hemorrhage. Conclusion.-Physicians in this study did not uniformly achieve a level of sensitivity for identification of intracerebral hemorrhage sufficient to permit safe selection of candidates for thrombolytic therapy.	Univ Calif Los Angeles, Sch Med, Ctr Emergency Med, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Stroke Ctr, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Schriger, DL (corresponding author), 924 Westwood Blvd,Suite 300, Los Angeles, CA 90024 USA.	schriger@ucla.edu		Schriger, David/0000-0003-0242-1127; Saver, Jeffrey/0000-0001-9141-2251				Adams HP, 1996, STROKE, V27, P1711; Adams HP, 1996, NEUROLOGY, V47, P835; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; CANDELISE L, 1995, LANCET, V346, P1509; Chavot D, 1996, CEREBROVASC DIS, V6, P182; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; EBEL RL, 1986, ESSENTIALS ED MEASUR, P335; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hommel M, 1996, NEW ENGL J MED, V335, P145; Larrue V, 1997, STROKE, V28, P957, DOI 10.1161/01.STR.28.5.957; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; *NAT STROK ASS, 1997, STROK CLIN UPD; Nightingale SL, 1996, JAMA-J AM MED ASSOC, V276, P443; SACCO RL, 1994, CLIN ATLAS CEREBROVA; *STAT CORP, 1997, STAT STAT SOFTW REL, P235; vonKummer R, 1997, RADIOLOGY, V205, P327, DOI 10.1148/radiology.205.2.9356611; Wainer H.W., 1990, COMPUTERIZED ADAPTIV	18	160	163	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 29	1998	279	16					1293	1297		10.1001/jama.279.16.1293	http://dx.doi.org/10.1001/jama.279.16.1293			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH270	9565011	Bronze			2022-12-01	WOS:000073090300036
J	Wennberg, DE; Lucas, FL; Birkmeyer, JD; Bredenberg, CE; Fisher, ES				Wennberg, DE; Lucas, FL; Birkmeyer, JD; Bredenberg, CE; Fisher, ES			Variation in carotid endarterectomy mortality in the Medicare population - Trial hospitals, volume, and patient characteristics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STENOSIS; ATHEROSCLEROSIS; COMPLICATIONS	Context.-The North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the Asymptomatic Carotid Atherosclerosis Study (ACAS) demonstrated the efficacy of carotid endarterectomy (CEA) in reducing the risk of stroke and death in selected patients when surgery was performed in institutions whose participation depended on demonstrated excellence. Thirty-day mortality rates in the trials were very low: 0.6% in NASCET and 0.1% in ACAS. Objective.-To assess perioperative mortality among Medicare patients undergoing CEA in all nonfederal institutional settings. Design.-Retrospective national cohort study. Setting and Patients.-All 113 300 Medicare patients undergoing CEA during 1992 and 1993 in "trial hospitals" (those participating in NASCET and ACAS, n=86) and "nontrial hospitals" tall other nonfederal institutions performing CEAs, n=2613). Nontrial hospitals were stratified into terciles based on volume of CEAs performed. Main Outcome Measures.-Crude and adjusted perioperative (30 day) mortality rates. Results.-The perioperative mortality rate was 1.4% (95% confidence interval [CI], 1.2%-1.7%) at trial hospitals; mortality in nontrial hospitals was higher: 1.7% (95% CI, 1.6%-1.8%) thigh volume); 1.9% (95% CI, 1.7%-2.1%) (average volume); 2.5% (95% CI, 2.0%-2.9%) (low volume); (P for trend, <.001). In multivariate modeling, patients undergoing their procedures at trial hospitals had a mortality risk reduction of 15% (95% CI, 0%-31%) compared with high-volume nontrial hospitals, 25% (95% CI, 7%-40%) compared with average-volume hospitals, and 43% (95% CI, 25%-56%) compared with low-volume hospitals (P for trend, <.001). Conclusion.-Medicare patients' perioperative mortality following CEA is substantially higher than that reported in the trials, even in those institutions that participated in the randomized studies. Caution is advised in translating the efficacy of carefully controlled studies of CEA to effectiveness in everyday practice.	Maine Med Ctr, Div Hlth Serv Res, Portland, ME 04102 USA; Maine Med Ctr, Dept Surg, Portland, ME 04102 USA; Maine Med Assessment Fdn, Augusta, ME USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Ctr Evaluat Clin Sci, Hanover, NH 03756 USA; Dept Vet Affairs Med Ctr, White River Jct, VT USA	Maine Medical Center; Maine Medical Center; Dartmouth College	Wennberg, DE (corresponding author), Maine Med Ctr, Div Hlth Serv Res, Portland, ME 04102 USA.	wennbd@mail.mmc.org						BARNETT HJM, 1995, ANN INTERN MED, V123, P723, DOI 10.7326/0003-4819-123-9-199511010-00012; BARNETT HJM, 1991, STROKE, V22, P711, DOI 10.1161/01.STR.22.6.711; Barnett HJM, 1996, NEUROLOGY, V46, P603, DOI 10.1212/WNL.46.3.603; BROOK RH, 1990, ANN INTERN MED, V113, P747, DOI 10.7326/0003-4819-113-10-747; BROTT T, 1995, ANN INTERN MED, V123, P720, DOI 10.7326/0003-4819-123-9-199511010-00011; DAVIDOFF F, 1995, ANN INTERN MED, V123, P729, DOI 10.7326/0003-4819-123-9-199511010-00015; DIENER HC, 1991, STROKE, V22, P1229; *EUR CAR SURG TRIA, 1996, LANCET, V347, P1592; FISHER ES, 1989, AM J PUBLIC HEALTH, V79, P1617, DOI 10.2105/AJPH.79.12.1617; Fleiss J.L., 1981, STAT METHODS RATES P; GRAVES EJ, 1997, VITAL HLTH STAT 13, V130, P124; Hertzer NR, 1996, J VASC SURG, V23, P167, DOI 10.1016/S0741-5214(05)80049-7; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; HSIA DC, 1992, J VASC SURG, V16, P201, DOI 10.1016/0741-5214(92)90108-K; KISTLER JP, 1991, NEW ENGL J MED, V325, P505, DOI 10.1056/NEJM199108153250709; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; Mitchell JB, 1996, HEALTH SERV RES, V31, P141; MOORE WS, 1991, STROKE, V22, P1353, DOI 10.1161/01.STR.22.11.1353; *N AM SYMPT CAR EN, 1991, STROKE, V22, P816; *NAT I NEUR DIS ST, 1994, CLIN AL CLIN ADV CAR; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Sarasin FP, 1995, NEUROLOGY, V45, P2147, DOI 10.1212/WNL.45.12.2147; Stukenborg GJ, 1997, ARCH NEUROL-CHICAGO, V54, P826, DOI 10.1001/archneur.1997.00550190018009; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WENNBERG J, 1997, DARTMOUTH ATLAS HLTH; WIEBERS DO, 1992, MAYO CLIN PROC, V67, P513; World Health Organisation, 1977, INT CLASS DIS 9 REV	31	364	381	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 29	1998	279	16					1278	1281		10.1001/jama.279.16.1278	http://dx.doi.org/10.1001/jama.279.16.1278			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH270	9565008	Bronze			2022-12-01	WOS:000073090300033
J	Artlett, CM; Smith, JB; Jimenez, SA				Artlett, CM; Smith, JB; Jimenez, SA			Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VERSUS-HOST DISEASE; BONE-MARROW TRANSPLANTATION; CHRONIC GRAFT; AUTOIMMUNE-DISEASE; SCLERODERMA; EPIDEMIOLOGY; BLOOD; CHIMERISM	Background Systemic sclerosis is a disease of unknown origin which often occurs in women after their childbearing years. It has many clinical and histopathological similarities to chronic graft-versus-host disease. Recent studies indicate that fetal stem cells can survive in the maternal circulation for many years post partum. This finding suggests that fetal cells persisting in the maternal circulation or tissues could be involved in the pathogenesis of systemic sclerosis by initiating a graft-versus-host reaction. Methods We used the polymerase chain reaction (PCR) to identify Y-chromosome sequences in DNA extracted from peripheral-blood cells and skin lesions from women with systemic sclerosis of recent onset. To confirm the PCR findings, we used fluorescence in situ hybridization of peripheral-blood cells and cells within chronic inflammatory-cell infiltrates in biopsy specimens of affected skin. Results Y-chromosome sequences were found in DNA from peripheral-blood cells in 32 of 69 women with systemic sclerosis (46 percent), as compared with 1 of 25 normal women (4 percent, P<0.001), and in T lymphocytes from 3 women with systemic sclerosis who had male offspring. Furthermore, Y-chromosome sequences were identified in skin-biopsy specimens from 11 of 19 women with systemic sclerosis (58 percent); 9 of the 11 were known to have carried male fetuses. Nucleated cells containing Y chromosomes were detected by fluorescence in situ hybridization in paraffin-embedded sections of skin lesions from all seven women we tested whose skin-biopsy specimens contained Y-chromosome sequences. Conclusions Fetal antimaternal graft-versus-host reactions may be involved in the pathogenesis of systemic sclerosis in some women. (C)1998, Massachusetts Medical Society.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Rheumatol, Philadelphia, PA 19107 USA	Jefferson University	Jimenez, SA (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Rheumatol, Rm 509,Bluemle Life Sci Bldg,233 S 10th St, Philadelphia, PA 19107 USA.			Jimenez, Sergio/0000-0001-5213-1203	NIADDK NIH HHS [AM19616] Funding Source: Medline; PHS HHS [CRMC-92-15] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM019616] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; APPLETON AL, 1994, BONE MARROW TRANSPL, V14, P157; Artlett CM, 1997, IMMUNOGENETICS, V47, P17, DOI 10.1007/s002510050321; BASSUKAS ID, 1992, MED HYPOTHESES, V38, P334, DOI 10.1016/0306-9877(92)90028-B; Bell SA, 1996, BRIT J DERMATOL, V134, P848; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; BLACK CM, 1989, RHEUM DIS CLIN N AM, V15, P193; BOS GMJ, 1989, TRANSPLANT P, V21, P3262; BRUBAKER DB, 1993, P SOC EXP BIOL MED, V202, P122; CHOSIDOW O, 1992, J AM ACAD DERMATOL, V26, P49, DOI 10.1016/0190-9622(92)70005-Z; CLEMENTS PJ, 1985, CURRENT TOPICS RHEUM, P376; FAGUNDUS DM, 1994, CLIN DERMATOL, V12, P407, DOI 10.1016/0738-081X(94)90293-3; FLEISCHMAJER R, 1977, ARTHRITIS RHEUM, V20, P975, DOI 10.1002/art.1780200410; GILL TJ, 1977, TRANSPLANT P, V9, P1423; GRAHAMBROWN RAC, 1983, CLIN EXP DERMATOL, V8, P531, DOI 10.1111/j.1365-2230.1983.tb01820.x; HERZOG P, 1980, J RHEUMATOL, V7, P56; JANINMERCIER A, 1984, AM J PATHOL, V115, P296; JIMENEZ SA, 1983, SEMIN ARTHRITIS RHEU, V13, P104, DOI 10.1016/0049-0172(83)90029-X; JUJI T, 1989, NEW ENGL J MED, V321, P56; KAHALEH MB, 1989, ANN INTERN MED, V110, P446, DOI 10.7326/0003-4819-110-6-446; LAMPERT IA, 1981, LANCET, V2, P1352; LAWLEY TJ, 1977, ANN INTERN MED, V87, P707, DOI 10.7326/0003-4819-87-6-707; MEDSGER TA, 1994, CLIN DERMATOL, V12, P207, DOI 10.1016/S0738-081X(94)90323-9; MEDSGER TA, 1971, ANN INTERN MED, V74, P714, DOI 10.7326/0003-4819-74-5-714; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nelson JL, 1996, ARTHRITIS RHEUM, V39, P191, DOI 10.1002/art.1780390203; OREILLY RJ, 1973, TRANSPLANTATION, V15, P505; PATRI S, 1994, PCR METH APPL, V3, P361; Postlethwaite Arnold E., 1993, Current Opinion in Rheumatology, V5, P766; SCHRODER J, 1975, J MED GENET, V12, P230, DOI 10.1136/jmg.12.3.230; SILMAN A, 1988, BRIT J RHEUMATOL, V27, P286; SILMAN AJ, 1988, ANN RHEUM DIS, V47, P441, DOI 10.1136/ard.47.6.441; SILMAN AJ, 1996, EPIDEMIOLOGY DEMOGRA, P23; Steele CD, 1996, CLIN OBSTET GYNECOL, V39, P801, DOI 10.1097/00003081-199612000-00009; STEEN VD, 1990, RHEUM DIS CLIN N AM, V16, P1; VALENTA LJ, 1987, ARCH DERMATOL, V123, P1438, DOI 10.1001/archderm.123.11.1438	36	364	371	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1186	1191		10.1056/NEJM199804233381704	http://dx.doi.org/10.1056/NEJM199804233381704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554859	Green Published			2022-12-01	WOS:000073208400004
J	Green, R; Switzer, C; Noller, HF				Green, R; Switzer, C; Noller, HF			Ribosome-catalyzed peptide-bond formation with an a-site substrate covalently linked to 23S ribosomal RNA	SCIENCE			English	Article							ESCHERICHIA-COLI RIBOSOMES; DIRECTED CROSS-LINKING; TRANSFERASE CENTER; DOMAIN-V; P-SITES; 16S RNA; IDENTIFICATION; POSITIONS; COMPLEXES; REGION	In the ribosome, the aminoacyl-transfer RNA (tRNA) analog 4-thio-dT-p-C-p-puromycin crosslinks photochemically with G2553 of 23S ribosomal RNA (rRNA). This covalently linked substrate reacts with a peptidyl-tRNA analog to form a peptide bond in a peptidyl transferase-catalyzed reaction. This result places the conserved 2555 loop of 23S rRNA at the peptidyl transferase A site and suggests that peptide bond formation can occur uncoupled from movement of the A-site tRNA. Crosslink formation depends on occupancy of the P site by a tRNA carrying an intact CCA acceptor end, indicating that peptidyl-tRNA, directly or indirectly, helps to create the peptidyl transferase A site.	Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA; Univ Calif Riverside, Dept Chem, Riverside, CA 92521 USA	University of California System; University of California Santa Cruz; University of California System; University of California Riverside	Noller, HF (corresponding author), Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA.	harry@nuvolari.ucsc.edu						ATKINSON T, 1985, OLIGONUCLEOTIDE SYNT, P35; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; ECKERMANN DJ, 1978, EUR J BIOCHEM, V82, P225, DOI 10.1111/j.1432-1033.1978.tb12015.x; GOLDBERG IH, 1967, BIOCHEMISTRY-US, V6, P383, DOI 10.1021/bi00854a003; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; Green R, 1996, RNA, V2, P1011; Green R.A., UNPUB; HALL CC, 1988, BIOCHEMISTRY-US, V27, P3983, DOI 10.1021/bi00411a014; HARDESTY B, 1986, STRUCTURE FUNCTION G, P495; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HISHIZAWA T, 1971, ARCH BIOCHEM BIOPHYS, V147, P624, DOI 10.1016/0003-9861(71)90421-8; Joseph S, 1996, EMBO J, V15, P910, DOI 10.1002/j.1460-2075.1996.tb00425.x; LIEBERMAN KR, 1995, PROG NUCLEIC ACID RE, V50, P1, DOI 10.1016/S0079-6603(08)60809-0; MITCHELL P, 1993, NUCLEIC ACIDS RES, V15, P8783; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OCONNOR M, 1993, P NATL ACAD SCI USA, V90, P9214, DOI 10.1073/pnas.90.19.9214; PESTKA S, 1969, COLD SPRING HARB SYM, V34, P395, DOI 10.1101/SQB.1969.034.01.046; PICKING WD, 1992, BIOCHEMISTRY-US, V31, P12565, DOI 10.1021/bi00165a004; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; Puglisi EV, 1997, NAT STRUCT BIOL, V4, P775; RODRIGUEZFONSECA C, 1995, J MOL BIOL, V247, P224, DOI 10.1006/jmbi.1994.0135; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHWARTZ I, 1978, BIOCHEMISTRY-US, V17, P2524, DOI 10.1021/bi00606a011; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; TATE W, 1990, NUCLEIC ACIDS RES, V18, P6537, DOI 10.1093/nar/18.22.6537; ULBRICH B, 1978, ARCH BIOCHEM BIOPHYS, V190, P149, DOI 10.1016/0003-9861(78)90262-X; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232	33	79	81	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1998	280	5361					286	289		10.1126/science.280.5361.286	http://dx.doi.org/10.1126/science.280.5361.286			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535658				2022-12-01	WOS:000073082400051
J	Bushdid, PB; Brantley, DM; Yull, FE; Blaeuer, GL; Hoffman, LH; Niswander, L; Kerr, LD				Bushdid, PB; Brantley, DM; Yull, FE; Blaeuer, GL; Hoffman, LH; Niswander, L; Kerr, LD			Inhibition of NF-kappa B activity results in disruption of the apical ectodermal ridge and aberrant limb morphogenesis	NATURE			English	Article							CHICK LIMB; SONIC-HEDGEHOG; VERTEBRATE LIMB; FEEDBACK LOOP; GROWTH; TRANSCRIPTION; DROSOPHILA; EXPRESSION; PROMOTER; INITIATION	In Drosophila, the Dorsal protein establishes the embryonic dorso-ventral axis during development(1), Here we show that the vertebrate homologue of Dorsal, nuclear factor-kappa B (NF-kappa B), is vital for the formation of the proximo-distal organizer of the developing limb bud, the apical ectodermal ridge (AER). Transcription of the NF-kappa B proto-oncogene c-rel is regulated, in part, during morphogenesis of the limb bud by AER-derived signals such as fibroblast growth factors. Interruption of NF-kappa B activity using viral-mediated delivery of an inhibitor results in a highly dysmorphic AER, reduction in overall limb size, loss of distal elements and reversal in the direction of limb outgrowth. Furthermore, inhibition of NF-kappa B activity in limb mesenchyme leads to a reduction in expression of Sonic hedgehog and Twist but derepresses expression of the bone morphogenetic protein-4 gene. These results are the first evidence that vertebrate NF-kappa B proteins act to transmit growth factor signals between the ectoderm and the underlying mesenchyme during embryonic limb formation.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr, Nashville, TN 37232 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Memorial Sloan Kettering Cancer Center	Kerr, LD (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA.		Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594				BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; Gitelman I, 1997, DEV BIOL, V189, P205, DOI 10.1006/dbio.1997.8614; GRUMONT RJ, 1993, CELL GROWTH DIFFER, V4, P731; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NUSSLEINVOLHARD C, 1980, NATURE, V283, P474, DOI 10.1038/283474a0; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; ROS MA, 1993, PROG CLIN BIOL RES, V383, P79; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SCHWYTER DH, 1995, MOL CELL BIOL, V15, P3960; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; TRANCKNER EB, 1995, EMBO J, V14, P2876; Vogel A, 1996, DEVELOPMENT, V122, P1737; WALL NA, 1995, MECH DEVELOP, V53, P383, DOI 10.1016/0925-4773(95)00453-X; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725	29	148	151	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					615	618		10.1038/33435	http://dx.doi.org/10.1038/33435			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560159				2022-12-01	WOS:000072987200063
J	Stansby, G				Stansby, G			Vein quality in vascular surgery	LANCET			English	Editorial Material							SAPHENOUS-VEIN; GRAFT; FAILURE; DISEASE		Imperial Coll Sch Med, Div Surg Anaesthet & Intens Care, London W2 1NY, England	Imperial College London	Stansby, G (corresponding author), Imperial Coll Sch Med, Div Surg Anaesthet & Intens Care, London W2 1NY, England.			Stansby, Gerard/0000-0001-5539-3049				ADCOCK OT, 1984, SURGERY, V96, P886; DAVIES MG, 1995, EUR J VASC ENDOVASC, V9, P7, DOI 10.1016/S1078-5884(05)80218-7; Giannoukas AD, 1997, EUR J VASC ENDOVASC, V14, P37, DOI 10.1016/S1078-5884(97)80223-7; HARRIS PL, 1993, BRIT J SURG, V80, P173, DOI 10.1002/bjs.1800800213; Hedin U, 1997, EUR J VASC ENDOVASC, V13, P101, DOI 10.1016/S1078-5884(97)80004-4; MOODY AP, 1992, EUR J VASCULAR SURG, V6, P509, DOI 10.1016/S0950-821X(05)80625-5; PANETTA TF, 1992, J VASC SURG, V15, P102, DOI 10.1016/0741-5214(92)70018-G; SALES CM, 1993, J VASC SURG, V18, P198, DOI 10.1016/0741-5214(93)90599-H; THIENE G, 1980, THORAX, V35, P519, DOI 10.1136/thx.35.7.519; Wilson YG, 1998, ANN ROY COLL SURG, V80, P3	10	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1001	1002		10.1016/S0140-6736(05)78990-X	http://dx.doi.org/10.1016/S0140-6736(05)78990-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546500				2022-12-01	WOS:000072927200004
J	Rosa, L; Rosa, E; Sarner, L; Barrett, S				Rosa, L; Rosa, E; Sarner, L; Barrett, S			A close look at therapeutic touch	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review								Context.-Therapeutic Touch (TT) is a widely used nursing practice rooted in mysticism but alleged to have a scientific basis. Practitioners of TT claim to treat many medical conditions by using their hands to manipulate a "human energy field" perceptible above the patient's skin. Objective.-To investigate whether TT practitioners can actually perceive a "human energy field." Design.-Twenty-one practitioners with TT experience for from 1 to 27 years were tested under blinded conditions to determine whether they could correctly identify which of their hands was closest to the investigator's hand. Placement of the investigator's hand was determined by flipping a coin. Fourteen practitioners were tested 10 times each, and 7 practitioners were tested 20 times each. Main Outcome Measure.-Practitioners of TT were asked to state whether the investigator's unseen hand hovered above their right hand or their left hand. To show the validity of TT theory, the practitioners should have been able to locate the investigator's hand 100% of the time. A score of 50% would be expected through chance alone. Results.-Practitioners of TT identified the correct hand in only 123 (44%) of 280 trials, which is close to what would be expected for random chance. There was no significant correlation between the practitioner's score and length of experience (r=0.23). The statistical power of this experiment was sufficient to conclude that if TT practitioners could reliably detect a human energy field, the study would have demonstrated this. Conclusions.-Twenty-one experienced TT practitioners were unable to detect the investigator's "energy field." Their failure to substantiate TT's most fundamental claim is unrefuted evidence that the claims of TT are groundless and that further professional use is unjustified.	Natl Therapeut Touch Study Grp, Loveland, CO 80537 USA; Natl Council Against Hlth Fraud Inc, Questionable Nurse Practices Task Force, Loveland, CO USA; Quackwatch Inc, Allentown, PA USA		Sarner, L (corresponding author), Natl Therapeut Touch Study Grp, 711 W 9th St, Loveland, CO 80537 USA.	nttsg@ezlink.com; sbinfo@quackwatch.com						BANDMAN EL, 1995, CRITICAL THINKING NU; BARRETT EAM, 1990, VISIONS ROGERS SCI B, P15; Bogulawski M, 1980, Top Clin Nurs, V2, P27; Boguslawski M, 1979, J Contin Educ Nurs, V10, P9; BOWERS DP, 1992, THESIS SAN JOSE STAT; BRIERTON TD, 1992, LABOR LAW J, V43, P411; BROWN CC, 1977, J ALTER ST CONSCIOUS, V3, P169; BROWN PR, 1981, THESIS U NEVADA RENO; BRUNJES CAF, 1983, TOP CLIN NURS, V5, P72; BULLOUGH VL, 1993, SKEPTICAL INQUIRER, V17, P169; BUSH AM, 1992, PSYCHOL REP, V70, P891, DOI 10.2466/PR0.70.3.891-896; BUTGEREIT B, 1994, BIRMINGHAM NEWS 1117, pA1; CABICO LL, 1992, THESIS DYOUVILLE COL; CALVERT R, 1994, MASSAGE MAGAZINES, V47, P56; CARPENITO LJ, 1995, NURISNG DIAGNOSIS AP, P355; CHIAPPONE J, 1989, LIGHT TOUCH EASY GUI, P14; Claman HN, 1994, REPORT CHANCELLORS C; CLARK AJ, 1992, 3 ANN W AL C CLIN NU; CLARK PE, 1984, NURS RES, V33, P37; *COL STAT BOARD NU, 1992, SUBC INV AW CONT ED; COWENS C, 1996, GIFT HEALING YOU CAN; DOLLAR CE, 1993, THESIS U MISSISSIPPI; EDGE H, 1979, 22 ANN CONV PAR ASS; EMERY CE, 1994, PROVIDENCE SUN  1127, pA1; FEDORUK RB, 1984, THESIS U MARYLAND BA; FIELY D, 1995, COLUMBUS DISPAT 0820, pB1; Fish S, 1993, J Christ Nurs, V10, P6; France N E, 1993, J Holist Nurs, V11, P319, DOI 10.1177/089801019301100402; Gagne D, 1994, Arch Psychiatr Nurs, V8, P184, DOI 10.1016/0883-9417(94)90052-3; GLAZER S, 1995, WASHINGTON POST 1219, P19; GUERRERO MA, 1985, THESIS U TEXAS GALVE; Haddad A, 1994, RN, V57, P21; HADDAD A, 1994, RN, V57, P24; HALE EH, 1986, THESIS TEXAS WOMENS; HAMILTONWYATT GK, 1988, THESIS MICHIGAN STAT; HEIDT P, 1981, NURS RES, V30, P32, DOI 10.1097/00006199-198101000-00014; Heidt P R, 1990, Image J Nurs Sch, V22, P180; HINZE ML, 1988, THESIS U TEXAS AUSTI; Hogg P, 1985, THESIS CALIFORNIA SC; Hover D, 1992, Beginnings, V12, P3; HUGHES PP, 1994, THESIS U NEW MEXICO; JACKSON MEM, 1981, THERPAEUTIC TOUCH BO, P72; JARBOUX D, 1994, BOULDER SUNDARY 0102, pE3; JOEL LA, 1995, AM J NURS, V95, P7; Karagulla S., 1989, CHAKRAS HUMAN ENERGY; KAUFFOLD MP, 1995, CHICAGO TRIBUNE 1119, P1; Keegan L, 1996, RN, V59, P59; Keegan L, 1989, J Post Anesth Nurs, V4, P17; KELLER E, 1986, NURS RES, V35, P101; KNASTER M, 1989, E W, V19, P54; KNASTER M, 1989, E W, V19, P59; KNASTER M, 1989, E W, V19, P79; Kramer N A, 1990, Pediatr Nurs, V16, P483; Krieger D, 1975, J N Y State Nurses Assoc, V6, P6; Krieger D, 1990, Imprint, V37, P86; Krieger D, 1975, Am J Nurs, V75, P784; KRIEGER D, 1979, AM J NURS, V79, P660, DOI 10.2307/3462338; KRIEGER D, 1975, J HOLISTIC HLTH, V1, P23; KRIEGER D, 1990, IMPRINT, V37, P86; KRIEGER D, 1997, THERAPEUTIC TOUCH IN, P162; KRIEGER D, 1972, HUMAN DIMENSIONS AUT, P12; Krieger D., 1987, LIVING THERAPEUTIC T; KRIEGER D, 1976, INT J PSYCHOENERGY S, V1, P121; KRIEGER D, 1987, LIVING THERAPEUTIC T, P157; KRIEGER D, 1973, P 9 ANA NURS RES C N, P39; Krieger D. K., 1993, ACCEPTING YOUR POWER; Leduc E, 1987, Neonatal Netw, V5, P46; Ledwith S P, 1995, RN, V58, P51; LEVINE ME, 1979, AM J NURS, V79, P1379, DOI 10.1097/00000446-197908000-00011; LIKONBERGER HJ, 1985, INTERPRETIVE STUDY N; LIONBERGER HJ, 1986, NURSING RES METHODOL, P169; MACKEY RB, 1995, AM J NURS, V95, P27; MACRAE J, 1979, AM J NURS, V79, P664; MAXWELL J, 1996, CHRISTIANITY TODAY, V40, P96; MEEHAN MTC, 1990, NATL LEAGUE NURISNG, P67; MEEHAN MTC, 1992, NURSING INTERVETIONS, P201; MEEHAN MTC, 1990, VISIONS ROGERS SCI B, P197; MEEHAN MTC, 1985, EFFECT THERAPEUTIC T; Meehan T C, 1993, Nurs Sci Q, V6, P69, DOI 10.1177/089431849300600206; MEEHAN TC, 1995, RES NURS HEALTH, V18, P471, DOI 10.1002/nur.4770180512; MEEHAN TC, 1995, AM J NURS, V95, P17; Mersmann C.A., 1993, THESIS NEW YORK U NE; MESENGER TC, 1994, J GERONTOL NURS, V20, P17; MISRA MM, 1993, THESIS CALIFORNIA ST; MOCCIA P, 1986, NEW APPROACHES THEOR, P15; MOCCIA P, 1994, TIME, V144, P18; Mulloney S S, 1996, J Cardiovasc Nurs, V10, P27; NODINE JL, 1987, THESIS U ARIZONA TUC; OLSON T, 1995, N&HC PERSPECT COMMUN, V16, P97; PARKES BS, 1985, THESIS U TEXAS AUSTI; PETERS PJ, 1992, THESIS WALDEN U MINN; POLK SH, 1995, THESIS ARIZONA STATE; POST NW, 1990, THESIS SAN JOSE STAT; PUTNAM ZE, 1995, MASSAGE THER J   FAL, P550; PUTNAM ZE, 1995, MASSAGE THER J   FAL, P47; QUINN J, 1982, INVESTIGATION EFFECT; Quinn J F, 1992, Holist Nurs Pract, V6, P26; Quinn J F, 1984, ANS Adv Nurs Sci, V6, P42; Quinn J F, 1989, Nurs Sci Q, V2, P79, DOI 10.1177/089431848900200207; Quinn J F, 1992, Holist Nurs Pract, V7, P32; QUINN JF, 1993, ADV NURS SCI, V15, P13, DOI 10.1097/00012272-199306000-00003; QUINN JF, 1979, AM J NURS, V79, P662; QUINN JF, 1994, THERAPEUTIC TOUCH HE; Randolph G, 1979, Top Clin Nurs, V1, P31; RANDOLPH GL, 1984, NURS RES, V33, P33; RAUCHEISEN ML, 1984, RN MAG, V47, P49; Rogers M.E., 1970, INTRO THEORETICAL BA; ROSA LA, 1906, SUREY THERAPEUTIC TO; ROSA LA, 1993, ROCKY MOUNTAIN SKEPT, V10, P10; SAMAREL N, 1992, J ADV NURS, V17, P651, DOI 10.1111/j.1365-2648.1992.tb01960.x; Sandroff R, 1980, RN, V43, P24; SANDROFF R, 1980, RN, V43, P82; SATIR F, 1994, OLYMPIAN        0719; SCHLOTFELDT RM, 1973, P 9 ANA NURS RES C N, P59; Schmidt C M, 1995, RN, V58, P54; SCHMIDT CM, 1995, RN, V58, P52; SCHMIDT CM, 1995, RN, V58, P54; SCHWEITZER SF, 1980, THESIS U NEVADA RENO; SHUZMAN E, 1993, THESIS NEW YORK U NE; SIES MM, 1993, THESIS MICHIGAN STAT; Simington J A, 1993, Clin Nurs Res, V2, P438, DOI 10.1177/105477389300200406; Snyder M, 1995, J Gerontol Nurs, V21, P34; SNYDER M, 1995, J GERONTOL NURS, V21, P54; SODERGREN KA, 1993, THESIS U MINNESOTA M; STRANEVA JAE, 1992, THESIS INDIANA U BLO; Swackhamer A H, 1995, RN, V58, P49; THARNSTROM CAL, 1993, THESIS SAN JOSE STAT; Thayer M B, 1990, Pediatr Nurs, V16, P70; THOMASBECKETT JG, 1991, THESIS MICHIGAN STAT; TURNER JG, 1996, EFFECT THERAPEUTIC T; TURNER JG, 1994, TRISERVICE NURSING R; WALIKE BC, 1975, AM J NURS, V75, P1278; WALIKE BC, 1975, AM J NURS, V75, P1275; WALKE BC, 1975, AM J NURS, V75, P1292; Wirth DP, 1993, COMPLEMENTARY THERAP, V1, P127; Wirth DP, 1990, SUBTLE ENERGIES, V1, P1; WOODS DL, 1993, THESIS SEATTLE U WAS; 1989, U COLORADO SCH N MAY, P1	138	135	137	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1005	1010		10.1001/jama.279.13.1005	http://dx.doi.org/10.1001/jama.279.13.1005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD283	9533499	Bronze, Green Published			2022-12-01	WOS:000072669700028
J	von Mutius, E; Weiland, SK; Fritzsch, C; Duhme, H; Keil, U				von Mutius, E; Weiland, SK; Fritzsch, C; Duhme, H; Keil, U			Increasing prevalence of hay fever and atopy among children in Leipzig, East Germany	LANCET			English	Article							RESPIRATORY SYMPTOMS; WEST-GERMANY; ASTHMA; SENSITIZATION; RESPONSIVENESS; REACTIVITY; BAVARIA; ADULTS; HEALTH; LIFE	Background Several surveys in children and adults have shown significantly lower prevalences of asthma and allergic diseases in eastern Europe than in western countries. In the former East Germany tremendous changes towards western lifestyle have occurred since unification. The aim of this survey was to investigate time trends in the prevalence of asthma and allergic diseases among children living in the eastern part of Germany. Methods In 1995-96, 2334 (87.5%) schoolchildren in Leipzig participated in a cross-sectional study that used the same methods as a previous survey done shortly after the fall of communism in 1991-92. A self-administered questionnaire was distributed to the parents. Children underwent cold-air challenge and allergy skinprick tests to SIX common aeroallergens. Findings The prevalence of hay fever (2.3% [34/1454] vs 5.1% [115/2252], p<0.0001) and atopic sensitisation (19.3% [252/1303] vs 26.7% [434/1624], p<0.0001) increased significantly between 1991-92 and 1995-96. However, there was no significant change in the prevalence of asthma, asthma-related symptoms, or bronchial hyper-responsiveness. Interpretation These findings suggest important differences in the development of atopic disorders. The children were born about 3 years before unification and were therefore exposed to western living conditions only after the third birthday: Thus, factors operating very early in life may be particularly important for the acquisition of childhood asthma, whereas the development of atopic sensitisation and hay fever may also be affected by environmental factors occurring beyond infancy.	Univ Munich, Childrens Hosp, D-8000 Munich, Germany; Univ Munster, Inst Epidemiol & Social Med, D-4400 Munster, Germany; Univ Leipzig, Childrens Hosp, D-7010 Leipzig, Germany	University of Munich; University of Munster; Leipzig University	von Mutius, E (corresponding author), Univ Munich, Kinderklin, Lindwurmstr 4, D-80337 Munich, Germany.							BERBIG B, 1991, ALLERGOLOGIE, V14, P51; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; EMANUEL MB, 1988, CLIN ALLERGY, V18, P295, DOI 10.1111/j.1365-2222.1988.tb02872.x; Jaross W., 1996, Reviews on Environmental Health, V11, P27; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; Livingstone AE, 1996, BRIT MED J, V312, P676; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MICHELS K, 1995, NEW ENGL J MED, V333, P130; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565, DOI 10.1164/ajrccm/147.3.565; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301, DOI 10.1159/000236541; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; vonMutius E, 1996, BRIT MED J, V312, P1448, DOI 10.1136/bmj.312.7044.1448; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; Warner JA, 1996, ALLERGY, V51, P447, DOI 10.1111/j.1398-9995.1996.tb00161.x; WINKLER G, 1992, ANN NUTR METAB, V36, P219, DOI 10.1159/000177721; WJST M, 1993, BRIT MED J, V307, P596, DOI 10.1136/bmj.307.6904.596; 1997, SACHSISCHES LANDESAM; 1997, STAT LANDESAMT SACHS	24	430	441	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					862	866		10.1016/S0140-6736(97)10100-3	http://dx.doi.org/10.1016/S0140-6736(97)10100-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525363				2022-12-01	WOS:000072645500012
J	Cahill, DP; Lengauer, C; Yu, J; Riggins, GJ; Willson, JKV; Markowitz, SD; Kinzler, KW; Vogelstein, B				Cahill, DP; Lengauer, C; Yu, J; Riggins, GJ; Willson, JKV; Markowitz, SD; Kinzler, KW; Vogelstein, B			Mutations of mitotic checkpoint genes in human cancers	NATURE			English	Article							SPINDLE ASSEMBLY CHECKPOINT; BUDDING YEAST; COLORECTAL-CANCER; MISMATCH REPAIR; MICROSATELLITE INSTABILITY; PROTEIN-KINASE; CELL-CYCLE; IDENTIFICATION; DEFECTS; MITOSIS	Genetic instability was one of the first characteristics to be postulated to underlie neoplasia(1-3). Such genetic instability occurs in two different forms. In a small fraction of colorectal and some other cancers, defective repair of mismatched bases results in an increased mutation rate at the nucleotide level and consequent widespread microsatellite instability(4-7). In most colorectal cancers, and probably in many other cancer types, a chromosomal instability (GIN) leading to an abnormal chromosome number (aneuploidy) is observed(8). The physiological and molecular bases of this pervasive abnormality are unknown. Here we show that CIN is consistently associated with the loss of function of a mitotic checkpoint, Moreover, in some cancers displaying CIN the loss of this checkpoint was associated with the mutational inactivation of a human homologue of the yeast BUB1 gene; BUB1 controls mitotic checkpoints and chromosome segregation in yeast, The normal mitotic checkpoints of cells displaying microsatellite instability become defective upon transfer of mutant hBUB1 alleles from either of two CIN cancers.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Program Human Genet, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Howard Hughes Med Inst, Cleveland, OH 44106 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; Case Western Reserve University; Case Western Reserve University; Howard Hughes Medical Institute	Lengauer, C (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Program Human Genet, 424 N Bond St, Baltimore, MD 21231 USA.	lengauer@welchlink.welch.jhu.edu	Yu, Jian/A-8301-2009	Yu, Jian/0000-0002-4021-1000; Cahill, Daniel/0000-0003-2552-6546				Boveri T, 1914, FRAGE ENTSTEHUNG MAL, V1; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; LENGAUER C, 1994, GENET ANAL-BIOMOL E, V11, P140, DOI 10.1016/1050-3862(94)90034-5; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOEB LA, 1991, CANCER RES, V51, P3075; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Pangilinan F, 1997, GENOMICS, V46, P379, DOI 10.1006/geno.1997.5068; Pangilinan F, 1996, MOL BIOL CELL, V7, P1195, DOI 10.1091/mbc.7.8.1195; PARSONS R, 1995, CANCER RES, V55, P5548; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Perucho M, 1996, BIOL CHEM, V377, P675; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Riggins GJ, 1997, CANCER RES, V57, P2578; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0	29	1272	1329	3	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 19	1998	392	6673					300	303		10.1038/32688	http://dx.doi.org/10.1038/32688			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521327				2022-12-01	WOS:000072612300052
J	Mizunuma, M; Hirata, D; Miyahara, K; Tsuchiya, E; Miyakawa, T				Mizunuma, M; Hirata, D; Miyahara, K; Tsuchiya, E; Miyakawa, T			Role of calcineurin and Mpk1 in regulating the onset of mitosis in budding yeast	NATURE			English	Article							MAP KINASE PATHWAY; SACCHAROMYCES-CEREVISIAE; HYPOTONIC SHOCK; CELL INTEGRITY; GENE; CALMODULIN; CALCIUM; PHOSPHATASE; ADAPTATION; EXPRESSION	Signalling via calcium is probably involved in regulating eukaryotic cell proliferation, but details of its mechanism of action are unknown(1,2). In Schizosaccharomyces pombe, the onset of mitosis is determined by activation of a complex of the p36(cdc2) protein kinase and a cyclin protein that is specific to the G2 phase of the cell cycle. This activation requires dephosphorylation of p34(cdc2) (ref. 3). Wee1, a tyrosine kinase that inhibits p34(cdc2) by phosphorylating it, is needed to determine the length of G2 phase, Here we show that calcium-activated pathways in Saccharomyces cerevisiae control the onset of mitosis by regulating Swe1, a Wee1 homologue. Zds1 (also known as Oss1 and Hst1) (refs 4-7) is important in repressing the transcription of SWE1 in G2 phase. In the presence of high calcium levels, cells lacking Zds1 are delayed in entering mitosis. Calcineurin(8-11) and Mpk1 (refs 12, 13) regulate Swe1 activation at the transcriptional and posttranslational levels, respectively, and both are required for the calcium-induced delay in G2 phase. These cellular pathways also induce a G2-phase delay In response to hypotonic shock.	Hiroshima Univ, Grad Sch Engn, Dept Mol Biotechnol, Higashihiroshima 739, Japan	Hiroshima University	Miyakawa, T (corresponding author), Hiroshima Univ, Grad Sch Engn, Dept Mol Biotechnol, Higashihiroshima 739, Japan.		Mizunuma, Masaki/V-2941-2017	Mizunuma, Masaki/0000-0002-1531-1763				Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; Bi EF, 1996, MOL CELL BIOL, V16, P5264; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FOOR F, 1992, NATURE, V360, P682; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; Ma XJ, 1996, GENE DEV, V10, P1327, DOI 10.1101/gad.10.11.1327; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; Nakamura T, 1996, MOL GEN GENET, V251, P211; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Tanaka S, 1996, GENES CELLS, V1, P905, DOI 10.1046/j.1365-2443.1996.d01-213.x; Tsuchiya E, 1996, GENE, V176, P35, DOI 10.1016/0378-1119(96)00204-1; Yu YX, 1996, MOL CELL BIOL, V16, P5254; ZARZOV P, 1996, EMBO J, V15, P81	25	115	116	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					303	306		10.1038/32695	http://dx.doi.org/10.1038/32695			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521328				2022-12-01	WOS:000072612300053
J	Mayer-Davis, EJ; D'Agostino, R; Karter, AJ; Haffner, SM; Rewers, MJ; Saad, M; Bergman, RN				Mayer-Davis, EJ; D'Agostino, R; Karter, AJ; Haffner, SM; Rewers, MJ; Saad, M; Bergman, RN		IRAS Invest	Intensity and amount of physical activity in relation to insulin sensitivity - The Insulin Resistance Atherosclerosis Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT DIABETES-MELLITUS; IMPAIRED GLUCOSE-TOLERANCE; NATIONAL-HEALTH; MINIMAL MODEL; YOUNG-ADULTS; EXERCISE; MUSCLE; OBESE; MEN; METABOLISM	Context.-Exercise training is associated with improved insulin sensitivity (S-I), but the potential impact of habitual, nonvigorous activity is uncertain. Objective.-To determine whether habitual, nonvigorous physical activity, as well as vigorous and overall activity, is associated with better S-I. Design.-A multicultural epidemiologic study. Setting.-The Insulin Resistance Atherosclerosis Study, conducted in Oakland, Calif; Los Angeles, Calif; the San Luis Valley, Cole; and San Antonio, Tex. Participants.-A total of 1467 men and women of African American, Hispanic, and non-Hispanic white ethnicity, aged 40 to 69 years, with glucose tolerance ranging from normal to mild non-insulin-dependent diabetes mellitus. Main Outcome Measure.-Insulin sensitivity as measured by an intravenous glucose tolerance test. Results.-The mean S-I for individuals who participated in vigorous activity 5 or more times per week was 1.59 min(-1).mu U-1.mL(-1).10(-4) (95% confidence interval [CI], 1.39-1.79) compared with 0.90 (95% CI, 0.83-0.97) for those who rarely or never participated in vigorous activity, after adjusting for potential confounders (P<.001). When habitual physical activity (estimated energy expenditure [EEE]) was assessed by 1-year recall of activities, the correlation coefficient between S-I and total EEE was 0.14 (P<.001), After adjustment for confounders, vigorous and nonvigorous levels of EEE (metabolic equivalent levels greater than or equal to 6.0 and <6.0, respectively) were each positively and independently associated with S-I (P less than or equal to.01 for each), The association was attenuated after adjustment for the potential mediators, body mass index (a measure of weight in kilograms divided by the square of the height in meters), and waist-to-hip ratio. Results were similar for subgroups of sex, ethnicity, and diabetes. Conclusions.-Increased participation in nonvigorous as well as overall and vigorous physical activity was associated with significantly higher S-I. These findings lend further support to current public health recommendations for increased moderate-intensity physical activity on most days.	Univ S Carolina, Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA; Kaiser Permanente, So Calif Permanente Med Grp, Div Res, Oakland, CA USA; Univ Texas, Hlth Sci Ctr, Dept Med, Div Clin Epidemiol, San Antonio, TX 78284 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Univ So Calif, Med Ctr, Dept Med, Los Angeles, CA USA; Univ So Calif, Med Ctr, Dept Physiol & Biophys, Los Angeles, CA USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Wake Forest University; Wake Forest Baptist Medical Center; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; University of Texas System; University of Texas Health San Antonio; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California	Mayer-Davis, EJ (corresponding author), Univ S Carolina, Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA.	ejmayerd@sph.sc.edu	Dagostino, Ralph/C-4060-2017	Dagostino, Ralph/0000-0002-3550-8395; Bergman, Richard/0000-0003-1539-4471	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL047887, U01HL047889, U01HL047890] Funding Source: NIH RePORTER; NHLBI NIH HHS [UO1-HL47887, UO1-HL47890, UO1-HL47889] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; [Anonymous], 1996, JAMA, V276, P241; BERGMAN RN, 1985, ENDOCR REV, V6, P45, DOI 10.1210/edrv-6-1-45; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BLOCK G, 1990, J CLIN EPIDEMIOL, V43, P1327, DOI 10.1016/0895-4356(90)90099-B; Boyko EJ, 1997, AM J EPIDEMIOL, V145, P18; BROZINICK JT, 1992, J APPL PHYSIOL, V73, P382, DOI 10.1152/jappl.1992.73.1.382; BURSTEIN R, 1990, J APPL PHYSIOL, V69, P299, DOI 10.1152/jappl.1990.69.1.299; Crespo CJ, 1996, ARCH INTERN MED, V156, P93, DOI 10.1001/archinte.156.1.93; Folsom AR, 1996, AM J EPIDEMIOL, V144, P235, DOI 10.1093/oxfordjournals.aje.a008918; FORD ES, 1995, DIABETES CARE, V18, P27, DOI 10.2337/diacare.18.1.27; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HOLLOSZY JO, 1986, ACTA MED SCAND, P55; HUGHES VA, 1993, AM J PHYSIOL, V264, pE855, DOI 10.1152/ajpendo.1993.264.6.E855; Kang J, 1996, DIABETES CARE, V19, P341, DOI 10.2337/diacare.19.4.341; KELLEY DE, 1995, INT J OBESITY, V19, pS14; KING DS, 1987, J APPL PHYSIOL, V63, P2247, DOI 10.1152/jappl.1987.63.6.2247; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; LEBLANC J, 1981, METABOLISM, V30, P1119, DOI 10.1016/0026-0495(81)90057-3; Lynch J, 1996, ARCH INTERN MED, V156, P1307, DOI 10.1001/archinte.156.12.1307; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P62; *NUTR COORD CTR, 1990, MINN NUTR DAT SYST C; PACINI G, 1986, COMPUT METH PROG BIO, V23, P113, DOI 10.1016/0169-2607(86)90106-9; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Perseghin G, 1996, NEW ENGL J MED, V335, P1357, DOI 10.1056/NEJM199610313351804; REGENSTEINER JG, 1991, DIABETES CARE, V14, P1066, DOI 10.2337/diacare.14.11.1066; REGENSTEINER JG, 1995, DIABETES CARE, V18, P490, DOI 10.2337/diacare.18.4.490; ROMIJN JA, 1993, AM J PHYSIOL, V265, pE380, DOI 10.1152/ajpendo.1993.265.3.E380; SAAD MF, 1994, DIABETES, V43, P1114, DOI 10.2337/diabetes.43.9.1114; *SAS I, 1989, SAS STAT US GUID VER, V2; SEGAL KR, 1991, J APPL PHYSIOL, V71, P2402, DOI 10.1152/jappl.1991.71.6.2402; SIDNEY S, 1991, AM J EPIDEMIOL, V133, P1231, DOI 10.1093/oxfordjournals.aje.a115835; SIEGEL PZ, 1995, AM J PUBLIC HEALTH, V85, P706, DOI 10.2105/AJPH.85.5.706; STEIL GM, 1993, DIABETES, V42, P250, DOI 10.2337/diabetes.42.2.250; Wagenknecht Lynne E., 1995, Annals of Epidemiology, V5, P464, DOI 10.1016/1047-2797(95)00062-3; WELCH S, 1990, J CLIN ENDOCR METAB, V71, P1508, DOI 10.1210/jcem-71-6-1508; Wolf A., 1992, American Journal of Epidemiology, V136, P992; World Health Organization, 1985, WHO TECHN REP SER, V727; YAMANOUCHI K, 1995, DIABETES CARE, V18, P775, DOI 10.2337/diacare.18.6.775	40	454	468	0	46	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					669	674		10.1001/jama.279.9.669	http://dx.doi.org/10.1001/jama.279.9.669			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496984	Bronze			2022-12-01	WOS:000072192800030
J	Xie, DX; Feys, BF; James, S; Nieto-Rostro, M; Turner, JG				Xie, DX; Feys, BF; James, S; Nieto-Rostro, M; Turner, JG			COI1: An Arabidopsis gene required for jasmonate-regulated defense and fertility	SCIENCE			English	Article							LEUCINE-RICH REPEATS; METHYL JASMONATE; YAC LIBRARY; THALIANA; RESISTANCE; PROTEIN; PLANTS; TRANSFORMATION; CONSTRUCTION; ENCODES	The coi1 mutation defines an Arabidopsis gene required for response to jasmonates, which regulate defense against insects and pathogens, wound healing, and pollen fertility. The wild-type allele, COI1, was mapped to a 90-kilobase genomic fragment and located by complementation of coi1-1 mutants. The predicted amino acid sequence of the COI1 protein contains 16 leucine-rich repeats and an F-box motif. It has similarity to the F-box proteins Arabidopsis TIR1, human Skp2, and yeast Grr1, which appear to function by targeting repressor proteins for removal by ubiquitination.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Turner, JG (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.		xie, daoxin d/C-8646-2017; Nieto-Rostro, Manuela/C-1621-2008					Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; CHRISTOU P, 1990, TRENDS BIOTECHNOL, V8, P145, DOI 10.1016/0167-7799(90)90160-Y; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; CREUSOT F, 1995, PLANT J, V8, P763, DOI 10.1046/j.1365-313X.1995.08050763.x; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; EPPEL CE, 1995, PLANT PHYSIOL, V109, P1813; FEYS BJF, 1994, PLANT CELL, V6, P751, DOI 10.1105/tpc.6.5.751; FLICK JS, 1991, MOL CELL BIOL, V11, P5101, DOI 10.1128/MCB.11.10.5101; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; JEFFERSON RA, 1987, EMBO J, V6, P3901; Jefferson RA., 1987, PLANT MOL BIOL REP, V5, P387, DOI DOI 10.1007/BF02667740; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; McConn M, 1997, P NATL ACAD SCI USA, V94, P5473, DOI 10.1073/pnas.94.10.5473; McConn M, 1996, PLANT CELL, V8, P403, DOI 10.1105/tpc.8.3.403; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; ODonnell PJ, 1996, SCIENCE, V274, P1914, DOI 10.1126/science.274.5294.1914; PENACORTES H, 1993, PLANTA, V191, P123, DOI 10.1007/BF00240903; Penninckx IAMA, 1996, PLANT CELL, V8, P2309, DOI 10.1105/tpc.8.12.2309; Rojo E, 1998, PLANT J, V13, P153, DOI 10.1046/j.1365-313X.1998.00020.x; Ruegger M, 1998, GENE DEV, V12, P198, DOI 10.1101/gad.12.2.198; RYAN CA, 1992, PLANT MOL BIOL, V19, P123, DOI 10.1007/BF00015610; SCHMIDT R, 1992, AUST J PLANT PHYSIOL, V19, P341, DOI 10.1071/PP9920341; SEMBDNER G, 1993, ANNU REV PLANT PHYS, V44, P569, DOI 10.1146/annurev.pp.44.060193.003033; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; STASWICK PE, 1992, P NATL ACAD SCI USA, V89, P6837, DOI 10.1073/pnas.89.15.6837; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; XIE DX, UNPUB; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	34	1199	1314	17	251	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 15	1998	280	5366					1091	1094		10.1126/science.280.5366.1091	http://dx.doi.org/10.1126/science.280.5366.1091			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9582125				2022-12-01	WOS:000073663600051
J	Carney, JP; Maser, RS; Olivares, H; Davis, EM; Le Beau, M; Yates, JR; Hays, L; Morgan, WF; Petrini, JHJ				Carney, JP; Maser, RS; Olivares, H; Davis, EM; Le Beau, M; Yates, JR; Hays, L; Morgan, WF; Petrini, JHJ			The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: Linkage of double-strand break repair to the cellular DNA damage response	CELL			English	Article							ATAXIA-TELANGIECTASIA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; BLOOMS SYNDROME; MEIOTIC RECOMBINATION; GENETIC-RECOMBINATION; HUMAN MRE11; IDENTIFICATION; RAD50; FIBROBLASTS	Nijmegen breakage syndrome (NBS) is an autosomal recessive disorder characterized by increased cancer incidence, cell cycle checkpoint defects, and ionizing radiation sensitivity. We have isolated the gene encoding p95, a member of the hMre11/hRad50 double-strand break repair complex. The p95 gene mapped to 8q21.3, the region that contains the NBS locus, and p95 was absent from NBS cells established from NBS patients, p95 deficiency in these cells completely abrogates the formation of hMre11/hRad50 ionizing radiation-induced foci. Comparison of the p95 cDNA to the NBS1 cDNA indicated that the p95 gene and NBS1 are identical. The implication of hMre11/hRad50/p95 protein complex in NBS reveals a direct molecular link between DSB repair and cell cycle checkpoint functions.	Univ Wisconsin, Sch Med, Genet Lab, Madison, WI 53706 USA; Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Washington; University of Washington Seattle; University of Chicago	Petrini, JHJ (corresponding author), Univ Wisconsin, Sch Med, Genet Lab, Madison, WI 53706 USA.		Maser, Richard/B-2970-2012		NCRR NIH HHS [5P41RR11823-02] Funding Source: Medline; NIGMS NIH HHS [GM56888, GM 52095] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052095, R01GM056888] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJIMURA M, 1993, GENETICS, V133, P51; BIGBEE WL, 1989, AM J HUM GENET, V44, P402; BLOCHER D, 1991, INT J RADIAT BIOL, V60, P791, DOI 10.1080/09553009114552601; BUBLEY GJ, 1987, SOMAT CELL MOLEC GEN, V13, P111, DOI 10.1007/BF01534691; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Cleaver J E, 1989, Birth Defects Orig Artic Ser, V25, P61; Connelly JC, 1997, J BIOL CHEM, V272, P19819, DOI 10.1074/jbc.272.32.19819; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; GERMAN J, 1983, CHROMOSOME MUTATION, P11; GIBSON FP, 1992, J BACTERIOL, V174, P1222, DOI 10.1128/jb.174.4.1222-1228.1992; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; HOJO ETS, 1995, MUTAT RES-ENVIR MUTA, V334, P59; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; Ivanov EL, 1996, GENETICS, V142, P693; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; James P, 1996, GENETICS, V144, P1425; Jayakumar A, 1996, P NATL ACAD SCI USA, V93, P14509, DOI 10.1073/pnas.93.25.14509; JOHZUKA K, 1995, GENETICS, V139, P1521; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; Link AJ, 1997, ELECTROPHORESIS, V18, P1314, DOI 10.1002/elps.1150180808; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuura S, 1997, AM J HUM GENET, V60, P1487, DOI 10.1086/515461; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MEYN MS, 1995, CANCER RES, V55, P5991; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; NELMS BE, 1998, IN PRESS SCIENCE; NISHIDA C, 1988, J BIOL CHEM, V263, P501; OGAWA H, 1995, ADV BIOPHYS, V31, P67, DOI 10.1016/0065-227X(95)99383-Z; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; PerezVera P, 1997, AM J MED GENET, V70, P24, DOI 10.1002/(SICI)1096-8628(19970502)70:1<24::AID-AJMG5>3.0.CO;2-R; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; PETRINI JHJ, 1994, J IMMUNOL, V152, P176; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; ROWLEY JD, 1994, LEUKEMIA, V8, pS1; Saar K, 1997, AM J HUM GENET, V60, P605; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stavnezer J, 1996, ADV IMMUNOL, V61, P79, DOI 10.1016/S0065-2776(08)60866-4; Stumm M, 1997, AM J HUM GENET, V60, P1246; Sullivan KE, 1997, CLIN IMMUNOL IMMUNOP, V82, P43, DOI 10.1006/clin.1996.4275; TAALMAN RDFM, 1983, MUTAT RES, V112, P23, DOI 10.1016/0167-8817(83)90021-4; TIMME TL, 1988, AM J MED SCI, V295, P40, DOI 10.1097/00000441-198801000-00009; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; vanderBurgt I, 1996, J MED GENET, V33, P153, DOI 10.1136/jmg.33.2.153; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; WEEMAES CMR, 1994, INT J RADIAT BIOL, V66, pS185; WEEMAES CMR, 1981, ACTA PAEDIATR SCAND, V70, P557, DOI 10.1111/j.1651-2227.1981.tb05740.x; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016; YOUNG BR, 1989, HUM GENET, V82, P113, DOI 10.1007/BF00284040	67	956	981	0	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1998	93	3					477	486		10.1016/S0092-8674(00)81175-7	http://dx.doi.org/10.1016/S0092-8674(00)81175-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590181	Bronze			2022-12-01	WOS:000073471500022
J	Gravel, S; Larrivee, M; Labrecque, P; Wellinger, RJ				Gravel, S; Larrivee, M; Labrecque, P; Wellinger, RJ			Yeast Ku as a regulator of chromosomal DNA end structure	SCIENCE			English	Article							STRAND-BREAK REPAIR; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; TELOMERE MAINTENANCE; BINDING PROTEIN; INVOLVEMENT; MECHANISM; ABSENCE; HDF1; GENE	During telomere replication in yeast, chromosome ends acquire an S-phase-specific overhang of the guanosine-rich strand. Here it is shown that in cells lacking Ku, a heterodimeric protein involved in nonhomologous DNA end joining, these overhangs are present throughout the cell cycle. In vivo cross-linking experiments demonstrated that Ku is bound to telomeric DNA, These results show that Ku plays a direct role in establishing a normal DNA end structure on yeast chromosomes, conceivably by functioning as a terminus-binding factor. Because Ku-mediated DNA end joining involving telomeres would result in chromosome instability, our data also suggest that Ku;has a distinct function when bound to telomeres.	Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Wellinger, RJ (corresponding author), Univ Sherbrooke, Fac Med, Dept Microbiol & Infectiol, 3001 12th Ave N, Sherbrooke, PQ J1H 5N4, Canada.		Wellinger, Raymund/K-3207-2019	Wellinger, Raymund/0000-0001-6670-2759				Barnes G, 1997, P NATL ACAD SCI USA, V94, P867, DOI 10.1073/pnas.94.3.867; Blackburn EH, 1995, TELOMERES; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; Feldmann H, 1996, J BIOL CHEM, V271, P27765, DOI 10.1074/jbc.271.44.27765; GRAVEL S, UNPUB; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; Mages GJ, 1996, J BIOL CHEM, V271, P7910, DOI 10.1074/jbc.271.14.7910; Milne GT, 1996, MOL CELL BIOL, V16, P4189; MIMORI T, 1986, J BIOL CHEM, V261, P375; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; Siede W, 1996, GENETICS, V142, P91; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Tsukamoto Y, 1996, NUCLEIC ACIDS RES, V24, P2067, DOI 10.1093/nar/24.11.2067; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	35	366	371	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1998	280	5364					741	744		10.1126/science.280.5364.741	http://dx.doi.org/10.1126/science.280.5364.741			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZL268	9563951				2022-12-01	WOS:000073415600049
J	Bush, TG; Savidge, TC; Freeman, TC; Cox, HJ; Campbell, EA; Mucke, L; Johnson, MH; Sofroniew, MV				Bush, TG; Savidge, TC; Freeman, TC; Cox, HJ; Campbell, EA; Mucke, L; Johnson, MH; Sofroniew, MV			Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice	CELL			English	Article							INFLAMMATORY BOWEL-DISEASE; FIBRILLARY ACIDIC PROTEIN; RECEPTOR MUTANT MICE; NERVOUS-SYSTEM; LACKING GDNF; INTESTINAL INFLAMMATION; REACTIVE ASTROCYTES; NEURONS; CELLS; EXPRESSION	To investigate the roles of astroglial cells, we targeted their ablation genetically. Transgenic mice were generated expressing herpes simplex virus thymidine kinase from the mouse glial fibrillary acidic protein (GFAP) promoter. In adult transgenic mice, 2 weeks of subcutaneous treatment with the antiviral agent ganciclovir preferentially ablated transgene-expressing, GFAP-positive glia from the jejunum and ileum, causing a fulminating and fatal jejuno-ileitis. This pathology was independent of bacterial overgrowth and was characterized by increased myeloperoxidase activity, moderate degeneration of myenteric neurons, and intraluminal hemorrhage. These findings demonstrate that enteric glia play an essential role in maintaining the integrity of the bowel and suggest that their loss or dysfunction may contribute to the cellular mechanisms of inflammatory bowel disease.	MRC, Cambridge Ctr Brain Repair, Cambridge CB2 2PY, England; Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Univ Birmingham, Inst Child Hlth, Birmingham B16 8ET, W Midlands, England; Sanger Ctr, Hinxton CB10 1SA, England; Univ Calif San Francisco, Gladstone Mol Neurobiol Program, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94141 USA	University of Cambridge; University of Cambridge; University of Birmingham; Wellcome Trust Sanger Institute; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Sofroniew, MV (corresponding author), MRC, Cambridge Ctr Brain Repair, Forvie Site,Robinson Way, Cambridge CB2 2PY, England.			johnson, martin/0000-0002-5906-5883; Freeman, Thomas/0000-0001-5235-8483; Mucke, Lennart/0000-0001-6256-9559	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALSHAWI R, 1988, MOL CELL BIOL, V8, P4821, DOI 10.1128/MCB.8.11.4821; Bar KJ, 1997, GASTROENTEROLOGY, V112, P1381, DOI 10.1016/S0016-5085(97)70154-9; BORRELLI E, 1989, NATURE, V339, P538, DOI 10.1038/339538a0; BUCHANAN RL, 1993, NEURON, V10, P839, DOI 10.1016/0896-6273(93)90200-B; Canfield V, 1996, P NATL ACAD SCI USA, V93, P2431, DOI 10.1073/pnas.93.6.2431; DAHL JL, 1987, GASTROENTEROLOGY, V92, P338, DOI 10.1016/0016-5085(87)90126-0; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; FRANK KB, 1984, J BIOL CHEM, V259, P1566; GERSHON MD, 1991, GLIA, V4, P195, DOI 10.1002/glia.440040211; Goyal RK, 1996, NEW ENGL J MED, V334, P1106, DOI 10.1056/NEJM199604253341707; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; HEYMAN RA, 1989, P NATL ACAD SCI USA, V86, P2698, DOI 10.1073/pnas.86.8.2698; Hogan B., 1986, MANIPULATING MOUSE E; Holst MC, 1995, J NEUROSCI METH, V62, P121, DOI 10.1016/0165-0270(95)00064-X; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; JESSEN KR, 1980, NATURE, V286, P736, DOI 10.1038/286736a0; JOHNSON WB, 1995, GLIA, V13, P174, DOI 10.1002/glia.440130304; Karaosmanoglu T, 1996, ANAT RECORD, V244, P470, DOI 10.1002/(SICI)1097-0185(199604)244:4<470::AID-AR5>3.0.CO;2-Z; KAWAJA MD, 1991, NEURON, V7, P1019, DOI 10.1016/0896-6273(91)90346-2; Kirchgessner AL, 1997, J NEUROSCI, V17, P8804; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; McCafferty DM, 1997, AM J PHYSIOL-GASTR L, V272, pG272, DOI 10.1152/ajpgi.1997.272.2.G272; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MILLER MJS, 1993, J PHARMACOL EXP THER, V264, P11; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sharkey KA, 1996, CAN J GASTROENTEROL, V10, P335, DOI 10.1155/1996/502865; SHARKEY KA, 1990, NEUROSCIENCE, V38, P13, DOI 10.1016/0306-4522(90)90370-J; STROBER W, 1993, CELL, V75, P203, DOI 10.1016/0092-8674(93)80062-J; Theodosis DT, 1996, TRENDS NEUROSCI, V19, P363, DOI 10.1016/0166-2236(96)10055-2; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; WALLACE H, 1991, ENDOCRINOLOGY, V129, P3217, DOI 10.1210/endo-129-6-3217	38	438	447	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 17	1998	93	2					189	201		10.1016/S0092-8674(00)81571-8	http://dx.doi.org/10.1016/S0092-8674(00)81571-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568712	Bronze			2022-12-01	WOS:000073174000006
J	Lee, HW; Blasco, MA; Gottlieb, GJ; Horner, JW; Greider, CW; DePinho, RA				Lee, HW; Blasco, MA; Gottlieb, GJ; Horner, JW; Greider, CW; DePinho, RA			Essential role of mouse telomerase in highly proliferative organs	NATURE			English	Article							IMMORTAL CELLS; RNA; CHROMOSOMES; ACTIVATION; GROWTH; YEAST; DNA	We have investigated the role of the enzyme telomerase in highly proliferative organs in successive generations of mice lacking telomerase RNA. Late-generation animals exhibited defective spermatogenesis, with increased programmed cell death (apoptosis) and decreased proliferation in the testis. The proliferative capacity of haematopoietic cells In the bone marrow and spleen was also compromised. These progressively adverse effects coincided with substantial erosion of telomeres (the termini of eukaryotic chromosomes) and fusion and loss of chromosomes. These findings indicate an essential role for telomerase, and hence telomeres, in the maintenance of genomic integrity and in the long-term viability of high-renewal organ systems.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Quest Diagnost Inc, Teterboro, NJ 07608 USA	Yeshiva University; Albert Einstein College of Medicine; Cold Spring Harbor Laboratory; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Greider, CW (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X; DePinho, Ronald/0000-0002-5625-577X				Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; Cannizzaro L A, 1997, Methods Mol Biol, V75, P313; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DROST JB, 1995, ENVIRON MOL MUTAGEN, V25, P48, DOI 10.1002/em.2850250609; ERSLEV AJ, 1993, HEMATOLOGY, P37; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GARAGNA S, 1995, CHROMOSOMA, V103, P685, DOI 10.1007/BF00344229; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HABER JE, 1984, GENETICS, V106, P207; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; McClintock B, 1941, GENETICS, V26, P234; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Muller H., 1938, COLLECT NET, V13, P182; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; NANDA I, 1995, CHROMOSOME RES, V3, P399, DOI 10.1007/BF00713889; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SHIMA H, 1990, ENDOCRINOLOGY, V127, P3222, DOI 10.1210/endo-127-6-3222; SINGER MS, 1994, SCIENCE, V266, P403; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WATT SM, 1992, CELL PROLIFERAT, V25, P263, DOI 10.1111/j.1365-2184.1992.tb01440.x; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Wright S, 1921, GENETICS, V6, P111; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	41	1047	1099	0	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					569	574		10.1038/33345	http://dx.doi.org/10.1038/33345			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560153				2022-12-01	WOS:000072987200049
J	Prescott, E; Hippe, M; Schnohr, P; Hein, HO; Vestbo, J				Prescott, E; Hippe, M; Schnohr, P; Hein, HO; Vestbo, J			Smoking and risk of myocardial infarction in women and men: longitudinal population study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP; CIGARETTE-SMOKING; CARDIOVASCULAR-DISEASE; BRITISH DOCTORS; OLDER MEN; MORTALITY; ESTROGEN; HEALTH	Objective: To compare risk of myocardial infarction associated with smoking in men and women, taking into consideration differences in smoking behaviour and a number of potential confounding variables. Design: Prospective cohort study with follow up of myocardial infarction. Setting: Pooled data from three population studies conducted in Copenhagen. Subjects: 11 472 women and 13 191 men followed for a mean of 12.3 years. Main outcome measures: First admission to hospital or death caused by myocardial infarction. Results: 1251 men and 512 women had a myocardial infarction during follow up. Compared with non-smokers, female current smokers had a relative risk of myocardial infarction of 2.24 (range 1.85-2.71) and male smokers 1.43 (1.26-1.62); ratio 1.57 (1.25-1.97). Relative risk of myocardial infarction increased with tobacco consumption in both men and women and was higher in inhalers than in non-inhalers. The risks associated with smoking, measured by both current and accumulated tobacco exposure, were consistently higher in women than in men and did not depend on age. This sex difference was not affected by adjustment for arterial blood pressure, total and high density lipoprotein cholesterol concentrations, triglyceride concentrations, diabetes, body mass index, height, alcohol intake, physical activity, and level of education. Conclusion: Women may be more sensitive than men to some of the harmful effects of smoking. Interactions between components of smoke and hormonal factors that may be involved in development of ischaemic heart disease should be examined further.	Univ Copenhagen, Inst Prevent Med, Copenhagen Ctr Prespect Populat Studies, Danish Epidemiol Sci Ctr, DK-1168 Copenhagen, Denmark; Univ Copenhagen, Bispebjerg Hosp, Copenhagen City Heart Study, DK-1168 Copenhagen, Denmark; Univ Copenhagen, Bispebjerg Hosp, Epidemiol Res Unit, DK-1168 Copenhagen, Denmark	Aarhus University; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Bispebjerg Hospital	Prescott, E (corresponding author), Kommune Hosp Copenhagen, Inst Prevent Med, DK-1399 Copenhagen K, Denmark.	eva.prescott@ipm.hosp.dk	Prescott, Eva/AAJ-7441-2020; Vestbo, Jorgen/Y-2912-2019	Vestbo, Jorgen/0000-0001-6355-6362; Prescott, Eva/0000-0002-4134-0349				BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; DAVIS MA, 1994, PREV MED, V23, P369, DOI 10.1006/pmed.1994.1051; Department of Health and Human Services. Epidemiology In National Heart Lung and Blood Institute, 1994, REP TASK FORC RES EP, P19; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1980, BRIT MED J, V280, P967, DOI 10.1136/bmj.280.6219.967; FLODERUS B, 1988, INT J EPIDEMIOL, V17, P332, DOI 10.1093/ije/17.2.332; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; JANGHORBANI M, 1993, INT J EPIDEMIOL, V22, P1056, DOI 10.1093/ije/22.6.1056; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LINDENSTROM E, 1993, STROKE, V24, P1468, DOI 10.1161/01.STR.24.10.1468; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; MICHNOVICZ JJ, 1989, METABOLISM, V38, P537, DOI 10.1016/0026-0495(89)90213-8; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; MILLER VT, 1991, OBSTET GYNECOL, V77, P235, DOI 10.1097/00006250-199102000-00014; Njolstad I, 1996, CIRCULATION, V93, P450; NYBOE J, 1991, AM HEART J, V122, P438, DOI 10.1016/0002-8703(91)90997-V; Peto R, 1994, MORTALITY SMOKING DE; PRESCOTT E, IN PRESS INT J EPIDE; SELTZER CC, 1989, J CLIN EPIDEMIOL, V42, P743, DOI 10.1016/0895-4356(89)90070-X; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; *STAT, 1997, STAT STAT SOFTW REL; THUN MJ, 1995, AM J PUBLIC HEALTH, V85, P1223, DOI 10.2105/AJPH.85.9.1223; TVERDAL A, 1993, J CLIN EPIDEMIOL, V46, P475, DOI 10.1016/0895-4356(93)90025-V; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680	25	376	391	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 4	1998	316	7137					1043	1047						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG302	9552903				2022-12-01	WOS:000072987400021
J	Hyatt, BA; Yost, HJ				Hyatt, BA; Yost, HJ			The left-right coordinator: The role of Vg1 in organizing left-right axis formation	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-4; LEFT-RIGHT ASYMMETRY; XENOPUS EMBRYOS; MESODERM INDUCTION; TRUNCATED ACTIVIN; NODAL EXPRESSION; SITUS-INVERSUS; NOGGIN; BMP-4; SPECIFICATION	The asymmetries of internal organs are consistently oriented along the left-right axis in all vertebrates, and perturbations of left-right orientation lead to significant congenital disease. We propose a model in which a "left-right coordinator" interacts with the Spemann organizer to coordinate the evolutionarily conserved three-dimensional asymmetries in the embryo. The Vg1 cell-signaling pathway plays a central role in left-right coordinator function. Antagonists of Vg1 alter left-right development; antagonists of other members of the TGF beta family do not. Cell-lineage directed expression of Vg1 protein can fully invert the left-right axis (situs inversus), can randomize left-right asymmetries, or can "rescue" a perturbed left-right axis in conjoined twins to normal orientation (situs solitus), indicating that Vg1 can mimic left-right coordinator activity. These are the first molecular manipulations in any vertebrate by which the left-right axis can be reliably controlled.	Univ Minnesota, Grad Program Mol Cell Dev Biol & Genet, Minneapolis, MN 55455 USA; Univ Utah, Huntsman Canc Inst, Ctr Children, Dept Oncol Sci, Salt Lake City, UT 84103 USA; Univ Utah, Huntsman Canc Inst, Ctr Children, Dept Pediat, Salt Lake City, UT 84103 USA	University of Minnesota System; University of Minnesota Twin Cities; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Yost, HJ (corresponding author), Univ Minnesota, Grad Program Mol Cell Dev Biol & Genet, Minneapolis, MN 55455 USA.							Bowers PN, 1996, PROG PEDIATR CARDIOL, V6, P53, DOI 10.1016/1058-9813(96)00171-3; Chang CB, 1997, DEVELOPMENT, V124, P827; Chen JN, 1997, DEVELOPMENT, V124, P4373; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1992, DEVELOPMENT, V115, P573; DANOS MC, 1995, DEVELOPMENT, V121, P1467; Danos MC, 1996, DEV BIOL, V177, P96, DOI 10.1006/dbio.1996.0148; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Frisch A, 1998, DEVELOPMENT, V125, P431; FUKUI A, 1993, DEV BIOL, V159, P131, DOI 10.1006/dbio.1993.1227; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HIROSE G, 1979, DEV BIOL, V71, P191, DOI 10.1016/0012-1606(79)90163-5; Hyatt BA, 1996, NATURE, V384, P62, DOI 10.1038/384062a0; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; JOHNSON AD, 1994, GENE, V147, P223, DOI 10.1016/0378-1119(94)90070-1; Jones CM, 1996, DEVELOPMENT, V122, P1545; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; Levin M, 1996, NATURE, V384, P321, DOI 10.1038/384321a0; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Lustig KD, 1996, DEVELOPMENT, V122, P3275; MOODY SA, 1987, DEV BIOL, V119, P560, DOI 10.1016/0012-1606(87)90059-5; NAKAMURA O, 1971, P JPN ACAD, V47, P407, DOI 10.2183/pjab1945.47.407; Nascone N, 1997, DEV BIOL, V189, P68, DOI 10.1006/dbio.1997.8635; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Psychoyos D, 1996, DEVELOPMENT, V122, P3263; ReemKalma Y, 1995, P NATL ACAD SCI USA, V92, P12141, DOI 10.1073/pnas.92.26.12141; Sampath K, 1997, DEVELOPMENT, V124, P3293; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Sasai Y, 1996, EMBO J, V15, P4547, DOI 10.1002/j.1460-2075.1996.tb00832.x; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; Spemann H, 1919, ARCH ENTWICKLUNG ORG, V45, P371, DOI 10.1007/BF02554405; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; Wilson PA, 1997, DEVELOPMENT, V124, P3177; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YOSH HJ, 1995, CELL, V82, P689; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0; YOST HJ, 1991, CIBA F SYMP, V162, P165; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	49	134	137	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					37	46		10.1016/S0092-8674(00)81144-7	http://dx.doi.org/10.1016/S0092-8674(00)81144-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546390	Bronze			2022-12-01	WOS:000072910800008
J	Nichols, WC; Seligsohn, U; Zivelin, A; Terry, VH; Hertel, CE; Wheatley, MA; Moussalli, MJ; Hauri, HP; Ciavarella, N; Kaufman, RJ; Ginsburg, D				Nichols, WC; Seligsohn, U; Zivelin, A; Terry, VH; Hertel, CE; Wheatley, MA; Moussalli, MJ; Hauri, HP; Ciavarella, N; Kaufman, RJ; Ginsburg, D			Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII	CELL			English	Article							EFFICIENT THROMBIN CLEAVAGE; FACTOR-BASED VECTOR; ENDOPLASMIC-RETICULUM; C INHIBITOR; MEMBRANE-PROTEIN; PROCOAGULANT ACTIVITY; LEGUMINOUS LECTINS; RECYCLING PATHWAY; MAMMALIAN-CELLS; CIS-GOLGI	Combined deficiency of factors V and VIII is an autosomal recessive bleeding disorder resulting from alterations in an unknown gene on chromosome 18q, distinct from the factor V and factor VIII genes. ERGIC-53, a component of the ER-Golgi intermediate compartment, was mapped to a YAC and BAC contig containing the critical region for the combined factors V and VIII deficiency gene. DNA sequence analysis identified two different mutations, accounting for all affected individuals in nine families studied. Immunofluorescence and Western analysis of immortalized lymphocytes from patients homozygous for either of the two mutations demonstrate complete lack of expression of the mutated gene in these cells. These findings suggest that ERGIC-53 may function as a molecular chaperone for the transport from ER to Golgi of a specific subset of secreted proteins, including coagulation factors V and VIII.	Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Chaim Sheba Med Ctr, Inst Thrombosis & Hemostasis, IL-52621 Tel Hashomer, Israel; Univ Basel, Biozentrum, Basel, Switzerland; Policlin Bari, Univ Hosp, Dept Blood Coagulat, I-70124 Bari, Italy; Policlin Bari, Univ Hosp, Hemophilia Ctr, I-70124 Bari, Italy	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; University of Basel; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Ginsburg, D (corresponding author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.			Wheatley, Matthew/0000-0002-4816-9548	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL039693, P01HL057346, R01HL039693] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39693, HL57346] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM KAR, 1985, SCAND J HAEMATOL, V34, P401; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BONTEMPO FA, 1987, BLOOD, V69, P1721; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; CANFIELD WM, 1982, J CLIN INVEST, V70, P1260, DOI 10.1172/JCI110725; CHANDRASEKHARAP.SC, 1992, ELECTROPHORESIS PROT, P235; CHIU HC, 1985, J CLIN INVEST, V75, P339, DOI 10.1172/JCI111706; COONEY KA, 1991, J CLIN INVEST, V87, P1227, DOI 10.1172/JCI115123; CRIPE LD, 1992, BIOCHEMISTRY-US, V31, P3777, DOI 10.1021/bi00130a007; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; GARDINER JE, 1984, THROMB RES, V36, P197, DOI 10.1016/0049-3848(84)90219-6; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GINSBURG D, 1997, EMERY RIMOINS PRINCI, P1651; GIROLAMI A, 1976, BLUT, V32, P415, DOI 10.1007/BF01013881; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; KAUFMAN RJ, 1998, IN PRESS THROMB HAEM; KIM UJ, 1992, NUCLEIC ACIDS RES, V20, P1083, DOI 10.1093/nar/20.5.1083; Kim UJ, 1996, P NATL ACAD SCI USA, V93, P6297, DOI 10.1073/pnas.93.13.6297; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MANN KG, 1984, J BIOL CHEM, V259, P2949; MARLAR RA, 1980, J CLIN INVEST, V66, P1186, DOI 10.1172/JCI109952; MAZZONE D, 1982, ACTA HAEMATOL-BASEL, V68, P337, DOI 10.1159/000207005; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; NeermanArbez M, 1997, AM J HUM GENET, V61, P143, DOI 10.1086/513897; Nichols WC, 1997, J CLIN INVEST, V99, P596, DOI 10.1172/JCI119201; Nichols WC, 1996, BLOOD, V88, P4429, DOI 10.1182/blood.V88.12.4429.bloodjournal88124429; OERI J, 1954, MED PROBL PAEDIAT, V1, P575; ORTEL TL, 1984, P NATL ACAD SCI-BIOL, V81, P4761, DOI 10.1073/pnas.81.15.4761; OZSOYLU S, 1983, ACTA HAEMATOL-BASEL, V70, P207, DOI 10.1159/000206726; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PITTMAN DD, 1994, BLOOD, V84, P4214, DOI 10.1182/blood.V84.12.4214.bloodjournal84124214; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SELIGSOHN U, 1982, NEW ENGL J MED, V307, P1191, DOI 10.1056/NEJM198211043071907; Seligsohn U, 1989, FACTOR 8 VON WILLEBR, P89; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; SUGDEN B, 1977, J VIROL, V23, P503, DOI 10.1128/JVI.23.3.503-508.1977; SUZUKI K, 1983, BLOOD, V62, P1266; Tagliavacca L, 1997, J BIOL CHEM, V272, P27428, DOI 10.1074/jbc.272.43.27428; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0	61	330	338	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1998	93	1					61	70		10.1016/S0092-8674(00)81146-0	http://dx.doi.org/10.1016/S0092-8674(00)81146-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546392	Bronze			2022-12-01	WOS:000072910800010
J	Singson, A; Mercer, KB; L'Hernault, SW				Singson, A; Mercer, KB; L'Hernault, SW			The C-elegans spe-9 gene encodes a sperm transmembrane protein that contains EGF-like repeats and is required for fertilization	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; EPIDERMAL GROWTH-FACTOR; MEMBRANE-PROTEIN; DROSOPHILA; DELTA; NOTCH; SERRATE; CELL; RECEPTOR; GENOME	In the nematode worm C. elegans, individuals with mutations in the spe-g gene produce spermatozoa with wild-type morphology and motility that cannot fertilize oocytes even after contact between gametes. Therefore, disruption of spe9 function affects either gamete recognition, adhesion, signaling, and/or fusion; The spe-g gene encodes a sperm transmembrane protein with an extracellular domain that contains ten epidermal growth factor-like repeats. A common feature of proteins that include epidermal growth factor-like motifs is their involvement in extracellular functions such as adhesive and ligand-receptor interactions. Additionally, the overall structure of the predicted SPE-9 protein is similar to that of ligands for the Notch/LIN-12/GLP-1 family of transmembrane receptors. These results suggest that SPE-9 functions in the specialized cell-cell interactions required for fertilization.	Emory Univ, Dept Biol, Atlanta, GA 30322 USA	Emory University	Singson, A (corresponding author), Emory Univ, Dept Biol, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040697, R29GM040697] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40697] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Achanzar WE, 1997, J CELL SCI, V110, P1073; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BRENNER S, 1974, GENETICS, V77, P71; Browning H, 1996, DEVELOPMENT, V122, P391; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; DAVIS C G, 1990, New Biologist, V2, P410; DONIACH T, 1984, DEV BIOL, V106, P223, DOI 10.1016/0012-1606(84)90077-0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; Fleming RJ, 1997, TRENDS CELL BIOL, V7, P437, DOI 10.1016/S0962-8924(97)01161-6; FOLTZ KR, 1993, DEV BIOL, V158, P46, DOI 10.1006/dbio.1993.1167; GREENSPAN R J, 1990, New Biologist, V2, P595; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; Herman RK, 1995, METHOD CELL BIOL, V48, P123; HIRSH D, 1976, DEV BIOL, V49, P200, DOI 10.1016/0012-1606(76)90267-0; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; Krause M, 1995, METHOD CELL BIOL, V48, P483; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; L'Hernault SW, 1997, C ELEGANS, P271; LHERNAULT SW, 1988, GENETICS, V120, P435; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; LHernault SW, 1995, METHOD CELL BIOL, V48, P273; LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PRIMAKOFF P, 1983, DEV BIOL, V98, P417, DOI 10.1016/0012-1606(83)90371-8; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Riddle DL, 1997, C ELEGANS; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEDL T, 1997, C ELEGANS, V2, P241; SHAKES DC, 1989, DEV BIOL, V134, P189, DOI 10.1016/0012-1606(89)90088-2; Snell WJ, 1996, CELL, V85, P629, DOI 10.1016/S0092-8674(00)81230-1; Sun X, 1996, DEVELOPMENT, V122, P2465; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; WARD S, 1979, DEV BIOL, V73, P304, DOI 10.1016/0012-1606(79)90069-1; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Yanagimachi R., 1994, P189	53	101	108	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 3	1998	93	1					71	79		10.1016/S0092-8674(00)81147-2	http://dx.doi.org/10.1016/S0092-8674(00)81147-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546393	Bronze			2022-12-01	WOS:000072910800011
J	Tacke, R; Tohyama, M; Ogawa, S; Manley, JL				Tacke, R; Tohyama, M; Ogawa, S; Manley, JL			Human Tra2 proteins are sequence-specific activators of pre-mRNA splicing	CELL			English	Article							T ALTERNATIVE EXON; RNA-BINDING PROTEINS; SR-PROTEINS; MESSENGER-RNA; PREMESSENGER RNA; SEX DETERMINATION; DROSOPHILA-MELANOGASTER; REGULATORY ELEMENTS; CONSERVED FAMILY; ENHANCER COMPLEX	The RNA-binding protein Tra2 is an important regulator of sex determination in Drosophila. Recently, two mammalian Tra2 homologs of unknown function have been described. Here, we show that human Tra2 proteins are present in HeLa cell nuclear extracts and that they bind efficiently and specifically to a previously characterized pre-mRNA splicing enhancer element. Indeed, both purified proteins bound preferentially to RNA sequences containing GAA repeats, characteristic of many enhancer elements. Neither Tra2 protein functioned in constitutive splicing in vitro, but both activated enhancer-dependent splicing in a sequence-specific manner and restored it after inhibition with competitor RNA. Our findings indicate that mammalian Tra2 proteins are sequence-specific splicing activators that likely participate in the control of cell-specific splicing patterns.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Osaka Univ, Sch Med, Dept Anat & Neurosci, Suita, Osaka 565, Japan	Columbia University; Osaka University	Manley, JL (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.			Manley, James/0000-0002-8341-1459	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048259, R37GM048259] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BAKER BS, 1980, GENETICS, V94, P383; Beil B, 1997, DNA CELL BIOL, V16, P679, DOI 10.1089/dna.1997.16.679; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Burtis KC, 1993, CURR OPIN CELL BIOL, V5, P1006, DOI 10.1016/0955-0674(93)90085-5; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; CRISPINO JD, 1994, SCIENCE, V265, P1866, DOI 10.1126/science.8091213; Dauwalder B, 1996, P NATL ACAD SCI USA, V93, P9004, DOI 10.1073/pnas.93.17.9004; Elrick LL, 1998, MOL CELL BIOL, V18, P343, DOI 10.1128/MCB.18.1.343; FU XD, 1995, RNA, V1, P663; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HAZELRIGG T, 1994, P NATL ACAD SCI USA, V91, P10752, DOI 10.1073/pnas.91.22.10752; HEINRICHS V, 1995, EMBO J, V14, P3987, DOI 10.1002/j.1460-2075.1995.tb00070.x; Heinrichs V, 1998, MOL CELL BIOL, V18, P450, DOI 10.1128/MCB.18.1.450; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; LYNCH KW, 1995, GENE DEV, V9, P284, DOI 10.1101/gad.9.3.284; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Madigan SJ, 1996, MOL CELL BIOL, V16, P4222; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MATSUO N, 1995, J BIOL CHEM, V270, P28216, DOI 10.1074/jbc.270.47.28216; Mattox W, 1996, GENETICS, V143, P303; MATTOX W, 1991, GENE DEV, V5, P786, DOI 10.1101/gad.5.5.786; PENG XB, 1995, MOL CELL BIOL, V15, P6273; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; RING HJ, 1994, MOL CELL BIOL, V14, P7499, DOI 10.1128/MCB.14.11.7499; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Segade F, 1996, FEBS LETT, V387, P152, DOI 10.1016/0014-5793(96)00496-6; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TARN WY, 1994, GENE DEV, V8, P2704, DOI 10.1101/gad.8.22.2704; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1994, GENE DEV, V8, P1703, DOI 10.1101/gad.8.14.1703; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; Tronchere H, 1997, NATURE, V388, P397, DOI 10.1038/41137; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/S0968-0004(96)10039-6; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; WANG J, 1995, RNA, V1, P335; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; YEAKLEY JM, 1993, MOL CELL BIOL, V13, P5999, DOI 10.1128/MCB.13.10.5999; Yeakley JM, 1996, P NATL ACAD SCI USA, V93, P7582, DOI 10.1073/pnas.93.15.7582; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	64	173	180	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 3	1998	93	1					139	148		10.1016/S0092-8674(00)81153-8	http://dx.doi.org/10.1016/S0092-8674(00)81153-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZF571	9546399	hybrid			2022-12-01	WOS:000072910800017
J	Wray, GA				Wray, GA			Transcription - Promoter logic	SCIENCE			English	Article							EMBRYO		SUNY Stony Brook, Dept Ecol & Evolut, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Wray, GA (corresponding author), SUNY Stony Brook, Dept Ecol & Evolut, Stony Brook, NY 11794 USA.							Arnone MI, 1997, DEVELOPMENT, V124, P1851; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896; YUH CH, 1994, MECH DEVELOP, V47, P165, DOI 10.1016/0925-4773(94)90088-4	4	15	16	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1871	1872		10.1126/science.279.5358.1871	http://dx.doi.org/10.1126/science.279.5358.1871			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9537905				2022-12-01	WOS:000072613300028
J	Billker, O; Lindo, V; Panico, M; Etienne, AE; Paxton, T; Dell, A; Rogers, M; Sinden, RE; Morris, HR				Billker, O; Lindo, V; Panico, M; Etienne, AE; Paxton, T; Dell, A; Rogers, M; Sinden, RE; Morris, HR			Identification of xanthurenic acid as the putative inducer of malaria development in the mosquito	NATURE			English	Article							PLASMODIUM; VECTOR	Malaria is transmitted from vertebrate host to mosquito vector by mature sexual blood-living stages called gametocytes(1,2). Within seconds of ingestion into the mosquito bloodmeal, gametocytes undergo gametogenesis. Induction requires the simultaneous exposure to at least two stimuli in vitro: a drop in bloodmeal temperature to 5 degrees C below that of the vertebrate host(1-3), and a rise in pH from 7.4 to 8.0-8.2 (refs 1, 4). In vivo the mosquito bloodmeal has a pH of between 7.5 and 7.6 (refs 5, 6). It is thought that in vivo the second inducer is an unknown mosquito-derived gametocyte-activating factor(5,7,8). Here we show that this factor is xanthurenic acid. We also show that low concentrations of xanthurenic acid can act together with pH to induce gametogenesis in vitro. Structurally related compounds are at least ninefold less effective at inducing gametogenesis in vitro. In Drosophila mutants with lesions in the kynurenine pathway of tryptophan metabolism (of which xanthurenic acid is a side product), no alternative active compound was detected in crude insect homogenates. These data could form the basis of the rational development of new methods of interrupting the transmission of malaria using-drugs or new refractory mosquito genotypes to block parasite gametogenesis.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2BB, England; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England; M Scan Inc, W Chester, PA 19380 USA	Imperial College London; Imperial College London	Sinden, RE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2BB, England.		Ranford-Cartwright, Lisa C/H-4701-2013	Ranford-Cartwright, Lisa C/0000-0003-1992-3940; Billker, Oliver/0000-0003-1716-168X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BATTERSBY A R, 1977, Tetrahedron Letters, V25, P2213; BEARD CB, 1995, J HERED, V86, P375, DOI 10.1093/oxfordjournals.jhered.a111606; BILLKER O, 1997, PARASITOLOGY, V14, P1; BISHOP A, 1956, PARASITOLOGY, V46, P192, DOI 10.1017/S0031182000026433; CARTER R, 1988, MALARIA PRINCIPLES P, P273; Cochran D.G., 1985, P467; Garcia GE, 1997, MOL BIOCHEM PARASIT, V88, P127, DOI 10.1016/S0166-6851(97)00086-8; HUNT E, 1973, BIOCHEM J, V135, P833, DOI 10.1042/bj1350833; KAYSER H, 1985, COMP INSECT PHYSL BI, V10, P368; MICKS DW, 1948, AM J HYG, V48, P182, DOI 10.1093/oxfordjournals.aje.a119234; MORRIS A, 1998, MASS SPECTROMETRY BI, V2, P53; MORRIS HR, 1980, NATURE, V285, P104, DOI 10.1038/285104a0; Morris HR, 1996, RAPID COMMUN MASS SP, V10, P889, DOI 10.1002/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F; Morris HR, 1997, J PROTEIN CHEM, V16, P469, DOI 10.1023/A:1026309410737; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; MORRIS HR, 1980, J NEUROCHEM, V34, P574, DOI 10.1111/j.1471-4159.1980.tb11183.x; NIJHOUT MM, 1978, PARASITOLOGY, V76, P39, DOI 10.1017/S0031182000047375; NIJHOUT MM, 1979, EXP PARASITOL, V48, P75, DOI 10.1016/0014-4894(79)90056-0; PHILLIPS JP, 1980, GENETICS BIOL DROS B, V2, P542; SINDEN RE, 1983, ADV PARASIT, V22, P153, DOI 10.1016/S0065-308X(08)60462-5; Sinden RE, 1996, ADV PARASIT, V38, P53, DOI 10.1016/S0065-308X(08)60033-0; SULLIVAN DT, 1979, BIOCHEM GENET, V17, P565, DOI 10.1007/BF00498891; SULLIVAN DT, 1975, BIOCHEM GENET, V13, P603, DOI 10.1007/BF00484918; TRUSCOTT RJW, 1995, CLIN SCI, V89, P591, DOI 10.1042/cs0890591; WESSING A, 1968, Z NATURFORSCH PT B, VB 23, P376; WILLIAMS SA, 1984, AM J CLIN NUTR, V40, P159, DOI 10.1093/ajcn/40.1.159	26	452	461	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					289	292		10.1038/32667	http://dx.doi.org/10.1038/32667			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521324				2022-12-01	WOS:000072612300049
J	Alderman, MH; Cohen, H; Madhavan, S				Alderman, MH; Cohen, H; Madhavan, S			Dietary sodium intake and mortality: the national health and nutrition examination survey (NHANES I)	LANCET			English	Article							LOWER BLOOD-PRESSURE; MYOCARDIAL-INFARCTION; OBSERVATIONAL DATA; UNITED-STATES; SALT; RISK; POPULATIONS; MEN	Background Population-wide restriction of dietary sodium has been recommended. However, little evidence directly links sodium intake to morbidity and mortality. The aim of this study was to assess the relation of sodium intake to subsequent all-cause and cardiovascular-disease (CVD) mortality in a general population. Methods The first National Health and Nutrition Examination Survey established baseline information during 1971-75 in a representative sample of 20 729 US adults (aged 25-75). 11 348 underwent medical examination and nutritional examination based on 24 h recall. Two had no data on sodium intake available. Vital status at June 30, 1992, was obtained for the 11 346 participants through interview, tracing, and searches of the national death index. Mortality was examined in sex-specific quartiles of sodium intake. calorie intake, and sodium/calorie ratio. Multiple regression analyses were done to assess the relations with mortality. Findings There were 3923 deaths, of which 1970 were due to CVD. All-cause mortality (per 1000 person-years; adjusted for age and sex) was inversely associated viith sex-specific quartiles of sodium intake (lowest to highest quartile 23.18 to 19.01, p<0.0001) and total calorie intake (25.03 to 18.40, p<0.0001) and showed a weak positive association with quartiles of sodium/calorie ratio (20.27 to 21.71, p=0.14). The pattern for CVD mortality was similar (sodium 11.80 to 9.60, p<0.0019; calories 12.80 to 8.94, p<0.0002; sodium/calorie ratio 9.73 to 11.35, p=0.017). In Cox multiple regression analysis, sodium intake was inversely associated with all-cause (p=0.0069) and CVD mortality (p=0.086) and sodium/calorie ratio was directly associated with all-cause (p=0.0004) and CVD mortality (p=0.0056). By contrast, calorie intake in the presence of the two measures of sodium intake was not independently associated with mortality (all-cause p=0.86; CVD p=0.74). Analysis restricted to participants with no history of CVD at baseline gave similar results. Interpretation This observational study does not justify any particular dietary recommendation. Specifically, these results do not support current recommendations for routine reduction of sodium consumption, nor do they justify advice to increase salt intake or to decrease its concentration in the diet.	Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Alderman, MH (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Social Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	alderman@aecom.yu.edu		Cohen, Hillel/0000-0002-4524-0898				Alaimo K, 1994, Adv Data, P1; ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144; ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; BEEVERS DG, 1989, J HUM HYPERTENS, V3, P279; COX CS, 1992, VITAL HLTH STAT, V1, P1; CUTLER JA, 1991, HYPERTENSION, V17, pI27, DOI 10.1161/01.HYP.17.1_Suppl.I27; DAHL LK, 1954, ARCH INTERN MED, V94, P525, DOI 10.1001/archinte.1954.00250040017003; DESIMONE G, 1990, CIRCULATION, V81, P107, DOI 10.1161/01.CIR.81.1.107; DWYER JT, 1994, AM J PUBLIC HEALTH, V84, P1299, DOI 10.2105/AJPH.84.8.1299; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; ELLIOTT P, 1991, HYPERTENSION, V17, pI3, DOI 10.1161/01.HYP.17.1_Suppl.I3; ENGSTROM AM, 1983, ANN INTERN MED, V98, P870, DOI 10.7326/0003-4819-98-5-870; FOLKOW B, 1989, ACTA PHYSIOL SCAND, V136, P89; FROST CD, 1991, BRIT MED J, V302, P815, DOI 10.1136/bmj.302.6780.815; GLEIBERMANN L., 1973, Ecology of Food and Nutrition, V2, P143, DOI 10.1080/03670244.1973.9990329; GRACIA G, 1997, HYPERTENSION, V29, P802; Hollenberg NK, 1997, HYPERTENSION, V29, P171, DOI 10.1161/01.HYP.29.1.171; Huijbregts P, 1997, BRIT MED J, V315, P13, DOI 10.1136/bmj.315.7099.13; JACKSON FLC, 1991, HYPERTENSION S1, V17, P129; JAMES GD, 1993, AM J HYPERTENS, V6, pA86; JENSEN OM, 1984, AM J EPIDEMIOL, V120, P281, DOI 10.1093/oxfordjournals.aje.a113891; KANT AK, 1995, AM J CLIN NUTR, V61, P11, DOI 10.1093/ajcn/61.1.11; KIM I, 1993, AM J PUBLIC HEALTH, V83, P546, DOI 10.2105/AJPH.83.4.546; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LUFT FC, 1979, CIRCULATION, V60, P697, DOI 10.1161/01.CIR.60.3.697; MacGregor GA, 1996, BRIT MED J, V312, P1287, DOI 10.1136/bmj.312.7041.1287; MCCARRON DA, 1984, SCIENCE, V224, P1392, DOI 10.1126/science.6729459; Midgley JP, 1996, JAMA-J AM MED ASSOC, V275, P1590, DOI 10.1001/jama.275.20.1590; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; *US DEP HHS, 1996, PUBL US TAP DOC NHAN; *USDA, 1995, DIET GUID ADV COMM R; Wassertheilsmoller S, 1991, ANN INTERN MED, V114, P613, DOI 10.7326/0003-4819-114-8-613	32	250	252	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					781	785		10.1016/S0140-6736(97)09092-2	http://dx.doi.org/10.1016/S0140-6736(97)09092-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519949				2022-12-01	WOS:000072521200010
J	Patel, SK; Indig, FE; Olivieri, N; Levine, ND; Latterich, M				Patel, SK; Indig, FE; Olivieri, N; Levine, ND; Latterich, M			Organelle membrane fusion: A novel function for the syntaxin homolog Ufe1p in ER membrane fusion	CELL			English	Article							ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; CELL-CYCLE; PROTEIN; GENE; DOCKING; REQUIRES; COMPLEX; PATHWAY; ENCODES	The fusion of endoplasmic reticulum (ER) membranes in yeast does not require Sec18p/NSF and Sec17p, two proteins needed for docking of vesicles with their target membrane. Instead, ER membranes require a NSF-related ATPase, Cdc48p. Since both vesicular and organelle fusion events use related ATPases, we investigated whether both fusion events are also SNARE mediated. We present evidence that the fusion of ER membranes requires Ufe1p, a t-SNARE that localizes to the ER, but no known v-SNAREs. We propose that the Ufe1 protein acts in the dual capacity of an organelle membrane fusion-associated SNARE by undergoing direct t-t-SNARE and Cdc48p interactions during organelle membrane fusion as well as a t-SNARE for vesicular traffic.	Salk Inst, La Jolla, CA 92037 USA	Salk Institute	Latterich, M (corresponding author), Salk Inst, La Jolla, CA 92037 USA.							ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Indig FE, 1997, BIOCHEM J, V327, P291, DOI 10.1042/bj3270291; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; KURIHARA LJ, 1994, J CELL BIOL, V126, P911, DOI 10.1083/jcb.126.4.911; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Pevsner J, 1996, J NEUROSCI RES, V45, P89, DOI 10.1002/(SICI)1097-4547(19960715)45:2<89::AID-JNR1>3.3.CO;2-K; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SWEET DJ, 1993, EMBO J, V12, P2831, DOI 10.1002/j.1460-2075.1993.tb05944.x; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299	33	135	138	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					611	620		10.1016/S0092-8674(00)81129-0	http://dx.doi.org/10.1016/S0092-8674(00)81129-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506516	Bronze			2022-12-01	WOS:000072406000007
J	Wu, LP; Anderson, KV				Wu, LP; Anderson, KV			Regulated nuclear import of Rel proteins in the Drosophila immune response	NATURE			English	Article							KAPPA-B-ALPHA; INDUCED PHOSPHORYLATION; DORSOVENTRAL PATTERN; DORSAL; CACTUS; GENE; DEGRADATION; EMBRYO; DISSOCIATION; EXPRESSION	The Drosophila immune response uses many of the same components as the mammalian innate immune response, including signalling pathways that activate transcription factors of the Rel/NK-kappa B family(1-4). In response to infection, two Rel proteins, Dif and Dorsal, translocate from the cytoplasm to the nuclei of larval fat-body cells(1,2,5). The Toll signalling pathway, which controls dorsal-ventral patterning during Drosophila embryogenesis(6), regulates the nuclear import of Dorsal in the immune response(2,7), but here we show that the Toll pathway is not required for nuclear import of Dif. Cytoplasmic retention of both Dorsal and Dif depends on Cactus protein; nuclear import of Dorsal and Dif is accompanied by degradation of Cactus. Therefore the two signalling pathways that target Cactus for degradation must discriminate between Cactus-Dorsal and Cactus-Dif complexes. We identified new genes that are required for normal induction of transcription of an antibacterial peptide during the immune response. Mutations in three of these genes prevent nuclear import of Dif in response to infection, and define new components of signalling pathways involving Rel. Mutations in three other genes cause constitutive nuclear localization of Dif; these mutations may block Rel protein activity by a novel mechanism.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Sloan Kettering Div, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Anderson, KV (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.			Wu, Louisa/0000-0001-8609-3081				ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bergmann A, 1996, MECH DEVELOP, V60, P109, DOI 10.1016/S0925-4773(96)00607-7; Corbo JC, 1996, MECH DEVELOP, V55, P211, DOI 10.1016/0925-4773(96)00506-0; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; HOFFMANN JA, 1993, FEBS LETT, V325, P63, DOI 10.1016/0014-5793(93)81414-U; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; Kadalayil L, 1997, NUCLEIC ACIDS RES, V25, P1233, DOI 10.1093/nar/25.6.1233; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; Klement JF, 1996, MOL CELL BIOL, V16, P2341; LEMAITRE B, 1995, EMBO J, V14, P536, DOI 10.1002/j.1460-2075.1995.tb07029.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; REICHHART JM, 1992, EMBO J, V11, P1469, DOI 10.1002/j.1460-2075.1992.tb05191.x; REICHHART JM, 1993, CR ACAD SCI III-VIE, V316, P1218; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120	28	140	143	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1998	392	6671					93	97		10.1038/32195	http://dx.doi.org/10.1038/32195			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510254				2022-12-01	WOS:000072373000057
J	Diaz, E; Pfeffer, SR				Diaz, E; Pfeffer, SR			TIP47: A cargo selection device for mannose 6-phosphate receptor trafficking	CELL			English	Article							TRANS-GOLGI NETWORK; FACTOR-II RECEPTOR; HIGH-AFFINITY INTERACTION; CYTOPLASMIC DOMAIN; RAPID INTERNALIZATION; ASSEMBLY PROTEINS; CYTOSOLIC PROTEIN; PLASMA-MEMBRANE; SIGNALS; TAIL	Mannose B-phosphate receptors (MPRs) transport newly synthesized lysosomal hydrolases from the Golgi to prelysosomes and then return to the Golgi for another round of transport. We have identified a 47 kDa protein (TIP47) that binds selectively to the cytoplasmic domains of cation-independent and cation-dependent MPRs. TIP47 is present in cytosol and on endosomes and is required for MPR transport from endosomes to the trans-Golgi network in vitro and in vivo. TIP47 recognizes a phenylalanine/tryptophan signal in the tail of the cation-dependent MPR that is essential for its proper sorting within the endosomal pathway. These data suggest that TIP47 binds MPR cytoplasmic domains and facilitates their collection into transport vesicles destined for the Golgi.	Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA	Stanford University	Pfeffer, SR (corresponding author), Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA.				NIDDK NIH HHS [DK37332] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK037332, R56DK037332, R01DK037332] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brodsky FM, 1997, TRENDS CELL BIOL, V7, P175, DOI 10.1016/S0962-8924(97)01038-6; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Diaz E, 1997, J CELL BIOL, V138, P283, DOI 10.1083/jcb.138.2.283; DINTZIS SM, 1994, J BIOL CHEM, V269, P12159; DRAPER RK, 1990, SCIENCE, V248, P1539, DOI 10.1126/science.2163108; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HUBER LA, 1993, J CELL BIOL, V123, P47, DOI 10.1083/jcb.123.1.47; Itin C, 1997, J BIOL CHEM, V272, P27737, DOI 10.1074/jbc.272.44.27737; JADOT M, 1992, J BIOL CHEM, V267, P11069; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; ROSORIUS O, 1993, J BIOL CHEM, V268, P21470; Schimmoller F, 1997, CURR BIOL, V7, pR235, DOI 10.1016/S0960-9822(06)00109-6; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOSA MA, 1993, J BIOL CHEM, V268, P12537; Wang XL, 1997, FEBS LETT, V402, P57, DOI 10.1016/S0014-5793(96)01500-1; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	42	320	330	1	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 1	1998	93	3					433	443		10.1016/S0092-8674(00)81171-X	http://dx.doi.org/10.1016/S0092-8674(00)81171-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZL787	9590177	Bronze			2022-12-01	WOS:000073471500018
J	Kreusch, A; Pfaffinger, PJ; Stevens, CF; Choe, S				Kreusch, A; Pfaffinger, PJ; Stevens, CF; Choe, S			Crystal structure of the tetramerization domain of the Shaker potassium channel	NATURE			English	Article							K+ CHANNEL; INACTIVATION; DROSOPHILA; STOICHIOMETRY; DIVERSITY; RECEPTOR; PEPTIDE; GENE	Voltage-dependent, ion-selective channels such as Na+, Ca2+ and K+ channel proteins function as tetrameric assemblies of identical or similar subunits(1-4). The clustering of four subunits is thought to create an aqueous pore(5,6) centred at the four-fold symmetry axis. The highly conserved, amino-terminal cytoplasmic domain (similar to 130 amino acids) immediately preceding the first putative transmembrane helix S1 is designated T1 It is known to confer specificity for tetramer formation(7,8), so the heteromeric assembly of K+-channel subunits is an important mechanism for the observed channel diversity(9-11). We have determined the crystal structure of the T1 domain of a Shaker potassium channel at 1.55 Angstrom resolution. The structure reveals that four identical subunits are arranged in a four-fold symmetry surrounding a centrally located pore about 20 Angstrom in length. Subfamily-specific assembly is provided primarily by polar interactions encoded in a conserved set of amino acids at its tetramerization interface. Most highly conserved amino acids in the T1 domain of all known potassium channels are found in the core of the protein, indicating a common structural framework for the tetramer assembly.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA; Baylor Coll Med, Houston, TX 77030 USA	Salk Institute; Salk Institute; Baylor College of Medicine	Choe, S (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Antz C, 1997, NATURE, V385, P272, DOI 10.1038/385272a0; BRUNGER AT, 1996, XPLOR VERSION 3 8; *COLL COMP PROJ, 1994, ACTA CRYSTALLOGR D, V50, P670; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FOSTER CD, 1992, NEURON, V9, P229, DOI 10.1016/0896-6273(92)90162-7; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOL WG, 1978, NATURE, V2734, P43; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIU T, 1997, NEURON, V19, P175; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SHEN NV, 1993, NEURON, V11, P67; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TORO L, 1992, NEURON, V9, P237, DOI 10.1016/0896-6273(92)90163-8; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511	30	262	265	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					945	948		10.1038/31978	http://dx.doi.org/10.1038/31978			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582078				2022-12-01	WOS:000073359900055
J	Auer, M; Scarborough, GA; Kuhlbrandt, W				Auer, M; Scarborough, GA; Kuhlbrandt, W			Three-dimensional map of the plasma membrane H+-ATPase in the open conformation	NATURE			English	Article							ELECTRON-MICROSCOPY; CYTOPLASMIC LOCATION; PROTEIN; MODEL; IDENTIFICATION; CRYOMICROSCOPY; VISUALIZATION; REGIONS; AMINO	The H+-ATPase from the plasma membrane of Neurospora crassa is an integral membrane protein of relative molecular mass 100K, which belongs to the P-type ATPase family that includes the plasma membrane Na+/K+-ATPase and the sarcoplasmic reticulum Ca2+-ATPase. The H+-ATPase pumps protons across the cell's plasma membrane using ATP as an energy source, generating a membrane potential in excess of 200 mV (refs 1-3). Despite the importance of P-type ATPases in controlling membrane potential and intracellular ion concentrations, little is known about the molecular mechanism they use for ion transport. This is largely due to the difficulty in growing well ordered crystals and the resulting lack of detail in the three-dimensional structure of these large membrane proteins. We have now obtained a three-dimensional map of the H+-ATPase by electron crystallography of two-dimensional crystals grown directly on electron microscope grids. At an in-plane resolution of 8 Angstrom, this map reveals ten membrane-spanning alpha-helices in the membrane domain, and four major cytoplasmic domains in the open conformation of the enzyme without bound ligands.	Max Planck Inst Biophys, Abt Strukturbiol, D-60528 Frankfurt, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	Max Planck Society; European Molecular Biology Laboratory (EMBL); University of North Carolina; University of North Carolina Chapel Hill	Kuhlbrandt, W (corresponding author), Max Planck Inst Biophys, Abt Strukturbiol, Heinrich Hoffman Str 7, D-60528 Frankfurt, Germany.	kuehlbrandt@biophys.mpg.de		Kuhlbrandt, Werner/0000-0002-2013-4810; Auer, Manfred/0000-0001-8920-3522				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; CHADWICK CC, 1987, ARCH BIOCHEM BIOPHYS, V252, P348, DOI 10.1016/0003-9861(87)90041-5; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; CYRKLAFF M, 1995, EMBO J, V14, P1854, DOI 10.1002/j.1460-2075.1995.tb07177.x; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; GOORMAGHTIGH E, 1986, J BIOL CHEM, V261, P7466; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KUHLBRANDT W, 1982, ULTRAMICROSCOPY, V7, P221, DOI 10.1016/0304-3991(82)90169-3; Li HL, 1997, NAT STRUCT BIOL, V4, P263, DOI 10.1038/nsb0497-263; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; NAKAMOTO RK, 1989, ANN NY ACAD SCI, V574, P165; NAKAMOTO RK, 1989, J BIOENERG BIOMEMBR, V21, P621, DOI 10.1007/BF00808117; RAO US, 1991, J BIOL CHEM, V266, P14740; RAO US, 1992, BIOCHIM BIOPHYS ACTA, V1108, P153, DOI 10.1016/0005-2736(92)90020-M; SCARBOROUGH GA, 1994, ACTA CRYSTALLOGR D, V50, P643, DOI 10.1107/S0907444993014283; SCARBOROUGH GA, 1990, J BIOL CHEM, V265, P16145; SCARBOROUGH GA, 1996, HDB BIOL PHYS, V2, P75; SCARBOROUGH GA, 1992, MOL ASPECTS MEMBRANE, P117; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; Sheehan B, 1996, J STRUCT BIOL, V116, P99, DOI 10.1006/jsbi.1996.0017; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512	30	184	191	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					840	843		10.1038/33967	http://dx.doi.org/10.1038/33967			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572146				2022-12-01	WOS:000073241200060
J	Cooper, JP; Watanabe, Y; Nurse, P				Cooper, JP; Watanabe, Y; Nurse, P			Fission yeast Taz1 protein is required for meiotic telomere clustering and recombination	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; MEIOSIS; CENTROMERES; INTEGRATION; GENES; DNA	The alignment of homologous chromosomes during meiosis is essential for their recombination and segregation. Telomeres form and protect the ends of eukaryotic linear chromosomes, and are composed of tandem repeats of a simple DNA sequence and the proteins that bind to these repeats(1-3). A role for telomeres in meiosis was suspected from observations of telomere clustering in meiotic cells(4-7), and has now been supported experimentally by the dramatic rearrangement of telomere locations during premeiotic stages in fission yeast(8,9). Here we show that the fission yeast telomere protein, Tazl (ref. 10), is required for stable association between telomeres and spindle pole bodies during meiotic prophase. In the absence of Tazl, telomere clustering at the spindle pole bodies is disrupted, meiotic recombination is reduced, and both spore viability and the ability of zygotes to re-enter mitosis are impaired to a level that would be expected if chromosome segregation were occurring randomly. Such telomeric association mediated by telomere-specific proteins may also be important for proper chromosome alignment and recombination during meiosis in humans.	Imperial Canc Res Fund, Cell Cycle Lab, London WC2A 3PX, England	Cancer Research UK	Cooper, JP (corresponding author), Imperial Canc Res Fund, Cell Cycle Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	cooperj@essex.uchsc.edu		Watanabe, Yoshinori/0000-0002-5488-4812; cooper, julia promisel/0000-0003-2171-2587				BAHLER J, 1991, CURR GENET, V19, P445, DOI 10.1007/BF00312735; Blackburn EH, 1995, TELOMERES; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Chikashige Y, 1997, EMBO J, V16, P193, DOI 10.1093/emboj/16.1.193; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; DERNBURG AF, 1995, TELOMERES, P295; EGEL R, 1973, MOL GEN GENET, V121, P277, DOI 10.1007/BF00267055; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUTZ H, 1971, GENETICS, V69, P331; GUTZ H, 1974, HDB GENETICS, P211; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; LOIDL J, 1990, GENOME, V33, P759, DOI 10.1139/g90-115; MELOSIS JB, 1990, DEV CELL BIOL SER, V22; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; SCHERTHAN H, 1994, J CELL BIOL, V127, P273, DOI 10.1083/jcb.127.2.273; Shimanuki M, 1997, MOL GEN GENET, V254, P238, DOI 10.1007/s004380050412; TODA T, 1984, CURR GENET, V8, P93, DOI 10.1007/BF00420224; UZAWA S, 1992, J CELL SCI, V101, P267; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	26	239	243	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					828	831		10.1038/33947	http://dx.doi.org/10.1038/33947			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572143				2022-12-01	WOS:000073241200057
J	Tollefson, AE; Hermiston, TW; Lichtenstein, DL; Colle, CF; Tripp, RA; Dimitrov, T; Toth, K; Wells, CE; Doherty, PC; Wold, WSM				Tollefson, AE; Hermiston, TW; Lichtenstein, DL; Colle, CF; Tripp, RA; Dimitrov, T; Toth, K; Wells, CE; Doherty, PC; Wold, WSM			Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR RECEPTOR; REGION E3; MEDIATED CYTOTOXICITY; PLASMA-MEMBRANE; MW PROTEIN; CYTOLYSIS; ACTIVATION; TRANSFORMATION; 10,400-DALTON	DNA viruses have evolved elaborate mechanisms To overcome host antiviral defences. In adenovirus-infected cells, programmed cell death (apoptosis) induced by the cytokine tumour necrosis factor (TNF) is inhibited by several adenovirus-encoded proteins(1-3). Occupation of the cell-surface receptor Fas, a member of the TNF-receptor superfamily that is expressed on most cell types, triggers apoptosis of that cell(4-6). Here we show that the adenovirus RID (for receptor internalization and degradation) protein complex, which is an inhibitor of TNF-induced apoptosis(2), mediates internalization of cell-surface Fas and its destruction inside lysosomes within the cell. Fas has not previously been shown to be internalized and then degraded. RID also mediates internalization of the receptor for epidermal growth factor(7,8), but it does not affect the transferrin receptor or class I antigens of the major histocompatibility complex. Removal of Fas from the surface of adenovirus-infected cells expressing RID may allow infected cells to resist Fas-mediated cell death and thus promote their survival.	St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA	Saint Louis University; St Jude Children's Research Hospital	Wold, WSM (corresponding author), St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	woldws@slu.edu	Tripp, Ralph A./F-5218-2011; Doherty, Peter Charles/C-4185-2013	Tripp, Ralph A./0000-0002-2924-9956; Doherty, Peter Charles/0000-0002-5028-3489; Toth, Karoly/0000-0001-6624-9683				AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; BABISS LE, 1984, J VIROL, V52, P389, DOI 10.1128/JVI.52.2.389-395.1984; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CARLIN CR, 1989, CELL, V57, P135, DOI 10.1016/0092-8674(89)90179-7; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CLARK WR, 1995, IMMUNOL REV, V146, P33, DOI 10.1111/j.1600-065X.1995.tb00682.x; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; GOODING LR, 1991, J VIROL, V65, P4114, DOI 10.1128/JVI.65.8.4114-4123.1991; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; GOODING LR, 1988, CELL, V53, P341, DOI 10.1016/0092-8674(88)90154-7; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HOFFMAN P, 1992, J BIOL CHEM, V267, P13480; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAATTELA M, 1995, ONCOGENE, V10, P2297; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OHEM A, 1992, J BIOL CHEM, V267, P10709; RANHEIM TS, 1993, J VIROL, V67, P2159, DOI 10.1128/JVI.67.4.2159-2167.1993; STEWART AR, 1995, J VIROL, V69, P172, DOI 10.1128/JVI.69.1.172-181.1995; SUBRAMANIAN T, 1984, J VIROL, V52, P336, DOI 10.1128/JVI.52.2.336-343.1984; TOLLEFSON AE, 1991, J VIROL, V65, P3095, DOI 10.1128/JVI.65.6.3095-3105.1991; TOLLEFSON AE, 1990, VIROLOGY, V175, P19, DOI 10.1016/0042-6822(90)90182-Q; TOLLEFSON AE, 1990, J VIROL, V64, P794, DOI 10.1128/JVI.64.2.794-801.1990; TRIPP RA, 1995, J IMMUNOL, V154, P6013; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	30	172	176	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1998	392	6677					726	730		10.1038/33712	http://dx.doi.org/10.1038/33712			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565035				2022-12-01	WOS:000073129000062
J	Davies, DG; Parsek, MR; Pearson, JP; Iglewski, BH; Costerton, JW; Greenberg, EP				Davies, DG; Parsek, MR; Pearson, JP; Iglewski, BH; Costerton, JW; Greenberg, EP			The involvement of cell-to-cell signals in the development of a bacterial biofilm	SCIENCE			English	Article							RHAMNOLIPID BIOSURFACTANT SYNTHESIS; AERUGINOSA VIRULENCE GENES; LUXR-LUXI FAMILY; PSEUDOMONAS-AERUGINOSA; SECONDARY METABOLITES; EXPRESSION; DETERMINANTS; REGULATORS; PAO1; LASR	Bacteria in nature often exist as sessile communities called biofilms. These communities develop structures that are morphologically and physiologically differentiated from free-living bacteria. A cell-to-cell signal is involved in the development of Pseudomonas aeruginosa biofilms. A specific signaling mutant, a lasl mutant, forms flat, undifferentiated biofilms that unlike wild-type biofilms are sensitive to the biocide sodium dodecyl sulfate, Mutant biofilms appeared normal when grown in the presence of a synthetic signal molecule. The involvement of an intercellular signal molecule in the development of P. aeruginosa biofilms suggests possible targets to control biofilm growth on catheters, in cystic fibrosis, and in other environments where P. aeruginosa biofilms are a persistent problem.	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Montana State Univ, Ctr Biofilm Engn, Bozeman, MT 59717 USA; Univ Rochester, Dept Microbiol & Immunol, Rochester, NY 14642 USA	University of Iowa; Montana State University System; Montana State University Bozeman; University of Rochester	Greenberg, EP (corresponding author), Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.	epgreen@blue.weeg.uiowa.edu		Greenberg, Everett/0000-0001-9474-8041	NIAID NIH HHS [AI33713, 5T32AI07362] Funding Source: Medline; NIGMS NIH HHS [GM 18740] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033713, R01AI033713, T32AI007362] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRINT JM, 1995, J BACTERIOL, V177, P7155, DOI 10.1128/jb.177.24.7155-7163.1995; BROWN ML, 1995, APPL ENVIRON MICROB, V61, P187, DOI 10.1128/AEM.61.1.187-193.1995; COHENBAZIRE G, 1957, J CELL COMP PHYSL, V49, P35; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431; DAVIES DG, 1993, APPL ENVIRON MICROB, V59, P1181, DOI 10.1128/AEM.59.4.1181-1186.1993; DEBEER D, 1994, BIOTECHNOL BIOENG, V44, P636, DOI 10.1002/bit.260440510; DOGGETT RG, 1966, J PEDIATR-US, V68, P215, DOI 10.1016/S0022-3476(66)80152-X; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; DWORKIN M, 1991, MICROBIAL CELL CELL, P179; EVANS LR, 1973, J BACTERIOL, V116, P915, DOI 10.1128/JB.116.2.915-924.1973; FASSEL TA, 1992, MICROSC RES TECHNIQ, V20, P87, DOI 10.1002/jemt.1070200109; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; GAMBELLO MJ, 1991, J BACTERIOL, V173, P3000, DOI 10.1128/JB.173.9.3000-3009.1991; KHOURY AE, 1992, AM SOC ARTIF INTERN, V38, P174; KINTNER PK, 1982, J FOOD SCI, V47, P756, DOI 10.1111/j.1365-2621.1982.tb12708.x; Latifi A, 1996, MOL MICROBIOL, V21, P1137, DOI 10.1046/j.1365-2958.1996.00063.x; LATIFI A, 1995, MOL MICROBIOL, V17, P333, DOI 10.1111/j.1365-2958.1995.mmi_17020333.x; LAWRENCE JR, 1991, J BACTERIOL, V173, P6558, DOI 10.1128/jb.173.20.6558-6567.1991; Losick R, 1997, SCI AM, V276, P68, DOI 10.1038/scientificamerican0297-68; McLean RJC, 1997, FEMS MICROBIOL LETT, V154, P259, DOI 10.1016/S0378-1097(97)00336-4; OCHSNER UA, 1995, P NATL ACAD SCI USA, V92, P6424, DOI 10.1073/pnas.92.14.6424; OCHSNER UA, 1994, J BACTERIOL, V176, P2044, DOI 10.1128/jb.176.7.2044-2054.1994; PASSADOR L, 1993, SCIENCE, V260, P1127, DOI 10.1126/science.8493556; Pearson JP, 1997, J BACTERIOL, V179, P5756, DOI 10.1128/jb.179.18.5756-5767.1997; PEARSON JP, 1994, P NATL ACAD SCI USA, V91, P197, DOI 10.1073/pnas.91.1.197; PEARSON JP, 1995, P NATL ACAD SCI USA, V92, P1490, DOI 10.1073/pnas.92.5.1490; Pesci EC, 1997, J BACTERIOL, V179, P3127, DOI 10.1128/jb.179.10.3127-3132.1997; Pesci EC, 1997, TRENDS MICROBIOL, V5, P132, DOI 10.1016/S0966-842X(97)01008-1; SUTHERLAND IW, 1977, SURFACE CARBOHYDRATE, P27; WINSON MK, 1995, P NATL ACAD SCI USA, V92, P9427, DOI 10.1073/pnas.92.20.9427	31	2353	2542	24	721	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1998	280	5361					295	298		10.1126/science.280.5361.295	http://dx.doi.org/10.1126/science.280.5361.295			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535661				2022-12-01	WOS:000073082400054
J	Puigserver, P; Wu, ZD; Park, CW; Graves, R; Wright, M; Spiegelman, BM				Puigserver, P; Wu, ZD; Park, CW; Graves, R; Wright, M; Spiegelman, BM			A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis	CELL			English	Article							BROWN ADIPOSE-TISSUE; MITOCHONDRIAL UNCOUPLING PROTEIN; THYROID-HORMONE RECEPTOR; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; ENERGY-BALANCE; MESSENGER-RNA; IN-VITRO; EXPRESSION; GENE	Adaptive thermogenesis is an important component of energy homeostasis and a metabolic defense against obesity. We have cloned a novel transcriptional coactivator of nuclear receptors, termed PGC-1, from a brown fat cDNA library. PGC-I mRNA expression is dramatically elevated upon cola exposure of mice in both brown fat and skeletal muscle, key thermogenic tissues. PGC-1 greatly increases the transcriptional activity of PPAR gamma and the thyroid hormone receptor on the uncoupling protein (UCP-1) promoter. Ectopic expression of PGC-1 in white adipose cells activates expression of UCP-1 and key mitochondrial enzymes of the respiratory chain, and increases the cellular content of mitochondrial DNA. These results indicate that PGC-1 plays a key role in linking nuclear receptors to the transcriptional program of adaptive thermogenesis.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Chicago, Dept Med, Div Gastroenterol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Chicago	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.			Wu, Zhidan/0000-0001-7289-9420	NIDDK NIH HHS [R37DK31405] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BOUILLARUD F, 1986, J BIOL CHEM, V5, P1487; BOURHIM M, 1990, AM J PHYSIOL, V258, pR1291, DOI 10.1152/ajpregu.1990.258.5.R1291; Cannon B, 1996, BIOCHEM SOC T, V24, P407, DOI 10.1042/bst0240407; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHAMPIGNY O, 1991, P NATL ACAD SCI USA, V88, P10774, DOI 10.1073/pnas.88.23.10774; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Flier JS, 1997, NAT GENET, V15, P223, DOI 10.1038/ng0397-223; FoellmiAdams LA, 1996, BIOCHEM PHARMACOL, V52, P693, DOI 10.1016/0006-2952(96)00345-0; GARRUTI G, 1992, INT J OBESITY, V16, P383; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HIMMSHAGEN J, 1989, CAN J PHYSIOL PHARM, V67, P394, DOI 10.1139/y89-063; HIMMSHAGEN J, 1995, P SOC EXP BIOL MED, V208, P159, DOI 10.3181/00379727-208-43847A; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Klingenspor M, 1996, BIOCHEM J, V316, P607, DOI 10.1042/bj3160607; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; Maniatis T., 1989, MOL CLONING LAB MANU; MARTIN I, 1995, BIOCHEM J, V308, P749, DOI 10.1042/bj3080749; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NICHOLLS D, 1986, BIOCHEM SOC T, V14, P223, DOI 10.1042/bst0140223; ONATE SA, 1995, SCIENCE, V270, P1354; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pillar TM, 1997, EUR J ENDOCRINOL, V136, P231, DOI 10.1530/eje.0.1360231; Puigserver P, 1996, BIOCHEM J, V317, P827, DOI 10.1042/bj3170827; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Silva JE, 1995, THYROID, V5, P481, DOI 10.1089/thy.1995.5.481; Silva JE, 1997, EUR J ENDOCRINOL, V136, P251, DOI 10.1530/eje.0.1360251; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tai TAC, 1996, J BIOL CHEM, V271, P29909, DOI 10.1074/jbc.271.47.29909; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V43, P1271; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WRUTNIAK C, 1995, J BIOL CHEM, V270, P16347, DOI 10.1074/jbc.270.27.16347; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	57	2899	3051	7	220	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					829	839		10.1016/S0092-8674(00)81410-5	http://dx.doi.org/10.1016/S0092-8674(00)81410-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529258	Bronze			2022-12-01	WOS:000072661200015
J	Xu, JM; Qiu, YH; DeMayo, FJ; Tsai, SY; Tsai, MJ; O'Malley, BW				Xu, JM; Qiu, YH; DeMayo, FJ; Tsai, SY; Tsai, MJ; O'Malley, BW			Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene	SCIENCE			English	Article							NUCLEAR RECEPTORS; SUPERFAMILY; ACTIVATION; TRANSCRIPTION; PROTEIN	The in vivo biological function of a steroid receptor coactivator was assessed in mice in which the SRC-1 gene was inactivated by gene targeting. Although in both sexes the homozygous mutants were viable and fertile, target organs such as uterus, prostate, testis, and mammary gland exhibited decreased growth and development in response to steroid hormones. Expression of RNA encoding TIF2, a member of the SRC-1 family, was increased in the SRC-1 null mutant, perhaps compensating partially for the loss of SRC-1 function in target tissues, The results indicate that SRC-1 mediates steroid hormone responses in vivo and that loss of its coactivator function results in partial resistance to hormone.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	O'Malley, BW (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; ONATE SA, 1995, SCIENCE, V270, P1354; Qiu YH, 1997, GENE DEV, V11, P1925, DOI 10.1101/gad.11.15.1925; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; SPENCER TE, 1997, NATURE, V389, P197; SPENCER TE, UNPUB; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang Y, 1997, GENE THER, V4, P432, DOI 10.1038/sj.gt.3300402; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; XU J, UNPUB	27	503	519	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1922	1925		10.1126/science.279.5358.1922	http://dx.doi.org/10.1126/science.279.5358.1922			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506940				2022-12-01	WOS:000072613300043
J	Pereira, PJB; Bergner, A; Macedo-Ribeiro, S; Huber, R; Matschiner, G; Fritz, H; Sommerhoff, CP; Bode, W				Pereira, PJB; Bergner, A; Macedo-Ribeiro, S; Huber, R; Matschiner, G; Fritz, H; Sommerhoff, CP; Bode, W			Human beta-tryptase is a ring-like tetramer with active sites facing a central pore	NATURE			English	Article							MAST-CELL TRYPTASE; CRYSTAL-STRUCTURE; BENZAMIDINE DERIVATIVES; INHIBITORS; TRYPSIN; INACTIVATION; RESOLUTION; BINDING	Human tryptase, a mast-cell-specific serine proteinase that may be involved in causing asthma and other allergic and inflammatory disorders(1-3), is unique in two respects: it is enzymatically active only as a heparin-stabilized tetramer, and it is resistant to all known endogenous proteinase inhibitors. The 3-Angstrom crystal structure of human beta-tryptase in a complex with 4-amidinophenyl pyruvic acid shows four quasi-equivalent monomers arranged in a square flat ring of pseudo 222 symmetry, Each monomer contacts its neighbours at two different interfaces through six loop segments. These loops are located around the active site of beta-tryptase and differ considerably in length and conformation from loops of other trypsin-like proteinases. The four active centres of the tetramer are directed towards an oval central Fore, restricting access for macromolecular substrates and enzyme inhibitors. Heparin chains might stabilize the complex by binding to an elongated patch of positively charged residues spanning two adjacent monomers. The nature of this unique tetrameric architecture explains many of tryptase's biochemical properties and provides a basis for the rational design of monofunctional and bifunctional tryptase inhibitors.	Max Planck Inst Biochem, Abt Stukturforsch, D-85152 Martinsried, Germany; Univ Munich, Klinikum Innenstadt, Chirurg Klin & Poliklin, Klin Chem & Klin Biochem Abt, D-80336 Munich, Germany	Max Planck Society; University of Munich	Bode, W (corresponding author), Max Planck Inst Biochem, Abt Stukturforsch, Klopferspitz 18A, D-85152 Martinsried, Germany.	bode@biochem.mpg.de	Pereira, Pedro/F-8972-2011; Macedo-Ribeiro, Sandra/D-9258-2011	Pereira, Pedro/0000-0003-0969-5438; Macedo-Ribeiro, Sandra/0000-0002-7698-1170; Bergner, Andreas/0000-0002-5843-4325				Addington AK, 1996, BIOCHEMISTRY-US, V35, P13511, DOI 10.1021/bi960042t; ALTER SC, 1987, BIOCHEM J, V248, P821, DOI 10.1042/bj2480821; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BRUNGER GJ, 1993, XPLOR VERSION 3 1 SY; Caughey G. H, 1995, MAST CELL PROTEASES; Caughey GH, 1997, AM J RESP CELL MOL, V16, P621, DOI 10.1165/ajrcmb.16.6.9191463; CAUGHEY GH, 1993, J PHARMACOL EXP THER, V264, P676; Clark James M., 1996, Drugs of the Future, V21, P811; EVANS R, 1990, VIA, V11, P134; Fiorucci L, 1997, FEBS LETT, V408, P85, DOI 10.1016/S0014-5793(97)00395-5; Fujinaga M, 1996, J MOL BIOL, V261, P267, DOI 10.1006/jmbi.1996.0458; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; KAM CM, 1995, ARCH BIOCHEM BIOPHYS, V316, P808, DOI 10.1006/abbi.1995.1108; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1993, DENZO FILM PROCESSIN; ROUSSEL A, 1989, TURBOFRODO SILICON G; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; SCHECHTER NM, 1993, BIOCHEMISTRY-US, V32, P2617, DOI 10.1021/bi00061a020; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1994, METHOD ENZYMOL, V244, P88; Seife C, 1997, SCIENCE, V277, P1602, DOI 10.1126/science.277.5332.1602; SOMMERHOFF CP, 1994, BIOL CHEM H-S, V375, P685, DOI 10.1515/bchm3.1994.375.10.685; Stubbs MT, 1997, J BIOL CHEM, V272, P19931, DOI 10.1074/jbc.272.32.19931; STURZEBECHER J, 1992, BIOL CHEM H-S, V373, P1025, DOI 10.1515/bchm3.1992.373.2.1025; WALTER J, 1983, H-S Z PHYSIOL CHEM, V364, P949, DOI 10.1515/bchm2.1983.364.2.949	30	269	280	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 19	1998	392	6673					306	311		10.1038/32703	http://dx.doi.org/10.1038/32703			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521329				2022-12-01	WOS:000072612300054
J	Blaxter, ML; De Ley, P; Garey, JR; Liu, LX; Scheldeman, P; Vierstraete, A; Vanfleteren, JR; Mackey, LY; Dorris, M; Frisse, LM; Vida, JT; Thomas, WK				Blaxter, ML; De Ley, P; Garey, JR; Liu, LX; Scheldeman, P; Vierstraete, A; Vanfleteren, JR; Mackey, LY; Dorris, M; Frisse, LM; Vida, JT; Thomas, WK			A molecular evolutionary framework for the phylum Nematoda	NATURE			English	Article							CEPHALOBIDAE; RHABDITIDAE; GENES	Nematodes are important: parasitic nematodes threaten the health of plants, animals and humans on a global scale(1,2); interstitial nematodes pervade sediment and soil ecosystems in overwhelming numbers(3); and Caenorhabditis elegans is a favourite experimental model system(4). A lack of dearly homologous characters and the absence of an informative fossil record have prevented us from deriving a consistent evolutionary framework for the phylum. Here we present a phylogenetic analysis, using 53 small subunit ribosomal DNA sequences from a wide range of nematodes. With this analysis, we can compare animal-parasitic, plant-parasitic and free-living taxa using a common measurement. Our results indicate that convergent morphological evolution may be extensive and that present higher-level classification of the Nematoda will need revision. We identify five major clades within the phylum, all of which include parasitic species. We suggest that animal parasitism arose independently at least four times, and plant parasitism three times. We clarify the relationship of C. elegans to major parasitic groups; this will allow more effective exploitation of our genetic and biological knowledge of this model species.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Ghent, Dept Morphol Systemat & Ecol, B-9000 Ghent, Belgium; Int Inst Parasitol, St Albans AL4 0XU, Herts, England; Univ S Florida, Dept Biol Sci, Tampa, FL 33620 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Dept Med, Harvard Thorndike Lab, Boston, MA 02215 USA; NemaPharm Inc, Cambridge, MA 02139 USA; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	University of Edinburgh; Ghent University; State University System of Florida; University of South Florida; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Baylor College of Medicine; University of Missouri System; University of Missouri Kansas City	Blaxter, ML (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, Kings Bldg, Edinburgh EH9 3JT, Midlothian, Scotland.	mark.blaxter@ed.ac.uk	Cote, Rick H/G-3363-2013; Blaxter, Mark L/B-4113-2010; Blaxter, Mark/O-2535-2019; Garey, James/J-1062-2017	Cote, Rick H/0000-0002-1573-6526; Blaxter, Mark L/0000-0003-2861-949X; Garey, James/0000-0001-8205-5563	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Anderson RC, 1992, NEMATODE PARASITES V; [Anonymous], 1993, MEGA MOL EVOLUTIONAR; BALDWIN JG, 1995, CAN J ZOOL, V73, P648, DOI 10.1139/z95-076; Baldwin JG, 1997, CAN J ZOOL, V75, P407, DOI 10.1139/z97-051; Baldwin JG, 1997, MOL PHYLOGENET EVOL, V8, P249, DOI 10.1006/mpev.1997.0433; Blaxter ML, 1996, MOL BIOCHEM PARASIT, V77, P77, DOI 10.1016/0166-6851(96)02571-6; DELEY P, 1995, NEMATOLOGICA, V41, P153, DOI 10.1163/003925995X00143; ELLIS RE, 1986, NUCLEIC ACIDS RES, V14, P2345, DOI 10.1093/nar/14.5.2345; ETZINGER A, 1997, SCIENCE, V278, P452; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FITCH DHA, 1995, MOL BIOL EVOL, V12, P346; LAMBSHEAD PJD, 1993, OCEANIS S D, V19, P5; Lorenzen S, 1994, PHYLOGENETIC SYSTEMA; Luc M, 1990, PLANT PARASITIC NEMA; MADDISON W, 1993, MACCLADE V3 0; Maggenti A.R., 1983, Systematics Association Special Volume Series, P25; Malakhov V. V., 1994, NEMATODES STRUCTURE; POINAR GO, 1993, FUND APPL NEMATOL, V16, P333; Poinar GO., 1983, NATURAL HIST NEMATOD; Riddle DL, 1997, C ELEGANS; Siddiqi M.R., 1983, Pakistan Journal of Nematology, V1, P79; Swofford D., 1998, PAUP PHYLOGENETIC AN; Swofford David L., 1996, P407; VanDePeer Y, 1996, P NATL ACAD SCI USA, V93, P7732, DOI 10.1073/pnas.93.15.7732; VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V10, P569; WINNEPENNINCKX B, 1995, MOL BIOL EVOL, V12, P1132; Yang Z, 1996, PHYLOGENETIC ANAL MA; ZARLENGA DS, 1994, EXP PARASITOL, V78, P28, DOI 10.1006/expr.1994.1003	29	1453	1515	9	280	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					71	75		10.1038/32160	http://dx.doi.org/10.1038/32160			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510248				2022-12-01	WOS:000072373000051
J	Sirrenberg, C; Endres, M; Folsch, H; Stuart, RA; Neupert, W; Brunner, M				Sirrenberg, C; Endres, M; Folsch, H; Stuart, RA; Neupert, W; Brunner, M			Carrier protein import into mitochondria mediated by the intermembrane proteins Tim10/Mrs11 and Tim12/Mrs5	NATURE			English	Article							INNER MEMBRANE; SPLICING DEFECTS; YEAST; SUPPRESSORS; DISSECTION; MACHINERY; HSP70	Import of nuclear-encoded precursor proteins into mitochondria and their subsequent sorting into mitochondrial subcompartments is mediated by translocase enzymes in the mitochondrial outer and inner membranes(1-3). Precursor proteins carrying amino-terminal targeting signals are translocated into the matrix by the integral inner membrane proteins Tim23 and Tim17 in cooperation with Tim44 and mitochondrial Hsp70 (refs 4-7). We describe here the discovery of a new pathway for the transport of members of the mitochondrial carrier family and other inner membrane proteins that contain internal targeting signals. Two related proteins in the intermembrane space, Tim10/Mrs11 (ref. 8) and Tim12/Mrs5 (ref. 9), interact sequentially with these precursors and facilitate their translocation across the outer membrane, irrespective of the membrane potential. Tim10 and Tim12 are found in a complex with Tim22, which takes over the precursor and mediates its membrane-potential-dependent insertion into the inner membrane. This interaction of Tim10 and Tim12 with the precursors depends on the presence of divalent metal ions. Both proteins contain a zinc-finger-like motif with four cysteines and bind equimolar amounts of zinc ions.	Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany	University of Munich	Neupert, W (corresponding author), Univ Munich, Inst Physiol Chem, Goethestr 33, D-80336 Munich, Germany.	neupert@bio.med.uni-muenchen.de		Folsch, Heike/0000-0003-0897-0311; Brunner, Michael/0000-0001-9798-3047				Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Brunner M, 1995, COLD SPRING HARB SYM, V60, P619, DOI 10.1101/SQB.1995.060.01.066; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; Jarosch E, 1997, MOL GEN GENET, V255, P157, DOI 10.1007/s004380050484; KRIZEK BA, 1993, INORG CHEM, V32, P937, DOI 10.1021/ic00058a030; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; WALDHERR M, 1993, CURR GENET, V24, P301, DOI 10.1007/BF00336780; WIESENBERGER G, 1991, J MOL BIOL, V217, P23, DOI 10.1016/0022-2836(91)90608-9	21	247	250	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					912	915		10.1038/36136	http://dx.doi.org/10.1038/36136			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495346				2022-12-01	WOS:000072230900057
J	Paassilta, M; Kervinen, K; Rantala, AO; Savolainen, MJ; Lilja, M; Reunanen, A; Kesaniemi, YA				Paassilta, M; Kervinen, K; Rantala, AO; Savolainen, MJ; Lilja, M; Reunanen, A; Kesaniemi, YA			Social alcohol consumption and low Lp(a) lipoprotein concentrations in middle aged Finnish men: population based study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE; RISK		Univ Oulu, Dept Internal Med, FIN-90220 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90220 Oulu, Finland; Natl Publ Hlth Inst, FIN-00300 Helsinki, Finland	University of Oulu; University of Oulu; Finland National Institute for Health & Welfare	Kesaniemi, YA (corresponding author), Univ Oulu, Dept Internal Med, Kajaanintie 50, FIN-90220 Oulu, Finland.							Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; KERVINEN K, 1991, LIFE SCI, V48, P2183, DOI 10.1016/0024-3205(91)90152-2; NAGO N, 1995, AM J EPIDEMIOL, V141, P815, DOI 10.1093/oxfordjournals.aje.a117516; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W	5	38	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					594	595		10.1136/bmj.316.7131.594	http://dx.doi.org/10.1136/bmj.316.7131.594			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518912	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000072213200030
J	Saunders, RC; Kolachana, BS; Bachevalier, J; Weinberger, DR				Saunders, RC; Kolachana, BS; Bachevalier, J; Weinberger, DR			Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine	NATURE			English	Article							VENTRAL TEGMENTAL AREA; CAUDATE-NUCLEUS; SUBCORTICAL DOPAMINE; RHESUS-MONKEY; RELEASE; CORTEX; RATS; SCHIZOPHRENIA; PROJECTIONS; DAMAGE	The effects of early brain damage are often, but not always, milder than the effects of comparable damage in adults, depending on the age at which injury occurred, the region of the brain damaged, and the brain functions involved(1-7). Studies of the impact of early brain damage have generally focused on functions primarily associated with the neural structures injured, even though the development and function of distant but interconnected neural systems might also show effects. Here we examine the regulation of striatal dopamine by the dorsolateral prefrontal cortex, in adult monkeys that had had either neonatal or adult lesions of the medial-temporal lobe and in normal animals. We use microdialysis to measure the dopamine response in the caudate nucleus after the infusion of amphetamine into the dorsolateral prefrontal cortex. Normal animals and those with adult lesions showed a reduction in dopamine overflow; in contrast, monkeys with neonatal lesions showed increased dopamine release. Thus, early injury to the primate medial-temporal lobe disrupts the normal regulation of striatal dopamine activity by the dorsolateral prefrontal cortex during adulthood. Early focal lesions may have substantial and long-lasting impacts on the function of a distant neural system.	Univ Texas, Dept Neurobiol & Anat, Houston, TX 77030 USA; St Elizabeths Hosp, NIMH, Ctr Neurosci, Clin Brain Disorders Branch, Washington, DC 20032 USA	University of Texas System; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Saunders, RC (corresponding author), NIMH, Clin Brain Disorders Branch, Bldg 49,Room 1B80,49 Convent Dr, Bethesda, MD 20892 USA.	rcs@ln.nimh.nih.gov						Bebbington P. E., 1995, P587; Bertolino A, 1997, CEREB CORTEX, V7, P740, DOI 10.1093/cercor/7.8.740; Breier A, 1997, P NATL ACAD SCI USA, V94, P2569, DOI 10.1073/pnas.94.6.2569; Carlsson A, 1997, LIFE SCI, V61, P75, DOI 10.1016/S0024-3205(97)00228-2; Fuster J, 1989, PREFRONTAL CORTEX; GOLDMAN PS, 1974, PLASTICITY RECOVERY, P147; GOLDMANRAKIC PS, 1984, NEUROSCIENCE, V12, P719, DOI 10.1016/0306-4522(84)90166-0; HIKOSAKA O, 1993, EXP BRAIN RES, V95, P457; JAKOB H, 1986, J NEURAL TRANSM, V65, P303, DOI 10.1007/BF01249090; Karreman M, 1996, J NEUROCHEM, V66, P589; KOLACHANA BS, 1995, NEUROSCIENCE, V69, P859, DOI 10.1016/0306-4522(95)00246-F; Kolachana BS, 1997, SYNAPSE, V25, P285; KOLB B, 1987, BEHAV BRAIN RES, V25, P205, DOI 10.1016/0166-4328(87)90069-6; KOLB B, 1994, BRAIN RES, V645, P85, DOI 10.1016/0006-8993(94)91641-1; Laruelle M, 1996, P NATL ACAD SCI USA, V93, P9235, DOI 10.1073/pnas.93.17.9235; LIPSKA BK, 1995, P NATL ACAD SCI USA, V92, P8906, DOI 10.1073/pnas.92.19.8906; MAHUT H, 1986, HIPPOCAMPUS, V4, P241; Malkova L, 1997, ANN NY ACAD SCI, V807, P538, DOI 10.1111/j.1749-6632.1997.tb51961.x; MALKOVA L, 1995, BEHAV NEUROSCI, V109, P212, DOI 10.1037/0735-7044.109.2.212; MOGHADDAM B, 1993, SYNAPSE, V13, P215, DOI 10.1002/syn.890130304; ROBERTS AC, 1994, J NEUROSCI, V14, P2531; RUSSCHEN FT, 1985, BRAIN RES, V329, P241, DOI 10.1016/0006-8993(85)90530-X; SESACK SR, 1992, J COMP NEUROL, V320, P145, DOI 10.1002/cne.903200202; SMITH Y, 1986, NEUROSCIENCE, V18, P347, DOI 10.1016/0306-4522(86)90159-4; TABER MT, 1995, J NEUROCHEM, V65, P1407; WEBSTER MJ, 1991, NEUROREPORT, V2, P769, DOI 10.1097/00001756-199112000-00010; Weinberger DR, 1996, PHILOS T R SOC B, V351, P1495, DOI 10.1098/rstb.1996.0135; WEINBERGER DR, 1995, SCHIZOPHR RES, V16, P87, DOI 10.1016/0920-9964(95)00013-C; [No title captured]	29	124	124	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1998	393	6681					169	171		10.1038/30245	http://dx.doi.org/10.1038/30245			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN200	9603519				2022-12-01	WOS:000073619900048
J	Sankila, R; Olsen, JH; Anderson, H; Garwicz, S; Glattre, E; Hertz, H; Langmark, F; Lanning, M; Moller, T; Tulinius, H				Sankila, R; Olsen, JH; Anderson, H; Garwicz, S; Glattre, E; Hertz, H; Langmark, F; Lanning, M; Moller, T; Tulinius, H		Assoc Nordic Canc Registries; Nordic Soc Paediatric Haematology Oncology	Risk of cancer among offspring of childhood-cancer survivors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Increasing numbers of children with cancer survive and reach reproductive age. However, the risk of cancer (other than retinoblastoma) in the offspring of survivors of childhood and adolescent cancer is uncertain. Methods Using data from national cancer and birth registries, we assessed the risk of cancer among 5847 offspring of 14,652 survivors of cancer in childhood or adolescence diagnosed since the 1940s and 1950s in Denmark, Finland, Iceland, Norway, and Sweden. The offspring were followed up for a diagnosis of cancer for 86,780 person-years, and standardized incidence ratios were calculated. Results Among the 5847 offspring, 44 malignant neoplasms were diagnosed (standardized incidence ratio, 2.6; 95 percent confidence interval, 1.9 to 3.5). There were 17 retinoblastomas, yielding a standardized incidence ratio of 37. There were 27 neoplasms other than retinoblastoma (standardized incidence ratio, 1.6; 95 percent confidence interval, 1.1 to 2.4). The second most common primary site of cancer among the offspring was the brain and nervous system, in which eight tumors were observed (standardized incidence ratio, 2.0; 95 percent confidence interval, 0.9 to 3.9). There were between zero and four apparently sporadic cases of cancer in other primary sites among the offspring. Excluding 4 likely cases of hereditary cancer and 2 subsequent cancers among the offspring with hereditary retinoblastoma, there were 22 sporadic cancers, for a standardized incidence ratio of 1.3 (95 percent confidence interval, 0.8 to 2.0). Conclusions There is no evidence of a significantly increased risk of nonhereditary cancer among the offspring of survivors of cancer in childhood. (C)1998, Massachusetts Medical Society.	Finnish Canc Registry, FIN-00170 Helsinki, Finland; Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark; So Swedish Reg Canc Registry, Lund, Sweden; Univ Lund Hosp, Dept Pediat, S-22185 Lund, Sweden; Canc Registry Norway, Oslo, Norway; Copenhagen Univ Hosp, Dept Pediat, Copenhagen, Denmark; Univ Hosp Oulu, Dept Pediat, Oulu, Finland; Iceland Canc Registry, Reykjavik, Iceland	Finnish Cancer Registry; Danish Cancer Society; Lund University; Skane University Hospital; University of Oslo; University of Copenhagen	Sankila, R (corresponding author), Finnish Canc Registry, Liisankatu 21 B, FIN-00170 Helsinki, Finland.			Olsen, Jorgen Helge/0000-0001-9633-5662				BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; BROWN PD, 1995, ACTA PAEDIATR, V84, P316, DOI 10.1111/j.1651-2227.1995.tb13636.x; *CAN SOC FINL, 1996, CANC SOC FINL PUBL, V57; HAWKINS MM, 1995, BRIT J CANCER, V71, P1335, DOI 10.1038/bjc.1995.259; HAWKINS MM, 1989, INT J CANCER, V43, P975, DOI 10.1002/ijc.2910430604; MULVIHILL JJ, 1987, LANCET, V2, P813; OLSEN JH, 1993, BRIT MED J, V307, P1030, DOI 10.1136/bmj.307.6911.1030; *WHO, 1957, MAN INT STAT CLASS D, V1	8	120	122	1	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1998	338	19					1339	1344		10.1056/NEJM199805073381902	http://dx.doi.org/10.1056/NEJM199805073381902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZL720	9571253	Bronze			2022-12-01	WOS:000073463700002
J	Schrenzel, J; Serrander, L; Banfi, B; Nusse, O; Fouyouzi, R; Lew, DP; Demaurex, N; Krause, KH				Schrenzel, J; Serrander, L; Banfi, B; Nusse, O; Fouyouzi, R; Lew, DP; Demaurex, N; Krause, KH			Electron currents generated by the human phagocyte NADPH oxidase	NATURE			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; HUMAN-NEUTROPHILS; CONDUCTANCE; METABOLISM; CHANNELS; CELLS	Electron transport across biological membranes is a well-known feature of bacteria, mitochondria and chloroplasts, where it provides motive forces for vectorial transport processes(1). In contrast, electron transport is generally not found in the plasma membrane of eukaryotic cells, possibly because it would interfere with electric processes at the plasma membrane. An exception is provided by the phagocyte NADPH oxidase, which generates superoxide (O-2(.-)) through electron transfer from cytosolic NADPH to extracellular oxygen(2-5). The enzyme is essential for host defence, and patients with chronic granulomatous disease, who lack the functional enzyme, suffer from severe infections(6,7). It has been suggested that electron transfer by the NADPH oxidase might be electrogenic(8). Here we demonstrate, using the whole-cell patch-clamp technique, the generation of electron currents by the NADPH oxidase in human eosinophil granulocytes. The currents were absent in granulocytes of sufferers of chronic granulomatous disease and under conditions of low oxygen. Generation of electron currents across the plasma membrane of eukaryotic cells has not been observed previously and might be - independently of the generation of superoxide - a physiologically relevant function of the phagocyte NADPH oxidase.	Univ Hosp Geneva, Dept Med, Div Infect Dis, CH-1211 Geneva 4, Switzerland; Univ Geneva, Med Ctr, Dept Physiol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Krause, KH (corresponding author), Univ Hosp Geneva, Dept Med, Div Infect Dis, CH-1211 Geneva 4, Switzerland.		Nüsse, Oliver/J-8645-2013; Schrenzel, Jacques/P-8525-2017; Krause, Karl-Heinz/E-8030-2011; Serrander, Lena/W-4117-2017	Nüsse, Oliver/0000-0003-0068-8346; Schrenzel, Jacques/0000-0001-5464-7764; Krause, Karl-Heinz/0000-0002-9033-6768; Serrander, Lena/0000-0002-9058-3582; Demaurex, Nicolas/0000-0002-9933-6772; Banfi, Botond/0000-0001-9273-1318				BENESCH RE, 1953, SCIENCE, V118, P447, DOI 10.1126/science.118.3068.447; Boxer L A, 1996, Pediatr Rev, V17, P19, DOI 10.1542/pir.17-1-19; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHERNY VV, 1995, J GEN PHYSIOL, V105, P861, DOI 10.1085/jgp.105.6.861; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, HOSP PRACT, V25, P51; CORRONS JLV, 1982, BLOOD, V59, P428; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DEMAUREX N, 1993, EUR J HAEMATOL, V51, P309; DEMAUREX N, 1992, J CLIN INVEST, V90, P830, DOI 10.1172/JCI115958; GALLIN EK, 1990, CURR TOP MEMBR TRANS, V35, P127; GORDIENKO DV, 1996, J PHYSL, V496, P229; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; Hille B., 1992, IONIC CHANNELS EXCIT; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; MITCHELL P, 1991, BIOSCIENCE REP, V11, P297, DOI 10.1007/BF01130212; NANDA A, 1991, Cellular Physiology and Biochemistry, V1, P65, DOI 10.1159/000154595; NEWBURGER PE, 1979, NEW ENGL J MED, V300, P178, DOI 10.1056/NEJM197901253000406; Saier MH, 1997, ASM NEWS, V63, P13; Schrenzel J, 1996, AM J PHYSIOL-CELL PH, V271, pC1861, DOI 10.1152/ajpcell.1996.271.6.C1861; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SHULT PA, 1985, J LAB CLIN MED, V106, P638; VARNAI P, 1993, J PHYSIOL-LONDON, V472, P373, DOI 10.1113/jphysiol.1993.sp019952; ZIMMERLI W, 1983, HELV PAEDIATR ACTA, V38, P51	24	165	168	2	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1998	392	6677					734	737		10.1038/33725	http://dx.doi.org/10.1038/33725			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565037				2022-12-01	WOS:000073129000064
J	Kanegae, Y; Tavares, AT; Belmonte, JCI; Verma, IM				Kanegae, Y; Tavares, AT; Belmonte, JCI; Verma, IM			Role of Rel/NF-kappa B transcription factors during the outgrowth of the vertebrate limb	NATURE			English	Article							APICAL ECTODERMAL RIDGE; SONIC-HEDGEHOG; FEEDBACK LOOP; CHICK; INITIATION; GROWTH; BUD; EXPRESSION; DROSOPHILA; INDUCTION	The development of the vertebrate limb serves as an amenable system for studying signaling pathways that lead to tissue patterning and proliferation(1). Limbs originate as a consequence of a differential growth of cells from the lateral plate mesoderm at specific axial levels(2). At the tip of the limb primordia the progress zone, a proliferating group of mesenchymal cells, induces the overlying ectoderm to differentiate into a specialized structure termed the apical ectodermal ridge. Subsequent limb outgrowth requires reciprocal signalling between the ridge and the progress zone(3-6). The Rel/NF-kappa B family of transcription factors is induced in response to several signals that lead to cell growth, differentiation, inflammatory responses, apoptosis and neoplastic transformation(7), In unstimulated cells, NF-kappa B is associated in the cytoplasm with an inhibitory protein, I-kappa B. In response to an external signal, I-kappa B is phosphorylated, ubiquitinated and degraded, releasing NF-kappa B to enter the nucleus and activate transcription(7). Here we show that Rel/NF-kappa B genes are expressed in the progress zone of the developing chick limb bud. When the activity of Rel/NF-kappa B proteins is blocked by infection with viral vectors that produce transdominant-negative I-kappa B alpha proteins, limb outgrowth is arrested, Our results indicate that Rel/NF-kappa B transcription factors play a role in vertebrate limb development.	Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Verma, IM (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Tavares, Ana Teresa/I-3086-2013	Tavares, Ana Teresa/0000-0002-3495-5513				BELMONTE JCI, 1993, CELL, V74, P645; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; DAVIDSON DR, 1991, NATURE, V352, P429, DOI 10.1038/352429a0; Deng CX, 1997, DEV BIOL, V185, P42, DOI 10.1006/dbio.1997.8553; ElGhouzzi V, 1997, NAT GENET, V15, P42; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; KIENY M, 1960, J EMBRYOL EXP MORPH, V8, P457; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; Ogura T, 1996, DEVELOPMENT, V122, P537; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROBERT B, 1991, GENE DEV, V5, P2363, DOI 10.1101/gad.5.12b.2363; ROWE DA, 1982, J EMBRYOL EXP MORPH, V68, P1; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SEARLS RL, 1971, DEV BIOL, V24, P198, DOI 10.1016/0012-1606(71)90095-9; SHEN RQ, 1994, CELL MOL BIOL RES, V40, P297; SHISHIDO E, 1993, DEVELOPMENT, V117, P751; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Vogel A, 1996, DEVELOPMENT, V122, P1737	30	182	187	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 9	1998	392	6676					611	614		10.1038/33429	http://dx.doi.org/10.1038/33429			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZG300	9560158				2022-12-01	WOS:000072987200062
J	Carvalho, JS; Moscoso, G; Ville, Y				Carvalho, JS; Moscoso, G; Ville, Y			First-trimester transabdominal fetal echocardiography	LANCET			English	Article							NUCHAL TRANSLUCENCY THICKNESS; CONGENITAL HEART-DISEASE; MATERNAL AGE; HIGH-RISK; DIAGNOSIS; GESTATION; PREGNANCIES; FETUSES; DEFECTS	Background Fetal echocardiography is usually done during the second trimester of pregnancy, but waiting until that time can lead to anxiety for the parents if the fetus is at high risk of having cardiac abnormalities. We report the feasibility of transabdominal first-trimester fetal echocardiography for early reassurance of normality or a prenatal diagnosis of a cardiac malformation. Methods We did first-trimester fetal echocardiography and colour-flow mapping with a 5 MHz curvilinear transducer at 13 weeks' gestation (range 12-13+6 days) in 15 fetuses at risk of cardiac defects. The fetus was judged to be normal if the investigation showed normal visceral situs, four-chamber view, and two normally related great arteries of similar size. We did second-trimester scans and neonatal follow-up for the women who continued with their pregnancies; necropsy was done in two cases of pregnancy termination. Findings Ten fetuses had normal hearts at the time of the first scan, which was confirmed during second-trimester assessment, In one fetus, the four-chamber view was asymmetrical and a moderate-sized apical muscular ventricular septal defect (VSD) was diagnosed after birth. In another two fetuses we diagnosed small muscular VSD on the second-trimester scans. A complex cardiac malformation was correctly diagnosed in one fetus at 12 weeks of gestation. Thus, in 11 fetuses, the imaging was of sufficient quality to reassure the family or to diagnose an abnormality. In the other four fetuses, the investigation was judged to be incomplete, but no definite cardiac abnormality was identified. Interpretation Transabdominal fetal echocardiography in the first trimester of pregnancy is feasible. In most patients the resolution of images is sufficient to allow assessment of basic cardiac anatomy, when normal, or detection of complex malformations, when present.	Royal Brompton Hosp NHS Trust, London SW3 6NP, England; St Georges Hosp NHS Trust, Fetal Med Unit, London, England	Royal Brompton Hospital; St Georges University London	Carvalho, JS (corresponding author), Royal Brompton Hosp NHS Trust, London SW3 6NP, England.	carvalho@eas-jsc.demon.co.uk	Carvalho, Julene/E-8842-2015	Carvalho, Julene/0000-0002-5698-5828				ACHIRON R, 1994, J ULTRAS MED, V13, P783; Allan LD, 1997, HEART, V77, P68, DOI 10.1136/hrt.77.1.68; ALLAN LD, 1994, J AM COLL CARDIOL, V23, P1452, DOI 10.1016/0735-1097(94)90391-3; ALLAN LD, 1986, AM J CARDIOL, V58, P334, DOI 10.1016/0002-9149(86)90072-X; Bjorkhem G, 1997, J Matern Fetal Med, V6, P87; BRONSHTEIN M, 1993, OBSTET GYNECOL, V82, P225; Buskens E, 1996, OBSTET GYNECOL, V87, P423, DOI 10.1016/0029-7844(95)00439-4; DAMELIO R, 1991, PRENATAL DIAG, V11, P69, DOI 10.1002/pd.1970110202; DOLKART LA, 1991, AM J OBSTET GYNECOL, V165, P688, DOI 10.1016/0002-9378(91)90310-N; DONNAI P, 1981, BRIT MED J, V282, P621, DOI 10.1136/bmj.282.6264.621; GEMBRUCH U, 1993, ULTRASOUND OBST GYN, V3, P310, DOI 10.1046/j.1469-0705.1993.03050310.x; GEMBRUCH U, 1990, OBSTET GYNECOL, V75, P496; GITTENBERGERDEG.AC, 1996, ULTRASOUND FETAL HEA, P1; Hyett J, 1996, ULTRASOUND OBST GYN, V7, P245, DOI 10.1046/j.1469-0705.1996.07040245.x; Hyett JA, 1997, ULTRASOUND OBST GYN, V10, P242, DOI 10.1046/j.1469-0705.1997.10040242.x; HYETT JA, 1995, AM J MED GENET, V58, P374, DOI 10.1002/ajmg.1320580415; OTT WJ, 1995, AM J OBSTET GYNECOL, V172, P1741, DOI 10.1016/0002-9378(95)91406-4; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; PANDYA PP, 1995, ULTRASOUND OBST GYN, V5, P15, DOI 10.1046/j.1469-0705.1995.05010015.x; Sebire NJ, 1996, BRIT J OBSTET GYNAEC, V103, P999, DOI 10.1111/j.1471-0528.1996.tb09550.x	20	83	86	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1023	1027		10.1016/S0140-6736(97)08406-7	http://dx.doi.org/10.1016/S0140-6736(97)08406-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546509				2022-12-01	WOS:000072927200013
J	Whittle, IR; Pringle, AM; Taylor, R				Whittle, IR; Pringle, AM; Taylor, R			Effects of resective surgery for left-sided intracranial tumours on language function: a prospective study	LANCET			English	Article							DOMINANT HEMISPHERE; LOCALIZATION; GLIOMAS; APHASIA; TUMORS; AGE	Background Although language disorders occur in about 50% of patients with a left hemispheric tumour and are a significant cause of morbidity, the effects of resective neurosurgery and their relation to tumour pathology are unclear. We report the immediate effects of resective surgery on language functions in a heterogeneous group of patients with left-sided intracranial tumours. Methods 40 patients were studied. The Western Aphasia Battery (WAB) and Boston Naming Test (BNT) were administered preoperatively and before discharge following resective neurosurgery. Dexamethasone dose at time of testing was recorded, as was time taken to complete the tests, and tumour neuropathology. Findings 15 patients with normal aphasia quotients and language quotients before resective surgery all had normal quotients postoperatively. 25 who were dysphasic tie, aphasia quotient <93.8) preoperatively showed significant postoperative improvements in both their mean aphasia quotient (from 81.8 to 89.1, p=0.004) and their mean language quotient (from 73.4 to 85.4, p=0.001), though 13 remained dysphasic. Two of the 25 dysphasic patients had their WAB scores lowered by tumour resection. The findings and postoperative changes in BNT scores were almost identical to the pattern of those in WAB scores. At second assessment, dexamethasone therapy was significantly (p<0.01) lower than preoperative dose (reduction from mean 10.3 mg/day to 0.7 mg/day in the dysphasic group). Patients with glioblastoma were more likely to have lower aphasia quotients, language quotients, and BNT scores than patients with anaplastic glioma, metastasis, or meningioma, Although the glioblastoma group had the greatest improvements in WAB operative scores, 57% remained dysphasic after resective surgery. Two additional patients declined postoperative assessment. Interpretation Resective surgery for left-sided intracranial tumours significantly improves language function in dysphasic patients, and is unlikely to impair language functions in non-dysphasic patients. Dysphasia and its response to resective surgery are related to the tumour neuropathology.	Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Whittle, IR (corresponding author), Western Gen Hosp, Dept Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	irw@skull.dcn.ac.ed.uk	whittle, ian/AAX-7309-2021					BRIGGS G G, 1975, Cortex, V11, P230; BURGER PC, 1988, J NEUROSURG, V68, P698, DOI 10.3171/jns.1988.68.5.0698; CABANTOG AM, 1994, CAN J NEUROL SCI, V21, P213, DOI 10.1017/S0317167100041184; CIRIC I, 1987, NEUROSURGERY, V21, P21, DOI 10.1227/00006123-198707000-00005; COHADON F, 1990, ADV TECHNICAL STANDA, V17, P190; Dorward NL, 1997, BRIT J NEUROSURG, V11, P101, DOI 10.1080/02688699746429; FADUL C, 1988, NEUROLOGY, V38, P1374, DOI 10.1212/WNL.38.9.1374; HAGLUND MM, 1994, NEUROSURGERY, V34, P567, DOI 10.1227/00006123-199404000-00001; HERMANN BP, 1994, NEUROSURGERY, V35, P52, DOI 10.1227/00006123-199407000-00008; Kaplan E, 1983, BOSTON NAMING TEST; Kertesz A., 1982, W APHASIA BATTERY; KETESZ A, 1979, APHASIA ASS DISORDER; LATIF AZB, 1998, IN PRESS J NEUROL NE; LATIF AZB, 1998, IN PRESS BR J NEUROS; MICELI G, 1981, ACTA NEUROL SCAND, V64, P370; OJEMANN G, 1989, J NEUROSURG, V71, P316, DOI 10.3171/jns.1989.71.3.0316; RECHT LD, 1989, NEUROLOGY, V39, P48, DOI 10.1212/WNL.39.1.48; ROSTOMILY RC, 1991, J NEUROSURG, V75, P62, DOI 10.3171/jns.1991.75.1.0062; Russell D, 1989, PATHOLOGY TUMOURS NE; SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22; Skirboll SS, 1996, NEUROSURGERY, V38, P678, DOI 10.1227/00006123-199604000-00008; TANDON P, 1993, ACT NEUR S, V56, P67; THOMSON AM, 1997, J NEUROSURG, V89, P923; VECHT CJ, 1990, J NEUROL NEUROSUR PS, V53, P466, DOI 10.1136/jnnp.53.6.466; WEISSMAN DE, 1987, J NEURO-ONCOL, V5, P125, DOI 10.1007/BF02571300; WHITTLE IR, 1991, AUST NZ J SURG, V61, P919, DOI 10.1111/j.1445-2197.1991.tb00010.x; WHITTLE IR, 1992, NEUROSURG QUART, V2, P174	27	31	33	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	APR 4	1998	351	9108					1014	1018		10.1016/S0140-6736(97)08295-0	http://dx.doi.org/10.1016/S0140-6736(97)08295-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF730	9546507				2022-12-01	WOS:000072927200011
J	Nightingale, SL				Nightingale, SL			New national campaign to help stop tobacco sales to children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					984	984		10.1001/jama.279.13.984	http://dx.doi.org/10.1001/jama.279.13.984			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533484				2022-12-01	WOS:000072669700005
J	Gulmezoglu, AM; Duley, L				Gulmezoglu, AM; Duley, L			Use of anticonvulsants in eclampsia and pre-eclampsia: survey of obstetricians in the United Kingdom and Republic of Ireland	BRITISH MEDICAL JOURNAL			English	Article									Radcliffe Infirm, Natl Perinatal Epidemiol Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Gulmezoglu, AM (corresponding author), United Kingdom Cochrane Ctr, NHS Res & Dev Programme, Summertown Pavil, Oxford OX2 7LG, England.	mgulmezoglu@cochrane.co.uk	Duley, Lelia/E-8107-2015	Duley, Lelia/0000-0001-6721-5178				CHAMBERLAIN GVP, 1978, BRIT MED J, V276, P626; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; DULEY L, 1995, LANCET, V345, P1455; DULEY L, 1997, COCHRANE LIB COCHRAN; HUTTON JD, 1992, BRIT J OBSTET GYNAEC, V99, P554, DOI 10.1111/j.1471-0528.1992.tb13819.x	5	36	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 28	1998	316	7136					975	976		10.1136/bmj.316.7136.975	http://dx.doi.org/10.1136/bmj.316.7136.975			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZF034	9550956	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000072856100020
J	Monzon, J; Liu, L; Brill, H; Goldstein, AM; Tucker, MA; From, L; McLaughlin, J; Hogg, D; Lassam, NJ				Monzon, J; Liu, L; Brill, H; Goldstein, AM; Tucker, MA; From, L; McLaughlin, J; Hogg, D; Lassam, NJ			CDKN2A mutations in multiple primary melanomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL MELANOMA; MALIGNANT-MELANOMA; GERMLINE MUTATIONS; CANCER; KINDREDS; RISK; RETINOBLASTOMA; GENE	Background Germ-line mutations in the CDKN2A tumor-suppressor gene (also known as p16, p16(INK4a), and MTS1) have been linked to the development of melanoma in some families with inherited melanoma. Whether mutations in CDKN2A confer a predisposition to sporadic (nonfamilial) melanoma is not known. In some patients with sporadic melanoma, one or more additional primary lesions develop, suggesting that some of these patients have an un derlying genetic susceptibility to the cancer. We hypothesized that this predisposition might be due to germ-line CDKN2A mutations. Methods We used the polymerase chain reaction, single-strand conformation polymorphism analysis, and direct DNA sequencing to identify germ-line mutations in the CDKN2A gene in patients with multiple primary melanomas who did not have family histories of the disease. A quantitative yeast two-hybrid assay was used to evaluate the functional importance of the CDKN2A variants. Results Of 33 patients with multiple primary melanomas, 5 (15 percent; 95 percent confidence interval, 4 percent to 27 percent) had germ-line CDKN2A mutations. These included a 24-bp insertion at the 5' end of the coding sequence, three missense mutations (Arg24Pro, Met53lle, and Ser56lle), and a 2-bp deletion at position 307 to 308 (resulting in a truncated CDKN2A protein). In three families, CDKN2A mutations identical to those in the probands were found in other family members. In two families with mutations, we uncovered previously unknown evidence of family histories of melanoma. Conclusions Some patients with multiple primary melanomas but without family histories of the disease have germ-line mutations of the CDKN2A gene. The presence of multiple primary melanomas may signal a genetic susceptibility to melanoma not only in the index patient but also in family members, who may benefit from melanoma-surveillance programs. (C) 1998, Massachusetts Medical Society.	Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Inst Med Sci, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Dermatol, Toronto, ON, Canada; Univ Toronto, Dept Prevent Med & Biostat, Toronto, ON, Canada; NCI, Genet Epidemiol Branch, Bethesda, MD 20892 USA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; University of Toronto; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lassam, NJ (corresponding author), Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Tucker, Margaret A/B-4297-2015; McLaughlin, John R/E-4577-2013					BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BATAILLE V, 1995, BRIT J DERMATOL, V132, P134, DOI 10.1111/j.1365-2133.1995.tb08639.x; BIRCH JM, 1987, BIOL CARCINOGENESIS, P165; Brobeil A, 1997, ANN SURG ONCOL, V4, P19, DOI 10.1007/BF02316806; Carey TE, 1996, ANN MED, V28, P183, DOI 10.3109/07853899609033118; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FRANK W, 1993, J DERMATOL SURG ONC, V19, P427, DOI 10.1111/j.1524-4725.1993.tb00369.x; GILES G, 1995, MELANOMA RES, V5, P433, DOI 10.1097/00008390-199512000-00007; GOLDSTEIN AM, 1995, DERMATOL CLIN, V13, P605, DOI 10.1016/S0733-8635(18)30066-4; Goldstein AM, 1997, J NATL CANCER I, V89, P676, DOI 10.1093/jnci/89.10.676; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GREENE MH, 1985, ANN INTERN MED, V102, P458, DOI 10.7326/0003-4819-102-4-458; GUPTA BK, 1991, CANCER-AM CANCER SOC, V67, P1984, DOI 10.1002/1097-0142(19910401)67:7<1984::AID-CNCR2820670727>3.0.CO;2-H; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Holland EA, 1995, ONCOGENE, V11, P2289; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KANG S, 1992, CANCER, V70, P1911, DOI 10.1002/1097-0142(19921001)70:7<1911::AID-CNCR2820700718>3.0.CO;2-Q; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LIU L, 1995, ONCOGENE, V11, P405; LYNCH HT, 1995, CANCER DETECT PREV, V19, P219; MOSELEY HS, 1979, CANCER, V43, P939, DOI 10.1002/1097-0142(197903)43:3<939::AID-CNCR2820430323>3.0.CO;2-N; Parry D, 1996, MOL CELL BIOL, V16, P3844; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REIMER RR, 1978, JAMA-J AM MED ASSOC, V239, P744, DOI 10.1001/jama.239.8.744; Rigel DS, 1996, J AM ACAD DERMATOL, V34, P839, DOI 10.1016/S0190-9622(96)90041-9; Rigel DS, 1997, MAYO CLIN PROC, V72, P367, DOI 10.4065/72.4.367; Schottenfeld D, 1996, CANC EPIDEMIOLOGY PR, P1370; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SLINGLUFF CL, 1993, SURGERY, V113, P330; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; TRABOULSI EI, 1988, ARCH OPHTHALMOL-CHIC, V106, P1059; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	36	201	211	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1998	338	13					879	887		10.1056/NEJM199803263381305	http://dx.doi.org/10.1056/NEJM199803263381305			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD284	9516223				2022-12-01	WOS:000072669800005
J	Jeffcoate, W				Jeffcoate, W			Obesity is a disease: food for thought	LANCET			English	Article							WEIGHT-LOSS; MORTALITY; WOMEN		City Hosp, Dept Endocrinol, Nottingham NG5 1PB, England	University of Nottingham	Jeffcoate, W (corresponding author), City Hosp, Dept Endocrinol, Nottingham NG5 1PB, England.							DIETZ WH, 1986, PEDIATR CLIN N AM, V33, P823; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; MULS E, 1995, INT J OBESITY, V19, pS46; PAMUK ER, 1992, AM J EPIDEMIOL, V136, P686, DOI 10.1093/oxfordjournals.aje.a116548; SOBAL J, 1989, PSYCHOL BULL, V105, P260, DOI 10.1037/0033-2909.105.2.260; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; Wilding J, 1997, BRIT MED BULL, V53, P286, DOI 10.1093/oxfordjournals.bmb.a011614; WILLIAMSON DF, 1995, AM J EPIDEMIOL, V141, P1128, DOI 10.1093/oxfordjournals.aje.a117386; WOODFORDE J, 1788, DIARY COUNTRY PARSON	9	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					903	904		10.1016/S0140-6736(97)11326-5	http://dx.doi.org/10.1016/S0140-6736(97)11326-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525389				2022-12-01	WOS:000072645500047
J	Savulescu, J				Savulescu, J			Commentary: Safety of participants in non-therapeutic research must be ensured	BRITISH MEDICAL JOURNAL			English	Editorial Material							HYPOXIA		Monash Univ, Ctr Human Bioeth, Clayton, Vic 3168, Australia	Monash University	Savulescu, J (corresponding author), Monash Univ, Ctr Human Bioeth, Gallery Bldg,Wellington Rd, Clayton, Vic 3168, Australia.							*COUNC INT ORG MED, 1993, INT ETH GUID BIOM RE; FOSTER L, 1996, MANUAL RES ETHICS CO; *ROYAL COLL PHYS, 1986, RES HLTH VOL WORK PA; SEVERINGHAUS JW, 1989, J CLIN MONITOR, V5, P72, DOI 10.1007/BF01617877; Waters KA, 1996, RESP PHYSIOL, V105, P135, DOI 10.1016/0034-5687(96)00046-1	5	13	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					891	892						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9569393				2022-12-01	WOS:000072713300023
J	Lin, Y; Nielsen, R; Murray, D; Hubbell, WL; Mailer, C; Robinson, BH; Gelb, MH				Lin, Y; Nielsen, R; Murray, D; Hubbell, WL; Mailer, C; Robinson, BH; Gelb, MH			Docking phospholipase A(2) on membranes using electrostatic potential-modulated spin relaxation magnetic resonance	SCIENCE			English	Article							BEE-VENOM PHOSPHOLIPASE-A2; PARAMAGNETIC RESONANCE; INTERFACIAL CATALYSIS; CRYSTAL-STRUCTURE; BACTERIORHODOPSIN MUTANTS; SUBSTRATE; COMPLEX; MECHANISM; BINDING; STATE	A method involving electron paramagnetic resonance spectroscopy of a site-selectively spin-labeled peripheral membrane protein in the presence and absence of membranes and of a water-soluble spin relaxant (chromium oxalate) has been developed to determine how bee venom phospholipase A(2) sits on the membrane. Theory based on the Poisson-Boltzmann equation shows that the rate of spin relaxation of a protein-bound nitroxide by a membrane-impermeant spin relaxant depends on the distance (up to tens of angstroms) from the spin probe to the membrane. The measurements define the interfacial binding surface of this secreted phospholipase A(2).	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol, Stony Brook, NY 11794 USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Dept Chem & Biochem, Los Angeles, CA 90024 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; University of California System; University of California Los Angeles	Robinson, BH (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.	robinson@chem.washington.edu; gelb@chem.washington.edu		gelb, michael/0000-0001-7000-5219	NCI NIH HHS [R01 CA052874] Funding Source: Medline; NHLBI NIH HHS [R37 HL036235, HL36235, R01 HL036235] Funding Source: Medline; NIEHS NIH HHS [P30 ES007033, P30 ES07033] Funding Source: Medline; NIGMS NIH HHS [P01 GM032681, GM32681] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052874] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036235, R23HL036235, R37HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032681] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARI A, 1987, COLD SPRING HARB SYM, V52, P441, DOI 10.1101/SQB.1987.052.01.051; ALTENBACH C, 1989, BIOPHYS J, V56, P1183, DOI 10.1016/S0006-3495(89)82765-1; ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; Annand RR, 1996, BIOCHEMISTRY-US, V35, P4591, DOI 10.1021/bi9528412; BAYBURT T, 1995, ANAL BIOCHEM, V232, P7, DOI 10.1006/abio.1995.9967; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; CASTLE JD, 1976, BIOCHEMISTRY-US, V15, P4818, DOI 10.1021/bi00667a011; DEREWENDA ZS, 1994, ADV PROTEIN CHEM, V45, P1; DIJKSTRA BW, 1983, J MOL BIOL, V168, P163, DOI 10.1016/S0022-2836(83)80328-3; DIN N, 1994, MOL MICROBIOL, V11, P747, DOI 10.1111/j.1365-2958.1994.tb00352.x; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; GHOMASCHCHI F, IN PRESS BIOCHEMISTR; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P9559, DOI 10.1021/bi00104a001; HAAS DA, 1993, BIOPHYS J, V64, P594, DOI 10.1016/S0006-3495(93)81418-8; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HUBBELL WL, UNPUB; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7306, DOI 10.1021/bi00243a036; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lakshminarayanaiah N., 1984, EQUATIONS MEMBRANE B; LANGEN R, UNPUB; MAILER C, 1985, REV SCI INSTRUM, V56, P1917, DOI 10.1063/1.1138445; MAILER C, 1991, J MAGN RESON, V91, P475, DOI 10.1016/0022-2364(91)90375-4; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Molin Y. N., 1980, SPIN EXCHANGE PRINCI; Press W. H., 1987, NUMERICAL RECIPES; ROBINSON BH, 1994, SCIENCE, V263, P490, DOI 10.1126/science.8290958; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SHIN YK, 1992, BIOPHYS J, V61, P1443, DOI 10.1016/S0006-3495(92)81950-1; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; THUREN T, 1984, BIOCHEMISTRY-US, V23, P5129, DOI 10.1021/bi00317a008; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; Yu BZ, 1997, BIOCHEMISTRY-US, V36, P3870, DOI 10.1021/bi961541x; [No title captured]	40	112	112	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1998	279	5358					1925	1929		10.1126/science.279.5358.1925	http://dx.doi.org/10.1126/science.279.5358.1925			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506941	Green Accepted			2022-12-01	WOS:000072613300044
J	Witkowski, FX; Leon, LJ; Penkoske, PA; Giles, WR; Spano, ML; Ditto, WL; Winfree, AT				Witkowski, FX; Leon, LJ; Penkoske, PA; Giles, WR; Spano, ML; Ditto, WL; Winfree, AT			Spatiotemporal evolution of ventricular fibrillation	NATURE			English	Article							MECHANISMS; MUSCLE	Sudden cardiac death is the leading cause of death in the industrialized world, with the majority of such tragedies being due to ventricular fibrillation(1). Ventricular fibrillation is a frenzied and irregular disturbance of the heart rhythm that quickly renders the heart incapable of sustaining life. Rotors, electrophysiological structures that emit rotating spiral waves, occur in several systems that all share with the heart the functional properties of excitability and refractoriness, These re-entrant waves, seen in numerical solutions of simplified models of cardiac tissue(2), may occur during ventricular tachycardias(3,4). It has been difficult to detect such forms of re-entry in fibrillating mammalian ventricles(5-8). Here we show that, in isolated perfused dog hearts, high spatial and temporal resolution mapping of optical transmembrane potentials can easily detect transiently erupting rotors during the early phase of ventricular fibrillation, This activity is characterized by a relatively high spatiotemporal cross-correlation. During this early fibrillatory interval, frequent wavefront collisions and wavebreak generation(9) are also dominant features. Interestingly, this spatiotemporal pattern undergoes an evolution to a less highly spatially correlated mechanism that lacks the epicardial manifestations of rotors despite continued myocardial perfusion.	Univ Alberta, Dept Med, Edmonton, AB T6G 2R7, Canada; Univ Alberta, Dept Surg, Edmonton, AB T6G 2R7, Canada; Ecole Polytech, Montreal, PQ H3C 3J7, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; USN, Ctr Surface Warfare, Bethesda, MD 20817 USA; Georgia Inst Technol, Sch Phys, Appl Chaos Lab, Atlanta, GA 30332 USA; Univ Arizona, Dept Ecol & Evolut Biol, Tucson, AZ 85721 USA	University of Alberta; University of Alberta; Universite de Montreal; Polytechnique Montreal; University of Calgary; United States Department of Defense; United States Navy; University System of Georgia; Georgia Institute of Technology; University of Arizona	Witkowski, FX (corresponding author), Univ Alberta, Dept Med, Edmonton, AB T6G 2R7, Canada.	fwitkows@gpu.srv.ualberta.ca	Ditto, William/AAK-9827-2020; Spano, Mark L/B-6883-2011	Ditto, William/0000-0002-7416-8012; 				Castellanos A., 1990, CARDIAC ELECTROPHYSI, P666; CHEN PS, 1988, CIRC RES, V62, P1191, DOI 10.1161/01.RES.62.6.1191; GRAY RA, 1995, SCIENCE, V270, P1222, DOI 10.1126/science.270.5239.1222; GRAY RA, 1996, CIRCULATION, V94, P1; Holden A, 1997, COMPUTATIONAL BIOL H; Holden AV, 1997, NATURE, V387, P655, DOI 10.1038/42597; Lee JJ, 1996, CIRC RES, V78, P660, DOI 10.1161/01.RES.78.4.660; PERTSOV AM, 1993, CIRC RES, V72, P631, DOI 10.1161/01.RES.72.3.631; ROGERS JM, 1996, CIRCULATION, V94, P1; RUSS JC, 1994, IMAGE PROCESSING HDB, P157; Wiggers CJ, 1930, AM HEART J, V5, P351, DOI 10.1016/S0002-8703(30)90334-1; WINFREE AT, 1994, SCIENCE, V266, P1003, DOI 10.1126/science.7973648; WINFREE AT, 1987, TIME BREAKS DOWN, V40, P292; WITKOWSKI FX, 1994, CIRC RES, V74, P507, DOI 10.1161/01.RES.74.3.507; Witkowski FX, 1998, CHAOS, V8, P94, DOI 10.1063/1.166290	15	398	419	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					78	82		10.1038/32170	http://dx.doi.org/10.1038/32170			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510250				2022-12-01	WOS:000072373000053
J	Turrigiano, GG; Leslie, KR; Desai, NS; Rutherford, LC; Nelson, SB				Turrigiano, GG; Leslie, KR; Desai, NS; Rutherford, LC; Nelson, SB			Activity-dependent scaling of quantal amplitude in neocortical neurons	NATURE			English	Article							CULTURED HIPPOCAMPAL-NEURONS; MINIATURE SYNAPTIC CURRENTS; LONG-TERM POTENTIATION; VISUAL-CORTEX; GLUTAMATE; SYNAPSES; COMPETITION; PLASTICITY; ACTIVATION; MATURATION	Information is stored in neural circuits through long-lasting changes in synaptic strengths(1,2). Most studies of information storage have focused on mechanisms such as long-term potentiation and depression (LTP and LTD), in which synaptic strengths change in a synapse-specific manner(3,4). In contrast, little attention has been paid to mechanisms that regulate the total synaptic strength of a neuron, Here we describe a new form of synaptic plasticity that increases or decreases the strength of all of a neuron's synaptic inputs as a function of activity, Chronic blockade of cortical culture activity increased the amplitude of miniature excitatory postsynaptic currents (mEPSCs) without changing their kinetics. Conversely, blocking GABA (gamma-aminobutyric acid)-mediated inhibition initially raised firing rates, but over a 48-hour period mESPC amplitudes decreased and firing rates returned to close to control values. These changes were at least partly due to postsynaptic alterations in the response tb glutamate, and apparently affected each synapse in proportion to its initial strength. Such 'synaptic scaling' may help to ensure that firing rates do not become saturated during developmental changes in the number and strength of synaptic inputs(5), as well as stabilizing synaptic strengths during Hebbian modification(6,7) and facilitating competition between synapses(7-9).	Brandeis Univ, Dept Biol, Waltham, MA 02254 USA; Brandeis Univ, Ctr Complex Syst, Waltham, MA 02254 USA	Brandeis University; Brandeis University	Turrigiano, GG (corresponding author), Brandeis Univ, Dept Biol, Waltham, MA 02254 USA.	turrigiano@binah.cc.brandeis.edu		Nelson, Sacha/0000-0002-0108-8599				AXELSSON J, 1957, J PHYSIOL-LONDON, V149, P178; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; Benson DL, 1996, J NEUROSCI, V16, P6424; BERG DK, 1975, J PHYSIOL-LONDON, V244, P659, DOI 10.1113/jphysiol.1975.sp010818; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; Colman H, 1997, SCIENCE, V275, P356, DOI 10.1126/science.275.5298.356; GERFINMOSER A, 1995, NEUROSCIENCE, V67, P849, DOI 10.1016/0306-4522(95)00130-B; Hebb D. O., 1949, ORG BEHAV NEUROPHYSI; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; Liang FY, 1997, J NEUROSCI, V17, P2168; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.neuro.18.1.319; LIU GS, 1995, NATURE, V375, P404, DOI 10.1038/375404a0; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MICHEVA KD, 1995, P NATL ACAD SCI USA, V92, P11834, DOI 10.1073/pnas.92.25.11834; Miller KD, 1996, NEURON, V17, P371, DOI 10.1016/S0896-6273(00)80169-5; MILLER KD, 1994, NEURAL COMPUT, V6, P100, DOI 10.1162/neco.1994.6.1.100; RAMAKERS GJA, 1990, EXP BRAIN RES, V79, P157; Rutherford LC, 1997, J NEUROSCI, V17, P4527; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972; WYLLIE DJA, 1994, NEURON, V12, P127, DOI 10.1016/0896-6273(94)90158-9	30	1561	1577	2	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					892	896		10.1038/36103	http://dx.doi.org/10.1038/36103			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495341				2022-12-01	WOS:000072230900052
J	Ando, Y; Anan, I; Suhr, O; Holmgren, G; Costa, PMP				Ando, Y; Anan, I; Suhr, O; Holmgren, G; Costa, PMP			Detection of a variant protein in hair: new diagnostic method in Portuguese type familial amyloid polyneuropathy	BRITISH MEDICAL JOURNAL			English	Article							TRANSTHYRETIN		Umea Univ Hosp, Dept Med, S-90185 Umea, Sweden; Umea Univ Hosp, Dept Clin Genet, S-90185 Umea, Sweden; Hosp St Antonio, Ctr Estudos Paramiloidose, P-4000 Porto, Portugal	Umea University; Umea University	Ando, Y (corresponding author), Umea Univ Hosp, Dept Med, S-90185 Umea, Sweden.		Costa, Paulo Pinho/B-4392-2008	Costa, Paulo Pinho/0000-0001-6125-7000; Ando, Yukio/0000-0001-7115-9105; Suhr, Ole/0000-0002-1175-2369				ANDO Y, 1993, INTERNAL MED, V32, P920, DOI 10.2169/internalmedicine.32.920; Benson MD, 1996, AMYLOID, V3, P44, DOI 10.3109/13506129609014354; COSTA PMP, 1993, SCAND J IMMUNOL, V38, P177, DOI 10.1111/j.1365-3083.1993.tb01710.x; HOLMGREN G, 1994, J MED GENET, V31, P351, DOI 10.1136/jmg.31.5.351; Petersen RB, 1997, ANN NEUROL, V41, P307, DOI 10.1002/ana.410410305	5	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1998	316	7143					1500	1501		10.1136/bmj.316.7143.1500	http://dx.doi.org/10.1136/bmj.316.7143.1500			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZP020	9582138	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000073707700028
J	Pisetsky, DS				Pisetsky, DS			Doing everything	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Vet Adm Med Ctr, Durham, NC 27705 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Pisetsky, DS (corresponding author), Vet Adm Med Ctr, Box 151G,Room E-1008,508 Fulton St, Durham, NC 27705 USA.								0	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1998	128	10					869	870		10.7326/0003-4819-128-10-199805150-00013	http://dx.doi.org/10.7326/0003-4819-128-10-199805150-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM889	9599202				2022-12-01	WOS:000073586500013
J	Liebowitz, D				Liebowitz, D			Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KAPPA-B ACTIVATION; LATENT MEMBRANE PROTEIN-1; TRANSFORMING PROTEIN; CELLS; EXPRESSION; LMP1; INDUCTION; DELETION; BCL-2; GENE	Background. Epstein-Barr virus (EBV) is associated with various malignant and benign lymphoproliferative disorders. It also efficiently transforms human B lymphocytes in vitro. The latent membrane protein 1 (LMP1) of EBV-infected cells plays a central part in this process by mimicking members of the family of tumor necrosis factor (TNF) receptors, thereby transmitting growth signals from the cell membrane to the nucleus through cytoplasmic TNF-receptor-associated factors (TRAFs). I sought evidence of LMP1-mediated signal transduction through TRAFs in tumor tissue from patients with post-transplantation lymphoproliferative disease and non-Hodgkin's lymphomas related to the acquired immunodeficiency syndrome (AIDS). Methods. The association of LMP1 with TRAF-1 or TRAF-3 in tumor tissue was studied with double-immunofluorescence microscopy and immunoprecipitation assays. Evidence of LMP1-TRAF signaling was sought with an electrophoretic mobility shift assay for the nuclear factor-kappa B (NF-kappa B) transcription factor. Results. Tumors from eight patients with post-transplantation lymphoproliferative disease, two patients with AIDS-associated non-Hodgkin's lymphoma, and three patients with endemic Burkitt's lymphoma were analyzed. Tumors from six of the patients with post-transplantation lymphoproliferative disease were positive for EBV and expressed LMP1; two samples were EBV-negative. Tumors from both patients with AIDS-associated non-Hodgkin's lymphoma were EBV-positive and expressed LMP1, whereas tumors from all three patients with Burkitt's tumors were positive for EBV but negative for LMP1. Double-immunofluorescence microscopy showed that LMP1 localized with and immunoprecipitated with TRAF-1 and TRAF-3 in all eight of the EBV-positive, LMP1-positive samples. An electrophoretic mobility shift assay revealed activated NF-kappa B in all eight EBV-positive, LMP1-positive samples as well, but not in either of the EBV-negative, LMP1-negative samples or in the three EBV-positive, LMP1-negative samples. Conclusions. LMP1-mediated signaling through the TRAF system has a role in the pathogenesis of the EBV-positive lymphomas that arise in immunosuppressed patients. (C) 1998, Massachusetts Medical Society.	Univ Chicago, Dept Med, Viral Oncol Labs, Sect Hematol Oncol & Virol, Chicago, IL 60637 USA	University of Chicago	Liebowitz, D (corresponding author), Univ Chicago, Med Ctr, Dept Med, Hematol Oncol Sect, 5841 S Maryland Ave,MC2115, Chicago, IL 60637 USA.				NCI NIH HHS [CA 73545] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA073545] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAICHWAL VR, 1988, ONCOGENE, V2, P461; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Devergne O, 1996, MOL CELL BIOL, V16, P7098; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HATZUBAI A, 1987, INT J CANCER, V40, P358, DOI 10.1002/ijc.2910400313; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KIEFF E, 1996, FIELDS VIROLOGY, V2, P2343; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; Liebowitz D., 1997, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, V14, pA51; Liebowitz David, 1993, P107; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG D, 1988, J VIROL, V62, P2337, DOI 10.1128/JVI.62.7.2337-2346.1988; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B	22	165	171	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 14	1998	338	20					1413	1421		10.1056/NEJM199805143382003	http://dx.doi.org/10.1056/NEJM199805143382003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM667	9580648				2022-12-01	WOS:000073563700003
J	Levine, MM; Dougan, G				Levine, MM; Dougan, G			Optimism over vaccines administered via mucosal surfaces	LANCET			English	Editorial Material							ADP-RIBOSYLTRANSFERASE ACTIVITY		Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA; WHO, Global Programme Vaccines & Immunizat, Geneva, Switzerland; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London, England	University System of Maryland; University of Maryland Baltimore; World Health Organization; Imperial College London	Levine, MM (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.							Aggerbeck H, 1997, VACCINE, V15, P307, DOI 10.1016/S0264-410X(96)00175-2; Agren LC, 1997, J IMMUNOL, V158, P3936; BELSHE RB, IN PRESS N ENGL J ME; Darji A, 1997, CELL, V91, P765, DOI 10.1016/S0092-8674(00)80465-1; DICKINSON BL, 1995, INFECT IMMUN, V63, P1617, DOI 10.1128/IAI.63.5.1617-1623.1995; DOUCE G, 1995, P NATL ACAD SCI USA, V92, P1644, DOI 10.1073/pnas.92.5.1644; Galen JE, 1997, VACCINE, V15, P700, DOI 10.1016/S0264-410X(96)00227-7; Giuliani MM, 1998, J EXP MED, V187, P1123, DOI 10.1084/jem.187.7.1123; Glenn GM, 1998, NATURE, V391, P851, DOI 10.1038/36014; GONZALEZ C, 1994, J INFECT DIS, V169, P927, DOI 10.1093/infdis/169.4.927; Hohmann EL, 1996, J INFECT DIS, V173, P1408, DOI 10.1093/infdis/173.6.1408; JOHN TJ, 1972, AM J EPIDEMIOL, V96, P263, DOI 10.1093/oxfordjournals.aje.a121457; Levine MM, 1995, B I PASTEUR, V93, P243, DOI 10.1016/0020-2452(96)85758-7; LOWELL GH, 1997, NEW GENERATION VACCI, P193; PerezSchael I, 1997, NEW ENGL J MED, V337, P1181, DOI 10.1056/NEJM199710233371701; Snapper CM, 1996, J IMMUNOL, V157, P2229; Tacket CO, 1998, NAT MED, V4, P607, DOI 10.1038/nm0598-607; Tacket CO, 1997, INFECT IMMUN, V65, P452, DOI 10.1128/IAI.65.2.452-456.1997	18	78	80	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 9	1998	351	9113					1375	1376		10.1016/S0140-6736(05)79439-3	http://dx.doi.org/10.1016/S0140-6736(05)79439-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM665	9593404				2022-12-01	WOS:000073563400004
J	Ferrell, JE; Machleder, EM				Ferrell, JE; Machleder, EM			The biochemical basis of an all-or-none cell fate switch in Xenopus oocytes	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; MOS; MATURATION; CASCADE; SYSTEMS; AMPLIFICATION; SENSITIVITY; INITIATION; EXTRACTS	Xenopus oocytes convert a continuously variable stimulus, the concentration of the maturation-inducing hormone progesterone, into an all-or-none biological response-oocyte maturation, Here evidence is presented that the all-or-none character of the response is generated by the mitogen-activated protein kinase (MAPK) cascade. Analysis of individual oocytes showed that the response of MAPK to progesterone or Mos was equivalent to that of a cooperative enzyme with a Hill coefficient of at least 35, more than 10 times the Hill coefficient for the binding of oxygen to hemoglobin. The response can be accounted for by the intrinsic ultrasensitivity of the oocyte's MAPK cascade and a positive feedback loop in which the cascade is embedded. These findings provide a biochemical rationale for the all-or-none character of this cell fate switch.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Ferrell, JE (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.	ferrell@cmgm.stanford.edu			NCI NIH HHS [CA09302] Funding Source: Medline; NIGMS NIH HHS [GM56383] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brown GC, 1997, TRENDS BIOCHEM SCI, V22, P288, DOI 10.1016/S0968-0004(97)82216-5; Burack WR, 1997, BIOCHEMISTRY-US, V36, P5929, DOI 10.1021/bi970535d; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; Ferrell JE, 1997, TRENDS BIOCHEM SCI, V22, P288, DOI 10.1016/S0968-0004(97)82217-7; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Gerhart J.C., 1980, Biological Regulation and Development, V2, P133; GOLDBETER A, 1982, Q REV BIOPHYS, V15, P555, DOI 10.1017/S0033583500003449; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Kholodenko BN, 1997, FEBS LETT, V414, P430, DOI 10.1016/S0014-5793(97)01018-1; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; MASUI Y, 1967, J EXP ZOOL, V166, P365, DOI 10.1002/jez.1401660309; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NEBREDA AR, 1995, EMBO J, V14, P5597, DOI 10.1002/j.1460-2075.1995.tb00247.x; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NOVAK B, 1993, J CELL SCI, V106, P1153; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Roy LM, 1996, ONCOGENE, V12, P2203; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SMITH LD, 1991, METHOD CELL BIOL, V36, P45; STRYER L, 1995, BIOCHEMISTRY-US, P168; Thron CD, 1996, BIOPHYS CHEM, V57, P239, DOI 10.1016/0301-4622(95)00075-5; Tyson JJ, 1996, TRENDS BIOCHEM SCI, V21, P89; WALLACE RA, 1973, J EXP ZOOL, V184, P321, DOI 10.1002/jez.1401840305; WASSERMAN WJ, 1974, BIOL REPROD, V11, P133, DOI 10.1095/biolreprod11.2.133; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	35	815	828	7	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 8	1998	280	5365					895	898		10.1126/science.280.5365.895	http://dx.doi.org/10.1126/science.280.5365.895			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572732				2022-12-01	WOS:000073532900039
J	Gupta, S; Ferguson, N; Anderson, R				Gupta, S; Ferguson, N; Anderson, R			Chaos, persistence, and evolution of strain structure in antigenically diverse infectious agents	SCIENCE			English	Article							OUTER-MEMBRANE PROTEIN; PLASMODIUM-FALCIPARUM; ERYTHROCYTES; DYNAMICS; CHILDREN	The effects of selection by host immune responses on transmission dynamics was analyzed in a broad class of antigenically diverse pathogens. Strong selection can cause pathogen populations to stably segregate into discrete strains with nonoverlapping antigenic repertoires. However, over a wide range of intermediate levels of selection, strain structure is unstable, varying in a manner that is either cyclical or chaotic. These results have implications for the interpretation of longitudinal epidemiological data on strain or serotype abundance, design of surveillance strategies, and the assessment of multivalent vaccine trials.	Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, England	University of Oxford	Gupta, S (corresponding author), Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, S Parks Rd, Oxford OX1 3PS, England.	sunetra.gupta@zoology.ox.ac.uk	Ferguson, Neil/B-8578-2008	Ferguson, Neil/0000-0002-1154-8093	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; Andreasen V, 1997, J MATH BIOL, V35, P825, DOI 10.1007/s002850050079; ANTHONY BF, 1976, AM J EPIDEMIOL, V104, P652, DOI 10.1093/oxfordjournals.aje.a112344; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BOLKER B, 1995, PHILOS T R SOC B, V348, P309, DOI 10.1098/rstb.1995.0070; CAUGANT DA, 1990, J INFECT DIS, V162, P867, DOI 10.1093/infdis/162.4.867; *CDC, 1997, MMWR-MORBID MORTAL W, P1; CLIFF A, 1986, SPATIAL ASPECTS INFL; Contamin H, 1996, AM J TROP MED HYG, V54, P632, DOI 10.4269/ajtmh.1996.54.632; Feavers IM, 1996, CLIN DIAGN LAB IMMUN, V3, P444, DOI 10.1128/CDLI.3.4.444-450.1996; FERGUSON NM, 1997, SPATIAL ECOLOGY ROLE; GUPTA S, 1994, SCIENCE, V263, P961, DOI 10.1126/science.8310293; Gupta S, 1996, NAT MED, V2, P437, DOI 10.1038/nm0496-437; GUPTA S, IN PRESSS P R SOC B; MAIDEN MCJ, 1995, SYMP SOC GEN MICROBI, V52, P269; RAKONJAC JV, 1995, INFECT IMMUN, V63, P622, DOI 10.1128/IAI.63.2.622-631.1995; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; VANDERLEY P, 1992, INFECT IMMUN, V60, P3156, DOI 10.1128/IAI.60.8.3156-3161.1992; WATSON DA, 1995, EUR J CLIN MICROBIOL, V14, P479, DOI 10.1007/BF02113425; 1993, MORB MORTAL WKLY REP, V42, P1; 1992, MORB MORTAL WKLY REP, V41, P3; 1992, MORB MORTAL WKLY REP, V41, P5	23	212	215	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1998	280	5365					912	915		10.1126/science.280.5365.912	http://dx.doi.org/10.1126/science.280.5365.912			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572737				2022-12-01	WOS:000073532900044
J	Qiu, Y; Ravi, L; Kung, HJ				Qiu, Y; Ravi, L; Kung, HJ			Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells	NATURE			English	Article							GROWTH-FACTOR; RECEPTOR; EXPRESSION; TRANSFORMATION; TRANSDUCTION; ACTIVATION	Interleukin-6 (IL-6) is a cytokine that was initially recognized as a regulator of immune and inflammatory responses(1), but it also regulates the growth of many tumour cells, including prostrate carcinoma(2-4). Overexpression of the growth-factor receptors ErbB2/neu and ErbB3 has been implicated in the neoplastic transformation of prostate carcinoma(5-7). Here we show that treatment of the prostate cancer cell line LNCaP with IL-6 induces tyrosine phosphorylation of ErbB2 and ErbB3, but not ErbB1/ EGFR. We also show that ErbB2 forms a complex with the gp130 subunit of the IL-6 receptor in an IL-6-dependent manner. This association is important because the inhibition of ErbB2 activity results in abrogation of IL-6-induced MAPK activation. Thus ErbB2 is a critical component of IL-6 signalling through the MAP kinase pathway. These data show how a cytokine receptor can diversify its signalling pathways by engaging with a growth-factor receptor kinase.	Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; Natl Hlth Res Inst, Mol & Genom Med Div, Taipei, Taiwan	Case Western Reserve University; National Health Research Institutes - Taiwan	Kung, HJ (corresponding author), Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	hxk5@po.cwru.edu	Kung, Hsing-Jien/C-7651-2013					BEERLI RR, 1994, J BIOL CHEM, V269, P23931; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chen-Kiang S, 1995, Curr Top Microbiol Immunol, V194, P189; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DOUGALL WC, 1994, ONCOGENE, V9, P2109; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HIRANO T, 1992, CHEM IMMUNOL, V51, P153; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUTCHINS D, 1994, INT J CANCER, V58, P80, DOI 10.1002/ijc.2910580114; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; Okamoto M, 1997, CANCER RES, V57, P141; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUI H, 1994, J BIOL CHEM, V269, P5364; SIEGALL CB, 1990, CANCER RES, V50, P7786; SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022-5347(17)35267-9; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; ZHAU HE, 1994, J CELL BIOCHEM, P208	24	242	251	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 7	1998	393	6680					83	85		10.1038/30012	http://dx.doi.org/10.1038/30012			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM028	9590694				2022-12-01	WOS:000073497500052
J	van Turennout, M; Hagoort, P; Brown, CM				van Turennout, M; Hagoort, P; Brown, CM			Brain activity during speaking: From syntax to phonology in 40 milliseconds	SCIENCE			English	Article							PARTIAL INFORMATION; LEXICAL ACCESS; POTENTIALS	In normal conversation, speakers translate thoughts into words at high speed. To enable this speed, the retrieval of distinct types of linguistic knowledge has to be orchestrated with millisecond precision. The nature of this orchestration is still largely unknown. This report presents dynamic measures of the real-time activation of two basic types of linguistic knowledge, syntax and phonology. Electrophysiological data demonstrate that during noun-phrase production speakers retrieve the syntactic gender of a noun before its abstract phonological properties. This two-step process operates at high speed: the data show that phonological information is already available 40 milliseconds after syntactic properties have been retrieved.	Max Planck Inst Psycholinguist, NL-6525 XD Nijmegen, Netherlands	Max Planck Society	van Turennout, M (corresponding author), NIMH, Lab Brain & Cognit, Bldg 10,Room 4C104,10 Ctr Dr,MSC 1366, Bethesda, MD 20892 USA.		Hagoort, Peter/B-7417-2012					Butterworth B., 1989, LEXICAL REPRESENTATI, P108; COLES MGH, 1989, PSYCHOPHYSIOLOGY, V26, P251, DOI 10.1111/j.1469-8986.1989.tb01916.x; COLES MGH, 1995, OX PSYCH S, P86; DEJONG R, 1988, J EXP PSYCHOL HUMAN, V14, P682, DOI 10.1037/0096-1523.14.4.682; DELL GS, 1992, COGNITION, V42, P287, DOI 10.1016/0010-0277(92)90046-K; GARRETT M, 1992, COGNITION, V42, P143, DOI 10.1016/0010-0277(92)90042-G; KUTAS M, 1980, BRAIN RES, V202, P95, DOI 10.1016/0006-8993(80)90646-0; LEVELT WJM, 1991, PSYCHOL REV, V98, P122, DOI 10.1037/0033-295X.98.1.122; LEVELT WJM, 1989, SPEAKING INTENTION A; MILLER J, 1992, J EXP PSYCHOL GEN, V121, P195, DOI 10.1037/0096-3445.121.2.195; Miozzo M, 1997, J COGNITIVE NEUROSCI, V9, P160, DOI 10.1162/jocn.1997.9.1.160; OSMAN A, 1992, J EXP PSYCHOL HUMAN, V18, P217, DOI 10.1037/0096-1523.18.1.217; SMID HGOM, 1992, J EXP PSYCHOL HUMAN, V18, P1101, DOI 10.1037/0096-1523.18.4.1101	13	177	179	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 24	1998	280	5363					572	574		10.1126/science.280.5363.572	http://dx.doi.org/10.1126/science.280.5363.572			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZJ684	9554845	Green Submitted			2022-12-01	WOS:000073242100042
J	Chicurel, ME; Singer, RH; Meyer, CJ; Ingber, DE				Chicurel, ME; Singer, RH; Meyer, CJ; Ingber, DE			Integrin binding and mechanical tension induce movement of mRNA and ribosomes to focal adhesions	NATURE			English	Article							ANCHORAGE-DEPENDENT FIBROBLASTS; SIGNAL-TRANSDUCTION MECHANISMS; PROTEIN-KINASE-C; MESSENGER-RNA; ENDOTHELIAL-CELLS; GROWTH; FIBRONECTIN; EIF-4E; HYBRIDIZATION; CYTOSKELETON	The extracellular matrix (ECM) activates signalling pathways that control cell behaviour by binding to cell-surface integrin receptors and inducing the formation of focal adhesion complexes (FACs)(1,2). In addition to clustered integrins, FACs contain proteins that mechanically couple the integrins to the cytoskeleton(3) and to immobilized signal-transducing molecules(1,2). Cell adhesion to the ECM also induces a rapid increase in the translation of preexisting messenger RNAs4,5. Gene expression can be controlled locally by targeting mRNAs to specialized cytoskeletal domains(6). Here we investigate whether cell binding to the ECM promotes formation of a cytoskeletal microcompartment specialized for translational control at the site of integrin binding. High-resolution in situ hybridization revealed that mRNA and ribosomes rapidly and specifically localized to FACs that form when cells bind to ECM-coated microbeads, Relocation of these protein synthesis components to the FAC depended on the ability of integrins to mechanically couple the ECM to the contractile cytoskeleton and on associated tension-moulding of the actin lattice. Our results suggest a new type of gene regulation by integrins and by mechanical stress which may involve translation of mRNAs into proteins near the sites of signal reception.	Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine	Ingber, DE (corresponding author), Childrens Hosp, Dept Surg, 300 Longwood Ave, Boston, MA 02115 USA.		Ingber, Donald E/AAC-5894-2019					Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; BASSELL GJ, 1994, J CELL BIOL, V126, P863, DOI 10.1083/jcb.126.4.863; BENECKE BJ, 1978, CELL, V14, P931, DOI 10.1016/0092-8674(78)90347-1; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; EDMONDS BT, 1995, J BIOL CHEM, V270, P15222, DOI 10.1074/jbc.270.25.15222; FARMER SR, 1978, CELL, V15, P627, DOI 10.1016/0092-8674(78)90031-4; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; INGBER DE, 1993, J CELL SCI, V104, P613; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LATHAM VM, 1994, J CELL BIOL, V126, P1211, DOI 10.1083/jcb.126.5.1211; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; LUCAS JJ, 1976, CELL, V7, P115, DOI 10.1016/0092-8674(76)90261-0; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Schmeichel KL, 1997, MOL BIOL CELL, V8, P219, DOI 10.1091/mbc.8.2.219; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; VANMANTEUFFEL S, 1996, P NATL ACAD SCI USA, V93, P4076; VUORI K, 1993, J BIOL CHEM, V268, P21459; Wada H, 1996, J BIOL CHEM, V271, P8359, DOI 10.1074/jbc.271.14.8359; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wang N, 1995, BIOCHEM CELL BIOL, V73, P327, DOI 10.1139/o95-041; Whalen SG, 1996, J BIOL CHEM, V271, P11831, DOI 10.1074/jbc.271.20.11831; ZHANG GH, 1994, NATURE, V372, P809	30	305	313	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 16	1998	392	6677					730	733		10.1038/33719	http://dx.doi.org/10.1038/33719			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565036				2022-12-01	WOS:000073129000063
J	Elmore, G; Barton, MB; Moceri, VM; Polk, S; Arena, PJ; Fletcher, SW				Elmore, G; Barton, MB; Moceri, VM; Polk, S; Arena, PJ; Fletcher, SW			Ten-year risk of false positive screening mammograms and clinical breast examinations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	National Meeting of the Society-of-General-Internal-Medicine	MAY 01-03, 1997	WASHINGTON, D.C.	Soc Gen Internal Med			PREDICTIVE VALUE; CANCER; AUDIT; ANXIETY	Background The cumulative risk of a false positive result of a breast-cancer screening test is unknown. Methods We performed a 10-year retrospective cohort study of breast-cancer screening and diagnostic evaluations among 2400 women who were 40 to 69 years old at study entry. Mammograms or clinical breast examinations that were interpreted as indeterminate, aroused a suspicion of cancer, or prompted recommendations for additional workup in women in whom breast cancer was not diagnosed within the next year were considered to be false positive tests. Results A total of 9762 screening mammograms and 10,905 screening clinical breast examinations were performed, for a median of 4 mammograms and 5 clinical breast examinations per woman over the 10-year period. Of the women who were screened, 23.8 percent had at least one false positive mammogram, 13.4 percent had at least one false positive breast examination, and 31.7 percent had at least one false positive result for either test. The estimated cumulative risk of a false positive result was 49.1 percent (95 percent confidence interval, 40.3 to 64.1 percent) after 10 mammograms and 22.3 percent (95 percent confidence interval, 19.2 to 27.5 percent) after 10 clinical breast examinations. The false positive tests led to 870 outpatient appointments, 539 diagnostic mammograms, 186 ultrasound examinations, 188 biopsies, and 1 hospitalization. We estimate that among women who do not have breast cancer, 18.6 percent (95 percent confidence interval, 9.8 to 41.2 percent) will undergo a biopsy after 10 mammograms, and 6.2 percent (95 percent confidence interval, 3.7 to 11.2 percent) after 10 clinical breast examinations. For every $100 spent for screening, an additional $33 was spent to evaluate the false positive results. Conclusions Over 10 years, one third of the women screened had abnormal test results requiring additional evaluation, even though no breast cancer was present. Techniques are needed to decrease false positive results while maintaining high sensitivity. Physicians should educate women about the risk of a false positive result of a screening test for breast cancer. (C) 1998, Massachusetts Medical Society.	Univ Washington, Sch Med, Div Gen Internal Med, Dept Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Epidemiol, Seattle, WA 98195 USA; Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Pilgrim Hlth Care, Dept Diagnost Radiol, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard Pilgrim Health Care; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School	Elmore, G (corresponding author), Univ Washington, Sch Med, Div Gen Internal Med, Dept Med, 1959 NE Pacific,Rm BB527E,Box 356429, Seattle, WA 98195 USA.		SALAZAR, ANTONIO/A-5806-2013	SALAZAR, ANTONIO/0000-0003-2639-2340				BARNETT GO, 1984, NEW ENGL J MED, V310, P1643, DOI 10.1056/NEJM198406213102506; BARNETT GO, 1979, P IEEE, V67, P1226, DOI 10.1109/PROC.1979.11438; Bassett LW, 1994, AHCPR PUBLICATION; BIRD RE, 1989, RADIOLOGY, V171, P87, DOI 10.1148/radiology.171.1.2494683; BROWN ML, 1995, AM J ROENTGENOL, V165, P1373, DOI 10.2214/ajr.165.6.7484568; BULL AR, 1991, BRIT J RADIOL, V64, P510, DOI 10.1259/0007-1285-64-762-510; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; ELLMAN R, 1989, BRIT J CANCER, V60, P781, DOI 10.1038/bjc.1989.359; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; GRAM IT, 1990, BRIT J CANCER, V62, P1018, DOI 10.1038/bjc.1990.430; GRAM IT, 1992, AM J PUBLIC HEALTH, V82, P249, DOI 10.2105/AJPH.82.2.249; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P39, DOI 10.1001/jama.276.1.39; KIRSCHNER CG, 1994, PHYSICIANS CURRENT P; KOPANS DB, 1992, AM J ROENTGENOL, V158, P521, DOI 10.2214/ajr.158.3.1310825; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; LERMAN C, 1991, HEALTH PSYCHOL, V10, P259, DOI 10.1037/0278-6133.10.4.259; LERMAN C, 1991, J CLIN ONCOL, V9, P1275, DOI 10.1200/JCO.1991.9.7.1275; Lidbrink E, 1996, BRIT MED J, V312, P273; LINVER MN, 1995, AM J ROENTGENOL, V165, P19, DOI 10.2214/ajr.165.1.7785586; Paskett ED, 1995, J WOMENS HEALTH, V4, P73; ROBERTSON CL, 1993, RADIOLOGY, V187, P75, DOI 10.1148/radiology.187.1.8451440; *SAS I, 1996, SAS VERS 6 11; SICKLES EA, 1992, RADIOL CLIN N AM, V30, P265; SUTTON S, 1995, J EPIDEMIOL COMMUN H, V49, P413, DOI 10.1136/jech.49.4.413; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, V2nd; 1995, MMWR MORB MORTAL WKL, V45, P57; 1996, FED REG, V61, P59490	27	760	776	1	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 16	1998	338	16					1089	1096		10.1056/NEJM199804163381601	http://dx.doi.org/10.1056/NEJM199804163381601			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH080	9545356	Bronze			2022-12-01	WOS:000073070100001
J	Devitt, A; Moffatt, OD; Raykundalia, C; Capra, JD; Simmons, DL; Gregory, CD				Devitt, A; Moffatt, OD; Raykundalia, C; Capra, JD; Simmons, DL; Gregory, CD			Human CD14 mediates recognition and phagocytosis of apoptotic cells	NATURE			English	Article							MACROPHAGE RECOGNITION; VITRONECTIN RECEPTOR; BINDING-PROTEIN; HUMAN-MONOCYTES; ANTIGEN; STIMULATION; ENDOTOXIN; ANTIBODY; POLYMERS; DEATH	Cells undergoing programmed cell death (apoptosis) are cleared rapidly in vivo by phagocytes without inducing inflammation(1), Here we show that the glycosylphosphatidylinositol-linked plasma-membrane glycoprotein CD14 (refs 2, 3) on the surface of human macrophages is important for the recognition and clearance of apoptotic cells, CD14 can also act as a receptor that binds bacterial lipopolysaccharide (LPS), triggering inflammatory responses(4), Overstimulation of CD14 by LPS can cause the often fatal toxic-shock syndrome(5,6). Here we show that apoptotic cells interact with CD14, triggering phagocytosis of the apoptotic cells, This interaction depends on a region of CD14 that is identical to, or at least closely associated with, a region known to bind LPS, However, apoptotic cells, unlike LPS, do not provoke the release of pro-inflammatory cytokines from macrophages, These results indicate that clearance of apoptotic cells is mediated by a receptor whose interactions with 'non-self' components (LPS) and 'self' components (apoptotic cells) produce distinct macrophage responses.	Univ Birmingham, Sch Med, Dept Immunol, Birmingham B15 2TT, W Midlands, England; Univ Nottingham, Sch Med, Queens Med Ctr, Inst Cell Signalling, Nottingham NG7 2UH, England; Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; SmithKline Beecham Pharmaceut, Harlow CM19 5AW, Essex, England	University of Birmingham; University of Nottingham; University of Nottingham; Oklahoma Medical Research Foundation; GlaxoSmithKline	Gregory, CD (corresponding author), Univ Birmingham, Sch Med, Dept Immunol, Birmingham B15 2TT, W Midlands, England.		Gregory, Chris/C-6927-2019	Gregory, Chris/0000-0002-7553-0132; Devitt, Andrew/0000-0002-4651-6761				Cavaillon JM, 1996, J ENDOTOXIN RES, V3, P471, DOI 10.1177/096805199600300605; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; DINI L, 1992, FEBS LETT, V296, P174, DOI 10.1016/0014-5793(92)80373-O; DUVALL E, 1985, IMMUNOLOGY, V56, P351; ESPEVIK T, 1993, EUR J IMMUNOL, V23, P255, DOI 10.1002/eji.1830230140; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; FERRERO E, 1993, P NATL ACAD SCI USA, V90, P380; FLORA PK, 1994, EUR J IMMUNOL, V24, P2625, DOI 10.1002/eji.1830241109; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; HARIOT A, 1996, IMMUNITY, V4, P407; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; NEWMAN SL, 1995, J IMMUNOL, V154, P753; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Petty HR, 1996, IMMUNOL TODAY, V17, P209, DOI 10.1016/0167-5699(96)30013-3; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; Pradhan D, 1997, MOL BIOL CELL, V8, P767, DOI 10.1091/mbc.8.5.767; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SIMMONS DL, 1989, BLOOD, V73, P284; SOELL M, 1995, J IMMUNOL, V154, P851; UGOLINI V, 1980, P NATL ACAD SCI-BIOL, V77, P6764, DOI 10.1073/pnas.77.11.6764; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Weidemann B, 1997, INFECT IMMUN, V65, P858, DOI 10.1128/IAI.65.3.858-864.1997; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160	30	547	561	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 2	1998	392	6675					505	509		10.1038/33169	http://dx.doi.org/10.1038/33169			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF215	9548256				2022-12-01	WOS:000072875200061
J	Gupta, VK; Skaife, JJ; Dubrovsky, TB; Abbott, NL				Gupta, VK; Skaife, JJ; Dubrovsky, TB; Abbott, NL			Optical amplification of ligand-receptor binding using liquid crystals	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; MOLECULAR RECOGNITION; ANTIBODIES; BIOTIN; DRUGS	Liquid crystals (LCs) were used to amplify and transduce receptor-mediated binding of proteins at surfaces into optical outputs, Spontaneously organized surfaces were designed so that protein molecules, upon binding to ligands hosted on these surfaces, triggered changes in the orientations of 1- to 20-micrometer-thick films of supported LCs, thus corresponding to a reorientation of similar to 10(5) to 10(6) mesogens per protein. Binding-induced changes in the intensity of light transmitted through the LC were easily seen with the naked eye and could be further amplified by using surfaces designed so that protein-ligand recognition causes twisted nematic LCs to untwist. This approach to the detection of ligand-receptor binding does not require labeling of the analyte, does not require the use of electroanalytical apparatus, provides a spatial resolution of micrometers, and is sufficiently simple that it may find use in biochemical assays and imaging of spatially resolved chemical libraries.	Univ Calif Davis, Dept Chem Engn & Mat Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Gupta, VK (corresponding author), Univ Calif Davis, Dept Chem Engn & Mat Sci, Davis, CA 95616 USA.	nlabbott@ucdavis.edu						BAGCI H, 1993, FEBS LETT, V322, P47, DOI 10.1016/0014-5793(93)81108-C; Bahadur B., 1990, LIQUID CRYSTALS APPL; Chandrasekhar S., 1992, LIQ CRYST, DOI 10.1017/CBO9780511622496; Charych D, 1996, CHEM BIOL, V3, P113, DOI 10.1016/S1074-5521(96)90287-2; CHARYCH DH, 1993, SCIENCE, V261, P585, DOI 10.1126/science.8342021; Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432; Crews H. M., 1995, BIOMARKERS FOOD CHEM; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; GAMALEYA NB, 1993, FORENSIC SCI INT, V63, P285, DOI 10.1016/0379-0738(93)90282-F; Gupta VK, 1996, LANGMUIR, V12, P2587, DOI 10.1021/la960003i; Gupta VK, 1997, SCIENCE, V276, P1533, DOI 10.1126/science.276.5318.1533; Gupta VK, 1996, PHYS REV E, V54, pR4540, DOI 10.1103/PhysRevE.54.R4540; KUMAR A, 1995, ACCOUNTS CHEM RES, V28, P219, DOI 10.1021/ar00053a003; Lin VSY, 1997, SCIENCE, V278, P840, DOI 10.1126/science.278.5339.840; Pan JJ, 1997, LANGMUIR, V13, P1365, DOI 10.1021/la9602675; Price C.P., 1991, PRINCIPLES PRACTICE; PRIME KL, 1993, J AM CHEM SOC, V115, P10714, DOI 10.1021/ja00076a032; SKAIFE JJ, UNPUB; SOLANS A, 1995, J ANAL TOXICOL, V19, P104, DOI 10.1093/jat/19.2.104; SPINKE J, 1993, J CHEM PHYS, V99, P7012, DOI 10.1063/1.465447; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Wild D., 2013, IMMUNOASSAY HDB	22	403	446	6	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2077	2080		10.1126/science.279.5359.2077	http://dx.doi.org/10.1126/science.279.5359.2077			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516101				2022-12-01	WOS:000072775600037
J	Ogg, GS; Jin, X; Bonhoeffer, S; Dunbar, PR; Nowak, MA; Monard, S; Segal, JP; Cao, YZ; Rowland-Jones, SL; Cerundolo, V; Hurley, A; Markowitz, M; Ho, DD; Nixon, DF; McMichael, AJ				Ogg, GS; Jin, X; Bonhoeffer, S; Dunbar, PR; Nowak, MA; Monard, S; Segal, JP; Cao, YZ; Rowland-Jones, SL; Cerundolo, V; Hurley, A; Markowitz, M; Ho, DD; Nixon, DF; McMichael, AJ			Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA	SCIENCE			English	Article							VIRUS TYPE-1 INFECTION; HIV-1 INFECTION; DISEASE PROGRESSION; IMMUNE-RESPONSES; HIGH-FREQUENCY; CELLS; IDENTIFICATION; VIREMIA; MEMORY; AIDS	Although cytotoxic T lymphocytes (CTLs) are thought to be involved in the control of human immunodeficiency virus-type 1 (HIV-1) infection, it has not been possible to demonstrate a direct relation between CTL activity and plasma RNA viral load. Human leukocyte antigen-peptide tetrameric complexes offer a specific means to directly quantitate circulating CTLs ex vivo. With the use of the tetrameric complexes, a significant inverse correlation was observed between HIV-specific CTL frequency and plasma RNA viral load. In contrast, no significant association was detected between the clearance rate of productively infected cells and frequency of HIV-specific CTLs. These data are consistent with a significant role for HIV-specific CTLs in the control of HIV infection and suggest a considerable cytopathic effect of the virus in vivo.	Nuffield Dept Med, Inst Mol Med, Oxford OX3 9DS, England; Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford; University of Oxford	McMichael, AJ (corresponding author), Nuffield Dept Med, Inst Mol Med, Oxford OX3 9DS, England.		Dunbar, Rod/C-2570-2012; Bonhoeffer, Sebastian/A-2735-2008; Nixon, Douglas/AAU-5734-2020; Nowak, Martin A/A-6977-2008	Dunbar, Rod/0000-0001-9626-2600; Bonhoeffer, Sebastian/0000-0001-8052-3925; Nixon, Douglas/0000-0002-2801-1786; Cerundolo, Vincenzo/0000-0003-0040-3793; Ogg, Graham/0000-0002-3097-045X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041534] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00102] Funding Source: Medline; NIAID NIH HHS [U01AI41534] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Bonhoeffer S, 1997, P NATL ACAD SCI USA, V94, P6971, DOI 10.1073/pnas.94.13.6971; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DUNBAR PR, UNPUB; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 1997, J EXP MED, V185, P1423, DOI 10.1084/jem.185.8.1423; GRANT MD, 1992, AIDS, V6, P1085, DOI 10.1097/00002030-199210000-00004; Greenough TC, 1997, J INFECT DIS, V176, P118, DOI 10.1086/514013; Harrer T, 1996, J IMMUNOL, V156, P2616; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; Klenerman P, 1996, P NATL ACAD SCI USA, V93, P15323, DOI 10.1073/pnas.93.26.15323; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OGG GS, UNPUB; PARKER KC, 1992, J IMMUNOL, V149, P3580; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; RINALDO CR, 1995, AIDS RES HUM RETROV, V11, P481, DOI 10.1089/aid.1995.11.481; Shiga H, 1996, AIDS, V10, P1075, DOI 10.1097/00002030-199609000-00004; Steven NM, 1997, J EXP MED, V185, P1605, DOI 10.1084/jem.185.9.1605; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	40	1208	1280	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2103	2106		10.1126/science.279.5359.2103	http://dx.doi.org/10.1126/science.279.5359.2103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516110				2022-12-01	WOS:000072775600046
J	Boyle, JS; Brady, JL; Lew, AM				Boyle, JS; Brady, JL; Lew, AM			Enhanced response to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction	NATURE			English	Article							PROTEIN; MICE; IMMUNIZATION; CTLA4IG; INVIVO	Viral infection and vaccination with DNA both induce similar immune responses to encoded antigens that are produced by the host(1,2). The availability of antigens in lymphoid organs is important in generating an immune response to viral challenge(3). Antigen availability may also be important in the response to DNA vaccines, because immune responses are stronger when antigen is secreted from DNA-transfected cells(4,5). We directed antigen to lymphoid organs by vaccination,vith DNA encoding antigen-ligand fusion proteins, The two ligands examined bind to receptors that are present on high endothelial venule cells of lymph nodes or on antigen-presenting cells. Here we show that both the humoral and the cellular immune responses to a model DNA vaccine were enhanced using either antigen-targeting strategy. Moreover, directing antigen to antigen-presenting cells speeded up, and altered the form of, the immune response, Directing antigen to sites of immune-response induction may represent a generic means of tailoring a potent and effective immune response to a DNA vaccine.	Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Brisbane, Qld 4029, Australia; Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, Melbourne, Vic 3050, Australia	QIMR Berghofer Medical Research Institute; Walter & Eliza Hall Institute	Lew, AM (corresponding author), Queensland Inst Med Res, Cooperat Res Ctr Vaccine Technol, Brisbane, Qld 4029, Australia.	lew@wehi.edu.au	Lew, Andrew M/C-7248-2013	Lew, Andrew M/0000-0002-2198-8164				AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Boyle JS, 1997, P NATL ACAD SCI USA, V94, P14626, DOI 10.1073/pnas.94.26.14626; Boyle JS, 1997, INT IMMUNOL, V9, P1897, DOI 10.1093/intimm/9.12.1897; Catalina MD, 1996, J EXP MED, V184, P2341, DOI 10.1084/jem.184.6.2341; Inchauspe G, 1997, DNA CELL BIOL, V16, P185, DOI 10.1089/dna.1997.16.185; JOHNSON KS, 1989, NATURE, V338, P585, DOI 10.1038/338585a0; Karrer U, 1997, J EXP MED, V185, P2157, DOI 10.1084/jem.185.12.2157; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Lew AM, 1996, TRANSPLANTATION, V62, P83, DOI 10.1097/00007890-199607150-00017; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MICHEL ML, 1995, P NATL ACAD SCI USA, V92, P5307, DOI 10.1073/pnas.92.12.5307; MOR G, 1995, J IMMUNOL, V155, P2039; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; SNAPPER CM, 1993, IMMUNOL TODAY, V14, P15, DOI 10.1016/0167-5699(93)90318-F; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8	19	215	255	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 26	1998	392	6674					408	411		10.1038/32932	http://dx.doi.org/10.1038/32932			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZD694	9537327				2022-12-01	WOS:000072713600057
J	Malone, KE; Daling, JR; Thompson, JD; O'Brien, CA; Francisco, LV; Ostrander, EA				Malone, KE; Daling, JR; Thompson, JD; O'Brien, CA; Francisco, LV; Ostrander, EA			BRCA1 mutations and breast cancer in the general population - Analyses in women before age 35 years and in women before age 45 years with first-degree family history	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EARLY-ONSET BREAST; OVARIAN-CANCER; YOUNG-WOMEN; JEWISH WOMEN; SURVIVAL; LINKAGE; ORIGINS; RISK	Context.-Studies of high-risk families with multiple early-onset cases of breast cancer have been useful for assessing the type and spectrum of germline mutations on the BRCA1 gene, but do not provide guidance to women with modest family history profiles. Thus, studies of women from the general population are needed to determine the BRCA1 mutation frequency in women perceived to be at high risk, and to develop profiles of those most likely to be carriers. Objective.-To characterize frequency and spectrum of germline BRCA1 mutations in 2 categories of women identified via population-based studies hypothesized to be at increased risk of carrying such mutations: those diagnosed as having breast cancer before age 35 years and those diagnosed before age 35 years who have first-degree breast cancer family history, Design.-Study subjects were drawn from 2 population-based case-control studies of breast cancer in young women on the basis of their family history or their age of diagnosis. Cases were younger than 35 years or were younger than 45 years with first-degree family history at the time of breast cancer diagnosis and were ascertained via a population-based cancer registry, and controls (women without breast cancer) were identified via random-digit dialing. Setting.-Three counties in western Washington State, Main Outcome Measure.-BRCA1 germline mutations in study subjects identified in DNA from peripheral blood lymphocytes by single-strand conformation polymorphism analysis using primer pairs that span the BRCA1 coding region and intron-exon boundaries. Results.-Of 193 women diagnosed as having breast cancer before age 35 years, none of whom were selected on the basis of family history status, 12 (6.2%, 95% confidence interval [CI], 3.2%-10.6%) had germline BRCA1 mutations. in 208 women diagnosed before age 45 years who had first-degree breast cancer family history, 15 (7.2%, 95% CI, 4.1%-11.6%) had germline mutations in BRCA1. In both groups, there were variations in mutation frequency noted by age and by family history. Mutation frequency decreased with increasing age of diagnosis. Higher proportions of mutations were seen in cases with at least 1 relative diagnosed as having breast cancer before age 45 years, in cases with greater numbers of affected relatives, and those with ovarian cancer family history. Mutation frequency did not vary by bilateral breast cancer family history. No frameshift or nonsense mutations were observed in 71 control women with a first-degree family history, although missense changes of unknown significance were seen in cases and controls. Conclusions.-Women with BRCA1 germline mutations lacked a common family history profile. Also, a large proportion of the women with a first-degree breast cancer family history and women diagnosed as having breast cancer before age 35 years did not carry germline BRCA1 mutations. Hence, while early-onset disease and a strong breast cancer family history may be useful guidelines for checking BRCA1 status, these findings on women drawn from the general population suggest that it may be difficult to develop BRCA1 mutation screening criteria among women with modest family history profiles.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Malone, KE (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,POB 19024,MP-381, Seattle, WA 98109 USA.			Ostrander, Elaine/0000-0001-6075-9738	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP095671] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA063705, R01CA041416] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-95671, R01-CA-41416, R01-CA-63705] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berman DB, 1996, AM J HUM GENET, V58, P1166; BRINTON LA, 1995, J NATL CANCER I, V87, P827, DOI 10.1093/jnci/87.11.827; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; COUCH FJ, 1995, J NCI MONOGR, V17, P9; DALING JR, 1994, JNCI-J NATL CANCER I, V86, P1584, DOI 10.1093/jnci/86.21.1584; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1995, AM J HUM GENET, V57, P1547; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Hakansson S, 1997, AM J HUM GENET, V60, P1068; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; JACQUEMIER J, 1995, LANCET, V345, P1503, DOI 10.1016/S0140-6736(95)91060-3; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(97)89007-7; Jordanova A, 1997, HUM MUTAT, V10, P65, DOI 10.1002/(SICI)1098-1004(1997)10:1<65::AID-HUMU9>3.3.CO;2-9; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; Malone KE, 1996, CANCER, V78, P1417, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1417::AID-CNCR7>3.3.CO;2-Q; Mathew CG, 1996, NEW ENGL J MED, V334, P1198; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1995, AM J HUM GENET, V56, P254; NAROD SA, 1991, LANCET, V338, P82; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P1; PORTER DE, 1994, BRIT J SURG, V81, P1512, DOI 10.1002/bjs.1800811038; Serova O, 1996, AM J HUM GENET, V58, P42; ShattuckEidens D, 1997, JAMA-J AM MED ASSOC, V278, P1242, DOI 10.1001/jama.278.15.1242; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; StoppaLyonnet D, 1997, AM J HUM GENET, V60, P1021; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Szabo CI, 1997, AM J HUM GENET, V60, P1013; TONIN P, 1995, AM J HUM GENET, V57, P189; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; Whittemore AS, 1997, AM J HUM GENET, V60, P496	37	182	188	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1998	279	12					922	929		10.1001/jama.279.12.922	http://dx.doi.org/10.1001/jama.279.12.922			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC304	9544766				2022-12-01	WOS:000072563600032
J	Nuki, G				Nuki, G			Ankylosing spondylitis, HLA B27, and beyond	LANCET			English	Editorial Material							HLA-B27 TRANSGENIC RATS; INFLAMMATORY DISEASE; ARTHRITIS; MODEL		Univ Edinburgh, Western Gen Hosp, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Nuki, G (corresponding author), Univ Edinburgh, Western Gen Hosp, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland.							Breban M, 1996, J IMMUNOL, V156, P794; BREWERTON DA, 1973, LANCET, V1, P904; Brown MA, 1997, ANN RHEUM DIS, V56, P68, DOI 10.1136/ard.56.1.68; Brown MA, 1997, ARTHRITIS RHEUM, V40, P1823, DOI 10.1002/art.1780401015; BROWN MA, 1997, BR J RHEUMATOL S1, V36; Brown Matthew, 1997, Current Opinion in Rheumatology, V9, P308; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HILL AVS, 1991, LANCET, V337, P640, DOI 10.1016/0140-6736(91)92452-8; KHAN M, 1997, J RHEUMATOL S3, V4, P39; KHARE SD, 1995, J EXP MED, V182, P1153, DOI 10.1084/jem.182.4.1153; LOPEZLARREA C, 1995, TISSUE ANTIGENS, V45, P169, DOI 10.1111/j.1399-0039.1995.tb02436.x; Nasution AR, 1997, J RHEUMATOL, V24, P1111; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; Smith GW, 1997, BRIT J RHEUMATOL, V36, P778; TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359; WRIGHT V, 1976, SERONEGATIVE POLYART, P1	16	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					767	769		10.1016/S0140-6736(05)78922-4	http://dx.doi.org/10.1016/S0140-6736(05)78922-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519942				2022-12-01	WOS:000072521200003
J	Takaku, K; Oshima, M; Miyoshi, H; Matsui, M; Seldin, MF; Taketo, MM				Takaku, K; Oshima, M; Miyoshi, H; Matsui, M; Seldin, MF; Taketo, MM			Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes	CELL			English	Article							GROWTH-FACTOR-BETA; FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-SUPPRESSOR GENE; TARGETED DISRUPTION; PANCREATIC-CANCER; COLORECTAL-CANCER; NEOPLASIA MIN; MOUSE; CARCINOMA; RECEPTOR	The DPC4 (SMAD4) gene plays a key role in the TGF beta signaling pathway. We inactivated its mouse homolog Dpc4 (Smad4). The homozygous mutants were embryonic lethal, whereas the heterozygotes showed no abnormality. We then introduced the Dpc4 mutation into the Apc(Delta 716) knockout mice, a model for human familiar adenomatous polyposis. Because both Ape and Dpc4 are located on chromosome 18, we constructed compound heterozygotes carrying both mutations on the same chromosome by meiotic recombination. In such mice, intestinal polyps developed into more malignant tumors than those in the simple Apc(Delta 716) heterozygotes, showing an extensive stromal cell proliferation, submucosal invasion, cell type heterogeneity, and in vivo transplantability. These results indicate that mutations in DPC4 (SMAD4) play a significant role in the malignant progression of colorectal tumors.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Biomed Genet, Tokyo 1130033, Japan; Banyu Tsukuba Res Inst Merck, Tsukuba, Ibaraki 3002611, Japan; Univ Calif Davis, Dept Biol Chem, Rowe Program Genet, Davis, CA 95616 USA	University of Tokyo; Merck & Company; University of California System; University of California Davis	Taketo, MM (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Biomed Genet, Tokyo 1130033, Japan.		Oshima, Masanobu/F-9958-2014	Oshima, Masanobu/0000-0002-3304-0004; Miyoshi, Hiroyuki/0000-0001-7400-0714	NHGRI NIH HHS [HG00734] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000734] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Anna CH, 1997, MAMM GENOME, V8, P443, DOI 10.1007/s003359900465; BECKWITH PS, 1991, ARCH SURG-CHICAGO, V126, P825; CAVENEE WK, 1986, COLD SPRING HARB SYM, V51, P829, DOI 10.1101/SQB.1986.051.01.096; COFFEY RJ, 1987, J CLIN INVEST, V80, P750, DOI 10.1172/JCI113130; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Fenoglio-Preiser CM, 1990, TUMORS INTESTINES; FILMUS J, 1992, ONCOGENE, V7, P521; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GARIBOLDI M, 1995, MAMM GENOME, V6, P581, DOI 10.1007/BF00352361; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1996, CANCER RES, V56, P490; HORII A, 1992, CANCER RES, V52, P6696; INAZAWA J, 1992, JPN J CANCER RES, V83, P1248, DOI 10.1111/j.1349-7006.1992.tb02753.x; JAGELMAN DG, 1988, LANCET, V1, P1149; JENNINGS MT, 1991, INT J CANCER, V49, P129, DOI 10.1002/ijc.2910490124; Johnson KR, 1997, MAMM GENOME, V7, pS295, DOI 10.1007/s003359900330; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kloppel G., 1993, PANCREAS, P871; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; LUONGO C, 1994, CANCER RES, V54, P5947; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; MULDER KM, 1988, CANCER RES, V48, P7120; OAKEY RJ, 1991, GENOMICS, V10, P338, DOI 10.1016/0888-7543(91)90317-8; Oshima H, 1997, CANCER RES, V57, P1644; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Sanabria JR, 1996, AM J SURG, V171, P136, DOI 10.1016/S0002-9610(99)80088-9; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; SHOEMAKER AR, 1995, CANCER RES, V55, P4479; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUGIHARA K, 1982, DIS COLON RECTUM, V25, P766, DOI 10.1007/BF02553308; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	51	479	499	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1998	92	5					645	656		10.1016/S0092-8674(00)81132-0	http://dx.doi.org/10.1016/S0092-8674(00)81132-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506519	Bronze			2022-12-01	WOS:000072406000010
J	Frenkel, LM; Mullins, JI; Learn, GH; Manns-Arcuino, L; Herring, BL; Kalish, ML; Steketee, RW; Thea, DM; Nichols, JE; Liu, SL; Harmache, A; He, X; Muthui, D; Madan, A; Hood, L; Haase, AT; Zupancic, M; Staskus, K; Wolinsky, S; Krogstad, P; Zhao, JQ; Chen, I; Koup, R; Ho, D; Korber, B; Apple, RJ; Coombs, RW; Pahwa, S; Roberts, NJ				Frenkel, LM; Mullins, JI; Learn, GH; Manns-Arcuino, L; Herring, BL; Kalish, ML; Steketee, RW; Thea, DM; Nichols, JE; Liu, SL; Harmache, A; He, X; Muthui, D; Madan, A; Hood, L; Haase, AT; Zupancic, M; Staskus, K; Wolinsky, S; Krogstad, P; Zhao, JQ; Chen, I; Koup, R; Ho, D; Korber, B; Apple, RJ; Coombs, RW; Pahwa, S; Roberts, NJ			Genetic evaluation of suspected cases of transient HIV-1 infection of infants	SCIENCE			English	Article							VIRUS; TRANSMISSION; INDIVIDUALS; ZIDOVUDINE; RESISTANCE; CLEARANCE; CHILDREN; AIDS	Detection of human immunodeficiency virus-type 1 (HIV-1) on only one or a few occasions in infants born to infected mothers has been interpreted to indicate that infection may be transient rather than persistent. Forty-two cases of suspected transient HIV-1 viremia among 1562 perinatally exposed seroreverting infants and one mother were reanalyzed. HIV-1 env sequences were not found in specimens from 20; in specimens from 6, somatic genetic analysis revealed that specimens were mistakenly attributed to an infant; and in specimens from 17, phylogenetic analysis failed to demonstrate the expected linkage between the infant's and the mother's virus. These findings argue that transient HIV-1 infection, if it exists, will only rarely be satisfactorily documented.	Univ Washington, Dept Pediat, Div Infect Dis, Seattle, WA 98105 USA; Univ Rochester, Dept Pediat, Rochester, NY 14642 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Med & Hlth Res Assoc New York City, New York, NY 10013 USA; Univ Rochester, Dept Med, Rochester, NY 14642 USA; Univ Texas, Med Branch, Dept Med & Microbiol & Immunol, Galveston, TX 77555 USA; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA; Northwestern Univ, Dept Med, Chicago, IL 60611 USA; Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Med & Microbiol & Immunol, Los Angeles, CA 90024 USA; Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Santa Fe Inst, Los Alamos, NM 87545 USA; Roche Mol Diagnost, Alameda, CA 94501 USA; NYU, N Shore Hosp, Dept Pediat, Manhasset, NY 11030 USA	University of Washington; University of Washington Seattle; University of Rochester; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centers for Disease Control & Prevention - USA; University of Rochester; University of Texas System; University of Texas Medical Branch Galveston; University of Washington; University of Washington Seattle; University of Minnesota System; University of Minnesota Twin Cities; Northwestern University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; The Santa Fe Institute; Roche Holding; New York University	Frenkel, LM (corresponding author), Univ Washington, Dept Pediat, Div Infect Dis, 4800 Sand Point Way NE,Box 329500, Seattle, WA 98105 USA.		Learn, Jerry/E-3356-2012; HARMACHE, Abdallah/AAS-2586-2021; Wolinsky, Steven/B-2893-2012; Krogstad, Paul/AAQ-8495-2020; HARMACHE, ABDALLAH/E-7274-2011; Learn, Gerald H/B-6934-2011; Pahwa, Savita/AAA-4900-2019; Herring, Belinda/M-7252-2015; Liu, Shan-Lu/L-5923-2016; apple, raymond J/I-4506-2012	Learn, Gerald H/0000-0003-0434-7733; Pahwa, Savita/0000-0002-4470-4216; Liu, Shan-Lu/0000-0003-1620-3817; apple, raymond J/0000-0002-8007-0345; Thea, Donald/0000-0002-6933-1030; Harmache, Abdallah/0000-0002-7377-7641; /0000-0001-8284-1505; Korber, Bette/0000-0002-2026-5757; Roberts Jr, Norbert J/0000-0002-4427-2986; Wolinsky, Steven/0000-0002-9625-6697	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757, U01AI032910] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27757, AI32910] Funding Source: Medline; PHS HHS [UO1-27658] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BORKOWSKY W, 1990, AIDS RES HUM RETROV, V6, P673, DOI 10.1089/aid.1990.6.673; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; Cao YZ, 1997, NAT MED, V3, P549, DOI 10.1038/nm0597-549; CONNOR EM, 1995, PEDIATR INFECT DIS J, V14, P536, DOI 10.1097/00006454-199506000-00012; Contag CH, 1997, J VIROL, V71, P1292, DOI 10.1128/JVI.71.2.1292-1300.1997; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; DELWART EL, 1995, AIDS RES HUM RETROV, V11, P1181; FRENKEL LM, 1995, CLIN INFECT DIS, V20, P1321, DOI 10.1093/clinids/20.5.1321; FRENKEL LM, UNPUB; HOFFENBACH A, 1989, J IMMUNOL, V142, P452; HOLMES EC, 1993, J INFECT DIS, V167, P1411, DOI 10.1093/infdis/167.6.1411; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LIU TM, 1995, J IMMUNOL, V154, P3147; MCCLURE MO, 1995, NATURE, V375, P637, DOI 10.1038/375637a0; McMichael A, 1996, NEW ENGL J MED, V334, P801, DOI 10.1056/NEJM199603213341215; Newell ML, 1996, LANCET, V347, P213, DOI 10.1016/S0140-6736(96)90401-8; PALUMBO P, 1995, J ACQ IMMUN DEF SYND, V10, P436, DOI 10.1097/00042560-199512000-00006; ROQUES PA, 1995, AIDS, V9, pF19; Schochetman Gerald, 1996, P25; Steketee RW, 1997, J INFECT DIS, V175, P707, DOI 10.1093/infdis/175.3.707	22	54	54	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 15	1998	280	5366					1073	1077		10.1126/science.280.5366.1073	http://dx.doi.org/10.1126/science.280.5366.1073			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZN615	9582120				2022-12-01	WOS:000073663600046
J	Tunstall-Pedoe, H				Tunstall-Pedoe, H			Myth and paradox of coronary risk and the menopause	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; HEART-DISEASE; CASE-FATALITY; WOMEN; POPULATION; DEATHS; HEALTH; SEX		Univ Dundee, Ninewells Hosp & Med Sch, Cardiovasc Epidemiol Unit, Dundee DD1 9SY, Scotland	University of Dundee	Tunstall-Pedoe, H (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Cardiovasc Epidemiol Unit, Dundee DD1 9SY, Scotland.							[Anonymous], 1977, MANUAL INT STAT CLAS; BarrettConnor E, 1997, CIRCULATION, V95, P252, DOI 10.1161/01.CIR.95.1.252; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; FURMAN RH, 1968, ANN NY ACAD SCI, V149, P822, DOI 10.1111/j.1749-6632.1968.tb53838.x; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; HELLER RF, 1978, BRIT MED J, V1, P472, DOI 10.1136/bmj.1.6111.472; KHAW KT, 1992, BRIT MED BULL, V48, P249, DOI 10.1093/oxfordjournals.bmb.a072546; LINDQUIST O, 1982, PREV MED, V11, P162, DOI 10.1016/0091-7435(82)90015-9; MEADE TW, 1992, BRIT MED BULL, V48, P276, DOI 10.1093/oxfordjournals.bmb.a072548; ROSENBERG L, 1981, AM J OBSTET GYNECOL, V139, P47, DOI 10.1016/0002-9378(81)90410-5; Stevenson JC, 1996, EUR J OBSTET GYN R B, V65, P39, DOI 10.1016/0028-2243(95)02301-8; TRACY RE, 1966, J CHRON DIS, V19, P1245, DOI 10.1016/0021-9681(66)90022-1; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; TUNSTALLPEDOE H, 1992, BRIT MED J, V305, P1096, DOI 10.1136/bmj.305.6861.1096-b; 1996, WRLD HLTH STAT ANN 1	17	135	136	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 9	1998	351	9113					1425	1427		10.1016/S0140-6736(97)11321-6	http://dx.doi.org/10.1016/S0140-6736(97)11321-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZM665	9593428				2022-12-01	WOS:000073563400042
J	Lee, M; Lenman, M; Banas, A; Bafor, M; Singh, S; Schweizer, M; Nilsson, R; Liljenberg, C; Dahlqvist, A; Gummeson, PO; Sjodahl, S; Green, A; Stymne, S				Lee, M; Lenman, M; Banas, A; Bafor, M; Singh, S; Schweizer, M; Nilsson, R; Liljenberg, C; Dahlqvist, A; Gummeson, PO; Sjodahl, S; Green, A; Stymne, S			Identification of non-heme diiron proteins that catalyze triple bond and epoxy group formation	SCIENCE			English	Article							FATTY-ACIDS; TRANSFORMATION; MONOOXYGENASE; BIOSYNTHESIS; DESATURASE; VECTORS; ENZYME	Acetylenic bonds are present in more than 600 naturally occurring compounds. Plant enzymes that catalyze the formation of the Delta 12 acetylenic bond in 9-octadecen-12-ynoic acid and the Delta 12 epoxy group in 12,13-epoxy-9-octadecenoic acid were characterized, and two genes, similar in sequence, were cloned. When these complementary DNAs were expressed in Arabidopsis thaliana, the content of acetylenic or epoxidated fatty acids in the seeds increased from 0 to 25 or 15 percent, respectively. Both enzymes have characteristics similar to the membrane proteins containing non-heme iron that have histidine-rich motifs.	Swedish Univ Agr Sci, Dept Plant Breeding Res, S-26831 Svalov, Sweden; Svalov Welbull AB, S-26881 Svalov, Sweden; CSIRO, Canberra, ACT 2601, Australia; Inst Food Res, Norwich NR4 7UA, Norfolk, England; Univ Gothenburg, Dept Plant Physiol, S-41319 Gothenburg, Sweden	Swedish University of Agricultural Sciences; Commonwealth Scientific & Industrial Research Organisation (CSIRO); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; University of Gothenburg	Stymne, S (corresponding author), Swedish Univ Agr Sci, Dept Plant Breeding Res, S-26831 Svalov, Sweden.	sten.stymne@vf.slu.se	Green, Allan G/C-6572-2008; Green, Allan/AAM-6856-2021; singh, surinder/C-9528-2009	singh, surinder/0000-0003-4488-8147; Banas, Antoni/0000-0001-9397-7627; Lee, Michael/0000-0002-6643-1984; Green, Allan/0000-0002-3248-2089				Badami R. C., 1981, Progress in Lipid Research, V19, P119, DOI 10.1016/0163-7827(80)90002-8; BAFOR M, 1993, ARCH BIOCHEM BIOPHYS, V303, P145, DOI 10.1006/abbi.1993.1265; BAGBY MO, 1967, Patent No. 3356699; Banas A, 1996, PHYSL BIOCH MOL BIOL, P57; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; BOHLMAN F, 1973, NATURALLY OCCURRING; BROUN P, 1996, PHYSL BIOCH MOL BIOL, P342; COLBERT JE, 1990, J AM CHEM SOC, V112, P3993, DOI 10.1021/ja00166a041; EARLE FR, 1966, LIPIDS, V1, P325, DOI 10.1007/BF02532675; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Engeseth N, 1996, PLANTA, V198, P238, DOI 10.1007/BF00206249; HAIGH WG, 1968, LIPIDS, V3, P307, DOI 10.1007/BF02530929; KOHN G, 1994, J PLANT PHYSIOL, V144, P265, DOI 10.1016/S0176-1617(11)81185-5; OKULEY J, 1994, PLANT CELL, V6, P147, DOI 10.1105/tpc.6.1.147; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Shanklin J, 1997, P NATL ACAD SCI USA, V94, P2981, DOI 10.1073/pnas.94.7.2981; SHANKLIN J, 1996, PHYSL BIOCH MOL BIOL, P6; Shu LJ, 1997, SCIENCE, V275, P515, DOI 10.1126/science.275.5299.515; STALBERG K, 1993, PLANT MOL BIOL, V23, P671, DOI 10.1007/BF00021523; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; Van De Loo Frank J., 1993, P91; VANDELOO FJ, 1995, P NATL ACAD SCI USA, V92, P6743, DOI 10.1073/pnas.92.15.6743; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7	23	198	250	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 8	1998	280	5365					915	918		10.1126/science.280.5365.915	http://dx.doi.org/10.1126/science.280.5365.915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZM380	9572738				2022-12-01	WOS:000073532900045
J	Li, WH; Llopis, J; Whitney, M; Zlokarnik, G; Tsien, RY				Li, WH; Llopis, J; Whitney, M; Zlokarnik, G; Tsien, RY			Cell-permeant caged InsP(3) ester shows that Ca2+ spike frequency can optimize gene expression	NATURE			English	Article							INOSITOL TRISPHOSPHATE; 1,4,5-TRISPHOSPHATE; RECOGNITION; RECEPTOR; SIGNALS	Inositol 1,4,5-trisphosphate (InsP(3)) releases calcium from intracellular stores and triggers complex waves and oscillations in levels of cytosolic free calcium(1-5). To determine which longer-term responses are controlled by oscillations in InsP(3) and cytosolic free calcium, it would be useful to deliver exogenous InsP(3), under spatial and temporal control, into populations of unpermeabilized cells. Here we report the 15-step synthesis of a membrane-permeant, caged InsP(3) derivative from myo-inositol. This derivative diffused into intact cells and was hydrolysed to produce a caged, metabolically stable InsP(3) derivative. This latter derivative accumulated in the cytosol at concentrations of hundreds of micromolar, without activating the InsP(3) receptor. Ultraviolet illumination uncaged an InsP(3) analogue nearly as potent as real InsP(3), and generated spikes of cytosolic free calcium, and stimulated gene expression via the nuclear factor of activated T cells(6,7). The same total amount of InsP(3) analogue elicited much more gene expression when released by repetitive flashes at 1-minute intervals than when released at 0.5- or greater than or equal to 2-minute intervals, as a single pulse, or as a slow sustained plateau, Thus, oscillations in cytosolic free calcium levels at roughly physiological rates maximize gene expression for a given amount of InsP(3).	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Aurora Biosci Corp, San Diego, CA 92121 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Tsien, RY (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Llopis, Juan/I-2622-2012	Llopis, Juan/0000-0002-9460-0642				ADAMS SR, 1993, ANNU REV PHYSIOL, V55, P755, DOI 10.1146/annurev.physiol.55.1.755; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HATCHARD CG, 1956, PROC R SOC LON SER-A, V235, P518, DOI 10.1098/rspa.1956.0102; HIRATA M, 1993, J BIOL CHEM, V268, P19260; HIRATA M, 1990, J BIOL CHEM, V265, P8404; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KOZIKOWSKI AP, 1993, J AM CHEM SOC, V115, P4429, DOI 10.1021/ja00064a002; Kuchtey J, 1996, J CELL PHYSIOL, V166, P643, DOI 10.1002/(SICI)1097-4652(199603)166:3<643::AID-JCP20>3.0.CO;2-6; Li WH, 1997, TETRAHEDRON, V53, P12017, DOI 10.1016/S0040-4020(97)00714-X; Oancea E, 1996, J BIOL CHEM, V271, P17253, DOI 10.1074/jbc.271.29.17253; POTTER BVL, 1995, ANGEW CHEM INT EDIT, V34, P1933, DOI 10.1002/anie.199519331; Smith GD, 1996, AM J PHYSIOL-CELL PH, V270, pC939, DOI 10.1152/ajpcell.1996.270.3.C939; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VACCA JP, 1989, TETRAHEDRON, V45, P5679, DOI 10.1016/S0040-4020(01)89510-7; WALKER JW, 1989, BIOCHEMISTRY-US, V28, P3272, DOI 10.1021/bi00434a023; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	26	740	750	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 30	1998	392	6679					936	941		10.1038/31965	http://dx.doi.org/10.1038/31965			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZK759	9582076				2022-12-01	WOS:000073359900053
J	Ingenito, EP; Evans, RB; Loring, SH; Kaczka, DW; Rodenhouse, JD; Body, SC; Sugarbaker, DJ; Mentzer, SJ; DeCamp, MM; Reilly, JJ				Ingenito, EP; Evans, RB; Loring, SH; Kaczka, DW; Rodenhouse, JD; Body, SC; Sugarbaker, DJ; Mentzer, SJ; DeCamp, MM; Reilly, JJ			Relation between preoperative inspiratory lung resistance and the outcome of lung-volume-reduction surgery for emphysema	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY-FUNCTION	Background Surgery to reduce lung volume has recently been reintroduced to alleviate dyspnea and improve exercise tolerance in selected patients with emphysema. A reliable means of identifying patients who are likely to benefit from this surgery is needed. Methods We measured lung resistance during inspiration, static recoil pressure at total lung capacity, static lung compliance, expiratory flow rates, and lung volumes in 29 patients with chronic obstructive lung disease before lung-volume-reduction surgery. The changes in the forced expiratory volume in one second (FEV1) six months after surgery were related to the preoperatively determined physiologic measures. A response to surgery was defined as an increase in the FEV1 of at least 0.2 liter and of at least 12 percent above base-line values. Results Of the 29 patients, 23 had some improvement in FEV1 including 15 who met the criteria for a response to surgery. Among the variables considered, only preoperative lung resistance during inspiration predicted changes in expiratory flow rates after surgery. Inspiratory lung resistance correlated significantly and inversely with improvement in FEV1 after surgery (r=-0.63, P<0.001). A preoperative criterion of an inspiratory resistance of 10 cm of water per liter per second had a sensitivity of 88 percent (14 of 16 patients) and a specificity of 92 percent (12 of 13 patients) in identifying patients who were likely to have a response to surgery. Conclusions Preoperative lung resistance during inspiration appears to be a useful measure for selecting patients with emphysema for lung-volume-reduction surgery. (C)1998, Massachusetts Medical Society.	Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Anesthesia, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center	Ingenito, EP (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.		Body, Simon C/O-2605-2013; Kaczka, David W./U-2580-2018; Kaczka, David Walter/A-2984-2008; Body, Simon/AAQ-7572-2020	Body, Simon C/0000-0001-6721-7050; Kaczka, David W./0000-0003-4378-5242; Kaczka, David Walter/0000-0003-4378-5242; Body, Simon/0000-0001-6721-7050	NHLBI NIH HHS [HL52586] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052586] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, AM J RESP CRIT CARE, V152, P2185; Bingisser R, 1996, J THORAC CARDIOV SUR, V112, P875, DOI 10.1016/S0022-5223(96)70086-7; BRANTIGAN OC, 1959, AM REV RESPIR DIS, V80, P194; Brenner M, 1996, CHEST, V110, P205, DOI 10.1378/chest.110.1.205; BROWN R, 1980, J APPL PHYSIOL, V49, P398, DOI 10.1152/jappl.1980.49.3.398; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; COOPER JD, 1995, J THORAC CARDIOV SUR, V109, P106, DOI 10.1016/S0022-5223(95)70426-4; CORBIN RP, 1979, AM REV RESPIR DIS, V120, P293; Daniel TM, 1996, ANN SURG, V223, P526, DOI 10.1097/00000658-199605000-00008; GRIMBY G, 1968, J CLIN INVEST, V47, P1455, DOI 10.1172/JCI105837; GURNEY JW, 1992, RADIOLOGY, V183, P457, DOI 10.1148/radiology.183.2.1561350; HOLOHAN TV, 1996, HEALTH TECHNOL ASSES, V10, P1; KACZKA DW, 1995, ANN BIOMED ENG, V23, P135, DOI 10.1007/BF02368321; Kotloff RM, 1996, CHEST, V110, P1399, DOI 10.1378/chest.110.6.1399; MEAD J, 1955, J CLIN INVEST, V34, P1005, DOI 10.1172/JCI103150; NAGELS J, 1950, J APPL PHYSIOL, V49, P408; Pride NB, 1986, HDB PHYSL RESP SYSTE, P659; SALAZAR E, 1964, J APPL PHYSIOL, V19, P97, DOI 10.1152/jappl.1964.19.1.97; Sciurba FC, 1996, NEW ENGL J MED, V334, P1095, DOI 10.1056/NEJM199604253341704; Slone RM, 1997, RADIOLOGY, V204, P685, DOI 10.1148/radiology.204.3.9280244; Snedecor G., 1989, AMES IOWA STATE U PR, V8; Swanson SJ, 1997, J AM COLL SURGEONS, V185, P25, DOI 10.1016/S1072-7515(01)00877-8; Wang SC, 1997, RADIOLOGY, V205, P243, DOI 10.1148/radiology.205.1.9314992; Yusen R D, 1996, Semin Thorac Cardiovasc Surg, V8, P83	24	81	83	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 23	1998	338	17					1181	1185		10.1056/NEJM199804233381703	http://dx.doi.org/10.1056/NEJM199804233381703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZJ376	9554858				2022-12-01	WOS:000073208400003
J	Rundlett, SE; Carmen, AA; Suka, N; Turner, BM; Grunstein, M				Rundlett, SE; Carmen, AA; Suka, N; Turner, BM; Grunstein, M			Transcriptional repression by UME6 involves deacetylation of lysine 5 of histone H4 by RPD3	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; YEAST	The histone deacetylase RPD3 can be targeted to certain genes through its interaction with DNA-binding regulatory proteins. RPD3 can then repress gene transcription(1-6). In the yeast Saccharomyces cerevisiae, association of RPD3 with the transcriptional repressors SIN3 and UME6 results in repression of reporter genes containing the UME6-binding site(3). RPD3 can deacetylate all histone HS acetylation sites in cell extracts(7). However, it is unknown how H4 proteins located at genes near UME6-binding sites are affected, nor whether the effect of RPD3 is localized to the promoter regions. Here we study the mechanism by which RPD3 represses gene activity by examining the acetylation state of histone proteins at UME6-regulated genes. We used antibodies specific for individual acetylation sites in H4 to immunoprecipitate chromatin fragments. A deletion of RPD3 or SIN3, but not of the related histone-deacetylase gene HDA1, results in increased acetylation of the lysine 5 residue of H4 in the promoters of the UME6-regulated INO1 (ref. 8), IME2! (ref. 3) and SPO13 (ref. 9) genes. As increased acetylation of this residue is not merely a consequence of gene transcription, acetylation of this site may be essential for regulating gene activity.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Birmingham, Sch Med, Dept Anat, Chromatin & Gene Express Grp, Birmingham B15 2TT, W Midlands, England	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Birmingham	Grunstein, M (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.	mg@mbi.ucla.edu						Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; CLARKE DJ, 1993, BIOCHEM J, V294, P557, DOI 10.1042/bj2940557; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; FLOMERFELT FA, 1993, J CELL PHYSIOL, V154, P573, DOI 10.1002/jcp.1041540316; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Guthrie C, 1991, GUIDE YEAST GENETICS; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAMAN H, 1995, MOL CELL BIOL, V15, P3608; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SLEKAR KH, 1995, NUCLEIC ACIDS RES, V23, P1964, DOI 10.1093/nar/23.11.1964; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; STRICH R, 1994, GENE DEV, V8, P796, DOI 10.1101/gad.8.7.796; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	24	358	365	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 23	1998	392	6678					831	835		10.1038/33952	http://dx.doi.org/10.1038/33952			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZJ679	9572144				2022-12-01	WOS:000073241200058
J	Nilson, LA; Schupbach, T				Nilson, LA; Schupbach, T			Localized requirements for windbeutel and pipe reveal a dorsoventral prepattern within the follicular epithelium of the Drosophila ovary	CELL			English	Article							DORSAL-VENTRAL POLARITY; EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; NUCLEAR-LOCALIZATION; EMBRYONIC POLARITY; TOLL GENE; GERM LINE; PROTEIN; PATTERN; CELLS	Establishment of dorsoventral polarity within the Drosophila embryo requires extraembryonic positional information generated during oogenesis. The genes windbeutel, pipe, and nudel are required within the somatic follicle cells of the ovary for production of this spatial cue. Using a novel follicle cell marker system, we have directly evaluated the effect of mutant follicle cell clones on the embryonic dorsoventral pattern. We find no spatially localized requirement for nudel activity. In contrast, windbeutel and pipe are required only within a restricted ventral region of the follicular epithelium. This ventral region can determine lateral embryonic cell fates nonautonomously, indicating that spatial information originating ventrally is subsequently refined, perhaps via diffusion, to yield the gradient of positional information that determines the embryonic dorsoventral pattern.	Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University	Schupbach, T (corresponding author), Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA.				NCI NIH HHS [P01 CA41086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA041086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; CHASAN R, 1992, DEVELOPMENT, V115, P607; Chasan Rebecca, 1993, P387; Chou TB, 1996, GENETICS, V144, P1673; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; HARRISON DA, 1993, CURR BIOL, V3, P424, DOI 10.1016/0960-9822(93)90349-S; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HAWLEY RJ, 1988, GENE DEV, V2, P341, DOI 10.1101/gad.2.3.341; HONG CC, 1995, CELL, V82, P785, DOI 10.1016/0092-8674(95)90475-1; Hong CC, 1996, GENETICS, V143, P1653; Huang AM, 1997, GENE DEV, V11, P1963, DOI 10.1101/gad.11.15.1963; King RC., 1970, OVARIAN DEV DROSOPHI; Konsolaki M, 1998, GENE DEV, V12, P120, DOI 10.1101/gad.12.1.120; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MARGOLIS J, 1995, DEVELOPMENT, V121, P3797; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; ROTH S, 1994, DEVELOPMENT, V120, P2245; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1993, DEVELOPMENT, V117, P1385; RUSHLOW CA, 1989, CELL, V59, P779; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHNEIDER DS, 1994, DEVELOPMENT, V120, P1243; SCHUPACH T, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P163; SCHUPBACH T, 1989, GENETICS, V121, P101; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; Spradling Allan C., 1993, P1; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1988, CELL, V55, P487, DOI 10.1016/0092-8674(88)90035-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; WIESCHAUS E, 1981, DEV BIOL, V88, P92, DOI 10.1016/0012-1606(81)90221-9; Wieschaus E., 1986, P199; XU T, 1993, DEVELOPMENT, V117, P1223	42	59	61	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 17	1998	93	2					253	262		10.1016/S0092-8674(00)81576-7	http://dx.doi.org/10.1016/S0092-8674(00)81576-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZJ045	9568717	Bronze			2022-12-01	WOS:000073174000011
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Synthetic protease switch	SCIENCE			English	Article																		SICES H, 1996, P NATL ACAD SCI USA, V95, P2828	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 17	1998	280	5362					456	456						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH907	9575087				2022-12-01	WOS:000073159600054
J	Kirsch, J; Betz, H				Kirsch, J; Betz, H			Glycine-receptor activation is required for receptor clustering in spinal neurons	NATURE			English	Article							GAMMA-AMINOBUTYRIC-ACID; DORSAL HORN NEURONS; GEPHYRIN; SYNAPSES; LOCALIZATION; SUBUNITS; PROTEIN; IDENTIFICATION; DEPOLARIZATION; EXPRESSION	The ability of nerve cells to receive up to several thousands of synaptic inputs from other neurons provides the anatomical basis for information processing in the vertebrate brain. The formation of functional synapses involves selective clustering of neurotransmitter receptors at presumptive postsynaptic regions of the neuronal plasma membrane(1-4). Receptor-associated proteins are believed to be crucial for this process. In spinal neurons, synaptic targeting of the inhibitory glycine receptor (GlyR)(5,6) depends on the expression of the anchoring protein gephyrin(7-9), Here we show that the competitive GlyR antagonist strychnine and L-type Ca2+ channel blockers inhibit the accumulation of GlyR and gephyrin at postsynaptic membrane areas in cultured rat spinal neurons. Our data are consistent with a model in which GlyR activation that results in Ca2+ influx is required for the clustering of gephyrin and GlyR at developing postsynaptic sites. Similar activity-driven mechanisms may be of general importance in synaptogenesis.	Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	Max Planck Society	Kirsch, J (corresponding author), Max Planck Inst Brain Res, Dept Neurochem, Duetschordenstr 46, D-60528 Frankfurt, Germany.	neurochemie@mpih-frankfurt.mpg.de						ALTSCHULER RA, 1986, BRAIN RES, V369, P316, DOI 10.1016/0006-8993(86)90542-1; Bechade C, 1996, EUR J NEUROSCI, V8, P429, DOI 10.1111/j.1460-9568.1996.tb01226.x; BECKER CM, 1992, HDB EXPT PHARM, V102, P540; BETZ H, 1985, ANGEW CHEM INT EDIT, V24, P365, DOI 10.1002/anie.198503651; Boehm S, 1997, J PHYSIOL-LONDON, V504, P683, DOI 10.1111/j.1469-7793.1997.683bd.x; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; CHANGEUX JP, 1976, NATURE, V264, P705, DOI 10.1038/264705a0; Craig AM, 1996, J NEUROSCI, V16, P3166; Ehlers MD, 1996, CURR OPIN CELL BIOL, V8, P484, DOI 10.1016/S0955-0674(96)80024-X; FRITSCHY JM, 1992, P NATL ACAD SCI USA, V89, P6726, DOI 10.1073/pnas.89.15.6726; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; Goslin K., 1991, CULTURING NERVE CELL, P251; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HOCH W, 1989, NEURON, V3, P339, DOI 10.1016/0896-6273(89)90258-4; KIRSCH J, 1995, MOL CELL NEUROSCI, V6, P450, DOI 10.1006/mcne.1995.1033; Kirsch J, 1996, MOL CELL NEUROSCI, V8, P93, DOI 10.1006/mcne.1996.0048; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; KIRSCH J, 1995, J NEUROSCI, V15, P4148; KNAUS P, 1986, J NEUROCHEM, V47, P1302; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; PFEIFFER F, 1984, P NATL ACAD SCI-BIOL, V81, P7224, DOI 10.1073/pnas.81.22.7224; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; REICHLING DB, 1994, J PHYSIOL-LONDON, V476, P411, DOI 10.1113/jphysiol.1994.sp020142; Sheng M, 1997, NATURE, V386, P221, DOI 10.1038/386221a0; TRILLER A, 1985, J CELL BIOL, V101, P683, DOI 10.1083/jcb.101.2.683; Virginio C, 1997, DEV BRAIN RES, V98, P30, DOI 10.1016/S0165-3806(96)00164-2; WANG J, 1994, EUR J NEUROSCI, V6, P1275, DOI 10.1111/j.1460-9568.1994.tb00317.x	29	223	227	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 16	1998	392	6677					717	720		10.1038/33694	http://dx.doi.org/10.1038/33694			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH612	9565032				2022-12-01	WOS:000073129000059
J	Doherty, PC				Doherty, PC			Update: Immunology - The numbers game for virus-specific CD8(+) T cells	SCIENCE			English	Editorial Material							MEMORY		St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Doherty, PC (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA.		Doherty, Peter Charles/C-4185-2013	Doherty, Peter Charles/0000-0002-5028-3489				Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; Doherty PC, 1996, IMMUNOL REV, V150, P23, DOI 10.1111/j.1600-065X.1996.tb00694.x; Klenerman P, 1997, NATURE, V390, P298, DOI 10.1038/36876; KURODA MJ, IN PRESS J EXP MED; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	10	72	80	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					227	227		10.1126/science.280.5361.227	http://dx.doi.org/10.1126/science.280.5361.227			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9565533				2022-12-01	WOS:000073082400036
J	Fatemi, M; Greenleaf, JF				Fatemi, M; Greenleaf, JF			Ultrasound-stimulated vibro-acoustic spectrography	SCIENCE			English	Article							RADIATION PRESSURE; FORCE	An ultrasound method based on radiation force is presented for imaging the acoustic response of a material to mechanical excitation, Acoustic energy was emitted from solids and tissues in response to an oscillatory radiation force produced by interfering focused beams of ultrasound. Frequency spec tra of ultrasound-stimulated acoustic emission exhibited object resonances. Raster-scanning the radiation force over the object and recording the amplitude and phase of the emitted sound resulted in data from which images related to the elastic compositions of the acoustically emitting objects could be computed. Acoustic emission signals distinguished tuning-fork resonances, submillimeter glass spheres, and calcification in excised arteries and detected object motions on the order of nanometers.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA	Mayo Clinic	Fatemi, M (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA.							BEYER RT, 1978, J ACOUST SOC AM, V63, P1025, DOI 10.1121/1.381833; CHU BT, 1982, J ACOUST SOC AM, V72, P1673, DOI 10.1121/1.388660; FISCH MR, 1976, J ACOUST SOC AM, V60, P623, DOI 10.1121/1.381124; Gao L, 1996, ULTRASOUND MED BIOL, V22, P959, DOI 10.1016/S0301-5629(96)00120-2; Jiang ZY, 1996, J ACOUST SOC AM, V100, P741, DOI 10.1121/1.416236; LIDE DR, 1991, CRC HDB CHEM PHYSICS, V72, P6; Maynard J, 1996, PHYS TODAY, V49, P26, DOI 10.1063/1.881483; Morse P.M., 1968, THEORETICAL ACOUSTIC; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; Rayleigh, 1902, PHILOS MAG, V3, P338, DOI 10.1080/14786440209462769; RAYLEIGH, 1905, PHIL MAG, V10, P364; Rudenko OV, 1996, J ACOUST SOC AM, V99, P2791, DOI 10.1121/1.414805; SUGIMOTO T, 1990, 1990 IEEE ULTR S P, V3, P1377; TORR GR, 1984, AM J PHYS, V52, P402, DOI 10.1119/1.13625; WESTERVELT PJ, 1951, J ACOUST SOC AM, V23, P312, DOI 10.1121/1.1906764	15	520	570	2	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					82	85		10.1126/science.280.5360.82	http://dx.doi.org/10.1126/science.280.5360.82			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525861				2022-12-01	WOS:000072885100038
J	Vermeer-de Bondt, PE; Labadie, J; Rumke, HC				Vermeer-de Bondt, PE; Labadie, J; Rumke, HC			Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; INFANTS		Natl Inst Publ Hlth & Environm, Lab Clin Vaccine Res, NL-3720 BA Bilthoven, Netherlands	Netherlands National Institute for Public Health & the Environment	Vermeer-de Bondt, PE (corresponding author), Natl Inst Publ Hlth & Environm, Lab Clin Vaccine Res, POB 1, NL-3720 BA Bilthoven, Netherlands.							BARAFF LJ, 1988, PEDIATRICS, V81, P789; CODY CL, 1981, PEDIATRICS, V68, P650; HANNIK CA, 1979, P 3 NT S PERT BETH 1, P279; Howson CP, 1991, ADVERSE EFFECTS PERT; OLIN P, 1997, EFFICACY TRIAL ACELL, V2	5	27	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 21	1998	316	7135					902	903		10.1136/bmj.316.7135.902	http://dx.doi.org/10.1136/bmj.316.7135.902			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD691	9552838	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000072713300028
J	McCall, BJ; Geballe, TR; Hinkle, KH; Oka, T				McCall, BJ; Geballe, TR; Hinkle, KH; Oka, T			Detection of H-3(+) in the diffuse interstellar medium toward Cygnus OB2 No. 12	SCIENCE			English	Article							ION-MOLECULE REACTIONS; PHYSICAL CONDITIONS; ABSORPTION-LINES; CLOUDS; STARS; H-3+; ABUNDANCES; ASSOCIATION	The molecular ion H-3(+) is considered the cornerstone of interstellar chemistry because it initiates the reactions responsible for the production of many larger molecules, Recently discovered in dense molecular clouds. H-3(+) has now been observed in the diffuse interstellar medium toward Cygnus OB2 No. 12, Analysis of H-3(+) chemistry suggests that the high H-3(+) column density (3.8 x 10(14) per square centimeter) is due not to a high H-3(+) concentration but to a long absorption path. This and other work demonstrate the ubiquity of H-3(+) and its potential as a probe of the physical and chemical conditions in the interstellar medium.	Univ Chicago, Dept Astron & Astrophys, Chicago, IL 60637 USA; Univ Chicago, Dept Chem, Chicago, IL 60637 USA; Univ Chicago, Enrico Fermi Inst, Chicago, IL 60637 USA; Joint Astron Ctr, Hilo, HI 96720 USA; Natl Opt Astron Observ, Tucson, AZ 85726 USA	University of Chicago; University of Chicago; University of Chicago; National Optical Astronomy Observatory	McCall, BJ (corresponding author), Univ Chicago, Dept Astron & Astrophys, 5640 S Ellis Ave, Chicago, IL 60637 USA.		McCall, Benjamin J/A-3136-2008	McCall, Benjamin/0000-0003-1022-7295				ADAMSON AJ, 1990, MON NOT R ASTRON SOC, V243, P400; AMANO T, 1988, ASTROPHYS J, V329, pL121, DOI 10.1086/185190; ANICICH VG, 1986, ASTROPHYS J SUPPL S, V62, P553, DOI 10.1086/191151; BIEGING JH, 1989, ASTROPHYS J, V340, P518, DOI 10.1086/167414; BLACK JH, 1990, ASTROPHYS J, V358, P459, DOI 10.1086/168999; BOHLIN RC, 1978, ASTROPHYS J, V224, P132, DOI 10.1086/156357; Cardelli JA, 1996, ASTROPHYS J, V467, P334, DOI 10.1086/177608; CHAFFEE FH, 1982, ASTROPHYS J SUPPL S, V50, P169, DOI 10.1086/190824; GEBALLE TH, UNPUB; Geballe TR, 1996, NATURE, V384, P334, DOI 10.1038/384334a0; GLASSGOLD AE, 1974, ASTROPHYS J, V193, P73, DOI 10.1086/153130; GREDEL R, 1994, ASTRON ASTROPHYS, V285, P640; HERBST E, 1973, ASTROPHYS J, V185, P505, DOI 10.1086/152436; HINKLE KH, IN PRESS P SOC PHOTO; Lee HH, 1996, ASTRON ASTROPHYS SUP, V119, P111, DOI 10.1051/aas:1996232; LEPP S, 1987, ASTROPHYS J, V321, P383, DOI 10.1086/165636; MASSEY P, 1991, ASTRON J, V101, P1408, DOI 10.1086/115774; MCCALL BJ, UNPUB; Morgan W. W., 1954, PUBL ASTRON SOC PAC, V66, P85; MOUNTAIN CM, 1990, P SOC PHOTO-OPT INS, V1235, P25, DOI 10.1117/12.19068; OKA T, 1981, PHILOS T R SOC A, V303, P543, DOI 10.1098/rsta.1981.0223; PERSI P, 1982, ASTRON ASTROPHYS, V111, pL7; RIEKE GH, 1985, ASTROPHYS J, V288, P618, DOI 10.1086/162827; RIEKE GH, 1974, ASTROPHYS J, V193, pL81, DOI 10.1086/181637; SHARPLESS S, 1957, PUBL ASTRON SOC PAC, V69, P239, DOI 10.1086/127056; TORRESDODGEN AV, 1991, MON NOT R ASTRON SOC, V249, P1; Uy D, 1997, PHYS REV LETT, V78, P3844, DOI 10.1103/PhysRevLett.78.3844; VANDISHOECK EF, 1986, ASTROPHYS J SUPPL S, V62, P109, DOI 10.1086/191135; WATSON WD, 1973, ASTROPHYS J, V183, pL17, DOI 10.1086/181242; WATSON WD, 1974, ASTROPHYS J, V188, P35, DOI 10.1086/152681; Whittet DCB, 1997, ASTROPHYS J, V490, P729, DOI 10.1086/304914	31	188	189	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1998	279	5358					1910	1913		10.1126/science.279.5358.1910	http://dx.doi.org/10.1126/science.279.5358.1910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506936				2022-12-01	WOS:000072613300039
J	Wylie, DRW; Bischof, WF; Frost, BJ				Wylie, DRW; Bischof, WF; Frost, BJ			Common reference frame for neural coding of translational and rotational optic flow	NATURE			English	Article							PIGEON VESTIBULOCEREBELLAR NEURONS; OPTOKINETIC STIMULATION; SPATIAL-ORGANIZATION; SELF-MOTION; VISUAL FLOW; RESPONSES; PERCEPTION; FLOCCULUS	Self-movement of an organism through the environment is guided jointly by information provided by the vestibular system and by visual pathways that are specialized for detecting 'optic flow'(1,2). Motion of any object through space, including the self-motion of organisms, can be described with reference to six degrees of freedom: rotation about three orthogonal axes, and translation along these axes, Here we describe neurons in the pigeon brain that respond best to optic flow resulting from translation along one of the three orthogonal axes, We show that these translational optic flow neurons, like rotational optic flow neuron(3-5), share a common spatial frame of reference with the semicircular canals of the vestibular system. The three axes to which these neurons respond best are the vertical axis and two horizontal axes orientated at 45 degrees to either side of the body midline.	Univ Alberta, Dept Psychol, Edmonton, AB T6G 2E9, Canada; Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada	University of Alberta; Queens University - Canada	Wylie, DRW (corresponding author), Univ Alberta, Dept Psychol, Edmonton, AB T6G 2E9, Canada.		Bischof, Walter/AAB-9343-2020	Bischof, Walter/0000-0001-5508-0421				ANDERSEN GJ, 1986, PSYCHOL BULL, V99, P52, DOI 10.1037/0033-2909.99.1.52; Becker, 1981, PROGR OCULOMOTOR RES, P475; Bradley DC, 1996, SCIENCE, V273, P1544, DOI 10.1126/science.273.5281.1544; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1329, DOI 10.1152/jn.1991.65.6.1329; GIBSON JJ, 1954, PSYCHOL REV, V61, P304, DOI 10.1037/h0061885; GRAF W, 1988, J NEUROPHYSIOL, V60, P2091, DOI 10.1152/jn.1988.60.6.2091; HESS BJM, 1991, J NEUROPHYSIOL, V66, P1805, DOI 10.1152/jn.1991.66.6.1805; JAY MF, 1984, NATURE, V309, P345, DOI 10.1038/309345a0; KNUDSEN EI, 1987, ANNU REV NEUROSCI, V10, P41, DOI 10.1146/annurev.ne.10.030187.000353; Krapp HG, 1996, NATURE, V384, P463, DOI 10.1038/384463a0; LEE DN, 1974, PERCEPT PSYCHOPHYS, V15, P529, DOI 10.3758/BF03199297; MACPHERSON JM, 1988, J NEUROPHYSIOL, V60, P204, DOI 10.1152/jn.1988.60.1.204; MASINO T, 1990, NATURE, V345, P434, DOI 10.1038/345434a0; Owen D. H., 1990, PERCEPTION CONTROL S, P289; SIMPSON JI, 1984, ANNU REV NEUROSCI, V7, P13, DOI 10.1146/annurev.ne.07.030184.000305; SIMPSON JI, 1985, ADAPTIVE MECHANISMS, P3; SOECHTING JF, 1992, ANNU REV NEUROSCI, V15, P167, DOI 10.1146/annurev.ne.15.030192.001123; WYLIE DR, 1993, J NEUROPHYSIOL, V70, P2647, DOI 10.1152/jn.1993.70.6.2647; WYLIE DR, 1990, VISUAL NEUROSCI, V5, P489, DOI 10.1017/S0952523800000614; WYLIE DR, 1993, J NEUROPHYSIOL, V70, P2632, DOI 10.1152/jn.1993.70.6.2632; [No title captured]	21	91	91	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					278	282		10.1038/32648	http://dx.doi.org/10.1038/32648			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521321				2022-12-01	WOS:000072612300046
J	Mallick-Wood, CA; Lewis, JM; Richie, LI; Owen, MJ; Tigelaar, RE; Hayday, AC				Mallick-Wood, CA; Lewis, JM; Richie, LI; Owen, MJ; Tigelaar, RE; Hayday, AC			Conservation of T cell receptor conformation in epidermal gamma delta cells with disrupted primary V-gamma gene usage	SCIENCE			English	Article							ALPHA-BETA; INTESTINAL EPITHELIUM; JUNCTIONAL SEQUENCES; LIMITED DIVERSITY; ANTIGEN RECEPTORS; DEFICIENT MICE; LYMPHOCYTES; THYMOCYTES; INFECTION; DISTINCT	A feature that distinguishes gamma delta T cell subsets from most alpha beta T cells and B cells is the association of expression of single T cell receptor (TCR) gamma and delta variable (V) region gene segments with specific anatomic sites. Mice lacking the TCR V(gamma)5 chain normally expressed by most dendritic epidermal T cells were shown to retain a conformational determined (idiotype) ordinarily expressed exclusively by such V(gamma)5(+) cells, Conservation by shuffled gamma delta TCR chains of an idiotype associated with a specific anatomic site indicates that for TCR gamma delta, as for immunoglobulin, conformation is associated to a greater extent with the function or development of lymphocyte repertoires than is the use of particular gene segments.	Yale Univ, Dept Mol Cell & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Dept Dermatol, New Haven, CT 06511 USA; Yale Univ, Immunobiol Sect, New Haven, CT 06511 USA; Imperial Canc Res Fund, London WC2A 3PX, England	Yale University; Yale University; Yale University; Yale University; Cancer Research UK	Mallick-Wood, CA (corresponding author), Yale Univ, Dept Mol Cell & Dev Biol, New Haven, CT 06520 USA.			Ehrlich, Lauren/0000-0002-1697-1755	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027855, R01AI027404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037759] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27404, AI27855] Funding Source: Medline; NIGMS NIH HHS [GM37759] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASARNOW DM, 1993, NATURE, V362, P158, DOI 10.1038/362158a0; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; CARDING S, 1989, GENE DEV, V4, P1304; DELFAU MH, 1992, EUR J IMMUNOL, V22, P2437, DOI 10.1002/eji.1830220937; EZQUERRA A, 1992, EUR J IMMUNOL, V22, P491, DOI 10.1002/eji.1830220230; HAVRAN WL, 1989, P NATL ACAD SCI USA, V86, P4185, DOI 10.1073/pnas.86.11.4185; HAVRAN WL, 1991, SCIENCE, V252, P1430, DOI 10.1126/science.1828619; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HAYDAY AC, IN PRESS ENCY IMMUNO; HEYBORNE K, 1993, J IMMUNOL, V151, P4523; HEYBORNE KD, 1992, J IMMUNOL, V149, P2872; Hong SC, 1996, J EXP MED, V183, P1437, DOI 10.1084/jem.183.4.1437; Housset D, 1997, EMBO J, V16, P4205, DOI 10.1093/emboj/16.14.4205; ITO K, 1989, P NATL ACAD SCI USA, V86, P631, DOI 10.1073/pnas.86.2.631; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; KYES S, 1989, P NATL ACAD SCI USA, V86, P5527, DOI 10.1073/pnas.86.14.5527; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MallickWood CA, 1996, P NATL ACAD SCI USA, V93, P9704, DOI 10.1073/pnas.93.18.9704; MALLICKWOOD CA, UNPUB; MCCONNELL TJ, 1989, J IMMUNOL, V142, P2924; MUKASA A, 1995, J IMMUNOL, V155, P2047; NIXONFULTON JL, 1988, J IMMUNOL, V141, P1897; Pao W, 1996, CURR BIOL, V6, P1317, DOI 10.1016/S0960-9822(02)70718-5; PEREIRA P, 1995, J EXP MED, V182, P1921, DOI 10.1084/jem.182.6.1921; RAULET DH, 1991, IMMUNOL REV, V120, P185, DOI 10.1111/j.1600-065X.1991.tb00592.x; Roberts SJ, 1996, P NATL ACAD SCI USA, V93, P11774, DOI 10.1073/pnas.93.21.11774; SANGER F, 1977, P NATL ACAD SCI USA, V74, P513; Sciammas R, 1997, J EXP MED, V185, P1969, DOI 10.1084/jem.185.11.1969; STINGL G, 1987, P NATL ACAD SCI USA, V84, P2430, DOI 10.1073/pnas.84.8.2430; TAKAGAKI Y, 1989, NATURE, V339, P712, DOI 10.1038/339712a0; TAKASHIMA A, 1988, J INVEST DERMATOL, V90, P671, DOI 10.1111/1523-1747.ep12560835; TIGELAAR R, 1995, J INVEST DERMATOL, V105, P435; TONEGUZZO F, 1988, BIOTECHNIQUES, V6, P460; Tsuji M, 1996, INT IMMUNOL, V8, P359, DOI 10.1093/intimm/8.3.359; VANDERHEYDE HC, 1995, J IMMUNOL, V154, P3985	37	104	104	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1729	1733		10.1126/science.279.5357.1729	http://dx.doi.org/10.1126/science.279.5357.1729			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497293				2022-12-01	WOS:000072490000058
J	Goldman, LK; Glantz, SA				Goldman, LK; Glantz, SA			Evaluation of antismoking advertising campaigns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MASS-MEDIA; CIGARETTE-SMOKING; TOBACCO CONTROL; CALIFORNIA; CONSUMPTION; PREVENTION; DIVERSION; ILLEGAL; MONEY	Context.-Active and passive smoking are the first and third leading preventable causes of death. Many states are running or initiating antitobacco media campaigns. Objective.-To review research on the effectiveness of different antismoking messages and published evidence of the effectiveness of paid antismoking advertising, Data Sources.-Focus group studies conducted by professional advertising agencies that contract with California, Massachusetts, and Michigan to run their antismoking advertising campaigns, the Centers for Disease Control and Prevention's Media Campaign Resource Book, and copies of the advertisements. In total, we reviewed the results of 186 focus groups involving more than 1500 children and adults dealing with 118 advertisements that had actually been aired and additional concept advertisements that were not produced, Published literature was located using MEDLINE and standard bibliographic sources on the effectiveness of large, paid antitobacco media campaigns, We also reviewed reports and studies conducted by, or for, the California and Massachusetts health departments on program effectiveness, and conducted our own comparison of California vs Massachusetts using cigarette consumption data from the Tobacco institute. Study Selection.-All available studies, Data Synthesis.-Eight advertising strategies to prevent people from starting to smoke and persuading them to stop were reviewed: industry manipulation, secondhand smoke, addiction, cessation, youth access, short-term effects, long-term health effects, and romantic rejection. These focus groups identified strategies that would be expected to be effective and ineffective. Regression analysis was used to compare the cost-effectiveness of the California and Massachusetts programs. Conclusions.-Focus group participants indicated that industry manipulation and secondhand smoke are the most effective strategies for denormalizing smoking and reducing cigarette consumption. Addiction and cessation can be effective when used in conjunction with the industry manipulation and secondhand smoke strategies, Youth access, short-term effects, long-term health effects, and romantic rejection are not effective strategies. More aggressive advertising strategies appear to be more effective at reducing tobacco consumption.	Univ Calif San Francisco, Inst Hlth Policy Studies, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Glantz, SA (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, Dept Med, Box 0124, San Francisco, CA 94143 USA.	glantz@cardio.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AR DEP HLTH SERV, 1996, AR TOB ED PREV PROGR; BAL DG, 1990, JAMA-J AM MED ASSOC, V264, P1570, DOI 10.1001/jama.264.12.1570; BALBACH ED, 1997, HOLDING GOVT ACCOUNT; Begay M E, 1997, Tob Control, V6, P213; BEGAY ME, 1995, QUESTION 1 TOBACCO E; BLUM A, 1994, AM J PREV MED, V10, P8, DOI 10.1016/S0749-3797(18)30543-9; *FED TRAD COMM, 1981, STAFF REP CIG ADV IN; Flynn BS, 1997, PREV MED, V26, P389, DOI 10.1006/pmed.1997.0159; FLYNN BS, 1994, AM J PUBLIC HEALTH, V84, P1148, DOI 10.2105/AJPH.84.7.1148; FLYNN BS, 1992, AM J PUBLIC HEALTH, V82, P827, DOI 10.2105/AJPH.82.6.827; FRIEDMAN M, 1996, TEEN ANTISMOKING STR; Glantz S., 1993, TOB CONTROL, V2, P311, DOI DOI 10.1136/TC.2.4.311; Glantz SA, 1996, AM J PUBLIC HEALTH, V86, P156, DOI 10.2105/AJPH.86.2.156; Glantz SA, 1997, AM J PUBLIC HEALTH, V87, P870, DOI 10.2105/AJPH.87.5.870; HARRIS JE, 1996, MMWR-MORBID MORTAL W, V45, P966; Harty KC, 1993, TOB CONTROL, V2, P271, DOI DOI 10.1136/TC.2.4.271; Haskins Jack, 1993, SUCCESSFUL ADVERTISI; Heiser PF, 1997, AM J PUBLIC HEALTH, V87, P968, DOI 10.2105/AJPH.87.6.968; HONIG B, 1990, TOBACCO FREE CALIFOR; HONIG B, 1992, TOBACCO FREE CALIFOR; *HOUST HERST FAV, EX TOB IND MAN POS Y; *HOUST HERST FAV, ASS MASS TOB CONTR P; *HOUST HERST FAV, EXPL RES AD SMOK AG; *HOUST HERST FAV, 1996, YOUTH EXPL 1996 MASS; HU TW, 1995, AM ECON REV, V85, P85; HU TW, 1995, AM J PUBLIC HEALTH, V85, P1218, DOI 10.2105/AJPH.85.9.1218; *I MED, 1994, GROW TOB FREE PREV N; JOHNSON CA, 1994, EVALUATION TOBACCO I; KEYE P, 1993, WHAT DONT WE KNOW HA; Koh H K, 1996, Tob Control, V5, P220, DOI 10.1136/tc.5.3.220; *LACHM RES MARK SE, 1995, CAL DEP HLTH SERV AN; *LACHM RES MARK SE, 1993, REACT SMOK REL ISS C; MCKENNA JW, 1994, AM J PREV MED, V10, P378, DOI 10.1016/S0749-3797(18)30569-5; MCKENNA JW, 1993, PUBLIC HEALTH REP, V108, P85; *MI DEP COMM HLTH, 1996, MICH DEP COMM HLTH P; MONARDI F, 1996, SHIFTING ALLEGIANCES; MURRAY DM, 1994, PREV MED, V23, P54, DOI 10.1006/pmed.1994.1008; *NORDH RES I, 1995, SMOK CESS FOC GROUPS; PECHMANN C, 1994, J CONSUM RES, V21, P236, DOI 10.1086/209395; Pechmann C, 1997, ADVERT CONS, P189; PECHMANN C, 1996, SMOKING MOVIES ANTIS; Pierce J.P, 1993, TOBACCO USE CALIFORN; Pierce JP, 1994, TOBACCO USE CALIFORN; POPHAM WJ, 1994, AM J PREV MED, V10, P319, DOI 10.1016/S0749-3797(18)30559-2; POPHAM WJ, 1993, PUBLIC HEALTH REP, V108, P510; *QUAL RES CTR, 1992, ANT STUD CREAT DEV R; *QUAL RES CTR, 1990, TOB ED RES PRES DRAF; ROSS M, 1996, TOBACCO TAX CAMPAIGN; RUSSELL S, 1996, SAN FRANCISCO C 0627, pA16; Schwartz J, 1998, WASHINGTON POST 0708, pA3; SCOTT S, 1997, CALIF J, P14; SKOLNICK AA, 1994, JAMA-J AM MED ASSOC, V271, P1387, DOI 10.1001/jama.271.18.1387; SKOLNICK AA, 1995, JAMA-J AM MED ASSOC, V273, P610, DOI 10.1001/jama.273.8.610; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V267, P2721, DOI 10.1001/jama.267.20.2721; STEELE C, 1996, COMMUNICATION   1204; *TOB ED RES OV COM, 1997, TOB FREE CAL REN COM; *TOB I, 1995, TAX BURD TOB, P33; Traynor MP, 1996, J HEALTH POLIT POLIC, V21, P543, DOI 10.1215/03616878-21-3-543; *TROTT ASS, 1993, QUAL RES CLIFF ANT C; *US DEP HHS, 1995, MED CAMP RES BOOK; *US DEP HHS, 1994, PREV TOB US YOUNG PE; WARREN J, 1998, LOS ANGELES TIM 0121, pA1; Worden JK, 1996, HEALTH EDUC QUART, V23, P453, DOI 10.1177/109019819602300406	63	245	248	0	40	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1998	279	10					772	777		10.1001/jama.279.10.772	http://dx.doi.org/10.1001/jama.279.10.772			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZA474	9508154				2022-12-01	WOS:000072366900035
J	Nightingale, SL				Nightingale, SL			Tobramycin inhalation product approved for use in cystic fibrosis therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2022-12-01	WOS:000072192800005
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Molecular plumbing	SCIENCE			English	Article									Medsite Commun, Boston, MA USA		Peters, R (corresponding author), Medsite Commun, Boston, MA USA.							L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Lantz G C, 1990, J Invest Surg, V3, P217, DOI 10.3109/08941939009140351; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816	3	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1230	1231						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9508694				2022-12-01	WOS:000072115200051
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Mass spectroscopic genomics	SCIENCE			English	Article									Medsite Commun, Boston, MA USA		Peters, R (corresponding author), Medsite Commun, Boston, MA USA.							Griffin TJ, 1997, NAT BIOTECHNOL, V15, P1368, DOI 10.1038/nbt1297-1368; TANG K, 1995, NUCLEIC ACIDS RES, V23, P3126, DOI 10.1093/nar/23.16.3126	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1230	1230						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9508694				2022-12-01	WOS:000072115200050
